id	sid	tid	token	lemma	pos
cord-014712-5u4e00q6	1	1	key	key	JJ
cord-014712-5u4e00q6	1	2	:	:	:
cord-014712-5u4e00q6	1	3	cord-014712	cord-014712	VB
cord-014712-5u4e00q6	1	4	-	-	HYPH
cord-014712-5u4e00q6	1	5	5u4e00q6	5u4e00q6	CD
cord-014712-5u4e00q6	1	6	authors	author	NNS
cord-014712-5u4e00q6	1	7	:	:	:
cord-014712-5u4e00q6	2	1	nan	nan	NNP
cord-014712-5u4e00q6	2	2	title	title	NN
cord-014712-5u4e00q6	2	3	:	:	:
cord-014712-5u4e00q6	2	4	Selected	Selected	NNP
cord-014712-5u4e00q6	2	5	Abstracts	abstract	NNS
cord-014712-5u4e00q6	2	6	from	from	IN
cord-014712-5u4e00q6	2	7	the	the	DT
cord-014712-5u4e00q6	2	8	100th	100th	JJ
cord-014712-5u4e00q6	2	9	J	J	NNP
cord-014712-5u4e00q6	2	10	Project	Project	NNP
cord-014712-5u4e00q6	2	11	Meeting	Meeting	NNP
cord-014712-5u4e00q6	2	12	,	,	,
cord-014712-5u4e00q6	2	13	Antalya	Antalya	NNP
cord-014712-5u4e00q6	2	14	,	,	,
cord-014712-5u4e00q6	2	15	Turkey	Turkey	NNP
cord-014712-5u4e00q6	2	16	,	,	,
cord-014712-5u4e00q6	2	17	March	March	NNP
cord-014712-5u4e00q6	2	18	12	12	CD
cord-014712-5u4e00q6	2	19	-	-	SYM
cord-014712-5u4e00q6	2	20	14	14	CD
cord-014712-5u4e00q6	2	21	,	,	,
cord-014712-5u4e00q6	2	22	2014	2014	CD
cord-014712-5u4e00q6	2	23	date	date	NN
cord-014712-5u4e00q6	2	24	:	:	:
cord-014712-5u4e00q6	2	25	2014	2014	CD
cord-014712-5u4e00q6	2	26	-	-	HYPH
cord-014712-5u4e00q6	2	27	08	08	CD
cord-014712-5u4e00q6	2	28	-	-	HYPH
cord-014712-5u4e00q6	2	29	02	02	CD
cord-014712-5u4e00q6	2	30	journal	journal	NN
cord-014712-5u4e00q6	2	31	:	:	:
cord-014712-5u4e00q6	2	32	J	J	NNP
cord-014712-5u4e00q6	2	33	Clin	Clin	NNP
cord-014712-5u4e00q6	2	34	Immunol	Immunol	NNP
cord-014712-5u4e00q6	2	35	DOI	DOI	NNP
cord-014712-5u4e00q6	2	36	:	:	:
cord-014712-5u4e00q6	2	37	10.1007	10.1007	CD
cord-014712-5u4e00q6	2	38	/	/	SYM
cord-014712-5u4e00q6	2	39	s10875	s10875	NN
cord-014712-5u4e00q6	2	40	-	-	HYPH
cord-014712-5u4e00q6	2	41	014	014	CD
cord-014712-5u4e00q6	2	42	-	-	HYPH
cord-014712-5u4e00q6	2	43	0065	0065	CD
cord-014712-5u4e00q6	2	44	-	-	SYM
cord-014712-5u4e00q6	2	45	9	9	CD
cord-014712-5u4e00q6	2	46	sha	sha	NN
cord-014712-5u4e00q6	2	47	:	:	:
cord-014712-5u4e00q6	3	1	250b55f6f9a3363dbbf85025450f6196249655a2	250b55f6f9a3363dbbf85025450f6196249655a2	LS
cord-014712-5u4e00q6	3	2	doc_id	doc_id	CD
cord-014712-5u4e00q6	3	3	:	:	:
cord-014712-5u4e00q6	3	4	14712	14712	CD
cord-014712-5u4e00q6	3	5	cord_uid	cord_uid	NNS
cord-014712-5u4e00q6	3	6	:	:	:
cord-014712-5u4e00q6	4	1	5u4e00q6	5u4e00q6	NFP
cord-014712-5u4e00q6	4	2	nan	nan	NNP
cord-014712-5u4e00q6	4	3	Hans	Hans	NNP
cord-014712-5u4e00q6	4	4	D.	D.	NNP
cord-014712-5u4e00q6	4	5	Ochs	Ochs	NNP
cord-014712-5u4e00q6	5	1	The	the	DT
cord-014712-5u4e00q6	5	2	identification	identification	NN
cord-014712-5u4e00q6	5	3	of	of	IN
cord-014712-5u4e00q6	5	4	single	single	JJ
cord-014712-5u4e00q6	5	5	gene	gene	NN
cord-014712-5u4e00q6	5	6	defects	defect	NNS
cord-014712-5u4e00q6	5	7	involving	involve	VBG
cord-014712-5u4e00q6	5	8	genes	gene	NNS
cord-014712-5u4e00q6	5	9	that	that	WDT
cord-014712-5u4e00q6	5	10	play	play	VBP
cord-014712-5u4e00q6	5	11	crucial	crucial	JJ
cord-014712-5u4e00q6	5	12	roles	role	NNS
cord-014712-5u4e00q6	5	13	in	in	IN
cord-014712-5u4e00q6	5	14	adaptive	adaptive	JJ
cord-014712-5u4e00q6	5	15	or	or	CC
cord-014712-5u4e00q6	5	16	innate	innate	JJ
cord-014712-5u4e00q6	5	17	immunity	immunity	NN
cord-014712-5u4e00q6	5	18	is	be	VBZ
cord-014712-5u4e00q6	5	19	not	not	RB
cord-014712-5u4e00q6	5	20	only	only	RB
cord-014712-5u4e00q6	5	21	important	important	JJ
cord-014712-5u4e00q6	5	22	for	for	IN
cord-014712-5u4e00q6	5	23	confirming	confirm	VBG
cord-014712-5u4e00q6	5	24	a	a	DT
cord-014712-5u4e00q6	5	25	PID	pid	NN
cord-014712-5u4e00q6	5	26	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	5	27	,	,	,
cord-014712-5u4e00q6	5	28	but	but	CC
cord-014712-5u4e00q6	5	29	may	may	MD
cord-014712-5u4e00q6	5	30	contribute	contribute	VB
cord-014712-5u4e00q6	5	31	to	to	IN
cord-014712-5u4e00q6	5	32	optimal	optimal	JJ
cord-014712-5u4e00q6	5	33	therapy	therapy	NN
cord-014712-5u4e00q6	5	34	,	,	,
cord-014712-5u4e00q6	5	35	and	and	CC
cord-014712-5u4e00q6	5	36	contribute	contribute	VB
cord-014712-5u4e00q6	5	37	to	to	IN
cord-014712-5u4e00q6	5	38	genetic	genetic	JJ
cord-014712-5u4e00q6	5	39	counseling	counseling	NN
cord-014712-5u4e00q6	5	40	,	,	,
cord-014712-5u4e00q6	5	41	carrier	carrier	NN
cord-014712-5u4e00q6	5	42	identification	identification	NN
cord-014712-5u4e00q6	5	43	and	and	CC
cord-014712-5u4e00q6	5	44	pre	pre	JJ
cord-014712-5u4e00q6	5	45	-	-	JJ
cord-014712-5u4e00q6	5	46	natal	natal	JJ
cord-014712-5u4e00q6	5	47	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	5	48	.	.	.
cord-014712-5u4e00q6	6	1	To	to	TO
cord-014712-5u4e00q6	6	2	accomplish	accomplish	VB
cord-014712-5u4e00q6	6	3	this	this	DT
cord-014712-5u4e00q6	6	4	,	,	,
cord-014712-5u4e00q6	6	5	the	the	DT
cord-014712-5u4e00q6	6	6	diagnostician	diagnostician	NN
cord-014712-5u4e00q6	6	7	has	have	VBZ
cord-014712-5u4e00q6	6	8	to	to	TO
cord-014712-5u4e00q6	6	9	consider	consider	VB
cord-014712-5u4e00q6	6	10	the	the	DT
cord-014712-5u4e00q6	6	11	inheritance	inheritance	NN
cord-014712-5u4e00q6	6	12	of	of	IN
cord-014712-5u4e00q6	6	13	these	these	DT
cord-014712-5u4e00q6	6	14	disorders	disorder	NNS
cord-014712-5u4e00q6	6	15	:	:	:
cord-014712-5u4e00q6	6	16	X	x	NN
cord-014712-5u4e00q6	6	17	-	-	HYPH
cord-014712-5u4e00q6	6	18	linked	link	VBN
cord-014712-5u4e00q6	6	19	,	,	,
cord-014712-5u4e00q6	6	20	autosomal	autosomal	JJ
cord-014712-5u4e00q6	6	21	recessive	recessive	JJ
cord-014712-5u4e00q6	6	22	,	,	,
cord-014712-5u4e00q6	6	23	autosomal	autosomal	JJ
cord-014712-5u4e00q6	6	24	dominant	dominant	JJ
cord-014712-5u4e00q6	6	25	and	and	CC
cord-014712-5u4e00q6	6	26	the	the	DT
cord-014712-5u4e00q6	6	27	type	type	NN
cord-014712-5u4e00q6	6	28	of	of	IN
cord-014712-5u4e00q6	6	29	mutation	mutation	NN
cord-014712-5u4e00q6	6	30	:	:	:
cord-014712-5u4e00q6	7	1	loss	loss	NN
cord-014712-5u4e00q6	7	2	of	of	IN
cord-014712-5u4e00q6	7	3	function	function	NN
cord-014712-5u4e00q6	7	4	,	,	,
cord-014712-5u4e00q6	7	5	hypomorphic	hypomorphic	JJ
cord-014712-5u4e00q6	7	6	,	,	,
cord-014712-5u4e00q6	7	7	dominant	dominant	JJ
cord-014712-5u4e00q6	7	8	negative	negative	JJ
cord-014712-5u4e00q6	7	9	or	or	CC
cord-014712-5u4e00q6	7	10	gain	gain	NN
cord-014712-5u4e00q6	7	11	of	of	IN
cord-014712-5u4e00q6	7	12	function	function	NN
cord-014712-5u4e00q6	7	13	.	.	.
cord-014712-5u4e00q6	8	1	Conventional	conventional	JJ
cord-014712-5u4e00q6	8	2	techniques	technique	NNS
cord-014712-5u4e00q6	8	3	to	to	TO
cord-014712-5u4e00q6	8	4	screen	screen	VB
cord-014712-5u4e00q6	8	5	for	for	IN
cord-014712-5u4e00q6	8	6	single	single	JJ
cord-014712-5u4e00q6	8	7	gene	gene	NN
cord-014712-5u4e00q6	8	8	mutations	mutation	NNS
cord-014712-5u4e00q6	8	9	include	include	VBP
cord-014712-5u4e00q6	8	10	flow	flow	NN
cord-014712-5u4e00q6	8	11	cytometry	cytometry	NN
cord-014712-5u4e00q6	8	12	to	to	TO
cord-014712-5u4e00q6	8	13	measure	measure	VB
cord-014712-5u4e00q6	8	14	disease	disease	NN
cord-014712-5u4e00q6	8	15	-	-	HYPH
cord-014712-5u4e00q6	8	16	specific	specific	JJ
cord-014712-5u4e00q6	8	17	expression	expression	NN
cord-014712-5u4e00q6	8	18	of	of	IN
cord-014712-5u4e00q6	8	19	proteins	protein	NNS
cord-014712-5u4e00q6	8	20	(	(	-LRB-
cord-014712-5u4e00q6	8	21	cell	cell	NN
cord-014712-5u4e00q6	8	22	surface	surface	NN
cord-014712-5u4e00q6	8	23	,	,	,
cord-014712-5u4e00q6	8	24	cytoplasmic	cytoplasmic	JJ
cord-014712-5u4e00q6	8	25	or	or	CC
cord-014712-5u4e00q6	8	26	nuclear	nuclear	JJ
cord-014712-5u4e00q6	8	27	)	)	-RRB-
cord-014712-5u4e00q6	8	28	or	or	CC
cord-014712-5u4e00q6	8	29	to	to	TO
cord-014712-5u4e00q6	8	30	analyze	analyze	VB
cord-014712-5u4e00q6	8	31	relevant	relevant	JJ
cord-014712-5u4e00q6	8	32	signaling	signal	VBG
cord-014712-5u4e00q6	8	33	pathways	pathway	NNS
cord-014712-5u4e00q6	8	34	(	(	-LRB-
cord-014712-5u4e00q6	8	35	e.g.	e.g.	IN
cord-014712-5u4e00q6	8	36	STAT5B	stat5b	NN
cord-014712-5u4e00q6	8	37	phosphorylation	phosphorylation	NN
cord-014712-5u4e00q6	8	38	via	via	IN
cord-014712-5u4e00q6	8	39	the	the	DT
cord-014712-5u4e00q6	8	40	IL-2R	IL-2R	NNP
cord-014712-5u4e00q6	8	41	;	;	:
cord-014712-5u4e00q6	8	42	pSTAT3	pstat3	NN
cord-014712-5u4e00q6	8	43	via	via	IN
cord-014712-5u4e00q6	8	44	the	the	DT
cord-014712-5u4e00q6	8	45	IL-10	IL-10	NNP
cord-014712-5u4e00q6	8	46	receptor	receptor	NN
cord-014712-5u4e00q6	8	47	)	)	-RRB-
cord-014712-5u4e00q6	8	48	;	;	:
cord-014712-5u4e00q6	8	49	and	and	CC
cord-014712-5u4e00q6	8	50	Sanger	Sanger	NNP
cord-014712-5u4e00q6	8	51	sequencing	sequencing	NN
cord-014712-5u4e00q6	8	52	of	of	IN
cord-014712-5u4e00q6	8	53	mRNA	mrna	NN
cord-014712-5u4e00q6	8	54	or	or	CC
cord-014712-5u4e00q6	8	55	genomic	genomic	JJ
cord-014712-5u4e00q6	8	56	DNA	dna	NN
cord-014712-5u4e00q6	8	57	using	use	VBG
cord-014712-5u4e00q6	8	58	Dye	Dye	NNP
cord-014712-5u4e00q6	8	59	-	-	HYPH
cord-014712-5u4e00q6	8	60	Terminator	Terminator	NNP
cord-014712-5u4e00q6	8	61	sequencing	sequencing	NN
cord-014712-5u4e00q6	8	62	.	.	.
cord-014712-5u4e00q6	9	1	Next	next	JJ
cord-014712-5u4e00q6	9	2	generation	generation	NN
cord-014712-5u4e00q6	9	3	sequencing	sequencing	NN
cord-014712-5u4e00q6	9	4	(	(	-LRB-
cord-014712-5u4e00q6	9	5	"	"	``
cord-014712-5u4e00q6	9	6	by	by	IN
cord-014712-5u4e00q6	9	7	synthesis	synthesis	NN
cord-014712-5u4e00q6	9	8	"	"	''
cord-014712-5u4e00q6	9	9	)	)	-RRB-
cord-014712-5u4e00q6	9	10	has	have	VBZ
cord-014712-5u4e00q6	9	11	been	be	VBN
cord-014712-5u4e00q6	9	12	refined	refine	VBN
cord-014712-5u4e00q6	9	13	,	,	,
cord-014712-5u4e00q6	9	14	and	and	CC
cord-014712-5u4e00q6	9	15	is	be	VBZ
cord-014712-5u4e00q6	9	16	being	be	VBG
cord-014712-5u4e00q6	9	17	used	use	VBN
cord-014712-5u4e00q6	9	18	increasingly	increasingly	RB
cord-014712-5u4e00q6	9	19	to	to	TO
cord-014712-5u4e00q6	9	20	study	study	VB
cord-014712-5u4e00q6	9	21	families	family	NNS
cord-014712-5u4e00q6	9	22	with	with	IN
cord-014712-5u4e00q6	9	23	multiple	multiple	JJ
cord-014712-5u4e00q6	9	24	affected	affect	VBN
cord-014712-5u4e00q6	9	25	members	member	NNS
cord-014712-5u4e00q6	9	26	with	with	IN
cord-014712-5u4e00q6	9	27	an	an	DT
cord-014712-5u4e00q6	9	28	atypical	atypical	JJ
cord-014712-5u4e00q6	9	29	PID	pid	NN
cord-014712-5u4e00q6	9	30	phenotype	phenotype	NN
cord-014712-5u4e00q6	9	31	,	,	,
cord-014712-5u4e00q6	9	32	or	or	CC
cord-014712-5u4e00q6	9	33	to	to	TO
cord-014712-5u4e00q6	9	34	explore	explore	VB
cord-014712-5u4e00q6	9	35	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	9	36	families	family	NNS
cord-014712-5u4e00q6	9	37	with	with	IN
cord-014712-5u4e00q6	9	38	one	one	CD
cord-014712-5u4e00q6	9	39	member	member	NN
cord-014712-5u4e00q6	9	40	affected	affect	VBD
cord-014712-5u4e00q6	9	41	.	.	.
cord-014712-5u4e00q6	10	1	Whole	whole	JJ
cord-014712-5u4e00q6	10	2	exome	exome	NN
cord-014712-5u4e00q6	10	3	sequencing	sequencing	NN
cord-014712-5u4e00q6	10	4	requires	require	VBZ
cord-014712-5u4e00q6	10	5	less	less	JJR
cord-014712-5u4e00q6	10	6	data	data	NN
cord-014712-5u4e00q6	10	7	analysis	analysis	NN
cord-014712-5u4e00q6	10	8	,	,	,
cord-014712-5u4e00q6	10	9	compared	compare	VBN
cord-014712-5u4e00q6	10	10	with	with	IN
cord-014712-5u4e00q6	10	11	whole	whole	JJ
cord-014712-5u4e00q6	10	12	genome	genome	NN
cord-014712-5u4e00q6	10	13	sequencing	sequencing	NN
cord-014712-5u4e00q6	10	14	,	,	,
cord-014712-5u4e00q6	10	15	but	but	CC
cord-014712-5u4e00q6	10	16	may	may	MD
cord-014712-5u4e00q6	10	17	miss	miss	VB
cord-014712-5u4e00q6	10	18	intronic	intronic	JJ
cord-014712-5u4e00q6	10	19	or	or	CC
cord-014712-5u4e00q6	10	20	regulatory	regulatory	JJ
cord-014712-5u4e00q6	10	21	elements	element	NNS
cord-014712-5u4e00q6	10	22	.	.	.
cord-014712-5u4e00q6	11	1	The	the	DT
cord-014712-5u4e00q6	11	2	challenge	challenge	NN
cord-014712-5u4e00q6	11	3	of	of	IN
cord-014712-5u4e00q6	11	4	whole	whole	JJ
cord-014712-5u4e00q6	11	5	exome	exome	NN
cord-014712-5u4e00q6	11	6	/	/	SYM
cord-014712-5u4e00q6	11	7	genome	genome	NN
cord-014712-5u4e00q6	11	8	sequencing	sequencing	NN
cord-014712-5u4e00q6	11	9	is	be	VBZ
cord-014712-5u4e00q6	11	10	to	to	TO
cord-014712-5u4e00q6	11	11	confirm	confirm	VB
cord-014712-5u4e00q6	11	12	that	that	IN
cord-014712-5u4e00q6	11	13	the	the	DT
cord-014712-5u4e00q6	11	14	multiple	multiple	JJ
cord-014712-5u4e00q6	11	15	variants	variant	NNS
cord-014712-5u4e00q6	11	16	identified	identify	VBN
cord-014712-5u4e00q6	11	17	by	by	IN
cord-014712-5u4e00q6	11	18	these	these	DT
cord-014712-5u4e00q6	11	19	techniques	technique	NNS
cord-014712-5u4e00q6	11	20	are	be	VBP
cord-014712-5u4e00q6	11	21	causative	causative	JJ
cord-014712-5u4e00q6	11	22	for	for	IN
cord-014712-5u4e00q6	11	23	the	the	DT
cord-014712-5u4e00q6	11	24	clinical	clinical	JJ
cord-014712-5u4e00q6	11	25	phenotype	phenotype	NN
cord-014712-5u4e00q6	11	26	of	of	IN
cord-014712-5u4e00q6	11	27	the	the	DT
cord-014712-5u4e00q6	11	28	study	study	NN
cord-014712-5u4e00q6	11	29	patient	patient	NN
cord-014712-5u4e00q6	11	30	.	.	.
cord-014712-5u4e00q6	12	1	However	however	RB
cord-014712-5u4e00q6	12	2	,	,	,
cord-014712-5u4e00q6	12	3	with	with	IN
cord-014712-5u4e00q6	12	4	increasing	increase	VBG
cord-014712-5u4e00q6	12	5	experience	experience	NN
cord-014712-5u4e00q6	12	6	,	,	,
cord-014712-5u4e00q6	12	7	next	next	JJ
cord-014712-5u4e00q6	12	8	generation	generation	NN
cord-014712-5u4e00q6	12	9	sequencing	sequencing	NN
cord-014712-5u4e00q6	12	10	will	will	MD
cord-014712-5u4e00q6	12	11	become	become	VB
cord-014712-5u4e00q6	12	12	a	a	DT
cord-014712-5u4e00q6	12	13	standard	standard	JJ
cord-014712-5u4e00q6	12	14	procedure	procedure	NN
cord-014712-5u4e00q6	12	15	for	for	IN
cord-014712-5u4e00q6	12	16	the	the	DT
cord-014712-5u4e00q6	12	17	identification	identification	NN
cord-014712-5u4e00q6	12	18	of	of	IN
cord-014712-5u4e00q6	12	19	genetic	genetic	JJ
cord-014712-5u4e00q6	12	20	defects	defect	NNS
cord-014712-5u4e00q6	12	21	responsible	responsible	JJ
cord-014712-5u4e00q6	12	22	for	for	IN
cord-014712-5u4e00q6	12	23	inherited	inherit	VBN
cord-014712-5u4e00q6	12	24	diseases	disease	NNS
cord-014712-5u4e00q6	12	25	,	,	,
cord-014712-5u4e00q6	12	26	including	include	VBG
cord-014712-5u4e00q6	12	27	PID	PID	NNP
cord-014712-5u4e00q6	12	28	.	.	.
cord-014712-5u4e00q6	13	1	Stephen	Stephen	NNP
cord-014712-5u4e00q6	13	2	Jolles	Jolles	NNP
cord-014712-5u4e00q6	13	3	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	13	4	Centre	Centre	NNP
cord-014712-5u4e00q6	13	5	for	for	IN
cord-014712-5u4e00q6	13	6	Wales	Wales	NNP
cord-014712-5u4e00q6	13	7	,	,	,
cord-014712-5u4e00q6	13	8	University	University	NNP
cord-014712-5u4e00q6	13	9	Hospital	Hospital	NNP
cord-014712-5u4e00q6	13	10	of	of	IN
cord-014712-5u4e00q6	13	11	Wales	Wales	NNP
cord-014712-5u4e00q6	13	12	,	,	,
cord-014712-5u4e00q6	13	13	Cardiff	Cardiff	NNP
cord-014712-5u4e00q6	13	14	,	,	,
cord-014712-5u4e00q6	13	15	UK	UK	NNP
cord-014712-5u4e00q6	13	16	.	.	.
cord-014712-5u4e00q6	14	1	Immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	14	2	(	(	-LRB-
cord-014712-5u4e00q6	14	3	Ig)-replacement	ig)-replacement	CD
cord-014712-5u4e00q6	14	4	therapy	therapy	NN
cord-014712-5u4e00q6	14	5	represents	represent	VBZ
cord-014712-5u4e00q6	14	6	the	the	DT
cord-014712-5u4e00q6	14	7	mainstay	mainstay	NN
cord-014712-5u4e00q6	14	8	of	of	IN
cord-014712-5u4e00q6	14	9	treatment	treatment	NN
cord-014712-5u4e00q6	14	10	for	for	IN
cord-014712-5u4e00q6	14	11	patients	patient	NNS
cord-014712-5u4e00q6	14	12	with	with	IN
cord-014712-5u4e00q6	14	13	primary	primary	JJ
cord-014712-5u4e00q6	14	14	antibody	antibody	NN
cord-014712-5u4e00q6	14	15	deficiency	deficiency	NN
cord-014712-5u4e00q6	14	16	and	and	CC
cord-014712-5u4e00q6	14	17	is	be	VBZ
cord-014712-5u4e00q6	14	18	administered	administer	VBN
cord-014712-5u4e00q6	14	19	either	either	CC
cord-014712-5u4e00q6	14	20	intravenously	intravenously	RB
cord-014712-5u4e00q6	14	21	(	(	-LRB-
cord-014712-5u4e00q6	14	22	IVIg	ivig	ADD
cord-014712-5u4e00q6	14	23	)	)	-RRB-
cord-014712-5u4e00q6	14	24	or	or	CC
cord-014712-5u4e00q6	14	25	subcutaneously	subcutaneously	RB
cord-014712-5u4e00q6	14	26	(	(	-LRB-
cord-014712-5u4e00q6	14	27	SCIg	SCIg	NNS
cord-014712-5u4e00q6	14	28	)	)	-RRB-
cord-014712-5u4e00q6	14	29	.	.	.
cord-014712-5u4e00q6	15	1	Recent	recent	JJ
cord-014712-5u4e00q6	15	2	developments	development	NNS
cord-014712-5u4e00q6	15	3	using	use	VBG
cord-014712-5u4e00q6	15	4	a	a	DT
cord-014712-5u4e00q6	15	5	high	high	JJ
cord-014712-5u4e00q6	15	6	-	-	HYPH
cord-014712-5u4e00q6	15	7	purity	purity	NN
cord-014712-5u4e00q6	15	8	recombinant	recombinant	JJ
cord-014712-5u4e00q6	15	9	human	human	JJ
cord-014712-5u4e00q6	15	10	hyaluronidase	hyaluronidase	NNP
cord-014712-5u4e00q6	15	11	have	have	VBP
cord-014712-5u4e00q6	15	12	allowed	allow	VBN
cord-014712-5u4e00q6	15	13	the	the	DT
cord-014712-5u4e00q6	15	14	longer	long	JJR
cord-014712-5u4e00q6	15	15	term	term	NN
cord-014712-5u4e00q6	15	16	repeated	repeat	VBN
cord-014712-5u4e00q6	15	17	use	use	NN
cord-014712-5u4e00q6	15	18	of	of	IN
cord-014712-5u4e00q6	15	19	this	this	DT
cord-014712-5u4e00q6	15	20	enzyme	enzyme	NN
cord-014712-5u4e00q6	15	21	to	to	TO
cord-014712-5u4e00q6	15	22	facilitate	facilitate	VB
cord-014712-5u4e00q6	15	23	the	the	DT
cord-014712-5u4e00q6	15	24	delivery	delivery	NN
cord-014712-5u4e00q6	15	25	of	of	IN
cord-014712-5u4e00q6	15	26	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	15	27	and	and	CC
cord-014712-5u4e00q6	15	28	other	other	JJ
cord-014712-5u4e00q6	15	29	molecules	molecule	NNS
cord-014712-5u4e00q6	15	30	including	include	VBG
cord-014712-5u4e00q6	15	31	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	15	32	,	,	,
cord-014712-5u4e00q6	15	33	local	local	JJ
cord-014712-5u4e00q6	15	34	anesthetics	anesthetic	NNS
cord-014712-5u4e00q6	15	35	,	,	,
cord-014712-5u4e00q6	15	36	insulin	insulin	NN
cord-014712-5u4e00q6	15	37	,	,	,
cord-014712-5u4e00q6	15	38	morphine	morphine	NN
cord-014712-5u4e00q6	15	39	and	and	CC
cord-014712-5u4e00q6	15	40	fluid	fluid	JJ
cord-014712-5u4e00q6	15	41	replacement	replacement	NN
cord-014712-5u4e00q6	15	42	into	into	IN
cord-014712-5u4e00q6	15	43	the	the	DT
cord-014712-5u4e00q6	15	44	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	15	45	space	space	NN
cord-014712-5u4e00q6	15	46	.	.	.
cord-014712-5u4e00q6	16	1	Hyaluronidase	Hyaluronidase	NNP
cord-014712-5u4e00q6	16	2	facilitated	facilitate	VBN
cord-014712-5u4e00q6	16	3	SCIg	SCIg	NNS
cord-014712-5u4e00q6	16	4	(	(	-LRB-
cord-014712-5u4e00q6	16	5	fSCIg	fSCIg	NNS
cord-014712-5u4e00q6	16	6	)	)	-RRB-
cord-014712-5u4e00q6	17	1	has	have	VBZ
cord-014712-5u4e00q6	17	2	helped	help	VBN
cord-014712-5u4e00q6	17	3	overcome	overcome	VB
cord-014712-5u4e00q6	17	4	the	the	DT
cord-014712-5u4e00q6	17	5	limitations	limitation	NNS
cord-014712-5u4e00q6	17	6	on	on	IN
cord-014712-5u4e00q6	17	7	the	the	DT
cord-014712-5u4e00q6	17	8	volume	volume	NN
cord-014712-5u4e00q6	17	9	which	which	WDT
cord-014712-5u4e00q6	17	10	can	can	MD
cord-014712-5u4e00q6	17	11	be	be	VB
cord-014712-5u4e00q6	17	12	delivered	deliver	VBN
cord-014712-5u4e00q6	17	13	into	into	IN
cord-014712-5u4e00q6	17	14	the	the	DT
cord-014712-5u4e00q6	17	15	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	17	16	tissues	tissue	NNS
cord-014712-5u4e00q6	17	17	by	by	IN
cord-014712-5u4e00q6	17	18	enabling	enable	VBG
cord-014712-5u4e00q6	17	19	dispersion	dispersion	NN
cord-014712-5u4e00q6	17	20	of	of	IN
cord-014712-5u4e00q6	17	21	SCIg	SCIg	NNS
cord-014712-5u4e00q6	17	22	and	and	CC
cord-014712-5u4e00q6	17	23	its	-PRON-	PRP$
cord-014712-5u4e00q6	17	24	absorption	absorption	NN
cord-014712-5u4e00q6	17	25	into	into	IN
cord-014712-5u4e00q6	17	26	lymphatics	lymphatic	NNS
cord-014712-5u4e00q6	17	27	.	.	.
cord-014712-5u4e00q6	18	1	The	the	DT
cord-014712-5u4e00q6	18	2	rate	rate	NN
cord-014712-5u4e00q6	18	3	of	of	IN
cord-014712-5u4e00q6	18	4	facilitated	facilitate	VBN
cord-014712-5u4e00q6	18	5	SCIg	SCIg	NNS
cord-014712-5u4e00q6	18	6	infusion	infusion	NN
cord-014712-5u4e00q6	18	7	is	be	VBZ
cord-014712-5u4e00q6	18	8	equivalent	equivalent	JJ
cord-014712-5u4e00q6	18	9	to	to	IN
cord-014712-5u4e00q6	18	10	that	that	DT
cord-014712-5u4e00q6	18	11	of	of	IN
cord-014712-5u4e00q6	18	12	IVIg	ivig	NN
cord-014712-5u4e00q6	18	13	,	,	,
cord-014712-5u4e00q6	18	14	and	and	CC
cord-014712-5u4e00q6	18	15	the	the	DT
cord-014712-5u4e00q6	18	16	volume	volume	NN
cord-014712-5u4e00q6	18	17	administered	administer	VBN
cord-014712-5u4e00q6	18	18	at	at	IN
cord-014712-5u4e00q6	18	19	a	a	DT
cord-014712-5u4e00q6	18	20	single	single	JJ
cord-014712-5u4e00q6	18	21	site	site	NN
cord-014712-5u4e00q6	18	22	can	can	MD
cord-014712-5u4e00q6	18	23	be	be	VB
cord-014712-5u4e00q6	18	24	greater	great	JJR
cord-014712-5u4e00q6	18	25	than	than	IN
cord-014712-5u4e00q6	18	26	700	700	CD
cord-014712-5u4e00q6	18	27	mL	ml	NN
cord-014712-5u4e00q6	18	28	,	,	,
cord-014712-5u4e00q6	18	29	an	an	DT
cord-014712-5u4e00q6	18	30	enormous	enormous	JJ
cord-014712-5u4e00q6	18	31	increase	increase	NN
cord-014712-5u4e00q6	18	32	over	over	IN
cord-014712-5u4e00q6	18	33	conventional	conventional	JJ
cord-014712-5u4e00q6	18	34	SCIg	SCIg	NNS
cord-014712-5u4e00q6	18	35	,	,	,
cord-014712-5u4e00q6	18	36	at	at	IN
cord-014712-5u4e00q6	19	1	20	20	CD
cord-014712-5u4e00q6	19	2	-	-	SYM
cord-014712-5u4e00q6	19	3	40	40	CD
cord-014712-5u4e00q6	19	4	mL.	mL.	NNS
cord-014712-5u4e00q6	19	5	The	the	DT
cord-014712-5u4e00q6	19	6	use	use	NN
cord-014712-5u4e00q6	19	7	of	of	IN
cord-014712-5u4e00q6	19	8	fSCIg	fSCIg	NNS
cord-014712-5u4e00q6	19	9	avoids	avoid	VBZ
cord-014712-5u4e00q6	19	10	many	many	JJ
cord-014712-5u4e00q6	19	11	of	of	IN
cord-014712-5u4e00q6	19	12	the	the	DT
cord-014712-5u4e00q6	19	13	systemic	systemic	JJ
cord-014712-5u4e00q6	19	14	side	side	NN
cord-014712-5u4e00q6	19	15	effects	effect	NNS
cord-014712-5u4e00q6	19	16	of	of	IN
cord-014712-5u4e00q6	19	17	IVIg	ivig	NN
cord-014712-5u4e00q6	19	18	,	,	,
cord-014712-5u4e00q6	19	19	and	and	CC
cord-014712-5u4e00q6	19	20	has	have	VBZ
cord-014712-5u4e00q6	19	21	higher	high	JJR
cord-014712-5u4e00q6	19	22	bioavailability	bioavailability	NN
cord-014712-5u4e00q6	19	23	than	than	IN
cord-014712-5u4e00q6	19	24	SCIg	SCIg	NNS
cord-014712-5u4e00q6	19	25	.	.	.
cord-014712-5u4e00q6	20	1	Over	over	IN
cord-014712-5u4e00q6	20	2	three	three	CD
cord-014712-5u4e00q6	20	3	years	year	NNS
cord-014712-5u4e00q6	20	4	of	of	IN
cord-014712-5u4e00q6	20	5	safety	safety	NN
cord-014712-5u4e00q6	20	6	data	datum	NNS
cord-014712-5u4e00q6	20	7	are	be	VBP
cord-014712-5u4e00q6	20	8	now	now	RB
cord-014712-5u4e00q6	20	9	available	available	JJ
cord-014712-5u4e00q6	20	10	for	for	IN
cord-014712-5u4e00q6	20	11	this	this	DT
cord-014712-5u4e00q6	20	12	approach	approach	NN
cord-014712-5u4e00q6	20	13	though	though	IN
cord-014712-5u4e00q6	20	14	longer	long	JJR
cord-014712-5u4e00q6	20	15	term	term	NN
cord-014712-5u4e00q6	20	16	safety	safety	NN
cord-014712-5u4e00q6	20	17	data	datum	NNS
cord-014712-5u4e00q6	20	18	and	and	CC
cord-014712-5u4e00q6	20	19	information	information	NN
cord-014712-5u4e00q6	20	20	on	on	IN
cord-014712-5u4e00q6	20	21	anti	anti	JJ
cord-014712-5u4e00q6	20	22	-	-	JJ
cord-014712-5u4e00q6	20	23	hylauronidase	hylauronidase	JJ
cord-014712-5u4e00q6	20	24	antibodies	antibody	NNS
cord-014712-5u4e00q6	20	25	and	and	CC
cord-014712-5u4e00q6	20	26	their	-PRON-	PRP$
cord-014712-5u4e00q6	20	27	relevance	relevance	NN
cord-014712-5u4e00q6	20	28	will	will	MD
cord-014712-5u4e00q6	20	29	be	be	VB
cord-014712-5u4e00q6	20	30	required	require	VBN
cord-014712-5u4e00q6	20	31	.	.	.
cord-014712-5u4e00q6	21	1	fSCIg	fSCIg	NNS
cord-014712-5u4e00q6	21	2	could	could	MD
cord-014712-5u4e00q6	21	3	aid	aid	VB
cord-014712-5u4e00q6	21	4	several	several	JJ
cord-014712-5u4e00q6	21	5	areas	area	NNS
cord-014712-5u4e00q6	21	6	of	of	IN
cord-014712-5u4e00q6	21	7	patient	patient	JJ
cord-014712-5u4e00q6	21	8	management	management	NN
cord-014712-5u4e00q6	21	9	in	in	IN
cord-014712-5u4e00q6	21	10	both	both	DT
cord-014712-5u4e00q6	21	11	primary	primary	JJ
cord-014712-5u4e00q6	21	12	antibody	antibody	NN
cord-014712-5u4e00q6	21	13	deficiency	deficiency	NN
cord-014712-5u4e00q6	21	14	and	and	CC
cord-014712-5u4e00q6	21	15	immunomodulatory	immunomodulatory	JJ
cord-014712-5u4e00q6	21	16	indications	indication	NNS
cord-014712-5u4e00q6	21	17	.	.	.
cord-014712-5u4e00q6	22	1	Key	key	JJ
cord-014712-5u4e00q6	22	2	factors	factor	NNS
cord-014712-5u4e00q6	22	3	influencing	influence	VBG
cord-014712-5u4e00q6	22	4	how	how	WRB
cord-014712-5u4e00q6	22	5	it	-PRON-	PRP
cord-014712-5u4e00q6	22	6	will	will	MD
cord-014712-5u4e00q6	22	7	be	be	VB
cord-014712-5u4e00q6	22	8	used	use	VBN
cord-014712-5u4e00q6	22	9	in	in	IN
cord-014712-5u4e00q6	22	10	future	future	NN
cord-014712-5u4e00q6	22	11	are	be	VBP
cord-014712-5u4e00q6	22	12	long	long	JJ
cord-014712-5u4e00q6	22	13	-	-	HYPH
cord-014712-5u4e00q6	22	14	term	term	NN
cord-014712-5u4e00q6	22	15	safety	safety	NN
cord-014712-5u4e00q6	22	16	data	datum	NNS
cord-014712-5u4e00q6	22	17	and	and	CC
cord-014712-5u4e00q6	22	18	cost	cost	NN
cord-014712-5u4e00q6	22	19	-	-	HYPH
cord-014712-5u4e00q6	22	20	benefit	benefit	NN
cord-014712-5u4e00q6	22	21	analysis	analysis	NN
cord-014712-5u4e00q6	22	22	.	.	.
cord-014712-5u4e00q6	23	1	date	date	NN
cord-014712-5u4e00q6	23	2	after	after	IN
cord-014712-5u4e00q6	23	3	the	the	DT
cord-014712-5u4e00q6	23	4	CD19	CD19	NNP
cord-014712-5u4e00q6	23	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	23	6	was	be	VBD
cord-014712-5u4e00q6	23	7	firstly	firstly	RB
cord-014712-5u4e00q6	23	8	described	describe	VBN
cord-014712-5u4e00q6	23	9	in	in	IN
cord-014712-5u4e00q6	23	10	a	a	DT
cord-014712-5u4e00q6	23	11	Turkish	turkish	JJ
cord-014712-5u4e00q6	23	12	girl	girl	NN
cord-014712-5u4e00q6	23	13	in	in	IN
cord-014712-5u4e00q6	23	14	2006	2006	CD
cord-014712-5u4e00q6	23	15	.	.	.
cord-014712-5u4e00q6	24	1	The	the	DT
cord-014712-5u4e00q6	24	2	patients	patient	NNS
cord-014712-5u4e00q6	24	3	with	with	IN
cord-014712-5u4e00q6	24	4	CD19	CD19	NNP
cord-014712-5u4e00q6	24	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	24	6	had	have	VBD
cord-014712-5u4e00q6	24	7	normal	normal	JJ
cord-014712-5u4e00q6	24	8	B	b	NN
cord-014712-5u4e00q6	24	9	-	-	HYPH
cord-014712-5u4e00q6	24	10	cell	cell	NN
cord-014712-5u4e00q6	24	11	differentiation	differentiation	NN
cord-014712-5u4e00q6	24	12	in	in	IN
cord-014712-5u4e00q6	24	13	bone	bone	NN
cord-014712-5u4e00q6	24	14	marrow	marrow	NN
cord-014712-5u4e00q6	24	15	,	,	,
cord-014712-5u4e00q6	24	16	normal	normal	JJ
cord-014712-5u4e00q6	24	17	absolute	absolute	JJ
cord-014712-5u4e00q6	24	18	number	number	NN
cord-014712-5u4e00q6	24	19	of	of	IN
cord-014712-5u4e00q6	24	20	B	b	NN
cord-014712-5u4e00q6	24	21	cells	cell	NNS
cord-014712-5u4e00q6	24	22	in	in	IN
cord-014712-5u4e00q6	24	23	peripheral	peripheral	JJ
cord-014712-5u4e00q6	24	24	blood	blood	NN
cord-014712-5u4e00q6	24	25	and	and	CC
cord-014712-5u4e00q6	24	26	normal	normal	JJ
cord-014712-5u4e00q6	24	27	BCR	BCR	NNP
cord-014712-5u4e00q6	24	28	repertoire	repertoire	NN
cord-014712-5u4e00q6	24	29	.	.	.
cord-014712-5u4e00q6	25	1	Also	also	RB
cord-014712-5u4e00q6	25	2	,	,	,
cord-014712-5u4e00q6	25	3	the	the	DT
cord-014712-5u4e00q6	25	4	patients	patient	NNS
cord-014712-5u4e00q6	25	5	had	have	VBD
cord-014712-5u4e00q6	25	6	normal	normal	JJ
cord-014712-5u4e00q6	25	7	stimulation	stimulation	NN
cord-014712-5u4e00q6	25	8	via	via	IN
cord-014712-5u4e00q6	25	9	the	the	DT
cord-014712-5u4e00q6	25	10	BCR	BCR	NNP
cord-014712-5u4e00q6	25	11	,	,	,
cord-014712-5u4e00q6	25	12	normal	normal	JJ
cord-014712-5u4e00q6	25	13	proliferation	proliferation	NN
cord-014712-5u4e00q6	25	14	response	response	NN
cord-014712-5u4e00q6	25	15	upon	upon	IN
cord-014712-5u4e00q6	25	16	antigen	antigen	NN
cord-014712-5u4e00q6	25	17	stimulation	stimulation	NN
cord-014712-5u4e00q6	25	18	but	but	CC
cord-014712-5u4e00q6	25	19	reduced	reduce	VBN
cord-014712-5u4e00q6	25	20	memory	memory	NN
cord-014712-5u4e00q6	25	21	-	-	HYPH
cord-014712-5u4e00q6	25	22	B	b	NN
cord-014712-5u4e00q6	25	23	-	-	HYPH
cord-014712-5u4e00q6	25	24	cell	cell	NN
cord-014712-5u4e00q6	25	25	compartment	compartment	NN
cord-014712-5u4e00q6	25	26	in	in	IN
cord-014712-5u4e00q6	25	27	peripheral	peripheral	JJ
cord-014712-5u4e00q6	25	28	blood	blood	NN
cord-014712-5u4e00q6	25	29	.	.	.
cord-014712-5u4e00q6	26	1	The	the	DT
cord-014712-5u4e00q6	26	2	CD19	CD19	NNP
cord-014712-5u4e00q6	26	3	deficiency	deficiency	NN
cord-014712-5u4e00q6	26	4	leads	lead	VBZ
cord-014712-5u4e00q6	26	5	to	to	IN
cord-014712-5u4e00q6	26	6	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	26	7	and	and	CC
cord-014712-5u4e00q6	26	8	impaired	impaired	JJ
cord-014712-5u4e00q6	26	9	antigen	antigen	NN
cord-014712-5u4e00q6	26	10	-	-	HYPH
cord-014712-5u4e00q6	26	11	specific	specific	JJ
cord-014712-5u4e00q6	26	12	humoral	humoral	JJ
cord-014712-5u4e00q6	26	13	immune	immune	JJ
cord-014712-5u4e00q6	26	14	responses	response	NNS
cord-014712-5u4e00q6	26	15	after	after	IN
cord-014712-5u4e00q6	26	16	vaccination	vaccination	NN
cord-014712-5u4e00q6	26	17	.	.	.
cord-014712-5u4e00q6	27	1	We	-PRON-	PRP
cord-014712-5u4e00q6	27	2	had	have	VBD
cord-014712-5u4e00q6	27	3	described	describe	VBN
cord-014712-5u4e00q6	27	4	thirty	thirty	CD
cord-014712-5u4e00q6	27	5	carriers	carrier	NNS
cord-014712-5u4e00q6	27	6	in	in	IN
cord-014712-5u4e00q6	27	7	relatives	relative	NNS
cord-014712-5u4e00q6	27	8	of	of	IN
cord-014712-5u4e00q6	27	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	27	10	two	two	CD
cord-014712-5u4e00q6	27	11	patients	patient	NNS
cord-014712-5u4e00q6	27	12	with	with	IN
cord-014712-5u4e00q6	27	13	CD19	CD19	NNP
cord-014712-5u4e00q6	27	14	deficieny	deficieny	NN
cord-014712-5u4e00q6	27	15	and	and	CC
cord-014712-5u4e00q6	27	16	also	also	RB
cord-014712-5u4e00q6	27	17	showed	show	VBD
cord-014712-5u4e00q6	27	18	that	that	IN
cord-014712-5u4e00q6	27	19	the	the	DT
cord-014712-5u4e00q6	27	20	MFI	MFI	NNP
cord-014712-5u4e00q6	27	21	value	value	NN
cord-014712-5u4e00q6	27	22	of	of	IN
cord-014712-5u4e00q6	27	23	CD19	CD19	NNP
cord-014712-5u4e00q6	27	24	and	and	CC
cord-014712-5u4e00q6	27	25	CD21	CD21	NNP
cord-014712-5u4e00q6	27	26	expressions	expression	NNS
cord-014712-5u4e00q6	27	27	were	be	VBD
cord-014712-5u4e00q6	27	28	lower	low	JJR
cord-014712-5u4e00q6	27	29	in	in	IN
cord-014712-5u4e00q6	27	30	the	the	DT
cord-014712-5u4e00q6	27	31	carriers	carrier	NNS
cord-014712-5u4e00q6	27	32	than	than	IN
cord-014712-5u4e00q6	27	33	in	in	IN
cord-014712-5u4e00q6	27	34	controls	control	NNS
cord-014712-5u4e00q6	27	35	.	.	.
cord-014712-5u4e00q6	28	1	During	during	IN
cord-014712-5u4e00q6	28	2	the	the	DT
cord-014712-5u4e00q6	28	3	last	last	JJ
cord-014712-5u4e00q6	28	4	five	five	CD
cord-014712-5u4e00q6	28	5	years	year	NNS
cord-014712-5u4e00q6	28	6	,	,	,
cord-014712-5u4e00q6	28	7	it	-PRON-	PRP
cord-014712-5u4e00q6	28	8	was	be	VBD
cord-014712-5u4e00q6	28	9	also	also	RB
cord-014712-5u4e00q6	28	10	showed	show	VBN
cord-014712-5u4e00q6	28	11	that	that	IN
cord-014712-5u4e00q6	28	12	the	the	DT
cord-014712-5u4e00q6	28	13	mutations	mutation	NNS
cord-014712-5u4e00q6	28	14	of	of	IN
cord-014712-5u4e00q6	28	15	the	the	DT
cord-014712-5u4e00q6	28	16	other	other	JJ
cord-014712-5u4e00q6	28	17	coreceptors	coreceptor	NNS
cord-014712-5u4e00q6	28	18	of	of	IN
cord-014712-5u4e00q6	28	19	B	b	NN
cord-014712-5u4e00q6	28	20	cells	cell	NNS
cord-014712-5u4e00q6	28	21	such	such	JJ
cord-014712-5u4e00q6	28	22	as	as	IN
cord-014712-5u4e00q6	28	23	CD81	CD81	NNP
cord-014712-5u4e00q6	28	24	and	and	CC
cord-014712-5u4e00q6	28	25	CD21	CD21	NNP
cord-014712-5u4e00q6	28	26	caused	cause	VBD
cord-014712-5u4e00q6	28	27	antibody	antibody	NN
cord-014712-5u4e00q6	28	28	deficiency	deficiency	NN
cord-014712-5u4e00q6	28	29	.	.	.
cord-014712-5u4e00q6	29	1	In	in	IN
cord-014712-5u4e00q6	29	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	29	3	,	,	,
cord-014712-5u4e00q6	29	4	the	the	DT
cord-014712-5u4e00q6	29	5	description	description	NN
cord-014712-5u4e00q6	29	6	of	of	IN
cord-014712-5u4e00q6	29	7	CD19	CD19	NNP
cord-014712-5u4e00q6	29	8	deficiency	deficiency	NN
cord-014712-5u4e00q6	29	9	reminds	remind	VBZ
cord-014712-5u4e00q6	29	10	the	the	DT
cord-014712-5u4e00q6	29	11	importance	importance	NN
cord-014712-5u4e00q6	29	12	of	of	IN
cord-014712-5u4e00q6	29	13	the	the	DT
cord-014712-5u4e00q6	29	14	molecules	molecule	NNS
cord-014712-5u4e00q6	29	15	on	on	IN
cord-014712-5u4e00q6	29	16	B	b	NN
cord-014712-5u4e00q6	29	17	cells	cell	NNS
cord-014712-5u4e00q6	29	18	and	and	CC
cord-014712-5u4e00q6	29	19	contribute	contribute	VBP
cord-014712-5u4e00q6	29	20	to	to	TO
cord-014712-5u4e00q6	29	21	identify	identify	VB
cord-014712-5u4e00q6	29	22	new	new	JJ
cord-014712-5u4e00q6	29	23	genetic	genetic	JJ
cord-014712-5u4e00q6	29	24	defects	defect	NNS
cord-014712-5u4e00q6	29	25	(	(	-LRB-
cord-014712-5u4e00q6	29	26	CD81	CD81	NNP
cord-014712-5u4e00q6	29	27	,	,	,
cord-014712-5u4e00q6	29	28	CD21	CD21	NNP
cord-014712-5u4e00q6	29	29	)	)	-RRB-
cord-014712-5u4e00q6	29	30	,	,	,
cord-014712-5u4e00q6	29	31	and	and	CC
cord-014712-5u4e00q6	29	32	it	-PRON-	PRP
cord-014712-5u4e00q6	29	33	was	be	VBD
cord-014712-5u4e00q6	29	34	showed	show	VBN
cord-014712-5u4e00q6	29	35	that	that	IN
cord-014712-5u4e00q6	29	36	coreceptors	coreceptor	NNS
cord-014712-5u4e00q6	29	37	could	could	MD
cord-014712-5u4e00q6	29	38	affect	affect	VB
cord-014712-5u4e00q6	29	39	the	the	DT
cord-014712-5u4e00q6	29	40	expressions	expression	NNS
cord-014712-5u4e00q6	29	41	and	and	CC
cord-014712-5u4e00q6	29	42	the	the	DT
cord-014712-5u4e00q6	29	43	functions	function	NNS
cord-014712-5u4e00q6	29	44	of	of	IN
cord-014712-5u4e00q6	29	45	each	each	DT
cord-014712-5u4e00q6	29	46	other	other	JJ
cord-014712-5u4e00q6	29	47	.	.	.
cord-014712-5u4e00q6	30	1	Ege	Ege	NNP
cord-014712-5u4e00q6	30	2	University	University	NNP
cord-014712-5u4e00q6	30	3	Faculty	Faculty	NNP
cord-014712-5u4e00q6	30	4	of	of	IN
cord-014712-5u4e00q6	30	5	Medicine	Medicine	NNP
cord-014712-5u4e00q6	30	6	,	,	,
cord-014712-5u4e00q6	30	7	Dept	Dept	NNP
cord-014712-5u4e00q6	30	8	of	of	IN
cord-014712-5u4e00q6	30	9	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	30	10	Immunology	Immunology	NNP
cord-014712-5u4e00q6	30	11	,	,	,
cord-014712-5u4e00q6	30	12	Izmir	Izmir	NNP
cord-014712-5u4e00q6	30	13	,	,	,
cord-014712-5u4e00q6	30	14	Turkey	Turkey	NNP
cord-014712-5u4e00q6	30	15	Ig	Ig	NNP
cord-014712-5u4e00q6	30	16	class	class	NN
cord-014712-5u4e00q6	30	17	switch	switch	NN
cord-014712-5u4e00q6	30	18	recombination	recombination	NN
cord-014712-5u4e00q6	30	19	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	30	20	are	be	VBP
cord-014712-5u4e00q6	30	21	rare	rare	JJ
cord-014712-5u4e00q6	30	22	PIDs	pid	NNS
cord-014712-5u4e00q6	30	23	(	(	-LRB-
cord-014712-5u4e00q6	30	24	1:500,000	1:500,000	CD
cord-014712-5u4e00q6	30	25	births	birth	NNS
cord-014712-5u4e00q6	30	26	)	)	-RRB-
cord-014712-5u4e00q6	30	27	with	with	IN
cord-014712-5u4e00q6	30	28	normal	normal	JJ
cord-014712-5u4e00q6	30	29	or	or	CC
cord-014712-5u4e00q6	30	30	elevated	elevated	JJ
cord-014712-5u4e00q6	30	31	serum	serum	NN
cord-014712-5u4e00q6	30	32	IgM	igm	NN
cord-014712-5u4e00q6	30	33	and	and	CC
cord-014712-5u4e00q6	30	34	low	low	NNP
cord-014712-5u4e00q6	30	35	IgG	IgG	NNP
cord-014712-5u4e00q6	30	36	,	,	,
cord-014712-5u4e00q6	30	37	IgA	IgA	NNP
cord-014712-5u4e00q6	30	38	and	and	CC
cord-014712-5u4e00q6	30	39	IgE	IgE	NNP
cord-014712-5u4e00q6	30	40	levels	level	NNS
cord-014712-5u4e00q6	30	41	,	,	,
cord-014712-5u4e00q6	30	42	defective	defective	JJ
cord-014712-5u4e00q6	30	43	or	or	CC
cord-014712-5u4e00q6	30	44	normal	normal	JJ
cord-014712-5u4e00q6	30	45	somatic	somatic	JJ
cord-014712-5u4e00q6	30	46	hypermutation	hypermutation	NN
cord-014712-5u4e00q6	30	47	,	,	,
cord-014712-5u4e00q6	30	48	defective	defective	JJ
cord-014712-5u4e00q6	30	49	T	T	NNP
cord-014712-5u4e00q6	30	50	/	/	SYM
cord-014712-5u4e00q6	30	51	B	b	NN
cord-014712-5u4e00q6	30	52	cooperation	cooperation	NN
cord-014712-5u4e00q6	30	53	(	(	-LRB-
cord-014712-5u4e00q6	30	54	50	50	CD
cord-014712-5u4e00q6	30	55	%	%	NN
cord-014712-5u4e00q6	30	56	)	)	-RRB-
cord-014712-5u4e00q6	30	57	,	,	,
cord-014712-5u4e00q6	30	58	intrinsic	intrinsic	JJ
cord-014712-5u4e00q6	30	59	B	B	NNP
cord-014712-5u4e00q6	30	60	cell	cell	NN
cord-014712-5u4e00q6	30	61	defect	defect	NN
cord-014712-5u4e00q6	30	62	(	(	-LRB-
cord-014712-5u4e00q6	30	63	50	50	CD
cord-014712-5u4e00q6	30	64	%	%	NN
cord-014712-5u4e00q6	30	65	)	)	-RRB-
cord-014712-5u4e00q6	30	66	,	,	,
cord-014712-5u4e00q6	30	67	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	30	68	to	to	IN
cord-014712-5u4e00q6	30	69	bacterial	bacterial	JJ
cord-014712-5u4e00q6	30	70	infections	infection	NNS
cord-014712-5u4e00q6	30	71	begining	begin	VBG
cord-014712-5u4e00q6	30	72	from	from	IN
cord-014712-5u4e00q6	30	73	the	the	DT
cord-014712-5u4e00q6	30	74	first	first	JJ
cord-014712-5u4e00q6	30	75	year	year	NN
cord-014712-5u4e00q6	30	76	of	of	IN
cord-014712-5u4e00q6	30	77	age	age	NN
cord-014712-5u4e00q6	30	78	(	(	-LRB-
cord-014712-5u4e00q6	30	79	impaired	impair	VBN
cord-014712-5u4e00q6	30	80	B	b	NN
cord-014712-5u4e00q6	30	81	cell	cell	NN
cord-014712-5u4e00q6	30	82	immunity	immunity	NN
cord-014712-5u4e00q6	30	83	)	)	-RRB-
cord-014712-5u4e00q6	30	84	and	and	CC
cord-014712-5u4e00q6	30	85	lack	lack	NN
cord-014712-5u4e00q6	30	86	of	of	IN
cord-014712-5u4e00q6	30	87	germinal	germinal	JJ
cord-014712-5u4e00q6	30	88	centres	centre	NNS
cord-014712-5u4e00q6	30	89	in	in	IN
cord-014712-5u4e00q6	30	90	secondary	secondary	JJ
cord-014712-5u4e00q6	30	91	lymphoid	lymphoid	JJ
cord-014712-5u4e00q6	30	92	organs	organ	NNS
cord-014712-5u4e00q6	30	93	.	.	.
cord-014712-5u4e00q6	31	1	We	-PRON-	PRP
cord-014712-5u4e00q6	31	2	present	present	VBP
cord-014712-5u4e00q6	31	3	a	a	DT
cord-014712-5u4e00q6	31	4	CD40L	cd40l	NN
cord-014712-5u4e00q6	31	5	defective	defective	JJ
cord-014712-5u4e00q6	31	6	case	case	NN
cord-014712-5u4e00q6	31	7	with	with	IN
cord-014712-5u4e00q6	31	8	clinical	clinical	JJ
cord-014712-5u4e00q6	31	9	findings	finding	NNS
cord-014712-5u4e00q6	31	10	such	such	JJ
cord-014712-5u4e00q6	31	11	as	as	IN
cord-014712-5u4e00q6	31	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	31	13	otitis	otitis	NN
cord-014712-5u4e00q6	31	14	media	medium	NNS
cord-014712-5u4e00q6	31	15	,	,	,
cord-014712-5u4e00q6	31	16	recurrent	recurrent	JJ
cord-014712-5u4e00q6	31	17	upper	upper	JJ
cord-014712-5u4e00q6	31	18	and	and	CC
cord-014712-5u4e00q6	31	19	lower	low	JJR
cord-014712-5u4e00q6	31	20	respiratory	respiratory	JJ
cord-014712-5u4e00q6	31	21	tract	tract	NN
cord-014712-5u4e00q6	31	22	infections	infection	NNS
cord-014712-5u4e00q6	31	23	,	,	,
cord-014712-5u4e00q6	31	24	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	31	25	,	,	,
cord-014712-5u4e00q6	31	26	arthritis	arthritis	NN
cord-014712-5u4e00q6	31	27	,	,	,
cord-014712-5u4e00q6	31	28	relapsing	relapse	VBG
cord-014712-5u4e00q6	31	29	polychondritis	polychondritis	NN
cord-014712-5u4e00q6	31	30	,	,	,
cord-014712-5u4e00q6	31	31	EBV	EBV	NNP
cord-014712-5u4e00q6	31	32	-	-	HYPH
cord-014712-5u4e00q6	31	33	associated	associate	VBN
cord-014712-5u4e00q6	31	34	cervical	cervical	JJ
cord-014712-5u4e00q6	31	35	lymphoproliferation	lymphoproliferation	NN
cord-014712-5u4e00q6	31	36	,	,	,
cord-014712-5u4e00q6	31	37	CMV	CMV	NNP
cord-014712-5u4e00q6	31	38	infection	infection	NN
cord-014712-5u4e00q6	31	39	,	,	,
cord-014712-5u4e00q6	31	40	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	31	41	,	,	,
cord-014712-5u4e00q6	31	42	liver	liver	NN
cord-014712-5u4e00q6	31	43	and	and	CC
cord-014712-5u4e00q6	31	44	spleen	spleen	NN
cord-014712-5u4e00q6	31	45	enlargement	enlargement	NN
cord-014712-5u4e00q6	31	46	,	,	,
cord-014712-5u4e00q6	31	47	multiple	multiple	JJ
cord-014712-5u4e00q6	31	48	nodules	nodule	NNS
cord-014712-5u4e00q6	31	49	in	in	IN
cord-014712-5u4e00q6	31	50	the	the	DT
cord-014712-5u4e00q6	31	51	liver	liver	NN
cord-014712-5u4e00q6	31	52	,	,	,
cord-014712-5u4e00q6	31	53	chronic	chronic	JJ
cord-014712-5u4e00q6	31	54	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	31	55	due	due	IN
cord-014712-5u4e00q6	31	56	to	to	IN
cord-014712-5u4e00q6	31	57	persistent	persistent	JJ
cord-014712-5u4e00q6	31	58	Cryptosporidium	cryptosporidium	NN
cord-014712-5u4e00q6	31	59	parvum	parvum	NN
cord-014712-5u4e00q6	31	60	,	,	,
cord-014712-5u4e00q6	31	61	fungal	fungal	JJ
cord-014712-5u4e00q6	31	62	pneumoniae	pneumoniae	NN
cord-014712-5u4e00q6	31	63	,	,	,
cord-014712-5u4e00q6	31	64	osteoporosis	osteoporosis	NN
cord-014712-5u4e00q6	31	65	,	,	,
cord-014712-5u4e00q6	31	66	and	and	CC
cord-014712-5u4e00q6	31	67	schwannoma	schwannoma	NNP
cord-014712-5u4e00q6	31	68	.	.	.
cord-014712-5u4e00q6	32	1	This	this	DT
cord-014712-5u4e00q6	32	2	case	case	NN
cord-014712-5u4e00q6	32	3	is	be	VBZ
cord-014712-5u4e00q6	32	4	remarkable	remarkable	JJ
cord-014712-5u4e00q6	32	5	with	with	IN
cord-014712-5u4e00q6	32	6	low	low	JJ
cord-014712-5u4e00q6	32	7	IgM	IgM	NNP
cord-014712-5u4e00q6	32	8	levels	level	NNS
cord-014712-5u4e00q6	32	9	and	and	CC
cord-014712-5u4e00q6	32	10	normal	normal	JJ
cord-014712-5u4e00q6	32	11	CD40L	cd40l	NN
cord-014712-5u4e00q6	32	12	ezpression	ezpression	NN
cord-014712-5u4e00q6	32	13	on	on	IN
cord-014712-5u4e00q6	32	14	activated	activate	VBN
cord-014712-5u4e00q6	32	15	T	T	NNP
cord-014712-5u4e00q6	32	16	cells	cell	NNS
cord-014712-5u4e00q6	32	17	although	although	IN
cord-014712-5u4e00q6	32	18	he	-PRON-	PRP
cord-014712-5u4e00q6	32	19	had	have	VBD
cord-014712-5u4e00q6	32	20	a	a	DT
cord-014712-5u4e00q6	32	21	novel	novel	JJ
cord-014712-5u4e00q6	32	22	mutation	mutation	NN
cord-014712-5u4e00q6	32	23	in	in	IN
cord-014712-5u4e00q6	32	24	CD40L	cd40l	NN
cord-014712-5u4e00q6	32	25	gene	gene	NN
cord-014712-5u4e00q6	32	26	(	(	-LRB-
cord-014712-5u4e00q6	32	27	a	a	DT
cord-014712-5u4e00q6	32	28	novel	novel	JJ
cord-014712-5u4e00q6	32	29	missense	missense	NN
cord-014712-5u4e00q6	32	30	mutation	mutation	NN
cord-014712-5u4e00q6	32	31	in	in	IN
cord-014712-5u4e00q6	32	32	CD40LG	CD40LG	NNP
cord-014712-5u4e00q6	33	1	(	(	-LRB-
cord-014712-5u4e00q6	33	2	c.	c.	NNP
cord-014712-5u4e00q6	33	3	C139	C139	NNP
cord-014712-5u4e00q6	33	4	T	T	NNP
cord-014712-5u4e00q6	33	5	)	)	-RRB-
cord-014712-5u4e00q6	33	6	,	,	,
cord-014712-5u4e00q6	33	7	leading	lead	VBG
cord-014712-5u4e00q6	33	8	to	to	IN
cord-014712-5u4e00q6	33	9	an	an	DT
cord-014712-5u4e00q6	33	10	a.	a.	NN
cord-014712-5u4e00q6	33	11	a.	a.	NN
cord-014712-5u4e00q6	33	12	change	change	NN
cord-014712-5u4e00q6	33	13	from	from	IN
cord-014712-5u4e00q6	33	14	histidine	histidine	NN
cord-014712-5u4e00q6	33	15	to	to	IN
cord-014712-5u4e00q6	33	16	tyrosine	tyrosine	NN
cord-014712-5u4e00q6	33	17	at	at	IN
cord-014712-5u4e00q6	33	18	position	position	NN
cord-014712-5u4e00q6	33	19	47	47	CD
cord-014712-5u4e00q6	33	20	(	(	-LRB-
cord-014712-5u4e00q6	33	21	H47Y	H47Y	NNP
cord-014712-5u4e00q6	33	22	)	)	-RRB-
cord-014712-5u4e00q6	33	23	at	at	IN
cord-014712-5u4e00q6	33	24	the	the	DT
cord-014712-5u4e00q6	33	25	start	start	NN
cord-014712-5u4e00q6	33	26	of	of	IN
cord-014712-5u4e00q6	33	27	the	the	DT
cord-014712-5u4e00q6	33	28	extracellular	extracellular	JJ
cord-014712-5u4e00q6	33	29	domain	domain	NN
cord-014712-5u4e00q6	33	30	)	)	-RRB-
cord-014712-5u4e00q6	33	31	.	.	.
cord-014712-5u4e00q6	34	1	In	in	IN
cord-014712-5u4e00q6	34	2	addition	addition	NN
cord-014712-5u4e00q6	34	3	,	,	,
cord-014712-5u4e00q6	34	4	we	-PRON-	PRP
cord-014712-5u4e00q6	34	5	present	present	VBP
cord-014712-5u4e00q6	34	6	two	two	CD
cord-014712-5u4e00q6	34	7	cases	case	NNS
cord-014712-5u4e00q6	34	8	with	with	IN
cord-014712-5u4e00q6	34	9	CD40	CD40	NNP
cord-014712-5u4e00q6	34	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	34	11	with	with	IN
cord-014712-5u4e00q6	34	12	normal	normal	JJ
cord-014712-5u4e00q6	34	13	CD40	CD40	NNP
cord-014712-5u4e00q6	34	14	expression	expression	NN
cord-014712-5u4e00q6	34	15	on	on	IN
cord-014712-5u4e00q6	34	16	B	b	NN
cord-014712-5u4e00q6	34	17	cells	cell	NNS
cord-014712-5u4e00q6	34	18	.	.	.
cord-014712-5u4e00q6	35	1	Both	both	DT
cord-014712-5u4e00q6	35	2	of	of	IN
cord-014712-5u4e00q6	35	3	these	these	DT
cord-014712-5u4e00q6	35	4	cases	case	NNS
cord-014712-5u4e00q6	35	5	had	have	VBD
cord-014712-5u4e00q6	35	6	homozygous	homozygous	JJ
cord-014712-5u4e00q6	35	7	-	-	HYPH
cord-014712-5u4e00q6	35	8	CD40-mutation	CD40-mutation	NNP
cord-014712-5u4e00q6	35	9	leading	lead	VBG
cord-014712-5u4e00q6	35	10	to	to	IN
cord-014712-5u4e00q6	35	11	a	a	DT
cord-014712-5u4e00q6	35	12	longer	long	RBR
cord-014712-5u4e00q6	35	13	protein	protein	NN
cord-014712-5u4e00q6	35	14	due	due	IN
cord-014712-5u4e00q6	35	15	to	to	IN
cord-014712-5u4e00q6	35	16	deletion	deletion	NN
cord-014712-5u4e00q6	35	17	of	of	IN
cord-014712-5u4e00q6	35	18	stop	stop	NN
cord-014712-5u4e00q6	35	19	-	-	HYPH
cord-014712-5u4e00q6	35	20	codon	codon	NN
cord-014712-5u4e00q6	35	21	.	.	.
cord-014712-5u4e00q6	36	1	In	in	IN
cord-014712-5u4e00q6	36	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	36	3	;	;	:
cord-014712-5u4e00q6	36	4	CD40	CD40	NNP
cord-014712-5u4e00q6	36	5	molecules	molecule	NNS
cord-014712-5u4e00q6	36	6	although	although	IN
cord-014712-5u4e00q6	36	7	non	non	JJ
cord-014712-5u4e00q6	36	8	-	-	JJ
cord-014712-5u4e00q6	36	9	functional	functional	JJ
cord-014712-5u4e00q6	36	10	in	in	IN
cord-014712-5u4e00q6	36	11	B	b	NN
cord-014712-5u4e00q6	36	12	cells	cell	NNS
cord-014712-5u4e00q6	36	13	,	,	,
cord-014712-5u4e00q6	36	14	may	may	MD
cord-014712-5u4e00q6	36	15	be	be	VB
cord-014712-5u4e00q6	36	16	normally	normally	RB
cord-014712-5u4e00q6	36	17	expressed	express	VBN
cord-014712-5u4e00q6	36	18	on	on	IN
cord-014712-5u4e00q6	36	19	cell	cell	NN
cord-014712-5u4e00q6	36	20	surface	surface	NN
cord-014712-5u4e00q6	36	21	.	.	.
cord-014712-5u4e00q6	37	1	These	these	DT
cord-014712-5u4e00q6	37	2	CD40	CD40	NNP
cord-014712-5u4e00q6	37	3	molecules	molecule	NNS
cord-014712-5u4e00q6	37	4	are	be	VBP
cord-014712-5u4e00q6	37	5	unable	unable	JJ
cord-014712-5u4e00q6	37	6	to	to	TO
cord-014712-5u4e00q6	37	7	trigger	trigger	VB
cord-014712-5u4e00q6	37	8	signal	signal	NN
cord-014712-5u4e00q6	37	9	,	,	,
cord-014712-5u4e00q6	37	10	because	because	IN
cord-014712-5u4e00q6	37	11	CD40L	cd40l	NN
cord-014712-5u4e00q6	37	12	+	+	CC
cord-014712-5u4e00q6	37	13	IL4	il4	NN
cord-014712-5u4e00q6	37	14	activation	activation	NN
cord-014712-5u4e00q6	37	15	leads	lead	VBZ
cord-014712-5u4e00q6	37	16	to	to	TO
cord-014712-5u4e00q6	37	17	complete	complete	JJ
cord-014712-5u4e00q6	37	18	lack	lack	NN
cord-014712-5u4e00q6	37	19	of	of	IN
cord-014712-5u4e00q6	37	20	proliferation	proliferation	NN
cord-014712-5u4e00q6	37	21	.	.	.
cord-014712-5u4e00q6	38	1	Evaluation	Evaluation	NNP
cord-014712-5u4e00q6	38	2	of	of	IN
cord-014712-5u4e00q6	38	3	CD40	CD40	NNP
cord-014712-5u4e00q6	38	4	or	or	CC
cord-014712-5u4e00q6	38	5	CD40L	cd40l	NN
cord-014712-5u4e00q6	38	6	expression	expression	NN
cord-014712-5u4e00q6	38	7	by	by	IN
cord-014712-5u4e00q6	38	8	flow	flow	NN
cord-014712-5u4e00q6	38	9	cytometry	cytometry	NN
cord-014712-5u4e00q6	38	10	may	may	MD
cord-014712-5u4e00q6	38	11	lead	lead	VB
cord-014712-5u4e00q6	38	12	false	false	JJ
cord-014712-5u4e00q6	38	13	results	result	NNS
cord-014712-5u4e00q6	38	14	.	.	.
cord-014712-5u4e00q6	39	1	Study	study	NN
cord-014712-5u4e00q6	39	2	of	of	IN
cord-014712-5u4e00q6	39	3	CD40L	cd40l	NN
cord-014712-5u4e00q6	39	4	+	+	CC
cord-014712-5u4e00q6	39	5	cytokine	cytokine	NN
cord-014712-5u4e00q6	39	6	(	(	-LRB-
cord-014712-5u4e00q6	39	7	or	or	CC
cord-014712-5u4e00q6	40	1	CD40	CD40	NNP
cord-014712-5u4e00q6	40	2	+	+	CC
cord-014712-5u4e00q6	40	3	cytokine)induced	cytokine)induced	NNP
cord-014712-5u4e00q6	40	4	B	b	NN
cord-014712-5u4e00q6	40	5	cell	cell	NN
cord-014712-5u4e00q6	40	6	proliferation	proliferation	NN
cord-014712-5u4e00q6	40	7	appears	appear	VBZ
cord-014712-5u4e00q6	40	8	as	as	IN
cord-014712-5u4e00q6	40	9	a	a	DT
cord-014712-5u4e00q6	40	10	useful	useful	JJ
cord-014712-5u4e00q6	40	11	tool	tool	NN
cord-014712-5u4e00q6	40	12	for	for	IN
cord-014712-5u4e00q6	40	13	these	these	DT
cord-014712-5u4e00q6	40	14	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	40	15	.	.	.
cord-014712-5u4e00q6	41	1	Institute	Institute	NNP
cord-014712-5u4e00q6	41	2	for	for	IN
cord-014712-5u4e00q6	41	3	Immunology	Immunology	NNP
cord-014712-5u4e00q6	41	4	and	and	CC
cord-014712-5u4e00q6	41	5	physiology	physiology	NN
cord-014712-5u4e00q6	41	6	(	(	-LRB-
cord-014712-5u4e00q6	41	7	UB	UB	NNP
cord-014712-5u4e00q6	41	8	RAS	RAS	NNP
cord-014712-5u4e00q6	41	9	)	)	-RRB-
cord-014712-5u4e00q6	41	10	.	.	.
cord-014712-5u4e00q6	42	1	Yekaterinburg	Yekaterinburg	NNP
cord-014712-5u4e00q6	42	2	,	,	,
cord-014712-5u4e00q6	42	3	Russia	Russia	NNP
cord-014712-5u4e00q6	42	4	2	2	CD
cord-014712-5u4e00q6	42	5	Regional	regional	JJ
cord-014712-5u4e00q6	42	6	children	child	NNS
cord-014712-5u4e00q6	42	7	clinical	clinical	JJ
cord-014712-5u4e00q6	42	8	hospital	hospital	NN
cord-014712-5u4e00q6	42	9	№	№	NNP
cord-014712-5u4e00q6	42	10	1	1	CD
cord-014712-5u4e00q6	42	11	,	,	,
cord-014712-5u4e00q6	42	12	Yekaterinburg	Yekaterinburg	NNP
cord-014712-5u4e00q6	42	13	,	,	,
cord-014712-5u4e00q6	42	14	Russia	Russia	NNP
cord-014712-5u4e00q6	42	15	The	the	DT
cord-014712-5u4e00q6	42	16	Ural	Ural	NNP
cord-014712-5u4e00q6	42	17	Regional	Regional	NNP
cord-014712-5u4e00q6	42	18	center	center	NN
cord-014712-5u4e00q6	42	19	of	of	IN
cord-014712-5u4e00q6	42	20	clinical	clinical	JJ
cord-014712-5u4e00q6	42	21	immunology	immunology	NN
cord-014712-5u4e00q6	42	22	,	,	,
cord-014712-5u4e00q6	42	23	which	which	WDT
cord-014712-5u4e00q6	42	24	based	base	VBN
cord-014712-5u4e00q6	42	25	on	on	IN
cord-014712-5u4e00q6	42	26	Children	Children	NNP
cord-014712-5u4e00q6	42	27	clinical	clinical	JJ
cord-014712-5u4e00q6	42	28	hospital	hospital	NN
cord-014712-5u4e00q6	42	29	number	number	NN
cord-014712-5u4e00q6	42	30	one	one	CD
cord-014712-5u4e00q6	42	31	(	(	-LRB-
cord-014712-5u4e00q6	42	32	№	№	NNP
cord-014712-5u4e00q6	42	33	1	1	CD
cord-014712-5u4e00q6	42	34	)	)	-RRB-
cord-014712-5u4e00q6	42	35	in	in	IN
cord-014712-5u4e00q6	42	36	Yekaterinburg	Yekaterinburg	NNP
cord-014712-5u4e00q6	42	37	,	,	,
cord-014712-5u4e00q6	42	38	observe	observe	VBP
cord-014712-5u4e00q6	42	39	patients	patient	NNS
cord-014712-5u4e00q6	42	40	from	from	IN
cord-014712-5u4e00q6	42	41	different	different	JJ
cord-014712-5u4e00q6	42	42	territories	territory	NNS
cord-014712-5u4e00q6	42	43	of	of	IN
cord-014712-5u4e00q6	42	44	Ural	Ural	NNP
cord-014712-5u4e00q6	42	45	region	region	NN
cord-014712-5u4e00q6	42	46	and	and	CC
cord-014712-5u4e00q6	42	47	neighboring	neighboring	NN
cord-014712-5u4e00q6	42	48	areas	area	NNS
cord-014712-5u4e00q6	42	49	.	.	.
cord-014712-5u4e00q6	43	1	It	-PRON-	PRP
cord-014712-5u4e00q6	43	2	consists	consist	VBZ
cord-014712-5u4e00q6	43	3	of	of	IN
cord-014712-5u4e00q6	43	4	laboratory	laboratory	NN
cord-014712-5u4e00q6	43	5	department	department	NN
cord-014712-5u4e00q6	43	6	,	,	,
cord-014712-5u4e00q6	43	7	consultative	consultative	NNP
cord-014712-5u4e00q6	43	8	department	department	NN
cord-014712-5u4e00q6	43	9	,	,	,
cord-014712-5u4e00q6	43	10	vaccination	vaccination	NN
cord-014712-5u4e00q6	43	11	and	and	CC
cord-014712-5u4e00q6	43	12	treatment	treatment	NN
cord-014712-5u4e00q6	43	13	rooms	room	NNS
cord-014712-5u4e00q6	43	14	,	,	,
cord-014712-5u4e00q6	43	15	beds	bed	NNS
cord-014712-5u4e00q6	43	16	and	and	CC
cord-014712-5u4e00q6	43	17	boxes	box	NNS
cord-014712-5u4e00q6	43	18	in	in	IN
cord-014712-5u4e00q6	43	19	special	special	JJ
cord-014712-5u4e00q6	43	20	departments	department	NNS
cord-014712-5u4e00q6	43	21	in	in	IN
cord-014712-5u4e00q6	43	22	the	the	DT
cord-014712-5u4e00q6	43	23	Regional	regional	JJ
cord-014712-5u4e00q6	43	24	children	child	NNS
cord-014712-5u4e00q6	43	25	hospital	hospital	NN
cord-014712-5u4e00q6	43	26	.	.	.
cord-014712-5u4e00q6	44	1	The	the	DT
cord-014712-5u4e00q6	44	2	close	close	JJ
cord-014712-5u4e00q6	44	3	collaboration	collaboration	NN
cord-014712-5u4e00q6	44	4	with	with	IN
cord-014712-5u4e00q6	44	5	J	J	NNP
cord-014712-5u4e00q6	44	6	-	-	HYPH
cord-014712-5u4e00q6	44	7	Project	Project	NNP
cord-014712-5u4e00q6	44	8	started	start	VBD
cord-014712-5u4e00q6	44	9	in	in	IN
cord-014712-5u4e00q6	44	10	2009	2009	CD
cord-014712-5u4e00q6	44	11	.	.	.
cord-014712-5u4e00q6	45	1	This	this	DT
cord-014712-5u4e00q6	45	2	is	be	VBZ
cord-014712-5u4e00q6	45	3	an	an	DT
cord-014712-5u4e00q6	45	4	example	example	NN
cord-014712-5u4e00q6	45	5	of	of	IN
cord-014712-5u4e00q6	45	6	such	such	JJ
cord-014712-5u4e00q6	45	7	collaboration	collaboration	NN
cord-014712-5u4e00q6	45	8	.	.	.
cord-014712-5u4e00q6	46	1	In	in	IN
cord-014712-5u4e00q6	46	2	Patient	Patient	NNP
cord-014712-5u4e00q6	46	3	A.	A.	NNP
cord-014712-5u4e00q6	46	4	an	an	DT
cord-014712-5u4e00q6	46	5	international	international	JJ
cord-014712-5u4e00q6	46	6	consilium	consilium	NN
cord-014712-5u4e00q6	46	7	was	be	VBD
cord-014712-5u4e00q6	46	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	46	9	a	a	DT
cord-014712-5u4e00q6	46	10	progressive	progressive	JJ
cord-014712-5u4e00q6	46	11	neurodegenerative	neurodegenerative	JJ
cord-014712-5u4e00q6	46	12	disease	disease	NN
cord-014712-5u4e00q6	46	13	as	as	IN
cord-014712-5u4e00q6	46	14	a	a	DT
cord-014712-5u4e00q6	46	15	manifestation	manifestation	NN
cord-014712-5u4e00q6	46	16	of	of	IN
cord-014712-5u4e00q6	46	17	Primary	Primary	NNP
cord-014712-5u4e00q6	46	18	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	46	19	:	:	:
cord-014712-5u4e00q6	47	1	X	X	NNS
cord-014712-5u4e00q6	47	2	-	-	HYPH
cord-014712-5u4e00q6	47	3	linked	link	VBN
cord-014712-5u4e00q6	47	4	agammaglobulinemia	agammaglobulinemia	NN
cord-014712-5u4e00q6	47	5	with	with	IN
cord-014712-5u4e00q6	47	6	B	b	NN
cord-014712-5u4e00q6	47	7	-	-	HYPH
cord-014712-5u4e00q6	47	8	cell	cell	NN
cord-014712-5u4e00q6	47	9	deficiency	deficiency	NN
cord-014712-5u4e00q6	47	10	.	.	.
cord-014712-5u4e00q6	48	1	MRI	MRI	NNP
cord-014712-5u4e00q6	48	2	results	result	NNS
cord-014712-5u4e00q6	48	3	:	:	:
cord-014712-5u4e00q6	48	4	unspecified	unspecified	JJ
cord-014712-5u4e00q6	48	5	leukodystrophya	leukodystrophya	NN
cord-014712-5u4e00q6	48	6	rapidly	rapidly	RB
cord-014712-5u4e00q6	48	7	progressive	progressive	JJ
cord-014712-5u4e00q6	48	8	multifocal	multifocal	JJ
cord-014712-5u4e00q6	48	9	brain	brain	NN
cord-014712-5u4e00q6	48	10	lesions	lesion	NNS
cord-014712-5u4e00q6	48	11	with	with	IN
cord-014712-5u4e00q6	48	12	demyelinating	demyelinating	NN
cord-014712-5u4e00q6	48	13	,	,	,
cord-014712-5u4e00q6	48	14	generalized	generalized	JJ
cord-014712-5u4e00q6	48	15	cerebral	cerebral	JJ
cord-014712-5u4e00q6	48	16	atrophy	atrophy	NN
cord-014712-5u4e00q6	48	17	,	,	,
cord-014712-5u4e00q6	48	18	III	iii	CD
cord-014712-5u4e00q6	48	19	degree	degree	NN
cord-014712-5u4e00q6	48	20	,	,	,
cord-014712-5u4e00q6	48	21	signs	sign	NNS
cord-014712-5u4e00q6	48	22	of	of	IN
cord-014712-5u4e00q6	48	23	periventricular	periventricular	NNP
cord-014712-5u4e00q6	48	24	leukomalacia	leukomalacia	NNP
cord-014712-5u4e00q6	48	25	in	in	IN
cord-014712-5u4e00q6	48	26	the	the	DT
cord-014712-5u4e00q6	48	27	anterior	anterior	JJ
cord-014712-5u4e00q6	48	28	horns	horn	NNS
cord-014712-5u4e00q6	48	29	of	of	IN
cord-014712-5u4e00q6	48	30	the	the	DT
cord-014712-5u4e00q6	48	31	lateral	lateral	JJ
cord-014712-5u4e00q6	48	32	ventricles	ventricle	NNS
cord-014712-5u4e00q6	48	33	.	.	.
cord-014712-5u4e00q6	49	1	The	the	DT
cord-014712-5u4e00q6	49	2	brain	brain	NN
cord-014712-5u4e00q6	49	3	biopsy	biopsy	NN
cord-014712-5u4e00q6	49	4	was	be	VBD
cord-014712-5u4e00q6	49	5	recommended	recommend	VBN
cord-014712-5u4e00q6	49	6	in	in	IN
cord-014712-5u4e00q6	49	7	order	order	NN
cord-014712-5u4e00q6	49	8	to	to	TO
cord-014712-5u4e00q6	49	9	clarify	clarify	VB
cord-014712-5u4e00q6	49	10	the	the	DT
cord-014712-5u4e00q6	49	11	nature	nature	NN
cord-014712-5u4e00q6	49	12	of	of	IN
cord-014712-5u4e00q6	49	13	the	the	DT
cord-014712-5u4e00q6	49	14	defeat	defeat	NN
cord-014712-5u4e00q6	49	15	of	of	IN
cord-014712-5u4e00q6	49	16	the	the	DT
cord-014712-5u4e00q6	49	17	pathological	pathological	JJ
cord-014712-5u4e00q6	49	18	process	process	NN
cord-014712-5u4e00q6	49	19	and	and	CC
cord-014712-5u4e00q6	49	20	define	define	VB
cord-014712-5u4e00q6	49	21	the	the	DT
cord-014712-5u4e00q6	49	22	role	role	NN
cord-014712-5u4e00q6	49	23	of	of	IN
cord-014712-5u4e00q6	49	24	the	the	DT
cord-014712-5u4e00q6	49	25	immune	immune	JJ
cord-014712-5u4e00q6	49	26	mechanisms	mechanism	NNS
cord-014712-5u4e00q6	49	27	of	of	IN
cord-014712-5u4e00q6	49	28	its	-PRON-	PRP$
cord-014712-5u4e00q6	49	29	development	development	NN
cord-014712-5u4e00q6	49	30	(	(	-LRB-
cord-014712-5u4e00q6	49	31	held	hold	VBN
cord-014712-5u4e00q6	49	32	in	in	IN
cord-014712-5u4e00q6	49	33	the	the	DT
cord-014712-5u4e00q6	49	34	neurosurgical	neurosurgical	JJ
cord-014712-5u4e00q6	49	35	department	department	NN
cord-014712-5u4e00q6	49	36	with	with	IN
cord-014712-5u4e00q6	49	37	subsequent	subsequent	JJ
cord-014712-5u4e00q6	49	38	histological	histological	JJ
cord-014712-5u4e00q6	49	39	and	and	CC
cord-014712-5u4e00q6	49	40	immunohistochemical	immunohistochemical	JJ
cord-014712-5u4e00q6	49	41	studies	study	NNS
cord-014712-5u4e00q6	49	42	)	)	-RRB-
cord-014712-5u4e00q6	49	43	.	.	.
cord-014712-5u4e00q6	50	1	Histological	histological	JJ
cord-014712-5u4e00q6	50	2	and	and	CC
cord-014712-5u4e00q6	50	3	immunohistochemical	immunohistochemical	JJ
cord-014712-5u4e00q6	50	4	study	study	NN
cord-014712-5u4e00q6	50	5	of	of	IN
cord-014712-5u4e00q6	50	6	the	the	DT
cord-014712-5u4e00q6	50	7	brain	brain	NN
cord-014712-5u4e00q6	50	8	tissue	tissue	NN
cord-014712-5u4e00q6	50	9	of	of	IN
cord-014712-5u4e00q6	50	10	the	the	DT
cord-014712-5u4e00q6	50	11	right	right	JJ
cord-014712-5u4e00q6	50	12	frontal	frontal	JJ
cord-014712-5u4e00q6	50	13	lobe	lobe	NN
cord-014712-5u4e00q6	50	14	:	:	:
cord-014712-5u4e00q6	50	15	a	a	DT
cord-014712-5u4e00q6	50	16	signs	sign	NNS
cord-014712-5u4e00q6	50	17	of	of	IN
cord-014712-5u4e00q6	50	18	productive	productive	JJ
cord-014712-5u4e00q6	50	19	meningoencephalitis	meningoencephalitis	NN
cord-014712-5u4e00q6	50	20	in	in	IN
cord-014712-5u4e00q6	50	21	brain	brain	NN
cord-014712-5u4e00q6	50	22	tissue	tissue	NN
cord-014712-5u4e00q6	50	23	with	with	IN
cord-014712-5u4e00q6	50	24	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	50	25	,	,	,
cord-014712-5u4e00q6	50	26	perivascular	perivascular	NNP
cord-014712-5u4e00q6	50	27	and	and	CC
cord-014712-5u4e00q6	50	28	focally	focally	RB
cord-014712-5u4e00q6	50	29	moderate	moderate	JJ
cord-014712-5u4e00q6	50	30	diffuse	diffuse	JJ
cord-014712-5u4e00q6	50	31	infiltration	infiltration	NN
cord-014712-5u4e00q6	50	32	of	of	IN
cord-014712-5u4e00q6	50	33	mononuclear	mononuclear	JJ
cord-014712-5u4e00q6	50	34	(	(	-LRB-
cord-014712-5u4e00q6	50	35	accumulation	accumulation	NN
cord-014712-5u4e00q6	50	36	of	of	IN
cord-014712-5u4e00q6	50	37	mononuclear	mononuclear	FW
cord-014712-5u4e00q6	50	38	CD45RB+	CD45RB+	NNP
cord-014712-5u4e00q6	50	39	,	,	,
cord-014712-5u4e00q6	50	40	vimentin+	vimentin+	NNP
cord-014712-5u4e00q6	50	41	)	)	-RRB-
cord-014712-5u4e00q6	50	42	,	,	,
cord-014712-5u4e00q6	50	43	most	most	JJS
cord-014712-5u4e00q6	50	44	of	of	IN
cord-014712-5u4e00q6	50	45	which	which	WDT
cord-014712-5u4e00q6	50	46	are	be	VBP
cord-014712-5u4e00q6	50	47	CD8	CD8	NNS
cord-014712-5u4e00q6	50	48	+	+	CC
cord-014712-5u4e00q6	50	49	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	50	50	with	with	IN
cord-014712-5u4e00q6	50	51	granules	granule	NNS
cord-014712-5u4e00q6	50	52	of	of	IN
cord-014712-5u4e00q6	50	53	granzymeB.	granzymeb.	NN
cord-014712-5u4e00q6	50	54	Around	around	RB
cord-014712-5u4e00q6	50	55	-dystrophy	-dystrophy	:
cord-014712-5u4e00q6	50	56	and	and	CC
cord-014712-5u4e00q6	50	57	necrobiosis	necrobiosis	NN
cord-014712-5u4e00q6	50	58	neurons	neuron	NNS
cord-014712-5u4e00q6	50	59	,	,	,
cord-014712-5u4e00q6	50	60	intracellular	intracellular	JJ
cord-014712-5u4e00q6	50	61	edema	edema	NN
cord-014712-5u4e00q6	50	62	,	,	,
cord-014712-5u4e00q6	51	1	small	small	JJ
cord-014712-5u4e00q6	51	2	focuses	focus	NNS
cord-014712-5u4e00q6	51	3	of	of	IN
cord-014712-5u4e00q6	51	4	gliosis	gliosis	NNP
cord-014712-5u4e00q6	51	5	-there	-there	NN
cord-014712-5u4e00q6	51	6	are	be	VBP
cord-014712-5u4e00q6	51	7	isolated	isolate	VBN
cord-014712-5u4e00q6	51	8	myeloid	myeloid	NN
cord-014712-5u4e00q6	51	9	cells	cell	NNS
cord-014712-5u4e00q6	51	10	(	(	-LRB-
cord-014712-5u4e00q6	51	11	myeloperoxidase	myeloperoxidase	NN
cord-014712-5u4e00q6	51	12	+	+	CC
cord-014712-5u4e00q6	51	13	)	)	-RRB-
cord-014712-5u4e00q6	51	14	and	and	CC
cord-014712-5u4e00q6	51	15	plasma	plasma	NN
cord-014712-5u4e00q6	51	16	cells	cell	NNS
cord-014712-5u4e00q6	51	17	with	with	IN
cord-014712-5u4e00q6	51	18	cytoplasmic	cytoplasmic	JJ
cord-014712-5u4e00q6	51	19	expression	expression	NN
cord-014712-5u4e00q6	51	20	of	of	IN
cord-014712-5u4e00q6	51	21	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	51	22	light	light	NN
cord-014712-5u4e00q6	51	23	chains	chain	NNS
cord-014712-5u4e00q6	51	24	lambda	lambda	NN
cord-014712-5u4e00q6	51	25	and	and	CC
cord-014712-5u4e00q6	51	26	kappa	kappa	NN
cord-014712-5u4e00q6	51	27	;	;	:
cord-014712-5u4e00q6	51	28	cells	cell	NNS
cord-014712-5u4e00q6	51	29	and	and	CC
cord-014712-5u4e00q6	51	30	the	the	DT
cord-014712-5u4e00q6	51	31	extracellular	extracellular	JJ
cord-014712-5u4e00q6	51	32	matrix	matrix	NN
cord-014712-5u4e00q6	51	33	of	of	IN
cord-014712-5u4e00q6	51	34	brain	brain	NN
cord-014712-5u4e00q6	51	35	tissue	tissue	NN
cord-014712-5u4e00q6	51	36	expressing	express	VBG
cord-014712-5u4e00q6	51	37	CD56	CD56	NNP
cord-014712-5u4e00q6	51	38	antigen	antigen	NN
cord-014712-5u4e00q6	51	39	and	and	CC
cord-014712-5u4e00q6	51	40	S100	s100	NN
cord-014712-5u4e00q6	51	41	protein	protein	NN
cord-014712-5u4e00q6	51	42	.	.	.
cord-014712-5u4e00q6	52	1	Virological	virological	JJ
cord-014712-5u4e00q6	52	2	and	and	CC
cord-014712-5u4e00q6	52	3	bacteriological	bacteriological	JJ
cord-014712-5u4e00q6	52	4	studies	study	NNS
cord-014712-5u4e00q6	52	5	of	of	IN
cord-014712-5u4e00q6	52	6	brain	brain	NN
cord-014712-5u4e00q6	52	7	tissue	tissue	NN
cord-014712-5u4e00q6	52	8	and	and	CC
cord-014712-5u4e00q6	52	9	liquor	liquor	NN
cord-014712-5u4e00q6	52	10	:	:	:
cord-014712-5u4e00q6	52	11	connection	connection	NN
cord-014712-5u4e00q6	52	12	of	of	IN
cord-014712-5u4e00q6	52	13	progressive	progressive	JJ
cord-014712-5u4e00q6	52	14	degenerative	degenerative	JJ
cord-014712-5u4e00q6	52	15	changes	change	NNS
cord-014712-5u4e00q6	52	16	and	and	CC
cord-014712-5u4e00q6	52	17	infectious	infectious	JJ
cord-014712-5u4e00q6	52	18	process	process	NN
cord-014712-5u4e00q6	52	19	were	be	VBD
cord-014712-5u4e00q6	52	20	n't	not	RB
cord-014712-5u4e00q6	52	21	obtained	obtain	VBN
cord-014712-5u4e00q6	52	22	Verified	verify	VBN
cord-014712-5u4e00q6	52	23	acknowledgments	acknowledgment	NNS
cord-014712-5u4e00q6	52	24	of	of	IN
cord-014712-5u4e00q6	52	25	an	an	DT
cord-014712-5u4e00q6	52	26	infectious	infectious	JJ
cord-014712-5u4e00q6	52	27	or	or	CC
cord-014712-5u4e00q6	52	28	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	52	29	process	process	NN
cord-014712-5u4e00q6	52	30	has	have	VBZ
cord-014712-5u4e00q6	52	31	not	not	RB
cord-014712-5u4e00q6	52	32	been	be	VBN
cord-014712-5u4e00q6	52	33	received	receive	VBN
cord-014712-5u4e00q6	52	34	.	.	.
cord-014712-5u4e00q6	53	1	Search	search	NN
cord-014712-5u4e00q6	53	2	for	for	IN
cord-014712-5u4e00q6	53	3	a	a	DT
cord-014712-5u4e00q6	53	4	genesis	genesis	NN
cord-014712-5u4e00q6	53	5	of	of	IN
cord-014712-5u4e00q6	53	6	cytotoxic	cytotoxic	JJ
cord-014712-5u4e00q6	53	7	process	process	NN
cord-014712-5u4e00q6	53	8	in	in	IN
cord-014712-5u4e00q6	53	9	the	the	DT
cord-014712-5u4e00q6	53	10	brain	brain	NN
cord-014712-5u4e00q6	53	11	continues	continue	VBZ
cord-014712-5u4e00q6	53	12	.	.	.
cord-014712-5u4e00q6	54	1	Center	Center	NNP
cord-014712-5u4e00q6	54	2	for	for	IN
cord-014712-5u4e00q6	54	3	Chronic	Chronic	NNP
cord-014712-5u4e00q6	54	4	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	54	5	,	,	,
cord-014712-5u4e00q6	54	6	University	University	NNP
cord-014712-5u4e00q6	54	7	Medical	Medical	NNP
cord-014712-5u4e00q6	54	8	Center	Center	NNP
cord-014712-5u4e00q6	54	9	Freiburg	Freiburg	NNP
cord-014712-5u4e00q6	54	10	and	and	CC
cord-014712-5u4e00q6	54	11	University	University	NNP
cord-014712-5u4e00q6	54	12	of	of	IN
cord-014712-5u4e00q6	54	13	Freiburg	Freiburg	NNP
cord-014712-5u4e00q6	54	14	,	,	,
cord-014712-5u4e00q6	54	15	Germany	Germany	NNP
cord-014712-5u4e00q6	54	16	The	the	DT
cord-014712-5u4e00q6	54	17	essential	essential	JJ
cord-014712-5u4e00q6	54	18	role	role	NN
cord-014712-5u4e00q6	54	19	for	for	IN
cord-014712-5u4e00q6	54	20	IgG	IgG	NNP
cord-014712-5u4e00q6	54	21	replacement	replacement	NN
cord-014712-5u4e00q6	54	22	therapy	therapy	NN
cord-014712-5u4e00q6	54	23	(	(	-LRB-
cord-014712-5u4e00q6	54	24	IgGRT	IgGRT	NNP
cord-014712-5u4e00q6	54	25	)	)	-RRB-
cord-014712-5u4e00q6	54	26	for	for	IN
cord-014712-5u4e00q6	54	27	Common	common	JJ
cord-014712-5u4e00q6	54	28	variable	variable	JJ
cord-014712-5u4e00q6	54	29	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	54	30	(	(	-LRB-
cord-014712-5u4e00q6	54	31	CVID	CVID	NNP
cord-014712-5u4e00q6	54	32	)	)	-RRB-
cord-014712-5u4e00q6	54	33	has	have	VBZ
cord-014712-5u4e00q6	54	34	been	be	VBN
cord-014712-5u4e00q6	54	35	demonstrated	demonstrate	VBN
cord-014712-5u4e00q6	54	36	in	in	IN
cord-014712-5u4e00q6	54	37	many	many	JJ
cord-014712-5u4e00q6	54	38	studies	study	NNS
cord-014712-5u4e00q6	54	39	and	and	CC
cord-014712-5u4e00q6	54	40	metaanalyses	metaanalyse	NNS
cord-014712-5u4e00q6	54	41	.	.	.
cord-014712-5u4e00q6	55	1	While	while	IN
cord-014712-5u4e00q6	55	2	patients	patient	NNS
cord-014712-5u4e00q6	55	3	with	with	IN
cord-014712-5u4e00q6	55	4	"	"	``
cord-014712-5u4e00q6	55	5	infection	infection	NN
cord-014712-5u4e00q6	55	6	only	only	RB
cord-014712-5u4e00q6	55	7	"	"	''
cord-014712-5u4e00q6	55	8	reach	reach	VB
cord-014712-5u4e00q6	55	9	a	a	DT
cord-014712-5u4e00q6	55	10	nearly	nearly	RB
cord-014712-5u4e00q6	55	11	normal	normal	JJ
cord-014712-5u4e00q6	55	12	life	life	NN
cord-014712-5u4e00q6	55	13	expectancy	expectancy	NN
cord-014712-5u4e00q6	55	14	-though	-though	.
cord-014712-5u4e00q6	56	1	still	still	RB
cord-014712-5u4e00q6	56	2	not	not	RB
cord-014712-5u4e00q6	56	3	quality	quality	NN
cord-014712-5u4e00q6	57	1	-under	-under	:
cord-014712-5u4e00q6	57	2	IgGRT	iggrt	JJ
cord-014712-5u4e00q6	57	3	,	,	,
cord-014712-5u4e00q6	57	4	CVID	CVID	NNP
cord-014712-5u4e00q6	57	5	patients	patient	NNS
cord-014712-5u4e00q6	57	6	with	with	IN
cord-014712-5u4e00q6	57	7	additional	additional	JJ
cord-014712-5u4e00q6	57	8	manifestations	manifestation	NNS
cord-014712-5u4e00q6	57	9	like	like	IN
cord-014712-5u4e00q6	57	10	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	57	11	lung	lung	NN
cord-014712-5u4e00q6	57	12	,	,	,
cord-014712-5u4e00q6	57	13	bowel	bowel	NN
cord-014712-5u4e00q6	57	14	or	or	CC
cord-014712-5u4e00q6	57	15	liver	liver	NN
cord-014712-5u4e00q6	57	16	disease	disease	NN
cord-014712-5u4e00q6	57	17	,	,	,
cord-014712-5u4e00q6	57	18	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	57	19	and/or	and/or	CC
cord-014712-5u4e00q6	57	20	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	57	21	disease	disease	NN
cord-014712-5u4e00q6	57	22	often	often	RB
cord-014712-5u4e00q6	57	23	require	require	VBP
cord-014712-5u4e00q6	57	24	additional	additional	JJ
cord-014712-5u4e00q6	57	25	immunosuppressive	immunosuppressive	JJ
cord-014712-5u4e00q6	57	26	treatment	treatment	NN
cord-014712-5u4e00q6	57	27	.	.	.
cord-014712-5u4e00q6	58	1	There	there	EX
cord-014712-5u4e00q6	58	2	is	be	VBZ
cord-014712-5u4e00q6	58	3	little	little	JJ
cord-014712-5u4e00q6	58	4	consensus	consensus	NN
cord-014712-5u4e00q6	58	5	on	on	IN
cord-014712-5u4e00q6	58	6	the	the	DT
cord-014712-5u4e00q6	58	7	form	form	NN
cord-014712-5u4e00q6	58	8	of	of	IN
cord-014712-5u4e00q6	58	9	immunosuppressive	immunosuppressive	JJ
cord-014712-5u4e00q6	58	10	regimen	regimen	NN
cord-014712-5u4e00q6	58	11	,	,	,
cord-014712-5u4e00q6	58	12	once	once	IN
cord-014712-5u4e00q6	58	13	steroids	steroid	NNS
cord-014712-5u4e00q6	58	14	have	have	VBP
cord-014712-5u4e00q6	58	15	failed	fail	VBN
cord-014712-5u4e00q6	58	16	,	,	,
cord-014712-5u4e00q6	58	17	with	with	IN
cord-014712-5u4e00q6	58	18	possibly	possibly	RB
cord-014712-5u4e00q6	58	19	the	the	DT
cord-014712-5u4e00q6	58	20	one	one	CD
cord-014712-5u4e00q6	58	21	exception	exception	NN
cord-014712-5u4e00q6	58	22	of	of	IN
cord-014712-5u4e00q6	58	23	Rituximab	Rituximab	NNP
cord-014712-5u4e00q6	58	24	treatment	treatment	NN
cord-014712-5u4e00q6	58	25	for	for	IN
cord-014712-5u4e00q6	58	26	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	58	27	cytopenia	cytopenia	NNP
cord-014712-5u4e00q6	58	28	.	.	.
cord-014712-5u4e00q6	59	1	Additional	additional	JJ
cord-014712-5u4e00q6	59	2	studies	study	NNS
cord-014712-5u4e00q6	59	3	are	be	VBP
cord-014712-5u4e00q6	59	4	essential	essential	JJ
cord-014712-5u4e00q6	59	5	to	to	TO
cord-014712-5u4e00q6	59	6	guide	guide	VB
cord-014712-5u4e00q6	59	7	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	59	8	algorithms	algorithm	NNS
cord-014712-5u4e00q6	59	9	.	.	.
cord-014712-5u4e00q6	60	1	Some	some	DT
cord-014712-5u4e00q6	60	2	of	of	IN
cord-014712-5u4e00q6	60	3	these	these	DT
cord-014712-5u4e00q6	60	4	patients	patient	NNS
cord-014712-5u4e00q6	60	5	suffer	suffer	VBP
cord-014712-5u4e00q6	60	6	from	from	IN
cord-014712-5u4e00q6	60	7	late	late	JJ
cord-014712-5u4e00q6	60	8	onset	onset	NN
cord-014712-5u4e00q6	60	9	combined	combine	VBN
cord-014712-5u4e00q6	60	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	60	11	(	(	-LRB-
cord-014712-5u4e00q6	60	12	LOCID	LOCID	NNP
cord-014712-5u4e00q6	60	13	)	)	-RRB-
cord-014712-5u4e00q6	60	14	.	.	.
cord-014712-5u4e00q6	61	1	As	as	IN
cord-014712-5u4e00q6	61	2	in	in	IN
cord-014712-5u4e00q6	61	3	classic	classic	JJ
cord-014712-5u4e00q6	61	4	forms	form	NNS
cord-014712-5u4e00q6	61	5	of	of	IN
cord-014712-5u4e00q6	61	6	combined	combine	VBN
cord-014712-5u4e00q6	61	7	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	61	8	,	,	,
cord-014712-5u4e00q6	61	9	IgGRT	IgGRT	-LRB-
cord-014712-5u4e00q6	61	10	can	can	MD
cord-014712-5u4e00q6	61	11	be	be	VB
cord-014712-5u4e00q6	61	12	only	only	RB
cord-014712-5u4e00q6	61	13	a	a	DT
cord-014712-5u4e00q6	61	14	part	part	NN
cord-014712-5u4e00q6	61	15	of	of	IN
cord-014712-5u4e00q6	61	16	the	the	DT
cord-014712-5u4e00q6	61	17	treatment	treatment	NN
cord-014712-5u4e00q6	61	18	strategy	strategy	NN
cord-014712-5u4e00q6	61	19	,	,	,
cord-014712-5u4e00q6	61	20	which	which	WDT
cord-014712-5u4e00q6	61	21	needs	need	VBZ
cord-014712-5u4e00q6	61	22	to	to	TO
cord-014712-5u4e00q6	61	23	additionally	additionally	RB
cord-014712-5u4e00q6	61	24	address	address	VB
cord-014712-5u4e00q6	61	25	the	the	DT
cord-014712-5u4e00q6	61	26	cellular	cellular	JJ
cord-014712-5u4e00q6	61	27	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	61	28	of	of	IN
cord-014712-5u4e00q6	61	29	the	the	DT
cord-014712-5u4e00q6	61	30	patients	patient	NNS
cord-014712-5u4e00q6	61	31	.	.	.
cord-014712-5u4e00q6	62	1	Therefore	therefore	RB
cord-014712-5u4e00q6	62	2	a	a	DT
cord-014712-5u4e00q6	62	3	retrospective	retrospective	JJ
cord-014712-5u4e00q6	62	4	survey	survey	NN
cord-014712-5u4e00q6	62	5	was	be	VBD
cord-014712-5u4e00q6	62	6	performed	perform	VBN
cord-014712-5u4e00q6	62	7	on	on	IN
cord-014712-5u4e00q6	62	8	patients	patient	NNS
cord-014712-5u4e00q6	62	9	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	62	10	with	with	IN
cord-014712-5u4e00q6	62	11	CVID	CVID	NNP
cord-014712-5u4e00q6	62	12	who	who	WP
cord-014712-5u4e00q6	62	13	underwent	undergo	VBD
cord-014712-5u4e00q6	62	14	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	62	15	stem	stem	NN
cord-014712-5u4e00q6	62	16	cell	cell	NN
cord-014712-5u4e00q6	62	17	transplantation	transplantation	NN
cord-014712-5u4e00q6	62	18	.	.	.
cord-014712-5u4e00q6	63	1	The	the	DT
cord-014712-5u4e00q6	63	2	results	result	NNS
cord-014712-5u4e00q6	63	3	of	of	IN
cord-014712-5u4e00q6	63	4	this	this	DT
cord-014712-5u4e00q6	63	5	study	study	NN
cord-014712-5u4e00q6	63	6	are	be	VBP
cord-014712-5u4e00q6	63	7	currently	currently	RB
cord-014712-5u4e00q6	63	8	in	in	IN
cord-014712-5u4e00q6	63	9	revision	revision	NN
cord-014712-5u4e00q6	63	10	.	.	.
cord-014712-5u4e00q6	64	1	In	in	IN
cord-014712-5u4e00q6	64	2	summary	summary	NN
cord-014712-5u4e00q6	64	3	,	,	,
cord-014712-5u4e00q6	64	4	IgGRT	IgGRT	NNP
cord-014712-5u4e00q6	64	5	is	be	VBZ
cord-014712-5u4e00q6	64	6	the	the	DT
cord-014712-5u4e00q6	64	7	baseline	baseline	JJ
cord-014712-5u4e00q6	64	8	therapy	therapy	NN
cord-014712-5u4e00q6	64	9	for	for	IN
cord-014712-5u4e00q6	64	10	CVID	CVID	NNP
cord-014712-5u4e00q6	64	11	but	but	CC
cord-014712-5u4e00q6	64	12	does	do	VBZ
cord-014712-5u4e00q6	64	13	not	not	RB
cord-014712-5u4e00q6	64	14	address	address	VB
cord-014712-5u4e00q6	64	15	sufficiently	sufficiently	RB
cord-014712-5u4e00q6	64	16	the	the	DT
cord-014712-5u4e00q6	64	17	immune	immune	JJ
cord-014712-5u4e00q6	64	18	dysregulation	dysregulation	NN
cord-014712-5u4e00q6	64	19	in	in	IN
cord-014712-5u4e00q6	64	20	a	a	DT
cord-014712-5u4e00q6	64	21	subgroup	subgroup	NN
cord-014712-5u4e00q6	64	22	of	of	IN
cord-014712-5u4e00q6	64	23	patients	patient	NNS
cord-014712-5u4e00q6	64	24	.	.	.
cord-014712-5u4e00q6	65	1	Better	well	RBR
cord-014712-5u4e00q6	65	2	predictive	predictive	JJ
cord-014712-5u4e00q6	65	3	markers	marker	NNS
cord-014712-5u4e00q6	65	4	have	have	VBP
cord-014712-5u4e00q6	65	5	to	to	TO
cord-014712-5u4e00q6	65	6	be	be	VB
cord-014712-5u4e00q6	65	7	identified	identify	VBN
cord-014712-5u4e00q6	65	8	for	for	IN
cord-014712-5u4e00q6	65	9	the	the	DT
cord-014712-5u4e00q6	65	10	selection	selection	NN
cord-014712-5u4e00q6	65	11	of	of	IN
cord-014712-5u4e00q6	65	12	patients	patient	NNS
cord-014712-5u4e00q6	65	13	for	for	IN
cord-014712-5u4e00q6	65	14	additional	additional	JJ
cord-014712-5u4e00q6	65	15	,	,	,
cord-014712-5u4e00q6	65	16	potentially	potentially	RB
cord-014712-5u4e00q6	65	17	even	even	RB
cord-014712-5u4e00q6	65	18	definite	definite	JJ
cord-014712-5u4e00q6	65	19	forms	form	NNS
cord-014712-5u4e00q6	65	20	of	of	IN
cord-014712-5u4e00q6	65	21	treatment	treatment	NN
cord-014712-5u4e00q6	65	22	in	in	IN
cord-014712-5u4e00q6	65	23	order	order	NN
cord-014712-5u4e00q6	65	24	to	to	TO
cord-014712-5u4e00q6	65	25	prevent	prevent	VB
cord-014712-5u4e00q6	65	26	the	the	DT
cord-014712-5u4e00q6	65	27	morbidity	morbidity	NN
cord-014712-5u4e00q6	65	28	and	and	CC
cord-014712-5u4e00q6	65	29	mortality	mortality	NN
cord-014712-5u4e00q6	65	30	associated	associate	VBN
cord-014712-5u4e00q6	65	31	with	with	IN
cord-014712-5u4e00q6	65	32	these	these	DT
cord-014712-5u4e00q6	65	33	secondary	secondary	JJ
cord-014712-5u4e00q6	65	34	manifestations	manifestation	NNS
cord-014712-5u4e00q6	65	35	of	of	IN
cord-014712-5u4e00q6	65	36	CVID	CVID	NNP
cord-014712-5u4e00q6	65	37	.	.	.
cord-014712-5u4e00q6	65	38	 	 	_SP
cord-014712-5u4e00q6	66	1	The	the	DT
cord-014712-5u4e00q6	66	2	first	first	JJ
cord-014712-5u4e00q6	66	3	department	department	NN
cord-014712-5u4e00q6	66	4	of	of	IN
cord-014712-5u4e00q6	66	5	primary	primary	JJ
cord-014712-5u4e00q6	66	6	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	66	7	in	in	IN
cord-014712-5u4e00q6	66	8	Russia	Russia	NNP
cord-014712-5u4e00q6	66	9	was	be	VBD
cord-014712-5u4e00q6	66	10	established	establish	VBN
cord-014712-5u4e00q6	66	11	on	on	IN
cord-014712-5u4e00q6	66	12	the	the	DT
cord-014712-5u4e00q6	66	13	basis	basis	NN
cord-014712-5u4e00q6	66	14	of	of	IN
cord-014712-5u4e00q6	66	15	the	the	DT
cord-014712-5u4e00q6	66	16	Institute	Institute	NNP
cord-014712-5u4e00q6	66	17	of	of	IN
cord-014712-5u4e00q6	66	18	Immunology	Immunology	NNP
cord-014712-5u4e00q6	66	19	in	in	IN
cord-014712-5u4e00q6	66	20	1980	1980	CD
cord-014712-5u4e00q6	66	21	,	,	,
cord-014712-5u4e00q6	66	22	when	when	WRB
cord-014712-5u4e00q6	66	23	3	3	CD
cord-014712-5u4e00q6	66	24	patients	patient	NNS
cord-014712-5u4e00q6	66	25	with	with	IN
cord-014712-5u4e00q6	66	26	PID	PID	NNP
cord-014712-5u4e00q6	66	27	were	be	VBD
cord-014712-5u4e00q6	66	28	registered	register	VBN
cord-014712-5u4e00q6	66	29	.	.	.
cord-014712-5u4e00q6	67	1	Currently	currently	RB
cord-014712-5u4e00q6	67	2	,	,	,
cord-014712-5u4e00q6	67	3	327	327	CD
cord-014712-5u4e00q6	67	4	patients	patient	NNS
cord-014712-5u4e00q6	67	5	with	with	IN
cord-014712-5u4e00q6	67	6	PID	PID	NNP
cord-014712-5u4e00q6	67	7	are	be	VBP
cord-014712-5u4e00q6	67	8	followed	follow	VBN
cord-014712-5u4e00q6	67	9	in	in	IN
cord-014712-5u4e00q6	67	10	the	the	DT
cord-014712-5u4e00q6	67	11	Department	Department	NNP
cord-014712-5u4e00q6	67	12	of	of	IN
cord-014712-5u4e00q6	67	13	immunopathology	immunopathology	NN
cord-014712-5u4e00q6	67	14	in	in	IN
cord-014712-5u4e00q6	67	15	adults	adult	NNS
cord-014712-5u4e00q6	67	16	.	.	.
cord-014712-5u4e00q6	68	1	65	65	CD
cord-014712-5u4e00q6	68	2	%	%	NN
cord-014712-5u4e00q6	68	3	of	of	IN
cord-014712-5u4e00q6	68	4	PID	pid	NN
cord-014712-5u4e00q6	68	5	adult	adult	NN
cord-014712-5u4e00q6	68	6	patients	patient	NNS
cord-014712-5u4e00q6	68	7	have	have	VBP
cord-014712-5u4e00q6	68	8	PID	PID	NNP
cord-014712-5u4e00q6	68	9	with	with	IN
cord-014712-5u4e00q6	68	10	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	68	11	deficiency	deficiency	NN
cord-014712-5u4e00q6	68	12	.	.	.
cord-014712-5u4e00q6	69	1	Analysis	analysis	NN
cord-014712-5u4e00q6	69	2	of	of	IN
cord-014712-5u4e00q6	69	3	this	this	DT
cord-014712-5u4e00q6	69	4	group	group	NN
cord-014712-5u4e00q6	69	5	of	of	IN
cord-014712-5u4e00q6	69	6	adult	adult	NN
cord-014712-5u4e00q6	69	7	patients	patient	NNS
cord-014712-5u4e00q6	69	8	showed	show	VBD
cord-014712-5u4e00q6	69	9	that	that	IN
cord-014712-5u4e00q6	69	10	the	the	DT
cord-014712-5u4e00q6	69	11	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	69	12	of	of	IN
cord-014712-5u4e00q6	69	13	PID	PID	NNP
cord-014712-5u4e00q6	69	14	,	,	,
cord-014712-5u4e00q6	69	15	on	on	IN
cord-014712-5u4e00q6	69	16	average	average	JJ
cord-014712-5u4e00q6	69	17	has	have	VBZ
cord-014712-5u4e00q6	69	18	a	a	DT
cord-014712-5u4e00q6	69	19	delay	delay	NN
cord-014712-5u4e00q6	69	20	of	of	IN
cord-014712-5u4e00q6	69	21	10	10	CD
cord-014712-5u4e00q6	69	22	-	-	SYM
cord-014712-5u4e00q6	69	23	15	15	CD
cord-014712-5u4e00q6	69	24	years	year	NNS
cord-014712-5u4e00q6	69	25	from	from	IN
cord-014712-5u4e00q6	69	26	the	the	DT
cord-014712-5u4e00q6	69	27	first	first	JJ
cord-014712-5u4e00q6	69	28	symptoms	symptom	NNS
cord-014712-5u4e00q6	69	29	.	.	.
cord-014712-5u4e00q6	70	1	In	in	IN
cord-014712-5u4e00q6	70	2	88	88	CD
cord-014712-5u4e00q6	70	3	%	%	NN
cord-014712-5u4e00q6	70	4	of	of	IN
cord-014712-5u4e00q6	70	5	cases	case	NNS
cord-014712-5u4e00q6	70	6	,	,	,
cord-014712-5u4e00q6	70	7	there	there	EX
cord-014712-5u4e00q6	70	8	is	be	VBZ
cord-014712-5u4e00q6	70	9	an	an	DT
cord-014712-5u4e00q6	70	10	infectious	infectious	JJ
cord-014712-5u4e00q6	70	11	clinical	clinical	JJ
cord-014712-5u4e00q6	70	12	phenotype	phenotype	NN
cord-014712-5u4e00q6	70	13	,	,	,
cord-014712-5u4e00q6	70	14	32	32	CD
cord-014712-5u4e00q6	70	15	%	%	NN
cord-014712-5u4e00q6	70	16	-combined	-combined	CD
cord-014712-5u4e00q6	70	17	infectiouslymphoproliferative	infectiouslymphoproliferative	JJ
cord-014712-5u4e00q6	70	18	phenotype	phenotype	NN
cord-014712-5u4e00q6	70	19	,	,	,
cord-014712-5u4e00q6	70	20	27	27	CD
cord-014712-5u4e00q6	70	21	%	%	NN
cord-014712-5u4e00q6	70	22	-infectious	-infectious	JJ
cord-014712-5u4e00q6	70	23	and	and	CC
cord-014712-5u4e00q6	70	24	enteropathy	enteropathy	NNP
cord-014712-5u4e00q6	70	25	.	.	.
cord-014712-5u4e00q6	71	1	The	the	DT
cord-014712-5u4e00q6	71	2	study	study	NN
cord-014712-5u4e00q6	71	3	of	of	IN
cord-014712-5u4e00q6	71	4	immunophenotyping	immunophenotyping	NN
cord-014712-5u4e00q6	71	5	of	of	IN
cord-014712-5u4e00q6	71	6	B	b	NN
cord-014712-5u4e00q6	71	7	-	-	HYPH
cord-014712-5u4e00q6	71	8	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	71	9	for	for	IN
cord-014712-5u4e00q6	71	10	the	the	DT
cord-014712-5u4e00q6	71	11	degree	degree	NN
cord-014712-5u4e00q6	71	12	of	of	IN
cord-014712-5u4e00q6	71	13	maturation	maturation	NN
cord-014712-5u4e00q6	71	14	in	in	IN
cord-014712-5u4e00q6	71	15	this	this	DT
cord-014712-5u4e00q6	71	16	group	group	NN
cord-014712-5u4e00q6	71	17	of	of	IN
cord-014712-5u4e00q6	71	18	patients	patient	NNS
cord-014712-5u4e00q6	71	19	was	be	VBD
cord-014712-5u4e00q6	71	20	begun	begin	VBN
cord-014712-5u4e00q6	71	21	.	.	.
cord-014712-5u4e00q6	72	1	13	13	CD
cord-014712-5u4e00q6	72	2	patients	patient	NNS
cord-014712-5u4e00q6	72	3	are	be	VBP
cord-014712-5u4e00q6	72	4	currently	currently	RB
cord-014712-5u4e00q6	72	5	included	include	VBN
cord-014712-5u4e00q6	72	6	in	in	IN
cord-014712-5u4e00q6	72	7	this	this	DT
cord-014712-5u4e00q6	72	8	study	study	NN
cord-014712-5u4e00q6	72	9	.	.	.
cord-014712-5u4e00q6	73	1	2	2	CD
cord-014712-5u4e00q6	73	2	patients	patient	NNS
cord-014712-5u4e00q6	73	3	showed	show	VBD
cord-014712-5u4e00q6	73	4	complete	complete	JJ
cord-014712-5u4e00q6	73	5	absence	absence	NN
cord-014712-5u4e00q6	73	6	of	of	IN
cord-014712-5u4e00q6	73	7	B	b	NN
cord-014712-5u4e00q6	73	8	-	-	HYPH
cord-014712-5u4e00q6	73	9	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	73	10	,	,	,
cord-014712-5u4e00q6	73	11	11	11	CD
cord-014712-5u4e00q6	73	12	-the	-the	DT
cord-014712-5u4e00q6	73	13	reduction	reduction	NN
cord-014712-5u4e00q6	73	14	of	of	IN
cord-014712-5u4e00q6	73	15	B	b	NN
cord-014712-5u4e00q6	73	16	-	-	HYPH
cord-014712-5u4e00q6	73	17	cells	cell	NNS
cord-014712-5u4e00q6	73	18	,	,	,
cord-014712-5u4e00q6	73	19	2	2	CD
cord-014712-5u4e00q6	73	20	patients	patient	NNS
cord-014712-5u4e00q6	73	21	of	of	IN
cord-014712-5u4e00q6	73	22	those	those	DT
cord-014712-5u4e00q6	73	23	have	have	VBP
cord-014712-5u4e00q6	73	24	a	a	DT
cord-014712-5u4e00q6	73	25	normal	normal	JJ
cord-014712-5u4e00q6	73	26	amount	amount	NN
cord-014712-5u4e00q6	73	27	switched	switch	VBN
cord-014712-5u4e00q6	73	28	memory	memory	NN
cord-014712-5u4e00q6	73	29	B	b	NN
cord-014712-5u4e00q6	73	30	cells	cell	NNS
cord-014712-5u4e00q6	73	31	(	(	-LRB-
cord-014712-5u4e00q6	73	32	MBC	MBC	NNP
cord-014712-5u4e00q6	73	33	)	)	-RRB-
cord-014712-5u4e00q6	73	34	,	,	,
cord-014712-5u4e00q6	73	35	9	9	CD
cord-014712-5u4e00q6	73	36	people	people	NNS
cord-014712-5u4e00q6	73	37	-a	-a	IN
cord-014712-5u4e00q6	73	38	decrease	decrease	NN
cord-014712-5u4e00q6	73	39	amount	amount	NN
cord-014712-5u4e00q6	73	40	of	of	IN
cord-014712-5u4e00q6	73	41	switched	switch	VBN
cord-014712-5u4e00q6	73	42	MBC	MBC	NNP
cord-014712-5u4e00q6	73	43	.	.	.
cord-014712-5u4e00q6	74	1	8	8	CD
cord-014712-5u4e00q6	74	2	persons	person	NNS
cord-014712-5u4e00q6	74	3	of	of	IN
cord-014712-5u4e00q6	74	4	the	the	DT
cord-014712-5u4e00q6	74	5	group	group	NN
cord-014712-5u4e00q6	74	6	with	with	IN
cord-014712-5u4e00q6	74	7	decreased	decrease	VBN
cord-014712-5u4e00q6	74	8	amount	amount	NN
cord-014712-5u4e00q6	74	9	of	of	IN
cord-014712-5u4e00q6	74	10	switched	switch	VBN
cord-014712-5u4e00q6	74	11	MBC	MBC	NNP
cord-014712-5u4e00q6	74	12	had	have	VBD
cord-014712-5u4e00q6	74	13	an	an	DT
cord-014712-5u4e00q6	74	14	expansion	expansion	NN
cord-014712-5u4e00q6	74	15	of	of	IN
cord-014712-5u4e00q6	74	16	transitional	transitional	JJ
cord-014712-5u4e00q6	74	17	MBC	MBC	NNP
cord-014712-5u4e00q6	74	18	.	.	.
cord-014712-5u4e00q6	75	1	At	at	IN
cord-014712-5u4e00q6	75	2	present	present	NN
cord-014712-5u4e00q6	75	3	,	,	,
cord-014712-5u4e00q6	75	4	a	a	DT
cord-014712-5u4e00q6	75	5	clear	clear	JJ
cord-014712-5u4e00q6	75	6	link	link	NN
cord-014712-5u4e00q6	75	7	of	of	IN
cord-014712-5u4e00q6	75	8	immunophenotypes	immunophenotype	NNS
cord-014712-5u4e00q6	75	9	with	with	IN
cord-014712-5u4e00q6	75	10	specific	specific	JJ
cord-014712-5u4e00q6	75	11	clinical	clinical	JJ
cord-014712-5u4e00q6	75	12	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	75	13	in	in	IN
cord-014712-5u4e00q6	75	14	not	not	RB
cord-014712-5u4e00q6	75	15	found	find	VBN
cord-014712-5u4e00q6	75	16	,	,	,
cord-014712-5u4e00q6	75	17	but	but	CC
cord-014712-5u4e00q6	75	18	this	this	DT
cord-014712-5u4e00q6	75	19	may	may	MD
cord-014712-5u4e00q6	75	20	be	be	VB
cord-014712-5u4e00q6	75	21	due	due	JJ
cord-014712-5u4e00q6	75	22	to	to	IN
cord-014712-5u4e00q6	75	23	small	small	JJ
cord-014712-5u4e00q6	75	24	sample	sample	NN
cord-014712-5u4e00q6	75	25	of	of	IN
cord-014712-5u4e00q6	75	26	patients	patient	NNS
cord-014712-5u4e00q6	75	27	at	at	IN
cord-014712-5u4e00q6	75	28	the	the	DT
cord-014712-5u4e00q6	75	29	moment	moment	NN
cord-014712-5u4e00q6	75	30	,	,	,
cord-014712-5u4e00q6	75	31	the	the	DT
cord-014712-5u4e00q6	75	32	investigation	investigation	NN
cord-014712-5u4e00q6	75	33	continues	continue	VBZ
cord-014712-5u4e00q6	75	34	.	.	.
cord-014712-5u4e00q6	76	1	For	for	IN
cord-014712-5u4e00q6	76	2	the	the	DT
cord-014712-5u4e00q6	76	3	treatment	treatment	NN
cord-014712-5u4e00q6	76	4	of	of	IN
cord-014712-5u4e00q6	76	5	this	this	DT
cord-014712-5u4e00q6	76	6	category	category	NN
cord-014712-5u4e00q6	76	7	of	of	IN
cord-014712-5u4e00q6	76	8	patients	patient	NNS
cord-014712-5u4e00q6	76	9	only	only	RB
cord-014712-5u4e00q6	76	10	intravenous	intravenous	JJ
cord-014712-5u4e00q6	76	11	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	76	12	are	be	VBP
cord-014712-5u4e00q6	76	13	available	available	JJ
cord-014712-5u4e00q6	76	14	in	in	IN
cord-014712-5u4e00q6	76	15	Russia	Russia	NNP
cord-014712-5u4e00q6	76	16	.	.	.
cord-014712-5u4e00q6	77	1	We	-PRON-	PRP
cord-014712-5u4e00q6	77	2	use	use	VBP
cord-014712-5u4e00q6	77	3	drugs	drug	NNS
cord-014712-5u4e00q6	77	4	in	in	IN
cord-014712-5u4e00q6	77	5	various	various	JJ
cord-014712-5u4e00q6	77	6	concentration	concentration	NN
cord-014712-5u4e00q6	77	7	of	of	IN
cord-014712-5u4e00q6	77	8	Russian	russian	JJ
cord-014712-5u4e00q6	77	9	and	and	CC
cord-014712-5u4e00q6	77	10	foreign	foreign	JJ
cord-014712-5u4e00q6	77	11	production	production	NN
cord-014712-5u4e00q6	77	12	.	.	.
cord-014712-5u4e00q6	78	1	The	the	DT
cord-014712-5u4e00q6	78	2	availability	availability	NN
cord-014712-5u4e00q6	78	3	of	of	IN
cord-014712-5u4e00q6	78	4	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	78	5	for	for	IN
cord-014712-5u4e00q6	78	6	the	the	DT
cord-014712-5u4e00q6	78	7	adult	adult	NN
cord-014712-5u4e00q6	78	8	patients	patient	NNS
cord-014712-5u4e00q6	78	9	unfortunately	unfortunately	RB
cord-014712-5u4e00q6	78	10	is	be	VBZ
cord-014712-5u4e00q6	78	11	not	not	RB
cord-014712-5u4e00q6	78	12	sufficient	sufficient	JJ
cord-014712-5u4e00q6	78	13	in	in	IN
cord-014712-5u4e00q6	78	14	Russia	Russia	NNP
cord-014712-5u4e00q6	78	15	,	,	,
cord-014712-5u4e00q6	78	16	so	so	RB
cord-014712-5u4e00q6	78	17	the	the	DT
cord-014712-5u4e00q6	78	18	recommended	recommend	VBN
cord-014712-5u4e00q6	78	19	pretransfusion	pretransfusion	NN
cord-014712-5u4e00q6	78	20	level	level	NN
cord-014712-5u4e00q6	78	21	of	of	IN
cord-014712-5u4e00q6	78	22	IgG	igg	NN
cord-014712-5u4e00q6	78	23	is	be	VBZ
cord-014712-5u4e00q6	78	24	not	not	RB
cord-014712-5u4e00q6	78	25	achieved	achieve	VBN
cord-014712-5u4e00q6	78	26	in	in	IN
cord-014712-5u4e00q6	78	27	about	about	RB
cord-014712-5u4e00q6	78	28	70	70	CD
cord-014712-5u4e00q6	78	29	%	%	NN
cord-014712-5u4e00q6	78	30	of	of	IN
cord-014712-5u4e00q6	78	31	patients	patient	NNS
cord-014712-5u4e00q6	78	32	.	.	.
cord-014712-5u4e00q6	79	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	79	2	work	work	NN
cord-014712-5u4e00q6	79	3	presents	present	VBZ
cord-014712-5u4e00q6	79	4	the	the	DT
cord-014712-5u4e00q6	79	5	experiences	experience	NNS
cord-014712-5u4e00q6	79	6	of	of	IN
cord-014712-5u4e00q6	79	7	our	-PRON-	PRP$
cord-014712-5u4e00q6	79	8	center	center	NN
cord-014712-5u4e00q6	79	9	with	with	IN
cord-014712-5u4e00q6	79	10	the	the	DT
cord-014712-5u4e00q6	79	11	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	79	12	form	form	NN
cord-014712-5u4e00q6	79	13	of	of	IN
cord-014712-5u4e00q6	79	14	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	79	15	therapy	therapy	NN
cord-014712-5u4e00q6	79	16	(	(	-LRB-
cord-014712-5u4e00q6	79	17	SCIG	SCIG	NNP
cord-014712-5u4e00q6	79	18	)	)	-RRB-
cord-014712-5u4e00q6	79	19	.	.	.
cord-014712-5u4e00q6	80	1	We	-PRON-	PRP
cord-014712-5u4e00q6	80	2	have	have	VBP
cord-014712-5u4e00q6	80	3	64	64	CD
cord-014712-5u4e00q6	80	4	patients	patient	NNS
cord-014712-5u4e00q6	80	5	on	on	IN
cord-014712-5u4e00q6	80	6	such	such	JJ
cord-014712-5u4e00q6	80	7	therapy	therapy	NN
cord-014712-5u4e00q6	80	8	.	.	.
cord-014712-5u4e00q6	81	1	The	the	DT
cord-014712-5u4e00q6	81	2	youngest	young	JJS
cord-014712-5u4e00q6	81	3	child	child	NN
cord-014712-5u4e00q6	81	4	is	be	VBZ
cord-014712-5u4e00q6	81	5	7	7	CD
cord-014712-5u4e00q6	81	6	months	month	NNS
cord-014712-5u4e00q6	81	7	old	old	JJ
cord-014712-5u4e00q6	81	8	.	.	.
cord-014712-5u4e00q6	82	1	The	the	DT
cord-014712-5u4e00q6	82	2	largest	large	JJS
cord-014712-5u4e00q6	82	3	group	group	NN
cord-014712-5u4e00q6	82	4	consists	consist	VBZ
cord-014712-5u4e00q6	82	5	of	of	IN
cord-014712-5u4e00q6	82	6	CVID	CVID	NNP
cord-014712-5u4e00q6	82	7	patients	patient	NNS
cord-014712-5u4e00q6	82	8	,	,	,
cord-014712-5u4e00q6	82	9	next	next	JJ
cord-014712-5u4e00q6	82	10	-	-	HYPH
cord-014712-5u4e00q6	82	11	XLA	XLA	NNP
cord-014712-5u4e00q6	82	12	patients	patient	NNS
cord-014712-5u4e00q6	82	13	.	.	.
cord-014712-5u4e00q6	83	1	We	-PRON-	PRP
cord-014712-5u4e00q6	83	2	also	also	RB
cord-014712-5u4e00q6	83	3	substitute	substitute	VBP
cord-014712-5u4e00q6	83	4	children	child	NNS
cord-014712-5u4e00q6	83	5	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	83	6	with	with	IN
cord-014712-5u4e00q6	83	7	the	the	DT
cord-014712-5u4e00q6	83	8	DGS	DGS	NNP
cord-014712-5u4e00q6	83	9	and	and	CC
cord-014712-5u4e00q6	83	10	accompanying	accompany	VBG
cord-014712-5u4e00q6	83	11	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	83	12	and	and	CC
cord-014712-5u4e00q6	83	13	some	some	DT
cord-014712-5u4e00q6	83	14	children	child	NNS
cord-014712-5u4e00q6	83	15	with	with	IN
cord-014712-5u4e00q6	83	16	subclasses	subclass	NNS
cord-014712-5u4e00q6	83	17	deficiency	deficiency	NN
cord-014712-5u4e00q6	83	18	as	as	RB
cord-014712-5u4e00q6	83	19	well	well	RB
cord-014712-5u4e00q6	83	20	as	as	IN
cord-014712-5u4e00q6	83	21	secondary	secondary	JJ
cord-014712-5u4e00q6	83	22	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	83	23	.	.	.
cord-014712-5u4e00q6	84	1	In	in	IN
cord-014712-5u4e00q6	84	2	most	most	JJS
cord-014712-5u4e00q6	84	3	cases	case	NNS
cord-014712-5u4e00q6	84	4	we	-PRON-	PRP
cord-014712-5u4e00q6	84	5	start	start	VBP
cord-014712-5u4e00q6	84	6	therapy	therapy	NN
cord-014712-5u4e00q6	84	7	with	with	IN
cord-014712-5u4e00q6	84	8	intravenous	intravenous	JJ
cord-014712-5u4e00q6	84	9	preparates	preparate	NNS
cord-014712-5u4e00q6	84	10	,	,	,
cord-014712-5u4e00q6	84	11	but	but	CC
cord-014712-5u4e00q6	84	12	there	there	EX
cord-014712-5u4e00q6	84	13	have	have	VBP
cord-014712-5u4e00q6	84	14	been	be	VBN
cord-014712-5u4e00q6	84	15	some	some	DT
cord-014712-5u4e00q6	84	16	children	child	NNS
cord-014712-5u4e00q6	84	17	to	to	TO
cord-014712-5u4e00q6	84	18	whom	whom	WP
cord-014712-5u4e00q6	84	19	we	-PRON-	PRP
cord-014712-5u4e00q6	84	20	proposed	propose	VBD
cord-014712-5u4e00q6	84	21	the	the	DT
cord-014712-5u4e00q6	84	22	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	84	23	form	form	NN
cord-014712-5u4e00q6	84	24	at	at	IN
cord-014712-5u4e00q6	84	25	the	the	DT
cord-014712-5u4e00q6	84	26	initial	initial	JJ
cord-014712-5u4e00q6	84	27	stage	stage	NN
cord-014712-5u4e00q6	84	28	of	of	IN
cord-014712-5u4e00q6	84	29	the	the	DT
cord-014712-5u4e00q6	84	30	therapy	therapy	NN
cord-014712-5u4e00q6	84	31	.	.	.
cord-014712-5u4e00q6	85	1	The	the	DT
cord-014712-5u4e00q6	85	2	main	main	JJ
cord-014712-5u4e00q6	85	3	factors	factor	NNS
cord-014712-5u4e00q6	85	4	which	which	WDT
cord-014712-5u4e00q6	85	5	made	make	VBD
cord-014712-5u4e00q6	85	6	us	-PRON-	PRP
cord-014712-5u4e00q6	85	7	change	change	VB
cord-014712-5u4e00q6	85	8	the	the	DT
cord-014712-5u4e00q6	85	9	mode	mode	NN
cord-014712-5u4e00q6	85	10	of	of	IN
cord-014712-5u4e00q6	85	11	the	the	DT
cord-014712-5u4e00q6	85	12	drug	drug	NN
cord-014712-5u4e00q6	85	13	application	application	NN
cord-014712-5u4e00q6	85	14	were	be	VBD
cord-014712-5u4e00q6	85	15	adverse	adverse	JJ
cord-014712-5u4e00q6	85	16	reactions	reaction	NNS
cord-014712-5u4e00q6	85	17	to	to	IN
cord-014712-5u4e00q6	85	18	IVIG	IVIG	NNP
cord-014712-5u4e00q6	85	19	,	,	,
cord-014712-5u4e00q6	85	20	poor	poor	JJ
cord-014712-5u4e00q6	85	21	vein	vein	NN
cord-014712-5u4e00q6	85	22	access	access	NN
cord-014712-5u4e00q6	85	23	and	and	CC
cord-014712-5u4e00q6	85	24	the	the	DT
cord-014712-5u4e00q6	85	25	parents`wish	parents`wish	NNP
cord-014712-5u4e00q6	85	26	.	.	.
cord-014712-5u4e00q6	86	1	The	the	DT
cord-014712-5u4e00q6	86	2	administration	administration	NN
cord-014712-5u4e00q6	86	3	of	of	IN
cord-014712-5u4e00q6	86	4	SCIG	SCIG	NNP
cord-014712-5u4e00q6	86	5	is	be	VBZ
cord-014712-5u4e00q6	86	6	very	very	RB
cord-014712-5u4e00q6	86	7	rarely	rarely	RB
cord-014712-5u4e00q6	86	8	complicated	complicate	VBN
cord-014712-5u4e00q6	86	9	by	by	IN
cord-014712-5u4e00q6	86	10	severe	severe	JJ
cord-014712-5u4e00q6	86	11	adverse	adverse	JJ
cord-014712-5u4e00q6	86	12	reactions	reaction	NNS
cord-014712-5u4e00q6	86	13	(	(	-LRB-
cord-014712-5u4e00q6	86	14	the	the	DT
cord-014712-5u4e00q6	86	15	risk	risk	NN
cord-014712-5u4e00q6	86	16	of	of	IN
cord-014712-5u4e00q6	86	17	their	-PRON-	PRP$
cord-014712-5u4e00q6	86	18	incidence	incidence	NN
cord-014712-5u4e00q6	86	19	amounts	amount	VBZ
cord-014712-5u4e00q6	86	20	to	to	IN
cord-014712-5u4e00q6	86	21	about	about	RB
cord-014712-5u4e00q6	86	22	0.3	0.3	CD
cord-014712-5u4e00q6	86	23	%	%	NN
cord-014712-5u4e00q6	86	24	)	)	-RRB-
cord-014712-5u4e00q6	86	25	.	.	.
cord-014712-5u4e00q6	87	1	Even	even	RB
cord-014712-5u4e00q6	87	2	patients	patient	NNS
cord-014712-5u4e00q6	87	3	with	with	IN
cord-014712-5u4e00q6	87	4	serious	serious	JJ
cord-014712-5u4e00q6	87	5	side	side	NN
cord-014712-5u4e00q6	87	6	effects	effect	NNS
cord-014712-5u4e00q6	87	7	to	to	IN
cord-014712-5u4e00q6	87	8	previous	previous	JJ
cord-014712-5u4e00q6	87	9	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	87	10	therapy	therapy	NN
cord-014712-5u4e00q6	87	11	and/or	and/or	CC
cord-014712-5u4e00q6	87	12	blood	blood	NN
cord-014712-5u4e00q6	87	13	transfusion	transfusion	NN
cord-014712-5u4e00q6	87	14	can	can	MD
cord-014712-5u4e00q6	87	15	be	be	VB
cord-014712-5u4e00q6	87	16	safely	safely	RB
cord-014712-5u4e00q6	87	17	treated	treat	VBN
cord-014712-5u4e00q6	87	18	with	with	IN
cord-014712-5u4e00q6	87	19	SCIG	SCIG	NNP
cord-014712-5u4e00q6	87	20	.	.	.
cord-014712-5u4e00q6	88	1	The	the	DT
cord-014712-5u4e00q6	88	2	most	most	RBS
cord-014712-5u4e00q6	88	3	common	common	JJ
cord-014712-5u4e00q6	88	4	side	side	NN
cord-014712-5u4e00q6	88	5	effects	effect	NNS
cord-014712-5u4e00q6	88	6	are	be	VBP
cord-014712-5u4e00q6	88	7	local	local	JJ
cord-014712-5u4e00q6	88	8	reactions	reaction	NNS
cord-014712-5u4e00q6	88	9	but	but	CC
cord-014712-5u4e00q6	88	10	their	-PRON-	PRP$
cord-014712-5u4e00q6	88	11	incidence	incidence	NN
cord-014712-5u4e00q6	88	12	decreases	decrease	VBZ
cord-014712-5u4e00q6	88	13	during	during	IN
cord-014712-5u4e00q6	88	14	following	follow	VBG
cord-014712-5u4e00q6	88	15	substitutions	substitution	NNS
cord-014712-5u4e00q6	88	16	.	.	.
cord-014712-5u4e00q6	89	1	We	-PRON-	PRP
cord-014712-5u4e00q6	89	2	can	can	MD
cord-014712-5u4e00q6	89	3	observe	observe	VB
cord-014712-5u4e00q6	89	4	swelling	swelling	NN
cord-014712-5u4e00q6	89	5	,	,	,
cord-014712-5u4e00q6	89	6	redness	redness	NN
cord-014712-5u4e00q6	89	7	,	,	,
cord-014712-5u4e00q6	89	8	induration	induration	NN
cord-014712-5u4e00q6	89	9	,	,	,
cord-014712-5u4e00q6	89	10	soreness	soreness	NN
cord-014712-5u4e00q6	89	11	.	.	.
cord-014712-5u4e00q6	90	1	But	but	CC
cord-014712-5u4e00q6	90	2	we	-PRON-	PRP
cord-014712-5u4e00q6	90	3	should	should	MD
cord-014712-5u4e00q6	90	4	remember	remember	VB
cord-014712-5u4e00q6	90	5	that	that	IN
cord-014712-5u4e00q6	90	6	more	more	RBR
cord-014712-5u4e00q6	90	7	severe	severe	JJ
cord-014712-5u4e00q6	90	8	side	side	NN
cord-014712-5u4e00q6	90	9	effects	effect	NNS
cord-014712-5u4e00q6	90	10	are	be	VBP
cord-014712-5u4e00q6	90	11	also	also	RB
cord-014712-5u4e00q6	90	12	possible	possible	JJ
cord-014712-5u4e00q6	90	13	,	,	,
cord-014712-5u4e00q6	90	14	for	for	IN
cord-014712-5u4e00q6	90	15	example	example	NN
cord-014712-5u4e00q6	90	16	:	:	:
cord-014712-5u4e00q6	90	17	the	the	DT
cord-014712-5u4e00q6	90	18	first	first	JJ
cord-014712-5u4e00q6	90	19	CVID	CVID	NNP
cord-014712-5u4e00q6	90	20	patient	patient	NN
cord-014712-5u4e00q6	90	21	presented	present	VBN
cord-014712-5u4e00q6	90	22	with	with	IN
cord-014712-5u4e00q6	90	23	fever	fever	NN
cord-014712-5u4e00q6	90	24	,	,	,
cord-014712-5u4e00q6	90	25	weakness	weakness	NN
cord-014712-5u4e00q6	90	26	,	,	,
cord-014712-5u4e00q6	90	27	difficulties	difficulty	NNS
cord-014712-5u4e00q6	90	28	in	in	IN
cord-014712-5u4e00q6	90	29	breathing	breathing	NN
cord-014712-5u4e00q6	90	30	during	during	IN
cord-014712-5u4e00q6	90	31	the	the	DT
cord-014712-5u4e00q6	90	32	3	3	CD
cord-014712-5u4e00q6	90	33	following	follow	VBG
cord-014712-5u4e00q6	90	34	infusions	infusion	NNS
cord-014712-5u4e00q6	90	35	.	.	.
cord-014712-5u4e00q6	91	1	Changing	change	VBG
cord-014712-5u4e00q6	91	2	the	the	DT
cord-014712-5u4e00q6	91	3	brand	brand	NN
cord-014712-5u4e00q6	91	4	of	of	IN
cord-014712-5u4e00q6	91	5	the	the	DT
cord-014712-5u4e00q6	91	6	drug	drug	NN
cord-014712-5u4e00q6	91	7	turned	turn	VBD
cord-014712-5u4e00q6	91	8	out	out	RP
cord-014712-5u4e00q6	91	9	to	to	TO
cord-014712-5u4e00q6	91	10	be	be	VB
cord-014712-5u4e00q6	91	11	a	a	DT
cord-014712-5u4e00q6	91	12	sufficient	sufficient	JJ
cord-014712-5u4e00q6	91	13	method	method	NN
cord-014712-5u4e00q6	91	14	of	of	IN
cord-014712-5u4e00q6	91	15	getting	get	VBG
cord-014712-5u4e00q6	91	16	rid	rid	VBN
cord-014712-5u4e00q6	91	17	of	of	IN
cord-014712-5u4e00q6	91	18	side	side	NN
cord-014712-5u4e00q6	91	19	effects	effect	NNS
cord-014712-5u4e00q6	91	20	.	.	.
cord-014712-5u4e00q6	92	1	The	the	DT
cord-014712-5u4e00q6	92	2	second	second	JJ
cord-014712-5u4e00q6	92	3	patient	patient	NN
cord-014712-5u4e00q6	92	4	,	,	,
cord-014712-5u4e00q6	92	5	also	also	RB
cord-014712-5u4e00q6	92	6	with	with	IN
cord-014712-5u4e00q6	92	7	CVID	CVID	NNP
cord-014712-5u4e00q6	92	8	,	,	,
cord-014712-5u4e00q6	92	9	suffered	suffer	VBD
cord-014712-5u4e00q6	92	10	from	from	IN
cord-014712-5u4e00q6	92	11	nausea	nausea	NN
cord-014712-5u4e00q6	92	12	,	,	,
cord-014712-5u4e00q6	92	13	headache	headache	NN
cord-014712-5u4e00q6	92	14	,	,	,
cord-014712-5u4e00q6	92	15	meningismus	meningismus	NNP
cord-014712-5u4e00q6	92	16	.	.	.
cord-014712-5u4e00q6	93	1	We	-PRON-	PRP
cord-014712-5u4e00q6	93	2	changed	change	VBD
cord-014712-5u4e00q6	93	3	the	the	DT
cord-014712-5u4e00q6	93	4	drug	drug	NN
cord-014712-5u4e00q6	93	5	brand	brand	NN
cord-014712-5u4e00q6	93	6	,	,	,
cord-014712-5u4e00q6	93	7	slowed	slow	VBD
cord-014712-5u4e00q6	93	8	down	down	IN
cord-014712-5u4e00q6	93	9	the	the	DT
cord-014712-5u4e00q6	93	10	infusion	infusion	NN
cord-014712-5u4e00q6	93	11	rate	rate	NN
cord-014712-5u4e00q6	93	12	and	and	CC
cord-014712-5u4e00q6	93	13	introduced	introduce	VBD
cord-014712-5u4e00q6	93	14	premedication	premedication	NN
cord-014712-5u4e00q6	93	15	with	with	IN
cord-014712-5u4e00q6	93	16	an	an	DT
cord-014712-5u4e00q6	93	17	antihistaminic	antihistaminic	NNP
cord-014712-5u4e00q6	93	18	drug	drug	NN
cord-014712-5u4e00q6	93	19	.	.	.
cord-014712-5u4e00q6	94	1	The	the	DT
cord-014712-5u4e00q6	94	2	third	third	JJ
cord-014712-5u4e00q6	94	3	patienta	patienta	JJ
cord-014712-5u4e00q6	94	4	girl	girl	NN
cord-014712-5u4e00q6	94	5	with	with	IN
cord-014712-5u4e00q6	94	6	DGS	DGS	NNP
cord-014712-5u4e00q6	94	7	and	and	CC
cord-014712-5u4e00q6	94	8	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	94	9	,	,	,
cord-014712-5u4e00q6	94	10	after	after	IN
cord-014712-5u4e00q6	94	11	having	have	VBG
cord-014712-5u4e00q6	94	12	been	be	VBN
cord-014712-5u4e00q6	94	13	operated	operate	VBN
cord-014712-5u4e00q6	94	14	on	on	IN
cord-014712-5u4e00q6	94	15	for	for	IN
cord-014712-5u4e00q6	94	16	hypoplastic	hypoplastic	JJ
cord-014712-5u4e00q6	94	17	left	left	JJ
cord-014712-5u4e00q6	94	18	heart	heart	NN
cord-014712-5u4e00q6	94	19	syndrome	syndrome	NN
cord-014712-5u4e00q6	94	20	,	,	,
cord-014712-5u4e00q6	94	21	responded	respond	VBD
cord-014712-5u4e00q6	94	22	to	to	IN
cord-014712-5u4e00q6	94	23	infusions	infusion	NNS
cord-014712-5u4e00q6	94	24	with	with	IN
cord-014712-5u4e00q6	94	25	high	high	JJ
cord-014712-5u4e00q6	94	26	fever	fever	NN
cord-014712-5u4e00q6	94	27	,	,	,
cord-014712-5u4e00q6	94	28	muscle	muscle	NN
cord-014712-5u4e00q6	94	29	and	and	CC
cord-014712-5u4e00q6	94	30	joint	joint	JJ
cord-014712-5u4e00q6	94	31	pain	pain	NN
cord-014712-5u4e00q6	94	32	,	,	,
cord-014712-5u4e00q6	94	33	skin	skin	NN
cord-014712-5u4e00q6	94	34	changes	change	NNS
cord-014712-5u4e00q6	94	35	(	(	-LRB-
cord-014712-5u4e00q6	94	36	erythrodermia	erythrodermia	NN
cord-014712-5u4e00q6	94	37	)	)	-RRB-
cord-014712-5u4e00q6	94	38	.	.	.
cord-014712-5u4e00q6	95	1	We	-PRON-	PRP
cord-014712-5u4e00q6	95	2	introduced	introduce	VBD
cord-014712-5u4e00q6	95	3	premedication	premedication	NN
cord-014712-5u4e00q6	95	4	,	,	,
cord-014712-5u4e00q6	95	5	changed	change	VBD
cord-014712-5u4e00q6	95	6	the	the	DT
cord-014712-5u4e00q6	95	7	drug	drug	NN
cord-014712-5u4e00q6	95	8	brand	brand	NN
cord-014712-5u4e00q6	95	9	and	and	CC
cord-014712-5u4e00q6	95	10	slowed	slow	VBD
cord-014712-5u4e00q6	95	11	the	the	DT
cord-014712-5u4e00q6	95	12	infusion	infusion	NN
cord-014712-5u4e00q6	95	13	rate	rate	NN
cord-014712-5u4e00q6	95	14	,	,	,
cord-014712-5u4e00q6	95	15	yet	yet	CC
cord-014712-5u4e00q6	95	16	without	without	IN
cord-014712-5u4e00q6	95	17	any	any	DT
cord-014712-5u4e00q6	95	18	positive	positive	JJ
cord-014712-5u4e00q6	95	19	effects	effect	NNS
cord-014712-5u4e00q6	95	20	.	.	.
cord-014712-5u4e00q6	96	1	In	in	IN
cord-014712-5u4e00q6	96	2	two	two	CD
cord-014712-5u4e00q6	96	3	patients	patient	NNS
cord-014712-5u4e00q6	96	4	we	-PRON-	PRP
cord-014712-5u4e00q6	96	5	observed	observe	VBD
cord-014712-5u4e00q6	96	6	adverse	adverse	JJ
cord-014712-5u4e00q6	96	7	reactions	reaction	NNS
cord-014712-5u4e00q6	96	8	after	after	IN
cord-014712-5u4e00q6	96	9	preparates	preparate	NNS
cord-014712-5u4e00q6	96	10	at	at	IN
cord-014712-5u4e00q6	96	11	a	a	DT
cord-014712-5u4e00q6	96	12	concentration	concentration	NN
cord-014712-5u4e00q6	96	13	of	of	IN
cord-014712-5u4e00q6	96	14	twenty	twenty	CD
cord-014712-5u4e00q6	96	15	percent	percent	NN
cord-014712-5u4e00q6	96	16	.	.	.
cord-014712-5u4e00q6	97	1	There	there	EX
cord-014712-5u4e00q6	97	2	were	be	VBD
cord-014712-5u4e00q6	97	3	:	:	:
cord-014712-5u4e00q6	97	4	weakness	weakness	NN
cord-014712-5u4e00q6	97	5	,	,	,
cord-014712-5u4e00q6	97	6	chills	chill	NNS
cord-014712-5u4e00q6	97	7	,	,	,
cord-014712-5u4e00q6	97	8	fever	fever	NN
cord-014712-5u4e00q6	97	9	,	,	,
cord-014712-5u4e00q6	97	10	headache	headache	NN
cord-014712-5u4e00q6	97	11	,	,	,
cord-014712-5u4e00q6	97	12	and	and	CC
cord-014712-5u4e00q6	97	13	very	very	RB
cord-014712-5u4e00q6	97	14	intense	intense	JJ
cord-014712-5u4e00q6	97	15	pain	pain	NN
cord-014712-5u4e00q6	97	16	in	in	IN
cord-014712-5u4e00q6	97	17	the	the	DT
cord-014712-5u4e00q6	97	18	place	place	NN
cord-014712-5u4e00q6	97	19	of	of	IN
cord-014712-5u4e00q6	97	20	injection	injection	NN
cord-014712-5u4e00q6	97	21	.	.	.
cord-014712-5u4e00q6	98	1	During	during	IN
cord-014712-5u4e00q6	98	2	the	the	DT
cord-014712-5u4e00q6	98	3	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	98	4	treatment	treatment	NN
cord-014712-5u4e00q6	98	5	of	of	IN
cord-014712-5u4e00q6	98	6	XLA	XLA	NNP
cord-014712-5u4e00q6	98	7	patients	patient	NNS
cord-014712-5u4e00q6	98	8	,	,	,
cord-014712-5u4e00q6	98	9	we	-PRON-	PRP
cord-014712-5u4e00q6	98	10	observe	observe	VBP
cord-014712-5u4e00q6	98	11	significant	significant	JJ
cord-014712-5u4e00q6	98	12	reduction	reduction	NN
cord-014712-5u4e00q6	98	13	in	in	IN
cord-014712-5u4e00q6	98	14	the	the	DT
cord-014712-5u4e00q6	98	15	number	number	NN
cord-014712-5u4e00q6	98	16	of	of	IN
cord-014712-5u4e00q6	98	17	infections	infection	NNS
cord-014712-5u4e00q6	98	18	and	and	CC
cord-014712-5u4e00q6	98	19	days	day	NNS
cord-014712-5u4e00q6	98	20	of	of	IN
cord-014712-5u4e00q6	98	21	school	school	NN
cord-014712-5u4e00q6	98	22	absence	absence	NN
cord-014712-5u4e00q6	98	23	.	.	.
cord-014712-5u4e00q6	99	1	Despite	despite	IN
cord-014712-5u4e00q6	99	2	that	that	DT
cord-014712-5u4e00q6	99	3	,	,	,
cord-014712-5u4e00q6	99	4	all	all	PDT
cord-014712-5u4e00q6	99	5	our	-PRON-	PRP$
cord-014712-5u4e00q6	99	6	patients	patient	NNS
cord-014712-5u4e00q6	99	7	with	with	IN
cord-014712-5u4e00q6	99	8	XLA	XLA	NNP
cord-014712-5u4e00q6	99	9	suffer	suffer	VBP
cord-014712-5u4e00q6	99	10	from	from	IN
cord-014712-5u4e00q6	99	11	chronic	chronic	JJ
cord-014712-5u4e00q6	99	12	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	99	13	.	.	.
cord-014712-5u4e00q6	100	1	Similar	similar	JJ
cord-014712-5u4e00q6	100	2	results	result	NNS
cord-014712-5u4e00q6	100	3	occurred	occur	VBD
cord-014712-5u4e00q6	100	4	in	in	IN
cord-014712-5u4e00q6	100	5	CVID	CVID	NNP
cord-014712-5u4e00q6	100	6	patients	patient	NNS
cord-014712-5u4e00q6	100	7	,	,	,
cord-014712-5u4e00q6	100	8	but	but	CC
cord-014712-5u4e00q6	100	9	the	the	DT
cord-014712-5u4e00q6	100	10	severity	severity	NN
cord-014712-5u4e00q6	100	11	of	of	IN
cord-014712-5u4e00q6	100	12	infections	infection	NNS
cord-014712-5u4e00q6	100	13	was	be	VBD
cord-014712-5u4e00q6	100	14	the	the	DT
cord-014712-5u4e00q6	100	15	same	same	JJ
cord-014712-5u4e00q6	100	16	.	.	.
cord-014712-5u4e00q6	101	1	The	the	DT
cord-014712-5u4e00q6	101	2	use	use	NN
cord-014712-5u4e00q6	101	3	of	of	IN
cord-014712-5u4e00q6	101	4	SCIG	SCIG	NNP
cord-014712-5u4e00q6	101	5	results	result	NNS
cord-014712-5u4e00q6	101	6	in	in	IN
cord-014712-5u4e00q6	101	7	more	more	RBR
cord-014712-5u4e00q6	101	8	stable	stable	JJ
cord-014712-5u4e00q6	101	9	and	and	CC
cord-014712-5u4e00q6	101	10	higher	high	JJR
cord-014712-5u4e00q6	101	11	IgG	igg	NN
cord-014712-5u4e00q6	101	12	through	through	IN
cord-014712-5u4e00q6	101	13	levels	level	NNS
cord-014712-5u4e00q6	101	14	especially	especially	RB
cord-014712-5u4e00q6	101	15	in	in	IN
cord-014712-5u4e00q6	101	16	XLA	XLA	NNP
cord-014712-5u4e00q6	101	17	patients	patient	NNS
cord-014712-5u4e00q6	101	18	.	.	.
cord-014712-5u4e00q6	102	1	In	in	IN
cord-014712-5u4e00q6	102	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	102	3	practice	practice	NN
cord-014712-5u4e00q6	102	4	,	,	,
cord-014712-5u4e00q6	102	5	we	-PRON-	PRP
cord-014712-5u4e00q6	102	6	had	have	VBD
cord-014712-5u4e00q6	102	7	only	only	RB
cord-014712-5u4e00q6	102	8	a	a	DT
cord-014712-5u4e00q6	102	9	few	few	JJ
cord-014712-5u4e00q6	102	10	cases	case	NNS
cord-014712-5u4e00q6	102	11	in	in	IN
cord-014712-5u4e00q6	102	12	which	which	WDT
cord-014712-5u4e00q6	102	13	IV	IV	NNP
cord-014712-5u4e00q6	102	14	form	form	NN
cord-014712-5u4e00q6	102	15	appeared	appear	VBD
cord-014712-5u4e00q6	102	16	to	to	TO
cord-014712-5u4e00q6	102	17	be	be	VB
cord-014712-5u4e00q6	102	18	better	well	JJR
cord-014712-5u4e00q6	102	19	than	than	IN
cord-014712-5u4e00q6	102	20	SC	SC	NNP
cord-014712-5u4e00q6	102	21	one	one	CD
cord-014712-5u4e00q6	102	22	.	.	.
cord-014712-5u4e00q6	103	1	In	in	IN
cord-014712-5u4e00q6	103	2	the	the	DT
cord-014712-5u4e00q6	103	3	case	case	NN
cord-014712-5u4e00q6	103	4	of	of	IN
cord-014712-5u4e00q6	103	5	two	two	CD
cord-014712-5u4e00q6	103	6	boys	boy	NNS
cord-014712-5u4e00q6	103	7	with	with	IN
cord-014712-5u4e00q6	103	8	HIGM	HIGM	NNP
cord-014712-5u4e00q6	103	9	syndrome	syndrome	NN
cord-014712-5u4e00q6	103	10	,	,	,
cord-014712-5u4e00q6	103	11	we	-PRON-	PRP
cord-014712-5u4e00q6	103	12	observed	observe	VBD
cord-014712-5u4e00q6	103	13	recurrent	recurrent	JJ
cord-014712-5u4e00q6	103	14	enthesitis	enthesitis	NN
cord-014712-5u4e00q6	103	15	of	of	IN
cord-014712-5u4e00q6	103	16	the	the	DT
cord-014712-5u4e00q6	103	17	first	first	JJ
cord-014712-5u4e00q6	103	18	patient	patient	NN
cord-014712-5u4e00q6	103	19	and	and	CC
cord-014712-5u4e00q6	103	20	progression	progression	NN
cord-014712-5u4e00q6	103	21	of	of	IN
cord-014712-5u4e00q6	103	22	lung	lung	NN
cord-014712-5u4e00q6	103	23	fibrosis	fibrosis	NN
cord-014712-5u4e00q6	103	24	of	of	IN
cord-014712-5u4e00q6	103	25	the	the	DT
cord-014712-5u4e00q6	103	26	other	other	JJ
cord-014712-5u4e00q6	103	27	.	.	.
cord-014712-5u4e00q6	104	1	IVIG	IVIG	NNP
cord-014712-5u4e00q6	104	2	was	be	VBD
cord-014712-5u4e00q6	104	3	better	well	JJR
cord-014712-5u4e00q6	104	4	to	to	TO
cord-014712-5u4e00q6	104	5	control	control	VB
cord-014712-5u4e00q6	104	6	platelets	platelet	NNS
cord-014712-5u4e00q6	104	7	levels	level	NNS
cord-014712-5u4e00q6	104	8	in	in	IN
cord-014712-5u4e00q6	104	9	the	the	DT
cord-014712-5u4e00q6	104	10	girl	girl	NN
cord-014712-5u4e00q6	104	11	with	with	IN
cord-014712-5u4e00q6	104	12	CVID	CVID	NNP
cord-014712-5u4e00q6	104	13	and	and	CC
cord-014712-5u4e00q6	104	14	thrombocytopenia	thrombocytopenia	NN
cord-014712-5u4e00q6	104	15	.	.	.
cord-014712-5u4e00q6	105	1	It	-PRON-	PRP
cord-014712-5u4e00q6	105	2	has	have	VBZ
cord-014712-5u4e00q6	105	3	also	also	RB
cord-014712-5u4e00q6	105	4	occurred	occur	VBN
cord-014712-5u4e00q6	105	5	that	that	IN
cord-014712-5u4e00q6	105	6	parents	parent	NNS
cord-014712-5u4e00q6	105	7	refuse	refuse	VBP
cord-014712-5u4e00q6	105	8	to	to	TO
cord-014712-5u4e00q6	105	9	allow	allow	VB
cord-014712-5u4e00q6	105	10	us	-PRON-	PRP
cord-014712-5u4e00q6	105	11	to	to	TO
cord-014712-5u4e00q6	105	12	start	start	VB
cord-014712-5u4e00q6	105	13	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	105	14	therapy	therapy	NN
cord-014712-5u4e00q6	105	15	,	,	,
cord-014712-5u4e00q6	105	16	giving	give	VBG
cord-014712-5u4e00q6	105	17	two	two	CD
cord-014712-5u4e00q6	105	18	main	main	JJ
cord-014712-5u4e00q6	105	19	reasons	reason	NNS
cord-014712-5u4e00q6	105	20	:	:	:
cord-014712-5u4e00q6	105	21	they	-PRON-	PRP
cord-014712-5u4e00q6	105	22	feel	feel	VBP
cord-014712-5u4e00q6	105	23	safer	safe	JJR
cord-014712-5u4e00q6	105	24	under	under	IN
cord-014712-5u4e00q6	105	25	frequent	frequent	JJ
cord-014712-5u4e00q6	105	26	doctor`s	doctor`s	NNP
cord-014712-5u4e00q6	105	27	control	control	NN
cord-014712-5u4e00q6	105	28	and	and	CC
cord-014712-5u4e00q6	105	29	they	-PRON-	PRP
cord-014712-5u4e00q6	105	30	are	be	VBP
cord-014712-5u4e00q6	105	31	afraid	afraid	JJ
cord-014712-5u4e00q6	105	32	of	of	IN
cord-014712-5u4e00q6	105	33	making	make	VBG
cord-014712-5u4e00q6	105	34	mistakes	mistake	NNS
cord-014712-5u4e00q6	105	35	in	in	IN
cord-014712-5u4e00q6	105	36	procedures	procedure	NNS
cord-014712-5u4e00q6	105	37	.	.	.
cord-014712-5u4e00q6	106	1	As	as	IN
cord-014712-5u4e00q6	106	2	for	for	IN
cord-014712-5u4e00q6	106	3	the	the	DT
cord-014712-5u4e00q6	106	4	youngest	young	JJS
cord-014712-5u4e00q6	106	5	children	child	NNS
cord-014712-5u4e00q6	106	6	(	(	-LRB-
cord-014712-5u4e00q6	106	7	below	below	IN
cord-014712-5u4e00q6	106	8	7)their	7)their	JJ
cord-014712-5u4e00q6	106	9	fear	fear	NN
cord-014712-5u4e00q6	106	10	of	of	IN
cord-014712-5u4e00q6	106	11	needle	needle	NN
cord-014712-5u4e00q6	106	12	is	be	VBZ
cord-014712-5u4e00q6	106	13	independent	independent	JJ
cord-014712-5u4e00q6	106	14	of	of	IN
cord-014712-5u4e00q6	106	15	its	-PRON-	PRP$
cord-014712-5u4e00q6	106	16	size	size	NN
cord-014712-5u4e00q6	106	17	,	,	,
cord-014712-5u4e00q6	106	18	which	which	WDT
cord-014712-5u4e00q6	106	19	is	be	VBZ
cord-014712-5u4e00q6	106	20	the	the	DT
cord-014712-5u4e00q6	106	21	third	third	JJ
cord-014712-5u4e00q6	106	22	reason	reason	NN
cord-014712-5u4e00q6	106	23	.	.	.
cord-014712-5u4e00q6	107	1	In	in	IN
cord-014712-5u4e00q6	107	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	107	3	,	,	,
cord-014712-5u4e00q6	107	4	we	-PRON-	PRP
cord-014712-5u4e00q6	107	5	would	would	MD
cord-014712-5u4e00q6	107	6	like	like	VB
cord-014712-5u4e00q6	107	7	to	to	TO
cord-014712-5u4e00q6	107	8	emphasize	emphasize	VB
cord-014712-5u4e00q6	107	9	that	that	IN
cord-014712-5u4e00q6	107	10	education	education	NN
cord-014712-5u4e00q6	107	11	programmes	programme	NNS
cord-014712-5u4e00q6	107	12	implemented	implement	VBN
cord-014712-5u4e00q6	107	13	by	by	IN
cord-014712-5u4e00q6	107	14	doctors	doctor	NNS
cord-014712-5u4e00q6	107	15	and	and	CC
cord-014712-5u4e00q6	107	16	nurses	nurse	NNS
cord-014712-5u4e00q6	107	17	are	be	VBP
cord-014712-5u4e00q6	107	18	essential	essential	JJ
cord-014712-5u4e00q6	107	19	to	to	TO
cord-014712-5u4e00q6	107	20	make	make	VB
cord-014712-5u4e00q6	107	21	this	this	DT
cord-014712-5u4e00q6	107	22	form	form	NN
cord-014712-5u4e00q6	107	23	of	of	IN
cord-014712-5u4e00q6	107	24	therapy	therapy	NN
cord-014712-5u4e00q6	107	25	easier	easy	JJR
cord-014712-5u4e00q6	107	26	,	,	,
cord-014712-5u4e00q6	107	27	safer	safe	JJR
cord-014712-5u4e00q6	107	28	and	and	CC
cord-014712-5u4e00q6	107	29	more	more	RBR
cord-014712-5u4e00q6	107	30	satisfying	satisfying	JJ
cord-014712-5u4e00q6	107	31	for	for	IN
cord-014712-5u4e00q6	107	32	patients	patient	NNS
cord-014712-5u4e00q6	107	33	and	and	CC
cord-014712-5u4e00q6	107	34	their	-PRON-	PRP$
cord-014712-5u4e00q6	107	35	parents	parent	NNS
cord-014712-5u4e00q6	107	36	.	.	.
cord-014712-5u4e00q6	108	1	Despite	despite	IN
cord-014712-5u4e00q6	108	2	intensive	intensive	JJ
cord-014712-5u4e00q6	108	3	investigation	investigation	NN
cord-014712-5u4e00q6	108	4	into	into	IN
cord-014712-5u4e00q6	108	5	the	the	DT
cord-014712-5u4e00q6	108	6	nature	nature	NN
cord-014712-5u4e00q6	108	7	of	of	IN
cord-014712-5u4e00q6	108	8	CVID	CVID	NNP
cord-014712-5u4e00q6	108	9	,	,	,
cord-014712-5u4e00q6	108	10	the	the	DT
cord-014712-5u4e00q6	108	11	exact	exact	JJ
cord-014712-5u4e00q6	108	12	molecular	molecular	JJ
cord-014712-5u4e00q6	108	13	defect(s	defect(s	NN
cord-014712-5u4e00q6	108	14	)	)	-RRB-
cord-014712-5u4e00q6	108	15	and	and	CC
cord-014712-5u4e00q6	108	16	pathogenesis	pathogenesis	NN
cord-014712-5u4e00q6	108	17	of	of	IN
cord-014712-5u4e00q6	108	18	disease	disease	NN
cord-014712-5u4e00q6	108	19	remain	remain	VBP
cord-014712-5u4e00q6	108	20	unknown	unknown	JJ
cord-014712-5u4e00q6	108	21	.	.	.
cord-014712-5u4e00q6	109	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	109	2	aim	aim	NN
cord-014712-5u4e00q6	109	3	was	be	VBD
cord-014712-5u4e00q6	109	4	to	to	TO
cord-014712-5u4e00q6	109	5	evaluate	evaluate	VB
cord-014712-5u4e00q6	109	6	the	the	DT
cord-014712-5u4e00q6	109	7	role	role	NN
cord-014712-5u4e00q6	109	8	of	of	IN
cord-014712-5u4e00q6	109	9	T	T	NNP
cord-014712-5u4e00q6	109	10	cells	cell	NNS
cord-014712-5u4e00q6	109	11	in	in	IN
cord-014712-5u4e00q6	109	12	the	the	DT
cord-014712-5u4e00q6	109	13	mechanisms	mechanism	NNS
cord-014712-5u4e00q6	109	14	of	of	IN
cord-014712-5u4e00q6	109	15	CVID	CVID	NNP
cord-014712-5u4e00q6	109	16	development	development	NN
cord-014712-5u4e00q6	109	17	.	.	.
cord-014712-5u4e00q6	110	1	Additionally	additionally	RB
cord-014712-5u4e00q6	110	2	the	the	DT
cord-014712-5u4e00q6	110	3	impact	impact	NN
cord-014712-5u4e00q6	110	4	of	of	IN
cord-014712-5u4e00q6	110	5	some	some	DT
cord-014712-5u4e00q6	110	6	innate	innate	JJ
cord-014712-5u4e00q6	110	7	and	and	CC
cord-014712-5u4e00q6	110	8	adaptive	adaptive	JJ
cord-014712-5u4e00q6	110	9	immunity	immunity	NN
cord-014712-5u4e00q6	110	10	related	relate	VBN
cord-014712-5u4e00q6	110	11	genes	gene	NNS
cord-014712-5u4e00q6	110	12	(	(	-LRB-
cord-014712-5u4e00q6	110	13	HLA	HLA	NNP
cord-014712-5u4e00q6	110	14	,	,	,
cord-014712-5u4e00q6	110	15	cytokine	cytokine	NN
cord-014712-5u4e00q6	110	16	gene	gene	NN
cord-014712-5u4e00q6	110	17	polymorphism	polymorphism	NN
cord-014712-5u4e00q6	110	18	,	,	,
cord-014712-5u4e00q6	110	19	MBL	MBL	NNP
cord-014712-5u4e00q6	110	20	genes	gene	NNS
cord-014712-5u4e00q6	110	21	)	)	-RRB-
cord-014712-5u4e00q6	110	22	was	be	VBD
cord-014712-5u4e00q6	110	23	investigated	investigate	VBN
cord-014712-5u4e00q6	110	24	.	.	.
cord-014712-5u4e00q6	111	1	Based	base	VBN
cord-014712-5u4e00q6	111	2	on	on	IN
cord-014712-5u4e00q6	111	3	previously	previously	RB
cord-014712-5u4e00q6	111	4	observed	observe	VBN
cord-014712-5u4e00q6	111	5	by	by	IN
cord-014712-5u4e00q6	111	6	us	us	NNP
cord-014712-5u4e00q6	111	7	constellation	constellation	NNP
cord-014712-5u4e00q6	111	8	of	of	IN
cord-014712-5u4e00q6	111	9	shared	share	VBN
cord-014712-5u4e00q6	111	10	immunogenetic	immunogenetic	JJ
cord-014712-5u4e00q6	111	11	profiles	profile	VBZ
cord-014712-5u4e00q6	111	12	a	a	DT
cord-014712-5u4e00q6	111	13	comparison	comparison	NN
cord-014712-5u4e00q6	111	14	of	of	IN
cord-014712-5u4e00q6	111	15	T	t	NN
cord-014712-5u4e00q6	111	16	-	-	HYPH
cord-014712-5u4e00q6	111	17	cell	cell	NN
cord-014712-5u4e00q6	111	18	phenotype	phenotype	NN
cord-014712-5u4e00q6	111	19	of	of	IN
cord-014712-5u4e00q6	111	20	CVID	CVID	NNP
cord-014712-5u4e00q6	111	21	patients	patient	NNS
cord-014712-5u4e00q6	111	22	,	,	,
cord-014712-5u4e00q6	111	23	and	and	CC
cord-014712-5u4e00q6	111	24	elderly	elderly	JJ
cord-014712-5u4e00q6	111	25	/	/	SYM
cord-014712-5u4e00q6	111	26	young	young	JJ
cord-014712-5u4e00q6	111	27	healthy	healthy	JJ
cord-014712-5u4e00q6	111	28	individuals	individual	NNS
cord-014712-5u4e00q6	111	29	was	be	VBD
cord-014712-5u4e00q6	111	30	performed	perform	VBN
cord-014712-5u4e00q6	111	31	.	.	.
cord-014712-5u4e00q6	112	1	Ten	ten	CD
cord-014712-5u4e00q6	112	2	patients	patient	NNS
cord-014712-5u4e00q6	112	3	with	with	IN
cord-014712-5u4e00q6	112	4	CVID	CVID	NNP
cord-014712-5u4e00q6	112	5	were	be	VBD
cord-014712-5u4e00q6	112	6	enrolled	enrol	VBN
cord-014712-5u4e00q6	112	7	(	(	-LRB-
cord-014712-5u4e00q6	112	8	4	4	CD
cord-014712-5u4e00q6	112	9	male	male	NN
cord-014712-5u4e00q6	112	10	,	,	,
cord-014712-5u4e00q6	112	11	6	6	CD
cord-014712-5u4e00q6	112	12	female	female	JJ
cord-014712-5u4e00q6	112	13	;	;	:
cord-014712-5u4e00q6	112	14	average	average	JJ
cord-014712-5u4e00q6	112	15	age	age	NN
cord-014712-5u4e00q6	112	16	-42,9	-42,9	NN
cord-014712-5u4e00q6	112	17	years	year	NNS
cord-014712-5u4e00q6	112	18	)	)	-RRB-
cord-014712-5u4e00q6	112	19	presented	present	VBN
cord-014712-5u4e00q6	112	20	mainly	mainly	RB
cord-014712-5u4e00q6	112	21	with	with	IN
cord-014712-5u4e00q6	112	22	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	112	23	infections	infection	NNS
cord-014712-5u4e00q6	112	24	,	,	,
cord-014712-5u4e00q6	112	25	followed	follow	VBN
cord-014712-5u4e00q6	112	26	by	by	IN
cord-014712-5u4e00q6	112	27	bronchoectasis	bronchoectasis	NN
cord-014712-5u4e00q6	112	28	and	and	CC
cord-014712-5u4e00q6	112	29	splenomegaly	splenomegaly	NN
cord-014712-5u4e00q6	112	30	.	.	.
cord-014712-5u4e00q6	113	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	113	2	study	study	NN
cord-014712-5u4e00q6	113	3	demonstrated	demonstrate	VBD
cord-014712-5u4e00q6	113	4	multiple	multiple	JJ
cord-014712-5u4e00q6	113	5	T	T	NNP
cord-014712-5u4e00q6	113	6	-	-	HYPH
cord-014712-5u4e00q6	113	7	and	and	CC
cord-014712-5u4e00q6	113	8	B	b	NN
cord-014712-5u4e00q6	113	9	-	-	HYPH
cord-014712-5u4e00q6	113	10	cell	cell	NN
cord-014712-5u4e00q6	113	11	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	113	12	in	in	IN
cord-014712-5u4e00q6	113	13	CVID	CVID	NNP
cord-014712-5u4e00q6	113	14	patients	patient	NNS
cord-014712-5u4e00q6	113	15	such	such	JJ
cord-014712-5u4e00q6	113	16	as	as	IN
cord-014712-5u4e00q6	113	17	:	:	:
cord-014712-5u4e00q6	113	18	decreased	decrease	VBD
cord-014712-5u4e00q6	113	19	CD4	CD4	NNP
cord-014712-5u4e00q6	113	20	+	+	CC
cord-014712-5u4e00q6	113	21	,	,	,
cord-014712-5u4e00q6	113	22	increased	increase	VBD
cord-014712-5u4e00q6	113	23	CD8	CD8	NNP
cord-014712-5u4e00q6	113	24	+	+	CC
cord-014712-5u4e00q6	113	25	T	T	NNP
cord-014712-5u4e00q6	113	26	cells	cell	NNS
cord-014712-5u4e00q6	113	27	and	and	CC
cord-014712-5u4e00q6	113	28	low	low	JJ
cord-014712-5u4e00q6	113	29	CD4	CD4	NNP
cord-014712-5u4e00q6	113	30	/	/	SYM
cord-014712-5u4e00q6	113	31	CD8	CD8	NNP
cord-014712-5u4e00q6	113	32	ratio	ratio	NN
cord-014712-5u4e00q6	113	33	,	,	,
cord-014712-5u4e00q6	113	34	loss	loss	NN
cord-014712-5u4e00q6	113	35	of	of	IN
cord-014712-5u4e00q6	113	36	naïve	naïve	JJ
cord-014712-5u4e00q6	113	37	and	and	CC
cord-014712-5u4e00q6	113	38	early	early	JJ
cord-014712-5u4e00q6	113	39	differentiated	differentiate	VBN
cord-014712-5u4e00q6	113	40	T	t	NN
cord-014712-5u4e00q6	113	41	cells	cell	NNS
cord-014712-5u4e00q6	113	42	,	,	,
cord-014712-5u4e00q6	113	43	expansion	expansion	NN
cord-014712-5u4e00q6	113	44	of	of	IN
cord-014712-5u4e00q6	113	45	terminal	terminal	JJ
cord-014712-5u4e00q6	113	46	effectors	effector	NNS
cord-014712-5u4e00q6	113	47	(	(	-LRB-
cord-014712-5u4e00q6	113	48	CD8	CD8	NNP
cord-014712-5u4e00q6	113	49	+	+	CC
cord-014712-5u4e00q6	114	1	CD45RA	cd45ra	NN
cord-014712-5u4e00q6	115	1	+	+	CC
cord-014712-5u4e00q6	115	2	CD62L-	cd62l-	NN
cord-014712-5u4e00q6	115	3	)	)	-RRB-
cord-014712-5u4e00q6	115	4	T	t	NN
cord-014712-5u4e00q6	115	5	cells	cell	NNS
cord-014712-5u4e00q6	115	6	,	,	,
cord-014712-5u4e00q6	115	7	memory	memory	NN
cord-014712-5u4e00q6	115	8	/	/	SYM
cord-014712-5u4e00q6	115	9	effectors	effector	NNS
cord-014712-5u4e00q6	115	10	(	(	-LRB-
cord-014712-5u4e00q6	115	11	CD8	CD8	NNP
cord-014712-5u4e00q6	115	12	+	+	SYM
cord-014712-5u4e00q6	115	13	CD28-CD27-	CD28-CD27-	NNP
cord-014712-5u4e00q6	115	14	)	)	-RRB-
cord-014712-5u4e00q6	115	15	and	and	CC
cord-014712-5u4e00q6	115	16	terminally	terminally	RB
cord-014712-5u4e00q6	115	17	differentiated	differentiated	JJ
cord-014712-5u4e00q6	115	18	(	(	-LRB-
cord-014712-5u4e00q6	116	1	CD8	CD8	NNP
cord-014712-5u4e00q6	116	2	+	+	CC
cord-014712-5u4e00q6	116	3	CD57	CD57	NNP
cord-014712-5u4e00q6	116	4	+	+	SYM
cord-014712-5u4e00q6	116	5	)	)	-RRB-
cord-014712-5u4e00q6	116	6	T	t	NN
cord-014712-5u4e00q6	116	7	cells	cell	NNS
cord-014712-5u4e00q6	116	8	.	.	.
cord-014712-5u4e00q6	117	1	Excessive	excessive	JJ
cord-014712-5u4e00q6	117	2	T	t	NN
cord-014712-5u4e00q6	117	3	-	-	HYPH
cord-014712-5u4e00q6	117	4	cell	cell	NN
cord-014712-5u4e00q6	117	5	activation	activation	NN
cord-014712-5u4e00q6	117	6	reflecting	reflect	VBG
cord-014712-5u4e00q6	117	7	the	the	DT
cord-014712-5u4e00q6	117	8	prevalence	prevalence	NN
cord-014712-5u4e00q6	117	9	of	of	IN
cord-014712-5u4e00q6	117	10	activated	activate	VBN
cord-014712-5u4e00q6	117	11	T	T	NNP
cord-014712-5u4e00q6	117	12	cell	cell	NN
cord-014712-5u4e00q6	117	13	phenotype	phenotype	NN
cord-014712-5u4e00q6	117	14	was	be	VBD
cord-014712-5u4e00q6	117	15	also	also	RB
cord-014712-5u4e00q6	117	16	detected	detect	VBN
cord-014712-5u4e00q6	117	17	,	,	,
cord-014712-5u4e00q6	117	18	due	due	JJ
cord-014712-5u4e00q6	117	19	perhaps	perhaps	RB
cord-014712-5u4e00q6	117	20	to	to	IN
cord-014712-5u4e00q6	117	21	an	an	DT
cord-014712-5u4e00q6	117	22	antigen	antigen	NN
cord-014712-5u4e00q6	117	23	-	-	HYPH
cord-014712-5u4e00q6	117	24	driven	drive	VBN
cord-014712-5u4e00q6	117	25	process	process	NN
cord-014712-5u4e00q6	117	26	.	.	.
cord-014712-5u4e00q6	118	1	The	the	DT
cord-014712-5u4e00q6	118	2	very	very	RB
cord-014712-5u4e00q6	118	3	low	low	JJ
cord-014712-5u4e00q6	118	4	numbers	number	NNS
cord-014712-5u4e00q6	118	5	of	of	IN
cord-014712-5u4e00q6	118	6	circulating	circulate	VBG
cord-014712-5u4e00q6	118	7	mature	mature	NN
cord-014712-5u4e00q6	119	1	(	(	-LRB-
cord-014712-5u4e00q6	119	2	CD21	CD21	NNP
cord-014712-5u4e00q6	119	3	+	+	CC
cord-014712-5u4e00q6	119	4	CD24	CD24	NNP
cord-014712-5u4e00q6	119	5	+	+	SYM
cord-014712-5u4e00q6	119	6	)	)	-RRB-
cord-014712-5u4e00q6	119	7	and	and	CC
cord-014712-5u4e00q6	119	8	class	class	NN
cord-014712-5u4e00q6	119	9	-	-	HYPH
cord-014712-5u4e00q6	119	10	switched	switch	VBN
cord-014712-5u4e00q6	119	11	memory	memory	NN
cord-014712-5u4e00q6	120	1	(	(	-LRB-
cord-014712-5u4e00q6	120	2	IgM	IgM	NNP
cord-014712-5u4e00q6	120	3	-	-	HYPH
cord-014712-5u4e00q6	120	4	IgD	IgD	NNP
cord-014712-5u4e00q6	120	5	-	-	HYPH
cord-014712-5u4e00q6	120	6	CD27	CD27	NNP
cord-014712-5u4e00q6	120	7	+	+	.
cord-014712-5u4e00q6	121	1	)	)	-RRB-
cord-014712-5u4e00q6	121	2	B	b	NN
cord-014712-5u4e00q6	121	3	cells	cell	NNS
cord-014712-5u4e00q6	121	4	were	be	VBD
cord-014712-5u4e00q6	121	5	pathognomic	pathognomic	JJ
cord-014712-5u4e00q6	121	6	for	for	IN
cord-014712-5u4e00q6	121	7	our	-PRON-	PRP$
cord-014712-5u4e00q6	121	8	patients	patient	NNS
cord-014712-5u4e00q6	121	9	and	and	CC
cord-014712-5u4e00q6	121	10	could	could	MD
cord-014712-5u4e00q6	121	11	be	be	VB
cord-014712-5u4e00q6	121	12	used	use	VBN
cord-014712-5u4e00q6	121	13	as	as	IN
cord-014712-5u4e00q6	121	14	an	an	DT
cord-014712-5u4e00q6	121	15	additional	additional	JJ
cord-014712-5u4e00q6	121	16	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	121	17	criteria	criterion	NNS
cord-014712-5u4e00q6	121	18	in	in	IN
cord-014712-5u4e00q6	121	19	the	the	DT
cord-014712-5u4e00q6	121	20	national	national	JJ
cord-014712-5u4e00q6	121	21	guidelines	guideline	NNS
cord-014712-5u4e00q6	121	22	.	.	.
cord-014712-5u4e00q6	122	1	Furthermore	furthermore	RB
cord-014712-5u4e00q6	122	2	high	high	JJ
cord-014712-5u4e00q6	122	3	level	level	NN
cord-014712-5u4e00q6	122	4	of	of	IN
cord-014712-5u4e00q6	122	5	nonclass	nonclass	NNP
cord-014712-5u4e00q6	122	6	switched	switch	VBN
cord-014712-5u4e00q6	122	7	(	(	-LRB-
cord-014712-5u4e00q6	122	8	IgM	IgM	NNP
cord-014712-5u4e00q6	122	9	+	+	CC
cord-014712-5u4e00q6	122	10	IgD	IgD	NNP
cord-014712-5u4e00q6	123	1	+	+	CC
cord-014712-5u4e00q6	124	1	CD27	CD27	NNP
cord-014712-5u4e00q6	124	2	+	+	JJ
cord-014712-5u4e00q6	124	3	)	)	-RRB-
cord-014712-5u4e00q6	125	1	B	b	NN
cord-014712-5u4e00q6	125	2	memory	memory	NN
cord-014712-5u4e00q6	125	3	cells	cell	NNS
cord-014712-5u4e00q6	125	4	and	and	CC
cord-014712-5u4e00q6	125	5	suppressed	suppress	VBD
cord-014712-5u4e00q6	125	6	NK	NK	NNP
cord-014712-5u4e00q6	125	7	cell	cell	NN
cord-014712-5u4e00q6	125	8	count	count	NN
cord-014712-5u4e00q6	125	9	was	be	VBD
cord-014712-5u4e00q6	125	10	observed	observe	VBN
cord-014712-5u4e00q6	125	11	.	.	.
cord-014712-5u4e00q6	126	1	Decreased	decrease	VBN
cord-014712-5u4e00q6	126	2	responsiveness	responsiveness	NN
cord-014712-5u4e00q6	126	3	to	to	IN
cord-014712-5u4e00q6	126	4	polyclonal	polyclonal	JJ
cord-014712-5u4e00q6	126	5	stimuli	stimulus	NNS
cord-014712-5u4e00q6	126	6	via	via	IN
cord-014712-5u4e00q6	126	7	CD3	CD3	NNP
cord-014712-5u4e00q6	126	8	and	and	CC
cord-014712-5u4e00q6	126	9	CD28	CD28	NNP
cord-014712-5u4e00q6	126	10	pathway	pathway	NN
cord-014712-5u4e00q6	126	11	correlated	correlate	VBN
cord-014712-5u4e00q6	126	12	with	with	IN
cord-014712-5u4e00q6	126	13	the	the	DT
cord-014712-5u4e00q6	126	14	loss	loss	NN
cord-014712-5u4e00q6	126	15	of	of	IN
cord-014712-5u4e00q6	126	16	CD28	CD28	NNP
cord-014712-5u4e00q6	126	17	expression	expression	NN
cord-014712-5u4e00q6	126	18	which	which	WDT
cord-014712-5u4e00q6	126	19	was	be	VBD
cord-014712-5u4e00q6	126	20	more	more	RBR
cord-014712-5u4e00q6	126	21	pronounced	pronounced	JJ
cord-014712-5u4e00q6	126	22	in	in	IN
cord-014712-5u4e00q6	126	23	the	the	DT
cord-014712-5u4e00q6	126	24	treatmentnaïve	treatmentnaïve	NN
cord-014712-5u4e00q6	126	25	CVID	CVID	NNP
cord-014712-5u4e00q6	126	26	patients	patient	NNS
cord-014712-5u4e00q6	126	27	.	.	.
cord-014712-5u4e00q6	127	1	These	these	DT
cord-014712-5u4e00q6	127	2	findings	finding	NNS
cord-014712-5u4e00q6	127	3	were	be	VBD
cord-014712-5u4e00q6	127	4	further	further	RB
cord-014712-5u4e00q6	127	5	discussed	discuss	VBN
cord-014712-5u4e00q6	127	6	in	in	IN
cord-014712-5u4e00q6	127	7	the	the	DT
cord-014712-5u4e00q6	127	8	context	context	NN
cord-014712-5u4e00q6	127	9	of	of	IN
cord-014712-5u4e00q6	127	10	the	the	DT
cord-014712-5u4e00q6	127	11	similarities	similarity	NNS
cord-014712-5u4e00q6	127	12	that	that	WDT
cord-014712-5u4e00q6	127	13	exist	exist	VBP
cord-014712-5u4e00q6	127	14	along	along	IN
cord-014712-5u4e00q6	127	15	with	with	IN
cord-014712-5u4e00q6	127	16	markers	marker	NNS
cord-014712-5u4e00q6	127	17	for	for	IN
cord-014712-5u4e00q6	127	18	immune	immune	JJ
cord-014712-5u4e00q6	127	19	senescence	senescence	NN
cord-014712-5u4e00q6	127	20	(	(	-LRB-
cord-014712-5u4e00q6	127	21	lack	lack	NN
cord-014712-5u4e00q6	127	22	of	of	IN
cord-014712-5u4e00q6	127	23	CD28	CD28	NNP
cord-014712-5u4e00q6	127	24	or	or	CC
cord-014712-5u4e00q6	127	25	expression	expression	NN
cord-014712-5u4e00q6	127	26	of	of	IN
cord-014712-5u4e00q6	127	27	CD57	CD57	NNP
cord-014712-5u4e00q6	127	28	)	)	-RRB-
cord-014712-5u4e00q6	127	29	.	.	.
cord-014712-5u4e00q6	128	1	Increased	increase	VBN
cord-014712-5u4e00q6	128	2	frequency	frequency	NN
cord-014712-5u4e00q6	128	3	of	of	IN
cord-014712-5u4e00q6	128	4	IFN	IFN	NNP
cord-014712-5u4e00q6	128	5	-	-	HYPH
cord-014712-5u4e00q6	128	6	γ	γ	NN
cord-014712-5u4e00q6	128	7	polymorphisms	polymorphism	NNS
cord-014712-5u4e00q6	128	8	associated	associate	VBN
cord-014712-5u4e00q6	128	9	with	with	IN
cord-014712-5u4e00q6	128	10	low	low	JJ
cord-014712-5u4e00q6	128	11	expression	expression	NN
cord-014712-5u4e00q6	128	12	level	level	NN
cord-014712-5u4e00q6	128	13	found	find	VBN
cord-014712-5u4e00q6	128	14	could	could	MD
cord-014712-5u4e00q6	128	15	indicate	indicate	VB
cord-014712-5u4e00q6	128	16	genetically	genetically	RB
cord-014712-5u4e00q6	128	17	predisposition	predisposition	NN
cord-014712-5u4e00q6	128	18	to	to	IN
cord-014712-5u4e00q6	128	19	high	high	JJ
cord-014712-5u4e00q6	128	20	activation	activation	NN
cord-014712-5u4e00q6	128	21	of	of	IN
cord-014712-5u4e00q6	128	22	TH2	TH2	NNP
cord-014712-5u4e00q6	128	23	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	128	24	in	in	IN
cord-014712-5u4e00q6	128	25	CVID	CVID	NNP
cord-014712-5u4e00q6	128	26	and	and	CC
cord-014712-5u4e00q6	128	27	consequently	consequently	RB
cord-014712-5u4e00q6	128	28	support	support	VBP
cord-014712-5u4e00q6	128	29	the	the	DT
cord-014712-5u4e00q6	128	30	concept	concept	NN
cord-014712-5u4e00q6	128	31	of	of	IN
cord-014712-5u4e00q6	128	32	impaired	impaired	JJ
cord-014712-5u4e00q6	128	33	TH1-type	th1-type	NN
cord-014712-5u4e00q6	128	34	responses	response	NNS
cord-014712-5u4e00q6	128	35	.	.	.
cord-014712-5u4e00q6	129	1	In	in	IN
cord-014712-5u4e00q6	129	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	129	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	129	4	study	study	NN
cord-014712-5u4e00q6	129	5	provided	provide	VBD
cord-014712-5u4e00q6	129	6	new	new	JJ
cord-014712-5u4e00q6	129	7	insight	insight	NN
cord-014712-5u4e00q6	129	8	into	into	IN
cord-014712-5u4e00q6	129	9	the	the	DT
cord-014712-5u4e00q6	129	10	pathogenesis	pathogenesis	NN
cord-014712-5u4e00q6	129	11	of	of	IN
cord-014712-5u4e00q6	129	12	CVID	CVID	NNP
cord-014712-5u4e00q6	129	13	.	.	.
cord-014712-5u4e00q6	130	1	This	this	DT
cord-014712-5u4e00q6	130	2	work	work	NN
cord-014712-5u4e00q6	130	3	was	be	VBD
cord-014712-5u4e00q6	130	4	partially	partially	RB
cord-014712-5u4e00q6	130	5	granted	grant	VBN
cord-014712-5u4e00q6	130	6	by	by	IN
cord-014712-5u4e00q6	130	7	Medical	Medical	NNP
cord-014712-5u4e00q6	130	8	University	University	NNP
cord-014712-5u4e00q6	130	9	Sofia	Sofia	NNP
cord-014712-5u4e00q6	130	10	,	,	,
cord-014712-5u4e00q6	130	11	Grant#55	Grant#55	NNP
cord-014712-5u4e00q6	130	12	BCG	BCG	NNP
cord-014712-5u4e00q6	130	13	vaccination	vaccination	NN
cord-014712-5u4e00q6	130	14	at	at	IN
cord-014712-5u4e00q6	130	15	birth	birth	NN
cord-014712-5u4e00q6	130	16	is	be	VBZ
cord-014712-5u4e00q6	130	17	the	the	DT
cord-014712-5u4e00q6	130	18	constant	constant	JJ
cord-014712-5u4e00q6	130	19	element	element	NN
cord-014712-5u4e00q6	130	20	of	of	IN
cord-014712-5u4e00q6	130	21	vaccination	vaccination	NN
cord-014712-5u4e00q6	130	22	programmes	programme	NNS
cord-014712-5u4e00q6	130	23	in	in	IN
cord-014712-5u4e00q6	130	24	Poland	Poland	NNP
cord-014712-5u4e00q6	130	25	.	.	.
cord-014712-5u4e00q6	131	1	High	high	JJ
cord-014712-5u4e00q6	131	2	reactogenic	reactogenic	NN
cord-014712-5u4e00q6	131	3	BCG	BCG	NNP
cord-014712-5u4e00q6	131	4	Danish	danish	JJ
cord-014712-5u4e00q6	131	5	vaccine	vaccine	NN
cord-014712-5u4e00q6	131	6	has	have	VBZ
cord-014712-5u4e00q6	131	7	been	be	VBN
cord-014712-5u4e00q6	131	8	replaced	replace	VBN
cord-014712-5u4e00q6	131	9	in	in	IN
cord-014712-5u4e00q6	131	10	1955	1955	CD
cord-014712-5u4e00q6	131	11	,	,	,
cord-014712-5u4e00q6	131	12	by	by	IN
cord-014712-5u4e00q6	131	13	BCG	BCG	NNP
cord-014712-5u4e00q6	131	14	Moreau	Moreau	NNP
cord-014712-5u4e00q6	131	15	vaccine	vaccine	NN
cord-014712-5u4e00q6	131	16	.	.	.
cord-014712-5u4e00q6	132	1	Frequency	frequency	NN
cord-014712-5u4e00q6	132	2	of	of	IN
cord-014712-5u4e00q6	132	3	disseminated	disseminate	VBN
cord-014712-5u4e00q6	132	4	BCG	BCG	NNP
cord-014712-5u4e00q6	132	5	infection	infection	NN
cord-014712-5u4e00q6	132	6	,	,	,
cord-014712-5u4e00q6	132	7	in	in	IN
cord-014712-5u4e00q6	132	8	children	child	NNS
cord-014712-5u4e00q6	132	9	with	with	IN
cord-014712-5u4e00q6	132	10	primary	primary	JJ
cord-014712-5u4e00q6	132	11	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	132	12	after	after	IN
cord-014712-5u4e00q6	132	13	BCG	BCG	NNP
cord-014712-5u4e00q6	132	14	Moreau	Moreau	NNP
cord-014712-5u4e00q6	132	15	vaccine	vaccine	NN
cord-014712-5u4e00q6	132	16	manufactured	manufacture	VBN
cord-014712-5u4e00q6	132	17	by	by	IN
cord-014712-5u4e00q6	132	18	Biomed	Biomed	NNP
cord-014712-5u4e00q6	132	19	,	,	,
cord-014712-5u4e00q6	132	20	Poland	Poland	NNP
cord-014712-5u4e00q6	132	21	were	be	VBD
cord-014712-5u4e00q6	132	22	estimated	estimate	VBN
cord-014712-5u4e00q6	132	23	.	.	.
cord-014712-5u4e00q6	133	1	One	one	CD
cord-014712-5u4e00q6	133	2	thousand	thousand	CD
cord-014712-5u4e00q6	133	3	five	five	CD
cord-014712-5u4e00q6	133	4	hundred	hundred	CD
cord-014712-5u4e00q6	133	5	sixty	sixty	CD
cord-014712-5u4e00q6	133	6	three	three	CD
cord-014712-5u4e00q6	133	7	cases	case	NNS
cord-014712-5u4e00q6	133	8	of	of	IN
cord-014712-5u4e00q6	133	9	primary	primary	JJ
cord-014712-5u4e00q6	133	10	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	133	11	were	be	VBD
cord-014712-5u4e00q6	133	12	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	133	13	in	in	IN
cord-014712-5u4e00q6	133	14	the	the	DT
cord-014712-5u4e00q6	133	15	Department	Department	NNP
cord-014712-5u4e00q6	133	16	of	of	IN
cord-014712-5u4e00q6	133	17	Immunology	Immunology	NNP
cord-014712-5u4e00q6	133	18	,	,	,
cord-014712-5u4e00q6	133	19	Children	Children	NNP
cord-014712-5u4e00q6	133	20	's	's	POS
cord-014712-5u4e00q6	133	21	Memorial	Memorial	NNP
cord-014712-5u4e00q6	133	22	Health	Health	NNP
cord-014712-5u4e00q6	133	23	Institute	Institute	NNP
cord-014712-5u4e00q6	133	24	in	in	IN
cord-014712-5u4e00q6	133	25	Warsaw	Warsaw	NNP
cord-014712-5u4e00q6	133	26	between	between	IN
cord-014712-5u4e00q6	133	27	1980	1980	CD
cord-014712-5u4e00q6	133	28	-2013	-2013	NNS
cord-014712-5u4e00q6	133	29	.	.	.
cord-014712-5u4e00q6	134	1	Among	among	IN
cord-014712-5u4e00q6	134	2	patients	patient	NNS
cord-014712-5u4e00q6	134	3	with	with	IN
cord-014712-5u4e00q6	134	4	T	T	NNP
cord-014712-5u4e00q6	134	5	cell	cell	NN
cord-014712-5u4e00q6	134	6	predominant	predominant	JJ
cord-014712-5u4e00q6	134	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	134	8	,	,	,
cord-014712-5u4e00q6	134	9	group	group	NN
cord-014712-5u4e00q6	134	10	high	high	JJ
cord-014712-5u4e00q6	134	11	risk	risk	NN
cord-014712-5u4e00q6	134	12	of	of	IN
cord-014712-5u4e00q6	134	13	BCG	BCG	NNP
cord-014712-5u4e00q6	134	14	infection	infection	NN
cord-014712-5u4e00q6	134	15	,	,	,
cord-014712-5u4e00q6	134	16	SCID	SCID	NNP
cord-014712-5u4e00q6	134	17	was	be	VBD
cord-014712-5u4e00q6	134	18	recognized	recognize	VBN
cord-014712-5u4e00q6	134	19	in	in	IN
cord-014712-5u4e00q6	134	20	62	62	CD
cord-014712-5u4e00q6	134	21	children	child	NNS
cord-014712-5u4e00q6	134	22	.	.	.
cord-014712-5u4e00q6	135	1	Mendelian	mendelian	JJ
cord-014712-5u4e00q6	135	2	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	135	3	to	to	IN
cord-014712-5u4e00q6	135	4	mycobactarial	mycobactarial	JJ
cord-014712-5u4e00q6	135	5	diseases	disease	NNS
cord-014712-5u4e00q6	135	6	(	(	-LRB-
cord-014712-5u4e00q6	135	7	MSMD	MSMD	NNP
cord-014712-5u4e00q6	135	8	)	)	-RRB-
cord-014712-5u4e00q6	135	9	was	be	VBD
cord-014712-5u4e00q6	135	10	detected	detect	VBN
cord-014712-5u4e00q6	135	11	in	in	IN
cord-014712-5u4e00q6	135	12	four	four	CD
cord-014712-5u4e00q6	135	13	patients	patient	NNS
cord-014712-5u4e00q6	135	14	:	:	:
cord-014712-5u4e00q6	136	1	IFGR1	IFGR1	NNP
cord-014712-5u4e00q6	136	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	136	3	and	and	CC
cord-014712-5u4e00q6	136	4	IL12	IL12	NNP
cord-014712-5u4e00q6	136	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	136	6	-equally	-equally	NN
cord-014712-5u4e00q6	137	1	in	in	IN
cord-014712-5u4e00q6	137	2	two	two	CD
cord-014712-5u4e00q6	137	3	patients	patient	NNS
cord-014712-5u4e00q6	137	4	,	,	,
cord-014712-5u4e00q6	137	5	and	and	CC
cord-014712-5u4e00q6	137	6	NEMO	NEMO	NNP
cord-014712-5u4e00q6	137	7	-in	-in	HYPH
cord-014712-5u4e00q6	137	8	one	one	CD
cord-014712-5u4e00q6	137	9	.	.	.
cord-014712-5u4e00q6	138	1	In	in	IN
cord-014712-5u4e00q6	138	2	the	the	DT
cord-014712-5u4e00q6	138	3	group	group	NN
cord-014712-5u4e00q6	138	4	of	of	IN
cord-014712-5u4e00q6	138	5	primary	primary	JJ
cord-014712-5u4e00q6	138	6	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	138	7	regarded	regard	VBN
cord-014712-5u4e00q6	138	8	to	to	TO
cord-014712-5u4e00q6	138	9	be	be	VB
cord-014712-5u4e00q6	138	10	less	less	RBR
cord-014712-5u4e00q6	138	11	prone	prone	JJ
cord-014712-5u4e00q6	138	12	to	to	IN
cord-014712-5u4e00q6	138	13	Mycobacterium	Mycobacterium	NNP
cord-014712-5u4e00q6	138	14	infections	infection	NNS
cord-014712-5u4e00q6	138	15	,	,	,
cord-014712-5u4e00q6	138	16	CGD	CGD	NNP
cord-014712-5u4e00q6	138	17	was	be	VBD
cord-014712-5u4e00q6	138	18	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	138	19	in52	in52	NNP
cord-014712-5u4e00q6	138	20	,	,	,
cord-014712-5u4e00q6	138	21	HIES	HIES	NNP
cord-014712-5u4e00q6	138	22	in	in	IN
cord-014712-5u4e00q6	138	23	20	20	CD
cord-014712-5u4e00q6	138	24	patients	patient	NNS
cord-014712-5u4e00q6	138	25	,	,	,
cord-014712-5u4e00q6	138	26	and	and	CC
cord-014712-5u4e00q6	138	27	XL	XL	NNP
cord-014712-5u4e00q6	138	28	-	-	HYPH
cord-014712-5u4e00q6	138	29	HIGM	HIGM	NNP
cord-014712-5u4e00q6	138	30	in	in	IN
cord-014712-5u4e00q6	138	31	4	4	CD
cord-014712-5u4e00q6	138	32	patients	patient	NNS
cord-014712-5u4e00q6	138	33	.	.	.
cord-014712-5u4e00q6	139	1	Disseminated	disseminate	VBN
cord-014712-5u4e00q6	139	2	BCG	BCG	NNP
cord-014712-5u4e00q6	139	3	infection	infection	NN
cord-014712-5u4e00q6	139	4	was	be	VBD
cord-014712-5u4e00q6	139	5	recognized	recognize	VBN
cord-014712-5u4e00q6	139	6	in	in	IN
cord-014712-5u4e00q6	139	7	10	10	CD
cord-014712-5u4e00q6	139	8	SCID	SCID	NNP
cord-014712-5u4e00q6	139	9	patients	patient	NNS
cord-014712-5u4e00q6	139	10	,	,	,
cord-014712-5u4e00q6	139	11	2	2	CD
cord-014712-5u4e00q6	139	12	of	of	IN
cord-014712-5u4e00q6	139	13	them	-PRON-	PRP
cord-014712-5u4e00q6	139	14	died	die	VBD
cord-014712-5u4e00q6	139	15	,	,	,
cord-014712-5u4e00q6	139	16	because	because	IN
cord-014712-5u4e00q6	139	17	of	of	IN
cord-014712-5u4e00q6	139	18	BCG	BCG	NNP
cord-014712-5u4e00q6	139	19	diseases	disease	NNS
cord-014712-5u4e00q6	139	20	.	.	.
cord-014712-5u4e00q6	140	1	All	all	DT
cord-014712-5u4e00q6	140	2	4	4	CD
cord-014712-5u4e00q6	140	3	patients	patient	NNS
cord-014712-5u4e00q6	140	4	with	with	IN
cord-014712-5u4e00q6	140	5	MSMD	MSMD	NNP
cord-014712-5u4e00q6	140	6	developed	develop	VBD
cord-014712-5u4e00q6	140	7	BCG	BCG	NNP
cord-014712-5u4e00q6	140	8	infection	infection	NN
cord-014712-5u4e00q6	140	9	,	,	,
cord-014712-5u4e00q6	140	10	one	one	CD
cord-014712-5u4e00q6	140	11	with	with	IN
cord-014712-5u4e00q6	140	12	IL-2	IL-2	NNP
cord-014712-5u4e00q6	140	13	deficiency	deficiency	NN
cord-014712-5u4e00q6	140	14	died	die	VBD
cord-014712-5u4e00q6	140	15	.	.	.
cord-014712-5u4e00q6	141	1	During	during	IN
cord-014712-5u4e00q6	141	2	nearly	nearly	RB
cord-014712-5u4e00q6	141	3	30-year	30-year	JJ
cord-014712-5u4e00q6	141	4	-	-	HYPH
cord-014712-5u4e00q6	141	5	follow	follow	NN
cord-014712-5u4e00q6	141	6	-	-	HYPH
cord-014712-5u4e00q6	141	7	up	up	NN
cord-014712-5u4e00q6	141	8	,	,	,
cord-014712-5u4e00q6	141	9	no	no	DT
cord-014712-5u4e00q6	141	10	case	case	NN
cord-014712-5u4e00q6	141	11	of	of	IN
cord-014712-5u4e00q6	141	12	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	141	13	or	or	CC
cord-014712-5u4e00q6	141	14	disseminated	disseminate	VBN
cord-014712-5u4e00q6	141	15	BCG	BCG	NNP
cord-014712-5u4e00q6	141	16	infection	infection	NN
cord-014712-5u4e00q6	141	17	have	have	VBP
cord-014712-5u4e00q6	141	18	been	be	VBN
cord-014712-5u4e00q6	141	19	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	141	20	among	among	IN
cord-014712-5u4e00q6	141	21	CGD	CGD	NNP
cord-014712-5u4e00q6	141	22	,	,	,
cord-014712-5u4e00q6	141	23	HIES	HIES	NNP
cord-014712-5u4e00q6	141	24	and	and	CC
cord-014712-5u4e00q6	141	25	XL	XL	NNP
cord-014712-5u4e00q6	141	26	-	-	HYPH
cord-014712-5u4e00q6	141	27	HIGM	HIGM	NNP
cord-014712-5u4e00q6	141	28	patients	patient	NNS
cord-014712-5u4e00q6	141	29	.	.	.
cord-014712-5u4e00q6	142	1	Early	early	JJ
cord-014712-5u4e00q6	142	2	anti	anti	JJ
cord-014712-5u4e00q6	142	3	-Tb	-tb	NN
cord-014712-5u4e00q6	142	4	drug	drug	NN
cord-014712-5u4e00q6	142	5	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	142	6	and	and	CC
cord-014712-5u4e00q6	142	7	usage	usage	NN
cord-014712-5u4e00q6	142	8	of	of	IN
cord-014712-5u4e00q6	142	9	wide	wide	JJ
cord-014712-5u4e00q6	142	10	range	range	NN
cord-014712-5u4e00q6	142	11	of	of	IN
cord-014712-5u4e00q6	142	12	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	142	13	in	in	IN
cord-014712-5u4e00q6	142	14	therapy	therapy	NN
cord-014712-5u4e00q6	142	15	is	be	VBZ
cord-014712-5u4e00q6	142	16	crucial	crucial	JJ
cord-014712-5u4e00q6	142	17	for	for	IN
cord-014712-5u4e00q6	142	18	cleaning	cleaning	NN
cord-014712-5u4e00q6	142	19	of	of	IN
cord-014712-5u4e00q6	142	20	BCG	BCG	NNP
cord-014712-5u4e00q6	142	21	infection	infection	NN
cord-014712-5u4e00q6	142	22	.	.	.
cord-014712-5u4e00q6	143	1	Peter	Peter	NNP
cord-014712-5u4e00q6	143	2	Čižnár	Čižnár	NNP
cord-014712-5u4e00q6	143	3	1	1	CD
cord-014712-5u4e00q6	143	4	;	;	:
cord-014712-5u4e00q6	143	5	Julia	Julia	NNP
cord-014712-5u4e00q6	143	6	Horáková	Horáková	NNP
cord-014712-5u4e00q6	143	7	2	2	CD
cord-014712-5u4e00q6	143	8	;	;	:
cord-014712-5u4e00q6	143	9	Peter	Peter	NNP
cord-014712-5u4e00q6	143	10	Švec	Švec	NNP
cord-014712-5u4e00q6	143	11	2	2	CD
cord-014712-5u4e00q6	143	12	;	;	:
cord-014712-5u4e00q6	143	13	Ivana	Ivana	NNP
cord-014712-5u4e00q6	143	14	Boďová	Boďová	NNP
cord-014712-5u4e00q6	143	15	2	2	CD
cord-014712-5u4e00q6	143	16	;	;	:
cord-014712-5u4e00q6	143	17	Sabina	Sabina	NNP
cord-014712-5u4e00q6	143	18	Šufliarska	Šufliarska	NNP
cord-014712-5u4e00q6	143	19	2	2	CD
cord-014712-5u4e00q6	143	20	;	;	:
cord-014712-5u4e00q6	143	21	Linda	Linda	NNP
cord-014712-5u4e00q6	143	22	Libai	Libai	NNP
cord-014712-5u4e00q6	143	23	Veghová	Veghová	NNP
cord-014712-5u4e00q6	143	24	1	1	CD
cord-014712-5u4e00q6	143	25	;	;	:
cord-014712-5u4e00q6	143	26	,	,	,
cord-014712-5u4e00q6	143	27	Marieta	Marieta	NNP
cord-014712-5u4e00q6	143	28	Hricová	Hricová	NNP
cord-014712-5u4e00q6	143	29	1	1	CD
cord-014712-5u4e00q6	143	30	1	1	CD
cord-014712-5u4e00q6	143	31	1	1	CD
cord-014712-5u4e00q6	143	32	st	st	NNP
cord-014712-5u4e00q6	143	33	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	143	34	department	department	NN
cord-014712-5u4e00q6	143	35	,	,	,
cord-014712-5u4e00q6	143	36	Comenius	Comenius	NNP
cord-014712-5u4e00q6	143	37	University	University	NNP
cord-014712-5u4e00q6	143	38	Medical	Medical	NNP
cord-014712-5u4e00q6	143	39	Faculty	Faculty	NNP
cord-014712-5u4e00q6	143	40	,	,	,
cord-014712-5u4e00q6	143	41	Children`s	children`s	DT
cord-014712-5u4e00q6	143	42	University	University	NNP
cord-014712-5u4e00q6	143	43	Hospital	Hospital	NNP
cord-014712-5u4e00q6	143	44	,	,	,
cord-014712-5u4e00q6	143	45	Bratislava	Bratislava	NNP
cord-014712-5u4e00q6	143	46	,	,	,
cord-014712-5u4e00q6	143	47	Slovakia	Slovakia	NNP
cord-014712-5u4e00q6	143	48	.	.	.
cord-014712-5u4e00q6	144	1	2	2	CD
cord-014712-5u4e00q6	144	2	Transplantation	transplantation	NN
cord-014712-5u4e00q6	144	3	unit	unit	NN
cord-014712-5u4e00q6	144	4	,	,	,
cord-014712-5u4e00q6	144	5	Department	Department	NNP
cord-014712-5u4e00q6	144	6	of	of	IN
cord-014712-5u4e00q6	144	7	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	144	8	Haematology	Haematology	NNP
cord-014712-5u4e00q6	144	9	and	and	CC
cord-014712-5u4e00q6	144	10	Oncology	Oncology	NNP
cord-014712-5u4e00q6	144	11	,	,	,
cord-014712-5u4e00q6	144	12	Children`s	children`s	DT
cord-014712-5u4e00q6	144	13	University	University	NNP
cord-014712-5u4e00q6	144	14	Hospital	Hospital	NNP
cord-014712-5u4e00q6	144	15	,	,	,
cord-014712-5u4e00q6	144	16	Bratislava	Bratislava	NNP
cord-014712-5u4e00q6	144	17	,	,	,
cord-014712-5u4e00q6	144	18	Slovakia	Slovakia	NNP
cord-014712-5u4e00q6	144	19	.	.	.
cord-014712-5u4e00q6	145	1	Objectives	objective	NNS
cord-014712-5u4e00q6	145	2	:	:	:
cord-014712-5u4e00q6	146	1	Severe	severe	JJ
cord-014712-5u4e00q6	146	2	combined	combine	VBN
cord-014712-5u4e00q6	146	3	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	146	4	(	(	-LRB-
cord-014712-5u4e00q6	146	5	SCID	SCID	NNP
cord-014712-5u4e00q6	146	6	)	)	-RRB-
cord-014712-5u4e00q6	146	7	is	be	VBZ
cord-014712-5u4e00q6	146	8	a	a	DT
cord-014712-5u4e00q6	146	9	group	group	NN
cord-014712-5u4e00q6	146	10	of	of	IN
cord-014712-5u4e00q6	146	11	disorders	disorder	NNS
cord-014712-5u4e00q6	146	12	due	due	JJ
cord-014712-5u4e00q6	146	13	to	to	IN
cord-014712-5u4e00q6	146	14	more	more	JJR
cord-014712-5u4e00q6	146	15	than	than	IN
cord-014712-5u4e00q6	146	16	15	15	CD
cord-014712-5u4e00q6	146	17	genetic	genetic	JJ
cord-014712-5u4e00q6	146	18	defects	defect	NNS
cord-014712-5u4e00q6	146	19	,	,	,
cord-014712-5u4e00q6	146	20	characterized	characterize	VBN
cord-014712-5u4e00q6	146	21	by	by	IN
cord-014712-5u4e00q6	146	22	increased	increase	VBN
cord-014712-5u4e00q6	146	23	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	146	24	to	to	IN
cord-014712-5u4e00q6	146	25	severe	severe	JJ
cord-014712-5u4e00q6	146	26	infections	infection	NNS
cord-014712-5u4e00q6	146	27	and	and	CC
cord-014712-5u4e00q6	146	28	early	early	JJ
cord-014712-5u4e00q6	146	29	life	life	NN
cord-014712-5u4e00q6	146	30	death	death	NN
cord-014712-5u4e00q6	146	31	.	.	.
cord-014712-5u4e00q6	147	1	The	the	DT
cord-014712-5u4e00q6	147	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	147	3	is	be	VBZ
cord-014712-5u4e00q6	147	4	supported	support	VBN
cord-014712-5u4e00q6	147	5	by	by	IN
cord-014712-5u4e00q6	147	6	the	the	DT
cord-014712-5u4e00q6	147	7	demonstration	demonstration	NN
cord-014712-5u4e00q6	147	8	of	of	IN
cord-014712-5u4e00q6	147	9	low	low	JJ
cord-014712-5u4e00q6	147	10	absolute	absolute	JJ
cord-014712-5u4e00q6	147	11	T	T	NNP
cord-014712-5u4e00q6	147	12	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	147	13	count	count	NN
cord-014712-5u4e00q6	147	14	variably	variably	RB
cord-014712-5u4e00q6	147	15	associated	associate	VBN
cord-014712-5u4e00q6	147	16	with	with	IN
cord-014712-5u4e00q6	147	17	numerical	numerical	JJ
cord-014712-5u4e00q6	147	18	defects	defect	NNS
cord-014712-5u4e00q6	147	19	of	of	IN
cord-014712-5u4e00q6	147	20	B	B	NNP
cord-014712-5u4e00q6	147	21	and	and	CC
cord-014712-5u4e00q6	147	22	NK	NK	NNP
cord-014712-5u4e00q6	147	23	cells	cell	NNS
cord-014712-5u4e00q6	147	24	.	.	.
cord-014712-5u4e00q6	148	1	Patients	patient	NNS
cord-014712-5u4e00q6	148	2	are	be	VBP
cord-014712-5u4e00q6	148	3	very	very	RB
cord-014712-5u4e00q6	148	4	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	148	5	regarding	regard	VBG
cord-014712-5u4e00q6	148	6	clinical	clinical	JJ
cord-014712-5u4e00q6	148	7	course	course	NN
cord-014712-5u4e00q6	148	8	,	,	,
cord-014712-5u4e00q6	148	9	immune	immune	JJ
cord-014712-5u4e00q6	148	10	parameters	parameter	NNS
cord-014712-5u4e00q6	148	11	and	and	CC
cord-014712-5u4e00q6	148	12	clinical	clinical	JJ
cord-014712-5u4e00q6	148	13	outcome	outcome	NN
cord-014712-5u4e00q6	148	14	.	.	.
cord-014712-5u4e00q6	149	1	BCG	BCG	NNP
cord-014712-5u4e00q6	149	2	(	(	-LRB-
cord-014712-5u4e00q6	149	3	Bacillus	Bacillus	NNP
cord-014712-5u4e00q6	149	4	Calmette	Calmette	NNP
cord-014712-5u4e00q6	149	5	-	-	HYPH
cord-014712-5u4e00q6	149	6	Guerin	Guerin	NNP
cord-014712-5u4e00q6	149	7	)	)	-RRB-
cord-014712-5u4e00q6	149	8	vaccine	vaccine	NN
cord-014712-5u4e00q6	149	9	,	,	,
cord-014712-5u4e00q6	149	10	a	a	DT
cord-014712-5u4e00q6	149	11	life	life	NN
cord-014712-5u4e00q6	149	12	attenuated	attenuated	JJ
cord-014712-5u4e00q6	149	13	vaccine	vaccine	NN
cord-014712-5u4e00q6	149	14	was	be	VBD
cord-014712-5u4e00q6	149	15	the	the	DT
cord-014712-5u4e00q6	149	16	part	part	NN
cord-014712-5u4e00q6	149	17	of	of	IN
cord-014712-5u4e00q6	149	18	Slovak	Slovak	NNP
cord-014712-5u4e00q6	149	19	Immunization	Immunization	NNP
cord-014712-5u4e00q6	149	20	Program	Program	NNP
cord-014712-5u4e00q6	149	21	,	,	,
cord-014712-5u4e00q6	149	22	administered	administer	VBN
cord-014712-5u4e00q6	149	23	at	at	IN
cord-014712-5u4e00q6	149	24	birth	birth	NN
cord-014712-5u4e00q6	149	25	until	until	IN
cord-014712-5u4e00q6	149	26	2011	2011	CD
cord-014712-5u4e00q6	149	27	.	.	.
cord-014712-5u4e00q6	150	1	A	a	DT
cord-014712-5u4e00q6	150	2	comparison	comparison	NN
cord-014712-5u4e00q6	150	3	of	of	IN
cord-014712-5u4e00q6	150	4	clinical	clinical	JJ
cord-014712-5u4e00q6	150	5	course	course	NN
cord-014712-5u4e00q6	150	6	of	of	IN
cord-014712-5u4e00q6	150	7	BCG	BCG	NNP
cord-014712-5u4e00q6	150	8	exposed	expose	VBN
cord-014712-5u4e00q6	150	9	(	(	-LRB-
cord-014712-5u4e00q6	150	10	BCG+	BCG+	NNP
cord-014712-5u4e00q6	150	11	)	)	-RRB-
cord-014712-5u4e00q6	150	12	and	and	CC
cord-014712-5u4e00q6	150	13	non	non	JJ
cord-014712-5u4e00q6	150	14	-	-	JJ
cord-014712-5u4e00q6	150	15	exposed	exposed	JJ
cord-014712-5u4e00q6	150	16	(	(	-LRB-
cord-014712-5u4e00q6	150	17	BCG-	BCG-	NNP
cord-014712-5u4e00q6	150	18	)	)	-RRB-
cord-014712-5u4e00q6	150	19	SCID	SCID	NNP
cord-014712-5u4e00q6	150	20	patients	patient	NNS
cord-014712-5u4e00q6	150	21	in	in	IN
cord-014712-5u4e00q6	150	22	Slovakia	Slovakia	NNP
cord-014712-5u4e00q6	150	23	in	in	IN
cord-014712-5u4e00q6	150	24	period	period	NN
cord-014712-5u4e00q6	150	25	of	of	IN
cord-014712-5u4e00q6	150	26	past	past	JJ
cord-014712-5u4e00q6	150	27	10	10	CD
cord-014712-5u4e00q6	150	28	years	year	NNS
cord-014712-5u4e00q6	150	29	are	be	VBP
cord-014712-5u4e00q6	150	30	given	give	VBN
cord-014712-5u4e00q6	150	31	.	.	.
cord-014712-5u4e00q6	151	1	Results	result	NNS
cord-014712-5u4e00q6	151	2	:	:	:
cord-014712-5u4e00q6	152	1	Incidence	incidence	NN
cord-014712-5u4e00q6	152	2	rate	rate	NN
cord-014712-5u4e00q6	152	3	of	of	IN
cord-014712-5u4e00q6	152	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	152	5	and	and	CC
cord-014712-5u4e00q6	152	6	treated	treat	VBN
cord-014712-5u4e00q6	152	7	SCID	SCID	NNP
cord-014712-5u4e00q6	152	8	in	in	IN
cord-014712-5u4e00q6	152	9	Slovakia	Slovakia	NNP
cord-014712-5u4e00q6	152	10	was	be	VBD
cord-014712-5u4e00q6	152	11	calculated	calculate	VBN
cord-014712-5u4e00q6	152	12	to	to	IN
cord-014712-5u4e00q6	152	13	1:87.000	1:87.000	CD
cord-014712-5u4e00q6	152	14	,	,	,
cord-014712-5u4e00q6	152	15	meaning	mean	VBG
cord-014712-5u4e00q6	152	16	1,5	1,5	CD
cord-014712-5u4e00q6	152	17	cases	case	NNS
cord-014712-5u4e00q6	152	18	per	per	IN
cord-014712-5u4e00q6	152	19	year	year	NN
cord-014712-5u4e00q6	152	20	.	.	.
cord-014712-5u4e00q6	153	1	In	in	IN
cord-014712-5u4e00q6	153	2	total	total	JJ
cord-014712-5u4e00q6	153	3	10	10	CD
cord-014712-5u4e00q6	153	4	cases	case	NNS
cord-014712-5u4e00q6	153	5	represent	represent	VBP
cord-014712-5u4e00q6	153	6	4	4	CD
cord-014712-5u4e00q6	153	7	ADA	ADA	NNP
cord-014712-5u4e00q6	153	8	patients	patient	NNS
cord-014712-5u4e00q6	153	9	,	,	,
cord-014712-5u4e00q6	153	10	2	2	CD
cord-014712-5u4e00q6	153	11	IL2RG	IL2RG	NNP
cord-014712-5u4e00q6	153	12	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	153	13	,	,	,
cord-014712-5u4e00q6	153	14	1	1	CD
cord-014712-5u4e00q6	153	15	case	case	NN
cord-014712-5u4e00q6	153	16	of	of	IN
cord-014712-5u4e00q6	153	17	complete	complete	JJ
cord-014712-5u4e00q6	153	18	del22q11	del22q11	NN
cord-014712-5u4e00q6	153	19	and	and	CC
cord-014712-5u4e00q6	153	20	in	in	IN
cord-014712-5u4e00q6	153	21	3	3	CD
cord-014712-5u4e00q6	153	22	cases	case	NNS
cord-014712-5u4e00q6	153	23	genetic	genetic	JJ
cord-014712-5u4e00q6	153	24	defect	defect	NN
cord-014712-5u4e00q6	153	25	was	be	VBD
cord-014712-5u4e00q6	153	26	not	not	RB
cord-014712-5u4e00q6	153	27	found	find	VBN
cord-014712-5u4e00q6	153	28	by	by	IN
cord-014712-5u4e00q6	153	29	analysis	analysis	NN
cord-014712-5u4e00q6	153	30	of	of	IN
cord-014712-5u4e00q6	153	31	RAG1/2	RAG1/2	NNP
cord-014712-5u4e00q6	153	32	,	,	,
cord-014712-5u4e00q6	153	33	IL2RG	IL2RG	NNP
cord-014712-5u4e00q6	153	34	,	,	,
cord-014712-5u4e00q6	153	35	Artemis	Artemis	NNP
cord-014712-5u4e00q6	153	36	,	,	,
cord-014712-5u4e00q6	153	37	IL7RA	IL7RA	NNP
cord-014712-5u4e00q6	153	38	,	,	,
cord-014712-5u4e00q6	153	39	JAK3	JAK3	NNP
cord-014712-5u4e00q6	153	40	and	and	CC
cord-014712-5u4e00q6	153	41	ADA	ADA	NNP
cord-014712-5u4e00q6	153	42	genes	gene	NNS
cord-014712-5u4e00q6	153	43	.	.	.
cord-014712-5u4e00q6	154	1	All	all	DT
cord-014712-5u4e00q6	154	2	patients	patient	NNS
cord-014712-5u4e00q6	154	3	were	be	VBD
cord-014712-5u4e00q6	154	4	confirmed	confirm	VBN
cord-014712-5u4e00q6	154	5	absent	absent	JJ
cord-014712-5u4e00q6	154	6	TREC	TREC	NNP
cord-014712-5u4e00q6	155	1	(	(	-LRB-
cord-014712-5u4e00q6	155	2	T	t	NN
cord-014712-5u4e00q6	155	3	-	-	HYPH
cord-014712-5u4e00q6	155	4	cell	cell	NN
cord-014712-5u4e00q6	155	5	receptor	receptor	NN
cord-014712-5u4e00q6	155	6	excision	excision	NN
cord-014712-5u4e00q6	155	7	circles	circle	NNS
cord-014712-5u4e00q6	155	8	)	)	-RRB-
cord-014712-5u4e00q6	156	1	copies	copy	NNS
cord-014712-5u4e00q6	156	2	in	in	IN
cord-014712-5u4e00q6	156	3	a	a	DT
cord-014712-5u4e00q6	156	4	retrospective	retrospective	JJ
cord-014712-5u4e00q6	156	5	neonatal	neonatal	JJ
cord-014712-5u4e00q6	156	6	Guthrie	Guthrie	NNP
cord-014712-5u4e00q6	156	7	card	card	NN
cord-014712-5u4e00q6	156	8	analysis	analysis	NN
cord-014712-5u4e00q6	156	9	.	.	.
cord-014712-5u4e00q6	157	1	Seven	seven	CD
cord-014712-5u4e00q6	157	2	out	out	IN
cord-014712-5u4e00q6	157	3	of	of	IN
cord-014712-5u4e00q6	157	4	these	these	DT
cord-014712-5u4e00q6	157	5	10	10	CD
cord-014712-5u4e00q6	157	6	patients	patient	NNS
cord-014712-5u4e00q6	157	7	underwent	undergo	VBD
cord-014712-5u4e00q6	157	8	HSCT	HSCT	NNP
cord-014712-5u4e00q6	157	9	,	,	,
cord-014712-5u4e00q6	157	10	in	in	IN
cord-014712-5u4e00q6	157	11	5	5	CD
cord-014712-5u4e00q6	157	12	the	the	DT
cord-014712-5u4e00q6	157	13	HSC	HSC	NNP
cord-014712-5u4e00q6	157	14	source	source	NN
cord-014712-5u4e00q6	157	15	was	be	VBD
cord-014712-5u4e00q6	157	16	a	a	DT
cord-014712-5u4e00q6	157	17	MUD	mud	NN
cord-014712-5u4e00q6	157	18	.	.	.
cord-014712-5u4e00q6	158	1	Favorite	favorite	JJ
cord-014712-5u4e00q6	158	2	outcome	outcome	NN
cord-014712-5u4e00q6	158	3	was	be	VBD
cord-014712-5u4e00q6	158	4	achieved	achieve	VBN
cord-014712-5u4e00q6	158	5	in	in	IN
cord-014712-5u4e00q6	158	6	6	6	CD
cord-014712-5u4e00q6	158	7	of	of	IN
cord-014712-5u4e00q6	158	8	them	-PRON-	PRP
cord-014712-5u4e00q6	158	9	.	.	.
cord-014712-5u4e00q6	159	1	Half	half	NN
cord-014712-5u4e00q6	159	2	of	of	IN
cord-014712-5u4e00q6	159	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	159	4	patients	patient	NNS
cord-014712-5u4e00q6	159	5	have	have	VBP
cord-014712-5u4e00q6	159	6	been	be	VBN
cord-014712-5u4e00q6	159	7	exposed	expose	VBN
cord-014712-5u4e00q6	159	8	to	to	IN
cord-014712-5u4e00q6	159	9	a	a	DT
cord-014712-5u4e00q6	159	10	live	live	JJ
cord-014712-5u4e00q6	159	11	BCG	BCG	NNP
cord-014712-5u4e00q6	159	12	vaccine	vaccine	NN
cord-014712-5u4e00q6	159	13	during	during	IN
cord-014712-5u4e00q6	159	14	neonatal	neonatal	JJ
cord-014712-5u4e00q6	159	15	period	period	NN
cord-014712-5u4e00q6	159	16	.	.	.
cord-014712-5u4e00q6	160	1	Patients	patient	NNS
cord-014712-5u4e00q6	160	2	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	160	3	with	with	IN
cord-014712-5u4e00q6	160	4	BCG	BCG	NNP
cord-014712-5u4e00q6	160	5	faced	face	VBD
cord-014712-5u4e00q6	160	6	severe	severe	JJ
cord-014712-5u4e00q6	160	7	complications	complication	NNS
cord-014712-5u4e00q6	160	8	and	and	CC
cord-014712-5u4e00q6	160	9	organ	organ	NN
cord-014712-5u4e00q6	160	10	damage	damage	NN
cord-014712-5u4e00q6	160	11	due	due	JJ
cord-014712-5u4e00q6	160	12	to	to	IN
cord-014712-5u4e00q6	160	13	generalized	generalized	JJ
cord-014712-5u4e00q6	160	14	skin	skin	NN
cord-014712-5u4e00q6	160	15	and	and	CC
cord-014712-5u4e00q6	160	16	organ	organ	NN
cord-014712-5u4e00q6	160	17	abscess	abscess	NN
cord-014712-5u4e00q6	160	18	formation	formation	NN
cord-014712-5u4e00q6	160	19	,	,	,
cord-014712-5u4e00q6	160	20	requiring	require	VBG
cord-014712-5u4e00q6	160	21	prolonged	prolong	VBN
cord-014712-5u4e00q6	160	22	(	(	-LRB-
cord-014712-5u4e00q6	160	23	up	up	IN
cord-014712-5u4e00q6	160	24	to	to	TO
cord-014712-5u4e00q6	160	25	18	18	CD
cord-014712-5u4e00q6	160	26	months	month	NNS
cord-014712-5u4e00q6	160	27	)	)	-RRB-
cord-014712-5u4e00q6	160	28	hospital	hospital	NN
cord-014712-5u4e00q6	160	29	care	care	NN
cord-014712-5u4e00q6	160	30	and	and	CC
cord-014712-5u4e00q6	160	31	complex	complex	JJ
cord-014712-5u4e00q6	160	32	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	160	33	therapy	therapy	NN
cord-014712-5u4e00q6	160	34	with	with	IN
cord-014712-5u4e00q6	160	35	more	more	JJR
cord-014712-5u4e00q6	160	36	than	than	IN
cord-014712-5u4e00q6	160	37	four	four	CD
cord-014712-5u4e00q6	160	38	types	type	NNS
cord-014712-5u4e00q6	160	39	of	of	IN
cord-014712-5u4e00q6	160	40	anti	anti	JJ
cord-014712-5u4e00q6	160	41	-	-	JJ
cord-014712-5u4e00q6	160	42	mycobacterium	mycobacterium	JJ
cord-014712-5u4e00q6	160	43	drugs	drug	NNS
cord-014712-5u4e00q6	160	44	,	,	,
cord-014712-5u4e00q6	160	45	for	for	IN
cord-014712-5u4e00q6	160	46	more	more	JJR
cord-014712-5u4e00q6	160	47	than	than	IN
cord-014712-5u4e00q6	160	48	2	2	CD
cord-014712-5u4e00q6	160	49	years	year	NNS
cord-014712-5u4e00q6	160	50	.	.	.
cord-014712-5u4e00q6	161	1	Average	average	JJ
cord-014712-5u4e00q6	161	2	length	length	NN
cord-014712-5u4e00q6	161	3	of	of	IN
cord-014712-5u4e00q6	161	4	hospital	hospital	NN
cord-014712-5u4e00q6	161	5	care	care	NN
cord-014712-5u4e00q6	161	6	for	for	IN
cord-014712-5u4e00q6	161	7	BCG	BCG	NNP
cord-014712-5u4e00q6	161	8	exposed	expose	VBN
cord-014712-5u4e00q6	161	9	patient	patient	NN
cord-014712-5u4e00q6	161	10	was	be	VBD
cord-014712-5u4e00q6	161	11	10,8	10,8	CD
cord-014712-5u4e00q6	161	12	months	month	NNS
cord-014712-5u4e00q6	161	13	vs.	vs.	CC
cord-014712-5u4e00q6	161	14	2,7	2,7	CD
cord-014712-5u4e00q6	161	15	months	month	NNS
cord-014712-5u4e00q6	161	16	in	in	IN
cord-014712-5u4e00q6	161	17	non	non	JJ
cord-014712-5u4e00q6	161	18	-	-	JJ
cord-014712-5u4e00q6	161	19	exposed	exposed	JJ
cord-014712-5u4e00q6	161	20	group	group	NN
cord-014712-5u4e00q6	161	21	(	(	-LRB-
cord-014712-5u4e00q6	161	22	p	p	NN
cord-014712-5u4e00q6	161	23	<	<	XX
cord-014712-5u4e00q6	161	24	0,05	0,05	NNP
cord-014712-5u4e00q6	161	25	)	)	-RRB-
cord-014712-5u4e00q6	161	26	.	.	.
cord-014712-5u4e00q6	162	1	No	no	DT
cord-014712-5u4e00q6	162	2	statistical	statistical	JJ
cord-014712-5u4e00q6	162	3	difference	difference	NN
cord-014712-5u4e00q6	162	4	was	be	VBD
cord-014712-5u4e00q6	162	5	found	find	VBN
cord-014712-5u4e00q6	162	6	between	between	IN
cord-014712-5u4e00q6	162	7	the	the	DT
cord-014712-5u4e00q6	162	8	time	time	NN
cord-014712-5u4e00q6	162	9	of	of	IN
cord-014712-5u4e00q6	162	10	recognized	recognize	VBN
cord-014712-5u4e00q6	162	11	first	first	JJ
cord-014712-5u4e00q6	162	12	symptoms	symptom	NNS
cord-014712-5u4e00q6	162	13	,	,	,
cord-014712-5u4e00q6	162	14	and	and	CC
cord-014712-5u4e00q6	162	15	time	time	NN
cord-014712-5u4e00q6	162	16	of	of	IN
cord-014712-5u4e00q6	162	17	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	162	18	in	in	IN
cord-014712-5u4e00q6	162	19	BCG	BCG	NNP
cord-014712-5u4e00q6	162	20	+	+	CC
cord-014712-5u4e00q6	162	21	and	and	CC
cord-014712-5u4e00q6	162	22	BCG	BCG	NNP
cord-014712-5u4e00q6	162	23	-	-	HYPH
cord-014712-5u4e00q6	162	24	group	group	NN
cord-014712-5u4e00q6	162	25	.	.	.
cord-014712-5u4e00q6	163	1	The	the	DT
cord-014712-5u4e00q6	163	2	clinical	clinical	JJ
cord-014712-5u4e00q6	163	3	presentation	presentation	NN
cord-014712-5u4e00q6	163	4	of	of	IN
cord-014712-5u4e00q6	163	5	non	non	JJ
cord-014712-5u4e00q6	163	6	-	-	JJ
cord-014712-5u4e00q6	163	7	BCG	bcg	JJ
cord-014712-5u4e00q6	163	8	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	163	9	patient	patient	NN
cord-014712-5u4e00q6	163	10	differs	differ	VBZ
cord-014712-5u4e00q6	163	11	in	in	IN
cord-014712-5u4e00q6	163	12	the	the	DT
cord-014712-5u4e00q6	163	13	initial	initial	JJ
cord-014712-5u4e00q6	163	14	symptoms	symptom	NNS
cord-014712-5u4e00q6	163	15	when	when	WRB
cord-014712-5u4e00q6	163	16	failure	failure	NN
cord-014712-5u4e00q6	163	17	to	to	TO
cord-014712-5u4e00q6	163	18	thrive	thrive	VB
cord-014712-5u4e00q6	163	19	and	and	CC
cord-014712-5u4e00q6	163	20	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	163	21	at	at	IN
cord-014712-5u4e00q6	163	22	4	4	CD
cord-014712-5u4e00q6	163	23	months	month	NNS
cord-014712-5u4e00q6	163	24	was	be	VBD
cord-014712-5u4e00q6	163	25	the	the	DT
cord-014712-5u4e00q6	163	26	most	most	RBS
cord-014712-5u4e00q6	163	27	common	common	JJ
cord-014712-5u4e00q6	163	28	finding	finding	NN
cord-014712-5u4e00q6	163	29	.	.	.
cord-014712-5u4e00q6	164	1	Post	post	JJ
cord-014712-5u4e00q6	164	2	-	-	JJ
cord-014712-5u4e00q6	164	3	transplantational	transplantational	JJ
cord-014712-5u4e00q6	164	4	recovery	recovery	NN
cord-014712-5u4e00q6	164	5	in	in	IN
cord-014712-5u4e00q6	164	6	BCG	BCG	NNP
cord-014712-5u4e00q6	164	7	-	-	HYPH
cord-014712-5u4e00q6	164	8	group	group	NN
cord-014712-5u4e00q6	164	9	was	be	VBD
cord-014712-5u4e00q6	164	10	less	less	RBR
cord-014712-5u4e00q6	164	11	complicated	complicated	JJ
cord-014712-5u4e00q6	164	12	.	.	.
cord-014712-5u4e00q6	165	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	165	2	:	:	:
cord-014712-5u4e00q6	166	1	Two	two	CD
cord-014712-5u4e00q6	166	2	major	major	JJ
cord-014712-5u4e00q6	166	3	improvements	improvement	NNS
cord-014712-5u4e00q6	166	4	for	for	IN
cord-014712-5u4e00q6	166	5	the	the	DT
cord-014712-5u4e00q6	166	6	outcome	outcome	NN
cord-014712-5u4e00q6	166	7	for	for	IN
cord-014712-5u4e00q6	166	8	SCID	SCID	NNP
cord-014712-5u4e00q6	166	9	patients	patient	NNS
cord-014712-5u4e00q6	166	10	in	in	IN
cord-014712-5u4e00q6	166	11	Slovakia	Slovakia	NNP
cord-014712-5u4e00q6	166	12	have	have	VBP
cord-014712-5u4e00q6	166	13	occurred	occur	VBN
cord-014712-5u4e00q6	166	14	in	in	IN
cord-014712-5u4e00q6	166	15	past	past	JJ
cord-014712-5u4e00q6	166	16	10	10	CD
cord-014712-5u4e00q6	166	17	years	year	NNS
cord-014712-5u4e00q6	166	18	.	.	.
cord-014712-5u4e00q6	167	1	Early	early	JJ
cord-014712-5u4e00q6	167	2	life	life	NN
cord-014712-5u4e00q6	167	3	vaccination	vaccination	NN
cord-014712-5u4e00q6	167	4	for	for	IN
cord-014712-5u4e00q6	167	5	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	167	6	has	have	VBZ
cord-014712-5u4e00q6	167	7	been	be	VBN
cord-014712-5u4e00q6	167	8	retreated	retreat	VBN
cord-014712-5u4e00q6	167	9	and	and	CC
cord-014712-5u4e00q6	167	10	improvements	improvement	NNS
cord-014712-5u4e00q6	167	11	in	in	IN
cord-014712-5u4e00q6	167	12	diagnostics	diagnostic	NNS
cord-014712-5u4e00q6	167	13	for	for	IN
cord-014712-5u4e00q6	167	14	severe	severe	JJ
cord-014712-5u4e00q6	167	15	T	t	NN
cord-014712-5u4e00q6	167	16	cell	cell	NN
cord-014712-5u4e00q6	167	17	defects	defect	NNS
cord-014712-5u4e00q6	167	18	have	have	VBP
cord-014712-5u4e00q6	167	19	been	be	VBN
cord-014712-5u4e00q6	167	20	made	make	VBN
cord-014712-5u4e00q6	167	21	,	,	,
cord-014712-5u4e00q6	167	22	including	include	VBG
cord-014712-5u4e00q6	167	23	flow	flow	NN
cord-014712-5u4e00q6	167	24	cytometry	cytometry	NN
cord-014712-5u4e00q6	167	25	phenotyping	phenotyping	NN
cord-014712-5u4e00q6	167	26	and	and	CC
cord-014712-5u4e00q6	167	27	genetic	genetic	JJ
cord-014712-5u4e00q6	167	28	testing	testing	NN
cord-014712-5u4e00q6	167	29	within	within	IN
cord-014712-5u4e00q6	167	30	the	the	DT
cord-014712-5u4e00q6	167	31	middle	middle	JJ
cord-014712-5u4e00q6	167	32	European	european	JJ
cord-014712-5u4e00q6	167	33	countries	country	NNS
cord-014712-5u4e00q6	167	34	cooperation	cooperation	NN
cord-014712-5u4e00q6	167	35	,	,	,
cord-014712-5u4e00q6	167	36	the	the	DT
cord-014712-5u4e00q6	167	37	J	J	NNP
cord-014712-5u4e00q6	167	38	-	-	HYPH
cord-014712-5u4e00q6	167	39	Project	Project	NNP
cord-014712-5u4e00q6	167	40	.	.	.
cord-014712-5u4e00q6	168	1	BCG	BCG	NNP
cord-014712-5u4e00q6	168	2	and	and	CC
cord-014712-5u4e00q6	168	3	late	late	JJ
cord-014712-5u4e00q6	168	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	168	5	prolongs	prolong	VBZ
cord-014712-5u4e00q6	168	6	time	time	NN
cord-014712-5u4e00q6	168	7	for	for	IN
cord-014712-5u4e00q6	168	8	hospital	hospital	NN
cord-014712-5u4e00q6	168	9	care	care	NN
cord-014712-5u4e00q6	168	10	,	,	,
cord-014712-5u4e00q6	168	11	immune	immune	JJ
cord-014712-5u4e00q6	168	12	reconstitution	reconstitution	NN
cord-014712-5u4e00q6	168	13	and	and	CC
cord-014712-5u4e00q6	168	14	carries	carry	VBZ
cord-014712-5u4e00q6	168	15	severe	severe	JJ
cord-014712-5u4e00q6	168	16	complications	complication	NNS
cord-014712-5u4e00q6	168	17	,	,	,
cord-014712-5u4e00q6	168	18	consequently	consequently	RB
cord-014712-5u4e00q6	168	19	it	-PRON-	PRP
cord-014712-5u4e00q6	168	20	increase	increase	VBP
cord-014712-5u4e00q6	168	21	the	the	DT
cord-014712-5u4e00q6	168	22	costs	cost	NNS
cord-014712-5u4e00q6	168	23	of	of	IN
cord-014712-5u4e00q6	168	24	health	health	NN
cord-014712-5u4e00q6	168	25	care	care	NN
cord-014712-5u4e00q6	168	26	and	and	CC
cord-014712-5u4e00q6	168	27	decrease	decrease	VB
cord-014712-5u4e00q6	168	28	the	the	DT
cord-014712-5u4e00q6	168	29	quality	quality	NN
cord-014712-5u4e00q6	168	30	of	of	IN
cord-014712-5u4e00q6	168	31	patients	patient	NNS
cord-014712-5u4e00q6	168	32	'	'	POS
cord-014712-5u4e00q6	168	33	life	life	NN
cord-014712-5u4e00q6	168	34	.	.	.
cord-014712-5u4e00q6	169	1	The	the	DT
cord-014712-5u4e00q6	169	2	perspective	perspective	NN
cord-014712-5u4e00q6	169	3	of	of	IN
cord-014712-5u4e00q6	169	4	newborn	newborn	JJ
cord-014712-5u4e00q6	169	5	screening	screening	NN
cord-014712-5u4e00q6	169	6	for	for	IN
cord-014712-5u4e00q6	169	7	SCID	SCID	NNP
cord-014712-5u4e00q6	169	8	would	would	MD
cord-014712-5u4e00q6	169	9	be	be	VB
cord-014712-5u4e00q6	169	10	the	the	DT
cord-014712-5u4e00q6	169	11	next	next	JJ
cord-014712-5u4e00q6	169	12	major	major	JJ
cord-014712-5u4e00q6	169	13	step	step	NN
cord-014712-5u4e00q6	169	14	in	in	IN
cord-014712-5u4e00q6	169	15	improving	improve	VBG
cord-014712-5u4e00q6	169	16	the	the	DT
cord-014712-5u4e00q6	169	17	outcome	outcome	NN
cord-014712-5u4e00q6	169	18	of	of	IN
cord-014712-5u4e00q6	169	19	SCID	SCID	NNP
cord-014712-5u4e00q6	169	20	patients	patient	NNS
cord-014712-5u4e00q6	169	21	.	.	.
cord-014712-5u4e00q6	170	1	Ahmed	Ahmed	NNP
cord-014712-5u4e00q6	170	2	Aziz	Aziz	NNP
cord-014712-5u4e00q6	170	3	Bousfiha	Bousfiha	NNP
cord-014712-5u4e00q6	170	4	1	1	CD
cord-014712-5u4e00q6	170	5	;	;	:
cord-014712-5u4e00q6	170	6	Leïla	Leïla	NNP
cord-014712-5u4e00q6	170	7	Jeddane	Jeddane	NNP
cord-014712-5u4e00q6	170	8	1	1	CD
cord-014712-5u4e00q6	170	9	;	;	:
cord-014712-5u4e00q6	171	1	Nahla	Nahla	NNP
cord-014712-5u4e00q6	171	2	Erwa	Erwa	NNP
cord-014712-5u4e00q6	171	3	2	2	CD
cord-014712-5u4e00q6	171	4	;	;	:
cord-014712-5u4e00q6	171	5	Monika	Monika	NNP
cord-014712-5u4e00q6	171	6	Esser	Esser	NNP
cord-014712-5u4e00q6	171	7	3	3	CD
cord-014712-5u4e00q6	171	8	;	;	.
cord-014712-5u4e00q6	172	1	Shereen	Shereen	NNP
cord-014712-5u4e00q6	172	2	M.	M.	NNP
cord-014712-5u4e00q6	172	3	Reda	Reda	NNP
cord-014712-5u4e00q6	172	4	4	4	CD
cord-014712-5u4e00q6	173	1	In	in	IN
cord-014712-5u4e00q6	173	2	Africa	Africa	NNP
cord-014712-5u4e00q6	173	3	,	,	,
cord-014712-5u4e00q6	173	4	primary	primary	JJ
cord-014712-5u4e00q6	173	5	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	173	6	are	be	VBP
cord-014712-5u4e00q6	173	7	still	still	RB
cord-014712-5u4e00q6	173	8	largely	largely	RB
cord-014712-5u4e00q6	173	9	undiagnosed	undiagnosed	JJ
cord-014712-5u4e00q6	173	10	,	,	,
cord-014712-5u4e00q6	173	11	with	with	IN
cord-014712-5u4e00q6	173	12	no	no	DT
cord-014712-5u4e00q6	173	13	cases	case	NNS
cord-014712-5u4e00q6	173	14	reported	report	VBN
cord-014712-5u4e00q6	173	15	in	in	IN
cord-014712-5u4e00q6	173	16	40	40	CD
cord-014712-5u4e00q6	173	17	of	of	IN
cord-014712-5u4e00q6	173	18	54	54	CD
cord-014712-5u4e00q6	173	19	countries	country	NNS
cord-014712-5u4e00q6	173	20	.	.	.
cord-014712-5u4e00q6	174	1	Though	though	IN
cord-014712-5u4e00q6	174	2	the	the	DT
cord-014712-5u4e00q6	174	3	African	African	NNP
cord-014712-5u4e00q6	174	4	Society	Society	NNP
cord-014712-5u4e00q6	174	5	for	for	IN
cord-014712-5u4e00q6	174	6	Immunodeficiencies	Immunodeficiencies	NNP
cord-014712-5u4e00q6	174	7	(	(	-LRB-
cord-014712-5u4e00q6	174	8	ASID	ASID	NNP
cord-014712-5u4e00q6	174	9	)	)	-RRB-
cord-014712-5u4e00q6	174	10	already	already	RB
cord-014712-5u4e00q6	174	11	organized	organize	VBD
cord-014712-5u4e00q6	174	12	3	3	CD
cord-014712-5u4e00q6	174	13	International	International	NNP
cord-014712-5u4e00q6	174	14	Meetings	Meetings	NNPS
cord-014712-5u4e00q6	174	15	and	and	CC
cord-014712-5u4e00q6	174	16	5	5	CD
cord-014712-5u4e00q6	174	17	training	training	NN
cord-014712-5u4e00q6	174	18	schools	school	NNS
cord-014712-5u4e00q6	174	19	,	,	,
cord-014712-5u4e00q6	174	20	their	-PRON-	PRP$
cord-014712-5u4e00q6	174	21	impact	impact	NN
cord-014712-5u4e00q6	174	22	outside	outside	IN
cord-014712-5u4e00q6	174	23	the	the	DT
cord-014712-5u4e00q6	174	24	hosting	host	VBG
cord-014712-5u4e00q6	174	25	country	country	NN
cord-014712-5u4e00q6	174	26	is	be	VBZ
cord-014712-5u4e00q6	174	27	still	still	RB
cord-014712-5u4e00q6	174	28	insufficient	insufficient	JJ
cord-014712-5u4e00q6	174	29	.	.	.
cord-014712-5u4e00q6	175	1	At	at	IN
cord-014712-5u4e00q6	175	2	this	this	DT
cord-014712-5u4e00q6	175	3	time	time	NN
cord-014712-5u4e00q6	175	4	,	,	,
cord-014712-5u4e00q6	175	5	only	only	RB
cord-014712-5u4e00q6	175	6	a	a	DT
cord-014712-5u4e00q6	175	7	few	few	JJ
cord-014712-5u4e00q6	175	8	PID	pid	NN
cord-014712-5u4e00q6	175	9	patients	patient	NNS
cord-014712-5u4e00q6	175	10	are	be	VBP
cord-014712-5u4e00q6	175	11	reported	report	VBN
cord-014712-5u4e00q6	175	12	in	in	IN
cord-014712-5u4e00q6	175	13	Africa	Africa	NNP
cord-014712-5u4e00q6	175	14	(	(	-LRB-
cord-014712-5u4e00q6	175	15	less	less	JJR
cord-014712-5u4e00q6	175	16	than	than	IN
cord-014712-5u4e00q6	175	17	2000	2000	CD
cord-014712-5u4e00q6	175	18	patients	patient	NNS
cord-014712-5u4e00q6	175	19	)	)	-RRB-
cord-014712-5u4e00q6	175	20	,	,	,
cord-014712-5u4e00q6	175	21	the	the	DT
cord-014712-5u4e00q6	175	22	majority	majority	NN
cord-014712-5u4e00q6	175	23	of	of	IN
cord-014712-5u4e00q6	175	24	whom	whom	WP
cord-014712-5u4e00q6	175	25	are	be	VBP
cord-014712-5u4e00q6	175	26	in	in	IN
cord-014712-5u4e00q6	175	27	North	North	NNP
cord-014712-5u4e00q6	175	28	Africa	Africa	NNP
cord-014712-5u4e00q6	175	29	and	and	CC
cord-014712-5u4e00q6	175	30	South	South	NNP
cord-014712-5u4e00q6	175	31	Africa	Africa	NNP
cord-014712-5u4e00q6	175	32	.	.	.
cord-014712-5u4e00q6	176	1	So	so	RB
cord-014712-5u4e00q6	176	2	,	,	,
cord-014712-5u4e00q6	176	3	ASID	ASID	NNP
cord-014712-5u4e00q6	176	4	propose	propose	VBP
cord-014712-5u4e00q6	176	5	the	the	DT
cord-014712-5u4e00q6	176	6	A	A	NNP
cord-014712-5u4e00q6	176	7	-	-	HYPH
cord-014712-5u4e00q6	176	8	Project	Project	NNP
cord-014712-5u4e00q6	176	9	,	,	,
cord-014712-5u4e00q6	176	10	a	a	DT
cord-014712-5u4e00q6	176	11	training	training	NN
cord-014712-5u4e00q6	176	12	program	program	NN
cord-014712-5u4e00q6	176	13	based	base	VBN
cord-014712-5u4e00q6	176	14	on	on	IN
cord-014712-5u4e00q6	176	15	the	the	DT
cord-014712-5u4e00q6	176	16	J	J	NNP
cord-014712-5u4e00q6	176	17	-	-	HYPH
cord-014712-5u4e00q6	176	18	Project	Project	NNP
cord-014712-5u4e00q6	176	19	.	.	.
cord-014712-5u4e00q6	177	1	Some	some	DT
cord-014712-5u4e00q6	177	2	issues	issue	NNS
cord-014712-5u4e00q6	177	3	prevent	prevent	VBP
cord-014712-5u4e00q6	177	4	effective	effective	JJ
cord-014712-5u4e00q6	177	5	training	training	NN
cord-014712-5u4e00q6	177	6	for	for	IN
cord-014712-5u4e00q6	177	7	PID	PID	NNP
cord-014712-5u4e00q6	177	8	in	in	IN
cord-014712-5u4e00q6	177	9	Africa	Africa	NNP
cord-014712-5u4e00q6	177	10	:	:	:
cord-014712-5u4e00q6	177	11	diversity	diversity	NN
cord-014712-5u4e00q6	177	12	of	of	IN
cord-014712-5u4e00q6	177	13	languages	language	NNS
cord-014712-5u4e00q6	177	14	,	,	,
cord-014712-5u4e00q6	177	15	only	only	RB
cord-014712-5u4e00q6	177	16	a	a	DT
cord-014712-5u4e00q6	177	17	few	few	JJ
cord-014712-5u4e00q6	177	18	are	be	VBP
cord-014712-5u4e00q6	177	19	initiated	initiate	VBN
cord-014712-5u4e00q6	177	20	to	to	IN
cord-014712-5u4e00q6	177	21	PID	PID	NNP
cord-014712-5u4e00q6	177	22	,	,	,
cord-014712-5u4e00q6	177	23	lack	lack	NN
cord-014712-5u4e00q6	177	24	of	of	IN
cord-014712-5u4e00q6	177	25	resources	resource	NNS
cord-014712-5u4e00q6	177	26	for	for	IN
cord-014712-5u4e00q6	177	27	travel	travel	NN
cord-014712-5u4e00q6	177	28	expenses	expense	NNS
cord-014712-5u4e00q6	177	29	,	,	,
cord-014712-5u4e00q6	177	30	difficulty	difficulty	NN
cord-014712-5u4e00q6	177	31	to	to	TO
cord-014712-5u4e00q6	177	32	access	access	NN
cord-014712-5u4e00q6	177	33	to	to	IN
cord-014712-5u4e00q6	177	34	care	care	NN
cord-014712-5u4e00q6	177	35	and	and	CC
cord-014712-5u4e00q6	177	36	shading	shade	VBG
cord-014712-5u4e00q6	177	37	by	by	IN
cord-014712-5u4e00q6	177	38	the	the	DT
cord-014712-5u4e00q6	177	39	HIV	HIV	NNP
cord-014712-5u4e00q6	177	40	pandemic	pandemic	NN
cord-014712-5u4e00q6	177	41	.	.	.
cord-014712-5u4e00q6	178	1	A	a	LS
cord-014712-5u4e00q6	178	2	-	-	:
cord-014712-5u4e00q6	178	3	Project	Project	NNP
cord-014712-5u4e00q6	178	4	is	be	VBZ
cord-014712-5u4e00q6	178	5	designed	design	VBN
cord-014712-5u4e00q6	178	6	as	as	IN
cord-014712-5u4e00q6	178	7	a	a	DT
cord-014712-5u4e00q6	178	8	one	one	CD
cord-014712-5u4e00q6	178	9	-	-	HYPH
cord-014712-5u4e00q6	178	10	day	day	NN
cord-014712-5u4e00q6	178	11	training	training	NN
cord-014712-5u4e00q6	178	12	by	by	IN
cord-014712-5u4e00q6	178	13	an	an	DT
cord-014712-5u4e00q6	178	14	African	african	JJ
cord-014712-5u4e00q6	178	15	PID	PID	NNP
cord-014712-5u4e00q6	178	16	expert	expert	NN
cord-014712-5u4e00q6	178	17	in	in	IN
cord-014712-5u4e00q6	178	18	a	a	DT
cord-014712-5u4e00q6	178	19	small	small	JJ
cord-014712-5u4e00q6	178	20	group	group	NN
cord-014712-5u4e00q6	178	21	of	of	IN
cord-014712-5u4e00q6	178	22	motivated	motivated	JJ
cord-014712-5u4e00q6	178	23	caregivers	caregiver	NNS
cord-014712-5u4e00q6	178	24	.	.	.
cord-014712-5u4e00q6	179	1	This	this	DT
cord-014712-5u4e00q6	179	2	project	project	NN
cord-014712-5u4e00q6	179	3	is	be	VBZ
cord-014712-5u4e00q6	179	4	adapted	adapt	VBN
cord-014712-5u4e00q6	179	5	to	to	IN
cord-014712-5u4e00q6	179	6	the	the	DT
cord-014712-5u4e00q6	179	7	African	african	JJ
cord-014712-5u4e00q6	179	8	context	context	NN
cord-014712-5u4e00q6	179	9	,	,	,
cord-014712-5u4e00q6	179	10	as	as	IN
cord-014712-5u4e00q6	179	11	it	-PRON-	PRP
cord-014712-5u4e00q6	179	12	only	only	RB
cord-014712-5u4e00q6	179	13	requests	request	VBZ
cord-014712-5u4e00q6	179	14	minimum	minimum	JJ
cord-014712-5u4e00q6	179	15	funding	funding	NN
cord-014712-5u4e00q6	179	16	and	and	CC
cord-014712-5u4e00q6	179	17	can	can	MD
cord-014712-5u4e00q6	179	18	reach	reach	VB
cord-014712-5u4e00q6	179	19	more	more	JJR
cord-014712-5u4e00q6	179	20	people	people	NNS
cord-014712-5u4e00q6	179	21	.	.	.
cord-014712-5u4e00q6	180	1	Each	each	DT
cord-014712-5u4e00q6	180	2	A	A	NNP
cord-014712-5u4e00q6	180	3	-	-	HYPH
cord-014712-5u4e00q6	180	4	Project	Project	NNP
cord-014712-5u4e00q6	180	5	will	will	MD
cord-014712-5u4e00q6	180	6	be	be	VB
cord-014712-5u4e00q6	180	7	co	co	VBN
cord-014712-5u4e00q6	180	8	-	-	VBN
cord-014712-5u4e00q6	180	9	organized	organize	VBN
cord-014712-5u4e00q6	180	10	by	by	IN
cord-014712-5u4e00q6	180	11	ASID	ASID	NNP
cord-014712-5u4e00q6	180	12	and	and	CC
cord-014712-5u4e00q6	180	13	a	a	DT
cord-014712-5u4e00q6	180	14	local	local	JJ
cord-014712-5u4e00q6	180	15	committee	committee	NN
cord-014712-5u4e00q6	180	16	,	,	,
cord-014712-5u4e00q6	180	17	and	and	CC
cord-014712-5u4e00q6	180	18	shall	shall	MD
cord-014712-5u4e00q6	180	19	lead	lead	VB
cord-014712-5u4e00q6	180	20	to	to	IN
cord-014712-5u4e00q6	180	21	some	some	DT
cord-014712-5u4e00q6	180	22	commitments	commitment	NNS
cord-014712-5u4e00q6	180	23	to	to	TO
cord-014712-5u4e00q6	180	24	be	be	VB
cord-014712-5u4e00q6	180	25	realized	realize	VBN
cord-014712-5u4e00q6	180	26	by	by	IN
cord-014712-5u4e00q6	180	27	locals	local	NNS
cord-014712-5u4e00q6	180	28	,	,	,
cord-014712-5u4e00q6	180	29	in	in	IN
cord-014712-5u4e00q6	180	30	particular	particular	JJ
cord-014712-5u4e00q6	180	31	the	the	DT
cord-014712-5u4e00q6	180	32	establishment	establishment	NN
cord-014712-5u4e00q6	180	33	of	of	IN
cord-014712-5u4e00q6	180	34	a	a	DT
cord-014712-5u4e00q6	180	35	registry	registry	NN
cord-014712-5u4e00q6	180	36	,	,	,
cord-014712-5u4e00q6	180	37	a	a	DT
cord-014712-5u4e00q6	180	38	network	network	NN
cord-014712-5u4e00q6	180	39	between	between	IN
cord-014712-5u4e00q6	180	40	physicians	physician	NNS
cord-014712-5u4e00q6	180	41	and	and	CC
cord-014712-5u4e00q6	180	42	scientists	scientist	NNS
cord-014712-5u4e00q6	180	43	and	and	CC
cord-014712-5u4e00q6	180	44	creation	creation	NN
cord-014712-5u4e00q6	180	45	of	of	IN
cord-014712-5u4e00q6	180	46	a	a	DT
cord-014712-5u4e00q6	180	47	patient	patient	JJ
cord-014712-5u4e00q6	180	48	association	association	NN
cord-014712-5u4e00q6	180	49	.	.	.
cord-014712-5u4e00q6	181	1	Moreover	moreover	RB
cord-014712-5u4e00q6	181	2	,	,	,
cord-014712-5u4e00q6	181	3	each	each	DT
cord-014712-5u4e00q6	181	4	A	A	NNP
cord-014712-5u4e00q6	181	5	-	-	HYPH
cord-014712-5u4e00q6	181	6	Project	Project	NNP
cord-014712-5u4e00q6	181	7	will	will	MD
cord-014712-5u4e00q6	181	8	be	be	VB
cord-014712-5u4e00q6	181	9	done	do	VBN
cord-014712-5u4e00q6	181	10	in	in	IN
cord-014712-5u4e00q6	181	11	the	the	DT
cord-014712-5u4e00q6	181	12	medical	medical	JJ
cord-014712-5u4e00q6	181	13	language	language	NN
cord-014712-5u4e00q6	181	14	used	use	VBN
cord-014712-5u4e00q6	181	15	in	in	IN
cord-014712-5u4e00q6	181	16	the	the	DT
cord-014712-5u4e00q6	181	17	country	country	NN
cord-014712-5u4e00q6	181	18	(	(	-LRB-
cord-014712-5u4e00q6	181	19	English	English	NNP
cord-014712-5u4e00q6	181	20	,	,	,
cord-014712-5u4e00q6	181	21	French	french	JJ
cord-014712-5u4e00q6	181	22	or	or	CC
cord-014712-5u4e00q6	181	23	Portuguese	Portuguese	NNP
cord-014712-5u4e00q6	181	24	)	)	-RRB-
cord-014712-5u4e00q6	181	25	.	.	.
cord-014712-5u4e00q6	182	1	The	the	DT
cord-014712-5u4e00q6	182	2	first	first	JJ
cord-014712-5u4e00q6	182	3	A	A	NNP
cord-014712-5u4e00q6	182	4	-	-	HYPH
cord-014712-5u4e00q6	182	5	Project	Project	NNP
cord-014712-5u4e00q6	182	6	was	be	VBD
cord-014712-5u4e00q6	182	7	already	already	RB
cord-014712-5u4e00q6	182	8	done	do	VBN
cord-014712-5u4e00q6	182	9	in	in	IN
cord-014712-5u4e00q6	182	10	Benin	Benin	NNP
cord-014712-5u4e00q6	182	11	,	,	,
cord-014712-5u4e00q6	182	12	and	and	CC
cord-014712-5u4e00q6	182	13	five	five	CD
cord-014712-5u4e00q6	182	14	more	more	JJR
cord-014712-5u4e00q6	182	15	are	be	VBP
cord-014712-5u4e00q6	182	16	already	already	RB
cord-014712-5u4e00q6	182	17	planned	plan	VBN
cord-014712-5u4e00q6	182	18	for	for	IN
cord-014712-5u4e00q6	182	19	2014	2014	CD
cord-014712-5u4e00q6	182	20	.	.	.
cord-014712-5u4e00q6	183	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	183	2	goal	goal	NN
cord-014712-5u4e00q6	183	3	is	be	VBZ
cord-014712-5u4e00q6	183	4	to	to	TO
cord-014712-5u4e00q6	183	5	reach	reach	VB
cord-014712-5u4e00q6	183	6	all	all	DT
cord-014712-5u4e00q6	183	7	40	40	CD
cord-014712-5u4e00q6	183	8	countries	country	NNS
cord-014712-5u4e00q6	183	9	where	where	WRB
cord-014712-5u4e00q6	183	10	no	no	DT
cord-014712-5u4e00q6	183	11	patient	patient	NN
cord-014712-5u4e00q6	183	12	were	be	VBD
cord-014712-5u4e00q6	183	13	reported	report	VBN
cord-014712-5u4e00q6	183	14	in	in	IN
cord-014712-5u4e00q6	183	15	3	3	CD
cord-014712-5u4e00q6	183	16	years	year	NNS
cord-014712-5u4e00q6	183	17	.	.	.
cord-014712-5u4e00q6	184	1	This	this	DT
cord-014712-5u4e00q6	184	2	clinical	clinical	JJ
cord-014712-5u4e00q6	184	3	program	program	NN
cord-014712-5u4e00q6	184	4	will	will	MD
cord-014712-5u4e00q6	184	5	raise	raise	VB
cord-014712-5u4e00q6	184	6	PID	PID	NNP
cord-014712-5u4e00q6	184	7	awareness	awareness	NN
cord-014712-5u4e00q6	184	8	in	in	IN
cord-014712-5u4e00q6	184	9	Africa	Africa	NNP
cord-014712-5u4e00q6	184	10	and	and	CC
cord-014712-5u4e00q6	184	11	can	can	MD
cord-014712-5u4e00q6	184	12	potentially	potentially	RB
cord-014712-5u4e00q6	184	13	discover	discover	VB
cord-014712-5u4e00q6	184	14	new	new	JJ
cord-014712-5u4e00q6	184	15	aspects	aspect	NNS
cord-014712-5u4e00q6	184	16	of	of	IN
cord-014712-5u4e00q6	184	17	the	the	DT
cord-014712-5u4e00q6	184	18	immunity	immunity	NN
cord-014712-5u4e00q6	184	19	.	.	.
cord-014712-5u4e00q6	185	1	Till	till	IN
cord-014712-5u4e00q6	185	2	very	very	RB
cord-014712-5u4e00q6	185	3	recently	recently	RB
cord-014712-5u4e00q6	185	4	Primary	primary	JJ
cord-014712-5u4e00q6	185	5	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	185	6	Diseases	Diseases	NNPS
cord-014712-5u4e00q6	185	7	(	(	-LRB-
cord-014712-5u4e00q6	185	8	PIDs	pid	NNS
cord-014712-5u4e00q6	185	9	)	)	-RRB-
cord-014712-5u4e00q6	185	10	were	be	VBD
cord-014712-5u4e00q6	185	11	not	not	RB
cord-014712-5u4e00q6	185	12	being	be	VBG
cord-014712-5u4e00q6	185	13	frequently	frequently	RB
cord-014712-5u4e00q6	185	14	recognized	recognize	VBN
cord-014712-5u4e00q6	185	15	in	in	IN
cord-014712-5u4e00q6	185	16	India	India	NNP
cord-014712-5u4e00q6	185	17	.	.	.
cord-014712-5u4e00q6	186	1	However	however	RB
cord-014712-5u4e00q6	186	2	,	,	,
cord-014712-5u4e00q6	186	3	the	the	DT
cord-014712-5u4e00q6	186	4	scenario	scenario	NN
cord-014712-5u4e00q6	186	5	has	have	VBZ
cord-014712-5u4e00q6	186	6	changed	change	VBN
cord-014712-5u4e00q6	186	7	over	over	IN
cord-014712-5u4e00q6	186	8	the	the	DT
cord-014712-5u4e00q6	186	9	last	last	JJ
cord-014712-5u4e00q6	186	10	5	5	CD
cord-014712-5u4e00q6	186	11	years	year	NNS
cord-014712-5u4e00q6	186	12	or	or	CC
cord-014712-5u4e00q6	186	13	so	so	RB
cord-014712-5u4e00q6	186	14	.	.	.
cord-014712-5u4e00q6	187	1	The	the	DT
cord-014712-5u4e00q6	187	2	Indian	Indian	NNP
cord-014712-5u4e00q6	187	3	Society	Society	NNP
cord-014712-5u4e00q6	187	4	for	for	IN
cord-014712-5u4e00q6	187	5	Primary	Primary	NNP
cord-014712-5u4e00q6	187	6	Immune	Immune	NNP
cord-014712-5u4e00q6	187	7	Deficiency	Deficiency	NNP
cord-014712-5u4e00q6	187	8	(	(	-LRB-
cord-014712-5u4e00q6	187	9	ISPID	ISPID	NNP
cord-014712-5u4e00q6	187	10	)	)	-RRB-
cord-014712-5u4e00q6	187	11	was	be	VBD
cord-014712-5u4e00q6	187	12	founded	found	VBN
cord-014712-5u4e00q6	187	13	in	in	IN
cord-014712-5u4e00q6	187	14	2010	2010	CD
cord-014712-5u4e00q6	187	15	-	-	SYM
cord-014712-5u4e00q6	187	16	2011	2011	CD
cord-014712-5u4e00q6	187	17	.	.	.
cord-014712-5u4e00q6	188	1	Over	over	IN
cord-014712-5u4e00q6	188	2	the	the	DT
cord-014712-5u4e00q6	188	3	last	last	JJ
cord-014712-5u4e00q6	188	4	4	4	CD
cord-014712-5u4e00q6	188	5	years	year	NNS
cord-014712-5u4e00q6	188	6	the	the	DT
cord-014712-5u4e00q6	188	7	ISPID	ISPID	NNP
cord-014712-5u4e00q6	188	8	has	have	VBZ
cord-014712-5u4e00q6	188	9	organized	organize	VBN
cord-014712-5u4e00q6	188	10	2	2	CD
cord-014712-5u4e00q6	188	11	International	International	NNP
cord-014712-5u4e00q6	188	12	Conferences	Conferences	NNPS
cord-014712-5u4e00q6	188	13	(	(	-LRB-
cord-014712-5u4e00q6	188	14	at	at	IN
cord-014712-5u4e00q6	188	15	New	New	NNP
cord-014712-5u4e00q6	188	16	Delhi	Delhi	NNP
cord-014712-5u4e00q6	188	17	and	and	CC
cord-014712-5u4e00q6	188	18	Mumbai	Mumbai	NNP
cord-014712-5u4e00q6	188	19	)	)	-RRB-
cord-014712-5u4e00q6	188	20	,	,	,
cord-014712-5u4e00q6	188	21	2	2	CD
cord-014712-5u4e00q6	188	22	National	National	NNP
cord-014712-5u4e00q6	188	23	Conferences	Conferences	NNPS
cord-014712-5u4e00q6	188	24	(	(	-LRB-
cord-014712-5u4e00q6	188	25	at	at	IN
cord-014712-5u4e00q6	188	26	Chandigarh	Chandigarh	NNP
cord-014712-5u4e00q6	188	27	and	and	CC
cord-014712-5u4e00q6	188	28	Varanasi	Varanasi	NNP
cord-014712-5u4e00q6	188	29	)	)	-RRB-
cord-014712-5u4e00q6	188	30	and	and	CC
cord-014712-5u4e00q6	188	31	2	2	CD
cord-014712-5u4e00q6	188	32	Continuing	Continuing	NNP
cord-014712-5u4e00q6	188	33	Medical	Medical	NNP
cord-014712-5u4e00q6	188	34	Education	Education	NNP
cord-014712-5u4e00q6	188	35	Programmes	Programmes	NNP
cord-014712-5u4e00q6	188	36	(	(	-LRB-
cord-014712-5u4e00q6	188	37	at	at	IN
cord-014712-5u4e00q6	188	38	New	New	NNP
cord-014712-5u4e00q6	188	39	Delhi	Delhi	NNP
cord-014712-5u4e00q6	188	40	and	and	CC
cord-014712-5u4e00q6	188	41	Lucknow	Lucknow	NNP
cord-014712-5u4e00q6	188	42	)	)	-RRB-
cord-014712-5u4e00q6	188	43	.	.	.
cord-014712-5u4e00q6	189	1	These	these	DT
cord-014712-5u4e00q6	189	2	meetings	meeting	NNS
cord-014712-5u4e00q6	189	3	have	have	VBP
cord-014712-5u4e00q6	189	4	served	serve	VBN
cord-014712-5u4e00q6	189	5	to	to	TO
cord-014712-5u4e00q6	189	6	act	act	VB
cord-014712-5u4e00q6	189	7	as	as	IN
cord-014712-5u4e00q6	189	8	catalysts	catalyst	NNS
cord-014712-5u4e00q6	189	9	for	for	IN
cord-014712-5u4e00q6	189	10	the	the	DT
cord-014712-5u4e00q6	189	11	cause	cause	NN
cord-014712-5u4e00q6	189	12	of	of	IN
cord-014712-5u4e00q6	189	13	PIDs	pid	NNS
cord-014712-5u4e00q6	189	14	and	and	CC
cord-014712-5u4e00q6	189	15	have	have	VBP
cord-014712-5u4e00q6	189	16	resulted	result	VBN
cord-014712-5u4e00q6	189	17	in	in	IN
cord-014712-5u4e00q6	189	18	increasing	increase	VBG
cord-014712-5u4e00q6	189	19	the	the	DT
cord-014712-5u4e00q6	189	20	awareness	awareness	NN
cord-014712-5u4e00q6	189	21	about	about	IN
cord-014712-5u4e00q6	189	22	these	these	DT
cord-014712-5u4e00q6	189	23	conditions	condition	NNS
cord-014712-5u4e00q6	189	24	amongst	amongst	IN
cord-014712-5u4e00q6	189	25	paediatricians	paediatrician	NNS
cord-014712-5u4e00q6	189	26	and	and	CC
cord-014712-5u4e00q6	189	27	physicians	physician	NNS
cord-014712-5u4e00q6	189	28	in	in	IN
cord-014712-5u4e00q6	189	29	our	-PRON-	PRP$
cord-014712-5u4e00q6	189	30	country	country	NN
cord-014712-5u4e00q6	189	31	.	.	.
cord-014712-5u4e00q6	190	1	Several	several	JJ
cord-014712-5u4e00q6	190	2	centres	centre	NNS
cord-014712-5u4e00q6	190	3	now	now	RB
cord-014712-5u4e00q6	190	4	have	have	VBP
cord-014712-5u4e00q6	190	5	the	the	DT
cord-014712-5u4e00q6	190	6	clinical	clinical	JJ
cord-014712-5u4e00q6	190	7	skills	skill	NNS
cord-014712-5u4e00q6	190	8	and	and	CC
cord-014712-5u4e00q6	190	9	the	the	DT
cord-014712-5u4e00q6	190	10	technical	technical	JJ
cord-014712-5u4e00q6	190	11	wherewithal	wherewithal	NN
cord-014712-5u4e00q6	190	12	to	to	TO
cord-014712-5u4e00q6	190	13	perform	perform	VB
cord-014712-5u4e00q6	190	14	laboratory	laboratory	NN
cord-014712-5u4e00q6	190	15	investigations	investigation	NNS
cord-014712-5u4e00q6	190	16	for	for	IN
cord-014712-5u4e00q6	190	17	these	these	DT
cord-014712-5u4e00q6	190	18	patients	patient	NNS
cord-014712-5u4e00q6	190	19	.	.	.
cord-014712-5u4e00q6	191	1	The	the	DT
cord-014712-5u4e00q6	191	2	repertoire	repertoire	NN
cord-014712-5u4e00q6	191	3	of	of	IN
cord-014712-5u4e00q6	191	4	tests	test	NNS
cord-014712-5u4e00q6	191	5	includes	include	VBZ
cord-014712-5u4e00q6	191	6	nephelometery	nephelometery	NNP
cord-014712-5u4e00q6	191	7	,	,	,
cord-014712-5u4e00q6	191	8	ELISA	ELISA	NNP
cord-014712-5u4e00q6	191	9	based	base	VBD
cord-014712-5u4e00q6	191	10	tests	test	NNS
cord-014712-5u4e00q6	191	11	and	and	CC
cord-014712-5u4e00q6	191	12	flow	flow	NN
cord-014712-5u4e00q6	191	13	cytometry	cytometry	NN
cord-014712-5u4e00q6	191	14	.	.	.
cord-014712-5u4e00q6	192	1	Facilities	facility	NNS
cord-014712-5u4e00q6	192	2	for	for	IN
cord-014712-5u4e00q6	192	3	molecular	molecular	JJ
cord-014712-5u4e00q6	192	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	192	5	of	of	IN
cord-014712-5u4e00q6	192	6	PIDs	pid	NNS
cord-014712-5u4e00q6	192	7	are	be	VBP
cord-014712-5u4e00q6	192	8	also	also	RB
cord-014712-5u4e00q6	192	9	being	be	VBG
cord-014712-5u4e00q6	192	10	developed	develop	VBN
cord-014712-5u4e00q6	192	11	at	at	IN
cord-014712-5u4e00q6	192	12	some	some	DT
cord-014712-5u4e00q6	192	13	of	of	IN
cord-014712-5u4e00q6	192	14	these	these	DT
cord-014712-5u4e00q6	192	15	centres	centre	NNS
cord-014712-5u4e00q6	192	16	.	.	.
cord-014712-5u4e00q6	193	1	A	a	DT
cord-014712-5u4e00q6	193	2	lot	lot	NN
cord-014712-5u4e00q6	193	3	more	more	JJR
cord-014712-5u4e00q6	193	4	,	,	,
cord-014712-5u4e00q6	193	5	however	however	RB
cord-014712-5u4e00q6	193	6	,	,	,
cord-014712-5u4e00q6	193	7	needs	need	VBZ
cord-014712-5u4e00q6	193	8	to	to	TO
cord-014712-5u4e00q6	193	9	be	be	VB
cord-014712-5u4e00q6	193	10	done	do	VBN
cord-014712-5u4e00q6	193	11	.	.	.
cord-014712-5u4e00q6	194	1	The	the	DT
cord-014712-5u4e00q6	194	2	clinical	clinical	JJ
cord-014712-5u4e00q6	194	3	phenotype	phenotype	NN
cord-014712-5u4e00q6	194	4	of	of	IN
cord-014712-5u4e00q6	194	5	several	several	JJ
cord-014712-5u4e00q6	194	6	PIDs	pid	NNS
cord-014712-5u4e00q6	194	7	in	in	IN
cord-014712-5u4e00q6	194	8	India	India	NNP
cord-014712-5u4e00q6	194	9	is	be	VBZ
cord-014712-5u4e00q6	194	10	likely	likely	JJ
cord-014712-5u4e00q6	194	11	to	to	TO
cord-014712-5u4e00q6	194	12	be	be	VB
cord-014712-5u4e00q6	194	13	different	different	JJ
cord-014712-5u4e00q6	194	14	from	from	IN
cord-014712-5u4e00q6	194	15	that	that	DT
cord-014712-5u4e00q6	194	16	in	in	IN
cord-014712-5u4e00q6	194	17	the	the	DT
cord-014712-5u4e00q6	194	18	West	West	NNP
cord-014712-5u4e00q6	194	19	1	1	CD
cord-014712-5u4e00q6	194	20	.	.	.
cord-014712-5u4e00q6	195	1	Further	further	RB
cord-014712-5u4e00q6	195	2	,	,	,
cord-014712-5u4e00q6	195	3	the	the	DT
cord-014712-5u4e00q6	195	4	type	type	NN
cord-014712-5u4e00q6	195	5	of	of	IN
cord-014712-5u4e00q6	195	6	infections	infection	NNS
cord-014712-5u4e00q6	195	7	in	in	IN
cord-014712-5u4e00q6	195	8	these	these	DT
cord-014712-5u4e00q6	195	9	patients	patient	NNS
cord-014712-5u4e00q6	195	10	is	be	VBZ
cord-014712-5u4e00q6	195	11	also	also	RB
cord-014712-5u4e00q6	195	12	likely	likely	JJ
cord-014712-5u4e00q6	195	13	to	to	TO
cord-014712-5u4e00q6	195	14	be	be	VB
cord-014712-5u4e00q6	195	15	different	different	JJ
cord-014712-5u4e00q6	195	16	.	.	.
cord-014712-5u4e00q6	196	1	This	this	DT
cord-014712-5u4e00q6	196	2	is	be	VBZ
cord-014712-5u4e00q6	196	3	because	because	IN
cord-014712-5u4e00q6	196	4	of	of	IN
cord-014712-5u4e00q6	196	5	the	the	DT
cord-014712-5u4e00q6	196	6	differences	difference	NNS
cord-014712-5u4e00q6	196	7	in	in	IN
cord-014712-5u4e00q6	196	8	the	the	DT
cord-014712-5u4e00q6	196	9	micro	micro	JJ
cord-014712-5u4e00q6	196	10	-	-	HYPH
cord-014712-5u4e00q6	196	11	and	and	CC
cord-014712-5u4e00q6	196	12	macro	macro	JJ
cord-014712-5u4e00q6	196	13	-	-	HYPH
cord-014712-5u4e00q6	196	14	environment	environment	NN
cord-014712-5u4e00q6	196	15	to	to	TO
cord-014712-5u4e00q6	196	16	which	which	WDT
cord-014712-5u4e00q6	196	17	these	these	DT
cord-014712-5u4e00q6	196	18	patients	patient	NNS
cord-014712-5u4e00q6	196	19	exposed	expose	VBN
cord-014712-5u4e00q6	196	20	in	in	IN
cord-014712-5u4e00q6	196	21	developing	develop	VBG
cord-014712-5u4e00q6	196	22	countries	country	NNS
cord-014712-5u4e00q6	196	23	.	.	.
cord-014712-5u4e00q6	197	1	These	these	DT
cord-014712-5u4e00q6	197	2	differences	difference	NNS
cord-014712-5u4e00q6	197	3	have	have	VBP
cord-014712-5u4e00q6	197	4	been	be	VBN
cord-014712-5u4e00q6	197	5	well	well	RB
cord-014712-5u4e00q6	197	6	brought	bring	VBN
cord-014712-5u4e00q6	197	7	in	in	RP
cord-014712-5u4e00q6	197	8	the	the	DT
cord-014712-5u4e00q6	197	9	recent	recent	JJ
cord-014712-5u4e00q6	197	10	publication	publication	NN
cord-014712-5u4e00q6	197	11	on	on	IN
cord-014712-5u4e00q6	197	12	chronic	chronic	JJ
cord-014712-5u4e00q6	197	13	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	197	14	disease	disease	NN
cord-014712-5u4e00q6	197	15	from	from	IN
cord-014712-5u4e00q6	197	16	our	-PRON-	PRP$
cord-014712-5u4e00q6	197	17	centre	centre	NN
cord-014712-5u4e00q6	197	18	2	2	CD
cord-014712-5u4e00q6	197	19	.	.	.
cord-014712-5u4e00q6	198	1	Further	further	RB
cord-014712-5u4e00q6	198	2	,	,	,
cord-014712-5u4e00q6	198	3	the	the	DT
cord-014712-5u4e00q6	198	4	genetic	genetic	JJ
cord-014712-5u4e00q6	198	5	background	background	NN
cord-014712-5u4e00q6	198	6	of	of	IN
cord-014712-5u4e00q6	198	7	the	the	DT
cord-014712-5u4e00q6	198	8	Indian	indian	JJ
cord-014712-5u4e00q6	198	9	population	population	NN
cord-014712-5u4e00q6	198	10	is	be	VBZ
cord-014712-5u4e00q6	198	11	diverse	diverse	JJ
cord-014712-5u4e00q6	198	12	and	and	CC
cord-014712-5u4e00q6	198	13	several	several	JJ
cord-014712-5u4e00q6	198	14	new	new	JJ
cord-014712-5u4e00q6	198	15	mutations	mutation	NNS
cord-014712-5u4e00q6	198	16	are	be	VBP
cord-014712-5u4e00q6	198	17	likely	likely	JJ
cord-014712-5u4e00q6	198	18	to	to	TO
cord-014712-5u4e00q6	198	19	be	be	VB
cord-014712-5u4e00q6	198	20	identified	identify	VBN
cord-014712-5u4e00q6	198	21	amongst	amongst	IN
cord-014712-5u4e00q6	198	22	these	these	DT
cord-014712-5u4e00q6	198	23	patients	patient	NNS
cord-014712-5u4e00q6	198	24	.	.	.
cord-014712-5u4e00q6	199	1	The	the	DT
cord-014712-5u4e00q6	199	2	Indian	Indian	NNP
cord-014712-5u4e00q6	199	3	Council	Council	NNP
cord-014712-5u4e00q6	199	4	of	of	IN
cord-014712-5u4e00q6	199	5	Medical	Medical	NNP
cord-014712-5u4e00q6	199	6	Research	Research	NNP
cord-014712-5u4e00q6	199	7	has	have	VBZ
cord-014712-5u4e00q6	199	8	taken	take	VBN
cord-014712-5u4e00q6	199	9	up	up	RP
cord-014712-5u4e00q6	199	10	the	the	DT
cord-014712-5u4e00q6	199	11	lead	lead	NN
cord-014712-5u4e00q6	199	12	in	in	IN
cord-014712-5u4e00q6	199	13	this	this	DT
cord-014712-5u4e00q6	199	14	regard	regard	NN
cord-014712-5u4e00q6	199	15	and	and	CC
cord-014712-5u4e00q6	199	16	is	be	VBZ
cord-014712-5u4e00q6	199	17	proposing	propose	VBG
cord-014712-5u4e00q6	199	18	to	to	TO
cord-014712-5u4e00q6	199	19	set	set	VB
cord-014712-5u4e00q6	199	20	up	up	RP
cord-014712-5u4e00q6	199	21	2	2	CD
cord-014712-5u4e00q6	199	22	Centres	Centres	NNPS
cord-014712-5u4e00q6	199	23	for	for	IN
cord-014712-5u4e00q6	199	24	Advanced	Advanced	NNP
cord-014712-5u4e00q6	199	25	Research	Research	NNP
cord-014712-5u4e00q6	199	26	(	(	-LRB-
cord-014712-5u4e00q6	199	27	CARs	car	NNS
cord-014712-5u4e00q6	199	28	)	)	-RRB-
cord-014712-5u4e00q6	199	29	in	in	IN
cord-014712-5u4e00q6	199	30	PIDs	pid	NNS
cord-014712-5u4e00q6	199	31	-1	-1	:
cord-014712-5u4e00q6	199	32	each	each	DT
cord-014712-5u4e00q6	199	33	at	at	IN
cord-014712-5u4e00q6	199	34	the	the	DT
cord-014712-5u4e00q6	199	35	Post	Post	NNP
cord-014712-5u4e00q6	199	36	Graduate	Graduate	NNP
cord-014712-5u4e00q6	199	37	Institute	Institute	NNP
cord-014712-5u4e00q6	199	38	of	of	IN
cord-014712-5u4e00q6	199	39	Medical	Medical	NNP
cord-014712-5u4e00q6	199	40	Education	Education	NNP
cord-014712-5u4e00q6	199	41	and	and	CC
cord-014712-5u4e00q6	199	42	Research	Research	NNP
cord-014712-5u4e00q6	199	43	,	,	,
cord-014712-5u4e00q6	199	44	Chandigarh	Chandigarh	NNP
cord-014712-5u4e00q6	199	45	and	and	CC
cord-014712-5u4e00q6	199	46	the	the	DT
cord-014712-5u4e00q6	199	47	Institute	Institute	NNP
cord-014712-5u4e00q6	199	48	of	of	IN
cord-014712-5u4e00q6	199	49	Immunohematology	Immunohematology	NNP
cord-014712-5u4e00q6	199	50	,	,	,
cord-014712-5u4e00q6	199	51	Mumbai	Mumbai	NNP
cord-014712-5u4e00q6	199	52	.	.	.
cord-014712-5u4e00q6	200	1	The	the	DT
cord-014712-5u4e00q6	200	2	Foundation	Foundation	NNP
cord-014712-5u4e00q6	200	3	for	for	IN
cord-014712-5u4e00q6	200	4	Primary	Primary	NNP
cord-014712-5u4e00q6	200	5	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	200	6	(	(	-LRB-
cord-014712-5u4e00q6	200	7	FPID	FPID	NNP
cord-014712-5u4e00q6	200	8	)	)	-RRB-
cord-014712-5u4e00q6	200	9	,	,	,
cord-014712-5u4e00q6	200	10	USA	USA	NNP
cord-014712-5u4e00q6	200	11	has	have	VBZ
cord-014712-5u4e00q6	200	12	also	also	RB
cord-014712-5u4e00q6	200	13	been	be	VBN
cord-014712-5u4e00q6	200	14	closely	closely	RB
cord-014712-5u4e00q6	200	15	involved	involved	JJ
cord-014712-5u4e00q6	200	16	in	in	IN
cord-014712-5u4e00q6	200	17	these	these	DT
cord-014712-5u4e00q6	200	18	efforts	effort	NNS
cord-014712-5u4e00q6	200	19	and	and	CC
cord-014712-5u4e00q6	200	20	has	have	VBZ
cord-014712-5u4e00q6	200	21	helped	help	VBN
cord-014712-5u4e00q6	200	22	facilitate	facilitate	VB
cord-014712-5u4e00q6	200	23	the	the	DT
cord-014712-5u4e00q6	200	24	development	development	NN
cord-014712-5u4e00q6	200	25	of	of	IN
cord-014712-5u4e00q6	200	26	these	these	DT
cord-014712-5u4e00q6	200	27	2	2	CD
cord-014712-5u4e00q6	200	28	CARs	car	NNS
cord-014712-5u4e00q6	200	29	.	.	.
cord-014712-5u4e00q6	201	1	The	the	DT
cord-014712-5u4e00q6	201	2	field	field	NN
cord-014712-5u4e00q6	201	3	of	of	IN
cord-014712-5u4e00q6	201	4	PID	PID	NNP
cord-014712-5u4e00q6	201	5	research	research	NN
cord-014712-5u4e00q6	201	6	in	in	IN
cord-014712-5u4e00q6	201	7	India	India	NNP
cord-014712-5u4e00q6	201	8	is	be	VBZ
cord-014712-5u4e00q6	201	9	wide	wide	RB
cord-014712-5u4e00q6	201	10	open	open	JJ
cord-014712-5u4e00q6	201	11	and	and	CC
cord-014712-5u4e00q6	201	12	we	-PRON-	PRP
cord-014712-5u4e00q6	201	13	are	be	VBP
cord-014712-5u4e00q6	201	14	likely	likely	JJ
cord-014712-5u4e00q6	201	15	to	to	TO
cord-014712-5u4e00q6	201	16	witness	witness	VB
cord-014712-5u4e00q6	201	17	new	new	JJ
cord-014712-5u4e00q6	201	18	and	and	CC
cord-014712-5u4e00q6	201	19	exciting	exciting	JJ
cord-014712-5u4e00q6	201	20	scientific	scientific	JJ
cord-014712-5u4e00q6	201	21	developments	development	NNS
cord-014712-5u4e00q6	201	22	in	in	IN
cord-014712-5u4e00q6	201	23	the	the	DT
cord-014712-5u4e00q6	201	24	coming	come	VBG
cord-014712-5u4e00q6	201	25	years	year	NNS
cord-014712-5u4e00q6	201	26	.	.	.
cord-014712-5u4e00q6	202	1	References	reference	NNS
cord-014712-5u4e00q6	202	2	:	:	:
cord-014712-5u4e00q6	202	3	1	1	CD
cord-014712-5u4e00q6	202	4	.	.	.
cord-014712-5u4e00q6	203	1	Gupta	Gupta	NNP
cord-014712-5u4e00q6	203	2	S	S	NNP
cord-014712-5u4e00q6	203	3	,	,	,
cord-014712-5u4e00q6	203	4	Madkaikar	Madkaikar	NNP
cord-014712-5u4e00q6	203	5	M	M	NNP
cord-014712-5u4e00q6	203	6	,	,	,
cord-014712-5u4e00q6	203	7	Singh	Singh	NNP
cord-014712-5u4e00q6	203	8	S	S	NNP
cord-014712-5u4e00q6	203	9	,	,	,
cord-014712-5u4e00q6	203	10	Sehgal	Sehgal	NNP
cord-014712-5u4e00q6	203	11	S.	S.	NNP
cord-014712-5u4e00q6	203	12	Primary	primary	JJ
cord-014712-5u4e00q6	203	13	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	203	14	in	in	IN
cord-014712-5u4e00q6	203	15	India	India	NNP
cord-014712-5u4e00q6	203	16	:	:	:
cord-014712-5u4e00q6	203	17	a	a	DT
cord-014712-5u4e00q6	203	18	perspective	perspective	NN
cord-014712-5u4e00q6	203	19	.	.	.
cord-014712-5u4e00q6	204	1	Annals	annals	NN
cord-014712-5u4e00q6	204	2	of	of	IN
cord-014712-5u4e00q6	204	3	the	the	DT
cord-014712-5u4e00q6	204	4	New	New	NNP
cord-014712-5u4e00q6	204	5	York	York	NNP
cord-014712-5u4e00q6	204	6	Academy	Academy	NNP
cord-014712-5u4e00q6	204	7	of	of	IN
cord-014712-5u4e00q6	204	8	Sciences	Sciences	NNPS
cord-014712-5u4e00q6	204	9	2012	2012	CD
cord-014712-5u4e00q6	204	10	;	;	:
cord-014712-5u4e00q6	204	11	1250	1250	CD
cord-014712-5u4e00q6	204	12	:	:	:
cord-014712-5u4e00q6	204	13	73	73	CD
cord-014712-5u4e00q6	204	14	-	-	SYM
cord-014712-5u4e00q6	204	15	79	79	CD
cord-014712-5u4e00q6	204	16	.	.	.
cord-014712-5u4e00q6	205	1	the	the	DT
cord-014712-5u4e00q6	205	2	prevention	prevention	NN
cord-014712-5u4e00q6	205	3	of	of	IN
cord-014712-5u4e00q6	205	4	PID	PID	NNP
cord-014712-5u4e00q6	205	5	's	's	POS
cord-014712-5u4e00q6	205	6	complications	complication	NNS
cord-014712-5u4e00q6	205	7	,	,	,
cord-014712-5u4e00q6	205	8	the	the	DT
cord-014712-5u4e00q6	205	9	improvement	improvement	NN
cord-014712-5u4e00q6	205	10	of	of	IN
cord-014712-5u4e00q6	205	11	the	the	DT
cord-014712-5u4e00q6	205	12	health	health	NN
cord-014712-5u4e00q6	205	13	care	care	NN
cord-014712-5u4e00q6	205	14	of	of	IN
cord-014712-5u4e00q6	205	15	patients	patient	NNS
cord-014712-5u4e00q6	205	16	with	with	IN
cord-014712-5u4e00q6	205	17	PID	PID	NNP
cord-014712-5u4e00q6	205	18	,	,	,
cord-014712-5u4e00q6	205	19	the	the	DT
cord-014712-5u4e00q6	205	20	creation	creation	NN
cord-014712-5u4e00q6	205	21	of	of	IN
cord-014712-5u4e00q6	205	22	the	the	DT
cord-014712-5u4e00q6	205	23	Registry	Registry	NNP
cord-014712-5u4e00q6	205	24	of	of	IN
cord-014712-5u4e00q6	205	25	the	the	DT
cord-014712-5u4e00q6	205	26	patients	patient	NNS
cord-014712-5u4e00q6	205	27	with	with	IN
cord-014712-5u4e00q6	205	28	PID	PID	NNP
cord-014712-5u4e00q6	205	29	,	,	,
cord-014712-5u4e00q6	205	30	the	the	DT
cord-014712-5u4e00q6	205	31	implementation	implementation	NN
cord-014712-5u4e00q6	205	32	of	of	IN
cord-014712-5u4e00q6	205	33	the	the	DT
cord-014712-5u4e00q6	205	34	finance	finance	NN
cord-014712-5u4e00q6	205	35	regulations	regulation	NNS
cord-014712-5u4e00q6	205	36	for	for	IN
cord-014712-5u4e00q6	205	37	detection	detection	NN
cord-014712-5u4e00q6	205	38	and	and	CC
cord-014712-5u4e00q6	205	39	treatment	treatment	NN
cord-014712-5u4e00q6	205	40	of	of	IN
cord-014712-5u4e00q6	205	41	patients	patient	NNS
cord-014712-5u4e00q6	205	42	with	with	IN
cord-014712-5u4e00q6	205	43	PID	PID	NNP
cord-014712-5u4e00q6	205	44	diseases	disease	NNS
cord-014712-5u4e00q6	205	45	in	in	IN
cord-014712-5u4e00q6	205	46	public	public	JJ
cord-014712-5u4e00q6	205	47	health	health	NN
cord-014712-5u4e00q6	205	48	facilities	facility	NNS
cord-014712-5u4e00q6	205	49	,	,	,
cord-014712-5u4e00q6	205	50	the	the	DT
cord-014712-5u4e00q6	205	51	training	training	NN
cord-014712-5u4e00q6	205	52	and	and	CC
cord-014712-5u4e00q6	205	53	professional	professional	JJ
cord-014712-5u4e00q6	205	54	development	development	NN
cord-014712-5u4e00q6	205	55	of	of	IN
cord-014712-5u4e00q6	205	56	medical	medical	JJ
cord-014712-5u4e00q6	205	57	professionals	professional	NNS
cord-014712-5u4e00q6	205	58	in	in	IN
cord-014712-5u4e00q6	205	59	this	this	DT
cord-014712-5u4e00q6	205	60	field	field	NN
cord-014712-5u4e00q6	205	61	.	.	.
cord-014712-5u4e00q6	206	1	Objective	objective	NN
cord-014712-5u4e00q6	206	2	:	:	:
cord-014712-5u4e00q6	207	1	To	to	TO
cord-014712-5u4e00q6	207	2	improve	improve	VB
cord-014712-5u4e00q6	207	3	the	the	DT
cord-014712-5u4e00q6	207	4	detection	detection	NN
cord-014712-5u4e00q6	207	5	and	and	CC
cord-014712-5u4e00q6	207	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	207	7	of	of	IN
cord-014712-5u4e00q6	207	8	PID	PID	NNP
cord-014712-5u4e00q6	207	9	diseases	disease	NNS
cord-014712-5u4e00q6	207	10	and	and	CC
cord-014712-5u4e00q6	207	11	the	the	DT
cord-014712-5u4e00q6	207	12	life	life	NN
cord-014712-5u4e00q6	207	13	quality	quality	NN
cord-014712-5u4e00q6	207	14	of	of	IN
cord-014712-5u4e00q6	207	15	patients	patient	NNS
cord-014712-5u4e00q6	207	16	with	with	IN
cord-014712-5u4e00q6	207	17	PID	PID	NNP
cord-014712-5u4e00q6	207	18	in	in	IN
cord-014712-5u4e00q6	207	19	the	the	DT
cord-014712-5u4e00q6	207	20	Republic	Republic	NNP
cord-014712-5u4e00q6	207	21	of	of	IN
cord-014712-5u4e00q6	207	22	Kazakhstan	Kazakhstan	NNP
cord-014712-5u4e00q6	207	23	.	.	.
cord-014712-5u4e00q6	208	1	Undertaken	undertake	VBN
cord-014712-5u4e00q6	208	2	activities	activity	NNS
cord-014712-5u4e00q6	208	3	for	for	IN
cord-014712-5u4e00q6	208	4	realization	realization	NN
cord-014712-5u4e00q6	208	5	of	of	IN
cord-014712-5u4e00q6	208	6	the	the	DT
cord-014712-5u4e00q6	208	7	project	project	NN
cord-014712-5u4e00q6	208	8	:	:	:
cord-014712-5u4e00q6	208	9	1	1	CD
cord-014712-5u4e00q6	208	10	.	.	.
cord-014712-5u4e00q6	209	1	Professor	Professor	NNP
cord-014712-5u4e00q6	209	2	.	.	.
cord-014712-5u4e00q6	210	1	L.	L.	NNP
cord-014712-5u4e00q6	210	2	Marodi	Marodi	NNP
cord-014712-5u4e00q6	210	3	visited	visit	VBD
cord-014712-5u4e00q6	210	4	Kazakhstan	Kazakhstan	NNP
cord-014712-5u4e00q6	210	5	in	in	IN
cord-014712-5u4e00q6	210	6	October	October	NNP
cord-014712-5u4e00q6	210	7	2012	2012	CD
cord-014712-5u4e00q6	210	8	and	and	CC
cord-014712-5u4e00q6	210	9	the	the	DT
cord-014712-5u4e00q6	210	10	meeting	meeting	NN
cord-014712-5u4e00q6	210	11	was	be	VBD
cord-014712-5u4e00q6	210	12	held	hold	VBN
cord-014712-5u4e00q6	210	13	in	in	IN
cord-014712-5u4e00q6	210	14	Ministry	Ministry	NNP
cord-014712-5u4e00q6	210	15	of	of	IN
cord-014712-5u4e00q6	210	16	Health	Health	NNP
cord-014712-5u4e00q6	210	17	of	of	IN
cord-014712-5u4e00q6	210	18	the	the	DT
cord-014712-5u4e00q6	210	19	Republic	Republic	NNP
cord-014712-5u4e00q6	210	20	of	of	IN
cord-014712-5u4e00q6	210	21	Kazakhstan	Kazakhstan	NNP
cord-014712-5u4e00q6	210	22	,	,	,
cord-014712-5u4e00q6	210	23	presentations	presentation	NNS
cord-014712-5u4e00q6	210	24	were	be	VBD
cord-014712-5u4e00q6	210	25	given	give	VBN
cord-014712-5u4e00q6	210	26	at	at	IN
cord-014712-5u4e00q6	210	27	the	the	DT
cord-014712-5u4e00q6	210	28	international	international	JJ
cord-014712-5u4e00q6	210	29	conference	conference	NN
cord-014712-5u4e00q6	210	30	held	hold	VBN
cord-014712-5u4e00q6	210	31	in	in	IN
cord-014712-5u4e00q6	210	32	National	National	NNP
cord-014712-5u4e00q6	210	33	Research	Research	NNP
cord-014712-5u4e00q6	210	34	Center	Center	NNP
cord-014712-5u4e00q6	210	35	for	for	IN
cord-014712-5u4e00q6	210	36	Maternal	Maternal	NNP
cord-014712-5u4e00q6	210	37	and	and	CC
cord-014712-5u4e00q6	210	38	Child	Child	NNP
cord-014712-5u4e00q6	210	39	Health	Health	NNP
cord-014712-5u4e00q6	210	40	,	,	,
cord-014712-5u4e00q6	210	41	the	the	DT
cord-014712-5u4e00q6	210	42	negotiations	negotiation	NNS
cord-014712-5u4e00q6	210	43	with	with	IN
cord-014712-5u4e00q6	210	44	Heads	head	NNS
cord-014712-5u4e00q6	210	45	of	of	IN
cord-014712-5u4e00q6	210	46	the	the	DT
cord-014712-5u4e00q6	210	47	National	National	NNP
cord-014712-5u4e00q6	210	48	Medical	Medical	NNP
cord-014712-5u4e00q6	210	49	Holding	Holding	NNP
cord-014712-5u4e00q6	210	50	'	'	POS
cord-014712-5u4e00q6	210	51	clinics	clinic	NNS
cord-014712-5u4e00q6	210	52	and	and	CC
cord-014712-5u4e00q6	210	53	Scientific	Scientific	NNP
cord-014712-5u4e00q6	210	54	Center	Center	NNP
cord-014712-5u4e00q6	210	55	of	of	IN
cord-014712-5u4e00q6	210	56	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	210	57	and	and	CC
cord-014712-5u4e00q6	210	58	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	210	59	Surgery	Surgery	NNP
cord-014712-5u4e00q6	210	60	were	be	VBD
cord-014712-5u4e00q6	210	61	held	hold	VBN
cord-014712-5u4e00q6	210	62	.	.	.
cord-014712-5u4e00q6	211	1	International	International	NNP
cord-014712-5u4e00q6	211	2	Islamic	Islamic	NNP
cord-014712-5u4e00q6	211	3	University	University	NNP
cord-014712-5u4e00q6	211	4	,	,	,
cord-014712-5u4e00q6	211	5	Kuantan	Kuantan	NNP
cord-014712-5u4e00q6	211	6	Pahang	Pahang	NNP
cord-014712-5u4e00q6	211	7	,	,	,
cord-014712-5u4e00q6	211	8	Malaysia	Malaysia	NNP
cord-014712-5u4e00q6	211	9	.	.	.
cord-014712-5u4e00q6	212	1	Two	two	CD
cord-014712-5u4e00q6	212	2	hundred	hundred	CD
cord-014712-5u4e00q6	212	3	and	and	CC
cord-014712-5u4e00q6	212	4	sixty	sixty	CD
cord-014712-5u4e00q6	212	5	three	three	CD
cord-014712-5u4e00q6	212	6	(	(	-LRB-
cord-014712-5u4e00q6	212	7	263	263	CD
cord-014712-5u4e00q6	212	8	)	)	-RRB-
cord-014712-5u4e00q6	212	9	suspected	suspect	VBN
cord-014712-5u4e00q6	212	10	PID	PID	NNP
cord-014712-5u4e00q6	212	11	(	(	-LRB-
cord-014712-5u4e00q6	212	12	primary	primary	JJ
cord-014712-5u4e00q6	212	13	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	212	14	)	)	-RRB-
cord-014712-5u4e00q6	212	15	cases	case	NNS
cord-014712-5u4e00q6	212	16	were	be	VBD
cord-014712-5u4e00q6	212	17	referred	refer	VBN
cord-014712-5u4e00q6	212	18	to	to	IN
cord-014712-5u4e00q6	212	19	clinical	clinical	JJ
cord-014712-5u4e00q6	212	20	immunologist	immunologist	NN
cord-014712-5u4e00q6	212	21	led	lead	VBN
cord-014712-5u4e00q6	212	22	clinics	clinic	NNS
cord-014712-5u4e00q6	212	23	in	in	IN
cord-014712-5u4e00q6	212	24	Malaysia	Malaysia	NNP
cord-014712-5u4e00q6	212	25	from	from	IN
cord-014712-5u4e00q6	212	26	1986	1986	CD
cord-014712-5u4e00q6	212	27	-2013	-2013	NNS
cord-014712-5u4e00q6	212	28	.	.	.
cord-014712-5u4e00q6	213	1	Patients	patient	NNS
cord-014712-5u4e00q6	213	2	referred	refer	VBN
cord-014712-5u4e00q6	213	3	were	be	VBD
cord-014712-5u4e00q6	213	4	from	from	IN
cord-014712-5u4e00q6	213	5	all	all	DT
cord-014712-5u4e00q6	213	6	states	state	NNS
cord-014712-5u4e00q6	213	7	of	of	IN
cord-014712-5u4e00q6	213	8	Malaysia	Malaysia	NNP
cord-014712-5u4e00q6	213	9	and	and	CC
cord-014712-5u4e00q6	213	10	seen	see	VBN
cord-014712-5u4e00q6	213	11	at	at	IN
cord-014712-5u4e00q6	213	12	the	the	DT
cord-014712-5u4e00q6	213	13	institute	institute	NN
cord-014712-5u4e00q6	213	14	of	of	IN
cord-014712-5u4e00q6	213	15	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	213	16	,	,	,
cord-014712-5u4e00q6	213	17	Hospital	Hospital	NNP
cord-014712-5u4e00q6	213	18	Kuala	Kuala	NNP
cord-014712-5u4e00q6	213	19	Lumpur	Lumpur	NNP
cord-014712-5u4e00q6	213	20	and	and	CC
cord-014712-5u4e00q6	213	21	university	university	NN
cord-014712-5u4e00q6	213	22	associated	associate	VBD
cord-014712-5u4e00q6	213	23	Hospitals	Hospitals	NNP
cord-014712-5u4e00q6	213	24	in	in	IN
cord-014712-5u4e00q6	213	25	North	North	NNP
cord-014712-5u4e00q6	213	26	and	and	CC
cord-014712-5u4e00q6	213	27	Central	Central	NNP
cord-014712-5u4e00q6	213	28	Peninsular	Peninsular	NNP
cord-014712-5u4e00q6	213	29	Malaysia	Malaysia	NNP
cord-014712-5u4e00q6	214	1	The	the	DT
cord-014712-5u4e00q6	214	2	initial	initial	JJ
cord-014712-5u4e00q6	214	3	PID	pid	NN
cord-014712-5u4e00q6	214	4	patients	patient	NNS
cord-014712-5u4e00q6	214	5	were	be	VBD
cord-014712-5u4e00q6	214	6	seen	see	VBN
cord-014712-5u4e00q6	214	7	by	by	IN
cord-014712-5u4e00q6	214	8	-1	-1	NN
cord-014712-5u4e00q6	215	1	pediatric	pediatric	JJ
cord-014712-5u4e00q6	215	2	immunologist	immunologist	NN
cord-014712-5u4e00q6	215	3	between	between	IN
cord-014712-5u4e00q6	215	4	1986	1986	CD
cord-014712-5u4e00q6	215	5	-	-	SYM
cord-014712-5u4e00q6	215	6	2006	2006	CD
cord-014712-5u4e00q6	215	7	followed	follow	VBD
cord-014712-5u4e00q6	215	8	by	by	IN
cord-014712-5u4e00q6	215	9	another	another	DT
cord-014712-5u4e00q6	215	10	2	2	CD
cord-014712-5u4e00q6	215	11	,	,	,
cord-014712-5u4e00q6	215	12	beginning	begin	VBG
cord-014712-5u4e00q6	215	13	in	in	IN
cord-014712-5u4e00q6	215	14	2007	2007	CD
cord-014712-5u4e00q6	215	15	followed	follow	VBN
cord-014712-5u4e00q6	215	16	by	by	IN
cord-014712-5u4e00q6	215	17	the	the	DT
cord-014712-5u4e00q6	215	18	other	other	JJ
cord-014712-5u4e00q6	215	19	in	in	IN
cord-014712-5u4e00q6	215	20	2012	2012	CD
cord-014712-5u4e00q6	215	21	.	.	.
cord-014712-5u4e00q6	216	1	There	there	EX
cord-014712-5u4e00q6	216	2	were	be	VBD
cord-014712-5u4e00q6	216	3	168	168	CD
cord-014712-5u4e00q6	216	4	(	(	-LRB-
cord-014712-5u4e00q6	216	5	68.7	68.7	CD
cord-014712-5u4e00q6	216	6	%	%	NN
cord-014712-5u4e00q6	216	7	)	)	-RRB-
cord-014712-5u4e00q6	216	8	patients	patient	NNS
cord-014712-5u4e00q6	216	9	with	with	IN
cord-014712-5u4e00q6	216	10	at	at	RB
cord-014712-5u4e00q6	216	11	least	least	JJS
cord-014712-5u4e00q6	216	12	1	1	CD
cord-014712-5u4e00q6	216	13	abnormality	abnormality	NN
cord-014712-5u4e00q6	216	14	on	on	IN
cord-014712-5u4e00q6	216	15	the	the	DT
cord-014712-5u4e00q6	216	16	immune	immune	JJ
cord-014712-5u4e00q6	216	17	prameter	prameter	NN
cord-014712-5u4e00q6	216	18	recorded	record	VBD
cord-014712-5u4e00q6	216	19	and	and	CC
cord-014712-5u4e00q6	216	20	regarded	regard	VBN
cord-014712-5u4e00q6	216	21	as	as	IN
cord-014712-5u4e00q6	216	22	probable	probable	JJ
cord-014712-5u4e00q6	216	23	PID	pid	NN
cord-014712-5u4e00q6	216	24	.	.	.
cord-014712-5u4e00q6	217	1	However	however	RB
cord-014712-5u4e00q6	217	2	153	153	CD
cord-014712-5u4e00q6	217	3	(	(	-LRB-
cord-014712-5u4e00q6	217	4	62.7	62.7	CD
cord-014712-5u4e00q6	217	5	%	%	NN
cord-014712-5u4e00q6	217	6	)	)	-RRB-
cord-014712-5u4e00q6	217	7	were	be	VBD
cord-014712-5u4e00q6	217	8	recorded	record	VBN
cord-014712-5u4e00q6	217	9	as	as	IN
cord-014712-5u4e00q6	217	10	PID	PID	NNP
cord-014712-5u4e00q6	217	11	based	base	VBN
cord-014712-5u4e00q6	217	12	on	on	IN
cord-014712-5u4e00q6	217	13	existing	exist	VBG
cord-014712-5u4e00q6	217	14	criteria	criterion	NNS
cord-014712-5u4e00q6	217	15	.	.	.
cord-014712-5u4e00q6	218	1	(	(	-LRB-
cord-014712-5u4e00q6	218	2	WHO	WHO	NNP
cord-014712-5u4e00q6	218	3	Scientific	Scientific	NNP
cord-014712-5u4e00q6	218	4	Committee	Committee	NNP
cord-014712-5u4e00q6	218	5	1986	1986	CD
cord-014712-5u4e00q6	218	6	,	,	,
cord-014712-5u4e00q6	218	7	IUIS	IUIS	NNP
cord-014712-5u4e00q6	218	8	Scientific	Scientific	NNP
cord-014712-5u4e00q6	218	9	Committee	Committee	NNP
cord-014712-5u4e00q6	218	10	,	,	,
cord-014712-5u4e00q6	218	11	primary	primary	JJ
cord-014712-5u4e00q6	218	12	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	218	13	disease.1999	disease.1999	NN
cord-014712-5u4e00q6	218	14	)	)	-RRB-
cord-014712-5u4e00q6	219	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	219	2	population	population	NN
cord-014712-5u4e00q6	219	3	were	be	VBD
cord-014712-5u4e00q6	219	4	mainly	mainly	RB
cord-014712-5u4e00q6	219	5	children	child	NNS
cord-014712-5u4e00q6	219	6	,	,	,
cord-014712-5u4e00q6	219	7	83	83	CD
cord-014712-5u4e00q6	219	8	%	%	NN
cord-014712-5u4e00q6	219	9	below	below	IN
cord-014712-5u4e00q6	219	10	10	10	CD
cord-014712-5u4e00q6	219	11	years	year	NNS
cord-014712-5u4e00q6	219	12	and	and	CC
cord-014712-5u4e00q6	219	13	36	36	CD
cord-014712-5u4e00q6	219	14	%	%	NN
cord-014712-5u4e00q6	219	15	below	below	IN
cord-014712-5u4e00q6	219	16	1	1	CD
cord-014712-5u4e00q6	219	17	year	year	NN
cord-014712-5u4e00q6	219	18	.	.	.
cord-014712-5u4e00q6	220	1	Only	only	RB
cord-014712-5u4e00q6	220	2	3	3	CD
cord-014712-5u4e00q6	220	3	were	be	VBD
cord-014712-5u4e00q6	220	4	above	above	IN
cord-014712-5u4e00q6	220	5	18	18	CD
cord-014712-5u4e00q6	220	6	years	year	NNS
cord-014712-5u4e00q6	220	7	.	.	.
cord-014712-5u4e00q6	221	1	PID	PID	NNP
cord-014712-5u4e00q6	221	2	were	be	VBD
cord-014712-5u4e00q6	221	3	classified	classify	VBN
cord-014712-5u4e00q6	221	4	as	as	IN
cord-014712-5u4e00q6	221	5	;	;	:
cord-014712-5u4e00q6	221	6	predominant	predominant	JJ
cord-014712-5u4e00q6	221	7	Antibody	Antibody	NNP
cord-014712-5u4e00q6	221	8	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	221	9	34	34	CD
cord-014712-5u4e00q6	221	10	%	%	NN
cord-014712-5u4e00q6	221	11	,	,	,
cord-014712-5u4e00q6	221	12	combined	combine	VBN
cord-014712-5u4e00q6	221	13	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	221	14	19.3	19.3	CD
cord-014712-5u4e00q6	221	15	%	%	NN
cord-014712-5u4e00q6	221	16	,	,	,
cord-014712-5u4e00q6	221	17	other	other	JJ
cord-014712-5u4e00q6	221	18	cellular	cellular	JJ
cord-014712-5u4e00q6	221	19	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	221	20	14.7	14.7	CD
cord-014712-5u4e00q6	221	21	%	%	NN
cord-014712-5u4e00q6	221	22	,	,	,
cord-014712-5u4e00q6	221	23	phagogocytic	phagogocytic	JJ
cord-014712-5u4e00q6	221	24	defect	defect	NN
cord-014712-5u4e00q6	221	25	11.3	11.3	CD
cord-014712-5u4e00q6	221	26	%	%	NN
cord-014712-5u4e00q6	221	27	,	,	,
cord-014712-5u4e00q6	221	28	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	221	29	associated	associate	VBD
cord-014712-5u4e00q6	221	30	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	221	31	disorders	disorder	NNS
cord-014712-5u4e00q6	221	32	2	2	CD
cord-014712-5u4e00q6	221	33	%	%	NN
cord-014712-5u4e00q6	221	34	.	.	.
cord-014712-5u4e00q6	222	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	222	2	data	datum	NNS
cord-014712-5u4e00q6	222	3	differed	differ	VBD
cord-014712-5u4e00q6	222	4	from	from	IN
cord-014712-5u4e00q6	222	5	most	most	JJS
cord-014712-5u4e00q6	222	6	classification	classification	NN
cord-014712-5u4e00q6	222	7	where	where	WRB
cord-014712-5u4e00q6	222	8	predominant	predominant	JJ
cord-014712-5u4e00q6	222	9	antibody	antibody	NN
cord-014712-5u4e00q6	222	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	222	11	is	be	VBZ
cord-014712-5u4e00q6	222	12	most	most	RBS
cord-014712-5u4e00q6	222	13	frequent	frequent	JJ
cord-014712-5u4e00q6	222	14	as	as	RB
cord-014712-5u4e00q6	222	15	high	high	JJ
cord-014712-5u4e00q6	222	16	as	as	IN
cord-014712-5u4e00q6	222	17	65	65	CD
cord-014712-5u4e00q6	222	18	%	%	NN
cord-014712-5u4e00q6	222	19	,	,	,
cord-014712-5u4e00q6	222	20	(	(	-LRB-
cord-014712-5u4e00q6	222	21	Steihm	Steihm	NNP
cord-014712-5u4e00q6	222	22	,	,	,
cord-014712-5u4e00q6	222	23	2004	2004	CD
cord-014712-5u4e00q6	222	24	)	)	-RRB-
cord-014712-5u4e00q6	222	25	.	.	.
cord-014712-5u4e00q6	223	1	Of	of	IN
cord-014712-5u4e00q6	223	2	the	the	DT
cord-014712-5u4e00q6	223	3	specific	specific	JJ
cord-014712-5u4e00q6	223	4	153	153	CD
cord-014712-5u4e00q6	223	5	PID	pid	NN
cord-014712-5u4e00q6	223	6	recorded	record	VBN
cord-014712-5u4e00q6	223	7	,	,	,
cord-014712-5u4e00q6	223	8	X	X	NNP
cord-014712-5u4e00q6	223	9	linked	link	VBD
cord-014712-5u4e00q6	223	10	a	a	DT
cord-014712-5u4e00q6	223	11	gammaglobulinemia	gammaglobulinemia	NN
cord-014712-5u4e00q6	223	12	(	(	-LRB-
cord-014712-5u4e00q6	223	13	XLA	XLA	NNP
cord-014712-5u4e00q6	223	14	)	)	-RRB-
cord-014712-5u4e00q6	223	15	19	19	CD
cord-014712-5u4e00q6	223	16	,	,	,
cord-014712-5u4e00q6	223	17	hyper	hyper	NNP
cord-014712-5u4e00q6	223	18	IgM	IgM	NNP
cord-014712-5u4e00q6	223	19	syndrome	syndrome	NN
cord-014712-5u4e00q6	223	20	(	(	-LRB-
cord-014712-5u4e00q6	223	21	HIGM	HIGM	NNP
cord-014712-5u4e00q6	223	22	)	)	-RRB-
cord-014712-5u4e00q6	223	23	11	11	CD
cord-014712-5u4e00q6	223	24	,	,	,
cord-014712-5u4e00q6	223	25	common	common	JJ
cord-014712-5u4e00q6	223	26	variable	variable	NN
cord-014712-5u4e00q6	223	27	Immunodeficiencis	Immunodeficiencis	NNP
cord-014712-5u4e00q6	223	28	(	(	-LRB-
cord-014712-5u4e00q6	223	29	CVID	CVID	NNP
cord-014712-5u4e00q6	223	30	7	7	CD
cord-014712-5u4e00q6	223	31	)	)	-RRB-
cord-014712-5u4e00q6	223	32	,	,	,
cord-014712-5u4e00q6	223	33	selective	selective	JJ
cord-014712-5u4e00q6	223	34	IgA	IgA	NNP
cord-014712-5u4e00q6	223	35	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	224	1	7	7	CD
cord-014712-5u4e00q6	224	2	severe	severe	JJ
cord-014712-5u4e00q6	224	3	combined	combine	VBN
cord-014712-5u4e00q6	224	4	Immunodeficiencies	Immunodeficiencies	NNP
cord-014712-5u4e00q6	224	5	(	(	-LRB-
cord-014712-5u4e00q6	224	6	SCID	SCID	NNP
cord-014712-5u4e00q6	224	7	)	)	-RRB-
cord-014712-5u4e00q6	224	8	17	17	CD
cord-014712-5u4e00q6	224	9	,	,	,
cord-014712-5u4e00q6	224	10	Di	Di	NNP
cord-014712-5u4e00q6	224	11	George	George	NNP
cord-014712-5u4e00q6	224	12	syndrome	syndrome	NN
cord-014712-5u4e00q6	225	1	(	(	-LRB-
cord-014712-5u4e00q6	225	2	DGS)12,chronic	DGS)12,chronic	NNP
cord-014712-5u4e00q6	225	3	granlomatous	granlomatous	JJ
cord-014712-5u4e00q6	225	4	Disease	Disease	NNP
cord-014712-5u4e00q6	225	5	(	(	-LRB-
cord-014712-5u4e00q6	225	6	CGD	CGD	NNP
cord-014712-5u4e00q6	225	7	)	)	-RRB-
cord-014712-5u4e00q6	225	8	14	14	CD
cord-014712-5u4e00q6	225	9	,	,	,
cord-014712-5u4e00q6	225	10	hyper	hyper	JJ
cord-014712-5u4e00q6	225	11	Immunoglobulin	Immunoglobulin	NNP
cord-014712-5u4e00q6	225	12	E	e	NN
cord-014712-5u4e00q6	225	13	syndrome	syndrome	NN
cord-014712-5u4e00q6	225	14	(	(	-LRB-
cord-014712-5u4e00q6	225	15	HIGE	HIGE	NNP
cord-014712-5u4e00q6	225	16	)	)	-RRB-
cord-014712-5u4e00q6	225	17	14	14	CD
cord-014712-5u4e00q6	225	18	,	,	,
cord-014712-5u4e00q6	225	19	primary	primary	JJ
cord-014712-5u4e00q6	225	20	CD4	CD4	NNP
cord-014712-5u4e00q6	225	21	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	225	22	6	6	CD
cord-014712-5u4e00q6	225	23	,	,	,
cord-014712-5u4e00q6	225	24	ataxia	ataxia	NNP
cord-014712-5u4e00q6	225	25	telangiectassi	telangiectassi	NNP
cord-014712-5u4e00q6	225	26	3	3	CD
cord-014712-5u4e00q6	225	27	%	%	NN
cord-014712-5u4e00q6	226	1	Malaysia	Malaysia	NNP
cord-014712-5u4e00q6	226	2	comprises	comprise	VBZ
cord-014712-5u4e00q6	226	3	of	of	IN
cord-014712-5u4e00q6	226	4	multi	multi	JJ
cord-014712-5u4e00q6	226	5	ethnic	ethnic	JJ
cord-014712-5u4e00q6	226	6	groups	group	NNS
cord-014712-5u4e00q6	226	7	with	with	IN
cord-014712-5u4e00q6	226	8	a	a	DT
cord-014712-5u4e00q6	226	9	population	population	NN
cord-014712-5u4e00q6	226	10	of	of	IN
cord-014712-5u4e00q6	226	11	29.6	29.6	CD
cord-014712-5u4e00q6	226	12	million	million	CD
cord-014712-5u4e00q6	226	13	in	in	IN
cord-014712-5u4e00q6	226	14	2013	2013	CD
cord-014712-5u4e00q6	226	15	.	.	.
cord-014712-5u4e00q6	227	1	PID	PID	NNP
cord-014712-5u4e00q6	227	2	amongst	amongst	IN
cord-014712-5u4e00q6	227	3	them	-PRON-	PRP
cord-014712-5u4e00q6	227	4	showed	show	VBD
cord-014712-5u4e00q6	227	5	,	,	,
cord-014712-5u4e00q6	227	6	Malays	Malays	NNPS
cord-014712-5u4e00q6	227	7	at	at	IN
cord-014712-5u4e00q6	227	8	61.4	61.4	CD
cord-014712-5u4e00q6	227	9	%	%	NN
cord-014712-5u4e00q6	227	10	,	,	,
cord-014712-5u4e00q6	227	11	Chinese	chinese	JJ
cord-014712-5u4e00q6	227	12	11	11	CD
cord-014712-5u4e00q6	227	13	%	%	NN
cord-014712-5u4e00q6	227	14	,	,	,
cord-014712-5u4e00q6	227	15	Indians	Indians	NNPS
cord-014712-5u4e00q6	227	16	23.7	23.7	CD
cord-014712-5u4e00q6	227	17	%	%	NN
cord-014712-5u4e00q6	227	18	and	and	CC
cord-014712-5u4e00q6	227	19	others	other	NNS
cord-014712-5u4e00q6	227	20	5.2	5.2	CD
cord-014712-5u4e00q6	227	21	%	%	NN
cord-014712-5u4e00q6	227	22	whilst	whilst	IN
cord-014712-5u4e00q6	227	23	the	the	DT
cord-014712-5u4e00q6	227	24	male	male	NN
cord-014712-5u4e00q6	227	25	predominate	predominate	VBP
cord-014712-5u4e00q6	227	26	over	over	IN
cord-014712-5u4e00q6	227	27	female	female	NN
cord-014712-5u4e00q6	227	28	at	at	IN
cord-014712-5u4e00q6	227	29	a	a	DT
cord-014712-5u4e00q6	227	30	ratio	ratio	NN
cord-014712-5u4e00q6	227	31	of	of	IN
cord-014712-5u4e00q6	227	32	2.8:1	2.8:1	CD
cord-014712-5u4e00q6	227	33	.	.	.
cord-014712-5u4e00q6	228	1	Family	family	NN
cord-014712-5u4e00q6	228	2	history	history	NN
cord-014712-5u4e00q6	228	3	of	of	IN
cord-014712-5u4e00q6	228	4	affected	affected	JJ
cord-014712-5u4e00q6	228	5	sibling	sibling	NN
cord-014712-5u4e00q6	228	6	or	or	CC
cord-014712-5u4e00q6	228	7	in	in	IN
cord-014712-5u4e00q6	228	8	first	first	JJ
cord-014712-5u4e00q6	228	9	degree	degree	NN
cord-014712-5u4e00q6	228	10	relative	relative	NN
cord-014712-5u4e00q6	228	11	,	,	,
cord-014712-5u4e00q6	228	12	or	or	CC
cord-014712-5u4e00q6	228	13	early	early	JJ
cord-014712-5u4e00q6	228	14	death	death	NN
cord-014712-5u4e00q6	228	15	with	with	IN
cord-014712-5u4e00q6	228	16	suspected	suspect	VBN
cord-014712-5u4e00q6	228	17	infant	infant	NN
cord-014712-5u4e00q6	228	18	dying	dying	NN
cord-014712-5u4e00q6	228	19	of	of	IN
cord-014712-5u4e00q6	228	20	infection	infection	NN
cord-014712-5u4e00q6	228	21	was	be	VBD
cord-014712-5u4e00q6	228	22	positive	positive	JJ
cord-014712-5u4e00q6	228	23	in	in	IN
cord-014712-5u4e00q6	228	24	53.3	53.3	CD
cord-014712-5u4e00q6	228	25	%	%	NN
cord-014712-5u4e00q6	228	26	which	which	WDT
cord-014712-5u4e00q6	228	27	is	be	VBZ
cord-014712-5u4e00q6	228	28	higher	high	JJR
cord-014712-5u4e00q6	228	29	than	than	IN
cord-014712-5u4e00q6	228	30	in	in	IN
cord-014712-5u4e00q6	228	31	most	most	JJS
cord-014712-5u4e00q6	228	32	reports	report	NNS
cord-014712-5u4e00q6	228	33	eg	eg	VBP
cord-014712-5u4e00q6	228	34	Egypt	Egypt	NNP
cord-014712-5u4e00q6	228	35	23.4	23.4	CD
cord-014712-5u4e00q6	228	36	%	%	NN
cord-014712-5u4e00q6	228	37	(	(	-LRB-
cord-014712-5u4e00q6	228	38	Reeda	Reeda	NNP
cord-014712-5u4e00q6	228	39	2009	2009	CD
cord-014712-5u4e00q6	228	40	)	)	-RRB-
cord-014712-5u4e00q6	228	41	.	.	.
cord-014712-5u4e00q6	229	1	This	this	DT
cord-014712-5u4e00q6	229	2	could	could	MD
cord-014712-5u4e00q6	229	3	be	be	VB
cord-014712-5u4e00q6	229	4	due	due	JJ
cord-014712-5u4e00q6	229	5	to	to	IN
cord-014712-5u4e00q6	229	6	high	high	JJ
cord-014712-5u4e00q6	229	7	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	229	8	in	in	IN
cord-014712-5u4e00q6	229	9	the	the	DT
cord-014712-5u4e00q6	229	10	population	population	NN
cord-014712-5u4e00q6	229	11	.	.	.
cord-014712-5u4e00q6	230	1	Alternatively	alternatively	RB
cord-014712-5u4e00q6	230	2	the	the	DT
cord-014712-5u4e00q6	230	3	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	230	4	sibling	sibling	NN
cord-014712-5u4e00q6	230	5	of	of	IN
cord-014712-5u4e00q6	230	6	affected	affected	JJ
cord-014712-5u4e00q6	230	7	patients	patient	NNS
cord-014712-5u4e00q6	230	8	is	be	VBZ
cord-014712-5u4e00q6	230	9	more	more	RBR
cord-014712-5u4e00q6	230	10	likely	likely	JJ
cord-014712-5u4e00q6	230	11	to	to	TO
cord-014712-5u4e00q6	230	12	be	be	VB
cord-014712-5u4e00q6	230	13	referred	refer	VBN
cord-014712-5u4e00q6	230	14	to	to	IN
cord-014712-5u4e00q6	230	15	the	the	DT
cord-014712-5u4e00q6	230	16	clinical	clinical	JJ
cord-014712-5u4e00q6	230	17	immunologist	immunologist	NN
cord-014712-5u4e00q6	230	18	.	.	.
cord-014712-5u4e00q6	231	1	SCID	SCID	NNP
cord-014712-5u4e00q6	231	2	records	record	VBZ
cord-014712-5u4e00q6	231	3	the	the	DT
cord-014712-5u4e00q6	231	4	most	most	RBS
cord-014712-5u4e00q6	231	5	varied	varied	JJ
cord-014712-5u4e00q6	231	6	organism	organism	NN
cord-014712-5u4e00q6	231	7	from	from	IN
cord-014712-5u4e00q6	231	8	the	the	DT
cord-014712-5u4e00q6	231	9	positive	positive	JJ
cord-014712-5u4e00q6	231	10	microbiological	microbiological	JJ
cord-014712-5u4e00q6	231	11	isolate	isolate	NN
cord-014712-5u4e00q6	232	1	viz	viz	NNP
cord-014712-5u4e00q6	232	2	bacteria	bacteria	NNS
cord-014712-5u4e00q6	232	3	4	4	CD
cord-014712-5u4e00q6	232	4	,	,	,
cord-014712-5u4e00q6	232	5	fungus	fungus	NN
cord-014712-5u4e00q6	232	6	2	2	CD
cord-014712-5u4e00q6	232	7	,	,	,
cord-014712-5u4e00q6	232	8	virus	virus	NN
cord-014712-5u4e00q6	232	9	1	1	CD
cord-014712-5u4e00q6	232	10	,	,	,
cord-014712-5u4e00q6	232	11	parasite	parasite	NN
cord-014712-5u4e00q6	232	12	2	2	CD
cord-014712-5u4e00q6	232	13	.	.	.
cord-014712-5u4e00q6	233	1	Chromobacterium	Chromobacterium	NNP
cord-014712-5u4e00q6	233	2	violaceum	violaceum	NNP
cord-014712-5u4e00q6	233	3	was	be	VBD
cord-014712-5u4e00q6	233	4	seen	see	VBN
cord-014712-5u4e00q6	233	5	in	in	IN
cord-014712-5u4e00q6	233	6	3	3	CD
cord-014712-5u4e00q6	233	7	CGD	CGD	NNP
cord-014712-5u4e00q6	233	8	patients	patient	NNS
cord-014712-5u4e00q6	233	9	in	in	IN
cord-014712-5u4e00q6	233	10	which	which	WDT
cord-014712-5u4e00q6	233	11	2	2	CD
cord-014712-5u4e00q6	233	12	deteriorated	deteriorate	VBD
cord-014712-5u4e00q6	233	13	with	with	IN
cord-014712-5u4e00q6	233	14	eventual	eventual	JJ
cord-014712-5u4e00q6	233	15	death	death	NN
cord-014712-5u4e00q6	233	16	.	.	.
cord-014712-5u4e00q6	234	1	As	as	IN
cord-014712-5u4e00q6	234	2	in	in	IN
cord-014712-5u4e00q6	234	3	many	many	JJ
cord-014712-5u4e00q6	234	4	national	national	JJ
cord-014712-5u4e00q6	234	5	registries	registry	NNS
cord-014712-5u4e00q6	234	6	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	234	7	delays	delay	NNS
cord-014712-5u4e00q6	234	8	remains	remain	VBZ
cord-014712-5u4e00q6	234	9	prominent	prominent	JJ
cord-014712-5u4e00q6	234	10	.	.	.
cord-014712-5u4e00q6	235	1	In	in	IN
cord-014712-5u4e00q6	235	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	235	3	series	series	NN
cord-014712-5u4e00q6	235	4	the	the	DT
cord-014712-5u4e00q6	235	5	mean	mean	JJ
cord-014712-5u4e00q6	235	6	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	235	7	delay	delay	NN
cord-014712-5u4e00q6	235	8	was	be	VBD
cord-014712-5u4e00q6	235	9	o	o	NN
cord-014712-5u4e00q6	235	10	3.61	3.61	CD
cord-014712-5u4e00q6	235	11	±	±	CD
cord-014712-5u4e00q6	235	12	4.82	4.82	CD
cord-014712-5u4e00q6	235	13	years	year	NNS
cord-014712-5u4e00q6	235	14	.	.	.
cord-014712-5u4e00q6	236	1	In	in	IN
cord-014712-5u4e00q6	236	2	comparison	comparison	NN
cord-014712-5u4e00q6	236	3	Thailand	Thailand	NNP
cord-014712-5u4e00q6	236	4	stands	stand	VBZ
cord-014712-5u4e00q6	236	5	at	at	IN
cord-014712-5u4e00q6	236	6	2.1	2.1	CD
cord-014712-5u4e00q6	236	7	±	±	CD
cord-014712-5u4e00q6	236	8	2.6	2.6	CD
cord-014712-5u4e00q6	236	9	years	year	NNS
cord-014712-5u4e00q6	236	10	,	,	,
cord-014712-5u4e00q6	236	11	while	while	IN
cord-014712-5u4e00q6	236	12	France	France	NNP
cord-014712-5u4e00q6	236	13	,	,	,
cord-014712-5u4e00q6	236	14	a	a	DT
cord-014712-5u4e00q6	236	15	median	median	NN
cord-014712-5u4e00q6	236	16	of	of	IN
cord-014712-5u4e00q6	236	17	1.3	1.3	CD
cord-014712-5u4e00q6	236	18	years	year	NNS
cord-014712-5u4e00q6	236	19	.	.	.
cord-014712-5u4e00q6	237	1	Malaysia	Malaysia	NNP
cord-014712-5u4e00q6	237	2	remains	remain	VBZ
cord-014712-5u4e00q6	237	3	committed	committed	JJ
cord-014712-5u4e00q6	237	4	to	to	TO
cord-014712-5u4e00q6	237	5	provide	provide	VB
cord-014712-5u4e00q6	237	6	better	well	JJR
cord-014712-5u4e00q6	237	7	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	237	8	services	service	NNS
cord-014712-5u4e00q6	237	9	and	and	CC
cord-014712-5u4e00q6	237	10	improved	improved	JJ
cord-014712-5u4e00q6	237	11	care	care	NN
cord-014712-5u4e00q6	237	12	of	of	IN
cord-014712-5u4e00q6	237	13	the	the	DT
cord-014712-5u4e00q6	237	14	PID	PID	NNP
cord-014712-5u4e00q6	237	15	patients	patient	NNS
cord-014712-5u4e00q6	237	16	through	through	IN
cord-014712-5u4e00q6	237	17	research	research	NN
cord-014712-5u4e00q6	237	18	collaboration	collaboration	NN
cord-014712-5u4e00q6	237	19	with	with	IN
cord-014712-5u4e00q6	237	20	foreign	foreign	JJ
cord-014712-5u4e00q6	237	21	partners	partner	NNS
cord-014712-5u4e00q6	237	22	with	with	IN
cord-014712-5u4e00q6	237	23	a	a	DT
cord-014712-5u4e00q6	237	24	drive	drive	NN
cord-014712-5u4e00q6	237	25	for	for	IN
cord-014712-5u4e00q6	237	26	creating	create	VBG
cord-014712-5u4e00q6	237	27	subspecialty	subspecialty	JJ
cord-014712-5u4e00q6	237	28	training	training	NN
cord-014712-5u4e00q6	237	29	.	.	.
cord-014712-5u4e00q6	238	1	Patient	patient	JJ
cord-014712-5u4e00q6	238	2	groups	group	NNS
cord-014712-5u4e00q6	238	3	aligned	align	VBN
cord-014712-5u4e00q6	238	4	to	to	IN
cord-014712-5u4e00q6	238	5	IPOPI	IPOPI	NNP
cord-014712-5u4e00q6	238	6	is	be	VBZ
cord-014712-5u4e00q6	238	7	now	now	RB
cord-014712-5u4e00q6	238	8	closer	close	JJR
cord-014712-5u4e00q6	238	9	to	to	IN
cord-014712-5u4e00q6	238	10	its	-PRON-	PRP$
cord-014712-5u4e00q6	238	11	formation	formation	NN
cord-014712-5u4e00q6	238	12	with	with	IN
cord-014712-5u4e00q6	238	13	the	the	DT
cord-014712-5u4e00q6	238	14	creation	creation	NN
cord-014712-5u4e00q6	238	15	of	of	IN
cord-014712-5u4e00q6	238	16	its	-PRON-	PRP$
cord-014712-5u4e00q6	238	17	protem	protem	NNP
cord-014712-5u4e00q6	238	18	committee	committee	NNP
cord-014712-5u4e00q6	238	19	ensuring	ensure	VBG
cord-014712-5u4e00q6	238	20	that	that	IN
cord-014712-5u4e00q6	238	21	patients	patient	NNS
cord-014712-5u4e00q6	238	22	'	'	POS
cord-014712-5u4e00q6	238	23	interest	interest	NN
cord-014712-5u4e00q6	238	24	will	will	MD
cord-014712-5u4e00q6	238	25	always	always	RB
cord-014712-5u4e00q6	238	26	be	be	VB
cord-014712-5u4e00q6	238	27	guarded	guard	VBN
cord-014712-5u4e00q6	238	28	Aknowledgement	Aknowledgement	NNP
cord-014712-5u4e00q6	238	29	.	.	.
cord-014712-5u4e00q6	239	1	The	the	DT
cord-014712-5u4e00q6	239	2	authors	author	NNS
cord-014712-5u4e00q6	239	3	thank	thank	VBP
cord-014712-5u4e00q6	239	4	all	all	DT
cord-014712-5u4e00q6	239	5	who	who	WP
cord-014712-5u4e00q6	239	6	had	have	VBD
cord-014712-5u4e00q6	239	7	contributed	contribute	VBN
cord-014712-5u4e00q6	239	8	directly	directly	RB
cord-014712-5u4e00q6	239	9	or	or	CC
cord-014712-5u4e00q6	239	10	indirectly	indirectly	RB
cord-014712-5u4e00q6	239	11	,	,	,
cord-014712-5u4e00q6	239	12	especially	especially	RB
cord-014712-5u4e00q6	239	13	medical	medical	JJ
cord-014712-5u4e00q6	239	14	officers	officer	NNS
cord-014712-5u4e00q6	239	15	,	,	,
cord-014712-5u4e00q6	239	16	nurses	nurse	NNS
cord-014712-5u4e00q6	239	17	,	,	,
cord-014712-5u4e00q6	239	18	consultant	consultant	NN
cord-014712-5u4e00q6	239	19	pediatricians	pediatrician	NNS
cord-014712-5u4e00q6	239	20	especially	especially	RB
cord-014712-5u4e00q6	240	1	Dr	Dr	NNP
cord-014712-5u4e00q6	240	2	Kamarul	Kamarul	NNP
cord-014712-5u4e00q6	240	3	Azhar	Azhar	NNP
cord-014712-5u4e00q6	240	4	,	,	,
cord-014712-5u4e00q6	240	5	Institut	Institut	NNP
cord-014712-5u4e00q6	240	6	of	of	IN
cord-014712-5u4e00q6	240	7	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	240	8	HKL	HKL	NNP
cord-014712-5u4e00q6	240	9	,	,	,
cord-014712-5u4e00q6	240	10	laboratory	laboratory	NN
cord-014712-5u4e00q6	240	11	scientists	scientist	NNS
cord-014712-5u4e00q6	240	12	especially	especially	RB
cord-014712-5u4e00q6	240	13	Dr	Dr	NNP
cord-014712-5u4e00q6	240	14	Shanaz	Shanaz	NNP
cord-014712-5u4e00q6	240	15	Murad	Murad	NNP
cord-014712-5u4e00q6	240	16	of	of	IN
cord-014712-5u4e00q6	240	17	the	the	DT
cord-014712-5u4e00q6	240	18	IMR	IMR	NNP
cord-014712-5u4e00q6	240	19	Kuala	Kuala	NNP
cord-014712-5u4e00q6	240	20	Lumpur	Lumpur	NNP
cord-014712-5u4e00q6	240	21	University	University	NNP
cord-014712-5u4e00q6	240	22	of	of	IN
cord-014712-5u4e00q6	240	23	Manchester	Manchester	NNP
cord-014712-5u4e00q6	240	24	,	,	,
cord-014712-5u4e00q6	240	25	UK	UK	NNP
cord-014712-5u4e00q6	241	1	Although	although	IN
cord-014712-5u4e00q6	241	2	the	the	DT
cord-014712-5u4e00q6	241	3	concept	concept	NN
cord-014712-5u4e00q6	241	4	of	of	IN
cord-014712-5u4e00q6	241	5	grouping	group	VBG
cord-014712-5u4e00q6	241	6	Mendelian	mendelian	JJ
cord-014712-5u4e00q6	241	7	disorders	disorder	NNS
cord-014712-5u4e00q6	241	8	associated	associate	VBN
cord-014712-5u4e00q6	241	9	with	with	IN
cord-014712-5u4e00q6	241	10	an	an	DT
cord-014712-5u4e00q6	241	11	upregulation	upregulation	NN
cord-014712-5u4e00q6	241	12	of	of	IN
cord-014712-5u4e00q6	241	13	type	type	NN
cord-014712-5u4e00q6	242	1	I	-PRON-	PRP
cord-014712-5u4e00q6	243	1	interferon	interferon	NNP
cord-014712-5u4e00q6	243	2	(	(	-LRB-
cord-014712-5u4e00q6	243	3	IFN	IFN	NNP
cord-014712-5u4e00q6	243	4	)	)	-RRB-
cord-014712-5u4e00q6	243	5	has	have	VBZ
cord-014712-5u4e00q6	243	6	not	not	RB
cord-014712-5u4e00q6	243	7	been	be	VBN
cord-014712-5u4e00q6	243	8	previously	previously	RB
cord-014712-5u4e00q6	243	9	recognised	recognise	VBN
cord-014712-5u4e00q6	243	10	in	in	IN
cord-014712-5u4e00q6	243	11	the	the	DT
cord-014712-5u4e00q6	243	12	medical	medical	JJ
cord-014712-5u4e00q6	243	13	literature	literature	NN
cord-014712-5u4e00q6	243	14	,	,	,
cord-014712-5u4e00q6	243	15	our	-PRON-	PRP$
cord-014712-5u4e00q6	243	16	past	past	JJ
cord-014712-5u4e00q6	243	17	and	and	CC
cord-014712-5u4e00q6	243	18	current	current	JJ
cord-014712-5u4e00q6	243	19	work	work	NN
cord-014712-5u4e00q6	243	20	argues	argue	VBZ
cord-014712-5u4e00q6	243	21	that	that	IN
cord-014712-5u4e00q6	243	22	this	this	DT
cord-014712-5u4e00q6	243	23	concept	concept	NN
cord-014712-5u4e00q6	243	24	has	have	VBZ
cord-014712-5u4e00q6	243	25	scientific	scientific	JJ
cord-014712-5u4e00q6	243	26	validity	validity	NN
cord-014712-5u4e00q6	243	27	and	and	CC
cord-014712-5u4e00q6	243	28	clinical	clinical	JJ
cord-014712-5u4e00q6	243	29	utility	utility	NN
cord-014712-5u4e00q6	243	30	.	.	.
cord-014712-5u4e00q6	244	1	I	-PRON-	PRP
cord-014712-5u4e00q6	244	2	will	will	MD
cord-014712-5u4e00q6	244	3	discuss	discuss	VB
cord-014712-5u4e00q6	244	4	the	the	DT
cord-014712-5u4e00q6	244	5	possibility	possibility	NN
cord-014712-5u4e00q6	244	6	that	that	IN
cord-014712-5u4e00q6	244	7	such	such	JJ
cord-014712-5u4e00q6	244	8	conditions	condition	NNS
cord-014712-5u4e00q6	244	9	can	can	MD
cord-014712-5u4e00q6	244	10	usefully	usefully	RB
cord-014712-5u4e00q6	244	11	be	be	VB
cord-014712-5u4e00q6	244	12	considered	consider	VBN
cord-014712-5u4e00q6	244	13	to	to	TO
cord-014712-5u4e00q6	244	14	represent	represent	VB
cord-014712-5u4e00q6	244	15	a	a	DT
cord-014712-5u4e00q6	244	16	novel	novel	JJ
cord-014712-5u4e00q6	244	17	set	set	NN
cord-014712-5u4e00q6	244	18	of	of	IN
cord-014712-5u4e00q6	244	19	inborn	inborn	JJ
cord-014712-5u4e00q6	244	20	errors	error	NNS
cord-014712-5u4e00q6	244	21	of	of	IN
cord-014712-5u4e00q6	244	22	immunity	immunity	NN
cord-014712-5u4e00q6	244	23	,	,	,
cord-014712-5u4e00q6	244	24	and	and	CC
cord-014712-5u4e00q6	244	25	that	that	IN
cord-014712-5u4e00q6	244	26	the	the	DT
cord-014712-5u4e00q6	244	27	recognition	recognition	NN
cord-014712-5u4e00q6	244	28	of	of	IN
cord-014712-5u4e00q6	244	29	diseases	disease	NNS
cord-014712-5u4e00q6	244	30	as	as	IN
cord-014712-5u4e00q6	244	31	type	type	NN
cord-014712-5u4e00q6	244	32	I	-PRON-	PRP
cord-014712-5u4e00q6	244	33	interferonopathies	interferonopathie	NNS
cord-014712-5u4e00q6	244	34	will	will	MD
cord-014712-5u4e00q6	244	35	have	have	VB
cord-014712-5u4e00q6	244	36	significance	significance	NN
cord-014712-5u4e00q6	244	37	for	for	IN
cord-014712-5u4e00q6	244	38	the	the	DT
cord-014712-5u4e00q6	244	39	development	development	NN
cord-014712-5u4e00q6	244	40	of	of	IN
cord-014712-5u4e00q6	244	41	targeted	target	VBN
cord-014712-5u4e00q6	244	42	therapies	therapy	NNS
cord-014712-5u4e00q6	244	43	,	,	,
cord-014712-5u4e00q6	244	44	as	as	RB
cord-014712-5u4e00q6	244	45	well	well	RB
cord-014712-5u4e00q6	244	46	as	as	IN
cord-014712-5u4e00q6	244	47	informing	inform	VBG
cord-014712-5u4e00q6	244	48	our	-PRON-	PRP$
cord-014712-5u4e00q6	244	49	understanding	understanding	NN
cord-014712-5u4e00q6	244	50	of	of	IN
cord-014712-5u4e00q6	244	51	viral	viral	JJ
cord-014712-5u4e00q6	244	52	and	and	CC
cord-014712-5u4e00q6	244	53	retroelement	retroelement	JJ
cord-014712-5u4e00q6	244	54	biology	biology	NN
cord-014712-5u4e00q6	244	55	,	,	,
cord-014712-5u4e00q6	244	56	and	and	CC
cord-014712-5u4e00q6	244	57	the	the	DT
cord-014712-5u4e00q6	244	58	pathogenesis	pathogenesis	NN
cord-014712-5u4e00q6	244	59	of	of	IN
cord-014712-5u4e00q6	244	60	some	some	DT
cord-014712-5u4e00q6	244	61	forms	form	NNS
cord-014712-5u4e00q6	244	62	of	of	IN
cord-014712-5u4e00q6	244	63	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	244	64	.	.	.
cord-014712-5u4e00q6	245	1	1	1	CD
cord-014712-5u4e00q6	245	2	Classic	Classic	NNP
cord-014712-5u4e00q6	245	3	Kaposi	Kaposi	NNP
cord-014712-5u4e00q6	245	4	sarcoma	sarcoma	NN
cord-014712-5u4e00q6	245	5	(	(	-LRB-
cord-014712-5u4e00q6	245	6	KS	KS	NNP
cord-014712-5u4e00q6	245	7	)	)	-RRB-
cord-014712-5u4e00q6	245	8	is	be	VBZ
cord-014712-5u4e00q6	245	9	exceedingly	exceedingly	RB
cord-014712-5u4e00q6	245	10	rare	rare	JJ
cord-014712-5u4e00q6	245	11	in	in	IN
cord-014712-5u4e00q6	245	12	children	child	NNS
cord-014712-5u4e00q6	245	13	from	from	IN
cord-014712-5u4e00q6	245	14	the	the	DT
cord-014712-5u4e00q6	245	15	Mediterranean	Mediterranean	NNP
cord-014712-5u4e00q6	245	16	Basin	Basin	NNP
cord-014712-5u4e00q6	245	17	,	,	,
cord-014712-5u4e00q6	245	18	despite	despite	IN
cord-014712-5u4e00q6	245	19	the	the	DT
cord-014712-5u4e00q6	245	20	high	high	JJ
cord-014712-5u4e00q6	245	21	prevalence	prevalence	NN
cord-014712-5u4e00q6	245	22	of	of	IN
cord-014712-5u4e00q6	245	23	HHV-8	HHV-8	NNP
cord-014712-5u4e00q6	245	24	infection	infection	NN
cord-014712-5u4e00q6	245	25	in	in	IN
cord-014712-5u4e00q6	245	26	this	this	DT
cord-014712-5u4e00q6	245	27	region	region	NN
cord-014712-5u4e00q6	245	28	.	.	.
cord-014712-5u4e00q6	246	1	We	-PRON-	PRP
cord-014712-5u4e00q6	246	2	hypothesized	hypothesize	VBD
cord-014712-5u4e00q6	246	3	that	that	IN
cord-014712-5u4e00q6	246	4	rare	rare	JJ
cord-014712-5u4e00q6	246	5	single	single	JJ
cord-014712-5u4e00q6	246	6	-	-	HYPH
cord-014712-5u4e00q6	246	7	gene	gene	NN
cord-014712-5u4e00q6	246	8	inborn	inborn	JJ
cord-014712-5u4e00q6	246	9	errors	error	NNS
cord-014712-5u4e00q6	246	10	of	of	IN
cord-014712-5u4e00q6	246	11	immunity	immunity	NN
cord-014712-5u4e00q6	246	12	to	to	IN
cord-014712-5u4e00q6	246	13	HHV-8	HHV-8	NNP
cord-014712-5u4e00q6	246	14	might	may	MD
cord-014712-5u4e00q6	246	15	underlie	underlie	VB
cord-014712-5u4e00q6	246	16	classic	classic	JJ
cord-014712-5u4e00q6	246	17	KS	KS	NNP
cord-014712-5u4e00q6	246	18	in	in	IN
cord-014712-5u4e00q6	246	19	childhood	childhood	NN
cord-014712-5u4e00q6	246	20	.	.	.
cord-014712-5u4e00q6	247	1	We	-PRON-	PRP
cord-014712-5u4e00q6	247	2	report	report	VBP
cord-014712-5u4e00q6	247	3	here	here	RB
cord-014712-5u4e00q6	247	4	autosomal	autosomal	JJ
cord-014712-5u4e00q6	247	5	recessive	recessive	JJ
cord-014712-5u4e00q6	247	6	OX40	OX40	NNP
cord-014712-5u4e00q6	247	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	247	8	in	in	IN
cord-014712-5u4e00q6	247	9	an	an	DT
cord-014712-5u4e00q6	247	10	otherwise	otherwise	RB
cord-014712-5u4e00q6	247	11	healthy	healthy	JJ
cord-014712-5u4e00q6	247	12	adult	adult	NN
cord-014712-5u4e00q6	247	13	with	with	IN
cord-014712-5u4e00q6	247	14	childhood	childhood	NN
cord-014712-5u4e00q6	247	15	-	-	HYPH
cord-014712-5u4e00q6	247	16	onset	onset	NN
cord-014712-5u4e00q6	247	17	classic	classic	JJ
cord-014712-5u4e00q6	247	18	KS	KS	NNP
cord-014712-5u4e00q6	247	19	.	.	.
cord-014712-5u4e00q6	248	1	OX40	OX40	NNP
cord-014712-5u4e00q6	248	2	is	be	VBZ
cord-014712-5u4e00q6	248	3	a	a	DT
cord-014712-5u4e00q6	248	4	costimulatory	costimulatory	NNP
cord-014712-5u4e00q6	248	5	receptor	receptor	NN
cord-014712-5u4e00q6	248	6	expressed	express	VBN
cord-014712-5u4e00q6	248	7	on	on	IN
cord-014712-5u4e00q6	248	8	activated	activate	VBN
cord-014712-5u4e00q6	248	9	T	t	NN
cord-014712-5u4e00q6	248	10	cells	cell	NNS
cord-014712-5u4e00q6	248	11	.	.	.
cord-014712-5u4e00q6	249	1	Its	-PRON-	PRP$
cord-014712-5u4e00q6	249	2	ligand	ligand	NN
cord-014712-5u4e00q6	249	3	is	be	VBZ
cord-014712-5u4e00q6	249	4	expressed	express	VBN
cord-014712-5u4e00q6	249	5	on	on	IN
cord-014712-5u4e00q6	249	6	various	various	JJ
cord-014712-5u4e00q6	249	7	cell	cell	NN
cord-014712-5u4e00q6	249	8	types	type	NNS
cord-014712-5u4e00q6	249	9	,	,	,
cord-014712-5u4e00q6	249	10	including	include	VBG
cord-014712-5u4e00q6	249	11	endothelial	endothelial	JJ
cord-014712-5u4e00q6	249	12	cells	cell	NNS
cord-014712-5u4e00q6	249	13	.	.	.
cord-014712-5u4e00q6	250	1	The	the	DT
cord-014712-5u4e00q6	250	2	mutant	mutant	JJ
cord-014712-5u4e00q6	250	3	OX40	OX40	NNP
cord-014712-5u4e00q6	250	4	protein	protein	NN
cord-014712-5u4e00q6	250	5	was	be	VBD
cord-014712-5u4e00q6	250	6	poorly	poorly	RB
cord-014712-5u4e00q6	250	7	expressed	express	VBN
cord-014712-5u4e00q6	250	8	on	on	IN
cord-014712-5u4e00q6	250	9	the	the	DT
cord-014712-5u4e00q6	250	10	cell	cell	NN
cord-014712-5u4e00q6	250	11	surface	surface	NN
cord-014712-5u4e00q6	250	12	and	and	CC
cord-014712-5u4e00q6	250	13	failed	fail	VBD
cord-014712-5u4e00q6	250	14	to	to	TO
cord-014712-5u4e00q6	250	15	bind	bind	VB
cord-014712-5u4e00q6	250	16	OX40	OX40	NNP
cord-014712-5u4e00q6	250	17	ligand	ligand	NN
cord-014712-5u4e00q6	250	18	,	,	,
cord-014712-5u4e00q6	250	19	resulting	result	VBG
cord-014712-5u4e00q6	250	20	in	in	IN
cord-014712-5u4e00q6	250	21	complete	complete	JJ
cord-014712-5u4e00q6	250	22	functional	functional	JJ
cord-014712-5u4e00q6	250	23	OX40	OX40	NNP
cord-014712-5u4e00q6	250	24	deficiency	deficiency	NN
cord-014712-5u4e00q6	250	25	.	.	.
cord-014712-5u4e00q6	251	1	The	the	DT
cord-014712-5u4e00q6	251	2	OX40-deficient	ox40-deficient	CD
cord-014712-5u4e00q6	251	3	patient	patient	NN
cord-014712-5u4e00q6	251	4	had	have	VBD
cord-014712-5u4e00q6	251	5	a	a	DT
cord-014712-5u4e00q6	251	6	low	low	JJ
cord-014712-5u4e00q6	251	7	proportion	proportion	NN
cord-014712-5u4e00q6	251	8	of	of	IN
cord-014712-5u4e00q6	251	9	effector	effector	JJ
cord-014712-5u4e00q6	251	10	memory	memory	NN
cord-014712-5u4e00q6	251	11	CD4	CD4	NNP
cord-014712-5u4e00q6	251	12	+	+	CC
cord-014712-5u4e00q6	251	13	T	t	NN
cord-014712-5u4e00q6	251	14	cells	cell	NNS
cord-014712-5u4e00q6	251	15	in	in	IN
cord-014712-5u4e00q6	251	16	the	the	DT
cord-014712-5u4e00q6	251	17	peripheral	peripheral	JJ
cord-014712-5u4e00q6	251	18	blood	blood	NN
cord-014712-5u4e00q6	251	19	,	,	,
cord-014712-5u4e00q6	251	20	consistent	consistent	JJ
cord-014712-5u4e00q6	251	21	with	with	IN
cord-014712-5u4e00q6	251	22	impaired	impaired	JJ
cord-014712-5u4e00q6	251	23	CD4	CD4	NNP
cord-014712-5u4e00q6	251	24	+	+	CC
cord-014712-5u4e00q6	251	25	T	t	NN
cord-014712-5u4e00q6	251	26	-	-	HYPH
cord-014712-5u4e00q6	251	27	cell	cell	NN
cord-014712-5u4e00q6	251	28	responses	response	NNS
cord-014712-5u4e00q6	251	29	to	to	TO
cord-014712-5u4e00q6	251	30	recall	recall	VB
cord-014712-5u4e00q6	251	31	antigens	antigen	NNS
cord-014712-5u4e00q6	251	32	in	in	IN
cord-014712-5u4e00q6	251	33	vitro	vitro	FW
cord-014712-5u4e00q6	251	34	.	.	.
cord-014712-5u4e00q6	252	1	The	the	DT
cord-014712-5u4e00q6	252	2	proportion	proportion	NN
cord-014712-5u4e00q6	252	3	of	of	IN
cord-014712-5u4e00q6	252	4	effector	effector	JJ
cord-014712-5u4e00q6	252	5	memory	memory	NN
cord-014712-5u4e00q6	252	6	CD8	CD8	NNP
cord-014712-5u4e00q6	252	7	+	+	CC
cord-014712-5u4e00q6	252	8	T	T	NNP
cord-014712-5u4e00q6	252	9	cells	cell	NNS
cord-014712-5u4e00q6	252	10	was	be	VBD
cord-014712-5u4e00q6	252	11	less	less	RBR
cord-014712-5u4e00q6	252	12	diminished	diminished	JJ
cord-014712-5u4e00q6	252	13	.	.	.
cord-014712-5u4e00q6	253	1	The	the	DT
cord-014712-5u4e00q6	253	2	proportion	proportion	NN
cord-014712-5u4e00q6	253	3	of	of	IN
cord-014712-5u4e00q6	253	4	circulating	circulate	VBG
cord-014712-5u4e00q6	253	5	memory	memory	NN
cord-014712-5u4e00q6	253	6	B	b	NN
cord-014712-5u4e00q6	253	7	cells	cell	NNS
cord-014712-5u4e00q6	253	8	was	be	VBD
cord-014712-5u4e00q6	253	9	low	low	JJ
cord-014712-5u4e00q6	253	10	,	,	,
cord-014712-5u4e00q6	253	11	but	but	CC
cord-014712-5u4e00q6	253	12	the	the	DT
cord-014712-5u4e00q6	253	13	antibody	antibody	NN
cord-014712-5u4e00q6	253	14	response	response	NN
cord-014712-5u4e00q6	253	15	in	in	IN
cord-014712-5u4e00q6	253	16	vivo	vivo	NN
cord-014712-5u4e00q6	253	17	was	be	VBD
cord-014712-5u4e00q6	253	18	intact	intact	JJ
cord-014712-5u4e00q6	253	19	,	,	,
cord-014712-5u4e00q6	253	20	including	include	VBG
cord-014712-5u4e00q6	253	21	to	to	IN
cord-014712-5u4e00q6	253	22	a	a	DT
cord-014712-5u4e00q6	253	23	vaccine	vaccine	NN
cord-014712-5u4e00q6	253	24	boost	boost	NN
cord-014712-5u4e00q6	253	25	.	.	.
cord-014712-5u4e00q6	254	1	Together	together	RB
cord-014712-5u4e00q6	254	2	,	,	,
cord-014712-5u4e00q6	254	3	these	these	DT
cord-014712-5u4e00q6	254	4	findings	finding	NNS
cord-014712-5u4e00q6	254	5	suggest	suggest	VBP
cord-014712-5u4e00q6	254	6	that	that	IN
cord-014712-5u4e00q6	254	7	human	human	JJ
cord-014712-5u4e00q6	254	8	OX40	OX40	NNP
cord-014712-5u4e00q6	254	9	is	be	VBZ
cord-014712-5u4e00q6	254	10	important	important	JJ
cord-014712-5u4e00q6	254	11	for	for	IN
cord-014712-5u4e00q6	254	12	CD4	CD4	NNP
cord-014712-5u4e00q6	254	13	+	+	CC
cord-014712-5u4e00q6	254	14	T	t	NN
cord-014712-5u4e00q6	254	15	-	-	HYPH
cord-014712-5u4e00q6	254	16	cell	cell	NN
cord-014712-5u4e00q6	254	17	memory	memory	NN
cord-014712-5u4e00q6	254	18	,	,	,
cord-014712-5u4e00q6	254	19	but	but	CC
cord-014712-5u4e00q6	254	20	redundant	redundant	JJ
cord-014712-5u4e00q6	254	21	for	for	IN
cord-014712-5u4e00q6	254	22	immunity	immunity	NN
cord-014712-5u4e00q6	254	23	to	to	IN
cord-014712-5u4e00q6	254	24	most	most	JJS
cord-014712-5u4e00q6	254	25	common	common	JJ
cord-014712-5u4e00q6	254	26	pathogens	pathogen	NNS
cord-014712-5u4e00q6	254	27	,	,	,
cord-014712-5u4e00q6	254	28	with	with	IN
cord-014712-5u4e00q6	254	29	the	the	DT
cord-014712-5u4e00q6	254	30	notable	notable	JJ
cord-014712-5u4e00q6	254	31	and	and	CC
cord-014712-5u4e00q6	254	32	surprising	surprising	JJ
cord-014712-5u4e00q6	254	33	exception	exception	NN
cord-014712-5u4e00q6	254	34	of	of	IN
cord-014712-5u4e00q6	254	35	HHV-8	HHV-8	NNP
cord-014712-5u4e00q6	254	36	.	.	.
cord-014712-5u4e00q6	255	1	The	the	DT
cord-014712-5u4e00q6	255	2	chronic	chronic	JJ
cord-014712-5u4e00q6	255	3	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	255	4	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	255	5	disease	disease	NN
cord-014712-5u4e00q6	255	6	(	(	-LRB-
cord-014712-5u4e00q6	255	7	CMCD	CMCD	NNP
cord-014712-5u4e00q6	255	8	)	)	-RRB-
cord-014712-5u4e00q6	255	9	is	be	VBZ
cord-014712-5u4e00q6	255	10	characterized	characterize	VBN
cord-014712-5u4e00q6	255	11	by	by	IN
cord-014712-5u4e00q6	255	12	persistent	persistent	JJ
cord-014712-5u4e00q6	255	13	or	or	CC
cord-014712-5u4e00q6	255	14	recurrent	recurrent	JJ
cord-014712-5u4e00q6	255	15	infection	infection	NN
cord-014712-5u4e00q6	255	16	of	of	IN
cord-014712-5u4e00q6	255	17	skin	skin	NN
cord-014712-5u4e00q6	255	18	,	,	,
cord-014712-5u4e00q6	255	19	nails	nail	NNS
cord-014712-5u4e00q6	255	20	,	,	,
cord-014712-5u4e00q6	255	21	oral	oral	JJ
cord-014712-5u4e00q6	255	22	,	,	,
cord-014712-5u4e00q6	255	23	or	or	CC
cord-014712-5u4e00q6	255	24	genital	genital	JJ
cord-014712-5u4e00q6	255	25	mucosae	mucosae	XX
cord-014712-5u4e00q6	255	26	with	with	IN
cord-014712-5u4e00q6	255	27	Candida	Candida	NNP
cord-014712-5u4e00q6	255	28	albicans	albican	NNS
cord-014712-5u4e00q6	255	29	.	.	.
cord-014712-5u4e00q6	256	1	IL-17-mediated	il-17-mediated	JJ
cord-014712-5u4e00q6	256	2	immunity	immunity	NN
cord-014712-5u4e00q6	256	3	has	have	VBZ
cord-014712-5u4e00q6	256	4	been	be	VBN
cord-014712-5u4e00q6	256	5	concerned	concern	VBN
cord-014712-5u4e00q6	256	6	in	in	IN
cord-014712-5u4e00q6	256	7	host	host	NN
cord-014712-5u4e00q6	256	8	defense	defense	NN
cord-014712-5u4e00q6	256	9	against	against	IN
cord-014712-5u4e00q6	256	10	Candida	Candida	NNP
cord-014712-5u4e00q6	256	11	on	on	IN
cord-014712-5u4e00q6	256	12	body	body	NN
cord-014712-5u4e00q6	256	13	surfaces	surface	NNS
cord-014712-5u4e00q6	256	14	.	.	.
cord-014712-5u4e00q6	257	1	We	-PRON-	PRP
cord-014712-5u4e00q6	257	2	have	have	VBP
cord-014712-5u4e00q6	257	3	investigated	investigate	VBN
cord-014712-5u4e00q6	257	4	nine	nine	CD
cord-014712-5u4e00q6	257	5	patients	patient	NNS
cord-014712-5u4e00q6	257	6	with	with	IN
cord-014712-5u4e00q6	257	7	chronic	chronic	JJ
cord-014712-5u4e00q6	257	8	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	257	9	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	257	10	disease	disease	NN
cord-014712-5u4e00q6	257	11	(	(	-LRB-
cord-014712-5u4e00q6	257	12	CMCD	CMCD	NNP
cord-014712-5u4e00q6	257	13	)	)	-RRB-
cord-014712-5u4e00q6	257	14	and	and	CC
cord-014712-5u4e00q6	257	15	signal	signal	NN
cord-014712-5u4e00q6	257	16	transducer	transducer	NN
cord-014712-5u4e00q6	257	17	and	and	CC
cord-014712-5u4e00q6	257	18	activators	activator	NNS
cord-014712-5u4e00q6	257	19	of	of	IN
cord-014712-5u4e00q6	257	20	transcription	transcription	NN
cord-014712-5u4e00q6	257	21	1	1	CD
cord-014712-5u4e00q6	257	22	(	(	-LRB-
cord-014712-5u4e00q6	257	23	STAT1	stat1	NN
cord-014712-5u4e00q6	257	24	)	)	-RRB-
cord-014712-5u4e00q6	257	25	mutations	mutation	NNS
cord-014712-5u4e00q6	257	26	.	.	.
cord-014712-5u4e00q6	258	1	The	the	DT
cord-014712-5u4e00q6	258	2	novel	novel	NN
cord-014712-5u4e00q6	258	3	c.537C	c.537C	NNP
cord-014712-5u4e00q6	258	4	>	>	XX
cord-014712-5u4e00q6	259	1	A	a	DT
cord-014712-5u4e00q6	259	2	(	(	-LRB-
cord-014712-5u4e00q6	259	3	N179	N179	NNP
cord-014712-5u4e00q6	259	4	K	K	NNP
cord-014712-5u4e00q6	259	5	)	)	-RRB-
cord-014712-5u4e00q6	259	6	and	and	CC
cord-014712-5u4e00q6	259	7	c.854A	c.854A	NNP
cord-014712-5u4e00q6	260	1	>	>	XX
cord-014712-5u4e00q6	261	1	G	G	NNP
cord-014712-5u4e00q6	261	2	(	(	-LRB-
cord-014712-5u4e00q6	261	3	Q285R	Q285R	NNP
cord-014712-5u4e00q6	261	4	)	)	-RRB-
cord-014712-5u4e00q6	261	5	mutations	mutation	NNS
cord-014712-5u4e00q6	261	6	in	in	IN
cord-014712-5u4e00q6	261	7	the	the	DT
cord-014712-5u4e00q6	261	8	coiled	coil	VBN
cord-014712-5u4e00q6	261	9	-	-	HYPH
cord-014712-5u4e00q6	261	10	coil	coil	NN
cord-014712-5u4e00q6	261	11	domain	domain	NN
cord-014712-5u4e00q6	261	12	(	(	-LRB-
cord-014712-5u4e00q6	261	13	CCD	CCD	NNP
cord-014712-5u4e00q6	261	14	)	)	-RRB-
cord-014712-5u4e00q6	261	15	and	and	CC
cord-014712-5u4e00q6	262	1	the	the	DT
cord-014712-5u4e00q6	262	2	c.1154C	c.1154C	NNP
cord-014712-5u4e00q6	262	3	>	>	XX
cord-014712-5u4e00q6	262	4	T	t	NN
cord-014712-5u4e00q6	262	5	(	(	-LRB-
cord-014712-5u4e00q6	262	6	T385	T385	NNP
cord-014712-5u4e00q6	262	7	M	m	CD
cord-014712-5u4e00q6	262	8	)	)	-RRB-
cord-014712-5u4e00q6	262	9	mutation	mutation	NN
cord-014712-5u4e00q6	262	10	in	in	IN
cord-014712-5u4e00q6	262	11	the	the	DT
cord-014712-5u4e00q6	262	12	DNA	dna	NN
cord-014712-5u4e00q6	262	13	-	-	HYPH
cord-014712-5u4e00q6	262	14	binding	bind	VBG
cord-014712-5u4e00q6	262	15	domain	domain	NN
cord-014712-5u4e00q6	262	16	(	(	-LRB-
cord-014712-5u4e00q6	262	17	DBD	DBD	NNP
cord-014712-5u4e00q6	262	18	)	)	-RRB-
cord-014712-5u4e00q6	262	19	of	of	IN
cord-014712-5u4e00q6	262	20	STAT1	stat1	NN
cord-014712-5u4e00q6	262	21	are	be	VBP
cord-014712-5u4e00q6	262	22	gain	gain	NN
cord-014712-5u4e00q6	262	23	-	-	HYPH
cord-014712-5u4e00q6	262	24	of	of	IN
cord-014712-5u4e00q6	262	25	-	-	HYPH
cord-014712-5u4e00q6	262	26	function	function	NN
cord-014712-5u4e00q6	262	27	(	(	-LRB-
cord-014712-5u4e00q6	262	28	GOF	GOF	NNP
cord-014712-5u4e00q6	262	29	)	)	-RRB-
cord-014712-5u4e00q6	262	30	for	for	IN
cord-014712-5u4e00q6	262	31	γ	γ	NN
cord-014712-5u4e00q6	262	32	-	-	HYPH
cord-014712-5u4e00q6	262	33	activated	activate	VBN
cord-014712-5u4e00q6	262	34	factor	factor	NN
cord-014712-5u4e00q6	262	35	(	(	-LRB-
cord-014712-5u4e00q6	262	36	GAF)-dependent	GAF)-dependent	VBG
cord-014712-5u4e00q6	262	37	cellular	cellular	JJ
cord-014712-5u4e00q6	262	38	responses	response	NNS
cord-014712-5u4e00q6	262	39	to	to	TO
cord-014712-5u4e00q6	262	40	STAT1	stat1	VB
cord-014712-5u4e00q6	262	41	.	.	.
cord-014712-5u4e00q6	263	1	Low	low	JJ
cord-014712-5u4e00q6	263	2	proportion	proportion	NN
cord-014712-5u4e00q6	263	3	of	of	IN
cord-014712-5u4e00q6	263	4	IL-17A	il-17a	NN
cord-014712-5u4e00q6	263	5	-	-	,
cord-014712-5u4e00q6	263	6	and	and	CC
cord-014712-5u4e00q6	263	7	IL-22-producing	IL-22-producing	NNP
cord-014712-5u4e00q6	263	8	T	T	NNP
cord-014712-5u4e00q6	263	9	cells	cell	NNS
cord-014712-5u4e00q6	263	10	,	,	,
cord-014712-5u4e00q6	263	11	lower	low	JJR
cord-014712-5u4e00q6	263	12	levels	level	NNS
cord-014712-5u4e00q6	263	13	of	of	IN
cord-014712-5u4e00q6	263	14	intracellular	intracellular	JJ
cord-014712-5u4e00q6	263	15	IL-17A	IL-17A	NNP
cord-014712-5u4e00q6	263	16	and	and	CC
cord-014712-5u4e00q6	263	17	IL-22	IL-22	NNP
cord-014712-5u4e00q6	263	18	by	by	IN
cord-014712-5u4e00q6	263	19	T	T	NNP
cord-014712-5u4e00q6	263	20	cells	cell	NNS
cord-014712-5u4e00q6	263	21	and	and	CC
cord-014712-5u4e00q6	263	22	impaired	impair	VBN
cord-014712-5u4e00q6	263	23	Candidainduced	Candidainduced	NNP
cord-014712-5u4e00q6	263	24	secretion	secretion	NN
cord-014712-5u4e00q6	263	25	of	of	IN
cord-014712-5u4e00q6	263	26	IL-17A	IL-17A	NNP
cord-014712-5u4e00q6	263	27	and	and	CC
cord-014712-5u4e00q6	263	28	IL-22	IL-22	NNP
cord-014712-5u4e00q6	263	29	by	by	IN
cord-014712-5u4e00q6	263	30	leukocytes	leukocyte	NNS
cord-014712-5u4e00q6	263	31	from	from	IN
cord-014712-5u4e00q6	263	32	CMC	CMC	NNP
cord-014712-5u4e00q6	263	33	patients	patient	NNS
cord-014712-5u4e00q6	263	34	compared	compare	VBN
cord-014712-5u4e00q6	263	35	to	to	IN
cord-014712-5u4e00q6	263	36	that	that	DT
cord-014712-5u4e00q6	263	37	in	in	IN
cord-014712-5u4e00q6	263	38	healthy	healthy	JJ
cord-014712-5u4e00q6	263	39	controls	control	NNS
cord-014712-5u4e00q6	263	40	were	be	VBD
cord-014712-5u4e00q6	263	41	found	find	VBN
cord-014712-5u4e00q6	263	42	.	.	.
cord-014712-5u4e00q6	264	1	The	the	DT
cord-014712-5u4e00q6	264	2	c.820C	c.820C	NNP
cord-014712-5u4e00q6	265	1	>	>	XX
cord-014712-5u4e00q6	266	1	T	T	NNP
cord-014712-5u4e00q6	266	2	(	(	-LRB-
cord-014712-5u4e00q6	266	3	R274W	r274w	NN
cord-014712-5u4e00q6	266	4	)	)	-RRB-
cord-014712-5u4e00q6	266	5	mutation	mutation	NN
cord-014712-5u4e00q6	266	6	affecting	affect	VBG
cord-014712-5u4e00q6	266	7	the	the	DT
cord-014712-5u4e00q6	266	8	CCD	ccd	NN
cord-014712-5u4e00q6	266	9	and	and	CC
cord-014712-5u4e00q6	266	10	the	the	DT
cord-014712-5u4e00q6	266	11	c.1154C	c.1154c	NN
cord-014712-5u4e00q6	266	12	>	>	XX
cord-014712-5u4e00q6	266	13	T	t	NN
cord-014712-5u4e00q6	266	14	(	(	-LRB-
cord-014712-5u4e00q6	266	15	T385	T385	NNP
cord-014712-5u4e00q6	266	16	M	m	CD
cord-014712-5u4e00q6	266	17	)	)	-RRB-
cord-014712-5u4e00q6	266	18	mutation	mutation	NN
cord-014712-5u4e00q6	266	19	affecting	affect	VBG
cord-014712-5u4e00q6	266	20	the	the	DT
cord-014712-5u4e00q6	266	21	DBD	DBD	NNP
cord-014712-5u4e00q6	266	22	of	of	IN
cord-014712-5u4e00q6	266	23	STAT1	stat1	NN
cord-014712-5u4e00q6	266	24	and	and	CC
cord-014712-5u4e00q6	266	25	resulted	result	VBD
cord-014712-5u4e00q6	266	26	in	in	IN
cord-014712-5u4e00q6	266	27	gain	gain	NN
cord-014712-5u4e00q6	266	28	-	-	HYPH
cord-014712-5u4e00q6	266	29	ofphosphorylation	ofphosphorylation	NN
cord-014712-5u4e00q6	266	30	and	and	CC
cord-014712-5u4e00q6	266	31	GOF	GOF	NNP
cord-014712-5u4e00q6	266	32	.	.	.
cord-014712-5u4e00q6	267	1	These	these	DT
cord-014712-5u4e00q6	267	2	mutant	mutant	JJ
cord-014712-5u4e00q6	267	3	alleles	allele	NNS
cord-014712-5u4e00q6	267	4	enhanced	enhance	VBD
cord-014712-5u4e00q6	267	5	the	the	DT
cord-014712-5u4e00q6	267	6	cellular	cellular	JJ
cord-014712-5u4e00q6	267	7	responses	response	NNS
cord-014712-5u4e00q6	267	8	to	to	IN
cord-014712-5u4e00q6	267	9	cytokines	cytokine	NNS
cord-014712-5u4e00q6	267	10	via	via	IN
cord-014712-5u4e00q6	267	11	STAT1	stat1	NN
cord-014712-5u4e00q6	267	12	signalling	signal	VBG
cord-014712-5u4e00q6	267	13	pathway	pathway	NN
cord-014712-5u4e00q6	267	14	.	.	.
cord-014712-5u4e00q6	268	1	These	these	DT
cord-014712-5u4e00q6	268	2	data	datum	NNS
cord-014712-5u4e00q6	268	3	provide	provide	VBP
cord-014712-5u4e00q6	268	4	further	further	JJ
cord-014712-5u4e00q6	268	5	insight	insight	NN
cord-014712-5u4e00q6	268	6	into	into	IN
cord-014712-5u4e00q6	268	7	the	the	DT
cord-014712-5u4e00q6	268	8	mechanism	mechanism	NN
cord-014712-5u4e00q6	268	9	of	of	IN
cord-014712-5u4e00q6	268	10	host	host	NN
cord-014712-5u4e00q6	268	11	defense	defense	NN
cord-014712-5u4e00q6	268	12	against	against	IN
cord-014712-5u4e00q6	268	13	Candida	Candida	NNP
cord-014712-5u4e00q6	268	14	.	.	.
cord-014712-5u4e00q6	269	1	Heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	269	2	gain	gain	NN
cord-014712-5u4e00q6	269	3	-	-	HYPH
cord-014712-5u4e00q6	269	4	of	of	IN
cord-014712-5u4e00q6	269	5	-	-	HYPH
cord-014712-5u4e00q6	269	6	function	function	NN
cord-014712-5u4e00q6	269	7	STAT1	stat1	NN
cord-014712-5u4e00q6	269	8	mutation	mutation	NN
cord-014712-5u4e00q6	269	9	is	be	VBZ
cord-014712-5u4e00q6	269	10	known	know	VBN
cord-014712-5u4e00q6	269	11	as	as	IN
cord-014712-5u4e00q6	269	12	a	a	DT
cord-014712-5u4e00q6	269	13	major	major	JJ
cord-014712-5u4e00q6	269	14	etiology	etiology	NN
cord-014712-5u4e00q6	269	15	of	of	IN
cord-014712-5u4e00q6	269	16	chronic	chronic	JJ
cord-014712-5u4e00q6	269	17	mucocutaneus	mucocutaneus	NN
cord-014712-5u4e00q6	269	18	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	269	19	.	.	.
cord-014712-5u4e00q6	270	1	GOF	GOF	NNP
cord-014712-5u4e00q6	270	2	mutation	mutation	NN
cord-014712-5u4e00q6	270	3	affecting	affect	VBG
cord-014712-5u4e00q6	270	4	the	the	DT
cord-014712-5u4e00q6	270	5	STAT1	stat1	NN
cord-014712-5u4e00q6	270	6	coiled	coil	VBN
cord-014712-5u4e00q6	270	7	-	-	HYPH
cord-014712-5u4e00q6	270	8	coil	coil	NN
cord-014712-5u4e00q6	270	9	domen	domen	NNP
cord-014712-5u4e00q6	270	10	(	(	-LRB-
cord-014712-5u4e00q6	270	11	D165	D165	NNP
cord-014712-5u4e00q6	270	12	G	g	NN
cord-014712-5u4e00q6	270	13	)	)	-RRB-
cord-014712-5u4e00q6	270	14	was	be	VBD
cord-014712-5u4e00q6	270	15	initially	initially	RB
cord-014712-5u4e00q6	270	16	discovered	discover	VBN
cord-014712-5u4e00q6	270	17	in	in	IN
cord-014712-5u4e00q6	270	18	13-year	13-year	JJ
cord-014712-5u4e00q6	270	19	boy	boy	NN
cord-014712-5u4e00q6	270	20	with	with	IN
cord-014712-5u4e00q6	270	21	CMC	CMC	NNP
cord-014712-5u4e00q6	270	22	.	.	.
cord-014712-5u4e00q6	271	1	GOF	GOF	NNP
cord-014712-5u4e00q6	271	2	mutation	mutation	NN
cord-014712-5u4e00q6	271	3	of	of	IN
cord-014712-5u4e00q6	271	4	DNA	dna	NN
cord-014712-5u4e00q6	271	5	-	-	HYPH
cord-014712-5u4e00q6	271	6	binding	bind	VBG
cord-014712-5u4e00q6	271	7	domen	domen	NN
cord-014712-5u4e00q6	271	8	(	(	-LRB-
cord-014712-5u4e00q6	271	9	T385	T385	NNP
cord-014712-5u4e00q6	271	10	M	M	NNP
cord-014712-5u4e00q6	271	11	)	)	-RRB-
cord-014712-5u4e00q6	271	12	was	be	VBD
cord-014712-5u4e00q6	271	13	found	find	VBN
cord-014712-5u4e00q6	271	14	in	in	IN
cord-014712-5u4e00q6	271	15	the	the	DT
cord-014712-5u4e00q6	271	16	second	second	JJ
cord-014712-5u4e00q6	271	17	our	-PRON-	PRP$
cord-014712-5u4e00q6	271	18	patient	patient	NN
cord-014712-5u4e00q6	271	19	with	with	IN
cord-014712-5u4e00q6	271	20	CMC	CMC	NNP
cord-014712-5u4e00q6	271	21	.	.	.
cord-014712-5u4e00q6	272	1	Both	both	DT
cord-014712-5u4e00q6	272	2	patients	patient	NNS
cord-014712-5u4e00q6	272	3	have	have	VBP
cord-014712-5u4e00q6	272	4	early	early	JJ
cord-014712-5u4e00q6	272	5	manifestation	manifestation	NN
cord-014712-5u4e00q6	272	6	of	of	IN
cord-014712-5u4e00q6	272	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	272	8	or	or	CC
cord-014712-5u4e00q6	272	9	persistent	persistent	JJ
cord-014712-5u4e00q6	272	10	infections	infection	NNS
cord-014712-5u4e00q6	272	11	of	of	IN
cord-014712-5u4e00q6	272	12	the	the	DT
cord-014712-5u4e00q6	272	13	skin	skin	NN
cord-014712-5u4e00q6	272	14	,	,	,
cord-014712-5u4e00q6	272	15	mucous	mucous	JJ
cord-014712-5u4e00q6	272	16	membranes	membrane	NNS
cord-014712-5u4e00q6	272	17	,	,	,
cord-014712-5u4e00q6	272	18	and	and	CC
cord-014712-5u4e00q6	272	19	nails	nail	NNS
cord-014712-5u4e00q6	272	20	with	with	IN
cord-014712-5u4e00q6	272	21	Candida	Candida	NNP
cord-014712-5u4e00q6	272	22	albicans	albican	NNS
cord-014712-5u4e00q6	272	23	.	.	.
cord-014712-5u4e00q6	273	1	They	-PRON-	PRP
cord-014712-5u4e00q6	273	2	also	also	RB
cord-014712-5u4e00q6	273	3	have	have	VBP
cord-014712-5u4e00q6	273	4	skin	skin	NN
cord-014712-5u4e00q6	273	5	infections	infection	NNS
cord-014712-5u4e00q6	273	6	with	with	IN
cord-014712-5u4e00q6	273	7	dermatophytes	dermatophyte	NNS
cord-014712-5u4e00q6	273	8	.	.	.
cord-014712-5u4e00q6	274	1	Patient	patient	NN
cord-014712-5u4e00q6	274	2	1	1	CD
cord-014712-5u4e00q6	274	3	presented	present	VBD
cord-014712-5u4e00q6	274	4	from	from	IN
cord-014712-5u4e00q6	274	5	the	the	DT
cord-014712-5u4e00q6	274	6	first	first	JJ
cord-014712-5u4e00q6	274	7	months	month	NNS
cord-014712-5u4e00q6	274	8	of	of	IN
cord-014712-5u4e00q6	274	9	age	age	NN
cord-014712-5u4e00q6	274	10	with	with	IN
cord-014712-5u4e00q6	274	11	severe	severe	JJ
cord-014712-5u4e00q6	274	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	274	13	sinopulmonary	sinopulmonary	JJ
cord-014712-5u4e00q6	274	14	infections	infection	NNS
cord-014712-5u4e00q6	274	15	.	.	.
cord-014712-5u4e00q6	275	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	275	2	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	275	3	and	and	CC
cord-014712-5u4e00q6	275	4	chronic	chronic	JJ
cord-014712-5u4e00q6	275	5	bronchitis	bronchitis	NN
cord-014712-5u4e00q6	275	6	complicated	complicate	VBN
cord-014712-5u4e00q6	275	7	by	by	IN
cord-014712-5u4e00q6	275	8	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	275	9	,	,	,
cord-014712-5u4e00q6	275	10	which	which	WDT
cord-014712-5u4e00q6	275	11	resulted	result	VBD
cord-014712-5u4e00q6	275	12	in	in	IN
cord-014712-5u4e00q6	275	13	cor	cor	NNP
cord-014712-5u4e00q6	275	14	pulmonale	pulmonale	NN
cord-014712-5u4e00q6	275	15	and	and	CC
cord-014712-5u4e00q6	275	16	congestive	congestive	JJ
cord-014712-5u4e00q6	275	17	heart	heart	NN
cord-014712-5u4e00q6	275	18	failure	failure	NN
cord-014712-5u4e00q6	275	19	.	.	.
cord-014712-5u4e00q6	276	1	Patient	patient	NN
cord-014712-5u4e00q6	276	2	2	2	CD
cord-014712-5u4e00q6	276	3	suffered	suffer	VBD
cord-014712-5u4e00q6	276	4	from	from	IN
cord-014712-5u4e00q6	276	5	recurrent	recurrent	JJ
cord-014712-5u4e00q6	276	6	HSV	HSV	NNP
cord-014712-5u4e00q6	276	7	infection	infection	NN
cord-014712-5u4e00q6	276	8	,	,	,
cord-014712-5u4e00q6	276	9	recurrent	recurrent	JJ
cord-014712-5u4e00q6	276	10	aphthous	aphthous	JJ
cord-014712-5u4e00q6	276	11	stomatitis	stomatitis	NN
cord-014712-5u4e00q6	276	12	,	,	,
cord-014712-5u4e00q6	276	13	has	have	VBZ
cord-014712-5u4e00q6	276	14	several	several	JJ
cord-014712-5u4e00q6	276	15	episodes	episode	NNS
cord-014712-5u4e00q6	276	16	of	of	IN
cord-014712-5u4e00q6	276	17	bacterial	bacterial	JJ
cord-014712-5u4e00q6	276	18	skin	skin	NN
cord-014712-5u4e00q6	276	19	infections	infection	NNS
cord-014712-5u4e00q6	276	20	.	.	.
cord-014712-5u4e00q6	277	1	He	-PRON-	PRP
cord-014712-5u4e00q6	277	2	also	also	RB
cord-014712-5u4e00q6	277	3	has	have	VBZ
cord-014712-5u4e00q6	277	4	chronic	chronic	JJ
cord-014712-5u4e00q6	277	5	bronchitis	bronchitis	NN
cord-014712-5u4e00q6	277	6	and	and	CC
cord-014712-5u4e00q6	277	7	several	several	JJ
cord-014712-5u4e00q6	277	8	episodes	episode	NNS
cord-014712-5u4e00q6	277	9	of	of	IN
cord-014712-5u4e00q6	277	10	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	277	11	,	,	,
cord-014712-5u4e00q6	277	12	but	but	CC
cord-014712-5u4e00q6	277	13	does	do	VBZ
cord-014712-5u4e00q6	277	14	not	not	RB
cord-014712-5u4e00q6	277	15	have	have	VB
cord-014712-5u4e00q6	277	16	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	277	17	.	.	.
cord-014712-5u4e00q6	278	1	Both	both	DT
cord-014712-5u4e00q6	278	2	boys	boy	NNS
cord-014712-5u4e00q6	278	3	developed	develop	VBD
cord-014712-5u4e00q6	278	4	esophageal	esophageal	JJ
cord-014712-5u4e00q6	278	5	stricture	stricture	NN
cord-014712-5u4e00q6	278	6	,	,	,
cord-014712-5u4e00q6	278	7	patient	patient	JJ
cord-014712-5u4e00q6	278	8	2	2	CD
cord-014712-5u4e00q6	278	9	necessitating	necessitate	VBG
cord-014712-5u4e00q6	278	10	Nissen	Nissen	NNP
cord-014712-5u4e00q6	278	11	fundoplication	fundoplication	NN
cord-014712-5u4e00q6	278	12	in	in	IN
cord-014712-5u4e00q6	278	13	the	the	DT
cord-014712-5u4e00q6	278	14	age	age	NN
cord-014712-5u4e00q6	278	15	of	of	IN
cord-014712-5u4e00q6	278	16	5	5	CD
cord-014712-5u4e00q6	278	17	years	year	NNS
cord-014712-5u4e00q6	278	18	.	.	.
cord-014712-5u4e00q6	279	1	The	the	DT
cord-014712-5u4e00q6	279	2	patients	patient	NNS
cord-014712-5u4e00q6	279	3	have	have	VBP
cord-014712-5u4e00q6	279	4	mild	mild	JJ
cord-014712-5u4e00q6	279	5	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	279	6	features	feature	NNS
cord-014712-5u4e00q6	279	7	:	:	:
cord-014712-5u4e00q6	279	8	uveitis	uveitis	NN
cord-014712-5u4e00q6	279	9	(	(	-LRB-
cord-014712-5u4e00q6	279	10	P1	P1	NNP
cord-014712-5u4e00q6	279	11	)	)	-RRB-
cord-014712-5u4e00q6	279	12	and	and	CC
cord-014712-5u4e00q6	279	13	alopecia	alopecia	NNP
cord-014712-5u4e00q6	279	14	(	(	-LRB-
cord-014712-5u4e00q6	279	15	P2	P2	NNP
cord-014712-5u4e00q6	279	16	)	)	-RRB-
cord-014712-5u4e00q6	279	17	.	.	.
cord-014712-5u4e00q6	280	1	Immunological	immunological	JJ
cord-014712-5u4e00q6	280	2	investigation	investigation	NN
cord-014712-5u4e00q6	280	3	revealed	reveal	VBD
cord-014712-5u4e00q6	280	4	different	different	JJ
cord-014712-5u4e00q6	280	5	impairment	impairment	NN
cord-014712-5u4e00q6	280	6	of	of	IN
cord-014712-5u4e00q6	280	7	immune	immune	JJ
cord-014712-5u4e00q6	280	8	system	system	NN
cord-014712-5u4e00q6	280	9	:	:	:
cord-014712-5u4e00q6	280	10	more	more	RBR
cord-014712-5u4e00q6	280	11	severe	severe	JJ
cord-014712-5u4e00q6	280	12	,	,	,
cord-014712-5u4e00q6	280	13	similar	similar	JJ
cord-014712-5u4e00q6	280	14	to	to	IN
cord-014712-5u4e00q6	280	15	combined	combine	VBN
cord-014712-5u4e00q6	280	16	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	280	17	in	in	IN
cord-014712-5u4e00q6	280	18	P1	P1	NNP
cord-014712-5u4e00q6	280	19	,	,	,
cord-014712-5u4e00q6	280	20	which	which	WDT
cord-014712-5u4e00q6	280	21	declines	decline	VBZ
cord-014712-5u4e00q6	280	22	with	with	IN
cord-014712-5u4e00q6	280	23	age	age	NN
cord-014712-5u4e00q6	280	24	.	.	.
cord-014712-5u4e00q6	281	1	The	the	DT
cord-014712-5u4e00q6	281	2	P2	P2	NNP
cord-014712-5u4e00q6	281	3	does	do	VBZ
cord-014712-5u4e00q6	281	4	not	not	RB
cord-014712-5u4e00q6	281	5	have	have	VB
cord-014712-5u4e00q6	281	6	changes	change	NNS
cord-014712-5u4e00q6	281	7	in	in	IN
cord-014712-5u4e00q6	281	8	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	281	9	number	number	NN
cord-014712-5u4e00q6	281	10	and	and	CC
cord-014712-5u4e00q6	281	11	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	281	12	's	's	POS
cord-014712-5u4e00q6	281	13	,	,	,
cord-014712-5u4e00q6	281	14	but	but	CC
cord-014712-5u4e00q6	281	15	impaired	impaired	JJ
cord-014712-5u4e00q6	281	16	antibody	antibody	NN
cord-014712-5u4e00q6	281	17	production	production	NN
cord-014712-5u4e00q6	281	18	to	to	IN
cord-014712-5u4e00q6	281	19	pneumococcal	pneumococcal	JJ
cord-014712-5u4e00q6	281	20	antigens	antigen	NNS
cord-014712-5u4e00q6	281	21	.	.	.
cord-014712-5u4e00q6	282	1	Western	western	JJ
cord-014712-5u4e00q6	282	2	blotting	blotting	NN
cord-014712-5u4e00q6	282	3	performed	perform	VBN
cord-014712-5u4e00q6	282	4	with	with	IN
cord-014712-5u4e00q6	282	5	nuclear	nuclear	JJ
cord-014712-5u4e00q6	282	6	extracts	extract	NNS
cord-014712-5u4e00q6	282	7	of	of	IN
cord-014712-5u4e00q6	282	8	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	282	9	of	of	IN
cord-014712-5u4e00q6	282	10	both	both	DT
cord-014712-5u4e00q6	282	11	patients	patient	NNS
cord-014712-5u4e00q6	282	12	showed	show	VBD
cord-014712-5u4e00q6	282	13	stronger	strong	JJR
cord-014712-5u4e00q6	282	14	STAT1	stat1	NN
cord-014712-5u4e00q6	282	15	phosphorylation	phosphorylation	NN
cord-014712-5u4e00q6	282	16	after	after	IN
cord-014712-5u4e00q6	282	17	stimulation	stimulation	NN
cord-014712-5u4e00q6	282	18	with	with	IN
cord-014712-5u4e00q6	282	19	cytokines	cytokine	NNS
cord-014712-5u4e00q6	282	20	IFNγ	IFNγ	NNS
cord-014712-5u4e00q6	282	21	,	,	,
cord-014712-5u4e00q6	282	22	IFNα	IFNα	NNS
cord-014712-5u4e00q6	282	23	,	,	,
cord-014712-5u4e00q6	282	24	IL-27	IL-27	NNP
cord-014712-5u4e00q6	282	25	.	.	.
cord-014712-5u4e00q6	283	1	Mononuclear	Mononuclear	NNP
cord-014712-5u4e00q6	283	2	blood	blood	NN
cord-014712-5u4e00q6	283	3	cells	cell	NNS
cord-014712-5u4e00q6	283	4	from	from	IN
cord-014712-5u4e00q6	283	5	both	both	DT
cord-014712-5u4e00q6	283	6	patients	patient	NNS
cord-014712-5u4e00q6	283	7	released	release	VBD
cord-014712-5u4e00q6	283	8	much	much	RB
cord-014712-5u4e00q6	283	9	smaller	small	JJR
cord-014712-5u4e00q6	283	10	amounts	amount	NNS
cord-014712-5u4e00q6	283	11	of	of	IN
cord-014712-5u4e00q6	283	12	IL-17A	IL-17A	NNP
cord-014712-5u4e00q6	283	13	and	and	CC
cord-014712-5u4e00q6	283	14	IL-22	IL-22	NNP
cord-014712-5u4e00q6	283	15	than	than	IN
cord-014712-5u4e00q6	283	16	Candida	Candida	NNP
cord-014712-5u4e00q6	283	17	-	-	HYPH
cord-014712-5u4e00q6	283	18	exposed	expose	VBN
cord-014712-5u4e00q6	283	19	cells	cell	NNS
cord-014712-5u4e00q6	283	20	from	from	IN
cord-014712-5u4e00q6	283	21	healthy	healthy	JJ
cord-014712-5u4e00q6	283	22	control	control	NN
cord-014712-5u4e00q6	283	23	.	.	.
cord-014712-5u4e00q6	284	1	STAT3	STAT3	NNP
cord-014712-5u4e00q6	285	1	activation	activation	NN
cord-014712-5u4e00q6	285	2	triggers	trigger	VBZ
cord-014712-5u4e00q6	285	3	transcription	transcription	NN
cord-014712-5u4e00q6	285	4	of	of	IN
cord-014712-5u4e00q6	285	5	interleukin	interleukin	NN
cord-014712-5u4e00q6	285	6	(	(	-LRB-
cord-014712-5u4e00q6	285	7	IL)-17	il)-17	NN
cord-014712-5u4e00q6	285	8	which	which	WDT
cord-014712-5u4e00q6	285	9	is	be	VBZ
cord-014712-5u4e00q6	285	10	crucial	crucial	JJ
cord-014712-5u4e00q6	285	11	for	for	IN
cord-014712-5u4e00q6	285	12	mounting	mount	VBG
cord-014712-5u4e00q6	285	13	protective	protective	JJ
cord-014712-5u4e00q6	285	14	immune	immune	JJ
cord-014712-5u4e00q6	285	15	responses	response	NNS
cord-014712-5u4e00q6	285	16	against	against	IN
cord-014712-5u4e00q6	285	17	fungi	fungus	NNS
cord-014712-5u4e00q6	285	18	.	.	.
cord-014712-5u4e00q6	286	1	Several	several	JJ
cord-014712-5u4e00q6	286	2	mutations	mutation	NNS
cord-014712-5u4e00q6	286	3	affecting	affect	VBG
cord-014712-5u4e00q6	286	4	the	the	DT
cord-014712-5u4e00q6	286	5	STAT3	STAT3	NNP
cord-014712-5u4e00q6	286	6	/	/	SYM
cord-014712-5u4e00q6	286	7	IL-17	IL-17	NNP
cord-014712-5u4e00q6	286	8	pathway	pathway	NN
cord-014712-5u4e00q6	286	9	have	have	VBP
cord-014712-5u4e00q6	286	10	been	be	VBN
cord-014712-5u4e00q6	286	11	reported	report	VBN
cord-014712-5u4e00q6	286	12	,	,	,
cord-014712-5u4e00q6	286	13	resulting	result	VBG
cord-014712-5u4e00q6	286	14	in	in	IN
cord-014712-5u4e00q6	286	15	selective	selective	JJ
cord-014712-5u4e00q6	286	16	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	286	17	to	to	IN
cord-014712-5u4e00q6	286	18	fungal	fungal	VB
cord-014712-5u4e00q6	286	19	(	(	-LRB-
cord-014712-5u4e00q6	286	20	Candida	candida	NN
cord-014712-5u4e00q6	286	21	)	)	-RRB-
cord-014712-5u4e00q6	286	22	infection	infection	NN
cord-014712-5u4e00q6	286	23	,	,	,
cord-014712-5u4e00q6	286	24	a	a	DT
cord-014712-5u4e00q6	286	25	hallmark	hallmark	NN
cord-014712-5u4e00q6	286	26	of	of	IN
cord-014712-5u4e00q6	286	27	Chronic	Chronic	NNP
cord-014712-5u4e00q6	286	28	Mucocutaneous	Mucocutaneous	NNP
cord-014712-5u4e00q6	286	29	Candidiasis	Candidiasis	NNP
cord-014712-5u4e00q6	286	30	(	(	-LRB-
cord-014712-5u4e00q6	286	31	CMC	CMC	NNP
cord-014712-5u4e00q6	286	32	)	)	-RRB-
cord-014712-5u4e00q6	286	33	.	.	.
cord-014712-5u4e00q6	287	1	In	in	IN
cord-014712-5u4e00q6	287	2	patients	patient	NNS
cord-014712-5u4e00q6	287	3	with	with	IN
cord-014712-5u4e00q6	287	4	autosomal	autosomal	JJ
cord-014712-5u4e00q6	287	5	-	-	HYPH
cord-014712-5u4e00q6	287	6	dominant	dominant	JJ
cord-014712-5u4e00q6	287	7	(	(	-LRB-
cord-014712-5u4e00q6	287	8	AD)-CMC	ad)-cmc	NN
cord-014712-5u4e00q6	287	9	we	-PRON-	PRP
cord-014712-5u4e00q6	287	10	previously	previously	RB
cord-014712-5u4e00q6	287	11	reported	report	VBD
cord-014712-5u4e00q6	288	1	defective	defective	JJ
cord-014712-5u4e00q6	288	2	Th17	Th17	NNP
cord-014712-5u4e00q6	288	3	responses	response	NNS
cord-014712-5u4e00q6	288	4	and	and	CC
cord-014712-5u4e00q6	288	5	identified	identify	VBD
cord-014712-5u4e00q6	288	6	an	an	DT
cord-014712-5u4e00q6	288	7	underlying	underlying	JJ
cord-014712-5u4e00q6	288	8	gain	gain	NN
cord-014712-5u4e00q6	288	9	-	-	HYPH
cord-014712-5u4e00q6	288	10	of	of	IN
cord-014712-5u4e00q6	288	11	-	-	HYPH
cord-014712-5u4e00q6	288	12	function	function	NN
cord-014712-5u4e00q6	288	13	(	(	-LRB-
cord-014712-5u4e00q6	288	14	GOF	GOF	NNP
cord-014712-5u4e00q6	288	15	)	)	-RRB-
cord-014712-5u4e00q6	288	16	STAT1	stat1	XX
cord-014712-5u4e00q6	288	17	mutation	mutation	NN
cord-014712-5u4e00q6	288	18	leading	lead	VBG
cord-014712-5u4e00q6	288	19	to	to	IN
cord-014712-5u4e00q6	288	20	hyperphosphorylation	hyperphosphorylation	NN
cord-014712-5u4e00q6	288	21	of	of	IN
cord-014712-5u4e00q6	288	22	STAT1	stat1	NN
cord-014712-5u4e00q6	288	23	.	.	.
cord-014712-5u4e00q6	289	1	How	how	WRB
cord-014712-5u4e00q6	289	2	this	this	DT
cord-014712-5u4e00q6	289	3	affects	affect	VBZ
cord-014712-5u4e00q6	289	4	STAT3	STAT3	NNP
cord-014712-5u4e00q6	289	5	or	or	CC
cord-014712-5u4e00q6	289	6	leads	lead	VBZ
cord-014712-5u4e00q6	289	7	to	to	IN
cord-014712-5u4e00q6	289	8	decreased	decrease	VBN
cord-014712-5u4e00q6	290	1	IL-17	IL-17	NNP
cord-014712-5u4e00q6	290	2	remains	remain	VBZ
cord-014712-5u4e00q6	290	3	to	to	TO
cord-014712-5u4e00q6	290	4	be	be	VB
cord-014712-5u4e00q6	290	5	determined	determine	VBN
cord-014712-5u4e00q6	290	6	.	.	.
cord-014712-5u4e00q6	291	1	In	in	IN
cord-014712-5u4e00q6	291	2	patients	patient	NNS
cord-014712-5u4e00q6	291	3	with	with	IN
cord-014712-5u4e00q6	291	4	AD	ad	NN
cord-014712-5u4e00q6	291	5	-	-	HYPH
cord-014712-5u4e00q6	291	6	CMC	CMC	NNP
cord-014712-5u4e00q6	291	7	,	,	,
cord-014712-5u4e00q6	291	8	we	-PRON-	PRP
cord-014712-5u4e00q6	291	9	assessed	assess	VBD
cord-014712-5u4e00q6	291	10	how	how	WRB
cord-014712-5u4e00q6	291	11	GOF	GOF	NNP
cord-014712-5u4e00q6	291	12	-	-	HYPH
cord-014712-5u4e00q6	291	13	STAT1	stat1	NN
cord-014712-5u4e00q6	291	14	mutations	mutation	NNS
cord-014712-5u4e00q6	291	15	affect	affect	VBP
cord-014712-5u4e00q6	291	16	STAT3	STAT3	NNP
cord-014712-5u4e00q6	291	17	activation	activation	NN
cord-014712-5u4e00q6	291	18	,	,	,
cord-014712-5u4e00q6	291	19	DNA	dna	NN
cord-014712-5u4e00q6	291	20	-	-	HYPH
cord-014712-5u4e00q6	291	21	binding	bind	VBG
cord-014712-5u4e00q6	291	22	,	,	,
cord-014712-5u4e00q6	291	23	gene	gene	NN
cord-014712-5u4e00q6	291	24	expression	expression	NN
cord-014712-5u4e00q6	291	25	,	,	,
cord-014712-5u4e00q6	291	26	cytokine	cytokine	NN
cord-014712-5u4e00q6	291	27	production	production	NN
cord-014712-5u4e00q6	291	28	and	and	CC
cord-014712-5u4e00q6	291	29	the	the	DT
cord-014712-5u4e00q6	291	30	effect	effect	NN
cord-014712-5u4e00q6	291	31	of	of	IN
cord-014712-5u4e00q6	291	32	epigenetic	epigenetic	JJ
cord-014712-5u4e00q6	291	33	modification	modification	NN
cord-014712-5u4e00q6	291	34	.	.	.
cord-014712-5u4e00q6	292	1	We	-PRON-	PRP
cord-014712-5u4e00q6	292	2	show	show	VBP
cord-014712-5u4e00q6	292	3	that	that	IN
cord-014712-5u4e00q6	292	4	stimulation	stimulation	NN
cord-014712-5u4e00q6	292	5	of	of	IN
cord-014712-5u4e00q6	292	6	STAT3	STAT3	NNP
cord-014712-5u4e00q6	292	7	in	in	IN
cord-014712-5u4e00q6	292	8	the	the	DT
cord-014712-5u4e00q6	292	9	presence	presence	NN
cord-014712-5u4e00q6	292	10	of	of	IN
cord-014712-5u4e00q6	292	11	GOF	GOF	NNP
cord-014712-5u4e00q6	292	12	-	-	HYPH
cord-014712-5u4e00q6	292	13	STAT1	stat1	NN
cord-014712-5u4e00q6	292	14	mutations	mutation	NNS
cord-014712-5u4e00q6	292	15	leads	lead	VBZ
cord-014712-5u4e00q6	292	16	to	to	IN
cord-014712-5u4e00q6	292	17	significantly	significantly	RB
cord-014712-5u4e00q6	292	18	reduced	reduce	VBN
cord-014712-5u4e00q6	292	19	transcription	transcription	NN
cord-014712-5u4e00q6	292	20	of	of	IN
cord-014712-5u4e00q6	292	21	STAT3-inducible	stat3-inducible	NN
cord-014712-5u4e00q6	292	22	genes	gene	NNS
cord-014712-5u4e00q6	292	23	(	(	-LRB-
cord-014712-5u4e00q6	292	24	RORC	RORC	NNS
cord-014712-5u4e00q6	292	25	/	/	SYM
cord-014712-5u4e00q6	292	26	IL-17/	IL-17/	NNP
cord-014712-5u4e00q6	292	27	IL-22	IL-22	NNP
cord-014712-5u4e00q6	292	28	/	/	SYM
cord-014712-5u4e00q6	292	29	IL-10	IL-10	NNP
cord-014712-5u4e00q6	292	30	/	/	SYM
cord-014712-5u4e00q6	292	31	c	c	NNP
cord-014712-5u4e00q6	292	32	-	-	:
cord-014712-5u4e00q6	292	33	Fos	Fos	NNP
cord-014712-5u4e00q6	292	34	/	/	SYM
cord-014712-5u4e00q6	292	35	SOCS3	SOCS3	NNP
cord-014712-5u4e00q6	292	36	/	/	SYM
cord-014712-5u4e00q6	292	37	c	c	NNP
cord-014712-5u4e00q6	292	38	-	-	HYPH
cord-014712-5u4e00q6	292	39	Myc	Myc	NNP
cord-014712-5u4e00q6	292	40	)	)	-RRB-
cord-014712-5u4e00q6	292	41	.	.	.
cord-014712-5u4e00q6	293	1	This	this	DT
cord-014712-5u4e00q6	293	2	was	be	VBD
cord-014712-5u4e00q6	293	3	not	not	RB
cord-014712-5u4e00q6	293	4	due	due	JJ
cord-014712-5u4e00q6	293	5	to	to	IN
cord-014712-5u4e00q6	293	6	impaired	impaired	JJ
cord-014712-5u4e00q6	293	7	STAT3	STAT3	NNP
cord-014712-5u4e00q6	293	8	phosphorylation	phosphorylation	NN
cord-014712-5u4e00q6	293	9	,	,	,
cord-014712-5u4e00q6	293	10	altered	alter	VBN
cord-014712-5u4e00q6	293	11	nuclear	nuclear	JJ
cord-014712-5u4e00q6	293	12	translocation	translocation	NN
cord-014712-5u4e00q6	293	13	nor	nor	CC
cord-014712-5u4e00q6	293	14	sequestration	sequestration	NN
cord-014712-5u4e00q6	293	15	of	of	IN
cord-014712-5u4e00q6	293	16	STAT3	STAT3	NNP
cord-014712-5u4e00q6	293	17	into	into	IN
cord-014712-5u4e00q6	294	1	STAT1	STAT1	NNP
cord-014712-5u4e00q6	294	2	/	/	SYM
cord-014712-5u4e00q6	294	3	STAT3	stat3	CD
cord-014712-5u4e00q6	294	4	heterodimers	heterodimer	NNS
cord-014712-5u4e00q6	294	5	.	.	.
cord-014712-5u4e00q6	295	1	DNA	dna	NN
cord-014712-5u4e00q6	295	2	binding	binding	NN
cord-014712-5u4e00q6	295	3	to	to	IN
cord-014712-5u4e00q6	295	4	a	a	DT
cord-014712-5u4e00q6	295	5	STAT	stat	NN
cord-014712-5u4e00q6	295	6	-	-	HYPH
cord-014712-5u4e00q6	295	7	consensus	consensus	NN
cord-014712-5u4e00q6	295	8	binding	bind	VBG
cord-014712-5u4e00q6	295	9	site	site	NN
cord-014712-5u4e00q6	295	10	construct	construct	NN
cord-014712-5u4e00q6	295	11	(	(	-LRB-
cord-014712-5u4e00q6	295	12	hSIE	hsie	NN
cord-014712-5u4e00q6	295	13	)	)	-RRB-
cord-014712-5u4e00q6	295	14	was	be	VBD
cord-014712-5u4e00q6	295	15	intact	intact	JJ
cord-014712-5u4e00q6	295	16	but	but	CC
cord-014712-5u4e00q6	295	17	binding	bind	VBG
cord-014712-5u4e00q6	295	18	to	to	IN
cord-014712-5u4e00q6	295	19	an	an	DT
cord-014712-5u4e00q6	295	20	endogenous	endogenous	JJ
cord-014712-5u4e00q6	295	21	STAT3	stat3	CD
cord-014712-5u4e00q6	295	22	DNA	dna	NN
cord-014712-5u4e00q6	295	23	target	target	NN
cord-014712-5u4e00q6	295	24	was	be	VBD
cord-014712-5u4e00q6	295	25	impaired	impair	VBN
cord-014712-5u4e00q6	295	26	.	.	.
cord-014712-5u4e00q6	296	1	The	the	DT
cord-014712-5u4e00q6	296	2	reduced	reduced	JJ
cord-014712-5u4e00q6	296	3	STAT3-dependent	STAT3-dependent	NNP
cord-014712-5u4e00q6	296	4	gene	gene	NN
cord-014712-5u4e00q6	296	5	transcription	transcription	NN
cord-014712-5u4e00q6	296	6	could	could	MD
cord-014712-5u4e00q6	296	7	be	be	VB
cord-014712-5u4e00q6	296	8	normalized	normalize	VBN
cord-014712-5u4e00q6	296	9	by	by	IN
cord-014712-5u4e00q6	296	10	inhibiting	inhibit	VBG
cord-014712-5u4e00q6	296	11	STAT1	stat1	NN
cord-014712-5u4e00q6	296	12	activation	activation	NN
cord-014712-5u4e00q6	296	13	by	by	IN
cord-014712-5u4e00q6	296	14	fludarabine	fludarabine	NN
cord-014712-5u4e00q6	296	15	or	or	CC
cord-014712-5u4e00q6	296	16	enhancing	enhance	VBG
cord-014712-5u4e00q6	296	17	acetylation	acetylation	NN
cord-014712-5u4e00q6	296	18	with	with	IN
cord-014712-5u4e00q6	296	19	histone	histone	NN
cord-014712-5u4e00q6	296	20	deacetylase	deacetylase	NN
cord-014712-5u4e00q6	296	21	(	(	-LRB-
cord-014712-5u4e00q6	296	22	HDAC	HDAC	NNP
cord-014712-5u4e00q6	296	23	)	)	-RRB-
cord-014712-5u4e00q6	297	1	inhibitors	inhibitor	NNS
cord-014712-5u4e00q6	297	2	trichostatin	trichostatin	NNP
cord-014712-5u4e00q6	298	1	A	a	NN
cord-014712-5u4e00q6	298	2	or	or	CC
cord-014712-5u4e00q6	298	3	ITF2357	ITF2357	NNP
cord-014712-5u4e00q6	298	4	.	.	.
cord-014712-5u4e00q6	299	1	Silencing	silence	VBG
cord-014712-5u4e00q6	299	2	HDAC1	hdac1	NN
cord-014712-5u4e00q6	299	3	,	,	,
cord-014712-5u4e00q6	299	4	HDA2	HDA2	NNP
cord-014712-5u4e00q6	299	5	and	and	CC
cord-014712-5u4e00q6	299	6	HDAC3	HDAC3	NNP
cord-014712-5u4e00q6	300	1	indicated	indicate	VBD
cord-014712-5u4e00q6	300	2	an	an	DT
cord-014712-5u4e00q6	300	3	important	important	JJ
cord-014712-5u4e00q6	300	4	role	role	NN
cord-014712-5u4e00q6	300	5	for	for	IN
cord-014712-5u4e00q6	300	6	HDAC1	HDAC1	NNP
cord-014712-5u4e00q6	300	7	.	.	.
cord-014712-5u4e00q6	301	1	Impaired	impaired	JJ
cord-014712-5u4e00q6	301	2	STAT3-dependent	STAT3-dependent	NNP
cord-014712-5u4e00q6	301	3	gene	gene	NN
cord-014712-5u4e00q6	301	4	transcription	transcription	NN
cord-014712-5u4e00q6	301	5	likely	likely	RB
cord-014712-5u4e00q6	301	6	underlies	underlie	VBZ
cord-014712-5u4e00q6	301	7	decreased	decrease	VBD
cord-014712-5u4e00q6	301	8	Th-17	Th-17	NNP
cord-014712-5u4e00q6	301	9	cytokine	cytokine	NN
cord-014712-5u4e00q6	301	10	production	production	NN
cord-014712-5u4e00q6	301	11	,	,	,
cord-014712-5u4e00q6	301	12	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	301	13	to	to	IN
cord-014712-5u4e00q6	301	14	fungal	fungal	JJ
cord-014712-5u4e00q6	301	15	infections	infection	NNS
cord-014712-5u4e00q6	301	16	and	and	CC
cord-014712-5u4e00q6	301	17	other	other	JJ
cord-014712-5u4e00q6	301	18	pathology	pathology	NN
cord-014712-5u4e00q6	301	19	seen	see	VBN
cord-014712-5u4e00q6	301	20	in	in	IN
cord-014712-5u4e00q6	301	21	AD	ad	NN
cord-014712-5u4e00q6	301	22	-	-	HYPH
cord-014712-5u4e00q6	301	23	CMC	CMC	NNP
cord-014712-5u4e00q6	301	24	patients	patient	NNS
cord-014712-5u4e00q6	301	25	and	and	CC
cord-014712-5u4e00q6	301	26	could	could	MD
cord-014712-5u4e00q6	301	27	be	be	VB
cord-014712-5u4e00q6	301	28	a	a	DT
cord-014712-5u4e00q6	301	29	new	new	JJ
cord-014712-5u4e00q6	301	30	target	target	NN
cord-014712-5u4e00q6	301	31	for	for	IN
cord-014712-5u4e00q6	301	32	defining	define	VBG
cord-014712-5u4e00q6	301	33	novel	novel	JJ
cord-014712-5u4e00q6	301	34	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	301	35	approaches	approach	NNS
cord-014712-5u4e00q6	301	36	for	for	IN
cord-014712-5u4e00q6	301	37	this	this	DT
cord-014712-5u4e00q6	301	38	potentially	potentially	RB
cord-014712-5u4e00q6	301	39	lethal	lethal	JJ
cord-014712-5u4e00q6	301	40	disease	disease	NN
cord-014712-5u4e00q6	301	41	.	.	.
cord-014712-5u4e00q6	302	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	302	2	features	feature	NNS
cord-014712-5u4e00q6	302	3	have	have	VBP
cord-014712-5u4e00q6	302	4	been	be	VBN
cord-014712-5u4e00q6	302	5	long	long	RB
cord-014712-5u4e00q6	302	6	thought	think	VBN
cord-014712-5u4e00q6	302	7	as	as	IN
cord-014712-5u4e00q6	302	8	association	association	NN
cord-014712-5u4e00q6	302	9	with	with	IN
cord-014712-5u4e00q6	302	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	302	11	disorders	disorder	NNS
cord-014712-5u4e00q6	302	12	,	,	,
cord-014712-5u4e00q6	302	13	but	but	CC
cord-014712-5u4e00q6	302	14	are	be	VBP
cord-014712-5u4e00q6	302	15	now	now	RB
cord-014712-5u4e00q6	302	16	viewed	view	VBN
cord-014712-5u4e00q6	302	17	as	as	IN
cord-014712-5u4e00q6	302	18	a	a	DT
cord-014712-5u4e00q6	302	19	crucial	crucial	JJ
cord-014712-5u4e00q6	302	20	component	component	NN
cord-014712-5u4e00q6	302	21	of	of	IN
cord-014712-5u4e00q6	302	22	some	some	DT
cord-014712-5u4e00q6	302	23	diseases	disease	NNS
cord-014712-5u4e00q6	302	24	attributed	attribute	VBN
cord-014712-5u4e00q6	302	25	to	to	IN
cord-014712-5u4e00q6	302	26	the	the	DT
cord-014712-5u4e00q6	302	27	breakdown	breakdown	NN
cord-014712-5u4e00q6	302	28	of	of	IN
cord-014712-5u4e00q6	302	29	self	self	NN
cord-014712-5u4e00q6	302	30	tolerance	tolerance	NN
cord-014712-5u4e00q6	302	31	or	or	CC
cord-014712-5u4e00q6	302	32	defects	defect	NNS
cord-014712-5u4e00q6	302	33	of	of	IN
cord-014712-5u4e00q6	302	34	immune	immune	JJ
cord-014712-5u4e00q6	302	35	regulators	regulator	NNS
cord-014712-5u4e00q6	302	36	.	.	.
cord-014712-5u4e00q6	303	1	It	-PRON-	PRP
cord-014712-5u4e00q6	303	2	had	have	VBD
cord-014712-5u4e00q6	303	3	been	be	VBN
cord-014712-5u4e00q6	303	4	previously	previously	RB
cord-014712-5u4e00q6	303	5	established	establish	VBN
cord-014712-5u4e00q6	303	6	that	that	IN
cord-014712-5u4e00q6	303	7	a	a	DT
cord-014712-5u4e00q6	303	8	single	single	JJ
cord-014712-5u4e00q6	303	9	gene	gene	NN
cord-014712-5u4e00q6	303	10	defect	defect	NN
cord-014712-5u4e00q6	303	11	of	of	IN
cord-014712-5u4e00q6	303	12	the	the	DT
cord-014712-5u4e00q6	303	13	Foxp3	foxp3	JJ
cord-014712-5u4e00q6	303	14	gene	gene	NN
cord-014712-5u4e00q6	303	15	(	(	-LRB-
cord-014712-5u4e00q6	303	16	FOXP3	foxp3	NN
cord-014712-5u4e00q6	303	17	in	in	IN
cord-014712-5u4e00q6	303	18	humans	human	NNS
cord-014712-5u4e00q6	303	19	)	)	-RRB-
cord-014712-5u4e00q6	303	20	caused	cause	VBD
cord-014712-5u4e00q6	303	21	widespread	widespread	JJ
cord-014712-5u4e00q6	303	22	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	303	23	in	in	IN
cord-014712-5u4e00q6	303	24	both	both	DT
cord-014712-5u4e00q6	303	25	humans	human	NNS
cord-014712-5u4e00q6	303	26	and	and	CC
cord-014712-5u4e00q6	303	27	mice	mouse	NNS
cord-014712-5u4e00q6	303	28	.	.	.
cord-014712-5u4e00q6	304	1	The	the	DT
cord-014712-5u4e00q6	304	2	clinical	clinical	JJ
cord-014712-5u4e00q6	304	3	syndromes	syndrome	NNS
cord-014712-5u4e00q6	304	4	observed	observe	VBN
cord-014712-5u4e00q6	304	5	in	in	IN
cord-014712-5u4e00q6	304	6	both	both	DT
cord-014712-5u4e00q6	304	7	scurfy	scurfy	NNP
cord-014712-5u4e00q6	304	8	mice	mouse	NNS
cord-014712-5u4e00q6	304	9	and	and	CC
cord-014712-5u4e00q6	304	10	humans	human	NNS
cord-014712-5u4e00q6	304	11	suffering	suffer	VBG
cord-014712-5u4e00q6	304	12	from	from	IN
cord-014712-5u4e00q6	304	13	IPEX	IPEX	NNP
cord-014712-5u4e00q6	304	14	are	be	VBP
cord-014712-5u4e00q6	304	15	similar	similar	JJ
cord-014712-5u4e00q6	304	16	to	to	IN
cord-014712-5u4e00q6	304	17	those	those	DT
cord-014712-5u4e00q6	304	18	observed	observe	VBN
cord-014712-5u4e00q6	304	19	in	in	IN
cord-014712-5u4e00q6	304	20	experimental	experimental	JJ
cord-014712-5u4e00q6	304	21	models	model	NNS
cord-014712-5u4e00q6	304	22	in	in	IN
cord-014712-5u4e00q6	304	23	which	which	WDT
cord-014712-5u4e00q6	304	24	Treg	Treg	NNP
cord-014712-5u4e00q6	304	25	are	be	VBP
cord-014712-5u4e00q6	304	26	selectively	selectively	RB
cord-014712-5u4e00q6	304	27	depleted	deplete	VBN
cord-014712-5u4e00q6	304	28	.	.	.
cord-014712-5u4e00q6	305	1	In	in	IN
cord-014712-5u4e00q6	305	2	2003	2003	CD
cord-014712-5u4e00q6	305	3	,	,	,
cord-014712-5u4e00q6	305	4	three	three	CD
cord-014712-5u4e00q6	305	5	groups	group	NNS
cord-014712-5u4e00q6	305	6	demonstrated	demonstrate	VBD
cord-014712-5u4e00q6	305	7	that	that	IN
cord-014712-5u4e00q6	305	8	these	these	DT
cord-014712-5u4e00q6	305	9	diseases	disease	NNS
cord-014712-5u4e00q6	305	10	were	be	VBD
cord-014712-5u4e00q6	305	11	indeed	indeed	RB
cord-014712-5u4e00q6	305	12	the	the	DT
cord-014712-5u4e00q6	305	13	result	result	NN
cord-014712-5u4e00q6	305	14	of	of	IN
cord-014712-5u4e00q6	305	15	a	a	DT
cord-014712-5u4e00q6	305	16	regulatory	regulatory	JJ
cord-014712-5u4e00q6	305	17	cell	cell	NN
cord-014712-5u4e00q6	305	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	305	19	.	.	.
cord-014712-5u4e00q6	306	1	Around	around	RB
cord-014712-5u4e00q6	306	2	one	one	CD
cord-014712-5u4e00q6	306	3	third	third	NN
cord-014712-5u4e00q6	306	4	of	of	IN
cord-014712-5u4e00q6	306	5	the	the	DT
cord-014712-5u4e00q6	306	6	patients	patient	NNS
cord-014712-5u4e00q6	306	7	with	with	IN
cord-014712-5u4e00q6	306	8	clinical	clinical	JJ
cord-014712-5u4e00q6	306	9	manifestation	manifestation	NN
cord-014712-5u4e00q6	306	10	closely	closely	RB
cord-014712-5u4e00q6	306	11	resembling	resemble	VBG
cord-014712-5u4e00q6	306	12	IPEX	IPEX	NNP
cord-014712-5u4e00q6	306	13	syndrome	syndrome	NN
cord-014712-5u4e00q6	306	14	,	,	,
cord-014712-5u4e00q6	306	15	FOXP3	FOXP3	NNP
cord-014712-5u4e00q6	306	16	is	be	VBZ
cord-014712-5u4e00q6	306	17	not	not	RB
cord-014712-5u4e00q6	306	18	mutated	mutate	VBN
cord-014712-5u4e00q6	306	19	,	,	,
cord-014712-5u4e00q6	306	20	these	these	DT
cord-014712-5u4e00q6	306	21	patients	patient	NNS
cord-014712-5u4e00q6	306	22	are	be	VBP
cord-014712-5u4e00q6	306	23	referred	refer	VBN
cord-014712-5u4e00q6	306	24	to	to	IN
cord-014712-5u4e00q6	306	25	as	as	RB
cord-014712-5u4e00q6	306	26	IPEX	IPEX	NNP
cord-014712-5u4e00q6	306	27	like	like	UH
cord-014712-5u4e00q6	306	28	.	.	.
cord-014712-5u4e00q6	307	1	Here	here	RB
cord-014712-5u4e00q6	307	2	we	-PRON-	PRP
cord-014712-5u4e00q6	307	3	present	present	VBP
cord-014712-5u4e00q6	307	4	a	a	DT
cord-014712-5u4e00q6	307	5	case	case	NN
cord-014712-5u4e00q6	307	6	;	;	:
cord-014712-5u4e00q6	307	7	a	a	DT
cord-014712-5u4e00q6	307	8	female	female	JJ
cord-014712-5u4e00q6	307	9	patient	patient	NN
cord-014712-5u4e00q6	307	10	13	13	CD
cord-014712-5u4e00q6	307	11	years	year	NNS
cord-014712-5u4e00q6	307	12	with	with	IN
cord-014712-5u4e00q6	307	13	multiple	multiple	JJ
cord-014712-5u4e00q6	307	14	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	307	15	manifestations	manifestation	NNS
cord-014712-5u4e00q6	307	16	;	;	:
cord-014712-5u4e00q6	307	17	DM	DM	NNP
cord-014712-5u4e00q6	307	18	,	,	,
cord-014712-5u4e00q6	307	19	Coeliac	coeliac	JJ
cord-014712-5u4e00q6	307	20	disease	disease	NN
cord-014712-5u4e00q6	307	21	and	and	CC
cord-014712-5u4e00q6	307	22	ulcerative	ulcerative	JJ
cord-014712-5u4e00q6	307	23	colitis	colitis	NN
cord-014712-5u4e00q6	307	24	with	with	IN
cord-014712-5u4e00q6	307	25	marked	marked	JJ
cord-014712-5u4e00q6	307	26	decrease	decrease	NN
cord-014712-5u4e00q6	307	27	in	in	IN
cord-014712-5u4e00q6	307	28	the	the	DT
cord-014712-5u4e00q6	307	29	percent	percent	NN
cord-014712-5u4e00q6	307	30	of	of	IN
cord-014712-5u4e00q6	307	31	CD4	CD4	NNP
cord-014712-5u4e00q6	307	32	+	+	CC
cord-014712-5u4e00q6	307	33	CD25	CD25	NNP
cord-014712-5u4e00q6	307	34	+	+	CC
cord-014712-5u4e00q6	307	35	FoxP3	FoxP3	NNP
cord-014712-5u4e00q6	307	36	+	+	CC
cord-014712-5u4e00q6	307	37	cells	cell	NNS
cord-014712-5u4e00q6	307	38	.	.	.
cord-014712-5u4e00q6	308	1	As	as	IN
cord-014712-5u4e00q6	308	2	she	-PRON-	PRP
cord-014712-5u4e00q6	308	3	has	have	VBZ
cord-014712-5u4e00q6	308	4	a	a	DT
cord-014712-5u4e00q6	308	5	siblings	sibling	NNS
cord-014712-5u4e00q6	308	6	suffering	suffer	VBG
cord-014712-5u4e00q6	308	7	from	from	IN
cord-014712-5u4e00q6	308	8	DM	DM	NNP
cord-014712-5u4e00q6	308	9	;	;	:
cord-014712-5u4e00q6	308	10	the	the	DT
cord-014712-5u4e00q6	308	11	whole	whole	JJ
cord-014712-5u4e00q6	308	12	family	family	NN
cord-014712-5u4e00q6	308	13	was	be	VBD
cord-014712-5u4e00q6	308	14	investigated	investigate	VBN
cord-014712-5u4e00q6	308	15	.	.	.
cord-014712-5u4e00q6	309	1	The	the	DT
cord-014712-5u4e00q6	309	2	father	father	NN
cord-014712-5u4e00q6	309	3	and	and	CC
cord-014712-5u4e00q6	309	4	the	the	DT
cord-014712-5u4e00q6	309	5	mother	mother	NN
cord-014712-5u4e00q6	309	6	had	have	VBD
cord-014712-5u4e00q6	309	7	0	0	CD
cord-014712-5u4e00q6	309	8	%	%	NN
cord-014712-5u4e00q6	309	9	CD4	CD4	NNP
cord-014712-5u4e00q6	309	10	+	+	CC
cord-014712-5u4e00q6	309	11	CD25	CD25	NNP
cord-014712-5u4e00q6	309	12	+	+	CC
cord-014712-5u4e00q6	309	13	FoxP3	FoxP3	NNP
cord-014712-5u4e00q6	309	14	+	+	CC
cord-014712-5u4e00q6	309	15	cells	cell	NNS
cord-014712-5u4e00q6	309	16	.	.	.
cord-014712-5u4e00q6	310	1	Background	background	NN
cord-014712-5u4e00q6	310	2	:	:	:
cord-014712-5u4e00q6	311	1	HIDs	HIDs	NNP
cord-014712-5u4e00q6	311	2	is	be	VBZ
cord-014712-5u4e00q6	311	3	an	an	DT
cord-014712-5u4e00q6	311	4	autosomal	autosomal	JJ
cord-014712-5u4e00q6	311	5	recessive	recessive	JJ
cord-014712-5u4e00q6	311	6	disease	disease	NN
cord-014712-5u4e00q6	311	7	,	,	,
cord-014712-5u4e00q6	311	8	first	first	RB
cord-014712-5u4e00q6	311	9	recognized	recognize	VBN
cord-014712-5u4e00q6	311	10	as	as	IN
cord-014712-5u4e00q6	311	11	a	a	DT
cord-014712-5u4e00q6	311	12	separated	separated	JJ
cord-014712-5u4e00q6	311	13	entity	entity	NN
cord-014712-5u4e00q6	311	14	at	at	IN
cord-014712-5u4e00q6	311	15	1984	1984	CD
cord-014712-5u4e00q6	311	16	.	.	.
cord-014712-5u4e00q6	312	1	In	in	IN
cord-014712-5u4e00q6	312	2	patients	patient	NNS
cord-014712-5u4e00q6	312	3	with	with	IN
cord-014712-5u4e00q6	312	4	HIDS	HIDS	NNP
cord-014712-5u4e00q6	312	5	,	,	,
cord-014712-5u4e00q6	312	6	the	the	DT
cord-014712-5u4e00q6	312	7	activity	activity	NN
cord-014712-5u4e00q6	312	8	of	of	IN
cord-014712-5u4e00q6	312	9	mevalonate	mevalonate	NNP
cord-014712-5u4e00q6	312	10	kinase	kinase	NN
cord-014712-5u4e00q6	312	11	is	be	VBZ
cord-014712-5u4e00q6	312	12	reduced	reduce	VBN
cord-014712-5u4e00q6	312	13	to	to	IN
cord-014712-5u4e00q6	312	14	5	5	CD
cord-014712-5u4e00q6	312	15	-	-	SYM
cord-014712-5u4e00q6	312	16	15	15	CD
cord-014712-5u4e00q6	312	17	%	%	NN
cord-014712-5u4e00q6	312	18	of	of	IN
cord-014712-5u4e00q6	312	19	normal	normal	JJ
cord-014712-5u4e00q6	312	20	levels	level	NNS
cord-014712-5u4e00q6	312	21	.	.	.
cord-014712-5u4e00q6	313	1	HIDS	HIDS	NNP
cord-014712-5u4e00q6	313	2	is	be	VBZ
cord-014712-5u4e00q6	313	3	caused	cause	VBN
cord-014712-5u4e00q6	313	4	by	by	IN
cord-014712-5u4e00q6	313	5	mutations	mutation	NNS
cord-014712-5u4e00q6	313	6	in	in	IN
cord-014712-5u4e00q6	313	7	the	the	DT
cord-014712-5u4e00q6	313	8	mevalonate	mevalonate	NN
cord-014712-5u4e00q6	313	9	kinase	kinase	NN
cord-014712-5u4e00q6	313	10	gene	gene	NN
cord-014712-5u4e00q6	313	11	(	(	-LRB-
cord-014712-5u4e00q6	313	12	MVK	MVK	NNP
cord-014712-5u4e00q6	313	13	)	)	-RRB-
cord-014712-5u4e00q6	313	14	,	,	,
cord-014712-5u4e00q6	313	15	located	locate	VBN
cord-014712-5u4e00q6	313	16	on	on	IN
cord-014712-5u4e00q6	313	17	the	the	DT
cord-014712-5u4e00q6	313	18	long	long	JJ
cord-014712-5u4e00q6	313	19	arm	arm	NN
cord-014712-5u4e00q6	313	20	of	of	IN
cord-014712-5u4e00q6	313	21	chromosome	chromosome	NN
cord-014712-5u4e00q6	313	22	12	12	CD
cord-014712-5u4e00q6	313	23	(	(	-LRB-
cord-014712-5u4e00q6	313	24	12q24	12q24	CD
cord-014712-5u4e00q6	313	25	)	)	-RRB-
cord-014712-5u4e00q6	313	26	.	.	.
cord-014712-5u4e00q6	314	1	It	-PRON-	PRP
cord-014712-5u4e00q6	314	2	is	be	VBZ
cord-014712-5u4e00q6	314	3	manifested	manifest	VBN
cord-014712-5u4e00q6	314	4	by	by	IN
cord-014712-5u4e00q6	314	5	cyclic	cyclic	JJ
cord-014712-5u4e00q6	314	6	attacks	attack	NNS
cord-014712-5u4e00q6	314	7	of	of	IN
cord-014712-5u4e00q6	314	8	fever	fever	NN
cord-014712-5u4e00q6	314	9	initiated	initiate	VBN
cord-014712-5u4e00q6	314	10	usually	usually	RB
cord-014712-5u4e00q6	314	11	during	during	IN
cord-014712-5u4e00q6	314	12	first	first	JJ
cord-014712-5u4e00q6	314	13	year	year	NN
cord-014712-5u4e00q6	314	14	of	of	IN
cord-014712-5u4e00q6	314	15	age	age	NN
cord-014712-5u4e00q6	314	16	.	.	.
cord-014712-5u4e00q6	315	1	The	the	DT
cord-014712-5u4e00q6	315	2	frequency	frequency	NN
cord-014712-5u4e00q6	315	3	and	and	CC
cord-014712-5u4e00q6	315	4	severity	severity	NN
cord-014712-5u4e00q6	315	5	of	of	IN
cord-014712-5u4e00q6	315	6	attacks	attack	NNS
cord-014712-5u4e00q6	315	7	tend	tend	VBP
cord-014712-5u4e00q6	315	8	to	to	TO
cord-014712-5u4e00q6	315	9	decrease	decrease	VB
cord-014712-5u4e00q6	315	10	later	later	RB
cord-014712-5u4e00q6	315	11	in	in	IN
cord-014712-5u4e00q6	315	12	life	life	NN
cord-014712-5u4e00q6	315	13	.	.	.
cord-014712-5u4e00q6	316	1	Materials	material	NNS
cord-014712-5u4e00q6	316	2	and	and	CC
cord-014712-5u4e00q6	316	3	method	method	NN
cord-014712-5u4e00q6	316	4	:	:	:
cord-014712-5u4e00q6	316	5	A	a	DT
cord-014712-5u4e00q6	316	6	retrospective	retrospective	JJ
cord-014712-5u4e00q6	316	7	analysis	analysis	NN
cord-014712-5u4e00q6	316	8	of	of	IN
cord-014712-5u4e00q6	316	9	medical	medical	JJ
cord-014712-5u4e00q6	316	10	history	history	NN
cord-014712-5u4e00q6	316	11	,	,	,
cord-014712-5u4e00q6	316	12	clinical	clinical	JJ
cord-014712-5u4e00q6	316	13	course	course	NN
cord-014712-5u4e00q6	316	14	and	and	CC
cord-014712-5u4e00q6	316	15	laboratory	laboratory	NN
cord-014712-5u4e00q6	316	16	findings	finding	NNS
cord-014712-5u4e00q6	316	17	of	of	IN
cord-014712-5u4e00q6	316	18	two	two	CD
cord-014712-5u4e00q6	316	19	Albanian	albanian	JJ
cord-014712-5u4e00q6	316	20	children	child	NNS
cord-014712-5u4e00q6	316	21	with	with	IN
cord-014712-5u4e00q6	316	22	periodic	periodic	JJ
cord-014712-5u4e00q6	316	23	fever	fever	NN
cord-014712-5u4e00q6	316	24	,	,	,
cord-014712-5u4e00q6	316	25	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	316	26	with	with	IN
cord-014712-5u4e00q6	316	27	hyper	hyper	JJ
cord-014712-5u4e00q6	316	28	IgD	IgD	NNP
cord-014712-5u4e00q6	316	29	syndrome	syndrome	NN
cord-014712-5u4e00q6	316	30	.	.	.
cord-014712-5u4e00q6	317	1	Results	result	NNS
cord-014712-5u4e00q6	317	2	:	:	:
cord-014712-5u4e00q6	318	1	Case	case	NN
cord-014712-5u4e00q6	318	2	presentation	presentation	NN
cord-014712-5u4e00q6	318	3	1	1	CD
cord-014712-5u4e00q6	318	4	:	:	:
cord-014712-5u4e00q6	319	1	An	an	DT
cord-014712-5u4e00q6	319	2	5-year	5-year	CD
cord-014712-5u4e00q6	319	3	-	-	HYPH
cord-014712-5u4e00q6	319	4	old	old	JJ
cord-014712-5u4e00q6	319	5	boy	boy	NN
cord-014712-5u4e00q6	319	6	admitted	admit	VBD
cord-014712-5u4e00q6	319	7	to	to	IN
cord-014712-5u4e00q6	319	8	the	the	DT
cord-014712-5u4e00q6	319	9	hospital	hospital	NN
cord-014712-5u4e00q6	319	10	because	because	IN
cord-014712-5u4e00q6	319	11	of	of	IN
cord-014712-5u4e00q6	319	12	periodic	periodic	JJ
cord-014712-5u4e00q6	319	13	fever	fever	NN
cord-014712-5u4e00q6	319	14	spikes	spike	NNS
cord-014712-5u4e00q6	319	15	,	,	,
cord-014712-5u4e00q6	319	16	which	which	WDT
cord-014712-5u4e00q6	319	17	occurred	occur	VBD
cord-014712-5u4e00q6	319	18	every	every	DT
cord-014712-5u4e00q6	319	19	3	3	CD
cord-014712-5u4e00q6	319	20	-	-	SYM
cord-014712-5u4e00q6	319	21	4	4	CD
cord-014712-5u4e00q6	319	22	weeks	week	NNS
cord-014712-5u4e00q6	319	23	and	and	CC
cord-014712-5u4e00q6	319	24	lasted	last	VBD
cord-014712-5u4e00q6	319	25	3	3	CD
cord-014712-5u4e00q6	319	26	-	-	SYM
cord-014712-5u4e00q6	319	27	5	5	CD
cord-014712-5u4e00q6	319	28	days	day	NNS
cord-014712-5u4e00q6	319	29	,	,	,
cord-014712-5u4e00q6	319	30	presented	present	VBN
cord-014712-5u4e00q6	319	31	since	since	IN
cord-014712-5u4e00q6	319	32	the	the	DT
cord-014712-5u4e00q6	319	33	first	first	JJ
cord-014712-5u4e00q6	319	34	year	year	NN
cord-014712-5u4e00q6	319	35	of	of	IN
cord-014712-5u4e00q6	319	36	life	life	NN
cord-014712-5u4e00q6	319	37	and	and	CC
cord-014712-5u4e00q6	319	38	coincided	coincide	VBD
cord-014712-5u4e00q6	319	39	with	with	IN
cord-014712-5u4e00q6	319	40	the	the	DT
cord-014712-5u4e00q6	319	41	beginning	beginning	NN
cord-014712-5u4e00q6	319	42	of	of	IN
cord-014712-5u4e00q6	319	43	immunization	immunization	NN
cord-014712-5u4e00q6	319	44	.	.	.
cord-014712-5u4e00q6	320	1	He	-PRON-	PRP
cord-014712-5u4e00q6	320	2	had	have	VBD
cord-014712-5u4e00q6	320	3	a	a	DT
cord-014712-5u4e00q6	320	4	tonsillectomy	tonsillectomy	NN
cord-014712-5u4e00q6	320	5	and	and	CC
cord-014712-5u4e00q6	320	6	adenoidectomy	adenoidectomy	NN
cord-014712-5u4e00q6	320	7	at	at	IN
cord-014712-5u4e00q6	320	8	the	the	DT
cord-014712-5u4e00q6	320	9	age	age	NN
cord-014712-5u4e00q6	320	10	of	of	IN
cord-014712-5u4e00q6	320	11	3	3	CD
cord-014712-5u4e00q6	320	12	.	.	.
cord-014712-5u4e00q6	321	1	The	the	DT
cord-014712-5u4e00q6	321	2	fever	fever	NN
cord-014712-5u4e00q6	321	3	attacks	attack	NNS
cord-014712-5u4e00q6	321	4	were	be	VBD
cord-014712-5u4e00q6	321	5	associated	associate	VBN
cord-014712-5u4e00q6	321	6	with	with	IN
cord-014712-5u4e00q6	321	7	chills	chill	NNS
cord-014712-5u4e00q6	321	8	,	,	,
cord-014712-5u4e00q6	321	9	malaise	malaise	NN
cord-014712-5u4e00q6	321	10	,	,	,
cord-014712-5u4e00q6	321	11	and	and	CC
cord-014712-5u4e00q6	321	12	abdominal	abdominal	JJ
cord-014712-5u4e00q6	321	13	pain	pain	NN
cord-014712-5u4e00q6	321	14	without	without	IN
cord-014712-5u4e00q6	321	15	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	321	16	signs	sign	NNS
cord-014712-5u4e00q6	321	17	.	.	.
cord-014712-5u4e00q6	322	1	Between	between	IN
cord-014712-5u4e00q6	322	2	attacks	attack	NNS
cord-014712-5u4e00q6	322	3	the	the	DT
cord-014712-5u4e00q6	322	4	patient	patient	NN
cord-014712-5u4e00q6	322	5	was	be	VBD
cord-014712-5u4e00q6	322	6	free	free	JJ
cord-014712-5u4e00q6	322	7	of	of	IN
cord-014712-5u4e00q6	322	8	symptoms	symptom	NNS
cord-014712-5u4e00q6	322	9	.	.	.
cord-014712-5u4e00q6	323	1	From	from	IN
cord-014712-5u4e00q6	323	2	his	-PRON-	PRP$
cord-014712-5u4e00q6	323	3	family	family	NN
cord-014712-5u4e00q6	323	4	history	history	NN
cord-014712-5u4e00q6	323	5	,	,	,
cord-014712-5u4e00q6	323	6	recurrent	recurrent	JJ
cord-014712-5u4e00q6	323	7	febrile	febrile	JJ
cord-014712-5u4e00q6	323	8	episodes	episode	NNS
cord-014712-5u4e00q6	323	9	during	during	IN
cord-014712-5u4e00q6	323	10	childhood	childhood	NN
cord-014712-5u4e00q6	323	11	were	be	VBD
cord-014712-5u4e00q6	323	12	reported	report	VBN
cord-014712-5u4e00q6	323	13	to	to	IN
cord-014712-5u4e00q6	323	14	his	-PRON-	PRP$
cord-014712-5u4e00q6	323	15	father	father	NN
cord-014712-5u4e00q6	323	16	.	.	.
cord-014712-5u4e00q6	324	1	Physical	physical	JJ
cord-014712-5u4e00q6	324	2	examination	examination	NN
cord-014712-5u4e00q6	324	3	showed	show	VBD
cord-014712-5u4e00q6	324	4	normal	normal	JJ
cord-014712-5u4e00q6	324	5	findings	finding	NNS
cord-014712-5u4e00q6	324	6	,	,	,
cord-014712-5u4e00q6	324	7	except	except	IN
cord-014712-5u4e00q6	324	8	for	for	IN
cord-014712-5u4e00q6	324	9	a	a	DT
cord-014712-5u4e00q6	324	10	cervical	cervical	JJ
cord-014712-5u4e00q6	324	11	lymphadenopathy	lymphadenopathy	NN
cord-014712-5u4e00q6	324	12	.	.	.
cord-014712-5u4e00q6	325	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	325	2	:	:	:
cord-014712-5u4e00q6	326	1	Marked	marked	JJ
cord-014712-5u4e00q6	326	2	increase	increase	NN
cord-014712-5u4e00q6	326	3	of	of	IN
cord-014712-5u4e00q6	326	4	erythrocyte	erythrocyte	NN
cord-014712-5u4e00q6	326	5	sedimentation	sedimentation	NN
cord-014712-5u4e00q6	326	6	rate	rate	NN
cord-014712-5u4e00q6	326	7	and	and	CC
cord-014712-5u4e00q6	326	8	CRP	crp	NN
cord-014712-5u4e00q6	326	9	.	.	.
cord-014712-5u4e00q6	327	1	WBC	WBC	NNP
cord-014712-5u4e00q6	327	2	-	-	HYPH
cord-014712-5u4e00q6	327	3	ranged	range	VBD
cord-014712-5u4e00q6	327	4	from	from	IN
cord-014712-5u4e00q6	327	5	5.710	5.710	CD
cord-014712-5u4e00q6	327	6	to	to	TO
cord-014712-5u4e00q6	327	7	12	12	CD
cord-014712-5u4e00q6	327	8	000	000	CD
cord-014712-5u4e00q6	327	9	/	/	SYM
cord-014712-5u4e00q6	327	10	mm	mm	NN
cord-014712-5u4e00q6	327	11	3	3	CD
cord-014712-5u4e00q6	327	12	.	.	.
cord-014712-5u4e00q6	328	1	,	,	,
cord-014712-5u4e00q6	328	2	high	high	JJ
cord-014712-5u4e00q6	328	3	ASTO	ASTO	NNP
cord-014712-5u4e00q6	328	4	.	.	.
cord-014712-5u4e00q6	329	1	Serum	serum	NN
cord-014712-5u4e00q6	329	2	IgD	igd	NN
cord-014712-5u4e00q6	329	3	was	be	VBD
cord-014712-5u4e00q6	329	4	repeated	repeat	VBN
cord-014712-5u4e00q6	329	5	several	several	JJ
cord-014712-5u4e00q6	329	6	times	time	NNS
cord-014712-5u4e00q6	329	7	and	and	CC
cord-014712-5u4e00q6	329	8	was	be	VBD
cord-014712-5u4e00q6	329	9	always	always	RB
cord-014712-5u4e00q6	329	10	elevated	elevated	JJ
cord-014712-5u4e00q6	329	11	(	(	-LRB-
cord-014712-5u4e00q6	329	12	mean	mean	JJ
cord-014712-5u4e00q6	329	13	value	value	NN
cord-014712-5u4e00q6	329	14	:	:	:
cord-014712-5u4e00q6	329	15	Serum	serum	NN
cord-014712-5u4e00q6	329	16	IgD	igd	NN
cord-014712-5u4e00q6	329	17	122	122	CD
cord-014712-5u4e00q6	329	18	IU	IU	NNP
cord-014712-5u4e00q6	329	19	/	/	SYM
cord-014712-5u4e00q6	329	20	mL	mL	NNP
cord-014712-5u4e00q6	329	21	)	)	-RRB-
cord-014712-5u4e00q6	329	22	.	.	.
cord-014712-5u4e00q6	330	1	The	the	DT
cord-014712-5u4e00q6	330	2	mutation	mutation	NN
cord-014712-5u4e00q6	330	3	V377I	v377i	NN
cord-014712-5u4e00q6	330	4	is	be	VBZ
cord-014712-5u4e00q6	330	5	found	find	VBN
cord-014712-5u4e00q6	330	6	from	from	IN
cord-014712-5u4e00q6	330	7	the	the	DT
cord-014712-5u4e00q6	330	8	genetic	genetic	JJ
cord-014712-5u4e00q6	330	9	examination	examination	NN
cord-014712-5u4e00q6	330	10	done	do	VBN
cord-014712-5u4e00q6	330	11	for	for	IN
cord-014712-5u4e00q6	330	12	gene	gene	NN
cord-014712-5u4e00q6	330	13	mutations	mutation	NNS
cord-014712-5u4e00q6	330	14	in	in	IN
cord-014712-5u4e00q6	330	15	chromosome	chromosome	NN
cord-014712-5u4e00q6	330	16	12	12	CD
cord-014712-5u4e00q6	330	17	(	(	-LRB-
cord-014712-5u4e00q6	330	18	12q24	12q24	CD
cord-014712-5u4e00q6	330	19	)	)	-RRB-
cord-014712-5u4e00q6	330	20	.	.	.
cord-014712-5u4e00q6	331	1	He	-PRON-	PRP
cord-014712-5u4e00q6	331	2	repeated	repeat	VBD
cord-014712-5u4e00q6	331	3	attacks	attack	NNS
cord-014712-5u4e00q6	331	4	after	after	IN
cord-014712-5u4e00q6	331	5	initial	initial	JJ
cord-014712-5u4e00q6	331	6	treatment	treatment	NN
cord-014712-5u4e00q6	331	7	with	with	IN
cord-014712-5u4e00q6	331	8	corticosteroid	corticosteroid	NN
cord-014712-5u4e00q6	331	9	,	,	,
cord-014712-5u4e00q6	331	10	than	than	IN
cord-014712-5u4e00q6	331	11	is	be	VBZ
cord-014712-5u4e00q6	331	12	suggested	suggest	VBN
cord-014712-5u4e00q6	331	13	.	.	.
cord-014712-5u4e00q6	332	1	The	the	DT
cord-014712-5u4e00q6	332	2	second	second	JJ
cord-014712-5u4e00q6	332	3	case	case	NN
cord-014712-5u4e00q6	332	4	was	be	VBD
cord-014712-5u4e00q6	332	5	a	a	DT
cord-014712-5u4e00q6	332	6	four	four	CD
cord-014712-5u4e00q6	332	7	-	-	HYPH
cord-014712-5u4e00q6	332	8	year	year	NN
cord-014712-5u4e00q6	332	9	-	-	HYPH
cord-014712-5u4e00q6	332	10	old	old	JJ
cord-014712-5u4e00q6	332	11	girl	girl	NN
cord-014712-5u4e00q6	332	12	hospitalized	hospitalize	VBD
cord-014712-5u4e00q6	332	13	five	five	CD
cord-014712-5u4e00q6	332	14	times	time	NNS
cord-014712-5u4e00q6	332	15	because	because	IN
cord-014712-5u4e00q6	332	16	of	of	IN
cord-014712-5u4e00q6	332	17	prolonged	prolonged	JJ
cord-014712-5u4e00q6	332	18	fever	fever	NN
cord-014712-5u4e00q6	332	19	,	,	,
cord-014712-5u4e00q6	332	20	and	and	CC
cord-014712-5u4e00q6	332	21	diagnosed	diagnose	VBD
cord-014712-5u4e00q6	332	22	as	as	IN
cord-014712-5u4e00q6	332	23	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	332	24	,	,	,
cord-014712-5u4e00q6	332	25	tonsillitis	tonsillitis	NN
cord-014712-5u4e00q6	332	26	,	,	,
cord-014712-5u4e00q6	332	27	acute	acute	JJ
cord-014712-5u4e00q6	332	28	otitis	otitis	NN
cord-014712-5u4e00q6	332	29	media	medium	NNS
cord-014712-5u4e00q6	332	30	and	and	CC
cord-014712-5u4e00q6	332	31	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	332	32	,	,	,
cord-014712-5u4e00q6	332	33	treated	treat	VBN
cord-014712-5u4e00q6	332	34	by	by	IN
cord-014712-5u4e00q6	332	35	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	332	36	.	.	.
cord-014712-5u4e00q6	333	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	333	2	laboratory	laboratory	NN
cord-014712-5u4e00q6	333	3	findings	finding	NNS
cord-014712-5u4e00q6	333	4	were	be	VBD
cord-014712-5u4e00q6	333	5	not	not	RB
cord-014712-5u4e00q6	333	6	remarkable	remarkable	JJ
cord-014712-5u4e00q6	333	7	except	except	IN
cord-014712-5u4e00q6	333	8	for	for	IN
cord-014712-5u4e00q6	333	9	increased	increase	VBN
cord-014712-5u4e00q6	333	10	acute	acute	JJ
cord-014712-5u4e00q6	333	11	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	333	12	responses	response	NNS
cord-014712-5u4e00q6	333	13	.	.	.
cord-014712-5u4e00q6	334	1	Serum	serum	NN
cord-014712-5u4e00q6	334	2	Amyloid	Amyloid	NNP
cord-014712-5u4e00q6	334	3	A	A	NNP
cord-014712-5u4e00q6	334	4	(	(	-LRB-
cord-014712-5u4e00q6	334	5	SAA	SAA	NNP
cord-014712-5u4e00q6	334	6	)	)	-RRB-
cord-014712-5u4e00q6	334	7	1100	1100	CD
cord-014712-5u4e00q6	335	1	μg/	μg/	NNP
cord-014712-5u4e00q6	336	1	l	l	NNP
cord-014712-5u4e00q6	336	2	(	(	-LRB-
cord-014712-5u4e00q6	336	3	8	8	CD
cord-014712-5u4e00q6	336	4	μg	μg	NNP
cord-014712-5u4e00q6	336	5	/	/	SYM
cord-014712-5u4e00q6	336	6	l	l	NNP
cord-014712-5u4e00q6	336	7	)	)	-RRB-
cord-014712-5u4e00q6	336	8	and	and	CC
cord-014712-5u4e00q6	336	9	IgD	IgD	NNP
cord-014712-5u4e00q6	336	10	was	be	VBD
cord-014712-5u4e00q6	336	11	extremely	extremely	RB
cord-014712-5u4e00q6	336	12	high	high	JJ
cord-014712-5u4e00q6	336	13	181.9	181.9	CD
cord-014712-5u4e00q6	336	14	IU	IU	NNP
cord-014712-5u4e00q6	336	15	/	/	,
cord-014712-5u4e00q6	336	16	ml	ml	NN
cord-014712-5u4e00q6	336	17	.	.	.
cord-014712-5u4e00q6	337	1	Genetic	genetic	JJ
cord-014712-5u4e00q6	337	2	examination	examination	NN
cord-014712-5u4e00q6	337	3	for	for	IN
cord-014712-5u4e00q6	337	4	two	two	CD
cord-014712-5u4e00q6	337	5	mutations	mutation	NNS
cord-014712-5u4e00q6	337	6	were	be	VBD
cord-014712-5u4e00q6	337	7	negative	negative	JJ
cord-014712-5u4e00q6	337	8	,	,	,
cord-014712-5u4e00q6	337	9	but	but	CC
cord-014712-5u4e00q6	337	10	reduced	reduce	VBN
cord-014712-5u4e00q6	337	11	mevalonate	mevalonate	NN
cord-014712-5u4e00q6	337	12	kinase	kinase	NN
cord-014712-5u4e00q6	337	13	activity	activity	NN
cord-014712-5u4e00q6	337	14	in	in	IN
cord-014712-5u4e00q6	337	15	white	white	JJ
cord-014712-5u4e00q6	337	16	blood	blood	NN
cord-014712-5u4e00q6	337	17	cells	cell	NNS
cord-014712-5u4e00q6	337	18	was	be	VBD
cord-014712-5u4e00q6	337	19	demonstrated	demonstrate	VBN
cord-014712-5u4e00q6	337	20	in	in	IN
cord-014712-5u4e00q6	337	21	more	more	RBR
cord-014712-5u4e00q6	337	22	thorough	thorough	JJ
cord-014712-5u4e00q6	337	23	investigations	investigation	NNS
cord-014712-5u4e00q6	337	24	.	.	.
cord-014712-5u4e00q6	338	1	Treatment	treatment	NN
cord-014712-5u4e00q6	338	2	regime	regime	NN
cord-014712-5u4e00q6	338	3	:	:	:
cord-014712-5u4e00q6	339	1	colchicine	colchicine	NNP
cord-014712-5u4e00q6	339	2	Conclusions	Conclusions	NNPS
cord-014712-5u4e00q6	339	3	:	:	:
cord-014712-5u4e00q6	340	1	Auto	auto	NN
cord-014712-5u4e00q6	340	2	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	340	3	syndromes	syndrome	NNS
cord-014712-5u4e00q6	340	4	always	always	RB
cord-014712-5u4e00q6	340	5	pose	pose	VBP
cord-014712-5u4e00q6	340	6	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	340	7	and	and	CC
cord-014712-5u4e00q6	340	8	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	340	9	challenges	challenge	NNS
cord-014712-5u4e00q6	340	10	to	to	IN
cord-014712-5u4e00q6	340	11	the	the	DT
cord-014712-5u4e00q6	340	12	clinicians	clinician	NNS
cord-014712-5u4e00q6	340	13	.	.	.
cord-014712-5u4e00q6	341	1	The	the	DT
cord-014712-5u4e00q6	341	2	clinical	clinical	JJ
cord-014712-5u4e00q6	341	3	description	description	NN
cord-014712-5u4e00q6	341	4	of	of	IN
cord-014712-5u4e00q6	341	5	the	the	DT
cord-014712-5u4e00q6	341	6	diversity	diversity	NN
cord-014712-5u4e00q6	341	7	of	of	IN
cord-014712-5u4e00q6	341	8	periodic	periodic	JJ
cord-014712-5u4e00q6	341	9	fever	fever	NN
cord-014712-5u4e00q6	341	10	syndromes	syndrome	NNS
cord-014712-5u4e00q6	341	11	is	be	VBZ
cord-014712-5u4e00q6	341	12	helpful	helpful	JJ
cord-014712-5u4e00q6	341	13	in	in	IN
cord-014712-5u4e00q6	341	14	the	the	DT
cord-014712-5u4e00q6	341	15	assessment	assessment	NN
cord-014712-5u4e00q6	341	16	and	and	CC
cord-014712-5u4e00q6	341	17	management	management	NN
cord-014712-5u4e00q6	341	18	of	of	IN
cord-014712-5u4e00q6	341	19	these	these	DT
cord-014712-5u4e00q6	341	20	patients	patient	NNS
cord-014712-5u4e00q6	341	21	.	.	.
cord-014712-5u4e00q6	342	1	Although	although	IN
cord-014712-5u4e00q6	342	2	HIDS	HIDS	NNP
cord-014712-5u4e00q6	342	3	is	be	VBZ
cord-014712-5u4e00q6	342	4	predominantly	predominantly	RB
cord-014712-5u4e00q6	342	5	identified	identify	VBN
cord-014712-5u4e00q6	342	6	in	in	IN
cord-014712-5u4e00q6	342	7	populations	population	NNS
cord-014712-5u4e00q6	342	8	from	from	IN
cord-014712-5u4e00q6	342	9	northern	northern	JJ
cord-014712-5u4e00q6	342	10	European	european	JJ
cord-014712-5u4e00q6	342	11	areas	area	NNS
cord-014712-5u4e00q6	342	12	,	,	,
cord-014712-5u4e00q6	342	13	it	-PRON-	PRP
cord-014712-5u4e00q6	342	14	has	have	VBZ
cord-014712-5u4e00q6	342	15	to	to	TO
cord-014712-5u4e00q6	342	16	be	be	VB
cord-014712-5u4e00q6	342	17	considered	consider	VBN
cord-014712-5u4e00q6	342	18	in	in	IN
cord-014712-5u4e00q6	342	19	children	child	NNS
cord-014712-5u4e00q6	342	20	with	with	IN
cord-014712-5u4e00q6	342	21	periodic	periodic	JJ
cord-014712-5u4e00q6	342	22	fever	fever	NN
cord-014712-5u4e00q6	342	23	.	.	.
cord-014712-5u4e00q6	343	1	Anastasiia	Anastasiia	NNP
cord-014712-5u4e00q6	343	2	Bondarenko	Bondarenko	NNP
cord-014712-5u4e00q6	343	3	1	1	CD
cord-014712-5u4e00q6	343	4	;	;	:
cord-014712-5u4e00q6	343	5	Liudmyla	Liudmyla	NNP
cord-014712-5u4e00q6	343	6	Chernyshova	Chernyshova	NNP
cord-014712-5u4e00q6	343	7	1	1	CD
cord-014712-5u4e00q6	343	8	;	;	:
cord-014712-5u4e00q6	344	1	Iryna	Iryna	NNP
cord-014712-5u4e00q6	344	2	Sychova	Sychova	NNP
cord-014712-5u4e00q6	344	3	2	2	CD
cord-014712-5u4e00q6	344	4	1	1	CD
cord-014712-5u4e00q6	344	5	Shupik	Shupik	NNP
cord-014712-5u4e00q6	344	6	National	National	NNP
cord-014712-5u4e00q6	344	7	Medical	Medical	NNP
cord-014712-5u4e00q6	344	8	Academy	Academy	NNP
cord-014712-5u4e00q6	344	9	of	of	IN
cord-014712-5u4e00q6	344	10	Postgraduate	Postgraduate	NNP
cord-014712-5u4e00q6	344	11	Education	Education	NNP
cord-014712-5u4e00q6	344	12	,	,	,
cord-014712-5u4e00q6	344	13	Kiev	Kiev	NNP
cord-014712-5u4e00q6	344	14	,	,	,
cord-014712-5u4e00q6	344	15	Ukraine	Ukraine	NNP
cord-014712-5u4e00q6	344	16	.	.	.
cord-014712-5u4e00q6	345	1	2	2	LS
cord-014712-5u4e00q6	346	1	Dniepropetrovsk	Dniepropetrovsk	NNP
cord-014712-5u4e00q6	346	2	Regional	Regional	NNP
cord-014712-5u4e00q6	346	3	Children	Children	NNPS
cord-014712-5u4e00q6	346	4	's	's	POS
cord-014712-5u4e00q6	346	5	Hospital	Hospital	NNP
cord-014712-5u4e00q6	346	6	,	,	,
cord-014712-5u4e00q6	346	7	Dniepropetrovsk	Dniepropetrovsk	NNP
cord-014712-5u4e00q6	346	8	,	,	,
cord-014712-5u4e00q6	346	9	Ukraine	Ukraine	NNP
cord-014712-5u4e00q6	346	10	.	.	.
cord-014712-5u4e00q6	347	1	Background	background	NN
cord-014712-5u4e00q6	347	2	.	.	.
cord-014712-5u4e00q6	348	1	Aspergillus	aspergillus	NN
cord-014712-5u4e00q6	348	2	is	be	VBZ
cord-014712-5u4e00q6	348	3	an	an	DT
cord-014712-5u4e00q6	348	4	actual	actual	JJ
cord-014712-5u4e00q6	348	5	pathogen	pathogen	NN
cord-014712-5u4e00q6	348	6	in	in	IN
cord-014712-5u4e00q6	348	7	chronic	chronic	JJ
cord-014712-5u4e00q6	348	8	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	348	9	disease	disease	NN
cord-014712-5u4e00q6	348	10	responsible	responsible	JJ
cord-014712-5u4e00q6	348	11	for	for	IN
cord-014712-5u4e00q6	348	12	about	about	RB
cord-014712-5u4e00q6	348	13	20	20	CD
cord-014712-5u4e00q6	348	14	%	%	NN
cord-014712-5u4e00q6	348	15	of	of	IN
cord-014712-5u4e00q6	348	16	all	all	DT
cord-014712-5u4e00q6	348	17	infections	infection	NNS
cord-014712-5u4e00q6	348	18	.	.	.
cord-014712-5u4e00q6	349	1	In	in	IN
cord-014712-5u4e00q6	349	2	70	70	CD
cord-014712-5u4e00q6	349	3	-	-	SYM
cord-014712-5u4e00q6	349	4	80	80	CD
cord-014712-5u4e00q6	349	5	%	%	NN
cord-014712-5u4e00q6	349	6	lungs	lung	NNS
cord-014712-5u4e00q6	349	7	are	be	VBP
cord-014712-5u4e00q6	349	8	involved	involve	VBN
cord-014712-5u4e00q6	349	9	and	and	CC
cord-014712-5u4e00q6	349	10	in	in	IN
cord-014712-5u4e00q6	349	11	5	5	CD
cord-014712-5u4e00q6	349	12	%	%	NN
cord-014712-5u4e00q6	349	13	-CNS	-cns	NN
cord-014712-5u4e00q6	349	14	.	.	.
cord-014712-5u4e00q6	350	1	Case	case	NN
cord-014712-5u4e00q6	350	2	.	.	.
cord-014712-5u4e00q6	351	1	We	-PRON-	PRP
cord-014712-5u4e00q6	351	2	report	report	VBP
cord-014712-5u4e00q6	351	3	a	a	DT
cord-014712-5u4e00q6	351	4	case	case	NN
cord-014712-5u4e00q6	351	5	of	of	IN
cord-014712-5u4e00q6	351	6	combined	combined	JJ
cord-014712-5u4e00q6	351	7	loci	locus	NNS
cord-014712-5u4e00q6	351	8	in	in	IN
cord-014712-5u4e00q6	351	9	9-years	9-years	CD
cord-014712-5u4e00q6	351	10	old	old	JJ
cord-014712-5u4e00q6	351	11	female	female	JJ
cord-014712-5u4e00q6	351	12	patient	patient	NN
cord-014712-5u4e00q6	351	13	with	with	IN
cord-014712-5u4e00q6	351	14	AR	AR	NNP
cord-014712-5u4e00q6	351	15	CGD	CGD	NNP
cord-014712-5u4e00q6	351	16	.	.	.
cord-014712-5u4e00q6	352	1	The	the	DT
cord-014712-5u4e00q6	352	2	child	child	NN
cord-014712-5u4e00q6	352	3	was	be	VBD
cord-014712-5u4e00q6	352	4	born	bear	VBN
cord-014712-5u4e00q6	352	5	from	from	IN
cord-014712-5u4e00q6	352	6	III	iii	CD
cord-014712-5u4e00q6	352	7	pregnancy	pregnancy	NN
cord-014712-5u4e00q6	352	8	,	,	,
cord-014712-5u4e00q6	352	9	II	II	NNP
cord-014712-5u4e00q6	352	10	delivery	delivery	NN
cord-014712-5u4e00q6	352	11	on	on	IN
cord-014712-5u4e00q6	352	12	37	37	CD
cord-014712-5u4e00q6	352	13	th	th	CD
cord-014712-5u4e00q6	352	14	week	week	NN
cord-014712-5u4e00q6	352	15	of	of	IN
cord-014712-5u4e00q6	352	16	gestation	gestation	NN
cord-014712-5u4e00q6	352	17	with	with	IN
cord-014712-5u4e00q6	352	18	body	body	NN
cord-014712-5u4e00q6	352	19	mass	mass	NNP
cord-014712-5u4e00q6	352	20	2750	2750	CD
cord-014712-5u4e00q6	352	21	g	g	NN
cord-014712-5u4e00q6	352	22	.	.	.
cord-014712-5u4e00q6	353	1	She	-PRON-	PRP
cord-014712-5u4e00q6	353	2	received	receive	VBD
cord-014712-5u4e00q6	353	3	BCG	BCG	NNP
cord-014712-5u4e00q6	353	4	vaccination	vaccination	NN
cord-014712-5u4e00q6	353	5	at	at	IN
cord-014712-5u4e00q6	353	6	4	4	CD
cord-014712-5u4e00q6	353	7	-th	-th	CD
cord-014712-5u4e00q6	353	8	day	day	NN
cord-014712-5u4e00q6	353	9	of	of	IN
cord-014712-5u4e00q6	353	10	birth	birth	NN
cord-014712-5u4e00q6	353	11	.	.	.
cord-014712-5u4e00q6	354	1	At	at	IN
cord-014712-5u4e00q6	354	2	3	3	CD
cord-014712-5u4e00q6	354	3	months	month	NNS
cord-014712-5u4e00q6	354	4	the	the	DT
cord-014712-5u4e00q6	354	5	local	local	JJ
cord-014712-5u4e00q6	354	6	inflammation	inflammation	NN
cord-014712-5u4e00q6	354	7	in	in	IN
cord-014712-5u4e00q6	354	8	site	site	NN
cord-014712-5u4e00q6	354	9	of	of	IN
cord-014712-5u4e00q6	354	10	BCG	BCG	NNP
cord-014712-5u4e00q6	354	11	with	with	IN
cord-014712-5u4e00q6	354	12	regional	regional	JJ
cord-014712-5u4e00q6	354	13	lymphadenitis	lymphadenitis	NNP
cord-014712-5u4e00q6	354	14	developed	develop	VBD
cord-014712-5u4e00q6	354	15	which	which	WDT
cord-014712-5u4e00q6	354	16	was	be	VBD
cord-014712-5u4e00q6	354	17	treated	treat	VBN
cord-014712-5u4e00q6	354	18	with	with	IN
cord-014712-5u4e00q6	354	19	isoniazid	isoniazid	NN
cord-014712-5u4e00q6	354	20	for	for	IN
cord-014712-5u4e00q6	354	21	3	3	CD
cord-014712-5u4e00q6	354	22	months	month	NNS
cord-014712-5u4e00q6	354	23	.	.	.
cord-014712-5u4e00q6	355	1	Then	then	RB
cord-014712-5u4e00q6	355	2	bilateral	bilateral	JJ
cord-014712-5u4e00q6	355	3	purulent	purulent	JJ
cord-014712-5u4e00q6	355	4	cervical	cervical	JJ
cord-014712-5u4e00q6	355	5	lymphadenitis	lymphadenitis	NN
cord-014712-5u4e00q6	355	6	developed	develop	VBN
cord-014712-5u4e00q6	355	7	at	at	IN
cord-014712-5u4e00q6	355	8	6	6	CD
cord-014712-5u4e00q6	355	9	,	,	,
cord-014712-5u4e00q6	355	10	9	9	CD
cord-014712-5u4e00q6	355	11	and	and	CC
cord-014712-5u4e00q6	355	12	11	11	CD
cord-014712-5u4e00q6	355	13	months	month	NNS
cord-014712-5u4e00q6	355	14	treated	treat	VBN
cord-014712-5u4e00q6	355	15	with	with	IN
cord-014712-5u4e00q6	355	16	wide	wide	JJ
cord-014712-5u4e00q6	355	17	spectrum	spectrum	NN
cord-014712-5u4e00q6	355	18	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	355	19	.	.	.
cord-014712-5u4e00q6	356	1	Culture	culture	NN
cord-014712-5u4e00q6	356	2	from	from	IN
cord-014712-5u4e00q6	356	3	pus	pus	NN
cord-014712-5u4e00q6	356	4	was	be	VBD
cord-014712-5u4e00q6	356	5	negative	negative	JJ
cord-014712-5u4e00q6	356	6	.	.	.
cord-014712-5u4e00q6	357	1	PCR	PCR	NNP
cord-014712-5u4e00q6	357	2	for	for	IN
cord-014712-5u4e00q6	357	3	mycobacterium	mycobacterium	NNP
cord-014712-5u4e00q6	357	4	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	357	5	complex	complex	NNP
cord-014712-5u4e00q6	357	6	was	be	VBD
cord-014712-5u4e00q6	357	7	negative	negative	JJ
cord-014712-5u4e00q6	357	8	.	.	.
cord-014712-5u4e00q6	358	1	At18	At18	NNP
cord-014712-5u4e00q6	359	1	months	month	NNS
cord-014712-5u4e00q6	359	2	systemic	systemic	JJ
cord-014712-5u4e00q6	359	3	infection	infection	NN
cord-014712-5u4e00q6	359	4	without	without	IN
cord-014712-5u4e00q6	359	5	loci	locus	NNS
cord-014712-5u4e00q6	359	6	occurred	occur	VBD
cord-014712-5u4e00q6	359	7	with	with	IN
cord-014712-5u4e00q6	359	8	fever	fever	NN
cord-014712-5u4e00q6	359	9	,	,	,
cord-014712-5u4e00q6	359	10	lymphadenopathy	lymphadenopathy	JJ
cord-014712-5u4e00q6	359	11	,	,	,
cord-014712-5u4e00q6	359	12	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-014712-5u4e00q6	359	13	,	,	,
cord-014712-5u4e00q6	359	14	loss	loss	NN
cord-014712-5u4e00q6	359	15	of	of	IN
cord-014712-5u4e00q6	359	16	weight	weight	NN
cord-014712-5u4e00q6	359	17	,	,	,
cord-014712-5u4e00q6	359	18	progressive	progressive	JJ
cord-014712-5u4e00q6	359	19	anemia	anemia	NN
cord-014712-5u4e00q6	359	20	,	,	,
cord-014712-5u4e00q6	359	21	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	359	22	changes	change	NNS
cord-014712-5u4e00q6	359	23	in	in	IN
cord-014712-5u4e00q6	359	24	blood	blood	NN
cord-014712-5u4e00q6	359	25	for	for	IN
cord-014712-5u4e00q6	359	26	almost	almost	RB
cord-014712-5u4e00q6	359	27	6	6	CD
cord-014712-5u4e00q6	359	28	months	month	NNS
cord-014712-5u4e00q6	359	29	.	.	.
cord-014712-5u4e00q6	360	1	Bacteriological	bacteriological	JJ
cord-014712-5u4e00q6	360	2	cultures	culture	NNS
cord-014712-5u4e00q6	360	3	were	be	VBD
cord-014712-5u4e00q6	360	4	negative	negative	JJ
cord-014712-5u4e00q6	360	5	.	.	.
cord-014712-5u4e00q6	361	1	Treatment	treatment	NN
cord-014712-5u4e00q6	361	2	with	with	IN
cord-014712-5u4e00q6	361	3	wide	wide	JJ
cord-014712-5u4e00q6	361	4	spectrum	spectrum	NN
cord-014712-5u4e00q6	361	5	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	361	6	was	be	VBD
cord-014712-5u4e00q6	361	7	insufficient	insufficient	JJ
cord-014712-5u4e00q6	361	8	for	for	IN
cord-014712-5u4e00q6	361	9	3	3	CD
cord-014712-5u4e00q6	361	10	months	month	NNS
cord-014712-5u4e00q6	361	11	.	.	.
cord-014712-5u4e00q6	362	1	Disseminated	disseminate	VBN
cord-014712-5u4e00q6	362	2	BCG	BCG	NNP
cord-014712-5u4e00q6	362	3	infection	infection	NN
cord-014712-5u4e00q6	362	4	was	be	VBD
cord-014712-5u4e00q6	362	5	suspected	suspect	VBN
cord-014712-5u4e00q6	362	6	and	and	CC
cord-014712-5u4e00q6	362	7	4-compound	4-compound	CD
cord-014712-5u4e00q6	362	8	AMB	AMB	NNP
cord-014712-5u4e00q6	362	9	treatment	treatment	NN
cord-014712-5u4e00q6	362	10	was	be	VBD
cord-014712-5u4e00q6	362	11	started	start	VBN
cord-014712-5u4e00q6	362	12	ex	ex	FW
cord-014712-5u4e00q6	362	13	juvantibus	juvantibus	NN
cord-014712-5u4e00q6	362	14	with	with	IN
cord-014712-5u4e00q6	362	15	positive	positive	JJ
cord-014712-5u4e00q6	362	16	effect	effect	NN
cord-014712-5u4e00q6	362	17	:	:	:
cord-014712-5u4e00q6	362	18	the	the	DT
cord-014712-5u4e00q6	362	19	fever	fever	NN
cord-014712-5u4e00q6	362	20	has	have	VBZ
cord-014712-5u4e00q6	362	21	stopped	stop	VBN
cord-014712-5u4e00q6	362	22	,	,	,
cord-014712-5u4e00q6	362	23	the	the	DT
cord-014712-5u4e00q6	362	24	sizes	size	NNS
cord-014712-5u4e00q6	362	25	of	of	IN
cord-014712-5u4e00q6	362	26	lymph	lymph	NN
cord-014712-5u4e00q6	362	27	nodes	node	NNS
cord-014712-5u4e00q6	362	28	,	,	,
cord-014712-5u4e00q6	362	29	liver	liver	NN
cord-014712-5u4e00q6	362	30	and	and	CC
cord-014712-5u4e00q6	362	31	spleen	spleen	NNS
cord-014712-5u4e00q6	362	32	have	have	VBP
cord-014712-5u4e00q6	362	33	decreased	decrease	VBN
cord-014712-5u4e00q6	362	34	,	,	,
cord-014712-5u4e00q6	362	35	the	the	DT
cord-014712-5u4e00q6	362	36	weight	weight	NN
cord-014712-5u4e00q6	362	37	of	of	IN
cord-014712-5u4e00q6	362	38	a	a	DT
cord-014712-5u4e00q6	362	39	body	body	NN
cord-014712-5u4e00q6	362	40	normalized	normalize	VBN
cord-014712-5u4e00q6	362	41	.	.	.
cord-014712-5u4e00q6	363	1	The	the	DT
cord-014712-5u4e00q6	363	2	child	child	NN
cord-014712-5u4e00q6	363	3	suffered	suffer	VBD
cord-014712-5u4e00q6	363	4	from	from	IN
cord-014712-5u4e00q6	363	5	recurrent	recurrent	JJ
cord-014712-5u4e00q6	363	6	pyogenic	pyogenic	JJ
cord-014712-5u4e00q6	363	7	infections	infection	NNS
cord-014712-5u4e00q6	363	8	,	,	,
cord-014712-5u4e00q6	363	9	underwent	undergo	VBD
cord-014712-5u4e00q6	363	10	disseminated	disseminate	VBN
cord-014712-5u4e00q6	363	11	salmonellosis	salmonellosis	NN
cord-014712-5u4e00q6	363	12	.	.	.
cord-014712-5u4e00q6	364	1	At	at	IN
cord-014712-5u4e00q6	364	2	the	the	DT
cord-014712-5u4e00q6	364	3	age	age	NN
cord-014712-5u4e00q6	364	4	of	of	IN
cord-014712-5u4e00q6	364	5	5	5	CD
cord-014712-5u4e00q6	364	6	years	year	NNS
cord-014712-5u4e00q6	364	7	blood	blood	NN
cord-014712-5u4e00q6	364	8	samples	sample	NNS
cord-014712-5u4e00q6	364	9	were	be	VBD
cord-014712-5u4e00q6	364	10	tested	test	VBN
cord-014712-5u4e00q6	364	11	at	at	IN
cord-014712-5u4e00q6	364	12	the	the	DT
cord-014712-5u4e00q6	364	13	Laboratory	Laboratory	NNP
cord-014712-5u4e00q6	364	14	of	of	IN
cord-014712-5u4e00q6	364	15	Human	Human	NNP
cord-014712-5u4e00q6	364	16	genetics	genetic	NNS
cord-014712-5u4e00q6	364	17	of	of	IN
cord-014712-5u4e00q6	364	18	Infectious	Infectious	NNP
cord-014712-5u4e00q6	364	19	Diseases	Diseases	NNPS
cord-014712-5u4e00q6	364	20	,	,	,
cord-014712-5u4e00q6	364	21	INSERM	INSERM	NNP
cord-014712-5u4e00q6	364	22	(	(	-LRB-
cord-014712-5u4e00q6	364	23	Paris	Paris	NNP
cord-014712-5u4e00q6	364	24	,	,	,
cord-014712-5u4e00q6	364	25	France	France	NNP
cord-014712-5u4e00q6	364	26	)	)	-RRB-
cord-014712-5u4e00q6	364	27	.	.	.
cord-014712-5u4e00q6	365	1	An	an	DT
cord-014712-5u4e00q6	365	2	absence	absence	NN
cord-014712-5u4e00q6	365	3	of	of	IN
cord-014712-5u4e00q6	365	4	p22	p22	NN
cord-014712-5u4e00q6	365	5	phox	phox	NNP
cord-014712-5u4e00q6	365	6	protein	protein	NN
cord-014712-5u4e00q6	365	7	expression	expression	NN
cord-014712-5u4e00q6	365	8	detected	detect	VBN
cord-014712-5u4e00q6	365	9	by	by	IN
cord-014712-5u4e00q6	365	10	western	western	JJ
cord-014712-5u4e00q6	365	11	blot	blot	NN
cord-014712-5u4e00q6	365	12	conferring	confer	VBG
cord-014712-5u4e00q6	365	13	a	a	DT
cord-014712-5u4e00q6	365	14	complete	complete	JJ
cord-014712-5u4e00q6	365	15	defect	defect	NN
cord-014712-5u4e00q6	365	16	in	in	IN
cord-014712-5u4e00q6	365	17	CYBA	CYBA	NNP
cord-014712-5u4e00q6	365	18	due	due	IN
cord-014712-5u4e00q6	365	19	to	to	IN
cord-014712-5u4e00q6	365	20	compound	compound	NN
cord-014712-5u4e00q6	365	21	of	of	IN
cord-014712-5u4e00q6	365	22	geterozigous	geterozigous	JJ
cord-014712-5u4e00q6	365	23	mutations	mutation	NNS
cord-014712-5u4e00q6	365	24	in	in	IN
cord-014712-5u4e00q6	365	25	16q24	16q24	CD
cord-014712-5u4e00q6	365	26	.	.	.
cord-014712-5u4e00q6	366	1	At	at	IN
cord-014712-5u4e00q6	366	2	6	6	CD
cord-014712-5u4e00q6	366	3	years	year	NNS
cord-014712-5u4e00q6	366	4	primary	primary	JJ
cord-014712-5u4e00q6	366	5	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	366	6	complex	complex	JJ
cord-014712-5u4e00q6	366	7	of	of	IN
cord-014712-5u4e00q6	366	8	right	right	JJ
cord-014712-5u4e00q6	366	9	upper	upper	JJ
cord-014712-5u4e00q6	366	10	lobe	lobe	NN
cord-014712-5u4e00q6	366	11	(	(	-LRB-
cord-014712-5u4e00q6	366	12	MBT	MBT	NNP
cord-014712-5u4e00q6	366	13	-	-	,
cord-014712-5u4e00q6	366	14	)	)	-RRB-
cord-014712-5u4e00q6	366	15	was	be	VBD
cord-014712-5u4e00q6	366	16	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	366	17	.	.	.
cord-014712-5u4e00q6	367	1	At	at	IN
cord-014712-5u4e00q6	367	2	the	the	DT
cord-014712-5u4e00q6	367	3	age	age	NN
cord-014712-5u4e00q6	367	4	of	of	IN
cord-014712-5u4e00q6	367	5	7	7	CD
cord-014712-5u4e00q6	367	6	during	during	IN
cord-014712-5u4e00q6	367	7	the	the	DT
cord-014712-5u4e00q6	367	8	unexplained	unexplained	JJ
cord-014712-5u4e00q6	367	9	fever	fever	NN
cord-014712-5u4e00q6	367	10	multiple	multiple	JJ
cord-014712-5u4e00q6	367	11	formations	formation	NNS
cord-014712-5u4e00q6	367	12	were	be	VBD
cord-014712-5u4e00q6	367	13	identified	identify	VBN
cord-014712-5u4e00q6	367	14	in	in	IN
cord-014712-5u4e00q6	367	15	the	the	DT
cord-014712-5u4e00q6	367	16	liver	liver	NN
cord-014712-5u4e00q6	367	17	,	,	,
cord-014712-5u4e00q6	367	18	biopsy	biopsy	NNP
cord-014712-5u4e00q6	367	19	showed	show	VBD
cord-014712-5u4e00q6	367	20	caseosis	caseosis	NNP
cord-014712-5u4e00q6	367	21	suspected	suspect	VBD
cord-014712-5u4e00q6	367	22	the	the	DT
cord-014712-5u4e00q6	367	23	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	367	24	nature	nature	NN
cord-014712-5u4e00q6	367	25	of	of	IN
cord-014712-5u4e00q6	367	26	lesions	lesion	NNS
cord-014712-5u4e00q6	367	27	but	but	CC
cord-014712-5u4e00q6	367	28	MBT	MBT	NNP
cord-014712-5u4e00q6	367	29	(	(	-LRB-
cord-014712-5u4e00q6	367	30	-	-	:
cord-014712-5u4e00q6	367	31	)	)	-RRB-
cord-014712-5u4e00q6	367	32	.	.	.
cord-014712-5u4e00q6	368	1	At	at	IN
cord-014712-5u4e00q6	368	2	the	the	DT
cord-014712-5u4e00q6	368	3	age	age	NN
cord-014712-5u4e00q6	368	4	of	of	IN
cord-014712-5u4e00q6	368	5	9	9	CD
cord-014712-5u4e00q6	368	6	years	year	NNS
cord-014712-5u4e00q6	368	7	because	because	IN
cord-014712-5u4e00q6	368	8	of	of	IN
cord-014712-5u4e00q6	368	9	shade	shade	NN
cord-014712-5u4e00q6	368	10	in	in	IN
cord-014712-5u4e00q6	368	11	the	the	DT
cord-014712-5u4e00q6	368	12	left	left	JJ
cord-014712-5u4e00q6	368	13	upper	upper	JJ
cord-014712-5u4e00q6	368	14	lobe	lobe	NN
cord-014712-5u4e00q6	368	15	and	and	CC
cord-014712-5u4e00q6	368	16	ineffective	ineffective	JJ
cord-014712-5u4e00q6	368	17	standard	standard	JJ
cord-014712-5u4e00q6	368	18	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	368	19	treatment	treatment	NN
cord-014712-5u4e00q6	368	20	the	the	DT
cord-014712-5u4e00q6	368	21	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	368	22	again	again	RB
cord-014712-5u4e00q6	368	23	was	be	VBD
cord-014712-5u4e00q6	368	24	suspected	suspect	VBN
cord-014712-5u4e00q6	368	25	.	.	.
cord-014712-5u4e00q6	369	1	Due	due	IN
cord-014712-5u4e00q6	369	2	to	to	IN
cord-014712-5u4e00q6	369	3	ineffective	ineffective	JJ
cord-014712-5u4e00q6	369	4	antimycobacterial	antimycobacterial	JJ
cord-014712-5u4e00q6	369	5	treatment	treatment	NN
cord-014712-5u4e00q6	369	6	for	for	IN
cord-014712-5u4e00q6	369	7	8	8	CD
cord-014712-5u4e00q6	369	8	months	month	NNS
cord-014712-5u4e00q6	370	1	multi	multi	JJ
cord-014712-5u4e00q6	370	2	drug	drug	NNP
cord-014712-5u4e00q6	370	3	resistant	resistant	JJ
cord-014712-5u4e00q6	370	4	tubercullosis	tubercullosis	NNP
cord-014712-5u4e00q6	370	5	was	be	VBD
cord-014712-5u4e00q6	370	6	considered	consider	VBN
cord-014712-5u4e00q6	370	7	.	.	.
cord-014712-5u4e00q6	371	1	Anti	anti	JJ
cord-014712-5u4e00q6	371	2	-	-	JJ
cord-014712-5u4e00q6	371	3	TB	TB	NNP
cord-014712-5u4e00q6	371	4	drugs	drug	NNS
cord-014712-5u4e00q6	371	5	II	II	NNP
cord-014712-5u4e00q6	371	6	line	line	NN
cord-014712-5u4e00q6	371	7	was	be	VBD
cord-014712-5u4e00q6	371	8	appointed	appoint	VBN
cord-014712-5u4e00q6	371	9	without	without	IN
cord-014712-5u4e00q6	371	10	clinical	clinical	JJ
cord-014712-5u4e00q6	371	11	response	response	NN
cord-014712-5u4e00q6	371	12	.	.	.
cord-014712-5u4e00q6	372	1	Fever	Fever	NNP
cord-014712-5u4e00q6	372	2	persisted	persist	VBD
cord-014712-5u4e00q6	372	3	.	.	.
cord-014712-5u4e00q6	373	1	MRI	MRI	NNP
cord-014712-5u4e00q6	373	2	of	of	IN
cord-014712-5u4e00q6	373	3	brain	brain	NN
cord-014712-5u4e00q6	373	4	revealed	reveal	VBD
cord-014712-5u4e00q6	373	5	mass	mass	JJ
cord-014712-5u4e00q6	373	6	lesion	lesion	NN
cord-014712-5u4e00q6	373	7	in	in	IN
cord-014712-5u4e00q6	373	8	the	the	DT
cord-014712-5u4e00q6	373	9	left	left	JJ
cord-014712-5u4e00q6	373	10	parietal	parietal	JJ
cord-014712-5u4e00q6	373	11	lobe	lobe	NN
cord-014712-5u4e00q6	373	12	.	.	.
cord-014712-5u4e00q6	374	1	Because	because	IN
cord-014712-5u4e00q6	374	2	of	of	IN
cord-014712-5u4e00q6	374	3	suspected	suspect	VBN
cord-014712-5u4e00q6	374	4	tumor	tumor	NN
cord-014712-5u4e00q6	374	5	the	the	DT
cord-014712-5u4e00q6	374	6	brain	brain	NN
cord-014712-5u4e00q6	374	7	biopsy	biopsy	NN
cord-014712-5u4e00q6	374	8	was	be	VBD
cord-014712-5u4e00q6	374	9	done	do	VBN
cord-014712-5u4e00q6	374	10	and	and	CC
cord-014712-5u4e00q6	374	11	the	the	DT
cord-014712-5u4e00q6	374	12	pus	pus	NN
cord-014712-5u4e00q6	374	13	was	be	VBD
cord-014712-5u4e00q6	374	14	obtained	obtain	VBN
cord-014712-5u4e00q6	374	15	.	.	.
cord-014712-5u4e00q6	375	1	Microbiological	microbiological	JJ
cord-014712-5u4e00q6	375	2	studies	study	NNS
cord-014712-5u4e00q6	375	3	revealed	reveal	VBD
cord-014712-5u4e00q6	375	4	Aspergillus	Aspergillus	NNP
cord-014712-5u4e00q6	375	5	fumigatus	fumigatus	NN
cord-014712-5u4e00q6	375	6	.	.	.
cord-014712-5u4e00q6	376	1	At	at	IN
cord-014712-5u4e00q6	376	2	the	the	DT
cord-014712-5u4e00q6	376	3	same	same	JJ
cord-014712-5u4e00q6	376	4	time	time	NN
cord-014712-5u4e00q6	376	5	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	376	6	tumor	tumor	NN
cord-014712-5u4e00q6	376	7	-	-	HYPH
cord-014712-5u4e00q6	376	8	like	like	JJ
cord-014712-5u4e00q6	376	9	infiltrate	infiltrate	VB
cord-014712-5u4e00q6	376	10	40	40	CD
cord-014712-5u4e00q6	376	11	х	х	NNS
cord-014712-5u4e00q6	376	12	20	20	CD
cord-014712-5u4e00q6	376	13	mm	mm	NNS
cord-014712-5u4e00q6	376	14	appeared	appear	VBD
cord-014712-5u4e00q6	376	15	on	on	IN
cord-014712-5u4e00q6	376	16	chest	chest	NN
cord-014712-5u4e00q6	376	17	in	in	IN
cord-014712-5u4e00q6	376	18	a	a	DT
cord-014712-5u4e00q6	376	19	proection	proection	NN
cord-014712-5u4e00q6	376	20	of	of	IN
cord-014712-5u4e00q6	376	21	lung	lung	NN
cord-014712-5u4e00q6	376	22	lesions	lesion	NNS
cord-014712-5u4e00q6	376	23	.	.	.
cord-014712-5u4e00q6	377	1	The	the	DT
cord-014712-5u4e00q6	377	2	pus	pus	NN
cord-014712-5u4e00q6	377	3	was	be	VBD
cord-014712-5u4e00q6	377	4	obtained	obtain	VBN
cord-014712-5u4e00q6	377	5	during	during	IN
cord-014712-5u4e00q6	377	6	thoracentesis	thoracentesis	NN
cord-014712-5u4e00q6	377	7	.	.	.
cord-014712-5u4e00q6	378	1	Result	result	NN
cord-014712-5u4e00q6	378	2	of	of	IN
cord-014712-5u4e00q6	378	3	microbiological	microbiological	JJ
cord-014712-5u4e00q6	378	4	studies	study	NNS
cord-014712-5u4e00q6	378	5	:	:	:
cord-014712-5u4e00q6	378	6	Aspergillus	Aspergillus	NNP
cord-014712-5u4e00q6	378	7	fumigatus	fumigatus	NN
cord-014712-5u4e00q6	378	8	.	.	.
cord-014712-5u4e00q6	379	1	Drainage	drainage	NN
cord-014712-5u4e00q6	379	2	of	of	IN
cord-014712-5u4e00q6	379	3	abscesses	abscess	NNS
cord-014712-5u4e00q6	379	4	and	and	CC
cord-014712-5u4e00q6	379	5	intravenous	intravenous	JJ
cord-014712-5u4e00q6	379	6	Voriconazolum	Voriconazolum	NNP
cord-014712-5u4e00q6	379	7	led	lead	VBD
cord-014712-5u4e00q6	379	8	to	to	IN
cord-014712-5u4e00q6	379	9	dramatic	dramatic	JJ
cord-014712-5u4e00q6	379	10	clinical	clinical	JJ
cord-014712-5u4e00q6	379	11	improvement	improvement	NN
cord-014712-5u4e00q6	379	12	and	and	CC
cord-014712-5u4e00q6	379	13	normalization	normalization	NN
cord-014712-5u4e00q6	379	14	of	of	IN
cord-014712-5u4e00q6	379	15	blood	blood	NN
cord-014712-5u4e00q6	379	16	parameters	parameter	NNS
cord-014712-5u4e00q6	379	17	.	.	.
cord-014712-5u4e00q6	380	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	380	2	.	.	.
cord-014712-5u4e00q6	381	1	Features	feature	NNS
cord-014712-5u4e00q6	381	2	of	of	IN
cord-014712-5u4e00q6	381	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	381	4	case	case	NN
cord-014712-5u4e00q6	381	5	is	be	VBZ
cord-014712-5u4e00q6	381	6	spread	spread	VBN
cord-014712-5u4e00q6	381	7	lesions	lesion	NNS
cord-014712-5u4e00q6	381	8	of	of	IN
cord-014712-5u4e00q6	381	9	aspergillosis	aspergillosis	NN
cord-014712-5u4e00q6	381	10	with	with	IN
cord-014712-5u4e00q6	381	11	relatively	relatively	RB
cord-014712-5u4e00q6	381	12	slow	slow	JJ
cord-014712-5u4e00q6	381	13	progression	progression	NN
cord-014712-5u4e00q6	381	14	of	of	IN
cord-014712-5u4e00q6	381	15	infection	infection	NN
cord-014712-5u4e00q6	381	16	.	.	.
cord-014712-5u4e00q6	382	1	High	high	JJ
cord-014712-5u4e00q6	382	2	incidence	incidence	NN
cord-014712-5u4e00q6	382	3	of	of	IN
cord-014712-5u4e00q6	382	4	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	382	5	in	in	IN
cord-014712-5u4e00q6	382	6	Ukraine	Ukraine	NNP
cord-014712-5u4e00q6	382	7	leads	lead	VBZ
cord-014712-5u4e00q6	382	8	to	to	IN
cord-014712-5u4e00q6	382	9	a	a	DT
cord-014712-5u4e00q6	382	10	high	high	JJ
cord-014712-5u4e00q6	382	11	suspicion	suspicion	NN
cord-014712-5u4e00q6	382	12	regarding	regard	VBG
cord-014712-5u4e00q6	382	13	this	this	DT
cord-014712-5u4e00q6	382	14	infection	infection	NN
cord-014712-5u4e00q6	382	15	.	.	.
cord-014712-5u4e00q6	383	1	Diagnosis	diagnosis	NN
cord-014712-5u4e00q6	383	2	of	of	IN
cord-014712-5u4e00q6	383	3	TB	TB	NNP
cord-014712-5u4e00q6	383	4	is	be	VBZ
cord-014712-5u4e00q6	383	5	mainly	mainly	RB
cord-014712-5u4e00q6	383	6	based	base	VBN
cord-014712-5u4e00q6	383	7	on	on	IN
cord-014712-5u4e00q6	383	8	instrumental	instrumental	JJ
cord-014712-5u4e00q6	383	9	studies	study	NNS
cord-014712-5u4e00q6	383	10	.	.	.
cord-014712-5u4e00q6	384	1	Radiological	radiological	JJ
cord-014712-5u4e00q6	384	2	and	and	CC
cord-014712-5u4e00q6	384	3	histological	histological	JJ
cord-014712-5u4e00q6	384	4	differential	differential	JJ
cord-014712-5u4e00q6	384	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	384	6	between	between	IN
cord-014712-5u4e00q6	384	7	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	384	8	and	and	CC
cord-014712-5u4e00q6	384	9	other	other	JJ
cord-014712-5u4e00q6	384	10	infections	infection	NNS
cord-014712-5u4e00q6	384	11	with	with	IN
cord-014712-5u4e00q6	384	12	granulomas	granuloma	NNS
cord-014712-5u4e00q6	384	13	in	in	IN
cord-014712-5u4e00q6	384	14	CGD	CGD	NNP
cord-014712-5u4e00q6	384	15	is	be	VBZ
cord-014712-5u4e00q6	384	16	difficult	difficult	JJ
cord-014712-5u4e00q6	384	17	.	.	.
cord-014712-5u4e00q6	385	1	High	high	JJ
cord-014712-5u4e00q6	385	2	suspicion	suspicion	NN
cord-014712-5u4e00q6	385	3	of	of	IN
cord-014712-5u4e00q6	385	4	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	385	5	led	lead	VBD
cord-014712-5u4e00q6	385	6	to	to	IN
cord-014712-5u4e00q6	385	7	late	late	JJ
cord-014712-5u4e00q6	385	8	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	385	9	of	of	IN
cord-014712-5u4e00q6	385	10	aspergillosis	aspergillosis	NNP
cord-014712-5u4e00q6	385	11	.	.	.
cord-014712-5u4e00q6	386	1	Great	Great	NNP
cord-014712-5u4e00q6	386	2	North	North	NNP
cord-014712-5u4e00q6	386	3	Children	Children	NNPS
cord-014712-5u4e00q6	386	4	's	's	POS
cord-014712-5u4e00q6	386	5	Hospital	Hospital	NNP
cord-014712-5u4e00q6	386	6	,	,	,
cord-014712-5u4e00q6	386	7	Newcastle	Newcastle	NNP
cord-014712-5u4e00q6	386	8	upon	upon	IN
cord-014712-5u4e00q6	386	9	Tyne	Tyne	NNP
cord-014712-5u4e00q6	386	10	Hospitals	Hospitals	NNP
cord-014712-5u4e00q6	386	11	NHS	NHS	NNP
cord-014712-5u4e00q6	386	12	Foundation	Foundation	NNP
cord-014712-5u4e00q6	386	13	Trust	Trust	NNP
cord-014712-5u4e00q6	386	14	,	,	,
cord-014712-5u4e00q6	386	15	and	and	CC
cord-014712-5u4e00q6	386	16	Primary	Primary	NNP
cord-014712-5u4e00q6	386	17	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	386	18	Group	Group	NNP
cord-014712-5u4e00q6	386	19	,	,	,
cord-014712-5u4e00q6	386	20	Institute	Institute	NNP
cord-014712-5u4e00q6	386	21	of	of	IN
cord-014712-5u4e00q6	386	22	Cellular	Cellular	NNP
cord-014712-5u4e00q6	386	23	Medicine	Medicine	NNP
cord-014712-5u4e00q6	386	24	,	,	,
cord-014712-5u4e00q6	386	25	Newcastle	Newcastle	NNP
cord-014712-5u4e00q6	386	26	University	University	NNP
cord-014712-5u4e00q6	386	27	,	,	,
cord-014712-5u4e00q6	386	28	Newcastle	Newcastle	NNP
cord-014712-5u4e00q6	386	29	upon	upon	IN
cord-014712-5u4e00q6	386	30	Tyne	Tyne	NNP
cord-014712-5u4e00q6	386	31	,	,	,
cord-014712-5u4e00q6	386	32	UK	UK	NNP
cord-014712-5u4e00q6	387	1	Even	even	RB
cord-014712-5u4e00q6	387	2	following	follow	VBG
cord-014712-5u4e00q6	387	3	the	the	DT
cord-014712-5u4e00q6	387	4	introduction	introduction	NN
cord-014712-5u4e00q6	387	5	of	of	IN
cord-014712-5u4e00q6	387	6	biologic	biologic	JJ
cord-014712-5u4e00q6	387	7	disease	disease	NN
cord-014712-5u4e00q6	387	8	modifying	modify	VBG
cord-014712-5u4e00q6	387	9	antirheumatic	antirheumatic	JJ
cord-014712-5u4e00q6	387	10	drugs	drug	NNS
cord-014712-5u4e00q6	387	11	(	(	-LRB-
cord-014712-5u4e00q6	387	12	DMARDs	dmard	NNS
cord-014712-5u4e00q6	387	13	)	)	-RRB-
cord-014712-5u4e00q6	387	14	,	,	,
cord-014712-5u4e00q6	387	15	a	a	DT
cord-014712-5u4e00q6	387	16	small	small	JJ
cord-014712-5u4e00q6	387	17	number	number	NN
cord-014712-5u4e00q6	387	18	of	of	IN
cord-014712-5u4e00q6	387	19	children	child	NNS
cord-014712-5u4e00q6	387	20	suffering	suffer	VBG
cord-014712-5u4e00q6	387	21	from	from	IN
cord-014712-5u4e00q6	387	22	severe	severe	JJ
cord-014712-5u4e00q6	387	23	,	,	,
cord-014712-5u4e00q6	387	24	refractory	refractory	JJ
cord-014712-5u4e00q6	387	25	autoimmune	autoimmune	NN
cord-014712-5u4e00q6	387	26	(	(	-LRB-
cord-014712-5u4e00q6	387	27	AI	AI	NNP
cord-014712-5u4e00q6	387	28	)	)	-RRB-
cord-014712-5u4e00q6	387	29	,	,	,
cord-014712-5u4e00q6	387	30	rheumatic	rheumatic	JJ
cord-014712-5u4e00q6	387	31	and/or	and/or	CC
cord-014712-5u4e00q6	387	32	autoinflammatory	autoinflammatory	JJ
cord-014712-5u4e00q6	387	33	disorders	disorder	NNS
cord-014712-5u4e00q6	387	34	will	will	MD
cord-014712-5u4e00q6	387	35	not	not	RB
cord-014712-5u4e00q6	387	36	get	get	VB
cord-014712-5u4e00q6	387	37	into	into	IN
cord-014712-5u4e00q6	387	38	clinical	clinical	JJ
cord-014712-5u4e00q6	387	39	remission	remission	NN
cord-014712-5u4e00q6	387	40	(	(	-LRB-
cord-014712-5u4e00q6	387	41	CR	CR	NNP
cord-014712-5u4e00q6	387	42	)	)	-RRB-
cord-014712-5u4e00q6	387	43	and	and	CC
cord-014712-5u4e00q6	387	44	will	will	MD
cord-014712-5u4e00q6	387	45	potentially	potentially	RB
cord-014712-5u4e00q6	387	46	further	further	RB
cord-014712-5u4e00q6	387	47	suffer	suffer	VB
cord-014712-5u4e00q6	387	48	from	from	IN
cord-014712-5u4e00q6	387	49	multiple	multiple	JJ
cord-014712-5u4e00q6	387	50	side	side	NN
cord-014712-5u4e00q6	387	51	-	-	HYPH
cord-014712-5u4e00q6	387	52	effects	effect	NNS
cord-014712-5u4e00q6	387	53	of	of	IN
cord-014712-5u4e00q6	387	54	combined	combined	JJ
cord-014712-5u4e00q6	387	55	and	and	CC
cord-014712-5u4e00q6	387	56	long	long	JJ
cord-014712-5u4e00q6	387	57	-	-	HYPH
cord-014712-5u4e00q6	387	58	term	term	NN
cord-014712-5u4e00q6	387	59	immunosuppressive	immunosuppressive	JJ
cord-014712-5u4e00q6	387	60	and	and	CC
cord-014712-5u4e00q6	387	61	anti	anti	JJ
cord-014712-5u4e00q6	387	62	-	-	JJ
cord-014712-5u4e00q6	387	63	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	387	64	therapies	therapy	NNS
cord-014712-5u4e00q6	387	65	,	,	,
cord-014712-5u4e00q6	387	66	in	in	IN
cord-014712-5u4e00q6	387	67	particular	particular	JJ
cord-014712-5u4e00q6	387	68	severe	severe	JJ
cord-014712-5u4e00q6	387	69	infections	infection	NNS
cord-014712-5u4e00q6	387	70	(	(	-LRB-
cord-014712-5u4e00q6	387	71	Marodi	Marodi	NNP
cord-014712-5u4e00q6	387	72	L	L	NNP
cord-014712-5u4e00q6	387	73	,	,	,
cord-014712-5u4e00q6	387	74	Casanova	Casanova	NNP
cord-014712-5u4e00q6	387	75	JL	JL	NNP
cord-014712-5u4e00q6	387	76	.	.	.
cord-014712-5u4e00q6	388	1	JACI	JACI	NNP
cord-014712-5u4e00q6	388	2	2010	2010	CD
cord-014712-5u4e00q6	388	3	;	;	:
cord-014712-5u4e00q6	388	4	Abinun	Abinun	NNP
cord-014712-5u4e00q6	388	5	M.	M.	NNP
cord-014712-5u4e00q6	388	6	Ped	Ped	NNP
cord-014712-5u4e00q6	388	7	Health	Health	NNP
cord-014712-5u4e00q6	388	8	2010	2010	CD
cord-014712-5u4e00q6	388	9	)	)	-RRB-
cord-014712-5u4e00q6	388	10	.	.	.
cord-014712-5u4e00q6	389	1	Whilst	whilst	IN
cord-014712-5u4e00q6	389	2	autologous	autologous	JJ
cord-014712-5u4e00q6	389	3	T	t	NN
cord-014712-5u4e00q6	389	4	cell	cell	NN
cord-014712-5u4e00q6	389	5	depleted	deplete	VBD
cord-014712-5u4e00q6	389	6	HSCT	HSCT	NNP
cord-014712-5u4e00q6	389	7	following	follow	VBG
cord-014712-5u4e00q6	389	8	the	the	DT
cord-014712-5u4e00q6	389	9	immunosuppressive	immunosuppressive	JJ
cord-014712-5u4e00q6	389	10	conditioning	conditioning	NN
cord-014712-5u4e00q6	389	11	regimen	regimen	NN
cord-014712-5u4e00q6	389	12	achieved	achieve	VBD
cord-014712-5u4e00q6	389	13	complete	complete	JJ
cord-014712-5u4e00q6	389	14	clinical	clinical	JJ
cord-014712-5u4e00q6	389	15	remission	remission	NN
cord-014712-5u4e00q6	389	16	in	in	IN
cord-014712-5u4e00q6	389	17	majority	majority	NN
cord-014712-5u4e00q6	389	18	of	of	IN
cord-014712-5u4e00q6	389	19	children	child	NNS
cord-014712-5u4e00q6	389	20	with	with	IN
cord-014712-5u4e00q6	389	21	severe	severe	JJ
cord-014712-5u4e00q6	389	22	juvenile	juvenile	JJ
cord-014712-5u4e00q6	389	23	idiopathic	idiopathic	JJ
cord-014712-5u4e00q6	389	24	arthritis	arthritis	NN
cord-014712-5u4e00q6	389	25	(	(	-LRB-
cord-014712-5u4e00q6	389	26	JIA	JIA	NNP
cord-014712-5u4e00q6	389	27	)	)	-RRB-
cord-014712-5u4e00q6	389	28	(	(	-LRB-
cord-014712-5u4e00q6	389	29	de	de	FW
cord-014712-5u4e00q6	389	30	Kleer	Kleer	NNP
cord-014712-5u4e00q6	389	31	IM	IM	NNP
cord-014712-5u4e00q6	389	32	et	et	NNP
cord-014712-5u4e00q6	389	33	al	al	NNP
cord-014712-5u4e00q6	389	34	.	.	.
cord-014712-5u4e00q6	390	1	Ann	Ann	NNP
cord-014712-5u4e00q6	390	2	Rheum	Rheum	NNP
cord-014712-5u4e00q6	390	3	Dis	Dis	NNP
cord-014712-5u4e00q6	390	4	2004	2004	CD
cord-014712-5u4e00q6	390	5	)	)	-RRB-
cord-014712-5u4e00q6	390	6	,	,	,
cord-014712-5u4e00q6	390	7	infection	infection	NN
cord-014712-5u4e00q6	390	8	-	-	HYPH
cord-014712-5u4e00q6	390	9	related	relate	VBN
cord-014712-5u4e00q6	390	10	mortality	mortality	NN
cord-014712-5u4e00q6	390	11	remains	remain	VBZ
cord-014712-5u4e00q6	390	12	significant	significant	JJ
cord-014712-5u4e00q6	391	1	(	(	-LRB-
cord-014712-5u4e00q6	391	2	Abinun	Abinun	NNP
cord-014712-5u4e00q6	391	3	M	M	NNP
cord-014712-5u4e00q6	391	4	et	et	NNP
cord-014712-5u4e00q6	391	5	al	al	NNP
cord-014712-5u4e00q6	391	6	.	.	.
cord-014712-5u4e00q6	392	1	Mol	Mol	NNP
cord-014712-5u4e00q6	392	2	Immunol	Immunol	NNP
cord-014712-5u4e00q6	392	3	2009	2009	CD
cord-014712-5u4e00q6	392	4	)	)	-RRB-
cord-014712-5u4e00q6	392	5	.	.	.
cord-014712-5u4e00q6	393	1	Therefore	therefore	RB
cord-014712-5u4e00q6	393	2	,	,	,
cord-014712-5u4e00q6	393	3	following	follow	VBG
cord-014712-5u4e00q6	393	4	the	the	DT
cord-014712-5u4e00q6	393	5	success	success	NN
cord-014712-5u4e00q6	393	6	of	of	IN
cord-014712-5u4e00q6	393	7	allogeneic	allogeneic	NN
cord-014712-5u4e00q6	393	8	HSCT	HSCT	NNP
cord-014712-5u4e00q6	393	9	in	in	IN
cord-014712-5u4e00q6	393	10	treating	treat	VBG
cord-014712-5u4e00q6	393	11	6	6	CD
cord-014712-5u4e00q6	393	12	children	child	NNS
cord-014712-5u4e00q6	393	13	with	with	IN
cord-014712-5u4e00q6	393	14	immunodysregulation	immunodysregulation	NN
cord-014712-5u4e00q6	393	15	,	,	,
cord-014712-5u4e00q6	393	16	polyendocrinopathy	polyendocrinopathy	NNP
cord-014712-5u4e00q6	393	17	,	,	,
cord-014712-5u4e00q6	393	18	enteropathy	enteropathy	NNP
cord-014712-5u4e00q6	393	19	,	,	,
cord-014712-5u4e00q6	393	20	X	x	NN
cord-014712-5u4e00q6	393	21	-	-	HYPH
cord-014712-5u4e00q6	393	22	linked	link	VBN
cord-014712-5u4e00q6	393	23	(	(	-LRB-
cord-014712-5u4e00q6	393	24	IPEX	IPEX	NNP
cord-014712-5u4e00q6	393	25	)	)	-RRB-
cord-014712-5u4e00q6	393	26	syndrome	syndrome	NN
cord-014712-5u4e00q6	394	1	(	(	-LRB-
cord-014712-5u4e00q6	394	2	Nademi	Nademi	NNP
cord-014712-5u4e00q6	394	3	Z	Z	NNP
cord-014712-5u4e00q6	394	4	et	et	FW
cord-014712-5u4e00q6	394	5	al	al	NNP
cord-014712-5u4e00q6	394	6	.	.	.
cord-014712-5u4e00q6	395	1	BMT	BMT	NNP
cord-014712-5u4e00q6	395	2	2014	2014	CD
cord-014712-5u4e00q6	395	3	)	)	-RRB-
cord-014712-5u4e00q6	395	4	,	,	,
cord-014712-5u4e00q6	395	5	we	-PRON-	PRP
cord-014712-5u4e00q6	395	6	treated	treat	VBD
cord-014712-5u4e00q6	395	7	further	further	RB
cord-014712-5u4e00q6	395	8	10	10	CD
cord-014712-5u4e00q6	395	9	children	child	NNS
cord-014712-5u4e00q6	395	10	with	with	IN
cord-014712-5u4e00q6	395	11	different	different	JJ
cord-014712-5u4e00q6	395	12	severe	severe	JJ
cord-014712-5u4e00q6	395	13	AI	ai	NN
cord-014712-5u4e00q6	395	14	(	(	-LRB-
cord-014712-5u4e00q6	395	15	ALPS	ALPS	NNP
cord-014712-5u4e00q6	395	16	,	,	,
cord-014712-5u4e00q6	395	17	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	395	18	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	395	19	syndrome	syndrome	NNP
cord-014712-5u4e00q6	395	20	(	(	-LRB-
cord-014712-5u4e00q6	395	21	n	n	NN
cord-014712-5u4e00q6	395	22	=	=	SYM
cord-014712-5u4e00q6	395	23	3	3	CD
cord-014712-5u4e00q6	395	24	)	)	-RRB-
cord-014712-5u4e00q6	395	25	;	;	,
cord-014712-5u4e00q6	395	26	complex	complex	JJ
cord-014712-5u4e00q6	395	27	AI	AI	NNP
cord-014712-5u4e00q6	395	28	disorder	disorder	NN
cord-014712-5u4e00q6	395	29	(	(	-LRB-
cord-014712-5u4e00q6	395	30	n	n	NN
cord-014712-5u4e00q6	395	31	=	=	SYM
cord-014712-5u4e00q6	395	32	1	1	CD
cord-014712-5u4e00q6	395	33	)	)	-RRB-
cord-014712-5u4e00q6	395	34	)	)	-RRB-
cord-014712-5u4e00q6	395	35	,	,	,
cord-014712-5u4e00q6	395	36	rheumatological	rheumatological	JJ
cord-014712-5u4e00q6	395	37	(	(	-LRB-
cord-014712-5u4e00q6	395	38	jSLE	jsle	JJ
cord-014712-5u4e00q6	395	39	,	,	,
cord-014712-5u4e00q6	395	40	juvenile	juvenile	JJ
cord-014712-5u4e00q6	395	41	systemic	systemic	JJ
cord-014712-5u4e00q6	395	42	lupus	lupus	NN
cord-014712-5u4e00q6	395	43	erythematosus	erythematosus	NN
cord-014712-5u4e00q6	395	44	(	(	-LRB-
cord-014712-5u4e00q6	395	45	n	n	NN
cord-014712-5u4e00q6	395	46	=	=	SYM
cord-014712-5u4e00q6	395	47	1	1	CD
cord-014712-5u4e00q6	395	48	)	)	-RRB-
cord-014712-5u4e00q6	395	49	;	;	:
cord-014712-5u4e00q6	396	1	JIA	JIA	NNP
cord-014712-5u4e00q6	396	2	(	(	-LRB-
cord-014712-5u4e00q6	396	3	n	n	NN
cord-014712-5u4e00q6	396	4	=	=	SYM
cord-014712-5u4e00q6	396	5	2	2	CD
cord-014712-5u4e00q6	396	6	)	)	-RRB-
cord-014712-5u4e00q6	396	7	)	)	-RRB-
cord-014712-5u4e00q6	396	8	and	and	CC
cord-014712-5u4e00q6	396	9	autoinflammatory	autoinflammatory	JJ
cord-014712-5u4e00q6	396	10	disorders	disorder	NNS
cord-014712-5u4e00q6	396	11	(	(	-LRB-
cord-014712-5u4e00q6	396	12	MKD	MKD	NNP
cord-014712-5u4e00q6	396	13	,	,	,
cord-014712-5u4e00q6	396	14	mevalonic	mevalonic	NNP
cord-014712-5u4e00q6	396	15	kinase	kinase	NN
cord-014712-5u4e00q6	396	16	deficiency/	deficiency/	CD
cord-014712-5u4e00q6	396	17	TRAPS	trap	NNS
cord-014712-5u4e00q6	396	18	,	,	,
cord-014712-5u4e00q6	396	19	TNF	tnf	NN
cord-014712-5u4e00q6	396	20	-	-	HYPH
cord-014712-5u4e00q6	396	21	receptor	receptor	NN
cord-014712-5u4e00q6	396	22	associated	associate	VBD
cord-014712-5u4e00q6	396	23	periodic	periodic	JJ
cord-014712-5u4e00q6	396	24	fever	fever	NN
cord-014712-5u4e00q6	396	25	syndrome	syndrome	NN
cord-014712-5u4e00q6	396	26	(	(	-LRB-
cord-014712-5u4e00q6	396	27	n	n	NN
cord-014712-5u4e00q6	396	28	=	=	SYM
cord-014712-5u4e00q6	396	29	1	1	CD
cord-014712-5u4e00q6	396	30	)	)	-RRB-
cord-014712-5u4e00q6	396	31	;	;	:
cord-014712-5u4e00q6	396	32	EOC	EOC	NNP
cord-014712-5u4e00q6	396	33	,	,	,
cord-014712-5u4e00q6	396	34	early	early	JJ
cord-014712-5u4e00q6	396	35	onset	onset	NN
cord-014712-5u4e00q6	396	36	colitis	colitis	NN
cord-014712-5u4e00q6	396	37	(	(	-LRB-
cord-014712-5u4e00q6	396	38	n	n	NN
cord-014712-5u4e00q6	396	39	=	=	SYM
cord-014712-5u4e00q6	396	40	2	2	CD
cord-014712-5u4e00q6	396	41	)	)	-RRB-
cord-014712-5u4e00q6	396	42	)	)	-RRB-
cord-014712-5u4e00q6	396	43	.	.	.
cord-014712-5u4e00q6	397	1	Overall	overall	RB
cord-014712-5u4e00q6	397	2	,	,	,
cord-014712-5u4e00q6	397	3	14	14	CD
cord-014712-5u4e00q6	397	4	of	of	IN
cord-014712-5u4e00q6	397	5	the	the	DT
cord-014712-5u4e00q6	397	6	16	16	CD
cord-014712-5u4e00q6	397	7	children	child	NNS
cord-014712-5u4e00q6	397	8	are	be	VBP
cord-014712-5u4e00q6	397	9	alive	alive	JJ
cord-014712-5u4e00q6	397	10	(	(	-LRB-
cord-014712-5u4e00q6	397	11	follow	follow	VB
cord-014712-5u4e00q6	397	12	up	up	RP
cord-014712-5u4e00q6	397	13	1	1	CD
cord-014712-5u4e00q6	397	14	-	-	HYPH
cord-014712-5u4e00q6	397	15	11	11	CD
cord-014712-5u4e00q6	397	16	years	year	NNS
cord-014712-5u4e00q6	397	17	)	)	-RRB-
cord-014712-5u4e00q6	397	18	,	,	,
cord-014712-5u4e00q6	397	19	12	12	CD
cord-014712-5u4e00q6	397	20	in	in	IN
cord-014712-5u4e00q6	397	21	complete	complete	JJ
cord-014712-5u4e00q6	397	22	and	and	CC
cord-014712-5u4e00q6	397	23	1	1	LS
cord-014712-5u4e00q6	397	24	(	(	-LRB-
cord-014712-5u4e00q6	397	25	complex	complex	JJ
cord-014712-5u4e00q6	397	26	AI	AI	NNP
cord-014712-5u4e00q6	397	27	disorder	disorder	NN
cord-014712-5u4e00q6	397	28	)	)	-RRB-
cord-014712-5u4e00q6	397	29	in	in	IN
cord-014712-5u4e00q6	397	30	partial	partial	JJ
cord-014712-5u4e00q6	397	31	CR	cr	NN
cord-014712-5u4e00q6	397	32	,	,	,
cord-014712-5u4e00q6	397	33	original	original	JJ
cord-014712-5u4e00q6	397	34	disease	disease	NN
cord-014712-5u4e00q6	397	35	(	(	-LRB-
cord-014712-5u4e00q6	397	36	ALPS	ALPS	NNP
cord-014712-5u4e00q6	397	37	)	)	-RRB-
cord-014712-5u4e00q6	397	38	relapsed	relapse	VBD
cord-014712-5u4e00q6	397	39	in	in	IN
cord-014712-5u4e00q6	397	40	1	1	CD
cord-014712-5u4e00q6	397	41	,	,	,
cord-014712-5u4e00q6	397	42	and	and	CC
cord-014712-5u4e00q6	397	43	2	2	CD
cord-014712-5u4e00q6	397	44	children	child	NNS
cord-014712-5u4e00q6	397	45	died	die	VBD
cord-014712-5u4e00q6	397	46	(	(	-LRB-
cord-014712-5u4e00q6	397	47	1	1	CD
cord-014712-5u4e00q6	397	48	each	each	DT
cord-014712-5u4e00q6	397	49	with	with	IN
cord-014712-5u4e00q6	397	50	ALPS	ALPS	NNP
cord-014712-5u4e00q6	397	51	and	and	CC
cord-014712-5u4e00q6	397	52	EOC	EOC	NNP
cord-014712-5u4e00q6	397	53	)	)	-RRB-
cord-014712-5u4e00q6	397	54	.	.	.
cord-014712-5u4e00q6	398	1	2	2	CD
cord-014712-5u4e00q6	398	2	children	child	NNS
cord-014712-5u4e00q6	398	3	had	have	VBD
cord-014712-5u4e00q6	398	4	significant	significant	JJ
cord-014712-5u4e00q6	398	5	,	,	,
cord-014712-5u4e00q6	398	6	but	but	CC
cord-014712-5u4e00q6	398	7	transient	transient	JJ
cord-014712-5u4e00q6	398	8	acute	acute	NN
cord-014712-5u4e00q6	398	9	(	(	-LRB-
cord-014712-5u4e00q6	398	10	grade	grade	NN
cord-014712-5u4e00q6	398	11	3	3	CD
cord-014712-5u4e00q6	398	12	-	-	SYM
cord-014712-5u4e00q6	398	13	4	4	CD
cord-014712-5u4e00q6	398	14	)	)	-RRB-
cord-014712-5u4e00q6	398	15	and	and	CC
cord-014712-5u4e00q6	398	16	chronic	chronic	JJ
cord-014712-5u4e00q6	398	17	(	(	-LRB-
cord-014712-5u4e00q6	398	18	limited	limited	JJ
cord-014712-5u4e00q6	398	19	)	)	-RRB-
cord-014712-5u4e00q6	398	20	graft	graft	NN
cord-014712-5u4e00q6	398	21	vs.	vs.	FW
cord-014712-5u4e00q6	398	22	host	host	NN
cord-014712-5u4e00q6	398	23	disease	disease	NN
cord-014712-5u4e00q6	398	24	(	(	-LRB-
cord-014712-5u4e00q6	398	25	GvHD	GvHD	NNP
cord-014712-5u4e00q6	398	26	)	)	-RRB-
cord-014712-5u4e00q6	398	27	,	,	,
cord-014712-5u4e00q6	398	28	3	3	CD
cord-014712-5u4e00q6	398	29	experienced	experience	VBD
cord-014712-5u4e00q6	398	30	multiple	multiple	JJ
cord-014712-5u4e00q6	398	31	virus	virus	NN
cord-014712-5u4e00q6	398	32	reactivation(s	reactivation(s	NNP
cord-014712-5u4e00q6	398	33	)	)	-RRB-
cord-014712-5u4e00q6	398	34	,	,	,
cord-014712-5u4e00q6	398	35	and	and	CC
cord-014712-5u4e00q6	398	36	remarkably	remarkably	RB
cord-014712-5u4e00q6	398	37	we	-PRON-	PRP
cord-014712-5u4e00q6	398	38	saw	see	VBD
cord-014712-5u4e00q6	398	39	significant	significant	JJ
cord-014712-5u4e00q6	398	40	secondary	secondary	JJ
cord-014712-5u4e00q6	398	41	AI	ai	NN
cord-014712-5u4e00q6	398	42	diseases	disease	NNS
cord-014712-5u4e00q6	398	43	post	post	VBP
cord-014712-5u4e00q6	398	44	-	-	JJ
cord-014712-5u4e00q6	398	45	HSCT	HSCT	NNP
cord-014712-5u4e00q6	399	1	(	(	-LRB-
cord-014712-5u4e00q6	399	2	transient	transient	JJ
cord-014712-5u4e00q6	399	3	nephritic	nephritic	NNP
cord-014712-5u4e00q6	399	4	syndrome	syndrome	NN
cord-014712-5u4e00q6	399	5	(	(	-LRB-
cord-014712-5u4e00q6	399	6	n	n	NN
cord-014712-5u4e00q6	399	7	=	=	SYM
cord-014712-5u4e00q6	399	8	2	2	CD
cord-014712-5u4e00q6	399	9	)	)	-RRB-
cord-014712-5u4e00q6	399	10	and	and	CC
cord-014712-5u4e00q6	399	11	cytopaenias	cytopaenias	NNP
cord-014712-5u4e00q6	399	12	(	(	-LRB-
cord-014712-5u4e00q6	399	13	n	n	NN
cord-014712-5u4e00q6	399	14	=	=	SYM
cord-014712-5u4e00q6	399	15	1	1	CD
cord-014712-5u4e00q6	399	16	)	)	-RRB-
cord-014712-5u4e00q6	399	17	;	;	:
cord-014712-5u4e00q6	399	18	psoriasis	psoriasis	NN
cord-014712-5u4e00q6	399	19	,	,	,
cord-014712-5u4e00q6	399	20	n	n	NN
cord-014712-5u4e00q6	399	21	=	=	SYM
cord-014712-5u4e00q6	399	22	1	1	CD
cord-014712-5u4e00q6	399	23	;	;	,
cord-014712-5u4e00q6	399	24	and	and	CC
cord-014712-5u4e00q6	399	25	thyroid	thyroid	NN
cord-014712-5u4e00q6	399	26	disorders	disorder	NNS
cord-014712-5u4e00q6	399	27	(	(	-LRB-
cord-014712-5u4e00q6	399	28	Grave	Grave	NNP
cord-014712-5u4e00q6	399	29	's	's	POS
cord-014712-5u4e00q6	399	30	thyrotoxicosis	thyrotoxicosis	NN
cord-014712-5u4e00q6	399	31	and	and	CC
cord-014712-5u4e00q6	399	32	hypothyroidism	hypothyroidism	NN
cord-014712-5u4e00q6	399	33	)	)	-RRB-
cord-014712-5u4e00q6	399	34	,	,	.
cord-014712-5u4e00q6	400	1	n	n	NN
cord-014712-5u4e00q6	400	2	=	=	SYM
cord-014712-5u4e00q6	400	3	2	2	CD
cord-014712-5u4e00q6	400	4	)	)	-RRB-
cord-014712-5u4e00q6	400	5	.	.	.
cord-014712-5u4e00q6	401	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	401	2	data	datum	NNS
cord-014712-5u4e00q6	401	3	add	add	VBP
cord-014712-5u4e00q6	401	4	to	to	IN
cord-014712-5u4e00q6	401	5	the	the	DT
cord-014712-5u4e00q6	401	6	positive	positive	JJ
cord-014712-5u4e00q6	401	7	experience	experience	NN
cord-014712-5u4e00q6	401	8	and	and	CC
cord-014712-5u4e00q6	401	9	evidence	evidence	NN
cord-014712-5u4e00q6	401	10	acquired	acquire	VBN
cord-014712-5u4e00q6	401	11	over	over	IN
cord-014712-5u4e00q6	401	12	the	the	DT
cord-014712-5u4e00q6	401	13	last	last	JJ
cord-014712-5u4e00q6	401	14	10	10	CD
cord-014712-5u4e00q6	401	15	-	-	SYM
cord-014712-5u4e00q6	401	16	15	15	CD
cord-014712-5u4e00q6	401	17	years	year	NNS
cord-014712-5u4e00q6	401	18	(	(	-LRB-
cord-014712-5u4e00q6	401	19	Daikeler	Daikeler	NNP
cord-014712-5u4e00q6	401	20	T	T	NNP
cord-014712-5u4e00q6	401	21	et	et	FW
cord-014712-5u4e00q6	401	22	al	al	NNP
cord-014712-5u4e00q6	401	23	.	.	.
cord-014712-5u4e00q6	402	1	BMT	BMT	NNP
cord-014712-5u4e00q6	402	2	2009	2009	CD
cord-014712-5u4e00q6	402	3	;	;	:
cord-014712-5u4e00q6	402	4	Snowden	Snowden	NNP
cord-014712-5u4e00q6	402	5	JA	JA	NNP
cord-014712-5u4e00q6	402	6	et	et	NNP
cord-014712-5u4e00q6	402	7	al	al	NNP
cord-014712-5u4e00q6	402	8	.	.	.
cord-014712-5u4e00q6	403	1	BJH	BJH	NNP
cord-014712-5u4e00q6	403	2	2012	2012	CD
cord-014712-5u4e00q6	403	3	)	)	-RRB-
cord-014712-5u4e00q6	403	4	to	to	TO
cord-014712-5u4e00q6	403	5	propose	propose	VB
cord-014712-5u4e00q6	403	6	the	the	DT
cord-014712-5u4e00q6	403	7	allogeneic	allogeneic	JJ
cord-014712-5u4e00q6	403	8	HSCT	HSCT	NNP
cord-014712-5u4e00q6	403	9	as	as	IN
cord-014712-5u4e00q6	403	10	a	a	DT
cord-014712-5u4e00q6	403	11	viable	viable	JJ
cord-014712-5u4e00q6	403	12	treatment	treatment	NN
cord-014712-5u4e00q6	403	13	option	option	NN
cord-014712-5u4e00q6	403	14	for	for	IN
cord-014712-5u4e00q6	403	15	the	the	DT
cord-014712-5u4e00q6	403	16	small	small	JJ
cord-014712-5u4e00q6	403	17	group	group	NN
cord-014712-5u4e00q6	403	18	of	of	IN
cord-014712-5u4e00q6	403	19	children	child	NNS
cord-014712-5u4e00q6	403	20	suffering	suffer	VBG
cord-014712-5u4e00q6	403	21	from	from	IN
cord-014712-5u4e00q6	403	22	severe	severe	JJ
cord-014712-5u4e00q6	403	23	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	403	24	disorders	disorder	NNS
cord-014712-5u4e00q6	403	25	.	.	.
cord-014712-5u4e00q6	404	1	The	the	DT
cord-014712-5u4e00q6	404	2	Wiskott	Wiskott	NNP
cord-014712-5u4e00q6	404	3	-	-	HYPH
cord-014712-5u4e00q6	404	4	Aldrich	Aldrich	NNP
cord-014712-5u4e00q6	404	5	syndrome	syndrome	NN
cord-014712-5u4e00q6	404	6	(	(	-LRB-
cord-014712-5u4e00q6	404	7	WAS	be	VBD
cord-014712-5u4e00q6	404	8	)	)	-RRB-
cord-014712-5u4e00q6	404	9	is	be	VBZ
cord-014712-5u4e00q6	404	10	an	an	DT
cord-014712-5u4e00q6	404	11	X	x	NN
cord-014712-5u4e00q6	404	12	-	-	HYPH
cord-014712-5u4e00q6	404	13	linked	link	VBN
cord-014712-5u4e00q6	404	14	primary	primary	JJ
cord-014712-5u4e00q6	404	15	immune	immune	JJ
cord-014712-5u4e00q6	404	16	deficiency	deficiency	NN
cord-014712-5u4e00q6	404	17	disorder	disorder	NN
cord-014712-5u4e00q6	404	18	characterized	characterize	VBN
cord-014712-5u4e00q6	404	19	by	by	IN
cord-014712-5u4e00q6	404	20	thrombocytopenia	thrombocytopenia	NN
cord-014712-5u4e00q6	404	21	,	,	,
cord-014712-5u4e00q6	404	22	microthrombocytopenia	microthrombocytopenia	NNP
cord-014712-5u4e00q6	404	23	,	,	,
cord-014712-5u4e00q6	404	24	recurrent	recurrent	JJ
cord-014712-5u4e00q6	404	25	,	,	,
cord-014712-5u4e00q6	404	26	mostly	mostly	RB
cord-014712-5u4e00q6	404	27	respiratory	respiratory	JJ
cord-014712-5u4e00q6	404	28	tract	tract	NN
cord-014712-5u4e00q6	404	29	infections	infection	NNS
cord-014712-5u4e00q6	404	30	,	,	,
cord-014712-5u4e00q6	404	31	eczema	eczema	NN
cord-014712-5u4e00q6	404	32	and	and	CC
cord-014712-5u4e00q6	404	33	increased	increase	VBN
cord-014712-5u4e00q6	404	34	risk	risk	NN
cord-014712-5u4e00q6	404	35	of	of	IN
cord-014712-5u4e00q6	404	36	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	404	37	disorders	disorder	NNS
cord-014712-5u4e00q6	404	38	and	and	CC
cord-014712-5u4e00q6	404	39	malignancies	malignancy	NNS
cord-014712-5u4e00q6	404	40	.	.	.
cord-014712-5u4e00q6	405	1	WAS	be	VBD
cord-014712-5u4e00q6	405	2	is	be	VBZ
cord-014712-5u4e00q6	405	3	caused	cause	VBN
cord-014712-5u4e00q6	405	4	by	by	IN
cord-014712-5u4e00q6	405	5	mutations	mutation	NNS
cord-014712-5u4e00q6	405	6	in	in	IN
cord-014712-5u4e00q6	405	7	the	the	DT
cord-014712-5u4e00q6	405	8	WASP	WASP	NNP
cord-014712-5u4e00q6	405	9	gene	gene	NN
cord-014712-5u4e00q6	405	10	which	which	WDT
cord-014712-5u4e00q6	405	11	encodes	encode	VBZ
cord-014712-5u4e00q6	405	12	WASP	WASP	NNP
cord-014712-5u4e00q6	405	13	,	,	,
cord-014712-5u4e00q6	405	14	a	a	DT
cord-014712-5u4e00q6	405	15	502-amino	502-amino	CD
cord-014712-5u4e00q6	405	16	acid	acid	NN
cord-014712-5u4e00q6	405	17	protein	protein	NN
cord-014712-5u4e00q6	405	18	.	.	.
cord-014712-5u4e00q6	406	1	WASP	WASP	NNP
cord-014712-5u4e00q6	406	2	plays	play	VBZ
cord-014712-5u4e00q6	406	3	a	a	DT
cord-014712-5u4e00q6	406	4	critical	critical	JJ
cord-014712-5u4e00q6	406	5	role	role	NN
cord-014712-5u4e00q6	406	6	in	in	IN
cord-014712-5u4e00q6	406	7	actin	actin	NN
cord-014712-5u4e00q6	406	8	cytoskeleton	cytoskeleton	NN
cord-014712-5u4e00q6	406	9	organization	organization	NN
cord-014712-5u4e00q6	406	10	,	,	,
cord-014712-5u4e00q6	406	11	signalling	signal	VBG
cord-014712-5u4e00q6	406	12	and	and	CC
cord-014712-5u4e00q6	406	13	different	different	JJ
cord-014712-5u4e00q6	406	14	functions	function	NNS
cord-014712-5u4e00q6	406	15	of	of	IN
cord-014712-5u4e00q6	406	16	immune	immune	JJ
cord-014712-5u4e00q6	406	17	cells	cell	NNS
cord-014712-5u4e00q6	406	18	.	.	.
cord-014712-5u4e00q6	407	1	We	-PRON-	PRP
cord-014712-5u4e00q6	407	2	present	present	VBP
cord-014712-5u4e00q6	407	3	here	here	RB
cord-014712-5u4e00q6	407	4	the	the	DT
cord-014712-5u4e00q6	407	5	results	result	NNS
cord-014712-5u4e00q6	407	6	of	of	IN
cord-014712-5u4e00q6	407	7	genetic	genetic	JJ
cord-014712-5u4e00q6	407	8	analysis	analysis	NN
cord-014712-5u4e00q6	407	9	of	of	IN
cord-014712-5u4e00q6	407	10	patients	patient	NNS
cord-014712-5u4e00q6	407	11	with	with	IN
cord-014712-5u4e00q6	407	12	WAS	be	VBD
cord-014712-5u4e00q6	407	13	from	from	IN
cord-014712-5u4e00q6	407	14	eleven	eleven	CD
cord-014712-5u4e00q6	407	15	Eastern	eastern	JJ
cord-014712-5u4e00q6	407	16	and	and	CC
cord-014712-5u4e00q6	407	17	Central	central	JJ
cord-014712-5u4e00q6	407	18	European	european	JJ
cord-014712-5u4e00q6	407	19	(	(	-LRB-
cord-014712-5u4e00q6	407	20	ECE	ECE	NNP
cord-014712-5u4e00q6	407	21	)	)	-RRB-
cord-014712-5u4e00q6	407	22	countries	country	NNS
cord-014712-5u4e00q6	407	23	,	,	,
cord-014712-5u4e00q6	407	24	Turkey	Turkey	NNP
cord-014712-5u4e00q6	407	25	,	,	,
cord-014712-5u4e00q6	407	26	Iran	Iran	NNP
cord-014712-5u4e00q6	407	27	and	and	CC
cord-014712-5u4e00q6	407	28	Azerbaijan	Azerbaijan	NNP
cord-014712-5u4e00q6	407	29	.	.	.
cord-014712-5u4e00q6	408	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	408	2	and	and	CC
cord-014712-5u4e00q6	408	3	laboratory	laboratory	NN
cord-014712-5u4e00q6	408	4	information	information	NN
cord-014712-5u4e00q6	408	5	of	of	IN
cord-014712-5u4e00q6	408	6	116	116	CD
cord-014712-5u4e00q6	408	7	affected	affect	VBN
cord-014712-5u4e00q6	408	8	males	male	NNS
cord-014712-5u4e00q6	408	9	and	and	CC
cord-014712-5u4e00q6	408	10	63	63	CD
cord-014712-5u4e00q6	408	11	carrier	carrier	NN
cord-014712-5u4e00q6	408	12	females	female	NNS
cord-014712-5u4e00q6	408	13	from	from	IN
cord-014712-5u4e00q6	408	14	106	106	CD
cord-014712-5u4e00q6	408	15	WAS	be	VBD
cord-014712-5u4e00q6	408	16	families	family	NNS
cord-014712-5u4e00q6	408	17	were	be	VBD
cord-014712-5u4e00q6	408	18	collected	collect	VBN
cord-014712-5u4e00q6	408	19	.	.	.
cord-014712-5u4e00q6	409	1	The	the	DT
cord-014712-5u4e00q6	409	2	WASP	WASP	NNP
cord-014712-5u4e00q6	409	3	gene	gene	NN
cord-014712-5u4e00q6	409	4	was	be	VBD
cord-014712-5u4e00q6	409	5	sequenced	sequence	VBN
cord-014712-5u4e00q6	409	6	from	from	IN
cord-014712-5u4e00q6	409	7	genomic	genomic	JJ
cord-014712-5u4e00q6	409	8	DNA	dna	NN
cord-014712-5u4e00q6	409	9	of	of	IN
cord-014712-5u4e00q6	409	10	patients	patient	NNS
cord-014712-5u4e00q6	409	11	with	with	IN
cord-014712-5u4e00q6	409	12	WAS	be	VBD
cord-014712-5u4e00q6	409	13	,	,	,
cord-014712-5u4e00q6	409	14	as	as	RB
cord-014712-5u4e00q6	409	15	well	well	RB
cord-014712-5u4e00q6	409	16	as	as	IN
cord-014712-5u4e00q6	409	17	their	-PRON-	PRP$
cord-014712-5u4e00q6	409	18	family	family	NN
cord-014712-5u4e00q6	409	19	members	member	NNS
cord-014712-5u4e00q6	409	20	to	to	TO
cord-014712-5u4e00q6	409	21	identify	identify	VB
cord-014712-5u4e00q6	409	22	carriers	carrier	NNS
cord-014712-5u4e00q6	409	23	.	.	.
cord-014712-5u4e00q6	410	1	In	in	IN
cord-014712-5u4e00q6	410	2	this	this	DT
cord-014712-5u4e00q6	410	3	large	large	JJ
cord-014712-5u4e00q6	410	4	cohort	cohort	NN
cord-014712-5u4e00q6	410	5	,	,	,
cord-014712-5u4e00q6	410	6	we	-PRON-	PRP
cord-014712-5u4e00q6	410	7	identified	identify	VBD
cord-014712-5u4e00q6	410	8	77	77	CD
cord-014712-5u4e00q6	410	9	unique	unique	JJ
cord-014712-5u4e00q6	410	10	mutations	mutation	NNS
cord-014712-5u4e00q6	410	11	including	include	VBG
cord-014712-5u4e00q6	410	12	23	23	CD
cord-014712-5u4e00q6	410	13	novel	novel	JJ
cord-014712-5u4e00q6	410	14	sequence	sequence	NN
cord-014712-5u4e00q6	410	15	variants	variant	NNS
cord-014712-5u4e00q6	410	16	.	.	.
cord-014712-5u4e00q6	411	1	The	the	DT
cord-014712-5u4e00q6	411	2	mutations	mutation	NNS
cord-014712-5u4e00q6	411	3	were	be	VBD
cord-014712-5u4e00q6	411	4	scattered	scatter	VBN
cord-014712-5u4e00q6	411	5	throughout	throughout	IN
cord-014712-5u4e00q6	411	6	the	the	DT
cord-014712-5u4e00q6	411	7	WASP	WASP	NNP
cord-014712-5u4e00q6	411	8	gene	gene	NN
cord-014712-5u4e00q6	411	9	and	and	CC
cord-014712-5u4e00q6	411	10	included	include	VBD
cord-014712-5u4e00q6	411	11	single	single	JJ
cord-014712-5u4e00q6	411	12	base	base	NN
cord-014712-5u4e00q6	411	13	pair	pair	NN
cord-014712-5u4e00q6	411	14	changes	change	NNS
cord-014712-5u4e00q6	411	15	(	(	-LRB-
cord-014712-5u4e00q6	411	16	20	20	CD
cord-014712-5u4e00q6	411	17	missense	missense	NN
cord-014712-5u4e00q6	411	18	and	and	CC
cord-014712-5u4e00q6	411	19	14	14	CD
cord-014712-5u4e00q6	411	20	nonsense	nonsense	NN
cord-014712-5u4e00q6	411	21	mutations	mutation	NNS
cord-014712-5u4e00q6	411	22	)	)	-RRB-
cord-014712-5u4e00q6	411	23	,	,	,
cord-014712-5u4e00q6	411	24	8	8	CD
cord-014712-5u4e00q6	411	25	small	small	JJ
cord-014712-5u4e00q6	411	26	insertions	insertion	NNS
cord-014712-5u4e00q6	411	27	,	,	,
cord-014712-5u4e00q6	411	28	22	22	CD
cord-014712-5u4e00q6	411	29	deletions	deletion	NNS
cord-014712-5u4e00q6	411	30	,	,	,
cord-014712-5u4e00q6	411	31	and	and	CC
cord-014712-5u4e00q6	411	32	12	12	CD
cord-014712-5u4e00q6	411	33	splice	splice	NN
cord-014712-5u4e00q6	411	34	site	site	NN
cord-014712-5u4e00q6	411	35	defects	defect	NNS
cord-014712-5u4e00q6	411	36	.	.	.
cord-014712-5u4e00q6	412	1	This	this	DT
cord-014712-5u4e00q6	412	2	study	study	NN
cord-014712-5u4e00q6	412	3	was	be	VBD
cord-014712-5u4e00q6	412	4	financially	financially	RB
cord-014712-5u4e00q6	412	5	supported	support	VBN
cord-014712-5u4e00q6	412	6	by	by	IN
cord-014712-5u4e00q6	412	7	the	the	DT
cord-014712-5u4e00q6	412	8	TÜBİTAK	TÜBİTAK	NNP
cord-014712-5u4e00q6	412	9	Project	Project	NNP
cord-014712-5u4e00q6	412	10	110S252	110s252	CD
cord-014712-5u4e00q6	412	11	and	and	CC
cord-014712-5u4e00q6	412	12	BAP	BAP	NNP
cord-014712-5u4e00q6	412	13	Project	Project	NNP
cord-014712-5u4e00q6	413	1	TDA-2013	tda-2013	NN
cord-014712-5u4e00q6	413	2	-	-	HYPH
cord-014712-5u4e00q6	413	3	4075	4075	CD
cord-014712-5u4e00q6	413	4	.	.	.
cord-014712-5u4e00q6	414	1	Background	background	NN
cord-014712-5u4e00q6	414	2	:	:	:
cord-014712-5u4e00q6	415	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	415	2	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	415	3	disease	disease	NN
cord-014712-5u4e00q6	415	4	(	(	-LRB-
cord-014712-5u4e00q6	415	5	CGD	CGD	NNP
cord-014712-5u4e00q6	415	6	)	)	-RRB-
cord-014712-5u4e00q6	415	7	is	be	VBZ
cord-014712-5u4e00q6	415	8	a	a	DT
cord-014712-5u4e00q6	415	9	rare	rare	JJ
cord-014712-5u4e00q6	415	10	primary	primary	JJ
cord-014712-5u4e00q6	415	11	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	415	12	disorder	disorder	NN
cord-014712-5u4e00q6	415	13	of	of	IN
cord-014712-5u4e00q6	415	14	phagocytes	phagocyte	NNS
cord-014712-5u4e00q6	415	15	.	.	.
cord-014712-5u4e00q6	416	1	resulting	result	VBG
cord-014712-5u4e00q6	416	2	in	in	IN
cord-014712-5u4e00q6	416	3	impaired	impaired	JJ
cord-014712-5u4e00q6	416	4	killing	killing	NN
cord-014712-5u4e00q6	416	5	of	of	IN
cord-014712-5u4e00q6	416	6	bacteria	bacteria	NNS
cord-014712-5u4e00q6	416	7	and	and	CC
cord-014712-5u4e00q6	416	8	fungi	fungus	NNS
cord-014712-5u4e00q6	416	9	.	.	.
cord-014712-5u4e00q6	417	1	A	a	DT
cord-014712-5u4e00q6	417	2	mutation	mutation	NN
cord-014712-5u4e00q6	417	3	in	in	IN
cord-014712-5u4e00q6	417	4	one	one	CD
cord-014712-5u4e00q6	417	5	of	of	IN
cord-014712-5u4e00q6	417	6	the	the	DT
cord-014712-5u4e00q6	417	7	four	four	CD
cord-014712-5u4e00q6	417	8	genes	gene	NNS
cord-014712-5u4e00q6	417	9	encoding	encode	VBG
cord-014712-5u4e00q6	417	10	the	the	DT
cord-014712-5u4e00q6	417	11	components	component	NNS
cord-014712-5u4e00q6	417	12	p22	p22	NNP
cord-014712-5u4e00q6	417	13	phox	phox	NNP
cord-014712-5u4e00q6	417	14	,	,	,
cord-014712-5u4e00q6	417	15	p47	p47	CD
cord-014712-5u4e00q6	417	16	phox	phox	NNP
cord-014712-5u4e00q6	417	17	,	,	,
cord-014712-5u4e00q6	417	18	p67	p67	NNP
cord-014712-5u4e00q6	417	19	phox	phox	NNP
cord-014712-5u4e00q6	417	20	and	and	CC
cord-014712-5u4e00q6	417	21	p40	p40	CD
cord-014712-5u4e00q6	417	22	phox	phox	NNS
cord-014712-5u4e00q6	417	23	of	of	IN
cord-014712-5u4e00q6	417	24	the	the	DT
cord-014712-5u4e00q6	417	25	leukocyte	leukocyte	NN
cord-014712-5u4e00q6	418	1	NADPH	NADPH	NNP
cord-014712-5u4e00q6	418	2	oxidase	oxidase	NN
cord-014712-5u4e00q6	418	3	leads	lead	VBZ
cord-014712-5u4e00q6	418	4	to	to	IN
cord-014712-5u4e00q6	418	5	autosomal	autosomal	JJ
cord-014712-5u4e00q6	418	6	recessive	recessive	JJ
cord-014712-5u4e00q6	418	7	(	(	-LRB-
cord-014712-5u4e00q6	418	8	AR)-CGD	ar)-cgd	NN
cord-014712-5u4e00q6	418	9	.	.	.
cord-014712-5u4e00q6	419	1	A	a	DT
cord-014712-5u4e00q6	419	2	mutation	mutation	NN
cord-014712-5u4e00q6	419	3	in	in	IN
cord-014712-5u4e00q6	419	4	the	the	DT
cord-014712-5u4e00q6	419	5	CYBB	CYBB	NNP
cord-014712-5u4e00q6	419	6	gene	gene	NN
cord-014712-5u4e00q6	419	7	encoding	encoding	NN
cord-014712-5u4e00q6	419	8	gp91	gp91	NN
cord-014712-5u4e00q6	419	9	phox	phox	NNP
cord-014712-5u4e00q6	419	10	leads	lead	VBZ
cord-014712-5u4e00q6	419	11	to	to	IN
cord-014712-5u4e00q6	419	12	X	x	NN
cord-014712-5u4e00q6	419	13	-	-	HYPH
cord-014712-5u4e00q6	419	14	linked	link	VBN
cord-014712-5u4e00q6	419	15	recessive	recessive	JJ
cord-014712-5u4e00q6	419	16	CGD	CGD	NNP
cord-014712-5u4e00q6	419	17	.	.	.
cord-014712-5u4e00q6	420	1	Methods	method	NNS
cord-014712-5u4e00q6	420	2	:	:	:
cord-014712-5u4e00q6	421	1	We	-PRON-	PRP
cord-014712-5u4e00q6	421	2	report	report	VBP
cord-014712-5u4e00q6	421	3	here	here	RB
cord-014712-5u4e00q6	421	4	the	the	DT
cord-014712-5u4e00q6	421	5	results	result	NNS
cord-014712-5u4e00q6	421	6	of	of	IN
cord-014712-5u4e00q6	421	7	genetically	genetically	RB
cord-014712-5u4e00q6	421	8	and	and	CC
cord-014712-5u4e00q6	421	9	functionally	functionally	RB
cord-014712-5u4e00q6	421	10	characterized	characterize	VBN
cord-014712-5u4e00q6	421	11	100	100	CD
cord-014712-5u4e00q6	421	12	patients	patient	NNS
cord-014712-5u4e00q6	421	13	with	with	IN
cord-014712-5u4e00q6	421	14	CGD	CGD	NNP
cord-014712-5u4e00q6	421	15	from	from	IN
cord-014712-5u4e00q6	421	16	83	83	CD
cord-014712-5u4e00q6	421	17	Turkish	turkish	JJ
cord-014712-5u4e00q6	421	18	families	family	NNS
cord-014712-5u4e00q6	421	19	in	in	IN
cord-014712-5u4e00q6	421	20	Turkey	Turkey	NNP
cord-014712-5u4e00q6	421	21	.	.	.
cord-014712-5u4e00q6	422	1	Results	result	NNS
cord-014712-5u4e00q6	422	2	:	:	:
cord-014712-5u4e00q6	423	1	Most	Most	JJS
cord-014712-5u4e00q6	423	2	of	of	IN
cord-014712-5u4e00q6	423	3	the	the	DT
cord-014712-5u4e00q6	423	4	families	family	NNS
cord-014712-5u4e00q6	423	5	(	(	-LRB-
cord-014712-5u4e00q6	423	6	62	62	CD
cord-014712-5u4e00q6	423	7	%	%	NN
cord-014712-5u4e00q6	423	8	)	)	-RRB-
cord-014712-5u4e00q6	423	9	have	have	VBP
cord-014712-5u4e00q6	423	10	an	an	DT
cord-014712-5u4e00q6	423	11	AR	AR	NNP
cord-014712-5u4e00q6	423	12	genotype	genotype	NN
cord-014712-5u4e00q6	423	13	(	(	-LRB-
cord-014712-5u4e00q6	423	14	%	%	NN
cord-014712-5u4e00q6	423	15	28	28	CD
cord-014712-5u4e00q6	423	16	p22	p22	NN
cord-014712-5u4e00q6	423	17	phox	phox	NNP
cord-014712-5u4e00q6	423	18	,	,	,
cord-014712-5u4e00q6	423	19	%	%	NN
cord-014712-5u4e00q6	423	20	20	20	CD
cord-014712-5u4e00q6	423	21	p47	p47	CD
cord-014712-5u4e00q6	423	22	phox	phox	NN
cord-014712-5u4e00q6	423	23	and	and	CC
cord-014712-5u4e00q6	423	24	%	%	NN
cord-014712-5u4e00q6	423	25	14	14	CD
cord-014712-5u4e00q6	423	26	p67	p67	NNP
cord-014712-5u4e00q6	423	27	phox	phox	NNP
cord-014712-5u4e00q6	423	28	)	)	-RRB-
cord-014712-5u4e00q6	423	29	and	and	CC
cord-014712-5u4e00q6	423	30	38	38	CD
cord-014712-5u4e00q6	423	31	%	%	NN
cord-014712-5u4e00q6	423	32	have	have	VBP
cord-014712-5u4e00q6	423	33	an	an	DT
cord-014712-5u4e00q6	423	34	X	x	NN
cord-014712-5u4e00q6	423	35	-	-	HYPH
cord-014712-5u4e00q6	423	36	linked	link	VBN
cord-014712-5u4e00q6	423	37	genotype	genotype	NN
cord-014712-5u4e00q6	423	38	.	.	.
cord-014712-5u4e00q6	424	1	Patients	patient	NNS
cord-014712-5u4e00q6	424	2	with	with	IN
cord-014712-5u4e00q6	424	3	A22	A22	NNP
cord-014712-5u4e00q6	424	4	0	0	CD
cord-014712-5u4e00q6	424	5	,	,	,
cord-014712-5u4e00q6	424	6	A67	A67	NNP
cord-014712-5u4e00q6	424	7	0	0	CD
cord-014712-5u4e00q6	424	8	and	and	CC
cord-014712-5u4e00q6	424	9	X91	x91	JJ
cord-014712-5u4e00q6	424	10	0	0	CD
cord-014712-5u4e00q6	424	11	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	424	12	with	with	IN
cord-014712-5u4e00q6	424	13	oxidase	oxidase	NN
cord-014712-5u4e00q6	424	14	null	null	NN
cord-014712-5u4e00q6	424	15	activity	activity	NN
cord-014712-5u4e00q6	425	1	(	(	-LRB-
cord-014712-5u4e00q6	425	2	DHR	DHR	NNP
cord-014712-5u4e00q6	425	3	stimulation	stimulation	NN
cord-014712-5u4e00q6	425	4	index	index	NN
cord-014712-5u4e00q6	425	5	of	of	IN
cord-014712-5u4e00q6	425	6	≤1.5	≤1.5	NNP
cord-014712-5u4e00q6	425	7	)	)	-RRB-
cord-014712-5u4e00q6	425	8	were	be	VBD
cord-014712-5u4e00q6	425	9	found	find	VBN
cord-014712-5u4e00q6	425	10	in	in	IN
cord-014712-5u4e00q6	425	11	73	73	CD
cord-014712-5u4e00q6	425	12	patients	patient	NNS
cord-014712-5u4e00q6	425	13	.	.	.
cord-014712-5u4e00q6	426	1	However	however	RB
cord-014712-5u4e00q6	426	2	,	,	,
cord-014712-5u4e00q6	426	3	in	in	IN
cord-014712-5u4e00q6	426	4	p47	p47	CD
cord-014712-5u4e00q6	426	5	phox	phox	NN
cord-014712-5u4e00q6	426	6	deficient	deficient	JJ
cord-014712-5u4e00q6	426	7	cases	case	NNS
cord-014712-5u4e00q6	426	8	and	and	CC
cord-014712-5u4e00q6	426	9	in	in	IN
cord-014712-5u4e00q6	426	10	7	7	CD
cord-014712-5u4e00q6	426	11	other	other	JJ
cord-014712-5u4e00q6	426	12	AR	AR	NNP
cord-014712-5u4e00q6	426	13	cases	case	NNS
cord-014712-5u4e00q6	426	14	with	with	IN
cord-014712-5u4e00q6	426	15	high	high	JJ
cord-014712-5u4e00q6	426	16	residual	residual	JJ
cord-014712-5u4e00q6	426	17	oxidase	oxidase	NN
cord-014712-5u4e00q6	426	18	activity	activity	NN
cord-014712-5u4e00q6	426	19	(	(	-LRB-
cord-014712-5u4e00q6	426	20	DHR	DHR	NNP
cord-014712-5u4e00q6	426	21	stimulation	stimulation	NN
cord-014712-5u4e00q6	426	22	index	index	NN
cord-014712-5u4e00q6	426	23	≥3	≥3	NNP
cord-014712-5u4e00q6	426	24	)	)	-RRB-
cord-014712-5u4e00q6	426	25	were	be	VBD
cord-014712-5u4e00q6	426	26	found	find	VBN
cord-014712-5u4e00q6	426	27	in	in	IN
cord-014712-5u4e00q6	426	28	27	27	CD
cord-014712-5u4e00q6	426	29	patients	patient	NNS
cord-014712-5u4e00q6	426	30	.	.	.
cord-014712-5u4e00q6	427	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	427	2	:	:	:
cord-014712-5u4e00q6	428	1	Residual	residual	JJ
cord-014712-5u4e00q6	428	2	oxidase	oxidase	NN
cord-014712-5u4e00q6	428	3	activity	activity	NN
cord-014712-5u4e00q6	428	4	is	be	VBZ
cord-014712-5u4e00q6	428	5	similarly	similarly	RB
cord-014712-5u4e00q6	428	6	lack	lack	JJ
cord-014712-5u4e00q6	428	7	in	in	IN
cord-014712-5u4e00q6	428	8	the	the	DT
cord-014712-5u4e00q6	428	9	X91	X91	NNP
cord-014712-5u4e00q6	428	10	0	0	NFP
cord-014712-5u4e00q6	428	11	,	,	,
cord-014712-5u4e00q6	428	12	A22	A22	NNP
cord-014712-5u4e00q6	428	13	0	0	NFP
cord-014712-5u4e00q6	428	14	and	and	CC
cord-014712-5u4e00q6	428	15	A67	a67	NN
cord-014712-5u4e00q6	428	16	0	0	CD
cord-014712-5u4e00q6	428	17	phenotype	phenotype	NN
cord-014712-5u4e00q6	428	18	except	except	IN
cord-014712-5u4e00q6	428	19	7	7	CD
cord-014712-5u4e00q6	428	20	AR	AR	NNP
cord-014712-5u4e00q6	428	21	cases	case	NNS
cord-014712-5u4e00q6	428	22	with	with	IN
cord-014712-5u4e00q6	428	23	missense	missense	NN
cord-014712-5u4e00q6	428	24	mutation	mutation	NN
cord-014712-5u4e00q6	428	25	.	.	.
cord-014712-5u4e00q6	429	1	In	in	IN
cord-014712-5u4e00q6	429	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	429	3	cohort	cohort	NN
cord-014712-5u4e00q6	429	4	,	,	,
cord-014712-5u4e00q6	429	5	the	the	DT
cord-014712-5u4e00q6	429	6	percentage	percentage	NN
cord-014712-5u4e00q6	429	7	of	of	IN
cord-014712-5u4e00q6	429	8	AR	AR	NNP
cord-014712-5u4e00q6	429	9	-	-	HYPH
cord-014712-5u4e00q6	429	10	CGD	CGD	NNP
cord-014712-5u4e00q6	429	11	was	be	VBD
cord-014712-5u4e00q6	429	12	different	different	JJ
cord-014712-5u4e00q6	429	13	from	from	IN
cord-014712-5u4e00q6	429	14	European	european	JJ
cord-014712-5u4e00q6	429	15	and	and	CC
cord-014712-5u4e00q6	429	16	USA	USA	NNP
cord-014712-5u4e00q6	429	17	registries	registry	NNS
cord-014712-5u4e00q6	429	18	(	(	-LRB-
cord-014712-5u4e00q6	429	19	in	in	IN
cord-014712-5u4e00q6	429	20	comparison	comparison	NN
cord-014712-5u4e00q6	429	21	with	with	IN
cord-014712-5u4e00q6	429	22	%	%	NN
cord-014712-5u4e00q6	429	23	5	5	CD
cord-014712-5u4e00q6	429	24	,	,	,
cord-014712-5u4e00q6	429	25	%	%	NN
cord-014712-5u4e00q6	429	26	5	5	CD
cord-014712-5u4e00q6	429	27	and	and	CC
cord-014712-5u4e00q6	429	28	30	30	CD
cord-014712-5u4e00q6	429	29	%	%	NN
cord-014712-5u4e00q6	429	30	of	of	IN
cord-014712-5u4e00q6	429	31	p22	p22	NN
cord-014712-5u4e00q6	429	32	phox	phox	NNP
cord-014712-5u4e00q6	429	33	,	,	,
cord-014712-5u4e00q6	429	34	p67	p67	NNP
cord-014712-5u4e00q6	429	35	phox	phox	NNP
cord-014712-5u4e00q6	429	36	and	and	CC
cord-014712-5u4e00q6	429	37	p47	p47	CD
cord-014712-5u4e00q6	429	38	phox	phox	NNP
cord-014712-5u4e00q6	429	39	deficient	deficient	JJ
cord-014712-5u4e00q6	429	40	AR	AR	NNP
cord-014712-5u4e00q6	429	41	-	-	HYPH
cord-014712-5u4e00q6	429	42	CGD	CGD	NNP
cord-014712-5u4e00q6	429	43	cases	case	NNS
cord-014712-5u4e00q6	429	44	,	,	,
cord-014712-5u4e00q6	429	45	respectively	respectively	RB
cord-014712-5u4e00q6	429	46	)	)	-RRB-
cord-014712-5u4e00q6	429	47	with	with	IN
cord-014712-5u4e00q6	429	48	the	the	DT
cord-014712-5u4e00q6	429	49	higher	high	JJR
cord-014712-5u4e00q6	429	50	percentage	percentage	NN
cord-014712-5u4e00q6	429	51	of	of	IN
cord-014712-5u4e00q6	429	52	patients	patient	NNS
cord-014712-5u4e00q6	429	53	with	with	IN
cord-014712-5u4e00q6	429	54	p22	p22	NN
cord-014712-5u4e00q6	429	55	phox	phox	NNP
cord-014712-5u4e00q6	429	56	(	(	-LRB-
cord-014712-5u4e00q6	429	57	28	28	CD
cord-014712-5u4e00q6	429	58	%	%	NN
cord-014712-5u4e00q6	429	59	)	)	-RRB-
cord-014712-5u4e00q6	429	60	and	and	CC
cord-014712-5u4e00q6	430	1	p67	p67	NNP
cord-014712-5u4e00q6	430	2	phox	phox	NNP
cord-014712-5u4e00q6	430	3	-deficent	-deficent	.
cord-014712-5u4e00q6	431	1	(	(	-LRB-
cord-014712-5u4e00q6	431	2	14	14	CD
cord-014712-5u4e00q6	431	3	%	%	NN
cord-014712-5u4e00q6	431	4	)	)	-RRB-
cord-014712-5u4e00q6	431	5	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	431	6	,	,	,
cord-014712-5u4e00q6	431	7	and	and	CC
cord-014712-5u4e00q6	431	8	the	the	DT
cord-014712-5u4e00q6	431	9	lower	low	JJR
cord-014712-5u4e00q6	431	10	percentage	percentage	NN
cord-014712-5u4e00q6	431	11	of	of	IN
cord-014712-5u4e00q6	431	12	patients	patient	NNS
cord-014712-5u4e00q6	431	13	with	with	IN
cord-014712-5u4e00q6	432	1	p47	p47	CD
cord-014712-5u4e00q6	432	2	phox	phox	NNP
cord-014712-5u4e00q6	432	3	-deficient	-deficient	:
cord-014712-5u4e00q6	432	4	(	(	-LRB-
cord-014712-5u4e00q6	432	5	20	20	CD
cord-014712-5u4e00q6	432	6	%	%	NN
cord-014712-5u4e00q6	432	7	)	)	-RRB-
cord-014712-5u4e00q6	432	8	phenotype	phenotype	NN
cord-014712-5u4e00q6	432	9	.	.	.
cord-014712-5u4e00q6	433	1	The	the	DT
cord-014712-5u4e00q6	433	2	basic	basic	JJ
cord-014712-5u4e00q6	433	3	difference	difference	NN
cord-014712-5u4e00q6	433	4	in	in	IN
cord-014712-5u4e00q6	433	5	our	-PRON-	PRP$
cord-014712-5u4e00q6	433	6	results	result	NNS
cord-014712-5u4e00q6	433	7	from	from	IN
cord-014712-5u4e00q6	433	8	those	those	DT
cord-014712-5u4e00q6	433	9	reported	report	VBN
cord-014712-5u4e00q6	433	10	is	be	VBZ
cord-014712-5u4e00q6	433	11	the	the	DT
cord-014712-5u4e00q6	433	12	higher	high	JJR
cord-014712-5u4e00q6	433	13	percentage	percentage	NN
cord-014712-5u4e00q6	433	14	of	of	IN
cord-014712-5u4e00q6	433	15	patients	patient	NNS
cord-014712-5u4e00q6	433	16	with	with	IN
cord-014712-5u4e00q6	433	17	AR	AR	NNP
cord-014712-5u4e00q6	433	18	-	-	HYPH
cord-014712-5u4e00q6	433	19	CGD	CGD	NNP
cord-014712-5u4e00q6	433	20	(	(	-LRB-
cord-014712-5u4e00q6	433	21	%	%	NN
cord-014712-5u4e00q6	433	22	62	62	CD
cord-014712-5u4e00q6	433	23	)	)	-RRB-
cord-014712-5u4e00q6	433	24	,	,	,
cord-014712-5u4e00q6	433	25	which	which	WDT
cord-014712-5u4e00q6	433	26	was	be	VBD
cord-014712-5u4e00q6	433	27	lower	low	JJR
cord-014712-5u4e00q6	433	28	than	than	IN
cord-014712-5u4e00q6	433	29	in	in	IN
cord-014712-5u4e00q6	433	30	the	the	DT
cord-014712-5u4e00q6	433	31	European	european	JJ
cord-014712-5u4e00q6	433	32	and	and	CC
cord-014712-5u4e00q6	433	33	USA	USA	NNP
cord-014712-5u4e00q6	433	34	registries	registry	NNS
cord-014712-5u4e00q6	433	35	,	,	,
cord-014712-5u4e00q6	433	36	probably	probably	RB
cord-014712-5u4e00q6	433	37	because	because	IN
cord-014712-5u4e00q6	433	38	of	of	IN
cord-014712-5u4e00q6	433	39	the	the	DT
cord-014712-5u4e00q6	433	40	higher	high	JJR
cord-014712-5u4e00q6	433	41	prevalence	prevalence	NN
cord-014712-5u4e00q6	433	42	of	of	IN
cord-014712-5u4e00q6	433	43	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	433	44	marriage	marriage	NN
cord-014712-5u4e00q6	433	45	in	in	IN
cord-014712-5u4e00q6	433	46	Turkey	Turkey	NNP
cord-014712-5u4e00q6	433	47	.	.	.
cord-014712-5u4e00q6	434	1	Introduction	introduction	NN
cord-014712-5u4e00q6	434	2	:	:	:
cord-014712-5u4e00q6	435	1	Schnitzler	Schnitzler	NNP
cord-014712-5u4e00q6	435	2	syndrome	syndrome	NN
cord-014712-5u4e00q6	435	3	is	be	VBZ
cord-014712-5u4e00q6	435	4	an	an	DT
cord-014712-5u4e00q6	435	5	autoinflammatory	autoinflammatory	JJ
cord-014712-5u4e00q6	435	6	disorder	disorder	NN
cord-014712-5u4e00q6	435	7	of	of	IN
cord-014712-5u4e00q6	435	8	unknown	unknown	JJ
cord-014712-5u4e00q6	435	9	etiology	etiology	NN
cord-014712-5u4e00q6	435	10	.	.	.
cord-014712-5u4e00q6	436	1	At	at	IN
cord-014712-5u4e00q6	436	2	least	least	JJS
cord-014712-5u4e00q6	436	3	some	some	DT
cord-014712-5u4e00q6	436	4	of	of	IN
cord-014712-5u4e00q6	436	5	its	-PRON-	PRP$
cord-014712-5u4e00q6	436	6	clinical	clinical	JJ
cord-014712-5u4e00q6	436	7	presentation	presentation	NN
cord-014712-5u4e00q6	436	8	is	be	VBZ
cord-014712-5u4e00q6	436	9	mediated	mediate	VBN
cord-014712-5u4e00q6	436	10	through	through	IN
cord-014712-5u4e00q6	436	11	an	an	DT
cord-014712-5u4e00q6	436	12	activation	activation	NN
cord-014712-5u4e00q6	436	13	of	of	IN
cord-014712-5u4e00q6	436	14	inflammasome	inflammasome	NN
cord-014712-5u4e00q6	436	15	and	and	CC
cord-014712-5u4e00q6	436	16	release	release	NN
cord-014712-5u4e00q6	436	17	of	of	IN
cord-014712-5u4e00q6	436	18	IL-1	IL-1	NNP
cord-014712-5u4e00q6	436	19	,	,	,
cord-014712-5u4e00q6	436	20	as	as	IN
cord-014712-5u4e00q6	436	21	was	be	VBD
cord-014712-5u4e00q6	436	22	repeatedly	repeatedly	RB
cord-014712-5u4e00q6	436	23	demonstrated	demonstrate	VBN
cord-014712-5u4e00q6	436	24	by	by	IN
cord-014712-5u4e00q6	436	25	a	a	DT
cord-014712-5u4e00q6	436	26	prominent	prominent	JJ
cord-014712-5u4e00q6	436	27	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	436	28	effect	effect	NN
cord-014712-5u4e00q6	436	29	of	of	IN
cord-014712-5u4e00q6	436	30	IL-1	IL-1	NNP
cord-014712-5u4e00q6	436	31	blockade	blockade	NN
cord-014712-5u4e00q6	436	32	.	.	.
cord-014712-5u4e00q6	437	1	Recent	recent	JJ
cord-014712-5u4e00q6	437	2	reports	report	NNS
cord-014712-5u4e00q6	437	3	bring	bring	VBP
cord-014712-5u4e00q6	437	4	an	an	DT
cord-014712-5u4e00q6	437	5	evidence	evidence	NN
cord-014712-5u4e00q6	437	6	of	of	IN
cord-014712-5u4e00q6	437	7	an	an	DT
cord-014712-5u4e00q6	437	8	important	important	JJ
cord-014712-5u4e00q6	437	9	role	role	NN
cord-014712-5u4e00q6	437	10	of	of	IN
cord-014712-5u4e00q6	437	11	mitochondria	mitochondrion	NNS
cord-014712-5u4e00q6	437	12	in	in	IN
cord-014712-5u4e00q6	437	13	inflammasome	inflammasome	NNP
cord-014712-5u4e00q6	437	14	activation	activation	NN
cord-014712-5u4e00q6	437	15	and	and	CC
cord-014712-5u4e00q6	437	16	in	in	IN
cord-014712-5u4e00q6	437	17	a	a	DT
cord-014712-5u4e00q6	437	18	pathogenesis	pathogenesis	NN
cord-014712-5u4e00q6	437	19	of	of	IN
cord-014712-5u4e00q6	437	20	autoinflammatory	autoinflammatory	JJ
cord-014712-5u4e00q6	437	21	diseases	disease	NNS
cord-014712-5u4e00q6	437	22	.	.	.
cord-014712-5u4e00q6	438	1	We	-PRON-	PRP
cord-014712-5u4e00q6	438	2	have	have	VBP
cord-014712-5u4e00q6	438	3	therefore	therefore	RB
cord-014712-5u4e00q6	438	4	investigated	investigate	VBN
cord-014712-5u4e00q6	438	5	mitochondrial	mitochondrial	JJ
cord-014712-5u4e00q6	438	6	function	function	NN
cord-014712-5u4e00q6	438	7	and	and	CC
cord-014712-5u4e00q6	438	8	structure	structure	NN
cord-014712-5u4e00q6	438	9	in	in	IN
cord-014712-5u4e00q6	438	10	patients	patient	NNS
cord-014712-5u4e00q6	438	11	with	with	IN
cord-014712-5u4e00q6	438	12	Schnitzler	Schnitzler	NNP
cord-014712-5u4e00q6	438	13	syndrome	syndrome	NN
cord-014712-5u4e00q6	438	14	.	.	.
cord-014712-5u4e00q6	439	1	Materials	material	NNS
cord-014712-5u4e00q6	439	2	and	and	CC
cord-014712-5u4e00q6	439	3	methods	method	NNS
cord-014712-5u4e00q6	439	4	:	:	:
cord-014712-5u4e00q6	439	5	Activity	activity	NN
cord-014712-5u4e00q6	439	6	and	and	CC
cord-014712-5u4e00q6	439	7	amount	amount	NN
cord-014712-5u4e00q6	439	8	of	of	IN
cord-014712-5u4e00q6	439	9	oxidative	oxidative	JJ
cord-014712-5u4e00q6	439	10	phosphorylation	phosphorylation	NN
cord-014712-5u4e00q6	439	11	complexes	complex	NNS
cord-014712-5u4e00q6	439	12	(	(	-LRB-
cord-014712-5u4e00q6	439	13	OXPHOS	OXPHOS	NNP
cord-014712-5u4e00q6	439	14	)	)	-RRB-
cord-014712-5u4e00q6	439	15	were	be	VBD
cord-014712-5u4e00q6	439	16	analysed	analyse	VBN
cord-014712-5u4e00q6	439	17	by	by	IN
cord-014712-5u4e00q6	439	18	spectrophotometry	spectrophotometry	NN
cord-014712-5u4e00q6	439	19	,	,	,
cord-014712-5u4e00q6	439	20	histochemistry	histochemistry	NNP
cord-014712-5u4e00q6	439	21	and	and	CC
cord-014712-5u4e00q6	439	22	imunoelectrophoretic	imunoelectrophoretic	JJ
cord-014712-5u4e00q6	439	23	methods	method	NNS
cord-014712-5u4e00q6	439	24	in	in	IN
cord-014712-5u4e00q6	439	25	fibroblast	fibroblast	NN
cord-014712-5u4e00q6	439	26	cell	cell	NN
cord-014712-5u4e00q6	439	27	lines	line	NNS
cord-014712-5u4e00q6	439	28	derived	derive	VBN
cord-014712-5u4e00q6	439	29	from	from	IN
cord-014712-5u4e00q6	439	30	skin	skin	NN
cord-014712-5u4e00q6	439	31	biopsies	biopsy	NNS
cord-014712-5u4e00q6	439	32	of	of	IN
cord-014712-5u4e00q6	439	33	three	three	CD
cord-014712-5u4e00q6	439	34	adult	adult	NN
cord-014712-5u4e00q6	439	35	male	male	JJ
cord-014712-5u4e00q6	439	36	patients	patient	NNS
cord-014712-5u4e00q6	439	37	with	with	IN
cord-014712-5u4e00q6	439	38	Schnitzler	Schnitzler	NNP
cord-014712-5u4e00q6	439	39	syndrome	syndrome	NN
cord-014712-5u4e00q6	439	40	.	.	.
cord-014712-5u4e00q6	440	1	Ultrastructure	Ultrastructure	NNP
cord-014712-5u4e00q6	440	2	of	of	IN
cord-014712-5u4e00q6	440	3	mitochondria	mitochondrion	NNS
cord-014712-5u4e00q6	440	4	,	,	,
cord-014712-5u4e00q6	440	5	mitochondrial	mitochondrial	NN
cord-014712-5u4e00q6	440	6	network	network	NN
cord-014712-5u4e00q6	440	7	and	and	CC
cord-014712-5u4e00q6	440	8	reactive	reactive	JJ
cord-014712-5u4e00q6	440	9	oxygen	oxygen	NN
cord-014712-5u4e00q6	440	10	species	specie	NNS
cord-014712-5u4e00q6	441	1	(	(	-LRB-
cord-014712-5u4e00q6	441	2	ROS	ROS	NNP
cord-014712-5u4e00q6	441	3	)	)	-RRB-
cord-014712-5u4e00q6	441	4	were	be	VBD
cord-014712-5u4e00q6	441	5	analysed	analyse	VBN
cord-014712-5u4e00q6	441	6	by	by	IN
cord-014712-5u4e00q6	441	7	fluorescent	fluorescent	NN
cord-014712-5u4e00q6	441	8	and	and	CC
cord-014712-5u4e00q6	441	9	electron	electron	NN
cord-014712-5u4e00q6	441	10	microscopy	microscopy	NN
cord-014712-5u4e00q6	441	11	.	.	.
cord-014712-5u4e00q6	442	1	Results	result	NNS
cord-014712-5u4e00q6	442	2	:	:	:
cord-014712-5u4e00q6	443	1	The	the	DT
cord-014712-5u4e00q6	443	2	activities	activity	NNS
cord-014712-5u4e00q6	443	3	and	and	CC
cord-014712-5u4e00q6	443	4	amount	amount	NN
cord-014712-5u4e00q6	443	5	of	of	IN
cord-014712-5u4e00q6	443	6	OXPHOS	OXPHOS	NNP
cord-014712-5u4e00q6	443	7	complexes	complex	NNS
cord-014712-5u4e00q6	444	1	I	-PRON-	PRP
cord-014712-5u4e00q6	444	2	,	,	,
cord-014712-5u4e00q6	444	3	III	III	NNP
cord-014712-5u4e00q6	444	4	and	and	CC
cord-014712-5u4e00q6	444	5	IV	IV	NNP
cord-014712-5u4e00q6	444	6	were	be	VBD
cord-014712-5u4e00q6	444	7	decreased	decrease	VBN
cord-014712-5u4e00q6	444	8	in	in	IN
cord-014712-5u4e00q6	444	9	patients	patient	NNS
cord-014712-5u4e00q6	444	10	with	with	IN
cord-014712-5u4e00q6	444	11	Schnitzler	Schnitzler	NNP
cord-014712-5u4e00q6	444	12	syndrome	syndrome	NN
cord-014712-5u4e00q6	444	13	.	.	.
cord-014712-5u4e00q6	445	1	Interindividual	Interindividual	NNP
cord-014712-5u4e00q6	445	2	differences	difference	NNS
cord-014712-5u4e00q6	445	3	in	in	IN
cord-014712-5u4e00q6	445	4	the	the	DT
cord-014712-5u4e00q6	445	5	degree	degree	NN
cord-014712-5u4e00q6	445	6	of	of	IN
cord-014712-5u4e00q6	445	7	impairment	impairment	NN
cord-014712-5u4e00q6	445	8	(	(	-LRB-
cord-014712-5u4e00q6	445	9	from	from	IN
cord-014712-5u4e00q6	445	10	severe	severe	JJ
cord-014712-5u4e00q6	445	11	to	to	IN
cord-014712-5u4e00q6	445	12	moderate	moderate	JJ
cord-014712-5u4e00q6	445	13	)	)	-RRB-
cord-014712-5u4e00q6	445	14	in	in	IN
cord-014712-5u4e00q6	445	15	analyzed	analyze	VBN
cord-014712-5u4e00q6	445	16	mitochondrial	mitochondrial	JJ
cord-014712-5u4e00q6	445	17	parameters	parameter	NNS
cord-014712-5u4e00q6	445	18	were	be	VBD
cord-014712-5u4e00q6	445	19	found	find	VBN
cord-014712-5u4e00q6	445	20	.	.	.
cord-014712-5u4e00q6	446	1	Content	content	NN
cord-014712-5u4e00q6	446	2	of	of	IN
cord-014712-5u4e00q6	446	3	ROS	ROS	NNP
cord-014712-5u4e00q6	446	4	,	,	,
cord-014712-5u4e00q6	446	5	previously	previously	RB
cord-014712-5u4e00q6	446	6	suggested	suggest	VBD
cord-014712-5u4e00q6	446	7	as	as	IN
cord-014712-5u4e00q6	446	8	main	main	JJ
cord-014712-5u4e00q6	446	9	inducers	inducer	NNS
cord-014712-5u4e00q6	446	10	of	of	IN
cord-014712-5u4e00q6	446	11	inflammasome	inflammasome	NNP
cord-014712-5u4e00q6	446	12	,	,	,
cord-014712-5u4e00q6	446	13	were	be	VBD
cord-014712-5u4e00q6	446	14	not	not	RB
cord-014712-5u4e00q6	446	15	significantly	significantly	RB
cord-014712-5u4e00q6	446	16	increased	increase	VBN
cord-014712-5u4e00q6	446	17	in	in	IN
cord-014712-5u4e00q6	446	18	cells	cell	NNS
cord-014712-5u4e00q6	446	19	with	with	IN
cord-014712-5u4e00q6	446	20	Schnitzler	Schnitzler	NNP
cord-014712-5u4e00q6	446	21	syndrome	syndrome	NN
cord-014712-5u4e00q6	446	22	.	.	.
cord-014712-5u4e00q6	447	1	We	-PRON-	PRP
cord-014712-5u4e00q6	447	2	,	,	,
cord-014712-5u4e00q6	447	3	however	however	RB
cord-014712-5u4e00q6	447	4	,	,	,
cord-014712-5u4e00q6	447	5	did	do	VBD
cord-014712-5u4e00q6	447	6	find	find	VB
cord-014712-5u4e00q6	447	7	consistent	consistent	JJ
cord-014712-5u4e00q6	447	8	and	and	CC
cord-014712-5u4e00q6	447	9	prominent	prominent	JJ
cord-014712-5u4e00q6	447	10	changes	change	NNS
cord-014712-5u4e00q6	447	11	in	in	IN
cord-014712-5u4e00q6	447	12	mitochondrial	mitochondrial	JJ
cord-014712-5u4e00q6	447	13	structure	structure	NN
cord-014712-5u4e00q6	447	14	of	of	IN
cord-014712-5u4e00q6	447	15	all	all	DT
cord-014712-5u4e00q6	447	16	three	three	CD
cord-014712-5u4e00q6	447	17	patients	patient	NNS
cord-014712-5u4e00q6	447	18	.	.	.
cord-014712-5u4e00q6	448	1	Disturbed	disturbed	JJ
cord-014712-5u4e00q6	448	2	mitochondrial	mitochondrial	JJ
cord-014712-5u4e00q6	448	3	network	network	NN
cord-014712-5u4e00q6	448	4	and	and	CC
cord-014712-5u4e00q6	448	5	mainly	mainly	RB
cord-014712-5u4e00q6	448	6	abnormal	abnormal	JJ
cord-014712-5u4e00q6	448	7	,	,	,
cord-014712-5u4e00q6	448	8	partially	partially	RB
cord-014712-5u4e00q6	448	9	swelling	swell	VBG
cord-014712-5u4e00q6	448	10	mitochondria	mitochondrion	NNS
cord-014712-5u4e00q6	448	11	with	with	IN
cord-014712-5u4e00q6	448	12	unusual	unusual	JJ
cord-014712-5u4e00q6	448	13	and	and	CC
cord-014712-5u4e00q6	448	14	sparse	sparse	JJ
cord-014712-5u4e00q6	448	15	cristae	cristae	NN
cord-014712-5u4e00q6	448	16	were	be	VBD
cord-014712-5u4e00q6	448	17	characteristic	characteristic	JJ
cord-014712-5u4e00q6	448	18	for	for	IN
cord-014712-5u4e00q6	448	19	all	all	DT
cord-014712-5u4e00q6	448	20	patients	patient	NNS
cord-014712-5u4e00q6	448	21	.	.	.
cord-014712-5u4e00q6	449	1	We	-PRON-	PRP
cord-014712-5u4e00q6	449	2	did	do	VBD
cord-014712-5u4e00q6	449	3	further	further	RB
cord-014712-5u4e00q6	449	4	notice	notice	VB
cord-014712-5u4e00q6	449	5	marked	mark	VBN
cord-014712-5u4e00q6	449	6	accumulation	accumulation	NN
cord-014712-5u4e00q6	449	7	of	of	IN
cord-014712-5u4e00q6	449	8	neutral	neutral	JJ
cord-014712-5u4e00q6	449	9	lipids	lipid	NNS
cord-014712-5u4e00q6	449	10	in	in	IN
cord-014712-5u4e00q6	449	11	all	all	DT
cord-014712-5u4e00q6	449	12	tested	test	VBN
cord-014712-5u4e00q6	449	13	fibroblasts	fibroblast	NNS
cord-014712-5u4e00q6	449	14	.	.	.
cord-014712-5u4e00q6	450	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	450	2	:	:	:
cord-014712-5u4e00q6	451	1	Severe	severe	JJ
cord-014712-5u4e00q6	451	2	structural	structural	JJ
cord-014712-5u4e00q6	451	3	damage	damage	NN
cord-014712-5u4e00q6	451	4	of	of	IN
cord-014712-5u4e00q6	451	5	mitochondria	mitochondrion	NNS
cord-014712-5u4e00q6	451	6	associated	associate	VBN
cord-014712-5u4e00q6	451	7	with	with	IN
cord-014712-5u4e00q6	451	8	milder	mild	JJR
cord-014712-5u4e00q6	451	9	functional	functional	JJ
cord-014712-5u4e00q6	451	10	changes	change	NNS
cord-014712-5u4e00q6	451	11	represented	represent	VBD
cord-014712-5u4e00q6	451	12	a	a	DT
cord-014712-5u4e00q6	451	13	consistent	consistent	JJ
cord-014712-5u4e00q6	451	14	feature	feature	NN
cord-014712-5u4e00q6	451	15	found	find	VBN
cord-014712-5u4e00q6	451	16	in	in	IN
cord-014712-5u4e00q6	451	17	all	all	DT
cord-014712-5u4e00q6	451	18	tested	test	VBN
cord-014712-5u4e00q6	451	19	Schnitzler	Schnitzler	NNP
cord-014712-5u4e00q6	451	20	syndrome	syndrome	NN
cord-014712-5u4e00q6	451	21	patients	patient	NNS
cord-014712-5u4e00q6	451	22	.	.	.
cord-014712-5u4e00q6	452	1	Along	along	IN
cord-014712-5u4e00q6	452	2	with	with	IN
cord-014712-5u4e00q6	452	3	progress	progress	NN
cord-014712-5u4e00q6	452	4	in	in	IN
cord-014712-5u4e00q6	452	5	basic	basic	JJ
cord-014712-5u4e00q6	452	6	and	and	CC
cord-014712-5u4e00q6	452	7	clinical	clinical	JJ
cord-014712-5u4e00q6	452	8	immunology	immunology	NN
cord-014712-5u4e00q6	452	9	worldwide	worldwide	RB
cord-014712-5u4e00q6	452	10	,	,	,
cord-014712-5u4e00q6	452	11	the	the	DT
cord-014712-5u4e00q6	452	12	knowledge	knowledge	NN
cord-014712-5u4e00q6	452	13	and	and	CC
cord-014712-5u4e00q6	452	14	activities	activity	NNS
cord-014712-5u4e00q6	452	15	in	in	IN
cord-014712-5u4e00q6	452	16	the	the	DT
cord-014712-5u4e00q6	452	17	field	field	NN
cord-014712-5u4e00q6	452	18	of	of	IN
cord-014712-5u4e00q6	452	19	primary	primary	JJ
cord-014712-5u4e00q6	452	20	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	452	21	(	(	-LRB-
cord-014712-5u4e00q6	452	22	PIDs	PIDs	NNP
cord-014712-5u4e00q6	452	23	)	)	-RRB-
cord-014712-5u4e00q6	452	24	have	have	VBP
cord-014712-5u4e00q6	452	25	developed	develop	VBN
cord-014712-5u4e00q6	452	26	during	during	IN
cord-014712-5u4e00q6	452	27	last	last	JJ
cord-014712-5u4e00q6	452	28	two	two	CD
cord-014712-5u4e00q6	452	29	decades	decade	NNS
cord-014712-5u4e00q6	452	30	.	.	.
cord-014712-5u4e00q6	453	1	In	in	IN
cord-014712-5u4e00q6	453	2	1997	1997	CD
cord-014712-5u4e00q6	453	3	,	,	,
cord-014712-5u4e00q6	453	4	a	a	DT
cord-014712-5u4e00q6	453	5	group	group	NN
cord-014712-5u4e00q6	453	6	of	of	IN
cord-014712-5u4e00q6	453	7	junior	junior	JJ
cord-014712-5u4e00q6	453	8	doctors	doctor	NNS
cord-014712-5u4e00q6	453	9	and	and	CC
cord-014712-5u4e00q6	453	10	students	student	NNS
cord-014712-5u4e00q6	453	11	joined	join	VBD
cord-014712-5u4e00q6	453	12	seniors	senior	NNS
cord-014712-5u4e00q6	453	13	in	in	IN
cord-014712-5u4e00q6	453	14	this	this	DT
cord-014712-5u4e00q6	453	15	filed	file	VBN
cord-014712-5u4e00q6	453	16	to	to	TO
cord-014712-5u4e00q6	453	17	establish	establish	VB
cord-014712-5u4e00q6	453	18	Iranian	iranian	JJ
cord-014712-5u4e00q6	453	19	Primary	Primary	NNP
cord-014712-5u4e00q6	453	20	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	453	21	Registry	Registry	NNP
cord-014712-5u4e00q6	453	22	(	(	-LRB-
cord-014712-5u4e00q6	453	23	IPIDR	IPIDR	NNP
cord-014712-5u4e00q6	453	24	)	)	-RRB-
cord-014712-5u4e00q6	453	25	.	.	.
cord-014712-5u4e00q6	454	1	Several	several	JJ
cord-014712-5u4e00q6	454	2	national	national	JJ
cord-014712-5u4e00q6	454	3	and	and	CC
cord-014712-5u4e00q6	454	4	international	international	JJ
cord-014712-5u4e00q6	454	5	research	research	NN
cord-014712-5u4e00q6	454	6	projects	project	NNS
cord-014712-5u4e00q6	454	7	have	have	VBP
cord-014712-5u4e00q6	454	8	been	be	VBN
cord-014712-5u4e00q6	454	9	done	do	VBN
cord-014712-5u4e00q6	454	10	so	so	RB
cord-014712-5u4e00q6	454	11	far	far	RB
cord-014712-5u4e00q6	454	12	which	which	WDT
cord-014712-5u4e00q6	454	13	led	lead	VBD
cord-014712-5u4e00q6	454	14	to	to	IN
cord-014712-5u4e00q6	454	15	lots	lot	NNS
cord-014712-5u4e00q6	454	16	of	of	IN
cord-014712-5u4e00q6	454	17	publications	publication	NNS
cord-014712-5u4e00q6	454	18	,	,	,
cord-014712-5u4e00q6	454	19	while	while	IN
cord-014712-5u4e00q6	454	20	improving	improve	VBG
cord-014712-5u4e00q6	454	21	the	the	DT
cord-014712-5u4e00q6	454	22	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	454	23	of	of	IN
cord-014712-5u4e00q6	454	24	patients	patient	NNS
cord-014712-5u4e00q6	454	25	with	with	IN
cord-014712-5u4e00q6	454	26	PIDs	pid	NNS
cord-014712-5u4e00q6	454	27	,	,	,
cord-014712-5u4e00q6	454	28	construction	construction	NN
cord-014712-5u4e00q6	454	29	of	of	IN
cord-014712-5u4e00q6	454	30	Iranian	Iranian	NNP
cord-014712-5u4e00q6	454	31	Primary	Primary	NNP
cord-014712-5u4e00q6	454	32	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	454	33	Association	Association	NNP
cord-014712-5u4e00q6	454	34	(	(	-LRB-
cord-014712-5u4e00q6	454	35	IPIA	IPIA	NNP
cord-014712-5u4e00q6	454	36	)	)	-RRB-
cord-014712-5u4e00q6	454	37	,	,	,
cord-014712-5u4e00q6	454	38	and	and	CC
cord-014712-5u4e00q6	454	39	establishment	establishment	NN
cord-014712-5u4e00q6	454	40	of	of	IN
cord-014712-5u4e00q6	454	41	Research	Research	NNP
cord-014712-5u4e00q6	454	42	Center	Center	NNP
cord-014712-5u4e00q6	454	43	for	for	IN
cord-014712-5u4e00q6	454	44	Immunodeficiencies	Immunodeficiencies	NNP
cord-014712-5u4e00q6	454	45	were	be	VBD
cord-014712-5u4e00q6	454	46	other	other	JJ
cord-014712-5u4e00q6	454	47	activities	activity	NNS
cord-014712-5u4e00q6	454	48	which	which	WDT
cord-014712-5u4e00q6	454	49	lead	lead	VBP
cord-014712-5u4e00q6	454	50	to	to	IN
cord-014712-5u4e00q6	454	51	better	well	JJR
cord-014712-5u4e00q6	454	52	management	management	NN
cord-014712-5u4e00q6	454	53	of	of	IN
cord-014712-5u4e00q6	454	54	the	the	DT
cord-014712-5u4e00q6	454	55	patients	patient	NNS
cord-014712-5u4e00q6	454	56	.	.	.
cord-014712-5u4e00q6	455	1	Organizing	organize	VBG
cord-014712-5u4e00q6	455	2	annual	annual	JJ
cord-014712-5u4e00q6	455	3	meeting	meeting	NN
cord-014712-5u4e00q6	455	4	on	on	IN
cord-014712-5u4e00q6	455	5	Clinical	Clinical	NNP
cord-014712-5u4e00q6	455	6	Immunology	Immunology	NNP
cord-014712-5u4e00q6	455	7	and	and	CC
cord-014712-5u4e00q6	455	8	Immunodeficiencies	Immunodeficiencies	NNP
cord-014712-5u4e00q6	455	9	,	,	,
cord-014712-5u4e00q6	455	10	celebrating	celebrate	VBG
cord-014712-5u4e00q6	455	11	PI	pi	NN
cord-014712-5u4e00q6	455	12	week	week	NN
cord-014712-5u4e00q6	455	13	annually	annually	RB
cord-014712-5u4e00q6	455	14	and	and	CC
cord-014712-5u4e00q6	455	15	active	active	JJ
cord-014712-5u4e00q6	455	16	participation	participation	NN
cord-014712-5u4e00q6	455	17	in	in	IN
cord-014712-5u4e00q6	455	18	the	the	DT
cord-014712-5u4e00q6	455	19	international	international	JJ
cord-014712-5u4e00q6	455	20	congresses	congress	NNS
cord-014712-5u4e00q6	455	21	were	be	VBD
cord-014712-5u4e00q6	455	22	all	all	DT
cord-014712-5u4e00q6	455	23	helped	help	VBN
cord-014712-5u4e00q6	455	24	in	in	RP
cord-014712-5u4e00q6	455	25	to	to	TO
cord-014712-5u4e00q6	455	26	increase	increase	VB
cord-014712-5u4e00q6	455	27	knowledge	knowledge	NN
cord-014712-5u4e00q6	455	28	of	of	IN
cord-014712-5u4e00q6	455	29	physicians	physician	NNS
cord-014712-5u4e00q6	455	30	in	in	IN
cord-014712-5u4e00q6	455	31	the	the	DT
cord-014712-5u4e00q6	455	32	country	country	NN
cord-014712-5u4e00q6	455	33	.	.	.
cord-014712-5u4e00q6	456	1	The	the	DT
cord-014712-5u4e00q6	456	2	overall	overall	JJ
cord-014712-5u4e00q6	456	3	activities	activity	NNS
cord-014712-5u4e00q6	456	4	in	in	IN
cord-014712-5u4e00q6	456	5	the	the	DT
cord-014712-5u4e00q6	456	6	field	field	NN
cord-014712-5u4e00q6	456	7	of	of	IN
cord-014712-5u4e00q6	456	8	PIDs	pid	NNS
cord-014712-5u4e00q6	456	9	led	lead	VBD
cord-014712-5u4e00q6	456	10	to	to	IN
cord-014712-5u4e00q6	456	11	an	an	DT
cord-014712-5u4e00q6	456	12	increased	increase	VBN
cord-014712-5u4e00q6	456	13	trend	trend	NN
cord-014712-5u4e00q6	456	14	in	in	IN
cord-014712-5u4e00q6	456	15	recognition	recognition	NN
cord-014712-5u4e00q6	456	16	of	of	IN
cord-014712-5u4e00q6	456	17	more	more	JJR
cord-014712-5u4e00q6	456	18	patients	patient	NNS
cord-014712-5u4e00q6	456	19	in	in	IN
cord-014712-5u4e00q6	456	20	the	the	DT
cord-014712-5u4e00q6	456	21	recent	recent	JJ
cord-014712-5u4e00q6	456	22	years	year	NNS
cord-014712-5u4e00q6	456	23	,	,	,
cord-014712-5u4e00q6	456	24	which	which	WDT
cord-014712-5u4e00q6	456	25	was	be	VBD
cord-014712-5u4e00q6	456	26	associated	associate	VBN
cord-014712-5u4e00q6	456	27	with	with	IN
cord-014712-5u4e00q6	456	28	decreased	decrease	VBN
cord-014712-5u4e00q6	456	29	delay	delay	NN
cord-014712-5u4e00q6	456	30	in	in	IN
cord-014712-5u4e00q6	456	31	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	456	32	.	.	.
cord-014712-5u4e00q6	457	1	Based	base	VBN
cord-014712-5u4e00q6	457	2	on	on	IN
cord-014712-5u4e00q6	457	3	recent	recent	JJ
cord-014712-5u4e00q6	457	4	report	report	NN
cord-014712-5u4e00q6	457	5	of	of	IN
cord-014712-5u4e00q6	457	6	the	the	DT
cord-014712-5u4e00q6	457	7	registry	registry	NN
cord-014712-5u4e00q6	457	8	,	,	,
cord-014712-5u4e00q6	457	9	published	publish	VBN
cord-014712-5u4e00q6	457	10	recently	recently	RB
cord-014712-5u4e00q6	457	11	in	in	IN
cord-014712-5u4e00q6	457	12	the	the	DT
cord-014712-5u4e00q6	457	13	J	J	NNP
cord-014712-5u4e00q6	457	14	Clin	Clin	NNP
cord-014712-5u4e00q6	457	15	Immunol	Immunol	NNP
cord-014712-5u4e00q6	457	16	,	,	,
cord-014712-5u4e00q6	457	17	more	more	JJR
cord-014712-5u4e00q6	457	18	than	than	IN
cord-014712-5u4e00q6	457	19	730	730	CD
cord-014712-5u4e00q6	457	20	new	new	JJ
cord-014712-5u4e00q6	457	21	patients	patient	NNS
cord-014712-5u4e00q6	457	22	with	with	IN
cord-014712-5u4e00q6	457	23	PID	PID	NNP
cord-014712-5u4e00q6	457	24	,	,	,
cord-014712-5u4e00q6	457	25	in	in	IN
cord-014712-5u4e00q6	457	26	addition	addition	NN
cord-014712-5u4e00q6	457	27	to	to	IN
cord-014712-5u4e00q6	457	28	previously	previously	RB
cord-014712-5u4e00q6	457	29	930	930	CD
cord-014712-5u4e00q6	457	30	reported	report	VBN
cord-014712-5u4e00q6	457	31	patients	patient	NNS
cord-014712-5u4e00q6	457	32	,	,	,
cord-014712-5u4e00q6	457	33	were	be	VBD
cord-014712-5u4e00q6	457	34	presented	present	VBN
cord-014712-5u4e00q6	457	35	.	.	.
cord-014712-5u4e00q6	458	1	Predominantly	predominantly	RB
cord-014712-5u4e00q6	458	2	antibody	antibody	NN
cord-014712-5u4e00q6	458	3	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	458	4	were	be	VBD
cord-014712-5u4e00q6	458	5	the	the	DT
cord-014712-5u4e00q6	458	6	most	most	RBS
cord-014712-5u4e00q6	458	7	common	common	JJ
cord-014712-5u4e00q6	458	8	form	form	NN
cord-014712-5u4e00q6	458	9	of	of	IN
cord-014712-5u4e00q6	458	10	disease	disease	NN
cord-014712-5u4e00q6	458	11	,	,	,
cord-014712-5u4e00q6	458	12	followed	follow	VBN
cord-014712-5u4e00q6	458	13	by	by	IN
cord-014712-5u4e00q6	458	14	combined	combined	JJ
cord-014712-5u4e00q6	458	15	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	458	16	,	,	,
cord-014712-5u4e00q6	458	17	congenital	congenital	JJ
cord-014712-5u4e00q6	458	18	defects	defect	NNS
cord-014712-5u4e00q6	458	19	of	of	IN
cord-014712-5u4e00q6	458	20	phagocytes	phagocyte	NNS
cord-014712-5u4e00q6	458	21	,	,	,
cord-014712-5u4e00q6	458	22	and	and	CC
cord-014712-5u4e00q6	458	23	other	other	JJ
cord-014712-5u4e00q6	458	24	well	well	RB
cord-014712-5u4e00q6	458	25	-	-	HYPH
cord-014712-5u4e00q6	458	26	defined	define	VBN
cord-014712-5u4e00q6	458	27	syndromes	syndrome	NNS
cord-014712-5u4e00q6	458	28	with	with	IN
cord-014712-5u4e00q6	458	29	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	458	30	.	.	.
cord-014712-5u4e00q6	459	1	The	the	DT
cord-014712-5u4e00q6	459	2	rapid	rapid	JJ
cord-014712-5u4e00q6	459	3	progress	progress	NN
cord-014712-5u4e00q6	459	4	in	in	IN
cord-014712-5u4e00q6	459	5	identification	identification	NN
cord-014712-5u4e00q6	459	6	and	and	CC
cord-014712-5u4e00q6	459	7	registration	registration	NN
cord-014712-5u4e00q6	459	8	of	of	IN
cord-014712-5u4e00q6	459	9	the	the	DT
cord-014712-5u4e00q6	459	10	patients	patient	NNS
cord-014712-5u4e00q6	459	11	with	with	IN
cord-014712-5u4e00q6	459	12	PIDs	pid	NNS
cord-014712-5u4e00q6	459	13	is	be	VBZ
cord-014712-5u4e00q6	459	14	important	important	JJ
cord-014712-5u4e00q6	459	15	not	not	RB
cord-014712-5u4e00q6	459	16	only	only	RB
cord-014712-5u4e00q6	459	17	as	as	IN
cord-014712-5u4e00q6	459	18	of	of	IN
cord-014712-5u4e00q6	459	19	epidemiological	epidemiological	JJ
cord-014712-5u4e00q6	459	20	aspect	aspect	NN
cord-014712-5u4e00q6	459	21	,	,	,
cord-014712-5u4e00q6	459	22	but	but	CC
cord-014712-5u4e00q6	459	23	also	also	RB
cord-014712-5u4e00q6	459	24	as	as	IN
cord-014712-5u4e00q6	459	25	of	of	IN
cord-014712-5u4e00q6	459	26	timely	timely	JJ
cord-014712-5u4e00q6	459	27	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	459	28	and	and	CC
cord-014712-5u4e00q6	459	29	appropriate	appropriate	JJ
cord-014712-5u4e00q6	459	30	treatment	treatment	NN
cord-014712-5u4e00q6	459	31	of	of	IN
cord-014712-5u4e00q6	459	32	the	the	DT
cord-014712-5u4e00q6	459	33	patients	patient	NNS
cord-014712-5u4e00q6	459	34	.	.	.
cord-014712-5u4e00q6	460	1	The	the	DT
cord-014712-5u4e00q6	460	2	J	J	NNP
cord-014712-5u4e00q6	460	3	Project	Project	NNP
cord-014712-5u4e00q6	460	4	physician	physician	NN
cord-014712-5u4e00q6	460	5	education	education	NN
cord-014712-5u4e00q6	460	6	and	and	CC
cord-014712-5u4e00q6	460	7	clinical	clinical	JJ
cord-014712-5u4e00q6	460	8	research	research	NN
cord-014712-5u4e00q6	460	9	collaboration	collaboration	NN
cord-014712-5u4e00q6	460	10	program	program	NN
cord-014712-5u4e00q6	460	11	was	be	VBD
cord-014712-5u4e00q6	460	12	launched	launch	VBN
cord-014712-5u4e00q6	460	13	in	in	IN
cord-014712-5u4e00q6	460	14	2004	2004	CD
cord-014712-5u4e00q6	460	15	in	in	IN
cord-014712-5u4e00q6	460	16	Eastern	Eastern	NNP
cord-014712-5u4e00q6	460	17	and	and	CC
cord-014712-5u4e00q6	460	18	Central	Central	NNP
cord-014712-5u4e00q6	460	19	Europe	Europe	NNP
cord-014712-5u4e00q6	460	20	(	(	-LRB-
cord-014712-5u4e00q6	460	21	ECE	ECE	NNP
cord-014712-5u4e00q6	460	22	)	)	-RRB-
cord-014712-5u4e00q6	460	23	.	.	.
cord-014712-5u4e00q6	461	1	In	in	IN
cord-014712-5u4e00q6	461	2	less	less	JJR
cord-014712-5u4e00q6	461	3	than	than	IN
cord-014712-5u4e00q6	461	4	10	10	CD
cord-014712-5u4e00q6	461	5	years	year	NNS
cord-014712-5u4e00q6	461	6	,	,	,
cord-014712-5u4e00q6	461	7	it	-PRON-	PRP
cord-014712-5u4e00q6	461	8	has	have	VBZ
cord-014712-5u4e00q6	461	9	achieved	achieve	VBN
cord-014712-5u4e00q6	461	10	remarkable	remarkable	JJ
cord-014712-5u4e00q6	461	11	success	success	NN
cord-014712-5u4e00q6	461	12	.	.	.
cord-014712-5u4e00q6	462	1	This	this	DT
cord-014712-5u4e00q6	462	2	project	project	NN
cord-014712-5u4e00q6	462	3	aims	aim	VBZ
cord-014712-5u4e00q6	462	4	to	to	TO
cord-014712-5u4e00q6	462	5	increase	increase	VB
cord-014712-5u4e00q6	462	6	knowledge	knowledge	NN
cord-014712-5u4e00q6	462	7	in	in	IN
cord-014712-5u4e00q6	462	8	the	the	DT
cord-014712-5u4e00q6	462	9	field	field	NN
cord-014712-5u4e00q6	462	10	of	of	IN
cord-014712-5u4e00q6	462	11	primary	primary	JJ
cord-014712-5u4e00q6	462	12	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	462	13	disorders	disorder	NNS
cord-014712-5u4e00q6	462	14	(	(	-LRB-
cord-014712-5u4e00q6	462	15	PID	PID	NNP
cord-014712-5u4e00q6	462	16	)	)	-RRB-
cord-014712-5u4e00q6	462	17	,	,	,
cord-014712-5u4e00q6	462	18	and	and	CC
cord-014712-5u4e00q6	462	19	to	to	TO
cord-014712-5u4e00q6	462	20	improve	improve	VB
cord-014712-5u4e00q6	462	21	the	the	DT
cord-014712-5u4e00q6	462	22	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	462	23	and	and	CC
cord-014712-5u4e00q6	462	24	treatment	treatment	NN
cord-014712-5u4e00q6	462	25	of	of	IN
cord-014712-5u4e00q6	462	26	patients	patient	NNS
cord-014712-5u4e00q6	462	27	worldwide	worldwide	RB
cord-014712-5u4e00q6	462	28	,	,	,
cord-014712-5u4e00q6	462	29	particularly	particularly	RB
cord-014712-5u4e00q6	462	30	in	in	IN
cord-014712-5u4e00q6	462	31	countries	country	NNS
cord-014712-5u4e00q6	462	32	with	with	IN
cord-014712-5u4e00q6	462	33	limited	limited	JJ
cord-014712-5u4e00q6	462	34	economic	economic	JJ
cord-014712-5u4e00q6	462	35	resources	resource	NNS
cord-014712-5u4e00q6	462	36	,	,	,
cord-014712-5u4e00q6	462	37	which	which	WDT
cord-014712-5u4e00q6	462	38	currently	currently	RB
cord-014712-5u4e00q6	462	39	report	report	VBP
cord-014712-5u4e00q6	462	40	fewer	few	JJR
cord-014712-5u4e00q6	462	41	such	such	JJ
cord-014712-5u4e00q6	462	42	patients	patient	NNS
cord-014712-5u4e00q6	462	43	than	than	IN
cord-014712-5u4e00q6	462	44	expected	expect	VBN
cord-014712-5u4e00q6	462	45	.	.	.
cord-014712-5u4e00q6	463	1	In	in	IN
cord-014712-5u4e00q6	463	2	most	most	JJS
cord-014712-5u4e00q6	463	3	ECE	ECE	NNP
cord-014712-5u4e00q6	463	4	countries	country	NNS
cord-014712-5u4e00q6	463	5	,	,	,
cord-014712-5u4e00q6	463	6	gene	gene	NN
cord-014712-5u4e00q6	463	7	sequencing	sequencing	NN
cord-014712-5u4e00q6	463	8	,	,	,
cord-014712-5u4e00q6	463	9	which	which	WDT
cord-014712-5u4e00q6	463	10	can	can	MD
cord-014712-5u4e00q6	463	11	provide	provide	VB
cord-014712-5u4e00q6	463	12	a	a	DT
cord-014712-5u4e00q6	463	13	definitive	definitive	JJ
cord-014712-5u4e00q6	463	14	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	463	15	of	of	IN
cord-014712-5u4e00q6	463	16	PID	PID	NNP
cord-014712-5u4e00q6	463	17	,	,	,
cord-014712-5u4e00q6	463	18	still	still	RB
cord-014712-5u4e00q6	463	19	remains	remain	VBZ
cord-014712-5u4e00q6	463	20	unavailable	unavailable	JJ
cord-014712-5u4e00q6	463	21	.	.	.
cord-014712-5u4e00q6	464	1	By	by	IN
cord-014712-5u4e00q6	464	2	contrast	contrast	NN
cord-014712-5u4e00q6	464	3	,	,	,
cord-014712-5u4e00q6	464	4	such	such	JJ
cord-014712-5u4e00q6	464	5	technology	technology	NN
cord-014712-5u4e00q6	464	6	is	be	VBZ
cord-014712-5u4e00q6	464	7	used	use	VBN
cord-014712-5u4e00q6	464	8	elsewhere	elsewhere	RB
cord-014712-5u4e00q6	464	9	to	to	TO
cord-014712-5u4e00q6	464	10	detect	detect	VB
cord-014712-5u4e00q6	464	11	the	the	DT
cord-014712-5u4e00q6	464	12	more	more	JJR
cord-014712-5u4e00q6	464	13	than	than	IN
cord-014712-5u4e00q6	464	14	200	200	CD
cord-014712-5u4e00q6	464	15	PID	pid	NN
cord-014712-5u4e00q6	464	16	-	-	HYPH
cord-014712-5u4e00q6	464	17	causing	cause	VBG
cord-014712-5u4e00q6	464	18	genes	gene	NNS
cord-014712-5u4e00q6	464	19	that	that	WDT
cord-014712-5u4e00q6	464	20	have	have	VBP
cord-014712-5u4e00q6	464	21	been	be	VBN
cord-014712-5u4e00q6	464	22	discovered	discover	VBN
cord-014712-5u4e00q6	464	23	in	in	IN
cord-014712-5u4e00q6	464	24	the	the	DT
cord-014712-5u4e00q6	464	25	last	last	JJ
cord-014712-5u4e00q6	464	26	three	three	CD
cord-014712-5u4e00q6	464	27	decades	decade	NNS
cord-014712-5u4e00q6	464	28	.	.	.
cord-014712-5u4e00q6	465	1	Thus	thus	RB
cord-014712-5u4e00q6	465	2	,	,	,
cord-014712-5u4e00q6	465	3	PID	PID	NNP
cord-014712-5u4e00q6	465	4	awareness	awareness	NN
cord-014712-5u4e00q6	465	5	programs	program	NNS
cord-014712-5u4e00q6	465	6	like	like	IN
cord-014712-5u4e00q6	465	7	the	the	DT
cord-014712-5u4e00q6	465	8	J	J	NNP
cord-014712-5u4e00q6	465	9	Project	Project	NNP
cord-014712-5u4e00q6	465	10	remain	remain	VBP
cord-014712-5u4e00q6	465	11	critically	critically	RB
cord-014712-5u4e00q6	465	12	important	important	JJ
cord-014712-5u4e00q6	465	13	,	,	,
cord-014712-5u4e00q6	465	14	to	to	TO
cord-014712-5u4e00q6	465	15	improve	improve	VB
cord-014712-5u4e00q6	465	16	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	465	17	facilities	facility	NNS
cord-014712-5u4e00q6	465	18	and	and	CC
cord-014712-5u4e00q6	465	19	treatment	treatment	NN
cord-014712-5u4e00q6	465	20	and	and	CC
cord-014712-5u4e00q6	465	21	to	to	TO
cord-014712-5u4e00q6	465	22	promote	promote	VB
cord-014712-5u4e00q6	465	23	clinical	clinical	JJ
cord-014712-5u4e00q6	465	24	research	research	NN
cord-014712-5u4e00q6	465	25	collaboration	collaboration	NN
cord-014712-5u4e00q6	465	26	.	.	.
cord-014712-5u4e00q6	466	1	This	this	DT
cord-014712-5u4e00q6	466	2	paper	paper	NN
cord-014712-5u4e00q6	466	3	highlights	highlight	VBZ
cord-014712-5u4e00q6	466	4	the	the	DT
cord-014712-5u4e00q6	466	5	achievements	achievement	NNS
cord-014712-5u4e00q6	466	6	of	of	IN
cord-014712-5u4e00q6	466	7	the	the	DT
cord-014712-5u4e00q6	466	8	J	J	NNP
cord-014712-5u4e00q6	466	9	Project	Project	NNP
cord-014712-5u4e00q6	466	10	and	and	CC
cord-014712-5u4e00q6	466	11	the	the	DT
cord-014712-5u4e00q6	466	12	spread	spread	NN
cord-014712-5u4e00q6	466	13	of	of	IN
cord-014712-5u4e00q6	466	14	its	-PRON-	PRP$
cord-014712-5u4e00q6	466	15	concepts	concept	NNS
cord-014712-5u4e00q6	466	16	and	and	CC
cord-014712-5u4e00q6	466	17	spirit	spirit	NN
cord-014712-5u4e00q6	466	18	to	to	IN
cord-014712-5u4e00q6	466	19	the	the	DT
cord-014712-5u4e00q6	466	20	countries	country	NNS
cord-014712-5u4e00q6	466	21	of	of	IN
cord-014712-5u4e00q6	466	22	Western	Western	NNP
cord-014712-5u4e00q6	466	23	Asia	Asia	NNP
cord-014712-5u4e00q6	466	24	.	.	.
cord-014712-5u4e00q6	467	1	Primary	Primary	NNP
cord-014712-5u4e00q6	467	2	Immunodeficiencis	Immunodeficiencis	NNP
cord-014712-5u4e00q6	467	3	(	(	-LRB-
cord-014712-5u4e00q6	467	4	PID	PID	NNP
cord-014712-5u4e00q6	467	5	)	)	-RRB-
cord-014712-5u4e00q6	467	6	are	be	VBP
cord-014712-5u4e00q6	467	7	rare	rare	JJ
cord-014712-5u4e00q6	467	8	genetically	genetically	RB
cord-014712-5u4e00q6	467	9	determined	determine	VBN
cord-014712-5u4e00q6	467	10	diseases	disease	NNS
cord-014712-5u4e00q6	467	11	,	,	,
cord-014712-5u4e00q6	467	12	occurring	occur	VBG
cord-014712-5u4e00q6	467	13	with	with	IN
cord-014712-5u4e00q6	467	14	an	an	DT
cord-014712-5u4e00q6	467	15	incidence	incidence	NN
cord-014712-5u4e00q6	467	16	of	of	IN
cord-014712-5u4e00q6	467	17	10	10	CD
cord-014712-5u4e00q6	467	18	per	per	IN
cord-014712-5u4e00q6	467	19	100	100	CD
cord-014712-5u4e00q6	467	20	000	000	CD
cord-014712-5u4e00q6	467	21	inhabitants	inhabitant	NNS
cord-014712-5u4e00q6	467	22	.	.	.
cord-014712-5u4e00q6	468	1	It	-PRON-	PRP
cord-014712-5u4e00q6	468	2	is	be	VBZ
cord-014712-5u4e00q6	468	3	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	468	4	group	group	NN
cord-014712-5u4e00q6	468	5	of	of	IN
cord-014712-5u4e00q6	468	6	disorders	disorder	NNS
cord-014712-5u4e00q6	468	7	,	,	,
cord-014712-5u4e00q6	468	8	from	from	IN
cord-014712-5u4e00q6	468	9	quite	quite	RB
cord-014712-5u4e00q6	468	10	commonly	commonly	RB
cord-014712-5u4e00q6	468	11	found	find	VBN
cord-014712-5u4e00q6	468	12	and	and	CC
cord-014712-5u4e00q6	468	13	usually	usually	RB
cord-014712-5u4e00q6	468	14	asymptomatic	asymptomatic	JJ
cord-014712-5u4e00q6	468	15	IgA	IgA	NNP
cord-014712-5u4e00q6	468	16	deficiency	deficiency	NN
cord-014712-5u4e00q6	468	17	(	(	-LRB-
cord-014712-5u4e00q6	468	18	1	1	CD
cord-014712-5u4e00q6	468	19	in	in	IN
cord-014712-5u4e00q6	468	20	600	600	CD
cord-014712-5u4e00q6	468	21	)	)	-RRB-
cord-014712-5u4e00q6	468	22	,	,	,
cord-014712-5u4e00q6	468	23	to	to	IN
cord-014712-5u4e00q6	468	24	a	a	DT
cord-014712-5u4e00q6	468	25	very	very	RB
cord-014712-5u4e00q6	468	26	rare	rare	JJ
cord-014712-5u4e00q6	468	27	diseases	disease	NNS
cord-014712-5u4e00q6	468	28	such	such	JJ
cord-014712-5u4e00q6	468	29	as	as	IN
cord-014712-5u4e00q6	468	30	Chediak	Chediak	NNP
cord-014712-5u4e00q6	468	31	-Higashi	-Higashi	.
cord-014712-5u4e00q6	468	32	(	(	-LRB-
cord-014712-5u4e00q6	468	33	1	1	CD
cord-014712-5u4e00q6	468	34	in	in	IN
cord-014712-5u4e00q6	468	35	2	2	CD
cord-014712-5u4e00q6	468	36	000	000	CD
cord-014712-5u4e00q6	468	37	000	000	CD
cord-014712-5u4e00q6	468	38	inhabitants	inhabitant	NNS
cord-014712-5u4e00q6	468	39	)	)	-RRB-
cord-014712-5u4e00q6	468	40	.	.	.
cord-014712-5u4e00q6	469	1	In	in	IN
cord-014712-5u4e00q6	469	2	2005	2005	CD
cord-014712-5u4e00q6	469	3	,	,	,
cord-014712-5u4e00q6	469	4	within	within	IN
cord-014712-5u4e00q6	469	5	the	the	DT
cord-014712-5u4e00q6	469	6	framework	framework	NN
cord-014712-5u4e00q6	469	7	of	of	IN
cord-014712-5u4e00q6	469	8	a	a	DT
cord-014712-5u4e00q6	469	9	government	government	NN
cord-014712-5u4e00q6	469	10	research	research	NN
cord-014712-5u4e00q6	469	11	project	project	NN
cord-014712-5u4e00q6	470	1	No	no	UH
cord-014712-5u4e00q6	470	2	.	.	.
cord-014712-5u4e00q6	471	1	PBZ	PBZ	NNP
cord-014712-5u4e00q6	471	2	-	-	HYPH
cord-014712-5u4e00q6	471	3	KBN-119/	KBN-119/	NNS
cord-014712-5u4e00q6	472	1	P05/	P05/	NNP
cord-014712-5u4e00q6	472	2	2005	2005	CD
cord-014712-5u4e00q6	473	1	-	-	:
cord-014712-5u4e00q6	473	2	"	"	``
cord-014712-5u4e00q6	473	3	Development	development	NN
cord-014712-5u4e00q6	473	4	,	,	,
cord-014712-5u4e00q6	473	5	improvement	improvement	NN
cord-014712-5u4e00q6	473	6	and	and	CC
cord-014712-5u4e00q6	473	7	implementation	implementation	NN
cord-014712-5u4e00q6	473	8	of	of	IN
cord-014712-5u4e00q6	473	9	highly	highly	RB
cord-014712-5u4e00q6	473	10	specialized	specialized	JJ
cord-014712-5u4e00q6	473	11	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	473	12	procedures	procedure	NNS
cord-014712-5u4e00q6	473	13	for	for	IN
cord-014712-5u4e00q6	473	14	immune	immune	NN
cord-014712-5u4e00q6	473	15	-	-	HYPH
cord-014712-5u4e00q6	473	16	mediated	mediate	VBN
cord-014712-5u4e00q6	473	17	diseases	disease	NNS
cord-014712-5u4e00q6	473	18	"	"	''
cord-014712-5u4e00q6	473	19	,	,	,
cord-014712-5u4e00q6	473	20	a	a	DT
cord-014712-5u4e00q6	473	21	network	network	NN
cord-014712-5u4e00q6	473	22	of	of	IN
cord-014712-5u4e00q6	473	23	cooperating	cooperate	VBG
cord-014712-5u4e00q6	473	24	national	national	JJ
cord-014712-5u4e00q6	473	25	centers	center	NNS
cord-014712-5u4e00q6	473	26	for	for	IN
cord-014712-5u4e00q6	473	27	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	473	28	and	and	CC
cord-014712-5u4e00q6	473	29	treatment	treatment	NN
cord-014712-5u4e00q6	473	30	of	of	IN
cord-014712-5u4e00q6	473	31	PID	PID	NNP
cord-014712-5u4e00q6	473	32	,	,	,
cord-014712-5u4e00q6	473	33	named	name	VBN
cord-014712-5u4e00q6	473	34	Polish	Polish	NNP
cord-014712-5u4e00q6	473	35	Working	Working	NNP
cord-014712-5u4e00q6	473	36	Group	Group	NNP
cord-014712-5u4e00q6	473	37	on	on	IN
cord-014712-5u4e00q6	473	38	Primary	Primary	NNP
cord-014712-5u4e00q6	473	39	Immunodeficiencies	Immunodeficiencies	NNP
cord-014712-5u4e00q6	473	40	(	(	-LRB-
cord-014712-5u4e00q6	473	41	PGR	PGR	NNP
cord-014712-5u4e00q6	473	42	PNO	PNO	NNP
cord-014712-5u4e00q6	473	43	)	)	-RRB-
cord-014712-5u4e00q6	473	44	was	be	VBD
cord-014712-5u4e00q6	473	45	founded	found	VBN
cord-014712-5u4e00q6	473	46	.	.	.
cord-014712-5u4e00q6	474	1	As	as	IN
cord-014712-5u4e00q6	474	2	a	a	DT
cord-014712-5u4e00q6	474	3	result	result	NN
cord-014712-5u4e00q6	474	4	of	of	IN
cord-014712-5u4e00q6	474	5	joint	joint	JJ
cord-014712-5u4e00q6	474	6	efforts	effort	NNS
cord-014712-5u4e00q6	474	7	of	of	IN
cord-014712-5u4e00q6	474	8	the	the	DT
cord-014712-5u4e00q6	474	9	Group	Group	NNP
cord-014712-5u4e00q6	474	10	as	as	RB
cord-014712-5u4e00q6	474	11	well	well	RB
cord-014712-5u4e00q6	474	12	as	as	IN
cord-014712-5u4e00q6	474	13	an	an	DT
cord-014712-5u4e00q6	474	14	implementation	implementation	NN
cord-014712-5u4e00q6	474	15	of	of	IN
cord-014712-5u4e00q6	474	16	three	three	CD
cord-014712-5u4e00q6	474	17	EU	EU	NNP
cord-014712-5u4e00q6	474	18	grants	grant	NNS
cord-014712-5u4e00q6	474	19	[	[	-LRB-
cord-014712-5u4e00q6	474	20	EURO	EURO	NNP
cord-014712-5u4e00q6	474	21	-	-	HYPH
cord-014712-5u4e00q6	474	22	PID	PID	NNP
cord-014712-5u4e00q6	474	23	-NAS	-NAS	:
cord-014712-5u4e00q6	474	24	QLRT	QLRT	NNP
cord-014712-5u4e00q6	475	1	-2001	-2001	:
cord-014712-5u4e00q6	476	1	-0274	-0274	.
cord-014712-5u4e00q6	477	1	(	(	-LRB-
cord-014712-5u4e00q6	477	2	2001	2001	CD
cord-014712-5u4e00q6	477	3	-2004	-2004	NNP
cord-014712-5u4e00q6	477	4	,	,	,
cord-014712-5u4e00q6	477	5	EURO	EURO	NNP
cord-014712-5u4e00q6	477	6	-	-	HYPH
cord-014712-5u4e00q6	477	7	POLICY	POLICY	NNP
cord-014712-5u4e00q6	477	8	-PID	-pid	ADD
cord-014712-5u4e00q6	478	1	SP23	SP23	NNP
cord-014712-5u4e00q6	478	2	-CT-2005	-CT-2005	NNP
cord-014712-5u4e00q6	478	3	-	-	HYPH
cord-014712-5u4e00q6	478	4	006411	006411	CD
cord-014712-5u4e00q6	479	1	,	,	,
cord-014712-5u4e00q6	479	2	EURO	EURO	NNP
cord-014712-5u4e00q6	479	3	-	-	HYPH
cord-014712-5u4e00q6	479	4	GENE	GENE	NNP
cord-014712-5u4e00q6	479	5	-SCAN	-SCAN	.
cord-014712-5u4e00q6	480	1	(	(	-LRB-
cord-014712-5u4e00q6	480	2	223	223	CD
cord-014712-5u4e00q6	480	3	,	,	,
cord-014712-5u4e00q6	480	4	293	293	CD
cord-014712-5u4e00q6	480	5	)	)	-RRB-
cord-014712-5u4e00q6	480	6	]	]	-RRB-
cord-014712-5u4e00q6	481	1	the	the	DT
cord-014712-5u4e00q6	481	2	number	number	NN
cord-014712-5u4e00q6	481	3	of	of	IN
cord-014712-5u4e00q6	481	4	centers	center	NNS
cord-014712-5u4e00q6	481	5	actively	actively	RB
cord-014712-5u4e00q6	481	6	working	work	VBG
cord-014712-5u4e00q6	481	7	in	in	IN
cord-014712-5u4e00q6	481	8	the	the	DT
cord-014712-5u4e00q6	481	9	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	481	10	and	and	CC
cord-014712-5u4e00q6	481	11	treatment	treatment	NN
cord-014712-5u4e00q6	481	12	of	of	IN
cord-014712-5u4e00q6	481	13	primary	primary	JJ
cord-014712-5u4e00q6	481	14	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	481	15	increased	increase	VBD
cord-014712-5u4e00q6	481	16	.	.	.
cord-014712-5u4e00q6	482	1	Up	up	IN
cord-014712-5u4e00q6	482	2	todate	todate	NN
cord-014712-5u4e00q6	482	3	PGR	PGR	NNP
cord-014712-5u4e00q6	482	4	PNO	PNO	NNP
cord-014712-5u4e00q6	482	5	includes	include	VBZ
cord-014712-5u4e00q6	482	6	15	15	CD
cord-014712-5u4e00q6	482	7	pediatric	pediatric	JJ
cord-014712-5u4e00q6	482	8	centers	center	NNS
cord-014712-5u4e00q6	482	9	,	,	,
cord-014712-5u4e00q6	482	10	and	and	CC
cord-014712-5u4e00q6	482	11	since	since	IN
cord-014712-5u4e00q6	482	12	2012	2012	CD
cord-014712-5u4e00q6	482	13	-11	-11	IN
cord-014712-5u4e00q6	482	14	centers	center	NNS
cord-014712-5u4e00q6	482	15	for	for	IN
cord-014712-5u4e00q6	482	16	adults	adult	NNS
cord-014712-5u4e00q6	482	17	.	.	.
cord-014712-5u4e00q6	483	1	Development	development	NN
cord-014712-5u4e00q6	483	2	and	and	CC
cord-014712-5u4e00q6	483	3	dissemination	dissemination	NN
cord-014712-5u4e00q6	483	4	of	of	IN
cord-014712-5u4e00q6	483	5	new	new	JJ
cord-014712-5u4e00q6	483	6	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	483	7	and	and	CC
cord-014712-5u4e00q6	483	8	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	483	9	standards	standard	NNS
cord-014712-5u4e00q6	483	10	contributed	contribute	VBD
cord-014712-5u4e00q6	483	11	significantly	significantly	RB
cord-014712-5u4e00q6	483	12	to	to	IN
cord-014712-5u4e00q6	483	13	the	the	DT
cord-014712-5u4e00q6	483	14	increase	increase	NN
cord-014712-5u4e00q6	483	15	in	in	IN
cord-014712-5u4e00q6	483	16	detection	detection	NN
cord-014712-5u4e00q6	483	17	PID	pid	NN
cord-014712-5u4e00q6	483	18	.	.	.
cord-014712-5u4e00q6	484	1	With	with	IN
cord-014712-5u4e00q6	484	2	early	early	JJ
cord-014712-5u4e00q6	484	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	484	4	of	of	IN
cord-014712-5u4e00q6	484	5	the	the	DT
cord-014712-5u4e00q6	484	6	disease	disease	NN
cord-014712-5u4e00q6	484	7	-the	-the	ADD
cord-014712-5u4e00q6	484	8	implementation	implementation	NN
cord-014712-5u4e00q6	484	9	of	of	IN
cord-014712-5u4e00q6	484	10	appropriate	appropriate	JJ
cord-014712-5u4e00q6	484	11	treatment	treatment	NN
cord-014712-5u4e00q6	484	12	,	,	,
cord-014712-5u4e00q6	484	13	including	include	VBG
cord-014712-5u4e00q6	484	14	gamma	gamma	NN
cord-014712-5u4e00q6	484	15	globulin	globulin	NN
cord-014712-5u4e00q6	484	16	replacement	replacement	NN
cord-014712-5u4e00q6	484	17	therapy	therapy	NN
cord-014712-5u4e00q6	484	18	together	together	RB
cord-014712-5u4e00q6	484	19	with	with	IN
cord-014712-5u4e00q6	484	20	quality	quality	NN
cord-014712-5u4e00q6	484	21	of	of	IN
cord-014712-5u4e00q6	484	22	life	life	NN
cord-014712-5u4e00q6	484	23	has	have	VBZ
cord-014712-5u4e00q6	484	24	improved	improve	VBN
cord-014712-5u4e00q6	484	25	.	.	.
cord-014712-5u4e00q6	485	1	In	in	IN
cord-014712-5u4e00q6	485	2	spite	spite	NN
cord-014712-5u4e00q6	485	3	of	of	IN
cord-014712-5u4e00q6	485	4	all	all	DT
cord-014712-5u4e00q6	485	5	efforts	effort	NNS
cord-014712-5u4e00q6	485	6	recognition	recognition	NN
cord-014712-5u4e00q6	485	7	of	of	IN
cord-014712-5u4e00q6	485	8	PID	PID	NNP
cord-014712-5u4e00q6	485	9	in	in	IN
cord-014712-5u4e00q6	485	10	Poland	Poland	NNP
cord-014712-5u4e00q6	485	11	is	be	VBZ
cord-014712-5u4e00q6	485	12	very	very	RB
cord-014712-5u4e00q6	485	13	rare	rare	JJ
cord-014712-5u4e00q6	485	14	and	and	CC
cord-014712-5u4e00q6	485	15	currently	currently	RB
cord-014712-5u4e00q6	485	16	is	be	VBZ
cord-014712-5u4e00q6	485	17	1.44	1.44	CD
cord-014712-5u4e00q6	485	18	to	to	TO
cord-014712-5u4e00q6	485	19	100	100	CD
cord-014712-5u4e00q6	485	20	000	000	CD
cord-014712-5u4e00q6	485	21	,	,	,
cord-014712-5u4e00q6	485	22	what	what	WP
cord-014712-5u4e00q6	485	23	is	be	VBZ
cord-014712-5u4e00q6	485	24	almost	almost	RB
cord-014712-5u4e00q6	485	25	10	10	CD
cord-014712-5u4e00q6	485	26	times	time	NNS
cord-014712-5u4e00q6	485	27	smaller	small	JJR
cord-014712-5u4e00q6	485	28	than	than	IN
cord-014712-5u4e00q6	485	29	in	in	IN
cord-014712-5u4e00q6	485	30	Europe	Europe	NNP
cord-014712-5u4e00q6	485	31	(	(	-LRB-
cord-014712-5u4e00q6	485	32	www.ESID.org	www.ESID.org	NNP
cord-014712-5u4e00q6	485	33	)	)	-RRB-
cord-014712-5u4e00q6	485	34	.	.	.
cord-014712-5u4e00q6	486	1	At	at	IN
cord-014712-5u4e00q6	486	2	the	the	DT
cord-014712-5u4e00q6	486	3	moment	moment	NN
cord-014712-5u4e00q6	486	4	,	,	,
cord-014712-5u4e00q6	486	5	a	a	DT
cord-014712-5u4e00q6	486	6	nationwide	nationwide	JJ
cord-014712-5u4e00q6	486	7	registry	registry	NN
cord-014712-5u4e00q6	486	8	of	of	IN
cord-014712-5u4e00q6	486	9	children	child	NNS
cord-014712-5u4e00q6	486	10	and	and	CC
cord-014712-5u4e00q6	486	11	adults	adult	NNS
cord-014712-5u4e00q6	486	12	with	with	IN
cord-014712-5u4e00q6	486	13	PID	PID	NNP
cord-014712-5u4e00q6	486	14	consists	consist	VBZ
cord-014712-5u4e00q6	486	15	of	of	IN
cord-014712-5u4e00q6	486	16	3	3	CD
cord-014712-5u4e00q6	486	17	368	368	CD
cord-014712-5u4e00q6	486	18	patients	patient	NNS
cord-014712-5u4e00q6	486	19	.	.	.
cord-014712-5u4e00q6	487	1	In	in	IN
cord-014712-5u4e00q6	487	2	September	September	NNP
cord-014712-5u4e00q6	487	3	2013	2013	CD
cord-014712-5u4e00q6	487	4	PGR	PGR	NNP
cord-014712-5u4e00q6	487	5	-PNO	-PNO	-LRB-
cord-014712-5u4e00q6	487	6	summarized	summarize	VBN
cord-014712-5u4e00q6	487	7	in	in	IN
cord-014712-5u4e00q6	487	8	the	the	DT
cord-014712-5u4e00q6	487	9	annual	annual	JJ
cord-014712-5u4e00q6	487	10	report	report	NN
cord-014712-5u4e00q6	487	11	the	the	DT
cord-014712-5u4e00q6	487	12	current	current	JJ
cord-014712-5u4e00q6	487	13	status	status	NN
cord-014712-5u4e00q6	487	14	of	of	IN
cord-014712-5u4e00q6	487	15	the	the	DT
cord-014712-5u4e00q6	487	16	substitution	substitution	NN
cord-014712-5u4e00q6	487	17	therapy	therapy	NN
cord-014712-5u4e00q6	487	18	with	with	IN
cord-014712-5u4e00q6	487	19	intravenous	intravenous	JJ
cord-014712-5u4e00q6	487	20	and	and	CC
cord-014712-5u4e00q6	487	21	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	487	22	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	487	23	therapy	therapy	NN
cord-014712-5u4e00q6	487	24	in	in	IN
cord-014712-5u4e00q6	487	25	children	child	NNS
cord-014712-5u4e00q6	487	26	and	and	CC
cord-014712-5u4e00q6	487	27	adults	adult	NNS
cord-014712-5u4e00q6	487	28	with	with	IN
cord-014712-5u4e00q6	487	29	PID	PID	NNP
cord-014712-5u4e00q6	487	30	in	in	IN
cord-014712-5u4e00q6	487	31	Poland	Poland	NNP
cord-014712-5u4e00q6	487	32	.	.	.
cord-014712-5u4e00q6	488	1	On	on	IN
cord-014712-5u4e00q6	488	2	the	the	DT
cord-014712-5u4e00q6	488	3	basis	basis	NN
cord-014712-5u4e00q6	488	4	of	of	IN
cord-014712-5u4e00q6	488	5	available	available	JJ
cord-014712-5u4e00q6	488	6	information	information	NN
cord-014712-5u4e00q6	488	7	,	,	,
cord-014712-5u4e00q6	488	8	half	half	NN
cord-014712-5u4e00q6	488	9	of	of	IN
cord-014712-5u4e00q6	488	10	all	all	DT
cord-014712-5u4e00q6	488	11	patients	patient	NNS
cord-014712-5u4e00q6	488	12	(	(	-LRB-
cord-014712-5u4e00q6	488	13	1	1	CD
cord-014712-5u4e00q6	488	14	684	684	CD
cord-014712-5u4e00q6	488	15	children	child	NNS
cord-014712-5u4e00q6	488	16	and	and	CC
cord-014712-5u4e00q6	488	17	adults	adult	NNS
cord-014712-5u4e00q6	488	18	)	)	-RRB-
cord-014712-5u4e00q6	488	19	were	be	VBD
cord-014712-5u4e00q6	488	20	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	488	21	to	to	TO
cord-014712-5u4e00q6	488	22	have	have	VB
cord-014712-5u4e00q6	488	23	antibody	antibody	NN
cord-014712-5u4e00q6	488	24	deficiency	deficiency	NN
cord-014712-5u4e00q6	488	25	.	.	.
cord-014712-5u4e00q6	489	1	These	these	DT
cord-014712-5u4e00q6	489	2	data	datum	NNS
cord-014712-5u4e00q6	489	3	are	be	VBP
cord-014712-5u4e00q6	489	4	similar	similar	JJ
cord-014712-5u4e00q6	489	5	to	to	IN
cord-014712-5u4e00q6	489	6	the	the	DT
cord-014712-5u4e00q6	489	7	register	register	NN
cord-014712-5u4e00q6	489	8	of	of	IN
cord-014712-5u4e00q6	489	9	a	a	DT
cord-014712-5u4e00q6	489	10	European	european	JJ
cord-014712-5u4e00q6	489	11	database	database	NN
cord-014712-5u4e00q6	489	12	ESID	ESID	NNP
cord-014712-5u4e00q6	489	13	,	,	,
cord-014712-5u4e00q6	489	14	where	where	WRB
cord-014712-5u4e00q6	489	15	the	the	DT
cord-014712-5u4e00q6	489	16	percentage	percentage	NN
cord-014712-5u4e00q6	489	17	of	of	IN
cord-014712-5u4e00q6	489	18	patients	patient	NNS
cord-014712-5u4e00q6	489	19	with	with	IN
cord-014712-5u4e00q6	489	20	PID	PID	NNP
cord-014712-5u4e00q6	489	21	with	with	IN
cord-014712-5u4e00q6	489	22	a	a	DT
cord-014712-5u4e00q6	489	23	predominance	predominance	NN
cord-014712-5u4e00q6	489	24	of	of	IN
cord-014712-5u4e00q6	489	25	antibody	antibody	NN
cord-014712-5u4e00q6	489	26	deficiency	deficiency	NN
cord-014712-5u4e00q6	489	27	is	be	VBZ
cord-014712-5u4e00q6	489	28	more	more	JJR
cord-014712-5u4e00q6	489	29	than	than	IN
cord-014712-5u4e00q6	489	30	56	56	CD
cord-014712-5u4e00q6	489	31	%	%	NN
cord-014712-5u4e00q6	490	1	(	(	-LRB-
cord-014712-5u4e00q6	490	2	www.ESID.org	www.ESID.org	NNP
cord-014712-5u4e00q6	490	3	)	)	-RRB-
cord-014712-5u4e00q6	490	4	Development	development	NN
cord-014712-5u4e00q6	490	5	and	and	CC
cord-014712-5u4e00q6	490	6	dissemination	dissemination	NN
cord-014712-5u4e00q6	490	7	of	of	IN
cord-014712-5u4e00q6	490	8	new	new	JJ
cord-014712-5u4e00q6	490	9	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	490	10	and	and	CC
cord-014712-5u4e00q6	490	11	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	490	12	standards	standard	NNS
cord-014712-5u4e00q6	490	13	as	as	RB
cord-014712-5u4e00q6	490	14	well	well	RB
cord-014712-5u4e00q6	490	15	as	as	IN
cord-014712-5u4e00q6	490	16	a	a	DT
cord-014712-5u4e00q6	490	17	national	national	JJ
cord-014712-5u4e00q6	490	18	cooperation	cooperation	NN
cord-014712-5u4e00q6	490	19	contribute	contribute	VB
cord-014712-5u4e00q6	490	20	significantly	significantly	RB
cord-014712-5u4e00q6	490	21	to	to	IN
cord-014712-5u4e00q6	490	22	the	the	DT
cord-014712-5u4e00q6	490	23	increased	increase	VBN
cord-014712-5u4e00q6	490	24	detection	detection	NN
cord-014712-5u4e00q6	490	25	of	of	IN
cord-014712-5u4e00q6	490	26	PID	PID	NNP
cord-014712-5u4e00q6	490	27	.	.	.
cord-014712-5u4e00q6	491	1	Early	early	JJ
cord-014712-5u4e00q6	491	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	491	3	of	of	IN
cord-014712-5u4e00q6	491	4	the	the	DT
cord-014712-5u4e00q6	491	5	disease	disease	NN
cord-014712-5u4e00q6	491	6	is	be	VBZ
cord-014712-5u4e00q6	491	7	followed	follow	VBN
cord-014712-5u4e00q6	491	8	by	by	IN
cord-014712-5u4e00q6	491	9	earlier	early	JJR
cord-014712-5u4e00q6	491	10	implementation	implementation	NN
cord-014712-5u4e00q6	491	11	of	of	IN
cord-014712-5u4e00q6	491	12	appropriate	appropriate	JJ
cord-014712-5u4e00q6	491	13	treatment	treatment	NN
cord-014712-5u4e00q6	491	14	,	,	,
cord-014712-5u4e00q6	491	15	including	include	VBG
cord-014712-5u4e00q6	491	16	gammaglobulin	gammaglobulin	NNP
cord-014712-5u4e00q6	491	17	replacement	replacement	NN
cord-014712-5u4e00q6	491	18	therapy	therapy	NN
cord-014712-5u4e00q6	491	19	together	together	RB
cord-014712-5u4e00q6	491	20	with	with	IN
cord-014712-5u4e00q6	491	21	improvement	improvement	NN
cord-014712-5u4e00q6	491	22	of	of	IN
cord-014712-5u4e00q6	491	23	quality	quality	NN
cord-014712-5u4e00q6	491	24	of	of	IN
cord-014712-5u4e00q6	491	25	life	life	NN
cord-014712-5u4e00q6	491	26	.	.	.
cord-014712-5u4e00q6	492	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	492	2	of	of	IN
cord-014712-5u4e00q6	492	3	WAS	be	VBD
cord-014712-5u4e00q6	492	4	were	be	VBD
cord-014712-5u4e00q6	492	5	identified	identify	VBN
cord-014712-5u4e00q6	492	6	in	in	IN
cord-014712-5u4e00q6	492	7	38	38	CD
cord-014712-5u4e00q6	492	8	WAS	be	VBD
cord-014712-5u4e00q6	492	9	boys	boy	NNS
cord-014712-5u4e00q6	492	10	and	and	CC
cord-014712-5u4e00q6	492	11	in	in	IN
cord-014712-5u4e00q6	492	12	10	10	CD
cord-014712-5u4e00q6	492	13	heterozygote	heterozygote	NN
cord-014712-5u4e00q6	492	14	mothers	mother	NNS
cord-014712-5u4e00q6	492	15	.	.	.
cord-014712-5u4e00q6	493	1	Frequently	frequently	RB
cord-014712-5u4e00q6	493	2	genetic	genetic	JJ
cord-014712-5u4e00q6	493	3	damages	damage	NNS
cord-014712-5u4e00q6	493	4	occur	occur	VBP
cord-014712-5u4e00q6	493	5	in	in	IN
cord-014712-5u4e00q6	493	6	1,2,7,10	1,2,7,10	CD
cord-014712-5u4e00q6	493	7	exones	exones	NNPS
cord-014712-5u4e00q6	493	8	and	and	CC
cord-014712-5u4e00q6	493	9	6,8	6,8	CD
cord-014712-5u4e00q6	493	10	intrones	introne	NNS
cord-014712-5u4e00q6	493	11	:	:	:
cord-014712-5u4e00q6	493	12	deletions	deletion	NNS
cord-014712-5u4e00q6	493	13	(	(	-LRB-
cord-014712-5u4e00q6	493	14	11	11	CD
cord-014712-5u4e00q6	493	15	)	)	-RRB-
cord-014712-5u4e00q6	493	16	,	,	,
cord-014712-5u4e00q6	493	17	splice	splice	NN
cord-014712-5u4e00q6	493	18	-	-	HYPH
cord-014712-5u4e00q6	493	19	site	site	NN
cord-014712-5u4e00q6	493	20	mutation	mutation	NN
cord-014712-5u4e00q6	493	21	(	(	-LRB-
cord-014712-5u4e00q6	493	22	9	9	CD
cord-014712-5u4e00q6	493	23	)	)	-RRB-
cord-014712-5u4e00q6	493	24	,	,	,
cord-014712-5u4e00q6	493	25	missens	missens	NNP
cord-014712-5u4e00q6	493	26	(	(	-LRB-
cord-014712-5u4e00q6	493	27	12	12	CD
cord-014712-5u4e00q6	493	28	)	)	-RRB-
cord-014712-5u4e00q6	493	29	,	,	,
cord-014712-5u4e00q6	493	30	insertions	insertion	NNS
cord-014712-5u4e00q6	493	31	(	(	-LRB-
cord-014712-5u4e00q6	493	32	6	6	CD
cord-014712-5u4e00q6	493	33	)	)	-RRB-
cord-014712-5u4e00q6	493	34	.	.	.
cord-014712-5u4e00q6	494	1	Deletions	deletion	NNS
cord-014712-5u4e00q6	494	2	and	and	CC
cord-014712-5u4e00q6	494	3	insertions	insertion	NNS
cord-014712-5u4e00q6	494	4	lead	lead	VBP
cord-014712-5u4e00q6	494	5	to	to	TO
cord-014712-5u4e00q6	494	6	stop	stop	VB
cord-014712-5u4e00q6	494	7	-	-	HYPH
cord-014712-5u4e00q6	494	8	codon	codon	NN
cord-014712-5u4e00q6	494	9	in	in	IN
cord-014712-5u4e00q6	494	10	7	7	CD
cord-014712-5u4e00q6	494	11	cases	case	NNS
cord-014712-5u4e00q6	494	12	.	.	.
cord-014712-5u4e00q6	495	1	31	31	CD
cord-014712-5u4e00q6	496	1	NBS	NBS	NNP
cord-014712-5u4e00q6	496	2	patients	patient	NNS
cord-014712-5u4e00q6	496	3	were	be	VBD
cord-014712-5u4e00q6	496	4	homozygous	homozygous	JJ
cord-014712-5u4e00q6	496	5	for	for	IN
cord-014712-5u4e00q6	496	6	657del5	657del5	CD
cord-014712-5u4e00q6	496	7	mutation	mutation	NN
cord-014712-5u4e00q6	496	8	and	and	CC
cord-014712-5u4e00q6	496	9	oneheterozygote	oneheterozygote	NN
cord-014712-5u4e00q6	496	10	for	for	IN
cord-014712-5u4e00q6	496	11	657del5	657del5	CD
cord-014712-5u4e00q6	496	12	had	have	VBD
cord-014712-5u4e00q6	497	1	681delT	681delt	CD
cord-014712-5u4e00q6	498	1	X	X	NNP
cord-014712-5u4e00q6	498	2	-	-	NN
cord-014712-5u4e00q6	498	3	CGD	CGD	NNP
cord-014712-5u4e00q6	498	4	:	:	:
cord-014712-5u4e00q6	498	5	deletions	deletion	NNS
cord-014712-5u4e00q6	498	6	(	(	-LRB-
cord-014712-5u4e00q6	498	7	10	10	CD
cord-014712-5u4e00q6	498	8	)	)	-RRB-
cord-014712-5u4e00q6	498	9	and	and	CC
cord-014712-5u4e00q6	498	10	nonsens	nonsens	NNP
cord-014712-5u4e00q6	498	11	(	(	-LRB-
cord-014712-5u4e00q6	498	12	6	6	CD
cord-014712-5u4e00q6	498	13	)	)	-RRB-
cord-014712-5u4e00q6	498	14	mutations	mutation	NNS
cord-014712-5u4e00q6	498	15	in	in	IN
cord-014712-5u4e00q6	498	16	different	different	JJ
cord-014712-5u4e00q6	498	17	exons	exon	NNS
cord-014712-5u4e00q6	498	18	of	of	IN
cord-014712-5u4e00q6	498	19	CYBB	CYBB	NNP
cord-014712-5u4e00q6	498	20	were	be	VBD
cord-014712-5u4e00q6	498	21	observed	observe	VBN
cord-014712-5u4e00q6	498	22	most	most	RBS
cord-014712-5u4e00q6	498	23	often	often	RB
cord-014712-5u4e00q6	498	24	.	.	.
cord-014712-5u4e00q6	499	1	In	in	IN
cord-014712-5u4e00q6	499	2	33	33	CD
cord-014712-5u4e00q6	499	3	families	family	NNS
cord-014712-5u4e00q6	499	4	was	be	VBD
cord-014712-5u4e00q6	499	5	performed	perform	VBN
cord-014712-5u4e00q6	499	6	prenatal	prenatal	JJ
cord-014712-5u4e00q6	499	7	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	499	8	:	:	:
cord-014712-5u4e00q6	500	1	X	X	NNS
cord-014712-5u4e00q6	500	2	-	-	NNS
cord-014712-5u4e00q6	500	3	SCID-4	scid-4	NN
cord-014712-5u4e00q6	500	4	,	,	,
cord-014712-5u4e00q6	500	5	HIGM1	higm1	NN
cord-014712-5u4e00q6	500	6	-	-	HYPH
cord-014712-5u4e00q6	500	7	4	4	CD
cord-014712-5u4e00q6	500	8	,	,	,
cord-014712-5u4e00q6	500	9	XLA-2	XLA-2	NNP
cord-014712-5u4e00q6	500	10	,	,	,
cord-014712-5u4e00q6	501	1	WAS-6	WAS-6	NNP
cord-014712-5u4e00q6	501	2	,	,	,
cord-014712-5u4e00q6	501	3	NBS-6	NBS-6	NNP
cord-014712-5u4e00q6	501	4	,	,	,
cord-014712-5u4e00q6	501	5	A	A	NNP
cord-014712-5u4e00q6	501	6	-	-	HYPH
cord-014712-5u4e00q6	501	7	T-4	t-4	NN
cord-014712-5u4e00q6	501	8	,	,	,
cord-014712-5u4e00q6	501	9	CGD-5	CGD-5	NNP
cord-014712-5u4e00q6	501	10	,	,	,
cord-014712-5u4e00q6	501	11	XLP-1	XLP-1	NNP
cord-014712-5u4e00q6	501	12	,	,	,
cord-014712-5u4e00q6	502	1	DNAlig4	DNAlig4	NNP
cord-014712-5u4e00q6	502	2	-	-	HYPH
cord-014712-5u4e00q6	502	3	1	1	CD
cord-014712-5u4e00q6	502	4	.	.	.
cord-014712-5u4e00q6	503	1	Healthy	healthy	JJ
cord-014712-5u4e00q6	503	2	children	child	NNS
cord-014712-5u4e00q6	503	3	-31	-31	CD
cord-014712-5u4e00q6	503	4	.	.	.
cord-014712-5u4e00q6	504	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	504	2	severe	severe	JJ
cord-014712-5u4e00q6	504	3	complicated	complicated	JJ
cord-014712-5u4e00q6	504	4	infections	infection	NNS
cord-014712-5u4e00q6	504	5	developed	develop	VBN
cord-014712-5u4e00q6	504	6	in	in	IN
cord-014712-5u4e00q6	504	7	90	90	CD
cord-014712-5u4e00q6	504	8	%	%	NN
cord-014712-5u4e00q6	504	9	of	of	IN
cord-014712-5u4e00q6	504	10	PID	pid	NN
cord-014712-5u4e00q6	504	11	patients	patient	NNS
cord-014712-5u4e00q6	504	12	.	.	.
cord-014712-5u4e00q6	505	1	Antibody	antibody	NN
cord-014712-5u4e00q6	505	2	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	505	3	:	:	:
cord-014712-5u4e00q6	505	4	bacterial	bacterial	JJ
cord-014712-5u4e00q6	505	5	infections	infection	NNS
cord-014712-5u4e00q6	505	6	-100	-100	NN
cord-014712-5u4e00q6	505	7	%	%	NN
cord-014712-5u4e00q6	505	8	,	,	,
cord-014712-5u4e00q6	505	9	enteroviral	enteroviral	JJ
cord-014712-5u4e00q6	505	10	-17	-17	CD
cord-014712-5u4e00q6	505	11	%	%	NN
cord-014712-5u4e00q6	505	12	,	,	,
cord-014712-5u4e00q6	505	13	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	505	14	2	2	CD
cord-014712-5u4e00q6	505	15	cases	case	NNS
cord-014712-5u4e00q6	505	16	,	,	,
cord-014712-5u4e00q6	505	17	atypical	atypical	JJ
cord-014712-5u4e00q6	505	18	mycobacteriosis	mycobacteriosis	NN
cord-014712-5u4e00q6	505	19	-1	-1	NNP
cord-014712-5u4e00q6	505	20	case	case	NN
cord-014712-5u4e00q6	505	21	.	.	.
cord-014712-5u4e00q6	506	1	Combined	combined	JJ
cord-014712-5u4e00q6	506	2	PID	pid	NN
cord-014712-5u4e00q6	506	3	:	:	:
cord-014712-5u4e00q6	506	4	bacterial	bacterial	JJ
cord-014712-5u4e00q6	506	5	infections	infection	NNS
cord-014712-5u4e00q6	507	1	-100	-100	NNP
cord-014712-5u4e00q6	508	1	%	%	NN
cord-014712-5u4e00q6	508	2	,	,	,
cord-014712-5u4e00q6	508	3	fungal	fungal	JJ
cord-014712-5u4e00q6	508	4	-40	-40	NNS
cord-014712-5u4e00q6	508	5	%	%	NN
cord-014712-5u4e00q6	508	6	,	,	,
cord-014712-5u4e00q6	508	7	viral	viral	JJ
cord-014712-5u4e00q6	508	8	-37	-37	NN
cord-014712-5u4e00q6	508	9	%	%	NN
cord-014712-5u4e00q6	508	10	,	,	,
cord-014712-5u4e00q6	508	11	opportunistic	opportunistic	JJ
cord-014712-5u4e00q6	508	12	(	(	-LRB-
cord-014712-5u4e00q6	508	13	Pneumocystis	Pneumocystis	NNP
cord-014712-5u4e00q6	508	14	jiroveci	jiroveci	NNS
cord-014712-5u4e00q6	508	15	)	)	-RRB-
cord-014712-5u4e00q6	509	1	-48	-48	NNP
cord-014712-5u4e00q6	509	2	%	%	NN
cord-014712-5u4e00q6	509	3	,	,	,
cord-014712-5u4e00q6	509	4	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	509	5	-70	-70	NN
cord-014712-5u4e00q6	509	6	%	%	NN
cord-014712-5u4e00q6	509	7	(	(	-LRB-
cord-014712-5u4e00q6	509	8	24	24	CD
cord-014712-5u4e00q6	509	9	-complication	-complication	CD
cord-014712-5u4e00q6	509	10	of	of	IN
cord-014712-5u4e00q6	509	11	BCG	BCG	NNP
cord-014712-5u4e00q6	509	12	vaccination	vaccination	NN
cord-014712-5u4e00q6	509	13	,	,	,
cord-014712-5u4e00q6	509	14	5	5	CD
cord-014712-5u4e00q6	509	15	-tuberculosis	-tuberculosis	CD
cord-014712-5u4e00q6	509	16	or	or	CC
cord-014712-5u4e00q6	509	17	atypical	atypical	JJ
cord-014712-5u4e00q6	509	18	mycobacteriosis	mycobacteriosis	NN
cord-014712-5u4e00q6	509	19	)	)	-RRB-
cord-014712-5u4e00q6	509	20	.	.	.
cord-014712-5u4e00q6	510	1	CGD	CGD	NNP
cord-014712-5u4e00q6	510	2	:	:	:
cord-014712-5u4e00q6	510	3	bacterial	bacterial	JJ
cord-014712-5u4e00q6	510	4	-62	-62	NN
cord-014712-5u4e00q6	510	5	%	%	NN
cord-014712-5u4e00q6	510	6	(	(	-LRB-
cord-014712-5u4e00q6	510	7	Staph.aureus	staph.aureu	NNS
cord-014712-5u4e00q6	510	8	,	,	,
cord-014712-5u4e00q6	510	9	E.coli	E.coli	NNS
cord-014712-5u4e00q6	510	10	,	,	,
cord-014712-5u4e00q6	510	11	B.cepatia	B.cepatia	NNP
cord-014712-5u4e00q6	510	12	,	,	,
cord-014712-5u4e00q6	510	13	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	510	14	spp	spp	NNS
cord-014712-5u4e00q6	510	15	.	.	.
cord-014712-5u4e00q6	511	1	,	,	,
cord-014712-5u4e00q6	511	2	Klebsiella	Klebsiella	NNP
cord-014712-5u4e00q6	511	3	spp	spp	NNS
cord-014712-5u4e00q6	511	4	.	.	.
cord-014712-5u4e00q6	511	5	)	)	-RRB-
cord-014712-5u4e00q6	511	6	,	,	,
cord-014712-5u4e00q6	511	7	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	511	8	-75	-75	CD
cord-014712-5u4e00q6	511	9	%	%	NN
cord-014712-5u4e00q6	511	10	(	(	-LRB-
cord-014712-5u4e00q6	511	11	85	85	CD
cord-014712-5u4e00q6	511	12	%	%	NN
cord-014712-5u4e00q6	511	13	BCG	BCG	NNP
cord-014712-5u4e00q6	511	14	origin	origin	NN
cord-014712-5u4e00q6	511	15	,	,	,
cord-014712-5u4e00q6	511	16	15	15	CD
cord-014712-5u4e00q6	511	17	%	%	NN
cord-014712-5u4e00q6	511	18	-tuberculosis	-tuberculosis	NN
cord-014712-5u4e00q6	511	19	)	)	-RRB-
cord-014712-5u4e00q6	511	20	,	,	,
cord-014712-5u4e00q6	511	21	aspergilosis	aspergilosis	NN
cord-014712-5u4e00q6	511	22	-30	-30	CD
cord-014712-5u4e00q6	511	23	%	%	NN
cord-014712-5u4e00q6	511	24	Immune	immune	JJ
cord-014712-5u4e00q6	511	25	disregulation	disregulation	NN
cord-014712-5u4e00q6	511	26	syndromes	syndrome	NNS
cord-014712-5u4e00q6	511	27	(	(	-LRB-
cord-014712-5u4e00q6	511	28	XLP1	XLP1	NNP
cord-014712-5u4e00q6	511	29	[	[	-LRB-
cord-014712-5u4e00q6	511	30	10	10	CD
cord-014712-5u4e00q6	511	31	]	]	-RRB-
cord-014712-5u4e00q6	511	32	and	and	CC
cord-014712-5u4e00q6	511	33	ALPS	ALPS	NNP
cord-014712-5u4e00q6	511	34	[	[	-LRB-
cord-014712-5u4e00q6	511	35	41	41	CD
cord-014712-5u4e00q6	511	36	]	]	-RRB-
cord-014712-5u4e00q6	511	37	)	)	-RRB-
cord-014712-5u4e00q6	511	38	:	:	:
cord-014712-5u4e00q6	511	39	bacterial	bacterial	JJ
cord-014712-5u4e00q6	511	40	infections	infection	NNS
cord-014712-5u4e00q6	511	41	-20	-20	NFP
cord-014712-5u4e00q6	511	42	%	%	NN
cord-014712-5u4e00q6	511	43	,	,	,
cord-014712-5u4e00q6	511	44	viral	viral	JJ
cord-014712-5u4e00q6	511	45	-8	-8	JJS
cord-014712-5u4e00q6	511	46	%	%	NN
cord-014712-5u4e00q6	511	47	(	(	-LRB-
cord-014712-5u4e00q6	511	48	EBV	EBV	NNP
cord-014712-5u4e00q6	511	49	)	)	-RRB-
cord-014712-5u4e00q6	511	50	.	.	.
cord-014712-5u4e00q6	512	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	512	2	violations	violation	NNS
cord-014712-5u4e00q6	512	3	were	be	VBD
cord-014712-5u4e00q6	512	4	observed	observe	VBN
cord-014712-5u4e00q6	512	5	in	in	IN
cord-014712-5u4e00q6	512	6	56	56	CD
cord-014712-5u4e00q6	512	7	%	%	NN
cord-014712-5u4e00q6	512	8	of	of	IN
cord-014712-5u4e00q6	512	9	all	all	DT
cord-014712-5u4e00q6	512	10	PID	PID	NNP
cord-014712-5u4e00q6	512	11	cases	case	NNS
cord-014712-5u4e00q6	512	12	:	:	:
cord-014712-5u4e00q6	512	13	5	5	CD
cord-014712-5u4e00q6	512	14	%	%	NN
cord-014712-5u4e00q6	512	15	of	of	IN
cord-014712-5u4e00q6	512	16	combined	combined	JJ
cord-014712-5u4e00q6	512	17	PID	pid	NN
cord-014712-5u4e00q6	512	18	,	,	,
cord-014712-5u4e00q6	512	19	35	35	CD
cord-014712-5u4e00q6	512	20	%	%	NN
cord-014712-5u4e00q6	512	21	of	of	IN
cord-014712-5u4e00q6	512	22	antibody	antibody	NN
cord-014712-5u4e00q6	512	23	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	512	24	,	,	,
cord-014712-5u4e00q6	512	25	65	65	CD
cord-014712-5u4e00q6	512	26	%	%	NN
cord-014712-5u4e00q6	512	27	of	of	IN
cord-014712-5u4e00q6	512	28	other	other	JJ
cord-014712-5u4e00q6	512	29	well	well	RB
cord-014712-5u4e00q6	512	30	defined	define	VBN
cord-014712-5u4e00q6	512	31	syndromes	syndrome	NNS
cord-014712-5u4e00q6	512	32	,	,	,
cord-014712-5u4e00q6	512	33	100	100	CD
cord-014712-5u4e00q6	512	34	%	%	NN
cord-014712-5u4e00q6	512	35	of	of	IN
cord-014712-5u4e00q6	512	36	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	512	37	syndromes	syndrome	NNS
cord-014712-5u4e00q6	512	38	.	.	.
cord-014712-5u4e00q6	513	1	Cytopenias	Cytopenias	NNP
cord-014712-5u4e00q6	513	2	developed	develop	VBD
cord-014712-5u4e00q6	513	3	in	in	IN
cord-014712-5u4e00q6	513	4	68	68	CD
cord-014712-5u4e00q6	513	5	%	%	NN
cord-014712-5u4e00q6	513	6	,	,	,
cord-014712-5u4e00q6	513	7	vasculitisin	vasculitisin	NNP
cord-014712-5u4e00q6	513	8	15	15	CD
cord-014712-5u4e00q6	513	9	%	%	NN
cord-014712-5u4e00q6	513	10	,	,	,
cord-014712-5u4e00q6	513	11	ulcer	ulcer	NN
cord-014712-5u4e00q6	513	12	colitisin	colitisin	NNP
cord-014712-5u4e00q6	513	13	14	14	CD
cord-014712-5u4e00q6	513	14	%	%	NN
cord-014712-5u4e00q6	513	15	,	,	,
cord-014712-5u4e00q6	513	16	arthritisin	arthritisin	VBD
cord-014712-5u4e00q6	513	17	11	11	CD
cord-014712-5u4e00q6	513	18	%	%	NN
cord-014712-5u4e00q6	513	19	.	.	.
cord-014712-5u4e00q6	514	1	Oncology	oncology	NN
cord-014712-5u4e00q6	514	2	diseases	disease	NNS
cord-014712-5u4e00q6	514	3	developed	develop	VBN
cord-014712-5u4e00q6	514	4	in	in	IN
cord-014712-5u4e00q6	514	5	4	4	CD
cord-014712-5u4e00q6	514	6	%	%	NN
cord-014712-5u4e00q6	514	7	of	of	IN
cord-014712-5u4e00q6	514	8	patients	patient	NNS
cord-014712-5u4e00q6	514	9	:	:	:
cord-014712-5u4e00q6	514	10	mainly	mainly	RB
cord-014712-5u4e00q6	514	11	in	in	IN
cord-014712-5u4e00q6	514	12	NBS	NBS	NNP
cord-014712-5u4e00q6	514	13	,	,	,
cord-014712-5u4e00q6	514	14	A	A	NNP
cord-014712-5u4e00q6	514	15	-	-	HYPH
cord-014712-5u4e00q6	514	16	T	T	NNP
cord-014712-5u4e00q6	514	17	,	,	,
cord-014712-5u4e00q6	514	18	WAS	be	VBD
cord-014712-5u4e00q6	514	19	and	and	CC
cord-014712-5u4e00q6	514	20	CVID	CVID	NNP
cord-014712-5u4e00q6	514	21	:	:	:
cord-014712-5u4e00q6	515	1	T	T	NNP
cord-014712-5u4e00q6	515	2	-	-	HYPH
cord-014712-5u4e00q6	515	3	and	and	CC
cord-014712-5u4e00q6	515	4	B	b	NN
cord-014712-5u4e00q6	515	5	-	-	HYPH
cord-014712-5u4e00q6	515	6	leukemia	leukemia	NN
cord-014712-5u4e00q6	515	7	's	's	POS
cord-014712-5u4e00q6	515	8	,	,	,
cord-014712-5u4e00q6	515	9	lymphomas	lymphoma	NNS
cord-014712-5u4e00q6	515	10	,	,	,
cord-014712-5u4e00q6	515	11	solid	solid	JJ
cord-014712-5u4e00q6	515	12	cancer	cancer	NN
cord-014712-5u4e00q6	515	13	.	.	.
cord-014712-5u4e00q6	516	1	The	the	DT
cord-014712-5u4e00q6	516	2	study	study	NN
cord-014712-5u4e00q6	516	3	of	of	IN
cord-014712-5u4e00q6	516	4	primary	primary	JJ
cord-014712-5u4e00q6	516	5	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	516	6	is	be	VBZ
cord-014712-5u4e00q6	516	7	a	a	DT
cord-014712-5u4e00q6	516	8	unique	unique	JJ
cord-014712-5u4e00q6	516	9	model	model	NN
cord-014712-5u4e00q6	516	10	for	for	IN
cord-014712-5u4e00q6	516	11	studying	study	VBG
cord-014712-5u4e00q6	516	12	the	the	DT
cord-014712-5u4e00q6	516	13	molecular	molecular	JJ
cord-014712-5u4e00q6	516	14	basis	basis	NN
cord-014712-5u4e00q6	516	15	of	of	IN
cord-014712-5u4e00q6	516	16	immunity	immunity	NN
cord-014712-5u4e00q6	516	17	.	.	.
cord-014712-5u4e00q6	517	1	Question	question	NN
cord-014712-5u4e00q6	517	2	about	about	IN
cord-014712-5u4e00q6	517	3	intravital	intravital	JJ
cord-014712-5u4e00q6	517	4	PID	PID	NNP
cord-014712-5u4e00q6	517	5	verification	verification	NN
cord-014712-5u4e00q6	517	6	is	be	VBZ
cord-014712-5u4e00q6	517	7	still	still	RB
cord-014712-5u4e00q6	517	8	relevant	relevant	JJ
cord-014712-5u4e00q6	517	9	.	.	.
cord-014712-5u4e00q6	518	1	A	a	DT
cord-014712-5u4e00q6	518	2	regional	regional	JJ
cord-014712-5u4e00q6	518	3	center	center	NN
cord-014712-5u4e00q6	518	4	of	of	IN
cord-014712-5u4e00q6	518	5	clinical	clinical	JJ
cord-014712-5u4e00q6	518	6	immunology	immunology	NN
cord-014712-5u4e00q6	518	7	was	be	VBD
cord-014712-5u4e00q6	518	8	established	establish	VBN
cord-014712-5u4e00q6	518	9	in	in	IN
cord-014712-5u4e00q6	518	10	1986	1986	CD
cord-014712-5u4e00q6	518	11	at	at	IN
cord-014712-5u4e00q6	518	12	the	the	DT
cord-014712-5u4e00q6	518	13	Regional	Regional	NNP
cord-014712-5u4e00q6	518	14	Children	Children	NNPS
cord-014712-5u4e00q6	518	15	's	's	POS
cord-014712-5u4e00q6	518	16	Clinical	Clinical	NNP
cord-014712-5u4e00q6	518	17	Hospital	Hospital	NNP
cord-014712-5u4e00q6	518	18	№	№	NNP
cord-014712-5u4e00q6	518	19	1	1	CD
cord-014712-5u4e00q6	518	20	,	,	,
cord-014712-5u4e00q6	518	21	Yekaterinburg	Yekaterinburg	NNP
cord-014712-5u4e00q6	518	22	.	.	.
cord-014712-5u4e00q6	519	1	The	the	DT
cord-014712-5u4e00q6	519	2	Regional	Regional	NNP
cord-014712-5u4e00q6	519	3	Clinical	Clinical	NNP
cord-014712-5u4e00q6	519	4	Hospital	Hospital	NNP
cord-014712-5u4e00q6	519	5	№	№	NNP
cord-014712-5u4e00q6	519	6	1	1	CD
cord-014712-5u4e00q6	519	7	joined	join	VBD
cord-014712-5u4e00q6	519	8	the	the	DT
cord-014712-5u4e00q6	519	9	center	center	NN
cord-014712-5u4e00q6	519	10	in	in	IN
cord-014712-5u4e00q6	519	11	2013	2013	CD
cord-014712-5u4e00q6	519	12	.	.	.
cord-014712-5u4e00q6	520	1	Institute	Institute	NNP
cord-014712-5u4e00q6	520	2	of	of	IN
cord-014712-5u4e00q6	520	3	Immunology	Immunology	NNP
cord-014712-5u4e00q6	520	4	and	and	CC
cord-014712-5u4e00q6	520	5	Physiology	Physiology	NNP
cord-014712-5u4e00q6	520	6	,	,	,
cord-014712-5u4e00q6	520	7	Ural	Ural	NNP
cord-014712-5u4e00q6	520	8	Branch	Branch	NNP
cord-014712-5u4e00q6	520	9	of	of	IN
cord-014712-5u4e00q6	520	10	the	the	DT
cord-014712-5u4e00q6	520	11	Russian	Russian	NNP
cord-014712-5u4e00q6	520	12	Academy	Academy	NNP
cord-014712-5u4e00q6	520	13	of	of	IN
cord-014712-5u4e00q6	520	14	Sciences	Sciences	NNPS
cord-014712-5u4e00q6	520	15	carries	carry	VBZ
cord-014712-5u4e00q6	520	16	scientific	scientific	JJ
cord-014712-5u4e00q6	520	17	management	management	NN
cord-014712-5u4e00q6	520	18	of	of	IN
cord-014712-5u4e00q6	520	19	the	the	DT
cord-014712-5u4e00q6	520	20	center	center	NN
cord-014712-5u4e00q6	520	21	.	.	.
cord-014712-5u4e00q6	521	1	The	the	DT
cord-014712-5u4e00q6	521	2	Centre	Centre	NNP
cord-014712-5u4e00q6	521	3	works	work	VBZ
cord-014712-5u4e00q6	521	4	closely	closely	RB
cord-014712-5u4e00q6	521	5	with	with	IN
cord-014712-5u4e00q6	521	6	foreign	foreign	JJ
cord-014712-5u4e00q6	521	7	counterparts	counterpart	NNS
cord-014712-5u4e00q6	521	8	in	in	IN
cord-014712-5u4e00q6	521	9	the	the	DT
cord-014712-5u4e00q6	521	10	international	international	JJ
cord-014712-5u4e00q6	521	11	project	project	NN
cord-014712-5u4e00q6	521	12	J	J	NNP
cord-014712-5u4e00q6	521	13	Project	Project	NNP
cord-014712-5u4e00q6	521	14	and	and	CC
cord-014712-5u4e00q6	521	15	it	-PRON-	PRP
cord-014712-5u4e00q6	521	16	has	have	VBZ
cord-014712-5u4e00q6	521	17	been	be	VBN
cord-014712-5u4e00q6	521	18	one	one	CD
cord-014712-5u4e00q6	521	19	of	of	IN
cord-014712-5u4e00q6	521	20	the	the	DT
cord-014712-5u4e00q6	521	21	centers	center	NNS
cord-014712-5u4e00q6	521	22	of	of	IN
cord-014712-5u4e00q6	521	23	JMF	JMF	NNP
cord-014712-5u4e00q6	521	24	since	since	IN
cord-014712-5u4e00q6	521	25	2013	2013	CD
cord-014712-5u4e00q6	521	26	.	.	.
cord-014712-5u4e00q6	522	1	Over	over	IN
cord-014712-5u4e00q6	522	2	28	28	CD
cord-014712-5u4e00q6	522	3	years	year	NNS
cord-014712-5u4e00q6	522	4	we	-PRON-	PRP
cord-014712-5u4e00q6	522	5	formed	form	VBD
cord-014712-5u4e00q6	522	6	a	a	DT
cord-014712-5u4e00q6	522	7	regional	regional	JJ
cord-014712-5u4e00q6	522	8	register	register	NN
cord-014712-5u4e00q6	522	9	of	of	IN
cord-014712-5u4e00q6	522	10	patients	patient	NNS
cord-014712-5u4e00q6	522	11	with	with	IN
cord-014712-5u4e00q6	522	12	Primary	Primary	NNP
cord-014712-5u4e00q6	522	13	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	522	14	,	,	,
cord-014712-5u4e00q6	522	15	comprising	comprise	VBG
cord-014712-5u4e00q6	522	16	309	309	CD
cord-014712-5u4e00q6	522	17	patients	patient	NNS
cord-014712-5u4e00q6	522	18	:	:	:
cord-014712-5u4e00q6	522	19	224	224	CD
cord-014712-5u4e00q6	522	20	children	child	NNS
cord-014712-5u4e00q6	522	21	and	and	CC
cord-014712-5u4e00q6	522	22	85	85	CD
cord-014712-5u4e00q6	522	23	adults	adult	NNS
cord-014712-5u4e00q6	522	24	.	.	.
cord-014712-5u4e00q6	523	1	Analysis	analysis	NN
cord-014712-5u4e00q6	523	2	of	of	IN
cord-014712-5u4e00q6	523	3	the	the	DT
cord-014712-5u4e00q6	523	4	regional	regional	JJ
cord-014712-5u4e00q6	523	5	register	register	NN
cord-014712-5u4e00q6	523	6	allows	allow	VBZ
cord-014712-5u4e00q6	523	7	to	to	TO
cord-014712-5u4e00q6	523	8	investigate	investigate	VB
cord-014712-5u4e00q6	523	9	the	the	DT
cord-014712-5u4e00q6	523	10	causes	cause	NNS
cord-014712-5u4e00q6	523	11	of	of	IN
cord-014712-5u4e00q6	523	12	deaths	death	NNS
cord-014712-5u4e00q6	523	13	in	in	IN
cord-014712-5u4e00q6	523	14	patients	patient	NNS
cord-014712-5u4e00q6	523	15	with	with	IN
cord-014712-5u4e00q6	523	16	PID	PID	NNP
cord-014712-5u4e00q6	523	17	.	.	.
cord-014712-5u4e00q6	524	1	Infectious	infectious	JJ
cord-014712-5u4e00q6	524	2	syndrome	syndrome	NN
cord-014712-5u4e00q6	524	3	mortality	mortality	NN
cord-014712-5u4e00q6	524	4	-sepsis	-sepsis	NN
cord-014712-5u4e00q6	524	5	,	,	,
cord-014712-5u4e00q6	524	6	generalized	generalized	JJ
cord-014712-5u4e00q6	524	7	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	524	8	infection	infection	NN
cord-014712-5u4e00q6	525	1	-22	-22	IN
cord-014712-5u4e00q6	525	2	patients	patient	NNS
cord-014712-5u4e00q6	525	3	,	,	,
cord-014712-5u4e00q6	525	4	proliferative	proliferative	JJ
cord-014712-5u4e00q6	525	5	process	process	NN
cord-014712-5u4e00q6	525	6	-4	-4	CD
cord-014712-5u4e00q6	525	7	patients	patient	NNS
cord-014712-5u4e00q6	525	8	,	,	,
cord-014712-5u4e00q6	525	9	dominate	dominate	VB
cord-014712-5u4e00q6	525	10	the	the	DT
cord-014712-5u4e00q6	525	11	mortality	mortality	NN
cord-014712-5u4e00q6	525	12	structure	structure	NN
cord-014712-5u4e00q6	525	13	.	.	.
cord-014712-5u4e00q6	526	1	Creation	creation	NN
cord-014712-5u4e00q6	526	2	of	of	IN
cord-014712-5u4e00q6	526	3	specialized	specialized	JJ
cord-014712-5u4e00q6	526	4	immunological	immunological	JJ
cord-014712-5u4e00q6	526	5	centers	center	NNS
cord-014712-5u4e00q6	526	6	permit	permit	VBP
cord-014712-5u4e00q6	526	7	to	to	TO
cord-014712-5u4e00q6	526	8	raise	raise	VB
cord-014712-5u4e00q6	526	9	the	the	DT
cord-014712-5u4e00q6	526	10	educational	educational	JJ
cord-014712-5u4e00q6	526	11	level	level	NN
cord-014712-5u4e00q6	526	12	of	of	IN
cord-014712-5u4e00q6	526	13	the	the	DT
cord-014712-5u4e00q6	526	14	medical	medical	JJ
cord-014712-5u4e00q6	526	15	staff	staff	NN
cord-014712-5u4e00q6	526	16	,	,	,
cord-014712-5u4e00q6	526	17	precisely	precisely	RB
cord-014712-5u4e00q6	526	18	identify	identify	VB
cord-014712-5u4e00q6	526	19	nosological	nosological	JJ
cord-014712-5u4e00q6	526	20	forms	form	NNS
cord-014712-5u4e00q6	526	21	of	of	IN
cord-014712-5u4e00q6	526	22	PID	PID	NNP
cord-014712-5u4e00q6	526	23	among	among	IN
cord-014712-5u4e00q6	526	24	different	different	JJ
cord-014712-5u4e00q6	526	25	groups	group	NNS
cord-014712-5u4e00q6	526	26	of	of	IN
cord-014712-5u4e00q6	526	27	patients	patient	NNS
cord-014712-5u4e00q6	526	28	,	,	,
cord-014712-5u4e00q6	526	29	to	to	TO
cord-014712-5u4e00q6	526	30	prevent	prevent	VB
cord-014712-5u4e00q6	526	31	the	the	DT
cord-014712-5u4e00q6	526	32	birth	birth	NN
cord-014712-5u4e00q6	526	33	of	of	IN
cord-014712-5u4e00q6	526	34	children	child	NNS
cord-014712-5u4e00q6	526	35	with	with	IN
cord-014712-5u4e00q6	526	36	PID	PID	NNP
cord-014712-5u4e00q6	526	37	,	,	,
cord-014712-5u4e00q6	526	38	increase	increase	VB
cord-014712-5u4e00q6	526	39	the	the	DT
cord-014712-5u4e00q6	526	40	length	length	NN
cord-014712-5u4e00q6	526	41	and	and	CC
cord-014712-5u4e00q6	526	42	quality	quality	NN
cord-014712-5u4e00q6	526	43	of	of	IN
cord-014712-5u4e00q6	526	44	life	life	NN
cord-014712-5u4e00q6	526	45	such	such	JJ
cord-014712-5u4e00q6	526	46	patients	patient	NNS
cord-014712-5u4e00q6	526	47	and	and	CC
cord-014712-5u4e00q6	526	48	take	take	VB
cord-014712-5u4e00q6	526	49	part	part	NN
cord-014712-5u4e00q6	526	50	in	in	IN
cord-014712-5u4e00q6	526	51	the	the	DT
cord-014712-5u4e00q6	526	52	collaboration	collaboration	NN
cord-014712-5u4e00q6	526	53	with	with	IN
cord-014712-5u4e00q6	526	54	international	international	JJ
cord-014712-5u4e00q6	526	55	experience	experience	NN
cord-014712-5u4e00q6	526	56	in	in	IN
cord-014712-5u4e00q6	526	57	the	the	DT
cord-014712-5u4e00q6	526	58	PID	PID	NNP
cord-014712-5u4e00q6	526	59	.	.	.
cord-014712-5u4e00q6	527	1	Introduction	introduction	NN
cord-014712-5u4e00q6	527	2	:	:	:
cord-014712-5u4e00q6	528	1	The	the	DT
cord-014712-5u4e00q6	528	2	aim	aim	NN
cord-014712-5u4e00q6	528	3	of	of	IN
cord-014712-5u4e00q6	528	4	this	this	DT
cord-014712-5u4e00q6	528	5	retrospective	retrospective	JJ
cord-014712-5u4e00q6	528	6	study	study	NN
cord-014712-5u4e00q6	528	7	is	be	VBZ
cord-014712-5u4e00q6	528	8	to	to	TO
cord-014712-5u4e00q6	528	9	determine	determine	VB
cord-014712-5u4e00q6	528	10	the	the	DT
cord-014712-5u4e00q6	528	11	frequency	frequency	NN
cord-014712-5u4e00q6	528	12	,	,	,
cord-014712-5u4e00q6	528	13	and	and	CC
cord-014712-5u4e00q6	528	14	demographic	demographic	JJ
cord-014712-5u4e00q6	528	15	,	,	,
cord-014712-5u4e00q6	528	16	clinical	clinical	JJ
cord-014712-5u4e00q6	528	17	and	and	CC
cord-014712-5u4e00q6	528	18	laboratory	laboratory	NN
cord-014712-5u4e00q6	528	19	features	feature	NNS
cord-014712-5u4e00q6	528	20	of	of	IN
cord-014712-5u4e00q6	528	21	adult	adult	NN
cord-014712-5u4e00q6	528	22	CVID	CVID	NNP
cord-014712-5u4e00q6	528	23	patients	patient	NNS
cord-014712-5u4e00q6	528	24	referred	refer	VBD
cord-014712-5u4e00q6	528	25	to	to	IN
cord-014712-5u4e00q6	528	26	our	-PRON-	PRP$
cord-014712-5u4e00q6	528	27	clinic	clinic	NN
cord-014712-5u4e00q6	528	28	.	.	.
cord-014712-5u4e00q6	529	1	Materials	material	NNS
cord-014712-5u4e00q6	529	2	and	and	CC
cord-014712-5u4e00q6	529	3	Methods	method	NNS
cord-014712-5u4e00q6	529	4	:	:	:
cord-014712-5u4e00q6	529	5	We	-PRON-	PRP
cord-014712-5u4e00q6	529	6	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	529	7	evaluated	evaluate	VBD
cord-014712-5u4e00q6	529	8	26	26	CD
cord-014712-5u4e00q6	529	9	adult	adult	NN
cord-014712-5u4e00q6	529	10	patients	patient	NNS
cord-014712-5u4e00q6	529	11	(	(	-LRB-
cord-014712-5u4e00q6	529	12	9	9	CD
cord-014712-5u4e00q6	529	13	female	female	JJ
cord-014712-5u4e00q6	529	14	(	(	-LRB-
cord-014712-5u4e00q6	529	15	%	%	NN
cord-014712-5u4e00q6	529	16	34,6	34,6	CD
cord-014712-5u4e00q6	529	17	)	)	-RRB-
cord-014712-5u4e00q6	529	18	,	,	,
cord-014712-5u4e00q6	529	19	17	17	CD
cord-014712-5u4e00q6	529	20	male	male	NN
cord-014712-5u4e00q6	529	21	(	(	-LRB-
cord-014712-5u4e00q6	529	22	%	%	NN
cord-014712-5u4e00q6	529	23	65,4	65,4	CD
cord-014712-5u4e00q6	529	24	)	)	-RRB-
cord-014712-5u4e00q6	529	25	;	;	:
cord-014712-5u4e00q6	529	26	aged	age	VBN
cord-014712-5u4e00q6	529	27	18	18	CD
cord-014712-5u4e00q6	529	28	to	to	TO
cord-014712-5u4e00q6	529	29	67	67	CD
cord-014712-5u4e00q6	529	30	years	year	NNS
cord-014712-5u4e00q6	529	31	:	:	:
cord-014712-5u4e00q6	529	32	median	median	NN
cord-014712-5u4e00q6	529	33	27	27	CD
cord-014712-5u4e00q6	529	34	years	year	NNS
cord-014712-5u4e00q6	529	35	)	)	-RRB-
cord-014712-5u4e00q6	529	36	who	who	WP
cord-014712-5u4e00q6	529	37	were	be	VBD
cord-014712-5u4e00q6	529	38	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	529	39	as	as	IN
cord-014712-5u4e00q6	529	40	CVID	CVID	NNP
cord-014712-5u4e00q6	529	41	according	accord	VBG
cord-014712-5u4e00q6	529	42	to	to	IN
cord-014712-5u4e00q6	529	43	ESID	ESID	NNP
cord-014712-5u4e00q6	529	44	and	and	CC
cord-014712-5u4e00q6	529	45	PAGID	PAGID	NNP
cord-014712-5u4e00q6	529	46	criteria	criterion	NNS
cord-014712-5u4e00q6	529	47	during	during	IN
cord-014712-5u4e00q6	529	48	a	a	DT
cord-014712-5u4e00q6	529	49	4	4	CD
cord-014712-5u4e00q6	529	50	year	year	NN
cord-014712-5u4e00q6	529	51	period	period	NN
cord-014712-5u4e00q6	529	52	(	(	-LRB-
cord-014712-5u4e00q6	529	53	January	January	NNP
cord-014712-5u4e00q6	529	54	2010-March	2010-march	CD
cord-014712-5u4e00q6	529	55	2014	2014	CD
cord-014712-5u4e00q6	529	56	)	)	-RRB-
cord-014712-5u4e00q6	529	57	.	.	.
cord-014712-5u4e00q6	530	1	Results	result	NNS
cord-014712-5u4e00q6	530	2	:	:	:
cord-014712-5u4e00q6	531	1	The	the	DT
cord-014712-5u4e00q6	531	2	median	median	JJ
cord-014712-5u4e00q6	531	3	current	current	JJ
cord-014712-5u4e00q6	531	4	age	age	NN
cord-014712-5u4e00q6	531	5	of	of	IN
cord-014712-5u4e00q6	531	6	26	26	CD
cord-014712-5u4e00q6	531	7	patients	patient	NNS
cord-014712-5u4e00q6	531	8	was	be	VBD
cord-014712-5u4e00q6	531	9	27	27	CD
cord-014712-5u4e00q6	531	10	,	,	,
cord-014712-5u4e00q6	531	11	and	and	CC
cord-014712-5u4e00q6	531	12	the	the	DT
cord-014712-5u4e00q6	531	13	median	median	JJ
cord-014712-5u4e00q6	531	14	CVID	CVID	NNP
cord-014712-5u4e00q6	531	15	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	531	16	age	age	NN
cord-014712-5u4e00q6	531	17	was	be	VBD
cord-014712-5u4e00q6	531	18	22,5	22,5	CD
cord-014712-5u4e00q6	531	19	years	year	NNS
cord-014712-5u4e00q6	531	20	.	.	.
cord-014712-5u4e00q6	532	1	The	the	DT
cord-014712-5u4e00q6	532	2	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	532	3	delay	delay	NN
cord-014712-5u4e00q6	532	4	in	in	IN
cord-014712-5u4e00q6	532	5	patients	patient	NNS
cord-014712-5u4e00q6	532	6	with	with	IN
cord-014712-5u4e00q6	532	7	CVID	CVID	NNP
cord-014712-5u4e00q6	532	8	was	be	VBD
cord-014712-5u4e00q6	532	9	4,5	4,5	CD
cord-014712-5u4e00q6	532	10	years	year	NNS
cord-014712-5u4e00q6	532	11	(	(	-LRB-
cord-014712-5u4e00q6	532	12	median	median	NN
cord-014712-5u4e00q6	532	13	)	)	-RRB-
cord-014712-5u4e00q6	532	14	.	.	.
cord-014712-5u4e00q6	533	1	CVID	CVID	NNP
cord-014712-5u4e00q6	533	2	patients	patient	NNS
cord-014712-5u4e00q6	533	3	presented	present	VBD
cord-014712-5u4e00q6	533	4	lower	low	JJR
cord-014712-5u4e00q6	533	5	levels	level	NNS
cord-014712-5u4e00q6	533	6	of	of	IN
cord-014712-5u4e00q6	533	7	IgM	IgM	NNP
cord-014712-5u4e00q6	533	8	(	(	-LRB-
cord-014712-5u4e00q6	533	9	12	12	CD
cord-014712-5u4e00q6	533	10	patients	patient	NNS
cord-014712-5u4e00q6	533	11	,	,	,
cord-014712-5u4e00q6	533	12	46,1	46,1	CD
cord-014712-5u4e00q6	533	13	%	%	NN
cord-014712-5u4e00q6	533	14	)	)	-RRB-
cord-014712-5u4e00q6	533	15	,	,	,
cord-014712-5u4e00q6	533	16	IgA	IgA	NNP
cord-014712-5u4e00q6	533	17	(	(	-LRB-
cord-014712-5u4e00q6	533	18	16	16	CD
cord-014712-5u4e00q6	533	19	patients	patient	NNS
cord-014712-5u4e00q6	533	20	,	,	,
cord-014712-5u4e00q6	533	21	61,5	61,5	CD
cord-014712-5u4e00q6	533	22	%	%	NN
cord-014712-5u4e00q6	533	23	)	)	-RRB-
cord-014712-5u4e00q6	533	24	and	and	CC
cord-014712-5u4e00q6	533	25	IgG	IgG	NNP
cord-014712-5u4e00q6	533	26	(	(	-LRB-
cord-014712-5u4e00q6	533	27	16	16	CD
cord-014712-5u4e00q6	533	28	patients	patient	NNS
cord-014712-5u4e00q6	533	29	,	,	,
cord-014712-5u4e00q6	533	30	61,5	61,5	CD
cord-014712-5u4e00q6	533	31	%	%	NN
cord-014712-5u4e00q6	533	32	)	)	-RRB-
cord-014712-5u4e00q6	533	33	.	.	.
cord-014712-5u4e00q6	534	1	According	accord	VBG
cord-014712-5u4e00q6	534	2	to	to	IN
cord-014712-5u4e00q6	534	3	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	534	4	lmunophenotypes	lmunophenotype	NNS
cord-014712-5u4e00q6	534	5	of	of	IN
cord-014712-5u4e00q6	534	6	CVID	CVID	NNP
cord-014712-5u4e00q6	534	7	patients	patient	NNS
cord-014712-5u4e00q6	534	8	,	,	,
cord-014712-5u4e00q6	534	9	CD4	CD4	NNP
cord-014712-5u4e00q6	534	10	(	(	-LRB-
cord-014712-5u4e00q6	534	11	15	15	CD
cord-014712-5u4e00q6	534	12	patients	patient	NNS
cord-014712-5u4e00q6	534	13	,	,	,
cord-014712-5u4e00q6	534	14	57,6	57,6	CD
cord-014712-5u4e00q6	534	15	%	%	NN
cord-014712-5u4e00q6	534	16	)	)	-RRB-
cord-014712-5u4e00q6	534	17	,	,	,
cord-014712-5u4e00q6	534	18	CD19	CD19	NNP
cord-014712-5u4e00q6	534	19	(	(	-LRB-
cord-014712-5u4e00q6	534	20	13	13	CD
cord-014712-5u4e00q6	534	21	patients	patient	NNS
cord-014712-5u4e00q6	534	22	,	,	,
cord-014712-5u4e00q6	534	23	50	50	CD
cord-014712-5u4e00q6	534	24	%	%	NN
cord-014712-5u4e00q6	534	25	)	)	-RRB-
cord-014712-5u4e00q6	534	26	and	and	CC
cord-014712-5u4e00q6	534	27	CD4	CD4	NNP
cord-014712-5u4e00q6	534	28	/	/	SYM
cord-014712-5u4e00q6	534	29	CD8	CD8	NNP
cord-014712-5u4e00q6	534	30	(	(	-LRB-
cord-014712-5u4e00q6	534	31	13	13	CD
cord-014712-5u4e00q6	534	32	patients	patient	NNS
cord-014712-5u4e00q6	534	33	,	,	,
cord-014712-5u4e00q6	534	34	50	50	CD
cord-014712-5u4e00q6	534	35	%	%	NN
cord-014712-5u4e00q6	534	36	)	)	-RRB-
cord-014712-5u4e00q6	534	37	values	value	NNS
cord-014712-5u4e00q6	534	38	were	be	VBD
cord-014712-5u4e00q6	534	39	observed	observe	VBN
cord-014712-5u4e00q6	534	40	the	the	DT
cord-014712-5u4e00q6	534	41	most	most	RBS
cord-014712-5u4e00q6	534	42	lower	low	JJR
cord-014712-5u4e00q6	534	43	ones	one	NNS
cord-014712-5u4e00q6	534	44	.	.	.
cord-014712-5u4e00q6	535	1	Discussion	discussion	NN
cord-014712-5u4e00q6	535	2	:	:	:
cord-014712-5u4e00q6	536	1	We	-PRON-	PRP
cord-014712-5u4e00q6	536	2	found	find	VBD
cord-014712-5u4e00q6	536	3	that	that	IN
cord-014712-5u4e00q6	536	4	both	both	DT
cord-014712-5u4e00q6	536	5	of	of	IN
cord-014712-5u4e00q6	536	6	the	the	DT
cord-014712-5u4e00q6	536	7	patients	patient	NNS
cord-014712-5u4e00q6	536	8	with	with	IN
cord-014712-5u4e00q6	536	9	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	536	10	showed	show	VBD
cord-014712-5u4e00q6	536	11	lower	low	JJR
cord-014712-5u4e00q6	536	12	levels	level	NNS
cord-014712-5u4e00q6	536	13	of	of	IN
cord-014712-5u4e00q6	536	14	immünoglobulins	immünoglobulin	NNS
cord-014712-5u4e00q6	536	15	and	and	CC
cord-014712-5u4e00q6	536	16	lower	low	JJR
cord-014712-5u4e00q6	536	17	imunophenotypes	imunophenotype	NNS
cord-014712-5u4e00q6	536	18	of	of	IN
cord-014712-5u4e00q6	536	19	B	B	NNP
cord-014712-5u4e00q6	536	20	cell	cell	NN
cord-014712-5u4e00q6	536	21	than	than	IN
cord-014712-5u4e00q6	536	22	the	the	DT
cord-014712-5u4e00q6	536	23	others	other	NNS
cord-014712-5u4e00q6	536	24	that	that	WDT
cord-014712-5u4e00q6	536	25	do	do	VBP
cord-014712-5u4e00q6	536	26	not	not	RB
cord-014712-5u4e00q6	536	27	have	have	VB
cord-014712-5u4e00q6	536	28	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	536	29	.	.	.
cord-014712-5u4e00q6	537	1	In	in	IN
cord-014712-5u4e00q6	537	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	537	3	patients	patient	NNS
cord-014712-5u4e00q6	537	4	CD4	CD4	NNP
cord-014712-5u4e00q6	537	5	,	,	,
cord-014712-5u4e00q6	537	6	CD19	CD19	NNP
cord-014712-5u4e00q6	537	7	and	and	CC
cord-014712-5u4e00q6	537	8	CD4	CD4	NNP
cord-014712-5u4e00q6	537	9	/	/	SYM
cord-014712-5u4e00q6	537	10	CD8	CD8	NNP
cord-014712-5u4e00q6	537	11	values	value	NNS
cord-014712-5u4e00q6	537	12	have	have	VBP
cord-014712-5u4e00q6	537	13	got	get	VBN
cord-014712-5u4e00q6	537	14	enough	enough	JJ
cord-014712-5u4e00q6	537	15	priority	priority	NN
cord-014712-5u4e00q6	537	16	to	to	TO
cord-014712-5u4e00q6	537	17	be	be	VB
cord-014712-5u4e00q6	537	18	mentioned	mention	VBN
cord-014712-5u4e00q6	537	19	about	about	IN
cord-014712-5u4e00q6	537	20	an	an	DT
cord-014712-5u4e00q6	537	21	immun	immun	JJ
cord-014712-5u4e00q6	537	22	deficiency	deficiency	NN
cord-014712-5u4e00q6	537	23	.	.	.
cord-014712-5u4e00q6	538	1	In	in	IN
cord-014712-5u4e00q6	538	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	538	3	,	,	,
cord-014712-5u4e00q6	538	4	despite	despite	IN
cord-014712-5u4e00q6	538	5	recent	recent	JJ
cord-014712-5u4e00q6	538	6	improvements	improvement	NNS
cord-014712-5u4e00q6	538	7	in	in	IN
cord-014712-5u4e00q6	538	8	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	538	9	tools	tool	NNS
cord-014712-5u4e00q6	538	10	,	,	,
cord-014712-5u4e00q6	538	11	the	the	DT
cord-014712-5u4e00q6	538	12	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	538	13	of	of	IN
cord-014712-5u4e00q6	538	14	mild	mild	JJ
cord-014712-5u4e00q6	538	15	or	or	CC
cord-014712-5u4e00q6	538	16	moderate	moderate	JJ
cord-014712-5u4e00q6	538	17	CVID	CVID	NNP
cord-014712-5u4e00q6	538	18	is	be	VBZ
cord-014712-5u4e00q6	538	19	often	often	RB
cord-014712-5u4e00q6	538	20	delayed	delay	VBN
cord-014712-5u4e00q6	538	21	.	.	.
cord-014712-5u4e00q6	539	1	However	however	RB
cord-014712-5u4e00q6	539	2	,	,	,
cord-014712-5u4e00q6	539	3	it	-PRON-	PRP
cord-014712-5u4e00q6	539	4	seems	seem	VBZ
cord-014712-5u4e00q6	539	5	that	that	IN
cord-014712-5u4e00q6	539	6	the	the	DT
cord-014712-5u4e00q6	539	7	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	539	8	of	of	IN
cord-014712-5u4e00q6	539	9	CVID	CVID	NNP
cord-014712-5u4e00q6	539	10	is	be	VBZ
cord-014712-5u4e00q6	539	11	delayed	delay	VBN
cord-014712-5u4e00q6	539	12	especially	especially	RB
cord-014712-5u4e00q6	539	13	in	in	IN
cord-014712-5u4e00q6	539	14	adulthood	adulthood	NN
cord-014712-5u4e00q6	539	15	on	on	IN
cord-014712-5u4e00q6	539	16	account	account	NN
cord-014712-5u4e00q6	539	17	of	of	IN
cord-014712-5u4e00q6	539	18	the	the	DT
cord-014712-5u4e00q6	539	19	fact	fact	NN
cord-014712-5u4e00q6	539	20	that	that	IN
cord-014712-5u4e00q6	539	21	the	the	DT
cord-014712-5u4e00q6	539	22	lack	lack	NN
cord-014712-5u4e00q6	539	23	of	of	IN
cord-014712-5u4e00q6	539	24	awareness	awareness	NN
cord-014712-5u4e00q6	539	25	of	of	IN
cord-014712-5u4e00q6	539	26	these	these	DT
cord-014712-5u4e00q6	539	27	illnesses	illness	NNS
cord-014712-5u4e00q6	539	28	among	among	IN
cord-014712-5u4e00q6	539	29	the	the	DT
cord-014712-5u4e00q6	539	30	medical	medical	JJ
cord-014712-5u4e00q6	539	31	professionals	professional	NNS
cord-014712-5u4e00q6	539	32	all	all	RB
cord-014712-5u4e00q6	539	33	over	over	IN
cord-014712-5u4e00q6	539	34	the	the	DT
cord-014712-5u4e00q6	539	35	world	world	NN
cord-014712-5u4e00q6	539	36	.	.	.
cord-014712-5u4e00q6	540	1	Primary	primary	JJ
cord-014712-5u4e00q6	540	2	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	540	3	disease	disease	NN
cord-014712-5u4e00q6	540	4	is	be	VBZ
cord-014712-5u4e00q6	540	5	important	important	JJ
cord-014712-5u4e00q6	540	6	in	in	IN
cord-014712-5u4e00q6	540	7	Turkey	Turkey	NNP
cord-014712-5u4e00q6	540	8	because	because	IN
cord-014712-5u4e00q6	540	9	of	of	IN
cord-014712-5u4e00q6	540	10	the	the	DT
cord-014712-5u4e00q6	540	11	high	high	JJ
cord-014712-5u4e00q6	540	12	rate	rate	NN
cord-014712-5u4e00q6	540	13	of	of	IN
cord-014712-5u4e00q6	540	14	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	540	15	marriage	marriage	NN
cord-014712-5u4e00q6	540	16	.	.	.
cord-014712-5u4e00q6	541	1	The	the	DT
cord-014712-5u4e00q6	541	2	lack	lack	NN
cord-014712-5u4e00q6	541	3	of	of	IN
cord-014712-5u4e00q6	541	4	awereness	awereness	NN
cord-014712-5u4e00q6	541	5	about	about	IN
cord-014712-5u4e00q6	541	6	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	541	7	can	can	MD
cord-014712-5u4e00q6	541	8	cause	cause	VB
cord-014712-5u4e00q6	541	9	late	late	JJ
cord-014712-5u4e00q6	541	10	-	-	HYPH
cord-014712-5u4e00q6	541	11	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	541	12	and	and	CC
cord-014712-5u4e00q6	541	13	severe	severe	JJ
cord-014712-5u4e00q6	541	14	complications	complication	NNS
cord-014712-5u4e00q6	541	15	.	.	.
cord-014712-5u4e00q6	542	1	The	the	DT
cord-014712-5u4e00q6	542	2	objective	objective	NN
cord-014712-5u4e00q6	542	3	of	of	IN
cord-014712-5u4e00q6	542	4	this	this	DT
cord-014712-5u4e00q6	542	5	study	study	NN
cord-014712-5u4e00q6	542	6	was	be	VBD
cord-014712-5u4e00q6	542	7	to	to	TO
cord-014712-5u4e00q6	542	8	assess	assess	VB
cord-014712-5u4e00q6	542	9	PID	PID	NNP
cord-014712-5u4e00q6	542	10	awereness	awereness	NN
cord-014712-5u4e00q6	542	11	before	before	RB
cord-014712-5u4e00q6	542	12	and	and	CC
cord-014712-5u4e00q6	542	13	after	after	IN
cord-014712-5u4e00q6	542	14	clinical	clinical	JJ
cord-014712-5u4e00q6	542	15	immunogy	immunogy	NN
cord-014712-5u4e00q6	542	16	education	education	NN
cord-014712-5u4e00q6	542	17	among	among	IN
cord-014712-5u4e00q6	542	18	medical	medical	JJ
cord-014712-5u4e00q6	542	19	students	student	NNS
cord-014712-5u4e00q6	542	20	.	.	.
cord-014712-5u4e00q6	543	1	One	one	CD
cord-014712-5u4e00q6	543	2	hundred	hundred	CD
cord-014712-5u4e00q6	543	3	and	and	CC
cord-014712-5u4e00q6	543	4	thirty	thirty	CD
cord-014712-5u4e00q6	543	5	-	-	HYPH
cord-014712-5u4e00q6	543	6	two	two	CD
cord-014712-5u4e00q6	543	7	questionnaires	questionnaire	NNS
cord-014712-5u4e00q6	543	8	0	0	CD
cord-014712-5u4e00q6	543	9	with	with	IN
cord-014712-5u4e00q6	543	10	71	71	CD
cord-014712-5u4e00q6	543	11	items	item	NNS
cord-014712-5u4e00q6	543	12	(	(	-LRB-
cord-014712-5u4e00q6	543	13	1	1	CD
cord-014712-5u4e00q6	543	14	)	)	-RRB-
cord-014712-5u4e00q6	543	15	were	be	VBD
cord-014712-5u4e00q6	543	16	distributed	distribute	VBN
cord-014712-5u4e00q6	543	17	to	to	IN
cord-014712-5u4e00q6	543	18	seventh	seventh	JJ
cord-014712-5u4e00q6	543	19	somestre	somestre	NNP
cord-014712-5u4e00q6	543	20	medical	medical	JJ
cord-014712-5u4e00q6	543	21	students	student	NNS
cord-014712-5u4e00q6	543	22	and	and	CC
cord-014712-5u4e00q6	543	23	116	116	CD
cord-014712-5u4e00q6	543	24	(	(	-LRB-
cord-014712-5u4e00q6	543	25	88	88	CD
cord-014712-5u4e00q6	543	26	%	%	NN
cord-014712-5u4e00q6	543	27	)	)	-RRB-
cord-014712-5u4e00q6	543	28	completed	complete	VBN
cord-014712-5u4e00q6	543	29	questionnaires	questionnaire	NNS
cord-014712-5u4e00q6	543	30	were	be	VBD
cord-014712-5u4e00q6	543	31	evaluated	evaluate	VBN
cord-014712-5u4e00q6	543	32	before	before	IN
cord-014712-5u4e00q6	543	33	(	(	-LRB-
cord-014712-5u4e00q6	543	34	first	first	RB
cord-014712-5u4e00q6	543	35	)	)	-RRB-
cord-014712-5u4e00q6	543	36	and	and	CC
cord-014712-5u4e00q6	543	37	after	after	IN
cord-014712-5u4e00q6	543	38	(	(	-LRB-
cord-014712-5u4e00q6	543	39	second	second	RB
cord-014712-5u4e00q6	543	40	)	)	-RRB-
cord-014712-5u4e00q6	543	41	their	-PRON-	PRP$
cord-014712-5u4e00q6	543	42	education	education	NN
cord-014712-5u4e00q6	543	43	about	about	IN
cord-014712-5u4e00q6	543	44	clinical	clinical	JJ
cord-014712-5u4e00q6	543	45	immunology	immunology	NN
cord-014712-5u4e00q6	543	46	courses	course	NNS
cord-014712-5u4e00q6	543	47	for	for	IN
cord-014712-5u4e00q6	543	48	6	6	CD
cord-014712-5u4e00q6	543	49	hours	hour	NNS
cord-014712-5u4e00q6	543	50	.	.	.
cord-014712-5u4e00q6	544	1	Questionnaire	questionnaire	NN
cord-014712-5u4e00q6	544	2	Scores	score	NNS
cord-014712-5u4e00q6	544	3	(	(	-LRB-
cord-014712-5u4e00q6	544	4	QS	QS	NNP
cord-014712-5u4e00q6	544	5	)	)	-RRB-
cord-014712-5u4e00q6	544	6	were	be	VBD
cord-014712-5u4e00q6	544	7	detected	detect	VBN
cord-014712-5u4e00q6	544	8	as	as	IN
cord-014712-5u4e00q6	544	9	total	total	JJ
cord-014712-5u4e00q6	544	10	correct	correct	JJ
cord-014712-5u4e00q6	544	11	answers	answer	NNS
cord-014712-5u4e00q6	544	12	.	.	.
cord-014712-5u4e00q6	545	1	The	the	DT
cord-014712-5u4e00q6	545	2	mean	mean	NN
cord-014712-5u4e00q6	545	3	of	of	IN
cord-014712-5u4e00q6	545	4	the	the	DT
cord-014712-5u4e00q6	545	5	first	first	JJ
cord-014712-5u4e00q6	545	6	QS	QS	NNP
cord-014712-5u4e00q6	545	7	was	be	VBD
cord-014712-5u4e00q6	546	1	37.4	37.4	CD
cord-014712-5u4e00q6	546	2	±	±	CD
cord-014712-5u4e00q6	546	3	3.7	3.7	CD
cord-014712-5u4e00q6	546	4	and	and	CC
cord-014712-5u4e00q6	546	5	second	second	JJ
cord-014712-5u4e00q6	546	6	QS	QS	NNP
cord-014712-5u4e00q6	546	7	was	be	VBD
cord-014712-5u4e00q6	546	8	42	42	CD
cord-014712-5u4e00q6	546	9	±	±	NNP
cord-014712-5u4e00q6	546	10	4.3	4.3	CD
cord-014712-5u4e00q6	546	11	(	(	-LRB-
cord-014712-5u4e00q6	546	12	p	p	NN
cord-014712-5u4e00q6	546	13	<	<	XX
cord-014712-5u4e00q6	546	14	0.05	0.05	CD
cord-014712-5u4e00q6	546	15	)	)	-RRB-
cord-014712-5u4e00q6	546	16	.	.	.
cord-014712-5u4e00q6	547	1	There	there	EX
cord-014712-5u4e00q6	547	2	was	be	VBD
cord-014712-5u4e00q6	547	3	no	no	DT
cord-014712-5u4e00q6	547	4	statistically	statistically	RB
cord-014712-5u4e00q6	547	5	difference	difference	NN
cord-014712-5u4e00q6	547	6	in	in	IN
cord-014712-5u4e00q6	547	7	gender	gender	NN
cord-014712-5u4e00q6	547	8	(	(	-LRB-
cord-014712-5u4e00q6	547	9	60	60	CD
cord-014712-5u4e00q6	547	10	M	m	NN
cord-014712-5u4e00q6	547	11	and	and	CC
cord-014712-5u4e00q6	547	12	56	56	CD
cord-014712-5u4e00q6	547	13	F	F	NNP
cord-014712-5u4e00q6	547	14	)	)	-RRB-
cord-014712-5u4e00q6	547	15	.	.	.
cord-014712-5u4e00q6	548	1	Of	of	IN
cord-014712-5u4e00q6	548	2	69	69	CD
cord-014712-5u4e00q6	548	3	questions	question	NNS
cord-014712-5u4e00q6	548	4	,	,	,
cord-014712-5u4e00q6	548	5	there	there	EX
cord-014712-5u4e00q6	548	6	were	be	VBD
cord-014712-5u4e00q6	548	7	39	39	CD
cord-014712-5u4e00q6	548	8	related	relate	VBN
cord-014712-5u4e00q6	548	9	with	with	IN
cord-014712-5u4e00q6	548	10	PID	PID	NNP
cord-014712-5u4e00q6	548	11	directly	directly	RB
cord-014712-5u4e00q6	548	12	.	.	.
cord-014712-5u4e00q6	549	1	The	the	DT
cord-014712-5u4e00q6	549	2	correct	correct	JJ
cord-014712-5u4e00q6	549	3	responses	response	NNS
cord-014712-5u4e00q6	549	4	rate	rate	VBP
cord-014712-5u4e00q6	549	5	less	less	JJR
cord-014712-5u4e00q6	549	6	than	than	IN
cord-014712-5u4e00q6	549	7	50	50	CD
cord-014712-5u4e00q6	549	8	%	%	NN
cord-014712-5u4e00q6	549	9	before	before	IN
cord-014712-5u4e00q6	549	10	education	education	NN
cord-014712-5u4e00q6	549	11	were	be	VBD
cord-014712-5u4e00q6	549	12	10	10	CD
cord-014712-5u4e00q6	549	13	of	of	IN
cord-014712-5u4e00q6	549	14	39	39	CD
cord-014712-5u4e00q6	549	15	questions	question	NNS
cord-014712-5u4e00q6	549	16	.	.	.
cord-014712-5u4e00q6	550	1	All	all	DT
cord-014712-5u4e00q6	550	2	participants	participant	NNS
cord-014712-5u4e00q6	550	3	corrected	correct	VBD
cord-014712-5u4e00q6	550	4	their	-PRON-	PRP$
cord-014712-5u4e00q6	550	5	responses	response	NNS
cord-014712-5u4e00q6	550	6	after	after	IN
cord-014712-5u4e00q6	550	7	education	education	NN
cord-014712-5u4e00q6	550	8	.	.	.
cord-014712-5u4e00q6	551	1	The	the	DT
cord-014712-5u4e00q6	551	2	best	good	JJS
cord-014712-5u4e00q6	551	3	improvement	improvement	NN
cord-014712-5u4e00q6	551	4	was	be	VBD
cord-014712-5u4e00q6	551	5	detected	detect	VBN
cord-014712-5u4e00q6	551	6	in	in	IN
cord-014712-5u4e00q6	551	7	the	the	DT
cord-014712-5u4e00q6	551	8	responses	response	NNS
cord-014712-5u4e00q6	551	9	of	of	IN
cord-014712-5u4e00q6	551	10	the	the	DT
cord-014712-5u4e00q6	551	11	clinical	clinical	JJ
cord-014712-5u4e00q6	551	12	signs	sign	NNS
cord-014712-5u4e00q6	551	13	related	relate	VBN
cord-014712-5u4e00q6	551	14	with	with	IN
cord-014712-5u4e00q6	551	15	PID	PID	NNP
cord-014712-5u4e00q6	551	16	.	.	.
cord-014712-5u4e00q6	552	1	It	-PRON-	PRP
cord-014712-5u4e00q6	552	2	was	be	VBD
cord-014712-5u4e00q6	552	3	remarkable	remarkable	JJ
cord-014712-5u4e00q6	552	4	that	that	IN
cord-014712-5u4e00q6	552	5	the	the	DT
cord-014712-5u4e00q6	552	6	participants	participant	NNS
cord-014712-5u4e00q6	552	7	have	have	VBP
cord-014712-5u4e00q6	552	8	known	know	VBN
cord-014712-5u4e00q6	552	9	the	the	DT
cord-014712-5u4e00q6	552	10	family	family	NN
cord-014712-5u4e00q6	552	11	history	history	NN
cord-014712-5u4e00q6	552	12	related	relate	VBN
cord-014712-5u4e00q6	552	13	with	with	IN
cord-014712-5u4e00q6	552	14	PID	PID	NNP
cord-014712-5u4e00q6	552	15	excellent	excellent	JJ
cord-014712-5u4e00q6	552	16	before	before	IN
cord-014712-5u4e00q6	552	17	education	education	NN
cord-014712-5u4e00q6	552	18	.	.	.
cord-014712-5u4e00q6	553	1	The	the	DT
cord-014712-5u4e00q6	553	2	majority	majority	NN
cord-014712-5u4e00q6	553	3	of	of	IN
cord-014712-5u4e00q6	553	4	the	the	DT
cord-014712-5u4e00q6	553	5	participants	participant	NNS
cord-014712-5u4e00q6	553	6	(	(	-LRB-
cord-014712-5u4e00q6	553	7	80	80	CD
cord-014712-5u4e00q6	553	8	%	%	NN
cord-014712-5u4e00q6	553	9	)	)	-RRB-
cord-014712-5u4e00q6	553	10	believed	believe	VBD
cord-014712-5u4e00q6	553	11	that	that	IN
cord-014712-5u4e00q6	553	12	a	a	DT
cord-014712-5u4e00q6	553	13	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	553	14	count	count	NN
cord-014712-5u4e00q6	553	15	of	of	IN
cord-014712-5u4e00q6	553	16	2500	2500	CD
cord-014712-5u4e00q6	553	17	/	/	SYM
cord-014712-5u4e00q6	553	18	mm3	mm3	NNS
cord-014712-5u4e00q6	553	19	was	be	VBD
cord-014712-5u4e00q6	553	20	related	relate	VBN
cord-014712-5u4e00q6	553	21	to	to	IN
cord-014712-5u4e00q6	553	22	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	553	23	.	.	.
cord-014712-5u4e00q6	554	1	NBT	NBT	NNP
cord-014712-5u4e00q6	554	2	and	and	CC
cord-014712-5u4e00q6	554	3	CH50	CH50	NNP
cord-014712-5u4e00q6	554	4	test	test	NN
cord-014712-5u4e00q6	554	5	were	be	VBD
cord-014712-5u4e00q6	554	6	not	not	RB
cord-014712-5u4e00q6	554	7	found	find	VBN
cord-014712-5u4e00q6	554	8	to	to	TO
cord-014712-5u4e00q6	554	9	be	be	VB
cord-014712-5u4e00q6	554	10	related	relate	VBN
cord-014712-5u4e00q6	554	11	with	with	IN
cord-014712-5u4e00q6	554	12	PID	PID	NNP
cord-014712-5u4e00q6	554	13	before	before	IN
cord-014712-5u4e00q6	554	14	education	education	NN
cord-014712-5u4e00q6	554	15	.	.	.
cord-014712-5u4e00q6	555	1	It	-PRON-	PRP
cord-014712-5u4e00q6	555	2	is	be	VBZ
cord-014712-5u4e00q6	555	3	also	also	RB
cord-014712-5u4e00q6	555	4	important	important	JJ
cord-014712-5u4e00q6	555	5	to	to	TO
cord-014712-5u4e00q6	555	6	increase	increase	VB
cord-014712-5u4e00q6	555	7	the	the	DT
cord-014712-5u4e00q6	555	8	awareness	awareness	NN
cord-014712-5u4e00q6	555	9	of	of	IN
cord-014712-5u4e00q6	555	10	PID	PID	NNP
cord-014712-5u4e00q6	555	11	among	among	IN
cord-014712-5u4e00q6	555	12	the	the	DT
cord-014712-5u4e00q6	555	13	physicians	physician	NNS
cord-014712-5u4e00q6	555	14	during	during	IN
cord-014712-5u4e00q6	555	15	their	-PRON-	PRP$
cord-014712-5u4e00q6	555	16	education	education	NN
cord-014712-5u4e00q6	555	17	in	in	IN
cord-014712-5u4e00q6	555	18	medical	medical	JJ
cord-014712-5u4e00q6	555	19	school	school	NN
cord-014712-5u4e00q6	555	20	and	and	CC
cord-014712-5u4e00q6	555	21	more	more	RBR
cord-014712-5u4e00q6	555	22	comprehensive	comprehensive	JJ
cord-014712-5u4e00q6	555	23	education	education	NN
cord-014712-5u4e00q6	555	24	in	in	IN
cord-014712-5u4e00q6	555	25	PID	PID	NNP
cord-014712-5u4e00q6	555	26	appears	appear	VBZ
cord-014712-5u4e00q6	555	27	to	to	TO
cord-014712-5u4e00q6	555	28	be	be	VB
cord-014712-5u4e00q6	555	29	useful	useful	JJ
cord-014712-5u4e00q6	555	30	for	for	IN
cord-014712-5u4e00q6	555	31	medical	medical	JJ
cord-014712-5u4e00q6	555	32	students	student	NNS
cord-014712-5u4e00q6	555	33	.	.	.
cord-014712-5u4e00q6	556	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	556	2	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	556	3	disease	disease	NN
cord-014712-5u4e00q6	556	4	(	(	-LRB-
cord-014712-5u4e00q6	556	5	CGD	CGD	NNP
cord-014712-5u4e00q6	556	6	)	)	-RRB-
cord-014712-5u4e00q6	556	7	is	be	VBZ
cord-014712-5u4e00q6	556	8	a	a	DT
cord-014712-5u4e00q6	556	9	rare	rare	JJ
cord-014712-5u4e00q6	556	10	primary	primary	JJ
cord-014712-5u4e00q6	556	11	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	556	12	with	with	IN
cord-014712-5u4e00q6	556	13	mutations	mutation	NNS
cord-014712-5u4e00q6	556	14	in	in	IN
cord-014712-5u4e00q6	556	15	NADPH	NADPH	NNP
cord-014712-5u4e00q6	556	16	oxidase	oxidase	NN
cord-014712-5u4e00q6	556	17	enzyme	enzyme	NN
cord-014712-5u4e00q6	556	18	complex	complex	NN
cord-014712-5u4e00q6	556	19	which	which	WDT
cord-014712-5u4e00q6	556	20	causes	cause	VBZ
cord-014712-5u4e00q6	556	21	failure	failure	NN
cord-014712-5u4e00q6	556	22	of	of	IN
cord-014712-5u4e00q6	556	23	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	556	24	cells	cell	NNS
cord-014712-5u4e00q6	556	25	to	to	TO
cord-014712-5u4e00q6	556	26	produce	produce	VB
cord-014712-5u4e00q6	556	27	superoxide	superoxide	NN
cord-014712-5u4e00q6	556	28	and	and	CC
cord-014712-5u4e00q6	556	29	subsequent	subsequent	JJ
cord-014712-5u4e00q6	556	30	intracellular	intracellular	JJ
cord-014712-5u4e00q6	556	31	killing	killing	NN
cord-014712-5u4e00q6	556	32	of	of	IN
cord-014712-5u4e00q6	556	33	microorganisms	microorganism	NNS
cord-014712-5u4e00q6	556	34	.	.	.
cord-014712-5u4e00q6	557	1	We	-PRON-	PRP
cord-014712-5u4e00q6	557	2	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	557	3	analysed	analyse	VBD
cord-014712-5u4e00q6	557	4	medical	medical	JJ
cord-014712-5u4e00q6	557	5	records	record	NNS
cord-014712-5u4e00q6	557	6	of	of	IN
cord-014712-5u4e00q6	557	7	patients	patient	NNS
cord-014712-5u4e00q6	557	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	557	9	with	with	IN
cord-014712-5u4e00q6	557	10	CGD	CGD	NNP
cord-014712-5u4e00q6	557	11	in	in	IN
cord-014712-5u4e00q6	557	12	the	the	DT
cord-014712-5u4e00q6	557	13	last	last	JJ
cord-014712-5u4e00q6	557	14	35	35	CD
cord-014712-5u4e00q6	557	15	years	year	NNS
cord-014712-5u4e00q6	557	16	from	from	IN
cord-014712-5u4e00q6	557	17	immunological	immunological	JJ
cord-014712-5u4e00q6	557	18	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	557	19	centres	centre	NNS
cord-014712-5u4e00q6	557	20	from	from	IN
cord-014712-5u4e00q6	557	21	9	9	CD
cord-014712-5u4e00q6	557	22	central	central	JJ
cord-014712-5u4e00q6	557	23	and	and	CC
cord-014712-5u4e00q6	557	24	eastern	eastern	JJ
cord-014712-5u4e00q6	557	25	European	european	JJ
cord-014712-5u4e00q6	557	26	countries	country	NNS
cord-014712-5u4e00q6	557	27	(	(	-LRB-
cord-014712-5u4e00q6	557	28	Estonia	Estonia	NNP
cord-014712-5u4e00q6	557	29	,	,	,
cord-014712-5u4e00q6	557	30	Poland	Poland	NNP
cord-014712-5u4e00q6	557	31	,	,	,
cord-014712-5u4e00q6	557	32	Belarus	Belarus	NNP
cord-014712-5u4e00q6	557	33	,	,	,
cord-014712-5u4e00q6	557	34	Ukraine	Ukraine	NNP
cord-014712-5u4e00q6	557	35	,	,	,
cord-014712-5u4e00q6	557	36	Czech	Czech	NNP
cord-014712-5u4e00q6	557	37	Republic	Republic	NNP
cord-014712-5u4e00q6	557	38	,	,	,
cord-014712-5u4e00q6	557	39	Slovakia	Slovakia	NNP
cord-014712-5u4e00q6	557	40	,	,	,
cord-014712-5u4e00q6	557	41	Hungary	Hungary	NNP
cord-014712-5u4e00q6	557	42	,	,	,
cord-014712-5u4e00q6	557	43	Serbia	Serbia	NNP
cord-014712-5u4e00q6	557	44	and	and	CC
cord-014712-5u4e00q6	557	45	Slovenia	Slovenia	NNP
cord-014712-5u4e00q6	557	46	)	)	-RRB-
cord-014712-5u4e00q6	557	47	and	and	CC
cord-014712-5u4e00q6	557	48	Russia	Russia	NNP
cord-014712-5u4e00q6	557	49	.	.	.
cord-014712-5u4e00q6	558	1	Genetic	genetic	JJ
cord-014712-5u4e00q6	558	2	sequencing	sequencing	NN
cord-014712-5u4e00q6	558	3	from	from	IN
cord-014712-5u4e00q6	558	4	patients	patient	NNS
cord-014712-5u4e00q6	558	5	'	'	POS
cord-014712-5u4e00q6	558	6	DNA	DNA	NNP
cord-014712-5u4e00q6	558	7	was	be	VBD
cord-014712-5u4e00q6	558	8	performed	perform	VBN
cord-014712-5u4e00q6	558	9	in	in	IN
cord-014712-5u4e00q6	558	10	genetic	genetic	JJ
cord-014712-5u4e00q6	558	11	centres	centre	NNS
cord-014712-5u4e00q6	558	12	in	in	IN
cord-014712-5u4e00q6	558	13	Ljubljana	Ljubljana	NNP
cord-014712-5u4e00q6	558	14	,	,	,
cord-014712-5u4e00q6	558	15	Belarus	Belarus	NNP
cord-014712-5u4e00q6	558	16	and	and	CC
cord-014712-5u4e00q6	558	17	Netherlands	Netherlands	NNP
cord-014712-5u4e00q6	558	18	for	for	IN
cord-014712-5u4e00q6	558	19	mutations	mutation	NNS
cord-014712-5u4e00q6	558	20	in	in	IN
cord-014712-5u4e00q6	558	21	known	know	VBN
cord-014712-5u4e00q6	558	22	genes	gene	NNS
cord-014712-5u4e00q6	558	23	involved	involve	VBN
cord-014712-5u4e00q6	558	24	in	in	IN
cord-014712-5u4e00q6	558	25	CGD	CGD	NNP
cord-014712-5u4e00q6	558	26	pathogenesis	pathogenesis	NN
cord-014712-5u4e00q6	558	27	:	:	:
cord-014712-5u4e00q6	558	28	CYBB	CYBB	NNP
cord-014712-5u4e00q6	558	29	,	,	,
cord-014712-5u4e00q6	558	30	CYBA	CYBA	NNP
cord-014712-5u4e00q6	558	31	,	,	,
cord-014712-5u4e00q6	558	32	NCF1	NCF1	NNP
cord-014712-5u4e00q6	558	33	,	,	,
cord-014712-5u4e00q6	558	34	NCF2	NCF2	NNP
cord-014712-5u4e00q6	558	35	.	.	.
cord-014712-5u4e00q6	559	1	We	-PRON-	PRP
cord-014712-5u4e00q6	559	2	included	include	VBD
cord-014712-5u4e00q6	559	3	104	104	CD
cord-014712-5u4e00q6	559	4	patients	patient	NNS
cord-014712-5u4e00q6	559	5	with	with	IN
cord-014712-5u4e00q6	559	6	CGD	CGD	NNP
cord-014712-5u4e00q6	559	7	in	in	IN
cord-014712-5u4e00q6	559	8	our	-PRON-	PRP$
cord-014712-5u4e00q6	559	9	cohort	cohort	NN
cord-014712-5u4e00q6	559	10	,	,	,
cord-014712-5u4e00q6	559	11	7	7	CD
cord-014712-5u4e00q6	559	12	were	be	VBD
cord-014712-5u4e00q6	559	13	female	female	JJ
cord-014712-5u4e00q6	559	14	.	.	.
cord-014712-5u4e00q6	560	1	The	the	DT
cord-014712-5u4e00q6	560	2	mean	mean	JJ
cord-014712-5u4e00q6	560	3	age	age	NN
cord-014712-5u4e00q6	560	4	at	at	IN
cord-014712-5u4e00q6	560	5	presentation	presentation	NN
cord-014712-5u4e00q6	560	6	of	of	IN
cord-014712-5u4e00q6	560	7	the	the	DT
cord-014712-5u4e00q6	560	8	disease	disease	NN
cord-014712-5u4e00q6	560	9	was	be	VBD
cord-014712-5u4e00q6	560	10	12	12	CD
cord-014712-5u4e00q6	560	11	months	month	NNS
cord-014712-5u4e00q6	560	12	and	and	CC
cord-014712-5u4e00q6	560	13	at	at	IN
cord-014712-5u4e00q6	560	14	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	560	15	3,9	3,9	CD
cord-014712-5u4e00q6	560	16	years	year	NNS
cord-014712-5u4e00q6	560	17	.	.	.
cord-014712-5u4e00q6	561	1	Lymphadenitis	Lymphadenitis	NNP
cord-014712-5u4e00q6	561	2	(	(	-LRB-
cord-014712-5u4e00q6	561	3	43	43	CD
cord-014712-5u4e00q6	561	4	%	%	NN
cord-014712-5u4e00q6	561	5	)	)	-RRB-
cord-014712-5u4e00q6	561	6	,	,	,
cord-014712-5u4e00q6	561	7	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	561	8	(	(	-LRB-
cord-014712-5u4e00q6	561	9	16	16	CD
cord-014712-5u4e00q6	561	10	%	%	NN
cord-014712-5u4e00q6	561	11	)	)	-RRB-
cord-014712-5u4e00q6	561	12	,	,	,
cord-014712-5u4e00q6	561	13	enteritis	enteritis	NN
cord-014712-5u4e00q6	561	14	(	(	-LRB-
cord-014712-5u4e00q6	561	15	16	16	CD
cord-014712-5u4e00q6	561	16	%	%	NN
cord-014712-5u4e00q6	561	17	)	)	-RRB-
cord-014712-5u4e00q6	561	18	,	,	,
cord-014712-5u4e00q6	561	19	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	561	20	infections	infection	NNS
cord-014712-5u4e00q6	561	21	(	(	-LRB-
cord-014712-5u4e00q6	561	22	13	13	CD
cord-014712-5u4e00q6	561	23	%	%	NN
cord-014712-5u4e00q6	561	24	)	)	-RRB-
cord-014712-5u4e00q6	561	25	,	,	,
cord-014712-5u4e00q6	561	26	liver	liver	NN
cord-014712-5u4e00q6	561	27	abscesses	abscess	NNS
cord-014712-5u4e00q6	561	28	(	(	-LRB-
cord-014712-5u4e00q6	561	29	4	4	CD
cord-014712-5u4e00q6	561	30	%	%	NN
cord-014712-5u4e00q6	561	31	)	)	-RRB-
cord-014712-5u4e00q6	561	32	and	and	CC
cord-014712-5u4e00q6	561	33	septicaemia	septicaemia	NN
cord-014712-5u4e00q6	561	34	(	(	-LRB-
cord-014712-5u4e00q6	561	35	6	6	CD
cord-014712-5u4e00q6	561	36	%	%	NN
cord-014712-5u4e00q6	561	37	)	)	-RRB-
cord-014712-5u4e00q6	561	38	were	be	VBD
cord-014712-5u4e00q6	561	39	the	the	DT
cord-014712-5u4e00q6	561	40	most	most	RBS
cord-014712-5u4e00q6	561	41	common	common	JJ
cord-014712-5u4e00q6	561	42	clinical	clinical	JJ
cord-014712-5u4e00q6	561	43	presentation	presentation	NN
cord-014712-5u4e00q6	561	44	.	.	.
cord-014712-5u4e00q6	562	1	Complications	complication	NNS
cord-014712-5u4e00q6	562	2	of	of	IN
cord-014712-5u4e00q6	562	3	BCG	BCG	NNP
cord-014712-5u4e00q6	562	4	vaccination	vaccination	NN
cord-014712-5u4e00q6	562	5	(	(	-LRB-
cord-014712-5u4e00q6	562	6	28	28	CD
cord-014712-5u4e00q6	562	7	%	%	NN
cord-014712-5u4e00q6	562	8	)	)	-RRB-
cord-014712-5u4e00q6	562	9	were	be	VBD
cord-014712-5u4e00q6	562	10	the	the	DT
cord-014712-5u4e00q6	562	11	most	most	RBS
cord-014712-5u4e00q6	562	12	common	common	JJ
cord-014712-5u4e00q6	562	13	presenting	present	VBG
cord-014712-5u4e00q6	562	14	infection	infection	NN
cord-014712-5u4e00q6	562	15	.	.	.
cord-014712-5u4e00q6	563	1	In	in	IN
cord-014712-5u4e00q6	563	2	total	total	JJ
cord-014712-5u4e00q6	563	3	917,4	917,4	CD
cord-014712-5u4e00q6	563	4	years	year	NNS
cord-014712-5u4e00q6	563	5	of	of	IN
cord-014712-5u4e00q6	563	6	followup	followup	NN
cord-014712-5u4e00q6	563	7	in	in	IN
cord-014712-5u4e00q6	563	8	our	-PRON-	PRP$
cord-014712-5u4e00q6	563	9	cohort	cohort	NN
cord-014712-5u4e00q6	563	10	,	,	,
cord-014712-5u4e00q6	563	11	the	the	DT
cord-014712-5u4e00q6	563	12	patients	patient	NNS
cord-014712-5u4e00q6	563	13	suffered	suffer	VBD
cord-014712-5u4e00q6	563	14	834	834	CD
cord-014712-5u4e00q6	563	15	different	different	JJ
cord-014712-5u4e00q6	563	16	severe	severe	JJ
cord-014712-5u4e00q6	563	17	infectious	infectious	JJ
cord-014712-5u4e00q6	563	18	episodes	episode	NNS
cord-014712-5u4e00q6	563	19	(	(	-LRB-
cord-014712-5u4e00q6	563	20	0.9	0.9	CD
cord-014712-5u4e00q6	563	21	per	per	IN
cord-014712-5u4e00q6	563	22	year	year	NN
cord-014712-5u4e00q6	563	23	)	)	-RRB-
cord-014712-5u4e00q6	563	24	.	.	.
cord-014712-5u4e00q6	564	1	Respiratory	respiratory	JJ
cord-014712-5u4e00q6	564	2	(	(	-LRB-
cord-014712-5u4e00q6	564	3	25	25	CD
cord-014712-5u4e00q6	564	4	%	%	NN
cord-014712-5u4e00q6	564	5	)	)	-RRB-
cord-014712-5u4e00q6	564	6	,	,	,
cord-014712-5u4e00q6	564	7	Lymph	lymph	NN
cord-014712-5u4e00q6	564	8	node	node	NN
cord-014712-5u4e00q6	564	9	(	(	-LRB-
cord-014712-5u4e00q6	564	10	25	25	CD
cord-014712-5u4e00q6	564	11	%	%	NN
cord-014712-5u4e00q6	564	12	)	)	-RRB-
cord-014712-5u4e00q6	564	13	and	and	CC
cord-014712-5u4e00q6	564	14	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	564	15	tract	tract	NN
cord-014712-5u4e00q6	564	16	(	(	-LRB-
cord-014712-5u4e00q6	564	17	18	18	CD
cord-014712-5u4e00q6	564	18	%	%	NN
cord-014712-5u4e00q6	564	19	)	)	-RRB-
cord-014712-5u4e00q6	564	20	infections	infection	NNS
cord-014712-5u4e00q6	564	21	represented	represent	VBD
cord-014712-5u4e00q6	564	22	the	the	DT
cord-014712-5u4e00q6	564	23	most	most	RBS
cord-014712-5u4e00q6	564	24	prevalent	prevalent	JJ
cord-014712-5u4e00q6	564	25	severe	severe	JJ
cord-014712-5u4e00q6	564	26	infections	infection	NNS
cord-014712-5u4e00q6	564	27	.	.	.
cord-014712-5u4e00q6	565	1	We	-PRON-	PRP
cord-014712-5u4e00q6	565	2	identified	identify	VBD
cord-014712-5u4e00q6	565	3	87	87	CD
cord-014712-5u4e00q6	565	4	different	different	JJ
cord-014712-5u4e00q6	565	5	mutations	mutation	NNS
cord-014712-5u4e00q6	565	6	out	out	IN
cord-014712-5u4e00q6	565	7	of	of	IN
cord-014712-5u4e00q6	565	8	104	104	CD
cord-014712-5u4e00q6	565	9	genes	gene	NNS
cord-014712-5u4e00q6	565	10	tested	test	VBN
cord-014712-5u4e00q6	565	11	.	.	.
cord-014712-5u4e00q6	566	1	In	in	IN
cord-014712-5u4e00q6	566	2	78	78	CD
cord-014712-5u4e00q6	566	3	patients	patient	NNS
cord-014712-5u4e00q6	566	4	we	-PRON-	PRP
cord-014712-5u4e00q6	566	5	identified	identify	VBD
cord-014712-5u4e00q6	566	6	different	different	JJ
cord-014712-5u4e00q6	566	7	mutations	mutation	NNS
cord-014712-5u4e00q6	566	8	in	in	IN
cord-014712-5u4e00q6	566	9	CYBB	CYBB	NNP
cord-014712-5u4e00q6	566	10	gene	gene	NN
cord-014712-5u4e00q6	566	11	,	,	,
cord-014712-5u4e00q6	566	12	2	2	CD
cord-014712-5u4e00q6	566	13	unrelated	unrelated	JJ
cord-014712-5u4e00q6	566	14	patients	patient	NNS
cord-014712-5u4e00q6	566	15	had	have	VBD
cord-014712-5u4e00q6	566	16	the	the	DT
cord-014712-5u4e00q6	566	17	same	same	JJ
cord-014712-5u4e00q6	566	18	mutation	mutation	NN
cord-014712-5u4e00q6	566	19	in	in	IN
cord-014712-5u4e00q6	566	20	CYBA	CYBA	NNP
cord-014712-5u4e00q6	566	21	gene	gene	NN
cord-014712-5u4e00q6	566	22	and	and	CC
cord-014712-5u4e00q6	566	23	in	in	IN
cord-014712-5u4e00q6	566	24	5	5	CD
cord-014712-5u4e00q6	566	25	patients	patient	NNS
cord-014712-5u4e00q6	566	26	had	have	VBD
cord-014712-5u4e00q6	566	27	typical	typical	JJ
cord-014712-5u4e00q6	566	28	deletion	deletion	NN
cord-014712-5u4e00q6	566	29	in	in	IN
cord-014712-5u4e00q6	566	30	NCF1	NCF1	NNP
cord-014712-5u4e00q6	566	31	gene	gene	NN
cord-014712-5u4e00q6	566	32	.	.	.
cord-014712-5u4e00q6	567	1	In	in	IN
cord-014712-5u4e00q6	567	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	567	3	cohort	cohort	NN
cord-014712-5u4e00q6	567	4	we	-PRON-	PRP
cord-014712-5u4e00q6	567	5	observed	observe	VBD
cord-014712-5u4e00q6	567	6	high	high	JJ
cord-014712-5u4e00q6	567	7	incidence	incidence	NN
cord-014712-5u4e00q6	567	8	of	of	IN
cord-014712-5u4e00q6	567	9	BCG	BCG	NNP
cord-014712-5u4e00q6	567	10	infections	infection	NNS
cord-014712-5u4e00q6	567	11	as	as	IN
cord-014712-5u4e00q6	567	12	a	a	DT
cord-014712-5u4e00q6	567	13	presenting	present	VBG
cord-014712-5u4e00q6	567	14	symptom	symptom	NN
cord-014712-5u4e00q6	567	15	.	.	.
cord-014712-5u4e00q6	568	1	Apart	apart	RB
cord-014712-5u4e00q6	568	2	from	from	IN
cord-014712-5u4e00q6	568	3	high	high	JJ
cord-014712-5u4e00q6	568	4	BCG	BCG	NNP
cord-014712-5u4e00q6	568	5	infections	infection	NNS
cord-014712-5u4e00q6	568	6	patients	patient	NNS
cord-014712-5u4e00q6	568	7	included	include	VBN
cord-014712-5u4e00q6	568	8	in	in	IN
cord-014712-5u4e00q6	568	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	568	10	study	study	NN
cord-014712-5u4e00q6	568	11	had	have	VBD
cord-014712-5u4e00q6	568	12	similar	similar	JJ
cord-014712-5u4e00q6	568	13	frequencies	frequency	NNS
cord-014712-5u4e00q6	568	14	of	of	IN
cord-014712-5u4e00q6	568	15	infections	infection	NNS
cord-014712-5u4e00q6	568	16	and	and	CC
cord-014712-5u4e00q6	568	17	infecting	infect	VBG
cord-014712-5u4e00q6	568	18	microorganisms	microorganism	NNS
cord-014712-5u4e00q6	568	19	as	as	IN
cord-014712-5u4e00q6	568	20	patients	patient	NNS
cord-014712-5u4e00q6	568	21	described	describe	VBN
cord-014712-5u4e00q6	568	22	in	in	IN
cord-014712-5u4e00q6	568	23	previous	previous	JJ
cord-014712-5u4e00q6	568	24	series	series	NN
cord-014712-5u4e00q6	568	25	.	.	.
cord-014712-5u4e00q6	569	1	Objectives	objective	NNS
cord-014712-5u4e00q6	569	2	:	:	:
cord-014712-5u4e00q6	570	1	The	the	DT
cord-014712-5u4e00q6	570	2	aim	aim	NN
cord-014712-5u4e00q6	570	3	of	of	IN
cord-014712-5u4e00q6	570	4	this	this	DT
cord-014712-5u4e00q6	570	5	study	study	NN
cord-014712-5u4e00q6	570	6	is	be	VBZ
cord-014712-5u4e00q6	570	7	to	to	TO
cord-014712-5u4e00q6	570	8	determine	determine	VB
cord-014712-5u4e00q6	570	9	the	the	DT
cord-014712-5u4e00q6	570	10	carrier	carrier	NN
cord-014712-5u4e00q6	570	11	rate	rate	NN
cord-014712-5u4e00q6	570	12	in	in	IN
cord-014712-5u4e00q6	570	13	healthy	healthy	JJ
cord-014712-5u4e00q6	570	14	controls	control	NNS
cord-014712-5u4e00q6	570	15	from	from	IN
cord-014712-5u4e00q6	570	16	Central	central	JJ
cord-014712-5u4e00q6	570	17	European	european	JJ
cord-014712-5u4e00q6	570	18	and	and	CC
cord-014712-5u4e00q6	570	19	Balkan	balkan	JJ
cord-014712-5u4e00q6	570	20	region	region	NN
cord-014712-5u4e00q6	570	21	.	.	.
cord-014712-5u4e00q6	571	1	Methods	method	NNS
cord-014712-5u4e00q6	571	2	:	:	:
cord-014712-5u4e00q6	571	3	We	-PRON-	PRP
cord-014712-5u4e00q6	571	4	screened	screen	VBD
cord-014712-5u4e00q6	571	5	more	more	JJR
cord-014712-5u4e00q6	571	6	than	than	IN
cord-014712-5u4e00q6	571	7	500	500	CD
cord-014712-5u4e00q6	571	8	healthy	healthy	JJ
cord-014712-5u4e00q6	571	9	subjects	subject	NNS
cord-014712-5u4e00q6	571	10	from	from	IN
cord-014712-5u4e00q6	571	11	5	5	CD
cord-014712-5u4e00q6	571	12	countries	country	NNS
cord-014712-5u4e00q6	571	13	in	in	IN
cord-014712-5u4e00q6	571	14	the	the	DT
cord-014712-5u4e00q6	571	15	region	region	NN
cord-014712-5u4e00q6	571	16	.	.	.
cord-014712-5u4e00q6	572	1	Exon	exon	NN
cord-014712-5u4e00q6	572	2	2	2	CD
cord-014712-5u4e00q6	572	3	and	and	CC
cord-014712-5u4e00q6	572	4	10	10	CD
cord-014712-5u4e00q6	572	5	was	be	VBD
cord-014712-5u4e00q6	572	6	PCR	PCR	NNP
cord-014712-5u4e00q6	572	7	amplified	amplify	VBN
cord-014712-5u4e00q6	572	8	and	and	CC
cord-014712-5u4e00q6	572	9	subsequently	subsequently	RB
cord-014712-5u4e00q6	572	10	sequenced	sequence	VBN
cord-014712-5u4e00q6	572	11	with	with	IN
cord-014712-5u4e00q6	572	12	ABI	ABI	NNP
cord-014712-5u4e00q6	572	13	prism	prism	NN
cord-014712-5u4e00q6	572	14	310	310	CD
cord-014712-5u4e00q6	572	15	genetic	genetic	JJ
cord-014712-5u4e00q6	572	16	analyzer	analyzer	NN
cord-014712-5u4e00q6	572	17	.	.	.
cord-014712-5u4e00q6	573	1	Results	result	NNS
cord-014712-5u4e00q6	573	2	:	:	:
cord-014712-5u4e00q6	574	1	Heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	574	2	mutations	mutation	NNS
cord-014712-5u4e00q6	574	3	were	be	VBD
cord-014712-5u4e00q6	574	4	found	find	VBN
cord-014712-5u4e00q6	574	5	in	in	IN
cord-014712-5u4e00q6	574	6	4	4	CD
cord-014712-5u4e00q6	574	7	%	%	NN
cord-014712-5u4e00q6	574	8	of	of	IN
cord-014712-5u4e00q6	574	9	apparently	apparently	RB
cord-014712-5u4e00q6	574	10	healthy	healthy	JJ
cord-014712-5u4e00q6	574	11	Hungarians	Hungarians	NNPS
cord-014712-5u4e00q6	574	12	,	,	,
cord-014712-5u4e00q6	574	13	7	7	CD
cord-014712-5u4e00q6	574	14	%	%	NN
cord-014712-5u4e00q6	574	15	of	of	IN
cord-014712-5u4e00q6	574	16	Slovenians	Slovenians	NNPS
cord-014712-5u4e00q6	574	17	,	,	,
cord-014712-5u4e00q6	574	18	8	8	CD
cord-014712-5u4e00q6	574	19	%	%	NN
cord-014712-5u4e00q6	574	20	of	of	IN
cord-014712-5u4e00q6	574	21	Bosnians	Bosnians	NNPS
cord-014712-5u4e00q6	574	22	,	,	,
cord-014712-5u4e00q6	574	23	11	11	CD
cord-014712-5u4e00q6	574	24	%	%	NN
cord-014712-5u4e00q6	574	25	of	of	IN
cord-014712-5u4e00q6	574	26	Serbians	Serbians	NNPS
cord-014712-5u4e00q6	574	27	and	and	CC
cord-014712-5u4e00q6	574	28	in	in	IN
cord-014712-5u4e00q6	574	29	16	16	CD
cord-014712-5u4e00q6	574	30	%	%	NN
cord-014712-5u4e00q6	574	31	of	of	IN
cord-014712-5u4e00q6	574	32	apparently	apparently	RB
cord-014712-5u4e00q6	574	33	healthy	healthy	JJ
cord-014712-5u4e00q6	574	34	Macedonians	Macedonians	NNPS
cord-014712-5u4e00q6	574	35	.	.	.
cord-014712-5u4e00q6	575	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	575	2	found	find	VBN
cord-014712-5u4e00q6	575	3	in	in	IN
cord-014712-5u4e00q6	575	4	Hungarian	hungarian	JJ
cord-014712-5u4e00q6	575	5	population	population	NN
cord-014712-5u4e00q6	575	6	were	be	VBD
cord-014712-5u4e00q6	575	7	as	as	IN
cord-014712-5u4e00q6	575	8	follows	follow	VBZ
cord-014712-5u4e00q6	575	9	:	:	:
cord-014712-5u4e00q6	575	10	V726A	V726A	NNP
cord-014712-5u4e00q6	575	11	(	(	-LRB-
cord-014712-5u4e00q6	575	12	1	1	CD
cord-014712-5u4e00q6	575	13	)	)	-RRB-
cord-014712-5u4e00q6	575	14	,	,	,
cord-014712-5u4e00q6	575	15	K695R	K695R	NNP
cord-014712-5u4e00q6	575	16	(	(	-LRB-
cord-014712-5u4e00q6	575	17	3	3	CD
cord-014712-5u4e00q6	575	18	)	)	-RRB-
cord-014712-5u4e00q6	575	19	.	.	.
cord-014712-5u4e00q6	576	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	576	2	found	find	VBN
cord-014712-5u4e00q6	576	3	in	in	IN
cord-014712-5u4e00q6	576	4	Slovenian	slovenian	JJ
cord-014712-5u4e00q6	576	5	population	population	NN
cord-014712-5u4e00q6	576	6	were	be	VBD
cord-014712-5u4e00q6	576	7	:	:	:
cord-014712-5u4e00q6	576	8	V726A	V726A	NNP
cord-014712-5u4e00q6	576	9	(	(	-LRB-
cord-014712-5u4e00q6	576	10	1	1	CD
cord-014712-5u4e00q6	576	11	)	)	-RRB-
cord-014712-5u4e00q6	576	12	,	,	,
cord-014712-5u4e00q6	576	13	K695R	K695R	NNP
cord-014712-5u4e00q6	576	14	(	(	-LRB-
cord-014712-5u4e00q6	576	15	5	5	CD
cord-014712-5u4e00q6	576	16	)	)	-RRB-
cord-014712-5u4e00q6	576	17	and	and	CC
cord-014712-5u4e00q6	576	18	E148Q	E148Q	NNPS
cord-014712-5u4e00q6	576	19	(	(	-LRB-
cord-014712-5u4e00q6	576	20	1	1	CD
cord-014712-5u4e00q6	576	21	)	)	-RRB-
cord-014712-5u4e00q6	576	22	.	.	.
cord-014712-5u4e00q6	577	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	577	2	found	find	VBN
cord-014712-5u4e00q6	577	3	in	in	IN
cord-014712-5u4e00q6	577	4	Bosnian	bosnian	JJ
cord-014712-5u4e00q6	577	5	population	population	NN
cord-014712-5u4e00q6	577	6	were	be	VBD
cord-014712-5u4e00q6	577	7	:	:	:
cord-014712-5u4e00q6	577	8	V726A	V726A	NNP
cord-014712-5u4e00q6	577	9	(	(	-LRB-
cord-014712-5u4e00q6	577	10	1	1	CD
cord-014712-5u4e00q6	577	11	)	)	-RRB-
cord-014712-5u4e00q6	577	12	,	,	,
cord-014712-5u4e00q6	577	13	K695R	K695R	NNP
cord-014712-5u4e00q6	577	14	(	(	-LRB-
cord-014712-5u4e00q6	577	15	6	6	CD
cord-014712-5u4e00q6	577	16	)	)	-RRB-
cord-014712-5u4e00q6	577	17	and	and	CC
cord-014712-5u4e00q6	577	18	F756C	F756C	NNP
cord-014712-5u4e00q6	577	19	(	(	-LRB-
cord-014712-5u4e00q6	577	20	1	1	CD
cord-014712-5u4e00q6	577	21	)	)	-RRB-
cord-014712-5u4e00q6	577	22	.	.	.
cord-014712-5u4e00q6	578	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	578	2	found	find	VBN
cord-014712-5u4e00q6	578	3	in	in	IN
cord-014712-5u4e00q6	578	4	Serbian	serbian	JJ
cord-014712-5u4e00q6	578	5	population	population	NN
cord-014712-5u4e00q6	578	6	were	be	VBD
cord-014712-5u4e00q6	578	7	:	:	:
cord-014712-5u4e00q6	578	8	E148Q	E148Q	NNP
cord-014712-5u4e00q6	578	9	(	(	-LRB-
cord-014712-5u4e00q6	578	10	6	6	CD
cord-014712-5u4e00q6	578	11	)	)	-RRB-
cord-014712-5u4e00q6	578	12	,	,	,
cord-014712-5u4e00q6	578	13	K695R	K695R	NNP
cord-014712-5u4e00q6	578	14	(	(	-LRB-
cord-014712-5u4e00q6	578	15	5	5	CD
cord-014712-5u4e00q6	578	16	)	)	-RRB-
cord-014712-5u4e00q6	578	17	.	.	.
cord-014712-5u4e00q6	579	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	579	2	found	find	VBN
cord-014712-5u4e00q6	579	3	in	in	IN
cord-014712-5u4e00q6	579	4	Macedonian	macedonian	JJ
cord-014712-5u4e00q6	579	5	population	population	NN
cord-014712-5u4e00q6	579	6	were	be	VBD
cord-014712-5u4e00q6	579	7	as	as	IN
cord-014712-5u4e00q6	579	8	follows	follow	VBZ
cord-014712-5u4e00q6	579	9	:	:	:
cord-014712-5u4e00q6	579	10	E148Q	E148Q	NNP
cord-014712-5u4e00q6	579	11	(	(	-LRB-
cord-014712-5u4e00q6	579	12	8)	8)	NN
cord-014712-5u4e00q6	579	13	,	,	,
cord-014712-5u4e00q6	579	14	K695R	K695R	NNP
cord-014712-5u4e00q6	579	15	(	(	-LRB-
cord-014712-5u4e00q6	579	16	7	7	CD
cord-014712-5u4e00q6	579	17	)	)	-RRB-
cord-014712-5u4e00q6	579	18	and	and	CC
cord-014712-5u4e00q6	579	19	M694V	M694V	NNP
cord-014712-5u4e00q6	579	20	(	(	-LRB-
cord-014712-5u4e00q6	579	21	1	1	CD
cord-014712-5u4e00q6	579	22	)	)	-RRB-
cord-014712-5u4e00q6	579	23	.	.	.
cord-014712-5u4e00q6	580	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	580	2	:	:	:
cord-014712-5u4e00q6	580	3	We	-PRON-	PRP
cord-014712-5u4e00q6	580	4	found	find	VBD
cord-014712-5u4e00q6	580	5	higher	high	JJR
cord-014712-5u4e00q6	580	6	than	than	IN
cord-014712-5u4e00q6	580	7	expected	expect	VBN
cord-014712-5u4e00q6	580	8	carrier	carrier	NN
cord-014712-5u4e00q6	580	9	rate	rate	NN
cord-014712-5u4e00q6	580	10	in	in	IN
cord-014712-5u4e00q6	580	11	screened	screen	VBN
cord-014712-5u4e00q6	580	12	populations	population	NNS
cord-014712-5u4e00q6	580	13	,	,	,
cord-014712-5u4e00q6	580	14	from	from	IN
cord-014712-5u4e00q6	580	15	4	4	CD
cord-014712-5u4e00q6	580	16	%	%	NN
cord-014712-5u4e00q6	580	17	to	to	IN
cord-014712-5u4e00q6	580	18	16	16	CD
cord-014712-5u4e00q6	580	19	%	%	NN
cord-014712-5u4e00q6	580	20	.	.	.
cord-014712-5u4e00q6	581	1	It	-PRON-	PRP
cord-014712-5u4e00q6	581	2	is	be	VBZ
cord-014712-5u4e00q6	581	3	interesting	interesting	JJ
cord-014712-5u4e00q6	581	4	to	to	TO
cord-014712-5u4e00q6	581	5	note	note	VB
cord-014712-5u4e00q6	581	6	that	that	IN
cord-014712-5u4e00q6	581	7	more	more	JJR
cord-014712-5u4e00q6	581	8	than	than	IN
cord-014712-5u4e00q6	581	9	half	half	PDT
cord-014712-5u4e00q6	581	10	(	(	-LRB-
cord-014712-5u4e00q6	581	11	60	60	CD
cord-014712-5u4e00q6	581	12	%	%	NN
cord-014712-5u4e00q6	581	13	)	)	-RRB-
cord-014712-5u4e00q6	581	14	of	of	IN
cord-014712-5u4e00q6	581	15	detected	detect	VBN
cord-014712-5u4e00q6	581	16	carriers	carrier	NNS
cord-014712-5u4e00q6	581	17	in	in	IN
cord-014712-5u4e00q6	581	18	all	all	DT
cord-014712-5u4e00q6	581	19	analyzed	analyze	VBN
cord-014712-5u4e00q6	581	20	populations	population	NNS
cord-014712-5u4e00q6	581	21	has	have	VBZ
cord-014712-5u4e00q6	581	22	K695R	K695R	NNP
cord-014712-5u4e00q6	581	23	mutation	mutation	NN
cord-014712-5u4e00q6	581	24	.	.	.
cord-014712-5u4e00q6	582	1	Progress	progress	VB
cord-014712-5u4e00q6	582	2	in	in	IN
cord-014712-5u4e00q6	582	3	the	the	DT
cord-014712-5u4e00q6	582	4	field	field	NN
cord-014712-5u4e00q6	582	5	of	of	IN
cord-014712-5u4e00q6	582	6	primary	primary	JJ
cord-014712-5u4e00q6	582	7	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	582	8	(	(	-LRB-
cord-014712-5u4e00q6	582	9	PIDs	PIDs	NNP
cord-014712-5u4e00q6	582	10	)	)	-RRB-
cord-014712-5u4e00q6	582	11	is	be	VBZ
cord-014712-5u4e00q6	582	12	reflected	reflect	VBN
cord-014712-5u4e00q6	582	13	in	in	IN
cord-014712-5u4e00q6	582	14	national	national	JJ
cord-014712-5u4e00q6	582	15	PID	pid	NN
cord-014712-5u4e00q6	582	16	registries	registry	NNS
cord-014712-5u4e00q6	582	17	.	.	.
cord-014712-5u4e00q6	583	1	Data	datum	NNS
cord-014712-5u4e00q6	583	2	from	from	IN
cord-014712-5u4e00q6	583	3	Slovenian	slovenian	JJ
cord-014712-5u4e00q6	583	4	PID	pid	NN
cord-014712-5u4e00q6	583	5	registry	registry	NN
cord-014712-5u4e00q6	583	6	were	be	VBD
cord-014712-5u4e00q6	583	7	analyzed	analyze	VBN
cord-014712-5u4e00q6	583	8	.	.	.
cord-014712-5u4e00q6	584	1	Patients	patient	NNS
cord-014712-5u4e00q6	584	2	'	'	POS
cord-014712-5u4e00q6	584	3	data	datum	NNS
cord-014712-5u4e00q6	584	4	were	be	VBD
cord-014712-5u4e00q6	584	5	collected	collect	VBN
cord-014712-5u4e00q6	584	6	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	584	7	before	before	IN
cord-014712-5u4e00q6	584	8	2007	2007	CD
cord-014712-5u4e00q6	584	9	and	and	CC
cord-014712-5u4e00q6	584	10	prospectively	prospectively	RB
cord-014712-5u4e00q6	584	11	afterward	afterward	RB
cord-014712-5u4e00q6	584	12	.	.	.
cord-014712-5u4e00q6	585	1	Patients	patient	NNS
cord-014712-5u4e00q6	585	2	were	be	VBD
cord-014712-5u4e00q6	585	3	classified	classify	VBN
cord-014712-5u4e00q6	585	4	according	accord	VBG
cord-014712-5u4e00q6	585	5	to	to	IN
cord-014712-5u4e00q6	585	6	international	international	JJ
cord-014712-5u4e00q6	585	7	classification	classification	NN
cord-014712-5u4e00q6	585	8	and	and	CC
cord-014712-5u4e00q6	585	9	updated	update	VBD
cord-014712-5u4e00q6	585	10	regularly	regularly	RB
cord-014712-5u4e00q6	585	11	.	.	.
cord-014712-5u4e00q6	586	1	Data	datum	NNS
cord-014712-5u4e00q6	586	2	of	of	IN
cord-014712-5u4e00q6	586	3	193	193	CD
cord-014712-5u4e00q6	586	4	patients	patient	NNS
cord-014712-5u4e00q6	586	5	with	with	IN
cord-014712-5u4e00q6	586	6	45	45	CD
cord-014712-5u4e00q6	586	7	different	different	JJ
cord-014712-5u4e00q6	586	8	PIDs	pid	NNS
cord-014712-5u4e00q6	586	9	were	be	VBD
cord-014712-5u4e00q6	586	10	analyzed	analyze	VBN
cord-014712-5u4e00q6	586	11	.	.	.
cord-014712-5u4e00q6	587	1	Interestingly	interestingly	RB
cord-014712-5u4e00q6	587	2	,	,	,
cord-014712-5u4e00q6	587	3	complement	complement	JJ
cord-014712-5u4e00q6	587	4	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	587	5	are	be	VBP
cord-014712-5u4e00q6	587	6	the	the	DT
cord-014712-5u4e00q6	587	7	most	most	RBS
cord-014712-5u4e00q6	587	8	common	common	JJ
cord-014712-5u4e00q6	587	9	,	,	,
cord-014712-5u4e00q6	587	10	accounting	account	VBG
cord-014712-5u4e00q6	587	11	for	for	IN
cord-014712-5u4e00q6	587	12	23	23	CD
cord-014712-5u4e00q6	587	13	%	%	NN
cord-014712-5u4e00q6	587	14	of	of	IN
cord-014712-5u4e00q6	587	15	all	all	DT
cord-014712-5u4e00q6	587	16	entries	entry	NNS
cord-014712-5u4e00q6	587	17	.	.	.
cord-014712-5u4e00q6	588	1	Second	second	LS
cord-014712-5u4e00q6	588	2	most	most	RBS
cord-014712-5u4e00q6	588	3	common	common	JJ
cord-014712-5u4e00q6	588	4	are	be	VBP
cord-014712-5u4e00q6	588	5	antibody	antibody	NN
cord-014712-5u4e00q6	588	6	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	588	7	with	with	IN
cord-014712-5u4e00q6	588	8	19	19	CD
cord-014712-5u4e00q6	588	9	%	%	NN
cord-014712-5u4e00q6	588	10	,	,	,
cord-014712-5u4e00q6	588	11	followed	follow	VBN
cord-014712-5u4e00q6	588	12	by	by	IN
cord-014712-5u4e00q6	588	13	well	well	RB
cord-014712-5u4e00q6	588	14	-	-	HYPH
cord-014712-5u4e00q6	588	15	defined	define	VBN
cord-014712-5u4e00q6	588	16	syndromes	syndrome	NNS
cord-014712-5u4e00q6	588	17	(	(	-LRB-
cord-014712-5u4e00q6	588	18	16	16	CD
cord-014712-5u4e00q6	588	19	%	%	NN
cord-014712-5u4e00q6	588	20	)	)	-RRB-
cord-014712-5u4e00q6	588	21	,	,	,
cord-014712-5u4e00q6	588	22	immune	immune	JJ
cord-014712-5u4e00q6	588	23	dysregulation	dysregulation	NN
cord-014712-5u4e00q6	588	24	(	(	-LRB-
cord-014712-5u4e00q6	588	25	13	13	CD
cord-014712-5u4e00q6	588	26	%	%	NN
cord-014712-5u4e00q6	588	27	)	)	-RRB-
cord-014712-5u4e00q6	588	28	,	,	,
cord-014712-5u4e00q6	588	29	neutrophil	neutrophil	NN
cord-014712-5u4e00q6	588	30	defects	defect	NNS
cord-014712-5u4e00q6	588	31	(	(	-LRB-
cord-014712-5u4e00q6	588	32	12	12	CD
cord-014712-5u4e00q6	588	33	%	%	NN
cord-014712-5u4e00q6	588	34	)	)	-RRB-
cord-014712-5u4e00q6	588	35	,	,	,
cord-014712-5u4e00q6	588	36	combined	combine	VBN
cord-014712-5u4e00q6	588	37	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	588	38	(	(	-LRB-
cord-014712-5u4e00q6	588	39	9	9	CD
cord-014712-5u4e00q6	588	40	%	%	NN
cord-014712-5u4e00q6	588	41	)	)	-RRB-
cord-014712-5u4e00q6	588	42	,	,	,
cord-014712-5u4e00q6	588	43	autoinflammatory	autoinflammatory	JJ
cord-014712-5u4e00q6	588	44	disorders	disorder	NNS
cord-014712-5u4e00q6	588	45	(	(	-LRB-
cord-014712-5u4e00q6	588	46	6	6	CD
cord-014712-5u4e00q6	588	47	%	%	NN
cord-014712-5u4e00q6	588	48	)	)	-RRB-
cord-014712-5u4e00q6	588	49	and	and	CC
cord-014712-5u4e00q6	588	50	defects	defect	NNS
cord-014712-5u4e00q6	588	51	of	of	IN
cord-014712-5u4e00q6	588	52	innate	innate	JJ
cord-014712-5u4e00q6	588	53	immunity	immunity	NN
cord-014712-5u4e00q6	588	54	(	(	-LRB-
cord-014712-5u4e00q6	588	55	2	2	CD
cord-014712-5u4e00q6	588	56	%	%	NN
cord-014712-5u4e00q6	588	57	)	)	-RRB-
cord-014712-5u4e00q6	588	58	.	.	.
cord-014712-5u4e00q6	589	1	Prevalence	prevalence	NN
cord-014712-5u4e00q6	589	2	of	of	IN
cord-014712-5u4e00q6	589	3	diagnosed	diagnosed	JJ
cord-014712-5u4e00q6	589	4	PIDs	pid	NNS
cord-014712-5u4e00q6	589	5	in	in	IN
cord-014712-5u4e00q6	589	6	Slovenia	Slovenia	NNP
cord-014712-5u4e00q6	589	7	has	have	VBZ
cord-014712-5u4e00q6	589	8	changed	change	VBN
cord-014712-5u4e00q6	589	9	in	in	IN
cord-014712-5u4e00q6	589	10	the	the	DT
cord-014712-5u4e00q6	589	11	last	last	JJ
cord-014712-5u4e00q6	589	12	5	5	CD
cord-014712-5u4e00q6	589	13	years	year	NNS
cord-014712-5u4e00q6	589	14	;	;	:
cord-014712-5u4e00q6	589	15	less	less	JJR
cord-014712-5u4e00q6	589	16	complement	complement	JJ
cord-014712-5u4e00q6	589	17	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	589	18	and	and	CC
cord-014712-5u4e00q6	589	19	more	more	JJR
cord-014712-5u4e00q6	589	20	antibody	antibody	NN
cord-014712-5u4e00q6	589	21	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	589	22	were	be	VBD
cord-014712-5u4e00q6	589	23	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	589	24	in	in	IN
cord-014712-5u4e00q6	589	25	comparison	comparison	NN
cord-014712-5u4e00q6	589	26	to	to	IN
cord-014712-5u4e00q6	589	27	previous	previous	JJ
cord-014712-5u4e00q6	589	28	decades	decade	NNS
cord-014712-5u4e00q6	589	29	.	.	.
cord-014712-5u4e00q6	590	1	The	the	DT
cord-014712-5u4e00q6	590	2	number	number	NN
cord-014712-5u4e00q6	590	3	of	of	IN
cord-014712-5u4e00q6	590	4	new	new	JJ
cord-014712-5u4e00q6	590	5	PID	PID	NNP
cord-014712-5u4e00q6	590	6	cases	case	NNS
cord-014712-5u4e00q6	590	7	has	have	VBZ
cord-014712-5u4e00q6	590	8	been	be	VBN
cord-014712-5u4e00q6	590	9	gradually	gradually	RB
cord-014712-5u4e00q6	590	10	increasing	increase	VBG
cord-014712-5u4e00q6	590	11	,	,	,
cord-014712-5u4e00q6	590	12	a	a	DT
cord-014712-5u4e00q6	590	13	more	more	RBR
cord-014712-5u4e00q6	590	14	prominent	prominent	JJ
cord-014712-5u4e00q6	590	15	increase	increase	NN
cord-014712-5u4e00q6	590	16	has	have	VBZ
cord-014712-5u4e00q6	590	17	been	be	VBN
cord-014712-5u4e00q6	590	18	noted	note	VBN
cord-014712-5u4e00q6	590	19	in	in	IN
cord-014712-5u4e00q6	590	20	the	the	DT
cord-014712-5u4e00q6	590	21	last	last	JJ
cord-014712-5u4e00q6	590	22	10	10	CD
cord-014712-5u4e00q6	590	23	years	year	NNS
cord-014712-5u4e00q6	590	24	.	.	.
cord-014712-5u4e00q6	591	1	The	the	DT
cord-014712-5u4e00q6	591	2	prevalence	prevalence	NN
cord-014712-5u4e00q6	591	3	increased	increase	VBD
cord-014712-5u4e00q6	591	4	most	most	RBS
cord-014712-5u4e00q6	591	5	for	for	IN
cord-014712-5u4e00q6	591	6	combined	combined	JJ
cord-014712-5u4e00q6	591	7	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	591	8	,	,	,
cord-014712-5u4e00q6	591	9	CVID	CVID	NNP
cord-014712-5u4e00q6	591	10	and	and	CC
cord-014712-5u4e00q6	591	11	autoinflammatory	autoinflammatory	JJ
cord-014712-5u4e00q6	591	12	disorders	disorder	NNS
cord-014712-5u4e00q6	591	13	.	.	.
cord-014712-5u4e00q6	592	1	The	the	DT
cord-014712-5u4e00q6	592	2	spectrum	spectrum	NN
cord-014712-5u4e00q6	592	3	of	of	IN
cord-014712-5u4e00q6	592	4	PID	PID	NNP
cord-014712-5u4e00q6	592	5	entities	entity	NNS
cord-014712-5u4e00q6	592	6	has	have	VBZ
cord-014712-5u4e00q6	592	7	also	also	RB
cord-014712-5u4e00q6	592	8	widened	widen	VBN
cord-014712-5u4e00q6	592	9	in	in	IN
cord-014712-5u4e00q6	592	10	the	the	DT
cord-014712-5u4e00q6	592	11	last	last	JJ
cord-014712-5u4e00q6	592	12	decade	decade	NN
cord-014712-5u4e00q6	592	13	.	.	.
cord-014712-5u4e00q6	593	1	Three	three	CD
cord-014712-5u4e00q6	593	2	patients	patient	NNS
cord-014712-5u4e00q6	593	3	with	with	IN
cord-014712-5u4e00q6	593	4	SCID	SCID	NNP
cord-014712-5u4e00q6	593	5	were	be	VBD
cord-014712-5u4e00q6	593	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	593	7	and	and	CC
cord-014712-5u4e00q6	593	8	successfully	successfully	RB
cord-014712-5u4e00q6	593	9	treated	treat	VBN
cord-014712-5u4e00q6	593	10	in	in	IN
cord-014712-5u4e00q6	593	11	the	the	DT
cord-014712-5u4e00q6	593	12	last	last	JJ
cord-014712-5u4e00q6	593	13	three	three	CD
cord-014712-5u4e00q6	593	14	years	year	NNS
cord-014712-5u4e00q6	593	15	(	(	-LRB-
cord-014712-5u4e00q6	593	16	incidence	incidence	NN
cord-014712-5u4e00q6	593	17	-1:25.000	-1:25.000	NFP
cord-014712-5u4e00q6	593	18	births	birth	NNS
cord-014712-5u4e00q6	593	19	)	)	-RRB-
cord-014712-5u4e00q6	593	20	.	.	.
cord-014712-5u4e00q6	594	1	High	high	JJ
cord-014712-5u4e00q6	594	2	prevalence	prevalence	NN
cord-014712-5u4e00q6	594	3	of	of	IN
cord-014712-5u4e00q6	594	4	complement	complement	NN
cord-014712-5u4e00q6	594	5	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	594	6	reflects	reflect	VBZ
cord-014712-5u4e00q6	594	7	early	early	JJ
cord-014712-5u4e00q6	594	8	implementation	implementation	NN
cord-014712-5u4e00q6	594	9	of	of	IN
cord-014712-5u4e00q6	594	10	good	good	JJ
cord-014712-5u4e00q6	594	11	complement	complement	NN
cord-014712-5u4e00q6	594	12	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	594	13	facilities	facility	NNS
cord-014712-5u4e00q6	594	14	and	and	CC
cord-014712-5u4e00q6	594	15	awareness	awareness	NN
cord-014712-5u4e00q6	594	16	among	among	IN
cord-014712-5u4e00q6	594	17	infectologists	infectologist	NNS
cord-014712-5u4e00q6	594	18	.	.	.
cord-014712-5u4e00q6	595	1	This	this	DT
cord-014712-5u4e00q6	595	2	group	group	NN
cord-014712-5u4e00q6	595	3	of	of	IN
cord-014712-5u4e00q6	595	4	patients	patient	NNS
cord-014712-5u4e00q6	595	5	was	be	VBD
cord-014712-5u4e00q6	595	6	prospectively	prospectively	RB
cord-014712-5u4e00q6	595	7	collected	collect	VBN
cord-014712-5u4e00q6	595	8	from	from	IN
cord-014712-5u4e00q6	595	9	1987	1987	CD
cord-014712-5u4e00q6	595	10	.	.	.
cord-014712-5u4e00q6	596	1	Combined	combined	JJ
cord-014712-5u4e00q6	596	2	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	596	3	,	,	,
cord-014712-5u4e00q6	596	4	CVID	CVID	NNP
cord-014712-5u4e00q6	596	5	and	and	CC
cord-014712-5u4e00q6	596	6	autoinflammatory	autoinflammatory	NNP
cord-014712-5u4e00q6	596	7	syndromes	syndrome	NNS
cord-014712-5u4e00q6	596	8	were	be	VBD
cord-014712-5u4e00q6	596	9	all	all	DT
cord-014712-5u4e00q6	596	10	probably	probably	RB
cord-014712-5u4e00q6	596	11	underdiagnosed	underdiagnosed	JJ
cord-014712-5u4e00q6	596	12	before	before	IN
cord-014712-5u4e00q6	596	13	due	due	IN
cord-014712-5u4e00q6	596	14	to	to	IN
cord-014712-5u4e00q6	596	15	lack	lack	NN
cord-014712-5u4e00q6	596	16	of	of	IN
cord-014712-5u4e00q6	596	17	awareness	awareness	NN
cord-014712-5u4e00q6	596	18	among	among	IN
cord-014712-5u4e00q6	596	19	physicians	physician	NNS
cord-014712-5u4e00q6	596	20	.	.	.
cord-014712-5u4e00q6	597	1	Distribution	distribution	NN
cord-014712-5u4e00q6	597	2	of	of	IN
cord-014712-5u4e00q6	597	3	PID	PID	NNP
cord-014712-5u4e00q6	597	4	groups	group	NNS
cord-014712-5u4e00q6	597	5	is	be	VBZ
cord-014712-5u4e00q6	597	6	more	more	RBR
cord-014712-5u4e00q6	597	7	consistent	consistent	JJ
cord-014712-5u4e00q6	597	8	with	with	IN
cord-014712-5u4e00q6	597	9	ESID	ESID	NNP
cord-014712-5u4e00q6	597	10	registry	registry	NN
cord-014712-5u4e00q6	597	11	in	in	IN
cord-014712-5u4e00q6	597	12	the	the	DT
cord-014712-5u4e00q6	597	13	last	last	JJ
cord-014712-5u4e00q6	597	14	five	five	CD
cord-014712-5u4e00q6	597	15	years	year	NNS
cord-014712-5u4e00q6	597	16	.	.	.
cord-014712-5u4e00q6	598	1	Identification	identification	NN
cord-014712-5u4e00q6	598	2	and	and	CC
cord-014712-5u4e00q6	598	3	successful	successful	JJ
cord-014712-5u4e00q6	598	4	treatment	treatment	NN
cord-014712-5u4e00q6	598	5	of	of	IN
cord-014712-5u4e00q6	598	6	SCID	SCID	NNP
cord-014712-5u4e00q6	598	7	patients	patient	NNS
cord-014712-5u4e00q6	598	8	in	in	IN
cord-014712-5u4e00q6	598	9	the	the	DT
cord-014712-5u4e00q6	598	10	last	last	JJ
cord-014712-5u4e00q6	598	11	years	year	NNS
cord-014712-5u4e00q6	598	12	is	be	VBZ
cord-014712-5u4e00q6	598	13	an	an	DT
cord-014712-5u4e00q6	598	14	important	important	JJ
cord-014712-5u4e00q6	598	15	quality	quality	NN
cord-014712-5u4e00q6	598	16	marker	marker	NN
cord-014712-5u4e00q6	598	17	.	.	.
cord-014712-5u4e00q6	599	1	Bulgarian	Bulgarian	NNP
cord-014712-5u4e00q6	599	2	Association	Association	NNP
cord-014712-5u4e00q6	599	3	for	for	IN
cord-014712-5u4e00q6	599	4	Clinical	Clinical	NNP
cord-014712-5u4e00q6	599	5	Immunology	Immunology	NNP
cord-014712-5u4e00q6	599	6	was	be	VBD
cord-014712-5u4e00q6	599	7	set	set	VBN
cord-014712-5u4e00q6	599	8	up	up	RP
cord-014712-5u4e00q6	599	9	in	in	IN
cord-014712-5u4e00q6	599	10	2005	2005	CD
cord-014712-5u4e00q6	599	11	aiming	aim	VBG
cord-014712-5u4e00q6	599	12	to	to	TO
cord-014712-5u4e00q6	599	13	get	get	VB
cord-014712-5u4e00q6	599	14	together	together	RB
cord-014712-5u4e00q6	599	15	all	all	DT
cord-014712-5u4e00q6	599	16	specialists	specialist	NNS
cord-014712-5u4e00q6	599	17	working	work	VBG
cord-014712-5u4e00q6	599	18	in	in	IN
cord-014712-5u4e00q6	599	19	the	the	DT
cord-014712-5u4e00q6	599	20	field	field	NN
cord-014712-5u4e00q6	599	21	of	of	IN
cord-014712-5u4e00q6	599	22	clinical	clinical	JJ
cord-014712-5u4e00q6	599	23	immunology	immunology	NN
cord-014712-5u4e00q6	599	24	.	.	.
cord-014712-5u4e00q6	600	1	One	one	CD
cord-014712-5u4e00q6	600	2	of	of	IN
cord-014712-5u4e00q6	600	3	the	the	DT
cord-014712-5u4e00q6	600	4	important	important	JJ
cord-014712-5u4e00q6	600	5	objectives	objective	NNS
cord-014712-5u4e00q6	600	6	of	of	IN
cord-014712-5u4e00q6	600	7	the	the	DT
cord-014712-5u4e00q6	600	8	association	association	NN
cord-014712-5u4e00q6	600	9	was	be	VBD
cord-014712-5u4e00q6	600	10	to	to	TO
cord-014712-5u4e00q6	600	11	raise	raise	VB
cord-014712-5u4e00q6	600	12	the	the	DT
cord-014712-5u4e00q6	600	13	public	public	JJ
cord-014712-5u4e00q6	600	14	awareness	awareness	NN
cord-014712-5u4e00q6	600	15	and	and	CC
cord-014712-5u4e00q6	600	16	attract	attract	VB
cord-014712-5u4e00q6	600	17	attention	attention	NN
cord-014712-5u4e00q6	600	18	of	of	IN
cord-014712-5u4e00q6	600	19	specialists	specialist	NNS
cord-014712-5u4e00q6	600	20	,	,	,
cord-014712-5u4e00q6	600	21	National	national	JJ
cord-014712-5u4e00q6	600	22	health	health	NN
cord-014712-5u4e00q6	600	23	system	system	NN
cord-014712-5u4e00q6	600	24	,	,	,
cord-014712-5u4e00q6	600	25	government	government	NN
cord-014712-5u4e00q6	600	26	and	and	CC
cord-014712-5u4e00q6	600	27	other	other	JJ
cord-014712-5u4e00q6	600	28	related	related	JJ
cord-014712-5u4e00q6	600	29	societies	society	NNS
cord-014712-5u4e00q6	600	30	in	in	IN
cord-014712-5u4e00q6	600	31	order	order	NN
cord-014712-5u4e00q6	600	32	to	to	TO
cord-014712-5u4e00q6	600	33	improve	improve	VB
cord-014712-5u4e00q6	600	34	the	the	DT
cord-014712-5u4e00q6	600	35	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	600	36	and	and	CC
cord-014712-5u4e00q6	600	37	access	access	NN
cord-014712-5u4e00q6	600	38	to	to	IN
cord-014712-5u4e00q6	600	39	treatment	treatment	NN
cord-014712-5u4e00q6	600	40	for	for	IN
cord-014712-5u4e00q6	600	41	children	child	NNS
cord-014712-5u4e00q6	600	42	and	and	CC
cord-014712-5u4e00q6	600	43	adults	adult	NNS
cord-014712-5u4e00q6	600	44	with	with	IN
cord-014712-5u4e00q6	600	45	PID	PID	NNP
cord-014712-5u4e00q6	600	46	.	.	.
cord-014712-5u4e00q6	601	1	Efforts	effort	NNS
cord-014712-5u4e00q6	601	2	of	of	IN
cord-014712-5u4e00q6	601	3	immunologists	immunologist	NNS
cord-014712-5u4e00q6	601	4	led	lead	VBD
cord-014712-5u4e00q6	601	5	to	to	IN
cord-014712-5u4e00q6	601	6	the	the	DT
cord-014712-5u4e00q6	601	7	following	follow	VBG
cord-014712-5u4e00q6	601	8	results	result	NNS
cord-014712-5u4e00q6	601	9	:	:	:
cord-014712-5u4e00q6	601	10	1	1	CD
cord-014712-5u4e00q6	601	11	.	.	.
cord-014712-5u4e00q6	602	1	Consensus	consensus	NN
cord-014712-5u4e00q6	602	2	on	on	IN
cord-014712-5u4e00q6	602	3	the	the	DT
cord-014712-5u4e00q6	602	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	602	5	and	and	CC
cord-014712-5u4e00q6	602	6	treatment	treatment	NN
cord-014712-5u4e00q6	602	7	of	of	IN
cord-014712-5u4e00q6	602	8	the	the	DT
cord-014712-5u4e00q6	602	9	basic	basic	JJ
cord-014712-5u4e00q6	602	10	PID	PID	NNP
cord-014712-5u4e00q6	602	11	groups	group	NNS
cord-014712-5u4e00q6	602	12	was	be	VBD
cord-014712-5u4e00q6	602	13	created	create	VBN
cord-014712-5u4e00q6	602	14	by	by	IN
cord-014712-5u4e00q6	602	15	the	the	DT
cord-014712-5u4e00q6	602	16	PID	PID	NNP
cord-014712-5u4e00q6	602	17	national	national	JJ
cord-014712-5u4e00q6	602	18	working	working	NN
cord-014712-5u4e00q6	602	19	group	group	NN
cord-014712-5u4e00q6	602	20	that	that	WDT
cord-014712-5u4e00q6	602	21	was	be	VBD
cord-014712-5u4e00q6	602	22	established	establish	VBN
cord-014712-5u4e00q6	602	23	in	in	IN
cord-014712-5u4e00q6	602	24	2010	2010	CD
cord-014712-5u4e00q6	602	25	,	,	,
cord-014712-5u4e00q6	602	26	and	and	CC
cord-014712-5u4e00q6	602	27	specific	specific	JJ
cord-014712-5u4e00q6	602	28	guidelines	guideline	NNS
cord-014712-5u4e00q6	602	29	were	be	VBD
cord-014712-5u4e00q6	602	30	disseminated	disseminate	VBN
cord-014712-5u4e00q6	602	31	as	as	RB
cord-014712-5u4e00q6	602	32	well	well	RB
cord-014712-5u4e00q6	602	33	.	.	.
cord-014712-5u4e00q6	603	1	Register	register	VB
cord-014712-5u4e00q6	603	2	for	for	IN
cord-014712-5u4e00q6	603	3	PID	PID	NNP
cord-014712-5u4e00q6	603	4	patients	patient	NNS
cord-014712-5u4e00q6	603	5	has	have	VBZ
cord-014712-5u4e00q6	603	6	been	be	VBN
cord-014712-5u4e00q6	603	7	set	set	VBN
cord-014712-5u4e00q6	603	8	up	up	RP
cord-014712-5u4e00q6	603	9	in	in	IN
cord-014712-5u4e00q6	603	10	Bulgaria	Bulgaria	NNP
cord-014712-5u4e00q6	603	11	that	that	WDT
cord-014712-5u4e00q6	603	12	allowed	allow	VBD
cord-014712-5u4e00q6	603	13	the	the	DT
cord-014712-5u4e00q6	603	14	collection	collection	NN
cord-014712-5u4e00q6	603	15	of	of	IN
cord-014712-5u4e00q6	603	16	data	datum	NNS
cord-014712-5u4e00q6	603	17	on	on	IN
cord-014712-5u4e00q6	603	18	the	the	DT
cord-014712-5u4e00q6	603	19	incidence	incidence	NN
cord-014712-5u4e00q6	603	20	and	and	CC
cord-014712-5u4e00q6	603	21	prevalence	prevalence	NN
cord-014712-5u4e00q6	603	22	of	of	IN
cord-014712-5u4e00q6	603	23	PID	pid	NN
cord-014712-5u4e00q6	603	24	and	and	CC
cord-014712-5u4e00q6	603	25	the	the	DT
cord-014712-5u4e00q6	603	26	negative	negative	JJ
cord-014712-5u4e00q6	603	27	effect	effect	NN
cord-014712-5u4e00q6	603	28	of	of	IN
cord-014712-5u4e00q6	603	29	these	these	DT
cord-014712-5u4e00q6	603	30	conditions	condition	NNS
cord-014712-5u4e00q6	603	31	on	on	IN
cord-014712-5u4e00q6	603	32	the	the	DT
cord-014712-5u4e00q6	603	33	population	population	NN
cord-014712-5u4e00q6	603	34	.	.	.
cord-014712-5u4e00q6	604	1	3	3	LS
cord-014712-5u4e00q6	604	2	.	.	.
cord-014712-5u4e00q6	605	1	Educational	educational	JJ
cord-014712-5u4e00q6	605	2	program	program	NN
cord-014712-5u4e00q6	605	3	to	to	TO
cord-014712-5u4e00q6	605	4	improve	improve	VB
cord-014712-5u4e00q6	605	5	the	the	DT
cord-014712-5u4e00q6	605	6	qualification	qualification	NN
cord-014712-5u4e00q6	605	7	of	of	IN
cord-014712-5u4e00q6	605	8	the	the	DT
cord-014712-5u4e00q6	605	9	physicians	physician	NNS
cord-014712-5u4e00q6	605	10	and	and	CC
cord-014712-5u4e00q6	605	11	provide	provide	VB
cord-014712-5u4e00q6	605	12	available	available	JJ
cord-014712-5u4e00q6	605	13	resources	resource	NNS
cord-014712-5u4e00q6	605	14	to	to	IN
cord-014712-5u4e00q6	605	15	general	general	JJ
cord-014712-5u4e00q6	605	16	practitioners	practitioner	NNS
cord-014712-5u4e00q6	605	17	and	and	CC
cord-014712-5u4e00q6	605	18	raise	raise	VB
cord-014712-5u4e00q6	605	19	the	the	DT
cord-014712-5u4e00q6	605	20	public	public	JJ
cord-014712-5u4e00q6	605	21	awareness	awareness	NN
cord-014712-5u4e00q6	605	22	were	be	VBD
cord-014712-5u4e00q6	605	23	introduced	introduce	VBN
cord-014712-5u4e00q6	605	24	.	.	.
cord-014712-5u4e00q6	606	1	Collaboration	collaboration	NN
cord-014712-5u4e00q6	606	2	with	with	IN
cord-014712-5u4e00q6	606	3	patient	patient	NN
cord-014712-5u4e00q6	606	4	's	's	POS
cord-014712-5u4e00q6	606	5	organizations	organization	NNS
cord-014712-5u4e00q6	606	6	was	be	VBD
cord-014712-5u4e00q6	606	7	developed	develop	VBN
cord-014712-5u4e00q6	606	8	.	.	.
cord-014712-5u4e00q6	607	1	5	5	LS
cord-014712-5u4e00q6	607	2	.	.	.
cord-014712-5u4e00q6	608	1	Treatment	treatment	NN
cord-014712-5u4e00q6	608	2	of	of	IN
cord-014712-5u4e00q6	608	3	PID	PID	NNP
cord-014712-5u4e00q6	608	4	patients	patient	NNS
cord-014712-5u4e00q6	608	5	has	have	VBZ
cord-014712-5u4e00q6	608	6	been	be	VBN
cord-014712-5u4e00q6	608	7	fully	fully	RB
cord-014712-5u4e00q6	608	8	covered	cover	VBN
cord-014712-5u4e00q6	608	9	by	by	IN
cord-014712-5u4e00q6	608	10	the	the	DT
cord-014712-5u4e00q6	608	11	public	public	JJ
cord-014712-5u4e00q6	608	12	health	health	NN
cord-014712-5u4e00q6	608	13	system	system	NN
cord-014712-5u4e00q6	608	14	since	since	IN
cord-014712-5u4e00q6	608	15	March	March	NNP
cord-014712-5u4e00q6	608	16	2013	2013	CD
cord-014712-5u4e00q6	608	17	.	.	.
cord-014712-5u4e00q6	609	1	All	all	PDT
cord-014712-5u4e00q6	609	2	these	these	DT
cord-014712-5u4e00q6	609	3	steps	step	NNS
cord-014712-5u4e00q6	609	4	made	make	VBD
cord-014712-5u4e00q6	609	5	it	-PRON-	PRP
cord-014712-5u4e00q6	609	6	possible	possible	JJ
cord-014712-5u4e00q6	609	7	to	to	TO
cord-014712-5u4e00q6	609	8	advance	advance	VB
cord-014712-5u4e00q6	609	9	the	the	DT
cord-014712-5u4e00q6	609	10	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	609	11	and	and	CC
cord-014712-5u4e00q6	609	12	management	management	NN
cord-014712-5u4e00q6	609	13	of	of	IN
cord-014712-5u4e00q6	609	14	PID	PID	NNP
cord-014712-5u4e00q6	609	15	in	in	IN
cord-014712-5u4e00q6	609	16	our	-PRON-	PRP$
cord-014712-5u4e00q6	609	17	country	country	NN
cord-014712-5u4e00q6	609	18	.	.	.
cord-014712-5u4e00q6	610	1	PEDIATRIC	pediatric	JJ
cord-014712-5u4e00q6	610	2	PID	pid	NN
cord-014712-5u4e00q6	610	3	PATIENTS	patient	NNS
cord-014712-5u4e00q6	610	4	CARE	care	VBP
cord-014712-5u4e00q6	611	1	-SINGLE	-SINGLE	:
cord-014712-5u4e00q6	611	2	CENTER	center	NN
cord-014712-5u4e00q6	611	3	EXPERIENCE	experience	NN
cord-014712-5u4e00q6	611	4	G.	G.	NNP
cord-014712-5u4e00q6	611	5	Petrova	Petrova	NNP
cord-014712-5u4e00q6	611	6	;	;	:
cord-014712-5u4e00q6	611	7	P.	P.	NNP
cord-014712-5u4e00q6	611	8	Perenovska	Perenovska	NNP
cord-014712-5u4e00q6	611	9	;	;	:
cord-014712-5u4e00q6	611	10	S.	S.	NNP
cord-014712-5u4e00q6	611	11	Mihailova	Mihailova	NNP
cord-014712-5u4e00q6	611	12	;	;	:
cord-014712-5u4e00q6	611	13	E.	E.	NNP
cord-014712-5u4e00q6	611	14	Naumova	Naumova	NNP
cord-014712-5u4e00q6	611	15	UMHAT	UMHAT	NNP
cord-014712-5u4e00q6	611	16	"	"	``
cord-014712-5u4e00q6	611	17	Alexandrovska	Alexandrovska	NNP
cord-014712-5u4e00q6	611	18	"	"	''
cord-014712-5u4e00q6	611	19	,	,	,
cord-014712-5u4e00q6	611	20	Sofia	Sofia	NNP
cord-014712-5u4e00q6	611	21	,	,	,
cord-014712-5u4e00q6	611	22	Bulgaria	Bulgaria	NNP
cord-014712-5u4e00q6	611	23	J	J	NNP
cord-014712-5u4e00q6	611	24	-	-	HYPH
cord-014712-5u4e00q6	611	25	project	project	NN
cord-014712-5u4e00q6	611	26	in	in	IN
cord-014712-5u4e00q6	611	27	Bulgaria	Bulgaria	NNP
cord-014712-5u4e00q6	611	28	started	start	VBD
cord-014712-5u4e00q6	611	29	in	in	IN
cord-014712-5u4e00q6	611	30	2005	2005	CD
cord-014712-5u4e00q6	611	31	and	and	CC
cord-014712-5u4e00q6	611	32	up	up	IN
cord-014712-5u4e00q6	611	33	to	to	IN
cord-014712-5u4e00q6	611	34	now	now	RB
cord-014712-5u4e00q6	611	35	we	-PRON-	PRP
cord-014712-5u4e00q6	611	36	have	have	VBP
cord-014712-5u4e00q6	611	37	elaborated	elaborate	VBN
cord-014712-5u4e00q6	611	38	programme	programme	NN
cord-014712-5u4e00q6	611	39	with	with	IN
cord-014712-5u4e00q6	611	40	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	611	41	criteria	criterion	NNS
cord-014712-5u4e00q6	611	42	,	,	,
cord-014712-5u4e00q6	611	43	well	well	RB
cord-014712-5u4e00q6	611	44	equipped	equipped	JJ
cord-014712-5u4e00q6	611	45	laboratory	laboratory	NN
cord-014712-5u4e00q6	611	46	,	,	,
cord-014712-5u4e00q6	611	47	established	establish	VBD
cord-014712-5u4e00q6	611	48	some	some	DT
cord-014712-5u4e00q6	611	49	mutual	mutual	JJ
cord-014712-5u4e00q6	611	50	connections	connection	NNS
cord-014712-5u4e00q6	611	51	with	with	IN
cord-014712-5u4e00q6	611	52	foreign	foreign	JJ
cord-014712-5u4e00q6	611	53	colleagues	colleague	NNS
cord-014712-5u4e00q6	611	54	,	,	,
cord-014712-5u4e00q6	611	55	held	hold	VBD
cord-014712-5u4e00q6	611	56	regional	regional	JJ
cord-014712-5u4e00q6	611	57	meetings	meeting	NNS
cord-014712-5u4e00q6	611	58	,	,	,
cord-014712-5u4e00q6	611	59	conferences	conference	NNS
cord-014712-5u4e00q6	611	60	;	;	,
cord-014712-5u4e00q6	611	61	created	create	VBN
cord-014712-5u4e00q6	611	62	clinical	clinical	JJ
cord-014712-5u4e00q6	611	63	standards	standard	NNS
cord-014712-5u4e00q6	611	64	for	for	IN
cord-014712-5u4e00q6	611	65	treatment	treatment	NN
cord-014712-5u4e00q6	611	66	and	and	CC
cord-014712-5u4e00q6	611	67	ensured	ensure	VBD
cord-014712-5u4e00q6	611	68	an	an	DT
cord-014712-5u4e00q6	611	69	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	611	70	treatment	treatment	NN
cord-014712-5u4e00q6	611	71	and	and	CC
cord-014712-5u4e00q6	611	72	replacement	replacement	NN
cord-014712-5u4e00q6	611	73	therapy	therapy	NN
cord-014712-5u4e00q6	611	74	.	.	.
cord-014712-5u4e00q6	612	1	Here	here	RB
cord-014712-5u4e00q6	612	2	are	be	VBP
cord-014712-5u4e00q6	612	3	examples	example	NNS
cord-014712-5u4e00q6	612	4	of	of	IN
cord-014712-5u4e00q6	612	5	some	some	DT
cord-014712-5u4e00q6	612	6	of	of	IN
cord-014712-5u4e00q6	612	7	the	the	DT
cord-014712-5u4e00q6	612	8	problems	problem	NNS
cord-014712-5u4e00q6	612	9	we	-PRON-	PRP
cord-014712-5u4e00q6	612	10	face	face	VBP
cord-014712-5u4e00q6	612	11	:	:	:
cord-014712-5u4e00q6	612	12	1	1	CD
cord-014712-5u4e00q6	612	13	.	.	.
cord-014712-5u4e00q6	613	1	Seven	seven	CD
cord-014712-5u4e00q6	613	2	-	-	HYPH
cord-014712-5u4e00q6	613	3	years	year	NNS
cord-014712-5u4e00q6	613	4	old	old	JJ
cord-014712-5u4e00q6	613	5	boy	boy	NN
cord-014712-5u4e00q6	613	6	with	with	IN
cord-014712-5u4e00q6	613	7	hypogamaglobulinaemia	hypogamaglobulinaemia	NNP
cord-014712-5u4e00q6	613	8	(	(	-LRB-
cord-014712-5u4e00q6	613	9	normal	normal	JJ
cord-014712-5u4e00q6	613	10	number	number	NN
cord-014712-5u4e00q6	613	11	B	b	NN
cord-014712-5u4e00q6	613	12	-	-	:
cord-014712-5u4e00q6	613	13	Ly	ly	NN
cord-014712-5u4e00q6	613	14	with	with	IN
cord-014712-5u4e00q6	613	15	abnormal	abnormal	JJ
cord-014712-5u4e00q6	613	16	function	function	NN
cord-014712-5u4e00q6	613	17	)	)	-RRB-
cord-014712-5u4e00q6	613	18	.	.	.
cord-014712-5u4e00q6	614	1	IVIG	IVIG	NNP
cord-014712-5u4e00q6	614	2	had	have	VBD
cord-014712-5u4e00q6	614	3	some	some	DT
cord-014712-5u4e00q6	614	4	initial	initial	JJ
cord-014712-5u4e00q6	614	5	effect	effect	NN
cord-014712-5u4e00q6	614	6	,	,	,
cord-014712-5u4e00q6	614	7	but	but	CC
cord-014712-5u4e00q6	614	8	lately	lately	RB
cord-014712-5u4e00q6	614	9	we	-PRON-	PRP
cord-014712-5u4e00q6	614	10	noted	note	VBD
cord-014712-5u4e00q6	614	11	very	very	RB
cord-014712-5u4e00q6	614	12	fast	fast	JJ
cord-014712-5u4e00q6	614	13	deceleration	deceleration	NN
cord-014712-5u4e00q6	614	14	in	in	IN
cord-014712-5u4e00q6	614	15	the	the	DT
cord-014712-5u4e00q6	614	16	overall	overall	JJ
cord-014712-5u4e00q6	614	17	health	health	NN
cord-014712-5u4e00q6	614	18	status	status	NN
cord-014712-5u4e00q6	614	19	with	with	IN
cord-014712-5u4e00q6	614	20	possible	possible	JJ
cord-014712-5u4e00q6	614	21	need	need	NN
cord-014712-5u4e00q6	614	22	of	of	IN
cord-014712-5u4e00q6	614	23	lung	lung	NN
cord-014712-5u4e00q6	614	24	transplantation	transplantation	NN
cord-014712-5u4e00q6	614	25	.	.	.
cord-014712-5u4e00q6	615	1	The	the	DT
cord-014712-5u4e00q6	615	2	case	case	NN
cord-014712-5u4e00q6	615	3	is	be	VBZ
cord-014712-5u4e00q6	615	4	posing	pose	VBG
cord-014712-5u4e00q6	615	5	a	a	DT
cord-014712-5u4e00q6	615	6	question	question	NN
cord-014712-5u4e00q6	615	7	what	what	WP
cord-014712-5u4e00q6	615	8	more	more	JJR
cord-014712-5u4e00q6	615	9	could	could	MD
cord-014712-5u4e00q6	615	10	we	-PRON-	PRP
cord-014712-5u4e00q6	615	11	do	do	VB
cord-014712-5u4e00q6	615	12	,	,	,
cord-014712-5u4e00q6	615	13	could	could	MD
cord-014712-5u4e00q6	615	14	we	-PRON-	PRP
cord-014712-5u4e00q6	615	15	have	have	VB
cord-014712-5u4e00q6	615	16	prevented	prevent	VBN
cord-014712-5u4e00q6	615	17	this	this	DT
cord-014712-5u4e00q6	615	18	rapid	rapid	JJ
cord-014712-5u4e00q6	615	19	worsening	worsening	NN
cord-014712-5u4e00q6	615	20	.	.	.
cord-014712-5u4e00q6	616	1	2	2	LS
cord-014712-5u4e00q6	616	2	.	.	.
cord-014712-5u4e00q6	617	1	Ten	ten	CD
cord-014712-5u4e00q6	617	2	-	-	HYPH
cord-014712-5u4e00q6	617	3	month	month	NN
cord-014712-5u4e00q6	617	4	old	old	JJ
cord-014712-5u4e00q6	617	5	girl	girl	NN
cord-014712-5u4e00q6	617	6	with	with	IN
cord-014712-5u4e00q6	617	7	SCID	SCID	NNP
cord-014712-5u4e00q6	617	8	with	with	IN
cord-014712-5u4e00q6	617	9	severe	severe	JJ
cord-014712-5u4e00q6	617	10	BCG	BCG	NNP
cord-014712-5u4e00q6	617	11	infection	infection	NN
cord-014712-5u4e00q6	617	12	after	after	IN
cord-014712-5u4e00q6	617	13	first	first	JJ
cord-014712-5u4e00q6	617	14	vaccination	vaccination	NN
cord-014712-5u4e00q6	617	15	,	,	,
cord-014712-5u4e00q6	617	16	referred	refer	VBD
cord-014712-5u4e00q6	617	17	relatively	relatively	RB
cord-014712-5u4e00q6	617	18	late	late	JJ
cord-014712-5u4e00q6	617	19	to	to	IN
cord-014712-5u4e00q6	617	20	our	-PRON-	PRP$
cord-014712-5u4e00q6	617	21	center	center	NN
cord-014712-5u4e00q6	617	22	,	,	,
cord-014712-5u4e00q6	617	23	but	but	CC
cord-014712-5u4e00q6	617	24	successfully	successfully	RB
cord-014712-5u4e00q6	617	25	transplanted	transplant	VBN
cord-014712-5u4e00q6	617	26	.	.	.
cord-014712-5u4e00q6	618	1	The	the	DT
cord-014712-5u4e00q6	618	2	case	case	NN
cord-014712-5u4e00q6	618	3	is	be	VBZ
cord-014712-5u4e00q6	618	4	posing	pose	VBG
cord-014712-5u4e00q6	618	5	a	a	DT
cord-014712-5u4e00q6	618	6	question	question	NN
cord-014712-5u4e00q6	618	7	about	about	IN
cord-014712-5u4e00q6	618	8	timing	timing	NN
cord-014712-5u4e00q6	618	9	of	of	IN
cord-014712-5u4e00q6	618	10	BCG	BCG	NNP
cord-014712-5u4e00q6	618	11	vaccination	vaccination	NN
cord-014712-5u4e00q6	618	12	and	and	CC
cord-014712-5u4e00q6	618	13	of	of	IN
cord-014712-5u4e00q6	618	14	referral	referral	NN
cord-014712-5u4e00q6	618	15	to	to	IN
cord-014712-5u4e00q6	618	16	specialized	specialized	JJ
cord-014712-5u4e00q6	618	17	center	center	NN
cord-014712-5u4e00q6	618	18	.	.	.
cord-014712-5u4e00q6	619	1	3	3	LS
cord-014712-5u4e00q6	619	2	.	.	.
cord-014712-5u4e00q6	620	1	Nine	nine	CD
cord-014712-5u4e00q6	620	2	-	-	HYPH
cord-014712-5u4e00q6	620	3	years	year	NNS
cord-014712-5u4e00q6	620	4	old	old	JJ
cord-014712-5u4e00q6	620	5	girl	girl	NN
cord-014712-5u4e00q6	620	6	with	with	IN
cord-014712-5u4e00q6	620	7	unidentified	unidentified	JJ
cord-014712-5u4e00q6	620	8	immune	immune	JJ
cord-014712-5u4e00q6	620	9	deficiency	deficiency	NN
cord-014712-5u4e00q6	620	10	,	,	,
cord-014712-5u4e00q6	620	11	normal	normal	JJ
cord-014712-5u4e00q6	620	12	immunological	immunological	JJ
cord-014712-5u4e00q6	620	13	follow	follow	VBP
cord-014712-5u4e00q6	620	14	up	up	RP
cord-014712-5u4e00q6	620	15	but	but	CC
cord-014712-5u4e00q6	620	16	clinical	clinical	JJ
cord-014712-5u4e00q6	620	17	course	course	NN
cord-014712-5u4e00q6	620	18	as	as	IN
cord-014712-5u4e00q6	620	19	an	an	DT
cord-014712-5u4e00q6	620	20	immune	immune	JJ
cord-014712-5u4e00q6	620	21	deficiency	deficiency	NN
cord-014712-5u4e00q6	620	22	with	with	IN
cord-014712-5u4e00q6	620	23	very	very	RB
cord-014712-5u4e00q6	620	24	favorable	favorable	JJ
cord-014712-5u4e00q6	620	25	effect	effect	NN
cord-014712-5u4e00q6	620	26	of	of	IN
cord-014712-5u4e00q6	620	27	IVIG	IVIG	NNP
cord-014712-5u4e00q6	620	28	according	accord	VBG
cord-014712-5u4e00q6	620	29	the	the	DT
cord-014712-5u4e00q6	620	30	parents	parent	NNS
cord-014712-5u4e00q6	620	31	.	.	.
cord-014712-5u4e00q6	621	1	The	the	DT
cord-014712-5u4e00q6	621	2	case	case	NN
cord-014712-5u4e00q6	621	3	is	be	VBZ
cord-014712-5u4e00q6	621	4	posing	pose	VBG
cord-014712-5u4e00q6	621	5	the	the	DT
cord-014712-5u4e00q6	621	6	question	question	NN
cord-014712-5u4e00q6	621	7	should	should	MD
cord-014712-5u4e00q6	621	8	we	-PRON-	PRP
cord-014712-5u4e00q6	621	9	stop	stop	VB
cord-014712-5u4e00q6	621	10	or	or	CC
cord-014712-5u4e00q6	621	11	should	should	MD
cord-014712-5u4e00q6	621	12	we	-PRON-	PRP
cord-014712-5u4e00q6	621	13	continue	continue	VB
cord-014712-5u4e00q6	621	14	IVIG	IVIG	NNP
cord-014712-5u4e00q6	621	15	,	,	,
cord-014712-5u4e00q6	621	16	despite	despite	IN
cord-014712-5u4e00q6	621	17	failing	fail	VBG
cord-014712-5u4e00q6	621	18	to	to	TO
cord-014712-5u4e00q6	621	19	find	find	VB
cord-014712-5u4e00q6	621	20	immunological	immunological	JJ
cord-014712-5u4e00q6	621	21	defect	defect	NN
cord-014712-5u4e00q6	621	22	,	,	,
cord-014712-5u4e00q6	621	23	based	base	VBN
cord-014712-5u4e00q6	621	24	on	on	IN
cord-014712-5u4e00q6	621	25	the	the	DT
cord-014712-5u4e00q6	621	26	good	good	JJ
cord-014712-5u4e00q6	621	27	clinical	clinical	JJ
cord-014712-5u4e00q6	621	28	response	response	NN
cord-014712-5u4e00q6	621	29	.	.	.
cord-014712-5u4e00q6	622	1	Unfortunately	unfortunately	RB
cord-014712-5u4e00q6	622	2	PIDs	pid	NNS
cord-014712-5u4e00q6	622	3	are	be	VBP
cord-014712-5u4e00q6	622	4	not	not	RB
cord-014712-5u4e00q6	622	5	very	very	RB
cord-014712-5u4e00q6	622	6	well	well	RB
cord-014712-5u4e00q6	622	7	recognized	recognized	JJ
cord-014712-5u4e00q6	622	8	and	and	CC
cord-014712-5u4e00q6	622	9	sometimes	sometimes	RB
cord-014712-5u4e00q6	622	10	the	the	DT
cord-014712-5u4e00q6	622	11	patients	patient	NNS
cord-014712-5u4e00q6	622	12	are	be	VBP
cord-014712-5u4e00q6	622	13	referred	refer	VBN
cord-014712-5u4e00q6	622	14	late	late	RB
cord-014712-5u4e00q6	622	15	.	.	.
cord-014712-5u4e00q6	623	1	Sometimes	sometimes	RB
cord-014712-5u4e00q6	623	2	poverty	poverty	NN
cord-014712-5u4e00q6	623	3	and	and	CC
cord-014712-5u4e00q6	623	4	lack	lack	NN
cord-014712-5u4e00q6	623	5	of	of	IN
cord-014712-5u4e00q6	623	6	knowledge	knowledge	NN
cord-014712-5u4e00q6	623	7	of	of	IN
cord-014712-5u4e00q6	623	8	patients	patient	NNS
cord-014712-5u4e00q6	623	9	leads	lead	VBZ
cord-014712-5u4e00q6	623	10	to	to	IN
cord-014712-5u4e00q6	623	11	miscalculation	miscalculation	NN
cord-014712-5u4e00q6	623	12	and	and	CC
cord-014712-5u4e00q6	623	13	neglecting	neglecting	NN
cord-014712-5u4e00q6	623	14	of	of	IN
cord-014712-5u4e00q6	623	15	their	-PRON-	PRP$
cord-014712-5u4e00q6	623	16	conditions	condition	NNS
cord-014712-5u4e00q6	623	17	by	by	IN
cord-014712-5u4e00q6	623	18	themselves	-PRON-	PRP
cord-014712-5u4e00q6	623	19	,	,	,
cord-014712-5u4e00q6	623	20	or	or	CC
cord-014712-5u4e00q6	623	21	refusal	refusal	VB
cord-014712-5u4e00q6	623	22	for	for	IN
cord-014712-5u4e00q6	623	23	specific	specific	JJ
cord-014712-5u4e00q6	623	24	tests	test	NNS
cord-014712-5u4e00q6	623	25	for	for	IN
cord-014712-5u4e00q6	623	26	clarifying	clarify	VBG
cord-014712-5u4e00q6	623	27	the	the	DT
cord-014712-5u4e00q6	623	28	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	623	29	.	.	.
cord-014712-5u4e00q6	624	1	Background	background	NN
cord-014712-5u4e00q6	624	2	:	:	:
cord-014712-5u4e00q6	625	1	Although	although	IN
cord-014712-5u4e00q6	625	2	rare	rare	JJ
cord-014712-5u4e00q6	625	3	,	,	,
cord-014712-5u4e00q6	625	4	Primary	primary	JJ
cord-014712-5u4e00q6	625	5	immune	immune	JJ
cord-014712-5u4e00q6	625	6	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	625	7	(	(	-LRB-
cord-014712-5u4e00q6	625	8	PID	PID	NNP
cord-014712-5u4e00q6	625	9	)	)	-RRB-
cord-014712-5u4e00q6	625	10	are	be	VBP
cord-014712-5u4e00q6	625	11	manifested	manifest	VBN
cord-014712-5u4e00q6	625	12	with	with	IN
cord-014712-5u4e00q6	625	13	high	high	JJ
cord-014712-5u4e00q6	625	14	rate	rate	NN
cord-014712-5u4e00q6	625	15	infections	infection	NNS
cord-014712-5u4e00q6	625	16	as	as	RB
cord-014712-5u4e00q6	625	17	well	well	RB
cord-014712-5u4e00q6	625	18	as	as	IN
cord-014712-5u4e00q6	625	19	with	with	IN
cord-014712-5u4e00q6	625	20	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	625	21	and	and	CC
cord-014712-5u4e00q6	625	22	malignant	malignant	JJ
cord-014712-5u4e00q6	625	23	disorders	disorder	NNS
cord-014712-5u4e00q6	625	24	that	that	WDT
cord-014712-5u4e00q6	625	25	are	be	VBP
cord-014712-5u4e00q6	625	26	treated	treat	VBN
cord-014712-5u4e00q6	625	27	hardly	hardly	RB
cord-014712-5u4e00q6	625	28	and	and	CC
cord-014712-5u4e00q6	625	29	inefficiently	inefficiently	RB
cord-014712-5u4e00q6	625	30	.	.	.
cord-014712-5u4e00q6	626	1	PID	PID	NNP
cord-014712-5u4e00q6	626	2	are	be	VBP
cord-014712-5u4e00q6	626	3	not	not	RB
cord-014712-5u4e00q6	626	4	only	only	RB
cord-014712-5u4e00q6	626	5	immunological	immunological	JJ
cord-014712-5u4e00q6	626	6	problem	problem	NN
cord-014712-5u4e00q6	626	7	;	;	:
cord-014712-5u4e00q6	626	8	they	-PRON-	PRP
cord-014712-5u4e00q6	626	9	require	require	VBP
cord-014712-5u4e00q6	626	10	close	close	JJ
cord-014712-5u4e00q6	626	11	collaboration	collaboration	NN
cord-014712-5u4e00q6	626	12	between	between	IN
cord-014712-5u4e00q6	626	13	immunologists	immunologist	NNS
cord-014712-5u4e00q6	626	14	,	,	,
cord-014712-5u4e00q6	626	15	pediatricians	pediatrician	NNS
cord-014712-5u4e00q6	626	16	,	,	,
cord-014712-5u4e00q6	626	17	ENT	ENT	NNP
cord-014712-5u4e00q6	626	18	,	,	,
cord-014712-5u4e00q6	626	19	lung	lung	NN
cord-014712-5u4e00q6	626	20	and	and	CC
cord-014712-5u4e00q6	626	21	gut	gut	NN
cord-014712-5u4e00q6	626	22	specialists	specialist	NNS
cord-014712-5u4e00q6	626	23	,	,	,
cord-014712-5u4e00q6	626	24	dermatologists	dermatologist	NNS
cord-014712-5u4e00q6	626	25	,	,	,
cord-014712-5u4e00q6	626	26	hematologists	hematologist	NNS
cord-014712-5u4e00q6	626	27	,	,	,
cord-014712-5u4e00q6	626	28	oncologists	oncologist	NNS
cord-014712-5u4e00q6	626	29	,	,	,
cord-014712-5u4e00q6	626	30	patients	patient	NNS
cord-014712-5u4e00q6	626	31	and	and	CC
cord-014712-5u4e00q6	626	32	administration	administration	NN
cord-014712-5u4e00q6	626	33	.	.	.
cord-014712-5u4e00q6	627	1	The	the	DT
cord-014712-5u4e00q6	627	2	aim	aim	NN
cord-014712-5u4e00q6	627	3	of	of	IN
cord-014712-5u4e00q6	627	4	this	this	DT
cord-014712-5u4e00q6	627	5	study	study	NN
cord-014712-5u4e00q6	627	6	was	be	VBD
cord-014712-5u4e00q6	627	7	to	to	TO
cord-014712-5u4e00q6	627	8	summarize	summarize	VB
cord-014712-5u4e00q6	627	9	the	the	DT
cord-014712-5u4e00q6	627	10	activity	activity	NN
cord-014712-5u4e00q6	627	11	on	on	IN
cord-014712-5u4e00q6	627	12	registration	registration	NN
cord-014712-5u4e00q6	627	13	and	and	CC
cord-014712-5u4e00q6	627	14	replacement	replacement	NN
cord-014712-5u4e00q6	627	15	therapy	therapy	NN
cord-014712-5u4e00q6	627	16	of	of	IN
cord-014712-5u4e00q6	627	17	PID	PID	NNP
cord-014712-5u4e00q6	627	18	patients	patient	NNS
cord-014712-5u4e00q6	627	19	in	in	IN
cord-014712-5u4e00q6	627	20	Plovdiv	Plovdiv	NNP
cord-014712-5u4e00q6	627	21	region	region	NN
cord-014712-5u4e00q6	627	22	at	at	IN
cord-014712-5u4e00q6	627	23	the	the	DT
cord-014712-5u4e00q6	627	24	University	University	NNP
cord-014712-5u4e00q6	627	25	Hospital	Hospital	NNP
cord-014712-5u4e00q6	627	26	"	"	''
cord-014712-5u4e00q6	627	27	St.	St.	NNP
cord-014712-5u4e00q6	627	28	George"-Plovdiv	George"-Plovdiv	NNP
cord-014712-5u4e00q6	627	29	for	for	IN
cord-014712-5u4e00q6	627	30	1	1	CD
cord-014712-5u4e00q6	627	31	year	year	NN
cord-014712-5u4e00q6	627	32	(	(	-LRB-
cord-014712-5u4e00q6	627	33	03.2013	03.2013	CD
cord-014712-5u4e00q6	627	34	-	-	HYPH
cord-014712-5u4e00q6	627	35	02.2014	02.2014	CD
cord-014712-5u4e00q6	627	36	)	)	-RRB-
cord-014712-5u4e00q6	627	37	.	.	.
cord-014712-5u4e00q6	628	1	Methodology	methodology	NN
cord-014712-5u4e00q6	628	2	:	:	:
cord-014712-5u4e00q6	629	1	Children	child	NNS
cord-014712-5u4e00q6	629	2	with	with	IN
cord-014712-5u4e00q6	629	3	PID	PID	NNP
cord-014712-5u4e00q6	629	4	of	of	IN
cord-014712-5u4e00q6	629	5	humoral	humoral	JJ
cord-014712-5u4e00q6	629	6	immunity	immunity	NN
cord-014712-5u4e00q6	629	7	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	629	8	at	at	IN
cord-014712-5u4e00q6	629	9	the	the	DT
cord-014712-5u4e00q6	629	10	Clinic	Clinic	NNP
cord-014712-5u4e00q6	629	11	of	of	IN
cord-014712-5u4e00q6	629	12	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	629	13	,	,	,
cord-014712-5u4e00q6	629	14	and	and	CC
cord-014712-5u4e00q6	629	15	adults	adult	NNS
cord-014712-5u4e00q6	629	16	with	with	IN
cord-014712-5u4e00q6	629	17	Hereditary	hereditary	JJ
cord-014712-5u4e00q6	629	18	angioedema	angioedema	NN
cord-014712-5u4e00q6	629	19	(	(	-LRB-
cord-014712-5u4e00q6	629	20	HAE	HAE	NNP
cord-014712-5u4e00q6	629	21	)	)	-RRB-
cord-014712-5u4e00q6	629	22	were	be	VBD
cord-014712-5u4e00q6	629	23	included	include	VBN
cord-014712-5u4e00q6	629	24	in	in	IN
cord-014712-5u4e00q6	629	25	the	the	DT
cord-014712-5u4e00q6	629	26	study	study	NN
cord-014712-5u4e00q6	629	27	using	use	VBG
cord-014712-5u4e00q6	629	28	immunological	immunological	JJ
cord-014712-5u4e00q6	629	29	and	and	CC
cord-014712-5u4e00q6	629	30	other	other	JJ
cord-014712-5u4e00q6	629	31	lab	lab	NN
cord-014712-5u4e00q6	629	32	tests	test	NNS
cord-014712-5u4e00q6	629	33	,	,	,
cord-014712-5u4e00q6	629	34	clinical	clinical	JJ
cord-014712-5u4e00q6	629	35	follow	follow	VB
cord-014712-5u4e00q6	629	36	up	up	RP
cord-014712-5u4e00q6	629	37	and	and	CC
cord-014712-5u4e00q6	629	38	treatment	treatment	NN
cord-014712-5u4e00q6	629	39	:	:	:
cord-014712-5u4e00q6	629	40	IV	IV	NNP
cord-014712-5u4e00q6	629	41	and	and	CC
cord-014712-5u4e00q6	629	42	SC	SC	NNP
cord-014712-5u4e00q6	629	43	Ig	Ig	NNP
cord-014712-5u4e00q6	629	44	for	for	IN
cord-014712-5u4e00q6	629	45	children	child	NNS
cord-014712-5u4e00q6	629	46	with	with	IN
cord-014712-5u4e00q6	629	47	PID	PID	NNP
cord-014712-5u4e00q6	629	48	and	and	CC
cord-014712-5u4e00q6	629	49	C1	C1	NNP
cord-014712-5u4e00q6	629	50	esterase	esterase	NN
cord-014712-5u4e00q6	629	51	inhibitor	inhibitor	NN
cord-014712-5u4e00q6	629	52	(	(	-LRB-
cord-014712-5u4e00q6	629	53	Ruconest	Ruconest	NNP
cord-014712-5u4e00q6	629	54	,	,	,
cord-014712-5u4e00q6	629	55	Berinert	Berinert	NNP
cord-014712-5u4e00q6	629	56	)	)	-RRB-
cord-014712-5u4e00q6	629	57	for	for	IN
cord-014712-5u4e00q6	629	58	HAE	HAE	NNP
cord-014712-5u4e00q6	629	59	patients	patient	NNS
cord-014712-5u4e00q6	629	60	.	.	.
cord-014712-5u4e00q6	630	1	Results	result	NNS
cord-014712-5u4e00q6	630	2	:	:	:
cord-014712-5u4e00q6	631	1	Three	three	CD
cord-014712-5u4e00q6	631	2	national	national	JJ
cord-014712-5u4e00q6	631	3	workshops	workshop	NNS
cord-014712-5u4e00q6	631	4	and	and	CC
cord-014712-5u4e00q6	631	5	a	a	DT
cord-014712-5u4e00q6	631	6	national	national	JJ
cord-014712-5u4e00q6	631	7	conference	conference	NN
cord-014712-5u4e00q6	631	8	on	on	IN
cord-014712-5u4e00q6	631	9	PID	PID	NNP
cord-014712-5u4e00q6	631	10	were	be	VBD
cord-014712-5u4e00q6	631	11	hosted	host	VBN
cord-014712-5u4e00q6	631	12	and	and	CC
cord-014712-5u4e00q6	631	13	organized	organize	VBN
cord-014712-5u4e00q6	631	14	in	in	IN
cord-014712-5u4e00q6	631	15	Plovdiv	Plovdiv	NNP
cord-014712-5u4e00q6	631	16	since	since	IN
cord-014712-5u4e00q6	631	17	2005	2005	CD
cord-014712-5u4e00q6	631	18	.	.	.
cord-014712-5u4e00q6	632	1	Well	well	UH
cord-014712-5u4e00q6	632	2	established	established	JJ
cord-014712-5u4e00q6	632	3	university	university	NN
cord-014712-5u4e00q6	632	4	hospital	hospital	NN
cord-014712-5u4e00q6	632	5	immunological	immunological	JJ
cord-014712-5u4e00q6	632	6	laboratory	laboratory	NN
cord-014712-5u4e00q6	632	7	,	,	,
cord-014712-5u4e00q6	632	8	detecting	detect	VBG
cord-014712-5u4e00q6	632	9	serum	serum	NN
cord-014712-5u4e00q6	632	10	immunogloblins	immunogloblin	NNS
cord-014712-5u4e00q6	632	11	,	,	,
cord-014712-5u4e00q6	632	12	blood	blood	NN
cord-014712-5u4e00q6	632	13	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	632	14	populations	population	NNS
cord-014712-5u4e00q6	632	15	and	and	CC
cord-014712-5u4e00q6	632	16	subpopulations	subpopulation	NNS
cord-014712-5u4e00q6	632	17	and	and	CC
cord-014712-5u4e00q6	632	18	complement	complement	VB
cord-014712-5u4e00q6	632	19	proteins	protein	NNS
cord-014712-5u4e00q6	632	20	;	;	:
cord-014712-5u4e00q6	632	21	Clinic	Clinic	NNP
cord-014712-5u4e00q6	632	22	of	of	IN
cord-014712-5u4e00q6	632	23	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	632	24	and	and	CC
cord-014712-5u4e00q6	632	25	Genetic	Genetic	NNP
cord-014712-5u4e00q6	632	26	Diseases	Diseases	NNPS
cord-014712-5u4e00q6	632	27	and	and	CC
cord-014712-5u4e00q6	632	28	an	an	DT
cord-014712-5u4e00q6	632	29	Information	information	NN
cord-014712-5u4e00q6	632	30	center	center	NN
cord-014712-5u4e00q6	632	31	for	for	IN
cord-014712-5u4e00q6	632	32	Rare	rare	JJ
cord-014712-5u4e00q6	632	33	diseases	disease	NNS
cord-014712-5u4e00q6	632	34	and	and	CC
cord-014712-5u4e00q6	632	35	Orphan	Orphan	NNP
cord-014712-5u4e00q6	632	36	drugs	drug	NNS
cord-014712-5u4e00q6	632	37	function	function	VBP
cord-014712-5u4e00q6	632	38	in	in	IN
cord-014712-5u4e00q6	632	39	Plovdiv	Plovdiv	NNP
cord-014712-5u4e00q6	632	40	.	.	.
cord-014712-5u4e00q6	633	1	An	an	DT
cord-014712-5u4e00q6	633	2	Expert	expert	NN
cord-014712-5u4e00q6	633	3	center	center	NN
cord-014712-5u4e00q6	633	4	for	for	IN
cord-014712-5u4e00q6	633	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	633	6	and	and	CC
cord-014712-5u4e00q6	633	7	treatment	treatment	NN
cord-014712-5u4e00q6	633	8	of	of	IN
cord-014712-5u4e00q6	633	9	PID	PID	NNP
cord-014712-5u4e00q6	633	10	was	be	VBD
cord-014712-5u4e00q6	633	11	created	create	VBN
cord-014712-5u4e00q6	633	12	at	at	IN
cord-014712-5u4e00q6	633	13	the	the	DT
cord-014712-5u4e00q6	633	14	University	University	NNP
cord-014712-5u4e00q6	633	15	Hospital	Hospital	NNP
cord-014712-5u4e00q6	633	16	.	.	.
cord-014712-5u4e00q6	634	1	It	-PRON-	PRP
cord-014712-5u4e00q6	634	2	is	be	VBZ
cord-014712-5u4e00q6	634	3	a	a	DT
cord-014712-5u4e00q6	634	4	team	team	NN
cord-014712-5u4e00q6	634	5	of	of	IN
cord-014712-5u4e00q6	634	6	two	two	CD
cord-014712-5u4e00q6	634	7	competent	competent	JJ
cord-014712-5u4e00q6	634	8	pediatricians	pediatrician	NNS
cord-014712-5u4e00q6	634	9	,	,	,
cord-014712-5u4e00q6	634	10	an	an	DT
cord-014712-5u4e00q6	634	11	immunologist	immunologist	NN
cord-014712-5u4e00q6	634	12	and	and	CC
cord-014712-5u4e00q6	634	13	an	an	DT
cord-014712-5u4e00q6	634	14	allergist	allergist	NN
cord-014712-5u4e00q6	634	15	.	.	.
cord-014712-5u4e00q6	635	1	The	the	DT
cord-014712-5u4e00q6	635	2	targets	target	NNS
cord-014712-5u4e00q6	635	3	are	be	VBP
cord-014712-5u4e00q6	635	4	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	635	5	PID	PID	NNP
cord-014712-5u4e00q6	635	6	children	child	NNS
cord-014712-5u4e00q6	635	7	,	,	,
cord-014712-5u4e00q6	635	8	outpatient	outpatient	NN
cord-014712-5u4e00q6	635	9	PID	pid	NN
cord-014712-5u4e00q6	635	10	children	child	NNS
cord-014712-5u4e00q6	635	11	and	and	CC
cord-014712-5u4e00q6	635	12	HAE	HAE	NNP
cord-014712-5u4e00q6	635	13	adults	adult	NNS
cord-014712-5u4e00q6	635	14	.	.	.
cord-014712-5u4e00q6	636	1	The	the	DT
cord-014712-5u4e00q6	636	2	Center	Center	NNP
cord-014712-5u4e00q6	636	3	introduced	introduce	VBD
cord-014712-5u4e00q6	636	4	regular	regular	JJ
cord-014712-5u4e00q6	636	5	replacement	replacement	NN
cord-014712-5u4e00q6	636	6	therapy	therapy	NN
cord-014712-5u4e00q6	636	7	with	with	IN
cord-014712-5u4e00q6	636	8	IV	IV	NNP
cord-014712-5u4e00q6	636	9	and	and	CC
cord-014712-5u4e00q6	636	10	SC	SC	NNP
cord-014712-5u4e00q6	636	11	IV	IV	NNP
cord-014712-5u4e00q6	636	12	and	and	CC
cord-014712-5u4e00q6	636	13	C1	C1	NNP
cord-014712-5u4e00q6	636	14	Inhibitor	Inhibitor	NNP
cord-014712-5u4e00q6	636	15	,	,	,
cord-014712-5u4e00q6	636	16	reimbursed	reimburse	VBN
cord-014712-5u4e00q6	636	17	by	by	IN
cord-014712-5u4e00q6	636	18	the	the	DT
cord-014712-5u4e00q6	636	19	National	National	NNP
cord-014712-5u4e00q6	636	20	Insurance	Insurance	NNP
cord-014712-5u4e00q6	636	21	.	.	.
cord-014712-5u4e00q6	637	1	Together	together	RB
cord-014712-5u4e00q6	637	2	with	with	IN
cord-014712-5u4e00q6	637	3	ICRDOD	ICRDOD	NNS
cord-014712-5u4e00q6	637	4	the	the	DT
cord-014712-5u4e00q6	637	5	experts	expert	NNS
cord-014712-5u4e00q6	637	6	provide	provide	VBP
cord-014712-5u4e00q6	637	7	education	education	NN
cord-014712-5u4e00q6	637	8	for	for	IN
cord-014712-5u4e00q6	637	9	patients	patient	NNS
cord-014712-5u4e00q6	637	10	and	and	CC
cord-014712-5u4e00q6	637	11	parents	parent	NNS
cord-014712-5u4e00q6	637	12	how	how	WRB
cord-014712-5u4e00q6	637	13	to	to	TO
cord-014712-5u4e00q6	637	14	perform	perform	VB
cord-014712-5u4e00q6	637	15	SC	SC	NNP
cord-014712-5u4e00q6	637	16	Ig	Ig	NNP
cord-014712-5u4e00q6	637	17	application	application	NN
cord-014712-5u4e00q6	637	18	as	as	RB
cord-014712-5u4e00q6	637	19	well	well	RB
cord-014712-5u4e00q6	637	20	as	as	IN
cord-014712-5u4e00q6	637	21	consultations	consultation	NNS
cord-014712-5u4e00q6	637	22	of	of	IN
cord-014712-5u4e00q6	637	23	patients	patient	NNS
cord-014712-5u4e00q6	637	24	and	and	CC
cord-014712-5u4e00q6	637	25	relatives	relative	NNS
cord-014712-5u4e00q6	637	26	about	about	IN
cord-014712-5u4e00q6	637	27	PID.Since	PID.Since	NNP
cord-014712-5u4e00q6	637	28	March	March	NNP
cord-014712-5u4e00q6	637	29	2013	2013	CD
cord-014712-5u4e00q6	637	30	indicated	indicate	VBD
cord-014712-5u4e00q6	637	31	reimbursed	reimburse	VBN
cord-014712-5u4e00q6	637	32	replacement	replacement	NN
cord-014712-5u4e00q6	637	33	therapy	therapy	NN
cord-014712-5u4e00q6	637	34	with	with	IN
cord-014712-5u4e00q6	637	35	IV	IV	NNP
cord-014712-5u4e00q6	638	1	Ig	Ig	NNP
cord-014712-5u4e00q6	638	2	-Octagam	-Octagam	NNP
cord-014712-5u4e00q6	638	3	,	,	,
cord-014712-5u4e00q6	638	4	started	start	VBD
cord-014712-5u4e00q6	638	5	regularly	regularly	RB
cord-014712-5u4e00q6	638	6	in	in	IN
cord-014712-5u4e00q6	638	7	5	5	CD
cord-014712-5u4e00q6	638	8	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	638	9	PID	PID	NNP
cord-014712-5u4e00q6	638	10	children	child	NNS
cord-014712-5u4e00q6	638	11	with	with	IN
cord-014712-5u4e00q6	638	12	Bruton	Bruton	NNP
cord-014712-5u4e00q6	638	13	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	638	14	,	,	,
cord-014712-5u4e00q6	638	15	CVID	CVID	NNP
cord-014712-5u4e00q6	638	16	,	,	,
cord-014712-5u4e00q6	638	17	Omenn	Omenn	NNP
cord-014712-5u4e00q6	638	18	syndrome	syndrome	NN
cord-014712-5u4e00q6	638	19	or	or	CC
cord-014712-5u4e00q6	638	20	IgG1	igg1	NN
cord-014712-5u4e00q6	638	21	ID	ID	NNP
cord-014712-5u4e00q6	638	22	.	.	.
cord-014712-5u4e00q6	639	1	These	these	DT
cord-014712-5u4e00q6	639	2	patients	patient	NNS
cord-014712-5u4e00q6	639	3	,	,	,
cord-014712-5u4e00q6	639	4	aged	age	VBN
cord-014712-5u4e00q6	639	5	form	form	NN
cord-014712-5u4e00q6	639	6	4	4	CD
cord-014712-5u4e00q6	639	7	to	to	TO
cord-014712-5u4e00q6	639	8	12	12	CD
cord-014712-5u4e00q6	639	9	years	year	NNS
cord-014712-5u4e00q6	639	10	,	,	,
cord-014712-5u4e00q6	639	11	had	have	VBD
cord-014712-5u4e00q6	639	12	2	2	CD
cord-014712-5u4e00q6	639	13	to	to	TO
cord-014712-5u4e00q6	639	14	6	6	CD
cord-014712-5u4e00q6	639	15	hospitalizations	hospitalization	NNS
cord-014712-5u4e00q6	639	16	for	for	IN
cord-014712-5u4e00q6	639	17	one	one	CD
cord-014712-5u4e00q6	639	18	year	year	NN
cord-014712-5u4e00q6	639	19	.	.	.
cord-014712-5u4e00q6	640	1	Four	four	CD
cord-014712-5u4e00q6	640	2	outpatient	outpatient	NN
cord-014712-5u4e00q6	640	3	children	child	NNS
cord-014712-5u4e00q6	640	4	with	with	IN
cord-014712-5u4e00q6	640	5	Omenn	Omenn	NNP
cord-014712-5u4e00q6	640	6	syndrome	syndrome	NN
cord-014712-5u4e00q6	640	7	or	or	CC
cord-014712-5u4e00q6	640	8	IgG1	igg1	NN
cord-014712-5u4e00q6	640	9	subclass	subclass	NN
cord-014712-5u4e00q6	640	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	640	11	were	be	VBD
cord-014712-5u4e00q6	640	12	subjected	subject	VBN
cord-014712-5u4e00q6	640	13	to	to	IN
cord-014712-5u4e00q6	640	14	SC	SC	NNP
cord-014712-5u4e00q6	640	15	Ig	Ig	NNP
cord-014712-5u4e00q6	640	16	-Gammanorm	-Gammanorm	NNP
cord-014712-5u4e00q6	640	17	,	,	,
cord-014712-5u4e00q6	640	18	and	and	CC
cord-014712-5u4e00q6	640	19	7	7	CD
cord-014712-5u4e00q6	640	20	HAE	HAE	NNP
cord-014712-5u4e00q6	640	21	type	type	NN
cord-014712-5u4e00q6	640	22	1	1	CD
cord-014712-5u4e00q6	640	23	outpatients	outpatient	NNS
cord-014712-5u4e00q6	640	24	had	have	VBD
cord-014712-5u4e00q6	640	25	good	good	JJ
cord-014712-5u4e00q6	640	26	response	response	NN
cord-014712-5u4e00q6	640	27	for	for	IN
cord-014712-5u4e00q6	640	28	replacement	replacement	NN
cord-014712-5u4e00q6	640	29	C1	C1	NNP
cord-014712-5u4e00q6	640	30	inhibitor	inhibitor	NN
cord-014712-5u4e00q6	640	31	therapy	therapy	NN
cord-014712-5u4e00q6	640	32	as	as	IN
cord-014712-5u4e00q6	640	33	follows	follow	VBZ
cord-014712-5u4e00q6	640	34	:	:	:
cord-014712-5u4e00q6	641	1	Conestat	Conestat	NNP
cord-014712-5u4e00q6	641	2	alfa	alfa	NNP
cord-014712-5u4e00q6	641	3	(	(	-LRB-
cord-014712-5u4e00q6	641	4	Ruconest)in	Ruconest)in	NNP
cord-014712-5u4e00q6	641	5	5	5	CD
cord-014712-5u4e00q6	641	6	HAE	HAE	NNP
cord-014712-5u4e00q6	641	7	adults	adult	NNS
cord-014712-5u4e00q6	641	8	(	(	-LRB-
cord-014712-5u4e00q6	641	9	150	150	CD
cord-014712-5u4e00q6	641	10	IU	IU	NNP
cord-014712-5u4e00q6	641	11	/	/	,
cord-014712-5u4e00q6	641	12	ml	ml	NN
cord-014712-5u4e00q6	641	13	weekly	weekly	NN
cord-014712-5u4e00q6	641	14	)	)	-RRB-
cord-014712-5u4e00q6	641	15	,	,	,
cord-014712-5u4e00q6	641	16	and	and	CC
cord-014712-5u4e00q6	641	17	Berinert	Berinert	NNP
cord-014712-5u4e00q6	641	18	(	(	-LRB-
cord-014712-5u4e00q6	641	19	20	20	CD
cord-014712-5u4e00q6	641	20	U	U	NNP
cord-014712-5u4e00q6	641	21	/	/	SYM
cord-014712-5u4e00q6	641	22	kg	kg	NN
cord-014712-5u4e00q6	641	23	b.w	b.w	NNP
cord-014712-5u4e00q6	641	24	.	.	NNP
cord-014712-5u4e00q6	641	25	weekley)in	weekley)in	NNP
cord-014712-5u4e00q6	641	26	2	2	CD
cord-014712-5u4e00q6	641	27	HAE	HAE	NNP
cord-014712-5u4e00q6	641	28	adult	adult	NN
cord-014712-5u4e00q6	641	29	patients	patient	NNS
cord-014712-5u4e00q6	641	30	.	.	.
cord-014712-5u4e00q6	642	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	642	2	:	:	:
cord-014712-5u4e00q6	643	1	The	the	DT
cord-014712-5u4e00q6	643	2	Expert	Expert	NNP
cord-014712-5u4e00q6	643	3	PID	PID	NNP
cord-014712-5u4e00q6	643	4	Center	Center	NNP
cord-014712-5u4e00q6	643	5	in	in	IN
cord-014712-5u4e00q6	643	6	Plovdiv	Plovdiv	NNP
cord-014712-5u4e00q6	643	7	University	University	NNP
cord-014712-5u4e00q6	643	8	Hospital	Hospital	NNP
cord-014712-5u4e00q6	643	9	provides	provide	VBZ
cord-014712-5u4e00q6	643	10	competent	competent	JJ
cord-014712-5u4e00q6	643	11	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	643	12	,	,	,
cord-014712-5u4e00q6	643	13	therapy	therapy	NN
cord-014712-5u4e00q6	643	14	,	,	,
cord-014712-5u4e00q6	643	15	education	education	NN
cord-014712-5u4e00q6	643	16	and	and	CC
cord-014712-5u4e00q6	643	17	consultations	consultation	NNS
cord-014712-5u4e00q6	643	18	for	for	IN
cord-014712-5u4e00q6	643	19	pediatric	pediatric	JJ
cord-014712-5u4e00q6	643	20	and	and	CC
cord-014712-5u4e00q6	643	21	adult	adult	NN
cord-014712-5u4e00q6	643	22	PID	pid	NN
cord-014712-5u4e00q6	643	23	patients	patient	NNS
cord-014712-5u4e00q6	643	24	from	from	IN
cord-014712-5u4e00q6	643	25	Plovdiv	Plovdiv	NNP
cord-014712-5u4e00q6	643	26	region	region	NN
cord-014712-5u4e00q6	643	27	.	.	.
cord-014712-5u4e00q6	644	1	The	the	DT
cord-014712-5u4e00q6	644	2	recent	recent	JJ
cord-014712-5u4e00q6	644	3	introduction	introduction	NN
cord-014712-5u4e00q6	644	4	of	of	IN
cord-014712-5u4e00q6	644	5	reimbursed	reimburse	VBN
cord-014712-5u4e00q6	644	6	replacement	replacement	NN
cord-014712-5u4e00q6	644	7	therapy	therapy	NN
cord-014712-5u4e00q6	644	8	for	for	IN
cord-014712-5u4e00q6	644	9	PID	PID	NNP
cord-014712-5u4e00q6	644	10	patients	patient	NNS
cord-014712-5u4e00q6	644	11	(	(	-LRB-
cord-014712-5u4e00q6	644	12	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	644	13	or	or	CC
cord-014712-5u4e00q6	644	14	outpatients	outpatient	NNS
cord-014712-5u4e00q6	644	15	)	)	-RRB-
cord-014712-5u4e00q6	644	16	allows	allow	VBZ
cord-014712-5u4e00q6	644	17	regular	regular	JJ
cord-014712-5u4e00q6	644	18	immunological	immunological	JJ
cord-014712-5u4e00q6	644	19	and	and	CC
cord-014712-5u4e00q6	644	20	clinical	clinical	JJ
cord-014712-5u4e00q6	644	21	follow	follow	NN
cord-014712-5u4e00q6	644	22	up	up	IN
cord-014712-5u4e00q6	644	23	of	of	IN
cord-014712-5u4e00q6	644	24	the	the	DT
cord-014712-5u4e00q6	644	25	diseases	disease	NNS
cord-014712-5u4e00q6	644	26	.	.	.
cord-014712-5u4e00q6	645	1	Background	background	NN
cord-014712-5u4e00q6	645	2	:	:	:
cord-014712-5u4e00q6	646	1	Intravenous	intravenous	JJ
cord-014712-5u4e00q6	646	2	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	646	3	(	(	-LRB-
cord-014712-5u4e00q6	646	4	IVIGs	ivig	NNS
cord-014712-5u4e00q6	646	5	)	)	-RRB-
cord-014712-5u4e00q6	646	6	are	be	VBP
cord-014712-5u4e00q6	646	7	scarce	scarce	JJ
cord-014712-5u4e00q6	646	8	biological	biological	JJ
cord-014712-5u4e00q6	646	9	products	product	NNS
cord-014712-5u4e00q6	646	10	used	use	VBN
cord-014712-5u4e00q6	646	11	in	in	IN
cord-014712-5u4e00q6	646	12	a	a	DT
cord-014712-5u4e00q6	646	13	broad	broad	JJ
cord-014712-5u4e00q6	646	14	variety	variety	NN
cord-014712-5u4e00q6	646	15	of	of	IN
cord-014712-5u4e00q6	646	16	disorders	disorder	NNS
cord-014712-5u4e00q6	646	17	.	.	.
cord-014712-5u4e00q6	647	1	Tolerance	tolerance	NN
cord-014712-5u4e00q6	647	2	to	to	IN
cord-014712-5u4e00q6	647	3	infusions	infusion	NNS
cord-014712-5u4e00q6	647	4	is	be	VBZ
cord-014712-5u4e00q6	647	5	usually	usually	RB
cord-014712-5u4e00q6	647	6	good	good	JJ
cord-014712-5u4e00q6	647	7	but	but	CC
cord-014712-5u4e00q6	647	8	adverse	adverse	JJ
cord-014712-5u4e00q6	647	9	events	event	NNS
cord-014712-5u4e00q6	647	10	,	,	,
cord-014712-5u4e00q6	647	11	including	include	VBG
cord-014712-5u4e00q6	647	12	some	some	DT
cord-014712-5u4e00q6	647	13	serious	serious	JJ
cord-014712-5u4e00q6	647	14	ones	one	NNS
cord-014712-5u4e00q6	647	15	,	,	,
cord-014712-5u4e00q6	647	16	have	have	VBP
cord-014712-5u4e00q6	647	17	been	be	VBN
cord-014712-5u4e00q6	647	18	reported	report	VBN
cord-014712-5u4e00q6	647	19	.	.	.
cord-014712-5u4e00q6	648	1	Methodology	methodology	NN
cord-014712-5u4e00q6	648	2	:	:	:
cord-014712-5u4e00q6	649	1	A	a	DT
cord-014712-5u4e00q6	649	2	cohort	cohort	NN
cord-014712-5u4e00q6	649	3	study	study	NN
cord-014712-5u4e00q6	649	4	aimed	aim	VBN
cord-014712-5u4e00q6	649	5	for	for	IN
cord-014712-5u4e00q6	649	6	detection	detection	NN
cord-014712-5u4e00q6	649	7	of	of	IN
cord-014712-5u4e00q6	649	8	adverse	adverse	JJ
cord-014712-5u4e00q6	649	9	events	event	NNS
cord-014712-5u4e00q6	649	10	that	that	WDT
cord-014712-5u4e00q6	649	11	occur	occur	VBP
cord-014712-5u4e00q6	649	12	during	during	IN
cord-014712-5u4e00q6	649	13	and	and	CC
cord-014712-5u4e00q6	649	14	following	follow	VBG
cord-014712-5u4e00q6	649	15	intravenous	intravenous	JJ
cord-014712-5u4e00q6	649	16	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	649	17	(	(	-LRB-
cord-014712-5u4e00q6	649	18	IVIG	IVIG	NNP
cord-014712-5u4e00q6	649	19	)	)	-RRB-
cord-014712-5u4e00q6	649	20	infusions	infusion	NNS
cord-014712-5u4e00q6	649	21	at	at	IN
cord-014712-5u4e00q6	649	22	Cairo	Cairo	NNP
cord-014712-5u4e00q6	649	23	University	University	NNP
cord-014712-5u4e00q6	649	24	Children	Children	NNP
cord-014712-5u4e00q6	649	25	Hospitals	Hospitals	NNPS
cord-014712-5u4e00q6	650	1	[	[	-LRB-
cord-014712-5u4e00q6	650	2	Patients	patient	NNS
cord-014712-5u4e00q6	650	3	were	be	VBD
cord-014712-5u4e00q6	650	4	recruited	recruit	VBN
cord-014712-5u4e00q6	650	5	at	at	IN
cord-014712-5u4e00q6	650	6	Neonatal	Neonatal	NNP
cord-014712-5u4e00q6	650	7	Intensive	Intensive	NNP
cord-014712-5u4e00q6	650	8	Care	Care	NNP
cord-014712-5u4e00q6	650	9	Units	Units	NNPS
cord-014712-5u4e00q6	650	10	(	(	-LRB-
cord-014712-5u4e00q6	650	11	NICU	NICU	NNP
cord-014712-5u4e00q6	650	12	)	)	-RRB-
cord-014712-5u4e00q6	650	13	,	,	,
cord-014712-5u4e00q6	650	14	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	650	15	Intensive	Intensive	NNP
cord-014712-5u4e00q6	650	16	Care	Care	NNP
cord-014712-5u4e00q6	650	17	Units	Units	NNPS
cord-014712-5u4e00q6	650	18	(	(	-LRB-
cord-014712-5u4e00q6	650	19	PICU	PICU	NNP
cord-014712-5u4e00q6	650	20	)	)	-RRB-
cord-014712-5u4e00q6	650	21	,	,	,
cord-014712-5u4e00q6	650	22	general	general	JJ
cord-014712-5u4e00q6	650	23	and	and	CC
cord-014712-5u4e00q6	650	24	specialized	specialized	JJ
cord-014712-5u4e00q6	650	25	inpatient	inpatient	JJ
cord-014712-5u4e00q6	650	26	wards	ward	NNS
cord-014712-5u4e00q6	650	27	]	]	-RRB-
cord-014712-5u4e00q6	650	28	over	over	IN
cord-014712-5u4e00q6	650	29	a	a	DT
cord-014712-5u4e00q6	650	30	time	time	NN
cord-014712-5u4e00q6	650	31	period	period	NN
cord-014712-5u4e00q6	650	32	of	of	IN
cord-014712-5u4e00q6	650	33	six	six	CD
cord-014712-5u4e00q6	650	34	months	month	NNS
cord-014712-5u4e00q6	650	35	,	,	,
cord-014712-5u4e00q6	650	36	from	from	IN
cord-014712-5u4e00q6	650	37	April	April	NNP
cord-014712-5u4e00q6	650	38	through	through	IN
cord-014712-5u4e00q6	650	39	September	September	NNP
cord-014712-5u4e00q6	650	40	,	,	,
cord-014712-5u4e00q6	650	41	2013	2013	CD
cord-014712-5u4e00q6	650	42	.	.	.
cord-014712-5u4e00q6	651	1	The	the	DT
cord-014712-5u4e00q6	651	2	study	study	NN
cord-014712-5u4e00q6	651	3	included	include	VBD
cord-014712-5u4e00q6	651	4	62	62	CD
cord-014712-5u4e00q6	651	5	transfusions	transfusion	NNS
cord-014712-5u4e00q6	651	6	for	for	IN
cord-014712-5u4e00q6	651	7	different	different	JJ
cord-014712-5u4e00q6	651	8	disease	disease	NN
cord-014712-5u4e00q6	651	9	conditions	condition	NNS
cord-014712-5u4e00q6	651	10	in	in	IN
cord-014712-5u4e00q6	651	11	55	55	CD
cord-014712-5u4e00q6	651	12	patients	patient	NNS
cord-014712-5u4e00q6	651	13	.	.	.
cord-014712-5u4e00q6	652	1	Three	three	CD
cord-014712-5u4e00q6	652	2	maltose	maltose	NN
cord-014712-5u4e00q6	652	3	-	-	HYPH
cord-014712-5u4e00q6	652	4	stabilized	stabilize	VBN
cord-014712-5u4e00q6	652	5	intravenous	intravenous	JJ
cord-014712-5u4e00q6	652	6	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	652	7	products	product	NNS
cord-014712-5u4e00q6	652	8	were	be	VBD
cord-014712-5u4e00q6	652	9	administered	administer	VBN
cord-014712-5u4e00q6	652	10	to	to	IN
cord-014712-5u4e00q6	652	11	patients	patient	NNS
cord-014712-5u4e00q6	652	12	.	.	.
cord-014712-5u4e00q6	653	1	Assessments	assessment	NNS
cord-014712-5u4e00q6	653	2	were	be	VBD
cord-014712-5u4e00q6	653	3	done	do	VBN
cord-014712-5u4e00q6	653	4	before	before	RB
cord-014712-5u4e00q6	653	5	,	,	,
cord-014712-5u4e00q6	653	6	during	during	IN
cord-014712-5u4e00q6	653	7	and	and	CC
cord-014712-5u4e00q6	653	8	after	after	IN
cord-014712-5u4e00q6	653	9	the	the	DT
cord-014712-5u4e00q6	653	10	infusions	infusion	NNS
cord-014712-5u4e00q6	653	11	.	.	.
cord-014712-5u4e00q6	654	1	Results	result	NNS
cord-014712-5u4e00q6	654	2	:	:	:
cord-014712-5u4e00q6	655	1	There	there	EX
cord-014712-5u4e00q6	655	2	were	be	VBD
cord-014712-5u4e00q6	655	3	22	22	CD
cord-014712-5u4e00q6	655	4	symptoms	symptom	NNS
cord-014712-5u4e00q6	655	5	and	and	CC
cord-014712-5u4e00q6	655	6	26	26	CD
cord-014712-5u4e00q6	655	7	laboratory	laboratory	NN
cord-014712-5u4e00q6	655	8	changes	change	NNS
cord-014712-5u4e00q6	655	9	of	of	IN
cord-014712-5u4e00q6	655	10	adverse	adverse	JJ
cord-014712-5u4e00q6	655	11	events	event	NNS
cord-014712-5u4e00q6	655	12	during	during	IN
cord-014712-5u4e00q6	655	13	IVIG	IVIG	NNP
cord-014712-5u4e00q6	655	14	transfusions	transfusion	NNS
cord-014712-5u4e00q6	655	15	,	,	,
cord-014712-5u4e00q6	655	16	with	with	IN
cord-014712-5u4e00q6	655	17	some	some	DT
cord-014712-5u4e00q6	655	18	patients	patient	NNS
cord-014712-5u4e00q6	655	19	experiencing	experience	VBG
cord-014712-5u4e00q6	655	20	more	more	JJR
cord-014712-5u4e00q6	655	21	than	than	IN
cord-014712-5u4e00q6	655	22	one	one	CD
cord-014712-5u4e00q6	655	23	adverse	adverse	JJ
cord-014712-5u4e00q6	655	24	reaction	reaction	NN
cord-014712-5u4e00q6	655	25	.	.	.
cord-014712-5u4e00q6	656	1	Adverse	adverse	JJ
cord-014712-5u4e00q6	656	2	events	event	NNS
cord-014712-5u4e00q6	656	3	were	be	VBD
cord-014712-5u4e00q6	656	4	noted	note	VBN
cord-014712-5u4e00q6	656	5	to	to	TO
cord-014712-5u4e00q6	656	6	occur	occur	VB
cord-014712-5u4e00q6	656	7	most	most	RBS
cord-014712-5u4e00q6	656	8	frequently	frequently	RB
cord-014712-5u4e00q6	656	9	within	within	IN
cord-014712-5u4e00q6	656	10	1	1	CD
cord-014712-5u4e00q6	656	11	to	to	IN
cord-014712-5u4e00q6	656	12	6	6	CD
cord-014712-5u4e00q6	656	13	h	h	NN
cord-014712-5u4e00q6	656	14	from	from	IN
cord-014712-5u4e00q6	656	15	onset	onset	NN
cord-014712-5u4e00q6	656	16	of	of	IN
cord-014712-5u4e00q6	656	17	IVIG	IVIG	NNP
cord-014712-5u4e00q6	656	18	infusion	infusion	NN
cord-014712-5u4e00q6	657	1	(	(	-LRB-
cord-014712-5u4e00q6	657	2	n	n	NN
cord-014712-5u4e00q6	657	3	=	=	SYM
cord-014712-5u4e00q6	657	4	9	9	CD
cord-014712-5u4e00q6	657	5	,	,	,
cord-014712-5u4e00q6	657	6	39.1	39.1	CD
cord-014712-5u4e00q6	657	7	%	%	NN
cord-014712-5u4e00q6	657	8	)	)	-RRB-
cord-014712-5u4e00q6	657	9	.	.	.
cord-014712-5u4e00q6	658	1	First	first	JJ
cord-014712-5u4e00q6	658	2	hour	hour	NN
cord-014712-5u4e00q6	658	3	after	after	IN
cord-014712-5u4e00q6	658	4	infusion	infusion	NN
cord-014712-5u4e00q6	658	5	onset	onset	NN
cord-014712-5u4e00q6	658	6	was	be	VBD
cord-014712-5u4e00q6	658	7	the	the	DT
cord-014712-5u4e00q6	658	8	most	most	RBS
cord-014712-5u4e00q6	658	9	common	common	JJ
cord-014712-5u4e00q6	658	10	timing	timing	NN
cord-014712-5u4e00q6	658	11	for	for	IN
cord-014712-5u4e00q6	658	12	symptoms	symptom	NNS
cord-014712-5u4e00q6	658	13	of	of	IN
cord-014712-5u4e00q6	658	14	adverse	adverse	JJ
cord-014712-5u4e00q6	658	15	reactions	reaction	NNS
cord-014712-5u4e00q6	658	16	(	(	-LRB-
cord-014712-5u4e00q6	658	17	n	n	NN
cord-014712-5u4e00q6	658	18	=	=	SYM
cord-014712-5u4e00q6	658	19	5	5	CD
cord-014712-5u4e00q6	658	20	,	,	,
cord-014712-5u4e00q6	658	21	21.7	21.7	CD
cord-014712-5u4e00q6	658	22	%	%	NN
cord-014712-5u4e00q6	658	23	)	)	-RRB-
cord-014712-5u4e00q6	658	24	.	.	.
cord-014712-5u4e00q6	659	1	Patient	patient	JJ
cord-014712-5u4e00q6	659	2	characteristics	characteristic	NNS
cord-014712-5u4e00q6	659	3	of	of	IN
cord-014712-5u4e00q6	659	4	those	those	DT
cord-014712-5u4e00q6	659	5	with	with	IN
cord-014712-5u4e00q6	659	6	adverse	adverse	JJ
cord-014712-5u4e00q6	659	7	reactions	reaction	NNS
cord-014712-5u4e00q6	659	8	:	:	:
cord-014712-5u4e00q6	659	9	Adverse	adverse	JJ
cord-014712-5u4e00q6	659	10	reactions	reaction	NNS
cord-014712-5u4e00q6	659	11	occurred	occur	VBD
cord-014712-5u4e00q6	659	12	in	in	IN
cord-014712-5u4e00q6	659	13	37.1	37.1	CD
cord-014712-5u4e00q6	659	14	%	%	NN
cord-014712-5u4e00q6	659	15	of	of	IN
cord-014712-5u4e00q6	659	16	the	the	DT
cord-014712-5u4e00q6	659	17	infusions	infusion	NNS
cord-014712-5u4e00q6	659	18	(	(	-LRB-
cord-014712-5u4e00q6	659	19	n	n	NN
cord-014712-5u4e00q6	659	20	=	=	SYM
cord-014712-5u4e00q6	659	21	23	23	CD
cord-014712-5u4e00q6	659	22	)	)	-RRB-
cord-014712-5u4e00q6	659	23	with	with	IN
cord-014712-5u4e00q6	659	24	the	the	DT
cord-014712-5u4e00q6	659	25	majority	majority	NN
cord-014712-5u4e00q6	659	26	belonging	belong	VBG
cord-014712-5u4e00q6	659	27	to	to	IN
cord-014712-5u4e00q6	659	28	the	the	DT
cord-014712-5u4e00q6	659	29	6	6	CD
cord-014712-5u4e00q6	659	30	-	-	SYM
cord-014712-5u4e00q6	659	31	9	9	CD
cord-014712-5u4e00q6	659	32	years	year	NNS
cord-014712-5u4e00q6	659	33	old	old	JJ
cord-014712-5u4e00q6	659	34	age	age	NN
cord-014712-5u4e00q6	659	35	group	group	NN
cord-014712-5u4e00q6	659	36	(	(	-LRB-
cord-014712-5u4e00q6	659	37	n	n	NN
cord-014712-5u4e00q6	659	38	=	=	SYM
cord-014712-5u4e00q6	659	39	10	10	CD
cord-014712-5u4e00q6	659	40	,	,	,
cord-014712-5u4e00q6	659	41	43.5	43.5	CD
cord-014712-5u4e00q6	659	42	%	%	NN
cord-014712-5u4e00q6	659	43	)	)	-RRB-
cord-014712-5u4e00q6	659	44	,	,	,
cord-014712-5u4e00q6	659	45	with	with	IN
cord-014712-5u4e00q6	659	46	variable	variable	JJ
cord-014712-5u4e00q6	659	47	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	659	48	categories	category	NNS
cord-014712-5u4e00q6	659	49	.	.	.
cord-014712-5u4e00q6	660	1	Ten	ten	CD
cord-014712-5u4e00q6	660	2	patients	patient	NNS
cord-014712-5u4e00q6	660	3	observed	observe	VBD
cord-014712-5u4e00q6	660	4	during	during	IN
cord-014712-5u4e00q6	660	5	14	14	CD
cord-014712-5u4e00q6	660	6	infusions	infusion	NNS
cord-014712-5u4e00q6	660	7	(	(	-LRB-
cord-014712-5u4e00q6	660	8	60.9	60.9	CD
cord-014712-5u4e00q6	660	9	%	%	NN
cord-014712-5u4e00q6	660	10	)	)	-RRB-
cord-014712-5u4e00q6	660	11	had	have	VBD
cord-014712-5u4e00q6	660	12	one	one	CD
cord-014712-5u4e00q6	660	13	or	or	CC
cord-014712-5u4e00q6	660	14	more	more	JJR
cord-014712-5u4e00q6	660	15	risk	risk	NN
cord-014712-5u4e00q6	660	16	factors	factor	NNS
cord-014712-5u4e00q6	660	17	for	for	IN
cord-014712-5u4e00q6	660	18	complications	complication	NNS
cord-014712-5u4e00q6	660	19	,	,	,
cord-014712-5u4e00q6	660	20	while	while	IN
cord-014712-5u4e00q6	660	21	6	6	CD
cord-014712-5u4e00q6	660	22	patients	patient	NNS
cord-014712-5u4e00q6	660	23	observed	observe	VBN
cord-014712-5u4e00q6	660	24	during	during	IN
cord-014712-5u4e00q6	660	25	9	9	CD
cord-014712-5u4e00q6	660	26	infusions	infusion	NNS
cord-014712-5u4e00q6	660	27	(	(	-LRB-
cord-014712-5u4e00q6	660	28	39.1	39.1	CD
cord-014712-5u4e00q6	660	29	%	%	NN
cord-014712-5u4e00q6	660	30	)	)	-RRB-
cord-014712-5u4e00q6	660	31	had	have	VBD
cord-014712-5u4e00q6	660	32	no	no	DT
cord-014712-5u4e00q6	660	33	risk	risk	NN
cord-014712-5u4e00q6	660	34	factors	factor	NNS
cord-014712-5u4e00q6	660	35	.	.	.
cord-014712-5u4e00q6	661	1	The	the	DT
cord-014712-5u4e00q6	661	2	commonest	common	JJS
cord-014712-5u4e00q6	661	3	risk	risk	NN
cord-014712-5u4e00q6	661	4	factor	factor	NN
cord-014712-5u4e00q6	661	5	was	be	VBD
cord-014712-5u4e00q6	661	6	administration	administration	NN
cord-014712-5u4e00q6	661	7	of	of	IN
cord-014712-5u4e00q6	661	8	nephrotoxic	nephrotoxic	NNP
cord-014712-5u4e00q6	661	9	drugs	drugs	NNPS
cord-014712-5u4e00q6	662	1	(	(	-LRB-
cord-014712-5u4e00q6	662	2	n	n	NN
cord-014712-5u4e00q6	662	3	=	=	SYM
cord-014712-5u4e00q6	662	4	8	8	CD
cord-014712-5u4e00q6	662	5	,	,	,
cord-014712-5u4e00q6	662	6	34.7	34.7	CD
cord-014712-5u4e00q6	662	7	%	%	NN
cord-014712-5u4e00q6	662	8	)	)	-RRB-
cord-014712-5u4e00q6	662	9	,	,	,
cord-014712-5u4e00q6	662	10	followed	follow	VBN
cord-014712-5u4e00q6	662	11	by	by	IN
cord-014712-5u4e00q6	662	12	presence	presence	NN
cord-014712-5u4e00q6	662	13	of	of	IN
cord-014712-5u4e00q6	662	14	a	a	DT
cord-014712-5u4e00q6	662	15	suspected	suspect	VBN
cord-014712-5u4e00q6	662	16	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	662	17	disorder	disorder	NN
cord-014712-5u4e00q6	662	18	(	(	-LRB-
cord-014712-5u4e00q6	662	19	n	n	NN
cord-014712-5u4e00q6	662	20	=	=	SYM
cord-014712-5u4e00q6	662	21	7	7	CD
cord-014712-5u4e00q6	662	22	,	,	,
cord-014712-5u4e00q6	662	23	30.4	30.4	CD
cord-014712-5u4e00q6	662	24	%	%	NN
cord-014712-5u4e00q6	662	25	)	)	-RRB-
cord-014712-5u4e00q6	662	26	and	and	CC
cord-014712-5u4e00q6	662	27	preexisting	preexisting	JJ
cord-014712-5u4e00q6	662	28	renal	renal	JJ
cord-014712-5u4e00q6	662	29	insufficiency	insufficiency	NN
cord-014712-5u4e00q6	663	1	(	(	-LRB-
cord-014712-5u4e00q6	663	2	n	n	NN
cord-014712-5u4e00q6	663	3	=	=	SYM
cord-014712-5u4e00q6	663	4	5	5	CD
cord-014712-5u4e00q6	663	5	,	,	,
cord-014712-5u4e00q6	663	6	21.7	21.7	CD
cord-014712-5u4e00q6	663	7	%	%	NN
cord-014712-5u4e00q6	663	8	)	)	-RRB-
cord-014712-5u4e00q6	663	9	.	.	.
cord-014712-5u4e00q6	664	1	Using	use	VBG
cord-014712-5u4e00q6	664	2	regression	regression	NN
cord-014712-5u4e00q6	664	3	analysis	analysis	NN
cord-014712-5u4e00q6	664	4	,	,	,
cord-014712-5u4e00q6	664	5	the	the	DT
cord-014712-5u4e00q6	664	6	predicting	predict	VBG
cord-014712-5u4e00q6	664	7	variables	variable	NNS
cord-014712-5u4e00q6	664	8	for	for	IN
cord-014712-5u4e00q6	664	9	each	each	DT
cord-014712-5u4e00q6	664	10	complication	complication	NN
cord-014712-5u4e00q6	664	11	were	be	VBD
cord-014712-5u4e00q6	664	12	noted	note	VBN
cord-014712-5u4e00q6	664	13	.For	.For	NFP
cord-014712-5u4e00q6	664	14	example	example	NN
cord-014712-5u4e00q6	664	15	,	,	,
cord-014712-5u4e00q6	664	16	fever	fever	NN
cord-014712-5u4e00q6	664	17	and	and	CC
cord-014712-5u4e00q6	664	18	chills	chill	NNS
cord-014712-5u4e00q6	664	19	were	be	VBD
cord-014712-5u4e00q6	664	20	related	relate	VBN
cord-014712-5u4e00q6	664	21	to	to	IN
cord-014712-5u4e00q6	664	22	infusion	infusion	NN
cord-014712-5u4e00q6	664	23	rate	rate	NN
cord-014712-5u4e00q6	664	24	and	and	CC
cord-014712-5u4e00q6	664	25	dose	dose	NN
cord-014712-5u4e00q6	664	26	whereas	whereas	IN
cord-014712-5u4e00q6	664	27	the	the	DT
cord-014712-5u4e00q6	664	28	predicting	predict	VBG
cord-014712-5u4e00q6	664	29	variables	variable	NNS
cord-014712-5u4e00q6	664	30	for	for	IN
cord-014712-5u4e00q6	664	31	pallor	pallor	NN
cord-014712-5u4e00q6	664	32	were	be	VBD
cord-014712-5u4e00q6	664	33	infusion	infusion	NN
cord-014712-5u4e00q6	664	34	rate	rate	NN
cord-014712-5u4e00q6	664	35	and	and	CC
cord-014712-5u4e00q6	664	36	presence	presence	NN
cord-014712-5u4e00q6	664	37	of	of	IN
cord-014712-5u4e00q6	664	38	existing	exist	VBG
cord-014712-5u4e00q6	664	39	risk	risk	NN
cord-014712-5u4e00q6	664	40	factors	factor	NNS
cord-014712-5u4e00q6	664	41	.	.	.
cord-014712-5u4e00q6	665	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	665	2	:	:	:
cord-014712-5u4e00q6	666	1	Clinicians	clinician	NNS
cord-014712-5u4e00q6	666	2	should	should	MD
cord-014712-5u4e00q6	666	3	be	be	VB
cord-014712-5u4e00q6	666	4	aware	aware	JJ
cord-014712-5u4e00q6	666	5	of	of	IN
cord-014712-5u4e00q6	666	6	the	the	DT
cord-014712-5u4e00q6	666	7	high	high	JJ
cord-014712-5u4e00q6	666	8	need	need	NN
cord-014712-5u4e00q6	666	9	for	for	IN
cord-014712-5u4e00q6	666	10	special	special	JJ
cord-014712-5u4e00q6	666	11	monitoring	monitoring	NN
cord-014712-5u4e00q6	666	12	while	while	IN
cord-014712-5u4e00q6	666	13	infusing	infuse	VBG
cord-014712-5u4e00q6	666	14	IVIG	IVIG	NNP
cord-014712-5u4e00q6	666	15	to	to	IN
cord-014712-5u4e00q6	666	16	patients	patient	NNS
cord-014712-5u4e00q6	666	17	with	with	IN
cord-014712-5u4e00q6	666	18	primary	primary	JJ
cord-014712-5u4e00q6	666	19	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	666	20	disorders	disorder	NNS
cord-014712-5u4e00q6	666	21	,	,	,
cord-014712-5u4e00q6	666	22	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	666	23	hematological	hematological	JJ
cord-014712-5u4e00q6	666	24	disorders	disorder	NNS
cord-014712-5u4e00q6	666	25	and	and	CC
cord-014712-5u4e00q6	666	26	sepsis	sepsis	NN
cord-014712-5u4e00q6	666	27	.	.	.
cord-014712-5u4e00q6	667	1	Certain	certain	JJ
cord-014712-5u4e00q6	667	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	667	3	of	of	IN
cord-014712-5u4e00q6	667	4	a	a	DT
cord-014712-5u4e00q6	667	5	Primary	primary	JJ
cord-014712-5u4e00q6	667	6	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	667	7	disorders	disorder	NNS
cord-014712-5u4e00q6	667	8	(	(	-LRB-
cord-014712-5u4e00q6	667	9	PID	PID	NNP
cord-014712-5u4e00q6	667	10	)	)	-RRB-
cord-014712-5u4e00q6	667	11	is	be	VBZ
cord-014712-5u4e00q6	667	12	most	most	RBS
cord-014712-5u4e00q6	667	13	confirmedly	confirmedly	RB
cord-014712-5u4e00q6	667	14	performed	perform	VBN
cord-014712-5u4e00q6	667	15	by	by	IN
cord-014712-5u4e00q6	667	16	investigation	investigation	NN
cord-014712-5u4e00q6	667	17	of	of	IN
cord-014712-5u4e00q6	667	18	a	a	DT
cord-014712-5u4e00q6	667	19	gene	gene	NN
cord-014712-5u4e00q6	667	20	defect	defect	NN
cord-014712-5u4e00q6	667	21	,	,	,
cord-014712-5u4e00q6	667	22	allowing	allow	VBG
cord-014712-5u4e00q6	667	23	genetic	genetic	JJ
cord-014712-5u4e00q6	667	24	counseling	counseling	NN
cord-014712-5u4e00q6	667	25	and	and	CC
cord-014712-5u4e00q6	667	26	screening	screening	NN
cord-014712-5u4e00q6	667	27	.	.	.
cord-014712-5u4e00q6	668	1	Molecular	molecular	JJ
cord-014712-5u4e00q6	668	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	668	3	helps	help	VBZ
cord-014712-5u4e00q6	668	4	both	both	DT
cord-014712-5u4e00q6	668	5	parents	parent	NNS
cord-014712-5u4e00q6	668	6	and	and	CC
cord-014712-5u4e00q6	668	7	index	index	NN
cord-014712-5u4e00q6	668	8	PID	pid	NN
cord-014712-5u4e00q6	668	9	patient	patient	NN
cord-014712-5u4e00q6	668	10	by	by	IN
cord-014712-5u4e00q6	668	11	carrier	carrier	NN
cord-014712-5u4e00q6	668	12	detection	detection	NN
cord-014712-5u4e00q6	668	13	and	and	CC
cord-014712-5u4e00q6	668	14	pre	pre	JJ
cord-014712-5u4e00q6	668	15	-	-	JJ
cord-014712-5u4e00q6	668	16	implantation	implantation	JJ
cord-014712-5u4e00q6	668	17	testing	testing	NN
cord-014712-5u4e00q6	668	18	for	for	IN
cord-014712-5u4e00q6	668	19	selecting	select	VBG
cord-014712-5u4e00q6	668	20	appropriate	appropriate	JJ
cord-014712-5u4e00q6	668	21	reproductive	reproductive	JJ
cord-014712-5u4e00q6	668	22	decisions	decision	NNS
cord-014712-5u4e00q6	668	23	.	.	.
cord-014712-5u4e00q6	669	1	Furthermore	furthermore	RB
cord-014712-5u4e00q6	669	2	,	,	,
cord-014712-5u4e00q6	669	3	for	for	IN
cord-014712-5u4e00q6	669	4	confirmation	confirmation	NN
cord-014712-5u4e00q6	669	5	of	of	IN
cord-014712-5u4e00q6	669	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	669	7	and	and	CC
cord-014712-5u4e00q6	669	8	establishment	establishment	NN
cord-014712-5u4e00q6	669	9	of	of	IN
cord-014712-5u4e00q6	669	10	the	the	DT
cord-014712-5u4e00q6	669	11	inheritance	inheritance	NN
cord-014712-5u4e00q6	669	12	pattern	pattern	NN
cord-014712-5u4e00q6	669	13	genetic	genetic	JJ
cord-014712-5u4e00q6	669	14	analysis	analysis	NN
cord-014712-5u4e00q6	669	15	is	be	VBZ
cord-014712-5u4e00q6	669	16	necessary	necessary	JJ
cord-014712-5u4e00q6	669	17	.	.	.
cord-014712-5u4e00q6	670	1	This	this	DT
cord-014712-5u4e00q6	670	2	survey	survey	NN
cord-014712-5u4e00q6	670	3	in	in	IN
cord-014712-5u4e00q6	670	4	all	all	DT
cord-014712-5u4e00q6	670	5	PID	PID	NNP
cord-014712-5u4e00q6	670	6	cohorts	cohort	NNS
cord-014712-5u4e00q6	670	7	should	should	MD
cord-014712-5u4e00q6	670	8	be	be	VB
cord-014712-5u4e00q6	670	9	considered	consider	VBN
cord-014712-5u4e00q6	670	10	for	for	IN
cord-014712-5u4e00q6	670	11	long	long	JJ
cord-014712-5u4e00q6	670	12	-	-	HYPH
cord-014712-5u4e00q6	670	13	term	term	NN
cord-014712-5u4e00q6	670	14	planning	planning	NN
cord-014712-5u4e00q6	670	15	such	such	JJ
cord-014712-5u4e00q6	670	16	as	as	IN
cord-014712-5u4e00q6	670	17	bone	bone	NN
cord-014712-5u4e00q6	670	18	marrow	marrow	NN
cord-014712-5u4e00q6	670	19	transplantation	transplantation	NN
cord-014712-5u4e00q6	670	20	of	of	IN
cord-014712-5u4e00q6	670	21	a	a	DT
cord-014712-5u4e00q6	670	22	PID	PID	NNP
cord-014712-5u4e00q6	670	23	infant	infant	NN
cord-014712-5u4e00q6	670	24	at	at	IN
cord-014712-5u4e00q6	670	25	birth	birth	NN
cord-014712-5u4e00q6	670	26	.	.	.
cord-014712-5u4e00q6	671	1	The	the	DT
cord-014712-5u4e00q6	671	2	result	result	NN
cord-014712-5u4e00q6	671	3	of	of	IN
cord-014712-5u4e00q6	671	4	this	this	DT
cord-014712-5u4e00q6	671	5	testing	testing	NN
cord-014712-5u4e00q6	671	6	also	also	RB
cord-014712-5u4e00q6	671	7	is	be	VBZ
cord-014712-5u4e00q6	671	8	important	important	JJ
cord-014712-5u4e00q6	671	9	for	for	IN
cord-014712-5u4e00q6	671	10	screening	screening	NN
cord-014712-5u4e00q6	671	11	of	of	IN
cord-014712-5u4e00q6	671	12	newborns	newborn	NNS
cord-014712-5u4e00q6	671	13	and	and	CC
cord-014712-5u4e00q6	671	14	for	for	IN
cord-014712-5u4e00q6	671	15	those	those	DT
cord-014712-5u4e00q6	671	16	in	in	IN
cord-014712-5u4e00q6	671	17	specific	specific	JJ
cord-014712-5u4e00q6	671	18	family	family	NN
cord-014712-5u4e00q6	671	19	or	or	CC
cord-014712-5u4e00q6	671	20	ethnic	ethnic	JJ
cord-014712-5u4e00q6	671	21	groups	group	NNS
cord-014712-5u4e00q6	671	22	.	.	.
cord-014712-5u4e00q6	672	1	The	the	DT
cord-014712-5u4e00q6	672	2	prevalence	prevalence	NN
cord-014712-5u4e00q6	672	3	of	of	IN
cord-014712-5u4e00q6	672	4	PIDs	pid	NNS
cord-014712-5u4e00q6	672	5	has	have	VBZ
cord-014712-5u4e00q6	672	6	been	be	VBN
cord-014712-5u4e00q6	672	7	estimated	estimate	VBN
cord-014712-5u4e00q6	672	8	to	to	TO
cord-014712-5u4e00q6	672	9	be	be	VB
cord-014712-5u4e00q6	672	10	more	more	JJR
cord-014712-5u4e00q6	672	11	than	than	IN
cord-014712-5u4e00q6	672	12	1/600	1/600	CD
cord-014712-5u4e00q6	672	13	worldwide	worldwide	RB
cord-014712-5u4e00q6	672	14	.	.	.
cord-014712-5u4e00q6	673	1	Based	base	VBN
cord-014712-5u4e00q6	673	2	on	on	IN
cord-014712-5u4e00q6	673	3	the	the	DT
cord-014712-5u4e00q6	673	4	total	total	JJ
cord-014712-5u4e00q6	673	5	population	population	NN
cord-014712-5u4e00q6	673	6	of	of	IN
cord-014712-5u4e00q6	673	7	Iran	Iran	NNP
cord-014712-5u4e00q6	673	8	reported	report	VBD
cord-014712-5u4e00q6	673	9	in	in	IN
cord-014712-5u4e00q6	673	10	2010	2010	CD
cord-014712-5u4e00q6	673	11	(	(	-LRB-
cord-014712-5u4e00q6	673	12	76,424,000	76,424,000	CD
cord-014712-5u4e00q6	673	13	)	)	-RRB-
cord-014712-5u4e00q6	673	14	,	,	,
cord-014712-5u4e00q6	673	15	the	the	DT
cord-014712-5u4e00q6	673	16	expected	expect	VBN
cord-014712-5u4e00q6	673	17	prevalence	prevalence	NN
cord-014712-5u4e00q6	673	18	of	of	IN
cord-014712-5u4e00q6	673	19	PIDs	pid	NNS
cord-014712-5u4e00q6	673	20	in	in	IN
cord-014712-5u4e00q6	673	21	Iran	Iran	NNP
cord-014712-5u4e00q6	673	22	would	would	MD
cord-014712-5u4e00q6	673	23	be	be	VB
cord-014712-5u4e00q6	673	24	more	more	JJR
cord-014712-5u4e00q6	673	25	than	than	IN
cord-014712-5u4e00q6	673	26	127,300	127,300	CD
cord-014712-5u4e00q6	673	27	individuals	individual	NNS
cord-014712-5u4e00q6	673	28	.	.	.
cord-014712-5u4e00q6	674	1	However	however	RB
cord-014712-5u4e00q6	674	2	,	,	,
cord-014712-5u4e00q6	674	3	because	because	IN
cord-014712-5u4e00q6	674	4	of	of	IN
cord-014712-5u4e00q6	674	5	the	the	DT
cord-014712-5u4e00q6	674	6	high	high	JJ
cord-014712-5u4e00q6	674	7	rate	rate	NN
cord-014712-5u4e00q6	674	8	of	of	IN
cord-014712-5u4e00q6	674	9	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	674	10	marriages	marriage	NNS
cord-014712-5u4e00q6	674	11	in	in	IN
cord-014712-5u4e00q6	674	12	Iran	Iran	NNP
cord-014712-5u4e00q6	674	13	and	and	CC
cord-014712-5u4e00q6	674	14	an	an	DT
cord-014712-5u4e00q6	674	15	increased	increase	VBN
cord-014712-5u4e00q6	674	16	risk	risk	NN
cord-014712-5u4e00q6	674	17	for	for	IN
cord-014712-5u4e00q6	674	18	development	development	NN
cord-014712-5u4e00q6	674	19	of	of	IN
cord-014712-5u4e00q6	674	20	disorders	disorder	NNS
cord-014712-5u4e00q6	674	21	with	with	IN
cord-014712-5u4e00q6	674	22	an	an	DT
cord-014712-5u4e00q6	674	23	autosomal	autosomal	JJ
cord-014712-5u4e00q6	674	24	recessive	recessive	JJ
cord-014712-5u4e00q6	674	25	pattern	pattern	NN
cord-014712-5u4e00q6	674	26	of	of	IN
cord-014712-5u4e00q6	674	27	inheritance	inheritance	NN
cord-014712-5u4e00q6	674	28	,	,	,
cord-014712-5u4e00q6	674	29	this	this	DT
cord-014712-5u4e00q6	674	30	prediction	prediction	NN
cord-014712-5u4e00q6	674	31	is	be	VBZ
cord-014712-5u4e00q6	674	32	likely	likely	JJ
cord-014712-5u4e00q6	674	33	to	to	TO
cord-014712-5u4e00q6	674	34	be	be	VB
cord-014712-5u4e00q6	674	35	an	an	DT
cord-014712-5u4e00q6	674	36	underestimation	underestimation	NN
cord-014712-5u4e00q6	674	37	.	.	.
cord-014712-5u4e00q6	675	1	To	to	IN
cord-014712-5u4e00q6	675	2	date	date	NN
cord-014712-5u4e00q6	675	3	,	,	,
cord-014712-5u4e00q6	675	4	2247	2247	CD
cord-014712-5u4e00q6	675	5	clinically	clinically	RB
cord-014712-5u4e00q6	675	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	675	7	patients	patient	NNS
cord-014712-5u4e00q6	675	8	of	of	IN
cord-014712-5u4e00q6	675	9	PIDs	pid	NNS
cord-014712-5u4e00q6	675	10	have	have	VBP
cord-014712-5u4e00q6	675	11	been	be	VBN
cord-014712-5u4e00q6	675	12	reported	report	VBN
cord-014712-5u4e00q6	675	13	in	in	IN
cord-014712-5u4e00q6	675	14	Iran	Iran	NNP
cord-014712-5u4e00q6	675	15	,	,	,
cord-014712-5u4e00q6	675	16	and	and	CC
cord-014712-5u4e00q6	675	17	a	a	DT
cord-014712-5u4e00q6	675	18	definite	definite	JJ
cord-014712-5u4e00q6	675	19	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	675	20	,	,	,
cord-014712-5u4e00q6	675	21	defined	define	VBN
cord-014712-5u4e00q6	675	22	by	by	IN
cord-014712-5u4e00q6	675	23	mutation	mutation	NN
cord-014712-5u4e00q6	675	24	analysis	analysis	NN
cord-014712-5u4e00q6	675	25	,	,	,
cord-014712-5u4e00q6	675	26	was	be	VBD
cord-014712-5u4e00q6	675	27	made	make	VBN
cord-014712-5u4e00q6	675	28	in	in	IN
cord-014712-5u4e00q6	675	29	790	790	CD
cord-014712-5u4e00q6	675	30	individuals	individual	NNS
cord-014712-5u4e00q6	675	31	.	.	.
cord-014712-5u4e00q6	676	1	As	as	IN
cord-014712-5u4e00q6	676	2	a	a	DT
cord-014712-5u4e00q6	676	3	result	result	NN
cord-014712-5u4e00q6	676	4	,	,	,
cord-014712-5u4e00q6	676	5	1.76	1.76	CD
cord-014712-5u4e00q6	676	6	%	%	NN
cord-014712-5u4e00q6	676	7	of	of	IN
cord-014712-5u4e00q6	676	8	the	the	DT
cord-014712-5u4e00q6	676	9	expected	expect	VBN
cord-014712-5u4e00q6	676	10	PID	PID	NNP
cord-014712-5u4e00q6	676	11	patients	patient	NNS
cord-014712-5u4e00q6	676	12	have	have	VBP
cord-014712-5u4e00q6	676	13	been	be	VBN
cord-014712-5u4e00q6	676	14	identified	identify	VBN
cord-014712-5u4e00q6	676	15	,	,	,
cord-014712-5u4e00q6	676	16	and	and	CC
cord-014712-5u4e00q6	676	17	among	among	IN
cord-014712-5u4e00q6	676	18	these	these	DT
cord-014712-5u4e00q6	676	19	,	,	,
cord-014712-5u4e00q6	676	20	35.2	35.2	CD
cord-014712-5u4e00q6	676	21	%	%	NN
cord-014712-5u4e00q6	676	22	have	have	VBP
cord-014712-5u4e00q6	676	23	been	be	VBN
cord-014712-5u4e00q6	676	24	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	676	25	at	at	IN
cord-014712-5u4e00q6	676	26	a	a	DT
cord-014712-5u4e00q6	676	27	molecular	molecular	JJ
cord-014712-5u4e00q6	676	28	level	level	NN
cord-014712-5u4e00q6	676	29	.	.	.
cord-014712-5u4e00q6	677	1	The	the	DT
cord-014712-5u4e00q6	677	2	proportion	proportion	NN
cord-014712-5u4e00q6	677	3	of	of	IN
cord-014712-5u4e00q6	677	4	genetically	genetically	RB
cord-014712-5u4e00q6	677	5	definite	definite	JJ
cord-014712-5u4e00q6	677	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	677	7	varied	varied	JJ
cord-014712-5u4e00q6	677	8	between	between	IN
cord-014712-5u4e00q6	677	9	84.5	84.5	CD
cord-014712-5u4e00q6	677	10	and	and	CC
cord-014712-5u4e00q6	677	11	0	0	CD
cord-014712-5u4e00q6	677	12	%	%	NN
cord-014712-5u4e00q6	677	13	in	in	IN
cord-014712-5u4e00q6	677	14	the	the	DT
cord-014712-5u4e00q6	677	15	different	different	JJ
cord-014712-5u4e00q6	677	16	disease	disease	NN
cord-014712-5u4e00q6	677	17	categories	category	NNS
cord-014712-5u4e00q6	677	18	.	.	.
cord-014712-5u4e00q6	678	1	This	this	DT
cord-014712-5u4e00q6	678	2	wide	wide	JJ
cord-014712-5u4e00q6	678	3	spectrum	spectrum	NN
cord-014712-5u4e00q6	678	4	might	may	MD
cord-014712-5u4e00q6	678	5	be	be	VB
cord-014712-5u4e00q6	678	6	due	due	JJ
cord-014712-5u4e00q6	678	7	to	to	IN
cord-014712-5u4e00q6	678	8	unknown	unknown	JJ
cord-014712-5u4e00q6	678	9	underlying	underlying	JJ
cord-014712-5u4e00q6	678	10	genetic	genetic	JJ
cord-014712-5u4e00q6	678	11	defects	defect	NNS
cord-014712-5u4e00q6	678	12	or	or	CC
cord-014712-5u4e00q6	678	13	modifying	modify	VBG
cord-014712-5u4e00q6	678	14	genes	gene	NNS
cord-014712-5u4e00q6	678	15	,	,	,
cord-014712-5u4e00q6	678	16	especially	especially	RB
cord-014712-5u4e00q6	678	17	in	in	IN
cord-014712-5u4e00q6	678	18	patients	patient	NNS
cord-014712-5u4e00q6	678	19	with	with	IN
cord-014712-5u4e00q6	678	20	predominantly	predominantly	RB
cord-014712-5u4e00q6	678	21	antibody	antibody	NN
cord-014712-5u4e00q6	678	22	deficiency	deficiency	NN
cord-014712-5u4e00q6	678	23	.	.	.
cord-014712-5u4e00q6	679	1	On	on	IN
cord-014712-5u4e00q6	679	2	the	the	DT
cord-014712-5u4e00q6	679	3	other	other	JJ
cord-014712-5u4e00q6	679	4	hand	hand	NN
cord-014712-5u4e00q6	679	5	,	,	,
cord-014712-5u4e00q6	679	6	the	the	DT
cord-014712-5u4e00q6	679	7	latter	latter	JJ
cord-014712-5u4e00q6	679	8	patients	patient	NNS
cord-014712-5u4e00q6	679	9	also	also	RB
cord-014712-5u4e00q6	679	10	had	have	VBD
cord-014712-5u4e00q6	679	11	the	the	DT
cord-014712-5u4e00q6	679	12	lowest	low	JJS
cord-014712-5u4e00q6	679	13	percentage	percentage	NN
cord-014712-5u4e00q6	679	14	of	of	IN
cord-014712-5u4e00q6	679	15	clinically	clinically	RB
cord-014712-5u4e00q6	679	16	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	679	17	cases	case	NNS
cord-014712-5u4e00q6	679	18	.	.	.
cord-014712-5u4e00q6	680	1	Croatia	Croatia	NNP
cord-014712-5u4e00q6	680	2	is	be	VBZ
cord-014712-5u4e00q6	680	3	a	a	DT
cord-014712-5u4e00q6	680	4	small	small	JJ
cord-014712-5u4e00q6	680	5	country	country	NN
cord-014712-5u4e00q6	680	6	with	with	IN
cord-014712-5u4e00q6	680	7	4	4	CD
cord-014712-5u4e00q6	680	8	267	267	CD
cord-014712-5u4e00q6	680	9	889	889	CD
cord-014712-5u4e00q6	680	10	inhabitants	inhabitant	NNS
cord-014712-5u4e00q6	680	11	.	.	.
cord-014712-5u4e00q6	681	1	According	accord	VBG
cord-014712-5u4e00q6	681	2	to	to	IN
cord-014712-5u4e00q6	681	3	expected	expect	VBN
cord-014712-5u4e00q6	681	4	prevalence	prevalence	NN
cord-014712-5u4e00q6	681	5	of	of	IN
cord-014712-5u4e00q6	681	6	PIDs	pid	NNS
cord-014712-5u4e00q6	681	7	we	-PRON-	PRP
cord-014712-5u4e00q6	681	8	expected	expect	VBD
cord-014712-5u4e00q6	681	9	approximately	approximately	RB
cord-014712-5u4e00q6	681	10	four	four	CD
cord-014712-5u4e00q6	681	11	hundred	hundred	CD
cord-014712-5u4e00q6	681	12	patients	patient	NNS
cord-014712-5u4e00q6	681	13	with	with	IN
cord-014712-5u4e00q6	681	14	PID	PID	NNP
cord-014712-5u4e00q6	681	15	.	.	.
cord-014712-5u4e00q6	682	1	For	for	IN
cord-014712-5u4e00q6	682	2	the	the	DT
cord-014712-5u4e00q6	682	3	past	past	JJ
cord-014712-5u4e00q6	682	4	few	few	JJ
cord-014712-5u4e00q6	682	5	years	year	NNS
cord-014712-5u4e00q6	682	6	University	University	NNP
cord-014712-5u4e00q6	682	7	Hospital	Hospital	NNP
cord-014712-5u4e00q6	682	8	Center	Center	NNP
cord-014712-5u4e00q6	682	9	Zagreb	Zagreb	NNP
cord-014712-5u4e00q6	682	10	is	be	VBZ
cord-014712-5u4e00q6	682	11	the	the	DT
cord-014712-5u4e00q6	682	12	reporting	reporting	NN
cord-014712-5u4e00q6	682	13	center	center	NN
cord-014712-5u4e00q6	682	14	for	for	IN
cord-014712-5u4e00q6	682	15	ESID	ESID	NNP
cord-014712-5u4e00q6	682	16	registry	registry	NN
cord-014712-5u4e00q6	682	17	.	.	.
cord-014712-5u4e00q6	683	1	It	-PRON-	PRP
cord-014712-5u4e00q6	683	2	is	be	VBZ
cord-014712-5u4e00q6	683	3	also	also	RB
cord-014712-5u4e00q6	683	4	the	the	DT
cord-014712-5u4e00q6	683	5	national	national	JJ
cord-014712-5u4e00q6	683	6	center	center	NN
cord-014712-5u4e00q6	683	7	for	for	IN
cord-014712-5u4e00q6	683	8	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	683	9	and	and	CC
cord-014712-5u4e00q6	683	10	treatment	treatment	NN
cord-014712-5u4e00q6	683	11	of	of	IN
cord-014712-5u4e00q6	683	12	PIDs	pid	NNS
cord-014712-5u4e00q6	683	13	,	,	,
cord-014712-5u4e00q6	683	14	including	include	VBG
cord-014712-5u4e00q6	683	15	haematopoietic	haematopoietic	JJ
cord-014712-5u4e00q6	683	16	stem	stem	NN
cord-014712-5u4e00q6	683	17	cell	cell	NN
cord-014712-5u4e00q6	683	18	transplantation	transplantation	NN
cord-014712-5u4e00q6	683	19	.	.	.
cord-014712-5u4e00q6	684	1	Current	current	JJ
cord-014712-5u4e00q6	684	2	PID	pid	NN
cord-014712-5u4e00q6	684	3	database	database	NN
cord-014712-5u4e00q6	684	4	is	be	VBZ
cord-014712-5u4e00q6	684	5	running	run	VBG
cord-014712-5u4e00q6	684	6	manually	manually	RB
cord-014712-5u4e00q6	684	7	,	,	,
cord-014712-5u4e00q6	684	8	with	with	IN
cord-014712-5u4e00q6	684	9	the	the	DT
cord-014712-5u4e00q6	684	10	exception	exception	NN
cord-014712-5u4e00q6	684	11	of	of	IN
cord-014712-5u4e00q6	684	12	patients	patient	NNS
cord-014712-5u4e00q6	684	13	reported	report	VBN
cord-014712-5u4e00q6	684	14	to	to	IN
cord-014712-5u4e00q6	684	15	ESID	ESID	NNP
cord-014712-5u4e00q6	684	16	registry	registry	NN
cord-014712-5u4e00q6	684	17	.	.	.
cord-014712-5u4e00q6	685	1	Most	Most	JJS
cord-014712-5u4e00q6	685	2	of	of	IN
cord-014712-5u4e00q6	685	3	them	-PRON-	PRP
cord-014712-5u4e00q6	685	4	are	be	VBP
cord-014712-5u4e00q6	685	5	of	of	IN
cord-014712-5u4e00q6	685	6	pediatric	pediatric	JJ
cord-014712-5u4e00q6	685	7	age	age	NN
cord-014712-5u4e00q6	685	8	,	,	,
cord-014712-5u4e00q6	685	9	reffered	reffere	VBN
cord-014712-5u4e00q6	685	10	to	to	IN
cord-014712-5u4e00q6	685	11	the	the	DT
cord-014712-5u4e00q6	685	12	hospital	hospital	NN
cord-014712-5u4e00q6	685	13	from	from	IN
cord-014712-5u4e00q6	685	14	all	all	RB
cord-014712-5u4e00q6	685	15	over	over	IN
cord-014712-5u4e00q6	685	16	the	the	DT
cord-014712-5u4e00q6	685	17	country	country	NN
cord-014712-5u4e00q6	685	18	.	.	.
cord-014712-5u4e00q6	686	1	The	the	DT
cord-014712-5u4e00q6	686	2	PIDs	pid	NNS
cord-014712-5u4e00q6	686	3	patients	patient	NNS
cord-014712-5u4e00q6	686	4	are	be	VBP
cord-014712-5u4e00q6	686	5	classified	classify	VBN
cord-014712-5u4e00q6	686	6	according	accord	VBG
cord-014712-5u4e00q6	686	7	to	to	IN
cord-014712-5u4e00q6	686	8	international	international	JJ
cord-014712-5u4e00q6	686	9	classification	classification	NN
cord-014712-5u4e00q6	686	10	(	(	-LRB-
cord-014712-5u4e00q6	686	11	IUIS	IUIS	NNP
cord-014712-5u4e00q6	686	12	-	-	HYPH
cord-014712-5u4e00q6	686	13	International	International	NNP
cord-014712-5u4e00q6	686	14	Union	Union	NNP
cord-014712-5u4e00q6	686	15	of	of	IN
cord-014712-5u4e00q6	686	16	Immunological	Immunological	NNP
cord-014712-5u4e00q6	686	17	Societies	Societies	NNPS
cord-014712-5u4e00q6	686	18	)	)	-RRB-
cord-014712-5u4e00q6	686	19	.	.	.
cord-014712-5u4e00q6	687	1	There	there	EX
cord-014712-5u4e00q6	687	2	are	be	VBP
cord-014712-5u4e00q6	687	3	121	121	CD
cord-014712-5u4e00q6	687	4	PIDs	pid	NNS
cord-014712-5u4e00q6	687	5	patients	patient	NNS
cord-014712-5u4e00q6	687	6	included	include	VBN
cord-014712-5u4e00q6	687	7	in	in	IN
cord-014712-5u4e00q6	687	8	the	the	DT
cord-014712-5u4e00q6	687	9	database	database	NN
cord-014712-5u4e00q6	687	10	at	at	IN
cord-014712-5u4e00q6	687	11	the	the	DT
cord-014712-5u4e00q6	687	12	moment	moment	NN
cord-014712-5u4e00q6	687	13	.	.	.
cord-014712-5u4e00q6	688	1	The	the	DT
cord-014712-5u4e00q6	688	2	majority	majority	NN
cord-014712-5u4e00q6	688	3	of	of	IN
cord-014712-5u4e00q6	688	4	them	-PRON-	PRP
cord-014712-5u4e00q6	688	5	have	have	VBP
cord-014712-5u4e00q6	688	6	antibody	antibody	NN
cord-014712-5u4e00q6	688	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	688	8	.	.	.
cord-014712-5u4e00q6	689	1	Combined	combine	VBN
cord-014712-5u4e00q6	689	2	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	689	3	and	and	CC
cord-014712-5u4e00q6	689	4	well	well	RB
cord-014712-5u4e00q6	689	5	defined	define	VBN
cord-014712-5u4e00q6	689	6	syndromes	syndrome	NNS
cord-014712-5u4e00q6	689	7	appear	appear	VBP
cord-014712-5u4e00q6	689	8	in	in	IN
cord-014712-5u4e00q6	689	9	equal	equal	JJ
cord-014712-5u4e00q6	689	10	distribution	distribution	NN
cord-014712-5u4e00q6	689	11	.	.	.
cord-014712-5u4e00q6	690	1	Other	other	JJ
cord-014712-5u4e00q6	690	2	types	type	NNS
cord-014712-5u4e00q6	690	3	of	of	IN
cord-014712-5u4e00q6	690	4	PIDs	pid	NNS
cord-014712-5u4e00q6	690	5	are	be	VBP
cord-014712-5u4e00q6	690	6	reported	report	VBN
cord-014712-5u4e00q6	690	7	in	in	IN
cord-014712-5u4e00q6	690	8	small	small	JJ
cord-014712-5u4e00q6	690	9	numbers	number	NNS
cord-014712-5u4e00q6	690	10	.	.	.
cord-014712-5u4e00q6	691	1	Although	although	IN
cord-014712-5u4e00q6	691	2	no	no	DT
cord-014712-5u4e00q6	691	3	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	691	4	was	be	VBD
cord-014712-5u4e00q6	691	5	reported	report	VBN
cord-014712-5u4e00q6	691	6	,	,	,
cord-014712-5u4e00q6	691	7	we	-PRON-	PRP
cord-014712-5u4e00q6	691	8	noticed	notice	VBD
cord-014712-5u4e00q6	691	9	the	the	DT
cord-014712-5u4e00q6	691	10	geografic	geografic	JJ
cord-014712-5u4e00q6	691	11	distribution	distribution	NN
cord-014712-5u4e00q6	691	12	of	of	IN
cord-014712-5u4e00q6	691	13	severe	severe	JJ
cord-014712-5u4e00q6	691	14	combined	combine	VBN
cord-014712-5u4e00q6	691	15	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	691	16	patients	patient	NNS
cord-014712-5u4e00q6	691	17	(	(	-LRB-
cord-014712-5u4e00q6	691	18	SCID	SCID	NNP
cord-014712-5u4e00q6	691	19	)	)	-RRB-
cord-014712-5u4e00q6	691	20	mostly	mostly	RB
cord-014712-5u4e00q6	691	21	in	in	IN
cord-014712-5u4e00q6	691	22	2	2	CD
cord-014712-5u4e00q6	691	23	regions	region	NNS
cord-014712-5u4e00q6	691	24	,	,	,
cord-014712-5u4e00q6	691	25	Istra	Istra	NNP
cord-014712-5u4e00q6	691	26	and	and	CC
cord-014712-5u4e00q6	691	27	Podravina	Podravina	NNP
cord-014712-5u4e00q6	691	28	.	.	.
cord-014712-5u4e00q6	692	1	It	-PRON-	PRP
cord-014712-5u4e00q6	692	2	can	can	MD
cord-014712-5u4e00q6	692	3	be	be	VB
cord-014712-5u4e00q6	692	4	explained	explain	VBN
cord-014712-5u4e00q6	692	5	with	with	IN
cord-014712-5u4e00q6	692	6	genetic	genetic	JJ
cord-014712-5u4e00q6	692	7	isolation	isolation	NN
cord-014712-5u4e00q6	692	8	.	.	.
cord-014712-5u4e00q6	693	1	The	the	DT
cord-014712-5u4e00q6	693	2	establishment	establishment	NN
cord-014712-5u4e00q6	693	3	of	of	IN
cord-014712-5u4e00q6	693	4	National	National	NNP
cord-014712-5u4e00q6	693	5	Online	Online	NNP
cord-014712-5u4e00q6	693	6	PID	PID	NNP
cord-014712-5u4e00q6	693	7	registry	registry	NN
cord-014712-5u4e00q6	693	8	is	be	VBZ
cord-014712-5u4e00q6	693	9	in	in	IN
cord-014712-5u4e00q6	693	10	process	process	NN
cord-014712-5u4e00q6	693	11	.	.	.
cord-014712-5u4e00q6	694	1	The	the	DT
cord-014712-5u4e00q6	694	2	aim	aim	NN
cord-014712-5u4e00q6	694	3	is	be	VBZ
cord-014712-5u4e00q6	694	4	to	to	TO
cord-014712-5u4e00q6	694	5	improve	improve	VB
cord-014712-5u4e00q6	694	6	the	the	DT
cord-014712-5u4e00q6	694	7	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	694	8	od	od	NN
cord-014712-5u4e00q6	694	9	PID	PID	NNP
cord-014712-5u4e00q6	694	10	specially	specially	RB
cord-014712-5u4e00q6	694	11	in	in	IN
cord-014712-5u4e00q6	694	12	adult	adult	NN
cord-014712-5u4e00q6	694	13	patients	patient	NNS
cord-014712-5u4e00q6	694	14	,	,	,
cord-014712-5u4e00q6	694	15	who	who	WP
cord-014712-5u4e00q6	694	16	are	be	VBP
cord-014712-5u4e00q6	694	17	not	not	RB
cord-014712-5u4e00q6	694	18	included	include	VBN
cord-014712-5u4e00q6	694	19	in	in	IN
cord-014712-5u4e00q6	694	20	present	present	JJ
cord-014712-5u4e00q6	694	21	database	database	NN
cord-014712-5u4e00q6	694	22	,	,	,
cord-014712-5u4e00q6	694	23	with	with	IN
cord-014712-5u4e00q6	694	24	exception	exception	NN
cord-014712-5u4e00q6	694	25	of	of	IN
cord-014712-5u4e00q6	694	26	the	the	DT
cord-014712-5u4e00q6	694	27	patients	patient	NNS
cord-014712-5u4e00q6	694	28	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	694	29	in	in	IN
cord-014712-5u4e00q6	694	30	childhood	childhood	NN
cord-014712-5u4e00q6	694	31	.	.	.
cord-014712-5u4e00q6	695	1	Primary	primary	JJ
cord-014712-5u4e00q6	695	2	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	695	3	disorders	disorder	NNS
cord-014712-5u4e00q6	695	4	are	be	VBP
cord-014712-5u4e00q6	695	5	underdiagnosed	underdiagnosed	JJ
cord-014712-5u4e00q6	695	6	in	in	IN
cord-014712-5u4e00q6	695	7	Croatia	Croatia	NNP
cord-014712-5u4e00q6	695	8	,	,	,
cord-014712-5u4e00q6	695	9	specially	specially	RB
cord-014712-5u4e00q6	695	10	in	in	IN
cord-014712-5u4e00q6	695	11	adults	adult	NNS
cord-014712-5u4e00q6	695	12	.	.	.
cord-014712-5u4e00q6	696	1	Establishing	establish	VBG
cord-014712-5u4e00q6	696	2	National	national	JJ
cord-014712-5u4e00q6	696	3	PID	PID	NNP
cord-014712-5u4e00q6	696	4	registry	registry	NN
cord-014712-5u4e00q6	696	5	will	will	MD
cord-014712-5u4e00q6	696	6	improve	improve	VB
cord-014712-5u4e00q6	696	7	the	the	DT
cord-014712-5u4e00q6	696	8	physicians	physician	NNS
cord-014712-5u4e00q6	696	9	awareness	awareness	NN
cord-014712-5u4e00q6	696	10	of	of	IN
cord-014712-5u4e00q6	696	11	PIDs	pid	NNS
cord-014712-5u4e00q6	696	12	,	,	,
cord-014712-5u4e00q6	696	13	which	which	WDT
cord-014712-5u4e00q6	696	14	is	be	VBZ
cord-014712-5u4e00q6	696	15	particularly	particularly	RB
cord-014712-5u4e00q6	696	16	important	important	JJ
cord-014712-5u4e00q6	696	17	for	for	IN
cord-014712-5u4e00q6	696	18	adult	adult	NN
cord-014712-5u4e00q6	696	19	patients	patient	NNS
cord-014712-5u4e00q6	696	20	.	.	.
cord-014712-5u4e00q6	697	1	We	-PRON-	PRP
cord-014712-5u4e00q6	697	2	expected	expect	VBD
cord-014712-5u4e00q6	697	3	the	the	DT
cord-014712-5u4e00q6	697	4	number	number	NN
cord-014712-5u4e00q6	697	5	of	of	IN
cord-014712-5u4e00q6	697	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	697	7	PID	PID	NNP
cord-014712-5u4e00q6	697	8	patients	patient	NNS
cord-014712-5u4e00q6	697	9	will	will	MD
cord-014712-5u4e00q6	697	10	rise	rise	VB
cord-014712-5u4e00q6	697	11	.	.	.
cord-014712-5u4e00q6	698	1	This	this	DT
cord-014712-5u4e00q6	698	2	will	will	MD
cord-014712-5u4e00q6	698	3	give	give	VB
cord-014712-5u4e00q6	698	4	the	the	DT
cord-014712-5u4e00q6	698	5	opportunity	opportunity	NN
cord-014712-5u4e00q6	698	6	to	to	TO
cord-014712-5u4e00q6	698	7	make	make	VB
cord-014712-5u4e00q6	698	8	progress	progress	NN
cord-014712-5u4e00q6	698	9	in	in	IN
cord-014712-5u4e00q6	698	10	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	698	11	and	and	CC
cord-014712-5u4e00q6	698	12	treatment	treatment	NN
cord-014712-5u4e00q6	698	13	,	,	,
cord-014712-5u4e00q6	698	14	and	and	CC
cord-014712-5u4e00q6	698	15	the	the	DT
cord-014712-5u4e00q6	698	16	opportunity	opportunity	NN
cord-014712-5u4e00q6	698	17	for	for	IN
cord-014712-5u4e00q6	698	18	further	further	JJ
cord-014712-5u4e00q6	698	19	epidemiological	epidemiological	JJ
cord-014712-5u4e00q6	698	20	and	and	CC
cord-014712-5u4e00q6	698	21	clinical	clinical	JJ
cord-014712-5u4e00q6	698	22	studies	study	NNS
cord-014712-5u4e00q6	698	23	.	.	.
cord-014712-5u4e00q6	699	1	Another	another	DT
cord-014712-5u4e00q6	699	2	25	25	CD
cord-014712-5u4e00q6	699	3	patients	patient	NNS
cord-014712-5u4e00q6	699	4	have	have	VBP
cord-014712-5u4e00q6	699	5	well	well	RB
cord-014712-5u4e00q6	699	6	defined	define	VBN
cord-014712-5u4e00q6	699	7	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	699	8	syndromes	syndrome	NNS
cord-014712-5u4e00q6	699	9	from	from	IN
cord-014712-5u4e00q6	699	10	which	which	WDT
cord-014712-5u4e00q6	699	11	:	:	:
cord-014712-5u4e00q6	699	12	11	11	CD
cord-014712-5u4e00q6	699	13	are	be	VBP
cord-014712-5u4e00q6	699	14	with	with	IN
cord-014712-5u4e00q6	699	15	Di	Di	NNP
cord-014712-5u4e00q6	699	16	George	George	NNP
cord-014712-5u4e00q6	699	17	anomaly	anomaly	NN
cord-014712-5u4e00q6	699	18	;	;	:
cord-014712-5u4e00q6	699	19	2	2	CD
cord-014712-5u4e00q6	699	20	with	with	IN
cord-014712-5u4e00q6	699	21	Wiskott	Wiskott	NNP
cord-014712-5u4e00q6	699	22	-	-	HYPH
cord-014712-5u4e00q6	699	23	Aldrich	Aldrich	NNP
cord-014712-5u4e00q6	699	24	syndrome	syndrome	NN
cord-014712-5u4e00q6	699	25	;	;	:
cord-014712-5u4e00q6	699	26	4	4	CD
cord-014712-5u4e00q6	699	27	with	with	IN
cord-014712-5u4e00q6	699	28	ataxia	ataxia	NN
cord-014712-5u4e00q6	699	29	-	-	HYPH
cord-014712-5u4e00q6	699	30	teleangiectasia	teleangiectasia	NN
cord-014712-5u4e00q6	699	31	;	;	:
cord-014712-5u4e00q6	699	32	4	4	CD
cord-014712-5u4e00q6	699	33	with	with	IN
cord-014712-5u4e00q6	699	34	Hyper	Hyper	NNP
cord-014712-5u4e00q6	699	35	IgE	IgE	NNP
cord-014712-5u4e00q6	699	36	Syndrome	Syndrome	NNP
cord-014712-5u4e00q6	699	37	;	;	:
cord-014712-5u4e00q6	699	38	1	1	CD
cord-014712-5u4e00q6	699	39	with	with	IN
cord-014712-5u4e00q6	699	40	Schimke	Schimke	NNP
cord-014712-5u4e00q6	699	41	Syndrome	Syndrome	NNP
cord-014712-5u4e00q6	699	42	and	and	CC
cord-014712-5u4e00q6	699	43	3	3	CD
cord-014712-5u4e00q6	699	44	are	be	VBP
cord-014712-5u4e00q6	699	45	with	with	IN
cord-014712-5u4e00q6	699	46	Nijmegen	Nijmegen	NNP
cord-014712-5u4e00q6	699	47	Breakage	Breakage	NNP
cord-014712-5u4e00q6	699	48	Syndrome	Syndrome	NNP
cord-014712-5u4e00q6	699	49	.	.	.
cord-014712-5u4e00q6	700	1	In	in	IN
cord-014712-5u4e00q6	700	2	early	early	JJ
cord-014712-5u4e00q6	700	3	nineties	ninety	NNS
cord-014712-5u4e00q6	700	4	,	,	,
cord-014712-5u4e00q6	700	5	two	two	CD
cord-014712-5u4e00q6	700	6	(	(	-LRB-
cord-014712-5u4e00q6	700	7	2	2	CD
cord-014712-5u4e00q6	700	8	)	)	-RRB-
cord-014712-5u4e00q6	700	9	of	of	IN
cord-014712-5u4e00q6	700	10	our	-PRON-	PRP$
cord-014712-5u4e00q6	700	11	patients	patient	NNS
cord-014712-5u4e00q6	700	12	had	have	VBD
cord-014712-5u4e00q6	700	13	chronic	chronic	JJ
cord-014712-5u4e00q6	700	14	mucocutaneus	mucocutaneus	NN
cord-014712-5u4e00q6	700	15	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	700	16	.	.	.
cord-014712-5u4e00q6	701	1	3	3	CD
cord-014712-5u4e00q6	701	2	patients	patient	NNS
cord-014712-5u4e00q6	701	3	are	be	VBP
cord-014712-5u4e00q6	701	4	registered	register	VBN
cord-014712-5u4e00q6	701	5	as	as	IN
cord-014712-5u4e00q6	701	6	X	X	NNS
cord-014712-5u4e00q6	701	7	-	-	HYPH
cord-014712-5u4e00q6	701	8	linked	link	VBN
cord-014712-5u4e00q6	701	9	SCID	SCID	NNP
cord-014712-5u4e00q6	701	10	and	and	CC
cord-014712-5u4e00q6	701	11	1	1	CD
cord-014712-5u4e00q6	701	12	with	with	IN
cord-014712-5u4e00q6	701	13	Xlinked	Xlinked	NNP
cord-014712-5u4e00q6	701	14	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	701	15	syndrome	syndrome	NN
cord-014712-5u4e00q6	701	16	(	(	-LRB-
cord-014712-5u4e00q6	701	17	XLP	XLP	NNP
cord-014712-5u4e00q6	701	18	)	)	-RRB-
cord-014712-5u4e00q6	701	19	.	.	.
cord-014712-5u4e00q6	702	1	1	1	CD
cord-014712-5u4e00q6	702	2	patient	patient	NN
cord-014712-5u4e00q6	702	3	has	have	VBZ
cord-014712-5u4e00q6	702	4	chronic	chronic	JJ
cord-014712-5u4e00q6	702	5	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	702	6	disease	disease	NN
cord-014712-5u4e00q6	702	7	;	;	:
cord-014712-5u4e00q6	702	8	3	3	CD
cord-014712-5u4e00q6	702	9	have	have	VBP
cord-014712-5u4e00q6	702	10	severe	severe	JJ
cord-014712-5u4e00q6	702	11	congenital	congenital	JJ
cord-014712-5u4e00q6	702	12	neutropenia	neutropenia	NN
cord-014712-5u4e00q6	702	13	and	and	CC
cord-014712-5u4e00q6	702	14	5	5	CD
cord-014712-5u4e00q6	702	15	have	have	VBP
cord-014712-5u4e00q6	702	16	hereditary	hereditary	JJ
cord-014712-5u4e00q6	702	17	angioedema	angioedema	NN
cord-014712-5u4e00q6	702	18	.	.	.
cord-014712-5u4e00q6	703	1	2	2	CD
cord-014712-5u4e00q6	703	2	patients	patient	NNS
cord-014712-5u4e00q6	703	3	are	be	VBP
cord-014712-5u4e00q6	703	4	with	with	IN
cord-014712-5u4e00q6	703	5	WHIM	WHIM	NNP
cord-014712-5u4e00q6	703	6	Syndrome	Syndrome	NNP
cord-014712-5u4e00q6	703	7	.	.	.
cord-014712-5u4e00q6	704	1	6	6	CD
cord-014712-5u4e00q6	704	2	patients	patient	NNS
cord-014712-5u4e00q6	704	3	are	be	VBP
cord-014712-5u4e00q6	704	4	with	with	IN
cord-014712-5u4e00q6	704	5	anti	anti	JJ
cord-014712-5u4e00q6	704	6	-	-	JJ
cord-014712-5u4e00q6	704	7	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	704	8	disorders	disorder	NNS
cord-014712-5u4e00q6	704	9	:	:	:
cord-014712-5u4e00q6	704	10	1	1	CD
cord-014712-5u4e00q6	704	11	has	have	VBZ
cord-014712-5u4e00q6	704	12	Hyper	hyper	JJ
cord-014712-5u4e00q6	704	13	Ig	Ig	NNP
cord-014712-5u4e00q6	704	14	D	D	NNP
cord-014712-5u4e00q6	704	15	Syndrome	syndrome	NN
cord-014712-5u4e00q6	704	16	(	(	-LRB-
cord-014712-5u4e00q6	704	17	HIDS	HIDS	NNP
cord-014712-5u4e00q6	704	18	)	)	-RRB-
cord-014712-5u4e00q6	704	19	and	and	CC
cord-014712-5u4e00q6	704	20	5	5	CD
cord-014712-5u4e00q6	704	21	have	have	VBP
cord-014712-5u4e00q6	704	22	Familial	familial	JJ
cord-014712-5u4e00q6	704	23	Mediterranean	Mediterranean	NNP
cord-014712-5u4e00q6	704	24	Fever	Fever	NNP
cord-014712-5u4e00q6	704	25	.	.	.
cord-014712-5u4e00q6	705	1	The	the	DT
cord-014712-5u4e00q6	705	2	J	J	NNP
cord-014712-5u4e00q6	705	3	-	-	HYPH
cord-014712-5u4e00q6	705	4	project	project	NN
cord-014712-5u4e00q6	705	5	realization	realization	NN
cord-014712-5u4e00q6	705	6	in	in	IN
cord-014712-5u4e00q6	705	7	the	the	DT
cord-014712-5u4e00q6	705	8	Republic	Republic	NNP
cord-014712-5u4e00q6	705	9	of	of	IN
cord-014712-5u4e00q6	705	10	Kazakhstan	Kazakhstan	NNP
cord-014712-5u4e00q6	705	11	allows	allow	VBZ
cord-014712-5u4e00q6	705	12	to	to	TO
cord-014712-5u4e00q6	705	13	update	update	VB
cord-014712-5u4e00q6	705	14	the	the	DT
cord-014712-5u4e00q6	705	15	PID	PID	NNP
cord-014712-5u4e00q6	705	16	problem	problem	NN
cord-014712-5u4e00q6	705	17	,	,	,
cord-014712-5u4e00q6	705	18	to	to	TO
cord-014712-5u4e00q6	705	19	raise	raise	VB
cord-014712-5u4e00q6	705	20	the	the	DT
cord-014712-5u4e00q6	705	21	availability	availability	NN
cord-014712-5u4e00q6	705	22	of	of	IN
cord-014712-5u4e00q6	705	23	early	early	JJ
cord-014712-5u4e00q6	705	24	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	705	25	of	of	IN
cord-014712-5u4e00q6	705	26	PID	PID	NNP
cord-014712-5u4e00q6	705	27	,	,	,
cord-014712-5u4e00q6	705	28	to	to	TO
cord-014712-5u4e00q6	705	29	improve	improve	VB
cord-014712-5u4e00q6	705	30	the	the	DT
cord-014712-5u4e00q6	705	31	life	life	NN
cord-014712-5u4e00q6	705	32	quality	quality	NN
cord-014712-5u4e00q6	705	33	of	of	IN
cord-014712-5u4e00q6	705	34	patients	patient	NNS
cord-014712-5u4e00q6	705	35	with	with	IN
cord-014712-5u4e00q6	705	36	PID	PID	NNP
cord-014712-5u4e00q6	705	37	by	by	IN
cord-014712-5u4e00q6	705	38	providing	provide	VBG
cord-014712-5u4e00q6	705	39	substitution	substitution	NN
cord-014712-5u4e00q6	705	40	therapy	therapy	NN
cord-014712-5u4e00q6	705	41	and	and	CC
cord-014712-5u4e00q6	705	42	as	as	IN
cord-014712-5u4e00q6	705	43	a	a	DT
cord-014712-5u4e00q6	705	44	result	result	NN
cord-014712-5u4e00q6	705	45	,	,	,
cord-014712-5u4e00q6	705	46	the	the	DT
cord-014712-5u4e00q6	705	47	infant	infant	NN
cord-014712-5u4e00q6	705	48	mortality	mortality	NN
cord-014712-5u4e00q6	705	49	and	and	CC
cord-014712-5u4e00q6	705	50	disability	disability	NN
cord-014712-5u4e00q6	705	51	rate	rate	NN
cord-014712-5u4e00q6	705	52	has	have	VBZ
cord-014712-5u4e00q6	705	53	been	be	VBN
cord-014712-5u4e00q6	705	54	reduced	reduce	VBN
cord-014712-5u4e00q6	705	55	.	.	.
cord-014712-5u4e00q6	706	1	Common	common	JJ
cord-014712-5u4e00q6	706	2	variable	variable	JJ
cord-014712-5u4e00q6	706	3	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	706	4	(	(	-LRB-
cord-014712-5u4e00q6	706	5	CVID	CVID	NNP
cord-014712-5u4e00q6	706	6	)	)	-RRB-
cord-014712-5u4e00q6	706	7	is	be	VBZ
cord-014712-5u4e00q6	706	8	the	the	DT
cord-014712-5u4e00q6	706	9	most	most	RBS
cord-014712-5u4e00q6	706	10	common	common	JJ
cord-014712-5u4e00q6	706	11	primary	primary	JJ
cord-014712-5u4e00q6	706	12	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	706	13	(	(	-LRB-
cord-014712-5u4e00q6	706	14	PID	PID	NNP
cord-014712-5u4e00q6	706	15	)	)	-RRB-
cord-014712-5u4e00q6	706	16	characterised	characterise	VBN
cord-014712-5u4e00q6	706	17	by	by	IN
cord-014712-5u4e00q6	706	18	impaired	impair	VBN
cord-014712-5u4e00q6	706	19	immunglobulin	immunglobulin	NN
cord-014712-5u4e00q6	706	20	production	production	NN
cord-014712-5u4e00q6	706	21	and	and	CC
cord-014712-5u4e00q6	706	22	immune	immune	JJ
cord-014712-5u4e00q6	706	23	dysregulation	dysregulation	NN
cord-014712-5u4e00q6	706	24	.	.	.
cord-014712-5u4e00q6	707	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	707	2	and	and	CC
cord-014712-5u4e00q6	707	3	recurrent	recurrent	JJ
cord-014712-5u4e00q6	707	4	infections	infection	NNS
cord-014712-5u4e00q6	707	5	and	and	CC
cord-014712-5u4e00q6	707	6	its	-PRON-	PRP$
cord-014712-5u4e00q6	707	7	results	result	NNS
cord-014712-5u4e00q6	707	8	are	be	VBP
cord-014712-5u4e00q6	707	9	typical	typical	JJ
cord-014712-5u4e00q6	707	10	manifestation	manifestation	NN
cord-014712-5u4e00q6	707	11	of	of	IN
cord-014712-5u4e00q6	707	12	this	this	DT
cord-014712-5u4e00q6	707	13	disease	disease	NN
cord-014712-5u4e00q6	707	14	.	.	.
cord-014712-5u4e00q6	708	1	In	in	IN
cord-014712-5u4e00q6	708	2	addition	addition	NN
cord-014712-5u4e00q6	708	3	there	there	EX
cord-014712-5u4e00q6	708	4	is	be	VBZ
cord-014712-5u4e00q6	708	5	a	a	DT
cord-014712-5u4e00q6	708	6	higher	high	JJR
cord-014712-5u4e00q6	708	7	risk	risk	NN
cord-014712-5u4e00q6	708	8	of	of	IN
cord-014712-5u4e00q6	708	9	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	708	10	disorders	disorder	NNS
cord-014712-5u4e00q6	708	11	,	,	,
cord-014712-5u4e00q6	708	12	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	708	13	or	or	CC
cord-014712-5u4e00q6	708	14	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	708	15	diseases	disease	NNS
cord-014712-5u4e00q6	708	16	and	and	CC
cord-014712-5u4e00q6	708	17	malignancies	malignancy	NNS
cord-014712-5u4e00q6	708	18	.	.	.
cord-014712-5u4e00q6	709	1	Successful	successful	JJ
cord-014712-5u4e00q6	709	2	management	management	NN
cord-014712-5u4e00q6	709	3	of	of	IN
cord-014712-5u4e00q6	709	4	CVID	CVID	NNP
cord-014712-5u4e00q6	709	5	patients	patient	NNS
cord-014712-5u4e00q6	709	6	is	be	VBZ
cord-014712-5u4e00q6	709	7	based	base	VBN
cord-014712-5u4e00q6	709	8	on	on	IN
cord-014712-5u4e00q6	709	9	prevention	prevention	NN
cord-014712-5u4e00q6	709	10	and	and	CC
cord-014712-5u4e00q6	709	11	consistent	consistent	JJ
cord-014712-5u4e00q6	709	12	therapy	therapy	NN
cord-014712-5u4e00q6	709	13	of	of	IN
cord-014712-5u4e00q6	709	14	infections	infection	NNS
cord-014712-5u4e00q6	709	15	with	with	IN
cord-014712-5u4e00q6	709	16	sufficient	sufficient	JJ
cord-014712-5u4e00q6	709	17	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	709	18	replacement	replacement	NN
cord-014712-5u4e00q6	709	19	and/or	and/or	CC
cord-014712-5u4e00q6	709	20	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	709	21	,	,	,
cord-014712-5u4e00q6	709	22	prevention	prevention	NN
cord-014712-5u4e00q6	709	23	and	and	CC
cord-014712-5u4e00q6	709	24	active	active	JJ
cord-014712-5u4e00q6	709	25	screening	screening	NN
cord-014712-5u4e00q6	709	26	of	of	IN
cord-014712-5u4e00q6	709	27	CVID	CVID	NNP
cord-014712-5u4e00q6	709	28	related	relate	VBN
cord-014712-5u4e00q6	709	29	complications	complication	NNS
cord-014712-5u4e00q6	709	30	.	.	.
cord-014712-5u4e00q6	710	1	In	in	IN
cord-014712-5u4e00q6	710	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	710	3	study	study	NN
cord-014712-5u4e00q6	710	4	we	-PRON-	PRP
cord-014712-5u4e00q6	710	5	analysed	analyse	VBD
cord-014712-5u4e00q6	710	6	data	datum	NNS
cord-014712-5u4e00q6	710	7	of	of	IN
cord-014712-5u4e00q6	710	8	41	41	CD
cord-014712-5u4e00q6	710	9	patients	patient	NNS
cord-014712-5u4e00q6	710	10	gained	gain	VBN
cord-014712-5u4e00q6	710	11	from	from	IN
cord-014712-5u4e00q6	710	12	medical	medical	JJ
cord-014712-5u4e00q6	710	13	records	record	NNS
cord-014712-5u4e00q6	710	14	.	.	.
cord-014712-5u4e00q6	711	1	These	these	DT
cord-014712-5u4e00q6	711	2	data	datum	NNS
cord-014712-5u4e00q6	711	3	were	be	VBD
cord-014712-5u4e00q6	711	4	also	also	RB
cord-014712-5u4e00q6	711	5	input	input	NN
cord-014712-5u4e00q6	711	6	into	into	IN
cord-014712-5u4e00q6	711	7	Czech	czech	JJ
cord-014712-5u4e00q6	711	8	PID	PID	NNP
cord-014712-5u4e00q6	711	9	Registry	Registry	NNP
cord-014712-5u4e00q6	711	10	and	and	CC
cord-014712-5u4e00q6	711	11	PID	PID	NNP
cord-014712-5u4e00q6	711	12	Registry	Registry	NNP
cord-014712-5u4e00q6	711	13	organized	organize	VBN
cord-014712-5u4e00q6	711	14	by	by	IN
cord-014712-5u4e00q6	711	15	ESID	ESID	NNP
cord-014712-5u4e00q6	711	16	(	(	-LRB-
cord-014712-5u4e00q6	711	17	European	European	NNP
cord-014712-5u4e00q6	711	18	Organisation	Organisation	NNP
cord-014712-5u4e00q6	711	19	for	for	IN
cord-014712-5u4e00q6	711	20	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	711	21	)	)	-RRB-
cord-014712-5u4e00q6	711	22	.	.	.
cord-014712-5u4e00q6	712	1	We	-PRON-	PRP
cord-014712-5u4e00q6	712	2	aimed	aim	VBD
cord-014712-5u4e00q6	712	3	at	at	IN
cord-014712-5u4e00q6	712	4	the	the	DT
cord-014712-5u4e00q6	712	5	period	period	NN
cord-014712-5u4e00q6	712	6	before	before	IN
cord-014712-5u4e00q6	712	7	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	712	8	-	-	HYPH
cord-014712-5u4e00q6	712	9	onset	onset	NN
cord-014712-5u4e00q6	712	10	of	of	IN
cord-014712-5u4e00q6	712	11	the	the	DT
cord-014712-5u4e00q6	712	12	symptoms	symptom	NNS
cord-014712-5u4e00q6	712	13	and	and	CC
cord-014712-5u4e00q6	712	14	their	-PRON-	PRP$
cord-014712-5u4e00q6	712	15	characters	character	NNS
cord-014712-5u4e00q6	712	16	and	and	CC
cord-014712-5u4e00q6	712	17	the	the	DT
cord-014712-5u4e00q6	712	18	course	course	NN
cord-014712-5u4e00q6	712	19	of	of	IN
cord-014712-5u4e00q6	712	20	the	the	DT
cord-014712-5u4e00q6	712	21	disease	disease	NN
cord-014712-5u4e00q6	712	22	-	-	HYPH
cord-014712-5u4e00q6	712	23	effect	effect	NN
cord-014712-5u4e00q6	712	24	of	of	IN
cord-014712-5u4e00q6	712	25	therapy	therapy	NN
cord-014712-5u4e00q6	712	26	,	,	,
cord-014712-5u4e00q6	712	27	occurence	occurence	NN
cord-014712-5u4e00q6	712	28	of	of	IN
cord-014712-5u4e00q6	712	29	the	the	DT
cord-014712-5u4e00q6	712	30	related	related	JJ
cord-014712-5u4e00q6	712	31	complications	complication	NNS
cord-014712-5u4e00q6	712	32	.	.	.
cord-014712-5u4e00q6	713	1	Finally	finally	RB
cord-014712-5u4e00q6	713	2	,	,	,
cord-014712-5u4e00q6	713	3	we	-PRON-	PRP
cord-014712-5u4e00q6	713	4	compared	compare	VBD
cord-014712-5u4e00q6	713	5	our	-PRON-	PRP$
cord-014712-5u4e00q6	713	6	data	datum	NNS
cord-014712-5u4e00q6	713	7	with	with	IN
cord-014712-5u4e00q6	713	8	similar	similar	JJ
cord-014712-5u4e00q6	713	9	performed	perform	VBN
cord-014712-5u4e00q6	713	10	studies	study	NNS
cord-014712-5u4e00q6	713	11	.	.	.
cord-014712-5u4e00q6	714	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	714	2	and	and	CC
cord-014712-5u4e00q6	714	3	recurrent	recurrent	JJ
cord-014712-5u4e00q6	714	4	upper	upper	JJ
cord-014712-5u4e00q6	714	5	and	and	CC
cord-014712-5u4e00q6	714	6	lower	low	JJR
cord-014712-5u4e00q6	714	7	respiratory	respiratory	JJ
cord-014712-5u4e00q6	714	8	infections	infection	NNS
cord-014712-5u4e00q6	714	9	were	be	VBD
cord-014712-5u4e00q6	714	10	the	the	DT
cord-014712-5u4e00q6	714	11	most	most	RBS
cord-014712-5u4e00q6	714	12	frequent	frequent	JJ
cord-014712-5u4e00q6	714	13	first	first	JJ
cord-014712-5u4e00q6	714	14	manifestation	manifestation	NN
cord-014712-5u4e00q6	714	15	of	of	IN
cord-014712-5u4e00q6	714	16	our	-PRON-	PRP$
cord-014712-5u4e00q6	714	17	CVID	CVID	NNP
cord-014712-5u4e00q6	714	18	patients	patient	NNS
cord-014712-5u4e00q6	714	19	,	,	,
cord-014712-5u4e00q6	714	20	but	but	CC
cord-014712-5u4e00q6	714	21	developed	develop	VBD
cord-014712-5u4e00q6	714	22	chronic	chronic	JJ
cord-014712-5u4e00q6	714	23	lung	lung	NN
cord-014712-5u4e00q6	714	24	disease	disease	NN
cord-014712-5u4e00q6	714	25	or	or	CC
cord-014712-5u4e00q6	714	26	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	714	27	disorder	disorder	NN
cord-014712-5u4e00q6	714	28	as	as	RB
cord-014712-5u4e00q6	714	29	well	well	RB
cord-014712-5u4e00q6	714	30	.	.	.
cord-014712-5u4e00q6	715	1	In	in	IN
cord-014712-5u4e00q6	715	2	all	all	DT
cord-014712-5u4e00q6	715	3	patients	patient	NNS
cord-014712-5u4e00q6	715	4	the	the	DT
cord-014712-5u4e00q6	715	5	intravenous	intravenous	JJ
cord-014712-5u4e00q6	715	6	or	or	CC
cord-014712-5u4e00q6	715	7	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	715	8	imunoglobulin	imunoglobulin	NNP
cord-014712-5u4e00q6	715	9	replacement	replacement	NN
cord-014712-5u4e00q6	715	10	therapy	therapy	NN
cord-014712-5u4e00q6	715	11	,	,	,
cord-014712-5u4e00q6	715	12	eventually	eventually	RB
cord-014712-5u4e00q6	715	13	combined	combine	VBN
cord-014712-5u4e00q6	715	14	therapy	therapy	NN
cord-014712-5u4e00q6	715	15	with	with	IN
cord-014712-5u4e00q6	715	16	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	715	17	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	715	18	,	,	,
cord-014712-5u4e00q6	715	19	was	be	VBD
cord-014712-5u4e00q6	715	20	initiated	initiate	VBN
cord-014712-5u4e00q6	715	21	.	.	.
cord-014712-5u4e00q6	716	1	Beside	beside	IN
cord-014712-5u4e00q6	716	2	chronic	chronic	JJ
cord-014712-5u4e00q6	716	3	lung	lung	NN
cord-014712-5u4e00q6	716	4	disease	disease	NN
cord-014712-5u4e00q6	716	5	the	the	DT
cord-014712-5u4e00q6	716	6	most	most	RBS
cord-014712-5u4e00q6	716	7	common	common	JJ
cord-014712-5u4e00q6	716	8	complications	complication	NNS
cord-014712-5u4e00q6	716	9	were	be	VBD
cord-014712-5u4e00q6	716	10	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	716	11	disorders	disorder	NNS
cord-014712-5u4e00q6	716	12	,	,	,
cord-014712-5u4e00q6	716	13	especially	especially	RB
cord-014712-5u4e00q6	716	14	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	716	15	thyroiditis	thyroiditis	NN
cord-014712-5u4e00q6	716	16	,	,	,
cord-014712-5u4e00q6	716	17	Evans	Evans	NNP
cord-014712-5u4e00q6	716	18	syndrome	syndrome	NN
cord-014712-5u4e00q6	716	19	,	,	,
cord-014712-5u4e00q6	716	20	trombocytopenia	trombocytopenia	NNP
cord-014712-5u4e00q6	716	21	(	(	-LRB-
cord-014712-5u4e00q6	716	22	ITP	ITP	NNP
cord-014712-5u4e00q6	716	23	)	)	-RRB-
cord-014712-5u4e00q6	716	24	,	,	,
cord-014712-5u4e00q6	716	25	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	716	26	hemolytic	hemolytic	JJ
cord-014712-5u4e00q6	716	27	anemia	anemia	NN
cord-014712-5u4e00q6	716	28	(	(	-LRB-
cord-014712-5u4e00q6	716	29	AIHA	AIHA	NNP
cord-014712-5u4e00q6	716	30	)	)	-RRB-
cord-014712-5u4e00q6	716	31	.	.	.
cord-014712-5u4e00q6	717	1	On	on	IN
cord-014712-5u4e00q6	717	2	the	the	DT
cord-014712-5u4e00q6	717	3	contrary	contrary	NN
cord-014712-5u4e00q6	717	4	we	-PRON-	PRP
cord-014712-5u4e00q6	717	5	revealed	reveal	VBD
cord-014712-5u4e00q6	717	6	2	2	CD
cord-014712-5u4e00q6	717	7	patients	patient	NNS
cord-014712-5u4e00q6	717	8	with	with	IN
cord-014712-5u4e00q6	717	9	insuline	insuline	NN
cord-014712-5u4e00q6	717	10	dependent	dependent	JJ
cord-014712-5u4e00q6	717	11	(	(	-LRB-
cord-014712-5u4e00q6	717	12	type	type	NN
cord-014712-5u4e00q6	717	13	1	1	CD
cord-014712-5u4e00q6	717	14	)	)	-RRB-
cord-014712-5u4e00q6	717	15	diabetes	diabete	VBZ
cord-014712-5u4e00q6	717	16	mellitus	mellitus	NN
cord-014712-5u4e00q6	717	17	and	and	CC
cord-014712-5u4e00q6	717	18	CVID	CVID	NNP
cord-014712-5u4e00q6	717	19	.	.	.
cord-014712-5u4e00q6	718	1	Only	only	RB
cord-014712-5u4e00q6	718	2	few	few	JJ
cord-014712-5u4e00q6	718	3	case	case	NN
cord-014712-5u4e00q6	718	4	reports	report	NNS
cord-014712-5u4e00q6	718	5	have	have	VBP
cord-014712-5u4e00q6	718	6	been	be	VBN
cord-014712-5u4e00q6	718	7	published	publish	VBN
cord-014712-5u4e00q6	718	8	with	with	IN
cord-014712-5u4e00q6	718	9	such	such	JJ
cord-014712-5u4e00q6	718	10	association	association	NN
cord-014712-5u4e00q6	718	11	.	.	.
cord-014712-5u4e00q6	719	1	Successful	successful	JJ
cord-014712-5u4e00q6	719	2	management	management	NN
cord-014712-5u4e00q6	719	3	of	of	IN
cord-014712-5u4e00q6	719	4	CVID	CVID	NNP
cord-014712-5u4e00q6	719	5	patients	patient	NNS
cord-014712-5u4e00q6	719	6	is	be	VBZ
cord-014712-5u4e00q6	719	7	based	base	VBN
cord-014712-5u4e00q6	719	8	on	on	IN
cord-014712-5u4e00q6	719	9	a	a	DT
cord-014712-5u4e00q6	719	10	prevention	prevention	NN
cord-014712-5u4e00q6	719	11	and	and	CC
cord-014712-5u4e00q6	719	12	a	a	DT
cord-014712-5u4e00q6	719	13	consistent	consistent	JJ
cord-014712-5u4e00q6	719	14	treatment	treatment	NN
cord-014712-5u4e00q6	719	15	of	of	IN
cord-014712-5u4e00q6	719	16	infections	infection	NNS
cord-014712-5u4e00q6	719	17	with	with	IN
cord-014712-5u4e00q6	719	18	sufficient	sufficient	JJ
cord-014712-5u4e00q6	719	19	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	719	20	replcement	replcement	NN
cord-014712-5u4e00q6	719	21	and/or	and/or	CC
cord-014712-5u4e00q6	719	22	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	719	23	therapy	therapy	NN
cord-014712-5u4e00q6	719	24	,	,	,
cord-014712-5u4e00q6	719	25	a	a	DT
cord-014712-5u4e00q6	719	26	prevention	prevention	NN
cord-014712-5u4e00q6	719	27	and	and	CC
cord-014712-5u4e00q6	719	28	an	an	DT
cord-014712-5u4e00q6	719	29	active	active	JJ
cord-014712-5u4e00q6	719	30	screening	screening	NN
cord-014712-5u4e00q6	719	31	of	of	IN
cord-014712-5u4e00q6	719	32	CVID	CVID	NNP
cord-014712-5u4e00q6	719	33	related	relate	VBN
cord-014712-5u4e00q6	719	34	complications	complication	NNS
cord-014712-5u4e00q6	719	35	.	.	.
cord-014712-5u4e00q6	720	1	Such	such	JJ
cord-014712-5u4e00q6	720	2	approach	approach	NN
cord-014712-5u4e00q6	720	3	can	can	MD
cord-014712-5u4e00q6	720	4	significantly	significantly	RB
cord-014712-5u4e00q6	720	5	improve	improve	VB
cord-014712-5u4e00q6	720	6	the	the	DT
cord-014712-5u4e00q6	720	7	prognosis	prognosis	NN
cord-014712-5u4e00q6	720	8	of	of	IN
cord-014712-5u4e00q6	720	9	CVID	CVID	NNP
cord-014712-5u4e00q6	720	10	patients	patient	NNS
cord-014712-5u4e00q6	720	11	and	and	CC
cord-014712-5u4e00q6	720	12	the	the	DT
cord-014712-5u4e00q6	720	13	quality	quality	NN
cord-014712-5u4e00q6	720	14	of	of	IN
cord-014712-5u4e00q6	720	15	their	-PRON-	PRP$
cord-014712-5u4e00q6	720	16	life	life	NN
cord-014712-5u4e00q6	720	17	.	.	.
cord-014712-5u4e00q6	721	1	Laura	Laura	NNP
cord-014712-5u4e00q6	721	2	Zilinskaite	Zilinskaite	NNP
cord-014712-5u4e00q6	721	3	1	1	CD
cord-014712-5u4e00q6	721	4	;	;	:
cord-014712-5u4e00q6	722	1	Ieva	Ieva	NNP
cord-014712-5u4e00q6	722	2	Bajoriuniene	Bajoriuniene	NNP
cord-014712-5u4e00q6	722	3	1,2	1,2	CD
cord-014712-5u4e00q6	722	4	;	;	:
cord-014712-5u4e00q6	722	5	Raimundas	Raimundas	NNP
cord-014712-5u4e00q6	722	6	Sakalauskas	Sakalauskas	NNP
cord-014712-5u4e00q6	722	7	1	1	CD
cord-014712-5u4e00q6	722	8	;	;	:
cord-014712-5u4e00q6	722	9	Brigita	Brigita	NNP
cord-014712-5u4e00q6	722	10	Sitkauskiene	Sitkauskiene	NNP
cord-014712-5u4e00q6	722	11	1,2	1,2	CD
cord-014712-5u4e00q6	722	12	1	1	CD
cord-014712-5u4e00q6	722	13	Department	Department	NNP
cord-014712-5u4e00q6	722	14	of	of	IN
cord-014712-5u4e00q6	722	15	Pulmonology	Pulmonology	NNP
cord-014712-5u4e00q6	722	16	and	and	CC
cord-014712-5u4e00q6	722	17	Immunology	Immunology	NNP
cord-014712-5u4e00q6	722	18	,	,	,
cord-014712-5u4e00q6	722	19	Lithuanian	Lithuanian	NNP
cord-014712-5u4e00q6	722	20	University	University	NNP
cord-014712-5u4e00q6	722	21	of	of	IN
cord-014712-5u4e00q6	722	22	Health	Health	NNP
cord-014712-5u4e00q6	722	23	Sciences	Sciences	NNPS
cord-014712-5u4e00q6	722	24	,	,	,
cord-014712-5u4e00q6	722	25	Kaunas	Kaunas	NNP
cord-014712-5u4e00q6	722	26	,	,	,
cord-014712-5u4e00q6	722	27	Lithuania	Lithuania	NNP
cord-014712-5u4e00q6	722	28	.	.	.
cord-014712-5u4e00q6	723	1	Background	background	NN
cord-014712-5u4e00q6	723	2	.	.	.
cord-014712-5u4e00q6	724	1	Primary	primary	JJ
cord-014712-5u4e00q6	724	2	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	724	3	(	(	-LRB-
cord-014712-5u4e00q6	724	4	PID	PID	NNP
cord-014712-5u4e00q6	724	5	)	)	-RRB-
cord-014712-5u4e00q6	724	6	is	be	VBZ
cord-014712-5u4e00q6	724	7	considered	consider	VBN
cord-014712-5u4e00q6	724	8	to	to	TO
cord-014712-5u4e00q6	724	9	be	be	VB
cord-014712-5u4e00q6	724	10	a	a	DT
cord-014712-5u4e00q6	724	11	rare	rare	JJ
cord-014712-5u4e00q6	724	12	disease	disease	NN
cord-014712-5u4e00q6	724	13	.	.	.
cord-014712-5u4e00q6	725	1	Despite	despite	IN
cord-014712-5u4e00q6	725	2	that	that	IN
cord-014712-5u4e00q6	725	3	it	-PRON-	PRP
cord-014712-5u4e00q6	725	4	is	be	VBZ
cord-014712-5u4e00q6	725	5	thought	think	VBN
cord-014712-5u4e00q6	725	6	that	that	IN
cord-014712-5u4e00q6	725	7	six	six	CD
cord-014712-5u4e00q6	725	8	million	million	CD
cord-014712-5u4e00q6	725	9	people	people	NNS
cord-014712-5u4e00q6	725	10	may	may	MD
cord-014712-5u4e00q6	725	11	be	be	VB
cord-014712-5u4e00q6	725	12	living	live	VBG
cord-014712-5u4e00q6	725	13	with	with	IN
cord-014712-5u4e00q6	725	14	a	a	DT
cord-014712-5u4e00q6	725	15	PID	PID	NNP
cord-014712-5u4e00q6	725	16	worldwide	worldwide	RB
cord-014712-5u4e00q6	725	17	.	.	.
cord-014712-5u4e00q6	726	1	In	in	IN
cord-014712-5u4e00q6	726	2	the	the	DT
cord-014712-5u4e00q6	726	3	Hospital	Hospital	NNP
cord-014712-5u4e00q6	726	4	of	of	IN
cord-014712-5u4e00q6	726	5	Lithuanian	Lithuanian	NNP
cord-014712-5u4e00q6	726	6	University	University	NNP
cord-014712-5u4e00q6	726	7	of	of	IN
cord-014712-5u4e00q6	726	8	Health	Health	NNP
cord-014712-5u4e00q6	726	9	Sciences	Sciences	NNPS
cord-014712-5u4e00q6	726	10	(	(	-LRB-
cord-014712-5u4e00q6	726	11	HLUHS	HLUHS	NNP
cord-014712-5u4e00q6	726	12	)	)	-RRB-
cord-014712-5u4e00q6	726	13	patients	patient	NNS
cord-014712-5u4e00q6	726	14	with	with	IN
cord-014712-5u4e00q6	726	15	suspected	suspect	VBN
cord-014712-5u4e00q6	726	16	immune	immune	JJ
cord-014712-5u4e00q6	726	17	disorders	disorder	NNS
cord-014712-5u4e00q6	726	18	have	have	VBP
cord-014712-5u4e00q6	726	19	been	be	VBN
cord-014712-5u4e00q6	726	20	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	726	21	and	and	CC
cord-014712-5u4e00q6	726	22	treated	treat	VBN
cord-014712-5u4e00q6	726	23	since	since	IN
cord-014712-5u4e00q6	726	24	1998	1998	CD
cord-014712-5u4e00q6	726	25	.	.	.
cord-014712-5u4e00q6	727	1	We	-PRON-	PRP
cord-014712-5u4e00q6	727	2	aimed	aim	VBD
cord-014712-5u4e00q6	727	3	to	to	TO
cord-014712-5u4e00q6	727	4	review	review	VB
cord-014712-5u4e00q6	727	5	the	the	DT
cord-014712-5u4e00q6	727	6	structure	structure	NN
cord-014712-5u4e00q6	727	7	of	of	IN
cord-014712-5u4e00q6	727	8	PID	PID	NNP
cord-014712-5u4e00q6	727	9	diagnosed	diagnose	VBD
cord-014712-5u4e00q6	727	10	and	and	CC
cord-014712-5u4e00q6	727	11	treated	treat	VBN
cord-014712-5u4e00q6	727	12	in	in	IN
cord-014712-5u4e00q6	727	13	HLUHS	HLUHS	NNP
cord-014712-5u4e00q6	727	14	during	during	IN
cord-014712-5u4e00q6	727	15	the	the	DT
cord-014712-5u4e00q6	727	16	last	last	JJ
cord-014712-5u4e00q6	727	17	five	five	CD
cord-014712-5u4e00q6	727	18	years	year	NNS
cord-014712-5u4e00q6	727	19	.	.	.
cord-014712-5u4e00q6	728	1	Methods	method	NNS
cord-014712-5u4e00q6	728	2	.	.	.
cord-014712-5u4e00q6	729	1	Data	datum	NNS
cord-014712-5u4e00q6	729	2	about	about	IN
cord-014712-5u4e00q6	729	3	patients	patient	NNS
cord-014712-5u4e00q6	729	4	with	with	IN
cord-014712-5u4e00q6	729	5	PID	PID	NNP
cord-014712-5u4e00q6	729	6	consulted	consult	VBD
cord-014712-5u4e00q6	729	7	in	in	IN
cord-014712-5u4e00q6	729	8	the	the	DT
cord-014712-5u4e00q6	729	9	HLUHS	HLUHS	NNP
cord-014712-5u4e00q6	729	10	was	be	VBD
cord-014712-5u4e00q6	729	11	collected	collect	VBN
cord-014712-5u4e00q6	729	12	from	from	IN
cord-014712-5u4e00q6	729	13	the	the	DT
cord-014712-5u4e00q6	729	14	Department	Department	NNP
cord-014712-5u4e00q6	729	15	of	of	IN
cord-014712-5u4e00q6	729	16	Medical	Medical	NNP
cord-014712-5u4e00q6	729	17	Statistics	Statistics	NNPS
cord-014712-5u4e00q6	729	18	.	.	.
cord-014712-5u4e00q6	730	1	Case	case	NN
cord-014712-5u4e00q6	730	2	histories	history	NNS
cord-014712-5u4e00q6	730	3	of	of	IN
cord-014712-5u4e00q6	730	4	these	these	DT
cord-014712-5u4e00q6	730	5	patients	patient	NNS
cord-014712-5u4e00q6	730	6	were	be	VBD
cord-014712-5u4e00q6	730	7	revised	revise	VBN
cord-014712-5u4e00q6	730	8	and	and	CC
cord-014712-5u4e00q6	730	9	patients	patient	NNS
cord-014712-5u4e00q6	730	10	'	'	POS
cord-014712-5u4e00q6	730	11	data	datum	NNS
cord-014712-5u4e00q6	730	12	was	be	VBD
cord-014712-5u4e00q6	730	13	collected	collect	VBN
cord-014712-5u4e00q6	730	14	:	:	:
cord-014712-5u4e00q6	730	15	onset	onset	NN
cord-014712-5u4e00q6	730	16	of	of	IN
cord-014712-5u4e00q6	730	17	symptoms	symptom	NNS
cord-014712-5u4e00q6	730	18	,	,	,
cord-014712-5u4e00q6	730	19	type	type	NN
cord-014712-5u4e00q6	730	20	and	and	CC
cord-014712-5u4e00q6	730	21	duration	duration	NN
cord-014712-5u4e00q6	730	22	of	of	IN
cord-014712-5u4e00q6	730	23	disorder	disorder	NN
cord-014712-5u4e00q6	730	24	,	,	,
cord-014712-5u4e00q6	730	25	type	type	NN
cord-014712-5u4e00q6	730	26	of	of	IN
cord-014712-5u4e00q6	730	27	treatment	treatment	NN
cord-014712-5u4e00q6	730	28	.	.	.
cord-014712-5u4e00q6	731	1	All	all	DT
cord-014712-5u4e00q6	731	2	patients	patient	NNS
cord-014712-5u4e00q6	731	3	with	with	IN
cord-014712-5u4e00q6	731	4	PID	PID	NNP
cord-014712-5u4e00q6	731	5	were	be	VBD
cord-014712-5u4e00q6	731	6	divided	divide	VBN
cord-014712-5u4e00q6	731	7	into	into	IN
cord-014712-5u4e00q6	731	8	several	several	JJ
cord-014712-5u4e00q6	731	9	groups	group	NNS
cord-014712-5u4e00q6	731	10	according	accord	VBG
cord-014712-5u4e00q6	731	11	to	to	IN
cord-014712-5u4e00q6	731	12	the	the	DT
cord-014712-5u4e00q6	731	13	classification	classification	NN
cord-014712-5u4e00q6	731	14	of	of	IN
cord-014712-5u4e00q6	731	15	International	International	NNP
cord-014712-5u4e00q6	731	16	Union	Union	NNP
cord-014712-5u4e00q6	731	17	of	of	IN
cord-014712-5u4e00q6	731	18	Immunological	Immunological	NNP
cord-014712-5u4e00q6	731	19	Societies	Societies	NNPS
cord-014712-5u4e00q6	731	20	Primary	Primary	NNP
cord-014712-5u4e00q6	731	21	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	731	22	Diseases	Diseases	NNPS
cord-014712-5u4e00q6	731	23	Classification	Classification	NNP
cord-014712-5u4e00q6	731	24	Committee	Committee	NNP
cord-014712-5u4e00q6	731	25	(	(	-LRB-
cord-014712-5u4e00q6	731	26	2011	2011	CD
cord-014712-5u4e00q6	731	27	)	)	-RRB-
cord-014712-5u4e00q6	731	28	.	.	.
cord-014712-5u4e00q6	732	1	Results	result	NNS
cord-014712-5u4e00q6	732	2	.	.	.
cord-014712-5u4e00q6	733	1	There	there	EX
cord-014712-5u4e00q6	733	2	were	be	VBD
cord-014712-5u4e00q6	733	3	57	57	CD
cord-014712-5u4e00q6	733	4	patients	patient	NNS
cord-014712-5u4e00q6	733	5	with	with	IN
cord-014712-5u4e00q6	733	6	PID	PID	NNP
cord-014712-5u4e00q6	733	7	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	733	8	in	in	IN
cord-014712-5u4e00q6	733	9	the	the	DT
cord-014712-5u4e00q6	733	10	Centre	Centre	NNP
cord-014712-5u4e00q6	733	11	.	.	.
cord-014712-5u4e00q6	734	1	Antibody	antibody	NN
cord-014712-5u4e00q6	734	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	734	3	was	be	VBD
cord-014712-5u4e00q6	734	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	734	5	for	for	IN
cord-014712-5u4e00q6	734	6	38	38	CD
cord-014712-5u4e00q6	734	7	patients	patient	NNS
cord-014712-5u4e00q6	734	8	:	:	:
cord-014712-5u4e00q6	734	9	3	3	LS
cord-014712-5u4e00q6	734	10	-Bruton	-Bruton	NNP
cord-014712-5u4e00q6	734	11	's	's	POS
cord-014712-5u4e00q6	734	12	disease	disease	NN
cord-014712-5u4e00q6	734	13	,	,	,
cord-014712-5u4e00q6	734	14	14common	14common	CD
cord-014712-5u4e00q6	734	15	variable	variable	JJ
cord-014712-5u4e00q6	734	16	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	734	17	(	(	-LRB-
cord-014712-5u4e00q6	734	18	CVID	CVID	NNP
cord-014712-5u4e00q6	734	19	)	)	-RRB-
cord-014712-5u4e00q6	734	20	and	and	CC
cord-014712-5u4e00q6	734	21	21selective	21selective	CD
cord-014712-5u4e00q6	734	22	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	734	23	(	(	-LRB-
cord-014712-5u4e00q6	734	24	Ig	Ig	NNP
cord-014712-5u4e00q6	734	25	)	)	-RRB-
cord-014712-5u4e00q6	734	26	A	a	DT
cord-014712-5u4e00q6	734	27	deficiency	deficiency	NN
cord-014712-5u4e00q6	734	28	.	.	.
cord-014712-5u4e00q6	735	1	Complement	complement	JJ
cord-014712-5u4e00q6	735	2	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	735	3	were	be	VBD
cord-014712-5u4e00q6	735	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	735	5	for	for	IN
cord-014712-5u4e00q6	735	6	13	13	CD
cord-014712-5u4e00q6	735	7	patients	patient	NNS
cord-014712-5u4e00q6	735	8	:	:	:
cord-014712-5u4e00q6	735	9	11	11	CD
cord-014712-5u4e00q6	735	10	-C1	-c1	DT
cord-014712-5u4e00q6	735	11	esterase	esterase	NN
cord-014712-5u4e00q6	735	12	inhibitor	inhibitor	NN
cord-014712-5u4e00q6	735	13	deficiency	deficiency	NN
cord-014712-5u4e00q6	735	14	and	and	CC
cord-014712-5u4e00q6	735	15	2	2	CD
cord-014712-5u4e00q6	735	16	-C4	-c4	NN
cord-014712-5u4e00q6	735	17	deficiency	deficiency	NN
cord-014712-5u4e00q6	735	18	.	.	.
cord-014712-5u4e00q6	736	1	Another	another	DT
cord-014712-5u4e00q6	736	2	well	well	RB
cord-014712-5u4e00q6	736	3	-	-	HYPH
cord-014712-5u4e00q6	736	4	defined	define	VBN
cord-014712-5u4e00q6	736	5	syndrome	syndrome	NN
cord-014712-5u4e00q6	736	6	with	with	IN
cord-014712-5u4e00q6	736	7	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	736	8	was	be	VBD
cord-014712-5u4e00q6	736	9	found	find	VBN
cord-014712-5u4e00q6	736	10	in	in	IN
cord-014712-5u4e00q6	736	11	six	six	CD
cord-014712-5u4e00q6	736	12	patients	patient	NNS
cord-014712-5u4e00q6	736	13	.	.	.
cord-014712-5u4e00q6	737	1	The	the	DT
cord-014712-5u4e00q6	737	2	most	most	RBS
cord-014712-5u4e00q6	737	3	prevalent	prevalent	JJ
cord-014712-5u4e00q6	737	4	symptom	symptom	NN
cord-014712-5u4e00q6	737	5	in	in	IN
cord-014712-5u4e00q6	737	6	patients	patient	NNS
cord-014712-5u4e00q6	737	7	with	with	IN
cord-014712-5u4e00q6	737	8	predominant	predominant	JJ
cord-014712-5u4e00q6	737	9	IgG	IgG	NNP
cord-014712-5u4e00q6	737	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	737	11	was	be	VBD
cord-014712-5u4e00q6	737	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	737	13	pneumonias	pneumonia	NNS
cord-014712-5u4e00q6	737	14	which	which	WDT
cord-014712-5u4e00q6	737	15	occurred	occur	VBD
cord-014712-5u4e00q6	737	16	at	at	IN
cord-014712-5u4e00q6	737	17	the	the	DT
cord-014712-5u4e00q6	737	18	age	age	NN
cord-014712-5u4e00q6	737	19	11.9	11.9	CD
cord-014712-5u4e00q6	737	20	±	±	CD
cord-014712-5u4e00q6	737	21	4.9	4.9	CD
cord-014712-5u4e00q6	737	22	yrs	yr	NNS
cord-014712-5u4e00q6	737	23	.	.	.
cord-014712-5u4e00q6	738	1	The	the	DT
cord-014712-5u4e00q6	738	2	mean	mean	JJ
cord-014712-5u4e00q6	738	3	time	time	NN
cord-014712-5u4e00q6	738	4	between	between	IN
cord-014712-5u4e00q6	738	5	the	the	DT
cord-014712-5u4e00q6	738	6	onset	onset	NN
cord-014712-5u4e00q6	738	7	of	of	IN
cord-014712-5u4e00q6	738	8	symptoms	symptom	NNS
cord-014712-5u4e00q6	738	9	and	and	CC
cord-014712-5u4e00q6	738	10	confirmation	confirmation	NN
cord-014712-5u4e00q6	738	11	of	of	IN
cord-014712-5u4e00q6	738	12	the	the	DT
cord-014712-5u4e00q6	738	13	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	738	14	was	be	VBD
cord-014712-5u4e00q6	738	15	14.6	14.6	CD
cord-014712-5u4e00q6	738	16	±	±	NNP
cord-014712-5u4e00q6	738	17	6.4	6.4	CD
cord-014712-5u4e00q6	738	18	yrs	yr	NNS
cord-014712-5u4e00q6	738	19	.	.	.
cord-014712-5u4e00q6	739	1	Thirteen	thirteen	CD
cord-014712-5u4e00q6	739	2	patients	patient	NNS
cord-014712-5u4e00q6	739	3	are	be	VBP
cord-014712-5u4e00q6	739	4	on	on	IN
cord-014712-5u4e00q6	739	5	the	the	DT
cord-014712-5u4e00q6	739	6	replacement	replacement	NN
cord-014712-5u4e00q6	739	7	therapy	therapy	NN
cord-014712-5u4e00q6	739	8	with	with	IN
cord-014712-5u4e00q6	739	9	intravenous	intravenous	JJ
cord-014712-5u4e00q6	739	10	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	739	11	.	.	.
cord-014712-5u4e00q6	740	1	These	these	DT
cord-014712-5u4e00q6	740	2	patients	patient	NNS
cord-014712-5u4e00q6	740	3	had	have	VBD
cord-014712-5u4e00q6	740	4	2	2	CD
cord-014712-5u4e00q6	740	5	-	-	SYM
cord-014712-5u4e00q6	740	6	6	6	CD
cord-014712-5u4e00q6	740	7	infections	infection	NNS
cord-014712-5u4e00q6	740	8	/	/	SYM
cord-014712-5u4e00q6	740	9	year	year	NN
cord-014712-5u4e00q6	740	10	before	before	IN
cord-014712-5u4e00q6	740	11	the	the	DT
cord-014712-5u4e00q6	740	12	treatment	treatment	NN
cord-014712-5u4e00q6	740	13	initiation	initiation	NN
cord-014712-5u4e00q6	740	14	and	and	CC
cord-014712-5u4e00q6	740	15	only	only	RB
cord-014712-5u4e00q6	740	16	0	0	CD
cord-014712-5u4e00q6	740	17	-	-	SYM
cord-014712-5u4e00q6	740	18	1	1	CD
cord-014712-5u4e00q6	740	19	infections	infection	NNS
cord-014712-5u4e00q6	740	20	/	/	SYM
cord-014712-5u4e00q6	740	21	year	year	NN
cord-014712-5u4e00q6	740	22	during	during	IN
cord-014712-5u4e00q6	740	23	the	the	DT
cord-014712-5u4e00q6	740	24	treatment	treatment	NN
cord-014712-5u4e00q6	740	25	.	.	.
cord-014712-5u4e00q6	741	1	•PID	•PID	NNP
cord-014712-5u4e00q6	741	2	center	center	NN
cord-014712-5u4e00q6	741	3	has	have	VBZ
cord-014712-5u4e00q6	741	4	successful	successful	JJ
cord-014712-5u4e00q6	741	5	sideproject	sideproject	NN
cord-014712-5u4e00q6	741	6	as	as	IN
cord-014712-5u4e00q6	741	7	Regional	Regional	NNP
cord-014712-5u4e00q6	741	8	charitable	charitable	JJ
cord-014712-5u4e00q6	741	9	public	public	JJ
cord-014712-5u4e00q6	741	10	organization	organization	NN
cord-014712-5u4e00q6	741	11	of	of	IN
cord-014712-5u4e00q6	741	12	invalids	invalid	NNS
cord-014712-5u4e00q6	741	13	"	"	``
cord-014712-5u4e00q6	741	14	Society	Society	NNP
cord-014712-5u4e00q6	741	15	of	of	IN
cord-014712-5u4e00q6	741	16	patients	patient	NNS
cord-014712-5u4e00q6	741	17	with	with	IN
cord-014712-5u4e00q6	741	18	primary	primary	JJ
cord-014712-5u4e00q6	741	19	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	741	20	diseases	disease	NNS
cord-014712-5u4e00q6	741	21	in	in	IN
cord-014712-5u4e00q6	741	22	St.	St.	NNP
cord-014712-5u4e00q6	741	23	Petersburg	Petersburg	NNP
cord-014712-5u4e00q6	741	24	"	"	``
cord-014712-5u4e00q6	741	25	Solovushka	Solovushka	NNP
cord-014712-5u4e00q6	741	26	(	(	-LRB-
cord-014712-5u4e00q6	741	27	Nightingale	Nightingale	NNP
cord-014712-5u4e00q6	741	28	)	)	-RRB-
cord-014712-5u4e00q6	741	29	"	"	''
cord-014712-5u4e00q6	741	30	"	"	''
cord-014712-5u4e00q6	741	31	.	.	.
cord-014712-5u4e00q6	742	1	Web	web	NN
cord-014712-5u4e00q6	742	2	site	site	NN
cord-014712-5u4e00q6	742	3	for	for	IN
cord-014712-5u4e00q6	742	4	patients	patient	NNS
cord-014712-5u4e00q6	742	5	(	(	-LRB-
cord-014712-5u4e00q6	742	6	www.opidspb.ru	www.opidspb.ru	NN
cord-014712-5u4e00q6	742	7	)	)	-RRB-
cord-014712-5u4e00q6	742	8	was	be	VBD
cord-014712-5u4e00q6	742	9	opened	open	VBN
cord-014712-5u4e00q6	742	10	due	due	IN
cord-014712-5u4e00q6	742	11	to	to	IN
cord-014712-5u4e00q6	742	12	mutual	mutual	JJ
cord-014712-5u4e00q6	742	13	efforts	effort	NNS
cord-014712-5u4e00q6	742	14	of	of	IN
cord-014712-5u4e00q6	742	15	PID	PID	NNP
cord-014712-5u4e00q6	742	16	center	center	NN
cord-014712-5u4e00q6	742	17	staff	staff	NN
cord-014712-5u4e00q6	742	18	and	and	CC
cord-014712-5u4e00q6	742	19	patients	patient	NNS
cord-014712-5u4e00q6	742	20	.	.	.
cord-014712-5u4e00q6	743	1	PID	PID	NNP
cord-014712-5u4e00q6	743	2	Center	Center	NNP
cord-014712-5u4e00q6	743	3	laboratory	laboratory	NN
cord-014712-5u4e00q6	743	4	is	be	VBZ
cord-014712-5u4e00q6	743	5	based	base	VBN
cord-014712-5u4e00q6	743	6	on	on	IN
cord-014712-5u4e00q6	743	7	SPb	SPb	NNP
cord-014712-5u4e00q6	743	8	Pasteur	Pasteur	NNP
cord-014712-5u4e00q6	743	9	Institute	Institute	NNP
cord-014712-5u4e00q6	743	10	Central	Central	NNP
cord-014712-5u4e00q6	743	11	Clinical	Clinical	NNP
cord-014712-5u4e00q6	743	12	Diagnostics	Diagnostics	NNPS
cord-014712-5u4e00q6	743	13	Laboratory	Laboratory	NNP
cord-014712-5u4e00q6	743	14	and	and	CC
cord-014712-5u4e00q6	743	15	Laboratory	Laboratory	NNP
cord-014712-5u4e00q6	743	16	of	of	IN
cord-014712-5u4e00q6	743	17	Molecular	Molecular	NNP
cord-014712-5u4e00q6	743	18	immunology	immunology	NN
cord-014712-5u4e00q6	743	19	and	and	CC
cord-014712-5u4e00q6	743	20	seroepidemiology	seroepidemiology	NN
cord-014712-5u4e00q6	743	21	.	.	.
cord-014712-5u4e00q6	744	1	Main	main	JJ
cord-014712-5u4e00q6	744	2	groups	group	NNS
cord-014712-5u4e00q6	744	3	of	of	IN
cord-014712-5u4e00q6	744	4	tests	test	NNS
cord-014712-5u4e00q6	744	5	perform	perform	VBP
cord-014712-5u4e00q6	744	6	for	for	IN
cord-014712-5u4e00q6	744	7	PID	pid	NN
cord-014712-5u4e00q6	744	8	patients	patient	NNS
cord-014712-5u4e00q6	744	9	are	be	VBP
cord-014712-5u4e00q6	744	10	:	:	:
cord-014712-5u4e00q6	744	11	general	general	JJ
cord-014712-5u4e00q6	744	12	clinical	clinical	JJ
cord-014712-5u4e00q6	744	13	assays	assay	NNS
cord-014712-5u4e00q6	744	14	;	;	,
cord-014712-5u4e00q6	744	15	flow	flow	VB
cord-014712-5u4e00q6	744	16	cytometry	cytometry	NN
cord-014712-5u4e00q6	744	17	(	(	-LRB-
cord-014712-5u4e00q6	744	18	6-color	6-color	CD
cord-014712-5u4e00q6	744	19	assay	assay	NN
cord-014712-5u4e00q6	744	20	on	on	IN
cord-014712-5u4e00q6	744	21	FACS	FACS	NNP
cord-014712-5u4e00q6	744	22	Canto	Canto	NNP
cord-014712-5u4e00q6	744	23	II	II	NNP
cord-014712-5u4e00q6	744	24	)	)	-RRB-
cord-014712-5u4e00q6	744	25	;	;	,
cord-014712-5u4e00q6	744	26	humoral	humoral	JJ
cord-014712-5u4e00q6	744	27	factors	factor	NNS
cord-014712-5u4e00q6	744	28	assays	assay	NNS
cord-014712-5u4e00q6	744	29	(	(	-LRB-
cord-014712-5u4e00q6	744	30	Ig	Ig	NNP
cord-014712-5u4e00q6	744	31	levels	level	NNS
cord-014712-5u4e00q6	744	32	,	,	,
cord-014712-5u4e00q6	744	33	IgG	IgG	NNP
cord-014712-5u4e00q6	744	34	subclasses	subclass	NNS
cord-014712-5u4e00q6	744	35	,	,	,
cord-014712-5u4e00q6	744	36	post	post	JJ
cord-014712-5u4e00q6	744	37	-	-	JJ
cord-014712-5u4e00q6	744	38	vaccination	vaccination	JJ
cord-014712-5u4e00q6	744	39	IgG	igg	NN
cord-014712-5u4e00q6	744	40	levels	level	NNS
cord-014712-5u4e00q6	744	41	,	,	,
cord-014712-5u4e00q6	744	42	etc	etc	FW
cord-014712-5u4e00q6	744	43	.	.	.
cord-014712-5u4e00q6	744	44	)	)	-RRB-
cord-014712-5u4e00q6	744	45	;	;	:
cord-014712-5u4e00q6	744	46	burst	burst	VB
cord-014712-5u4e00q6	744	47	-	-	HYPH
cord-014712-5u4e00q6	744	48	test	test	NN
cord-014712-5u4e00q6	744	49	on	on	IN
cord-014712-5u4e00q6	744	50	flow	flow	NN
cord-014712-5u4e00q6	744	51	cytometer	cytometer	NN
cord-014712-5u4e00q6	744	52	;	;	,
cord-014712-5u4e00q6	744	53	genetic	genetic	JJ
cord-014712-5u4e00q6	744	54	analysis	analysis	NN
cord-014712-5u4e00q6	744	55	of	of	IN
cord-014712-5u4e00q6	744	56	Btk	Btk	NNP
cord-014712-5u4e00q6	744	57	,	,	,
cord-014712-5u4e00q6	744	58	Rag1	Rag1	NNP
cord-014712-5u4e00q6	744	59	,	,	,
cord-014712-5u4e00q6	744	60	Rag2,WAS	Rag2,WAS	NNP
cord-014712-5u4e00q6	744	61	,	,	,
cord-014712-5u4e00q6	744	62	CYBB	CYBB	NNP
cord-014712-5u4e00q6	744	63	genes	gene	NNS
cord-014712-5u4e00q6	744	64	.	.	.
cord-014712-5u4e00q6	745	1	Despite	despite	IN
cord-014712-5u4e00q6	745	2	of	of	IN
cord-014712-5u4e00q6	745	3	relatively	relatively	RB
cord-014712-5u4e00q6	745	4	short	short	JJ
cord-014712-5u4e00q6	745	5	story	story	NN
cord-014712-5u4e00q6	745	6	of	of	IN
cord-014712-5u4e00q6	745	7	SPb	SPb	NNP
cord-014712-5u4e00q6	745	8	PID	PID	NNP
cord-014712-5u4e00q6	745	9	Center	Center	NNP
cord-014712-5u4e00q6	745	10	it	-PRON-	PRP
cord-014712-5u4e00q6	745	11	has	have	VBZ
cord-014712-5u4e00q6	745	12	a	a	DT
cord-014712-5u4e00q6	745	13	variety	variety	NN
cord-014712-5u4e00q6	745	14	of	of	IN
cord-014712-5u4e00q6	745	15	completely	completely	RB
cord-014712-5u4e00q6	745	16	diagnosted	diagnoste	VBN
cord-014712-5u4e00q6	745	17	and	and	CC
cord-014712-5u4e00q6	745	18	successfully	successfully	RB
cord-014712-5u4e00q6	745	19	cured	cure	VBN
cord-014712-5u4e00q6	745	20	cases	case	NNS
cord-014712-5u4e00q6	745	21	of	of	IN
cord-014712-5u4e00q6	745	22	PID	PID	NNP
cord-014712-5u4e00q6	745	23	including	include	VBG
cord-014712-5u4e00q6	745	24	agammaglobulinemia	agammaglobulinemia	NN
cord-014712-5u4e00q6	745	25	with	with	IN
cord-014712-5u4e00q6	745	26	B	b	NN
cord-014712-5u4e00q6	745	27	-	-	HYPH
cord-014712-5u4e00q6	745	28	cell	cell	NN
cord-014712-5u4e00q6	745	29	in	in	IN
cord-014712-5u4e00q6	745	30	Identical	Identical	NNP
cord-014712-5u4e00q6	745	31	siblings	sibling	NNS
cord-014712-5u4e00q6	745	32	,	,	,
cord-014712-5u4e00q6	745	33	Wiskott	Wiskott	NNP
cord-014712-5u4e00q6	745	34	-	-	HYPH
cord-014712-5u4e00q6	745	35	Aldrich	Aldrich	NNP
cord-014712-5u4e00q6	745	36	syndrome	syndrome	NN
cord-014712-5u4e00q6	745	37	,	,	,
cord-014712-5u4e00q6	745	38	chronic	chronic	JJ
cord-014712-5u4e00q6	745	39	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	745	40	disease	disease	NN
cord-014712-5u4e00q6	745	41	(	(	-LRB-
cord-014712-5u4e00q6	745	42	CGD	CGD	NNP
cord-014712-5u4e00q6	745	43	)	)	-RRB-
cord-014712-5u4e00q6	745	44	,	,	,
cord-014712-5u4e00q6	745	45	etc	etc	FW
cord-014712-5u4e00q6	745	46	.	.	.
cord-014712-5u4e00q6	746	1	Introduction	introduction	NN
cord-014712-5u4e00q6	746	2	:	:	:
cord-014712-5u4e00q6	747	1	The	the	DT
cord-014712-5u4e00q6	747	2	primary	primary	JJ
cord-014712-5u4e00q6	747	3	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	747	4	diseases	disease	NNS
cord-014712-5u4e00q6	747	5	are	be	VBP
cord-014712-5u4e00q6	747	6	a	a	DT
cord-014712-5u4e00q6	747	7	group	group	NN
cord-014712-5u4e00q6	747	8	of	of	IN
cord-014712-5u4e00q6	747	9	disorders	disorder	NNS
cord-014712-5u4e00q6	747	10	caused	cause	VBN
cord-014712-5u4e00q6	747	11	by	by	IN
cord-014712-5u4e00q6	747	12	basic	basic	JJ
cord-014712-5u4e00q6	747	13	defects	defect	NNS
cord-014712-5u4e00q6	747	14	in	in	IN
cord-014712-5u4e00q6	747	15	immune	immune	JJ
cord-014712-5u4e00q6	747	16	function	function	NN
cord-014712-5u4e00q6	747	17	that	that	WDT
cord-014712-5u4e00q6	747	18	are	be	VBP
cord-014712-5u4e00q6	747	19	intrinsic	intrinsic	JJ
cord-014712-5u4e00q6	747	20	to	to	IN
cord-014712-5u4e00q6	747	21	,	,	,
cord-014712-5u4e00q6	747	22	or	or	CC
cord-014712-5u4e00q6	747	23	inherent	inherent	JJ
cord-014712-5u4e00q6	747	24	in	in	IN
cord-014712-5u4e00q6	747	25	,	,	,
cord-014712-5u4e00q6	747	26	the	the	DT
cord-014712-5u4e00q6	747	27	cells	cell	NNS
cord-014712-5u4e00q6	747	28	and	and	CC
cord-014712-5u4e00q6	747	29	proteins	protein	NNS
cord-014712-5u4e00q6	747	30	of	of	IN
cord-014712-5u4e00q6	747	31	the	the	DT
cord-014712-5u4e00q6	747	32	immune	immune	JJ
cord-014712-5u4e00q6	747	33	system	system	NN
cord-014712-5u4e00q6	747	34	.	.	.
cord-014712-5u4e00q6	748	1	There	there	EX
cord-014712-5u4e00q6	748	2	are	be	VBP
cord-014712-5u4e00q6	748	3	more	more	JJR
cord-014712-5u4e00q6	748	4	than	than	IN
cord-014712-5u4e00q6	748	5	200	200	CD
cord-014712-5u4e00q6	748	6	primary	primary	JJ
cord-014712-5u4e00q6	748	7	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	748	8	diseases	disease	NNS
cord-014712-5u4e00q6	748	9	..	..	.
cord-014712-5u4e00q6	749	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	749	2	studies	study	NNS
cord-014712-5u4e00q6	749	3	are	be	VBP
cord-014712-5u4e00q6	749	4	necessary	necessary	JJ
cord-014712-5u4e00q6	749	5	to	to	TO
cord-014712-5u4e00q6	749	6	determine	determine	VB
cord-014712-5u4e00q6	749	7	the	the	DT
cord-014712-5u4e00q6	749	8	presence	presence	NN
cord-014712-5u4e00q6	749	9	of	of	IN
cord-014712-5u4e00q6	749	10	a	a	DT
cord-014712-5u4e00q6	749	11	primary	primary	JJ
cord-014712-5u4e00q6	749	12	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	749	13	diseases	disease	NNS
cord-014712-5u4e00q6	749	14	.	.	.
cord-014712-5u4e00q6	750	1	The	the	DT
cord-014712-5u4e00q6	750	2	standard	standard	JJ
cord-014712-5u4e00q6	750	3	screening	screening	NN
cord-014712-5u4e00q6	750	4	tests	test	NNS
cord-014712-5u4e00q6	750	5	for	for	IN
cord-014712-5u4e00q6	750	6	antibody	antibody	NN
cord-014712-5u4e00q6	750	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	750	8	starts	start	VBZ
cord-014712-5u4e00q6	750	9	with	with	IN
cord-014712-5u4e00q6	750	10	measurement	measurement	NN
cord-014712-5u4e00q6	750	11	of	of	IN
cord-014712-5u4e00q6	750	12	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	750	13	levels	level	NNS
cord-014712-5u4e00q6	750	14	in	in	IN
cord-014712-5u4e00q6	750	15	the	the	DT
cord-014712-5u4e00q6	750	16	blood	blood	NN
cord-014712-5u4e00q6	750	17	serum	serum	NN
cord-014712-5u4e00q6	750	18	.	.	.
cord-014712-5u4e00q6	751	1	These	these	DT
cord-014712-5u4e00q6	751	2	consist	consist	VBP
cord-014712-5u4e00q6	751	3	of	of	IN
cord-014712-5u4e00q6	751	4	IgG	IgG	NNP
cord-014712-5u4e00q6	751	5	,	,	,
cord-014712-5u4e00q6	751	6	IgA	IgA	NNP
cord-014712-5u4e00q6	751	7	and	and	CC
cord-014712-5u4e00q6	751	8	IgM	IgM	NNP
cord-014712-5u4e00q6	751	9	levels	level	NNS
cord-014712-5u4e00q6	751	10	.	.	.
cord-014712-5u4e00q6	752	1	The	the	DT
cord-014712-5u4e00q6	752	2	results	result	NNS
cord-014712-5u4e00q6	752	3	must	must	MD
cord-014712-5u4e00q6	752	4	be	be	VB
cord-014712-5u4e00q6	752	5	compared	compare	VBN
cord-014712-5u4e00q6	752	6	to	to	IN
cord-014712-5u4e00q6	752	7	agematched	agematched	JJ
cord-014712-5u4e00q6	752	8	controls	control	NNS
cord-014712-5u4e00q6	752	9	.	.	.
cord-014712-5u4e00q6	753	1	Additional	additional	JJ
cord-014712-5u4e00q6	753	2	studies	study	NNS
cord-014712-5u4e00q6	753	3	used	use	VBD
cord-014712-5u4e00q6	753	4	to	to	TO
cord-014712-5u4e00q6	753	5	evaluate	evaluate	VB
cord-014712-5u4e00q6	753	6	patients	patient	NNS
cord-014712-5u4e00q6	753	7	with	with	IN
cord-014712-5u4e00q6	753	8	antibody	antibody	NN
cord-014712-5u4e00q6	753	9	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	753	10	include	include	VBP
cord-014712-5u4e00q6	753	11	measuring	measure	VBG
cord-014712-5u4e00q6	753	12	the	the	DT
cord-014712-5u4e00q6	753	13	different	different	JJ
cord-014712-5u4e00q6	753	14	types	type	NNS
cord-014712-5u4e00q6	753	15	of	of	IN
cord-014712-5u4e00q6	753	16	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	753	17	in	in	IN
cord-014712-5u4e00q6	753	18	the	the	DT
cord-014712-5u4e00q6	753	19	blood	blood	NN
cord-014712-5u4e00q6	753	20	by	by	IN
cord-014712-5u4e00q6	753	21	marking	mark	VBG
cord-014712-5u4e00q6	753	22	those	those	DT
cord-014712-5u4e00q6	753	23	cells	cell	NNS
cord-014712-5u4e00q6	753	24	with	with	IN
cord-014712-5u4e00q6	753	25	molecules	molecule	NNS
cord-014712-5u4e00q6	753	26	that	that	WDT
cord-014712-5u4e00q6	753	27	can	can	MD
cord-014712-5u4e00q6	753	28	identify	identify	VB
cord-014712-5u4e00q6	753	29	the	the	DT
cord-014712-5u4e00q6	753	30	different	different	JJ
cord-014712-5u4e00q6	753	31	types	type	NNS
cord-014712-5u4e00q6	753	32	.	.	.
cord-014712-5u4e00q6	754	1	A	a	DT
cord-014712-5u4e00q6	754	2	commonly	commonly	RB
cord-014712-5u4e00q6	754	3	used	use	VBN
cord-014712-5u4e00q6	754	4	test	test	NN
cord-014712-5u4e00q6	754	5	is	be	VBZ
cord-014712-5u4e00q6	754	6	called	call	VBN
cord-014712-5u4e00q6	754	7	flow	flow	NN
cord-014712-5u4e00q6	754	8	cytometry	cytometry	NN
cord-014712-5u4e00q6	754	9	that	that	WDT
cord-014712-5u4e00q6	754	10	can	can	MD
cord-014712-5u4e00q6	754	11	identify	identify	VB
cord-014712-5u4e00q6	754	12	B	b	NN
cord-014712-5u4e00q6	754	13	-	-	HYPH
cord-014712-5u4e00q6	754	14	cells	cell	NNS
cord-014712-5u4e00q6	754	15	and	and	CC
cord-014712-5u4e00q6	754	16	T	T	NNP
cord-014712-5u4e00q6	754	17	Cells	cell	NNS
cord-014712-5u4e00q6	754	18	present	present	JJ
cord-014712-5u4e00q6	754	19	in	in	IN
cord-014712-5u4e00q6	754	20	the	the	DT
cord-014712-5u4e00q6	754	21	circulation	circulation	NN
cord-014712-5u4e00q6	754	22	.	.	.
cord-014712-5u4e00q6	755	1	Methods	method	NNS
cord-014712-5u4e00q6	755	2	:	:	:
cord-014712-5u4e00q6	755	3	In	in	IN
cord-014712-5u4e00q6	755	4	2008	2008	CD
cord-014712-5u4e00q6	755	5	in	in	IN
cord-014712-5u4e00q6	755	6	our	-PRON-	PRP$
cord-014712-5u4e00q6	755	7	laboratory	laboratory	NN
cord-014712-5u4e00q6	755	8	of	of	IN
cord-014712-5u4e00q6	755	9	Immunology	Immunology	NNP
cord-014712-5u4e00q6	755	10	is	be	VBZ
cord-014712-5u4e00q6	755	11	created	create	VBN
cord-014712-5u4e00q6	755	12	the	the	DT
cord-014712-5u4e00q6	755	13	sector	sector	NN
cord-014712-5u4e00q6	755	14	of	of	IN
cord-014712-5u4e00q6	755	15	examination	examination	NN
cord-014712-5u4e00q6	755	16	for	for	IN
cord-014712-5u4e00q6	755	17	the	the	DT
cord-014712-5u4e00q6	755	18	PID	PID	NNP
cord-014712-5u4e00q6	755	19	and	and	CC
cord-014712-5u4e00q6	755	20	we	-PRON-	PRP
cord-014712-5u4e00q6	755	21	measure	measure	VBP
cord-014712-5u4e00q6	755	22	the	the	DT
cord-014712-5u4e00q6	755	23	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	755	24	levels	level	NNS
cord-014712-5u4e00q6	755	25	with	with	IN
cord-014712-5u4e00q6	755	26	a	a	DT
cord-014712-5u4e00q6	755	27	Beckman	Beckman	NNP
cord-014712-5u4e00q6	755	28	Coulter	Coulter	NNP
cord-014712-5u4e00q6	755	29	IMMAGE	IMMAGE	NNP
cord-014712-5u4e00q6	755	30	Immunochemistry	Immunochemistry	NNP
cord-014712-5u4e00q6	755	31	System	System	NNP
cord-014712-5u4e00q6	755	32	fully	fully	RB
cord-014712-5u4e00q6	755	33	automated	automate	VBD
cord-014712-5u4e00q6	755	34	rate	rate	NN
cord-014712-5u4e00q6	755	35	turbidometry	turbidometry	NN
cord-014712-5u4e00q6	755	36	and	and	CC
cord-014712-5u4e00q6	755	37	rate	rate	NNP
cord-014712-5u4e00q6	755	38	nephelometry	nephelometry	NNP
cord-014712-5u4e00q6	755	39	method	method	NN
cord-014712-5u4e00q6	755	40	.	.	.
cord-014712-5u4e00q6	756	1	We	-PRON-	PRP
cord-014712-5u4e00q6	756	2	have	have	VBP
cord-014712-5u4e00q6	756	3	determine	determine	VB
cord-014712-5u4e00q6	756	4	the	the	DT
cord-014712-5u4e00q6	756	5	aged	age	VBN
cord-014712-5u4e00q6	756	6	-	-	HYPH
cord-014712-5u4e00q6	756	7	matched	match	VBN
cord-014712-5u4e00q6	756	8	levels	level	NNS
cord-014712-5u4e00q6	756	9	of	of	IN
cord-014712-5u4e00q6	756	10	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	756	11	in	in	IN
cord-014712-5u4e00q6	756	12	our	-PRON-	PRP$
cord-014712-5u4e00q6	756	13	laboratory	laboratory	NN
cord-014712-5u4e00q6	756	14	.	.	.
cord-014712-5u4e00q6	757	1	We	-PRON-	PRP
cord-014712-5u4e00q6	757	2	have	have	VBP
cord-014712-5u4e00q6	757	3	install	install	VBN
cord-014712-5u4e00q6	757	4	also	also	RB
cord-014712-5u4e00q6	757	5	a	a	DT
cord-014712-5u4e00q6	757	6	new	new	JJ
cord-014712-5u4e00q6	757	7	flow	flow	NN
cord-014712-5u4e00q6	757	8	Cytometer	Cytometer	NNP
cord-014712-5u4e00q6	757	9	of	of	IN
cord-014712-5u4e00q6	757	10	Beckman	Beckman	NNP
cord-014712-5u4e00q6	757	11	Coulter	Coulter	NNP
cord-014712-5u4e00q6	757	12	company	company	NN
cord-014712-5u4e00q6	758	1	and	and	CC
cord-014712-5u4e00q6	758	2	we	-PRON-	PRP
cord-014712-5u4e00q6	758	3	can	can	MD
cord-014712-5u4e00q6	758	4	determine	determine	VB
cord-014712-5u4e00q6	758	5	the	the	DT
cord-014712-5u4e00q6	758	6	B	b	NN
cord-014712-5u4e00q6	758	7	Cells	cell	NNS
cord-014712-5u4e00q6	758	8	by	by	IN
cord-014712-5u4e00q6	758	9	CD19	CD19	NNP
cord-014712-5u4e00q6	758	10	marker	marker	NN
cord-014712-5u4e00q6	758	11	and	and	CC
cord-014712-5u4e00q6	758	12	T	t	NN
cord-014712-5u4e00q6	758	13	cell	cell	NN
cord-014712-5u4e00q6	758	14	with	with	IN
cord-014712-5u4e00q6	758	15	CD3	CD3	NNP
cord-014712-5u4e00q6	758	16	,	,	,
cord-014712-5u4e00q6	758	17	CD4	CD4	NNP
cord-014712-5u4e00q6	758	18	and	and	CC
cord-014712-5u4e00q6	758	19	CD8	CD8	NNP
cord-014712-5u4e00q6	758	20	marker	marker	NN
cord-014712-5u4e00q6	758	21	.	.	.
cord-014712-5u4e00q6	759	1	This	this	DT
cord-014712-5u4e00q6	759	2	examinations	examination	NNS
cord-014712-5u4e00q6	759	3	has	have	VBZ
cord-014712-5u4e00q6	759	4	been	be	VBN
cord-014712-5u4e00q6	759	5	of	of	IN
cord-014712-5u4e00q6	759	6	great	great	JJ
cord-014712-5u4e00q6	759	7	help	help	NN
cord-014712-5u4e00q6	759	8	in	in	IN
cord-014712-5u4e00q6	759	9	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	759	10	of	of	IN
cord-014712-5u4e00q6	759	11	primary	primary	JJ
cord-014712-5u4e00q6	759	12	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	759	13	.	.	.
cord-014712-5u4e00q6	760	1	Results	result	NNS
cord-014712-5u4e00q6	760	2	:	:	:
cord-014712-5u4e00q6	761	1	In	in	IN
cord-014712-5u4e00q6	761	2	years	year	NNS
cord-014712-5u4e00q6	761	3	2010	2010	CD
cord-014712-5u4e00q6	761	4	-	-	SYM
cord-014712-5u4e00q6	761	5	2013	2013	CD
cord-014712-5u4e00q6	761	6	from	from	IN
cord-014712-5u4e00q6	761	7	the	the	DT
cord-014712-5u4e00q6	761	8	examination	examination	NN
cord-014712-5u4e00q6	761	9	of	of	IN
cord-014712-5u4e00q6	761	10	children	child	NNS
cord-014712-5u4e00q6	761	11	aged	age	VBN
cord-014712-5u4e00q6	761	12	from	from	IN
cord-014712-5u4e00q6	761	13	0	0	CD
cord-014712-5u4e00q6	761	14	-	-	SYM
cord-014712-5u4e00q6	761	15	14	14	CD
cord-014712-5u4e00q6	761	16	years	year	NNS
cord-014712-5u4e00q6	761	17	old	old	JJ
cord-014712-5u4e00q6	761	18	reported	report	VBD
cord-014712-5u4e00q6	761	19	in	in	IN
cord-014712-5u4e00q6	761	20	our	-PRON-	PRP$
cord-014712-5u4e00q6	761	21	laboratory	laboratory	NN
cord-014712-5u4e00q6	761	22	for	for	IN
cord-014712-5u4e00q6	761	23	immunological	immunological	JJ
cord-014712-5u4e00q6	761	24	examination	examination	NN
cord-014712-5u4e00q6	761	25	from	from	IN
cord-014712-5u4e00q6	761	26	the	the	DT
cord-014712-5u4e00q6	761	27	pediatric	pediatric	JJ
cord-014712-5u4e00q6	761	28	department	department	NN
cord-014712-5u4e00q6	761	29	of	of	IN
cord-014712-5u4e00q6	761	30	UHC	UHC	NNP
cord-014712-5u4e00q6	761	31	Mother	Mother	NNP
cord-014712-5u4e00q6	761	32	Teresa	Teresa	NNP
cord-014712-5u4e00q6	761	33	in	in	IN
cord-014712-5u4e00q6	761	34	Tirana	Tirana	NNP
cord-014712-5u4e00q6	761	35	we	-PRON-	PRP
cord-014712-5u4e00q6	761	36	have	have	VBP
cord-014712-5u4e00q6	761	37	selected	select	VBN
cord-014712-5u4e00q6	761	38	41	41	CD
cord-014712-5u4e00q6	761	39	cases	case	NNS
cord-014712-5u4e00q6	761	40	with	with	IN
cord-014712-5u4e00q6	761	41	disorders	disorder	NNS
cord-014712-5u4e00q6	761	42	regarding	regard	VBG
cord-014712-5u4e00q6	761	43	the	the	DT
cord-014712-5u4e00q6	761	44	primary	primary	JJ
cord-014712-5u4e00q6	761	45	immune	immune	JJ
cord-014712-5u4e00q6	761	46	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	761	47	.	.	.
cord-014712-5u4e00q6	762	1	We	-PRON-	PRP
cord-014712-5u4e00q6	762	2	have	have	VBP
cord-014712-5u4e00q6	762	3	5	5	CD
cord-014712-5u4e00q6	762	4	cases	case	NNS
cord-014712-5u4e00q6	762	5	(	(	-LRB-
cord-014712-5u4e00q6	762	6	3	3	CD
cord-014712-5u4e00q6	762	7	cases	case	NNS
cord-014712-5u4e00q6	762	8	reported	report	VBN
cord-014712-5u4e00q6	762	9	in	in	IN
cord-014712-5u4e00q6	762	10	2008	2008	CD
cord-014712-5u4e00q6	762	11	-	-	SYM
cord-014712-5u4e00q6	762	12	2009	2009	CD
cord-014712-5u4e00q6	762	13	and	and	CC
cord-014712-5u4e00q6	762	14	2	2	CD
cord-014712-5u4e00q6	762	15	new	new	JJ
cord-014712-5u4e00q6	762	16	cases	case	NNS
cord-014712-5u4e00q6	762	17	)	)	-RRB-
cord-014712-5u4e00q6	762	18	with	with	IN
cord-014712-5u4e00q6	762	19	nul	nul	NNP
cord-014712-5u4e00q6	762	20	B	B	NNP
cord-014712-5u4e00q6	762	21	cell	cell	NN
cord-014712-5u4e00q6	762	22	in	in	IN
cord-014712-5u4e00q6	762	23	Cytoflorometry	Cytoflorometry	NNP
cord-014712-5u4e00q6	762	24	(	(	-LRB-
cord-014712-5u4e00q6	762	25	B	b	NN
cord-014712-5u4e00q6	762	26	Cd19	Cd19	NNP
cord-014712-5u4e00q6	762	27	cell	cell	NN
cord-014712-5u4e00q6	762	28	=	=	SYM
cord-014712-5u4e00q6	762	29	0	0	CD
cord-014712-5u4e00q6	762	30	%	%	NN
cord-014712-5u4e00q6	762	31	)	)	-RRB-
cord-014712-5u4e00q6	762	32	.	.	.
cord-014712-5u4e00q6	763	1	The	the	DT
cord-014712-5u4e00q6	763	2	level	level	NN
cord-014712-5u4e00q6	763	3	of	of	IN
cord-014712-5u4e00q6	763	4	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	763	5	was	be	VBD
cord-014712-5u4e00q6	763	6	indetectable	indetectable	JJ
cord-014712-5u4e00q6	763	7	for	for	IN
cord-014712-5u4e00q6	763	8	IgG	IgG	NNP
cord-014712-5u4e00q6	763	9	,	,	,
cord-014712-5u4e00q6	763	10	IgA	IgA	NNP
cord-014712-5u4e00q6	763	11	and	and	CC
cord-014712-5u4e00q6	763	12	IgM	IgM	NNP
cord-014712-5u4e00q6	763	13	in	in	IN
cord-014712-5u4e00q6	763	14	the	the	DT
cord-014712-5u4e00q6	763	15	moment	moment	NN
cord-014712-5u4e00q6	763	16	of	of	IN
cord-014712-5u4e00q6	763	17	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	763	18	.	.	.
cord-014712-5u4e00q6	764	1	They	-PRON-	PRP
cord-014712-5u4e00q6	764	2	were	be	VBD
cord-014712-5u4e00q6	765	1	boys	boy	NNS
cord-014712-5u4e00q6	765	2	and	and	CC
cord-014712-5u4e00q6	765	3	the	the	DT
cord-014712-5u4e00q6	765	4	age	age	NN
cord-014712-5u4e00q6	765	5	at	at	IN
cord-014712-5u4e00q6	765	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	765	7	was	be	VBD
cord-014712-5u4e00q6	765	8	3	3	CD
cord-014712-5u4e00q6	765	9	and	and	CC
cord-014712-5u4e00q6	765	10	4	4	CD
cord-014712-5u4e00q6	765	11	years	year	NNS
cord-014712-5u4e00q6	766	1	and	and	CC
cord-014712-5u4e00q6	766	2	actually	actually	RB
cord-014712-5u4e00q6	766	3	they	-PRON-	PRP
cord-014712-5u4e00q6	766	4	are	be	VBP
cord-014712-5u4e00q6	766	5	4	4	CD
cord-014712-5u4e00q6	766	6	and	and	CC
cord-014712-5u4e00q6	766	7	6	6	CD
cord-014712-5u4e00q6	766	8	years	year	NNS
cord-014712-5u4e00q6	766	9	treated	treat	VBN
cord-014712-5u4e00q6	766	10	with	with	IN
cord-014712-5u4e00q6	766	11	IVIG	IVIG	NNP
cord-014712-5u4e00q6	766	12	.	.	.
cord-014712-5u4e00q6	767	1	We	-PRON-	PRP
cord-014712-5u4e00q6	767	2	have	have	VBP
cord-014712-5u4e00q6	767	3	classified	classify	VBN
cord-014712-5u4e00q6	767	4	them	-PRON-	PRP
cord-014712-5u4e00q6	767	5	as	as	IN
cord-014712-5u4e00q6	767	6	Bruton	Bruton	NNP
cord-014712-5u4e00q6	767	7	(	(	-LRB-
cord-014712-5u4e00q6	767	8	XLA	XLA	NNP
cord-014712-5u4e00q6	767	9	)	)	-RRB-
cord-014712-5u4e00q6	767	10	.	.	.
cord-014712-5u4e00q6	768	1	We	-PRON-	PRP
cord-014712-5u4e00q6	768	2	have	have	VBP
cord-014712-5u4e00q6	768	3	12	12	CD
cord-014712-5u4e00q6	768	4	case	case	NN
cord-014712-5u4e00q6	768	5	with	with	IN
cord-014712-5u4e00q6	768	6	low	low	JJ
cord-014712-5u4e00q6	768	7	Cd19	Cd19	NNP
cord-014712-5u4e00q6	768	8	B	b	NN
cord-014712-5u4e00q6	768	9	-	-	HYPH
cord-014712-5u4e00q6	768	10	cell	cell	NN
cord-014712-5u4e00q6	768	11	in	in	IN
cord-014712-5u4e00q6	768	12	circulation	circulation	NN
cord-014712-5u4e00q6	768	13	but	but	CC
cord-014712-5u4e00q6	768	14	only	only	RB
cord-014712-5u4e00q6	768	15	in	in	IN
cord-014712-5u4e00q6	768	16	4	4	CD
cord-014712-5u4e00q6	768	17	of	of	IN
cord-014712-5u4e00q6	768	18	them	-PRON-	PRP
cord-014712-5u4e00q6	768	19	we	-PRON-	PRP
cord-014712-5u4e00q6	768	20	have	have	VBP
cord-014712-5u4e00q6	768	21	done	do	VBN
cord-014712-5u4e00q6	768	22	the	the	DT
cord-014712-5u4e00q6	768	23	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	768	24	level	level	NN
cord-014712-5u4e00q6	768	25	.	.	.
cord-014712-5u4e00q6	769	1	The	the	DT
cord-014712-5u4e00q6	769	2	low	low	JJ
cord-014712-5u4e00q6	769	3	level	level	NN
cord-014712-5u4e00q6	769	4	of	of	IN
cord-014712-5u4e00q6	769	5	Cd19	Cd19	NNP
cord-014712-5u4e00q6	769	6	B	b	NN
cord-014712-5u4e00q6	769	7	cell	cell	NN
cord-014712-5u4e00q6	769	8	is	be	VBZ
cord-014712-5u4e00q6	769	9	accompanied	accompany	VBN
cord-014712-5u4e00q6	769	10	with	with	IN
cord-014712-5u4e00q6	769	11	different	different	JJ
cord-014712-5u4e00q6	769	12	kind	kind	NN
cord-014712-5u4e00q6	769	13	of	of	IN
cord-014712-5u4e00q6	769	14	hypoglobulinemies	hypoglobulinemie	NNS
cord-014712-5u4e00q6	769	15	:	:	:
cord-014712-5u4e00q6	769	16	1Common	1common	CD
cord-014712-5u4e00q6	769	17	Variable	variable	JJ
cord-014712-5u4e00q6	769	18	Immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	769	19	CVID	CVID	NNP
cord-014712-5u4e00q6	769	20	,	,	,
cord-014712-5u4e00q6	769	21	1	1	CD
cord-014712-5u4e00q6	769	22	with	with	IN
cord-014712-5u4e00q6	769	23	isolated	isolate	VBN
cord-014712-5u4e00q6	769	24	IgA	IgA	NNP
cord-014712-5u4e00q6	769	25	deficiency	deficiency	NN
cord-014712-5u4e00q6	769	26	,	,	,
cord-014712-5u4e00q6	769	27	1	1	CD
cord-014712-5u4e00q6	769	28	with	with	IN
cord-014712-5u4e00q6	769	29	IgG	IgG	NNP
cord-014712-5u4e00q6	769	30	deficiency	deficiency	NN
cord-014712-5u4e00q6	769	31	and	and	CC
cord-014712-5u4e00q6	769	32	1	1	CD
cord-014712-5u4e00q6	769	33	with	with	IN
cord-014712-5u4e00q6	769	34	both	both	CC
cord-014712-5u4e00q6	769	35	IgG	IgG	NNP
cord-014712-5u4e00q6	769	36	+	+	SYM
cord-014712-5u4e00q6	769	37	IgM	IgM	NNP
cord-014712-5u4e00q6	769	38	deficiency	deficiency	NN
cord-014712-5u4e00q6	769	39	.	.	.
cord-014712-5u4e00q6	770	1	The	the	DT
cord-014712-5u4e00q6	770	2	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	770	3	disorders	disorder	NNS
cord-014712-5u4e00q6	770	4	:	:	:
cord-014712-5u4e00q6	770	5	we	-PRON-	PRP
cord-014712-5u4e00q6	770	6	have	have	VBP
cord-014712-5u4e00q6	770	7	classified	classify	VBN
cord-014712-5u4e00q6	770	8	them	-PRON-	PRP
cord-014712-5u4e00q6	770	9	according	accord	VBG
cord-014712-5u4e00q6	770	10	the	the	DT
cord-014712-5u4e00q6	770	11	antibody	antibody	NN
cord-014712-5u4e00q6	770	12	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	770	13	(	(	-LRB-
cord-014712-5u4e00q6	770	14	tab1	tab1	NN
cord-014712-5u4e00q6	770	15	)	)	-RRB-
cord-014712-5u4e00q6	770	16	and	and	CC
cord-014712-5u4e00q6	770	17	we	-PRON-	PRP
cord-014712-5u4e00q6	770	18	noted	note	VBD
cord-014712-5u4e00q6	770	19	that	that	IN
cord-014712-5u4e00q6	770	20	the	the	DT
cord-014712-5u4e00q6	770	21	most	most	RBS
cord-014712-5u4e00q6	770	22	frequent	frequent	JJ
cord-014712-5u4e00q6	770	23	one	one	NN
cord-014712-5u4e00q6	770	24	is	be	VBZ
cord-014712-5u4e00q6	770	25	the	the	DT
cord-014712-5u4e00q6	770	26	deficiency	deficiency	NN
cord-014712-5u4e00q6	770	27	of	of	IN
cord-014712-5u4e00q6	770	28	IgA	IgA	NNP
cord-014712-5u4e00q6	770	29	(	(	-LRB-
cord-014712-5u4e00q6	770	30	12/19	12/19	CD
cord-014712-5u4e00q6	770	31	or	or	CC
cord-014712-5u4e00q6	770	32	63.2	63.2	CD
cord-014712-5u4e00q6	770	33	%	%	NN
cord-014712-5u4e00q6	770	34	-from	-from	NN
cord-014712-5u4e00q6	770	35	which	which	WDT
cord-014712-5u4e00q6	770	36	6	6	CD
cord-014712-5u4e00q6	770	37	IgA	IgA	NNP
cord-014712-5u4e00q6	770	38	isolated	isolate	VBN
cord-014712-5u4e00q6	770	39	,	,	,
cord-014712-5u4e00q6	770	40	5	5	CD
cord-014712-5u4e00q6	770	41	accompanied	accompany	VBN
cord-014712-5u4e00q6	770	42	with	with	IN
cord-014712-5u4e00q6	770	43	low	low	JJ
cord-014712-5u4e00q6	770	44	IgM	IgM	NNP
cord-014712-5u4e00q6	770	45	and	and	CC
cord-014712-5u4e00q6	770	46	1	1	CD
cord-014712-5u4e00q6	770	47	with	with	IN
cord-014712-5u4e00q6	770	48	low	low	JJ
cord-014712-5u4e00q6	770	49	IgG	igg	NN
cord-014712-5u4e00q6	770	50	)	)	-RRB-
cord-014712-5u4e00q6	770	51	with	with	IN
cord-014712-5u4e00q6	770	52	average	average	JJ
cord-014712-5u4e00q6	770	53	age	age	NN
cord-014712-5u4e00q6	770	54	at	at	IN
cord-014712-5u4e00q6	770	55	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	770	56	5.09	5.09	CD
cord-014712-5u4e00q6	770	57	years	year	NNS
cord-014712-5u4e00q6	770	58	old	old	JJ
cord-014712-5u4e00q6	770	59	.	.	.
cord-014712-5u4e00q6	771	1	In	in	IN
cord-014712-5u4e00q6	771	2	children	child	NNS
cord-014712-5u4e00q6	771	3	in	in	IN
cord-014712-5u4e00q6	771	4	the	the	DT
cord-014712-5u4e00q6	771	5	first	first	JJ
cord-014712-5u4e00q6	771	6	years	year	NNS
cord-014712-5u4e00q6	771	7	of	of	IN
cord-014712-5u4e00q6	771	8	live	live	JJ
cord-014712-5u4e00q6	771	9	aged	age	VBN
cord-014712-5u4e00q6	771	10	from	from	IN
cord-014712-5u4e00q6	771	11	0.8	0.8	CD
cord-014712-5u4e00q6	771	12	to	to	TO
cord-014712-5u4e00q6	771	13	2	2	CD
cord-014712-5u4e00q6	771	14	years	year	NNS
cord-014712-5u4e00q6	771	15	old	old	JJ
cord-014712-5u4e00q6	771	16	we	-PRON-	PRP
cord-014712-5u4e00q6	771	17	found	find	VBD
cord-014712-5u4e00q6	771	18	8	8	CD
cord-014712-5u4e00q6	771	19	case	case	NN
cord-014712-5u4e00q6	771	20	with	with	IN
cord-014712-5u4e00q6	771	21	transient	transient	JJ
cord-014712-5u4e00q6	771	22	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	771	23	of	of	IN
cord-014712-5u4e00q6	771	24	infancy	infancy	NN
cord-014712-5u4e00q6	771	25	.	.	.
cord-014712-5u4e00q6	772	1	According	accord	VBG
cord-014712-5u4e00q6	772	2	this	this	DT
cord-014712-5u4e00q6	772	3	survey	survey	NN
cord-014712-5u4e00q6	772	4	we	-PRON-	PRP
cord-014712-5u4e00q6	772	5	can	can	MD
cord-014712-5u4e00q6	772	6	report	report	VB
cord-014712-5u4e00q6	772	7	our	-PRON-	PRP$
cord-014712-5u4e00q6	772	8	92	92	CD
cord-014712-5u4e00q6	772	9	cases	case	NNS
cord-014712-5u4e00q6	772	10	of	of	IN
cord-014712-5u4e00q6	772	11	primary	primary	JJ
cord-014712-5u4e00q6	772	12	immunodefiecies	immunodefiecie	NNS
cord-014712-5u4e00q6	772	13	in	in	IN
cord-014712-5u4e00q6	772	14	UHC	UHC	NNP
cord-014712-5u4e00q6	772	15	Mother	Mother	NNP
cord-014712-5u4e00q6	772	16	Teresa	Teresa	NNP
cord-014712-5u4e00q6	772	17	of	of	IN
cord-014712-5u4e00q6	772	18	Tirana	Tirana	NNP
cord-014712-5u4e00q6	772	19	with	with	IN
cord-014712-5u4e00q6	772	20	different	different	JJ
cord-014712-5u4e00q6	772	21	classification	classification	NN
cord-014712-5u4e00q6	772	22	Conclusion	conclusion	NN
cord-014712-5u4e00q6	772	23	:	:	:
cord-014712-5u4e00q6	772	24	The	the	DT
cord-014712-5u4e00q6	772	25	finding	finding	NN
cord-014712-5u4e00q6	772	26	are	be	VBP
cord-014712-5u4e00q6	772	27	to	to	TO
cord-014712-5u4e00q6	772	28	be	be	VB
cord-014712-5u4e00q6	772	29	completed	complete	VBN
cord-014712-5u4e00q6	772	30	with	with	IN
cord-014712-5u4e00q6	772	31	other	other	JJ
cord-014712-5u4e00q6	772	32	cases	case	NNS
cord-014712-5u4e00q6	772	33	in	in	IN
cord-014712-5u4e00q6	772	34	Albania	Albania	NNP
cord-014712-5u4e00q6	773	1	and	and	CC
cord-014712-5u4e00q6	773	2	it	-PRON-	PRP
cord-014712-5u4e00q6	773	3	is	be	VBZ
cord-014712-5u4e00q6	773	4	necessary	necessary	JJ
cord-014712-5u4e00q6	773	5	to	to	TO
cord-014712-5u4e00q6	773	6	do	do	VB
cord-014712-5u4e00q6	773	7	the	the	DT
cord-014712-5u4e00q6	773	8	national	national	JJ
cord-014712-5u4e00q6	773	9	register	register	NN
cord-014712-5u4e00q6	773	10	for	for	IN
cord-014712-5u4e00q6	773	11	PID	PID	NNP
cord-014712-5u4e00q6	773	12	in	in	IN
cord-014712-5u4e00q6	773	13	order	order	NN
cord-014712-5u4e00q6	773	14	to	to	TO
cord-014712-5u4e00q6	773	15	estimate	estimate	VB
cord-014712-5u4e00q6	773	16	exactly	exactly	RB
cord-014712-5u4e00q6	773	17	the	the	DT
cord-014712-5u4e00q6	773	18	prevalence	prevalence	NN
cord-014712-5u4e00q6	773	19	of	of	IN
cord-014712-5u4e00q6	773	20	this	this	DT
cord-014712-5u4e00q6	773	21	disorders	disorder	NNS
cord-014712-5u4e00q6	773	22	in	in	IN
cord-014712-5u4e00q6	773	23	our	-PRON-	PRP$
cord-014712-5u4e00q6	773	24	country	country	NN
cord-014712-5u4e00q6	773	25	.	.	.
cord-014712-5u4e00q6	774	1	Nyíregyháza	Nyíregyháza	NNP
cord-014712-5u4e00q6	774	2	-	-	HYPH
cord-014712-5u4e00q6	774	3	Debrecen	Debrecen	NNP
cord-014712-5u4e00q6	774	4	,	,	,
cord-014712-5u4e00q6	774	5	Hungary	Hungary	NNP
cord-014712-5u4e00q6	775	1	The	the	DT
cord-014712-5u4e00q6	775	2	STAT3	STAT3	NNP
cord-014712-5u4e00q6	775	3	mutation	mutation	NN
cord-014712-5u4e00q6	775	4	was	be	VBD
cord-014712-5u4e00q6	775	5	confirmed	confirm	VBN
cord-014712-5u4e00q6	775	6	in	in	IN
cord-014712-5u4e00q6	775	7	2007	2007	CD
cord-014712-5u4e00q6	775	8	as	as	IN
cord-014712-5u4e00q6	775	9	the	the	DT
cord-014712-5u4e00q6	775	10	cause	cause	NN
cord-014712-5u4e00q6	775	11	of	of	IN
cord-014712-5u4e00q6	775	12	autosomal	autosomal	JJ
cord-014712-5u4e00q6	775	13	dominant	dominant	JJ
cord-014712-5u4e00q6	775	14	hyper	hyper	NNP
cord-014712-5u4e00q6	775	15	-	-	HYPH
cord-014712-5u4e00q6	775	16	IgE	ige	JJ
cord-014712-5u4e00q6	775	17	syndrome	syndrome	NN
cord-014712-5u4e00q6	775	18	(	(	-LRB-
cord-014712-5u4e00q6	775	19	AD	ad	NN
cord-014712-5u4e00q6	775	20	-	-	HYPH
cord-014712-5u4e00q6	775	21	HIES	HIES	NNP
cord-014712-5u4e00q6	775	22	)	)	-RRB-
cord-014712-5u4e00q6	775	23	.	.	.
cord-014712-5u4e00q6	776	1	The	the	DT
cord-014712-5u4e00q6	776	2	disease	disease	NN
cord-014712-5u4e00q6	776	3	,	,	,
cord-014712-5u4e00q6	776	4	which	which	WDT
cord-014712-5u4e00q6	776	5	also	also	RB
cord-014712-5u4e00q6	776	6	mentioned	mention	VBD
cord-014712-5u4e00q6	776	7	in	in	IN
cord-014712-5u4e00q6	776	8	the	the	DT
cord-014712-5u4e00q6	776	9	literature	literature	NN
cord-014712-5u4e00q6	776	10	as	as	IN
cord-014712-5u4e00q6	776	11	Job	Job	NNP
cord-014712-5u4e00q6	776	12	's	's	POS
cord-014712-5u4e00q6	776	13	syndrome	syndrome	NN
cord-014712-5u4e00q6	776	14	,	,	,
cord-014712-5u4e00q6	776	15	is	be	VBZ
cord-014712-5u4e00q6	776	16	a	a	DT
cord-014712-5u4e00q6	776	17	rare	rare	JJ
cord-014712-5u4e00q6	776	18	primary	primary	JJ
cord-014712-5u4e00q6	776	19	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	776	20	.	.	.
cord-014712-5u4e00q6	777	1	This	this	DT
cord-014712-5u4e00q6	777	2	disease	disease	NN
cord-014712-5u4e00q6	777	3	can	can	MD
cord-014712-5u4e00q6	777	4	be	be	VB
cord-014712-5u4e00q6	777	5	characterized	characterize	VBN
cord-014712-5u4e00q6	777	6	by	by	IN
cord-014712-5u4e00q6	777	7	the	the	DT
cord-014712-5u4e00q6	777	8	following	follow	VBG
cord-014712-5u4e00q6	777	9	classic	classic	JJ
cord-014712-5u4e00q6	777	10	triad	triad	NN
cord-014712-5u4e00q6	777	11	:	:	:
cord-014712-5u4e00q6	777	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	777	13	purulent	purulent	JJ
cord-014712-5u4e00q6	777	14	skin	skin	NN
cord-014712-5u4e00q6	777	15	infections	infection	NNS
cord-014712-5u4e00q6	777	16	,	,	,
cord-014712-5u4e00q6	777	17	cold	cold	JJ
cord-014712-5u4e00q6	777	18	abscessus	abscessus	NN
cord-014712-5u4e00q6	777	19	which	which	WDT
cord-014712-5u4e00q6	777	20	are	be	VBP
cord-014712-5u4e00q6	777	21	formed	form	VBN
cord-014712-5u4e00q6	777	22	in	in	IN
cord-014712-5u4e00q6	777	23	the	the	DT
cord-014712-5u4e00q6	777	24	ground	ground	NN
cord-014712-5u4e00q6	777	25	of	of	IN
cord-014712-5u4e00q6	777	26	chronic	chronic	JJ
cord-014712-5u4e00q6	777	27	ekcematoid	ekcematoid	NNP
cord-014712-5u4e00q6	777	28	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	777	29	,	,	,
cord-014712-5u4e00q6	777	30	pneumatocele	pneumatocele	NNP
cord-014712-5u4e00q6	777	31	,	,	,
cord-014712-5u4e00q6	777	32	formation	formation	NN
cord-014712-5u4e00q6	777	33	causing	cause	VBG
cord-014712-5u4e00q6	777	34	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	777	35	and	and	CC
cord-014712-5u4e00q6	777	36	extremely	extremely	RB
cord-014712-5u4e00q6	777	37	high	high	JJ
cord-014712-5u4e00q6	777	38	IgE	ige	NN
cord-014712-5u4e00q6	777	39	level	level	NN
cord-014712-5u4e00q6	777	40	.	.	.
cord-014712-5u4e00q6	778	1	Dental	dental	JJ
cord-014712-5u4e00q6	778	2	training	training	NN
cord-014712-5u4e00q6	778	3	interdependency	interdependency	NN
cord-014712-5u4e00q6	778	4	as	as	RB
cord-014712-5u4e00q6	778	5	well	well	RB
cord-014712-5u4e00q6	778	6	as	as	IN
cord-014712-5u4e00q6	778	7	bone	bone	NN
cord-014712-5u4e00q6	778	8	and	and	CC
cord-014712-5u4e00q6	778	9	connective	connective	JJ
cord-014712-5u4e00q6	778	10	tissue	tissue	NN
cord-014712-5u4e00q6	778	11	disorders	disorder	NNS
cord-014712-5u4e00q6	778	12	frequently	frequently	RB
cord-014712-5u4e00q6	778	13	occur	occur	VBP
cord-014712-5u4e00q6	778	14	in	in	IN
cord-014712-5u4e00q6	778	15	the	the	DT
cord-014712-5u4e00q6	778	16	nonimmunological	nonimmunological	JJ
cord-014712-5u4e00q6	778	17	symptoms	symptom	NNS
cord-014712-5u4e00q6	778	18	as	as	IN
cord-014712-5u4e00q6	778	19	multi	multi	JJ
cord-014712-5u4e00q6	778	20	-	-	JJ
cord-014712-5u4e00q6	778	21	systemic	systemic	JJ
cord-014712-5u4e00q6	778	22	disease	disease	NN
cord-014712-5u4e00q6	778	23	.	.	.
cord-014712-5u4e00q6	779	1	The	the	DT
cord-014712-5u4e00q6	779	2	STAT	stat	NN
cord-014712-5u4e00q6	779	3	3	3	CD
cord-014712-5u4e00q6	779	4	protein	protein	NN
cord-014712-5u4e00q6	779	5	has	have	VBZ
cord-014712-5u4e00q6	779	6	an	an	DT
cord-014712-5u4e00q6	779	7	important	important	JJ
cord-014712-5u4e00q6	779	8	role	role	NN
cord-014712-5u4e00q6	779	9	in	in	IN
cord-014712-5u4e00q6	779	10	the	the	DT
cord-014712-5u4e00q6	779	11	area	area	NN
cord-014712-5u4e00q6	779	12	of	of	IN
cord-014712-5u4e00q6	779	13	wound	wound	NN
cord-014712-5u4e00q6	779	14	healing	healing	NN
cord-014712-5u4e00q6	779	15	,	,	,
cord-014712-5u4e00q6	779	16	immunity	immunity	NN
cord-014712-5u4e00q6	779	17	,	,	,
cord-014712-5u4e00q6	779	18	tumor	tumor	NN
cord-014712-5u4e00q6	779	19	and	and	CC
cord-014712-5u4e00q6	779	20	neovascularization	neovascularization	NN
cord-014712-5u4e00q6	779	21	.	.	.
cord-014712-5u4e00q6	780	1	We	-PRON-	PRP
cord-014712-5u4e00q6	780	2	would	would	MD
cord-014712-5u4e00q6	780	3	like	like	VB
cord-014712-5u4e00q6	780	4	to	to	TO
cord-014712-5u4e00q6	780	5	show	show	VB
cord-014712-5u4e00q6	780	6	this	this	DT
cord-014712-5u4e00q6	780	7	in	in	IN
cord-014712-5u4e00q6	780	8	case	case	NN
cord-014712-5u4e00q6	780	9	of	of	IN
cord-014712-5u4e00q6	780	10	3-years	3-years	CD
cord-014712-5u4e00q6	780	11	old	old	JJ
cord-014712-5u4e00q6	780	12	Kitti	Kitti	NNP
cord-014712-5u4e00q6	780	13	whom	whom	WP
cord-014712-5u4e00q6	780	14	the	the	DT
cord-014712-5u4e00q6	780	15	perinatal	perinatal	JJ
cord-014712-5u4e00q6	780	16	medical	medical	JJ
cord-014712-5u4e00q6	780	17	history	history	NN
cord-014712-5u4e00q6	780	18	was	be	VBD
cord-014712-5u4e00q6	780	19	eventless	eventless	JJ
cord-014712-5u4e00q6	780	20	.	.	.
cord-014712-5u4e00q6	781	1	There	there	EX
cord-014712-5u4e00q6	781	2	is	be	VBZ
cord-014712-5u4e00q6	781	3	a	a	DT
cord-014712-5u4e00q6	781	4	frequent	frequent	JJ
cord-014712-5u4e00q6	781	5	hospitalization	hospitalization	NN
cord-014712-5u4e00q6	781	6	in	in	IN
cord-014712-5u4e00q6	781	7	Kitti	Kitti	NNP
cord-014712-5u4e00q6	781	8	's	's	POS
cord-014712-5u4e00q6	781	9	case	case	NN
cord-014712-5u4e00q6	781	10	history	history	NN
cord-014712-5u4e00q6	781	11	since	since	IN
cord-014712-5u4e00q6	781	12	her	-PRON-	PRP$
cord-014712-5u4e00q6	781	13	infancy	infancy	NN
cord-014712-5u4e00q6	781	14	.	.	.
cord-014712-5u4e00q6	782	1	Due	due	IN
cord-014712-5u4e00q6	782	2	to	to	IN
cord-014712-5u4e00q6	782	3	the	the	DT
cord-014712-5u4e00q6	782	4	age	age	NN
cord-014712-5u4e00q6	782	5	of	of	IN
cord-014712-5u4e00q6	782	6	three	three	CD
cord-014712-5u4e00q6	782	7	months	month	NNS
cord-014712-5u4e00q6	782	8	because	because	IN
cord-014712-5u4e00q6	782	9	of	of	IN
cord-014712-5u4e00q6	782	10	serious	serious	JJ
cord-014712-5u4e00q6	782	11	exsiccotoxicosis	exsiccotoxicosis	NN
cord-014712-5u4e00q6	782	12	,	,	,
cord-014712-5u4e00q6	782	13	5	5	CD
cord-014712-5u4e00q6	782	14	months	month	NNS
cord-014712-5u4e00q6	782	15	old	old	JJ
cord-014712-5u4e00q6	782	16	bilateral	bilateral	JJ
cord-014712-5u4e00q6	782	17	bronchopneumonia	bronchopneumonia	NN
cord-014712-5u4e00q6	782	18	and	and	CC
cord-014712-5u4e00q6	782	19	pleurisy	pleurisy	NN
cord-014712-5u4e00q6	782	20	required	require	VBD
cord-014712-5u4e00q6	782	21	ICU	ICU	NNP
cord-014712-5u4e00q6	782	22	care	care	NN
cord-014712-5u4e00q6	782	23	.	.	.
cord-014712-5u4e00q6	783	1	Bronchoscopy	Bronchoscopy	NNP
cord-014712-5u4e00q6	783	2	was	be	VBD
cord-014712-5u4e00q6	783	3	made	make	VBN
cord-014712-5u4e00q6	783	4	because	because	IN
cord-014712-5u4e00q6	783	5	of	of	IN
cord-014712-5u4e00q6	783	6	recurrent	recurrent	JJ
cord-014712-5u4e00q6	783	7	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	783	8	,	,	,
cord-014712-5u4e00q6	783	9	which	which	WDT
cord-014712-5u4e00q6	783	10	excluded	exclude	VBD
cord-014712-5u4e00q6	783	11	the	the	DT
cord-014712-5u4e00q6	783	12	bronchial	bronchial	JJ
cord-014712-5u4e00q6	783	13	malformation	malformation	NN
cord-014712-5u4e00q6	783	14	.	.	.
cord-014712-5u4e00q6	784	1	Lately	lately	RB
cord-014712-5u4e00q6	784	2	rather	rather	RB
cord-014712-5u4e00q6	784	3	otitis	otitis	NN
cord-014712-5u4e00q6	784	4	,	,	,
cord-014712-5u4e00q6	784	5	mastoiditis	mastoiditis	NNP
cord-014712-5u4e00q6	784	6	and	and	CC
cord-014712-5u4e00q6	784	7	airway	airway	JJ
cord-014712-5u4e00q6	784	8	obstructive	obstructive	JJ
cord-014712-5u4e00q6	784	9	symptoms	symptom	NNS
cord-014712-5u4e00q6	784	10	dominated	dominate	VBD
cord-014712-5u4e00q6	784	11	the	the	DT
cord-014712-5u4e00q6	784	12	clinical	clinical	JJ
cord-014712-5u4e00q6	784	13	picture	picture	NN
cord-014712-5u4e00q6	784	14	.	.	.
cord-014712-5u4e00q6	785	1	From	from	IN
cord-014712-5u4e00q6	785	2	serum	serum	NN
cord-014712-5u4e00q6	785	3	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	785	4	-	-	HYPH
cord-014712-5u4e00q6	785	5	IgG	igg	NN
cord-014712-5u4e00q6	785	6	is	be	VBZ
cord-014712-5u4e00q6	785	7	very	very	RB
cord-014712-5u4e00q6	785	8	low	low	JJ
cord-014712-5u4e00q6	785	9	,	,	,
cord-014712-5u4e00q6	785	10	whereas	whereas	IN
cord-014712-5u4e00q6	785	11	high	high	JJ
cord-014712-5u4e00q6	785	12	levels	level	NNS
cord-014712-5u4e00q6	785	13	of	of	IN
cord-014712-5u4e00q6	785	14	IgEwas	IgEwas	NNP
cord-014712-5u4e00q6	785	15	indicated	indicate	VBD
cord-014712-5u4e00q6	785	16	.	.	.
cord-014712-5u4e00q6	786	1	On	on	IN
cord-014712-5u4e00q6	786	2	this	this	DT
cord-014712-5u4e00q6	786	3	basis	basis	NN
cord-014712-5u4e00q6	786	4	,	,	,
cord-014712-5u4e00q6	786	5	the	the	DT
cord-014712-5u4e00q6	786	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	786	7	of	of	IN
cord-014712-5u4e00q6	786	8	Job	Job	NNP
cord-014712-5u4e00q6	786	9	's	's	POS
cord-014712-5u4e00q6	786	10	syndrome	syndrome	NN
cord-014712-5u4e00q6	786	11	was	be	VBD
cord-014712-5u4e00q6	786	12	up	up	RB
cord-014712-5u4e00q6	786	13	,	,	,
cord-014712-5u4e00q6	786	14	which	which	WDT
cord-014712-5u4e00q6	786	15	is	be	VBZ
cord-014712-5u4e00q6	786	16	a	a	DT
cord-014712-5u4e00q6	786	17	negative	negative	JJ
cord-014712-5u4e00q6	786	18	STAT3	stat3	NN
cord-014712-5u4e00q6	786	19	mutations	mutation	NNS
cord-014712-5u4e00q6	786	20	as	as	IN
cord-014712-5u4e00q6	786	21	the	the	DT
cord-014712-5u4e00q6	786	22	molecular	molecular	JJ
cord-014712-5u4e00q6	786	23	genetic	genetic	JJ
cord-014712-5u4e00q6	786	24	test	test	NN
cord-014712-5u4e00q6	786	25	performed	perform	VBD
cord-014712-5u4e00q6	786	26	demonstrated	demonstrate	VBD
cord-014712-5u4e00q6	786	27	.	.	.
cord-014712-5u4e00q6	787	1	The	the	DT
cord-014712-5u4e00q6	787	2	disease	disease	NN
cord-014712-5u4e00q6	787	3	has	have	VBZ
cord-014712-5u4e00q6	787	4	a	a	DT
cord-014712-5u4e00q6	787	5	great	great	JJ
cord-014712-5u4e00q6	787	6	clinical	clinical	JJ
cord-014712-5u4e00q6	787	7	importance	importance	NN
cord-014712-5u4e00q6	787	8	,	,	,
cord-014712-5u4e00q6	787	9	since	since	IN
cord-014712-5u4e00q6	787	10	the	the	DT
cord-014712-5u4e00q6	787	11	risk	risk	NN
cord-014712-5u4e00q6	787	12	of	of	IN
cord-014712-5u4e00q6	787	13	emergence	emergence	NN
cord-014712-5u4e00q6	787	14	of	of	IN
cord-014712-5u4e00q6	787	15	serious	serious	JJ
cord-014712-5u4e00q6	787	16	and	and	CC
cord-014712-5u4e00q6	787	17	often	often	RB
cord-014712-5u4e00q6	787	18	life	life	NN
cord-014712-5u4e00q6	787	19	-	-	HYPH
cord-014712-5u4e00q6	787	20	threatining	threatining	JJ
cord-014712-5u4e00q6	787	21	complications	complication	NNS
cord-014712-5u4e00q6	787	22	are	be	VBP
cord-014712-5u4e00q6	787	23	high	high	JJ
cord-014712-5u4e00q6	787	24	.	.	.
cord-014712-5u4e00q6	788	1	Because	because	IN
cord-014712-5u4e00q6	788	2	of	of	IN
cord-014712-5u4e00q6	788	3	the	the	DT
cord-014712-5u4e00q6	788	4	prevention	prevention	NN
cord-014712-5u4e00q6	788	5	of	of	IN
cord-014712-5u4e00q6	788	6	disseminated	disseminate	VBN
cord-014712-5u4e00q6	788	7	infections	infection	NNS
cord-014712-5u4e00q6	788	8	,	,	,
cord-014712-5u4e00q6	788	9	the	the	DT
cord-014712-5u4e00q6	788	10	early	early	JJ
cord-014712-5u4e00q6	788	11	detection	detection	NN
cord-014712-5u4e00q6	788	12	and	and	CC
cord-014712-5u4e00q6	788	13	the	the	DT
cord-014712-5u4e00q6	788	14	appropriate	appropriate	JJ
cord-014712-5u4e00q6	788	15	treatment	treatment	NN
cord-014712-5u4e00q6	788	16	are	be	VBP
cord-014712-5u4e00q6	788	17	essential	essential	JJ
cord-014712-5u4e00q6	788	18	.	.	.
cord-014712-5u4e00q6	789	1	In	in	IN
cord-014712-5u4e00q6	789	2	default	default	NN
cord-014712-5u4e00q6	789	3	of	of	IN
cord-014712-5u4e00q6	789	4	causal	causal	JJ
cord-014712-5u4e00q6	789	5	therapy	therapy	NN
cord-014712-5u4e00q6	789	6	,	,	,
cord-014712-5u4e00q6	789	7	the	the	DT
cord-014712-5u4e00q6	789	8	treatment	treatment	NN
cord-014712-5u4e00q6	789	9	primarily	primarily	RB
cord-014712-5u4e00q6	789	10	concern	concern	NN
cord-014712-5u4e00q6	789	11	to	to	IN
cord-014712-5u4e00q6	789	12	prevention	prevention	NN
cord-014712-5u4e00q6	789	13	of	of	IN
cord-014712-5u4e00q6	789	14	infections	infection	NNS
cord-014712-5u4e00q6	789	15	,	,	,
cord-014712-5u4e00q6	789	16	or	or	CC
cord-014712-5u4e00q6	789	17	their	-PRON-	PRP$
cord-014712-5u4e00q6	789	18	aggressive	aggressive	JJ
cord-014712-5u4e00q6	789	19	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	789	20	therapy	therapy	NN
cord-014712-5u4e00q6	789	21	.	.	.
cord-014712-5u4e00q6	790	1	Calcium	calcium	NN
cord-014712-5u4e00q6	790	2	and	and	CC
cord-014712-5u4e00q6	790	3	vitamin	vitamin	NN
cord-014712-5u4e00q6	790	4	D	d	NN
cord-014712-5u4e00q6	790	5	and	and	CC
cord-014712-5u4e00q6	790	6	as	as	RB
cord-014712-5u4e00q6	790	7	well	well	RB
cord-014712-5u4e00q6	790	8	as	as	IN
cord-014712-5u4e00q6	790	9	histamine	histamine	NN
cord-014712-5u4e00q6	790	10	1	1	CD
cord-014712-5u4e00q6	790	11	on	on	IN
cord-014712-5u4e00q6	790	12	the	the	DT
cord-014712-5u4e00q6	790	13	case	case	NN
cord-014712-5u4e00q6	790	14	of	of	IN
cord-014712-5u4e00q6	790	15	itchy	itchy	JJ
cord-014712-5u4e00q6	790	16	skin	skin	NN
cord-014712-5u4e00q6	790	17	symptoms	symptom	NNS
cord-014712-5u4e00q6	790	18	are	be	VBP
cord-014712-5u4e00q6	790	19	reccurrended	reccurrende	VBN
cord-014712-5u4e00q6	790	20	to	to	TO
cord-014712-5u4e00q6	790	21	use	use	VB
cord-014712-5u4e00q6	790	22	.	.	.
cord-014712-5u4e00q6	791	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	791	2	of	of	IN
cord-014712-5u4e00q6	791	3	Molecular	Molecular	NNP
cord-014712-5u4e00q6	791	4	Immunogenetics	Immunogenetics	NNP
cord-014712-5u4e00q6	791	5	,	,	,
cord-014712-5u4e00q6	791	6	Human	Human	NNP
cord-014712-5u4e00q6	791	7	Genetics	Genetics	NNP
cord-014712-5u4e00q6	791	8	Institute	Institute	NNP
cord-014712-5u4e00q6	791	9	,	,	,
cord-014712-5u4e00q6	791	10	CNRS	CNRS	NNP
cord-014712-5u4e00q6	791	11	and	and	CC
cord-014712-5u4e00q6	791	12	University	University	NNP
cord-014712-5u4e00q6	791	13	Montpellier	Montpellier	NNP
cord-014712-5u4e00q6	791	14	2	2	CD
cord-014712-5u4e00q6	791	15	,	,	,
cord-014712-5u4e00q6	791	16	Montpellier	Montpellier	NNP
cord-014712-5u4e00q6	791	17	,	,	,
cord-014712-5u4e00q6	791	18	France	France	NNP
cord-014712-5u4e00q6	791	19	.	.	.
cord-014712-5u4e00q6	792	1	We	-PRON-	PRP
cord-014712-5u4e00q6	792	2	performed	perform	VBD
cord-014712-5u4e00q6	792	3	clinical	clinical	JJ
cord-014712-5u4e00q6	792	4	,	,	,
cord-014712-5u4e00q6	792	5	immunological	immunological	JJ
cord-014712-5u4e00q6	792	6	and	and	CC
cord-014712-5u4e00q6	792	7	genetic	genetic	JJ
cord-014712-5u4e00q6	792	8	studies	study	NNS
cord-014712-5u4e00q6	792	9	of	of	IN
cord-014712-5u4e00q6	792	10	12	12	CD
cord-014712-5u4e00q6	792	11	hyper	hyper	NNP
cord-014712-5u4e00q6	792	12	-	-	HYPH
cord-014712-5u4e00q6	792	13	IgE	ige	JJ
cord-014712-5u4e00q6	792	14	syndrome	syndrome	NN
cord-014712-5u4e00q6	792	15	(	(	-LRB-
cord-014712-5u4e00q6	792	16	HIES	HIES	NNP
cord-014712-5u4e00q6	792	17	)	)	-RRB-
cord-014712-5u4e00q6	792	18	patients	patient	NNS
cord-014712-5u4e00q6	792	19	from	from	IN
cord-014712-5u4e00q6	792	20	4	4	CD
cord-014712-5u4e00q6	792	21	Hungarian	hungarian	JJ
cord-014712-5u4e00q6	792	22	,	,	,
cord-014712-5u4e00q6	792	23	2	2	CD
cord-014712-5u4e00q6	792	24	Lebanese	lebanese	JJ
cord-014712-5u4e00q6	792	25	,	,	,
cord-014712-5u4e00q6	792	26	one	one	CD
cord-014712-5u4e00q6	792	27	Russian	russian	JJ
cord-014712-5u4e00q6	792	28	,	,	,
cord-014712-5u4e00q6	792	29	one	one	CD
cord-014712-5u4e00q6	792	30	Polish	Polish	NNP
cord-014712-5u4e00q6	792	31	,	,	,
cord-014712-5u4e00q6	792	32	and	and	CC
cord-014712-5u4e00q6	792	33	one	one	CD
cord-014712-5u4e00q6	792	34	Swedish	swedish	JJ
cord-014712-5u4e00q6	792	35	families	family	NNS
cord-014712-5u4e00q6	792	36	with	with	IN
cord-014712-5u4e00q6	792	37	autosomal	autosomal	JJ
cord-014712-5u4e00q6	792	38	dominant	dominant	JJ
cord-014712-5u4e00q6	792	39	(	(	-LRB-
cord-014712-5u4e00q6	792	40	AD	ad	NN
cord-014712-5u4e00q6	792	41	)	)	-RRB-
cord-014712-5u4e00q6	792	42	or	or	CC
cord-014712-5u4e00q6	792	43	sporadic	sporadic	JJ
cord-014712-5u4e00q6	792	44	forms	form	NNS
cord-014712-5u4e00q6	792	45	of	of	IN
cord-014712-5u4e00q6	792	46	the	the	DT
cord-014712-5u4e00q6	792	47	disease	disease	NN
cord-014712-5u4e00q6	792	48	to	to	TO
cord-014712-5u4e00q6	792	49	reveal	reveal	VB
cord-014712-5u4e00q6	792	50	cross	cross	NN
cord-014712-5u4e00q6	792	51	-	-	JJ
cord-014712-5u4e00q6	792	52	ethnicity	ethnicity	NN
cord-014712-5u4e00q6	792	53	of	of	IN
cord-014712-5u4e00q6	792	54	recurrent	recurrent	JJ
cord-014712-5u4e00q6	792	55	and	and	CC
cord-014712-5u4e00q6	792	56	novel	novel	NN
cord-014712-5u4e00q6	792	57	mutations	mutation	NNS
cord-014712-5u4e00q6	792	58	in	in	IN
cord-014712-5u4e00q6	792	59	the	the	DT
cord-014712-5u4e00q6	792	60	signal	signal	NN
cord-014712-5u4e00q6	792	61	transducer	transducer	NN
cord-014712-5u4e00q6	792	62	and	and	CC
cord-014712-5u4e00q6	792	63	activator	activator	NN
cord-014712-5u4e00q6	792	64	of	of	IN
cord-014712-5u4e00q6	792	65	transcription-3	transcription-3	NN
cord-014712-5u4e00q6	792	66	gene	gene	NN
cord-014712-5u4e00q6	792	67	(	(	-LRB-
cord-014712-5u4e00q6	792	68	STAT3	STAT3	NNP
cord-014712-5u4e00q6	792	69	)	)	-RRB-
cord-014712-5u4e00q6	792	70	.	.	.
cord-014712-5u4e00q6	793	1	Four	four	CD
cord-014712-5u4e00q6	793	2	patients	patient	NNS
cord-014712-5u4e00q6	793	3	from	from	IN
cord-014712-5u4e00q6	793	4	3	3	CD
cord-014712-5u4e00q6	793	5	Hungarian	hungarian	JJ
cord-014712-5u4e00q6	793	6	families	family	NNS
cord-014712-5u4e00q6	793	7	,	,	,
cord-014712-5u4e00q6	793	8	and	and	CC
cord-014712-5u4e00q6	793	9	one	one	CD
cord-014712-5u4e00q6	793	10	Russian	russian	JJ
cord-014712-5u4e00q6	793	11	,	,	,
cord-014712-5u4e00q6	793	12	and	and	CC
cord-014712-5u4e00q6	793	13	one	one	CD
cord-014712-5u4e00q6	793	14	Swedish	swedish	JJ
cord-014712-5u4e00q6	793	15	patient	patient	NN
cord-014712-5u4e00q6	793	16	carried	carry	VBD
cord-014712-5u4e00q6	793	17	the	the	DT
cord-014712-5u4e00q6	793	18	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	793	19	R382W	R382W	NNP
cord-014712-5u4e00q6	793	20	germline	germline	NN
cord-014712-5u4e00q6	793	21	mutation	mutation	NN
cord-014712-5u4e00q6	793	22	at	at	IN
cord-014712-5u4e00q6	793	23	the	the	DT
cord-014712-5u4e00q6	793	24	DNA	dna	NN
cord-014712-5u4e00q6	793	25	-	-	HYPH
cord-014712-5u4e00q6	793	26	binding	bind	VBG
cord-014712-5u4e00q6	793	27	site	site	NN
cord-014712-5u4e00q6	793	28	of	of	IN
cord-014712-5u4e00q6	793	29	STAT3	STAT3	NNP
cord-014712-5u4e00q6	793	30	.	.	.
cord-014712-5u4e00q6	794	1	The	the	DT
cord-014712-5u4e00q6	794	2	recurrent	recurrent	JJ
cord-014712-5u4e00q6	794	3	V637	v637	NN
cord-014712-5u4e00q6	794	4	M	m	NN
cord-014712-5u4e00q6	794	5	mutation	mutation	NN
cord-014712-5u4e00q6	794	6	affecting	affect	VBG
cord-014712-5u4e00q6	794	7	the	the	DT
cord-014712-5u4e00q6	794	8	SRC	SRC	NNP
cord-014712-5u4e00q6	794	9	homology	homology	NN
cord-014712-5u4e00q6	794	10	2	2	CD
cord-014712-5u4e00q6	794	11	(	(	-LRB-
cord-014712-5u4e00q6	794	12	SH2	SH2	NNP
cord-014712-5u4e00q6	794	13	)	)	-RRB-
cord-014712-5u4e00q6	794	14	domain	domain	NN
cord-014712-5u4e00q6	794	15	was	be	VBD
cord-014712-5u4e00q6	794	16	detected	detect	VBN
cord-014712-5u4e00q6	794	17	in	in	IN
cord-014712-5u4e00q6	794	18	one	one	CD
cord-014712-5u4e00q6	794	19	Lebanese	lebanese	JJ
cord-014712-5u4e00q6	794	20	and	and	CC
cord-014712-5u4e00q6	794	21	one	one	CD
cord-014712-5u4e00q6	794	22	Polish	polish	JJ
cord-014712-5u4e00q6	794	23	family	family	NN
cord-014712-5u4e00q6	794	24	,	,	,
cord-014712-5u4e00q6	794	25	and	and	CC
cord-014712-5u4e00q6	794	26	the	the	DT
cord-014712-5u4e00q6	794	27	V463del	v463del	JJ
cord-014712-5u4e00q6	794	28	deletion	deletion	NN
cord-014712-5u4e00q6	794	29	located	locate	VBN
cord-014712-5u4e00q6	794	30	in	in	IN
cord-014712-5u4e00q6	794	31	the	the	DT
cord-014712-5u4e00q6	794	32	DNA	dna	NN
cord-014712-5u4e00q6	794	33	-	-	HYPH
cord-014712-5u4e00q6	794	34	binding	bind	VBG
cord-014712-5u4e00q6	794	35	domain	domain	NN
cord-014712-5u4e00q6	794	36	was	be	VBD
cord-014712-5u4e00q6	794	37	unveiled	unveil	VBN
cord-014712-5u4e00q6	794	38	in	in	IN
cord-014712-5u4e00q6	794	39	another	another	DT
cord-014712-5u4e00q6	794	40	Lebanese	lebanese	JJ
cord-014712-5u4e00q6	794	41	family	family	NN
cord-014712-5u4e00q6	794	42	.	.	.
cord-014712-5u4e00q6	795	1	A	a	DT
cord-014712-5u4e00q6	795	2	novel	novel	JJ
cord-014712-5u4e00q6	795	3	H332Y	h332y	NN
cord-014712-5u4e00q6	795	4	mutation	mutation	NN
cord-014712-5u4e00q6	795	5	affecting	affect	VBG
cord-014712-5u4e00q6	795	6	the	the	DT
cord-014712-5u4e00q6	795	7	DNA	dna	NN
cord-014712-5u4e00q6	795	8	-	-	HYPH
cord-014712-5u4e00q6	795	9	binding	bind	VBG
cord-014712-5u4e00q6	795	10	site	site	NN
cord-014712-5u4e00q6	795	11	of	of	IN
cord-014712-5u4e00q6	795	12	STAT3	STAT3	NNP
cord-014712-5u4e00q6	795	13	in	in	IN
cord-014712-5u4e00q6	795	14	three	three	CD
cord-014712-5u4e00q6	795	15	Hungarian	hungarian	JJ
cord-014712-5u4e00q6	795	16	patients	patient	NNS
cord-014712-5u4e00q6	795	17	from	from	IN
cord-014712-5u4e00q6	795	18	a	a	DT
cord-014712-5u4e00q6	795	19	Gypsy	Gypsy	NNP
cord-014712-5u4e00q6	795	20	family	family	NN
cord-014712-5u4e00q6	795	21	was	be	VBD
cord-014712-5u4e00q6	795	22	also	also	RB
cord-014712-5u4e00q6	795	23	found	find	VBN
cord-014712-5u4e00q6	795	24	.	.	.
cord-014712-5u4e00q6	796	1	The	the	DT
cord-014712-5u4e00q6	796	2	segregation	segregation	NN
cord-014712-5u4e00q6	796	3	of	of	IN
cord-014712-5u4e00q6	796	4	this	this	DT
cord-014712-5u4e00q6	796	5	mutation	mutation	NN
cord-014712-5u4e00q6	796	6	with	with	IN
cord-014712-5u4e00q6	796	7	HIES	HIES	NNP
cord-014712-5u4e00q6	796	8	,	,	,
cord-014712-5u4e00q6	796	9	restriction	restriction	NN
cord-014712-5u4e00q6	796	10	fragment	fragment	NN
cord-014712-5u4e00q6	796	11	length	length	NN
cord-014712-5u4e00q6	796	12	polymorphism	polymorphism	NN
cord-014712-5u4e00q6	796	13	analysis	analysis	NN
cord-014712-5u4e00q6	796	14	of	of	IN
cord-014712-5u4e00q6	796	15	STAT3	STAT3	NNP
cord-014712-5u4e00q6	796	16	from	from	IN
cord-014712-5u4e00q6	796	17	patients	patient	NNS
cord-014712-5u4e00q6	796	18	and	and	CC
cord-014712-5u4e00q6	796	19	controls	control	NNS
cord-014712-5u4e00q6	796	20	and	and	CC
cord-014712-5u4e00q6	796	21	the	the	DT
cord-014712-5u4e00q6	796	22	negligible	negligible	JJ
cord-014712-5u4e00q6	796	23	production	production	NN
cord-014712-5u4e00q6	796	24	upon	upon	IN
cord-014712-5u4e00q6	796	25	IL-6	IL-6	NNP
cord-014712-5u4e00q6	796	26	stimulation	stimulation	NN
cord-014712-5u4e00q6	796	27	of	of	IN
cord-014712-5u4e00q6	796	28	monocyte	monocyte	NNP
cord-014712-5u4e00q6	796	29	chemotactic	chemotactic	JJ
cord-014712-5u4e00q6	796	30	protein-1	protein-1	NNP
cord-014712-5u4e00q6	796	31	by	by	IN
cord-014712-5u4e00q6	796	32	the	the	DT
cord-014712-5u4e00q6	796	33	patient	patient	NN
cord-014712-5u4e00q6	796	34	's	's	POS
cord-014712-5u4e00q6	796	35	blood	blood	NN
cord-014712-5u4e00q6	796	36	mononuclear	mononuclear	NN
cord-014712-5u4e00q6	796	37	cells	cell	NNS
cord-014712-5u4e00q6	796	38	suggested	suggest	VBD
cord-014712-5u4e00q6	796	39	that	that	IN
cord-014712-5u4e00q6	796	40	the	the	DT
cord-014712-5u4e00q6	796	41	H332Y	H332Y	NNP
cord-014712-5u4e00q6	796	42	mutation	mutation	NN
cord-014712-5u4e00q6	796	43	was	be	VBD
cord-014712-5u4e00q6	796	44	disease	disease	NN
cord-014712-5u4e00q6	796	45	-	-	HYPH
cord-014712-5u4e00q6	796	46	causing	causing	NN
cord-014712-5u4e00q6	796	47	.	.	.
cord-014712-5u4e00q6	797	1	These	these	DT
cord-014712-5u4e00q6	797	2	data	datum	NNS
cord-014712-5u4e00q6	797	3	suggest	suggest	VBP
cord-014712-5u4e00q6	797	4	,	,	,
cord-014712-5u4e00q6	797	5	that	that	DT
cord-014712-5u4e00q6	797	6	dominant	dominant	JJ
cord-014712-5u4e00q6	797	7	negative	negative	JJ
cord-014712-5u4e00q6	797	8	mutations	mutation	NNS
cord-014712-5u4e00q6	797	9	of	of	IN
cord-014712-5u4e00q6	797	10	the	the	DT
cord-014712-5u4e00q6	797	11	DNA	dna	NN
cord-014712-5u4e00q6	797	12	-	-	HYPH
cord-014712-5u4e00q6	797	13	binding	binding	JJ
cord-014712-5u4e00q6	797	14	and	and	CC
cord-014712-5u4e00q6	797	15	SH2	sh2	NN
cord-014712-5u4e00q6	797	16	domains	domain	NNS
cord-014712-5u4e00q6	797	17	of	of	IN
cord-014712-5u4e00q6	797	18	STAT3	STAT3	NNP
cord-014712-5u4e00q6	797	19	cause	cause	VBP
cord-014712-5u4e00q6	797	20	AD	ad	NN
cord-014712-5u4e00q6	797	21	and	and	CC
cord-014712-5u4e00q6	797	22	sporadic	sporadic	JJ
cord-014712-5u4e00q6	797	23	cases	case	NNS
cord-014712-5u4e00q6	797	24	of	of	IN
cord-014712-5u4e00q6	797	25	HIES	HIES	NNP
cord-014712-5u4e00q6	797	26	in	in	IN
cord-014712-5u4e00q6	797	27	different	different	JJ
cord-014712-5u4e00q6	797	28	ethnic	ethnic	JJ
cord-014712-5u4e00q6	797	29	groups	group	NNS
cord-014712-5u4e00q6	797	30	with	with	IN
cord-014712-5u4e00q6	797	31	R382W	R382W	NNS
cord-014712-5u4e00q6	797	32	as	as	IN
cord-014712-5u4e00q6	797	33	the	the	DT
cord-014712-5u4e00q6	797	34	predominant	predominant	JJ
cord-014712-5u4e00q6	797	35	mutation	mutation	NN
cord-014712-5u4e00q6	797	36	found	find	VBN
cord-014712-5u4e00q6	797	37	in	in	IN
cord-014712-5u4e00q6	797	38	5	5	CD
cord-014712-5u4e00q6	797	39	of	of	IN
cord-014712-5u4e00q6	797	40	the	the	DT
cord-014712-5u4e00q6	797	41	9	9	CD
cord-014712-5u4e00q6	797	42	families	family	NNS
cord-014712-5u4e00q6	797	43	.	.	.
cord-014712-5u4e00q6	798	1	Functional	functional	JJ
cord-014712-5u4e00q6	798	2	and	and	CC
cord-014712-5u4e00q6	798	3	genetic	genetic	JJ
cord-014712-5u4e00q6	798	4	data	data	NN
cord-014712-5u4e00q6	798	5	support	support	NN
cord-014712-5u4e00q6	798	6	that	that	IN
cord-014712-5u4e00q6	798	7	the	the	DT
cord-014712-5u4e00q6	798	8	novel	novel	JJ
cord-014712-5u4e00q6	798	9	H332Y	h332y	NN
cord-014712-5u4e00q6	798	10	mutation	mutation	NN
cord-014712-5u4e00q6	798	11	may	may	MD
cord-014712-5u4e00q6	798	12	result	result	VB
cord-014712-5u4e00q6	798	13	in	in	IN
cord-014712-5u4e00q6	798	14	the	the	DT
cord-014712-5u4e00q6	798	15	loss	loss	NN
cord-014712-5u4e00q6	798	16	of	of	IN
cord-014712-5u4e00q6	798	17	function	function	NN
cord-014712-5u4e00q6	798	18	of	of	IN
cord-014712-5u4e00q6	798	19	STAT3	STAT3	NNP
cord-014712-5u4e00q6	798	20	and	and	CC
cord-014712-5u4e00q6	798	21	leads	lead	VBZ
cord-014712-5u4e00q6	798	22	to	to	IN
cord-014712-5u4e00q6	798	23	the	the	DT
cord-014712-5u4e00q6	798	24	HIES	HIES	NNP
cord-014712-5u4e00q6	798	25	phenotype	phenotype	NN
cord-014712-5u4e00q6	798	26	.	.	.
cord-014712-5u4e00q6	799	1	Published	publish	VBN
cord-014712-5u4e00q6	799	2	in	in	IN
cord-014712-5u4e00q6	799	3	Molecular	Molecular	NNP
cord-014712-5u4e00q6	799	4	Immunology	Immunology	NNP
cord-014712-5u4e00q6	799	5	.	.	.
cord-014712-5u4e00q6	800	1	46:202	46:202	CD
cord-014712-5u4e00q6	800	2	-	-	SYM
cord-014712-5u4e00q6	800	3	6	6	CD
cord-014712-5u4e00q6	800	4	.	.	.
cord-014712-5u4e00q6	801	1	Males	male	NNS
cord-014712-5u4e00q6	801	2	with	with	IN
cord-014712-5u4e00q6	801	3	an	an	DT
cord-014712-5u4e00q6	801	4	expressed	expressed	JJ
cord-014712-5u4e00q6	801	5	mutation	mutation	NN
cord-014712-5u4e00q6	801	6	in	in	IN
cord-014712-5u4e00q6	801	7	the	the	DT
cord-014712-5u4e00q6	801	8	SAP	SAP	NNP
cord-014712-5u4e00q6	801	9	(	(	-LRB-
cord-014712-5u4e00q6	801	10	signaling	signal	VBG
cord-014712-5u4e00q6	801	11	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	801	12	activating	activate	VBG
cord-014712-5u4e00q6	801	13	molecule	molecule	NN
cord-014712-5u4e00q6	801	14	[	[	-LRB-
cord-014712-5u4e00q6	801	15	SLAM]-associed	slam]-associed	JJ
cord-014712-5u4e00q6	801	16	protein	protein	NN
cord-014712-5u4e00q6	801	17	)	)	-RRB-
cord-014712-5u4e00q6	801	18	gene	gene	NN
cord-014712-5u4e00q6	801	19	have	have	VBP
cord-014712-5u4e00q6	801	20	an	an	DT
cord-014712-5u4e00q6	801	21	X	x	NN
cord-014712-5u4e00q6	801	22	-	-	HYPH
cord-014712-5u4e00q6	801	23	linked	link	VBN
cord-014712-5u4e00q6	801	24	syndrome	syndrome	NN
cord-014712-5u4e00q6	801	25	characterized	characterize	VBN
cord-014712-5u4e00q6	801	26	by	by	IN
cord-014712-5u4e00q6	801	27	an	an	DT
cord-014712-5u4e00q6	801	28	increased	increase	VBN
cord-014712-5u4e00q6	801	29	vulnerability	vulnerability	NN
cord-014712-5u4e00q6	801	30	to	to	IN
cord-014712-5u4e00q6	801	31	infection	infection	NN
cord-014712-5u4e00q6	801	32	with	with	IN
cord-014712-5u4e00q6	801	33	Epstein	Epstein	NNP
cord-014712-5u4e00q6	801	34	-	-	HYPH
cord-014712-5u4e00q6	801	35	Barr	Barr	NNP
cord-014712-5u4e00q6	801	36	virus	virus	NN
cord-014712-5u4e00q6	801	37	(	(	-LRB-
cord-014712-5u4e00q6	801	38	EBV	EBV	NNP
cord-014712-5u4e00q6	801	39	)	)	-RRB-
cord-014712-5u4e00q6	801	40	.	.	.
cord-014712-5u4e00q6	802	1	We	-PRON-	PRP
cord-014712-5u4e00q6	802	2	evaluated	evaluate	VBD
cord-014712-5u4e00q6	802	3	two	two	CD
cord-014712-5u4e00q6	802	4	related	related	JJ
cord-014712-5u4e00q6	802	5	male	male	JJ
cord-014712-5u4e00q6	802	6	patients	patient	NNS
cord-014712-5u4e00q6	802	7	with	with	IN
cord-014712-5u4e00q6	802	8	fatal	fatal	JJ
cord-014712-5u4e00q6	802	9	infectious	infectious	JJ
cord-014712-5u4e00q6	802	10	mononucleosis	mononucleosis	NN
cord-014712-5u4e00q6	802	11	(	(	-LRB-
cord-014712-5u4e00q6	802	12	FIM	FIM	NNP
cord-014712-5u4e00q6	802	13	)	)	-RRB-
cord-014712-5u4e00q6	802	14	and	and	CC
cord-014712-5u4e00q6	802	15	mutation	mutation	NN
cord-014712-5u4e00q6	802	16	in	in	IN
cord-014712-5u4e00q6	802	17	the	the	DT
cord-014712-5u4e00q6	802	18	SAP	SAP	NNP
cord-014712-5u4e00q6	802	19	gene	gene	NN
cord-014712-5u4e00q6	802	20	.	.	.
cord-014712-5u4e00q6	803	1	Sequence	sequence	NN
cord-014712-5u4e00q6	803	2	analysis	analysis	NN
cord-014712-5u4e00q6	803	3	revealed	reveal	VBD
cord-014712-5u4e00q6	803	4	hemizygous	hemizygous	JJ
cord-014712-5u4e00q6	803	5	G	G	NNP
cord-014712-5u4e00q6	803	6	to	to	IN
cord-014712-5u4e00q6	803	7	A	a	DT
cord-014712-5u4e00q6	803	8	transition	transition	NN
cord-014712-5u4e00q6	803	9	at	at	IN
cord-014712-5u4e00q6	803	10	nucleotide	nucleotide	JJ
cord-014712-5u4e00q6	803	11	position	position	NN
cord-014712-5u4e00q6	803	12	47	47	CD
cord-014712-5u4e00q6	803	13	in	in	IN
cord-014712-5u4e00q6	803	14	exon	exon	NN
cord-014712-5u4e00q6	803	15	1	1	CD
cord-014712-5u4e00q6	803	16	in	in	IN
cord-014712-5u4e00q6	803	17	one	one	CD
cord-014712-5u4e00q6	803	18	of	of	IN
cord-014712-5u4e00q6	803	19	the	the	DT
cord-014712-5u4e00q6	803	20	patients	patient	NNS
cord-014712-5u4e00q6	803	21	,	,	,
cord-014712-5u4e00q6	803	22	and	and	CC
cord-014712-5u4e00q6	803	23	heterozygosity	heterozygosity	NN
cord-014712-5u4e00q6	803	24	for	for	IN
cord-014712-5u4e00q6	803	25	this	this	DT
cord-014712-5u4e00q6	803	26	mutation	mutation	NN
cord-014712-5u4e00q6	803	27	in	in	IN
cord-014712-5u4e00q6	803	28	the	the	DT
cord-014712-5u4e00q6	803	29	genomic	genomic	JJ
cord-014712-5u4e00q6	803	30	DNA	dna	NN
cord-014712-5u4e00q6	803	31	from	from	IN
cord-014712-5u4e00q6	803	32	his	-PRON-	PRP$
cord-014712-5u4e00q6	803	33	mother	mother	NN
cord-014712-5u4e00q6	803	34	and	and	CC
cord-014712-5u4e00q6	803	35	maternal	maternal	JJ
cord-014712-5u4e00q6	803	36	grandmother	grandmother	NN
cord-014712-5u4e00q6	803	37	.	.	.
cord-014712-5u4e00q6	804	1	This	this	DT
cord-014712-5u4e00q6	804	2	mutation	mutation	NN
cord-014712-5u4e00q6	804	3	resulted	result	VBD
cord-014712-5u4e00q6	804	4	in	in	IN
cord-014712-5u4e00q6	804	5	asparagine	asparagine	NN
cord-014712-5u4e00q6	804	6	instead	instead	RB
cord-014712-5u4e00q6	804	7	of	of	IN
cord-014712-5u4e00q6	804	8	glycine	glycine	NN
cord-014712-5u4e00q6	804	9	in	in	IN
cord-014712-5u4e00q6	804	10	the	the	DT
cord-014712-5u4e00q6	804	11	sequence	sequence	NN
cord-014712-5u4e00q6	804	12	of	of	IN
cord-014712-5u4e00q6	804	13	the	the	DT
cord-014712-5u4e00q6	804	14	SAP	SAP	NNP
cord-014712-5u4e00q6	804	15	protein	protein	NN
cord-014712-5u4e00q6	804	16	at	at	IN
cord-014712-5u4e00q6	804	17	amino	amino	NN
cord-014712-5u4e00q6	804	18	acid	acid	NN
cord-014712-5u4e00q6	804	19	position	position	NN
cord-014712-5u4e00q6	804	20	16	16	CD
cord-014712-5u4e00q6	804	21	.	.	.
cord-014712-5u4e00q6	805	1	To	to	TO
cord-014712-5u4e00q6	805	2	analyse	analyse	VB
cord-014712-5u4e00q6	805	3	the	the	DT
cord-014712-5u4e00q6	805	4	effect	effect	NN
cord-014712-5u4e00q6	805	5	of	of	IN
cord-014712-5u4e00q6	805	6	this	this	DT
cord-014712-5u4e00q6	805	7	missense	missense	JJ
cord-014712-5u4e00q6	805	8	mutation	mutation	NN
cord-014712-5u4e00q6	805	9	on	on	IN
cord-014712-5u4e00q6	805	10	protein	protein	NN
cord-014712-5u4e00q6	805	11	function	function	NN
cord-014712-5u4e00q6	805	12	cDNA	cDNA	NNP
cord-014712-5u4e00q6	805	13	was	be	VBD
cord-014712-5u4e00q6	805	14	generated	generate	VBN
cord-014712-5u4e00q6	805	15	by	by	IN
cord-014712-5u4e00q6	805	16	site	site	NN
cord-014712-5u4e00q6	805	17	-	-	HYPH
cord-014712-5u4e00q6	805	18	directed	direct	VBN
cord-014712-5u4e00q6	805	19	mutagenesis	mutagenesis	NN
cord-014712-5u4e00q6	805	20	and	and	CC
cord-014712-5u4e00q6	805	21	cloned	clone	VBN
cord-014712-5u4e00q6	805	22	in	in	IN
cord-014712-5u4e00q6	805	23	pCMV	pcmv	NN
cord-014712-5u4e00q6	805	24	-	-	HYPH
cord-014712-5u4e00q6	805	25	FLAG	flag	NN
cord-014712-5u4e00q6	805	26	vector	vector	NN
cord-014712-5u4e00q6	805	27	.	.	.
cord-014712-5u4e00q6	806	1	We	-PRON-	PRP
cord-014712-5u4e00q6	806	2	found	find	VBD
cord-014712-5u4e00q6	806	3	that	that	IN
cord-014712-5u4e00q6	806	4	the	the	DT
cord-014712-5u4e00q6	806	5	mutant	mutant	JJ
cord-014712-5u4e00q6	806	6	SAP	SAP	NNP
cord-014712-5u4e00q6	806	7	(	(	-LRB-
cord-014712-5u4e00q6	806	8	SAP	SAP	NNP
cord-014712-5u4e00q6	806	9	/	/	SYM
cord-014712-5u4e00q6	806	10	G16D	G16D	NNP
cord-014712-5u4e00q6	806	11	)	)	-RRB-
cord-014712-5u4e00q6	806	12	protein	protein	NN
cord-014712-5u4e00q6	806	13	was	be	VBD
cord-014712-5u4e00q6	806	14	defective	defective	JJ
cord-014712-5u4e00q6	806	15	in	in	IN
cord-014712-5u4e00q6	806	16	protein	protein	NN
cord-014712-5u4e00q6	806	17	folding	folding	NN
cord-014712-5u4e00q6	806	18	as	as	IN
cord-014712-5u4e00q6	806	19	manifested	manifest	VBN
cord-014712-5u4e00q6	806	20	by	by	IN
cord-014712-5u4e00q6	806	21	the	the	DT
cord-014712-5u4e00q6	806	22	reduced	reduce	VBN
cord-014712-5u4e00q6	806	23	half	half	JJ
cord-014712-5u4e00q6	806	24	-	-	HYPH
cord-014712-5u4e00q6	806	25	life	life	NN
cord-014712-5u4e00q6	806	26	compared	compare	VBN
cord-014712-5u4e00q6	806	27	to	to	IN
cord-014712-5u4e00q6	806	28	that	that	DT
cord-014712-5u4e00q6	806	29	of	of	IN
cord-014712-5u4e00q6	806	30	wild	wild	JJ
cord-014712-5u4e00q6	806	31	type	type	NN
cord-014712-5u4e00q6	806	32	SAP	SAP	NNP
cord-014712-5u4e00q6	806	33	.	.	.
cord-014712-5u4e00q6	807	1	Furthermore	furthermore	RB
cord-014712-5u4e00q6	807	2	,	,	,
cord-014712-5u4e00q6	807	3	the	the	DT
cord-014712-5u4e00q6	807	4	SAP	SAP	NNP
cord-014712-5u4e00q6	807	5	/	/	SYM
cord-014712-5u4e00q6	807	6	G16D	G16D	NNP
cord-014712-5u4e00q6	807	7	protein	protein	NN
cord-014712-5u4e00q6	807	8	was	be	VBD
cord-014712-5u4e00q6	807	9	defective	defective	JJ
cord-014712-5u4e00q6	807	10	in	in	IN
cord-014712-5u4e00q6	807	11	binding	bind	VBG
cord-014712-5u4e00q6	807	12	to	to	IN
cord-014712-5u4e00q6	807	13	its	-PRON-	PRP$
cord-014712-5u4e00q6	807	14	philological	philological	JJ
cord-014712-5u4e00q6	807	15	ligands	ligand	NNS
cord-014712-5u4e00q6	807	16	SLAM	slam	VBP
cord-014712-5u4e00q6	807	17	and	and	CC
cord-014712-5u4e00q6	807	18	2B4	2b4	CD
cord-014712-5u4e00q6	807	19	.	.	.
cord-014712-5u4e00q6	808	1	These	these	DT
cord-014712-5u4e00q6	808	2	results	result	NNS
cord-014712-5u4e00q6	808	3	suggest	suggest	VBP
cord-014712-5u4e00q6	808	4	that	that	IN
cord-014712-5u4e00q6	808	5	defects	defect	NNS
cord-014712-5u4e00q6	808	6	in	in	IN
cord-014712-5u4e00q6	808	7	protein	protein	NN
cord-014712-5u4e00q6	808	8	folding	folding	NN
cord-014712-5u4e00q6	808	9	and	and	CC
cord-014712-5u4e00q6	808	10	ligand	ligand	NN
cord-014712-5u4e00q6	808	11	binding	binding	NN
cord-014712-5u4e00q6	808	12	collectively	collectively	RB
cord-014712-5u4e00q6	808	13	contribute	contribute	VBP
cord-014712-5u4e00q6	808	14	to	to	IN
cord-014712-5u4e00q6	808	15	the	the	DT
cord-014712-5u4e00q6	808	16	loss	loss	NN
cord-014712-5u4e00q6	808	17	of	of	IN
cord-014712-5u4e00q6	808	18	function	function	NN
cord-014712-5u4e00q6	808	19	of	of	IN
cord-014712-5u4e00q6	808	20	the	the	DT
cord-014712-5u4e00q6	808	21	SAP	SAP	NNP
cord-014712-5u4e00q6	808	22	protein	protein	NN
cord-014712-5u4e00q6	808	23	in	in	IN
cord-014712-5u4e00q6	808	24	patients	patient	NNS
cord-014712-5u4e00q6	808	25	carrying	carry	VBG
cord-014712-5u4e00q6	808	26	G16D	G16D	NNP
cord-014712-5u4e00q6	808	27	mutation	mutation	NN
cord-014712-5u4e00q6	808	28	.	.	.
cord-014712-5u4e00q6	809	1	Dedicator	Dedicator	NNP
cord-014712-5u4e00q6	809	2	of	of	IN
cord-014712-5u4e00q6	809	3	cytokinesis	cytokinesis	NN
cord-014712-5u4e00q6	809	4	8	8	CD
cord-014712-5u4e00q6	809	5	(	(	-LRB-
cord-014712-5u4e00q6	809	6	DOCK8	dock8	NN
cord-014712-5u4e00q6	809	7	)	)	-RRB-
cord-014712-5u4e00q6	809	8	deficiency	deficiency	NN
cord-014712-5u4e00q6	809	9	is	be	VBZ
cord-014712-5u4e00q6	809	10	an	an	DT
cord-014712-5u4e00q6	809	11	innate	innate	JJ
cord-014712-5u4e00q6	809	12	error	error	NN
cord-014712-5u4e00q6	809	13	of	of	IN
cord-014712-5u4e00q6	809	14	adaptive	adaptive	JJ
cord-014712-5u4e00q6	809	15	immunity	immunity	NN
cord-014712-5u4e00q6	809	16	characterized	characterize	VBN
cord-014712-5u4e00q6	809	17	by	by	IN
cord-014712-5u4e00q6	809	18	recurrent	recurrent	JJ
cord-014712-5u4e00q6	809	19	viral	viral	JJ
cord-014712-5u4e00q6	809	20	,	,	,
cord-014712-5u4e00q6	809	21	bacterial	bacterial	JJ
cord-014712-5u4e00q6	809	22	and	and	CC
cord-014712-5u4e00q6	809	23	fungal	fungal	JJ
cord-014712-5u4e00q6	809	24	infections	infection	NNS
cord-014712-5u4e00q6	809	25	,	,	,
cord-014712-5u4e00q6	809	26	very	very	RB
cord-014712-5u4e00q6	809	27	high	high	JJ
cord-014712-5u4e00q6	809	28	serum	serum	NN
cord-014712-5u4e00q6	809	29	IgE	IgE	NNP
cord-014712-5u4e00q6	809	30	concentration	concentration	NN
cord-014712-5u4e00q6	809	31	and	and	CC
cord-014712-5u4e00q6	809	32	a	a	DT
cord-014712-5u4e00q6	809	33	progressive	progressive	JJ
cord-014712-5u4e00q6	809	34	deterioration	deterioration	NN
cord-014712-5u4e00q6	809	35	of	of	IN
cord-014712-5u4e00q6	809	36	T	T	NNP
cord-014712-5u4e00q6	809	37	-	-	HYPH
cord-014712-5u4e00q6	809	38	and	and	CC
cord-014712-5u4e00q6	809	39	B	B	NNP
cord-014712-5u4e00q6	809	40	cell	cell	NN
cord-014712-5u4e00q6	809	41	-	-	HYPH
cord-014712-5u4e00q6	809	42	mediated	mediate	VBN
cord-014712-5u4e00q6	809	43	immunity	immunity	NN
cord-014712-5u4e00q6	809	44	.	.	.
cord-014712-5u4e00q6	810	1	Traditional	traditional	JJ
cord-014712-5u4e00q6	810	2	Sanger	Sanger	NNP
cord-014712-5u4e00q6	810	3	sequencing	sequencing	NN
cord-014712-5u4e00q6	810	4	may	may	MD
cord-014712-5u4e00q6	810	5	fail	fail	VB
cord-014712-5u4e00q6	810	6	to	to	TO
cord-014712-5u4e00q6	810	7	identify	identify	VB
cord-014712-5u4e00q6	810	8	mutations	mutation	NNS
cord-014712-5u4e00q6	810	9	in	in	IN
cord-014712-5u4e00q6	810	10	DOCK8	dock8	NN
cord-014712-5u4e00q6	810	11	,	,	,
cord-014712-5u4e00q6	810	12	due	due	IN
cord-014712-5u4e00q6	810	13	to	to	IN
cord-014712-5u4e00q6	810	14	overlapping	overlap	VBG
cord-014712-5u4e00q6	810	15	large	large	JJ
cord-014712-5u4e00q6	810	16	deletions	deletion	NNS
cord-014712-5u4e00q6	810	17	in	in	IN
cord-014712-5u4e00q6	810	18	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	810	19	patients	patient	NNS
cord-014712-5u4e00q6	810	20	.	.	.
cord-014712-5u4e00q6	811	1	We	-PRON-	PRP
cord-014712-5u4e00q6	811	2	studied	study	VBD
cord-014712-5u4e00q6	811	3	the	the	DT
cord-014712-5u4e00q6	811	4	genetic	genetic	JJ
cord-014712-5u4e00q6	811	5	and	and	CC
cord-014712-5u4e00q6	811	6	immunological	immunological	JJ
cord-014712-5u4e00q6	811	7	features	feature	NNS
cord-014712-5u4e00q6	811	8	of	of	IN
cord-014712-5u4e00q6	811	9	two	two	CD
cord-014712-5u4e00q6	811	10	sisters	sister	NNS
cord-014712-5u4e00q6	811	11	(	(	-LRB-
cord-014712-5u4e00q6	811	12	11	11	CD
cord-014712-5u4e00q6	811	13	and	and	CC
cord-014712-5u4e00q6	811	14	6	6	CD
cord-014712-5u4e00q6	811	15	years	year	NNS
cord-014712-5u4e00q6	811	16	of	of	IN
cord-014712-5u4e00q6	811	17	age	age	NN
cord-014712-5u4e00q6	811	18	)	)	-RRB-
cord-014712-5u4e00q6	811	19	born	bear	VBN
cord-014712-5u4e00q6	811	20	to	to	IN
cord-014712-5u4e00q6	811	21	healthy	healthy	JJ
cord-014712-5u4e00q6	811	22	Hungarian	hungarian	JJ
cord-014712-5u4e00q6	811	23	parents	parent	NNS
cord-014712-5u4e00q6	811	24	.	.	.
cord-014712-5u4e00q6	812	1	Mutational	mutational	JJ
cord-014712-5u4e00q6	812	2	analysis	analysis	NN
cord-014712-5u4e00q6	812	3	of	of	IN
cord-014712-5u4e00q6	812	4	genomic	genomic	JJ
cord-014712-5u4e00q6	812	5	DNA	dna	NN
cord-014712-5u4e00q6	812	6	and	and	CC
cord-014712-5u4e00q6	812	7	cDNA	cdna	NN
cord-014712-5u4e00q6	812	8	from	from	IN
cord-014712-5u4e00q6	812	9	the	the	DT
cord-014712-5u4e00q6	812	10	patients	patient	NNS
cord-014712-5u4e00q6	812	11	and	and	CC
cord-014712-5u4e00q6	812	12	parents	parent	NNS
cord-014712-5u4e00q6	812	13	by	by	IN
cord-014712-5u4e00q6	812	14	a	a	DT
cord-014712-5u4e00q6	812	15	combination	combination	NN
cord-014712-5u4e00q6	812	16	of	of	IN
cord-014712-5u4e00q6	812	17	PCR	PCR	NNP
cord-014712-5u4e00q6	812	18	and	and	CC
cord-014712-5u4e00q6	812	19	bidirectional	bidirectional	JJ
cord-014712-5u4e00q6	812	20	targeted	target	VBN
cord-014712-5u4e00q6	812	21	sequencing	sequencing	NN
cord-014712-5u4e00q6	812	22	failed	fail	VBD
cord-014712-5u4e00q6	812	23	to	to	TO
cord-014712-5u4e00q6	812	24	identify	identify	VB
cord-014712-5u4e00q6	812	25	the	the	DT
cord-014712-5u4e00q6	812	26	mutation	mutation	NN
cord-014712-5u4e00q6	812	27	.	.	.
cord-014712-5u4e00q6	813	1	However	however	RB
cord-014712-5u4e00q6	813	2	,	,	,
cord-014712-5u4e00q6	813	3	a	a	DT
cord-014712-5u4e00q6	813	4	multiple	multiple	JJ
cord-014712-5u4e00q6	813	5	ligation	ligation	NN
cord-014712-5u4e00q6	813	6	-	-	HYPH
cord-014712-5u4e00q6	813	7	dependent	dependent	JJ
cord-014712-5u4e00q6	813	8	probe	probe	NN
cord-014712-5u4e00q6	813	9	amplification	amplification	NN
cord-014712-5u4e00q6	813	10	(	(	-LRB-
cord-014712-5u4e00q6	813	11	MLPA	MLPA	NNP
cord-014712-5u4e00q6	813	12	)	)	-RRB-
cord-014712-5u4e00q6	813	13	assay	assay	NN
cord-014712-5u4e00q6	813	14	revealed	reveal	VBD
cord-014712-5u4e00q6	813	15	two	two	CD
cord-014712-5u4e00q6	813	16	previously	previously	RB
cord-014712-5u4e00q6	813	17	unknown	unknown	JJ
cord-014712-5u4e00q6	813	18	large	large	JJ
cord-014712-5u4e00q6	813	19	deletions	deletion	NNS
cord-014712-5u4e00q6	813	20	,	,	,
cord-014712-5u4e00q6	813	21	del1	del1	NNP
cord-014712-5u4e00q6	813	22	-	-	HYPH
cord-014712-5u4e00q6	813	23	14	14	CD
cord-014712-5u4e00q6	813	24	exons	exon	NNS
cord-014712-5u4e00q6	813	25	and	and	CC
cord-014712-5u4e00q6	813	26	del8	del8	NN
cord-014712-5u4e00q6	813	27	-	-	HYPH
cord-014712-5u4e00q6	813	28	18	18	CD
cord-014712-5u4e00q6	813	29	exons	exon	NNS
cord-014712-5u4e00q6	813	30	,	,	,
cord-014712-5u4e00q6	813	31	of	of	IN
cord-014712-5u4e00q6	813	32	DOCK8	dock8	XX
cord-014712-5u4e00q6	813	33	in	in	IN
cord-014712-5u4e00q6	813	34	both	both	DT
cord-014712-5u4e00q6	813	35	patients	patient	NNS
cord-014712-5u4e00q6	813	36	.	.	.
cord-014712-5u4e00q6	814	1	The	the	DT
cord-014712-5u4e00q6	814	2	children	child	NNS
cord-014712-5u4e00q6	814	3	's	's	POS
cord-014712-5u4e00q6	814	4	mother	mother	NN
cord-014712-5u4e00q6	814	5	was	be	VBD
cord-014712-5u4e00q6	814	6	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	814	7	for	for	IN
cord-014712-5u4e00q6	814	8	the	the	DT
cord-014712-5u4e00q6	814	9	del1	del1	NNP
cord-014712-5u4e00q6	814	10	-	-	HYPH
cord-014712-5u4e00q6	814	11	14	14	CD
cord-014712-5u4e00q6	814	12	exons	exon	NNS
cord-014712-5u4e00q6	814	13	mutation	mutation	NN
cord-014712-5u4e00q6	814	14	,	,	,
cord-014712-5u4e00q6	814	15	whereas	whereas	IN
cord-014712-5u4e00q6	814	16	the	the	DT
cord-014712-5u4e00q6	814	17	father	father	NN
cord-014712-5u4e00q6	814	18	carried	carry	VBD
cord-014712-5u4e00q6	814	19	the	the	DT
cord-014712-5u4e00q6	814	20	del8	del8	NN
cord-014712-5u4e00q6	814	21	-	-	SYM
cord-014712-5u4e00q6	814	22	18	18	CD
cord-014712-5u4e00q6	814	23	exons	exon	NNS
cord-014712-5u4e00q6	814	24	deletion	deletion	NN
cord-014712-5u4e00q6	814	25	.	.	.
cord-014712-5u4e00q6	815	1	Immunoblot	Immunoblot	NNP
cord-014712-5u4e00q6	815	2	analysis	analysis	NN
cord-014712-5u4e00q6	815	3	showed	show	VBD
cord-014712-5u4e00q6	815	4	an	an	DT
cord-014712-5u4e00q6	815	5	absence	absence	NN
cord-014712-5u4e00q6	815	6	of	of	IN
cord-014712-5u4e00q6	815	7	DOCK8	dock8	NN
cord-014712-5u4e00q6	815	8	protein	protein	NN
cord-014712-5u4e00q6	815	9	from	from	IN
cord-014712-5u4e00q6	815	10	the	the	DT
cord-014712-5u4e00q6	815	11	peripheral	peripheral	JJ
cord-014712-5u4e00q6	815	12	blood	blood	NN
cord-014712-5u4e00q6	815	13	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	815	14	of	of	IN
cord-014712-5u4e00q6	815	15	both	both	DT
cord-014712-5u4e00q6	815	16	patients	patient	NNS
cord-014712-5u4e00q6	815	17	.	.	.
cord-014712-5u4e00q6	816	1	These	these	DT
cord-014712-5u4e00q6	816	2	data	datum	NNS
cord-014712-5u4e00q6	816	3	suggest	suggest	VBP
cord-014712-5u4e00q6	816	4	that	that	IN
cord-014712-5u4e00q6	816	5	the	the	DT
cord-014712-5u4e00q6	816	6	new	new	JJ
cord-014712-5u4e00q6	816	7	compound	compound	NN
cord-014712-5u4e00q6	816	8	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	816	9	del1	del1	NNP
cord-014712-5u4e00q6	816	10	-	-	HYPH
cord-014712-5u4e00q6	816	11	14	14	CD
cord-014712-5u4e00q6	816	12	exons	exon	NNS
cord-014712-5u4e00q6	816	13	and	and	CC
cord-014712-5u4e00q6	816	14	del8	del8	NN
cord-014712-5u4e00q6	816	15	-	-	HYPH
cord-014712-5u4e00q6	816	16	18	18	CD
cord-014712-5u4e00q6	816	17	exons	exon	NNS
cord-014712-5u4e00q6	816	18	mutations	mutation	NNS
cord-014712-5u4e00q6	816	19	result	result	VBP
cord-014712-5u4e00q6	816	20	in	in	IN
cord-014712-5u4e00q6	816	21	a	a	DT
cord-014712-5u4e00q6	816	22	loss	loss	NN
cord-014712-5u4e00q6	816	23	of	of	IN
cord-014712-5u4e00q6	816	24	DOCK8	dock8	NN
cord-014712-5u4e00q6	816	25	protein	protein	NN
cord-014712-5u4e00q6	816	26	function	function	NN
cord-014712-5u4e00q6	816	27	and	and	CC
cord-014712-5u4e00q6	816	28	a	a	DT
cord-014712-5u4e00q6	816	29	typical	typical	JJ
cord-014712-5u4e00q6	816	30	DOCK8	dock8	NN
cord-014712-5u4e00q6	816	31	deficiency	deficiency	NN
cord-014712-5u4e00q6	816	32	phenotype	phenotype	NN
cord-014712-5u4e00q6	816	33	.	.	.
cord-014712-5u4e00q6	817	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	817	2	findings	finding	NNS
cord-014712-5u4e00q6	817	3	suggest	suggest	VBP
cord-014712-5u4e00q6	817	4	that	that	IN
cord-014712-5u4e00q6	817	5	traditional	traditional	JJ
cord-014712-5u4e00q6	817	6	sequencing	sequencing	NN
cord-014712-5u4e00q6	817	7	technology	technology	NN
cord-014712-5u4e00q6	817	8	may	may	MD
cord-014712-5u4e00q6	817	9	give	give	VB
cord-014712-5u4e00q6	817	10	misleading	misleading	JJ
cord-014712-5u4e00q6	817	11	results	result	NNS
cord-014712-5u4e00q6	817	12	in	in	IN
cord-014712-5u4e00q6	817	13	such	such	JJ
cord-014712-5u4e00q6	817	14	cases	case	NNS
cord-014712-5u4e00q6	817	15	and	and	CC
cord-014712-5u4e00q6	817	16	that	that	IN
cord-014712-5u4e00q6	817	17	MLPA	MLPA	NNP
cord-014712-5u4e00q6	817	18	may	may	MD
cord-014712-5u4e00q6	817	19	be	be	VB
cord-014712-5u4e00q6	817	20	indispensible	indispensible	JJ
cord-014712-5u4e00q6	817	21	for	for	IN
cord-014712-5u4e00q6	817	22	the	the	DT
cord-014712-5u4e00q6	817	23	definition	definition	NN
cord-014712-5u4e00q6	817	24	of	of	IN
cord-014712-5u4e00q6	817	25	the	the	DT
cord-014712-5u4e00q6	817	26	large	large	JJ
cord-014712-5u4e00q6	817	27	deletions	deletion	NNS
cord-014712-5u4e00q6	817	28	frequently	frequently	RB
cord-014712-5u4e00q6	817	29	observed	observe	VBD
cord-014712-5u4e00q6	817	30	in	in	IN
cord-014712-5u4e00q6	817	31	patients	patient	NNS
cord-014712-5u4e00q6	817	32	with	with	IN
cord-014712-5u4e00q6	817	33	DOCK8	dock8	NN
cord-014712-5u4e00q6	817	34	deficiency	deficiency	NN
cord-014712-5u4e00q6	817	35	.	.	.
cord-014712-5u4e00q6	818	1	We	-PRON-	PRP
cord-014712-5u4e00q6	818	2	describe	describe	VBP
cord-014712-5u4e00q6	818	3	here	here	RB
cord-014712-5u4e00q6	818	4	a	a	DT
cord-014712-5u4e00q6	818	5	patient	patient	NN
cord-014712-5u4e00q6	818	6	with	with	IN
cord-014712-5u4e00q6	818	7	invasive	invasive	JJ
cord-014712-5u4e00q6	818	8	Cryptococcus	Cryptococcus	NNP
cord-014712-5u4e00q6	818	9	laurentii	laurentii	NN
cord-014712-5u4e00q6	818	10	infection	infection	NN
cord-014712-5u4e00q6	818	11	and	and	CC
cord-014712-5u4e00q6	818	12	the	the	DT
cord-014712-5u4e00q6	818	13	X	x	NN
cord-014712-5u4e00q6	818	14	-	-	HYPH
cord-014712-5u4e00q6	818	15	linked	link	VBN
cord-014712-5u4e00q6	818	16	form	form	NN
cord-014712-5u4e00q6	818	17	of	of	IN
cord-014712-5u4e00q6	818	18	hyper	hyper	JJ
cord-014712-5u4e00q6	818	19	-	-	JJ
cord-014712-5u4e00q6	818	20	IgM	igm	JJ
cord-014712-5u4e00q6	818	21	syndrome	syndrome	NN
cord-014712-5u4e00q6	818	22	(	(	-LRB-
cord-014712-5u4e00q6	818	23	X	X	NNP
cord-014712-5u4e00q6	818	24	-	-	NNP
cord-014712-5u4e00q6	818	25	HIGM	HIGM	NNP
cord-014712-5u4e00q6	818	26	)	)	-RRB-
cord-014712-5u4e00q6	818	27	.	.	.
cord-014712-5u4e00q6	819	1	C.laurentii	C.laurentii	NNP
cord-014712-5u4e00q6	819	2	is	be	VBZ
cord-014712-5u4e00q6	819	3	an	an	DT
cord-014712-5u4e00q6	819	4	extremely	extremely	RB
cord-014712-5u4e00q6	819	5	rare	rare	JJ
cord-014712-5u4e00q6	819	6	human	human	JJ
cord-014712-5u4e00q6	819	7	pathogen	pathogen	NN
cord-014712-5u4e00q6	819	8	.	.	.
cord-014712-5u4e00q6	820	1	This	this	DT
cord-014712-5u4e00q6	820	2	fungus	fungus	NN
cord-014712-5u4e00q6	820	3	was	be	VBD
cord-014712-5u4e00q6	820	4	previously	previously	RB
cord-014712-5u4e00q6	820	5	considered	consider	VBN
cord-014712-5u4e00q6	820	6	saprophytic	saprophytic	JJ
cord-014712-5u4e00q6	820	7	and	and	CC
cord-014712-5u4e00q6	820	8	non	non	JJ
cord-014712-5u4e00q6	820	9	-	-	JJ
cord-014712-5u4e00q6	820	10	pathogenic	pathogenic	JJ
cord-014712-5u4e00q6	820	11	to	to	IN
cord-014712-5u4e00q6	820	12	humans	human	NNS
cord-014712-5u4e00q6	820	13	,	,	,
cord-014712-5u4e00q6	820	14	but	but	CC
cord-014712-5u4e00q6	820	15	it	-PRON-	PRP
cord-014712-5u4e00q6	820	16	has	have	VBZ
cord-014712-5u4e00q6	820	17	been	be	VBN
cord-014712-5u4e00q6	820	18	isolated	isolate	VBN
cord-014712-5u4e00q6	820	19	as	as	IN
cord-014712-5u4e00q6	820	20	the	the	DT
cord-014712-5u4e00q6	820	21	etiologic	etiologic	JJ
cord-014712-5u4e00q6	820	22	agent	agent	NN
cord-014712-5u4e00q6	820	23	of	of	IN
cord-014712-5u4e00q6	820	24	skin	skin	NN
cord-014712-5u4e00q6	820	25	infection	infection	NN
cord-014712-5u4e00q6	820	26	,	,	,
cord-014712-5u4e00q6	820	27	keratitis	keratitis	NN
cord-014712-5u4e00q6	820	28	,	,	,
cord-014712-5u4e00q6	820	29	endophthalmitis	endophthalmitis	NNP
cord-014712-5u4e00q6	820	30	,	,	,
cord-014712-5u4e00q6	820	31	lung	lung	NN
cord-014712-5u4e00q6	820	32	abscess	abscess	NN
cord-014712-5u4e00q6	820	33	,	,	,
cord-014712-5u4e00q6	820	34	peritonitis	peritonitis	NN
cord-014712-5u4e00q6	820	35	,	,	,
cord-014712-5u4e00q6	820	36	meningitis	meningitis	NN
cord-014712-5u4e00q6	820	37	,	,	,
cord-014712-5u4e00q6	820	38	and	and	CC
cord-014712-5u4e00q6	820	39	fungemia	fungemia	NN
cord-014712-5u4e00q6	820	40	.	.	.
cord-014712-5u4e00q6	821	1	Most	most	RBS
cord-014712-5u4e00q6	821	2	affected	affect	VBN
cord-014712-5u4e00q6	821	3	individuals	individual	NNS
cord-014712-5u4e00q6	821	4	had	have	VBD
cord-014712-5u4e00q6	821	5	a	a	DT
cord-014712-5u4e00q6	821	6	compromised	compromised	JJ
cord-014712-5u4e00q6	821	7	immune	immune	JJ
cord-014712-5u4e00q6	821	8	system	system	NN
cord-014712-5u4e00q6	821	9	because	because	IN
cord-014712-5u4e00q6	821	10	of	of	IN
cord-014712-5u4e00q6	821	11	leukemia	leukemia	NN
cord-014712-5u4e00q6	821	12	,	,	,
cord-014712-5u4e00q6	821	13	cancer	cancer	NN
cord-014712-5u4e00q6	821	14	,	,	,
cord-014712-5u4e00q6	821	15	diabetes	diabetes	NN
cord-014712-5u4e00q6	821	16	mellitus	mellitus	NN
cord-014712-5u4e00q6	821	17	,	,	,
cord-014712-5u4e00q6	821	18	AIDS	AIDS	NNP
cord-014712-5u4e00q6	821	19	,	,	,
cord-014712-5u4e00q6	821	20	or	or	CC
cord-014712-5u4e00q6	821	21	prematurity	prematurity	NN
cord-014712-5u4e00q6	821	22	.	.	.
cord-014712-5u4e00q6	822	1	Repeated	repeat	VBN
cord-014712-5u4e00q6	822	2	isolation	isolation	NN
cord-014712-5u4e00q6	822	3	of	of	IN
cord-014712-5u4e00q6	822	4	C.laurentii	C.laurentii	NNP
cord-014712-5u4e00q6	822	5	from	from	IN
cord-014712-5u4e00q6	822	6	the	the	DT
cord-014712-5u4e00q6	822	7	oropharynx	oropharynx	NN
cord-014712-5u4e00q6	822	8	of	of	IN
cord-014712-5u4e00q6	822	9	an	an	DT
cord-014712-5u4e00q6	822	10	immunocompromised	immunocompromised	JJ
cord-014712-5u4e00q6	822	11	patient	patient	NN
cord-014712-5u4e00q6	822	12	has	have	VBZ
cord-014712-5u4e00q6	822	13	also	also	RB
cord-014712-5u4e00q6	822	14	been	be	VBN
cord-014712-5u4e00q6	822	15	docu-	docu-	JJ
cord-014712-5u4e00q6	823	1	The	the	DT
cord-014712-5u4e00q6	823	2	Wiskott	Wiskott	NNP
cord-014712-5u4e00q6	823	3	-	-	HYPH
cord-014712-5u4e00q6	823	4	Aldrich	Aldrich	NNP
cord-014712-5u4e00q6	823	5	syndrome	syndrome	NN
cord-014712-5u4e00q6	823	6	(	(	-LRB-
cord-014712-5u4e00q6	823	7	WAS	be	VBD
cord-014712-5u4e00q6	823	8	)	)	-RRB-
cord-014712-5u4e00q6	823	9	is	be	VBZ
cord-014712-5u4e00q6	823	10	an	an	DT
cord-014712-5u4e00q6	823	11	X	x	NN
cord-014712-5u4e00q6	823	12	-	-	HYPH
cord-014712-5u4e00q6	823	13	linked	link	VBN
cord-014712-5u4e00q6	823	14	recessive	recessive	JJ
cord-014712-5u4e00q6	823	15	immune	immune	JJ
cord-014712-5u4e00q6	823	16	deficiency	deficiency	NN
cord-014712-5u4e00q6	823	17	disorder	disorder	NN
cord-014712-5u4e00q6	823	18	characterized	characterize	VBN
cord-014712-5u4e00q6	823	19	by	by	IN
cord-014712-5u4e00q6	823	20	thrombocytopenia	thrombocytopenia	NN
cord-014712-5u4e00q6	823	21	,	,	,
cord-014712-5u4e00q6	823	22	small	small	JJ
cord-014712-5u4e00q6	823	23	platelet	platelet	NN
cord-014712-5u4e00q6	823	24	size	size	NN
cord-014712-5u4e00q6	823	25	,	,	,
cord-014712-5u4e00q6	823	26	eczema	eczema	NN
cord-014712-5u4e00q6	823	27	,	,	,
cord-014712-5u4e00q6	823	28	recurrent	recurrent	JJ
cord-014712-5u4e00q6	823	29	infections	infection	NNS
cord-014712-5u4e00q6	823	30	,	,	,
cord-014712-5u4e00q6	823	31	and	and	CC
cord-014712-5u4e00q6	823	32	increased	increase	VBN
cord-014712-5u4e00q6	823	33	risk	risk	NN
cord-014712-5u4e00q6	823	34	of	of	IN
cord-014712-5u4e00q6	823	35	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	823	36	disorders	disorder	NNS
cord-014712-5u4e00q6	823	37	and	and	CC
cord-014712-5u4e00q6	823	38	malignancies	malignancy	NNS
cord-014712-5u4e00q6	823	39	.	.	.
cord-014712-5u4e00q6	824	1	WAS	be	VBD
cord-014712-5u4e00q6	824	2	is	be	VBZ
cord-014712-5u4e00q6	824	3	caused	cause	VBN
cord-014712-5u4e00q6	824	4	by	by	IN
cord-014712-5u4e00q6	824	5	mutations	mutation	NNS
cord-014712-5u4e00q6	824	6	in	in	IN
cord-014712-5u4e00q6	824	7	the	the	DT
cord-014712-5u4e00q6	824	8	WASP	WASP	NNP
cord-014712-5u4e00q6	824	9	gene	gene	NN
cord-014712-5u4e00q6	824	10	which	which	WDT
cord-014712-5u4e00q6	824	11	encodes	encode	VBZ
cord-014712-5u4e00q6	824	12	WASP	WASP	NNP
cord-014712-5u4e00q6	824	13	,	,	,
cord-014712-5u4e00q6	824	14	a	a	DT
cord-014712-5u4e00q6	824	15	502-amino	502-amino	CD
cord-014712-5u4e00q6	824	16	acid	acid	NN
cord-014712-5u4e00q6	824	17	protein	protein	NN
cord-014712-5u4e00q6	824	18	.	.	.
cord-014712-5u4e00q6	825	1	WASP	WASP	NNP
cord-014712-5u4e00q6	825	2	plays	play	VBZ
cord-014712-5u4e00q6	825	3	a	a	DT
cord-014712-5u4e00q6	825	4	critical	critical	JJ
cord-014712-5u4e00q6	825	5	role	role	NN
cord-014712-5u4e00q6	825	6	in	in	IN
cord-014712-5u4e00q6	825	7	actin	actin	NN
cord-014712-5u4e00q6	825	8	cytoskeleton	cytoskeleton	NN
cord-014712-5u4e00q6	825	9	organization	organization	NN
cord-014712-5u4e00q6	825	10	and	and	CC
cord-014712-5u4e00q6	825	11	signalling	signal	VBG
cord-014712-5u4e00q6	825	12	,	,	,
cord-014712-5u4e00q6	825	13	and	and	CC
cord-014712-5u4e00q6	825	14	functions	function	NNS
cord-014712-5u4e00q6	825	15	of	of	IN
cord-014712-5u4e00q6	825	16	immune	immune	JJ
cord-014712-5u4e00q6	825	17	cells	cell	NNS
cord-014712-5u4e00q6	825	18	.	.	.
cord-014712-5u4e00q6	826	1	We	-PRON-	PRP
cord-014712-5u4e00q6	826	2	present	present	VBP
cord-014712-5u4e00q6	826	3	here	here	RB
cord-014712-5u4e00q6	826	4	the	the	DT
cord-014712-5u4e00q6	826	5	results	result	NNS
cord-014712-5u4e00q6	826	6	of	of	IN
cord-014712-5u4e00q6	826	7	genetic	genetic	JJ
cord-014712-5u4e00q6	826	8	analysis	analysis	NN
cord-014712-5u4e00q6	826	9	of	of	IN
cord-014712-5u4e00q6	826	10	patients	patient	NNS
cord-014712-5u4e00q6	826	11	with	with	IN
cord-014712-5u4e00q6	826	12	WAS	be	VBD
cord-014712-5u4e00q6	826	13	from	from	IN
cord-014712-5u4e00q6	826	14	eleven	eleven	CD
cord-014712-5u4e00q6	826	15	Eastern	eastern	JJ
cord-014712-5u4e00q6	826	16	and	and	CC
cord-014712-5u4e00q6	826	17	Central	central	JJ
cord-014712-5u4e00q6	826	18	European	european	JJ
cord-014712-5u4e00q6	826	19	(	(	-LRB-
cord-014712-5u4e00q6	826	20	ECE	ECE	NNP
cord-014712-5u4e00q6	826	21	)	)	-RRB-
cord-014712-5u4e00q6	826	22	countries	country	NNS
cord-014712-5u4e00q6	826	23	and	and	CC
cord-014712-5u4e00q6	826	24	Turkey	Turkey	NNP
cord-014712-5u4e00q6	826	25	.	.	.
cord-014712-5u4e00q6	827	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	827	2	and	and	CC
cord-014712-5u4e00q6	827	3	haematological	haematological	JJ
cord-014712-5u4e00q6	827	4	information	information	NN
cord-014712-5u4e00q6	827	5	of	of	IN
cord-014712-5u4e00q6	827	6	87	87	CD
cord-014712-5u4e00q6	827	7	affected	affect	VBN
cord-014712-5u4e00q6	827	8	males	male	NNS
cord-014712-5u4e00q6	827	9	and	and	CC
cord-014712-5u4e00q6	827	10	48	48	CD
cord-014712-5u4e00q6	827	11	carrier	carrier	NN
cord-014712-5u4e00q6	827	12	females	female	NNS
cord-014712-5u4e00q6	827	13	from	from	IN
cord-014712-5u4e00q6	827	14	77	77	CD
cord-014712-5u4e00q6	827	15	WAS	be	VBD
cord-014712-5u4e00q6	827	16	families	family	NNS
cord-014712-5u4e00q6	827	17	were	be	VBD
cord-014712-5u4e00q6	827	18	collected	collect	VBN
cord-014712-5u4e00q6	827	19	.	.	.
cord-014712-5u4e00q6	828	1	The	the	DT
cord-014712-5u4e00q6	828	2	WASP	WASP	NNP
cord-014712-5u4e00q6	828	3	gene	gene	NN
cord-014712-5u4e00q6	828	4	was	be	VBD
cord-014712-5u4e00q6	828	5	sequenced	sequence	VBN
cord-014712-5u4e00q6	828	6	from	from	IN
cord-014712-5u4e00q6	828	7	genomic	genomic	JJ
cord-014712-5u4e00q6	828	8	DNA	dna	NN
cord-014712-5u4e00q6	828	9	of	of	IN
cord-014712-5u4e00q6	828	10	patients	patient	NNS
cord-014712-5u4e00q6	828	11	with	with	IN
cord-014712-5u4e00q6	828	12	WAS	be	VBD
cord-014712-5u4e00q6	828	13	,	,	,
cord-014712-5u4e00q6	828	14	as	as	RB
cord-014712-5u4e00q6	828	15	well	well	RB
cord-014712-5u4e00q6	828	16	as	as	IN
cord-014712-5u4e00q6	828	17	their	-PRON-	PRP$
cord-014712-5u4e00q6	828	18	family	family	NN
cord-014712-5u4e00q6	828	19	members	member	NNS
cord-014712-5u4e00q6	828	20	to	to	TO
cord-014712-5u4e00q6	828	21	identify	identify	VB
cord-014712-5u4e00q6	828	22	carriers	carrier	NNS
cord-014712-5u4e00q6	828	23	.	.	.
cord-014712-5u4e00q6	829	1	In	in	IN
cord-014712-5u4e00q6	829	2	this	this	DT
cord-014712-5u4e00q6	829	3	large	large	JJ
cord-014712-5u4e00q6	829	4	cohort	cohort	NN
cord-014712-5u4e00q6	829	5	,	,	,
cord-014712-5u4e00q6	829	6	we	-PRON-	PRP
cord-014712-5u4e00q6	829	7	identified	identify	VBD
cord-014712-5u4e00q6	829	8	62	62	CD
cord-014712-5u4e00q6	829	9	unique	unique	JJ
cord-014712-5u4e00q6	829	10	mutations	mutation	NNS
cord-014712-5u4e00q6	829	11	including	include	VBG
cord-014712-5u4e00q6	829	12	17	17	CD
cord-014712-5u4e00q6	829	13	novel	novel	JJ
cord-014712-5u4e00q6	829	14	sequence	sequence	NN
cord-014712-5u4e00q6	829	15	variants	variant	NNS
cord-014712-5u4e00q6	829	16	.	.	.
cord-014712-5u4e00q6	830	1	The	the	DT
cord-014712-5u4e00q6	830	2	mutations	mutation	NNS
cord-014712-5u4e00q6	830	3	were	be	VBD
cord-014712-5u4e00q6	830	4	scattered	scatter	VBN
cord-014712-5u4e00q6	830	5	throughout	throughout	IN
cord-014712-5u4e00q6	830	6	the	the	DT
cord-014712-5u4e00q6	830	7	WASP	WASP	NNP
cord-014712-5u4e00q6	830	8	gene	gene	NN
cord-014712-5u4e00q6	830	9	and	and	CC
cord-014712-5u4e00q6	830	10	included	include	VBD
cord-014712-5u4e00q6	830	11	single	single	JJ
cord-014712-5u4e00q6	830	12	base	base	NN
cord-014712-5u4e00q6	830	13	pair	pair	NN
cord-014712-5u4e00q6	830	14	changes	change	NNS
cord-014712-5u4e00q6	830	15	(	(	-LRB-
cord-014712-5u4e00q6	830	16	17	17	CD
cord-014712-5u4e00q6	830	17	missense	missense	NN
cord-014712-5u4e00q6	830	18	and	and	CC
cord-014712-5u4e00q6	830	19	11	11	CD
cord-014712-5u4e00q6	830	20	nonsense	nonsense	NN
cord-014712-5u4e00q6	830	21	mutations	mutation	NNS
cord-014712-5u4e00q6	830	22	)	)	-RRB-
cord-014712-5u4e00q6	830	23	,	,	,
cord-014712-5u4e00q6	830	24	7	7	CD
cord-014712-5u4e00q6	830	25	small	small	JJ
cord-014712-5u4e00q6	830	26	insertions	insertion	NNS
cord-014712-5u4e00q6	830	27	,	,	,
cord-014712-5u4e00q6	830	28	18	18	CD
cord-014712-5u4e00q6	830	29	deletions	deletion	NNS
cord-014712-5u4e00q6	830	30	,	,	,
cord-014712-5u4e00q6	830	31	and	and	CC
cord-014712-5u4e00q6	830	32	9	9	CD
cord-014712-5u4e00q6	830	33	splice	splice	NN
cord-014712-5u4e00q6	830	34	site	site	NN
cord-014712-5u4e00q6	830	35	defects	defect	NNS
cord-014712-5u4e00q6	830	36	.	.	.
cord-014712-5u4e00q6	831	1	Genetic	genetic	JJ
cord-014712-5u4e00q6	831	2	counselling	counselling	NN
cord-014712-5u4e00q6	831	3	and	and	CC
cord-014712-5u4e00q6	831	4	prenatal	prenatal	JJ
cord-014712-5u4e00q6	831	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	831	6	were	be	VBD
cord-014712-5u4e00q6	831	7	applied	apply	VBN
cord-014712-5u4e00q6	831	8	in	in	IN
cord-014712-5u4e00q6	831	9	four	four	CD
cord-014712-5u4e00q6	831	10	affected	affect	VBN
cord-014712-5u4e00q6	831	11	families	family	NNS
cord-014712-5u4e00q6	831	12	.	.	.
cord-014712-5u4e00q6	832	1	Introduction	introduction	NN
cord-014712-5u4e00q6	832	2	:	:	:
cord-014712-5u4e00q6	833	1	MHC	MHC	NNP
cord-014712-5u4e00q6	833	2	-	-	HYPH
cord-014712-5u4e00q6	833	3	Class	Class	NNP
cord-014712-5u4e00q6	833	4	II	II	NNP
cord-014712-5u4e00q6	833	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	833	6	is	be	VBZ
cord-014712-5u4e00q6	833	7	an	an	DT
cord-014712-5u4e00q6	833	8	autosomal	autosomal	JJ
cord-014712-5u4e00q6	833	9	recessively	recessively	RB
cord-014712-5u4e00q6	833	10	inherited	inherit	VBN
cord-014712-5u4e00q6	833	11	combined	combine	VBN
cord-014712-5u4e00q6	833	12	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	833	13	disorder	disorder	NN
cord-014712-5u4e00q6	833	14	characterized	characterize	VBN
cord-014712-5u4e00q6	833	15	by	by	IN
cord-014712-5u4e00q6	833	16	less	less	JJR
cord-014712-5u4e00q6	833	17	than	than	IN
cord-014712-5u4e00q6	833	18	5	5	CD
cord-014712-5u4e00q6	833	19	%	%	NN
cord-014712-5u4e00q6	833	20	expression	expression	NN
cord-014712-5u4e00q6	833	21	of	of	IN
cord-014712-5u4e00q6	833	22	HLA	HLA	NNP
cord-014712-5u4e00q6	833	23	-	-	HYPH
cord-014712-5u4e00q6	833	24	DR	DR	NNP
cord-014712-5u4e00q6	833	25	on	on	IN
cord-014712-5u4e00q6	833	26	B	b	NN
cord-014712-5u4e00q6	833	27	cells	cell	NNS
cord-014712-5u4e00q6	833	28	or	or	CC
cord-014712-5u4e00q6	833	29	monocytes	monocyte	NNS
cord-014712-5u4e00q6	833	30	.	.	.
cord-014712-5u4e00q6	834	1	It	-PRON-	PRP
cord-014712-5u4e00q6	834	2	is	be	VBZ
cord-014712-5u4e00q6	834	3	caused	cause	VBN
cord-014712-5u4e00q6	834	4	by	by	IN
cord-014712-5u4e00q6	834	5	mutation	mutation	NN
cord-014712-5u4e00q6	834	6	of	of	IN
cord-014712-5u4e00q6	834	7	genes	gene	NNS
cord-014712-5u4e00q6	834	8	(	(	-LRB-
cord-014712-5u4e00q6	834	9	CIITA	CIITA	NNP
cord-014712-5u4e00q6	834	10	,	,	,
cord-014712-5u4e00q6	834	11	RFXANK	RFXANK	NNP
cord-014712-5u4e00q6	834	12	,	,	,
cord-014712-5u4e00q6	834	13	RFX5	RFX5	NNP
cord-014712-5u4e00q6	834	14	,	,	,
cord-014712-5u4e00q6	834	15	RFXAP	RFXAP	NNP
cord-014712-5u4e00q6	834	16	)	)	-RRB-
cord-014712-5u4e00q6	834	17	regulating	regulate	VBG
cord-014712-5u4e00q6	834	18	transcription	transcription	NN
cord-014712-5u4e00q6	834	19	factors	factor	NNS
cord-014712-5u4e00q6	834	20	which	which	WDT
cord-014712-5u4e00q6	834	21	controls	control	VBZ
cord-014712-5u4e00q6	834	22	expression	expression	NN
cord-014712-5u4e00q6	834	23	of	of	IN
cord-014712-5u4e00q6	834	24	MHC	MHC	NNP
cord-014712-5u4e00q6	834	25	-	-	HYPH
cord-014712-5u4e00q6	834	26	Class	Class	NNP
cord-014712-5u4e00q6	834	27	-	-	HYPH
cord-014712-5u4e00q6	834	28	II	II	NNP
cord-014712-5u4e00q6	834	29	molecules	molecule	NNS
cord-014712-5u4e00q6	834	30	on	on	IN
cord-014712-5u4e00q6	834	31	cell	cell	NN
cord-014712-5u4e00q6	834	32	surface	surface	NN
cord-014712-5u4e00q6	834	33	.	.	.
cord-014712-5u4e00q6	835	1	MHC	MHC	NNP
cord-014712-5u4e00q6	835	2	-	-	HYPH
cord-014712-5u4e00q6	835	3	Class	Class	NNP
cord-014712-5u4e00q6	835	4	II	II	NNP
cord-014712-5u4e00q6	835	5	molecules	molecule	NNS
cord-014712-5u4e00q6	835	6	are	be	VBP
cord-014712-5u4e00q6	835	7	expressed	express	VBN
cord-014712-5u4e00q6	835	8	on	on	IN
cord-014712-5u4e00q6	835	9	thymic	thymic	JJ
cord-014712-5u4e00q6	835	10	epithelial	epithelial	JJ
cord-014712-5u4e00q6	835	11	cells	cell	NNS
cord-014712-5u4e00q6	835	12	,	,	,
cord-014712-5u4e00q6	835	13	antigen	antigen	NN
cord-014712-5u4e00q6	835	14	presenting	present	VBG
cord-014712-5u4e00q6	835	15	cells	cell	NNS
cord-014712-5u4e00q6	835	16	(	(	-LRB-
cord-014712-5u4e00q6	835	17	B	b	NN
cord-014712-5u4e00q6	835	18	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	835	19	,	,	,
cord-014712-5u4e00q6	835	20	dendritic	dendritic	JJ
cord-014712-5u4e00q6	835	21	cells	cell	NNS
cord-014712-5u4e00q6	835	22	,	,	,
cord-014712-5u4e00q6	835	23	monocytes	monocyte	NNS
cord-014712-5u4e00q6	835	24	and	and	CC
cord-014712-5u4e00q6	835	25	macrophages	macrophage	NNS
cord-014712-5u4e00q6	835	26	)	)	-RRB-
cord-014712-5u4e00q6	835	27	and	and	CC
cord-014712-5u4e00q6	835	28	activated	activate	VBD
cord-014712-5u4e00q6	835	29	T	T	NNP
cord-014712-5u4e00q6	835	30	cells	cell	NNS
cord-014712-5u4e00q6	835	31	.	.	.
cord-014712-5u4e00q6	836	1	These	these	DT
cord-014712-5u4e00q6	836	2	molecules	molecule	NNS
cord-014712-5u4e00q6	836	3	are	be	VBP
cord-014712-5u4e00q6	836	4	of	of	IN
cord-014712-5u4e00q6	836	5	critical	critical	JJ
cord-014712-5u4e00q6	836	6	importance	importance	NN
cord-014712-5u4e00q6	836	7	to	to	IN
cord-014712-5u4e00q6	836	8	immunity	immunity	NN
cord-014712-5u4e00q6	836	9	,	,	,
cord-014712-5u4e00q6	836	10	CD4	CD4	NNP
cord-014712-5u4e00q6	836	11	+	+	CC
cord-014712-5u4e00q6	836	12	T	T	NNP
cord-014712-5u4e00q6	836	13	cell	cell	NN
cord-014712-5u4e00q6	836	14	development	development	NN
cord-014712-5u4e00q6	836	15	,	,	,
cord-014712-5u4e00q6	836	16	antibody	antibody	NN
cord-014712-5u4e00q6	836	17	production	production	NN
cord-014712-5u4e00q6	836	18	,	,	,
cord-014712-5u4e00q6	836	19	tolerance	tolerance	NN
cord-014712-5u4e00q6	836	20	induction	induction	NN
cord-014712-5u4e00q6	836	21	and	and	CC
cord-014712-5u4e00q6	836	22	inlammatory	inlammatory	NN
cord-014712-5u4e00q6	836	23	response	response	NN
cord-014712-5u4e00q6	836	24	.	.	.
cord-014712-5u4e00q6	837	1	Consequently	consequently	RB
cord-014712-5u4e00q6	837	2	,	,	,
cord-014712-5u4e00q6	837	3	patients	patient	NNS
cord-014712-5u4e00q6	837	4	present	present	JJ
cord-014712-5u4e00q6	837	5	with	with	IN
cord-014712-5u4e00q6	837	6	clinical	clinical	JJ
cord-014712-5u4e00q6	837	7	findings	finding	NNS
cord-014712-5u4e00q6	837	8	related	relate	VBN
cord-014712-5u4e00q6	837	9	to	to	IN
cord-014712-5u4e00q6	837	10	combined	combine	VBN
cord-014712-5u4e00q6	837	11	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	837	12	during	during	IN
cord-014712-5u4e00q6	837	13	infancy	infancy	NN
cord-014712-5u4e00q6	837	14	.	.	.
cord-014712-5u4e00q6	838	1	Material	material	NN
cord-014712-5u4e00q6	838	2	and	and	CC
cord-014712-5u4e00q6	838	3	Methods	method	NNS
cord-014712-5u4e00q6	838	4	:	:	:
cord-014712-5u4e00q6	838	5	Medical	medical	JJ
cord-014712-5u4e00q6	838	6	records	record	NNS
cord-014712-5u4e00q6	838	7	of	of	IN
cord-014712-5u4e00q6	838	8	thirteen	thirteen	CD
cord-014712-5u4e00q6	838	9	patients	patient	NNS
cord-014712-5u4e00q6	838	10	with	with	IN
cord-014712-5u4e00q6	838	11	MHC	MHC	NNP
cord-014712-5u4e00q6	838	12	-	-	HYPH
cord-014712-5u4e00q6	838	13	Class	Class	NNP
cord-014712-5u4e00q6	838	14	II	II	NNP
cord-014712-5u4e00q6	838	15	deficiency	deficiency	NN
cord-014712-5u4e00q6	838	16	,	,	,
cord-014712-5u4e00q6	838	17	followed	follow	VBN
cord-014712-5u4e00q6	838	18	-	-	HYPH
cord-014712-5u4e00q6	838	19	up	up	NN
cord-014712-5u4e00q6	838	20	in	in	IN
cord-014712-5u4e00q6	838	21	Ankara	Ankara	NNP
cord-014712-5u4e00q6	838	22	University	University	NNP
cord-014712-5u4e00q6	838	23	,	,	,
cord-014712-5u4e00q6	838	24	Medical	Medical	NNP
cord-014712-5u4e00q6	838	25	School	School	NNP
cord-014712-5u4e00q6	838	26	,	,	,
cord-014712-5u4e00q6	838	27	Division	Division	NNP
cord-014712-5u4e00q6	838	28	of	of	IN
cord-014712-5u4e00q6	838	29	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	838	30	Immunology	Immunology	NNP
cord-014712-5u4e00q6	838	31	/	/	SYM
cord-014712-5u4e00q6	838	32	Allergy	allergy	NN
cord-014712-5u4e00q6	838	33	from	from	IN
cord-014712-5u4e00q6	838	34	1999	1999	CD
cord-014712-5u4e00q6	838	35	to	to	IN
cord-014712-5u4e00q6	838	36	2013	2013	CD
cord-014712-5u4e00q6	838	37	,	,	,
cord-014712-5u4e00q6	838	38	were	be	VBD
cord-014712-5u4e00q6	838	39	evaluated	evaluate	VBN
cord-014712-5u4e00q6	838	40	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	838	41	.	.	.
cord-014712-5u4e00q6	839	1	Findings	finding	NNS
cord-014712-5u4e00q6	839	2	:	:	:
cord-014712-5u4e00q6	840	1	During	during	IN
cord-014712-5u4e00q6	840	2	study	study	NN
cord-014712-5u4e00q6	840	3	period	period	NN
cord-014712-5u4e00q6	840	4	,	,	,
cord-014712-5u4e00q6	840	5	6	6	CD
cord-014712-5u4e00q6	840	6	male	male	NN
cord-014712-5u4e00q6	840	7	and	and	CC
cord-014712-5u4e00q6	840	8	7	7	CD
cord-014712-5u4e00q6	840	9	female	female	JJ
cord-014712-5u4e00q6	840	10	patients	patient	NNS
cord-014712-5u4e00q6	840	11	were	be	VBD
cord-014712-5u4e00q6	840	12	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	840	13	with	with	IN
cord-014712-5u4e00q6	840	14	MHC	MHC	NNP
cord-014712-5u4e00q6	840	15	-	-	HYPH
cord-014712-5u4e00q6	840	16	Class	Class	NNP
cord-014712-5u4e00q6	840	17	II	II	NNP
cord-014712-5u4e00q6	840	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	840	19	.	.	.
cord-014712-5u4e00q6	841	1	Age	age	NN
cord-014712-5u4e00q6	841	2	of	of	IN
cord-014712-5u4e00q6	841	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	841	4	were	be	VBD
cord-014712-5u4e00q6	841	5	between	between	IN
cord-014712-5u4e00q6	841	6	3	3	CD
cord-014712-5u4e00q6	841	7	months	month	NNS
cord-014712-5u4e00q6	841	8	and	and	CC
cord-014712-5u4e00q6	841	9	4	4	CD
cord-014712-5u4e00q6	841	10	years	year	NNS
cord-014712-5u4e00q6	841	11	of	of	IN
cord-014712-5u4e00q6	841	12	age	age	NN
cord-014712-5u4e00q6	841	13	.	.	.
cord-014712-5u4e00q6	842	1	Consanguinity	Consanguinity	NNP
cord-014712-5u4e00q6	842	2	were	be	VBD
cord-014712-5u4e00q6	842	3	present	present	JJ
cord-014712-5u4e00q6	842	4	in	in	IN
cord-014712-5u4e00q6	842	5	eleven	eleven	CD
cord-014712-5u4e00q6	842	6	out	out	IN
cord-014712-5u4e00q6	842	7	of	of	IN
cord-014712-5u4e00q6	842	8	thirteen	thirteen	CD
cord-014712-5u4e00q6	842	9	patients	patient	NNS
cord-014712-5u4e00q6	842	10	.	.	.
cord-014712-5u4e00q6	843	1	Most	most	RBS
cord-014712-5u4e00q6	843	2	frequent	frequent	JJ
cord-014712-5u4e00q6	843	3	clinical	clinical	JJ
cord-014712-5u4e00q6	843	4	findings	finding	NNS
cord-014712-5u4e00q6	843	5	during	during	IN
cord-014712-5u4e00q6	843	6	initial	initial	JJ
cord-014712-5u4e00q6	843	7	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	843	8	were	be	VBD
cord-014712-5u4e00q6	843	9	failure	failure	NN
cord-014712-5u4e00q6	843	10	to	to	TO
cord-014712-5u4e00q6	843	11	thrive	thrive	VB
cord-014712-5u4e00q6	843	12	,	,	,
cord-014712-5u4e00q6	843	13	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	843	14	and	and	CC
cord-014712-5u4e00q6	843	15	oral	oral	JJ
cord-014712-5u4e00q6	843	16	moniliasis	moniliasis	NNP
cord-014712-5u4e00q6	843	17	.	.	.
cord-014712-5u4e00q6	844	1	Lymphopenia	Lymphopenia	NNP
cord-014712-5u4e00q6	844	2	was	be	VBD
cord-014712-5u4e00q6	844	3	absent	absent	JJ
cord-014712-5u4e00q6	844	4	in	in	IN
cord-014712-5u4e00q6	844	5	all	all	DT
cord-014712-5u4e00q6	844	6	of	of	IN
cord-014712-5u4e00q6	844	7	the	the	DT
cord-014712-5u4e00q6	844	8	patients	patient	NNS
cord-014712-5u4e00q6	844	9	,	,	,
cord-014712-5u4e00q6	844	10	however	however	RB
cord-014712-5u4e00q6	844	11	,	,	,
cord-014712-5u4e00q6	844	12	low	low	JJ
cord-014712-5u4e00q6	844	13	serum	serum	NN
cord-014712-5u4e00q6	844	14	IgG	igg	NN
cord-014712-5u4e00q6	844	15	level	level	NN
cord-014712-5u4e00q6	844	16	was	be	VBD
cord-014712-5u4e00q6	844	17	present	present	JJ
cord-014712-5u4e00q6	844	18	in	in	IN
cord-014712-5u4e00q6	844	19	all	all	DT
cord-014712-5u4e00q6	844	20	of	of	IN
cord-014712-5u4e00q6	844	21	them	-PRON-	PRP
cord-014712-5u4e00q6	844	22	.	.	.
cord-014712-5u4e00q6	845	1	Except	except	IN
cord-014712-5u4e00q6	845	2	for	for	IN
cord-014712-5u4e00q6	845	3	the	the	DT
cord-014712-5u4e00q6	845	4	15	15	CD
cord-014712-5u4e00q6	845	5	yo	yo	NN
cord-014712-5u4e00q6	845	6	female	female	JJ
cord-014712-5u4e00q6	845	7	patient	patient	NN
cord-014712-5u4e00q6	845	8	with	with	IN
cord-014712-5u4e00q6	845	9	a	a	DT
cord-014712-5u4e00q6	845	10	positive	positive	JJ
cord-014712-5u4e00q6	845	11	family	family	NN
cord-014712-5u4e00q6	845	12	history	history	NN
cord-014712-5u4e00q6	845	13	and	and	CC
cord-014712-5u4e00q6	845	14	whose	whose	WP$
cord-014712-5u4e00q6	845	15	HLA	HLA	NNP
cord-014712-5u4e00q6	845	16	-	-	HYPH
cord-014712-5u4e00q6	845	17	DR	DR	NNP
cord-014712-5u4e00q6	845	18	expression	expression	NN
cord-014712-5u4e00q6	845	19	was	be	VBD
cord-014712-5u4e00q6	845	20	0,2	0,2	CD
cord-014712-5u4e00q6	845	21	%	%	NN
cord-014712-5u4e00q6	845	22	,	,	,
cord-014712-5u4e00q6	845	23	HLA	HLA	NNP
cord-014712-5u4e00q6	845	24	-	-	HYPH
cord-014712-5u4e00q6	845	25	DR	DR	NNP
cord-014712-5u4e00q6	845	26	expression	expression	NN
cord-014712-5u4e00q6	845	27	was	be	VBD
cord-014712-5u4e00q6	845	28	0	0	CD
cord-014712-5u4e00q6	845	29	%	%	NN
cord-014712-5u4e00q6	845	30	in	in	IN
cord-014712-5u4e00q6	845	31	the	the	DT
cord-014712-5u4e00q6	845	32	rest	rest	NN
cord-014712-5u4e00q6	845	33	of	of	IN
cord-014712-5u4e00q6	845	34	the	the	DT
cord-014712-5u4e00q6	845	35	patients	patient	NNS
cord-014712-5u4e00q6	845	36	.	.	.
cord-014712-5u4e00q6	846	1	Eight	eight	CD
cord-014712-5u4e00q6	846	2	patients	patient	NNS
cord-014712-5u4e00q6	846	3	underwent	undergo	VBD
cord-014712-5u4e00q6	846	4	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	846	5	stem	stem	NN
cord-014712-5u4e00q6	846	6	cell	cell	NN
cord-014712-5u4e00q6	846	7	transplantation	transplantation	NN
cord-014712-5u4e00q6	846	8	(	(	-LRB-
cord-014712-5u4e00q6	846	9	HSCT	HSCT	NNP
cord-014712-5u4e00q6	846	10	)	)	-RRB-
cord-014712-5u4e00q6	846	11	.	.	.
cord-014712-5u4e00q6	847	1	Two	two	CD
cord-014712-5u4e00q6	847	2	patients	patient	NNS
cord-014712-5u4e00q6	847	3	were	be	VBD
cord-014712-5u4e00q6	847	4	lost	lose	VBN
cord-014712-5u4e00q6	847	5	soon	soon	RB
cord-014712-5u4e00q6	847	6	after	after	IN
cord-014712-5u4e00q6	847	7	HSCT	HSCT	NNP
cord-014712-5u4e00q6	847	8	due	due	IN
cord-014712-5u4e00q6	847	9	to	to	IN
cord-014712-5u4e00q6	847	10	complications	complication	NNS
cord-014712-5u4e00q6	847	11	and	and	CC
cord-014712-5u4e00q6	847	12	three	three	CD
cord-014712-5u4e00q6	847	13	patients	patient	NNS
cord-014712-5u4e00q6	847	14	died	die	VBD
cord-014712-5u4e00q6	847	15	of	of	IN
cord-014712-5u4e00q6	847	16	opportunistic	opportunistic	JJ
cord-014712-5u4e00q6	847	17	infections	infection	NNS
cord-014712-5u4e00q6	847	18	.	.	.
cord-014712-5u4e00q6	848	1	Four	four	CD
cord-014712-5u4e00q6	848	2	patients	patient	NNS
cord-014712-5u4e00q6	848	3	died	die	VBD
cord-014712-5u4e00q6	848	4	of	of	IN
cord-014712-5u4e00q6	848	5	severe	severe	JJ
cord-014712-5u4e00q6	848	6	opportunistic	opportunistic	JJ
cord-014712-5u4e00q6	848	7	infections	infection	NNS
cord-014712-5u4e00q6	848	8	without	without	IN
cord-014712-5u4e00q6	848	9	underwent	undergo	VBD
cord-014712-5u4e00q6	848	10	HSCT	HSCT	NNP
cord-014712-5u4e00q6	848	11	.	.	.
cord-014712-5u4e00q6	849	1	Results	result	NNS
cord-014712-5u4e00q6	849	2	:	:	:
cord-014712-5u4e00q6	850	1	MHC	MHC	NNP
cord-014712-5u4e00q6	850	2	-	-	HYPH
cord-014712-5u4e00q6	850	3	Class	Class	NNP
cord-014712-5u4e00q6	850	4	II	II	NNP
cord-014712-5u4e00q6	850	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	850	6	is	be	VBZ
cord-014712-5u4e00q6	850	7	a	a	DT
cord-014712-5u4e00q6	850	8	combined	combine	VBN
cord-014712-5u4e00q6	850	9	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	850	10	and	and	CC
cord-014712-5u4e00q6	850	11	not	not	RB
cord-014712-5u4e00q6	850	12	considered	consider	VBN
cord-014712-5u4e00q6	850	13	a	a	DT
cord-014712-5u4e00q6	850	14	rare	rare	JJ
cord-014712-5u4e00q6	850	15	disease	disease	NN
cord-014712-5u4e00q6	850	16	in	in	IN
cord-014712-5u4e00q6	850	17	our	-PRON-	PRP$
cord-014712-5u4e00q6	850	18	country	country	NN
cord-014712-5u4e00q6	850	19	.	.	.
cord-014712-5u4e00q6	851	1	To	to	IN
cord-014712-5u4e00q6	851	2	date	date	NN
cord-014712-5u4e00q6	851	3	,	,	,
cord-014712-5u4e00q6	851	4	only	only	RB
cord-014712-5u4e00q6	851	5	known	know	VBN
cord-014712-5u4e00q6	851	6	treatment	treatment	NN
cord-014712-5u4e00q6	851	7	is	be	VBZ
cord-014712-5u4e00q6	851	8	HSCT	HSCT	NNP
cord-014712-5u4e00q6	851	9	.	.	.
cord-014712-5u4e00q6	852	1	Since	since	IN
cord-014712-5u4e00q6	852	2	it	-PRON-	PRP
cord-014712-5u4e00q6	852	3	has	have	VBZ
cord-014712-5u4e00q6	852	4	poor	poor	JJ
cord-014712-5u4e00q6	852	5	prognosis	prognosis	NN
cord-014712-5u4e00q6	852	6	,	,	,
cord-014712-5u4e00q6	852	7	HSCT	HSCT	NNP
cord-014712-5u4e00q6	852	8	should	should	MD
cord-014712-5u4e00q6	852	9	be	be	VB
cord-014712-5u4e00q6	852	10	performed	perform	VBN
cord-014712-5u4e00q6	852	11	before	before	IN
cord-014712-5u4e00q6	852	12	development	development	NN
cord-014712-5u4e00q6	852	13	of	of	IN
cord-014712-5u4e00q6	852	14	chronic	chronic	JJ
cord-014712-5u4e00q6	852	15	viral	viral	JJ
cord-014712-5u4e00q6	852	16	infections	infection	NNS
cord-014712-5u4e00q6	852	17	and	and	CC
cord-014712-5u4e00q6	852	18	sequelae	sequela	NNS
cord-014712-5u4e00q6	852	19	related	relate	VBN
cord-014712-5u4e00q6	852	20	to	to	IN
cord-014712-5u4e00q6	852	21	infections	infection	NNS
cord-014712-5u4e00q6	852	22	in	in	IN
cord-014712-5u4e00q6	852	23	patients	patient	NNS
cord-014712-5u4e00q6	852	24	who	who	WP
cord-014712-5u4e00q6	852	25	have	have	VBP
cord-014712-5u4e00q6	852	26	HLA	HLA	NNP
cord-014712-5u4e00q6	852	27	-	-	HYPH
cord-014712-5u4e00q6	852	28	matched	match	VBN
cord-014712-5u4e00q6	852	29	sibling	sibling	NN
cord-014712-5u4e00q6	852	30	.	.	.
cord-014712-5u4e00q6	853	1	Fatih	Fatih	NNP
cord-014712-5u4e00q6	853	2	Celmeli	Celmeli	NNP
cord-014712-5u4e00q6	853	3	1	1	CD
cord-014712-5u4e00q6	853	4	;	;	:
cord-014712-5u4e00q6	853	5	Giancarlo	Giancarlo	NNP
cord-014712-5u4e00q6	853	6	la	la	NNP
cord-014712-5u4e00q6	853	7	Marca	Marca	NNP
cord-014712-5u4e00q6	853	8	2	2	CD
cord-014712-5u4e00q6	853	9	;	;	:
cord-014712-5u4e00q6	853	10	Ines	Ines	NNP
cord-014712-5u4e00q6	853	11	Santisteban	Santisteban	NNP
cord-014712-5u4e00q6	853	12	3	3	CD
cord-014712-5u4e00q6	853	13	;	;	:
cord-014712-5u4e00q6	853	14	Michael	Michael	NNP
cord-014712-5u4e00q6	853	15	S.	S.	NNP
cord-014712-5u4e00q6	853	16	Hershfield	Hershfield	NNP
cord-014712-5u4e00q6	853	17	3	3	CD
cord-014712-5u4e00q6	853	18	1	1	CD
cord-014712-5u4e00q6	854	1	Purine	Purine	NNP
cord-014712-5u4e00q6	854	2	nucleoside	nucleoside	NN
cord-014712-5u4e00q6	854	3	phosphorylase	phosphorylase	NN
cord-014712-5u4e00q6	854	4	deficiency	deficiency	NN
cord-014712-5u4e00q6	854	5	(	(	-LRB-
cord-014712-5u4e00q6	854	6	PNP	PNP	NNP
cord-014712-5u4e00q6	854	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	854	8	)	)	-RRB-
cord-014712-5u4e00q6	854	9	is	be	VBZ
cord-014712-5u4e00q6	854	10	a	a	DT
cord-014712-5u4e00q6	854	11	rare	rare	JJ
cord-014712-5u4e00q6	854	12	autosomal	autosomal	JJ
cord-014712-5u4e00q6	854	13	recessively	recessively	RB
cord-014712-5u4e00q6	854	14	inherited	inherit	VBN
cord-014712-5u4e00q6	854	15	type	type	NN
cord-014712-5u4e00q6	854	16	of	of	IN
cord-014712-5u4e00q6	854	17	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	854	18	.	.	.
cord-014712-5u4e00q6	855	1	PNP	PNP	NNP
cord-014712-5u4e00q6	855	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	855	3	constitutes	constitute	VBZ
cord-014712-5u4e00q6	855	4	about	about	RB
cord-014712-5u4e00q6	855	5	1	1	CD
cord-014712-5u4e00q6	855	6	to	to	IN
cord-014712-5u4e00q6	855	7	2	2	CD
cord-014712-5u4e00q6	855	8	percent	percent	NN
cord-014712-5u4e00q6	855	9	of	of	IN
cord-014712-5u4e00q6	855	10	all	all	DT
cord-014712-5u4e00q6	855	11	combined	combine	VBN
cord-014712-5u4e00q6	855	12	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	855	13	.	.	.
cord-014712-5u4e00q6	856	1	It	-PRON-	PRP
cord-014712-5u4e00q6	856	2	is	be	VBZ
cord-014712-5u4e00q6	856	3	characterized	characterize	VBN
cord-014712-5u4e00q6	856	4	by	by	IN
cord-014712-5u4e00q6	856	5	progressive	progressive	JJ
cord-014712-5u4e00q6	856	6	combined	combine	VBN
cord-014712-5u4e00q6	856	7	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	856	8	and	and	CC
cord-014712-5u4e00q6	856	9	neurologic	neurologic	JJ
cord-014712-5u4e00q6	856	10	findings	finding	NNS
cord-014712-5u4e00q6	856	11	which	which	WDT
cord-014712-5u4e00q6	856	12	includes	include	VBZ
cord-014712-5u4e00q6	856	13	ataxia	ataxia	NN
cord-014712-5u4e00q6	856	14	,	,	,
cord-014712-5u4e00q6	856	15	developmental	developmental	JJ
cord-014712-5u4e00q6	856	16	delay	delay	NN
cord-014712-5u4e00q6	856	17	,	,	,
cord-014712-5u4e00q6	856	18	and	and	CC
cord-014712-5u4e00q6	856	19	spasticity	spasticity	NN
cord-014712-5u4e00q6	856	20	.	.	.
cord-014712-5u4e00q6	857	1	The	the	DT
cord-014712-5u4e00q6	857	2	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	857	3	is	be	VBZ
cord-014712-5u4e00q6	857	4	progressive	progressive	JJ
cord-014712-5u4e00q6	857	5	,	,	,
cord-014712-5u4e00q6	857	6	with	with	IN
cord-014712-5u4e00q6	857	7	normal	normal	JJ
cord-014712-5u4e00q6	857	8	immune	immune	JJ
cord-014712-5u4e00q6	857	9	functions	function	NNS
cord-014712-5u4e00q6	857	10	at	at	IN
cord-014712-5u4e00q6	857	11	birth	birth	NN
cord-014712-5u4e00q6	857	12	,	,	,
cord-014712-5u4e00q6	857	13	but	but	CC
cord-014712-5u4e00q6	857	14	severe	severe	JJ
cord-014712-5u4e00q6	857	15	T	t	NN
cord-014712-5u4e00q6	857	16	cell	cell	NN
cord-014712-5u4e00q6	857	17	deficiency	deficiency	NN
cord-014712-5u4e00q6	857	18	with	with	IN
cord-014712-5u4e00q6	857	19	variable	variable	JJ
cord-014712-5u4e00q6	857	20	B	b	NN
cord-014712-5u4e00q6	857	21	cell	cell	NN
cord-014712-5u4e00q6	857	22	functions	function	NNS
cord-014712-5u4e00q6	857	23	presented	present	VBN
cord-014712-5u4e00q6	857	24	by	by	IN
cord-014712-5u4e00q6	857	25	the	the	DT
cord-014712-5u4e00q6	857	26	age	age	NN
cord-014712-5u4e00q6	857	27	of	of	IN
cord-014712-5u4e00q6	857	28	2	2	CD
cord-014712-5u4e00q6	857	29	years	year	NNS
cord-014712-5u4e00q6	857	30	.	.	.
cord-014712-5u4e00q6	858	1	The	the	DT
cord-014712-5u4e00q6	858	2	only	only	JJ
cord-014712-5u4e00q6	858	3	curative	curative	JJ
cord-014712-5u4e00q6	858	4	treatment	treatment	NN
cord-014712-5u4e00q6	858	5	is	be	VBZ
cord-014712-5u4e00q6	858	6	the	the	DT
cord-014712-5u4e00q6	858	7	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	858	8	stem	stem	NN
cord-014712-5u4e00q6	858	9	cell	cell	NN
cord-014712-5u4e00q6	858	10	transplantation	transplantation	NN
cord-014712-5u4e00q6	858	11	(	(	-LRB-
cord-014712-5u4e00q6	858	12	HSCT	HSCT	NNP
cord-014712-5u4e00q6	858	13	)	)	-RRB-
cord-014712-5u4e00q6	858	14	.	.	.
cord-014712-5u4e00q6	859	1	Here	here	RB
cord-014712-5u4e00q6	859	2	,	,	,
cord-014712-5u4e00q6	859	3	we	-PRON-	PRP
cord-014712-5u4e00q6	859	4	present	present	VBP
cord-014712-5u4e00q6	859	5	a	a	DT
cord-014712-5u4e00q6	859	6	14	14	CD
cord-014712-5u4e00q6	859	7	year	year	NN
cord-014712-5u4e00q6	859	8	-	-	HYPH
cord-014712-5u4e00q6	859	9	old	old	JJ
cord-014712-5u4e00q6	859	10	girl	girl	NN
cord-014712-5u4e00q6	859	11	with	with	IN
cord-014712-5u4e00q6	859	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	859	13	respiratory	respiratory	JJ
cord-014712-5u4e00q6	859	14	tract	tract	NN
cord-014712-5u4e00q6	859	15	infections	infection	NNS
cord-014712-5u4e00q6	859	16	,	,	,
cord-014712-5u4e00q6	859	17	short	short	JJ
cord-014712-5u4e00q6	859	18	stature	stature	NN
cord-014712-5u4e00q6	859	19	and	and	CC
cord-014712-5u4e00q6	859	20	spastic	spastic	JJ
cord-014712-5u4e00q6	859	21	paraplegia	paraplegia	NN
cord-014712-5u4e00q6	859	22	.	.	.
cord-014712-5u4e00q6	860	1	Immunological	immunological	JJ
cord-014712-5u4e00q6	860	2	,	,	,
cord-014712-5u4e00q6	860	3	biochemically	biochemically	RB
cord-014712-5u4e00q6	860	4	and	and	CC
cord-014712-5u4e00q6	860	5	genetics	genetics	NN
cord-014712-5u4e00q6	860	6	investigation	investigation	NN
cord-014712-5u4e00q6	860	7	revealed	reveal	VBD
cord-014712-5u4e00q6	860	8	PNP	PNP	NNP
cord-014712-5u4e00q6	860	9	deficiency	deficiency	NN
cord-014712-5u4e00q6	860	10	with	with	IN
cord-014712-5u4e00q6	860	11	A117	A117	NNP
cord-014712-5u4e00q6	860	12	T	T	NNP
cord-014712-5u4e00q6	860	13	mutation	mutation	NN
cord-014712-5u4e00q6	860	14	in	in	IN
cord-014712-5u4e00q6	860	15	PNP	PNP	NNP
cord-014712-5u4e00q6	860	16	gene	gene	NN
cord-014712-5u4e00q6	860	17	.	.	.
cord-014712-5u4e00q6	861	1	Case	case	NN
cord-014712-5u4e00q6	861	2	report	report	NN
cord-014712-5u4e00q6	861	3	:	:	:
cord-014712-5u4e00q6	861	4	A	a	DT
cord-014712-5u4e00q6	861	5	14	14	CD
cord-014712-5u4e00q6	861	6	years	year	NNS
cord-014712-5u4e00q6	861	7	-	-	HYPH
cord-014712-5u4e00q6	861	8	old	old	JJ
cord-014712-5u4e00q6	861	9	girl	girl	NN
cord-014712-5u4e00q6	861	10	was	be	VBD
cord-014712-5u4e00q6	861	11	referred	refer	VBN
cord-014712-5u4e00q6	861	12	to	to	IN
cord-014712-5u4e00q6	861	13	our	-PRON-	PRP$
cord-014712-5u4e00q6	861	14	pediatric	pediatric	JJ
cord-014712-5u4e00q6	861	15	immunology	immunology	NN
cord-014712-5u4e00q6	861	16	clinic	clinic	NN
cord-014712-5u4e00q6	861	17	for	for	IN
cord-014712-5u4e00q6	861	18	recurrent	recurrent	JJ
cord-014712-5u4e00q6	861	19	sinopulmonary	sinopulmonary	JJ
cord-014712-5u4e00q6	861	20	infections	infection	NNS
cord-014712-5u4e00q6	861	21	since	since	IN
cord-014712-5u4e00q6	861	22	6	6	CD
cord-014712-5u4e00q6	861	23	year	year	NN
cord-014712-5u4e00q6	861	24	of	of	IN
cord-014712-5u4e00q6	861	25	age	age	NN
cord-014712-5u4e00q6	861	26	.	.	.
cord-014712-5u4e00q6	862	1	She	-PRON-	PRP
cord-014712-5u4e00q6	862	2	was	be	VBD
cord-014712-5u4e00q6	862	3	full	full	JJ
cord-014712-5u4e00q6	862	4	term	term	NN
cord-014712-5u4e00q6	862	5	neonate	neonate	NN
cord-014712-5u4e00q6	862	6	and	and	CC
cord-014712-5u4e00q6	862	7	her	-PRON-	PRP$
cord-014712-5u4e00q6	862	8	parents	parent	NNS
cord-014712-5u4e00q6	862	9	were	be	VBD
cord-014712-5u4e00q6	862	10	not	not	RB
cord-014712-5u4e00q6	862	11	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	862	12	.	.	.
cord-014712-5u4e00q6	863	1	She	-PRON-	PRP
cord-014712-5u4e00q6	863	2	had	have	VBD
cord-014712-5u4e00q6	863	3	a	a	DT
cord-014712-5u4e00q6	863	4	history	history	NN
cord-014712-5u4e00q6	863	5	of	of	IN
cord-014712-5u4e00q6	863	6	prolonged	prolonged	JJ
cord-014712-5u4e00q6	863	7	and	and	CC
cord-014712-5u4e00q6	863	8	resistant	resistant	JJ
cord-014712-5u4e00q6	863	9	bronchopneumonia	bronchopneumonia	NN
cord-014712-5u4e00q6	863	10	,	,	,
cord-014712-5u4e00q6	863	11	and	and	CC
cord-014712-5u4e00q6	863	12	an	an	DT
cord-014712-5u4e00q6	863	13	attack	attack	NN
cord-014712-5u4e00q6	863	14	of	of	IN
cord-014712-5u4e00q6	863	15	generalized	generalized	JJ
cord-014712-5u4e00q6	863	16	chickenpox	chickenpox	NN
cord-014712-5u4e00q6	863	17	complicated	complicate	VBN
cord-014712-5u4e00q6	863	18	with	with	IN
cord-014712-5u4e00q6	863	19	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	863	20	.	.	.
cord-014712-5u4e00q6	864	1	She	-PRON-	PRP
cord-014712-5u4e00q6	864	2	had	have	VBD
cord-014712-5u4e00q6	864	3	also	also	RB
cord-014712-5u4e00q6	864	4	severe	severe	JJ
cord-014712-5u4e00q6	864	5	zona	zona	NNP
cord-014712-5u4e00q6	864	6	infection	infection	NN
cord-014712-5u4e00q6	864	7	resolved	resolve	VBN
cord-014712-5u4e00q6	864	8	with	with	IN
cord-014712-5u4e00q6	864	9	ulceration	ulceration	NN
cord-014712-5u4e00q6	864	10	in	in	IN
cord-014712-5u4e00q6	864	11	cornea	cornea	NN
cord-014712-5u4e00q6	864	12	,	,	,
cord-014712-5u4e00q6	864	13	one	one	CD
cord-014712-5u4e00q6	864	14	year	year	NN
cord-014712-5u4e00q6	864	15	ago	ago	RB
cord-014712-5u4e00q6	864	16	.	.	.
cord-014712-5u4e00q6	865	1	She	-PRON-	PRP
cord-014712-5u4e00q6	865	2	has	have	VBZ
cord-014712-5u4e00q6	865	3	been	be	VBN
cord-014712-5u4e00q6	865	4	suffering	suffer	VBG
cord-014712-5u4e00q6	865	5	from	from	IN
cord-014712-5u4e00q6	865	6	frequent	frequent	JJ
cord-014712-5u4e00q6	865	7	infections	infection	NNS
cord-014712-5u4e00q6	865	8	like	like	IN
cord-014712-5u4e00q6	865	9	chronic	chronic	JJ
cord-014712-5u4e00q6	865	10	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	865	11	,	,	,
cord-014712-5u4e00q6	865	12	oral	oral	JJ
cord-014712-5u4e00q6	865	13	moniliasis	moniliasis	NN
cord-014712-5u4e00q6	865	14	,	,	,
cord-014712-5u4e00q6	865	15	recurrent	recurrent	JJ
cord-014712-5u4e00q6	865	16	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	865	17	and	and	CC
cord-014712-5u4e00q6	865	18	sclerosing	sclerosing	NN
cord-014712-5u4e00q6	865	19	cholangitis	cholangitis	NN
cord-014712-5u4e00q6	865	20	.	.	.
cord-014712-5u4e00q6	866	1	She	-PRON-	PRP
cord-014712-5u4e00q6	866	2	has	have	VBZ
cord-014712-5u4e00q6	866	3	also	also	RB
cord-014712-5u4e00q6	866	4	nonprogressive	nonprogressive	JJ
cord-014712-5u4e00q6	866	5	cerebral	cerebral	JJ
cord-014712-5u4e00q6	866	6	palsy	palsy	JJ
cord-014712-5u4e00q6	866	7	,	,	,
cord-014712-5u4e00q6	866	8	spastic	spastic	JJ
cord-014712-5u4e00q6	866	9	paraplegia	paraplegia	NN
cord-014712-5u4e00q6	866	10	,	,	,
cord-014712-5u4e00q6	866	11	behavioral	behavioral	JJ
cord-014712-5u4e00q6	866	12	problems	problem	NNS
cord-014712-5u4e00q6	866	13	and	and	CC
cord-014712-5u4e00q6	866	14	limited	limited	JJ
cord-014712-5u4e00q6	866	15	motor	motor	NN
cord-014712-5u4e00q6	866	16	and	and	CC
cord-014712-5u4e00q6	866	17	mental	mental	JJ
cord-014712-5u4e00q6	866	18	retardation	retardation	NN
cord-014712-5u4e00q6	866	19	.	.	.
cord-014712-5u4e00q6	867	1	There	there	EX
cord-014712-5u4e00q6	867	2	was	be	VBD
cord-014712-5u4e00q6	867	3	no	no	DT
cord-014712-5u4e00q6	867	4	family	family	NN
cord-014712-5u4e00q6	867	5	history	history	NN
cord-014712-5u4e00q6	867	6	of	of	IN
cord-014712-5u4e00q6	867	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	867	8	infections	infection	NNS
cord-014712-5u4e00q6	867	9	or	or	CC
cord-014712-5u4e00q6	867	10	immunological	immunological	JJ
cord-014712-5u4e00q6	867	11	disorders	disorder	NNS
cord-014712-5u4e00q6	867	12	.	.	.
cord-014712-5u4e00q6	868	1	On	on	IN
cord-014712-5u4e00q6	868	2	her	-PRON-	PRP$
cord-014712-5u4e00q6	868	3	physical	physical	JJ
cord-014712-5u4e00q6	868	4	examination	examination	NN
cord-014712-5u4e00q6	868	5	,	,	,
cord-014712-5u4e00q6	868	6	there	there	EX
cord-014712-5u4e00q6	868	7	was	be	VBD
cord-014712-5u4e00q6	868	8	failure	failure	NN
cord-014712-5u4e00q6	868	9	to	to	TO
cord-014712-5u4e00q6	868	10	thrive	thrive	VB
cord-014712-5u4e00q6	868	11	,	,	,
cord-014712-5u4e00q6	868	12	(	(	-LRB-
cord-014712-5u4e00q6	868	13	her	-PRON-	PRP$
cord-014712-5u4e00q6	868	14	weight	weight	NN
cord-014712-5u4e00q6	868	15	and	and	CC
cord-014712-5u4e00q6	868	16	height	height	NN
cord-014712-5u4e00q6	868	17	<3	<3	NNP
cord-014712-5u4e00q6	868	18	rd	rd	NNP
cord-014712-5u4e00q6	868	19	p	p	NNP
cord-014712-5u4e00q6	868	20	)	)	-RRB-
cord-014712-5u4e00q6	868	21	oral	oral	JJ
cord-014712-5u4e00q6	868	22	moniliasis	moniliasis	NNP
cord-014712-5u4e00q6	868	23	,	,	,
cord-014712-5u4e00q6	868	24	bilateral	bilateral	JJ
cord-014712-5u4e00q6	868	25	crepitus	crepitus	NN
cord-014712-5u4e00q6	868	26	ralls	ralls	NNP
cord-014712-5u4e00q6	868	27	,	,	,
cord-014712-5u4e00q6	868	28	and	and	CC
cord-014712-5u4e00q6	868	29	splenomegaly	splenomegaly	NN
cord-014712-5u4e00q6	868	30	.	.	.
cord-014712-5u4e00q6	869	1	She	-PRON-	PRP
cord-014712-5u4e00q6	869	2	has	have	VBZ
cord-014712-5u4e00q6	869	3	also	also	RB
cord-014712-5u4e00q6	869	4	marked	mark	VBN
cord-014712-5u4e00q6	869	5	spasticity	spasticity	NN
cord-014712-5u4e00q6	869	6	with	with	IN
cord-014712-5u4e00q6	869	7	brisk	brisk	JJ
cord-014712-5u4e00q6	869	8	reflexes	reflex	NNS
cord-014712-5u4e00q6	869	9	in	in	IN
cord-014712-5u4e00q6	869	10	lower	low	JJR
cord-014712-5u4e00q6	869	11	extremities	extremity	NNS
cord-014712-5u4e00q6	869	12	.	.	.
cord-014712-5u4e00q6	870	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	870	2	tests	test	NNS
cord-014712-5u4e00q6	870	3	revealed	reveal	VBD
cord-014712-5u4e00q6	870	4	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	870	5	:	:	:
cord-014712-5u4e00q6	870	6	hemoglobin	hemoglobin	NN
cord-014712-5u4e00q6	870	7	11	11	CD
cord-014712-5u4e00q6	870	8	g	g	NN
cord-014712-5u4e00q6	870	9	/	/	SYM
cord-014712-5u4e00q6	870	10	dl	dl	NN
cord-014712-5u4e00q6	870	11	and	and	CC
cord-014712-5u4e00q6	870	12	platelets	platelet	NNS
cord-014712-5u4e00q6	870	13	158000	158000	CD
cord-014712-5u4e00q6	870	14	/	/	SYM
cord-014712-5u4e00q6	870	15	mm	mm	NN
cord-014712-5u4e00q6	870	16	3	3	CD
cord-014712-5u4e00q6	871	1	WBC	WBC	NNP
cord-014712-5u4e00q6	871	2	4000	4000	CD
cord-014712-5u4e00q6	871	3	/	/	SYM
cord-014712-5u4e00q6	871	4	mm	mm	NNP
cord-014712-5u4e00q6	871	5	3	3	CD
cord-014712-5u4e00q6	871	6	,	,	,
cord-014712-5u4e00q6	871	7	absolute	absolute	JJ
cord-014712-5u4e00q6	871	8	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	871	9	560	560	CD
cord-014712-5u4e00q6	871	10	/	/	SYM
cord-014712-5u4e00q6	871	11	mm	mm	NN
cord-014712-5u4e00q6	871	12	3	3	CD
cord-014712-5u4e00q6	871	13	.	.	.
cord-014712-5u4e00q6	872	1	The	the	DT
cord-014712-5u4e00q6	872	2	laboratory	laboratory	NN
cord-014712-5u4e00q6	872	3	results	result	NNS
cord-014712-5u4e00q6	872	4	are	be	VBP
cord-014712-5u4e00q6	872	5	shown	show	VBN
cord-014712-5u4e00q6	872	6	in	in	IN
cord-014712-5u4e00q6	872	7	the	the	DT
cord-014712-5u4e00q6	872	8	table	table	NN
cord-014712-5u4e00q6	872	9	.	.	.
cord-014712-5u4e00q6	873	1	Lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	873	2	proliferation	proliferation	NN
cord-014712-5u4e00q6	873	3	is	be	VBZ
cord-014712-5u4e00q6	873	4	lower	low	JJR
cord-014712-5u4e00q6	873	5	than	than	IN
cord-014712-5u4e00q6	873	6	normal	normal	JJ
cord-014712-5u4e00q6	873	7	limits	limit	NNS
cord-014712-5u4e00q6	873	8	in	in	IN
cord-014712-5u4e00q6	873	9	response	response	NN
cord-014712-5u4e00q6	873	10	to	to	IN
cord-014712-5u4e00q6	873	11	PHA	PHA	NNP
cord-014712-5u4e00q6	873	12	stimulation	stimulation	NN
cord-014712-5u4e00q6	873	13	(	(	-LRB-
cord-014712-5u4e00q6	873	14	WST1	wst1	JJ
cord-014712-5u4e00q6	873	15	assay	assay	NN
cord-014712-5u4e00q6	873	16	)	)	-RRB-
cord-014712-5u4e00q6	873	17	.	.	.
cord-014712-5u4e00q6	874	1	PPD	PPD	NNP
cord-014712-5u4e00q6	874	2	response	response	NN
cord-014712-5u4e00q6	874	3	and	and	CC
cord-014712-5u4e00q6	874	4	HIV	HIV	NNP
cord-014712-5u4e00q6	874	5	was	be	VBD
cord-014712-5u4e00q6	874	6	negative	negative	JJ
cord-014712-5u4e00q6	874	7	.	.	.
cord-014712-5u4e00q6	875	1	AntiHbs	AntiHbs	NNP
cord-014712-5u4e00q6	875	2	,	,	,
cord-014712-5u4e00q6	875	3	and	and	CC
cord-014712-5u4e00q6	875	4	antiHAV	antiHAV	NNP
cord-014712-5u4e00q6	875	5	were	be	VBD
cord-014712-5u4e00q6	875	6	negative	negative	JJ
cord-014712-5u4e00q6	875	7	despite	despite	IN
cord-014712-5u4e00q6	875	8	vaccination	vaccination	NN
cord-014712-5u4e00q6	875	9	.	.	.
cord-014712-5u4e00q6	876	1	Uric	uric	JJ
cord-014712-5u4e00q6	876	2	acid	acid	NN
cord-014712-5u4e00q6	876	3	level	level	NN
cord-014712-5u4e00q6	876	4	1,8	1,8	CD
cord-014712-5u4e00q6	876	5	mg	mg	NNP
cord-014712-5u4e00q6	876	6	/	/	SYM
cord-014712-5u4e00q6	876	7	dl	dl	NNP
cord-014712-5u4e00q6	876	8	.	.	.
cord-014712-5u4e00q6	877	1	Direct	Direct	NNP
cord-014712-5u4e00q6	877	2	Coombs	Coombs	NNP
cord-014712-5u4e00q6	877	3	was	be	VBD
cord-014712-5u4e00q6	877	4	negative	negative	JJ
cord-014712-5u4e00q6	877	5	,	,	,
cord-014712-5u4e00q6	877	6	thyroid	thyroid	JJ
cord-014712-5u4e00q6	877	7	autoantibodies	autoantibody	NNS
cord-014712-5u4e00q6	877	8	were	be	VBD
cord-014712-5u4e00q6	877	9	within	within	IN
cord-014712-5u4e00q6	877	10	normal	normal	JJ
cord-014712-5u4e00q6	877	11	limits	limit	NNS
cord-014712-5u4e00q6	877	12	.	.	.
cord-014712-5u4e00q6	878	1	Genetic	genetic	JJ
cord-014712-5u4e00q6	878	2	analysis	analysis	NN
cord-014712-5u4e00q6	878	3	revealed	reveal	VBD
cord-014712-5u4e00q6	878	4	homozygous	homozygous	JJ
cord-014712-5u4e00q6	878	5	missense	missense	NN
cord-014712-5u4e00q6	878	6	mutation	mutation	NN
cord-014712-5u4e00q6	878	7	(	(	-LRB-
cord-014712-5u4e00q6	878	8	c.349	c.349	JJ
cord-014712-5u4e00q6	878	9	G	g	NN
cord-014712-5u4e00q6	878	10	>	>	XX
cord-014712-5u4e00q6	878	11	A	a	NN
cord-014712-5u4e00q6	878	12	)	)	-RRB-
cord-014712-5u4e00q6	878	13	,	,	,
cord-014712-5u4e00q6	878	14	which	which	WDT
cord-014712-5u4e00q6	878	15	causes	cause	VBZ
cord-014712-5u4e00q6	878	16	the	the	DT
cord-014712-5u4e00q6	878	17	A117	A117	NNP
cord-014712-5u4e00q6	878	18	T	T	NNP
cord-014712-5u4e00q6	878	19	amino	amino	NN
cord-014712-5u4e00q6	878	20	acid	acid	NN
cord-014712-5u4e00q6	878	21	substitution	substitution	NN
cord-014712-5u4e00q6	878	22	in	in	IN
cord-014712-5u4e00q6	878	23	PNP	PNP	NNP
cord-014712-5u4e00q6	878	24	gene	gene	NN
cord-014712-5u4e00q6	878	25	,	,	,
cord-014712-5u4e00q6	878	26	in	in	IN
cord-014712-5u4e00q6	878	27	exon	exon	NN
cord-014712-5u4e00q6	878	28	4	4	CD
cord-014712-5u4e00q6	878	29	,	,	,
cord-014712-5u4e00q6	878	30	which	which	WDT
cord-014712-5u4e00q6	878	31	has	have	VBZ
cord-014712-5u4e00q6	878	32	previously	previously	RB
cord-014712-5u4e00q6	878	33	been	be	VBN
cord-014712-5u4e00q6	878	34	reported	report	VBN
cord-014712-5u4e00q6	878	35	.	.	.
cord-014712-5u4e00q6	879	1	Additionally	additionally	RB
cord-014712-5u4e00q6	879	2	,	,	,
cord-014712-5u4e00q6	879	3	a	a	DT
cord-014712-5u4e00q6	879	4	homozygous	homozygous	JJ
cord-014712-5u4e00q6	879	5	G	G	NNP
cord-014712-5u4e00q6	879	6	/	/	SYM
cord-014712-5u4e00q6	879	7	A	a	DT
cord-014712-5u4e00q6	879	8	polymorphic	polymorphic	JJ
cord-014712-5u4e00q6	879	9	site	site	NN
cord-014712-5u4e00q6	879	10	in	in	IN
cord-014712-5u4e00q6	879	11	IVS3	IVS3	NNP
cord-014712-5u4e00q6	879	12	has	have	VBZ
cord-014712-5u4e00q6	879	13	been	be	VBN
cord-014712-5u4e00q6	879	14	detected	detect	VBN
cord-014712-5u4e00q6	879	15	(	(	-LRB-
cord-014712-5u4e00q6	879	16	c.285	c.285	JJ
cord-014712-5u4e00q6	879	17	+	+	SYM
cord-014712-5u4e00q6	879	18	10	10	CD
cord-014712-5u4e00q6	879	19	G	g	NN
cord-014712-5u4e00q6	879	20	(	(	-LRB-
cord-014712-5u4e00q6	879	21	IVS3	IVS3	NNP
cord-014712-5u4e00q6	879	22	+	+	SYM
cord-014712-5u4e00q6	879	23	10	10	CD
cord-014712-5u4e00q6	879	24	G	g	NN
cord-014712-5u4e00q6	879	25	)	)	-RRB-
cord-014712-5u4e00q6	879	26	)	)	-RRB-
cord-014712-5u4e00q6	879	27	.	.	.
cord-014712-5u4e00q6	880	1	Discussion	discussion	NN
cord-014712-5u4e00q6	880	2	:	:	:
cord-014712-5u4e00q6	881	1	PNP	PNP	NNP
cord-014712-5u4e00q6	881	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	881	3	is	be	VBZ
cord-014712-5u4e00q6	881	4	caused	cause	VBN
cord-014712-5u4e00q6	881	5	by	by	IN
cord-014712-5u4e00q6	881	6	mutations	mutation	NNS
cord-014712-5u4e00q6	881	7	in	in	IN
cord-014712-5u4e00q6	881	8	the	the	DT
cord-014712-5u4e00q6	881	9	PNP	PNP	NNP
cord-014712-5u4e00q6	881	10	gene	gene	NN
cord-014712-5u4e00q6	881	11	at	at	IN
cord-014712-5u4e00q6	881	12	14q13.1	14q13.1	CD
cord-014712-5u4e00q6	881	13	.	.	.
cord-014712-5u4e00q6	882	1	This	this	DT
cord-014712-5u4e00q6	882	2	gene	gene	NN
cord-014712-5u4e00q6	882	3	encodes	encode	VBZ
cord-014712-5u4e00q6	882	4	the	the	DT
cord-014712-5u4e00q6	882	5	protein	protein	NN
cord-014712-5u4e00q6	882	6	purine	purine	NN
cord-014712-5u4e00q6	882	7	nucleoside	nucleoside	NN
cord-014712-5u4e00q6	882	8	phosphorylase	phosphorylase	NN
cord-014712-5u4e00q6	882	9	,	,	,
cord-014712-5u4e00q6	882	10	one	one	CD
cord-014712-5u4e00q6	882	11	of	of	IN
cord-014712-5u4e00q6	882	12	the	the	DT
cord-014712-5u4e00q6	882	13	enzymes	enzyme	NNS
cord-014712-5u4e00q6	882	14	involved	involve	VBN
cord-014712-5u4e00q6	882	15	in	in	IN
cord-014712-5u4e00q6	882	16	the	the	DT
cord-014712-5u4e00q6	882	17	purine	purine	NNP
cord-014712-5u4e00q6	882	18	salvage	salvage	NN
cord-014712-5u4e00q6	882	19	pathway	pathway	NN
cord-014712-5u4e00q6	882	20	.	.	.
cord-014712-5u4e00q6	883	1	Adenosine	adenosine	NN
cord-014712-5u4e00q6	883	2	deaminase	deaminase	NN
cord-014712-5u4e00q6	883	3	(	(	-LRB-
cord-014712-5u4e00q6	883	4	ADA	ADA	NNP
cord-014712-5u4e00q6	883	5	)	)	-RRB-
cord-014712-5u4e00q6	883	6	deaminates	deaminate	VBZ
cord-014712-5u4e00q6	883	7	adenosine	adenosine	NN
cord-014712-5u4e00q6	883	8	to	to	TO
cord-014712-5u4e00q6	883	9	yield	yield	VB
cord-014712-5u4e00q6	883	10	inosine	inosine	NNP
cord-014712-5u4e00q6	883	11	,	,	,
cord-014712-5u4e00q6	883	12	which	which	WDT
cord-014712-5u4e00q6	883	13	is	be	VBZ
cord-014712-5u4e00q6	883	14	then	then	RB
cord-014712-5u4e00q6	883	15	converted	convert	VBN
cord-014712-5u4e00q6	883	16	to	to	IN
cord-014712-5u4e00q6	883	17	hypoxanthine	hypoxanthine	NNP
cord-014712-5u4e00q6	883	18	by	by	IN
cord-014712-5u4e00q6	883	19	PNP	PNP	NNP
cord-014712-5u4e00q6	883	20	.	.	.
cord-014712-5u4e00q6	884	1	PNP	PNP	NNP
cord-014712-5u4e00q6	884	2	also	also	RB
cord-014712-5u4e00q6	884	3	converts	convert	VBZ
cord-014712-5u4e00q6	884	4	guanosine	guanosine	NN
cord-014712-5u4e00q6	884	5	to	to	IN
cord-014712-5u4e00q6	884	6	guanine	guanine	NN
cord-014712-5u4e00q6	884	7	.	.	.
cord-014712-5u4e00q6	885	1	A	a	DT
cord-014712-5u4e00q6	885	2	number	number	NN
cord-014712-5u4e00q6	885	3	of	of	IN
cord-014712-5u4e00q6	885	4	metabolites	metabolite	NNS
cord-014712-5u4e00q6	885	5	are	be	VBP
cord-014712-5u4e00q6	885	6	elevated	elevate	VBN
cord-014712-5u4e00q6	885	7	in	in	IN
cord-014712-5u4e00q6	885	8	the	the	DT
cord-014712-5u4e00q6	885	9	plasma	plasma	NN
cord-014712-5u4e00q6	885	10	and	and	CC
cord-014712-5u4e00q6	885	11	urine	urine	NN
cord-014712-5u4e00q6	885	12	in	in	IN
cord-014712-5u4e00q6	885	13	PNP	PNP	NNP
cord-014712-5u4e00q6	885	14	deficiency	deficiency	NN
cord-014712-5u4e00q6	885	15	,	,	,
cord-014712-5u4e00q6	885	16	including	include	VBG
cord-014712-5u4e00q6	885	17	deoxyguanosine	deoxyguanosine	NNP
cord-014712-5u4e00q6	885	18	and	and	CC
cord-014712-5u4e00q6	885	19	deoxyinosine	deoxyinosine	NNP
cord-014712-5u4e00q6	885	20	.	.	.
cord-014712-5u4e00q6	886	1	There	there	EX
cord-014712-5u4e00q6	886	2	is	be	VBZ
cord-014712-5u4e00q6	886	3	an	an	DT
cord-014712-5u4e00q6	886	4	intracellular	intracellular	JJ
cord-014712-5u4e00q6	886	5	accumulation	accumulation	NN
cord-014712-5u4e00q6	886	6	of	of	IN
cord-014712-5u4e00q6	886	7	their	-PRON-	PRP$
cord-014712-5u4e00q6	886	8	deoxy	deoxy	NN
cord-014712-5u4e00q6	886	9	triphosphate	triphosphate	NN
cord-014712-5u4e00q6	886	10	compounds	compound	NNS
cord-014712-5u4e00q6	886	11	,	,	,
cord-014712-5u4e00q6	886	12	particularly	particularly	RB
cord-014712-5u4e00q6	886	13	deoxyguanosine	deoxyguanosine	NNP
cord-014712-5u4e00q6	886	14	triphosphate	triphosphate	NNP
cord-014712-5u4e00q6	886	15	(	(	-LRB-
cord-014712-5u4e00q6	886	16	dGTP	dGTP	NNP
cord-014712-5u4e00q6	886	17	)	)	-RRB-
cord-014712-5u4e00q6	886	18	.	.	.
cord-014712-5u4e00q6	887	1	The	the	DT
cord-014712-5u4e00q6	887	2	latter	latter	JJ
cord-014712-5u4e00q6	887	3	is	be	VBZ
cord-014712-5u4e00q6	887	4	toxic	toxic	JJ
cord-014712-5u4e00q6	887	5	to	to	IN
cord-014712-5u4e00q6	887	6	T	t	NN
cord-014712-5u4e00q6	887	7	cells	cell	NNS
cord-014712-5u4e00q6	887	8	,	,	,
cord-014712-5u4e00q6	887	9	a	a	DT
cord-014712-5u4e00q6	887	10	property	property	NN
cord-014712-5u4e00q6	887	11	similar	similar	JJ
cord-014712-5u4e00q6	887	12	to	to	IN
cord-014712-5u4e00q6	887	13	deoxyadenosine	deoxyadenosine	VB
cord-014712-5u4e00q6	887	14	triphosphate	triphosphate	NN
cord-014712-5u4e00q6	887	15	in	in	IN
cord-014712-5u4e00q6	887	16	adenosine	adenosine	NN
cord-014712-5u4e00q6	887	17	deaminase	deaminase	NNP
cord-014712-5u4e00q6	887	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	887	19	.	.	.
cord-014712-5u4e00q6	888	1	In	in	IN
cord-014712-5u4e00q6	888	2	this	this	DT
cord-014712-5u4e00q6	888	3	report	report	NN
cord-014712-5u4e00q6	888	4	,	,	,
cord-014712-5u4e00q6	888	5	we	-PRON-	PRP
cord-014712-5u4e00q6	888	6	demonstrate	demonstrate	VBP
cord-014712-5u4e00q6	888	7	the	the	DT
cord-014712-5u4e00q6	888	8	clinical	clinical	JJ
cord-014712-5u4e00q6	888	9	characteristic	characteristic	NN
cord-014712-5u4e00q6	888	10	of	of	IN
cord-014712-5u4e00q6	888	11	the	the	DT
cord-014712-5u4e00q6	888	12	patient	patient	NN
cord-014712-5u4e00q6	888	13	with	with	IN
cord-014712-5u4e00q6	888	14	late	late	JJ
cord-014712-5u4e00q6	888	15	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	888	16	of	of	IN
cord-014712-5u4e00q6	888	17	PNP	PNP	NNP
cord-014712-5u4e00q6	888	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	888	19	.	.	.
cord-014712-5u4e00q6	889	1	PNP	PNP	NNP
cord-014712-5u4e00q6	889	2	mutations	mutation	NNS
cord-014712-5u4e00q6	889	3	likely	likely	RB
cord-014712-5u4e00q6	889	4	lead	lead	VBP
cord-014712-5u4e00q6	889	5	to	to	IN
cord-014712-5u4e00q6	889	6	an	an	DT
cord-014712-5u4e00q6	889	7	intense	intense	JJ
cord-014712-5u4e00q6	889	8	alteration	alteration	NN
cord-014712-5u4e00q6	889	9	of	of	IN
cord-014712-5u4e00q6	889	10	the	the	DT
cord-014712-5u4e00q6	889	11	enzyme	enzyme	NN
cord-014712-5u4e00q6	889	12	activity	activity	NN
cord-014712-5u4e00q6	889	13	which	which	WDT
cord-014712-5u4e00q6	889	14	in	in	IN
cord-014712-5u4e00q6	889	15	turn	turn	NN
cord-014712-5u4e00q6	889	16	,	,	,
cord-014712-5u4e00q6	889	17	cause	cause	VB
cord-014712-5u4e00q6	889	18	severe	severe	JJ
cord-014712-5u4e00q6	889	19	and	and	CC
cord-014712-5u4e00q6	889	20	early	early	JJ
cord-014712-5u4e00q6	889	21	onset	onset	NN
cord-014712-5u4e00q6	889	22	of	of	IN
cord-014712-5u4e00q6	889	23	the	the	DT
cord-014712-5u4e00q6	889	24	clinical	clinical	JJ
cord-014712-5u4e00q6	889	25	findings	finding	NNS
cord-014712-5u4e00q6	889	26	.	.	.
cord-014712-5u4e00q6	890	1	However	however	RB
cord-014712-5u4e00q6	890	2	,	,	,
cord-014712-5u4e00q6	890	3	in	in	IN
cord-014712-5u4e00q6	890	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	890	5	case	case	NN
cord-014712-5u4e00q6	890	6	,	,	,
cord-014712-5u4e00q6	890	7	the	the	DT
cord-014712-5u4e00q6	890	8	clinical	clinical	JJ
cord-014712-5u4e00q6	890	9	onset	onset	NN
cord-014712-5u4e00q6	890	10	of	of	IN
cord-014712-5u4e00q6	890	11	the	the	DT
cord-014712-5u4e00q6	890	12	disease	disease	NN
cord-014712-5u4e00q6	890	13	is	be	VBZ
cord-014712-5u4e00q6	890	14	quite	quite	RB
cord-014712-5u4e00q6	890	15	late	late	JJ
cord-014712-5u4e00q6	890	16	(	(	-LRB-
cord-014712-5u4e00q6	890	17	after	after	IN
cord-014712-5u4e00q6	890	18	6	6	CD
cord-014712-5u4e00q6	890	19	years	year	NNS
cord-014712-5u4e00q6	890	20	)	)	-RRB-
cord-014712-5u4e00q6	890	21	which	which	WDT
cord-014712-5u4e00q6	890	22	can	can	MD
cord-014712-5u4e00q6	890	23	be	be	VB
cord-014712-5u4e00q6	890	24	explained	explain	VBN
cord-014712-5u4e00q6	890	25	by	by	IN
cord-014712-5u4e00q6	890	26	the	the	DT
cord-014712-5u4e00q6	890	27	residual	residual	JJ
cord-014712-5u4e00q6	890	28	activity	activity	NN
cord-014712-5u4e00q6	890	29	of	of	IN
cord-014712-5u4e00q6	890	30	the	the	DT
cord-014712-5u4e00q6	890	31	PNP	PNP	NNP
cord-014712-5u4e00q6	890	32	.	.	.
cord-014712-5u4e00q6	891	1	In	in	IN
cord-014712-5u4e00q6	891	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	891	3	patients	patient	NNS
cord-014712-5u4e00q6	891	4	with	with	IN
cord-014712-5u4e00q6	891	5	PNP	PNP	NNP
cord-014712-5u4e00q6	891	6	deficiency	deficiency	NN
cord-014712-5u4e00q6	891	7	can	can	MD
cord-014712-5u4e00q6	891	8	be	be	VB
cord-014712-5u4e00q6	891	9	late	late	JJ
cord-014712-5u4e00q6	891	10	onset	onset	NN
cord-014712-5u4e00q6	891	11	.	.	.
cord-014712-5u4e00q6	892	1	Additionally	additionally	RB
cord-014712-5u4e00q6	892	2	,	,	,
cord-014712-5u4e00q6	892	3	late	late	JJ
cord-014712-5u4e00q6	892	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	892	5	of	of	IN
cord-014712-5u4e00q6	892	6	this	this	DT
cord-014712-5u4e00q6	892	7	patient	patient	NN
cord-014712-5u4e00q6	892	8	can	can	MD
cord-014712-5u4e00q6	892	9	cause	cause	VB
cord-014712-5u4e00q6	892	10	severe	severe	JJ
cord-014712-5u4e00q6	892	11	comorbidity	comorbidity	NN
cord-014712-5u4e00q6	892	12	which	which	WDT
cord-014712-5u4e00q6	892	13	limits	limit	VBZ
cord-014712-5u4e00q6	892	14	the	the	DT
cord-014712-5u4e00q6	892	15	chance	chance	NN
cord-014712-5u4e00q6	892	16	of	of	IN
cord-014712-5u4e00q6	892	17	bone	bone	NN
cord-014712-5u4e00q6	892	18	marrow	marrow	NN
cord-014712-5u4e00q6	892	19	transplantation	transplantation	NN
cord-014712-5u4e00q6	892	20	.	.	.
cord-014712-5u4e00q6	893	1	Di	Di	NNP
cord-014712-5u4e00q6	893	2	George	George	NNP
cord-014712-5u4e00q6	893	3	syndrome	syndrome	NN
cord-014712-5u4e00q6	893	4	,	,	,
cord-014712-5u4e00q6	893	5	a	a	DT
cord-014712-5u4e00q6	893	6	disorder	disorder	NN
cord-014712-5u4e00q6	893	7	caused	cause	VBN
cord-014712-5u4e00q6	893	8	by	by	IN
cord-014712-5u4e00q6	893	9	a	a	DT
cord-014712-5u4e00q6	893	10	defect	defect	NN
cord-014712-5u4e00q6	893	11	in	in	IN
cord-014712-5u4e00q6	893	12	chromosome	chromosome	NN
cord-014712-5u4e00q6	893	13	22	22	CD
cord-014712-5u4e00q6	893	14	(	(	-LRB-
cord-014712-5u4e00q6	893	15	22q11.2	22q11.2	CD
cord-014712-5u4e00q6	893	16	deletion	deletion	NN
cord-014712-5u4e00q6	893	17	)	)	-RRB-
cord-014712-5u4e00q6	893	18	,	,	,
cord-014712-5u4e00q6	893	19	results	result	NNS
cord-014712-5u4e00q6	893	20	in	in	IN
cord-014712-5u4e00q6	893	21	the	the	DT
cord-014712-5u4e00q6	893	22	poor	poor	JJ
cord-014712-5u4e00q6	893	23	development	development	NN
cord-014712-5u4e00q6	893	24	of	of	IN
cord-014712-5u4e00q6	893	25	several	several	JJ
cord-014712-5u4e00q6	893	26	body	body	NN
cord-014712-5u4e00q6	893	27	systems	system	NNS
cord-014712-5u4e00q6	893	28	.	.	.
cord-014712-5u4e00q6	894	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	894	2	features	feature	NNS
cord-014712-5u4e00q6	894	3	include	include	VBP
cord-014712-5u4e00q6	894	4	congenital	congenital	JJ
cord-014712-5u4e00q6	894	5	heart	heart	NN
cord-014712-5u4e00q6	894	6	defects	defect	NNS
cord-014712-5u4e00q6	894	7	,	,	,
cord-014712-5u4e00q6	894	8	hypoparathyroidism	hypoparathyroidism	NN
cord-014712-5u4e00q6	894	9	and	and	CC
cord-014712-5u4e00q6	894	10	thymic	thymic	JJ
cord-014712-5u4e00q6	894	11	hypoplasia	hypoplasia	NN
cord-014712-5u4e00q6	894	12	or	or	CC
cord-014712-5u4e00q6	894	13	aplasia	aplasia	NNP
cord-014712-5u4e00q6	894	14	leading	lead	VBG
cord-014712-5u4e00q6	894	15	to	to	IN
cord-014712-5u4e00q6	894	16	T	t	NN
cord-014712-5u4e00q6	894	17	-	-	HYPH
cord-014712-5u4e00q6	894	18	cell	cell	NN
cord-014712-5u4e00q6	894	19	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	894	20	.	.	.
cord-014712-5u4e00q6	895	1	The	the	DT
cord-014712-5u4e00q6	895	2	aim	aim	NN
cord-014712-5u4e00q6	895	3	of	of	IN
cord-014712-5u4e00q6	895	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	895	5	study	study	NN
cord-014712-5u4e00q6	895	6	is	be	VBZ
cord-014712-5u4e00q6	895	7	to	to	TO
cord-014712-5u4e00q6	895	8	screen	screen	VB
cord-014712-5u4e00q6	895	9	and	and	CC
cord-014712-5u4e00q6	895	10	determine	determine	VB
cord-014712-5u4e00q6	895	11	the	the	DT
cord-014712-5u4e00q6	895	12	incidence	incidence	NN
cord-014712-5u4e00q6	895	13	of	of	IN
cord-014712-5u4e00q6	895	14	Di	Di	NNP
cord-014712-5u4e00q6	895	15	George	George	NNP
cord-014712-5u4e00q6	895	16	syndrome	syndrome	NN
cord-014712-5u4e00q6	895	17	within	within	IN
cord-014712-5u4e00q6	895	18	only	only	RB
cord-014712-5u4e00q6	895	19	one	one	CD
cord-014712-5u4e00q6	895	20	tube	tube	NN
cord-014712-5u4e00q6	895	21	of	of	IN
cord-014712-5u4e00q6	895	22	blood	blood	NN
cord-014712-5u4e00q6	895	23	in	in	IN
cord-014712-5u4e00q6	895	24	children	child	NNS
cord-014712-5u4e00q6	895	25	with	with	IN
cord-014712-5u4e00q6	895	26	congenital	congenital	JJ
cord-014712-5u4e00q6	895	27	heart	heart	NN
cord-014712-5u4e00q6	895	28	anomalies	anomaly	NNS
cord-014712-5u4e00q6	895	29	in	in	IN
cord-014712-5u4e00q6	895	30	our	-PRON-	PRP$
cord-014712-5u4e00q6	895	31	population	population	NN
cord-014712-5u4e00q6	895	32	.	.	.
cord-014712-5u4e00q6	896	1	Children	child	NNS
cord-014712-5u4e00q6	896	2	who	who	WP
cord-014712-5u4e00q6	896	3	were	be	VBD
cord-014712-5u4e00q6	896	4	found	find	VBN
cord-014712-5u4e00q6	896	5	to	to	TO
cord-014712-5u4e00q6	896	6	have	have	VB
cord-014712-5u4e00q6	896	7	a	a	DT
cord-014712-5u4e00q6	896	8	cardiac	cardiac	JJ
cord-014712-5u4e00q6	896	9	defect	defect	NN
cord-014712-5u4e00q6	896	10	during	during	IN
cord-014712-5u4e00q6	896	11	routine	routine	JJ
cord-014712-5u4e00q6	896	12	visits	visit	NNS
cord-014712-5u4e00q6	896	13	in	in	IN
cord-014712-5u4e00q6	896	14	pediatric	pediatric	JJ
cord-014712-5u4e00q6	896	15	cardiology	cardiology	NN
cord-014712-5u4e00q6	896	16	and	and	CC
cord-014712-5u4e00q6	896	17	neonatalogy	neonatalogy	NNP
cord-014712-5u4e00q6	896	18	departments	department	NNS
cord-014712-5u4e00q6	896	19	were	be	VBD
cord-014712-5u4e00q6	896	20	included	include	VBN
cord-014712-5u4e00q6	896	21	into	into	IN
cord-014712-5u4e00q6	896	22	the	the	DT
cord-014712-5u4e00q6	896	23	study	study	NN
cord-014712-5u4e00q6	896	24	.	.	.
cord-014712-5u4e00q6	897	1	Cases	case	NNS
cord-014712-5u4e00q6	897	2	with	with	IN
cord-014712-5u4e00q6	897	3	known	know	VBN
cord-014712-5u4e00q6	897	4	genetic	genetic	JJ
cord-014712-5u4e00q6	897	5	syndromes	syndrome	NNS
cord-014712-5u4e00q6	897	6	and	and	CC
cord-014712-5u4e00q6	897	7	newborns	newborn	NNS
cord-014712-5u4e00q6	897	8	younger	young	JJR
cord-014712-5u4e00q6	897	9	than	than	IN
cord-014712-5u4e00q6	897	10	32	32	CD
cord-014712-5u4e00q6	897	11	gestational	gestational	JJ
cord-014712-5u4e00q6	897	12	weeks	week	NNS
cord-014712-5u4e00q6	897	13	of	of	IN
cord-014712-5u4e00q6	897	14	age	age	NN
cord-014712-5u4e00q6	897	15	and	and	CC
cord-014712-5u4e00q6	897	16	small	small	JJ
cord-014712-5u4e00q6	897	17	for	for	IN
cord-014712-5u4e00q6	897	18	gestational	gestational	JJ
cord-014712-5u4e00q6	897	19	age	age	NN
cord-014712-5u4e00q6	897	20	(	(	-LRB-
cord-014712-5u4e00q6	897	21	birth	birth	NN
cord-014712-5u4e00q6	897	22	weight	weight	NN
cord-014712-5u4e00q6	897	23	<	<	XX
cord-014712-5u4e00q6	897	24	2500	2500	CD
cord-014712-5u4e00q6	897	25	gr	gr	NNS
cord-014712-5u4e00q6	897	26	)	)	-RRB-
cord-014712-5u4e00q6	897	27	were	be	VBD
cord-014712-5u4e00q6	897	28	excluded	exclude	VBN
cord-014712-5u4e00q6	897	29	.	.	.
cord-014712-5u4e00q6	898	1	A	a	DT
cord-014712-5u4e00q6	898	2	total	total	NN
cord-014712-5u4e00q6	898	3	of	of	IN
cord-014712-5u4e00q6	898	4	136	136	CD
cord-014712-5u4e00q6	898	5	patients	patient	NNS
cord-014712-5u4e00q6	898	6	were	be	VBD
cord-014712-5u4e00q6	898	7	included	include	VBN
cord-014712-5u4e00q6	898	8	.	.	.
cord-014712-5u4e00q6	899	1	There	there	EX
cord-014712-5u4e00q6	899	2	were	be	VBD
cord-014712-5u4e00q6	899	3	79	79	CD
cord-014712-5u4e00q6	899	4	(	(	-LRB-
cord-014712-5u4e00q6	899	5	58	58	CD
cord-014712-5u4e00q6	899	6	%	%	NN
cord-014712-5u4e00q6	899	7	)	)	-RRB-
cord-014712-5u4e00q6	899	8	males	male	NNS
cord-014712-5u4e00q6	899	9	and	and	CC
cord-014712-5u4e00q6	899	10	57	57	CD
cord-014712-5u4e00q6	899	11	(	(	-LRB-
cord-014712-5u4e00q6	899	12	42	42	CD
cord-014712-5u4e00q6	899	13	%	%	NN
cord-014712-5u4e00q6	899	14	)	)	-RRB-
cord-014712-5u4e00q6	899	15	females	female	NNS
cord-014712-5u4e00q6	899	16	.	.	.
cord-014712-5u4e00q6	900	1	Age	age	NN
cord-014712-5u4e00q6	900	2	ranged	range	VBD
cord-014712-5u4e00q6	900	3	between	between	IN
cord-014712-5u4e00q6	900	4	0	0	CD
cord-014712-5u4e00q6	900	5	-	-	SYM
cord-014712-5u4e00q6	900	6	80	80	CD
cord-014712-5u4e00q6	900	7	months	month	NNS
cord-014712-5u4e00q6	900	8	(	(	-LRB-
cord-014712-5u4e00q6	900	9	10.2	10.2	CD
cord-014712-5u4e00q6	900	10	±	±	CD
cord-014712-5u4e00q6	900	11	15.9	15.9	CD
cord-014712-5u4e00q6	900	12	months	month	NNS
cord-014712-5u4e00q6	900	13	)	)	-RRB-
cord-014712-5u4e00q6	900	14	.	.	.
cord-014712-5u4e00q6	901	1	Parental	parental	JJ
cord-014712-5u4e00q6	901	2	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	901	3	was	be	VBD
cord-014712-5u4e00q6	901	4	17	17	CD
cord-014712-5u4e00q6	901	5	%	%	NN
cord-014712-5u4e00q6	901	6	(	(	-LRB-
cord-014712-5u4e00q6	901	7	n	n	NN
cord-014712-5u4e00q6	901	8	=	=	SYM
cord-014712-5u4e00q6	901	9	23	23	CD
cord-014712-5u4e00q6	901	10	)	)	-RRB-
cord-014712-5u4e00q6	901	11	in	in	IN
cord-014712-5u4e00q6	901	12	the	the	DT
cord-014712-5u4e00q6	901	13	study	study	NN
cord-014712-5u4e00q6	901	14	group	group	NN
cord-014712-5u4e00q6	901	15	.	.	.
cord-014712-5u4e00q6	902	1	The	the	DT
cord-014712-5u4e00q6	902	2	majority	majority	NN
cord-014712-5u4e00q6	902	3	of	of	IN
cord-014712-5u4e00q6	902	4	patients	patient	NNS
cord-014712-5u4e00q6	902	5	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	902	6	after	after	IN
cord-014712-5u4e00q6	902	7	murmur	murmur	NN
cord-014712-5u4e00q6	902	8	was	be	VBD
cord-014712-5u4e00q6	902	9	heard	hear	VBN
cord-014712-5u4e00q6	902	10	during	during	IN
cord-014712-5u4e00q6	902	11	the	the	DT
cord-014712-5u4e00q6	902	12	routine	routine	JJ
cord-014712-5u4e00q6	902	13	physical	physical	JJ
cord-014712-5u4e00q6	902	14	examination	examination	NN
cord-014712-5u4e00q6	902	15	(	(	-LRB-
cord-014712-5u4e00q6	902	16	n	n	NN
cord-014712-5u4e00q6	902	17	=	=	SYM
cord-014712-5u4e00q6	902	18	62	62	CD
cord-014712-5u4e00q6	902	19	,	,	,
cord-014712-5u4e00q6	902	20	46	46	CD
cord-014712-5u4e00q6	902	21	%	%	NN
cord-014712-5u4e00q6	902	22	)	)	-RRB-
cord-014712-5u4e00q6	902	23	.	.	.
cord-014712-5u4e00q6	903	1	Five	five	CD
cord-014712-5u4e00q6	903	2	patients	patient	NNS
cord-014712-5u4e00q6	903	3	(	(	-LRB-
cord-014712-5u4e00q6	903	4	3	3	CD
cord-014712-5u4e00q6	903	5	%	%	NN
cord-014712-5u4e00q6	903	6	)	)	-RRB-
cord-014712-5u4e00q6	903	7	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	903	8	antenatally	antenatally	RB
cord-014712-5u4e00q6	903	9	.	.	.
cord-014712-5u4e00q6	904	1	Remaining	remain	VBG
cord-014712-5u4e00q6	904	2	clinical	clinical	JJ
cord-014712-5u4e00q6	904	3	signs	sign	NNS
cord-014712-5u4e00q6	904	4	on	on	IN
cord-014712-5u4e00q6	904	5	admission	admission	NN
cord-014712-5u4e00q6	904	6	were	be	VBD
cord-014712-5u4e00q6	904	7	as	as	IN
cord-014712-5u4e00q6	904	8	follows	follow	VBZ
cord-014712-5u4e00q6	904	9	;	;	:
cord-014712-5u4e00q6	904	10	respiratory	respiratory	JJ
cord-014712-5u4e00q6	904	11	distress	distress	NN
cord-014712-5u4e00q6	904	12	(	(	-LRB-
cord-014712-5u4e00q6	904	13	n	n	NN
cord-014712-5u4e00q6	904	14	=	=	SYM
cord-014712-5u4e00q6	904	15	33	33	CD
cord-014712-5u4e00q6	904	16	,	,	,
cord-014712-5u4e00q6	904	17	24	24	CD
cord-014712-5u4e00q6	904	18	%	%	NN
cord-014712-5u4e00q6	904	19	)	)	-RRB-
cord-014712-5u4e00q6	904	20	,	,	,
cord-014712-5u4e00q6	904	21	tachycardia	tachycardia	FW
cord-014712-5u4e00q6	904	22	(	(	-LRB-
cord-014712-5u4e00q6	904	23	n	n	NN
cord-014712-5u4e00q6	904	24	=	=	SYM
cord-014712-5u4e00q6	904	25	20	20	CD
cord-014712-5u4e00q6	904	26	,	,	,
cord-014712-5u4e00q6	904	27	15	15	CD
cord-014712-5u4e00q6	904	28	%	%	NN
cord-014712-5u4e00q6	904	29	)	)	-RRB-
cord-014712-5u4e00q6	904	30	and	and	CC
cord-014712-5u4e00q6	904	31	central	central	JJ
cord-014712-5u4e00q6	904	32	cyanosis	cyanosis	NN
cord-014712-5u4e00q6	904	33	(	(	-LRB-
cord-014712-5u4e00q6	904	34	n	n	NN
cord-014712-5u4e00q6	904	35	=	=	SYM
cord-014712-5u4e00q6	904	36	16	16	CD
cord-014712-5u4e00q6	904	37	,	,	,
cord-014712-5u4e00q6	904	38	12	12	CD
cord-014712-5u4e00q6	904	39	%	%	NN
cord-014712-5u4e00q6	904	40	)	)	-RRB-
cord-014712-5u4e00q6	904	41	.	.	.
cord-014712-5u4e00q6	905	1	Echocardiagorafic	Echocardiagorafic	NNP
cord-014712-5u4e00q6	905	2	examinations	examination	NNS
cord-014712-5u4e00q6	905	3	revealed	reveal	VBD
cord-014712-5u4e00q6	905	4	ventricular	ventricular	JJ
cord-014712-5u4e00q6	905	5	septal	septal	JJ
cord-014712-5u4e00q6	905	6	defect	defect	NN
cord-014712-5u4e00q6	905	7	(	(	-LRB-
cord-014712-5u4e00q6	905	8	VSD	VSD	NNP
cord-014712-5u4e00q6	905	9	)	)	-RRB-
cord-014712-5u4e00q6	905	10	(	(	-LRB-
cord-014712-5u4e00q6	905	11	n	n	NN
cord-014712-5u4e00q6	905	12	=	=	SYM
cord-014712-5u4e00q6	905	13	27	27	CD
cord-014712-5u4e00q6	905	14	)	)	-RRB-
cord-014712-5u4e00q6	905	15	,	,	,
cord-014712-5u4e00q6	905	16	tetralogy	tetralogy	NN
cord-014712-5u4e00q6	905	17	of	of	IN
cord-014712-5u4e00q6	905	18	fallot	fallot	NN
cord-014712-5u4e00q6	905	19	(	(	-LRB-
cord-014712-5u4e00q6	905	20	TOF	TOF	NNP
cord-014712-5u4e00q6	905	21	)	)	-RRB-
cord-014712-5u4e00q6	905	22	(	(	-LRB-
cord-014712-5u4e00q6	905	23	n	n	NN
cord-014712-5u4e00q6	905	24	=	=	SYM
cord-014712-5u4e00q6	905	25	17	17	CD
cord-014712-5u4e00q6	905	26	)	)	-RRB-
cord-014712-5u4e00q6	905	27	,	,	,
cord-014712-5u4e00q6	905	28	VSD	VSD	NNP
cord-014712-5u4e00q6	905	29	-	-	HYPH
cord-014712-5u4e00q6	905	30	ASD	ASD	NNP
cord-014712-5u4e00q6	905	31	(	(	-LRB-
cord-014712-5u4e00q6	905	32	n	n	NN
cord-014712-5u4e00q6	905	33	=	=	SYM
cord-014712-5u4e00q6	905	34	13	13	CD
cord-014712-5u4e00q6	905	35	)	)	-RRB-
cord-014712-5u4e00q6	905	36	,	,	,
cord-014712-5u4e00q6	905	37	aortic	aortic	JJ
cord-014712-5u4e00q6	905	38	coarctation	coarctation	NN
cord-014712-5u4e00q6	905	39	(	(	-LRB-
cord-014712-5u4e00q6	905	40	n	n	NN
cord-014712-5u4e00q6	905	41	=	=	SYM
cord-014712-5u4e00q6	905	42	11	11	CD
cord-014712-5u4e00q6	905	43	)	)	-RRB-
cord-014712-5u4e00q6	905	44	,	,	,
cord-014712-5u4e00q6	905	45	double	double	JJ
cord-014712-5u4e00q6	905	46	outlet	outlet	NN
cord-014712-5u4e00q6	905	47	right	right	JJ
cord-014712-5u4e00q6	905	48	venticle	venticle	NN
cord-014712-5u4e00q6	905	49	(	(	-LRB-
cord-014712-5u4e00q6	905	50	DORV	DORV	NNP
cord-014712-5u4e00q6	905	51	)	)	-RRB-
cord-014712-5u4e00q6	905	52	(	(	-LRB-
cord-014712-5u4e00q6	905	53	n	n	NN
cord-014712-5u4e00q6	905	54	=	=	SYM
cord-014712-5u4e00q6	905	55	10	10	CD
cord-014712-5u4e00q6	905	56	)	)	-RRB-
cord-014712-5u4e00q6	905	57	,	,	,
cord-014712-5u4e00q6	905	58	transposition	transposition	NN
cord-014712-5u4e00q6	905	59	of	of	IN
cord-014712-5u4e00q6	905	60	the	the	DT
cord-014712-5u4e00q6	905	61	great	great	JJ
cord-014712-5u4e00q6	905	62	arteries	artery	NNS
cord-014712-5u4e00q6	905	63	(	(	-LRB-
cord-014712-5u4e00q6	905	64	n	n	NN
cord-014712-5u4e00q6	905	65	=	=	SYM
cord-014712-5u4e00q6	905	66	6	6	CD
cord-014712-5u4e00q6	905	67	)	)	-RRB-
cord-014712-5u4e00q6	905	68	,	,	,
cord-014712-5u4e00q6	905	69	truncus	truncus	NNP
cord-014712-5u4e00q6	905	70	arteriosus	arteriosus	NNP
cord-014712-5u4e00q6	905	71	(	(	-LRB-
cord-014712-5u4e00q6	905	72	n	n	NN
cord-014712-5u4e00q6	905	73	=	=	SYM
cord-014712-5u4e00q6	905	74	5	5	CD
cord-014712-5u4e00q6	905	75	)	)	-RRB-
cord-014712-5u4e00q6	905	76	and	and	CC
cord-014712-5u4e00q6	905	77	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	905	78	atresia	atresia	NN
cord-014712-5u4e00q6	905	79	(	(	-LRB-
cord-014712-5u4e00q6	905	80	n	n	NN
cord-014712-5u4e00q6	905	81	=	=	SYM
cord-014712-5u4e00q6	905	82	6	6	CD
cord-014712-5u4e00q6	905	83	)	)	-RRB-
cord-014712-5u4e00q6	905	84	.	.	.
cord-014712-5u4e00q6	906	1	Pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	906	2	stenosis	stenosis	NN
cord-014712-5u4e00q6	906	3	,	,	,
cord-014712-5u4e00q6	906	4	endocardial	endocardial	JJ
cord-014712-5u4e00q6	906	5	cushion	cushion	NN
cord-014712-5u4e00q6	906	6	defects	defect	NNS
cord-014712-5u4e00q6	906	7	,	,	,
cord-014712-5u4e00q6	906	8	total	total	JJ
cord-014712-5u4e00q6	906	9	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	906	10	venous	venous	JJ
cord-014712-5u4e00q6	906	11	return	return	NN
cord-014712-5u4e00q6	906	12	anomaly	anomaly	NN
cord-014712-5u4e00q6	906	13	and	and	CC
cord-014712-5u4e00q6	906	14	hypoplastic	hypoplastic	JJ
cord-014712-5u4e00q6	906	15	left	left	JJ
cord-014712-5u4e00q6	906	16	heart	heart	NN
cord-014712-5u4e00q6	906	17	were	be	VBD
cord-014712-5u4e00q6	906	18	the	the	DT
cord-014712-5u4e00q6	906	19	other	other	JJ
cord-014712-5u4e00q6	906	20	defects	defect	NNS
cord-014712-5u4e00q6	906	21	.	.	.
cord-014712-5u4e00q6	907	1	22q11.2	22q11.2	CD
cord-014712-5u4e00q6	907	2	deletion	deletion	NN
cord-014712-5u4e00q6	907	3	was	be	VBD
cord-014712-5u4e00q6	907	4	ascertained	ascertain	VBN
cord-014712-5u4e00q6	907	5	in	in	IN
cord-014712-5u4e00q6	907	6	7	7	CD
cord-014712-5u4e00q6	907	7	(	(	-LRB-
cord-014712-5u4e00q6	907	8	5.1	5.1	CD
cord-014712-5u4e00q6	907	9	%	%	NN
cord-014712-5u4e00q6	907	10	)	)	-RRB-
cord-014712-5u4e00q6	907	11	patients	patient	NNS
cord-014712-5u4e00q6	907	12	;	;	:
cord-014712-5u4e00q6	907	13	these	these	DT
cord-014712-5u4e00q6	907	14	patients	patient	NNS
cord-014712-5u4e00q6	907	15	were	be	VBD
cord-014712-5u4e00q6	907	16	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	907	17	to	to	TO
cord-014712-5u4e00q6	907	18	have	have	VB
cord-014712-5u4e00q6	907	19	TOF	TOF	NNP
cord-014712-5u4e00q6	907	20	(	(	-LRB-
cord-014712-5u4e00q6	907	21	28.6	28.6	CD
cord-014712-5u4e00q6	907	22	%	%	NN
cord-014712-5u4e00q6	907	23	)	)	-RRB-
cord-014712-5u4e00q6	907	24	,	,	,
cord-014712-5u4e00q6	907	25	truncus	truncus	NNP
cord-014712-5u4e00q6	907	26	arteriosus	arteriosus	NNP
cord-014712-5u4e00q6	907	27	(	(	-LRB-
cord-014712-5u4e00q6	907	28	14.6	14.6	CD
cord-014712-5u4e00q6	907	29	%	%	NN
cord-014712-5u4e00q6	907	30	)	)	-RRB-
cord-014712-5u4e00q6	907	31	,	,	,
cord-014712-5u4e00q6	907	32	DORV	DORV	NNP
cord-014712-5u4e00q6	907	33	(	(	-LRB-
cord-014712-5u4e00q6	907	34	14.3	14.3	CD
cord-014712-5u4e00q6	907	35	%	%	NN
cord-014712-5u4e00q6	907	36	)	)	-RRB-
cord-014712-5u4e00q6	907	37	,	,	,
cord-014712-5u4e00q6	907	38	VSD	VSD	NNP
cord-014712-5u4e00q6	907	39	(	(	-LRB-
cord-014712-5u4e00q6	907	40	14.3	14.3	CD
cord-014712-5u4e00q6	907	41	%	%	NN
cord-014712-5u4e00q6	907	42	)	)	-RRB-
cord-014712-5u4e00q6	907	43	and	and	CC
cord-014712-5u4e00q6	907	44	VSD	VSD	NNP
cord-014712-5u4e00q6	907	45	-	-	HYPH
cord-014712-5u4e00q6	907	46	ASD	ASD	NNP
cord-014712-5u4e00q6	907	47	(	(	-LRB-
cord-014712-5u4e00q6	907	48	14.3	14.3	CD
cord-014712-5u4e00q6	907	49	%	%	NN
cord-014712-5u4e00q6	907	50	)	)	-RRB-
cord-014712-5u4e00q6	907	51	.	.	.
cord-014712-5u4e00q6	908	1	Preliminary	preliminary	JJ
cord-014712-5u4e00q6	908	2	results	result	NNS
cord-014712-5u4e00q6	908	3	of	of	IN
cord-014712-5u4e00q6	908	4	the	the	DT
cord-014712-5u4e00q6	908	5	study	study	NN
cord-014712-5u4e00q6	908	6	showed	show	VBD
cord-014712-5u4e00q6	908	7	that	that	IN
cord-014712-5u4e00q6	908	8	the	the	DT
cord-014712-5u4e00q6	908	9	frequency	frequency	NN
cord-014712-5u4e00q6	908	10	of	of	IN
cord-014712-5u4e00q6	908	11	22q11.2	22q11.2	CD
cord-014712-5u4e00q6	908	12	deletion	deletion	NN
cord-014712-5u4e00q6	908	13	is	be	VBZ
cord-014712-5u4e00q6	908	14	5	5	CD
cord-014712-5u4e00q6	908	15	%	%	NN
cord-014712-5u4e00q6	908	16	in	in	IN
cord-014712-5u4e00q6	908	17	patients	patient	NNS
cord-014712-5u4e00q6	908	18	with	with	IN
cord-014712-5u4e00q6	908	19	known	know	VBN
cord-014712-5u4e00q6	908	20	cardiac	cardiac	JJ
cord-014712-5u4e00q6	908	21	defects	defect	NNS
cord-014712-5u4e00q6	908	22	.	.	.
cord-014712-5u4e00q6	909	1	Single	single	JJ
cord-014712-5u4e00q6	909	2	tube	tube	NN
cord-014712-5u4e00q6	909	3	of	of	IN
cord-014712-5u4e00q6	909	4	blood	blood	NN
cord-014712-5u4e00q6	909	5	is	be	VBZ
cord-014712-5u4e00q6	909	6	enough	enough	JJ
cord-014712-5u4e00q6	909	7	for	for	IN
cord-014712-5u4e00q6	909	8	flow	flow	NN
cord-014712-5u4e00q6	909	9	cytometric	cytometric	JJ
cord-014712-5u4e00q6	909	10	and	and	CC
cord-014712-5u4e00q6	909	11	genetic	genetic	JJ
cord-014712-5u4e00q6	909	12	analyses	analysis	NNS
cord-014712-5u4e00q6	909	13	.	.	.
cord-014712-5u4e00q6	910	1	Further	further	JJ
cord-014712-5u4e00q6	910	2	studies	study	NNS
cord-014712-5u4e00q6	910	3	involving	involve	VBG
cord-014712-5u4e00q6	910	4	higher	high	JJR
cord-014712-5u4e00q6	910	5	number	number	NN
cord-014712-5u4e00q6	910	6	of	of	IN
cord-014712-5u4e00q6	910	7	patients	patient	NNS
cord-014712-5u4e00q6	910	8	is	be	VBZ
cord-014712-5u4e00q6	910	9	mandatory	mandatory	JJ
cord-014712-5u4e00q6	910	10	to	to	TO
cord-014712-5u4e00q6	910	11	give	give	VB
cord-014712-5u4e00q6	910	12	sufficient	sufficient	JJ
cord-014712-5u4e00q6	910	13	information	information	NN
cord-014712-5u4e00q6	910	14	about	about	IN
cord-014712-5u4e00q6	910	15	the	the	DT
cord-014712-5u4e00q6	910	16	exact	exact	JJ
cord-014712-5u4e00q6	910	17	incidence	incidence	NN
cord-014712-5u4e00q6	910	18	of	of	IN
cord-014712-5u4e00q6	910	19	the	the	DT
cord-014712-5u4e00q6	910	20	disease	disease	NN
cord-014712-5u4e00q6	910	21	.	.	.
cord-014712-5u4e00q6	911	1	DI	DI	NNP
cord-014712-5u4e00q6	911	2	GEORGE	GEORGE	NNP
cord-014712-5u4e00q6	911	3	SYNDROME	SYNDROME	NNP
cord-014712-5u4e00q6	912	1	-WHERE	-WHERE	.
cord-014712-5u4e00q6	913	1	DO	do	VBP
cord-014712-5u4e00q6	913	2	WE	we	PRP
cord-014712-5u4e00q6	913	3	STAND	stand	VB
cord-014712-5u4e00q6	913	4	NOW	now	RB
cord-014712-5u4e00q6	913	5	?	?	.
cord-014712-5u4e00q6	914	1	Małgorzata	Małgorzata	NNP
cord-014712-5u4e00q6	914	2	Pac	Pac	NNP
cord-014712-5u4e00q6	914	3	;	;	:
cord-014712-5u4e00q6	914	4	Małgorzata	Małgorzata	NNP
cord-014712-5u4e00q6	914	5	Skomska	Skomska	NNP
cord-014712-5u4e00q6	914	6	;	;	:
cord-014712-5u4e00q6	914	7	Ewa	Ewa	NNP
cord-014712-5u4e00q6	914	8	Bernatowska	Bernatowska	NNP
cord-014712-5u4e00q6	914	9	Department	Department	NNP
cord-014712-5u4e00q6	914	10	of	of	IN
cord-014712-5u4e00q6	914	11	Immunology	Immunology	NNP
cord-014712-5u4e00q6	914	12	,	,	,
cord-014712-5u4e00q6	914	13	The	the	DT
cord-014712-5u4e00q6	914	14	Children	Children	NNPS
cord-014712-5u4e00q6	914	15	's	's	POS
cord-014712-5u4e00q6	914	16	Memorial	Memorial	NNP
cord-014712-5u4e00q6	914	17	Health	Health	NNP
cord-014712-5u4e00q6	914	18	Institute	Institute	NNP
cord-014712-5u4e00q6	914	19	,	,	,
cord-014712-5u4e00q6	914	20	Warsaw	Warsaw	NNP
cord-014712-5u4e00q6	914	21	,	,	,
cord-014712-5u4e00q6	914	22	Poland	Poland	NNP
cord-014712-5u4e00q6	914	23	Di	Di	NNP
cord-014712-5u4e00q6	914	24	George	George	NNP
cord-014712-5u4e00q6	914	25	syndrome	syndrome	NN
cord-014712-5u4e00q6	914	26	(	(	-LRB-
cord-014712-5u4e00q6	914	27	DGS	DGS	NNP
cord-014712-5u4e00q6	914	28	)	)	-RRB-
cord-014712-5u4e00q6	915	1	classically	classically	RB
cord-014712-5u4e00q6	915	2	comprises	comprise	VBZ
cord-014712-5u4e00q6	915	3	T	t	NN
cord-014712-5u4e00q6	915	4	-	-	HYPH
cord-014712-5u4e00q6	915	5	cell	cell	NN
cord-014712-5u4e00q6	915	6	deficiency	deficiency	NN
cord-014712-5u4e00q6	915	7	(	(	-LRB-
cord-014712-5u4e00q6	915	8	due	due	IN
cord-014712-5u4e00q6	915	9	to	to	IN
cord-014712-5u4e00q6	915	10	thymic	thymic	JJ
cord-014712-5u4e00q6	915	11	hypoplasia	hypoplasia	NN
cord-014712-5u4e00q6	915	12	)	)	-RRB-
cord-014712-5u4e00q6	915	13	,	,	,
cord-014712-5u4e00q6	915	14	hypoparathyroidism	hypoparathyroidism	NNP
cord-014712-5u4e00q6	915	15	,	,	,
cord-014712-5u4e00q6	915	16	cardiac	cardiac	JJ
cord-014712-5u4e00q6	915	17	malformations	malformation	NNS
cord-014712-5u4e00q6	915	18	,	,	,
cord-014712-5u4e00q6	915	19	and	and	CC
cord-014712-5u4e00q6	915	20	facial	facial	JJ
cord-014712-5u4e00q6	915	21	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	915	22	.	.	.
cord-014712-5u4e00q6	916	1	Deletions	deletion	NNS
cord-014712-5u4e00q6	916	2	of	of	IN
cord-014712-5u4e00q6	916	3	the	the	DT
cord-014712-5u4e00q6	916	4	long	long	JJ
cord-014712-5u4e00q6	916	5	arm	arm	NN
cord-014712-5u4e00q6	916	6	of	of	IN
cord-014712-5u4e00q6	916	7	chromosome	chromosome	NN
cord-014712-5u4e00q6	916	8	22	22	CD
cord-014712-5u4e00q6	916	9	at	at	IN
cord-014712-5u4e00q6	916	10	position	position	NN
cord-014712-5u4e00q6	916	11	q.11	q.11	NNP
cord-014712-5u4e00q6	916	12	are	be	VBP
cord-014712-5u4e00q6	916	13	most	most	RBS
cord-014712-5u4e00q6	916	14	commonly	commonly	RB
cord-014712-5u4e00q6	916	15	associated	associate	VBN
cord-014712-5u4e00q6	916	16	with	with	IN
cord-014712-5u4e00q6	916	17	DGS	DGS	NNP
cord-014712-5u4e00q6	916	18	.	.	.
cord-014712-5u4e00q6	917	1	Syndrome	syndrome	NN
cord-014712-5u4e00q6	917	2	is	be	VBZ
cord-014712-5u4e00q6	917	3	also	also	RB
cord-014712-5u4e00q6	917	4	found	find	VBN
cord-014712-5u4e00q6	917	5	associated	associate	VBN
cord-014712-5u4e00q6	917	6	with	with	IN
cord-014712-5u4e00q6	917	7	other	other	JJ
cord-014712-5u4e00q6	917	8	genetic	genetic	JJ
cord-014712-5u4e00q6	917	9	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	917	10	(	(	-LRB-
cord-014712-5u4e00q6	917	11	10p	10p	CD
cord-014712-5u4e00q6	917	12	deletions	deletion	NNS
cord-014712-5u4e00q6	917	13	,	,	,
cord-014712-5u4e00q6	917	14	CHAR	CHAR	NNP
cord-014712-5u4e00q6	917	15	GE	GE	NNP
cord-014712-5u4e00q6	917	16	)	)	-RRB-
cord-014712-5u4e00q6	917	17	,	,	,
cord-014712-5u4e00q6	917	18	certain	certain	JJ
cord-014712-5u4e00q6	917	19	teratogenic	teratogenic	JJ
cord-014712-5u4e00q6	917	20	influences	influence	NNS
cord-014712-5u4e00q6	917	21	(	(	-LRB-
cord-014712-5u4e00q6	917	22	retinoid	retinoid	NN
cord-014712-5u4e00q6	917	23	acid	acid	NN
cord-014712-5u4e00q6	917	24	,	,	,
cord-014712-5u4e00q6	917	25	foetal	foetal	JJ
cord-014712-5u4e00q6	917	26	alcoholic	alcoholic	JJ
cord-014712-5u4e00q6	917	27	syndrome	syndrome	NN
cord-014712-5u4e00q6	917	28	,	,	,
cord-014712-5u4e00q6	917	29	maternal	maternal	JJ
cord-014712-5u4e00q6	917	30	diabetes	diabetes	NN
cord-014712-5u4e00q6	917	31	)	)	-RRB-
cord-014712-5u4e00q6	917	32	.	.	.
cord-014712-5u4e00q6	918	1	The	the	DT
cord-014712-5u4e00q6	918	2	DGS	DGS	NNP
cord-014712-5u4e00q6	918	3	phenotype	phenotype	NN
cord-014712-5u4e00q6	918	4	is	be	VBZ
cord-014712-5u4e00q6	918	5	very	very	RB
cord-014712-5u4e00q6	918	6	heterogenous	heterogenous	JJ
cord-014712-5u4e00q6	918	7	with	with	IN
cord-014712-5u4e00q6	918	8	variable	variable	JJ
cord-014712-5u4e00q6	918	9	expression	expression	NN
cord-014712-5u4e00q6	918	10	of	of	IN
cord-014712-5u4e00q6	918	11	the	the	DT
cord-014712-5u4e00q6	918	12	different	different	JJ
cord-014712-5u4e00q6	918	13	features	feature	NNS
cord-014712-5u4e00q6	918	14	including	include	VBG
cord-014712-5u4e00q6	918	15	the	the	DT
cord-014712-5u4e00q6	918	16	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	918	17	.	.	.
cord-014712-5u4e00q6	919	1	The	the	DT
cord-014712-5u4e00q6	919	2	initial	initial	JJ
cord-014712-5u4e00q6	919	3	treatment	treatment	NN
cord-014712-5u4e00q6	919	4	emphasis	emphasis	NN
cord-014712-5u4e00q6	919	5	is	be	VBZ
cord-014712-5u4e00q6	919	6	to	to	TO
cord-014712-5u4e00q6	919	7	control	control	VB
cord-014712-5u4e00q6	919	8	the	the	DT
cord-014712-5u4e00q6	919	9	hypoparathyroidism	hypoparathyroidism	NN
cord-014712-5u4e00q6	919	10	.	.	.
cord-014712-5u4e00q6	920	1	Correction	correction	NN
cord-014712-5u4e00q6	920	2	of	of	IN
cord-014712-5u4e00q6	920	3	congenital	congenital	JJ
cord-014712-5u4e00q6	920	4	heart	heart	NN
cord-014712-5u4e00q6	920	5	defects	defect	NNS
cord-014712-5u4e00q6	920	6	(	(	-LRB-
cord-014712-5u4e00q6	920	7	if	if	IN
cord-014712-5u4e00q6	920	8	present	present	NN
cord-014712-5u4e00q6	920	9	)	)	-RRB-
cord-014712-5u4e00q6	920	10	is	be	VBZ
cord-014712-5u4e00q6	920	11	usually	usually	RB
cord-014712-5u4e00q6	920	12	needed	need	VBN
cord-014712-5u4e00q6	920	13	.	.	.
cord-014712-5u4e00q6	921	1	The	the	DT
cord-014712-5u4e00q6	921	2	best	good	JJS
cord-014712-5u4e00q6	921	3	treatment	treatment	NN
cord-014712-5u4e00q6	921	4	of	of	IN
cord-014712-5u4e00q6	921	5	the	the	DT
cord-014712-5u4e00q6	921	6	immune	immune	JJ
cord-014712-5u4e00q6	921	7	defects	defect	NNS
cord-014712-5u4e00q6	921	8	of	of	IN
cord-014712-5u4e00q6	921	9	DGS	DGS	NNP
cord-014712-5u4e00q6	921	10	is	be	VBZ
cord-014712-5u4e00q6	921	11	still	still	RB
cord-014712-5u4e00q6	921	12	controversial	controversial	JJ
cord-014712-5u4e00q6	921	13	.	.	.
cord-014712-5u4e00q6	922	1	Both	both	DT
cord-014712-5u4e00q6	922	2	HSCT	HSCT	NNP
cord-014712-5u4e00q6	922	3	and	and	CC
cord-014712-5u4e00q6	922	4	transplant	transplant	NN
cord-014712-5u4e00q6	922	5	with	with	IN
cord-014712-5u4e00q6	922	6	fetal	fetal	JJ
cord-014712-5u4e00q6	922	7	thymus	thymus	NN
cord-014712-5u4e00q6	922	8	are	be	VBP
cord-014712-5u4e00q6	922	9	the	the	DT
cord-014712-5u4e00q6	922	10	option	option	NN
cord-014712-5u4e00q6	922	11	for	for	IN
cord-014712-5u4e00q6	922	12	complete	complete	JJ
cord-014712-5u4e00q6	922	13	DGS	DGS	NNP
cord-014712-5u4e00q6	922	14	(	(	-LRB-
cord-014712-5u4e00q6	922	15	cDGS	cDGS	NNP
cord-014712-5u4e00q6	922	16	)	)	-RRB-
cord-014712-5u4e00q6	922	17	.	.	.
cord-014712-5u4e00q6	923	1	Long	long	JJ
cord-014712-5u4e00q6	923	2	term	term	NN
cord-014712-5u4e00q6	923	3	survival	survival	NN
cord-014712-5u4e00q6	923	4	after	after	IN
cord-014712-5u4e00q6	923	5	HSCT	HSCT	NNP
cord-014712-5u4e00q6	923	6	has	have	VBZ
cord-014712-5u4e00q6	923	7	been	be	VBN
cord-014712-5u4e00q6	923	8	reported	report	VBN
cord-014712-5u4e00q6	923	9	,	,	,
cord-014712-5u4e00q6	923	10	though	though	IN
cord-014712-5u4e00q6	923	11	at	at	IN
cord-014712-5u4e00q6	923	12	a	a	DT
cord-014712-5u4e00q6	923	13	lower	low	JJR
cord-014712-5u4e00q6	923	14	rate	rate	NN
cord-014712-5u4e00q6	923	15	(	(	-LRB-
cord-014712-5u4e00q6	923	16	41	41	CD
cord-014712-5u4e00q6	923	17	-	-	SYM
cord-014712-5u4e00q6	923	18	48	48	CD
cord-014712-5u4e00q6	923	19	%	%	NN
cord-014712-5u4e00q6	923	20	)	)	-RRB-
cord-014712-5u4e00q6	923	21	compared	compare	VBN
cord-014712-5u4e00q6	923	22	to	to	IN
cord-014712-5u4e00q6	923	23	survival	survival	NN
cord-014712-5u4e00q6	923	24	after	after	IN
cord-014712-5u4e00q6	923	25	HSCT	HSCT	NNP
cord-014712-5u4e00q6	923	26	for	for	IN
cord-014712-5u4e00q6	923	27	SCID	SCID	NNP
cord-014712-5u4e00q6	923	28	.	.	.
cord-014712-5u4e00q6	924	1	Survival	survival	NN
cord-014712-5u4e00q6	924	2	in	in	IN
cord-014712-5u4e00q6	924	3	the	the	DT
cord-014712-5u4e00q6	924	4	subgroup	subgroup	NN
cord-014712-5u4e00q6	924	5	receiving	receive	VBG
cord-014712-5u4e00q6	924	6	matched	match	VBN
cord-014712-5u4e00q6	924	7	sibling	sibling	NN
cord-014712-5u4e00q6	924	8	donor	donor	NN
cord-014712-5u4e00q6	924	9	transplants	transplant	NNS
cord-014712-5u4e00q6	924	10	was	be	VBD
cord-014712-5u4e00q6	924	11	better	well	JJR
cord-014712-5u4e00q6	924	12	at	at	IN
cord-014712-5u4e00q6	924	13	over	over	IN
cord-014712-5u4e00q6	924	14	60	60	CD
cord-014712-5u4e00q6	924	15	%	%	NN
cord-014712-5u4e00q6	924	16	.	.	.
cord-014712-5u4e00q6	925	1	The	the	DT
cord-014712-5u4e00q6	925	2	use	use	NN
cord-014712-5u4e00q6	925	3	of	of	IN
cord-014712-5u4e00q6	925	4	post	post	JJ
cord-014712-5u4e00q6	925	5	natal	natal	JJ
cord-014712-5u4e00q6	925	6	human	human	JJ
cord-014712-5u4e00q6	925	7	thymus	thymus	NN
cord-014712-5u4e00q6	925	8	was	be	VBD
cord-014712-5u4e00q6	925	9	pioneered	pioneer	VBN
cord-014712-5u4e00q6	925	10	by	by	IN
cord-014712-5u4e00q6	925	11	Markert	Markert	NNP
cord-014712-5u4e00q6	925	12	at	at	IN
cord-014712-5u4e00q6	925	13	Duke	Duke	NNP
cord-014712-5u4e00q6	925	14	University	University	NNP
cord-014712-5u4e00q6	925	15	and	and	CC
cord-014712-5u4e00q6	925	16	has	have	VBZ
cord-014712-5u4e00q6	925	17	become	become	VBN
cord-014712-5u4e00q6	925	18	established	establish	VBN
cord-014712-5u4e00q6	925	19	as	as	IN
cord-014712-5u4e00q6	925	20	the	the	DT
cord-014712-5u4e00q6	925	21	treatment	treatment	NN
cord-014712-5u4e00q6	925	22	of	of	IN
cord-014712-5u4e00q6	925	23	choice	choice	NN
cord-014712-5u4e00q6	925	24	for	for	IN
cord-014712-5u4e00q6	925	25	cDGS	cdg	NNS
cord-014712-5u4e00q6	925	26	,	,	,
cord-014712-5u4e00q6	925	27	with	with	IN
cord-014712-5u4e00q6	925	28	the	the	DT
cord-014712-5u4e00q6	925	29	result	result	NN
cord-014712-5u4e00q6	925	30	of	of	IN
cord-014712-5u4e00q6	925	31	43	43	CD
cord-014712-5u4e00q6	925	32	out	out	IN
cord-014712-5u4e00q6	925	33	of	of	IN
cord-014712-5u4e00q6	925	34	60	60	CD
cord-014712-5u4e00q6	925	35	treated	treat	VBN
cord-014712-5u4e00q6	925	36	patients	patient	NNS
cord-014712-5u4e00q6	925	37	survived	survive	VBD
cord-014712-5u4e00q6	925	38	(	(	-LRB-
cord-014712-5u4e00q6	925	39	72	72	CD
cord-014712-5u4e00q6	925	40	%	%	NN
cord-014712-5u4e00q6	925	41	)	)	-RRB-
cord-014712-5u4e00q6	925	42	.	.	.
cord-014712-5u4e00q6	926	1	More	more	RBR
cord-014712-5u4e00q6	926	2	recently	recently	RB
cord-014712-5u4e00q6	926	3	this	this	DT
cord-014712-5u4e00q6	926	4	approach	approach	NN
cord-014712-5u4e00q6	926	5	has	have	VBZ
cord-014712-5u4e00q6	926	6	also	also	RB
cord-014712-5u4e00q6	926	7	been	be	VBN
cord-014712-5u4e00q6	926	8	used	use	VBN
cord-014712-5u4e00q6	926	9	in	in	IN
cord-014712-5u4e00q6	926	10	London	London	NNP
cord-014712-5u4e00q6	926	11	,	,	,
cord-014712-5u4e00q6	926	12	at	at	IN
cord-014712-5u4e00q6	926	13	GOSH	GOSH	NNP
cord-014712-5u4e00q6	926	14	.	.	.
cord-014712-5u4e00q6	926	15	.	.	.
cord-014712-5u4e00q6	927	1	Under	under	IN
cord-014712-5u4e00q6	927	2	care	care	NN
cord-014712-5u4e00q6	927	3	of	of	IN
cord-014712-5u4e00q6	927	4	CMHI	CMHI	NNP
cord-014712-5u4e00q6	927	5	there	there	RB
cord-014712-5u4e00q6	927	6	are119	are119	NNP
cord-014712-5u4e00q6	928	1	patients	patient	NNS
cord-014712-5u4e00q6	928	2	fulfilling	fulfil	VBG
cord-014712-5u4e00q6	928	3	ESID	ESID	NNP
cord-014712-5u4e00q6	928	4	criteria	criterion	NNS
cord-014712-5u4e00q6	928	5	,	,	,
cord-014712-5u4e00q6	928	6	59	59	CD
cord-014712-5u4e00q6	928	7	girls	girl	NNS
cord-014712-5u4e00q6	928	8	(	(	-LRB-
cord-014712-5u4e00q6	928	9	49.6	49.6	CD
cord-014712-5u4e00q6	928	10	%	%	NN
cord-014712-5u4e00q6	928	11	)	)	-RRB-
cord-014712-5u4e00q6	928	12	and	and	CC
cord-014712-5u4e00q6	928	13	60	60	CD
cord-014712-5u4e00q6	928	14	boys	boy	NNS
cord-014712-5u4e00q6	928	15	(	(	-LRB-
cord-014712-5u4e00q6	928	16	50.4	50.4	CD
cord-014712-5u4e00q6	928	17	%	%	NN
cord-014712-5u4e00q6	928	18	)	)	-RRB-
cord-014712-5u4e00q6	928	19	,	,	,
cord-014712-5u4e00q6	928	20	age	age	NN
cord-014712-5u4e00q6	928	21	2/12	2/12	CD
cord-014712-5u4e00q6	928	22	-23	-23	CD
cord-014712-5u4e00q6	929	1	y.o	y.o	NNP
cord-014712-5u4e00q6	929	2	.	.	.
cord-014712-5u4e00q6	930	1	In	in	IN
cord-014712-5u4e00q6	930	2	70	70	CD
cord-014712-5u4e00q6	930	3	%	%	NN
cord-014712-5u4e00q6	930	4	of	of	IN
cord-014712-5u4e00q6	930	5	them	-PRON-	PRP
cord-014712-5u4e00q6	930	6	22q11	22q11	CD
cord-014712-5u4e00q6	930	7	deletion	deletion	NN
cord-014712-5u4e00q6	930	8	in	in	IN
cord-014712-5u4e00q6	930	9	locus	locus	NN
cord-014712-5u4e00q6	930	10	D22S75	D22S75	NNP
cord-014712-5u4e00q6	930	11	was	be	VBD
cord-014712-5u4e00q6	930	12	found	find	VBN
cord-014712-5u4e00q6	930	13	.	.	.
cord-014712-5u4e00q6	931	1	The	the	DT
cord-014712-5u4e00q6	931	2	vast	vast	JJ
cord-014712-5u4e00q6	931	3	majority	majority	NN
cord-014712-5u4e00q6	931	4	children	child	NNS
cord-014712-5u4e00q6	931	5	were	be	VBD
cord-014712-5u4e00q6	931	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	931	7	as	as	IN
cord-014712-5u4e00q6	931	8	partial	partial	JJ
cord-014712-5u4e00q6	931	9	DGS	DGS	NNP
cord-014712-5u4e00q6	931	10	.	.	.
cord-014712-5u4e00q6	932	1	None	none	NN
cord-014712-5u4e00q6	932	2	of	of	IN
cord-014712-5u4e00q6	932	3	them	-PRON-	PRP
cord-014712-5u4e00q6	932	4	had	have	VBD
cord-014712-5u4e00q6	932	5	significant	significant	JJ
cord-014712-5u4e00q6	932	6	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	932	7	and	and	CC
cord-014712-5u4e00q6	933	1	no	no	DT
cord-014712-5u4e00q6	933	2	regular	regular	JJ
cord-014712-5u4e00q6	933	3	IVIG	IVIG	NNP
cord-014712-5u4e00q6	933	4	therapy	therapy	NN
cord-014712-5u4e00q6	933	5	or	or	CC
cord-014712-5u4e00q6	933	6	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	933	7	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	933	8	were	be	VBD
cord-014712-5u4e00q6	933	9	required	require	VBN
cord-014712-5u4e00q6	933	10	..	..	.
cord-014712-5u4e00q6	934	1	The	the	DT
cord-014712-5u4e00q6	934	2	mean	mean	JJ
cord-014712-5u4e00q6	934	3	number	number	NN
cord-014712-5u4e00q6	934	4	and	and	CC
cord-014712-5u4e00q6	934	5	percentage	percentage	NN
cord-014712-5u4e00q6	934	6	of	of	IN
cord-014712-5u4e00q6	934	7	CD3	CD3	NNP
cord-014712-5u4e00q6	934	8	,	,	,
cord-014712-5u4e00q6	934	9	CD8	CD8	NNP
cord-014712-5u4e00q6	934	10	and	and	CC
cord-014712-5u4e00q6	934	11	CD4	CD4	NNP
cord-014712-5u4e00q6	934	12	lymphocytes	lymphocyte	VBZ
cord-014712-5u4e00q6	934	13	as	as	RB
cord-014712-5u4e00q6	934	14	well	well	RB
cord-014712-5u4e00q6	934	15	as	as	IN
cord-014712-5u4e00q6	934	16	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	934	17	answer	answer	NN
cord-014712-5u4e00q6	934	18	to	to	IN
cord-014712-5u4e00q6	934	19	PHA	PHA	NNP
cord-014712-5u4e00q6	934	20	and	and	CC
cord-014712-5u4e00q6	934	21	CD3	CD3	NNP
cord-014712-5u4e00q6	934	22	in	in	IN
cord-014712-5u4e00q6	934	23	DGS	DGS	NNP
cord-014712-5u4e00q6	934	24	patients	patient	NNS
cord-014712-5u4e00q6	934	25	were	be	VBD
cord-014712-5u4e00q6	934	26	slightly	slightly	RB
cord-014712-5u4e00q6	934	27	diminished	diminish	VBN
cord-014712-5u4e00q6	934	28	.	.	.
cord-014712-5u4e00q6	935	1	In	in	IN
cord-014712-5u4e00q6	935	2	many	many	JJ
cord-014712-5u4e00q6	935	3	improvement	improvement	NN
cord-014712-5u4e00q6	935	4	of	of	IN
cord-014712-5u4e00q6	935	5	cellular	cellular	JJ
cord-014712-5u4e00q6	935	6	immunity	immunity	NN
cord-014712-5u4e00q6	935	7	was	be	VBD
cord-014712-5u4e00q6	935	8	observed	observe	VBN
cord-014712-5u4e00q6	935	9	with	with	IN
cord-014712-5u4e00q6	935	10	age	age	NN
cord-014712-5u4e00q6	935	11	.	.	.
cord-014712-5u4e00q6	936	1	About	about	RB
cord-014712-5u4e00q6	936	2	86	86	CD
cord-014712-5u4e00q6	936	3	%	%	NN
cord-014712-5u4e00q6	936	4	presented	present	VBN
cord-014712-5u4e00q6	936	5	with	with	IN
cord-014712-5u4e00q6	936	6	congenital	congenital	JJ
cord-014712-5u4e00q6	936	7	heart	heart	NN
cord-014712-5u4e00q6	936	8	disease	disease	NN
cord-014712-5u4e00q6	936	9	,	,	,
cord-014712-5u4e00q6	936	10	requiring	require	VBG
cord-014712-5u4e00q6	936	11	surgery	surgery	NN
cord-014712-5u4e00q6	936	12	,	,	,
cord-014712-5u4e00q6	936	13	while	while	IN
cord-014712-5u4e00q6	936	14	almost	almost	RB
cord-014712-5u4e00q6	936	15	50	50	CD
cord-014712-5u4e00q6	936	16	%	%	NN
cord-014712-5u4e00q6	936	17	had	have	VBD
cord-014712-5u4e00q6	936	18	the	the	DT
cord-014712-5u4e00q6	936	19	symptoms	symptom	NNS
cord-014712-5u4e00q6	936	20	of	of	IN
cord-014712-5u4e00q6	936	21	hypocalcemia	hypocalcemia	NN
cord-014712-5u4e00q6	936	22	and	and	CC
cord-014712-5u4e00q6	936	23	hypoparathyroidism	hypoparathyroidism	NN
cord-014712-5u4e00q6	936	24	,	,	,
cord-014712-5u4e00q6	936	25	next	next	JJ
cord-014712-5u4e00q6	936	26	46	46	CD
cord-014712-5u4e00q6	936	27	%	%	NN
cord-014712-5u4e00q6	936	28	-speech	-speech	NN
cord-014712-5u4e00q6	936	29	and	and	CC
cord-014712-5u4e00q6	936	30	learning	learn	VBG
cord-014712-5u4e00q6	936	31	difficulties	difficulty	NNS
cord-014712-5u4e00q6	936	32	.	.	.
cord-014712-5u4e00q6	937	1	One	one	CD
cord-014712-5u4e00q6	937	2	child	child	NN
cord-014712-5u4e00q6	937	3	was	be	VBD
cord-014712-5u4e00q6	937	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	937	5	as	as	IN
cord-014712-5u4e00q6	937	6	cDGS	cdgs	JJ
cord-014712-5u4e00q6	937	7	.	.	.
cord-014712-5u4e00q6	938	1	SCID	SCID	NNP
cord-014712-5u4e00q6	938	2	is	be	VBZ
cord-014712-5u4e00q6	938	3	a	a	DT
cord-014712-5u4e00q6	938	4	rare	rare	JJ
cord-014712-5u4e00q6	938	5	,	,	,
cord-014712-5u4e00q6	938	6	inherited	inherited	JJ
cord-014712-5u4e00q6	938	7	condition	condition	NN
cord-014712-5u4e00q6	938	8	,	,	,
cord-014712-5u4e00q6	938	9	is	be	VBZ
cord-014712-5u4e00q6	938	10	caused	cause	VBN
cord-014712-5u4e00q6	938	11	by	by	IN
cord-014712-5u4e00q6	938	12	numerous	numerous	JJ
cord-014712-5u4e00q6	938	13	molecular	molecular	JJ
cord-014712-5u4e00q6	938	14	defects	defect	NNS
cord-014712-5u4e00q6	938	15	that	that	WDT
cord-014712-5u4e00q6	938	16	lead	lead	VBP
cord-014712-5u4e00q6	938	17	to	to	IN
cord-014712-5u4e00q6	938	18	severe	severe	JJ
cord-014712-5u4e00q6	938	19	compromise	compromise	NN
cord-014712-5u4e00q6	938	20	in	in	IN
cord-014712-5u4e00q6	938	21	the	the	DT
cord-014712-5u4e00q6	938	22	number	number	NN
cord-014712-5u4e00q6	938	23	and	and	CC
cord-014712-5u4e00q6	938	24	function	function	NN
cord-014712-5u4e00q6	938	25	of	of	IN
cord-014712-5u4e00q6	938	26	T	t	NN
cord-014712-5u4e00q6	938	27	cells	cell	NNS
cord-014712-5u4e00q6	938	28	,	,	,
cord-014712-5u4e00q6	938	29	B	b	NN
cord-014712-5u4e00q6	938	30	cells	cell	NNS
cord-014712-5u4e00q6	938	31	,	,	,
cord-014712-5u4e00q6	938	32	and	and	CC
cord-014712-5u4e00q6	938	33	occasionally	occasionally	RB
cord-014712-5u4e00q6	938	34	natural	natural	JJ
cord-014712-5u4e00q6	938	35	killer	killer	NN
cord-014712-5u4e00q6	938	36	cells	cell	NNS
cord-014712-5u4e00q6	938	37	.	.	.
cord-014712-5u4e00q6	939	1	Seventeen	seventeen	CD
cord-014712-5u4e00q6	939	2	patents	patent	NNS
cord-014712-5u4e00q6	939	3	with	with	IN
cord-014712-5u4e00q6	939	4	SCID	SCID	NNP
cord-014712-5u4e00q6	939	5	were	be	VBD
cord-014712-5u4e00q6	939	6	registered	register	VBN
cord-014712-5u4e00q6	939	7	during	during	IN
cord-014712-5u4e00q6	939	8	the	the	DT
cord-014712-5u4e00q6	939	9	period	period	NN
cord-014712-5u4e00q6	939	10	from	from	IN
cord-014712-5u4e00q6	939	11	1994	1994	CD
cord-014712-5u4e00q6	939	12	till	till	IN
cord-014712-5u4e00q6	939	13	2013	2013	CD
cord-014712-5u4e00q6	939	14	in	in	IN
cord-014712-5u4e00q6	939	15	the	the	DT
cord-014712-5u4e00q6	939	16	Children	Children	NNPS
cord-014712-5u4e00q6	939	17	's	's	POS
cord-014712-5u4e00q6	939	18	Clinical	Clinical	NNP
cord-014712-5u4e00q6	939	19	University	University	NNP
cord-014712-5u4e00q6	939	20	Hospital	Hospital	NNP
cord-014712-5u4e00q6	939	21	.	.	.
cord-014712-5u4e00q6	940	1	Medical	medical	JJ
cord-014712-5u4e00q6	940	2	charts	chart	NNS
cord-014712-5u4e00q6	940	3	of	of	IN
cord-014712-5u4e00q6	940	4	these	these	DT
cord-014712-5u4e00q6	940	5	patients	patient	NNS
cord-014712-5u4e00q6	940	6	have	have	VBP
cord-014712-5u4e00q6	940	7	been	be	VBN
cord-014712-5u4e00q6	940	8	reviewed	review	VBN
cord-014712-5u4e00q6	940	9	.	.	.
cord-014712-5u4e00q6	941	1	There	there	EX
cord-014712-5u4e00q6	941	2	were	be	VBD
cord-014712-5u4e00q6	941	3	9	9	CD
cord-014712-5u4e00q6	941	4	boys	boy	NNS
cord-014712-5u4e00q6	941	5	and	and	CC
cord-014712-5u4e00q6	941	6	8	8	CD
cord-014712-5u4e00q6	941	7	girls	girl	NNS
cord-014712-5u4e00q6	941	8	.	.	.
cord-014712-5u4e00q6	942	1	Positive	positive	JJ
cord-014712-5u4e00q6	942	2	family	family	NN
cord-014712-5u4e00q6	942	3	history	history	NN
cord-014712-5u4e00q6	942	4	was	be	VBD
cord-014712-5u4e00q6	942	5	in	in	IN
cord-014712-5u4e00q6	942	6	4	4	CD
cord-014712-5u4e00q6	942	7	families	family	NNS
cord-014712-5u4e00q6	942	8	.	.	.
cord-014712-5u4e00q6	943	1	Mean	mean	JJ
cord-014712-5u4e00q6	943	2	age	age	NN
cord-014712-5u4e00q6	943	3	at	at	IN
cord-014712-5u4e00q6	943	4	the	the	DT
cord-014712-5u4e00q6	943	5	onset	onset	NN
cord-014712-5u4e00q6	943	6	of	of	IN
cord-014712-5u4e00q6	943	7	symptoms	symptom	NNS
cord-014712-5u4e00q6	943	8	and	and	CC
cord-014712-5u4e00q6	943	9	SCID	SCID	NNP
cord-014712-5u4e00q6	943	10	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	943	11	was	be	VBD
cord-014712-5u4e00q6	943	12	1.7	1.7	CD
cord-014712-5u4e00q6	943	13	±	±	CD
cord-014712-5u4e00q6	943	14	1.23	1.23	CD
cord-014712-5u4e00q6	943	15	and	and	CC
cord-014712-5u4e00q6	943	16	4.03	4.03	CD
cord-014712-5u4e00q6	943	17	±	±	CD
cord-014712-5u4e00q6	943	18	1.6	1.6	CD
cord-014712-5u4e00q6	943	19	months	month	NNS
cord-014712-5u4e00q6	943	20	,	,	,
cord-014712-5u4e00q6	943	21	respectively	respectively	RB
cord-014712-5u4e00q6	943	22	.	.	.
cord-014712-5u4e00q6	944	1	Pneumonia	pneumonia	NN
cord-014712-5u4e00q6	944	2	(	(	-LRB-
cord-014712-5u4e00q6	944	3	65	65	CD
cord-014712-5u4e00q6	944	4	%	%	NN
cord-014712-5u4e00q6	944	5	)	)	-RRB-
cord-014712-5u4e00q6	944	6	,	,	,
cord-014712-5u4e00q6	944	7	candidacies	candidacy	NNS
cord-014712-5u4e00q6	944	8	(	(	-LRB-
cord-014712-5u4e00q6	944	9	65	65	CD
cord-014712-5u4e00q6	944	10	%	%	NN
cord-014712-5u4e00q6	944	11	)	)	-RRB-
cord-014712-5u4e00q6	944	12	,	,	,
cord-014712-5u4e00q6	944	13	BCG	BCG	NNP
cord-014712-5u4e00q6	944	14	infection	infection	NN
cord-014712-5u4e00q6	944	15	(	(	-LRB-
cord-014712-5u4e00q6	944	16	47	47	CD
cord-014712-5u4e00q6	944	17	%	%	NN
cord-014712-5u4e00q6	944	18	)	)	-RRB-
cord-014712-5u4e00q6	944	19	,	,	,
cord-014712-5u4e00q6	944	20	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	944	21	(	(	-LRB-
cord-014712-5u4e00q6	944	22	35	35	CD
cord-014712-5u4e00q6	944	23	%	%	NN
cord-014712-5u4e00q6	944	24	)	)	-RRB-
cord-014712-5u4e00q6	944	25	were	be	VBD
cord-014712-5u4e00q6	944	26	the	the	DT
cord-014712-5u4e00q6	944	27	most	most	RBS
cord-014712-5u4e00q6	944	28	important	important	JJ
cord-014712-5u4e00q6	944	29	infections	infection	NNS
cord-014712-5u4e00q6	944	30	.	.	.
cord-014712-5u4e00q6	945	1	Anemia	anemia	NN
cord-014712-5u4e00q6	945	2	and	and	CC
cord-014712-5u4e00q6	945	3	relative	relative	JJ
cord-014712-5u4e00q6	945	4	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	945	5	were	be	VBD
cord-014712-5u4e00q6	945	6	in	in	IN
cord-014712-5u4e00q6	945	7	76	76	CD
cord-014712-5u4e00q6	945	8	%	%	NN
cord-014712-5u4e00q6	945	9	cases	case	NNS
cord-014712-5u4e00q6	945	10	,	,	,
cord-014712-5u4e00q6	945	11	growth	growth	NN
cord-014712-5u4e00q6	945	12	retardation	retardation	NN
cord-014712-5u4e00q6	945	13	,	,	,
cord-014712-5u4e00q6	945	14	hypotrophy	hypotrophy	NNP
cord-014712-5u4e00q6	945	15	had	have	VBD
cord-014712-5u4e00q6	945	16	59	59	CD
cord-014712-5u4e00q6	945	17	%	%	NN
cord-014712-5u4e00q6	945	18	children	child	NNS
cord-014712-5u4e00q6	945	19	.	.	.
cord-014712-5u4e00q6	946	1	Pathogens	pathogen	NNS
cord-014712-5u4e00q6	946	2	such	such	JJ
cord-014712-5u4e00q6	946	3	as	as	IN
cord-014712-5u4e00q6	946	4	Candida	Candida	NNP
cord-014712-5u4e00q6	946	5	albicans	albican	NNS
cord-014712-5u4e00q6	946	6	(	(	-LRB-
cord-014712-5u4e00q6	946	7	11	11	CD
cord-014712-5u4e00q6	946	8	)	)	-RRB-
cord-014712-5u4e00q6	946	9	,	,	,
cord-014712-5u4e00q6	946	10	Mycobacterium	Mycobacterium	NNP
cord-014712-5u4e00q6	946	11	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	946	12	complex	complex	JJ
cord-014712-5u4e00q6	946	13	(	(	-LRB-
cord-014712-5u4e00q6	946	14	8)	8)	NN
cord-014712-5u4e00q6	946	15	,	,	,
cord-014712-5u4e00q6	946	16	CMV	CMV	NNP
cord-014712-5u4e00q6	946	17	(	(	-LRB-
cord-014712-5u4e00q6	946	18	3	3	CD
cord-014712-5u4e00q6	946	19	)	)	-RRB-
cord-014712-5u4e00q6	946	20	and	and	CC
cord-014712-5u4e00q6	946	21	others	other	NNS
cord-014712-5u4e00q6	946	22	have	have	VBP
cord-014712-5u4e00q6	946	23	been	be	VBN
cord-014712-5u4e00q6	946	24	identified	identify	VBN
cord-014712-5u4e00q6	946	25	.	.	.
cord-014712-5u4e00q6	947	1	Totally	totally	RB
cord-014712-5u4e00q6	947	2	15	15	CD
cord-014712-5u4e00q6	947	3	patients	patient	NNS
cord-014712-5u4e00q6	947	4	died	die	VBD
cord-014712-5u4e00q6	947	5	.	.	.
cord-014712-5u4e00q6	948	1	Two	two	CD
cord-014712-5u4e00q6	948	2	girls	girl	NNS
cord-014712-5u4e00q6	948	3	are	be	VBP
cord-014712-5u4e00q6	948	4	alive	alive	JJ
cord-014712-5u4e00q6	948	5	(	(	-LRB-
cord-014712-5u4e00q6	948	6	29	29	CD
cord-014712-5u4e00q6	948	7	and	and	CC
cord-014712-5u4e00q6	948	8	17	17	CD
cord-014712-5u4e00q6	948	9	months	month	NNS
cord-014712-5u4e00q6	948	10	post	post	JJ
cord-014712-5u4e00q6	948	11	-	-	JJ
cord-014712-5u4e00q6	948	12	transplant	transplant	NN
cord-014712-5u4e00q6	948	13	)	)	-RRB-
cord-014712-5u4e00q6	948	14	.	.	.
cord-014712-5u4e00q6	949	1	Autopsy	Autopsy	NNP
cord-014712-5u4e00q6	949	2	was	be	VBD
cord-014712-5u4e00q6	949	3	done	do	VBN
cord-014712-5u4e00q6	949	4	in	in	IN
cord-014712-5u4e00q6	949	5	8	8	CD
cord-014712-5u4e00q6	949	6	patients	patient	NNS
cord-014712-5u4e00q6	949	7	.	.	.
cord-014712-5u4e00q6	950	1	We	-PRON-	PRP
cord-014712-5u4e00q6	950	2	saw	see	VBD
cord-014712-5u4e00q6	950	3	different	different	JJ
cord-014712-5u4e00q6	950	4	changes	change	NNS
cord-014712-5u4e00q6	950	5	in	in	IN
cord-014712-5u4e00q6	950	6	thymus	thymus	NN
cord-014712-5u4e00q6	950	7	and	and	CC
cord-014712-5u4e00q6	950	8	lymphatic	lymphatic	JJ
cord-014712-5u4e00q6	950	9	nodes	node	NNS
cord-014712-5u4e00q6	950	10	.	.	.
cord-014712-5u4e00q6	951	1	Artemis	Artemis	NNP
cord-014712-5u4e00q6	951	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	951	3	(	(	-LRB-
cord-014712-5u4e00q6	951	4	n	n	NN
cord-014712-5u4e00q6	951	5	=	=	SYM
cord-014712-5u4e00q6	951	6	1	1	CD
cord-014712-5u4e00q6	951	7	)	)	-RRB-
cord-014712-5u4e00q6	951	8	,	,	,
cord-014712-5u4e00q6	951	9	T	T	NNP
cord-014712-5u4e00q6	951	10	-	-	HYPH
cord-014712-5u4e00q6	951	11	B	B	NNP
cord-014712-5u4e00q6	951	12	-	-	HYPH
cord-014712-5u4e00q6	951	13	SCID	SCID	NNP
cord-014712-5u4e00q6	951	14	(	(	-LRB-
cord-014712-5u4e00q6	951	15	n	n	NN
cord-014712-5u4e00q6	951	16	=	=	SYM
cord-014712-5u4e00q6	951	17	4	4	CD
cord-014712-5u4e00q6	951	18	)	)	-RRB-
cord-014712-5u4e00q6	951	19	,	,	,
cord-014712-5u4e00q6	951	20	T	T	NNP
cord-014712-5u4e00q6	951	21	-	-	HYPH
cord-014712-5u4e00q6	951	22	B	B	NNP
cord-014712-5u4e00q6	952	1	+	+	CC
cord-014712-5u4e00q6	952	2	SCID	SCID	NNP
cord-014712-5u4e00q6	952	3	(	(	-LRB-
cord-014712-5u4e00q6	952	4	n	n	NN
cord-014712-5u4e00q6	952	5	=	=	SYM
cord-014712-5u4e00q6	952	6	5	5	CD
cord-014712-5u4e00q6	952	7	)	)	-RRB-
cord-014712-5u4e00q6	952	8	,	,	,
cord-014712-5u4e00q6	952	9	γc	γc	NNP
cord-014712-5u4e00q6	952	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	953	1	(	(	-LRB-
cord-014712-5u4e00q6	953	2	n	n	NN
cord-014712-5u4e00q6	953	3	=	=	SYM
cord-014712-5u4e00q6	953	4	1	1	CD
cord-014712-5u4e00q6	953	5	mutation	mutation	NN
cord-014712-5u4e00q6	953	6	R224W	r224w	NN
cord-014712-5u4e00q6	953	7	in	in	IN
cord-014712-5u4e00q6	953	8	γ	γ	NN
cord-014712-5u4e00q6	953	9	-	-	HYPH
cord-014712-5u4e00q6	953	10	chain	chain	NN
cord-014712-5u4e00q6	953	11	of	of	IN
cord-014712-5u4e00q6	953	12	receptor	receptor	NN
cord-014712-5u4e00q6	953	13	for	for	IN
cord-014712-5u4e00q6	953	14	IL-2	IL-2	NNP
cord-014712-5u4e00q6	953	15	)	)	-RRB-
cord-014712-5u4e00q6	953	16	,	,	,
cord-014712-5u4e00q6	953	17	unspecified	unspecified	JJ
cord-014712-5u4e00q6	953	18	SCID	SCID	NNP
cord-014712-5u4e00q6	953	19	(	(	-LRB-
cord-014712-5u4e00q6	953	20	n	n	NN
cord-014712-5u4e00q6	953	21	=	=	SYM
cord-014712-5u4e00q6	953	22	6	6	CD
cord-014712-5u4e00q6	953	23	)	)	-RRB-
cord-014712-5u4e00q6	953	24	were	be	VBD
cord-014712-5u4e00q6	953	25	detected	detect	VBN
cord-014712-5u4e00q6	953	26	.	.	.
cord-014712-5u4e00q6	954	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	954	2	:	:	:
cord-014712-5u4e00q6	955	1	Generalized	generalized	JJ
cord-014712-5u4e00q6	955	2	BCG	BCG	NNP
cord-014712-5u4e00q6	955	3	infection	infection	NN
cord-014712-5u4e00q6	955	4	had	have	VBD
cord-014712-5u4e00q6	955	5	47	47	CD
cord-014712-5u4e00q6	955	6	%	%	NN
cord-014712-5u4e00q6	955	7	of	of	IN
cord-014712-5u4e00q6	955	8	our	-PRON-	PRP$
cord-014712-5u4e00q6	955	9	SCID	SCID	NNP
cord-014712-5u4e00q6	955	10	patients	patient	NNS
cord-014712-5u4e00q6	955	11	.	.	.
cord-014712-5u4e00q6	956	1	(	(	-LRB-
cord-014712-5u4e00q6	956	2	Incidence	incidence	NN
cord-014712-5u4e00q6	956	3	of	of	IN
cord-014712-5u4e00q6	956	4	TB	TB	NNP
cord-014712-5u4e00q6	956	5	is	be	VBZ
cord-014712-5u4e00q6	956	6	still	still	RB
cord-014712-5u4e00q6	956	7	high	high	JJ
cord-014712-5u4e00q6	956	8	36.2	36.2	CD
cord-014712-5u4e00q6	956	9	/	/	SYM
cord-014712-5u4e00q6	956	10	100	100	CD
cord-014712-5u4e00q6	956	11	000	000	CD
cord-014712-5u4e00q6	956	12	population	population	NN
cord-014712-5u4e00q6	956	13	in	in	IN
cord-014712-5u4e00q6	956	14	Latvia	Latvia	NNP
cord-014712-5u4e00q6	956	15	and	and	CC
cord-014712-5u4e00q6	956	16	newborns	newborn	NNS
cord-014712-5u4e00q6	956	17	obligatory	obligatory	JJ
cord-014712-5u4e00q6	956	18	are	be	VBP
cord-014712-5u4e00q6	956	19	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	956	20	on	on	IN
cord-014712-5u4e00q6	956	21	the	the	DT
cord-014712-5u4e00q6	956	22	second	second	JJ
cord-014712-5u4e00q6	956	23	to	to	IN
cord-014712-5u4e00q6	956	24	fifth	fifth	JJ
cord-014712-5u4e00q6	956	25	day	day	NN
cord-014712-5u4e00q6	956	26	of	of	IN
cord-014712-5u4e00q6	956	27	life	life	NN
cord-014712-5u4e00q6	956	28	)	)	-RRB-
cord-014712-5u4e00q6	956	29	.	.	.
cord-014712-5u4e00q6	957	1	Due	due	IN
cord-014712-5u4e00q6	957	2	to	to	IN
cord-014712-5u4e00q6	957	3	possibility	possibility	NN
cord-014712-5u4e00q6	957	4	of	of	IN
cord-014712-5u4e00q6	957	5	absence	absence	NN
cord-014712-5u4e00q6	957	6	for	for	IN
cord-014712-5u4e00q6	957	7	PID	PID	NNP
cord-014712-5u4e00q6	957	8	routine	routine	JJ
cord-014712-5u4e00q6	957	9	genetic	genetic	JJ
cord-014712-5u4e00q6	957	10	identification	identification	NN
cord-014712-5u4e00q6	957	11	in	in	IN
cord-014712-5u4e00q6	957	12	only	only	JJ
cord-014712-5u4e00q6	957	13	few	few	JJ
cord-014712-5u4e00q6	957	14	SCID	SCID	NNP
cord-014712-5u4e00q6	957	15	forms	form	NNS
cord-014712-5u4e00q6	957	16	were	be	VBD
cord-014712-5u4e00q6	957	17	identified	identify	VBN
cord-014712-5u4e00q6	957	18	precisely	precisely	RB
cord-014712-5u4e00q6	957	19	.	.	.
cord-014712-5u4e00q6	958	1	Children	child	NNS
cord-014712-5u4e00q6	958	2	's	's	POS
cord-014712-5u4e00q6	958	3	Hospital	Hospital	NNP
cord-014712-5u4e00q6	958	4	,	,	,
cord-014712-5u4e00q6	958	5	University	University	NNP
cord-014712-5u4e00q6	958	6	of	of	IN
cord-014712-5u4e00q6	958	7	Freiburg	Freiburg	NNP
cord-014712-5u4e00q6	958	8	,	,	,
cord-014712-5u4e00q6	958	9	Freiburg	Freiburg	NNP
cord-014712-5u4e00q6	958	10	,	,	,
cord-014712-5u4e00q6	958	11	Germany	Germany	NNP
cord-014712-5u4e00q6	958	12	.	.	.
cord-014712-5u4e00q6	959	1	Purpose	purpose	NN
cord-014712-5u4e00q6	959	2	:	:	:
cord-014712-5u4e00q6	959	3	IPEX	IPEX	NNP
cord-014712-5u4e00q6	960	1	(	(	-LRB-
cord-014712-5u4e00q6	960	2	Immunodysregulation	Immunodysregulation	NNP
cord-014712-5u4e00q6	960	3	,	,	,
cord-014712-5u4e00q6	960	4	Polyendocrinopathy	Polyendocrinopathy	NNP
cord-014712-5u4e00q6	960	5	,	,	,
cord-014712-5u4e00q6	960	6	Enteropathy	Enteropathy	NNP
cord-014712-5u4e00q6	960	7	,	,	,
cord-014712-5u4e00q6	960	8	X	x	NN
cord-014712-5u4e00q6	960	9	-	-	HYPH
cord-014712-5u4e00q6	960	10	linked	link	VBN
cord-014712-5u4e00q6	960	11	)	)	-RRB-
cord-014712-5u4e00q6	960	12	is	be	VBZ
cord-014712-5u4e00q6	960	13	a	a	DT
cord-014712-5u4e00q6	960	14	rare	rare	JJ
cord-014712-5u4e00q6	960	15	X	x	NN
cord-014712-5u4e00q6	960	16	-	-	HYPH
cord-014712-5u4e00q6	960	17	linked	link	VBN
cord-014712-5u4e00q6	960	18	recessive	recessive	JJ
cord-014712-5u4e00q6	960	19	life	life	NN
cord-014712-5u4e00q6	960	20	-	-	HYPH
cord-014712-5u4e00q6	960	21	threatening	threaten	VBG
cord-014712-5u4e00q6	960	22	disorder	disorder	NN
cord-014712-5u4e00q6	960	23	characterized	characterize	VBN
cord-014712-5u4e00q6	960	24	by	by	IN
cord-014712-5u4e00q6	960	25	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	960	26	and	and	CC
cord-014712-5u4e00q6	960	27	early	early	JJ
cord-014712-5u4e00q6	960	28	death	death	NN
cord-014712-5u4e00q6	960	29	.	.	.
cord-014712-5u4e00q6	961	1	Pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	961	2	complication	complication	NN
cord-014712-5u4e00q6	961	3	related	relate	VBN
cord-014712-5u4e00q6	961	4	with	with	IN
cord-014712-5u4e00q6	961	5	IPEX	IPEX	NNP
cord-014712-5u4e00q6	961	6	has	have	VBZ
cord-014712-5u4e00q6	961	7	not	not	RB
cord-014712-5u4e00q6	961	8	elucidated	elucidate	VBN
cord-014712-5u4e00q6	961	9	exactly	exactly	RB
cord-014712-5u4e00q6	961	10	.	.	.
cord-014712-5u4e00q6	962	1	Here	here	RB
cord-014712-5u4e00q6	962	2	,	,	,
cord-014712-5u4e00q6	962	3	we	-PRON-	PRP
cord-014712-5u4e00q6	962	4	report	report	VBP
cord-014712-5u4e00q6	962	5	4	4	CD
cord-014712-5u4e00q6	962	6	I.E.	I.E.	NNP
cord-014712-5u4e00q6	962	7	patients	patient	NNS
cord-014712-5u4e00q6	962	8	,	,	,
cord-014712-5u4e00q6	962	9	3	3	CD
cord-014712-5u4e00q6	962	10	of	of	IN
cord-014712-5u4e00q6	962	11	which	which	WDT
cord-014712-5u4e00q6	962	12	died	die	VBD
cord-014712-5u4e00q6	962	13	from	from	IN
cord-014712-5u4e00q6	962	14	severe	severe	JJ
cord-014712-5u4e00q6	962	15	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	962	16	disease	disease	NN
cord-014712-5u4e00q6	962	17	.	.	.
cord-014712-5u4e00q6	963	1	Methods	method	NNS
cord-014712-5u4e00q6	963	2	:	:	:
cord-014712-5u4e00q6	963	3	Clinical	clinical	JJ
cord-014712-5u4e00q6	963	4	data	datum	NNS
cord-014712-5u4e00q6	963	5	and	and	CC
cord-014712-5u4e00q6	963	6	laboratory	laboratory	NN
cord-014712-5u4e00q6	963	7	findings	finding	NNS
cord-014712-5u4e00q6	963	8	included	include	VBD
cord-014712-5u4e00q6	963	9	autoantibodies	autoantibody	NNS
cord-014712-5u4e00q6	963	10	,	,	,
cord-014712-5u4e00q6	963	11	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	963	12	levels	level	NNS
cord-014712-5u4e00q6	963	13	as	as	RB
cord-014712-5u4e00q6	963	14	well	well	RB
cord-014712-5u4e00q6	963	15	as	as	IN
cord-014712-5u4e00q6	963	16	number	number	NN
cord-014712-5u4e00q6	963	17	of	of	IN
cord-014712-5u4e00q6	963	18	T	T	NNP
cord-014712-5u4e00q6	963	19	,	,	,
cord-014712-5u4e00q6	963	20	B	B	NNP
cord-014712-5u4e00q6	963	21	and	and	CC
cord-014712-5u4e00q6	963	22	NK	NK	NNP
cord-014712-5u4e00q6	963	23	cells	cell	NNS
cord-014712-5u4e00q6	963	24	were	be	VBD
cord-014712-5u4e00q6	963	25	evaluated	evaluate	VBN
cord-014712-5u4e00q6	963	26	.	.	.
cord-014712-5u4e00q6	964	1	FOXP3	FOXP3	NNP
cord-014712-5u4e00q6	964	2	expression	expression	NN
cord-014712-5u4e00q6	964	3	was	be	VBD
cord-014712-5u4e00q6	964	4	performed	perform	VBN
cord-014712-5u4e00q6	964	5	by	by	IN
cord-014712-5u4e00q6	964	6	flow	flow	NN
cord-014712-5u4e00q6	964	7	cytometry	cytometry	NN
cord-014712-5u4e00q6	964	8	.	.	.
cord-014712-5u4e00q6	965	1	Genomic	genomic	JJ
cord-014712-5u4e00q6	965	2	DNA	dna	NN
cord-014712-5u4e00q6	965	3	was	be	VBD
cord-014712-5u4e00q6	965	4	isolated	isolate	VBN
cord-014712-5u4e00q6	965	5	and	and	CC
cord-014712-5u4e00q6	965	6	all	all	DT
cord-014712-5u4e00q6	965	7	exons	exon	NNS
cord-014712-5u4e00q6	965	8	and	and	CC
cord-014712-5u4e00q6	965	9	exon	exon	NN
cord-014712-5u4e00q6	965	10	-	-	HYPH
cord-014712-5u4e00q6	965	11	intron	intron	NN
cord-014712-5u4e00q6	965	12	boundaries	boundary	NNS
cord-014712-5u4e00q6	965	13	of	of	IN
cord-014712-5u4e00q6	965	14	the	the	DT
cord-014712-5u4e00q6	965	15	FOXP3	FOXP3	NNP
cord-014712-5u4e00q6	965	16	gene	gene	NN
cord-014712-5u4e00q6	965	17	were	be	VBD
cord-014712-5u4e00q6	965	18	sequenced	sequence	VBN
cord-014712-5u4e00q6	965	19	by	by	IN
cord-014712-5u4e00q6	965	20	Sanger	Sanger	NNP
cord-014712-5u4e00q6	965	21	sequencing	sequencing	NN
cord-014712-5u4e00q6	965	22	.	.	.
cord-014712-5u4e00q6	966	1	Results	result	NNS
cord-014712-5u4e00q6	966	2	:	:	:
cord-014712-5u4e00q6	967	1	Patient	patient	JJ
cord-014712-5u4e00q6	967	2	I	-PRON-	PRP
cord-014712-5u4e00q6	967	3	(	(	-LRB-
cord-014712-5u4e00q6	967	4	PI	PI	NNP
cord-014712-5u4e00q6	967	5	)	)	-RRB-
cord-014712-5u4e00q6	967	6	presented	present	VBN
cord-014712-5u4e00q6	967	7	with	with	IN
cord-014712-5u4e00q6	967	8	nephrotic	nephrotic	JJ
cord-014712-5u4e00q6	967	9	syndrome	syndrome	NN
cord-014712-5u4e00q6	967	10	at	at	IN
cord-014712-5u4e00q6	967	11	3	3	CD
cord-014712-5u4e00q6	967	12	years	year	NNS
cord-014712-5u4e00q6	967	13	of	of	IN
cord-014712-5u4e00q6	967	14	age	age	NN
cord-014712-5u4e00q6	967	15	and	and	CC
cord-014712-5u4e00q6	967	16	then	then	RB
cord-014712-5u4e00q6	967	17	developed	develop	VBD
cord-014712-5u4e00q6	967	18	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	967	19	hepatitis	hepatitis	NN
cord-014712-5u4e00q6	967	20	without	without	IN
cord-014712-5u4e00q6	967	21	eczema	eczema	NN
cord-014712-5u4e00q6	967	22	,	,	,
cord-014712-5u4e00q6	967	23	enteropathy	enteropathy	NNP
cord-014712-5u4e00q6	967	24	or	or	CC
cord-014712-5u4e00q6	967	25	high	high	JJ
cord-014712-5u4e00q6	967	26	IgE	IgE	NNP
cord-014712-5u4e00q6	967	27	and	and	CC
cord-014712-5u4e00q6	967	28	died	die	VBD
cord-014712-5u4e00q6	967	29	at	at	IN
cord-014712-5u4e00q6	967	30	9	9	CD
cord-014712-5u4e00q6	967	31	years	year	NNS
cord-014712-5u4e00q6	967	32	of	of	IN
cord-014712-5u4e00q6	967	33	age	age	NN
cord-014712-5u4e00q6	967	34	due	due	JJ
cord-014712-5u4e00q6	967	35	to	to	IN
cord-014712-5u4e00q6	967	36	acute	acute	JJ
cord-014712-5u4e00q6	967	37	respiratory	respiratory	JJ
cord-014712-5u4e00q6	967	38	distress	distress	NN
cord-014712-5u4e00q6	967	39	syndrome	syndrome	NN
cord-014712-5u4e00q6	967	40	(	(	-LRB-
cord-014712-5u4e00q6	967	41	ARDS	ARDS	NNP
cord-014712-5u4e00q6	967	42	)	)	-RRB-
cord-014712-5u4e00q6	967	43	.	.	.
cord-014712-5u4e00q6	968	1	Two	two	CD
cord-014712-5u4e00q6	968	2	cousins	cousin	NNS
cord-014712-5u4e00q6	968	3	of	of	IN
cord-014712-5u4e00q6	968	4	PI	PI	NNP
cord-014712-5u4e00q6	968	5	had	have	VBD
cord-014712-5u4e00q6	968	6	the	the	DT
cord-014712-5u4e00q6	968	7	same	same	JJ
cord-014712-5u4e00q6	968	8	hypomorphic	hypomorphic	JJ
cord-014712-5u4e00q6	968	9	splice	splice	NN
cord-014712-5u4e00q6	968	10	site	site	NN
cord-014712-5u4e00q6	968	11	mutation	mutation	NN
cord-014712-5u4e00q6	968	12	leading	lead	VBG
cord-014712-5u4e00q6	968	13	to	to	IN
cord-014712-5u4e00q6	968	14	normal	normal	JJ
cord-014712-5u4e00q6	968	15	FOXP3	foxp3	NN
cord-014712-5u4e00q6	968	16	protein	protein	NN
cord-014712-5u4e00q6	968	17	expression	expression	NN
cord-014712-5u4e00q6	968	18	and	and	CC
cord-014712-5u4e00q6	968	19	suppressive	suppressive	JJ
cord-014712-5u4e00q6	968	20	capacity	capacity	NN
cord-014712-5u4e00q6	968	21	.	.	.
cord-014712-5u4e00q6	969	1	However	however	RB
cord-014712-5u4e00q6	969	2	,	,	,
cord-014712-5u4e00q6	969	3	they	-PRON-	PRP
cord-014712-5u4e00q6	969	4	exhibited	exhibit	VBD
cord-014712-5u4e00q6	969	5	typical	typical	JJ
cord-014712-5u4e00q6	969	6	symptoms	symptom	NNS
cord-014712-5u4e00q6	969	7	such	such	JJ
cord-014712-5u4e00q6	969	8	as	as	IN
cord-014712-5u4e00q6	969	9	eczema	eczema	NN
cord-014712-5u4e00q6	969	10	,	,	,
cord-014712-5u4e00q6	969	11	diabetes	diabetes	NN
cord-014712-5u4e00q6	969	12	and	and	CC
cord-014712-5u4e00q6	969	13	enteropathy	enteropathy	VBZ
cord-014712-5u4e00q6	969	14	with	with	IN
cord-014712-5u4e00q6	969	15	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	969	16	at	at	IN
cord-014712-5u4e00q6	969	17	early	early	JJ
cord-014712-5u4e00q6	969	18	age	age	NN
cord-014712-5u4e00q6	969	19	(	(	-LRB-
cord-014712-5u4e00q6	969	20	PII	PII	NNP
cord-014712-5u4e00q6	969	21	,	,	,
cord-014712-5u4e00q6	969	22	PIII	PIII	NNP
cord-014712-5u4e00q6	969	23	)	)	-RRB-
cord-014712-5u4e00q6	969	24	and	and	CC
cord-014712-5u4e00q6	969	25	were	be	VBD
cord-014712-5u4e00q6	969	26	transplanted	transplant	VBN
cord-014712-5u4e00q6	969	27	in	in	IN
cord-014712-5u4e00q6	969	28	infancy	infancy	NN
cord-014712-5u4e00q6	969	29	.	.	.
cord-014712-5u4e00q6	970	1	One	one	CD
cord-014712-5u4e00q6	970	2	of	of	IN
cord-014712-5u4e00q6	970	3	them	-PRON-	PRP
cord-014712-5u4e00q6	970	4	had	have	VBD
cord-014712-5u4e00q6	970	5	severe	severe	JJ
cord-014712-5u4e00q6	970	6	respiratory	respiratory	JJ
cord-014712-5u4e00q6	970	7	distress	distress	NN
cord-014712-5u4e00q6	970	8	right	right	RB
cord-014712-5u4e00q6	970	9	after	after	IN
cord-014712-5u4e00q6	970	10	birth	birth	NN
cord-014712-5u4e00q6	970	11	(	(	-LRB-
cord-014712-5u4e00q6	970	12	PIII	PIII	NNP
cord-014712-5u4e00q6	970	13	)	)	-RRB-
cord-014712-5u4e00q6	970	14	.	.	.
cord-014712-5u4e00q6	971	1	Patient	patient	JJ
cord-014712-5u4e00q6	971	2	IV	IV	NNP
cord-014712-5u4e00q6	971	3	from	from	IN
cord-014712-5u4e00q6	971	4	another	another	DT
cord-014712-5u4e00q6	971	5	family	family	NN
cord-014712-5u4e00q6	971	6	presented	present	VBN
cord-014712-5u4e00q6	971	7	with	with	IN
cord-014712-5u4e00q6	971	8	chronic	chronic	JJ
cord-014712-5u4e00q6	971	9	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	971	10	without	without	IN
cord-014712-5u4e00q6	971	11	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	971	12	manifestations	manifestation	NNS
cord-014712-5u4e00q6	971	13	and	and	CC
cord-014712-5u4e00q6	971	14	died	die	VBD
cord-014712-5u4e00q6	971	15	due	due	IN
cord-014712-5u4e00q6	971	16	to	to	IN
cord-014712-5u4e00q6	971	17	ARDS	ARDS	NNP
cord-014712-5u4e00q6	971	18	.	.	.
cord-014712-5u4e00q6	972	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	972	2	:	:	:
cord-014712-5u4e00q6	972	3	Lung	lung	NN
cord-014712-5u4e00q6	972	4	disease	disease	NN
cord-014712-5u4e00q6	972	5	related	relate	VBN
cord-014712-5u4e00q6	972	6	to	to	IN
cord-014712-5u4e00q6	972	7	IPEX	IPEX	NNP
cord-014712-5u4e00q6	972	8	syndrome	syndrome	NN
cord-014712-5u4e00q6	972	9	has	have	VBZ
cord-014712-5u4e00q6	972	10	not	not	RB
cord-014712-5u4e00q6	972	11	been	be	VBN
cord-014712-5u4e00q6	972	12	reported	report	VBN
cord-014712-5u4e00q6	972	13	before	before	RB
cord-014712-5u4e00q6	972	14	and	and	CC
cord-014712-5u4e00q6	972	15	this	this	DT
cord-014712-5u4e00q6	972	16	entity	entity	NN
cord-014712-5u4e00q6	972	17	could	could	MD
cord-014712-5u4e00q6	972	18	be	be	VB
cord-014712-5u4e00q6	972	19	a	a	DT
cord-014712-5u4e00q6	972	20	critical	critical	JJ
cord-014712-5u4e00q6	972	21	factor	factor	NN
cord-014712-5u4e00q6	972	22	in	in	IN
cord-014712-5u4e00q6	972	23	disease	disease	NN
cord-014712-5u4e00q6	972	24	outcome	outcome	NN
cord-014712-5u4e00q6	972	25	.	.	.
cord-014712-5u4e00q6	973	1	Severe	severe	JJ
cord-014712-5u4e00q6	973	2	combined	combined	JJ
cord-014712-5u4e00q6	973	3	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	973	4	(	(	-LRB-
cord-014712-5u4e00q6	973	5	SCIDs	SCIDs	NNP
cord-014712-5u4e00q6	973	6	)	)	-RRB-
cord-014712-5u4e00q6	973	7	are	be	VBP
cord-014712-5u4e00q6	973	8	a	a	DT
cord-014712-5u4e00q6	973	9	group	group	NN
cord-014712-5u4e00q6	973	10	of	of	IN
cord-014712-5u4e00q6	973	11	primary	primary	JJ
cord-014712-5u4e00q6	973	12	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	973	13	that	that	WDT
cord-014712-5u4e00q6	973	14	comprise	comprise	VBP
cord-014712-5u4e00q6	973	15	a	a	DT
cord-014712-5u4e00q6	973	16	number	number	NN
cord-014712-5u4e00q6	973	17	of	of	IN
cord-014712-5u4e00q6	973	18	monogenic	monogenic	NNP
cord-014712-5u4e00q6	973	19	disorders	disorder	NNS
cord-014712-5u4e00q6	973	20	characterized	characterize	VBN
cord-014712-5u4e00q6	973	21	by	by	IN
cord-014712-5u4e00q6	973	22	a	a	DT
cord-014712-5u4e00q6	973	23	block	block	NN
cord-014712-5u4e00q6	973	24	in	in	IN
cord-014712-5u4e00q6	973	25	T	t	NN
cord-014712-5u4e00q6	973	26	cell	cell	NN
cord-014712-5u4e00q6	973	27	differentiation	differentiation	NN
cord-014712-5u4e00q6	973	28	with	with	IN
cord-014712-5u4e00q6	973	29	or	or	CC
cord-014712-5u4e00q6	973	30	without	without	IN
cord-014712-5u4e00q6	973	31	impairment	impairment	NN
cord-014712-5u4e00q6	973	32	of	of	IN
cord-014712-5u4e00q6	973	33	B	b	NN
cord-014712-5u4e00q6	973	34	cell	cell	NN
cord-014712-5u4e00q6	973	35	and	and	CC
cord-014712-5u4e00q6	973	36	natural	natural	JJ
cord-014712-5u4e00q6	973	37	killer	killer	NN
cord-014712-5u4e00q6	973	38	(	(	-LRB-
cord-014712-5u4e00q6	973	39	NK	NK	NNP
cord-014712-5u4e00q6	973	40	)	)	-RRB-
cord-014712-5u4e00q6	973	41	cells	cell	NNS
cord-014712-5u4e00q6	973	42	.	.	.
cord-014712-5u4e00q6	974	1	Without	without	IN
cord-014712-5u4e00q6	974	2	early	early	JJ
cord-014712-5u4e00q6	974	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	974	4	and	and	CC
cord-014712-5u4e00q6	974	5	treatment	treatment	NN
cord-014712-5u4e00q6	974	6	most	most	JJS
cord-014712-5u4e00q6	974	7	children	child	NNS
cord-014712-5u4e00q6	974	8	die	die	VBP
cord-014712-5u4e00q6	974	9	in	in	IN
cord-014712-5u4e00q6	974	10	the	the	DT
cord-014712-5u4e00q6	974	11	first	first	JJ
cord-014712-5u4e00q6	974	12	year	year	NN
cord-014712-5u4e00q6	974	13	of	of	IN
cord-014712-5u4e00q6	974	14	life	life	NN
cord-014712-5u4e00q6	974	15	.	.	.
cord-014712-5u4e00q6	975	1	A	a	DT
cord-014712-5u4e00q6	975	2	lack	lack	NN
cord-014712-5u4e00q6	975	3	or	or	CC
cord-014712-5u4e00q6	975	4	very	very	RB
cord-014712-5u4e00q6	975	5	low	low	JJ
cord-014712-5u4e00q6	975	6	number	number	NN
cord-014712-5u4e00q6	975	7	of	of	IN
cord-014712-5u4e00q6	975	8	T	t	NN
cord-014712-5u4e00q6	975	9	-	-	HYPH
cord-014712-5u4e00q6	975	10	cell	cell	NN
cord-014712-5u4e00q6	975	11	receptor	receptor	NN
cord-014712-5u4e00q6	975	12	excision	excision	NN
cord-014712-5u4e00q6	975	13	circle	circle	NN
cord-014712-5u4e00q6	975	14	(	(	-LRB-
cord-014712-5u4e00q6	975	15	TREC	TREC	NNP
cord-014712-5u4e00q6	975	16	)	)	-RRB-
cord-014712-5u4e00q6	975	17	detected	detect	VBN
cord-014712-5u4e00q6	975	18	by	by	IN
cord-014712-5u4e00q6	975	19	realtime	realtime	JJ
cord-014712-5u4e00q6	975	20	quantitative	quantitative	JJ
cord-014712-5u4e00q6	975	21	polymerase	polymerase	NN
cord-014712-5u4e00q6	975	22	chain	chain	NN
cord-014712-5u4e00q6	975	23	reaction	reaction	NN
cord-014712-5u4e00q6	975	24	assay	assay	NN
cord-014712-5u4e00q6	975	25	(	(	-LRB-
cord-014712-5u4e00q6	975	26	qPCR	qPCR	NNP
cord-014712-5u4e00q6	975	27	)	)	-RRB-
cord-014712-5u4e00q6	975	28	is	be	VBZ
cord-014712-5u4e00q6	975	29	consistent	consistent	JJ
cord-014712-5u4e00q6	975	30	with	with	IN
cord-014712-5u4e00q6	975	31	T	t	NN
cord-014712-5u4e00q6	975	32	-	-	HYPH
cord-014712-5u4e00q6	975	33	cell	cell	NN
cord-014712-5u4e00q6	975	34	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	975	35	and	and	CC
cord-014712-5u4e00q6	975	36	has	have	VBZ
cord-014712-5u4e00q6	975	37	repeatedly	repeatedly	RB
cord-014712-5u4e00q6	975	38	demonstrated	demonstrate	VBN
cord-014712-5u4e00q6	975	39	clinical	clinical	JJ
cord-014712-5u4e00q6	975	40	validity	validity	NN
cord-014712-5u4e00q6	975	41	in	in	IN
cord-014712-5u4e00q6	975	42	population	population	NN
cord-014712-5u4e00q6	975	43	based	base	VBN
cord-014712-5u4e00q6	975	44	newborn	newborn	JJ
cord-014712-5u4e00q6	975	45	screening	screening	NN
cord-014712-5u4e00q6	975	46	for	for	IN
cord-014712-5u4e00q6	975	47	SCID	SCID	NNP
cord-014712-5u4e00q6	975	48	.	.	.
cord-014712-5u4e00q6	976	1	However	however	RB
cord-014712-5u4e00q6	976	2	,	,	,
cord-014712-5u4e00q6	976	3	the	the	DT
cord-014712-5u4e00q6	976	4	impact	impact	NN
cord-014712-5u4e00q6	976	5	of	of	IN
cord-014712-5u4e00q6	976	6	population	population	NN
cord-014712-5u4e00q6	976	7	screening	screening	NN
cord-014712-5u4e00q6	976	8	will	will	MD
cord-014712-5u4e00q6	976	9	be	be	VB
cord-014712-5u4e00q6	976	10	less	less	JJR
cord-014712-5u4e00q6	976	11	in	in	IN
cord-014712-5u4e00q6	976	12	communities	community	NNS
cord-014712-5u4e00q6	976	13	with	with	IN
cord-014712-5u4e00q6	976	14	high	high	JJ
cord-014712-5u4e00q6	976	15	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	976	16	and	and	CC
cord-014712-5u4e00q6	976	17	family	family	NN
cord-014712-5u4e00q6	976	18	history	history	NN
cord-014712-5u4e00q6	976	19	of	of	IN
cord-014712-5u4e00q6	976	20	SCID	SCID	NNP
cord-014712-5u4e00q6	976	21	,	,	,
cord-014712-5u4e00q6	976	22	in	in	IN
cord-014712-5u4e00q6	976	23	which	which	WDT
cord-014712-5u4e00q6	976	24	targeted	target	VBN
cord-014712-5u4e00q6	976	25	screening	screening	NN
cord-014712-5u4e00q6	976	26	may	may	MD
cord-014712-5u4e00q6	976	27	be	be	VB
cord-014712-5u4e00q6	976	28	more	more	RBR
cord-014712-5u4e00q6	976	29	appropriate	appropriate	JJ
cord-014712-5u4e00q6	976	30	.	.	.
cord-014712-5u4e00q6	977	1	Here	here	RB
cord-014712-5u4e00q6	977	2	,	,	,
cord-014712-5u4e00q6	977	3	we	-PRON-	PRP
cord-014712-5u4e00q6	977	4	screened	screen	VBD
cord-014712-5u4e00q6	977	5	100	100	CD
cord-014712-5u4e00q6	977	6	high	high	JJ
cord-014712-5u4e00q6	977	7	risk	risk	NN
cord-014712-5u4e00q6	977	8	neonates	neonate	NNS
cord-014712-5u4e00q6	977	9	and	and	CC
cord-014712-5u4e00q6	977	10	infants	infant	NNS
cord-014712-5u4e00q6	977	11	(	(	-LRB-
cord-014712-5u4e00q6	977	12	with	with	IN
cord-014712-5u4e00q6	977	13	one	one	CD
cord-014712-5u4e00q6	977	14	or	or	CC
cord-014712-5u4e00q6	977	15	more	more	JJR
cord-014712-5u4e00q6	977	16	of	of	IN
cord-014712-5u4e00q6	977	17	the	the	DT
cord-014712-5u4e00q6	977	18	following	follow	VBG
cord-014712-5u4e00q6	977	19	:	:	:
cord-014712-5u4e00q6	977	20	clinical	clinical	JJ
cord-014712-5u4e00q6	977	21	presentation	presentation	NN
cord-014712-5u4e00q6	977	22	and/or	and/or	CC
cord-014712-5u4e00q6	977	23	family	family	NN
cord-014712-5u4e00q6	977	24	history	history	NN
cord-014712-5u4e00q6	977	25	suggestive	suggestive	JJ
cord-014712-5u4e00q6	977	26	of	of	IN
cord-014712-5u4e00q6	977	27	PID	pid	NN
cord-014712-5u4e00q6	977	28	,	,	,
cord-014712-5u4e00q6	977	29	failure	failure	NN
cord-014712-5u4e00q6	977	30	to	to	TO
cord-014712-5u4e00q6	977	31	thrive	thrive	VB
cord-014712-5u4e00q6	977	32	otherwise	otherwise	RB
cord-014712-5u4e00q6	977	33	unexplained	unexplained	JJ
cord-014712-5u4e00q6	977	34	,	,	,
cord-014712-5u4e00q6	977	35	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	977	36	)	)	-RRB-
cord-014712-5u4e00q6	977	37	at	at	IN
cord-014712-5u4e00q6	977	38	Cairo	Cairo	NNP
cord-014712-5u4e00q6	977	39	University	University	NNP
cord-014712-5u4e00q6	977	40	Hospitals	Hospitals	NNPS
cord-014712-5u4e00q6	977	41	.	.	.
cord-014712-5u4e00q6	978	1	Their	-PRON-	PRP$
cord-014712-5u4e00q6	978	2	full	full	JJ
cord-014712-5u4e00q6	978	3	history	history	NN
cord-014712-5u4e00q6	978	4	and	and	CC
cord-014712-5u4e00q6	978	5	clinical	clinical	JJ
cord-014712-5u4e00q6	978	6	examination	examination	NN
cord-014712-5u4e00q6	978	7	were	be	VBD
cord-014712-5u4e00q6	978	8	recorded	record	VBN
cord-014712-5u4e00q6	978	9	.	.	.
cord-014712-5u4e00q6	979	1	Immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	979	2	profile	profile	NN
cord-014712-5u4e00q6	979	3	and	and	CC
cord-014712-5u4e00q6	979	4	immunophenotyping	immunophenotyping	NN
cord-014712-5u4e00q6	979	5	of	of	IN
cord-014712-5u4e00q6	979	6	peripheral	peripheral	JJ
cord-014712-5u4e00q6	979	7	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	979	8	were	be	VBD
cord-014712-5u4e00q6	979	9	performed	perform	VBN
cord-014712-5u4e00q6	979	10	as	as	IN
cord-014712-5u4e00q6	979	11	confirmatory	confirmatory	JJ
cord-014712-5u4e00q6	979	12	tests	test	NNS
cord-014712-5u4e00q6	979	13	.	.	.
cord-014712-5u4e00q6	980	1	Sixteen	sixteen	CD
cord-014712-5u4e00q6	980	2	classical	classical	JJ
cord-014712-5u4e00q6	980	3	SCID	SCID	NNP
cord-014712-5u4e00q6	980	4	cases	case	NNS
cord-014712-5u4e00q6	980	5	were	be	VBD
cord-014712-5u4e00q6	980	6	detected	detect	VBN
cord-014712-5u4e00q6	980	7	,	,	,
cord-014712-5u4e00q6	980	8	as	as	RB
cord-014712-5u4e00q6	980	9	well	well	RB
cord-014712-5u4e00q6	980	10	as	as	IN
cord-014712-5u4e00q6	980	11	another	another	DT
cord-014712-5u4e00q6	980	12	2	2	CD
cord-014712-5u4e00q6	980	13	SCID	SCID	NNP
cord-014712-5u4e00q6	980	14	variants	variant	NNS
cord-014712-5u4e00q6	980	15	(	(	-LRB-
cord-014712-5u4e00q6	980	16	Omenn	Omenn	NNP
cord-014712-5u4e00q6	980	17	syndrome	syndrome	NN
cord-014712-5u4e00q6	980	18	and	and	CC
cord-014712-5u4e00q6	980	19	Major	Major	NNP
cord-014712-5u4e00q6	980	20	Histocompatibility	Histocompatibility	NNP
cord-014712-5u4e00q6	980	21	Complex	Complex	NNP
cord-014712-5u4e00q6	980	22	class	class	NN
cord-014712-5u4e00q6	980	23	II	ii	CD
cord-014712-5u4e00q6	980	24	deficiency	deficiency	NN
cord-014712-5u4e00q6	980	25	)	)	-RRB-
cord-014712-5u4e00q6	980	26	(	(	-LRB-
cord-014712-5u4e00q6	980	27	totally	totally	RB
cord-014712-5u4e00q6	980	28	18.4	18.4	CD
cord-014712-5u4e00q6	980	29	%	%	NN
cord-014712-5u4e00q6	980	30	of	of	IN
cord-014712-5u4e00q6	980	31	all	all	DT
cord-014712-5u4e00q6	980	32	subjects	subject	NNS
cord-014712-5u4e00q6	980	33	screened	screen	VBN
cord-014712-5u4e00q6	980	34	)	)	-RRB-
cord-014712-5u4e00q6	980	35	.	.	.
cord-014712-5u4e00q6	981	1	The	the	DT
cord-014712-5u4e00q6	981	2	rate	rate	NN
cord-014712-5u4e00q6	981	3	of	of	IN
cord-014712-5u4e00q6	981	4	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	981	5	in	in	IN
cord-014712-5u4e00q6	981	6	this	this	DT
cord-014712-5u4e00q6	981	7	group	group	NN
cord-014712-5u4e00q6	981	8	was	be	VBD
cord-014712-5u4e00q6	981	9	77.8	77.8	CD
cord-014712-5u4e00q6	981	10	%	%	NN
cord-014712-5u4e00q6	981	11	.	.	.
cord-014712-5u4e00q6	982	1	Secondary	secondary	JJ
cord-014712-5u4e00q6	982	2	causes	cause	NNS
cord-014712-5u4e00q6	982	3	of	of	IN
cord-014712-5u4e00q6	982	4	Low	Low	NNP
cord-014712-5u4e00q6	982	5	TRECs	trec	NNS
cord-014712-5u4e00q6	982	6	,	,	,
cord-014712-5u4e00q6	982	7	other	other	JJ
cord-014712-5u4e00q6	982	8	than	than	IN
cord-014712-5u4e00q6	982	9	SCID	SCID	NNP
cord-014712-5u4e00q6	983	1	,	,	,
cord-014712-5u4e00q6	983	2	in	in	IN
cord-014712-5u4e00q6	983	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	983	4	series	series	NN
cord-014712-5u4e00q6	983	5	included	include	VBD
cord-014712-5u4e00q6	983	6	:	:	:
cord-014712-5u4e00q6	983	7	bacterial	bacterial	JJ
cord-014712-5u4e00q6	983	8	septicemia	septicemia	NN
cord-014712-5u4e00q6	983	9	(	(	-LRB-
cord-014712-5u4e00q6	983	10	4	4	CD
cord-014712-5u4e00q6	983	11	preterm	preterm	NNS
cord-014712-5u4e00q6	983	12	,	,	,
cord-014712-5u4e00q6	983	13	1full	1full	CD
cord-014712-5u4e00q6	983	14	-	-	HYPH
cord-014712-5u4e00q6	983	15	term	term	NN
cord-014712-5u4e00q6	983	16	)	)	-RRB-
cord-014712-5u4e00q6	983	17	,	,	,
cord-014712-5u4e00q6	983	18	prematurity	prematurity	NN
cord-014712-5u4e00q6	983	19	(	(	-LRB-
cord-014712-5u4e00q6	983	20	2	2	CD
cord-014712-5u4e00q6	983	21	cases	case	NNS
cord-014712-5u4e00q6	983	22	)	)	-RRB-
cord-014712-5u4e00q6	983	23	,	,	,
cord-014712-5u4e00q6	983	24	one	one	CD
cord-014712-5u4e00q6	983	25	preterm	preterm	JJ
cord-014712-5u4e00q6	983	26	with	with	IN
cord-014712-5u4e00q6	983	27	omphalocele	omphalocele	NNP
cord-014712-5u4e00q6	983	28	and	and	CC
cord-014712-5u4e00q6	983	29	facial	facial	JJ
cord-014712-5u4e00q6	983	30	dysmorphism	dysmorphism	NN
cord-014712-5u4e00q6	983	31	,	,	,
cord-014712-5u4e00q6	983	32	one	one	CD
cord-014712-5u4e00q6	983	33	preterm	preterm	JJR
cord-014712-5u4e00q6	983	34	with	with	IN
cord-014712-5u4e00q6	983	35	Congenital	congenital	JJ
cord-014712-5u4e00q6	983	36	Adrenal	adrenal	JJ
cord-014712-5u4e00q6	983	37	Hyperplasia	hyperplasia	NN
cord-014712-5u4e00q6	983	38	,	,	,
cord-014712-5u4e00q6	983	39	one	one	CD
cord-014712-5u4e00q6	983	40	full	full	JJ
cord-014712-5u4e00q6	983	41	term	term	NN
cord-014712-5u4e00q6	983	42	with	with	IN
cord-014712-5u4e00q6	983	43	Microvillus	Microvillus	NNP
cord-014712-5u4e00q6	983	44	Inclusion	Inclusion	NNP
cord-014712-5u4e00q6	983	45	Disease	Disease	NNP
cord-014712-5u4e00q6	983	46	,	,	,
cord-014712-5u4e00q6	983	47	and	and	CC
cord-014712-5u4e00q6	983	48	one	one	CD
cord-014712-5u4e00q6	983	49	full	full	JJ
cord-014712-5u4e00q6	983	50	term	term	NN
cord-014712-5u4e00q6	983	51	with	with	IN
cord-014712-5u4e00q6	983	52	Idiopathic	Idiopathic	NNP
cord-014712-5u4e00q6	983	53	Tcell	Tcell	NNP
cord-014712-5u4e00q6	983	54	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	983	55	.	.	.
cord-014712-5u4e00q6	984	1	This	this	DT
cord-014712-5u4e00q6	984	2	demonstrates	demonstrate	VBZ
cord-014712-5u4e00q6	984	3	that	that	IN
cord-014712-5u4e00q6	984	4	in	in	IN
cord-014712-5u4e00q6	984	5	populations	population	NNS
cord-014712-5u4e00q6	984	6	with	with	IN
cord-014712-5u4e00q6	984	7	high	high	JJ
cord-014712-5u4e00q6	984	8	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	984	9	rates	rate	NNS
cord-014712-5u4e00q6	984	10	,	,	,
cord-014712-5u4e00q6	984	11	as	as	IN
cord-014712-5u4e00q6	984	12	in	in	IN
cord-014712-5u4e00q6	984	13	Egypt	Egypt	NNP
cord-014712-5u4e00q6	984	14	,	,	,
cord-014712-5u4e00q6	984	15	targeted	target	VBN
cord-014712-5u4e00q6	984	16	(	(	-LRB-
cord-014712-5u4e00q6	984	17	non	non	JJ
cord-014712-5u4e00q6	984	18	-	-	JJ
cord-014712-5u4e00q6	984	19	population	population	JJ
cord-014712-5u4e00q6	984	20	based	base	VBN
cord-014712-5u4e00q6	984	21	)	)	-RRB-
cord-014712-5u4e00q6	985	1	TRECs	trec	NNS
cord-014712-5u4e00q6	985	2	assay	assay	NN
cord-014712-5u4e00q6	985	3	may	may	MD
cord-014712-5u4e00q6	985	4	provide	provide	VB
cord-014712-5u4e00q6	985	5	a	a	DT
cord-014712-5u4e00q6	985	6	more	more	RBR
cord-014712-5u4e00q6	985	7	efficient	efficient	JJ
cord-014712-5u4e00q6	985	8	screening	screening	NN
cord-014712-5u4e00q6	985	9	strategy	strategy	NN
cord-014712-5u4e00q6	985	10	.	.	.
cord-014712-5u4e00q6	986	1	CASE	case	NN
cord-014712-5u4e00q6	986	2	1	1	CD
cord-014712-5u4e00q6	986	3	:	:	:
cord-014712-5u4e00q6	987	1	A	a	DT
cord-014712-5u4e00q6	987	2	is	be	VBZ
cord-014712-5u4e00q6	987	3	a	a	DT
cord-014712-5u4e00q6	987	4	4	4	CD
cord-014712-5u4e00q6	987	5	years	year	NNS
cord-014712-5u4e00q6	987	6	old	old	JJ
cord-014712-5u4e00q6	987	7	Female	Female	NNP
cord-014712-5u4e00q6	987	8	,	,	,
cord-014712-5u4e00q6	987	9	1	1	CD
cord-014712-5u4e00q6	987	10	st	st	NNP
cord-014712-5u4e00q6	987	11	kid	kid	NN
cord-014712-5u4e00q6	987	12	of	of	IN
cord-014712-5u4e00q6	987	13	non	non	JJ
cord-014712-5u4e00q6	987	14	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	987	15	marriage	marriage	NN
cord-014712-5u4e00q6	987	16	presented	present	VBN
cord-014712-5u4e00q6	987	17	with	with	IN
cord-014712-5u4e00q6	987	18	fever	fever	NN
cord-014712-5u4e00q6	987	19	for	for	IN
cord-014712-5u4e00q6	987	20	5	5	CD
cord-014712-5u4e00q6	987	21	months	month	NNS
cord-014712-5u4e00q6	987	22	.	.	.
cord-014712-5u4e00q6	988	1	One	one	CD
cord-014712-5u4e00q6	988	2	week	week	NN
cord-014712-5u4e00q6	988	3	after	after	IN
cord-014712-5u4e00q6	988	4	the	the	DT
cord-014712-5u4e00q6	988	5	onset	onset	NN
cord-014712-5u4e00q6	988	6	of	of	IN
cord-014712-5u4e00q6	988	7	the	the	DT
cord-014712-5u4e00q6	988	8	fever	fever	NN
cord-014712-5u4e00q6	988	9	red	red	JJ
cord-014712-5u4e00q6	988	10	patches	patch	NNS
cord-014712-5u4e00q6	988	11	appeared	appear	VBD
cord-014712-5u4e00q6	988	12	on	on	IN
cord-014712-5u4e00q6	988	13	the	the	DT
cord-014712-5u4e00q6	988	14	face	face	NN
cord-014712-5u4e00q6	988	15	,	,	,
cord-014712-5u4e00q6	988	16	hands	hand	NNS
cord-014712-5u4e00q6	988	17	,	,	,
cord-014712-5u4e00q6	988	18	abdomen	abdomen	NN
cord-014712-5u4e00q6	988	19	,	,	,
cord-014712-5u4e00q6	988	20	LL	LL	NNP
cord-014712-5u4e00q6	988	21	.	.	.
cord-014712-5u4e00q6	989	1	Mother	mother	NN
cord-014712-5u4e00q6	989	2	sought	seek	VBD
cord-014712-5u4e00q6	989	3	medical	medical	JJ
cord-014712-5u4e00q6	989	4	advice	advice	NN
cord-014712-5u4e00q6	989	5	and	and	CC
cord-014712-5u4e00q6	989	6	received	receive	VBD
cord-014712-5u4e00q6	989	7	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	989	8	,	,	,
cord-014712-5u4e00q6	989	9	antipyretics	antipyretic	NNS
cord-014712-5u4e00q6	989	10	and	and	CC
cord-014712-5u4e00q6	989	11	oral	oral	JJ
cord-014712-5u4e00q6	989	12	steroids	steroid	NNS
cord-014712-5u4e00q6	989	13	for	for	IN
cord-014712-5u4e00q6	989	14	about	about	RB
cord-014712-5u4e00q6	989	15	one	one	CD
cord-014712-5u4e00q6	989	16	month	month	NN
cord-014712-5u4e00q6	989	17	with	with	IN
cord-014712-5u4e00q6	989	18	no	no	DT
cord-014712-5u4e00q6	989	19	signs	sign	NNS
cord-014712-5u4e00q6	989	20	of	of	IN
cord-014712-5u4e00q6	989	21	improvements	improvement	NNS
cord-014712-5u4e00q6	989	22	regarding	regard	VBG
cord-014712-5u4e00q6	989	23	fever	fever	NN
cord-014712-5u4e00q6	989	24	.	.	.
cord-014712-5u4e00q6	990	1	One	one	CD
cord-014712-5u4e00q6	990	2	week	week	NN
cord-014712-5u4e00q6	990	3	later	later	RB
cord-014712-5u4e00q6	990	4	the	the	DT
cord-014712-5u4e00q6	990	5	mother	mother	NN
cord-014712-5u4e00q6	990	6	noticed	notice	VBD
cord-014712-5u4e00q6	990	7	pallor	pallor	NN
cord-014712-5u4e00q6	990	8	and	and	CC
cord-014712-5u4e00q6	990	9	sought	seek	VBD
cord-014712-5u4e00q6	990	10	medical	medical	JJ
cord-014712-5u4e00q6	990	11	advice	advice	NN
cord-014712-5u4e00q6	990	12	and	and	CC
cord-014712-5u4e00q6	990	13	the	the	DT
cord-014712-5u4e00q6	990	14	baby	baby	NN
cord-014712-5u4e00q6	990	15	was	be	VBD
cord-014712-5u4e00q6	990	16	admitted	admit	VBN
cord-014712-5u4e00q6	990	17	to	to	IN
cord-014712-5u4e00q6	990	18	local	local	JJ
cord-014712-5u4e00q6	990	19	hospital	hospital	NN
cord-014712-5u4e00q6	990	20	and	and	CC
cord-014712-5u4e00q6	990	21	received	receive	VBD
cord-014712-5u4e00q6	990	22	one	one	CD
cord-014712-5u4e00q6	990	23	bag	bag	NN
cord-014712-5u4e00q6	990	24	of	of	IN
cord-014712-5u4e00q6	990	25	blood	blood	NN
cord-014712-5u4e00q6	990	26	.	.	.
cord-014712-5u4e00q6	991	1	And	and	CC
cord-014712-5u4e00q6	991	2	then	then	RB
cord-014712-5u4e00q6	991	3	she	-PRON-	PRP
cord-014712-5u4e00q6	991	4	was	be	VBD
cord-014712-5u4e00q6	991	5	referred	refer	VBN
cord-014712-5u4e00q6	991	6	to	to	IN
cord-014712-5u4e00q6	991	7	our	-PRON-	PRP$
cord-014712-5u4e00q6	991	8	hospital	hospital	NN
cord-014712-5u4e00q6	991	9	(	(	-LRB-
cord-014712-5u4e00q6	991	10	Zagazig	Zagazig	NNP
cord-014712-5u4e00q6	991	11	University	University	NNP
cord-014712-5u4e00q6	991	12	Hospital	Hospital	NNP
cord-014712-5u4e00q6	991	13	)	)	-RRB-
cord-014712-5u4e00q6	991	14	where	where	WRB
cord-014712-5u4e00q6	991	15	she	-PRON-	PRP
cord-014712-5u4e00q6	991	16	developed	develop	VBD
cord-014712-5u4e00q6	991	17	acute	acute	JJ
cord-014712-5u4e00q6	991	18	pallor	pallor	NN
cord-014712-5u4e00q6	991	19	again	again	RB
cord-014712-5u4e00q6	991	20	which	which	WDT
cord-014712-5u4e00q6	991	21	needed	need	VBD
cord-014712-5u4e00q6	991	22	recurrent	recurrent	JJ
cord-014712-5u4e00q6	991	23	Blood	blood	NN
cord-014712-5u4e00q6	991	24	transfusions	transfusion	NNS
cord-014712-5u4e00q6	991	25	.	.	.
cord-014712-5u4e00q6	992	1	Dark	dark	JJ
cord-014712-5u4e00q6	992	2	colored	colored	JJ
cord-014712-5u4e00q6	992	3	urine	urine	NN
cord-014712-5u4e00q6	992	4	occurred	occur	VBD
cord-014712-5u4e00q6	992	5	in	in	IN
cord-014712-5u4e00q6	992	6	frequent	frequent	JJ
cord-014712-5u4e00q6	992	7	attacks	attack	NNS
cord-014712-5u4e00q6	992	8	with	with	IN
cord-014712-5u4e00q6	992	9	abdominal	abdominal	JJ
cord-014712-5u4e00q6	992	10	enlargement	enlargement	NN
cord-014712-5u4e00q6	992	11	and	and	CC
cord-014712-5u4e00q6	992	12	pain	pain	NN
cord-014712-5u4e00q6	992	13	,	,	,
cord-014712-5u4e00q6	992	14	and	and	CC
cord-014712-5u4e00q6	992	15	interestingly	interestingly	RB
cord-014712-5u4e00q6	992	16	upto	upto	IN
cord-014712-5u4e00q6	992	17	this	this	DT
cord-014712-5u4e00q6	992	18	time	time	NN
cord-014712-5u4e00q6	992	19	,	,	,
cord-014712-5u4e00q6	992	20	no	no	DT
cord-014712-5u4e00q6	992	21	improvement	improvement	NN
cord-014712-5u4e00q6	992	22	regarding	regard	VBG
cord-014712-5u4e00q6	992	23	fever	fever	NN
cord-014712-5u4e00q6	992	24	,	,	,
cord-014712-5u4e00q6	992	25	bone	bone	NN
cord-014712-5u4e00q6	992	26	pain	pain	NN
cord-014712-5u4e00q6	992	27	or	or	CC
cord-014712-5u4e00q6	992	28	pallor	pallor	NN
cord-014712-5u4e00q6	992	29	.	.	.
cord-014712-5u4e00q6	993	1	On	on	IN
cord-014712-5u4e00q6	993	2	examination	examination	NN
cord-014712-5u4e00q6	993	3	she	-PRON-	PRP
cord-014712-5u4e00q6	993	4	was	be	VBD
cord-014712-5u4e00q6	993	5	Underbuilt	Underbuilt	NNP
cord-014712-5u4e00q6	993	6	(	(	-LRB-
cord-014712-5u4e00q6	993	7	all	all	DT
cord-014712-5u4e00q6	993	8	parameters	parameter	NNS
cord-014712-5u4e00q6	993	9	are	be	VBP
cord-014712-5u4e00q6	993	10	under	under	IN
cord-014712-5u4e00q6	993	11	3rd	3rd	JJ
cord-014712-5u4e00q6	993	12	centile	centile	NN
cord-014712-5u4e00q6	993	13	)	)	-RRB-
cord-014712-5u4e00q6	993	14	,	,	,
cord-014712-5u4e00q6	993	15	pallor	pallor	NN
cord-014712-5u4e00q6	993	16	,	,	,
cord-014712-5u4e00q6	993	17	tinge	tinge	NN
cord-014712-5u4e00q6	993	18	of	of	IN
cord-014712-5u4e00q6	993	19	jaundice	jaundice	NN
cord-014712-5u4e00q6	993	20	,	,	,
cord-014712-5u4e00q6	993	21	generalized	generalized	JJ
cord-014712-5u4e00q6	993	22	skin	skin	NN
cord-014712-5u4e00q6	993	23	pigmentation	pigmentation	NN
cord-014712-5u4e00q6	993	24	,	,	,
cord-014712-5u4e00q6	993	25	generalized	generalize	VBN
cord-014712-5u4e00q6	993	26	lymphadenopathy	lymphadenopathy	NN
cord-014712-5u4e00q6	993	27	,	,	,
cord-014712-5u4e00q6	993	28	2	2	CD
cord-014712-5u4e00q6	993	29	nd	nd	NNP
cord-014712-5u4e00q6	993	30	degree	degree	NN
cord-014712-5u4e00q6	993	31	clubbing	clubbing	NN
cord-014712-5u4e00q6	993	32	and	and	CC
cord-014712-5u4e00q6	993	33	HSM	HSM	NNP
cord-014712-5u4e00q6	993	34	Investigations	Investigations	NNPS
cord-014712-5u4e00q6	993	35	:	:	:
cord-014712-5u4e00q6	993	36	CBC	CBC	NNP
cord-014712-5u4e00q6	993	37	(	(	-LRB-
cord-014712-5u4e00q6	993	38	pancytopenia	pancytopenia	NNP
cord-014712-5u4e00q6	993	39	with	with	IN
cord-014712-5u4e00q6	993	40	reticulocytopenia	reticulocytopenia	NNP
cord-014712-5u4e00q6	993	41	)	)	-RRB-
cord-014712-5u4e00q6	993	42	-LFT	-LFT	.
cord-014712-5u4e00q6	994	1	(	(	-LRB-
cord-014712-5u4e00q6	994	2	increased	increase	VBN
cord-014712-5u4e00q6	994	3	AST	AST	NNP
cord-014712-5u4e00q6	994	4	with	with	IN
cord-014712-5u4e00q6	994	5	indirect	indirect	JJ
cord-014712-5u4e00q6	994	6	hyperbilirubinemia)-KFT	hyperbilirubinemia)-KFT	NNS
cord-014712-5u4e00q6	994	7	(	(	-LRB-
cord-014712-5u4e00q6	994	8	normal)-LDH	normal)-LDH	NNP
cord-014712-5u4e00q6	994	9	(	(	-LRB-
cord-014712-5u4e00q6	994	10	Highly	highly	RB
cord-014712-5u4e00q6	994	11	elevated	elevated	JJ
cord-014712-5u4e00q6	994	12	7238	7238	CD
cord-014712-5u4e00q6	994	13	U	U	NNP
cord-014712-5u4e00q6	994	14	/	/	SYM
cord-014712-5u4e00q6	994	15	L)-ESR	L)-ESR	NNP
cord-014712-5u4e00q6	994	16	(	(	-LRB-
cord-014712-5u4e00q6	994	17	105	105	CD
cord-014712-5u4e00q6	994	18	)	)	-RRB-
cord-014712-5u4e00q6	995	1	-Fibrinogen	-Fibrinogen	.
cord-014712-5u4e00q6	996	1	(	(	-LRB-
cord-014712-5u4e00q6	996	2	0.336	0.336	CD
cord-014712-5u4e00q6	996	3	gm/	gm/	NNP
cord-014712-5u4e00q6	996	4	L)serum	L)serum	NNP
cord-014712-5u4e00q6	996	5	triglycerides	triglyceride	NNS
cord-014712-5u4e00q6	996	6	(	(	-LRB-
cord-014712-5u4e00q6	996	7	315.7	315.7	CD
cord-014712-5u4e00q6	996	8	mg	mg	NNP
cord-014712-5u4e00q6	996	9	/	/	SYM
cord-014712-5u4e00q6	996	10	dl)-EBV	dl)-EBV	NNP
cord-014712-5u4e00q6	996	11	-	-	HYPH
cord-014712-5u4e00q6	996	12	VCM	VCM	NNP
cord-014712-5u4e00q6	996	13	IgM	IgM	NNP
cord-014712-5u4e00q6	996	14	positive	positive	JJ
cord-014712-5u4e00q6	996	15	and	and	CC
cord-014712-5u4e00q6	996	16	IgG	IgG	NNP
cord-014712-5u4e00q6	996	17	negative	negative	JJ
cord-014712-5u4e00q6	996	18	-C3	-C3	:
cord-014712-5u4e00q6	996	19	(	(	-LRB-
cord-014712-5u4e00q6	996	20	1.3	1.3	CD
cord-014712-5u4e00q6	996	21	normal	normal	JJ
cord-014712-5u4e00q6	996	22	)	)	-RRB-
cord-014712-5u4e00q6	996	23	-RF	-RF	:
cord-014712-5u4e00q6	996	24	and	and	CC
cord-014712-5u4e00q6	996	25	ANA(-ve	ANA(-ve	NNP
cord-014712-5u4e00q6	996	26	)	)	-RRB-
cord-014712-5u4e00q6	997	1	-Serum	-Serum	NNP
cord-014712-5u4e00q6	998	1	ferritin	ferritin	NN
cord-014712-5u4e00q6	998	2	(	(	-LRB-
cord-014712-5u4e00q6	998	3	32436	32436	CD
cord-014712-5u4e00q6	998	4	ng	ng	NN
cord-014712-5u4e00q6	998	5	/	/	SYM
cord-014712-5u4e00q6	998	6	ml	ml	NN
cord-014712-5u4e00q6	998	7	)	)	-RRB-
cord-014712-5u4e00q6	999	1	-CD	-cd	RB
cord-014712-5u4e00q6	1000	1	56	56	CD
cord-014712-5u4e00q6	1000	2	is	be	VBZ
cord-014712-5u4e00q6	1001	1	low	low	JJ
cord-014712-5u4e00q6	1001	2	-Bone	-Bone	NNP
cord-014712-5u4e00q6	1001	3	marrow	marrow	NN
cord-014712-5u4e00q6	1001	4	biobsy	biobsy	NN
cord-014712-5u4e00q6	1001	5	revealed	reveal	VBD
cord-014712-5u4e00q6	1001	6	dysplastic	dysplastic	JJ
cord-014712-5u4e00q6	1001	7	changes	change	NNS
cord-014712-5u4e00q6	1001	8	-L.N.	-L.N.	.
cord-014712-5u4e00q6	1002	1	biopsy	biopsy	NNP
cord-014712-5u4e00q6	1002	2	revealed	reveal	VBD
cord-014712-5u4e00q6	1002	3	non	non	JJ
cord-014712-5u4e00q6	1002	4	specific	specific	JJ
cord-014712-5u4e00q6	1002	5	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	1002	6	changes	change	NNS
cord-014712-5u4e00q6	1002	7	.	.	.
cord-014712-5u4e00q6	1003	1	Treatment	treatment	NN
cord-014712-5u4e00q6	1003	2	:	:	:
cord-014712-5u4e00q6	1003	3	HLH	HLH	NNP
cord-014712-5u4e00q6	1003	4	protocol	protocol	NN
cord-014712-5u4e00q6	1003	5	94	94	CD
cord-014712-5u4e00q6	1003	6	with	with	IN
cord-014712-5u4e00q6	1003	7	no	no	DT
cord-014712-5u4e00q6	1003	8	SCT	SCT	NNP
cord-014712-5u4e00q6	1003	9	Prognosis	prognosis	NN
cord-014712-5u4e00q6	1003	10	:	:	:
cord-014712-5u4e00q6	1004	1	patient	patient	NNP
cord-014712-5u4e00q6	1004	2	passed	pass	VBD
cord-014712-5u4e00q6	1004	3	initial	initial	JJ
cord-014712-5u4e00q6	1004	4	phase	phase	NN
cord-014712-5u4e00q6	1004	5	with	with	IN
cord-014712-5u4e00q6	1004	6	complete	complete	JJ
cord-014712-5u4e00q6	1004	7	resolution	resolution	NN
cord-014712-5u4e00q6	1004	8	and	and	CC
cord-014712-5u4e00q6	1004	9	waiting	wait	VBG
cord-014712-5u4e00q6	1004	10	for	for	IN
cord-014712-5u4e00q6	1004	11	BMT	BMT	NNP
cord-014712-5u4e00q6	1004	12	CASE	CASE	NNP
cord-014712-5u4e00q6	1004	13	2	2	CD
cord-014712-5u4e00q6	1004	14	:	:	:
cord-014712-5u4e00q6	1004	15	M	M	NNP
cord-014712-5u4e00q6	1004	16	is	be	VBZ
cord-014712-5u4e00q6	1004	17	4	4	CD
cord-014712-5u4e00q6	1004	18	months	month	NNS
cord-014712-5u4e00q6	1004	19	old	old	JJ
cord-014712-5u4e00q6	1004	20	boy	boy	NN
cord-014712-5u4e00q6	1004	21	,	,	,
cord-014712-5u4e00q6	1004	22	2	2	CD
cord-014712-5u4e00q6	1004	23	nd	nd	NNP
cord-014712-5u4e00q6	1004	24	kid	kid	NN
cord-014712-5u4e00q6	1004	25	of	of	IN
cord-014712-5u4e00q6	1004	26	non	non	JJ
cord-014712-5u4e00q6	1004	27	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	1004	28	marriage	marriage	NN
cord-014712-5u4e00q6	1005	1	(	(	-LRB-
cord-014712-5u4e00q6	1005	2	the	the	DT
cord-014712-5u4e00q6	1005	3	1	1	CD
cord-014712-5u4e00q6	1005	4	st	st	NNP
cord-014712-5u4e00q6	1005	5	is	be	VBZ
cord-014712-5u4e00q6	1005	6	healthy	healthy	JJ
cord-014712-5u4e00q6	1005	7	3	3	CD
cord-014712-5u4e00q6	1005	8	years	year	NNS
cord-014712-5u4e00q6	1005	9	old	old	JJ
cord-014712-5u4e00q6	1005	10	female	female	NN
cord-014712-5u4e00q6	1005	11	)	)	-RRB-
cord-014712-5u4e00q6	1005	12	presented	present	VBN
cord-014712-5u4e00q6	1005	13	with	with	IN
cord-014712-5u4e00q6	1005	14	fever	fever	NN
cord-014712-5u4e00q6	1005	15	and	and	CC
cord-014712-5u4e00q6	1005	16	difficult	difficult	JJ
cord-014712-5u4e00q6	1005	17	breathing	breathing	NN
cord-014712-5u4e00q6	1005	18	since	since	IN
cord-014712-5u4e00q6	1005	19	the	the	DT
cord-014712-5u4e00q6	1005	20	age	age	NN
cord-014712-5u4e00q6	1005	21	of	of	IN
cord-014712-5u4e00q6	1005	22	2	2	CD
cord-014712-5u4e00q6	1005	23	months	month	NNS
cord-014712-5u4e00q6	1005	24	.	.	.
cord-014712-5u4e00q6	1006	1	The	the	DT
cord-014712-5u4e00q6	1006	2	fever	fever	NN
cord-014712-5u4e00q6	1006	3	was	be	VBD
cord-014712-5u4e00q6	1006	4	of	of	IN
cord-014712-5u4e00q6	1006	5	gradual	gradual	JJ
cord-014712-5u4e00q6	1006	6	onset	onset	NN
cord-014712-5u4e00q6	1006	7	stationary	stationary	JJ
cord-014712-5u4e00q6	1006	8	course	course	NN
cord-014712-5u4e00q6	1006	9	and	and	CC
cord-014712-5u4e00q6	1006	10	not	not	RB
cord-014712-5u4e00q6	1006	11	responding	respond	VBG
cord-014712-5u4e00q6	1006	12	to	to	IN
cord-014712-5u4e00q6	1006	13	treatment	treatment	NN
cord-014712-5u4e00q6	1006	14	with	with	IN
cord-014712-5u4e00q6	1006	15	antipyretics	antipyretic	NNS
cord-014712-5u4e00q6	1006	16	and	and	CC
cord-014712-5u4e00q6	1006	17	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	1006	18	.	.	.
cord-014712-5u4e00q6	1007	1	One	one	CD
cord-014712-5u4e00q6	1007	2	week	week	NN
cord-014712-5u4e00q6	1007	3	later	later	RB
cord-014712-5u4e00q6	1007	4	the	the	DT
cord-014712-5u4e00q6	1007	5	mother	mother	NN
cord-014712-5u4e00q6	1007	6	noticed	notice	VBD
cord-014712-5u4e00q6	1007	7	abdominal	abdominal	JJ
cord-014712-5u4e00q6	1007	8	enlargement	enlargement	NN
cord-014712-5u4e00q6	1007	9	with	with	IN
cord-014712-5u4e00q6	1007	10	red	red	JJ
cord-014712-5u4e00q6	1007	11	rash	rash	NN
cord-014712-5u4e00q6	1007	12	over	over	IN
cord-014712-5u4e00q6	1007	13	the	the	DT
cord-014712-5u4e00q6	1007	14	abdomen	abdomen	NN
cord-014712-5u4e00q6	1007	15	that	that	WDT
cord-014712-5u4e00q6	1007	16	was	be	VBD
cord-014712-5u4e00q6	1007	17	associated	associate	VBN
cord-014712-5u4e00q6	1007	18	with	with	IN
cord-014712-5u4e00q6	1007	19	pallor	pallor	NN
cord-014712-5u4e00q6	1007	20	but	but	CC
cord-014712-5u4e00q6	1008	1	there	there	EX
cord-014712-5u4e00q6	1008	2	was	be	VBD
cord-014712-5u4e00q6	1008	3	no	no	DT
cord-014712-5u4e00q6	1008	4	evidence	evidence	NN
cord-014712-5u4e00q6	1008	5	of	of	IN
cord-014712-5u4e00q6	1008	6	bleeding	bleed	VBG
cord-014712-5u4e00q6	1008	7	from	from	IN
cord-014712-5u4e00q6	1008	8	any	any	DT
cord-014712-5u4e00q6	1008	9	site	site	NN
cord-014712-5u4e00q6	1008	10	,	,	,
cord-014712-5u4e00q6	1008	11	no	no	DT
cord-014712-5u4e00q6	1008	12	change	change	NN
cord-014712-5u4e00q6	1008	13	in	in	IN
cord-014712-5u4e00q6	1008	14	the	the	DT
cord-014712-5u4e00q6	1008	15	color	color	NN
cord-014712-5u4e00q6	1008	16	of	of	IN
cord-014712-5u4e00q6	1008	17	urine	urine	NN
cord-014712-5u4e00q6	1008	18	,	,	,
cord-014712-5u4e00q6	1008	19	no	no	DT
cord-014712-5u4e00q6	1008	20	jaundice	jaundice	NN
cord-014712-5u4e00q6	1008	21	,	,	,
cord-014712-5u4e00q6	1008	22	no	no	DT
cord-014712-5u4e00q6	1008	23	ecchymosis	ecchymosis	NN
cord-014712-5u4e00q6	1008	24	,	,	,
cord-014712-5u4e00q6	1008	25	no	no	DT
cord-014712-5u4e00q6	1008	26	joint	joint	JJ
cord-014712-5u4e00q6	1008	27	swelling	swelling	NN
cord-014712-5u4e00q6	1008	28	then	then	RB
cord-014712-5u4e00q6	1008	29	he	-PRON-	PRP
cord-014712-5u4e00q6	1008	30	is	be	VBZ
cord-014712-5u4e00q6	1008	31	referred	refer	VBN
cord-014712-5u4e00q6	1008	32	to	to	IN
cord-014712-5u4e00q6	1008	33	our	-PRON-	PRP$
cord-014712-5u4e00q6	1008	34	hospital	hospital	NN
cord-014712-5u4e00q6	1008	35	(	(	-LRB-
cord-014712-5u4e00q6	1008	36	Zagazig	Zagazig	NNP
cord-014712-5u4e00q6	1008	37	University	University	NNP
cord-014712-5u4e00q6	1008	38	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1008	39	)	)	-RRB-
cord-014712-5u4e00q6	1008	40	.	.	.
cord-014712-5u4e00q6	1009	1	This	this	DT
cord-014712-5u4e00q6	1009	2	boy	boy	NN
cord-014712-5u4e00q6	1009	3	is	be	VBZ
cord-014712-5u4e00q6	1009	4	delivered	deliver	VBN
cord-014712-5u4e00q6	1009	5	by	by	IN
cord-014712-5u4e00q6	1009	6	NVD	NVD	NNP
cord-014712-5u4e00q6	1009	7	at	at	IN
cord-014712-5u4e00q6	1009	8	term	term	NN
cord-014712-5u4e00q6	1009	9	with	with	IN
cord-014712-5u4e00q6	1009	10	no	no	DT
cord-014712-5u4e00q6	1009	11	evidence	evidence	NN
cord-014712-5u4e00q6	1009	12	of	of	IN
cord-014712-5u4e00q6	1009	13	any	any	DT
cord-014712-5u4e00q6	1009	14	problem	problem	NN
cord-014712-5u4e00q6	1009	15	either	either	CC
cord-014712-5u4e00q6	1009	16	during	during	IN
cord-014712-5u4e00q6	1009	17	pregnancy	pregnancy	NN
cord-014712-5u4e00q6	1009	18	or	or	CC
cord-014712-5u4e00q6	1009	19	delivery	delivery	NN
cord-014712-5u4e00q6	1009	20	,	,	,
cord-014712-5u4e00q6	1009	21	he	-PRON-	PRP
cord-014712-5u4e00q6	1009	22	is	be	VBZ
cord-014712-5u4e00q6	1009	23	exclusively	exclusively	RB
cord-014712-5u4e00q6	1009	24	breast	breast	NN
cord-014712-5u4e00q6	1009	25	fed	feed	VBN
cord-014712-5u4e00q6	1009	26	and	and	CC
cord-014712-5u4e00q6	1009	27	vaccinated	vaccinate	VBD
cord-014712-5u4e00q6	1009	28	as	as	IN
cord-014712-5u4e00q6	1009	29	scheduled	schedule	VBN
cord-014712-5u4e00q6	1009	30	.	.	.
cord-014712-5u4e00q6	1010	1	Examination	examination	NN
cord-014712-5u4e00q6	1010	2	:	:	:
cord-014712-5u4e00q6	1010	3	his	-PRON-	PRP$
cord-014712-5u4e00q6	1010	4	weight	weight	NN
cord-014712-5u4e00q6	1010	5	was	be	VBD
cord-014712-5u4e00q6	1010	6	6	6	CD
cord-014712-5u4e00q6	1010	7	kg	kg	NNS
cord-014712-5u4e00q6	1010	8	,	,	,
cord-014712-5u4e00q6	1010	9	length	length	NN
cord-014712-5u4e00q6	1010	10	53	53	CD
cord-014712-5u4e00q6	1010	11	cm	cm	NNS
cord-014712-5u4e00q6	1010	12	,	,	,
cord-014712-5u4e00q6	1010	13	and	and	CC
cord-014712-5u4e00q6	1010	14	head	head	VB
cord-014712-5u4e00q6	1010	15	circumference	circumference	NN
cord-014712-5u4e00q6	1010	16	35	35	CD
cord-014712-5u4e00q6	1010	17	cm	cm	NNS
cord-014712-5u4e00q6	1010	18	all	all	DT
cord-014712-5u4e00q6	1010	19	are	be	VBP
cord-014712-5u4e00q6	1010	20	average	average	JJ
cord-014712-5u4e00q6	1010	21	for	for	IN
cord-014712-5u4e00q6	1010	22	age	age	NN
cord-014712-5u4e00q6	1010	23	,	,	,
cord-014712-5u4e00q6	1010	24	he	-PRON-	PRP
cord-014712-5u4e00q6	1010	25	was	be	VBD
cord-014712-5u4e00q6	1010	26	pale	pale	JJ
cord-014712-5u4e00q6	1010	27	with	with	IN
cord-014712-5u4e00q6	1010	28	no	no	DT
cord-014712-5u4e00q6	1010	29	jaundice	jaundice	NN
cord-014712-5u4e00q6	1010	30	or	or	CC
cord-014712-5u4e00q6	1010	31	cyanosis	cyanosis	NN
cord-014712-5u4e00q6	1011	1	he	-PRON-	PRP
cord-014712-5u4e00q6	1011	2	had	have	VBD
cord-014712-5u4e00q6	1011	3	HSM	HSM	NNP
cord-014712-5u4e00q6	1011	4	and	and	CC
cord-014712-5u4e00q6	1011	5	other	other	JJ
cord-014712-5u4e00q6	1011	6	systemic	systemic	JJ
cord-014712-5u4e00q6	1011	7	examination	examination	NN
cord-014712-5u4e00q6	1011	8	was	be	VBD
cord-014712-5u4e00q6	1011	9	quite	quite	RB
cord-014712-5u4e00q6	1011	10	well	well	RB
cord-014712-5u4e00q6	1011	11	.	.	.
cord-014712-5u4e00q6	1012	1	Children	child	NNS
cord-014712-5u4e00q6	1012	2	with	with	IN
cord-014712-5u4e00q6	1012	3	PID	PID	NNP
cord-014712-5u4e00q6	1012	4	usually	usually	RB
cord-014712-5u4e00q6	1012	5	are	be	VBP
cord-014712-5u4e00q6	1012	6	admitting	admit	VBG
cord-014712-5u4e00q6	1012	7	to	to	IN
cord-014712-5u4e00q6	1012	8	the	the	DT
cord-014712-5u4e00q6	1012	9	hospitals	hospital	NNS
cord-014712-5u4e00q6	1012	10	and	and	CC
cord-014712-5u4e00q6	1012	11	intensive	intensive	JJ
cord-014712-5u4e00q6	1012	12	care	care	NN
cord-014712-5u4e00q6	1012	13	units	unit	NNS
cord-014712-5u4e00q6	1012	14	of	of	IN
cord-014712-5u4e00q6	1012	15	infants	infant	NNS
cord-014712-5u4e00q6	1012	16	'	'	POS
cord-014712-5u4e00q6	1012	17	pathology	pathology	NN
cord-014712-5u4e00q6	1012	18	Regional	Regional	NNP
cord-014712-5u4e00q6	1012	19	Children	Children	NNP
cord-014712-5u4e00q6	1012	20	Clinical	Clinical	NNP
cord-014712-5u4e00q6	1012	21	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1012	22	№	№	NNP
cord-014712-5u4e00q6	1012	23	1	1	CD
cord-014712-5u4e00q6	1012	24	,	,	,
cord-014712-5u4e00q6	1012	25	but	but	CC
cord-014712-5u4e00q6	1012	26	at	at	IN
cord-014712-5u4e00q6	1012	27	a	a	DT
cord-014712-5u4e00q6	1012	28	later	later	JJ
cord-014712-5u4e00q6	1012	29	date	date	NN
cord-014712-5u4e00q6	1012	30	,	,	,
cord-014712-5u4e00q6	1012	31	in	in	IN
cord-014712-5u4e00q6	1012	32	serious	serious	JJ
cord-014712-5u4e00q6	1012	33	condition	condition	NN
cord-014712-5u4e00q6	1012	34	,	,	,
cord-014712-5u4e00q6	1012	35	after	after	IN
cord-014712-5u4e00q6	1012	36	the	the	DT
cord-014712-5u4e00q6	1012	37	development	development	NN
cord-014712-5u4e00q6	1012	38	of	of	IN
cord-014712-5u4e00q6	1012	39	clinical	clinical	JJ
cord-014712-5u4e00q6	1012	40	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1012	41	in	in	IN
cord-014712-5u4e00q6	1012	42	the	the	DT
cord-014712-5u4e00q6	1012	43	form	form	NN
cord-014712-5u4e00q6	1012	44	of	of	IN
cord-014712-5u4e00q6	1012	45	severe	severe	JJ
cord-014712-5u4e00q6	1012	46	generalized	generalized	JJ
cord-014712-5u4e00q6	1012	47	infectious	infectious	JJ
cord-014712-5u4e00q6	1012	48	disease	disease	NN
cord-014712-5u4e00q6	1012	49	,	,	,
cord-014712-5u4e00q6	1012	50	or	or	CC
cord-014712-5u4e00q6	1012	51	various	various	JJ
cord-014712-5u4e00q6	1012	52	complications	complication	NNS
cord-014712-5u4e00q6	1012	53	including	include	VBG
cord-014712-5u4e00q6	1012	54	hematological	hematological	JJ
cord-014712-5u4e00q6	1012	55	.	.	.
cord-014712-5u4e00q6	1013	1	The	the	DT
cord-014712-5u4e00q6	1013	2	screening	screening	NN
cord-014712-5u4e00q6	1013	3	technology	technology	NN
cord-014712-5u4e00q6	1013	4	approves	approve	VBZ
cord-014712-5u4e00q6	1013	5	children	child	NNS
cord-014712-5u4e00q6	1013	6	to	to	TO
cord-014712-5u4e00q6	1013	7	be	be	VB
cord-014712-5u4e00q6	1013	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1013	9	in	in	IN
cord-014712-5u4e00q6	1013	10	newborn	newborn	JJ
cord-014712-5u4e00q6	1013	11	period	period	NN
cord-014712-5u4e00q6	1013	12	and	and	CC
cord-014712-5u4e00q6	1013	13	to	to	TO
cord-014712-5u4e00q6	1013	14	be	be	VB
cord-014712-5u4e00q6	1013	15	observing	observe	VBG
cord-014712-5u4e00q6	1013	16	by	by	IN
cord-014712-5u4e00q6	1013	17	immunologist	immunologist	NN
cord-014712-5u4e00q6	1013	18	and	and	CC
cord-014712-5u4e00q6	1013	19	hematologist	hematologist	NN
cord-014712-5u4e00q6	1013	20	for	for	IN
cord-014712-5u4e00q6	1013	21	the	the	DT
cord-014712-5u4e00q6	1013	22	next	next	JJ
cord-014712-5u4e00q6	1013	23	preventative	preventative	JJ
cord-014712-5u4e00q6	1013	24	therapy	therapy	NN
cord-014712-5u4e00q6	1013	25	and	and	CC
cord-014712-5u4e00q6	1013	26	bone	bone	NN
cord-014712-5u4e00q6	1013	27	marrow	marrow	NN
cord-014712-5u4e00q6	1013	28	transplantation	transplantation	NN
cord-014712-5u4e00q6	1013	29	or	or	CC
cord-014712-5u4e00q6	1013	30	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	1013	31	stem	stem	NN
cord-014712-5u4e00q6	1013	32	cell	cell	NN
cord-014712-5u4e00q6	1013	33	transplantation	transplantation	NN
cord-014712-5u4e00q6	1013	34	.	.	.
cord-014712-5u4e00q6	1014	1	Costs	cost	NNS
cord-014712-5u4e00q6	1014	2	for	for	IN
cord-014712-5u4e00q6	1014	3	the	the	DT
cord-014712-5u4e00q6	1014	4	differential	differential	JJ
cord-014712-5u4e00q6	1014	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1014	6	and	and	CC
cord-014712-5u4e00q6	1014	7	verification	verification	NN
cord-014712-5u4e00q6	1014	8	of	of	IN
cord-014712-5u4e00q6	1014	9	the	the	DT
cord-014712-5u4e00q6	1014	10	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1014	11	before	before	IN
cord-014712-5u4e00q6	1014	12	the	the	DT
cord-014712-5u4e00q6	1014	13	manifestation	manifestation	NN
cord-014712-5u4e00q6	1014	14	and	and	CC
cord-014712-5u4e00q6	1014	15	complications	complication	NNS
cord-014712-5u4e00q6	1014	16	development	development	NN
cord-014712-5u4e00q6	1014	17	of	of	IN
cord-014712-5u4e00q6	1014	18	PID	PID	NNP
cord-014712-5u4e00q6	1015	1	-51	-51	NN
cord-014712-5u4e00q6	1015	2	245	245	CD
cord-014712-5u4e00q6	1015	3	USD	usd	NN
cord-014712-5u4e00q6	1015	4	.	.	.
cord-014712-5u4e00q6	1016	1	Costs	cost	NNS
cord-014712-5u4e00q6	1016	2	for	for	IN
cord-014712-5u4e00q6	1016	3	the	the	DT
cord-014712-5u4e00q6	1016	4	differential	differential	JJ
cord-014712-5u4e00q6	1016	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1016	6	and	and	CC
cord-014712-5u4e00q6	1016	7	verification	verification	NN
cord-014712-5u4e00q6	1016	8	of	of	IN
cord-014712-5u4e00q6	1016	9	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1016	10	after	after	IN
cord-014712-5u4e00q6	1016	11	manifestation	manifestation	NN
cord-014712-5u4e00q6	1016	12	and	and	CC
cord-014712-5u4e00q6	1016	13	complications	complication	NNS
cord-014712-5u4e00q6	1016	14	development	development	NN
cord-014712-5u4e00q6	1016	15	of	of	IN
cord-014712-5u4e00q6	1016	16	PID	PID	NNP
cord-014712-5u4e00q6	1016	17	would	would	MD
cord-014712-5u4e00q6	1016	18	be	be	VB
cord-014712-5u4e00q6	1016	19	115	115	CD
cord-014712-5u4e00q6	1016	20	208	208	CD
cord-014712-5u4e00q6	1016	21	USD	usd	NN
cord-014712-5u4e00q6	1016	22	in	in	IN
cord-014712-5u4e00q6	1016	23	2	2	CD
cord-014712-5u4e00q6	1016	24	months	month	NNS
cord-014712-5u4e00q6	1016	25	.	.	.
cord-014712-5u4e00q6	1017	1	Economic	economic	JJ
cord-014712-5u4e00q6	1017	2	loss	loss	NN
cord-014712-5u4e00q6	1017	3	prevention	prevention	NN
cord-014712-5u4e00q6	1017	4	in	in	IN
cord-014712-5u4e00q6	1017	5	PID	PID	NNP
cord-014712-5u4e00q6	1017	6	-63	-63	NNP
cord-014712-5u4e00q6	1017	7	872	872	CD
cord-014712-5u4e00q6	1017	8	USD	usd	NN
cord-014712-5u4e00q6	1017	9	.	.	.
cord-014712-5u4e00q6	1018	1	Economic	economic	JJ
cord-014712-5u4e00q6	1018	2	loss	loss	NN
cord-014712-5u4e00q6	1018	3	prevention	prevention	NN
cord-014712-5u4e00q6	1018	4	in	in	IN
cord-014712-5u4e00q6	1018	5	T	T	NNP
cord-014712-5u4e00q6	1018	6	-lymphopenia	-lymphopenia	NN
cord-014712-5u4e00q6	1018	7	-105	-105	NN
cord-014712-5u4e00q6	1018	8	884	884	CD
cord-014712-5u4e00q6	1018	9	USD	usd	NN
cord-014712-5u4e00q6	1018	10	.	.	.
cord-014712-5u4e00q6	1019	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1019	2	also	also	RB
cord-014712-5u4e00q6	1019	3	should	should	MD
cord-014712-5u4e00q6	1019	4	include	include	VB
cord-014712-5u4e00q6	1019	5	into	into	IN
cord-014712-5u4e00q6	1019	6	account	account	NN
cord-014712-5u4e00q6	1019	7	the	the	DT
cord-014712-5u4e00q6	1019	8	contribution	contribution	NN
cord-014712-5u4e00q6	1019	9	to	to	IN
cord-014712-5u4e00q6	1019	10	the	the	DT
cord-014712-5u4e00q6	1019	11	state	state	NN
cord-014712-5u4e00q6	1019	12	's	's	POS
cord-014712-5u4e00q6	1019	13	economy	economy	NN
cord-014712-5u4e00q6	1019	14	,	,	,
cord-014712-5u4e00q6	1019	15	which	which	WDT
cord-014712-5u4e00q6	1019	16	will	will	MD
cord-014712-5u4e00q6	1019	17	later	later	RB
cord-014712-5u4e00q6	1019	18	be	be	VB
cord-014712-5u4e00q6	1019	19	obtained	obtain	VBN
cord-014712-5u4e00q6	1019	20	,	,	,
cord-014712-5u4e00q6	1019	21	due	due	IN
cord-014712-5u4e00q6	1019	22	to	to	IN
cord-014712-5u4e00q6	1019	23	the	the	DT
cord-014712-5u4e00q6	1019	24	presence	presence	NN
cord-014712-5u4e00q6	1019	25	of	of	IN
cord-014712-5u4e00q6	1019	26	a	a	DT
cord-014712-5u4e00q6	1019	27	healthy	healthy	JJ
cord-014712-5u4e00q6	1019	28	member	member	NN
cord-014712-5u4e00q6	1019	29	of	of	IN
cord-014712-5u4e00q6	1019	30	society	society	NN
cord-014712-5u4e00q6	1019	31	.	.	.
cord-014712-5u4e00q6	1020	1	AT	at	IN
cord-014712-5u4e00q6	1020	2	is	be	VBZ
cord-014712-5u4e00q6	1020	3	an	an	DT
cord-014712-5u4e00q6	1020	4	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1020	5	recessive	recessive	JJ
cord-014712-5u4e00q6	1020	6	multisystem	multisystem	JJ
cord-014712-5u4e00q6	1020	7	disorder	disorder	NN
cord-014712-5u4e00q6	1020	8	characterized	characterize	VBN
cord-014712-5u4e00q6	1020	9	by	by	IN
cord-014712-5u4e00q6	1020	10	progressive	progressive	JJ
cord-014712-5u4e00q6	1020	11	cerebellar	cerebellar	JJ
cord-014712-5u4e00q6	1020	12	ataxia	ataxia	NN
cord-014712-5u4e00q6	1020	13	,	,	,
cord-014712-5u4e00q6	1020	14	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1020	15	and	and	CC
cord-014712-5u4e00q6	1020	16	increased	increase	VBN
cord-014712-5u4e00q6	1020	17	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	1020	18	to	to	IN
cord-014712-5u4e00q6	1020	19	infections	infection	NNS
cord-014712-5u4e00q6	1020	20	and	and	CC
cord-014712-5u4e00q6	1020	21	malignancies	malignancy	NNS
cord-014712-5u4e00q6	1020	22	,	,	,
cord-014712-5u4e00q6	1020	23	particularly	particularly	RB
cord-014712-5u4e00q6	1020	24	lymphomas	lymphoma	NNS
cord-014712-5u4e00q6	1020	25	and	and	CC
cord-014712-5u4e00q6	1020	26	leukemia	leukemia	NN
cord-014712-5u4e00q6	1020	27	.	.	.
cord-014712-5u4e00q6	1021	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1021	2	immune	immune	JJ
cord-014712-5u4e00q6	1021	3	investigations	investigation	NNS
cord-014712-5u4e00q6	1021	4	typically	typically	RB
cord-014712-5u4e00q6	1021	5	show	show	VBP
cord-014712-5u4e00q6	1021	6	decreased	decrease	VBD
cord-014712-5u4e00q6	1021	7	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1021	8	Tcells	Tcells	NNP
cord-014712-5u4e00q6	1021	9	,	,	,
cord-014712-5u4e00q6	1021	10	particularly	particularly	RB
cord-014712-5u4e00q6	1021	11	of	of	IN
cord-014712-5u4e00q6	1021	12	naïve	naïve	JJ
cord-014712-5u4e00q6	1021	13	T	t	NN
cord-014712-5u4e00q6	1021	14	cells	cell	NNS
cord-014712-5u4e00q6	1021	15	,	,	,
cord-014712-5u4e00q6	1021	16	with	with	IN
cord-014712-5u4e00q6	1021	17	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1021	18	in	in	IN
cord-014712-5u4e00q6	1021	19	vitro	vitro	FW
cord-014712-5u4e00q6	1021	20	response	response	NN
cord-014712-5u4e00q6	1021	21	to	to	IN
cord-014712-5u4e00q6	1021	22	mitogens	mitogens	NNP
cord-014712-5u4e00q6	1021	23	.	.	.
cord-014712-5u4e00q6	1022	1	Most	Most	JJS
cord-014712-5u4e00q6	1022	2	AT	at	IN
cord-014712-5u4e00q6	1022	3	patients	patient	NNS
cord-014712-5u4e00q6	1022	4	have	have	VBP
cord-014712-5u4e00q6	1022	5	decreased	decrease	VBN
cord-014712-5u4e00q6	1022	6	serum	serum	NN
cord-014712-5u4e00q6	1022	7	IgA	IgA	NNP
cord-014712-5u4e00q6	1022	8	and	and	CC
cord-014712-5u4e00q6	1022	9	IgG	IgG	NNP
cord-014712-5u4e00q6	1022	10	subclass	subclass	NN
cord-014712-5u4e00q6	1022	11	concentrations	concentration	NNS
cord-014712-5u4e00q6	1022	12	.	.	.
cord-014712-5u4e00q6	1023	1	While	while	IN
cord-014712-5u4e00q6	1023	2	about	about	RB
cord-014712-5u4e00q6	1023	3	10	10	CD
cord-014712-5u4e00q6	1023	4	%	%	NN
cord-014712-5u4e00q6	1023	5	of	of	IN
cord-014712-5u4e00q6	1023	6	patients	patient	NNS
cord-014712-5u4e00q6	1023	7	with	with	IN
cord-014712-5u4e00q6	1023	8	AT	AT	NNP
cord-014712-5u4e00q6	1023	9	show	show	NN
cord-014712-5u4e00q6	1023	10	raised	raise	VBD
cord-014712-5u4e00q6	1023	11	serum	serum	NN
cord-014712-5u4e00q6	1023	12	IgM	IgM	NNP
cord-014712-5u4e00q6	1023	13	concentrations	concentration	NNS
cord-014712-5u4e00q6	1023	14	during	during	IN
cord-014712-5u4e00q6	1023	15	the	the	DT
cord-014712-5u4e00q6	1023	16	course	course	NN
cord-014712-5u4e00q6	1023	17	of	of	IN
cord-014712-5u4e00q6	1023	18	the	the	DT
cord-014712-5u4e00q6	1023	19	disease	disease	NN
cord-014712-5u4e00q6	1023	20	,	,	,
cord-014712-5u4e00q6	1023	21	it	-PRON-	PRP
cord-014712-5u4e00q6	1023	22	is	be	VBZ
cord-014712-5u4e00q6	1023	23	unusual	unusual	JJ
cord-014712-5u4e00q6	1023	24	to	to	TO
cord-014712-5u4e00q6	1023	25	find	find	VB
cord-014712-5u4e00q6	1023	26	a	a	DT
cord-014712-5u4e00q6	1023	27	high	high	JJ
cord-014712-5u4e00q6	1023	28	level	level	NN
cord-014712-5u4e00q6	1023	29	of	of	IN
cord-014712-5u4e00q6	1023	30	IgM	IgM	NNP
cord-014712-5u4e00q6	1023	31	at	at	IN
cord-014712-5u4e00q6	1023	32	onset	onset	NN
cord-014712-5u4e00q6	1023	33	.	.	.
cord-014712-5u4e00q6	1024	1	As	as	IN
cord-014712-5u4e00q6	1024	2	cerebellar	cerebellar	JJ
cord-014712-5u4e00q6	1024	3	ataxia	ataxia	NN
cord-014712-5u4e00q6	1024	4	and	and	CC
cord-014712-5u4e00q6	1024	5	oculocutaneous	oculocutaneous	JJ
cord-014712-5u4e00q6	1024	6	telangiectasia	telangiectasia	NNP
cord-014712-5u4e00q6	1024	7	are	be	VBP
cord-014712-5u4e00q6	1024	8	not	not	RB
cord-014712-5u4e00q6	1024	9	present	present	JJ
cord-014712-5u4e00q6	1024	10	at	at	IN
cord-014712-5u4e00q6	1024	11	very	very	RB
cord-014712-5u4e00q6	1024	12	young	young	JJ
cord-014712-5u4e00q6	1024	13	age	age	NN
cord-014712-5u4e00q6	1024	14	,	,	,
cord-014712-5u4e00q6	1024	15	these	these	DT
cord-014712-5u4e00q6	1024	16	patients	patient	NNS
cord-014712-5u4e00q6	1024	17	are	be	VBP
cord-014712-5u4e00q6	1024	18	often	often	RB
cord-014712-5u4e00q6	1024	19	erroneously	erroneously	RB
cord-014712-5u4e00q6	1024	20	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1024	21	as	as	IN
cord-014712-5u4e00q6	1024	22	hyper	hyper	JJ
cord-014712-5u4e00q6	1024	23	IgM	IgM	NNP
cord-014712-5u4e00q6	1024	24	syndrome	syndrome	NN
cord-014712-5u4e00q6	1024	25	(	(	-LRB-
cord-014712-5u4e00q6	1024	26	HIGM	HIGM	NNP
cord-014712-5u4e00q6	1024	27	)	)	-RRB-
cord-014712-5u4e00q6	1024	28	.	.	.
cord-014712-5u4e00q6	1025	1	To	to	TO
cord-014712-5u4e00q6	1025	2	prevent	prevent	VB
cord-014712-5u4e00q6	1025	3	mistaking	mistake	VBG
cord-014712-5u4e00q6	1025	4	A	a	DT
cord-014712-5u4e00q6	1025	5	-	-	HYPH
cord-014712-5u4e00q6	1025	6	T	t	NN
cord-014712-5u4e00q6	1025	7	patients	patient	NNS
cord-014712-5u4e00q6	1025	8	for	for	IN
cord-014712-5u4e00q6	1025	9	HIGM	HIGM	NNP
cord-014712-5u4e00q6	1026	1	it	-PRON-	PRP
cord-014712-5u4e00q6	1026	2	is	be	VBZ
cord-014712-5u4e00q6	1026	3	proposed	propose	VBN
cord-014712-5u4e00q6	1026	4	to	to	TO
cord-014712-5u4e00q6	1026	5	add	add	VB
cord-014712-5u4e00q6	1026	6	DNA	dna	NN
cord-014712-5u4e00q6	1026	7	repair	repair	NN
cord-014712-5u4e00q6	1026	8	disorders	disorder	NNS
cord-014712-5u4e00q6	1026	9	as	as	IN
cord-014712-5u4e00q6	1026	10	a	a	DT
cord-014712-5u4e00q6	1026	11	possible	possible	JJ
cord-014712-5u4e00q6	1026	12	cause	cause	NN
cord-014712-5u4e00q6	1026	13	of	of	IN
cord-014712-5u4e00q6	1026	14	HIGM	HIGM	NNP
cord-014712-5u4e00q6	1026	15	.	.	.
cord-014712-5u4e00q6	1026	16	.	.	.
cord-014712-5u4e00q6	1027	1	Diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1027	2	of	of	IN
cord-014712-5u4e00q6	1027	3	AT	AT	NNP
cord-014712-5u4e00q6	1027	4	,	,	,
cord-014712-5u4e00q6	1027	5	suggested	suggest	VBN
cord-014712-5u4e00q6	1027	6	by	by	IN
cord-014712-5u4e00q6	1027	7	elevated	elevate	VBN
cord-014712-5u4e00q6	1027	8	alfa	alfa	NNP
cord-014712-5u4e00q6	1027	9	-	-	HYPH
cord-014712-5u4e00q6	1027	10	feto	feto	NNP
cord-014712-5u4e00q6	1027	11	-	-	HYPH
cord-014712-5u4e00q6	1027	12	protein	protein	NN
cord-014712-5u4e00q6	1027	13	and	and	CC
cord-014712-5u4e00q6	1027	14	increased	increased	JJ
cord-014712-5u4e00q6	1027	15	sensitivity	sensitivity	NN
cord-014712-5u4e00q6	1027	16	of	of	IN
cord-014712-5u4e00q6	1027	17	patients	patient	NNS
cord-014712-5u4e00q6	1027	18	'	'	POS
cord-014712-5u4e00q6	1027	19	cells	cell	NNS
cord-014712-5u4e00q6	1027	20	to	to	IN
cord-014712-5u4e00q6	1027	21	irradiation	irradiation	NN
cord-014712-5u4e00q6	1027	22	,	,	,
cord-014712-5u4e00q6	1027	23	can	can	MD
cord-014712-5u4e00q6	1027	24	be	be	VB
cord-014712-5u4e00q6	1027	25	confirmed	confirm	VBN
cord-014712-5u4e00q6	1027	26	by	by	IN
cord-014712-5u4e00q6	1027	27	identifying	identify	VBG
cord-014712-5u4e00q6	1027	28	a	a	DT
cord-014712-5u4e00q6	1027	29	mutation	mutation	NN
cord-014712-5u4e00q6	1027	30	in	in	IN
cord-014712-5u4e00q6	1027	31	the	the	DT
cord-014712-5u4e00q6	1027	32	ATM	atm	NN
cord-014712-5u4e00q6	1027	33	gene	gene	NN
cord-014712-5u4e00q6	1027	34	.	.	.
cord-014712-5u4e00q6	1028	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1028	2	report	report	VBP
cord-014712-5u4e00q6	1028	3	3	3	CD
cord-014712-5u4e00q6	1028	4	female	female	JJ
cord-014712-5u4e00q6	1028	5	case	case	NN
cord-014712-5u4e00q6	1028	6	of	of	IN
cord-014712-5u4e00q6	1028	7	AT	at	IN
cord-014712-5u4e00q6	1028	8	that	that	DT
cord-014712-5u4e00q6	1028	9	with	with	IN
cord-014712-5u4e00q6	1028	10	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1028	11	of	of	IN
cord-014712-5u4e00q6	1028	12	hyper	hyper	JJ
cord-014712-5u4e00q6	1028	13	IGM	IGM	NNP
cord-014712-5u4e00q6	1028	14	received	receive	VBD
cord-014712-5u4e00q6	1028	15	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1028	16	but	but	CC
cord-014712-5u4e00q6	1028	17	later	later	RBR
cord-014712-5u4e00q6	1028	18	they	-PRON-	PRP
cord-014712-5u4e00q6	1028	19	had	have	VBD
cord-014712-5u4e00q6	1028	20	manifestation	manifestation	NN
cord-014712-5u4e00q6	1028	21	of	of	IN
cord-014712-5u4e00q6	1028	22	ataxia	ataxia	NN
cord-014712-5u4e00q6	1028	23	in	in	IN
cord-014712-5u4e00q6	1028	24	the	the	DT
cord-014712-5u4e00q6	1028	25	course	course	NN
cord-014712-5u4e00q6	1028	26	of	of	IN
cord-014712-5u4e00q6	1028	27	their	-PRON-	PRP$
cord-014712-5u4e00q6	1028	28	disease	disease	NN
cord-014712-5u4e00q6	1028	29	and	and	CC
cord-014712-5u4e00q6	1028	30	then	then	RB
cord-014712-5u4e00q6	1028	31	had	have	VBD
cord-014712-5u4e00q6	1028	32	telangiectasia	telangiectasia	NNS
cord-014712-5u4e00q6	1028	33	of	of	IN
cord-014712-5u4e00q6	1028	34	conjunctiva	conjunctiva	NN
cord-014712-5u4e00q6	1028	35	.	.	.
cord-014712-5u4e00q6	1029	1	First	first	JJ
cord-014712-5u4e00q6	1029	2	case	case	NN
cord-014712-5u4e00q6	1029	3	was	be	VBD
cord-014712-5u4e00q6	1029	4	a	a	DT
cord-014712-5u4e00q6	1029	5	3	3	CD
cord-014712-5u4e00q6	1029	6	yrs	yrs	NN
cord-014712-5u4e00q6	1029	7	girl	girl	NN
cord-014712-5u4e00q6	1029	8	that	that	WDT
cord-014712-5u4e00q6	1029	9	was	be	VBD
cord-014712-5u4e00q6	1029	10	suffered	suffer	VBN
cord-014712-5u4e00q6	1029	11	from	from	IN
cord-014712-5u4e00q6	1029	12	ITP	ITP	NNP
cord-014712-5u4e00q6	1029	13	and	and	CC
cord-014712-5u4e00q6	1029	14	granulomatosis	granulomatosis	NNP
cord-014712-5u4e00q6	1029	15	lesion	lesion	NN
cord-014712-5u4e00q6	1029	16	of	of	IN
cord-014712-5u4e00q6	1029	17	skin	skin	NN
cord-014712-5u4e00q6	1029	18	associated	associate	VBN
cord-014712-5u4e00q6	1029	19	with	with	IN
cord-014712-5u4e00q6	1029	20	Hyper	hyper	JJ
cord-014712-5u4e00q6	1029	21	IgM	igm	NN
cord-014712-5u4e00q6	1029	22	before	before	IN
cord-014712-5u4e00q6	1029	23	AT	at	IN
cord-014712-5u4e00q6	1029	24	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1029	25	.	.	.
cord-014712-5u4e00q6	1030	1	Second	second	JJ
cord-014712-5u4e00q6	1030	2	case	case	NN
cord-014712-5u4e00q6	1030	3	was	be	VBD
cord-014712-5u4e00q6	1030	4	a	a	DT
cord-014712-5u4e00q6	1030	5	6	6	CD
cord-014712-5u4e00q6	1030	6	years	year	NNS
cord-014712-5u4e00q6	1030	7	old	old	JJ
cord-014712-5u4e00q6	1030	8	girl	girl	NN
cord-014712-5u4e00q6	1030	9	with	with	IN
cord-014712-5u4e00q6	1030	10	microcephaly	microcephaly	NNS
cord-014712-5u4e00q6	1030	11	,	,	,
cord-014712-5u4e00q6	1030	12	sever	sever	VB
cord-014712-5u4e00q6	1030	13	FTT	FTT	NNP
cord-014712-5u4e00q6	1030	14	,	,	,
cord-014712-5u4e00q6	1030	15	neurodevelopmental	neurodevelopmental	JJ
cord-014712-5u4e00q6	1030	16	delay	delay	NN
cord-014712-5u4e00q6	1030	17	,	,	,
cord-014712-5u4e00q6	1030	18	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1030	19	faces	face	NNS
cord-014712-5u4e00q6	1030	20	and	and	CC
cord-014712-5u4e00q6	1030	21	hypo	hypo	NN
cord-014712-5u4e00q6	1030	22	and	and	CC
cord-014712-5u4e00q6	1030	23	hyperpigmentation	hyperpigmentation	NN
cord-014712-5u4e00q6	1030	24	lesions	lesion	NNS
cord-014712-5u4e00q6	1030	25	and	and	CC
cord-014712-5u4e00q6	1030	26	anemia	anemia	NN
cord-014712-5u4e00q6	1030	27	.	.	.
cord-014712-5u4e00q6	1031	1	With	with	IN
cord-014712-5u4e00q6	1031	2	respect	respect	NN
cord-014712-5u4e00q6	1031	3	to	to	IN
cord-014712-5u4e00q6	1031	4	these	these	DT
cord-014712-5u4e00q6	1031	5	manifestation	manifestation	NN
cord-014712-5u4e00q6	1031	6	and	and	CC
cord-014712-5u4e00q6	1031	7	increased	increase	VBN
cord-014712-5u4e00q6	1031	8	AFP	AFP	NNP
cord-014712-5u4e00q6	1031	9	,	,	,
cord-014712-5u4e00q6	1031	10	Nijmegan	Nijmegan	NNP
cord-014712-5u4e00q6	1031	11	breakage	breakage	NN
cord-014712-5u4e00q6	1031	12	syndrome	syndrome	NN
cord-014712-5u4e00q6	1031	13	was	be	VBD
cord-014712-5u4e00q6	1031	14	suggested	suggest	VBN
cord-014712-5u4e00q6	1031	15	.	.	.
cord-014712-5u4e00q6	1032	1	Third	third	JJ
cord-014712-5u4e00q6	1032	2	case	case	NN
cord-014712-5u4e00q6	1032	3	was	be	VBD
cord-014712-5u4e00q6	1032	4	suffered	suffer	VBN
cord-014712-5u4e00q6	1032	5	from	from	IN
cord-014712-5u4e00q6	1032	6	HyperIgM	HyperIgM	NNP
cord-014712-5u4e00q6	1032	7	before	before	IN
cord-014712-5u4e00q6	1032	8	A	a	DT
cord-014712-5u4e00q6	1032	9	T	t	NN
cord-014712-5u4e00q6	1032	10	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1032	11	for	for	IN
cord-014712-5u4e00q6	1032	12	2	2	CD
cord-014712-5u4e00q6	1032	13	years	year	NNS
cord-014712-5u4e00q6	1032	14	.	.	.
cord-014712-5u4e00q6	1033	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1033	2	present	present	VBP
cord-014712-5u4e00q6	1033	3	a	a	DT
cord-014712-5u4e00q6	1033	4	patient	patient	NN
cord-014712-5u4e00q6	1033	5	with	with	IN
cord-014712-5u4e00q6	1033	6	a	a	DT
cord-014712-5u4e00q6	1033	7	DOCK8	dock8	NN
cord-014712-5u4e00q6	1033	8	deficiency	deficiency	NN
cord-014712-5u4e00q6	1033	9	.	.	.
cord-014712-5u4e00q6	1034	1	Mutations	mutation	NNS
cord-014712-5u4e00q6	1034	2	in	in	IN
cord-014712-5u4e00q6	1034	3	the	the	DT
cord-014712-5u4e00q6	1034	4	dedicator	dedicator	NN
cord-014712-5u4e00q6	1034	5	of	of	IN
cord-014712-5u4e00q6	1034	6	cytokinesis	cytokinesis	NN
cord-014712-5u4e00q6	1034	7	8	8	CD
cord-014712-5u4e00q6	1034	8	gene	gene	NN
cord-014712-5u4e00q6	1034	9	(	(	-LRB-
cord-014712-5u4e00q6	1034	10	DOCK8	DOCK8	NNP
cord-014712-5u4e00q6	1034	11	)	)	-RRB-
cord-014712-5u4e00q6	1034	12	cause	cause	VB
cord-014712-5u4e00q6	1034	13	a	a	DT
cord-014712-5u4e00q6	1034	14	combined	combined	JJ
cord-014712-5u4e00q6	1034	15	primary	primary	JJ
cord-014712-5u4e00q6	1034	16	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1034	17	syndrome	syndrome	NN
cord-014712-5u4e00q6	1034	18	that	that	WDT
cord-014712-5u4e00q6	1034	19	is	be	VBZ
cord-014712-5u4e00q6	1034	20	characterized	characterize	VBN
cord-014712-5u4e00q6	1034	21	by	by	IN
cord-014712-5u4e00q6	1034	22	elevated	elevated	JJ
cord-014712-5u4e00q6	1034	23	serum	serum	NN
cord-014712-5u4e00q6	1034	24	IgE	IgE	NNP
cord-014712-5u4e00q6	1034	25	levels	level	NNS
cord-014712-5u4e00q6	1034	26	,	,	,
cord-014712-5u4e00q6	1034	27	depressed	depressed	JJ
cord-014712-5u4e00q6	1034	28	IgM	IgM	NNP
cord-014712-5u4e00q6	1034	29	levels	level	NNS
cord-014712-5u4e00q6	1034	30	,	,	,
cord-014712-5u4e00q6	1034	31	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	1034	32	,	,	,
cord-014712-5u4e00q6	1034	33	sinopulmonary	sinopulmonary	JJ
cord-014712-5u4e00q6	1034	34	infections	infection	NNS
cord-014712-5u4e00q6	1034	35	,	,	,
cord-014712-5u4e00q6	1034	36	cutaneous	cutaneous	JJ
cord-014712-5u4e00q6	1034	37	viral	viral	JJ
cord-014712-5u4e00q6	1034	38	infections	infection	NNS
cord-014712-5u4e00q6	1034	39	,	,	,
cord-014712-5u4e00q6	1034	40	and	and	CC
cord-014712-5u4e00q6	1034	41	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	1034	42	.	.	.
cord-014712-5u4e00q6	1035	1	Onset	onset	NN
cord-014712-5u4e00q6	1035	2	of	of	IN
cord-014712-5u4e00q6	1035	3	the	the	DT
cord-014712-5u4e00q6	1035	4	disease	disease	NN
cord-014712-5u4e00q6	1035	5	was	be	VBD
cord-014712-5u4e00q6	1035	6	observed	observe	VBN
cord-014712-5u4e00q6	1035	7	at	at	IN
cord-014712-5u4e00q6	1035	8	1-month	1-month	CD
cord-014712-5u4e00q6	1035	9	of	of	IN
cord-014712-5u4e00q6	1035	10	age	age	NN
cord-014712-5u4e00q6	1035	11	with	with	IN
cord-014712-5u4e00q6	1035	12	severe	severe	JJ
cord-014712-5u4e00q6	1035	13	eczema	eczema	NN
cord-014712-5u4e00q6	1035	14	and	and	CC
cord-014712-5u4e00q6	1035	15	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1035	16	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1035	17	infections	infection	NNS
cord-014712-5u4e00q6	1035	18	(	(	-LRB-
cord-014712-5u4e00q6	1035	19	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1035	20	,	,	,
cord-014712-5u4e00q6	1035	21	bronchitis	bronchitis	NN
cord-014712-5u4e00q6	1035	22	,	,	,
cord-014712-5u4e00q6	1035	23	otitis	otitis	NN
cord-014712-5u4e00q6	1035	24	)	)	-RRB-
cord-014712-5u4e00q6	1035	25	.	.	.
cord-014712-5u4e00q6	1036	1	At	at	IN
cord-014712-5u4e00q6	1036	2	5	5	CD
cord-014712-5u4e00q6	1036	3	years	year	NNS
cord-014712-5u4e00q6	1036	4	of	of	IN
cord-014712-5u4e00q6	1036	5	age	age	NN
cord-014712-5u4e00q6	1036	6	neuroblastoma	neuroblastoma	NN
cord-014712-5u4e00q6	1036	7	was	be	VBD
cord-014712-5u4e00q6	1036	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1036	9	.	.	.
cord-014712-5u4e00q6	1037	1	From	from	IN
cord-014712-5u4e00q6	1037	2	the	the	DT
cord-014712-5u4e00q6	1037	3	age	age	NN
cord-014712-5u4e00q6	1037	4	of	of	IN
cord-014712-5u4e00q6	1037	5	6	6	CD
cord-014712-5u4e00q6	1037	6	years	year	NNS
cord-014712-5u4e00q6	1037	7	he	-PRON-	PRP
cord-014712-5u4e00q6	1037	8	started	start	VBD
cord-014712-5u4e00q6	1037	9	with	with	IN
cord-014712-5u4e00q6	1037	10	severe	severe	JJ
cord-014712-5u4e00q6	1037	11	skin	skin	NN
cord-014712-5u4e00q6	1037	12	infection	infection	NN
cord-014712-5u4e00q6	1037	13	,	,	,
cord-014712-5u4e00q6	1037	14	subsequently	subsequently	RB
cord-014712-5u4e00q6	1037	15	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1037	16	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	1037	17	aspergillosis	aspergillosis	NNP
cord-014712-5u4e00q6	1037	18	was	be	VBD
cord-014712-5u4e00q6	1037	19	established	establish	VBN
cord-014712-5u4e00q6	1037	20	based	base	VBN
cord-014712-5u4e00q6	1037	21	on	on	IN
cord-014712-5u4e00q6	1037	22	skin	skin	NN
cord-014712-5u4e00q6	1037	23	biopsy	biopsy	NN
cord-014712-5u4e00q6	1037	24	and	and	CC
cord-014712-5u4e00q6	1037	25	bacteriological	bacteriological	JJ
cord-014712-5u4e00q6	1037	26	studies	study	NNS
cord-014712-5u4e00q6	1037	27	.	.	.
cord-014712-5u4e00q6	1038	1	Immunological	immunological	JJ
cord-014712-5u4e00q6	1038	2	investigations	investigation	NNS
cord-014712-5u4e00q6	1038	3	revealed	reveal	VBD
cord-014712-5u4e00q6	1038	4	persistent	persistent	JJ
cord-014712-5u4e00q6	1038	5	leukocytosis	leukocytosis	NNP
cord-014712-5u4e00q6	1038	6	,	,	,
cord-014712-5u4e00q6	1038	7	hypereosinophilia	hypereosinophilia	NNP
cord-014712-5u4e00q6	1038	8	,	,	,
cord-014712-5u4e00q6	1038	9	low	low	JJ
cord-014712-5u4e00q6	1038	10	level	level	NN
cord-014712-5u4e00q6	1038	11	of	of	IN
cord-014712-5u4e00q6	1038	12	IgM	IgM	NNP
cord-014712-5u4e00q6	1038	13	and	and	CC
cord-014712-5u4e00q6	1038	14	increased	increase	VBD
cord-014712-5u4e00q6	1038	15	IgE	IgE	NNP
cord-014712-5u4e00q6	1038	16	up	up	IN
cord-014712-5u4e00q6	1038	17	to	to	IN
cord-014712-5u4e00q6	1038	18	5	5	CD
cord-014712-5u4e00q6	1038	19	000	000	CD
cord-014712-5u4e00q6	1038	20	IU	IU	NNP
cord-014712-5u4e00q6	1038	21	/	/	,
cord-014712-5u4e00q6	1038	22	ml	ml	NN
cord-014712-5u4e00q6	1038	23	.	.	.
cord-014712-5u4e00q6	1039	1	So	so	RB
cord-014712-5u4e00q6	1039	2	Hyper	Hyper	NNP
cord-014712-5u4e00q6	1039	3	IgE	IgE	NNP
cord-014712-5u4e00q6	1039	4	syndrome	syndrome	NN
cord-014712-5u4e00q6	1039	5	was	be	VBD
cord-014712-5u4e00q6	1039	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1039	7	and	and	CC
cord-014712-5u4e00q6	1039	8	genetically	genetically	RB
cord-014712-5u4e00q6	1039	9	confirmed	confirm	VBN
cord-014712-5u4e00q6	1039	10	when	when	WRB
cord-014712-5u4e00q6	1039	11	a	a	DT
cord-014712-5u4e00q6	1039	12	large	large	JJ
cord-014712-5u4e00q6	1039	13	deletion	deletion	NN
cord-014712-5u4e00q6	1039	14	of	of	IN
cord-014712-5u4e00q6	1039	15	the	the	DT
cord-014712-5u4e00q6	1039	16	DOCK8-gene	DOCK8-gene	NNP
cord-014712-5u4e00q6	1039	17	was	be	VBD
cord-014712-5u4e00q6	1039	18	identified	identify	VBN
cord-014712-5u4e00q6	1039	19	.	.	.
cord-014712-5u4e00q6	1040	1	Stem	stem	JJ
cord-014712-5u4e00q6	1040	2	cell	cell	NN
cord-014712-5u4e00q6	1040	3	transplantation	transplantation	NN
cord-014712-5u4e00q6	1040	4	was	be	VBD
cord-014712-5u4e00q6	1040	5	performed	perform	VBN
cord-014712-5u4e00q6	1040	6	in	in	IN
cord-014712-5u4e00q6	1040	7	2012	2012	CD
cord-014712-5u4e00q6	1040	8	when	when	WRB
cord-014712-5u4e00q6	1040	9	the	the	DT
cord-014712-5u4e00q6	1040	10	patient	patient	NN
cord-014712-5u4e00q6	1040	11	was	be	VBD
cord-014712-5u4e00q6	1040	12	11	11	CD
cord-014712-5u4e00q6	1040	13	y.o	y.o	NNP
cord-014712-5u4e00q6	1040	14	.	.	.
cord-014712-5u4e00q6	1041	1	One	one	CD
cord-014712-5u4e00q6	1041	2	year	year	NN
cord-014712-5u4e00q6	1041	3	later	later	RB
cord-014712-5u4e00q6	1041	4	progressive	progressive	JJ
cord-014712-5u4e00q6	1041	5	multifocal	multifocal	JJ
cord-014712-5u4e00q6	1041	6	leukoencephalopathy	leukoencephalopathy	NNP
cord-014712-5u4e00q6	1041	7	secondary	secondary	JJ
cord-014712-5u4e00q6	1041	8	to	to	IN
cord-014712-5u4e00q6	1041	9	infection	infection	NN
cord-014712-5u4e00q6	1041	10	by	by	IN
cord-014712-5u4e00q6	1041	11	Polyomavirus	Polyomavirus	NNP
cord-014712-5u4e00q6	1041	12	JC	JC	NNP
cord-014712-5u4e00q6	1041	13	was	be	VBD
cord-014712-5u4e00q6	1041	14	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1041	15	.	.	.
cord-014712-5u4e00q6	1042	1	But	but	CC
cord-014712-5u4e00q6	1042	2	after	after	IN
cord-014712-5u4e00q6	1042	3	immunosuppressive	immunosuppressive	JJ
cord-014712-5u4e00q6	1042	4	therapy	therapy	NN
cord-014712-5u4e00q6	1042	5	with	with	IN
cord-014712-5u4e00q6	1042	6	Cyclosporine	Cyclosporine	NNP
cord-014712-5u4e00q6	1042	7	Awas	Awas	NNP
cord-014712-5u4e00q6	1042	8	suspended	suspend	VBD
cord-014712-5u4e00q6	1042	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	1042	10	patient	patient	NN
cord-014712-5u4e00q6	1042	11	's	's	POS
cord-014712-5u4e00q6	1042	12	condition	condition	NN
cord-014712-5u4e00q6	1042	13	improved	improve	VBD
cord-014712-5u4e00q6	1042	14	:	:	:
cord-014712-5u4e00q6	1042	15	the	the	DT
cord-014712-5u4e00q6	1042	16	load	load	NN
cord-014712-5u4e00q6	1042	17	of	of	IN
cord-014712-5u4e00q6	1042	18	Polyomavirus	Polyomavirus	NNP
cord-014712-5u4e00q6	1042	19	JC	JC	NNP
cord-014712-5u4e00q6	1042	20	on	on	IN
cord-014712-5u4e00q6	1042	21	plasma	plasma	NN
cord-014712-5u4e00q6	1042	22	showed	show	VBD
cord-014712-5u4e00q6	1042	23	a	a	DT
cord-014712-5u4e00q6	1042	24	decrease	decrease	NN
cord-014712-5u4e00q6	1042	25	;	;	:
cord-014712-5u4e00q6	1042	26	MRI	MRI	NNP
cord-014712-5u4e00q6	1042	27	brain	brain	NN
cord-014712-5u4e00q6	1042	28	was	be	VBD
cord-014712-5u4e00q6	1042	29	essentially	essentially	RB
cord-014712-5u4e00q6	1042	30	stable	stable	JJ
cord-014712-5u4e00q6	1042	31	;	;	:
cord-014712-5u4e00q6	1042	32	immunological	immunological	JJ
cord-014712-5u4e00q6	1042	33	tests	test	NNS
cord-014712-5u4e00q6	1042	34	showed	show	VBD
cord-014712-5u4e00q6	1042	35	an	an	DT
cord-014712-5u4e00q6	1042	36	initial	initial	JJ
cord-014712-5u4e00q6	1042	37	improvement	improvement	NN
cord-014712-5u4e00q6	1042	38	of	of	IN
cord-014712-5u4e00q6	1042	39	subpopulations	subpopulation	NNS
cord-014712-5u4e00q6	1042	40	and	and	CC
cord-014712-5u4e00q6	1042	41	proliferative	proliferative	JJ
cord-014712-5u4e00q6	1042	42	response	response	NN
cord-014712-5u4e00q6	1042	43	to	to	IN
cord-014712-5u4e00q6	1042	44	mitogens	mitogens	NNP
cord-014712-5u4e00q6	1042	45	;	;	,
cord-014712-5u4e00q6	1042	46	donor	donor	NN
cord-014712-5u4e00q6	1042	47	chimerism	chimerism	NN
cord-014712-5u4e00q6	1042	48	100	100	CD
cord-014712-5u4e00q6	1042	49	%	%	NN
cord-014712-5u4e00q6	1042	50	stable	stable	JJ
cord-014712-5u4e00q6	1042	51	.	.	.
cord-014712-5u4e00q6	1043	1	Özdemir	Özdemir	NNP
cord-014712-5u4e00q6	1043	2	Öner	Öner	NNP
cord-014712-5u4e00q6	1043	3	1	1	CD
cord-014712-5u4e00q6	1044	1	;	;	:
cord-014712-5u4e00q6	1044	2	Bozdoğan	Bozdoğan	NNP
cord-014712-5u4e00q6	1044	3	Sıla	Sıla	NNP
cord-014712-5u4e00q6	1044	4	2	2	CD
cord-014712-5u4e00q6	1044	5	1	1	CD
cord-014712-5u4e00q6	1044	6	Department	Department	NNP
cord-014712-5u4e00q6	1044	7	of	of	IN
cord-014712-5u4e00q6	1044	8	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	1044	9	,	,	,
cord-014712-5u4e00q6	1044	10	Division	Division	NNP
cord-014712-5u4e00q6	1044	11	of	of	IN
cord-014712-5u4e00q6	1044	12	Allergy	Allergy	NNP
cord-014712-5u4e00q6	1044	13	/	/	SYM
cord-014712-5u4e00q6	1044	14	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1044	15	,	,	,
cord-014712-5u4e00q6	1044	16	Sakarya	Sakarya	NNP
cord-014712-5u4e00q6	1044	17	University	University	NNP
cord-014712-5u4e00q6	1044	18	,	,	,
cord-014712-5u4e00q6	1044	19	Medical	Medical	NNP
cord-014712-5u4e00q6	1044	20	Faculty	Faculty	NNP
cord-014712-5u4e00q6	1044	21	,	,	,
cord-014712-5u4e00q6	1044	22	Adapazarı	Adapazarı	NNP
cord-014712-5u4e00q6	1044	23	,	,	,
cord-014712-5u4e00q6	1044	24	Türkiye	Türkiye	NNP
cord-014712-5u4e00q6	1044	25	.	.	.
cord-014712-5u4e00q6	1045	1	Background	background	NN
cord-014712-5u4e00q6	1045	2	:	:	:
cord-014712-5u4e00q6	1046	1	Bronchiolitis	bronchiolitis	NN
cord-014712-5u4e00q6	1046	2	and	and	CC
cord-014712-5u4e00q6	1046	3	infantile	infantile	JJ
cord-014712-5u4e00q6	1046	4	asthma	asthma	NN
cord-014712-5u4e00q6	1046	5	are	be	VBP
cord-014712-5u4e00q6	1046	6	the	the	DT
cord-014712-5u4e00q6	1046	7	most	most	RBS
cord-014712-5u4e00q6	1046	8	frequent	frequent	JJ
cord-014712-5u4e00q6	1046	9	causes	cause	NNS
cord-014712-5u4e00q6	1046	10	for	for	IN
cord-014712-5u4e00q6	1046	11	typical	typical	JJ
cord-014712-5u4e00q6	1046	12	wheezing	wheezing	JJ
cord-014712-5u4e00q6	1046	13	signs	sign	NNS
cord-014712-5u4e00q6	1046	14	in	in	IN
cord-014712-5u4e00q6	1046	15	infants	infant	NNS
cord-014712-5u4e00q6	1046	16	.	.	.
cord-014712-5u4e00q6	1047	1	However	however	RB
cord-014712-5u4e00q6	1047	2	,	,	,
cord-014712-5u4e00q6	1047	3	when	when	WRB
cord-014712-5u4e00q6	1047	4	a	a	DT
cord-014712-5u4e00q6	1047	5	physician	physician	NN
cord-014712-5u4e00q6	1047	6	comes	come	VBZ
cord-014712-5u4e00q6	1047	7	across	across	IN
cord-014712-5u4e00q6	1047	8	patients	patient	NNS
cord-014712-5u4e00q6	1047	9	with	with	IN
cord-014712-5u4e00q6	1047	10	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1047	11	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1047	12	are	be	VBP
cord-014712-5u4e00q6	1047	13	resistant	resistant	JJ
cord-014712-5u4e00q6	1047	14	to	to	IN
cord-014712-5u4e00q6	1047	15	β2-agonist	β2-agonist	NN
cord-014712-5u4e00q6	1047	16	and	and	CC
cord-014712-5u4e00q6	1047	17	anti	anti	JJ
cord-014712-5u4e00q6	1047	18	-	-	JJ
cord-014712-5u4e00q6	1047	19	cholinergic	cholinergic	JJ
cord-014712-5u4e00q6	1047	20	therapy	therapy	NN
cord-014712-5u4e00q6	1047	21	,	,	,
cord-014712-5u4e00q6	1047	22	known	know	VBN
cord-014712-5u4e00q6	1047	23	as	as	IN
cord-014712-5u4e00q6	1047	24	atypical	atypical	JJ
cord-014712-5u4e00q6	1047	25	wheezing	wheezing	JJ
cord-014712-5u4e00q6	1047	26	cases	case	NNS
cord-014712-5u4e00q6	1047	27	;	;	:
cord-014712-5u4e00q6	1047	28	he	-PRON-	PRP
cord-014712-5u4e00q6	1047	29	should	should	MD
cord-014712-5u4e00q6	1047	30	investigate	investigate	VB
cord-014712-5u4e00q6	1047	31	for	for	IN
cord-014712-5u4e00q6	1047	32	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1047	33	in	in	IN
cord-014712-5u4e00q6	1047	34	these	these	DT
cord-014712-5u4e00q6	1047	35	patients	patient	NNS
cord-014712-5u4e00q6	1047	36	.	.	.
cord-014712-5u4e00q6	1048	1	Aim	aim	VB
cord-014712-5u4e00q6	1048	2	:	:	:
cord-014712-5u4e00q6	1048	3	Here	here	RB
cord-014712-5u4e00q6	1048	4	,	,	,
cord-014712-5u4e00q6	1048	5	three	three	CD
cord-014712-5u4e00q6	1048	6	cases	case	NNS
cord-014712-5u4e00q6	1048	7	are	be	VBP
cord-014712-5u4e00q6	1048	8	reported	report	VBN
cord-014712-5u4e00q6	1048	9	to	to	TO
cord-014712-5u4e00q6	1048	10	make	make	VB
cord-014712-5u4e00q6	1048	11	pediatricians	pediatrician	NNS
cord-014712-5u4e00q6	1048	12	aware	aware	JJ
cord-014712-5u4e00q6	1048	13	of	of	IN
cord-014712-5u4e00q6	1048	14	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1048	15	,	,	,
cord-014712-5u4e00q6	1048	16	which	which	WDT
cord-014712-5u4e00q6	1048	17	is	be	VBZ
cord-014712-5u4e00q6	1048	18	one	one	CD
cord-014712-5u4e00q6	1048	19	of	of	IN
cord-014712-5u4e00q6	1048	20	the	the	DT
cord-014712-5u4e00q6	1048	21	reasons	reason	NNS
cord-014712-5u4e00q6	1048	22	causing	cause	VBG
cord-014712-5u4e00q6	1048	23	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1048	24	and	and	CC
cord-014712-5u4e00q6	1048	25	persistent	persistent	JJ
cord-014712-5u4e00q6	1048	26	wheezing	wheezing	JJ
cord-014712-5u4e00q6	1048	27	attacks	attack	NNS
cord-014712-5u4e00q6	1048	28	during	during	IN
cord-014712-5u4e00q6	1048	29	infancy	infancy	NN
cord-014712-5u4e00q6	1048	30	and	and	CC
cord-014712-5u4e00q6	1048	31	beyond	beyond	IN
cord-014712-5u4e00q6	1048	32	.	.	.
cord-014712-5u4e00q6	1049	1	Case	case	NN
cord-014712-5u4e00q6	1049	2	presentations	presentation	NNS
cord-014712-5u4e00q6	1049	3	:	:	:
cord-014712-5u4e00q6	1050	1	Case	case	NN
cord-014712-5u4e00q6	1050	2	1	1	CD
cord-014712-5u4e00q6	1050	3	:	:	:
cord-014712-5u4e00q6	1050	4	24	24	CD
cord-014712-5u4e00q6	1050	5	month	month	NN
cord-014712-5u4e00q6	1050	6	-	-	HYPH
cord-014712-5u4e00q6	1050	7	old	old	JJ
cord-014712-5u4e00q6	1050	8	girl	girl	NN
cord-014712-5u4e00q6	1050	9	presented	present	VBN
cord-014712-5u4e00q6	1050	10	to	to	IN
cord-014712-5u4e00q6	1050	11	us	-PRON-	PRP
cord-014712-5u4e00q6	1050	12	with	with	IN
cord-014712-5u4e00q6	1050	13	complaining	complain	VBG
cord-014712-5u4e00q6	1050	14	of	of	IN
cord-014712-5u4e00q6	1050	15	coughing	cough	VBG
cord-014712-5u4e00q6	1050	16	and	and	CC
cord-014712-5u4e00q6	1050	17	persistent	persistent	JJ
cord-014712-5u4e00q6	1050	18	wheezing	wheezing	NN
cord-014712-5u4e00q6	1050	19	.	.	.
cord-014712-5u4e00q6	1051	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1051	2	has	have	VBZ
cord-014712-5u4e00q6	1051	3	been	be	VBN
cord-014712-5u4e00q6	1051	4	having	have	VBG
cord-014712-5u4e00q6	1051	5	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1051	6	and	and	CC
cord-014712-5u4e00q6	1051	7	breathing	breathe	VBG
cord-014712-5u4e00q6	1051	8	difficulty	difficulty	NN
cord-014712-5u4e00q6	1051	9	for	for	IN
cord-014712-5u4e00q6	1051	10	the	the	DT
cord-014712-5u4e00q6	1051	11	last	last	JJ
cord-014712-5u4e00q6	1051	12	2	2	CD
cord-014712-5u4e00q6	1051	13	months	month	NNS
cord-014712-5u4e00q6	1051	14	after	after	IN
cord-014712-5u4e00q6	1051	15	she	-PRON-	PRP
cord-014712-5u4e00q6	1051	16	got	get	VBD
cord-014712-5u4e00q6	1051	17	upper	upper	JJ
cord-014712-5u4e00q6	1051	18	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1051	19	tract	tract	NN
cord-014712-5u4e00q6	1051	20	infection	infection	NN
cord-014712-5u4e00q6	1051	21	.	.	.
cord-014712-5u4e00q6	1052	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1052	2	symptoms	symptom	NNS
cord-014712-5u4e00q6	1052	3	persisted	persist	VBD
cord-014712-5u4e00q6	1052	4	even	even	RB
cord-014712-5u4e00q6	1052	5	though	though	IN
cord-014712-5u4e00q6	1052	6	she	-PRON-	PRP
cord-014712-5u4e00q6	1052	7	was	be	VBD
cord-014712-5u4e00q6	1052	8	using	use	VBG
cord-014712-5u4e00q6	1052	9	religiously	religiously	RB
cord-014712-5u4e00q6	1052	10	nebulized	nebulize	VBN
cord-014712-5u4e00q6	1052	11	salbutamol	salbutamol	NN
cord-014712-5u4e00q6	1052	12	+	+	CC
cord-014712-5u4e00q6	1052	13	budesonid	budesonid	NNP
cord-014712-5u4e00q6	1052	14	therapy	therapy	NN
cord-014712-5u4e00q6	1052	15	.	.	.
cord-014712-5u4e00q6	1053	1	Before	before	IN
cord-014712-5u4e00q6	1053	2	this	this	DT
cord-014712-5u4e00q6	1053	3	episode	episode	NN
cord-014712-5u4e00q6	1053	4	,	,	,
cord-014712-5u4e00q6	1053	5	she	-PRON-	PRP
cord-014712-5u4e00q6	1053	6	had	have	VBD
cord-014712-5u4e00q6	1053	7	had	have	VBN
cord-014712-5u4e00q6	1053	8	9	9	CD
cord-014712-5u4e00q6	1053	9	other	other	JJ
cord-014712-5u4e00q6	1053	10	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1053	11	attacks	attack	NNS
cord-014712-5u4e00q6	1053	12	in	in	IN
cord-014712-5u4e00q6	1053	13	her	-PRON-	PRP$
cord-014712-5u4e00q6	1053	14	past	past	JJ
cord-014712-5u4e00q6	1053	15	medical	medical	JJ
cord-014712-5u4e00q6	1053	16	history	history	NN
cord-014712-5u4e00q6	1053	17	beginning	begin	VBG
cord-014712-5u4e00q6	1053	18	from	from	IN
cord-014712-5u4e00q6	1053	19	2	2	CD
cord-014712-5u4e00q6	1053	20	months	month	NNS
cord-014712-5u4e00q6	1053	21	of	of	IN
cord-014712-5u4e00q6	1053	22	age	age	NN
cord-014712-5u4e00q6	1053	23	.	.	.
cord-014712-5u4e00q6	1054	1	In	in	IN
cord-014712-5u4e00q6	1054	2	her	-PRON-	PRP$
cord-014712-5u4e00q6	1054	3	family	family	NN
cord-014712-5u4e00q6	1054	4	history	history	NN
cord-014712-5u4e00q6	1054	5	,	,	,
cord-014712-5u4e00q6	1054	6	her	-PRON-	PRP$
cord-014712-5u4e00q6	1054	7	father	father	NN
cord-014712-5u4e00q6	1054	8	has	have	VBZ
cord-014712-5u4e00q6	1054	9	asthma	asthma	NN
cord-014712-5u4e00q6	1054	10	.	.	.
cord-014712-5u4e00q6	1055	1	Physical	physical	JJ
cord-014712-5u4e00q6	1055	2	examination	examination	NN
cord-014712-5u4e00q6	1055	3	revealed	reveal	VBD
cord-014712-5u4e00q6	1055	4	her	-PRON-	PRP$
cord-014712-5u4e00q6	1055	5	breathing	breathing	NN
cord-014712-5u4e00q6	1055	6	difficulty	difficulty	NN
cord-014712-5u4e00q6	1055	7	.	.	.
cord-014712-5u4e00q6	1056	1	Ronchi	Ronchi	NNP
cord-014712-5u4e00q6	1056	2	as	as	RB
cord-014712-5u4e00q6	1056	3	well	well	RB
cord-014712-5u4e00q6	1056	4	as	as	IN
cord-014712-5u4e00q6	1056	5	rales	rale	NNS
cord-014712-5u4e00q6	1056	6	were	be	VBD
cord-014712-5u4e00q6	1056	7	heard	hear	VBN
cord-014712-5u4e00q6	1056	8	on	on	IN
cord-014712-5u4e00q6	1056	9	the	the	DT
cord-014712-5u4e00q6	1056	10	auscultation	auscultation	NN
cord-014712-5u4e00q6	1056	11	of	of	IN
cord-014712-5u4e00q6	1056	12	her	-PRON-	PRP$
cord-014712-5u4e00q6	1056	13	lungs	lung	NNS
cord-014712-5u4e00q6	1056	14	.	.	.
cord-014712-5u4e00q6	1057	1	At	at	IN
cord-014712-5u4e00q6	1057	2	the	the	DT
cord-014712-5u4e00q6	1057	3	fourth	fourth	JJ
cord-014712-5u4e00q6	1057	4	day	day	NN
cord-014712-5u4e00q6	1057	5	of	of	IN
cord-014712-5u4e00q6	1057	6	admission	admission	NN
cord-014712-5u4e00q6	1057	7	,	,	,
cord-014712-5u4e00q6	1057	8	she	-PRON-	PRP
cord-014712-5u4e00q6	1057	9	was	be	VBD
cord-014712-5u4e00q6	1057	10	given	give	VBN
cord-014712-5u4e00q6	1057	11	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1057	12	500mg	500mg	NNP
cord-014712-5u4e00q6	1057	13	/	/	SYM
cord-014712-5u4e00q6	1057	14	kg	kg	NN
cord-014712-5u4e00q6	1057	15	/	/	SYM
cord-014712-5u4e00q6	1057	16	dose	dose	NN
cord-014712-5u4e00q6	1057	17	.	.	.
cord-014712-5u4e00q6	1058	1	Later	later	RB
cord-014712-5u4e00q6	1058	2	,	,	,
cord-014712-5u4e00q6	1058	3	her	-PRON-	PRP$
cord-014712-5u4e00q6	1058	4	symptoms	symptom	NNS
cord-014712-5u4e00q6	1058	5	did	do	VBD
cord-014712-5u4e00q6	1058	6	improve	improve	VB
cord-014712-5u4e00q6	1058	7	and	and	CC
cord-014712-5u4e00q6	1058	8	not	not	RB
cord-014712-5u4e00q6	1058	9	recur	recur	VB
cord-014712-5u4e00q6	1058	10	for	for	IN
cord-014712-5u4e00q6	1058	11	the	the	DT
cord-014712-5u4e00q6	1058	12	last	last	JJ
cord-014712-5u4e00q6	1058	13	5	5	CD
cord-014712-5u4e00q6	1058	14	months	month	NNS
cord-014712-5u4e00q6	1058	15	.	.	.
cord-014712-5u4e00q6	1059	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1059	2	findings	finding	NNS
cord-014712-5u4e00q6	1059	3	showed	show	VBD
cord-014712-5u4e00q6	1059	4	normal	normal	JJ
cord-014712-5u4e00q6	1059	5	routine	routine	JJ
cord-014712-5u4e00q6	1059	6	biochemistry	biochemistry	NN
cord-014712-5u4e00q6	1059	7	,	,	,
cord-014712-5u4e00q6	1059	8	complete	complete	VB
cord-014712-5u4e00q6	1059	9	blood	blood	NN
cord-014712-5u4e00q6	1059	10	count	count	NN
cord-014712-5u4e00q6	1059	11	and	and	CC
cord-014712-5u4e00q6	1059	12	sedimentation	sedimentation	NN
cord-014712-5u4e00q6	1059	13	rate	rate	NN
cord-014712-5u4e00q6	1059	14	.	.	.
cord-014712-5u4e00q6	1060	1	Chest	chest	NN
cord-014712-5u4e00q6	1060	2	X	x	NN
cord-014712-5u4e00q6	1060	3	-	-	NN
cord-014712-5u4e00q6	1060	4	ray	ray	NN
cord-014712-5u4e00q6	1060	5	showed	show	VBD
cord-014712-5u4e00q6	1060	6	normal	normal	JJ
cord-014712-5u4e00q6	1060	7	findings	finding	NNS
cord-014712-5u4e00q6	1060	8	.	.	.
cord-014712-5u4e00q6	1061	1	Echography	Echography	NNP
cord-014712-5u4e00q6	1061	2	was	be	VBD
cord-014712-5u4e00q6	1061	3	normal	normal	JJ
cord-014712-5u4e00q6	1061	4	.	.	.
cord-014712-5u4e00q6	1062	1	pH	pH	NNP
cord-014712-5u4e00q6	1062	2	-	-	HYPH
cord-014712-5u4e00q6	1062	3	metry	metry	NNP
cord-014712-5u4e00q6	1062	4	for	for	IN
cord-014712-5u4e00q6	1062	5	reflux	reflux	NN
cord-014712-5u4e00q6	1062	6	investigation	investigation	NN
cord-014712-5u4e00q6	1062	7	was	be	VBD
cord-014712-5u4e00q6	1062	8	normal	normal	JJ
cord-014712-5u4e00q6	1062	9	.	.	.
cord-014712-5u4e00q6	1063	1	Sweat	sweat	NN
cord-014712-5u4e00q6	1063	2	test	test	NN
cord-014712-5u4e00q6	1063	3	was	be	VBD
cord-014712-5u4e00q6	1063	4	normal	normal	JJ
cord-014712-5u4e00q6	1063	5	.	.	.
cord-014712-5u4e00q6	1064	1	In	in	IN
cord-014712-5u4e00q6	1064	2	the	the	DT
cord-014712-5u4e00q6	1064	3	serological	serological	JJ
cord-014712-5u4e00q6	1064	4	evaluation	evaluation	NN
cord-014712-5u4e00q6	1064	5	:	:	:
cord-014712-5u4e00q6	1064	6	low	low	JJ
cord-014712-5u4e00q6	1064	7	IgG	igg	NN
cord-014712-5u4e00q6	1064	8	level	level	NN
cord-014712-5u4e00q6	1064	9	for	for	IN
cord-014712-5u4e00q6	1064	10	his	-PRON-	PRP$
cord-014712-5u4e00q6	1064	11	age	age	NN
cord-014712-5u4e00q6	1064	12	(	(	-LRB-
cord-014712-5u4e00q6	1064	13	358	358	CD
cord-014712-5u4e00q6	1064	14	mg	mg	NNP
cord-014712-5u4e00q6	1064	15	/	/	SYM
cord-014712-5u4e00q6	1064	16	dl	dl	NNP
cord-014712-5u4e00q6	1064	17	)	)	-RRB-
cord-014712-5u4e00q6	1064	18	was	be	VBD
cord-014712-5u4e00q6	1064	19	detected	detect	VBN
cord-014712-5u4e00q6	1064	20	at	at	IN
cord-014712-5u4e00q6	1064	21	two	two	CD
cord-014712-5u4e00q6	1064	22	different	different	JJ
cord-014712-5u4e00q6	1064	23	times	time	NNS
cord-014712-5u4e00q6	1064	24	.	.	.
cord-014712-5u4e00q6	1065	1	IgG	IgG	NNP
cord-014712-5u4e00q6	1065	2	subgroups	subgroups	NNP
cord-014712-5u4e00q6	1065	3	,	,	,
cord-014712-5u4e00q6	1065	4	IgM	IgM	NNP
cord-014712-5u4e00q6	1065	5	(	(	-LRB-
cord-014712-5u4e00q6	1065	6	156	156	CD
cord-014712-5u4e00q6	1065	7	mg/	mg/	NN
cord-014712-5u4e00q6	1065	8	dl	dl	NNP
cord-014712-5u4e00q6	1065	9	)	)	-RRB-
cord-014712-5u4e00q6	1065	10	,	,	,
cord-014712-5u4e00q6	1065	11	IgA	IgA	NNP
cord-014712-5u4e00q6	1065	12	(	(	-LRB-
cord-014712-5u4e00q6	1065	13	34	34	CD
cord-014712-5u4e00q6	1065	14	mg	mg	NNP
cord-014712-5u4e00q6	1065	15	/	/	SYM
cord-014712-5u4e00q6	1065	16	dl	dl	NNP
cord-014712-5u4e00q6	1065	17	)	)	-RRB-
cord-014712-5u4e00q6	1065	18	and	and	CC
cord-014712-5u4e00q6	1065	19	IgE	IgE	NNP
cord-014712-5u4e00q6	1065	20	(	(	-LRB-
cord-014712-5u4e00q6	1065	21	68	68	CD
cord-014712-5u4e00q6	1065	22	)	)	-RRB-
cord-014712-5u4e00q6	1065	23	levels	level	NNS
cord-014712-5u4e00q6	1065	24	were	be	VBD
cord-014712-5u4e00q6	1065	25	within	within	IN
cord-014712-5u4e00q6	1065	26	normal	normal	JJ
cord-014712-5u4e00q6	1065	27	.	.	.
cord-014712-5u4e00q6	1066	1	Case	case	NN
cord-014712-5u4e00q6	1066	2	2	2	CD
cord-014712-5u4e00q6	1066	3	:	:	:
cord-014712-5u4e00q6	1066	4	8-month	8-month	JJ
cord-014712-5u4e00q6	1066	5	-	-	HYPH
cord-014712-5u4e00q6	1066	6	old	old	JJ
cord-014712-5u4e00q6	1066	7	girl	girl	NN
cord-014712-5u4e00q6	1066	8	came	come	VBD
cord-014712-5u4e00q6	1066	9	to	to	IN
cord-014712-5u4e00q6	1066	10	our	-PRON-	PRP$
cord-014712-5u4e00q6	1066	11	outpatient	outpatient	NN
cord-014712-5u4e00q6	1066	12	clinic	clinic	NN
cord-014712-5u4e00q6	1066	13	with	with	IN
cord-014712-5u4e00q6	1066	14	complaints	complaint	NNS
cord-014712-5u4e00q6	1066	15	of	of	IN
cord-014712-5u4e00q6	1066	16	coughing	cough	VBG
cord-014712-5u4e00q6	1066	17	and	and	CC
cord-014712-5u4e00q6	1066	18	wheezing	wheezing	NN
cord-014712-5u4e00q6	1066	19	.	.	.
cord-014712-5u4e00q6	1067	1	At	at	IN
cord-014712-5u4e00q6	1067	2	2	2	CD
cord-014712-5u4e00q6	1067	3	months	month	NNS
cord-014712-5u4e00q6	1067	4	of	of	IN
cord-014712-5u4e00q6	1067	5	age	age	NN
cord-014712-5u4e00q6	1067	6	,	,	,
cord-014712-5u4e00q6	1067	7	she	-PRON-	PRP
cord-014712-5u4e00q6	1067	8	had	have	VBD
cord-014712-5u4e00q6	1067	9	urinary	urinary	JJ
cord-014712-5u4e00q6	1067	10	and	and	CC
cord-014712-5u4e00q6	1067	11	upper	upper	JJ
cord-014712-5u4e00q6	1067	12	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1067	13	tract	tract	NN
cord-014712-5u4e00q6	1067	14	infections	infection	NNS
cord-014712-5u4e00q6	1067	15	.	.	.
cord-014712-5u4e00q6	1068	1	Despite	despite	IN
cord-014712-5u4e00q6	1068	2	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	1068	3	therapy	therapy	NN
cord-014712-5u4e00q6	1068	4	,	,	,
cord-014712-5u4e00q6	1068	5	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1068	6	persisted	persist	VBD
cord-014712-5u4e00q6	1068	7	for	for	IN
cord-014712-5u4e00q6	1068	8	2	2	CD
cord-014712-5u4e00q6	1068	9	months	month	NNS
cord-014712-5u4e00q6	1068	10	and	and	CC
cord-014712-5u4e00q6	1068	11	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1068	12	severity	severity	NN
cord-014712-5u4e00q6	1068	13	increased	increase	VBD
cord-014712-5u4e00q6	1068	14	and	and	CC
cord-014712-5u4e00q6	1068	15	it	-PRON-	PRP
cord-014712-5u4e00q6	1068	16	did	do	VBD
cord-014712-5u4e00q6	1068	17	not	not	RB
cord-014712-5u4e00q6	1068	18	respond	respond	VB
cord-014712-5u4e00q6	1068	19	to	to	IN
cord-014712-5u4e00q6	1068	20	β2-agonist	β2-agonist	NN
cord-014712-5u4e00q6	1068	21	therapy	therapy	NN
cord-014712-5u4e00q6	1068	22	.	.	.
cord-014712-5u4e00q6	1069	1	Thereafter	thereafter	RB
cord-014712-5u4e00q6	1069	2	,	,	,
cord-014712-5u4e00q6	1069	3	she	-PRON-	PRP
cord-014712-5u4e00q6	1069	4	was	be	VBD
cord-014712-5u4e00q6	1069	5	admitted	admit	VBN
cord-014712-5u4e00q6	1069	6	to	to	IN
cord-014712-5u4e00q6	1069	7	the	the	DT
cord-014712-5u4e00q6	1069	8	hospital	hospital	NN
cord-014712-5u4e00q6	1069	9	for	for	IN
cord-014712-5u4e00q6	1069	10	7	7	CD
cord-014712-5u4e00q6	1069	11	days	day	NNS
cord-014712-5u4e00q6	1069	12	and	and	CC
cord-014712-5u4e00q6	1069	13	symptoms	symptom	NNS
cord-014712-5u4e00q6	1069	14	resolved	resolve	VBD
cord-014712-5u4e00q6	1069	15	.	.	.
cord-014712-5u4e00q6	1070	1	However	however	RB
cord-014712-5u4e00q6	1070	2	,	,	,
cord-014712-5u4e00q6	1070	3	she	-PRON-	PRP
cord-014712-5u4e00q6	1070	4	came	come	VBD
cord-014712-5u4e00q6	1070	5	back	back	RB
cord-014712-5u4e00q6	1070	6	to	to	IN
cord-014712-5u4e00q6	1070	7	hospital	hospital	NN
cord-014712-5u4e00q6	1070	8	due	due	IN
cord-014712-5u4e00q6	1070	9	to	to	IN
cord-014712-5u4e00q6	1070	10	recurrence	recurrence	NN
cord-014712-5u4e00q6	1070	11	of	of	IN
cord-014712-5u4e00q6	1070	12	her	-PRON-	PRP$
cord-014712-5u4e00q6	1070	13	symptoms	symptom	NNS
cord-014712-5u4e00q6	1070	14	in	in	IN
cord-014712-5u4e00q6	1070	15	10	10	CD
cord-014712-5u4e00q6	1070	16	days	day	NNS
cord-014712-5u4e00q6	1070	17	.	.	.
cord-014712-5u4e00q6	1071	1	In	in	IN
cord-014712-5u4e00q6	1071	2	her	-PRON-	PRP$
cord-014712-5u4e00q6	1071	3	family	family	NN
cord-014712-5u4e00q6	1071	4	history	history	NN
cord-014712-5u4e00q6	1071	5	,	,	,
cord-014712-5u4e00q6	1071	6	grandmother	grandmother	NN
cord-014712-5u4e00q6	1071	7	and	and	CC
cord-014712-5u4e00q6	1071	8	her	-PRON-	PRP$
cord-014712-5u4e00q6	1071	9	cousins	cousin	NNS
cord-014712-5u4e00q6	1071	10	have	have	VBP
cord-014712-5u4e00q6	1071	11	asthma	asthma	NN
cord-014712-5u4e00q6	1071	12	.	.	.
cord-014712-5u4e00q6	1072	1	Physical	physical	JJ
cord-014712-5u4e00q6	1072	2	examination	examination	NN
cord-014712-5u4e00q6	1072	3	showed	show	VBD
cord-014712-5u4e00q6	1072	4	breathing	breathe	VBG
cord-014712-5u4e00q6	1072	5	difficulty	difficulty	NN
cord-014712-5u4e00q6	1072	6	.	.	.
cord-014712-5u4e00q6	1073	1	Ronchi	Ronchi	NNP
cord-014712-5u4e00q6	1073	2	as	as	RB
cord-014712-5u4e00q6	1073	3	well	well	RB
cord-014712-5u4e00q6	1073	4	as	as	IN
cord-014712-5u4e00q6	1073	5	rales	rale	NNS
cord-014712-5u4e00q6	1073	6	were	be	VBD
cord-014712-5u4e00q6	1073	7	heard	hear	VBN
cord-014712-5u4e00q6	1073	8	on	on	IN
cord-014712-5u4e00q6	1073	9	her	-PRON-	PRP$
cord-014712-5u4e00q6	1073	10	lungs	lung	NNS
cord-014712-5u4e00q6	1073	11	.	.	.
cord-014712-5u4e00q6	1074	1	Although	although	IN
cord-014712-5u4e00q6	1074	2	salbutamol	salbutamol	NNP
cord-014712-5u4e00q6	1074	3	,	,	,
cord-014712-5u4e00q6	1074	4	ipratropium	ipratropium	NNP
cord-014712-5u4e00q6	1074	5	,	,	,
cord-014712-5u4e00q6	1074	6	antibiotherapy	antibiotherapy	NNP
cord-014712-5u4e00q6	1074	7	(	(	-LRB-
cord-014712-5u4e00q6	1074	8	clarithromycin	clarithromycin	NNP
cord-014712-5u4e00q6	1074	9	)	)	-RRB-
cord-014712-5u4e00q6	1074	10	and	and	CC
cord-014712-5u4e00q6	1074	11	anti	anti	JJ
cord-014712-5u4e00q6	1074	12	-	-	JJ
cord-014712-5u4e00q6	1074	13	reflux	reflux	JJ
cord-014712-5u4e00q6	1074	14	therapies	therapy	NNS
cord-014712-5u4e00q6	1074	15	were	be	VBD
cord-014712-5u4e00q6	1074	16	given	give	VBN
cord-014712-5u4e00q6	1074	17	,	,	,
cord-014712-5u4e00q6	1074	18	her	-PRON-	PRP$
cord-014712-5u4e00q6	1074	19	symptoms	symptom	NNS
cord-014712-5u4e00q6	1074	20	did	do	VBD
cord-014712-5u4e00q6	1074	21	not	not	RB
cord-014712-5u4e00q6	1074	22	improve	improve	VB
cord-014712-5u4e00q6	1074	23	for	for	IN
cord-014712-5u4e00q6	1074	24	2	2	CD
cord-014712-5u4e00q6	1074	25	weeks	week	NNS
cord-014712-5u4e00q6	1074	26	.	.	.
cord-014712-5u4e00q6	1075	1	At	at	IN
cord-014712-5u4e00q6	1075	2	the	the	DT
cord-014712-5u4e00q6	1075	3	15th	15th	JJ
cord-014712-5u4e00q6	1075	4	day	day	NN
cord-014712-5u4e00q6	1075	5	of	of	IN
cord-014712-5u4e00q6	1075	6	admission	admission	NN
cord-014712-5u4e00q6	1075	7	,	,	,
cord-014712-5u4e00q6	1075	8	she	-PRON-	PRP
cord-014712-5u4e00q6	1075	9	was	be	VBD
cord-014712-5u4e00q6	1075	10	given	give	VBN
cord-014712-5u4e00q6	1075	11	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1075	12	500mg	500mg	NNP
cord-014712-5u4e00q6	1075	13	/	/	SYM
cord-014712-5u4e00q6	1075	14	kg	kg	NN
cord-014712-5u4e00q6	1075	15	/	/	SYM
cord-014712-5u4e00q6	1075	16	dose	dose	NN
cord-014712-5u4e00q6	1075	17	.	.	.
cord-014712-5u4e00q6	1076	1	Later	later	RB
cord-014712-5u4e00q6	1076	2	,	,	,
cord-014712-5u4e00q6	1076	3	her	-PRON-	PRP$
cord-014712-5u4e00q6	1076	4	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1076	5	system	system	NN
cord-014712-5u4e00q6	1076	6	symptoms	symptom	NNS
cord-014712-5u4e00q6	1076	7	did	do	VBD
cord-014712-5u4e00q6	1076	8	not	not	RB
cord-014712-5u4e00q6	1076	9	recur	recur	VB
cord-014712-5u4e00q6	1076	10	for	for	IN
cord-014712-5u4e00q6	1076	11	the	the	DT
cord-014712-5u4e00q6	1076	12	last	last	JJ
cord-014712-5u4e00q6	1076	13	several	several	JJ
cord-014712-5u4e00q6	1076	14	months	month	NNS
cord-014712-5u4e00q6	1076	15	.	.	.
cord-014712-5u4e00q6	1077	1	Once	once	IN
cord-014712-5u4e00q6	1077	2	she	-PRON-	PRP
cord-014712-5u4e00q6	1077	3	was	be	VBD
cord-014712-5u4e00q6	1077	4	evaluated	evaluate	VBN
cord-014712-5u4e00q6	1077	5	for	for	IN
cord-014712-5u4e00q6	1077	6	persistent	persistent	JJ
cord-014712-5u4e00q6	1077	7	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1077	8	attacks	attack	NNS
cord-014712-5u4e00q6	1077	9	during	during	IN
cord-014712-5u4e00q6	1077	10	admission	admission	NN
cord-014712-5u4e00q6	1077	11	,	,	,
cord-014712-5u4e00q6	1077	12	biochemistry	biochemistry	NN
cord-014712-5u4e00q6	1077	13	,	,	,
cord-014712-5u4e00q6	1077	14	CBC	CBC	NNP
cord-014712-5u4e00q6	1077	15	,	,	,
cord-014712-5u4e00q6	1077	16	ESR	ESR	NNP
cord-014712-5u4e00q6	1077	17	were	be	VBD
cord-014712-5u4e00q6	1077	18	normal	normal	JJ
cord-014712-5u4e00q6	1077	19	.	.	.
cord-014712-5u4e00q6	1078	1	Chest	chest	NN
cord-014712-5u4e00q6	1078	2	X	x	NN
cord-014712-5u4e00q6	1078	3	-	-	NN
cord-014712-5u4e00q6	1078	4	ray	ray	NN
cord-014712-5u4e00q6	1078	5	and	and	CC
cord-014712-5u4e00q6	1078	6	echography	echography	NN
cord-014712-5u4e00q6	1078	7	were	be	VBD
cord-014712-5u4e00q6	1078	8	normal	normal	JJ
cord-014712-5u4e00q6	1078	9	.	.	.
cord-014712-5u4e00q6	1079	1	In	in	IN
cord-014712-5u4e00q6	1079	2	serological	serological	JJ
cord-014712-5u4e00q6	1079	3	evaluation	evaluation	NN
cord-014712-5u4e00q6	1079	4	:	:	:
cord-014712-5u4e00q6	1079	5	low	low	JJ
cord-014712-5u4e00q6	1079	6	IgG	igg	NN
cord-014712-5u4e00q6	1079	7	level	level	NN
cord-014712-5u4e00q6	1079	8	for	for	IN
cord-014712-5u4e00q6	1079	9	his	-PRON-	PRP$
cord-014712-5u4e00q6	1079	10	age	age	NN
cord-014712-5u4e00q6	1079	11	(	(	-LRB-
cord-014712-5u4e00q6	1079	12	304	304	CD
cord-014712-5u4e00q6	1079	13	mg	mg	NNP
cord-014712-5u4e00q6	1079	14	/	/	SYM
cord-014712-5u4e00q6	1079	15	dl	dl	NNP
cord-014712-5u4e00q6	1079	16	)	)	-RRB-
cord-014712-5u4e00q6	1079	17	was	be	VBD
cord-014712-5u4e00q6	1079	18	detected	detect	VBN
cord-014712-5u4e00q6	1079	19	at	at	IN
cord-014712-5u4e00q6	1079	20	two	two	CD
cord-014712-5u4e00q6	1079	21	different	different	JJ
cord-014712-5u4e00q6	1079	22	times	time	NNS
cord-014712-5u4e00q6	1079	23	.	.	.
cord-014712-5u4e00q6	1080	1	IgG	IgG	NNP
cord-014712-5u4e00q6	1080	2	subgroups	subgroups	NNP
cord-014712-5u4e00q6	1080	3	,	,	,
cord-014712-5u4e00q6	1080	4	IgM	IgM	NNP
cord-014712-5u4e00q6	1080	5	(	(	-LRB-
cord-014712-5u4e00q6	1080	6	106	106	CD
cord-014712-5u4e00q6	1080	7	mg	mg	NNP
cord-014712-5u4e00q6	1080	8	/	/	SYM
cord-014712-5u4e00q6	1080	9	dl	dl	NNP
cord-014712-5u4e00q6	1080	10	)	)	-RRB-
cord-014712-5u4e00q6	1080	11	,	,	,
cord-014712-5u4e00q6	1080	12	IgA	IgA	NNP
cord-014712-5u4e00q6	1080	13	(	(	-LRB-
cord-014712-5u4e00q6	1080	14	34	34	CD
cord-014712-5u4e00q6	1080	15	mg	mg	NNP
cord-014712-5u4e00q6	1080	16	/	/	SYM
cord-014712-5u4e00q6	1080	17	dl	dl	NNP
cord-014712-5u4e00q6	1080	18	)	)	-RRB-
cord-014712-5u4e00q6	1080	19	and	and	CC
cord-014712-5u4e00q6	1080	20	IgE	IgE	NNP
cord-014712-5u4e00q6	1080	21	(	(	-LRB-
cord-014712-5u4e00q6	1080	22	<	<	NNP
cord-014712-5u4e00q6	1080	23	5	5	CD
cord-014712-5u4e00q6	1080	24	)	)	-RRB-
cord-014712-5u4e00q6	1080	25	levels	level	NNS
cord-014712-5u4e00q6	1080	26	were	be	VBD
cord-014712-5u4e00q6	1080	27	normal	normal	JJ
cord-014712-5u4e00q6	1080	28	.	.	.
cord-014712-5u4e00q6	1081	1	Case	case	NN
cord-014712-5u4e00q6	1081	2	3	3	CD
cord-014712-5u4e00q6	1081	3	:	:	:
cord-014712-5u4e00q6	1082	1	20	20	CD
cord-014712-5u4e00q6	1082	2	month	month	NN
cord-014712-5u4e00q6	1082	3	-	-	HYPH
cord-014712-5u4e00q6	1082	4	old	old	JJ
cord-014712-5u4e00q6	1082	5	boy	boy	NN
cord-014712-5u4e00q6	1082	6	was	be	VBD
cord-014712-5u4e00q6	1082	7	brought	bring	VBN
cord-014712-5u4e00q6	1082	8	to	to	IN
cord-014712-5u4e00q6	1082	9	us	-PRON-	PRP
cord-014712-5u4e00q6	1082	10	complaints	complaint	NNS
cord-014712-5u4e00q6	1082	11	of	of	IN
cord-014712-5u4e00q6	1082	12	having	have	VBG
cord-014712-5u4e00q6	1082	13	frequent	frequent	JJ
cord-014712-5u4e00q6	1082	14	lower	low	JJR
cord-014712-5u4e00q6	1082	15	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1082	16	tract	tract	NN
cord-014712-5u4e00q6	1082	17	infections	infection	NNS
cord-014712-5u4e00q6	1082	18	(	(	-LRB-
cord-014712-5u4e00q6	1082	19	bronchiolitis	bronchiolitis	NN
cord-014712-5u4e00q6	1082	20	)	)	-RRB-
cord-014712-5u4e00q6	1082	21	.	.	.
cord-014712-5u4e00q6	1083	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1083	2	was	be	VBD
cord-014712-5u4e00q6	1083	3	experiencing	experience	VBG
cord-014712-5u4e00q6	1083	4	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1083	5	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1083	6	attacks	attack	NNS
cord-014712-5u4e00q6	1083	7	almost	almost	RB
cord-014712-5u4e00q6	1083	8	every	every	DT
cord-014712-5u4e00q6	1083	9	other	other	JJ
cord-014712-5u4e00q6	1083	10	week	week	NN
cord-014712-5u4e00q6	1083	11	for	for	IN
cord-014712-5u4e00q6	1083	12	the	the	DT
cord-014712-5u4e00q6	1083	13	last	last	JJ
cord-014712-5u4e00q6	1083	14	6	6	CD
cord-014712-5u4e00q6	1083	15	months	month	NNS
cord-014712-5u4e00q6	1083	16	.	.	.
cord-014712-5u4e00q6	1084	1	In	in	IN
cord-014712-5u4e00q6	1084	2	past	past	JJ
cord-014712-5u4e00q6	1084	3	medical	medical	JJ
cord-014712-5u4e00q6	1084	4	history	history	NN
cord-014712-5u4e00q6	1084	5	,	,	,
cord-014712-5u4e00q6	1084	6	he	-PRON-	PRP
cord-014712-5u4e00q6	1084	7	was	be	VBD
cord-014712-5u4e00q6	1084	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1084	9	with	with	IN
cord-014712-5u4e00q6	1084	10	trisomy	trisomy	NN
cord-014712-5u4e00q6	1084	11	21	21	CD
cord-014712-5u4e00q6	1084	12	and	and	CC
cord-014712-5u4e00q6	1084	13	hypothyroidism	hypothyroidism	NN
cord-014712-5u4e00q6	1084	14	at	at	IN
cord-014712-5u4e00q6	1084	15	the	the	DT
cord-014712-5u4e00q6	1084	16	3	3	CD
cord-014712-5u4e00q6	1084	17	months	month	NNS
cord-014712-5u4e00q6	1084	18	of	of	IN
cord-014712-5u4e00q6	1084	19	age	age	NN
cord-014712-5u4e00q6	1084	20	.	.	.
cord-014712-5u4e00q6	1085	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1085	2	went	go	VBD
cord-014712-5u4e00q6	1085	3	thru	thru	IN
cord-014712-5u4e00q6	1085	4	an	an	DT
cord-014712-5u4e00q6	1085	5	operation	operation	NN
cord-014712-5u4e00q6	1085	6	for	for	IN
cord-014712-5u4e00q6	1085	7	atrio	atrio	NNP
cord-014712-5u4e00q6	1085	8	-	-	HYPH
cord-014712-5u4e00q6	1085	9	venticular	venticular	NNP
cord-014712-5u4e00q6	1085	10	septal	septal	JJ
cord-014712-5u4e00q6	1085	11	defect	defect	NN
cord-014712-5u4e00q6	1085	12	.	.	.
cord-014712-5u4e00q6	1086	1	Physical	physical	JJ
cord-014712-5u4e00q6	1086	2	exam	exam	NN
cord-014712-5u4e00q6	1086	3	revealed	reveal	VBD
cord-014712-5u4e00q6	1086	4	dyspnea	dyspnea	NN
cord-014712-5u4e00q6	1086	5	,	,	,
cord-014712-5u4e00q6	1086	6	tachypnea	tachypnea	NNP
cord-014712-5u4e00q6	1086	7	and	and	CC
cord-014712-5u4e00q6	1086	8	wheezing	wheezing	NN
cord-014712-5u4e00q6	1086	9	.	.	.
cord-014712-5u4e00q6	1087	1	Crackles	crackle	NNS
cord-014712-5u4e00q6	1087	2	were	be	VBD
cord-014712-5u4e00q6	1087	3	heard	hear	VBN
cord-014712-5u4e00q6	1087	4	on	on	IN
cord-014712-5u4e00q6	1087	5	the	the	DT
cord-014712-5u4e00q6	1087	6	chest	chest	NN
cord-014712-5u4e00q6	1087	7	auscultation	auscultation	NN
cord-014712-5u4e00q6	1087	8	.	.	.
cord-014712-5u4e00q6	1088	1	Abdominal	abdominal	JJ
cord-014712-5u4e00q6	1088	2	,	,	,
cord-014712-5u4e00q6	1088	3	cardio	cardio	NN
cord-014712-5u4e00q6	1088	4	-	-	HYPH
cord-014712-5u4e00q6	1088	5	vascular	vascular	JJ
cord-014712-5u4e00q6	1088	6	and	and	CC
cord-014712-5u4e00q6	1088	7	the	the	DT
cord-014712-5u4e00q6	1088	8	rest	rest	NN
cord-014712-5u4e00q6	1088	9	of	of	IN
cord-014712-5u4e00q6	1088	10	the	the	DT
cord-014712-5u4e00q6	1088	11	examination	examination	NN
cord-014712-5u4e00q6	1088	12	were	be	VBD
cord-014712-5u4e00q6	1088	13	normal	normal	JJ
cord-014712-5u4e00q6	1088	14	.	.	.
cord-014712-5u4e00q6	1089	1	When	when	WRB
cord-014712-5u4e00q6	1089	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1089	3	was	be	VBD
cord-014712-5u4e00q6	1089	4	evaluated	evaluate	VBN
cord-014712-5u4e00q6	1089	5	for	for	IN
cord-014712-5u4e00q6	1089	6	frequent	frequent	JJ
cord-014712-5u4e00q6	1089	7	wheezing	wheezing	JJ
cord-014712-5u4e00q6	1089	8	attacks	attack	NNS
cord-014712-5u4e00q6	1089	9	in	in	IN
cord-014712-5u4e00q6	1089	10	our	-PRON-	PRP$
cord-014712-5u4e00q6	1089	11	outpatient	outpatient	NN
cord-014712-5u4e00q6	1089	12	clinic	clinic	NN
cord-014712-5u4e00q6	1089	13	,	,	,
cord-014712-5u4e00q6	1089	14	routine	routine	JJ
cord-014712-5u4e00q6	1089	15	biochemistry	biochemistry	NN
cord-014712-5u4e00q6	1089	16	,	,	,
cord-014712-5u4e00q6	1089	17	CBC	CBC	NNP
cord-014712-5u4e00q6	1089	18	and	and	CC
cord-014712-5u4e00q6	1089	19	ESR	ESR	NNP
cord-014712-5u4e00q6	1089	20	were	be	VBD
cord-014712-5u4e00q6	1089	21	normal	normal	JJ
cord-014712-5u4e00q6	1089	22	.	.	.
cord-014712-5u4e00q6	1090	1	Chest	chest	NN
cord-014712-5u4e00q6	1090	2	X	x	NN
cord-014712-5u4e00q6	1090	3	-	-	NN
cord-014712-5u4e00q6	1090	4	ray	ray	NN
cord-014712-5u4e00q6	1090	5	showed	show	VBD
cord-014712-5u4e00q6	1090	6	normal	normal	JJ
cord-014712-5u4e00q6	1090	7	findings	finding	NNS
cord-014712-5u4e00q6	1090	8	.	.	.
cord-014712-5u4e00q6	1091	1	In	in	IN
cord-014712-5u4e00q6	1091	2	serological	serological	JJ
cord-014712-5u4e00q6	1091	3	evaluation	evaluation	NN
cord-014712-5u4e00q6	1091	4	:	:	:
cord-014712-5u4e00q6	1091	5	low	low	JJ
cord-014712-5u4e00q6	1091	6	IgG	igg	NN
cord-014712-5u4e00q6	1091	7	level	level	NN
cord-014712-5u4e00q6	1091	8	for	for	IN
cord-014712-5u4e00q6	1091	9	his	-PRON-	PRP$
cord-014712-5u4e00q6	1091	10	age	age	NN
cord-014712-5u4e00q6	1091	11	(	(	-LRB-
cord-014712-5u4e00q6	1091	12	300mg	300mg	NNP
cord-014712-5u4e00q6	1091	13	/	/	SYM
cord-014712-5u4e00q6	1091	14	dl	dl	NNP
cord-014712-5u4e00q6	1091	15	)	)	-RRB-
cord-014712-5u4e00q6	1091	16	was	be	VBD
cord-014712-5u4e00q6	1091	17	detected	detect	VBN
cord-014712-5u4e00q6	1091	18	twice	twice	RB
cord-014712-5u4e00q6	1091	19	.	.	.
cord-014712-5u4e00q6	1092	1	IgG	IgG	NNP
cord-014712-5u4e00q6	1092	2	subgroups	subgroups	NNP
cord-014712-5u4e00q6	1092	3	,	,	,
cord-014712-5u4e00q6	1092	4	IgM	IgM	NNP
cord-014712-5u4e00q6	1092	5	,	,	,
cord-014712-5u4e00q6	1092	6	IgA	IgA	NNP
cord-014712-5u4e00q6	1092	7	and	and	CC
cord-014712-5u4e00q6	1092	8	IgE	IgE	NNP
cord-014712-5u4e00q6	1092	9	levels	level	NNS
cord-014712-5u4e00q6	1092	10	were	be	VBD
cord-014712-5u4e00q6	1092	11	within	within	IN
cord-014712-5u4e00q6	1092	12	normal	normal	JJ
cord-014712-5u4e00q6	1092	13	.	.	.
cord-014712-5u4e00q6	1093	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1093	2	was	be	VBD
cord-014712-5u4e00q6	1093	3	given	give	VBN
cord-014712-5u4e00q6	1093	4	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1093	5	400mg	400mg	NNP
cord-014712-5u4e00q6	1093	6	/	/	SYM
cord-014712-5u4e00q6	1093	7	kg	kg	NN
cord-014712-5u4e00q6	1093	8	/	/	SYM
cord-014712-5u4e00q6	1093	9	dose	dose	NN
cord-014712-5u4e00q6	1093	10	.	.	.
cord-014712-5u4e00q6	1094	1	For	for	IN
cord-014712-5u4e00q6	1094	2	the	the	DT
cord-014712-5u4e00q6	1094	3	last	last	JJ
cord-014712-5u4e00q6	1094	4	three	three	CD
cord-014712-5u4e00q6	1094	5	months	month	NNS
cord-014712-5u4e00q6	1094	6	,	,	,
cord-014712-5u4e00q6	1094	7	he	-PRON-	PRP
cord-014712-5u4e00q6	1094	8	did	do	VBD
cord-014712-5u4e00q6	1094	9	not	not	RB
cord-014712-5u4e00q6	1094	10	have	have	VB
cord-014712-5u4e00q6	1094	11	any	any	DT
cord-014712-5u4e00q6	1094	12	lower	low	JJR
cord-014712-5u4e00q6	1094	13	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1094	14	tract	tract	NN
cord-014712-5u4e00q6	1094	15	infection	infection	NN
cord-014712-5u4e00q6	1094	16	.	.	.
cord-014712-5u4e00q6	1095	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1095	2	:	:	:
cord-014712-5u4e00q6	1096	1	The	the	DT
cord-014712-5u4e00q6	1096	2	awareness	awareness	NN
cord-014712-5u4e00q6	1096	3	of	of	IN
cord-014712-5u4e00q6	1096	4	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1096	5	among	among	IN
cord-014712-5u4e00q6	1096	6	pediatricians	pediatrician	NNS
cord-014712-5u4e00q6	1096	7	has	have	VBZ
cord-014712-5u4e00q6	1096	8	been	be	VBN
cord-014712-5u4e00q6	1096	9	greatly	greatly	RB
cord-014712-5u4e00q6	1096	10	improved	improve	VBN
cord-014712-5u4e00q6	1096	11	.	.	.
cord-014712-5u4e00q6	1097	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	1097	2	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1097	3	tract	tract	NN
cord-014712-5u4e00q6	1097	4	infections	infection	NNS
cord-014712-5u4e00q6	1097	5	are	be	VBP
cord-014712-5u4e00q6	1097	6	major	major	JJ
cord-014712-5u4e00q6	1097	7	infections	infection	NNS
cord-014712-5u4e00q6	1097	8	in	in	IN
cord-014712-5u4e00q6	1097	9	these	these	DT
cord-014712-5u4e00q6	1097	10	patients	patient	NNS
cord-014712-5u4e00q6	1097	11	.	.	.
cord-014712-5u4e00q6	1098	1	THI	THI	NNP
cord-014712-5u4e00q6	1098	2	is	be	VBZ
cord-014712-5u4e00q6	1098	3	a	a	DT
cord-014712-5u4e00q6	1098	4	relatively	relatively	RB
cord-014712-5u4e00q6	1098	5	common	common	JJ
cord-014712-5u4e00q6	1098	6	condition	condition	NN
cord-014712-5u4e00q6	1098	7	associated	associate	VBN
cord-014712-5u4e00q6	1098	8	with	with	IN
cord-014712-5u4e00q6	1098	9	infant	infant	NN
cord-014712-5u4e00q6	1098	10	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1098	11	.	.	.
cord-014712-5u4e00q6	1099	1	In	in	IN
cord-014712-5u4e00q6	1099	2	patients	patient	NNS
cord-014712-5u4e00q6	1099	3	with	with	IN
cord-014712-5u4e00q6	1099	4	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1099	5	and/or	and/or	CC
cord-014712-5u4e00q6	1099	6	persistent	persistent	JJ
cord-014712-5u4e00q6	1099	7	wheezing	wheezing	JJ
cord-014712-5u4e00q6	1099	8	symptoms	symptom	NNS
cord-014712-5u4e00q6	1099	9	during	during	IN
cord-014712-5u4e00q6	1099	10	infancy	infancy	NN
cord-014712-5u4e00q6	1099	11	and	and	CC
cord-014712-5u4e00q6	1099	12	beyond	beyond	IN
cord-014712-5u4e00q6	1099	13	,	,	,
cord-014712-5u4e00q6	1099	14	especially	especially	RB
cord-014712-5u4e00q6	1099	15	resistant	resistant	JJ
cord-014712-5u4e00q6	1099	16	to	to	IN
cord-014712-5u4e00q6	1099	17	therapy	therapy	NN
cord-014712-5u4e00q6	1099	18	,	,	,
cord-014712-5u4e00q6	1099	19	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1099	20	should	should	MD
cord-014712-5u4e00q6	1099	21	be	be	VB
cord-014712-5u4e00q6	1099	22	excluded	exclude	VBN
cord-014712-5u4e00q6	1099	23	from	from	IN
cord-014712-5u4e00q6	1099	24	possible	possible	JJ
cord-014712-5u4e00q6	1099	25	diagnoses	diagnosis	NNS
cord-014712-5u4e00q6	1099	26	.	.	.
cord-014712-5u4e00q6	1100	1	Background	background	NN
cord-014712-5u4e00q6	1100	2	:	:	:
cord-014712-5u4e00q6	1101	1	The	the	DT
cord-014712-5u4e00q6	1101	2	acquisition	acquisition	NN
cord-014712-5u4e00q6	1101	3	of	of	IN
cord-014712-5u4e00q6	1101	4	new	new	JJ
cord-014712-5u4e00q6	1101	5	food	food	NN
cord-014712-5u4e00q6	1101	6	allergy	allergy	NN
cord-014712-5u4e00q6	1101	7	after	after	IN
cord-014712-5u4e00q6	1101	8	transplantation	transplantation	NN
cord-014712-5u4e00q6	1101	9	or	or	CC
cord-014712-5u4e00q6	1101	10	transplant	transplant	NN
cord-014712-5u4e00q6	1101	11	-	-	HYPH
cord-014712-5u4e00q6	1101	12	acquired	acquire	VBN
cord-014712-5u4e00q6	1101	13	food	food	NN
cord-014712-5u4e00q6	1101	14	allergy	allergy	NN
cord-014712-5u4e00q6	1101	15	(	(	-LRB-
cord-014712-5u4e00q6	1101	16	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1101	17	)	)	-RRB-
cord-014712-5u4e00q6	1101	18	is	be	VBZ
cord-014712-5u4e00q6	1101	19	usually	usually	RB
cord-014712-5u4e00q6	1101	20	reported	report	VBN
cord-014712-5u4e00q6	1101	21	in	in	IN
cord-014712-5u4e00q6	1101	22	adults	adult	NNS
cord-014712-5u4e00q6	1101	23	and	and	CC
cord-014712-5u4e00q6	1101	24	rarely	rarely	RB
cord-014712-5u4e00q6	1101	25	in	in	IN
cord-014712-5u4e00q6	1101	26	children	child	NNS
cord-014712-5u4e00q6	1101	27	.	.	.
cord-014712-5u4e00q6	1102	1	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1102	2	is	be	VBZ
cord-014712-5u4e00q6	1102	3	described	describe	VBN
cord-014712-5u4e00q6	1102	4	mainly	mainly	RB
cord-014712-5u4e00q6	1102	5	after	after	IN
cord-014712-5u4e00q6	1102	6	liver	liver	NN
cord-014712-5u4e00q6	1102	7	,	,	,
cord-014712-5u4e00q6	1102	8	but	but	CC
cord-014712-5u4e00q6	1102	9	also	also	RB
cord-014712-5u4e00q6	1102	10	after	after	IN
cord-014712-5u4e00q6	1102	11	small	small	JJ
cord-014712-5u4e00q6	1102	12	bowel	bowel	NN
cord-014712-5u4e00q6	1102	13	/	/	SYM
cord-014712-5u4e00q6	1102	14	intestinal	intestinal	JJ
cord-014712-5u4e00q6	1102	15	,	,	,
cord-014712-5u4e00q6	1102	16	lung	lung	NN
cord-014712-5u4e00q6	1102	17	and	and	CC
cord-014712-5u4e00q6	1102	18	heart	heart	NN
cord-014712-5u4e00q6	1102	19	transplantations	transplantation	NNS
cord-014712-5u4e00q6	1102	20	.	.	.
cord-014712-5u4e00q6	1103	1	In	in	IN
cord-014712-5u4e00q6	1103	2	different	different	JJ
cord-014712-5u4e00q6	1103	3	studies	study	NNS
cord-014712-5u4e00q6	1103	4	,	,	,
cord-014712-5u4e00q6	1103	5	the	the	DT
cord-014712-5u4e00q6	1103	6	male	male	JJ
cord-014712-5u4e00q6	1103	7	/	/	SYM
cord-014712-5u4e00q6	1103	8	female	female	JJ
cord-014712-5u4e00q6	1103	9	ratio	ratio	NN
cord-014712-5u4e00q6	1103	10	is	be	VBZ
cord-014712-5u4e00q6	1103	11	equal	equal	JJ
cord-014712-5u4e00q6	1103	12	.	.	.
cord-014712-5u4e00q6	1104	1	Literature	literature	NN
cord-014712-5u4e00q6	1104	2	data	datum	NNS
cord-014712-5u4e00q6	1104	3	suggest	suggest	VBP
cord-014712-5u4e00q6	1104	4	that	that	IN
cord-014712-5u4e00q6	1104	5	children	child	NNS
cord-014712-5u4e00q6	1104	6	with	with	IN
cord-014712-5u4e00q6	1104	7	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1104	8	typically	typically	RB
cord-014712-5u4e00q6	1104	9	present	present	VBP
cord-014712-5u4e00q6	1104	10	within	within	IN
cord-014712-5u4e00q6	1104	11	the	the	DT
cord-014712-5u4e00q6	1104	12	first	first	JJ
cord-014712-5u4e00q6	1104	13	year	year	NN
cord-014712-5u4e00q6	1104	14	after	after	IN
cord-014712-5u4e00q6	1104	15	surgery	surgery	NN
cord-014712-5u4e00q6	1105	1	and	and	CC
cord-014712-5u4e00q6	1105	2	they	-PRON-	PRP
cord-014712-5u4e00q6	1105	3	are	be	VBP
cord-014712-5u4e00q6	1105	4	typically	typically	RB
cord-014712-5u4e00q6	1105	5	allergic	allergic	JJ
cord-014712-5u4e00q6	1105	6	to	to	IN
cord-014712-5u4e00q6	1105	7	multiple	multiple	JJ
cord-014712-5u4e00q6	1105	8	foods	food	NNS
cord-014712-5u4e00q6	1105	9	.	.	.
cord-014712-5u4e00q6	1106	1	Aim	aim	VB
cord-014712-5u4e00q6	1106	2	:	:	:
cord-014712-5u4e00q6	1107	1	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1107	2	is	be	VBZ
cord-014712-5u4e00q6	1107	3	generally	generally	RB
cord-014712-5u4e00q6	1107	4	characterized	characterize	VBN
cord-014712-5u4e00q6	1107	5	with	with	IN
cord-014712-5u4e00q6	1107	6	allergy	allergy	NN
cord-014712-5u4e00q6	1107	7	to	to	IN
cord-014712-5u4e00q6	1107	8	multiple	multiple	JJ
cord-014712-5u4e00q6	1107	9	foods	food	NNS
cord-014712-5u4e00q6	1107	10	and	and	CC
cord-014712-5u4e00q6	1107	11	increased	increase	VBN
cord-014712-5u4e00q6	1107	12	level	level	NN
cord-014712-5u4e00q6	1107	13	of	of	IN
cord-014712-5u4e00q6	1107	14	total	total	NN
cord-014712-5u4e00q6	1107	15	and/or	and/or	CC
cord-014712-5u4e00q6	1107	16	spesific	spesific	JJ
cord-014712-5u4e00q6	1107	17	IgE.	ige.	NN
cord-014712-5u4e00q6	1108	1	Here	here	RB
cord-014712-5u4e00q6	1108	2	,	,	,
cord-014712-5u4e00q6	1108	3	a	a	DT
cord-014712-5u4e00q6	1108	4	patient	patient	NN
cord-014712-5u4e00q6	1109	1	although	although	IN
cord-014712-5u4e00q6	1109	2	who	who	WP
cord-014712-5u4e00q6	1109	3	had	have	VBD
cord-014712-5u4e00q6	1109	4	normal	normal	JJ
cord-014712-5u4e00q6	1109	5	total	total	NN
cord-014712-5u4e00q6	1109	6	.	.	.
cord-014712-5u4e00q6	1110	1	IgE	IgE	NNP
cord-014712-5u4e00q6	1110	2	and	and	CC
cord-014712-5u4e00q6	1110	3	specific	specific	NNP
cord-014712-5u4e00q6	1110	4	IgE	IgE	NNP
cord-014712-5u4e00q6	1110	5	test	test	NN
cord-014712-5u4e00q6	1110	6	results	result	NNS
cord-014712-5u4e00q6	1110	7	,	,	,
cord-014712-5u4e00q6	1110	8	he	-PRON-	PRP
cord-014712-5u4e00q6	1110	9	developed	develop	VBD
cord-014712-5u4e00q6	1110	10	reaction	reaction	NN
cord-014712-5u4e00q6	1110	11	to	to	IN
cord-014712-5u4e00q6	1110	12	skin	skin	NN
cord-014712-5u4e00q6	1110	13	prick	prick	NN
cord-014712-5u4e00q6	1110	14	test	test	NN
cord-014712-5u4e00q6	1110	15	for	for	IN
cord-014712-5u4e00q6	1110	16	cow	cow	NN
cord-014712-5u4e00q6	1110	17	's	's	POS
cord-014712-5u4e00q6	1110	18	milk	milk	NN
cord-014712-5u4e00q6	1110	19	is	be	VBZ
cord-014712-5u4e00q6	1110	20	presented	present	VBN
cord-014712-5u4e00q6	1110	21	and	and	CC
cord-014712-5u4e00q6	1110	22	his	-PRON-	PRP$
cord-014712-5u4e00q6	1110	23	clinical	clinical	JJ
cord-014712-5u4e00q6	1110	24	presentation	presentation	NN
cord-014712-5u4e00q6	1110	25	will	will	MD
cord-014712-5u4e00q6	1110	26	be	be	VB
cord-014712-5u4e00q6	1110	27	discussed	discuss	VBN
cord-014712-5u4e00q6	1110	28	.	.	.
cord-014712-5u4e00q6	1111	1	Case	case	NN
cord-014712-5u4e00q6	1111	2	presentation	presentation	NN
cord-014712-5u4e00q6	1111	3	:	:	:
cord-014712-5u4e00q6	1112	1	15	15	CD
cord-014712-5u4e00q6	1112	2	month	month	NN
cord-014712-5u4e00q6	1112	3	-	-	HYPH
cord-014712-5u4e00q6	1112	4	old	old	JJ
cord-014712-5u4e00q6	1112	5	-	-	HYPH
cord-014712-5u4e00q6	1112	6	boy	boy	NN
cord-014712-5u4e00q6	1112	7	came	come	VBD
cord-014712-5u4e00q6	1112	8	to	to	IN
cord-014712-5u4e00q6	1112	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	1112	10	allergy	allergy	NN
cord-014712-5u4e00q6	1112	11	clinic	clinic	NN
cord-014712-5u4e00q6	1112	12	with	with	IN
cord-014712-5u4e00q6	1112	13	complaints	complaint	NNS
cord-014712-5u4e00q6	1112	14	of	of	IN
cord-014712-5u4e00q6	1112	15	vomiting	vomit	VBG
cord-014712-5u4e00q6	1112	16	after	after	IN
cord-014712-5u4e00q6	1112	17	drinking	drink	VBG
cord-014712-5u4e00q6	1112	18	cow	cow	NN
cord-014712-5u4e00q6	1112	19	's	's	POS
cord-014712-5u4e00q6	1112	20	milk	milk	NN
cord-014712-5u4e00q6	1112	21	and	and	CC
cord-014712-5u4e00q6	1112	22	skin	skin	NN
cord-014712-5u4e00q6	1112	23	rush	rush	NN
cord-014712-5u4e00q6	1112	24	on	on	IN
cord-014712-5u4e00q6	1112	25	the	the	DT
cord-014712-5u4e00q6	1112	26	area	area	NN
cord-014712-5u4e00q6	1112	27	where	where	WRB
cord-014712-5u4e00q6	1112	28	contact	contact	NN
cord-014712-5u4e00q6	1112	29	ed	ed	NN
cord-014712-5u4e00q6	1112	30	with	with	IN
cord-014712-5u4e00q6	1112	31	chocolate	chocolate	NN
cord-014712-5u4e00q6	1112	32	.	.	.
cord-014712-5u4e00q6	1113	1	In	in	IN
cord-014712-5u4e00q6	1113	2	his	-PRON-	PRP$
cord-014712-5u4e00q6	1113	3	past	past	JJ
cord-014712-5u4e00q6	1113	4	medical	medical	JJ
cord-014712-5u4e00q6	1113	5	histroy	histroy	NN
cord-014712-5u4e00q6	1113	6	,	,	,
cord-014712-5u4e00q6	1113	7	left	leave	VBD
cord-014712-5u4e00q6	1113	8	lateral	lateral	JJ
cord-014712-5u4e00q6	1113	9	segment	segment	NN
cord-014712-5u4e00q6	1113	10	of	of	IN
cord-014712-5u4e00q6	1113	11	liver	liver	NN
cord-014712-5u4e00q6	1113	12	(	(	-LRB-
cord-014712-5u4e00q6	1113	13	donor	donor	NN
cord-014712-5u4e00q6	1113	14	was	be	VBD
cord-014712-5u4e00q6	1113	15	his	-PRON-	PRP$
cord-014712-5u4e00q6	1113	16	mother	mother	NN
cord-014712-5u4e00q6	1113	17	)	)	-RRB-
cord-014712-5u4e00q6	1113	18	was	be	VBD
cord-014712-5u4e00q6	1113	19	transplanted	transplant	VBN
cord-014712-5u4e00q6	1113	20	to	to	IN
cord-014712-5u4e00q6	1113	21	him	-PRON-	PRP
cord-014712-5u4e00q6	1113	22	when	when	WRB
cord-014712-5u4e00q6	1113	23	he	-PRON-	PRP
cord-014712-5u4e00q6	1113	24	was	be	VBD
cord-014712-5u4e00q6	1113	25	at	at	IN
cord-014712-5u4e00q6	1113	26	5	5	CD
cord-014712-5u4e00q6	1113	27	months	month	NNS
cord-014712-5u4e00q6	1113	28	.	.	.
cord-014712-5u4e00q6	1114	1	The	the	DT
cord-014712-5u4e00q6	1114	2	liver	liver	NN
cord-014712-5u4e00q6	1114	3	donor	donor	NN
cord-014712-5u4e00q6	1114	4	was	be	VBD
cord-014712-5u4e00q6	1114	5	not	not	RB
cord-014712-5u4e00q6	1114	6	recorded	record	VBN
cord-014712-5u4e00q6	1114	7	as	as	IN
cord-014712-5u4e00q6	1114	8	having	have	VBG
cord-014712-5u4e00q6	1114	9	a	a	DT
cord-014712-5u4e00q6	1114	10	history	history	NN
cord-014712-5u4e00q6	1114	11	of	of	IN
cord-014712-5u4e00q6	1114	12	allergic	allergic	JJ
cord-014712-5u4e00q6	1114	13	disease	disease	NN
cord-014712-5u4e00q6	1114	14	.	.	.
cord-014712-5u4e00q6	1115	1	Methylprednisolone	Methylprednisolone	NNP
cord-014712-5u4e00q6	1115	2	and	and	CC
cord-014712-5u4e00q6	1115	3	tacrolimus	tacrolimus	NN
cord-014712-5u4e00q6	1115	4	immunosuppression	immunosuppression	NN
cord-014712-5u4e00q6	1115	5	were	be	VBD
cord-014712-5u4e00q6	1115	6	used	use	VBN
cord-014712-5u4e00q6	1115	7	after	after	IN
cord-014712-5u4e00q6	1115	8	the	the	DT
cord-014712-5u4e00q6	1115	9	transplantation	transplantation	NN
cord-014712-5u4e00q6	1115	10	,	,	,
cord-014712-5u4e00q6	1115	11	and	and	CC
cord-014712-5u4e00q6	1115	12	tacrolimus	tacrolimus	NN
cord-014712-5u4e00q6	1115	13	therapy	therapy	NN
cord-014712-5u4e00q6	1115	14	was	be	VBD
cord-014712-5u4e00q6	1115	15	continued	continue	VBN
cord-014712-5u4e00q6	1115	16	for	for	IN
cord-014712-5u4e00q6	1115	17	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	1115	18	of	of	IN
cord-014712-5u4e00q6	1115	19	chronic	chronic	JJ
cord-014712-5u4e00q6	1115	20	rejection	rejection	NN
cord-014712-5u4e00q6	1115	21	.	.	.
cord-014712-5u4e00q6	1116	1	When	when	WRB
cord-014712-5u4e00q6	1116	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1116	3	was	be	VBD
cord-014712-5u4e00q6	1116	4	at	at	IN
cord-014712-5u4e00q6	1116	5	7	7	CD
cord-014712-5u4e00q6	1116	6	months	month	NNS
cord-014712-5u4e00q6	1116	7	,	,	,
cord-014712-5u4e00q6	1116	8	family	family	NN
cord-014712-5u4e00q6	1116	9	fed	feed	VBD
cord-014712-5u4e00q6	1116	10	the	the	DT
cord-014712-5u4e00q6	1116	11	patient	patient	NN
cord-014712-5u4e00q6	1116	12	with	with	IN
cord-014712-5u4e00q6	1116	13	cow	cow	NN
cord-014712-5u4e00q6	1116	14	's	's	POS
cord-014712-5u4e00q6	1116	15	milk	milk	NN
cord-014712-5u4e00q6	1116	16	but	but	CC
cord-014712-5u4e00q6	1116	17	3	3	CD
cord-014712-5u4e00q6	1116	18	hours	hour	NNS
cord-014712-5u4e00q6	1116	19	later	later	RBR
cord-014712-5u4e00q6	1116	20	he	-PRON-	PRP
cord-014712-5u4e00q6	1116	21	began	begin	VBD
cord-014712-5u4e00q6	1116	22	to	to	TO
cord-014712-5u4e00q6	1116	23	vomit	vomit	VB
cord-014712-5u4e00q6	1116	24	.	.	.
cord-014712-5u4e00q6	1117	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1117	2	vomited	vomit	VBD
cord-014712-5u4e00q6	1117	3	five	five	CD
cord-014712-5u4e00q6	1117	4	times	time	NNS
cord-014712-5u4e00q6	1117	5	in	in	IN
cord-014712-5u4e00q6	1117	6	two	two	CD
cord-014712-5u4e00q6	1117	7	hours	hour	NNS
cord-014712-5u4e00q6	1117	8	.	.	.
cord-014712-5u4e00q6	1118	1	Then	then	RB
cord-014712-5u4e00q6	1118	2	,	,	,
cord-014712-5u4e00q6	1118	3	he	-PRON-	PRP
cord-014712-5u4e00q6	1118	4	developed	develop	VBD
cord-014712-5u4e00q6	1118	5	constipation	constipation	NN
cord-014712-5u4e00q6	1118	6	.	.	.
cord-014712-5u4e00q6	1119	1	Rectal	rectal	JJ
cord-014712-5u4e00q6	1119	2	irrigation	irrigation	NN
cord-014712-5u4e00q6	1119	3	was	be	VBD
cord-014712-5u4e00q6	1119	4	used	use	VBN
cord-014712-5u4e00q6	1119	5	.	.	.
cord-014712-5u4e00q6	1120	1	Then	then	RB
cord-014712-5u4e00q6	1120	2	oral	oral	JJ
cord-014712-5u4e00q6	1120	3	intake	intake	NN
cord-014712-5u4e00q6	1120	4	stopped	stop	VBD
cord-014712-5u4e00q6	1120	5	for	for	IN
cord-014712-5u4e00q6	1120	6	two	two	CD
cord-014712-5u4e00q6	1120	7	days	day	NNS
cord-014712-5u4e00q6	1120	8	.	.	.
cord-014712-5u4e00q6	1121	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1121	2	was	be	VBD
cord-014712-5u4e00q6	1121	3	thought	think	VBN
cord-014712-5u4e00q6	1121	4	to	to	TO
cord-014712-5u4e00q6	1121	5	be	be	VB
cord-014712-5u4e00q6	1121	6	having	have	VBG
cord-014712-5u4e00q6	1121	7	food	food	NN
cord-014712-5u4e00q6	1121	8	protein	protein	NN
cord-014712-5u4e00q6	1121	9	induced	induce	VBN
cord-014712-5u4e00q6	1121	10	enterocolitis	enterocolitis	NN
cord-014712-5u4e00q6	1121	11	.	.	.
cord-014712-5u4e00q6	1122	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1122	2	vomiting	vomiting	NN
cord-014712-5u4e00q6	1122	3	complaints	complaint	NNS
cord-014712-5u4e00q6	1122	4	repeated	repeat	VBN
cord-014712-5u4e00q6	1122	5	after	after	IN
cord-014712-5u4e00q6	1122	6	intake	intake	NN
cord-014712-5u4e00q6	1122	7	of	of	IN
cord-014712-5u4e00q6	1122	8	formula	formula	NN
cord-014712-5u4e00q6	1122	9	and	and	CC
cord-014712-5u4e00q6	1122	10	baby	baby	NN
cord-014712-5u4e00q6	1122	11	food	food	NN
cord-014712-5u4e00q6	1122	12	which	which	WDT
cord-014712-5u4e00q6	1122	13	include	include	VBP
cord-014712-5u4e00q6	1122	14	grain	grain	NN
cord-014712-5u4e00q6	1122	15	.	.	.
cord-014712-5u4e00q6	1123	1	So	so	RB
cord-014712-5u4e00q6	1123	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1123	3	fed	feed	VBD
cord-014712-5u4e00q6	1123	4	with	with	IN
cord-014712-5u4e00q6	1123	5	special	special	JJ
cord-014712-5u4e00q6	1123	6	formula	formula	NN
cord-014712-5u4e00q6	1123	7	including	include	VBG
cord-014712-5u4e00q6	1123	8	short	short	JJ
cord-014712-5u4e00q6	1123	9	-	-	HYPH
cord-014712-5u4e00q6	1123	10	chain	chain	NN
cord-014712-5u4e00q6	1123	11	peptides	peptide	NNS
cord-014712-5u4e00q6	1123	12	and	and	CC
cord-014712-5u4e00q6	1123	13	free	free	JJ
cord-014712-5u4e00q6	1123	14	aminoacids	aminoacid	NNS
cord-014712-5u4e00q6	1123	15	and	and	CC
cord-014712-5u4e00q6	1123	16	his	-PRON-	PRP$
cord-014712-5u4e00q6	1123	17	symptoms	symptom	NNS
cord-014712-5u4e00q6	1123	18	improved	improve	VBD
cord-014712-5u4e00q6	1123	19	.	.	.
cord-014712-5u4e00q6	1124	1	Past	past	JJ
cord-014712-5u4e00q6	1124	2	medical	medical	JJ
cord-014712-5u4e00q6	1124	3	history	history	NN
cord-014712-5u4e00q6	1124	4	:	:	:
cord-014712-5u4e00q6	1124	5	Extrahepatic	extrahepatic	JJ
cord-014712-5u4e00q6	1124	6	biliary	biliary	JJ
cord-014712-5u4e00q6	1124	7	atresia	atresia	NN
cord-014712-5u4e00q6	1124	8	was	be	VBD
cord-014712-5u4e00q6	1124	9	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1124	10	at	at	IN
cord-014712-5u4e00q6	1124	11	3	3	CD
cord-014712-5u4e00q6	1124	12	weeks	week	NNS
cord-014712-5u4e00q6	1124	13	age	age	NN
cord-014712-5u4e00q6	1124	14	with	with	IN
cord-014712-5u4e00q6	1124	15	conjugated	conjugate	VBN
cord-014712-5u4e00q6	1124	16	hyperbilirubinemia	hyperbilirubinemia	NNP
cord-014712-5u4e00q6	1124	17	(	(	-LRB-
cord-014712-5u4e00q6	1124	18	according	accord	VBG
cord-014712-5u4e00q6	1124	19	to	to	IN
cord-014712-5u4e00q6	1124	20	scintigraphy	scintigraphy	NN
cord-014712-5u4e00q6	1124	21	and	and	CC
cord-014712-5u4e00q6	1124	22	biopsy	biopsy	NN
cord-014712-5u4e00q6	1124	23	results	result	NNS
cord-014712-5u4e00q6	1124	24	)	)	-RRB-
cord-014712-5u4e00q6	1124	25	.	.	.
cord-014712-5u4e00q6	1125	1	Family	family	NN
cord-014712-5u4e00q6	1125	2	history	history	NN
cord-014712-5u4e00q6	1125	3	:	:	:
cord-014712-5u4e00q6	1126	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1126	2	father	father	NN
cord-014712-5u4e00q6	1126	3	has	have	VBZ
cord-014712-5u4e00q6	1126	4	penicillin	penicillin	NN
cord-014712-5u4e00q6	1126	5	allergy	allergy	NN
cord-014712-5u4e00q6	1126	6	and	and	CC
cord-014712-5u4e00q6	1126	7	his	-PRON-	PRP$
cord-014712-5u4e00q6	1126	8	aunt	aunt	NN
cord-014712-5u4e00q6	1126	9	has	have	VBZ
cord-014712-5u4e00q6	1126	10	asthma	asthma	NN
cord-014712-5u4e00q6	1126	11	.	.	.
cord-014712-5u4e00q6	1127	1	At	at	IN
cord-014712-5u4e00q6	1127	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	1127	3	outpatient	outpatient	NN
cord-014712-5u4e00q6	1127	4	clinic	clinic	NN
cord-014712-5u4e00q6	1127	5	:	:	:
cord-014712-5u4e00q6	1127	6	Height	height	NN
cord-014712-5u4e00q6	1127	7	and	and	CC
cord-014712-5u4e00q6	1127	8	weight	weight	NN
cord-014712-5u4e00q6	1127	9	were	be	VBD
cord-014712-5u4e00q6	1127	10	within	within	IN
cord-014712-5u4e00q6	1127	11	normal	normal	JJ
cord-014712-5u4e00q6	1127	12	percentiles	percentile	NNS
cord-014712-5u4e00q6	1127	13	.	.	.
cord-014712-5u4e00q6	1128	1	Physical	physical	JJ
cord-014712-5u4e00q6	1128	2	examination	examination	NN
cord-014712-5u4e00q6	1128	3	reevaled	reevale	VBD
cord-014712-5u4e00q6	1128	4	normal	normal	JJ
cord-014712-5u4e00q6	1128	5	examination	examination	NN
cord-014712-5u4e00q6	1128	6	findings	finding	NNS
cord-014712-5u4e00q6	1128	7	.	.	.
cord-014712-5u4e00q6	1129	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1129	2	findings	finding	NNS
cord-014712-5u4e00q6	1129	3	:	:	:
cord-014712-5u4e00q6	1130	1	WBC	WBC	NNP
cord-014712-5u4e00q6	1130	2	was	be	VBD
cord-014712-5u4e00q6	1130	3	4.420	4.420	CD
cord-014712-5u4e00q6	1130	4	/	/	SYM
cord-014712-5u4e00q6	1130	5	mm3	mm3	NNS
cord-014712-5u4e00q6	1130	6	,	,	,
cord-014712-5u4e00q6	1130	7	with	with	IN
cord-014712-5u4e00q6	1130	8	21	21	CD
cord-014712-5u4e00q6	1130	9	%	%	NN
cord-014712-5u4e00q6	1130	10	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	1130	11	,	,	,
cord-014712-5u4e00q6	1130	12	6	6	CD
cord-014712-5u4e00q6	1130	13	%	%	NN
cord-014712-5u4e00q6	1130	14	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1130	15	and	and	CC
cord-014712-5u4e00q6	1130	16	69	69	CD
cord-014712-5u4e00q6	1130	17	%	%	NN
cord-014712-5u4e00q6	1130	18	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1130	19	.	.	.
cord-014712-5u4e00q6	1131	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1131	2	hemoglobin	hemoglobin	NN
cord-014712-5u4e00q6	1131	3	was	be	VBD
cord-014712-5u4e00q6	1131	4	8.2	8.2	CD
cord-014712-5u4e00q6	1131	5	g/	g/	JJ
cord-014712-5u4e00q6	1131	6	dL	dl	NN
cord-014712-5u4e00q6	1131	7	,	,	,
cord-014712-5u4e00q6	1131	8	platelet	platelet	NN
cord-014712-5u4e00q6	1131	9	count	count	NN
cord-014712-5u4e00q6	1131	10	was	be	VBD
cord-014712-5u4e00q6	1131	11	280.000	280.000	CD
cord-014712-5u4e00q6	1131	12	/	/	SYM
cord-014712-5u4e00q6	1131	13	mm3	mm3	NNS
cord-014712-5u4e00q6	1131	14	.	.	.
cord-014712-5u4e00q6	1132	1	Total	total	JJ
cord-014712-5u4e00q6	1132	2	IgE	IgE	NNP
cord-014712-5u4e00q6	1132	3	:	:	:
cord-014712-5u4e00q6	1132	4	<	<	NNP
cord-014712-5u4e00q6	1132	5	5	5	CD
cord-014712-5u4e00q6	1132	6	and	and	CC
cord-014712-5u4e00q6	1132	7	ImmunoCAP	ImmunoCAP	NNP
cord-014712-5u4e00q6	1132	8	specific	specific	JJ
cord-014712-5u4e00q6	1132	9	IgE	IgE	NNP
cord-014712-5u4e00q6	1132	10	against	against	IN
cord-014712-5u4e00q6	1132	11	milk	milk	NN
cord-014712-5u4e00q6	1132	12	,	,	,
cord-014712-5u4e00q6	1132	13	grain	grain	NN
cord-014712-5u4e00q6	1132	14	and	and	CC
cord-014712-5u4e00q6	1132	15	other	other	JJ
cord-014712-5u4e00q6	1132	16	classsic	classsic	JJ
cord-014712-5u4e00q6	1132	17	foods	food	NNS
cord-014712-5u4e00q6	1132	18	was	be	VBD
cord-014712-5u4e00q6	1132	19	<	<	XX
cord-014712-5u4e00q6	1132	20	0.35	0.35	CD
cord-014712-5u4e00q6	1132	21	.	.	.
cord-014712-5u4e00q6	1133	1	Skin	skin	NN
cord-014712-5u4e00q6	1133	2	prick	prick	NN
cord-014712-5u4e00q6	1133	3	test	test	NN
cord-014712-5u4e00q6	1133	4	results	result	NNS
cord-014712-5u4e00q6	1133	5	:	:	:
cord-014712-5u4e00q6	1133	6	saline	saline	NN
cord-014712-5u4e00q6	1133	7	:	:	:
cord-014712-5u4e00q6	1133	8	0x0	0x0	CD
cord-014712-5u4e00q6	1133	9	mm	mm	NN
cord-014712-5u4e00q6	1133	10	,	,	,
cord-014712-5u4e00q6	1133	11	histamine	histamine	NN
cord-014712-5u4e00q6	1133	12	4x4	4x4	CD
cord-014712-5u4e00q6	1133	13	mm	mm	NN
cord-014712-5u4e00q6	1133	14	,	,	,
cord-014712-5u4e00q6	1133	15	fresh	fresh	JJ
cord-014712-5u4e00q6	1133	16	cow	cow	NN
cord-014712-5u4e00q6	1133	17	's	's	POS
cord-014712-5u4e00q6	1133	18	milk:2x2	milk:2x2	NN
cord-014712-5u4e00q6	1133	19	mm	mm	NNP
cord-014712-5u4e00q6	1133	20	,	,	,
cord-014712-5u4e00q6	1133	21	other	other	JJ
cord-014712-5u4e00q6	1133	22	food	food	NN
cord-014712-5u4e00q6	1133	23	allergens	allergen	NNS
cord-014712-5u4e00q6	1133	24	(	(	-LRB-
cord-014712-5u4e00q6	1133	25	peanut	peanut	NN
cord-014712-5u4e00q6	1133	26	,	,	,
cord-014712-5u4e00q6	1133	27	egg	egg	NN
cord-014712-5u4e00q6	1133	28	,	,	,
cord-014712-5u4e00q6	1133	29	fish	fish	NN
cord-014712-5u4e00q6	1133	30	,	,	,
cord-014712-5u4e00q6	1133	31	soybean	soybean	NN
cord-014712-5u4e00q6	1133	32	,	,	,
cord-014712-5u4e00q6	1133	33	wheat	wheat	NN
cord-014712-5u4e00q6	1133	34	)	)	-RRB-
cord-014712-5u4e00q6	1133	35	:	:	:
cord-014712-5u4e00q6	1133	36	0x0	0x0	CD
cord-014712-5u4e00q6	1133	37	mm	mm	NN
cord-014712-5u4e00q6	1133	38	.	.	.
cord-014712-5u4e00q6	1134	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1134	2	:	:	:
cord-014712-5u4e00q6	1135	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	1135	2	patient	patient	NN
cord-014712-5u4e00q6	1135	3	seemed	seem	VBD
cord-014712-5u4e00q6	1135	4	to	to	TO
cord-014712-5u4e00q6	1135	5	have	have	VB
cord-014712-5u4e00q6	1135	6	cow	cow	NN
cord-014712-5u4e00q6	1135	7	's	's	POS
cord-014712-5u4e00q6	1135	8	milk	milk	NN
cord-014712-5u4e00q6	1135	9	allergy	allergy	NN
cord-014712-5u4e00q6	1135	10	related	relate	VBN
cord-014712-5u4e00q6	1135	11	to	to	IN
cord-014712-5u4e00q6	1135	12	liver	liver	NN
cord-014712-5u4e00q6	1135	13	transplantation	transplantation	NN
cord-014712-5u4e00q6	1135	14	.	.	.
cord-014712-5u4e00q6	1136	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1136	2	investigations	investigation	NNS
cord-014712-5u4e00q6	1136	3	and	and	CC
cord-014712-5u4e00q6	1136	4	clinical	clinical	JJ
cord-014712-5u4e00q6	1136	5	presentation	presentation	NN
cord-014712-5u4e00q6	1136	6	of	of	IN
cord-014712-5u4e00q6	1136	7	the	the	DT
cord-014712-5u4e00q6	1136	8	patient	patient	NN
cord-014712-5u4e00q6	1136	9	did	do	VBD
cord-014712-5u4e00q6	1136	10	not	not	RB
cord-014712-5u4e00q6	1136	11	look	look	VB
cord-014712-5u4e00q6	1136	12	like	like	IN
cord-014712-5u4e00q6	1136	13	typical	typical	JJ
cord-014712-5u4e00q6	1136	14	IgE	ige	NN
cord-014712-5u4e00q6	1136	15	-	-	HYPH
cord-014712-5u4e00q6	1136	16	mediated	mediate	VBN
cord-014712-5u4e00q6	1136	17	food	food	NN
cord-014712-5u4e00q6	1136	18	allergy	allergy	NN
cord-014712-5u4e00q6	1136	19	,	,	,
cord-014712-5u4e00q6	1136	20	which	which	WDT
cord-014712-5u4e00q6	1136	21	is	be	VBZ
cord-014712-5u4e00q6	1136	22	expected	expect	VBN
cord-014712-5u4e00q6	1136	23	in	in	IN
cord-014712-5u4e00q6	1136	24	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1136	25	.	.	.
cord-014712-5u4e00q6	1136	26	 	 	_SP
cord-014712-5u4e00q6	1137	1	Patient	patient	JJ
cord-014712-5u4e00q6	1137	2	History	history	NN
cord-014712-5u4e00q6	1137	3	:	:	:
cord-014712-5u4e00q6	1137	4	33	33	CD
cord-014712-5u4e00q6	1137	5	years	year	NNS
cord-014712-5u4e00q6	1137	6	old	old	JJ
cord-014712-5u4e00q6	1137	7	male	male	JJ
cord-014712-5u4e00q6	1137	8	patient	patient	NN
cord-014712-5u4e00q6	1137	9	,	,	.
cord-014712-5u4e00q6	1138	1	The	the	DT
cord-014712-5u4e00q6	1138	2	first	first	JJ
cord-014712-5u4e00q6	1138	3	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1138	4	at	at	IN
cord-014712-5u4e00q6	1138	5	the	the	DT
cord-014712-5u4e00q6	1138	6	age	age	NN
cord-014712-5u4e00q6	1138	7	of	of	IN
cord-014712-5u4e00q6	1138	8	18	18	CD
cord-014712-5u4e00q6	1138	9	followed	follow	VBN
cord-014712-5u4e00q6	1138	10	by	by	IN
cord-014712-5u4e00q6	1138	11	3	3	CD
cord-014712-5u4e00q6	1138	12	times	time	NNS
cord-014712-5u4e00q6	1138	13	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1138	14	attacks	attack	NNS
cord-014712-5u4e00q6	1138	15	/	/	SYM
cord-014712-5u4e00q6	1138	16	year	year	NN
cord-014712-5u4e00q6	1138	17	,	,	,
cord-014712-5u4e00q6	1138	18	otitis	otitis	NN
cord-014712-5u4e00q6	1138	19	media	medium	NNS
cord-014712-5u4e00q6	1138	20	and	and	CC
cord-014712-5u4e00q6	1138	21	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	1138	22	.	.	.
cord-014712-5u4e00q6	1139	1	Hospitalization	hospitalization	NN
cord-014712-5u4e00q6	1139	2	due	due	JJ
cord-014712-5u4e00q6	1139	3	to	to	IN
cord-014712-5u4e00q6	1139	4	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1139	5	insufficiency	insufficiency	NN
cord-014712-5u4e00q6	1139	6	caused	cause	VBN
cord-014712-5u4e00q6	1139	7	by	by	IN
cord-014712-5u4e00q6	1139	8	bronchiolitis	bronchiolitis	NNP
cord-014712-5u4e00q6	1139	9	obliterans	obliterans	NNP
cord-014712-5u4e00q6	1139	10	and	and	CC
cord-014712-5u4e00q6	1139	11	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1139	12	with	with	IN
cord-014712-5u4e00q6	1139	13	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1139	14	at	at	IN
cord-014712-5u4e00q6	1139	15	the	the	DT
cord-014712-5u4e00q6	1139	16	age	age	NN
cord-014712-5u4e00q6	1139	17	of	of	IN
cord-014712-5u4e00q6	1139	18	27	27	CD
cord-014712-5u4e00q6	1139	19	.	.	.
cord-014712-5u4e00q6	1140	1	No	no	DT
cord-014712-5u4e00q6	1140	2	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	1140	3	.	.	.
cord-014712-5u4e00q6	1141	1	Patient	patient	JJ
cord-014712-5u4e00q6	1141	2	findings	finding	NNS
cord-014712-5u4e00q6	1141	3	at	at	IN
cord-014712-5u4e00q6	1141	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1141	5	(	(	-LRB-
cord-014712-5u4e00q6	1141	6	02/2008	02/2008	CD
cord-014712-5u4e00q6	1141	7	)	)	-RRB-
cord-014712-5u4e00q6	1141	8	had	have	VBD
cord-014712-5u4e00q6	1141	9	hepatospenomegaly	hepatospenomegaly	NNP
cord-014712-5u4e00q6	1141	10	,	,	,
cord-014712-5u4e00q6	1141	11	bilaterally	bilaterally	RB
cord-014712-5u4e00q6	1141	12	cervical	cervical	JJ
cord-014712-5u4e00q6	1141	13	,	,	,
cord-014712-5u4e00q6	1141	14	supraclavicular	supraclavicular	NNP
cord-014712-5u4e00q6	1141	15	axillar	axillar	NNP
cord-014712-5u4e00q6	1141	16	LAP	LAP	NNP
cord-014712-5u4e00q6	1141	17	,	,	,
cord-014712-5u4e00q6	1141	18	osteoporosis	osteoporosis	NN
cord-014712-5u4e00q6	1141	19	,	,	,
cord-014712-5u4e00q6	1141	20	bronchiolitis	bronchiolitis	NNP
cord-014712-5u4e00q6	1141	21	obliterans	obliterans	NNP
cord-014712-5u4e00q6	1141	22	organizing	organize	VBG
cord-014712-5u4e00q6	1141	23	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1141	24	,	,	,
cord-014712-5u4e00q6	1141	25	hyper	hyper	JJ
cord-014712-5u4e00q6	1141	26	IgM	IgM	NNP
cord-014712-5u4e00q6	1141	27	,	,	,
cord-014712-5u4e00q6	1141	28	lower	low	JJR
cord-014712-5u4e00q6	1141	29	IgG	IgG	NNP
cord-014712-5u4e00q6	1141	30	,	,	,
cord-014712-5u4e00q6	1141	31	IgA	IgA	NNP
cord-014712-5u4e00q6	1141	32	,	,	,
cord-014712-5u4e00q6	1141	33	IgE	IgE	NNP
cord-014712-5u4e00q6	1141	34	,	,	,
cord-014712-5u4e00q6	1141	35	low	low	JJ
cord-014712-5u4e00q6	1141	36	B	b	NN
cord-014712-5u4e00q6	1141	37	-	-	HYPH
cord-014712-5u4e00q6	1141	38	cell	cell	NN
cord-014712-5u4e00q6	1141	39	.	.	.
cord-014712-5u4e00q6	1142	1	No	no	DT
cord-014712-5u4e00q6	1142	2	response	response	NN
cord-014712-5u4e00q6	1142	3	to	to	IN
cord-014712-5u4e00q6	1142	4	tetanus	tetanus	NN
cord-014712-5u4e00q6	1142	5	toxoid	toxoid	NN
cord-014712-5u4e00q6	1142	6	.	.	.
cord-014712-5u4e00q6	1143	1	İsohemagglutinin	İsohemagglutinin	NNP
cord-014712-5u4e00q6	1143	2	AntiB	AntiB	NNP
cord-014712-5u4e00q6	1143	3	was	be	VBD
cord-014712-5u4e00q6	1143	4	¼.	¼.	CD
cord-014712-5u4e00q6	1143	5	CD40,CD40L	cd40,cd40l	NN
cord-014712-5u4e00q6	1143	6	,	,	,
cord-014712-5u4e00q6	1143	7	AID	aid	NN
cord-014712-5u4e00q6	1143	8	,	,	,
cord-014712-5u4e00q6	1143	9	TACI	TACI	NNP
cord-014712-5u4e00q6	1143	10	,	,	,
cord-014712-5u4e00q6	1143	11	BAFFR	BAFFR	NNP
cord-014712-5u4e00q6	1143	12	,	,	,
cord-014712-5u4e00q6	1143	13	ICOS	ICOS	NNP
cord-014712-5u4e00q6	1143	14	gene	gene	NN
cord-014712-5u4e00q6	1143	15	mutation	mutation	NN
cord-014712-5u4e00q6	1143	16	were	be	VBD
cord-014712-5u4e00q6	1143	17	negative	negative	JJ
cord-014712-5u4e00q6	1143	18	.	.	.
cord-014712-5u4e00q6	1144	1	Protein	protein	NN
cord-014712-5u4e00q6	1144	2	electrophoresis	electrophoresis	NN
cord-014712-5u4e00q6	1144	3	revealed	reveal	VBD
cord-014712-5u4e00q6	1144	4	polyclonal	polyclonal	JJ
cord-014712-5u4e00q6	1144	5	IgM	IgM	NNP
cord-014712-5u4e00q6	1144	6	increase	increase	NN
cord-014712-5u4e00q6	1144	7	,	,	,
cord-014712-5u4e00q6	1144	8	immunofixation	immunofixation	NN
cord-014712-5u4e00q6	1144	9	was	be	VBD
cord-014712-5u4e00q6	1144	10	no	no	DT
cord-014712-5u4e00q6	1144	11	clonality	clonality	NN
cord-014712-5u4e00q6	1144	12	.	.	.
cord-014712-5u4e00q6	1145	1	lymph	lymph	NN
cord-014712-5u4e00q6	1145	2	node	node	NN
cord-014712-5u4e00q6	1145	3	biopsy	biopsy	NN
cord-014712-5u4e00q6	1145	4	result	result	NN
cord-014712-5u4e00q6	1145	5	was	be	VBD
cord-014712-5u4e00q6	1145	6	available	available	JJ
cord-014712-5u4e00q6	1145	7	paracortical	paracortical	JJ
cord-014712-5u4e00q6	1145	8	expantion	expantion	NN
cord-014712-5u4e00q6	1145	9	.	.	.
cord-014712-5u4e00q6	1146	1	CD3(+	cd3(+	ADD
cord-014712-5u4e00q6	1146	2	)	)	-RRB-
cord-014712-5u4e00q6	1147	1	T	T	NNP
cord-014712-5u4e00q6	1147	2	and	and	CC
cord-014712-5u4e00q6	1147	3	CD20	CD20	NNP
cord-014712-5u4e00q6	1147	4	were	be	VBD
cord-014712-5u4e00q6	1147	5	positive	positive	JJ
cord-014712-5u4e00q6	1147	6	.	.	.
cord-014712-5u4e00q6	1148	1	B	b	NN
cord-014712-5u4e00q6	1148	2	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1148	3	distribution	distribution	NN
cord-014712-5u4e00q6	1148	4	were	be	VBD
cord-014712-5u4e00q6	1148	5	normal	normal	JJ
cord-014712-5u4e00q6	1148	6	.	.	.
cord-014712-5u4e00q6	1149	1	Malignancy	malignancy	NN
cord-014712-5u4e00q6	1149	2	ruled	rule	VBD
cord-014712-5u4e00q6	1149	3	out	out	RP
cord-014712-5u4e00q6	1149	4	.	.	.
cord-014712-5u4e00q6	1150	1	No	no	DT
cord-014712-5u4e00q6	1150	2	giant	giant	JJ
cord-014712-5u4e00q6	1150	3	germinal	germinal	JJ
cord-014712-5u4e00q6	1150	4	centers	center	NNS
cord-014712-5u4e00q6	1150	5	.	.	.
cord-014712-5u4e00q6	1151	1	Evaluation	evaluation	NN
cord-014712-5u4e00q6	1151	2	of	of	IN
cord-014712-5u4e00q6	1151	3	bone	bone	NN
cord-014712-5u4e00q6	1151	4	marrow	marrow	NN
cord-014712-5u4e00q6	1151	5	aspiration/	aspiration/	IN
cord-014712-5u4e00q6	1151	6	biopsy	biopsy	NN
cord-014712-5u4e00q6	1151	7	were	be	VBD
cord-014712-5u4e00q6	1151	8	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1151	9	localization	localization	NN
cord-014712-5u4e00q6	1151	10	of	of	IN
cord-014712-5u4e00q6	1151	11	megakaryocytes	megakaryocyte	NNS
cord-014712-5u4e00q6	1151	12	,	,	,
cord-014712-5u4e00q6	1151	13	dismegakaryopoiesis	dismegakaryopoiesis	NNP
cord-014712-5u4e00q6	1151	14	,	,	,
cord-014712-5u4e00q6	1151	15	blasts	blast	NNS
cord-014712-5u4e00q6	1151	16	in	in	IN
cord-014712-5u4e00q6	1151	17	normal	normal	JJ
cord-014712-5u4e00q6	1151	18	range	range	NN
cord-014712-5u4e00q6	1151	19	.	.	.
cord-014712-5u4e00q6	1152	1	Lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1152	2	ratio	ratio	NN
cord-014712-5u4e00q6	1152	3	10	10	CD
cord-014712-5u4e00q6	1152	4	%	%	NN
cord-014712-5u4e00q6	1152	5	mostly	mostly	RB
cord-014712-5u4e00q6	1152	6	consisting	consist	VBG
cord-014712-5u4e00q6	1152	7	of	of	IN
cord-014712-5u4e00q6	1152	8	CD3	CD3	NNP
cord-014712-5u4e00q6	1152	9	+	+	CC
cord-014712-5u4e00q6	1152	10	cells	cell	NNS
cord-014712-5u4e00q6	1152	11	,	,	,
cord-014712-5u4e00q6	1153	1	CD20	cd20	NN
cord-014712-5u4e00q6	1153	2	+	+	CC
cord-014712-5u4e00q6	1153	3	cells	cell	NNS
cord-014712-5u4e00q6	1153	4	were	be	VBD
cord-014712-5u4e00q6	1153	5	rare	rare	JJ
cord-014712-5u4e00q6	1153	6	,	,	,
cord-014712-5u4e00q6	1153	7	Plasma	plasma	NN
cord-014712-5u4e00q6	1153	8	cell	cell	NN
cord-014712-5u4e00q6	1153	9	ratio	ratio	NN
cord-014712-5u4e00q6	1153	10	was	be	VBD
cord-014712-5u4e00q6	1153	11	2	2	CD
cord-014712-5u4e00q6	1153	12	%	%	NN
cord-014712-5u4e00q6	1153	13	,	,	,
cord-014712-5u4e00q6	1153	14	amyloid	amyloid	NN
cord-014712-5u4e00q6	1153	15	negative	negative	JJ
cord-014712-5u4e00q6	1153	16	.	.	.
cord-014712-5u4e00q6	1154	1	Progression	progression	NN
cord-014712-5u4e00q6	1154	2	of	of	IN
cord-014712-5u4e00q6	1154	3	patient	patient	NN
cord-014712-5u4e00q6	1154	4	,	,	,
cord-014712-5u4e00q6	1154	5	IgM	IgM	NNP
cord-014712-5u4e00q6	1154	6	level	level	NNP
cord-014712-5u4e00q6	1154	7	and	and	CC
cord-014712-5u4e00q6	1154	8	spnenomegaly	spnenomegaly	NNP
cord-014712-5u4e00q6	1154	9	were	be	VBD
cord-014712-5u4e00q6	1154	10	increased	increase	VBN
cord-014712-5u4e00q6	1154	11	and	and	CC
cord-014712-5u4e00q6	1154	12	patient	patient	NN
cord-014712-5u4e00q6	1154	13	had	have	VBD
cord-014712-5u4e00q6	1154	14	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1154	15	failure	failure	NN
cord-014712-5u4e00q6	1154	16	.	.	.
cord-014712-5u4e00q6	1155	1	Splenectomy	Splenectomy	NNP
cord-014712-5u4e00q6	1155	2	could	could	MD
cord-014712-5u4e00q6	1155	3	not	not	RB
cord-014712-5u4e00q6	1155	4	be	be	VB
cord-014712-5u4e00q6	1155	5	done	do	VBN
cord-014712-5u4e00q6	1155	6	due	due	IN
cord-014712-5u4e00q6	1155	7	to	to	IN
cord-014712-5u4e00q6	1155	8	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1155	9	failure	failure	NN
cord-014712-5u4e00q6	1155	10	.	.	.
cord-014712-5u4e00q6	1156	1	Than	than	IN
cord-014712-5u4e00q6	1156	2	patient	patient	JJ
cord-014712-5u4e00q6	1156	3	was	be	VBD
cord-014712-5u4e00q6	1156	4	treated	treat	VBN
cord-014712-5u4e00q6	1156	5	with	with	IN
cord-014712-5u4e00q6	1156	6	Rituximab	Rituximab	NNP
cord-014712-5u4e00q6	1156	7	(	(	-LRB-
cord-014712-5u4e00q6	1156	8	375mg	375mg	NNP
cord-014712-5u4e00q6	1156	9	/	/	SYM
cord-014712-5u4e00q6	1156	10	kg	kg	NN
cord-014712-5u4e00q6	1156	11	/	/	SYM
cord-014712-5u4e00q6	1156	12	week	week	NN
cord-014712-5u4e00q6	1156	13	)	)	-RRB-
cord-014712-5u4e00q6	1156	14	.	.	.
cord-014712-5u4e00q6	1157	1	After	after	IN
cord-014712-5u4e00q6	1157	2	Rituximab	Rituximab	NNP
cord-014712-5u4e00q6	1157	3	therapy	therapy	NN
cord-014712-5u4e00q6	1157	4	,	,	,
cord-014712-5u4e00q6	1157	5	lymph	lymph	NN
cord-014712-5u4e00q6	1157	6	nodes	node	NNS
cord-014712-5u4e00q6	1157	7	and	and	CC
cord-014712-5u4e00q6	1157	8	splenomegaly	splenomegaly	NN
cord-014712-5u4e00q6	1157	9	were	be	VBD
cord-014712-5u4e00q6	1157	10	(	(	-LRB-
cord-014712-5u4e00q6	1157	11	5	5	CD
cord-014712-5u4e00q6	1157	12	cm	cm	NNP
cord-014712-5u4e00q6	1157	13	)	)	-RRB-
cord-014712-5u4e00q6	1157	14	,	,	,
cord-014712-5u4e00q6	1157	15	regressed	regress	VBD
cord-014712-5u4e00q6	1157	16	and	and	CC
cord-014712-5u4e00q6	1157	17	IgM	IgM	NNP
cord-014712-5u4e00q6	1157	18	level	level	NN
cord-014712-5u4e00q6	1157	19	decreased	decrease	VBD
cord-014712-5u4e00q6	1157	20	(	(	-LRB-
cord-014712-5u4e00q6	1157	21	from	from	IN
cord-014712-5u4e00q6	1157	22	4390	4390	CD
cord-014712-5u4e00q6	1157	23	mg	mg	NNP
cord-014712-5u4e00q6	1157	24	/	/	SYM
cord-014712-5u4e00q6	1157	25	dl	dl	NNP
cord-014712-5u4e00q6	1157	26	to	to	IN
cord-014712-5u4e00q6	1157	27	2040	2040	CD
cord-014712-5u4e00q6	1157	28	mg	mg	NNP
cord-014712-5u4e00q6	1157	29	/	/	SYM
cord-014712-5u4e00q6	1157	30	dl	dl	NNP
cord-014712-5u4e00q6	1157	31	)	)	-RRB-
cord-014712-5u4e00q6	1157	32	,	,	,
cord-014712-5u4e00q6	1157	33	increased	increase	VBN
cord-014712-5u4e00q6	1157	34	effort	effort	NN
cord-014712-5u4e00q6	1157	35	capacity	capacity	NN
cord-014712-5u4e00q6	1157	36	.	.	.
cord-014712-5u4e00q6	1158	1	After	after	IN
cord-014712-5u4e00q6	1158	2	7	7	CD
cord-014712-5u4e00q6	1158	3	month	month	NN
cord-014712-5u4e00q6	1158	4	after	after	IN
cord-014712-5u4e00q6	1158	5	rituximab	rituximab	NN
cord-014712-5u4e00q6	1158	6	therapy	therapy	NN
cord-014712-5u4e00q6	1158	7	splenomegaly	splenomegaly	NNP
cord-014712-5u4e00q6	1158	8	and	and	CC
cord-014712-5u4e00q6	1158	9	IgM	IgM	NNP
cord-014712-5u4e00q6	1158	10	level	level	NN
cord-014712-5u4e00q6	1158	11	were	be	VBD
cord-014712-5u4e00q6	1158	12	progressed	progress	VBN
cord-014712-5u4e00q6	1158	13	.	.	.
cord-014712-5u4e00q6	1159	1	Splenoctomy	Splenoctomy	NNP
cord-014712-5u4e00q6	1159	2	was	be	VBD
cord-014712-5u4e00q6	1159	3	performed	perform	VBN
cord-014712-5u4e00q6	1159	4	.	.	.
cord-014712-5u4e00q6	1160	1	Pathological	pathological	JJ
cord-014712-5u4e00q6	1160	2	evaluation	evaluation	NN
cord-014712-5u4e00q6	1160	3	of	of	IN
cord-014712-5u4e00q6	1160	4	the	the	DT
cord-014712-5u4e00q6	1160	5	spleen	spleen	NN
cord-014712-5u4e00q6	1160	6	malignancy	malignancy	NN
cord-014712-5u4e00q6	1160	7	ruled	rule	VBD
cord-014712-5u4e00q6	1160	8	out	out	RP
cord-014712-5u4e00q6	1160	9	.	.	.
cord-014712-5u4e00q6	1161	1	Current	current	JJ
cord-014712-5u4e00q6	1161	2	IgM	igm	NN
cord-014712-5u4e00q6	1161	3	level	level	NN
cord-014712-5u4e00q6	1161	4	is	be	VBZ
cord-014712-5u4e00q6	1161	5	6300	6300	CD
cord-014712-5u4e00q6	1161	6	mg	mg	NNP
cord-014712-5u4e00q6	1161	7	/	/	SYM
cord-014712-5u4e00q6	1161	8	dl	dl	NN
cord-014712-5u4e00q6	1161	9	.	.	.
cord-014712-5u4e00q6	1162	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1162	2	:	:	:
cord-014712-5u4e00q6	1163	1	The	the	DT
cord-014712-5u4e00q6	1163	2	most	most	RBS
cord-014712-5u4e00q6	1163	3	convinient	convinient	JJ
cord-014712-5u4e00q6	1163	4	scenerio	scenerio	NN
cord-014712-5u4e00q6	1163	5	for	for	IN
cord-014712-5u4e00q6	1163	6	this	this	DT
cord-014712-5u4e00q6	1163	7	patient	patient	NN
cord-014712-5u4e00q6	1163	8	would	would	MD
cord-014712-5u4e00q6	1163	9	be	be	VB
cord-014712-5u4e00q6	1163	10	a	a	DT
cord-014712-5u4e00q6	1163	11	CSR	CSR	NNP
cord-014712-5u4e00q6	1163	12	defect	defect	NN
cord-014712-5u4e00q6	1163	13	of	of	IN
cord-014712-5u4e00q6	1163	14	unknown	unknown	JJ
cord-014712-5u4e00q6	1163	15	etiology	etiology	NN
cord-014712-5u4e00q6	1163	16	presented	present	VBN
cord-014712-5u4e00q6	1163	17	as	as	IN
cord-014712-5u4e00q6	1163	18	CVID	CVID	NNP
cord-014712-5u4e00q6	1163	19	.	.	.
cord-014712-5u4e00q6	1164	1	The	the	DT
cord-014712-5u4e00q6	1164	2	recent	recent	JJ
cord-014712-5u4e00q6	1164	3	litarature	litarature	NN
cord-014712-5u4e00q6	1164	4	revealed	reveal	VBD
cord-014712-5u4e00q6	1164	5	genetic	genetic	JJ
cord-014712-5u4e00q6	1164	6	defects	defect	NNS
cord-014712-5u4e00q6	1164	7	of	of	IN
cord-014712-5u4e00q6	1164	8	some	some	DT
cord-014712-5u4e00q6	1164	9	molecules	molecule	NNS
cord-014712-5u4e00q6	1164	10	operating	operate	VBG
cord-014712-5u4e00q6	1164	11	in	in	IN
cord-014712-5u4e00q6	1164	12	DNA	dna	NN
cord-014712-5u4e00q6	1164	13	repair	repair	NN
cord-014712-5u4e00q6	1164	14	pathways	pathway	NNS
cord-014712-5u4e00q6	1164	15	such	such	JJ
cord-014712-5u4e00q6	1164	16	as	as	IN
cord-014712-5u4e00q6	1164	17	MSH2	MSH2	NNP
cord-014712-5u4e00q6	1164	18	,	,	,
cord-014712-5u4e00q6	1164	19	MSH4	MSH4	NNP
cord-014712-5u4e00q6	1164	20	,	,	,
cord-014712-5u4e00q6	1164	21	MSH5	MSH5	NNP
cord-014712-5u4e00q6	1164	22	,	,	,
cord-014712-5u4e00q6	1164	23	MSH6	MSH6	NNPS
cord-014712-5u4e00q6	1164	24	,	,	,
cord-014712-5u4e00q6	1164	25	MLH1	MLH1	NNP
cord-014712-5u4e00q6	1164	26	,	,	,
cord-014712-5u4e00q6	1164	27	RAD50	RAD50	NNP
cord-014712-5u4e00q6	1164	28	,	,	,
cord-014712-5u4e00q6	1164	29	RAD	RAD	NNP
cord-014712-5u4e00q6	1164	30	52	52	CD
cord-014712-5u4e00q6	1164	31	,	,	,
cord-014712-5u4e00q6	1164	32	NBS1	NBS1	NNP
cord-014712-5u4e00q6	1164	33	leading	lead	VBG
cord-014712-5u4e00q6	1164	34	to	to	IN
cord-014712-5u4e00q6	1164	35	CSR	CSR	NNP
cord-014712-5u4e00q6	1164	36	abnormality	abnormality	NN
cord-014712-5u4e00q6	1164	37	and	and	CC
cord-014712-5u4e00q6	1164	38	impaired	impaired	JJ
cord-014712-5u4e00q6	1164	39	antibody	antibody	NN
cord-014712-5u4e00q6	1164	40	maturation	maturation	NN
cord-014712-5u4e00q6	1164	41	.	.	.
cord-014712-5u4e00q6	1165	1	CVID	CVID	NNP
cord-014712-5u4e00q6	1165	2	is	be	VBZ
cord-014712-5u4e00q6	1165	3	characterized	characterize	VBN
cord-014712-5u4e00q6	1165	4	by	by	IN
cord-014712-5u4e00q6	1165	5	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1165	6	,	,	,
cord-014712-5u4e00q6	1165	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1165	8	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1165	9	and	and	CC
cord-014712-5u4e00q6	1165	10	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	1165	11	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1165	12	infections	infection	NNS
cord-014712-5u4e00q6	1165	13	.	.	.
cord-014712-5u4e00q6	1166	1	Good	Good	NNP
cord-014712-5u4e00q6	1166	2	's	's	POS
cord-014712-5u4e00q6	1166	3	Syndrome(GS	Syndrome(GS	NNP
cord-014712-5u4e00q6	1166	4	)	)	-RRB-
cord-014712-5u4e00q6	1166	5	is	be	VBZ
cord-014712-5u4e00q6	1166	6	a	a	DT
cord-014712-5u4e00q6	1166	7	thymoma	thymoma	NN
cord-014712-5u4e00q6	1166	8	-	-	HYPH
cord-014712-5u4e00q6	1166	9	related	relate	VBN
cord-014712-5u4e00q6	1166	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1166	11	and	and	CC
cord-014712-5u4e00q6	1166	12	characterized	characterize	VBN
cord-014712-5u4e00q6	1166	13	by	by	IN
cord-014712-5u4e00q6	1166	14	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1166	15	,	,	,
cord-014712-5u4e00q6	1166	16	decreased	decrease	VBD
cord-014712-5u4e00q6	1166	17	B	B	NNP
cord-014712-5u4e00q6	1166	18	cell	cell	NN
cord-014712-5u4e00q6	1166	19	and	and	CC
cord-014712-5u4e00q6	1166	20	variable	variable	JJ
cord-014712-5u4e00q6	1166	21	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1166	22	in	in	IN
cord-014712-5u4e00q6	1166	23	cell	cell	NN
cord-014712-5u4e00q6	1166	24	-	-	HYPH
cord-014712-5u4e00q6	1166	25	mediated	mediate	VBN
cord-014712-5u4e00q6	1166	26	immunity	immunity	NN
cord-014712-5u4e00q6	1166	27	.	.	.
cord-014712-5u4e00q6	1167	1	Case	case	NN
cord-014712-5u4e00q6	1167	2	:	:	:
cord-014712-5u4e00q6	1168	1	A	a	DT
cord-014712-5u4e00q6	1168	2	47-year	47-year	JJ
cord-014712-5u4e00q6	1168	3	old	old	JJ
cord-014712-5u4e00q6	1168	4	male	male	JJ
cord-014712-5u4e00q6	1168	5	patient	patient	NN
cord-014712-5u4e00q6	1168	6	presented	present	VBN
cord-014712-5u4e00q6	1168	7	with	with	IN
cord-014712-5u4e00q6	1168	8	a	a	DT
cord-014712-5u4e00q6	1168	9	palpable	palpable	JJ
cord-014712-5u4e00q6	1168	10	anterior	anterior	JJ
cord-014712-5u4e00q6	1168	11	chest	chest	NN
cord-014712-5u4e00q6	1168	12	wall	wall	NN
cord-014712-5u4e00q6	1168	13	mass	mass	NNP
cord-014712-5u4e00q6	1168	14	.	.	.
cord-014712-5u4e00q6	1169	1	In	in	IN
cord-014712-5u4e00q6	1169	2	2005	2005	CD
cord-014712-5u4e00q6	1169	3	,	,	,
cord-014712-5u4e00q6	1169	4	he	-PRON-	PRP
cord-014712-5u4e00q6	1169	5	was	be	VBD
cord-014712-5u4e00q6	1169	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1169	7	with	with	IN
cord-014712-5u4e00q6	1169	8	rheumatoid	rheumatoid	NN
cord-014712-5u4e00q6	1169	9	arthritis	arthritis	NN
cord-014712-5u4e00q6	1169	10	.	.	.
cord-014712-5u4e00q6	1170	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1170	2	showed	show	VBD
cord-014712-5u4e00q6	1170	3	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1170	4	and	and	CC
cord-014712-5u4e00q6	1170	5	all	all	DT
cord-014712-5u4e00q6	1170	6	autoantibodies	autoantibody	NNS
cord-014712-5u4e00q6	1170	7	were	be	VBD
cord-014712-5u4e00q6	1170	8	negative	negative	JJ
cord-014712-5u4e00q6	1170	9	.	.	.
cord-014712-5u4e00q6	1171	1	CD19	CD19	NNP
cord-014712-5u4e00q6	1171	2	+	+	CC
cord-014712-5u4e00q6	1171	3	,	,	,
cord-014712-5u4e00q6	1171	4	CD20	CD20	NNP
cord-014712-5u4e00q6	1171	5	+	+	XX
cord-014712-5u4e00q6	1171	6	,	,	,
cord-014712-5u4e00q6	1171	7	CD22	CD22	NNP
cord-014712-5u4e00q6	1171	8	+	+	CC
cord-014712-5u4e00q6	1171	9	cells	cell	NNS
cord-014712-5u4e00q6	1171	10	were	be	VBD
cord-014712-5u4e00q6	1171	11	<	<	XX
cord-014712-5u4e00q6	1171	12	1	1	CD
cord-014712-5u4e00q6	1171	13	%	%	NN
cord-014712-5u4e00q6	1171	14	.	.	.
cord-014712-5u4e00q6	1172	1	Bone	bone	NN
cord-014712-5u4e00q6	1172	2	marrow(BM	marrow(BM	NNP
cord-014712-5u4e00q6	1172	3	)	)	-RRB-
cord-014712-5u4e00q6	1172	4	examination	examination	NN
cord-014712-5u4e00q6	1172	5	demonstrated	demonstrate	VBD
cord-014712-5u4e00q6	1172	6	low	low	JJ
cord-014712-5u4e00q6	1172	7	CD20	cd20	NN
cord-014712-5u4e00q6	1172	8	+	+	CC
cord-014712-5u4e00q6	1172	9	B	b	NN
cord-014712-5u4e00q6	1172	10	-	-	HYPH
cord-014712-5u4e00q6	1172	11	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1172	12	and	and	CC
cord-014712-5u4e00q6	1172	13	increase	increase	NN
cord-014712-5u4e00q6	1172	14	in	in	IN
cord-014712-5u4e00q6	1172	15	CD3	CD3	NNP
cord-014712-5u4e00q6	1172	16	+	+	CC
cord-014712-5u4e00q6	1172	17	T	T	NNP
cord-014712-5u4e00q6	1172	18	cells	cell	NNS
cord-014712-5u4e00q6	1172	19	.	.	.
cord-014712-5u4e00q6	1173	1	Tuberculin	Tuberculin	NNP
cord-014712-5u4e00q6	1173	2	skin	skin	NN
cord-014712-5u4e00q6	1173	3	test	test	NN
cord-014712-5u4e00q6	1173	4	was	be	VBD
cord-014712-5u4e00q6	1173	5	positive	positive	JJ
cord-014712-5u4e00q6	1173	6	.	.	.
cord-014712-5u4e00q6	1174	1	T	t	NN
cord-014712-5u4e00q6	1174	2	-	-	HYPH
cord-014712-5u4e00q6	1174	3	cell	cell	NN
cord-014712-5u4e00q6	1174	4	proliferative	proliferative	JJ
cord-014712-5u4e00q6	1174	5	response	response	NN
cord-014712-5u4e00q6	1174	6	was	be	VBD
cord-014712-5u4e00q6	1174	7	normal	normal	JJ
cord-014712-5u4e00q6	1174	8	.	.	.
cord-014712-5u4e00q6	1175	1	Immunizations	immunization	NNS
cord-014712-5u4e00q6	1175	2	with	with	IN
cord-014712-5u4e00q6	1175	3	H.influenzae	h.influenzae	JJ
cord-014712-5u4e00q6	1175	4	type	type	NN
cord-014712-5u4e00q6	1175	5	-	-	HYPH
cord-014712-5u4e00q6	1175	6	b	b	NN
cord-014712-5u4e00q6	1175	7	and	and	CC
cord-014712-5u4e00q6	1175	8	tetanus	tetanus	NN
cord-014712-5u4e00q6	1175	9	toxoid	toxoid	NN
cord-014712-5u4e00q6	1175	10	revealed	reveal	VBD
cord-014712-5u4e00q6	1175	11	no	no	DT
cord-014712-5u4e00q6	1175	12	response	response	NN
cord-014712-5u4e00q6	1175	13	.	.	.
cord-014712-5u4e00q6	1176	1	Anti	Anti	NNP
cord-014712-5u4e00q6	1176	2	-	-	NNP
cord-014712-5u4e00q6	1176	3	B	b	JJ
cord-014712-5u4e00q6	1176	4	titer	titer	NN
cord-014712-5u4e00q6	1176	5	was	be	VBD
cord-014712-5u4e00q6	1176	6	low	low	JJ
cord-014712-5u4e00q6	1176	7	.	.	.
cord-014712-5u4e00q6	1177	1	TACI	TACI	NNP
cord-014712-5u4e00q6	1177	2	,	,	,
cord-014712-5u4e00q6	1177	3	Btk	Btk	NNP
cord-014712-5u4e00q6	1177	4	and	and	CC
cord-014712-5u4e00q6	1177	5	ICOS	ICOS	NNP
cord-014712-5u4e00q6	1177	6	mutattions	mutattion	NNS
cord-014712-5u4e00q6	1177	7	were	be	VBD
cord-014712-5u4e00q6	1177	8	negative	negative	JJ
cord-014712-5u4e00q6	1177	9	.	.	.
cord-014712-5u4e00q6	1178	1	Ultrasonography	Ultrasonography	NNP
cord-014712-5u4e00q6	1178	2	showed	show	VBD
cord-014712-5u4e00q6	1178	3	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-014712-5u4e00q6	1178	4	.	.	.
cord-014712-5u4e00q6	1179	1	Mild	mild	JJ
cord-014712-5u4e00q6	1179	2	edema	edema	NN
cord-014712-5u4e00q6	1179	3	,	,	,
cord-014712-5u4e00q6	1179	4	mononuclear	mononuclear	JJ
cord-014712-5u4e00q6	1179	5	cell	cell	NN
cord-014712-5u4e00q6	1179	6	infiltration	infiltration	NN
cord-014712-5u4e00q6	1179	7	(	(	-LRB-
cord-014712-5u4e00q6	1179	8	suggested	suggest	VBD
cord-014712-5u4e00q6	1179	9	the	the	DT
cord-014712-5u4e00q6	1179	10	early	early	JJ
cord-014712-5u4e00q6	1179	11	stages	stage	NNS
cord-014712-5u4e00q6	1179	12	of	of	IN
cord-014712-5u4e00q6	1179	13	extrahepatic	extrahepatic	JJ
cord-014712-5u4e00q6	1179	14	biliary	biliary	JJ
cord-014712-5u4e00q6	1179	15	obstruction	obstruction	NN
cord-014712-5u4e00q6	1179	16	)	)	-RRB-
cord-014712-5u4e00q6	1179	17	were	be	VBD
cord-014712-5u4e00q6	1179	18	detected	detect	VBN
cord-014712-5u4e00q6	1179	19	on	on	IN
cord-014712-5u4e00q6	1179	20	liver	liver	NN
cord-014712-5u4e00q6	1179	21	biopsy	biopsy	NN
cord-014712-5u4e00q6	1179	22	.	.	.
cord-014712-5u4e00q6	1180	1	In	in	IN
cord-014712-5u4e00q6	1180	2	the	the	DT
cord-014712-5u4e00q6	1180	3	medical	medical	JJ
cord-014712-5u4e00q6	1180	4	history	history	NN
cord-014712-5u4e00q6	1180	5	,	,	,
cord-014712-5u4e00q6	1180	6	he	-PRON-	PRP
cord-014712-5u4e00q6	1180	7	had	have	VBD
cord-014712-5u4e00q6	1180	8	reported	report	VBN
cord-014712-5u4e00q6	1180	9	chronic	chronic	JJ
cord-014712-5u4e00q6	1180	10	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	1180	11	,	,	,
cord-014712-5u4e00q6	1180	12	otitis	otitis	NN
cord-014712-5u4e00q6	1180	13	and	and	CC
cord-014712-5u4e00q6	1180	14	bronchitis	bronchitis	NN
cord-014712-5u4e00q6	1180	15	dating	date	VBG
cord-014712-5u4e00q6	1180	16	back	back	RB
cord-014712-5u4e00q6	1180	17	to	to	IN
cord-014712-5u4e00q6	1180	18	3rd	3rd	JJ
cord-014712-5u4e00q6	1180	19	decade	decade	NN
cord-014712-5u4e00q6	1180	20	of	of	IN
cord-014712-5u4e00q6	1180	21	life	life	NN
cord-014712-5u4e00q6	1180	22	.	.	.
cord-014712-5u4e00q6	1181	1	At	at	IN
cord-014712-5u4e00q6	1181	2	age	age	NN
cord-014712-5u4e00q6	1181	3	38	38	CD
cord-014712-5u4e00q6	1181	4	,	,	,
cord-014712-5u4e00q6	1181	5	he	-PRON-	PRP
cord-014712-5u4e00q6	1181	6	underwent	undergo	VBD
cord-014712-5u4e00q6	1181	7	surgery	surgery	NN
cord-014712-5u4e00q6	1181	8	for	for	IN
cord-014712-5u4e00q6	1181	9	thymoma	thymoma	NNP
cord-014712-5u4e00q6	1181	10	.	.	.
cord-014712-5u4e00q6	1182	1	In	in	IN
cord-014712-5u4e00q6	1182	2	follow	follow	NN
cord-014712-5u4e00q6	1182	3	-	-	HYPH
cord-014712-5u4e00q6	1182	4	up	up	NN
cord-014712-5u4e00q6	1182	5	,	,	,
cord-014712-5u4e00q6	1182	6	the	the	DT
cord-014712-5u4e00q6	1182	7	computed	compute	VBN
cord-014712-5u4e00q6	1182	8	tomography	tomography	NN
cord-014712-5u4e00q6	1182	9	showed	show	VBD
cord-014712-5u4e00q6	1182	10	soft	soft	JJ
cord-014712-5u4e00q6	1182	11	tissue	tissue	NN
cord-014712-5u4e00q6	1182	12	mass	mass	NN
cord-014712-5u4e00q6	1182	13	on	on	IN
cord-014712-5u4e00q6	1182	14	the	the	DT
cord-014712-5u4e00q6	1182	15	anterior	anterior	JJ
cord-014712-5u4e00q6	1182	16	chest	chest	NN
cord-014712-5u4e00q6	1182	17	wall	wall	NN
cord-014712-5u4e00q6	1182	18	and	and	CC
cord-014712-5u4e00q6	1182	19	pathology	pathology	NN
cord-014712-5u4e00q6	1182	20	was	be	VBD
cord-014712-5u4e00q6	1182	21	thymoma	thymoma	NNP
cord-014712-5u4e00q6	1182	22	.	.	.
cord-014712-5u4e00q6	1183	1	Discussion	discussion	NN
cord-014712-5u4e00q6	1183	2	:	:	:
cord-014712-5u4e00q6	1184	1	Frequent	frequent	JJ
cord-014712-5u4e00q6	1184	2	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1184	3	infections	infection	NNS
cord-014712-5u4e00q6	1184	4	with	with	IN
cord-014712-5u4e00q6	1184	5	encapsulated	encapsulate	VBN
cord-014712-5u4e00q6	1184	6	pathogens	pathogen	NNS
cord-014712-5u4e00q6	1184	7	beginning	begin	VBG
cord-014712-5u4e00q6	1184	8	at	at	IN
cord-014712-5u4e00q6	1184	9	the	the	DT
cord-014712-5u4e00q6	1184	10	age	age	NN
cord-014712-5u4e00q6	1184	11	of	of	IN
cord-014712-5u4e00q6	1184	12	30	30	CD
cord-014712-5u4e00q6	1184	13	,	,	,
cord-014712-5u4e00q6	1184	14	lack	lack	NN
cord-014712-5u4e00q6	1184	15	of	of	IN
cord-014712-5u4e00q6	1184	16	opportunistic	opportunistic	JJ
cord-014712-5u4e00q6	1184	17	pathogen	pathogen	NN
cord-014712-5u4e00q6	1184	18	infections	infection	NNS
cord-014712-5u4e00q6	1184	19	,	,	,
cord-014712-5u4e00q6	1184	20	presence	presence	NN
cord-014712-5u4e00q6	1184	21	of	of	IN
cord-014712-5u4e00q6	1184	22	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-014712-5u4e00q6	1184	23	and	and	CC
cord-014712-5u4e00q6	1184	24	rheumatoid	rheumatoid	NNP
cord-014712-5u4e00q6	1184	25	arthritis	arthritis	NN
cord-014712-5u4e00q6	1184	26	,	,	,
cord-014712-5u4e00q6	1184	27	BM	BM	NNP
cord-014712-5u4e00q6	1184	28	examination	examination	NN
cord-014712-5u4e00q6	1184	29	findings	finding	NNS
cord-014712-5u4e00q6	1184	30	and	and	CC
cord-014712-5u4e00q6	1184	31	successful	successful	JJ
cord-014712-5u4e00q6	1184	32	management	management	NN
cord-014712-5u4e00q6	1184	33	of	of	IN
cord-014712-5u4e00q6	1184	34	infections	infection	NNS
cord-014712-5u4e00q6	1184	35	with	with	IN
cord-014712-5u4e00q6	1184	36	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1184	37	therapy	therapy	NN
cord-014712-5u4e00q6	1184	38	all	all	DT
cord-014712-5u4e00q6	1184	39	indicated	indicate	VBD
cord-014712-5u4e00q6	1184	40	a	a	DT
cord-014712-5u4e00q6	1184	41	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1184	42	of	of	IN
cord-014712-5u4e00q6	1184	43	CVID	CVID	NNP
cord-014712-5u4e00q6	1184	44	.	.	.
cord-014712-5u4e00q6	1185	1	The	the	DT
cord-014712-5u4e00q6	1185	2	coexistence	coexistence	NN
cord-014712-5u4e00q6	1185	3	of	of	IN
cord-014712-5u4e00q6	1185	4	CVID	CVID	NNP
cord-014712-5u4e00q6	1185	5	and	and	CC
cord-014712-5u4e00q6	1185	6	thymoma	thymoma	NNP
cord-014712-5u4e00q6	1185	7	has	have	VBZ
cord-014712-5u4e00q6	1185	8	been	be	VBN
cord-014712-5u4e00q6	1185	9	reported	report	VBN
cord-014712-5u4e00q6	1185	10	in	in	IN
cord-014712-5u4e00q6	1185	11	the	the	DT
cord-014712-5u4e00q6	1185	12	literature	literature	NN
cord-014712-5u4e00q6	1185	13	.	.	.
cord-014712-5u4e00q6	1186	1	Introduction	introduction	NN
cord-014712-5u4e00q6	1186	2	:	:	:
cord-014712-5u4e00q6	1187	1	Common	common	JJ
cord-014712-5u4e00q6	1187	2	variable	variable	JJ
cord-014712-5u4e00q6	1187	3	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1187	4	(	(	-LRB-
cord-014712-5u4e00q6	1187	5	CVID	CVID	NNP
cord-014712-5u4e00q6	1187	6	)	)	-RRB-
cord-014712-5u4e00q6	1187	7	is	be	VBZ
cord-014712-5u4e00q6	1187	8	a	a	DT
cord-014712-5u4e00q6	1187	9	primary	primary	JJ
cord-014712-5u4e00q6	1187	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1187	11	disorder	disorder	NN
cord-014712-5u4e00q6	1187	12	characterized	characterize	VBN
cord-014712-5u4e00q6	1187	13	by	by	IN
cord-014712-5u4e00q6	1187	14	impaired	impair	VBN
cord-014712-5u4e00q6	1187	15	B	b	NN
cord-014712-5u4e00q6	1187	16	cell	cell	NN
cord-014712-5u4e00q6	1187	17	differentiation	differentiation	NN
cord-014712-5u4e00q6	1187	18	with	with	IN
cord-014712-5u4e00q6	1187	19	defective	defective	JJ
cord-014712-5u4e00q6	1187	20	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1187	21	production	production	NN
cord-014712-5u4e00q6	1187	22	.	.	.
cord-014712-5u4e00q6	1188	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1188	2	has	have	VBZ
cord-014712-5u4e00q6	1188	3	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	1188	4	clinical	clinical	JJ
cord-014712-5u4e00q6	1188	5	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1188	6	including	include	VBG
cord-014712-5u4e00q6	1188	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1188	8	infections	infection	NNS
cord-014712-5u4e00q6	1188	9	,	,	,
cord-014712-5u4e00q6	1188	10	chronic	chronic	JJ
cord-014712-5u4e00q6	1188	11	lung	lung	NN
cord-014712-5u4e00q6	1188	12	disease	disease	NN
cord-014712-5u4e00q6	1188	13	,	,	,
cord-014712-5u4e00q6	1188	14	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1188	15	disorders	disorder	NNS
cord-014712-5u4e00q6	1188	16	,	,	,
cord-014712-5u4e00q6	1188	17	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	1188	18	disease	disease	NN
cord-014712-5u4e00q6	1188	19	,	,	,
cord-014712-5u4e00q6	1188	20	and	and	CC
cord-014712-5u4e00q6	1188	21	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	1188	22	to	to	IN
cord-014712-5u4e00q6	1188	23	lymphoma	lymphoma	NN
cord-014712-5u4e00q6	1188	24	.	.	.
cord-014712-5u4e00q6	1189	1	Patients	patient	NNS
cord-014712-5u4e00q6	1189	2	with	with	IN
cord-014712-5u4e00q6	1189	3	this	this	DT
cord-014712-5u4e00q6	1189	4	disorder	disorder	NN
cord-014712-5u4e00q6	1189	5	have	have	VBP
cord-014712-5u4e00q6	1189	6	evidence	evidence	NN
cord-014712-5u4e00q6	1189	7	of	of	IN
cord-014712-5u4e00q6	1189	8	immune	immune	JJ
cord-014712-5u4e00q6	1189	9	dysregulation	dysregulation	NN
cord-014712-5u4e00q6	1189	10	leading	lead	VBG
cord-014712-5u4e00q6	1189	11	to	to	IN
cord-014712-5u4e00q6	1189	12	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	1189	13	.	.	.
cord-014712-5u4e00q6	1190	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1190	2	cytopenias	cytopenia	NNS
cord-014712-5u4e00q6	1190	3	are	be	VBP
cord-014712-5u4e00q6	1190	4	a	a	DT
cord-014712-5u4e00q6	1190	5	more	more	RBR
cord-014712-5u4e00q6	1190	6	common	common	JJ
cord-014712-5u4e00q6	1190	7	presenting	present	VBG
cord-014712-5u4e00q6	1190	8	disorder	disorder	NN
cord-014712-5u4e00q6	1190	9	in	in	IN
cord-014712-5u4e00q6	1190	10	children	child	NNS
cord-014712-5u4e00q6	1190	11	and	and	CC
cord-014712-5u4e00q6	1190	12	may	may	MD
cord-014712-5u4e00q6	1190	13	be	be	VB
cord-014712-5u4e00q6	1190	14	the	the	DT
cord-014712-5u4e00q6	1190	15	initial	initial	JJ
cord-014712-5u4e00q6	1190	16	manifestation	manifestation	NN
cord-014712-5u4e00q6	1190	17	of	of	IN
cord-014712-5u4e00q6	1190	18	the	the	DT
cord-014712-5u4e00q6	1190	19	disease	disease	NN
cord-014712-5u4e00q6	1190	20	.	.	.
cord-014712-5u4e00q6	1191	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1191	2	want	want	VBP
cord-014712-5u4e00q6	1191	3	to	to	TO
cord-014712-5u4e00q6	1191	4	present	present	VB
cord-014712-5u4e00q6	1191	5	a	a	DT
cord-014712-5u4e00q6	1191	6	patient	patient	NN
cord-014712-5u4e00q6	1191	7	presenting	present	VBG
cord-014712-5u4e00q6	1191	8	with	with	IN
cord-014712-5u4e00q6	1191	9	autoimmunue	autoimmunue	JJ
cord-014712-5u4e00q6	1191	10	hemolytic	hemolytic	JJ
cord-014712-5u4e00q6	1191	11	anemia	anemia	NN
cord-014712-5u4e00q6	1191	12	and	and	CC
cord-014712-5u4e00q6	1191	13	finally	finally	RB
cord-014712-5u4e00q6	1191	14	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1191	15	as	as	IN
cord-014712-5u4e00q6	1191	16	CVID	CVID	NNP
cord-014712-5u4e00q6	1191	17	.	.	.
cord-014712-5u4e00q6	1192	1	Case	case	NN
cord-014712-5u4e00q6	1192	2	:	:	:
cord-014712-5u4e00q6	1193	1	A	a	DT
cord-014712-5u4e00q6	1193	2	15	15	CD
cord-014712-5u4e00q6	1193	3	years	year	NNS
cord-014712-5u4e00q6	1193	4	old	old	JJ
cord-014712-5u4e00q6	1193	5	,	,	,
cord-014712-5u4e00q6	1193	6	previously	previously	RB
cord-014712-5u4e00q6	1193	7	healthy	healthy	JJ
cord-014712-5u4e00q6	1193	8	female	female	JJ
cord-014712-5u4e00q6	1193	9	patient	patient	NN
cord-014712-5u4e00q6	1193	10	applied	apply	VBN
cord-014712-5u4e00q6	1193	11	to	to	IN
cord-014712-5u4e00q6	1193	12	emergency	emergency	NN
cord-014712-5u4e00q6	1193	13	clinic	clinic	NN
cord-014712-5u4e00q6	1193	14	with	with	IN
cord-014712-5u4e00q6	1193	15	complaint	complaint	NN
cord-014712-5u4e00q6	1193	16	of	of	IN
cord-014712-5u4e00q6	1193	17	paleness	paleness	NN
cord-014712-5u4e00q6	1193	18	,	,	,
cord-014712-5u4e00q6	1193	19	light	light	JJ
cord-014712-5u4e00q6	1193	20	headedness	headedness	NN
cord-014712-5u4e00q6	1193	21	and	and	CC
cord-014712-5u4e00q6	1193	22	yellow	yellow	JJ
cord-014712-5u4e00q6	1193	23	discoloration	discoloration	NN
cord-014712-5u4e00q6	1193	24	of	of	IN
cord-014712-5u4e00q6	1193	25	her	-PRON-	PRP$
cord-014712-5u4e00q6	1193	26	scleras	sclera	NNS
cord-014712-5u4e00q6	1193	27	.	.	.
cord-014712-5u4e00q6	1194	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1194	2	history	history	NN
cord-014712-5u4e00q6	1194	3	was	be	VBD
cord-014712-5u4e00q6	1194	4	not	not	RB
cord-014712-5u4e00q6	1194	5	compatible	compatible	JJ
cord-014712-5u4e00q6	1194	6	with	with	IN
cord-014712-5u4e00q6	1194	7	blood	blood	NN
cord-014712-5u4e00q6	1194	8	loss	loss	NN
cord-014712-5u4e00q6	1194	9	.	.	.
cord-014712-5u4e00q6	1195	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1195	2	denied	deny	VBD
cord-014712-5u4e00q6	1195	3	having	have	VBG
cord-014712-5u4e00q6	1195	4	melena	melena	NNP
cord-014712-5u4e00q6	1195	5	,	,	,
cord-014712-5u4e00q6	1195	6	hemotochezia	hemotochezia	NNP
cord-014712-5u4e00q6	1195	7	or	or	CC
cord-014712-5u4e00q6	1195	8	hematuria	hematuria	NN
cord-014712-5u4e00q6	1195	9	.	.	.
cord-014712-5u4e00q6	1196	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1196	2	mensturation	mensturation	NN
cord-014712-5u4e00q6	1196	3	history	history	NN
cord-014712-5u4e00q6	1196	4	was	be	VBD
cord-014712-5u4e00q6	1196	5	also	also	RB
cord-014712-5u4e00q6	1196	6	normal	normal	JJ
cord-014712-5u4e00q6	1196	7	.	.	.
cord-014712-5u4e00q6	1197	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1197	2	hemoglobin	hemoglobin	NN
cord-014712-5u4e00q6	1197	3	level	level	NN
cord-014712-5u4e00q6	1197	4	was	be	VBD
cord-014712-5u4e00q6	1197	5	7.2	7.2	CD
cord-014712-5u4e00q6	1197	6	gr	gr	NNP
cord-014712-5u4e00q6	1197	7	/	/	SYM
cord-014712-5u4e00q6	1197	8	dl	dl	NNP
cord-014712-5u4e00q6	1197	9	,	,	,
cord-014712-5u4e00q6	1197	10	reticulocyte	reticulocyte	NNP
cord-014712-5u4e00q6	1197	11	count	count	NNP
cord-014712-5u4e00q6	1197	12	was	be	VBD
cord-014712-5u4e00q6	1197	13	%	%	NN
cord-014712-5u4e00q6	1197	14	4.17	4.17	CD
cord-014712-5u4e00q6	1197	15	,	,	,
cord-014712-5u4e00q6	1197	16	complete	complete	JJ
cord-014712-5u4e00q6	1197	17	blood	blood	NN
cord-014712-5u4e00q6	1197	18	count	count	NN
cord-014712-5u4e00q6	1197	19	was	be	VBD
cord-014712-5u4e00q6	1197	20	otherwise	otherwise	RB
cord-014712-5u4e00q6	1197	21	normal	normal	JJ
cord-014712-5u4e00q6	1197	22	.	.	.
cord-014712-5u4e00q6	1198	1	Direct	Direct	NNP
cord-014712-5u4e00q6	1198	2	coombs	coombs	NNP
cord-014712-5u4e00q6	1198	3	was	be	VBD
cord-014712-5u4e00q6	1198	4	(	(	-LRB-
cord-014712-5u4e00q6	1198	5	+	+	.
cord-014712-5u4e00q6	1199	1	+	+	CC
cord-014712-5u4e00q6	1199	2	+	+	NN
cord-014712-5u4e00q6	1199	3	)	)	-RRB-
cord-014712-5u4e00q6	1199	4	.	.	.
cord-014712-5u4e00q6	1200	1	For	for	IN
cord-014712-5u4e00q6	1200	2	the	the	DT
cord-014712-5u4e00q6	1200	3	differential	differential	JJ
cord-014712-5u4e00q6	1200	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1200	5	of	of	IN
cord-014712-5u4e00q6	1200	6	immune	immune	JJ
cord-014712-5u4e00q6	1200	7	hemolytic	hemolytic	JJ
cord-014712-5u4e00q6	1200	8	anemia	anemia	NN
cord-014712-5u4e00q6	1200	9	,	,	,
cord-014712-5u4e00q6	1200	10	viral	viral	JJ
cord-014712-5u4e00q6	1200	11	serology	serology	NN
cord-014712-5u4e00q6	1200	12	,	,	,
cord-014712-5u4e00q6	1200	13	ANA	ANA	NNP
cord-014712-5u4e00q6	1200	14	and	and	CC
cord-014712-5u4e00q6	1200	15	anti	anti	JJ
cord-014712-5u4e00q6	1200	16	-	-	NN
cord-014712-5u4e00q6	1200	17	dsDNA	dsdna	JJ
cord-014712-5u4e00q6	1200	18	were	be	VBD
cord-014712-5u4e00q6	1200	19	studied	study	VBN
cord-014712-5u4e00q6	1200	20	,	,	,
cord-014712-5u4e00q6	1200	21	but	but	CC
cord-014712-5u4e00q6	1200	22	the	the	DT
cord-014712-5u4e00q6	1200	23	results	result	NNS
cord-014712-5u4e00q6	1200	24	were	be	VBD
cord-014712-5u4e00q6	1200	25	normal	normal	JJ
cord-014712-5u4e00q6	1200	26	.	.	.
cord-014712-5u4e00q6	1201	1	IgG	IgG	NNP
cord-014712-5u4e00q6	1201	2	,	,	,
cord-014712-5u4e00q6	1201	3	IgM	IgM	NNP
cord-014712-5u4e00q6	1201	4	and	and	CC
cord-014712-5u4e00q6	1201	5	IgA	IgA	NNP
cord-014712-5u4e00q6	1201	6	levels	level	NNS
cord-014712-5u4e00q6	1201	7	were	be	VBD
cord-014712-5u4e00q6	1201	8	lower	low	JJR
cord-014712-5u4e00q6	1201	9	than	than	IN
cord-014712-5u4e00q6	1201	10	normal	normal	JJ
cord-014712-5u4e00q6	1201	11	normal	normal	JJ
cord-014712-5u4e00q6	1201	12	for	for	IN
cord-014712-5u4e00q6	1201	13	her	-PRON-	PRP$
cord-014712-5u4e00q6	1201	14	age	age	NN
cord-014712-5u4e00q6	1201	15	.	.	.
cord-014712-5u4e00q6	1202	1	Other	other	JJ
cord-014712-5u4e00q6	1202	2	causes	cause	NNS
cord-014712-5u4e00q6	1202	3	of	of	IN
cord-014712-5u4e00q6	1202	4	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1202	5	were	be	VBD
cord-014712-5u4e00q6	1202	6	excluded	exclude	VBN
cord-014712-5u4e00q6	1202	7	.	.	.
cord-014712-5u4e00q6	1203	1	Blood	blood	NN
cord-014712-5u4e00q6	1203	2	group	group	NN
cord-014712-5u4e00q6	1203	3	was	be	VBD
cord-014712-5u4e00q6	1203	4	ARh	ARh	NNS
cord-014712-5u4e00q6	1203	5	(	(	-LRB-
cord-014712-5u4e00q6	1203	6	+	+	CC
cord-014712-5u4e00q6	1203	7	)	)	-RRB-
cord-014712-5u4e00q6	1203	8	,	,	,
cord-014712-5u4e00q6	1203	9	blood	blood	NN
cord-014712-5u4e00q6	1203	10	isohemagglutinin	isohemagglutinin	NNP
cord-014712-5u4e00q6	1203	11	were	be	VBD
cord-014712-5u4e00q6	1203	12	Anti	Anti	NNP
cord-014712-5u4e00q6	1203	13	A(-	A(-	NNP
cord-014712-5u4e00q6	1203	14	)	)	-RRB-
cord-014712-5u4e00q6	1203	15	and	and	CC
cord-014712-5u4e00q6	1203	16	Anti	Anti	NNP
cord-014712-5u4e00q6	1203	17	B	B	NNP
cord-014712-5u4e00q6	1203	18	(	(	-LRB-
cord-014712-5u4e00q6	1203	19	-/1	-/1	NNP
cord-014712-5u4e00q6	1203	20	+	+	CC
cord-014712-5u4e00q6	1203	21	)	)	-RRB-
cord-014712-5u4e00q6	1203	22	.	.	.
cord-014712-5u4e00q6	1204	1	Lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1204	2	subsets	subset	NNS
cord-014712-5u4e00q6	1204	3	were	be	VBD
cord-014712-5u4e00q6	1204	4	also	also	RB
cord-014712-5u4e00q6	1204	5	studided	studided	JJ
cord-014712-5u4e00q6	1204	6	.	.	.
cord-014712-5u4e00q6	1205	1	As	as	IN
cord-014712-5u4e00q6	1205	2	the	the	DT
cord-014712-5u4e00q6	1205	3	patient	patient	NN
cord-014712-5u4e00q6	1205	4	has	have	VBZ
cord-014712-5u4e00q6	1205	5	reduced	reduce	VBN
cord-014712-5u4e00q6	1205	6	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1205	7	levels	level	NNS
cord-014712-5u4e00q6	1205	8	with	with	IN
cord-014712-5u4e00q6	1205	9	normal	normal	JJ
cord-014712-5u4e00q6	1205	10	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1205	11	subset	subset	NN
cord-014712-5u4e00q6	1205	12	analysis	analysis	NN
cord-014712-5u4e00q6	1205	13	,	,	,
cord-014712-5u4e00q6	1205	14	she	-PRON-	PRP
cord-014712-5u4e00q6	1205	15	presented	present	VBD
cord-014712-5u4e00q6	1205	16	after	after	IN
cord-014712-5u4e00q6	1205	17	puberty	puberty	NN
cord-014712-5u4e00q6	1205	18	and	and	CC
cord-014712-5u4e00q6	1205	19	other	other	JJ
cord-014712-5u4e00q6	1205	20	defined	define	VBN
cord-014712-5u4e00q6	1205	21	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1205	22	states	state	NNS
cord-014712-5u4e00q6	1205	23	were	be	VBD
cord-014712-5u4e00q6	1205	24	excluded	exclude	VBN
cord-014712-5u4e00q6	1205	25	,	,	,
cord-014712-5u4e00q6	1205	26	she	-PRON-	PRP
cord-014712-5u4e00q6	1205	27	was	be	VBD
cord-014712-5u4e00q6	1205	28	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1205	29	as	as	IN
cord-014712-5u4e00q6	1205	30	CVID	CVID	NNP
cord-014712-5u4e00q6	1205	31	and	and	CC
cord-014712-5u4e00q6	1205	32	monthly	monthly	JJ
cord-014712-5u4e00q6	1205	33	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1205	34	replacement	replacement	NN
cord-014712-5u4e00q6	1205	35	therapy	therapy	NN
cord-014712-5u4e00q6	1205	36	was	be	VBD
cord-014712-5u4e00q6	1205	37	planned	plan	VBN
cord-014712-5u4e00q6	1205	38	.	.	.
cord-014712-5u4e00q6	1206	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1206	2	had	have	VBD
cord-014712-5u4e00q6	1206	3	aseptic	aseptic	JJ
cord-014712-5u4e00q6	1206	4	meningitis	meningitis	NN
cord-014712-5u4e00q6	1206	5	after	after	IN
cord-014712-5u4e00q6	1206	6	her	-PRON-	PRP$
cord-014712-5u4e00q6	1206	7	first	first	JJ
cord-014712-5u4e00q6	1206	8	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1206	9	transfusion	transfusion	NN
cord-014712-5u4e00q6	1206	10	.	.	.
cord-014712-5u4e00q6	1207	1	The	the	DT
cord-014712-5u4e00q6	1207	2	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1207	3	preparation	preparation	NN
cord-014712-5u4e00q6	1207	4	was	be	VBD
cord-014712-5u4e00q6	1207	5	changed	change	VBN
cord-014712-5u4e00q6	1207	6	with	with	IN
cord-014712-5u4e00q6	1207	7	another	another	DT
cord-014712-5u4e00q6	1207	8	trade	trade	NN
cord-014712-5u4e00q6	1207	9	and	and	CC
cord-014712-5u4e00q6	1207	10	she	-PRON-	PRP
cord-014712-5u4e00q6	1207	11	did	do	VBD
cord-014712-5u4e00q6	1207	12	not	not	RB
cord-014712-5u4e00q6	1207	13	have	have	VB
cord-014712-5u4e00q6	1207	14	any	any	DT
cord-014712-5u4e00q6	1207	15	problem	problem	NN
cord-014712-5u4e00q6	1207	16	during	during	IN
cord-014712-5u4e00q6	1207	17	the	the	DT
cord-014712-5u4e00q6	1207	18	following	follow	VBG
cord-014712-5u4e00q6	1207	19	treatments	treatment	NNS
cord-014712-5u4e00q6	1207	20	.	.	.
cord-014712-5u4e00q6	1208	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1208	2	has	have	VBZ
cord-014712-5u4e00q6	1208	3	been	be	VBN
cord-014712-5u4e00q6	1208	4	one	one	CD
cord-014712-5u4e00q6	1208	5	year	year	NN
cord-014712-5u4e00q6	1208	6	since	since	IN
cord-014712-5u4e00q6	1208	7	she	-PRON-	PRP
cord-014712-5u4e00q6	1208	8	was	be	VBD
cord-014712-5u4e00q6	1208	9	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1209	1	and	and	CC
cord-014712-5u4e00q6	1209	2	she	-PRON-	PRP
cord-014712-5u4e00q6	1209	3	did	do	VBD
cord-014712-5u4e00q6	1209	4	not	not	RB
cord-014712-5u4e00q6	1209	5	have	have	VB
cord-014712-5u4e00q6	1209	6	any	any	DT
cord-014712-5u4e00q6	1209	7	other	other	JJ
cord-014712-5u4e00q6	1209	8	medical	medical	JJ
cord-014712-5u4e00q6	1209	9	problems	problem	NNS
cord-014712-5u4e00q6	1209	10	.	.	.
cord-014712-5u4e00q6	1210	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1210	2	:	:	:
cord-014712-5u4e00q6	1211	1	The	the	DT
cord-014712-5u4e00q6	1211	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1211	3	of	of	IN
cord-014712-5u4e00q6	1211	4	CVID	CVID	NNP
cord-014712-5u4e00q6	1211	5	requires	require	VBZ
cord-014712-5u4e00q6	1211	6	decreased	decrease	VBN
cord-014712-5u4e00q6	1211	7	IgG	IgG	NNP
cord-014712-5u4e00q6	1211	8	,	,	,
cord-014712-5u4e00q6	1211	9	IgM	IgM	NNP
cord-014712-5u4e00q6	1211	10	and	and	CC
cord-014712-5u4e00q6	1211	11	IgA	IgA	NNP
cord-014712-5u4e00q6	1211	12	levels	level	NNS
cord-014712-5u4e00q6	1211	13	are	be	VBP
cord-014712-5u4e00q6	1211	14	also	also	RB
cord-014712-5u4e00q6	1211	15	reduced	reduce	VBN
cord-014712-5u4e00q6	1211	16	but	but	CC
cord-014712-5u4e00q6	1211	17	are	be	VBP
cord-014712-5u4e00q6	1211	18	less	less	RBR
cord-014712-5u4e00q6	1211	19	valuable	valuable	JJ
cord-014712-5u4e00q6	1211	20	for	for	IN
cord-014712-5u4e00q6	1211	21	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1211	22	.	.	.
cord-014712-5u4e00q6	1212	1	IgE	IgE	NNP
cord-014712-5u4e00q6	1212	2	level	level	NN
cord-014712-5u4e00q6	1212	3	is	be	VBZ
cord-014712-5u4e00q6	1212	4	checked	check	VBN
cord-014712-5u4e00q6	1212	5	to	to	TO
cord-014712-5u4e00q6	1212	6	exclude	exclude	VB
cord-014712-5u4e00q6	1212	7	other	other	JJ
cord-014712-5u4e00q6	1212	8	disorders	disorder	NNS
cord-014712-5u4e00q6	1212	9	.	.	.
cord-014712-5u4e00q6	1213	1	IgG	IgG	NNP
cord-014712-5u4e00q6	1213	2	subclass	subclass	NN
cord-014712-5u4e00q6	1213	3	determinations	determination	NNS
cord-014712-5u4e00q6	1213	4	are	be	VBP
cord-014712-5u4e00q6	1213	5	indicated	indicate	VBN
cord-014712-5u4e00q6	1213	6	if	if	IN
cord-014712-5u4e00q6	1213	7	antibody	antibody	NN
cord-014712-5u4e00q6	1213	8	titers	titer	NNS
cord-014712-5u4e00q6	1213	9	are	be	VBP
cord-014712-5u4e00q6	1213	10	decreased	decrease	VBN
cord-014712-5u4e00q6	1213	11	but	but	CC
cord-014712-5u4e00q6	1213	12	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1213	13	levels	level	NNS
cord-014712-5u4e00q6	1213	14	are	be	VBP
cord-014712-5u4e00q6	1213	15	near	near	IN
cord-014712-5u4e00q6	1213	16	normal	normal	JJ
cord-014712-5u4e00q6	1213	17	.	.	.
cord-014712-5u4e00q6	1214	1	Hypogammaglobulinemia	Hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1214	2	secondary	secondary	JJ
cord-014712-5u4e00q6	1214	3	to	to	IN
cord-014712-5u4e00q6	1214	4	other	other	JJ
cord-014712-5u4e00q6	1214	5	disorders	disorder	NNS
cord-014712-5u4e00q6	1214	6	should	should	MD
cord-014712-5u4e00q6	1214	7	be	be	VB
cord-014712-5u4e00q6	1214	8	excluded	exclude	VBN
cord-014712-5u4e00q6	1214	9	.	.	.
cord-014712-5u4e00q6	1215	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1215	2	conditions	condition	NNS
cord-014712-5u4e00q6	1215	3	can	can	MD
cord-014712-5u4e00q6	1215	4	be	be	VB
cord-014712-5u4e00q6	1215	5	the	the	DT
cord-014712-5u4e00q6	1215	6	presenting	present	VBG
cord-014712-5u4e00q6	1215	7	signs	sign	NNS
cord-014712-5u4e00q6	1215	8	/	/	SYM
cord-014712-5u4e00q6	1215	9	symptoms	symptom	NNS
cord-014712-5u4e00q6	1215	10	in	in	IN
cord-014712-5u4e00q6	1215	11	CVID	CVID	NNP
cord-014712-5u4e00q6	1215	12	.	.	.
cord-014712-5u4e00q6	1216	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1216	2	hematologic	hematologic	JJ
cord-014712-5u4e00q6	1216	3	disorders	disorder	NNS
cord-014712-5u4e00q6	1216	4	may	may	MD
cord-014712-5u4e00q6	1216	5	precede	precede	VB
cord-014712-5u4e00q6	1216	6	,	,	,
cord-014712-5u4e00q6	1216	7	present	present	JJ
cord-014712-5u4e00q6	1216	8	at	at	IN
cord-014712-5u4e00q6	1216	9	the	the	DT
cord-014712-5u4e00q6	1216	10	time	time	NN
cord-014712-5u4e00q6	1216	11	of	of	IN
cord-014712-5u4e00q6	1216	12	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1216	13	or	or	CC
cord-014712-5u4e00q6	1216	14	develope	develope	VB
cord-014712-5u4e00q6	1216	15	during	during	IN
cord-014712-5u4e00q6	1216	16	the	the	DT
cord-014712-5u4e00q6	1216	17	course	course	NN
cord-014712-5u4e00q6	1216	18	of	of	IN
cord-014712-5u4e00q6	1216	19	CVID	CVID	NNP
cord-014712-5u4e00q6	1216	20	in	in	IN
cord-014712-5u4e00q6	1216	21	approximately	approximately	RB
cord-014712-5u4e00q6	1216	22	one	one	CD
cord-014712-5u4e00q6	1216	23	-	-	HYPH
cord-014712-5u4e00q6	1216	24	half	half	NN
cord-014712-5u4e00q6	1216	25	of	of	IN
cord-014712-5u4e00q6	1216	26	the	the	DT
cord-014712-5u4e00q6	1216	27	patients	patient	NNS
cord-014712-5u4e00q6	1216	28	with	with	IN
cord-014712-5u4e00q6	1216	29	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1216	30	problems	problem	NNS
cord-014712-5u4e00q6	1216	31	.	.	.
cord-014712-5u4e00q6	1217	1	Selective	selective	JJ
cord-014712-5u4e00q6	1217	2	immunoglobuline	immunoglobuline	JJ
cord-014712-5u4e00q6	1217	3	deficiency	deficiency	NN
cord-014712-5u4e00q6	1217	4	is	be	VBZ
cord-014712-5u4e00q6	1217	5	an	an	DT
cord-014712-5u4e00q6	1217	6	uncommon	uncommon	JJ
cord-014712-5u4e00q6	1217	7	dysgamaglobulinemia	dysgamaglobulinemia	NN
cord-014712-5u4e00q6	1217	8	,	,	,
cord-014712-5u4e00q6	1217	9	in	in	IN
cord-014712-5u4e00q6	1217	10	which	which	WDT
cord-014712-5u4e00q6	1217	11	immunoglobuline	immunoglobuline	NNP
cord-014712-5u4e00q6	1217	12	levels	level	NNS
cord-014712-5u4e00q6	1217	13	except	except	IN
cord-014712-5u4e00q6	1217	14	IgM	IgM	NNP
cord-014712-5u4e00q6	1217	15	level	level	NN
cord-014712-5u4e00q6	1217	16	are	be	VBP
cord-014712-5u4e00q6	1217	17	normal	normal	JJ
cord-014712-5u4e00q6	1217	18	.	.	.
cord-014712-5u4e00q6	1218	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1218	2	can	can	MD
cord-014712-5u4e00q6	1218	3	be	be	VB
cord-014712-5u4e00q6	1218	4	primary	primary	JJ
cord-014712-5u4e00q6	1218	5	or	or	CC
cord-014712-5u4e00q6	1218	6	secondary	secondary	JJ
cord-014712-5u4e00q6	1218	7	to	to	IN
cord-014712-5u4e00q6	1218	8	cancer	cancer	NN
cord-014712-5u4e00q6	1218	9	,	,	,
cord-014712-5u4e00q6	1218	10	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1218	11	diseases	disease	NNS
cord-014712-5u4e00q6	1218	12	,	,	,
cord-014712-5u4e00q6	1218	13	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	1218	14	system	system	NN
cord-014712-5u4e00q6	1218	15	diseases	disease	NNS
cord-014712-5u4e00q6	1218	16	and	and	CC
cord-014712-5u4e00q6	1218	17	immunosuppressive	immunosuppressive	JJ
cord-014712-5u4e00q6	1218	18	therapy	therapy	NN
cord-014712-5u4e00q6	1218	19	.	.	.
cord-014712-5u4e00q6	1219	1	Patients	patient	NNS
cord-014712-5u4e00q6	1219	2	can	can	MD
cord-014712-5u4e00q6	1219	3	be	be	VB
cord-014712-5u4e00q6	1219	4	asymptomatic	asymptomatic	JJ
cord-014712-5u4e00q6	1219	5	or	or	CC
cord-014712-5u4e00q6	1219	6	have	have	VBP
cord-014712-5u4e00q6	1219	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1219	8	infections	infection	NNS
cord-014712-5u4e00q6	1219	9	,	,	,
cord-014712-5u4e00q6	1219	10	asthma	asthma	NN
cord-014712-5u4e00q6	1219	11	,	,	,
cord-014712-5u4e00q6	1219	12	angioedema	angioedema	NN
cord-014712-5u4e00q6	1219	13	,	,	,
cord-014712-5u4e00q6	1219	14	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1219	15	diseases	disease	NNS
cord-014712-5u4e00q6	1219	16	,	,	,
cord-014712-5u4e00q6	1219	17	celiac	celiac	JJ
cord-014712-5u4e00q6	1219	18	disease	disease	NN
cord-014712-5u4e00q6	1219	19	and	and	CC
cord-014712-5u4e00q6	1219	20	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	1219	21	.	.	.
cord-014712-5u4e00q6	1220	1	Allergic	allergic	JJ
cord-014712-5u4e00q6	1220	2	diatheses	diathese	NNS
cord-014712-5u4e00q6	1220	3	are	be	VBP
cord-014712-5u4e00q6	1220	4	the	the	DT
cord-014712-5u4e00q6	1220	5	second	second	JJ
cord-014712-5u4e00q6	1220	6	commonest	common	JJS
cord-014712-5u4e00q6	1220	7	presentation	presentation	NN
cord-014712-5u4e00q6	1220	8	of	of	IN
cord-014712-5u4e00q6	1220	9	selective	selective	JJ
cord-014712-5u4e00q6	1220	10	IgM	IgM	NNP
cord-014712-5u4e00q6	1220	11	deficiency	deficiency	NN
cord-014712-5u4e00q6	1220	12	.	.	.
cord-014712-5u4e00q6	1221	1	In	in	IN
cord-014712-5u4e00q6	1221	2	this	this	DT
cord-014712-5u4e00q6	1221	3	presentation	presentation	NN
cord-014712-5u4e00q6	1221	4	,	,	,
cord-014712-5u4e00q6	1221	5	we	-PRON-	PRP
cord-014712-5u4e00q6	1221	6	report	report	VBP
cord-014712-5u4e00q6	1221	7	a	a	DT
cord-014712-5u4e00q6	1221	8	case	case	NN
cord-014712-5u4e00q6	1221	9	with	with	IN
cord-014712-5u4e00q6	1221	10	asthma	asthma	NN
cord-014712-5u4e00q6	1221	11	and	and	CC
cord-014712-5u4e00q6	1221	12	angioedema	angioedema	NN
cord-014712-5u4e00q6	1221	13	who	who	WP
cord-014712-5u4e00q6	1221	14	has	have	VBZ
cord-014712-5u4e00q6	1221	15	selective	selective	JJ
cord-014712-5u4e00q6	1221	16	immunoglobuline	immunoglobuline	NNP
cord-014712-5u4e00q6	1221	17	M	M	NNP
cord-014712-5u4e00q6	1221	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	1221	19	.	.	.
cord-014712-5u4e00q6	1222	1	A	a	DT
cord-014712-5u4e00q6	1222	2	16	16	CD
cord-014712-5u4e00q6	1222	3	year	year	NN
cord-014712-5u4e00q6	1222	4	old	old	JJ
cord-014712-5u4e00q6	1222	5	male	male	JJ
cord-014712-5u4e00q6	1222	6	patient	patient	NN
cord-014712-5u4e00q6	1222	7	who	who	WP
cord-014712-5u4e00q6	1222	8	has	have	VBZ
cord-014712-5u4e00q6	1222	9	been	be	VBN
cord-014712-5u4e00q6	1222	10	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1222	11	with	with	IN
cord-014712-5u4e00q6	1222	12	asthma	asthma	NN
cord-014712-5u4e00q6	1222	13	for	for	IN
cord-014712-5u4e00q6	1222	14	12	12	CD
cord-014712-5u4e00q6	1222	15	years	year	NNS
cord-014712-5u4e00q6	1222	16	with	with	IN
cord-014712-5u4e00q6	1222	17	a	a	DT
cord-014712-5u4e00q6	1222	18	well	well	RB
cord-014712-5u4e00q6	1222	19	controlled	control	VBN
cord-014712-5u4e00q6	1222	20	asthma	asthma	NN
cord-014712-5u4e00q6	1222	21	for	for	IN
cord-014712-5u4e00q6	1222	22	2	2	CD
cord-014712-5u4e00q6	1222	23	years	year	NNS
cord-014712-5u4e00q6	1222	24	presented	present	VBN
cord-014712-5u4e00q6	1222	25	with	with	IN
cord-014712-5u4e00q6	1222	26	labial	labial	JJ
cord-014712-5u4e00q6	1222	27	angioedema	angioedema	NN
cord-014712-5u4e00q6	1222	28	.	.	.
cord-014712-5u4e00q6	1223	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1223	2	had	have	VBD
cord-014712-5u4e00q6	1223	3	labial	labial	JJ
cord-014712-5u4e00q6	1223	4	angioedema	angioedema	NN
cord-014712-5u4e00q6	1223	5	daily	daily	RB
cord-014712-5u4e00q6	1223	6	without	without	IN
cord-014712-5u4e00q6	1223	7	antihistamines	antihistamine	NNS
cord-014712-5u4e00q6	1223	8	.	.	.
cord-014712-5u4e00q6	1224	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1224	2	did	do	VBD
cord-014712-5u4e00q6	1224	3	not	not	RB
cord-014712-5u4e00q6	1224	4	have	have	VB
cord-014712-5u4e00q6	1224	5	any	any	DT
cord-014712-5u4e00q6	1224	6	suspected	suspect	VBN
cord-014712-5u4e00q6	1224	7	food	food	NN
cord-014712-5u4e00q6	1224	8	or	or	CC
cord-014712-5u4e00q6	1224	9	drug	drug	NN
cord-014712-5u4e00q6	1224	10	allergy	allergy	NN
cord-014712-5u4e00q6	1224	11	.	.	.
cord-014712-5u4e00q6	1225	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1225	2	did	do	VBD
cord-014712-5u4e00q6	1225	3	not	not	RB
cord-014712-5u4e00q6	1225	4	have	have	VB
cord-014712-5u4e00q6	1225	5	family	family	NN
cord-014712-5u4e00q6	1225	6	history	history	NN
cord-014712-5u4e00q6	1225	7	of	of	IN
cord-014712-5u4e00q6	1225	8	angioedema	angioedema	NN
cord-014712-5u4e00q6	1225	9	.	.	.
cord-014712-5u4e00q6	1226	1	Physical	physical	JJ
cord-014712-5u4e00q6	1226	2	examination	examination	NN
cord-014712-5u4e00q6	1226	3	was	be	VBD
cord-014712-5u4e00q6	1226	4	normal	normal	JJ
cord-014712-5u4e00q6	1226	5	under	under	IN
cord-014712-5u4e00q6	1226	6	antihistamine	antihistamine	NN
cord-014712-5u4e00q6	1226	7	therapy	therapy	NN
cord-014712-5u4e00q6	1226	8	.	.	.
cord-014712-5u4e00q6	1227	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1227	2	evaluation	evaluation	NN
cord-014712-5u4e00q6	1227	3	revealed	reveal	VBD
cord-014712-5u4e00q6	1227	4	a	a	DT
cord-014712-5u4e00q6	1227	5	4.3	4.3	CD
cord-014712-5u4e00q6	1227	6	%	%	NN
cord-014712-5u4e00q6	1227	7	percentage	percentage	NN
cord-014712-5u4e00q6	1227	8	of	of	IN
cord-014712-5u4e00q6	1227	9	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1227	10	.	.	.
cord-014712-5u4e00q6	1228	1	Absolute	absolute	JJ
cord-014712-5u4e00q6	1228	2	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1228	3	count	count	NN
cord-014712-5u4e00q6	1228	4	was	be	VBD
cord-014712-5u4e00q6	1228	5	2700	2700	CD
cord-014712-5u4e00q6	1228	6	,	,	,
cord-014712-5u4e00q6	1228	7	absolute	absolute	JJ
cord-014712-5u4e00q6	1228	8	neutrophil	neutrophil	NN
cord-014712-5u4e00q6	1228	9	count	count	NN
cord-014712-5u4e00q6	1228	10	was	be	VBD
cord-014712-5u4e00q6	1228	11	7000	7000	CD
cord-014712-5u4e00q6	1228	12	cells	cell	NNS
cord-014712-5u4e00q6	1228	13	/	/	SYM
cord-014712-5u4e00q6	1228	14	mm	mm	NN
cord-014712-5u4e00q6	1228	15	3	3	CD
cord-014712-5u4e00q6	1228	16	.	.	.
cord-014712-5u4e00q6	1229	1	Immunoglobuline	Immunoglobuline	NNP
cord-014712-5u4e00q6	1229	2	E	e	NN
cord-014712-5u4e00q6	1229	3	value	value	NN
cord-014712-5u4e00q6	1229	4	was	be	VBD
cord-014712-5u4e00q6	1229	5	260	260	CD
cord-014712-5u4e00q6	1229	6	ng	ng	NN
cord-014712-5u4e00q6	1229	7	/	/	SYM
cord-014712-5u4e00q6	1229	8	ml	ml	NN
cord-014712-5u4e00q6	1229	9	,	,	,
cord-014712-5u4e00q6	1229	10	levels	level	NNS
cord-014712-5u4e00q6	1229	11	of	of	IN
cord-014712-5u4e00q6	1229	12	immunoglobuline	immunoglobuline	NNP
cord-014712-5u4e00q6	1229	13	G	G	NNP
cord-014712-5u4e00q6	1229	14	and	and	CC
cord-014712-5u4e00q6	1229	15	A	A	NNP
cord-014712-5u4e00q6	1229	16	were	be	VBD
cord-014712-5u4e00q6	1229	17	within	within	IN
cord-014712-5u4e00q6	1229	18	normal	normal	JJ
cord-014712-5u4e00q6	1229	19	limits	limit	NNS
cord-014712-5u4e00q6	1229	20	for	for	IN
cord-014712-5u4e00q6	1229	21	age	age	NN
cord-014712-5u4e00q6	1229	22	.	.	.
cord-014712-5u4e00q6	1230	1	Immunoglobulin	Immunoglobulin	NNP
cord-014712-5u4e00q6	1230	2	M	M	NNP
cord-014712-5u4e00q6	1230	3	value	value	NN
cord-014712-5u4e00q6	1230	4	was	be	VBD
cord-014712-5u4e00q6	1230	5	28.7	28.7	CD
cord-014712-5u4e00q6	1230	6	mg	mg	NNP
cord-014712-5u4e00q6	1230	7	/	/	SYM
cord-014712-5u4e00q6	1230	8	dl	dl	NNP
cord-014712-5u4e00q6	1230	9	(	(	-LRB-
cord-014712-5u4e00q6	1230	10	73	73	CD
cord-014712-5u4e00q6	1230	11	-	-	SYM
cord-014712-5u4e00q6	1230	12	448	448	CD
cord-014712-5u4e00q6	1230	13	)	)	-RRB-
cord-014712-5u4e00q6	1230	14	.	.	.
cord-014712-5u4e00q6	1231	1	Anti	Anti	NNP
cord-014712-5u4e00q6	1231	2	A	A	NNP
cord-014712-5u4e00q6	1231	3	was	be	VBD
cord-014712-5u4e00q6	1231	4	1/8	1/8	CD
cord-014712-5u4e00q6	1231	5	,	,	,
cord-014712-5u4e00q6	1231	6	anti	anti	NNP
cord-014712-5u4e00q6	1231	7	B	B	NNP
cord-014712-5u4e00q6	1231	8	was	be	VBD
cord-014712-5u4e00q6	1231	9	½	½	JJ
cord-014712-5u4e00q6	1231	10	positive	positive	JJ
cord-014712-5u4e00q6	1231	11	,	,	,
cord-014712-5u4e00q6	1231	12	antiHbs	antiHbs	NNP
cord-014712-5u4e00q6	1231	13	was	be	VBD
cord-014712-5u4e00q6	1231	14	above	above	IN
cord-014712-5u4e00q6	1231	15	1000	1000	CD
cord-014712-5u4e00q6	1231	16	mlu	mlu	NNP
cord-014712-5u4e00q6	1231	17	/	/	SYM
cord-014712-5u4e00q6	1231	18	mL.	mL.	NNP
cord-014712-5u4e00q6	1231	19	Lymphocyte	Lymphocyte	NNP
cord-014712-5u4e00q6	1231	20	subsets	subset	NNS
cord-014712-5u4e00q6	1231	21	were	be	VBD
cord-014712-5u4e00q6	1231	22	normal	normal	JJ
cord-014712-5u4e00q6	1231	23	.	.	.
cord-014712-5u4e00q6	1232	1	Because	because	IN
cord-014712-5u4e00q6	1232	2	of	of	IN
cord-014712-5u4e00q6	1232	3	the	the	DT
cord-014712-5u4e00q6	1232	4	continuous	continuous	JJ
cord-014712-5u4e00q6	1232	5	usage	usage	NN
cord-014712-5u4e00q6	1232	6	of	of	IN
cord-014712-5u4e00q6	1232	7	antihistamines	antihistamine	NNS
cord-014712-5u4e00q6	1232	8	,	,	,
cord-014712-5u4e00q6	1232	9	prick	prick	NN
cord-014712-5u4e00q6	1232	10	tests	test	NNS
cord-014712-5u4e00q6	1232	11	could	could	MD
cord-014712-5u4e00q6	1232	12	not	not	RB
cord-014712-5u4e00q6	1232	13	be	be	VB
cord-014712-5u4e00q6	1232	14	done	do	VBN
cord-014712-5u4e00q6	1232	15	.	.	.
cord-014712-5u4e00q6	1233	1	Levels	level	NNS
cord-014712-5u4e00q6	1233	2	of	of	IN
cord-014712-5u4e00q6	1233	3	D1	d1	NN
cord-014712-5u4e00q6	1233	4	was17.8	was17.8	RB
cord-014712-5u4e00q6	1233	5	,	,	,
cord-014712-5u4e00q6	1233	6	D2	D2	NNP
cord-014712-5u4e00q6	1233	7	was12.4	was12.4	NNP
cord-014712-5u4e00q6	1233	8	kU	kU	NNP
cord-014712-5u4e00q6	1234	1	A	a	DT
cord-014712-5u4e00q6	1234	2	/l	/l	NN
cord-014712-5u4e00q6	1234	3	.	.	.
cord-014712-5u4e00q6	1235	1	Thyroid	thyroid	NN
cord-014712-5u4e00q6	1235	2	functions	function	NNS
cord-014712-5u4e00q6	1235	3	,	,	,
cord-014712-5u4e00q6	1235	4	antiTPO	antiTPO	NNP
cord-014712-5u4e00q6	1235	5	,	,	,
cord-014712-5u4e00q6	1235	6	C3	C3	NNP
cord-014712-5u4e00q6	1235	7	,	,	,
cord-014712-5u4e00q6	1235	8	C4	C4	NNP
cord-014712-5u4e00q6	1235	9	and	and	CC
cord-014712-5u4e00q6	1235	10	C1	C1	NNP
cord-014712-5u4e00q6	1236	1	esterase	esterase	NN
cord-014712-5u4e00q6	1236	2	inhibitor	inhibitor	NN
cord-014712-5u4e00q6	1236	3	values	value	NNS
cord-014712-5u4e00q6	1236	4	were	be	VBD
cord-014712-5u4e00q6	1236	5	normal	normal	JJ
cord-014712-5u4e00q6	1236	6	.	.	.
cord-014712-5u4e00q6	1237	1	Antinuclear	antinuclear	JJ
cord-014712-5u4e00q6	1237	2	antibodies	antibody	NNS
cord-014712-5u4e00q6	1237	3	and	and	CC
cord-014712-5u4e00q6	1237	4	antitransglutaminase	antitransglutaminase	NNP
cord-014712-5u4e00q6	1237	5	lgA	lgA	NNP
cord-014712-5u4e00q6	1237	6	was	be	VBD
cord-014712-5u4e00q6	1237	7	negative	negative	JJ
cord-014712-5u4e00q6	1237	8	.	.	.
cord-014712-5u4e00q6	1238	1	Immunoglobuline	Immunoglobuline	NNP
cord-014712-5u4e00q6	1238	2	M	M	NNP
cord-014712-5u4e00q6	1238	3	value	value	NN
cord-014712-5u4e00q6	1238	4	of	of	IN
cord-014712-5u4e00q6	1238	5	his	-PRON-	PRP$
cord-014712-5u4e00q6	1238	6	father	father	NN
cord-014712-5u4e00q6	1238	7	was	be	VBD
cord-014712-5u4e00q6	1238	8	normal	normal	JJ
cord-014712-5u4e00q6	1238	9	,	,	,
cord-014712-5u4e00q6	1238	10	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1238	11	M	M	NNP
cord-014712-5u4e00q6	1238	12	value	value	NN
cord-014712-5u4e00q6	1238	13	of	of	IN
cord-014712-5u4e00q6	1238	14	his	-PRON-	PRP$
cord-014712-5u4e00q6	1238	15	brother	brother	NN
cord-014712-5u4e00q6	1238	16	was	be	VBD
cord-014712-5u4e00q6	1238	17	53.50	53.50	CD
cord-014712-5u4e00q6	1238	18	mg	mg	NNP
cord-014712-5u4e00q6	1238	19	/	/	SYM
cord-014712-5u4e00q6	1238	20	dl	dl	NNP
cord-014712-5u4e00q6	1238	21	(	(	-LRB-
cord-014712-5u4e00q6	1238	22	88	88	CD
cord-014712-5u4e00q6	1238	23	-	-	SYM
cord-014712-5u4e00q6	1238	24	322	322	CD
cord-014712-5u4e00q6	1238	25	)	)	-RRB-
cord-014712-5u4e00q6	1238	26	.	.	.
cord-014712-5u4e00q6	1239	1	Selective	selective	JJ
cord-014712-5u4e00q6	1239	2	immunoglobuline	immunoglobuline	JJ
cord-014712-5u4e00q6	1239	3	deficiency	deficiency	NN
cord-014712-5u4e00q6	1239	4	is	be	VBZ
cord-014712-5u4e00q6	1239	5	a	a	DT
cord-014712-5u4e00q6	1239	6	rarely	rarely	RB
cord-014712-5u4e00q6	1239	7	seen	see	VBN
cord-014712-5u4e00q6	1239	8	dysgamaglobulinemia	dysgamaglobulinemia	NN
cord-014712-5u4e00q6	1239	9	.	.	.
cord-014712-5u4e00q6	1240	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1240	2	was	be	VBD
cord-014712-5u4e00q6	1240	3	reported	report	VBN
cord-014712-5u4e00q6	1240	4	in	in	IN
cord-014712-5u4e00q6	1240	5	children	child	NNS
cord-014712-5u4e00q6	1240	6	with	with	IN
cord-014712-5u4e00q6	1240	7	asthma	asthma	NN
cord-014712-5u4e00q6	1240	8	,	,	,
cord-014712-5u4e00q6	1240	9	but	but	CC
cord-014712-5u4e00q6	1240	10	it	-PRON-	PRP
cord-014712-5u4e00q6	1240	11	was	be	VBD
cord-014712-5u4e00q6	1240	12	not	not	RB
cord-014712-5u4e00q6	1240	13	reported	report	VBN
cord-014712-5u4e00q6	1240	14	in	in	IN
cord-014712-5u4e00q6	1240	15	children	child	NNS
cord-014712-5u4e00q6	1240	16	with	with	IN
cord-014712-5u4e00q6	1240	17	angioedema	angioedema	NN
cord-014712-5u4e00q6	1240	18	.	.	.
cord-014712-5u4e00q6	1241	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1241	2	can	can	MD
cord-014712-5u4e00q6	1241	3	have	have	VB
cord-014712-5u4e00q6	1241	4	value	value	NN
cord-014712-5u4e00q6	1241	5	in	in	IN
cord-014712-5u4e00q6	1241	6	the	the	DT
cord-014712-5u4e00q6	1241	7	clinical	clinical	JJ
cord-014712-5u4e00q6	1241	8	evaluation	evaluation	NN
cord-014712-5u4e00q6	1241	9	of	of	IN
cord-014712-5u4e00q6	1241	10	patients	patient	NNS
cord-014712-5u4e00q6	1241	11	with	with	IN
cord-014712-5u4e00q6	1241	12	angioedema	angioedema	NN
cord-014712-5u4e00q6	1241	13	.	.	.
cord-014712-5u4e00q6	1242	1	Cukurova	Cukurova	NNP
cord-014712-5u4e00q6	1242	2	University	University	NNP
cord-014712-5u4e00q6	1242	3	,	,	,
cord-014712-5u4e00q6	1242	4	Department	Department	NNP
cord-014712-5u4e00q6	1242	5	of	of	IN
cord-014712-5u4e00q6	1242	6	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	1242	7	Allergy	Allergy	NNP
cord-014712-5u4e00q6	1242	8	and	and	CC
cord-014712-5u4e00q6	1242	9	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1242	10	,	,	,
cord-014712-5u4e00q6	1242	11	Adana	Adana	NNP
cord-014712-5u4e00q6	1242	12	,	,	,
cord-014712-5u4e00q6	1242	13	Turkey	Turkey	NNP
cord-014712-5u4e00q6	1242	14	A	a	DT
cord-014712-5u4e00q6	1242	15	patient	patient	NN
cord-014712-5u4e00q6	1242	16	who	who	WP
cord-014712-5u4e00q6	1242	17	is	be	VBZ
cord-014712-5u4e00q6	1242	18	at	at	IN
cord-014712-5u4e00q6	1242	19	age	age	NN
cord-014712-5u4e00q6	1242	20	of	of	IN
cord-014712-5u4e00q6	1242	21	11	11	CD
cord-014712-5u4e00q6	1242	22	years	year	NNS
cord-014712-5u4e00q6	1242	23	at	at	IN
cord-014712-5u4e00q6	1242	24	present	present	NN
cord-014712-5u4e00q6	1242	25	and	and	CC
cord-014712-5u4e00q6	1242	26	who	who	WP
cord-014712-5u4e00q6	1242	27	has	have	VBZ
cord-014712-5u4e00q6	1242	28	been	be	VBN
cord-014712-5u4e00q6	1242	29	followed	follow	VBN
cord-014712-5u4e00q6	1242	30	up	up	RP
cord-014712-5u4e00q6	1242	31	at	at	IN
cord-014712-5u4e00q6	1242	32	the	the	DT
cord-014712-5u4e00q6	1242	33	our	-PRON-	PRP$
cord-014712-5u4e00q6	1242	34	clinic	clinic	NN
cord-014712-5u4e00q6	1242	35	with	with	IN
cord-014712-5u4e00q6	1242	36	XLA	XLA	NNP
cord-014712-5u4e00q6	1242	37	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1242	38	presented	present	VBN
cord-014712-5u4e00q6	1242	39	with	with	IN
cord-014712-5u4e00q6	1242	40	pain	pain	NN
cord-014712-5u4e00q6	1242	41	in	in	IN
cord-014712-5u4e00q6	1242	42	his	-PRON-	PRP$
cord-014712-5u4e00q6	1242	43	ankles	ankle	NNS
cord-014712-5u4e00q6	1242	44	and	and	CC
cord-014712-5u4e00q6	1242	45	wrists	wrist	NNS
cord-014712-5u4e00q6	1242	46	and	and	CC
cord-014712-5u4e00q6	1242	47	swelling	swelling	NN
cord-014712-5u4e00q6	1242	48	of	of	IN
cord-014712-5u4e00q6	1242	49	his	-PRON-	PRP$
cord-014712-5u4e00q6	1242	50	right	right	JJ
cord-014712-5u4e00q6	1242	51	knee	knee	NN
cord-014712-5u4e00q6	1242	52	.	.	.
cord-014712-5u4e00q6	1243	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1243	2	also	also	RB
cord-014712-5u4e00q6	1243	3	was	be	VBD
cord-014712-5u4e00q6	1243	4	suffering	suffer	VBG
cord-014712-5u4e00q6	1243	5	from	from	IN
cord-014712-5u4e00q6	1243	6	skin	skin	NN
cord-014712-5u4e00q6	1243	7	tightening	tightening	NN
cord-014712-5u4e00q6	1243	8	of	of	IN
cord-014712-5u4e00q6	1243	9	the	the	DT
cord-014712-5u4e00q6	1243	10	lower	low	JJR
cord-014712-5u4e00q6	1243	11	extremities	extremity	NNS
cord-014712-5u4e00q6	1243	12	.	.	.
cord-014712-5u4e00q6	1244	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1244	2	physical	physical	JJ
cord-014712-5u4e00q6	1244	3	examination	examination	NN
cord-014712-5u4e00q6	1244	4	revealed	reveal	VBD
cord-014712-5u4e00q6	1244	5	arthitis	arthitis	NN
cord-014712-5u4e00q6	1244	6	of	of	IN
cord-014712-5u4e00q6	1244	7	the	the	DT
cord-014712-5u4e00q6	1244	8	right	right	JJ
cord-014712-5u4e00q6	1244	9	knee	knee	NN
cord-014712-5u4e00q6	1244	10	and	and	CC
cord-014712-5u4e00q6	1244	11	sclerotic	sclerotic	JJ
cord-014712-5u4e00q6	1244	12	changes	change	NNS
cord-014712-5u4e00q6	1244	13	were	be	VBD
cord-014712-5u4e00q6	1244	14	detected	detect	VBN
cord-014712-5u4e00q6	1244	15	in	in	IN
cord-014712-5u4e00q6	1244	16	the	the	DT
cord-014712-5u4e00q6	1244	17	skin	skin	NN
cord-014712-5u4e00q6	1244	18	.	.	.
cord-014712-5u4e00q6	1245	1	Skin	skin	NN
cord-014712-5u4e00q6	1245	2	biopsy	biopsy	NN
cord-014712-5u4e00q6	1245	3	was	be	VBD
cord-014712-5u4e00q6	1245	4	performed	perform	VBN
cord-014712-5u4e00q6	1245	5	and	and	CC
cord-014712-5u4e00q6	1245	6	it	-PRON-	PRP
cord-014712-5u4e00q6	1245	7	revealed	reveal	VBD
cord-014712-5u4e00q6	1245	8	morphea	morphea	NNP
cord-014712-5u4e00q6	1245	9	(	(	-LRB-
cord-014712-5u4e00q6	1245	10	localized	localized	JJ
cord-014712-5u4e00q6	1245	11	scleroderma	scleroderma	NNS
cord-014712-5u4e00q6	1245	12	)	)	-RRB-
cord-014712-5u4e00q6	1245	13	.	.	.
cord-014712-5u4e00q6	1246	1	After	after	IN
cord-014712-5u4e00q6	1246	2	the	the	DT
cord-014712-5u4e00q6	1246	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1246	4	of	of	IN
cord-014712-5u4e00q6	1246	5	morphea	morphea	NN
cord-014712-5u4e00q6	1246	6	and	and	CC
cord-014712-5u4e00q6	1246	7	arthritis	arthritis	NN
cord-014712-5u4e00q6	1246	8	,	,	,
cord-014712-5u4e00q6	1246	9	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1246	10	2	2	CD
cord-014712-5u4e00q6	1246	11	gm	gm	NNP
cord-014712-5u4e00q6	1246	12	/	/	SYM
cord-014712-5u4e00q6	1246	13	kg	kg	NNP
cord-014712-5u4e00q6	1246	14	and	and	CC
cord-014712-5u4e00q6	1246	15	NSAID	NSAID	NNP
cord-014712-5u4e00q6	1246	16	were	be	VBD
cord-014712-5u4e00q6	1246	17	applied	apply	VBN
cord-014712-5u4e00q6	1246	18	.	.	.
cord-014712-5u4e00q6	1247	1	Following	follow	VBG
cord-014712-5u4e00q6	1247	2	the	the	DT
cord-014712-5u4e00q6	1247	3	treatment	treatment	NN
cord-014712-5u4e00q6	1247	4	skin	skin	NN
cord-014712-5u4e00q6	1247	5	findings	finding	NNS
cord-014712-5u4e00q6	1247	6	and	and	CC
cord-014712-5u4e00q6	1247	7	arthritis	arthritis	NN
cord-014712-5u4e00q6	1247	8	resolved	resolve	VBD
cord-014712-5u4e00q6	1247	9	,	,	,
cord-014712-5u4e00q6	1247	10	however	however	RB
cord-014712-5u4e00q6	1247	11	approximately	approximately	RB
cord-014712-5u4e00q6	1247	12	two	two	CD
cord-014712-5u4e00q6	1247	13	months	month	NNS
cord-014712-5u4e00q6	1247	14	later	later	IN
cord-014712-5u4e00q6	1247	15	liver	liver	NN
cord-014712-5u4e00q6	1247	16	enzymes	enzyme	NNS
cord-014712-5u4e00q6	1247	17	were	be	VBD
cord-014712-5u4e00q6	1247	18	detected	detect	VBN
cord-014712-5u4e00q6	1247	19	to	to	TO
cord-014712-5u4e00q6	1247	20	be	be	VB
cord-014712-5u4e00q6	1247	21	high	high	JJ
cord-014712-5u4e00q6	1247	22	in	in	IN
cord-014712-5u4e00q6	1247	23	his	-PRON-	PRP$
cord-014712-5u4e00q6	1247	24	routine	routine	JJ
cord-014712-5u4e00q6	1247	25	control	control	NN
cord-014712-5u4e00q6	1247	26	.	.	.
cord-014712-5u4e00q6	1248	1	Liver	liver	NN
cord-014712-5u4e00q6	1248	2	biopsy	biopsy	NN
cord-014712-5u4e00q6	1248	3	performed	perform	VBN
cord-014712-5u4e00q6	1248	4	to	to	TO
cord-014712-5u4e00q6	1248	5	clarify	clarify	VB
cord-014712-5u4e00q6	1248	6	the	the	DT
cord-014712-5u4e00q6	1248	7	aetiology	aetiology	NN
cord-014712-5u4e00q6	1248	8	of	of	IN
cord-014712-5u4e00q6	1248	9	elevated	elevated	JJ
cord-014712-5u4e00q6	1248	10	liver	liver	NN
cord-014712-5u4e00q6	1248	11	enzymes	enzyme	NNS
cord-014712-5u4e00q6	1248	12	was	be	VBD
cord-014712-5u4e00q6	1248	13	reported	report	VBN
cord-014712-5u4e00q6	1248	14	as	as	IN
cord-014712-5u4e00q6	1248	15	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1248	16	hepatitis	hepatitis	NNP
cord-014712-5u4e00q6	1248	17	.	.	.
cord-014712-5u4e00q6	1249	1	In	in	IN
cord-014712-5u4e00q6	1249	2	addition	addition	NN
cord-014712-5u4e00q6	1249	3	to	to	IN
cord-014712-5u4e00q6	1249	4	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1249	5	2	2	CD
cord-014712-5u4e00q6	1249	6	gm	gm	NNP
cord-014712-5u4e00q6	1249	7	/	/	SYM
cord-014712-5u4e00q6	1249	8	kg	kg	NNP
cord-014712-5u4e00q6	1249	9	,	,	,
cord-014712-5u4e00q6	1249	10	budenofalk	budenofalk	NNP
cord-014712-5u4e00q6	1249	11	6mg	6mg	NNP
cord-014712-5u4e00q6	1249	12	/	/	SYM
cord-014712-5u4e00q6	1249	13	day	day	NN
cord-014712-5u4e00q6	1249	14	was	be	VBD
cord-014712-5u4e00q6	1249	15	started	start	VBN
cord-014712-5u4e00q6	1249	16	.	.	.
cord-014712-5u4e00q6	1250	1	After	after	IN
cord-014712-5u4e00q6	1250	2	3	3	CD
cord-014712-5u4e00q6	1250	3	months	month	NNS
cord-014712-5u4e00q6	1250	4	of	of	IN
cord-014712-5u4e00q6	1250	5	treatment	treatment	NN
cord-014712-5u4e00q6	1250	6	,	,	,
cord-014712-5u4e00q6	1250	7	his	-PRON-	PRP$
cord-014712-5u4e00q6	1250	8	liver	liver	NN
cord-014712-5u4e00q6	1250	9	enzymes	enzyme	NNS
cord-014712-5u4e00q6	1250	10	normalized	normalize	VBN
cord-014712-5u4e00q6	1250	11	.	.	.
cord-014712-5u4e00q6	1251	1	Currently	currently	RB
cord-014712-5u4e00q6	1251	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1251	3	is	be	VBZ
cord-014712-5u4e00q6	1251	4	being	be	VBG
cord-014712-5u4e00q6	1251	5	treated	treat	VBN
cord-014712-5u4e00q6	1251	6	with	with	IN
cord-014712-5u4e00q6	1251	7	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1251	8	monthly	monthly	JJ
cord-014712-5u4e00q6	1251	9	and	and	CC
cord-014712-5u4e00q6	1251	10	ursofalk	ursofalk	JJ
cord-014712-5u4e00q6	1251	11	daily	daily	RB
cord-014712-5u4e00q6	1251	12	.	.	.
cord-014712-5u4e00q6	1252	1	Patients	patient	NNS
cord-014712-5u4e00q6	1252	2	with	with	IN
cord-014712-5u4e00q6	1252	3	XLA	XLA	NNP
cord-014712-5u4e00q6	1252	4	typically	typically	RB
cord-014712-5u4e00q6	1252	5	present	present	JJ
cord-014712-5u4e00q6	1252	6	with	with	IN
cord-014712-5u4e00q6	1252	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1252	8	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1252	9	infections	infection	NNS
cord-014712-5u4e00q6	1252	10	and	and	CC
cord-014712-5u4e00q6	1252	11	it	-PRON-	PRP
cord-014712-5u4e00q6	1252	12	might	may	MD
cord-014712-5u4e00q6	1252	13	be	be	VB
cord-014712-5u4e00q6	1252	14	associated	associate	VBN
cord-014712-5u4e00q6	1252	15	with	with	IN
cord-014712-5u4e00q6	1252	16	some	some	DT
cord-014712-5u4e00q6	1252	17	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1252	18	diseases	disease	NNS
cord-014712-5u4e00q6	1252	19	.	.	.
cord-014712-5u4e00q6	1253	1	There	there	EX
cord-014712-5u4e00q6	1253	2	are	be	VBP
cord-014712-5u4e00q6	1253	3	not	not	RB
cord-014712-5u4e00q6	1253	4	any	any	DT
cord-014712-5u4e00q6	1253	5	reports	report	NNS
cord-014712-5u4e00q6	1253	6	indicating	indicate	VBG
cord-014712-5u4e00q6	1253	7	an	an	DT
cord-014712-5u4e00q6	1253	8	associaton	associaton	NNP
cord-014712-5u4e00q6	1253	9	of	of	IN
cord-014712-5u4e00q6	1253	10	autoimmune	autoimmune	NNP
cord-014712-5u4e00q6	1253	11	hepatitis	hepatitis	NNP
cord-014712-5u4e00q6	1253	12	and	and	CC
cord-014712-5u4e00q6	1253	13	scleroderma	scleroderma	NNS
cord-014712-5u4e00q6	1253	14	with	with	IN
cord-014712-5u4e00q6	1253	15	XLA	XLA	NNP
cord-014712-5u4e00q6	1253	16	.	.	.
cord-014712-5u4e00q6	1254	1	Bruton	Bruton	NNP
cord-014712-5u4e00q6	1254	2	agammaglobulinemia	agammaglobulinemia	NNP
cord-014712-5u4e00q6	1254	3	is	be	VBZ
cord-014712-5u4e00q6	1254	4	an	an	DT
cord-014712-5u4e00q6	1254	5	inherited	inherit	VBN
cord-014712-5u4e00q6	1254	6	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1254	7	disease	disease	NN
cord-014712-5u4e00q6	1254	8	caused	cause	VBN
cord-014712-5u4e00q6	1254	9	by	by	IN
cord-014712-5u4e00q6	1254	10	mutations	mutation	NNS
cord-014712-5u4e00q6	1254	11	in	in	IN
cord-014712-5u4e00q6	1254	12	the	the	DT
cord-014712-5u4e00q6	1254	13	gene	gene	NN
cord-014712-5u4e00q6	1254	14	coding	coding	NN
cord-014712-5u4e00q6	1254	15	for	for	IN
cord-014712-5u4e00q6	1254	16	Bruton	Bruton	NNP
cord-014712-5u4e00q6	1254	17	tyrosine	tyrosine	NN
cord-014712-5u4e00q6	1254	18	kinase	kinase	NN
cord-014712-5u4e00q6	1254	19	(	(	-LRB-
cord-014712-5u4e00q6	1254	20	BTK	BTK	NNP
cord-014712-5u4e00q6	1254	21	)	)	-RRB-
cord-014712-5u4e00q6	1254	22	.	.	.
cord-014712-5u4e00q6	1255	1	The	the	DT
cord-014712-5u4e00q6	1255	2	median	median	JJ
cord-014712-5u4e00q6	1255	3	age	age	NN
cord-014712-5u4e00q6	1255	4	at	at	IN
cord-014712-5u4e00q6	1255	5	the	the	DT
cord-014712-5u4e00q6	1255	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1255	7	of	of	IN
cord-014712-5u4e00q6	1255	8	the	the	DT
cord-014712-5u4e00q6	1255	9	antibody	antibody	NN
cord-014712-5u4e00q6	1255	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	1255	11	is	be	VBZ
cord-014712-5u4e00q6	1255	12	about	about	IN
cord-014712-5u4e00q6	1255	13	4.6	4.6	CD
cord-014712-5u4e00q6	1255	14	years	year	NNS
cord-014712-5u4e00q6	1255	15	in	in	IN
cord-014712-5u4e00q6	1255	16	Turkey	Turkey	NNP
cord-014712-5u4e00q6	1255	17	.	.	.
cord-014712-5u4e00q6	1256	1	Here	here	RB
cord-014712-5u4e00q6	1256	2	,	,	,
cord-014712-5u4e00q6	1256	3	we	-PRON-	PRP
cord-014712-5u4e00q6	1256	4	report	report	VBP
cord-014712-5u4e00q6	1256	5	a	a	DT
cord-014712-5u4e00q6	1256	6	case	case	NN
cord-014712-5u4e00q6	1256	7	of	of	IN
cord-014712-5u4e00q6	1256	8	Bruton	Bruton	NNP
cord-014712-5u4e00q6	1256	9	Disease	Disease	NNP
cord-014712-5u4e00q6	1256	10	presenting	present	VBG
cord-014712-5u4e00q6	1256	11	with	with	IN
cord-014712-5u4e00q6	1256	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1256	13	cervical	cervical	JJ
cord-014712-5u4e00q6	1256	14	abscess	abscess	NN
cord-014712-5u4e00q6	1256	15	at	at	IN
cord-014712-5u4e00q6	1256	16	two	two	CD
cord-014712-5u4e00q6	1256	17	months	month	NNS
cord-014712-5u4e00q6	1256	18	old	old	JJ
cord-014712-5u4e00q6	1256	19	infant	infant	NN
cord-014712-5u4e00q6	1256	20	.	.	.
cord-014712-5u4e00q6	1257	1	A	a	DT
cord-014712-5u4e00q6	1257	2	2-months	2-months	CD
cord-014712-5u4e00q6	1257	3	-	-	HYPH
cord-014712-5u4e00q6	1257	4	old	old	JJ
cord-014712-5u4e00q6	1257	5	boy	boy	NN
cord-014712-5u4e00q6	1257	6	was	be	VBD
cord-014712-5u4e00q6	1257	7	firstly	firstly	RB
cord-014712-5u4e00q6	1257	8	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	1257	9	for	for	IN
cord-014712-5u4e00q6	1257	10	the	the	DT
cord-014712-5u4e00q6	1257	11	treatment	treatment	NN
cord-014712-5u4e00q6	1257	12	of	of	IN
cord-014712-5u4e00q6	1257	13	the	the	DT
cord-014712-5u4e00q6	1257	14	right	right	JJ
cord-014712-5u4e00q6	1257	15	cervical	cervical	JJ
cord-014712-5u4e00q6	1257	16	abscess	abscess	NN
cord-014712-5u4e00q6	1257	17	at	at	IN
cord-014712-5u4e00q6	1257	18	25	25	CD
cord-014712-5u4e00q6	1257	19	days	day	NNS
cord-014712-5u4e00q6	1257	20	old	old	JJ
cord-014712-5u4e00q6	1257	21	.	.	.
cord-014712-5u4e00q6	1258	1	After	after	IN
cord-014712-5u4e00q6	1258	2	the	the	DT
cord-014712-5u4e00q6	1258	3	recurrence	recurrence	NN
cord-014712-5u4e00q6	1258	4	of	of	IN
cord-014712-5u4e00q6	1258	5	swelling	swell	VBG
cord-014712-5u4e00q6	1258	6	on	on	IN
cord-014712-5u4e00q6	1258	7	the	the	DT
cord-014712-5u4e00q6	1258	8	cervical	cervical	JJ
cord-014712-5u4e00q6	1258	9	area	area	NN
cord-014712-5u4e00q6	1258	10	,	,	,
cord-014712-5u4e00q6	1258	11	the	the	DT
cord-014712-5u4e00q6	1258	12	patient	patient	NN
cord-014712-5u4e00q6	1258	13	was	be	VBD
cord-014712-5u4e00q6	1258	14	referred	refer	VBN
cord-014712-5u4e00q6	1258	15	to	to	IN
cord-014712-5u4e00q6	1258	16	the	the	DT
cord-014712-5u4e00q6	1258	17	admitted	admit	VBN
cord-014712-5u4e00q6	1258	18	to	to	IN
cord-014712-5u4e00q6	1258	19	hospital	hospital	NN
cord-014712-5u4e00q6	1258	20	secondly	secondly	RB
cord-014712-5u4e00q6	1258	21	.	.	.
cord-014712-5u4e00q6	1259	1	There	there	EX
cord-014712-5u4e00q6	1259	2	was	be	VBD
cord-014712-5u4e00q6	1259	3	no	no	DT
cord-014712-5u4e00q6	1259	4	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	1259	5	between	between	IN
cord-014712-5u4e00q6	1259	6	parents	parent	NNS
cord-014712-5u4e00q6	1259	7	and	and	CC
cord-014712-5u4e00q6	1259	8	,	,	,
cord-014712-5u4e00q6	1259	9	his	-PRON-	PRP$
cord-014712-5u4e00q6	1259	10	family	family	NN
cord-014712-5u4e00q6	1259	11	history	history	NN
cord-014712-5u4e00q6	1259	12	was	be	VBD
cord-014712-5u4e00q6	1259	13	unremarkable	unremarkable	JJ
cord-014712-5u4e00q6	1259	14	except	except	IN
cord-014712-5u4e00q6	1259	15	four	four	CD
cord-014712-5u4e00q6	1259	16	of	of	IN
cord-014712-5u4e00q6	1259	17	the	the	DT
cord-014712-5u4e00q6	1259	18	mother	mother	NN
cord-014712-5u4e00q6	1259	19	's	's	POS
cord-014712-5u4e00q6	1259	20	cousins	cousin	NNS
cord-014712-5u4e00q6	1259	21	,	,	,
cord-014712-5u4e00q6	1259	22	died	die	VBD
cord-014712-5u4e00q6	1259	23	because	because	IN
cord-014712-5u4e00q6	1259	24	of	of	IN
cord-014712-5u4e00q6	1259	25	unknown	unknown	JJ
cord-014712-5u4e00q6	1259	26	etiology	etiology	NN
cord-014712-5u4e00q6	1259	27	in	in	IN
cord-014712-5u4e00q6	1259	28	infancy	infancy	NN
cord-014712-5u4e00q6	1259	29	.	.	.
cord-014712-5u4e00q6	1260	1	On	on	IN
cord-014712-5u4e00q6	1260	2	his	-PRON-	PRP$
cord-014712-5u4e00q6	1260	3	physical	physical	JJ
cord-014712-5u4e00q6	1260	4	examination	examination	NN
cord-014712-5u4e00q6	1260	5	,	,	,
cord-014712-5u4e00q6	1260	6	his	-PRON-	PRP$
cord-014712-5u4e00q6	1260	7	weight	weight	NN
cord-014712-5u4e00q6	1260	8	,	,	,
cord-014712-5u4e00q6	1260	9	height	height	NNP
cord-014712-5u4e00q6	1260	10	andhead	andhead	NNP
cord-014712-5u4e00q6	1260	11	circumference	circumference	NN
cord-014712-5u4e00q6	1260	12	were	be	VBD
cord-014712-5u4e00q6	1260	13	normal	normal	JJ
cord-014712-5u4e00q6	1260	14	range	range	NN
cord-014712-5u4e00q6	1260	15	by	by	IN
cord-014712-5u4e00q6	1260	16	age	age	NN
cord-014712-5u4e00q6	1260	17	.	.	.
cord-014712-5u4e00q6	1261	1	There	there	EX
cord-014712-5u4e00q6	1261	2	were	be	VBD
cord-014712-5u4e00q6	1261	3	no	no	DT
cord-014712-5u4e00q6	1261	4	visible	visible	JJ
cord-014712-5u4e00q6	1261	5	tonsils	tonsil	NNS
cord-014712-5u4e00q6	1261	6	.	.	.
cord-014712-5u4e00q6	1262	1	There	there	EX
cord-014712-5u4e00q6	1262	2	was	be	VBD
cord-014712-5u4e00q6	1262	3	a	a	DT
cord-014712-5u4e00q6	1262	4	palpable	palpable	JJ
cord-014712-5u4e00q6	1262	5	,	,	,
cord-014712-5u4e00q6	1262	6	mobile	mobile	JJ
cord-014712-5u4e00q6	1262	7	1x1	1x1	NNP
cord-014712-5u4e00q6	1262	8	cm	cm	NN
cord-014712-5u4e00q6	1262	9	mass	mass	NN
cord-014712-5u4e00q6	1262	10	on	on	IN
cord-014712-5u4e00q6	1262	11	right	right	JJ
cord-014712-5u4e00q6	1262	12	upper	upper	JJ
cord-014712-5u4e00q6	1262	13	cervical	cervical	JJ
cord-014712-5u4e00q6	1262	14	area	area	NN
cord-014712-5u4e00q6	1262	15	.	.	.
cord-014712-5u4e00q6	1263	1	The	the	DT
cord-014712-5u4e00q6	1263	2	Molecular	Molecular	NNP
cord-014712-5u4e00q6	1263	3	analysis	analysis	NN
cord-014712-5u4e00q6	1263	4	of	of	IN
cord-014712-5u4e00q6	1263	5	the	the	DT
cord-014712-5u4e00q6	1263	6	causal	causal	JJ
cord-014712-5u4e00q6	1263	7	gene	gene	NN
cord-014712-5u4e00q6	1263	8	for	for	IN
cord-014712-5u4e00q6	1263	9	Bruton	Bruton	NNP
cord-014712-5u4e00q6	1263	10	's	's	POS
cord-014712-5u4e00q6	1263	11	tyrosine	tyrosine	NN
cord-014712-5u4e00q6	1263	12	kinase	kinase	NN
cord-014712-5u4e00q6	1263	13	(	(	-LRB-
cord-014712-5u4e00q6	1263	14	BTK	BTK	NNP
cord-014712-5u4e00q6	1263	15	gene	gene	NN
cord-014712-5u4e00q6	1263	16	)	)	-RRB-
cord-014712-5u4e00q6	1263	17	revealed	reveal	VBD
cord-014712-5u4e00q6	1263	18	the	the	DT
cord-014712-5u4e00q6	1263	19	mutation	mutation	NN
cord-014712-5u4e00q6	1263	20	in	in	IN
cord-014712-5u4e00q6	1263	21	exon	exon	NN
cord-014712-5u4e00q6	1263	22	19	19	CD
cord-014712-5u4e00q6	1263	23	.	.	.
cord-014712-5u4e00q6	1264	1	This	this	DT
cord-014712-5u4e00q6	1264	2	mutation	mutation	NN
cord-014712-5u4e00q6	1264	3	g.67662delG	g.67662delG	NNP
cord-014712-5u4e00q6	1264	4	(	(	-LRB-
cord-014712-5u4e00q6	1264	5	c.1750	c.1750	NNP
cord-014712-5u4e00q6	1264	6	+	+	SYM
cord-014712-5u4e00q6	1264	7	57del	57del	NN
cord-014712-5u4e00q6	1264	8	)	)	-RRB-
cord-014712-5u4e00q6	1264	9	leads	lead	VBZ
cord-014712-5u4e00q6	1264	10	to	to	IN
cord-014712-5u4e00q6	1264	11	the	the	DT
cord-014712-5u4e00q6	1264	12	changes	change	NNS
cord-014712-5u4e00q6	1264	13	of	of	IN
cord-014712-5u4e00q6	1264	14	amino	amino	NN
cord-014712-5u4e00q6	1264	15	acid	acid	NN
cord-014712-5u4e00q6	1264	16	order	order	NN
cord-014712-5u4e00q6	1264	17	in	in	IN
cord-014712-5u4e00q6	1264	18	the	the	DT
cord-014712-5u4e00q6	1264	19	protein	protein	NN
cord-014712-5u4e00q6	1264	20	with	with	IN
cord-014712-5u4e00q6	1264	21	the	the	DT
cord-014712-5u4e00q6	1264	22	subsequent	subsequent	JJ
cord-014712-5u4e00q6	1264	23	changes	change	NNS
cord-014712-5u4e00q6	1264	24	in	in	IN
cord-014712-5u4e00q6	1264	25	activity	activity	NN
cord-014712-5u4e00q6	1264	26	of	of	IN
cord-014712-5u4e00q6	1264	27	BTK	BTK	NNP
cord-014712-5u4e00q6	1264	28	(	(	-LRB-
cord-014712-5u4e00q6	1264	29	at	at	IN
cord-014712-5u4e00q6	1264	30	the	the	DT
cord-014712-5u4e00q6	1264	31	level	level	NN
cord-014712-5u4e00q6	1264	32	of	of	IN
cord-014712-5u4e00q6	1264	33	DNA	dna	NN
cord-014712-5u4e00q6	1264	34	:	:	:
cord-014712-5u4e00q6	1264	35	substitution	substitution	NN
cord-014712-5u4e00q6	1264	36	of	of	IN
cord-014712-5u4e00q6	1264	37	glutamic	glutamic	NN
cord-014712-5u4e00q6	1264	38	acid	acid	NN
cord-014712-5u4e00q6	1264	39	(	(	-LRB-
cord-014712-5u4e00q6	1264	40	p.	p.	NN
cord-014712-5u4e00q6	1265	1	Glu507	glu507	LS
cord-014712-5u4e00q6	1265	2	*	*	NFP
cord-014712-5u4e00q6	1265	3	)	)	-RRB-
cord-014712-5u4e00q6	1265	4	causes	cause	VBZ
cord-014712-5u4e00q6	1265	5	non	non	JJ
cord-014712-5u4e00q6	1265	6	-	-	JJ
cord-014712-5u4e00q6	1265	7	sense	sense	JJ
cord-014712-5u4e00q6	1265	8	mutation	mutation	NN
cord-014712-5u4e00q6	1265	9	leading	lead	VBG
cord-014712-5u4e00q6	1265	10	to	to	IN
cord-014712-5u4e00q6	1265	11	the	the	DT
cord-014712-5u4e00q6	1265	12	formation	formation	NN
cord-014712-5u4e00q6	1265	13	of	of	IN
cord-014712-5u4e00q6	1265	14	stop	stop	NN
cord-014712-5u4e00q6	1265	15	codon	codon	NN
cord-014712-5u4e00q6	1265	16	with	with	IN
cord-014712-5u4e00q6	1265	17	premature	premature	JJ
cord-014712-5u4e00q6	1265	18	end	end	NN
cord-014712-5u4e00q6	1265	19	of	of	IN
cord-014712-5u4e00q6	1265	20	DNA	dna	NN
cord-014712-5u4e00q6	1265	21	transcription	transcription	NN
cord-014712-5u4e00q6	1265	22	to	to	TO
cord-014712-5u4e00q6	1265	23	cause	cause	VB
cord-014712-5u4e00q6	1265	24	STOP	STOP	NNP
cord-014712-5u4e00q6	1265	25	codon	codon	NN
cord-014712-5u4e00q6	1265	26	.	.	.
cord-014712-5u4e00q6	1266	1	After	after	IN
cord-014712-5u4e00q6	1266	2	initiating	initiate	VBG
cord-014712-5u4e00q6	1266	3	the	the	DT
cord-014712-5u4e00q6	1266	4	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1266	5	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1266	6	with	with	IN
cord-014712-5u4e00q6	1266	7	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	1266	8	,	,	,
cord-014712-5u4e00q6	1266	9	the	the	DT
cord-014712-5u4e00q6	1266	10	cervical	cervical	JJ
cord-014712-5u4e00q6	1266	11	mass	mass	NN
cord-014712-5u4e00q6	1266	12	was	be	VBD
cord-014712-5u4e00q6	1266	13	getting	get	VBG
cord-014712-5u4e00q6	1266	14	smaller	small	JJR
cord-014712-5u4e00q6	1266	15	in	in	IN
cord-014712-5u4e00q6	1266	16	a	a	DT
cord-014712-5u4e00q6	1266	17	short	short	JJ
cord-014712-5u4e00q6	1266	18	period	period	NN
cord-014712-5u4e00q6	1266	19	,	,	,
cord-014712-5u4e00q6	1266	20	and	and	CC
cord-014712-5u4e00q6	1266	21	had	have	VBD
cord-014712-5u4e00q6	1266	22	not	not	RB
cord-014712-5u4e00q6	1266	23	observed	observe	VBN
cord-014712-5u4e00q6	1266	24	again	again	RB
cord-014712-5u4e00q6	1266	25	.	.	.
cord-014712-5u4e00q6	1267	1	Neutropenia	neutropenia	NN
cord-014712-5u4e00q6	1267	2	was	be	VBD
cord-014712-5u4e00q6	1267	3	improved	improve	VBN
cord-014712-5u4e00q6	1267	4	within	within	IN
cord-014712-5u4e00q6	1267	5	the	the	DT
cord-014712-5u4e00q6	1267	6	3	3	CD
cord-014712-5u4e00q6	1267	7	months	month	NNS
cord-014712-5u4e00q6	1267	8	.	.	.
cord-014712-5u4e00q6	1268	1	This	this	DT
cord-014712-5u4e00q6	1268	2	case	case	NN
cord-014712-5u4e00q6	1268	3	is	be	VBZ
cord-014712-5u4e00q6	1268	4	an	an	DT
cord-014712-5u4e00q6	1268	5	important	important	JJ
cord-014712-5u4e00q6	1268	6	example	example	NN
cord-014712-5u4e00q6	1268	7	to	to	TO
cord-014712-5u4e00q6	1268	8	diagnose	diagnose	VB
cord-014712-5u4e00q6	1268	9	Bruton	Bruton	NNP
cord-014712-5u4e00q6	1268	10	Disease	Disease	NNP
cord-014712-5u4e00q6	1268	11	in	in	IN
cord-014712-5u4e00q6	1268	12	early	early	JJ
cord-014712-5u4e00q6	1268	13	life	life	NN
cord-014712-5u4e00q6	1268	14	.	.	.
cord-014712-5u4e00q6	1269	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1269	2	demonstrates	demonstrate	VBZ
cord-014712-5u4e00q6	1269	3	that	that	IN
cord-014712-5u4e00q6	1269	4	maintaining	maintain	VBG
cord-014712-5u4e00q6	1269	5	a	a	DT
cord-014712-5u4e00q6	1269	6	high	high	JJ
cord-014712-5u4e00q6	1269	7	level	level	NN
cord-014712-5u4e00q6	1269	8	of	of	IN
cord-014712-5u4e00q6	1269	9	clinical	clinical	JJ
cord-014712-5u4e00q6	1269	10	suspicion	suspicion	NN
cord-014712-5u4e00q6	1269	11	is	be	VBZ
cord-014712-5u4e00q6	1269	12	essential	essential	JJ
cord-014712-5u4e00q6	1269	13	for	for	IN
cord-014712-5u4e00q6	1269	14	the	the	DT
cord-014712-5u4e00q6	1269	15	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1269	16	of	of	IN
cord-014712-5u4e00q6	1269	17	Bruton	Bruton	NNP
cord-014712-5u4e00q6	1269	18	Disease	Disease	NNP
cord-014712-5u4e00q6	1269	19	in	in	IN
cord-014712-5u4e00q6	1269	20	a	a	DT
cord-014712-5u4e00q6	1269	21	child	child	NN
cord-014712-5u4e00q6	1269	22	with	with	IN
cord-014712-5u4e00q6	1269	23	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1269	24	cervical	cervical	JJ
cord-014712-5u4e00q6	1269	25	masses	masse	NNS
cord-014712-5u4e00q6	1269	26	.	.	.
cord-014712-5u4e00q6	1270	1	Elif	Elif	NNP
cord-014712-5u4e00q6	1270	2	Azarsiz	Azarsiz	NNP
cord-014712-5u4e00q6	1270	3	;	;	:
cord-014712-5u4e00q6	1270	4	Neslihan	Neslihan	NNP
cord-014712-5u4e00q6	1270	5	Edeer	Edeer	NNP
cord-014712-5u4e00q6	1270	6	Karaca	Karaca	NNP
cord-014712-5u4e00q6	1270	7	;	;	:
cord-014712-5u4e00q6	1270	8	Guzide	Guzide	NNP
cord-014712-5u4e00q6	1270	9	Aksu	Aksu	NNP
cord-014712-5u4e00q6	1270	10	;	;	:
cord-014712-5u4e00q6	1270	11	Necil	Necil	NNP
cord-014712-5u4e00q6	1270	12	Kutukculer	Kutukculer	NNP
cord-014712-5u4e00q6	1270	13	Ege	Ege	NNP
cord-014712-5u4e00q6	1270	14	University	University	NNP
cord-014712-5u4e00q6	1270	15	Faculty	Faculty	NNP
cord-014712-5u4e00q6	1270	16	of	of	IN
cord-014712-5u4e00q6	1270	17	Medicine	Medicine	NNP
cord-014712-5u4e00q6	1270	18	,	,	,
cord-014712-5u4e00q6	1270	19	Department	Department	NNP
cord-014712-5u4e00q6	1270	20	of	of	IN
cord-014712-5u4e00q6	1270	21	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	1270	22	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1270	23	,	,	,
cord-014712-5u4e00q6	1270	24	Izmir	Izmir	NNP
cord-014712-5u4e00q6	1270	25	,	,	,
cord-014712-5u4e00q6	1270	26	Turkey	Turkey	NNP
cord-014712-5u4e00q6	1270	27	Transient	transient	JJ
cord-014712-5u4e00q6	1270	28	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1270	29	of	of	IN
cord-014712-5u4e00q6	1270	30	infancy	infancy	NN
cord-014712-5u4e00q6	1271	1	(	(	-LRB-
cord-014712-5u4e00q6	1271	2	THI	THI	NNP
cord-014712-5u4e00q6	1271	3	)	)	-RRB-
cord-014712-5u4e00q6	1271	4	is	be	VBZ
cord-014712-5u4e00q6	1271	5	characterized	characterize	VBN
cord-014712-5u4e00q6	1271	6	by	by	IN
cord-014712-5u4e00q6	1271	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1271	8	infections	infection	NNS
cord-014712-5u4e00q6	1271	9	and	and	CC
cord-014712-5u4e00q6	1271	10	reduced	reduce	VBN
cord-014712-5u4e00q6	1271	11	serum	serum	NN
cord-014712-5u4e00q6	1271	12	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1271	13	levels	level	NNS
cord-014712-5u4e00q6	1271	14	.	.	.
cord-014712-5u4e00q6	1272	1	Typically	typically	RB
cord-014712-5u4e00q6	1272	2	,	,	,
cord-014712-5u4e00q6	1272	3	THI	THI	NNP
cord-014712-5u4e00q6	1272	4	patients	patient	NNS
cord-014712-5u4e00q6	1272	5	recover	recover	VBP
cord-014712-5u4e00q6	1272	6	spontaneously	spontaneously	RB
cord-014712-5u4e00q6	1272	7	,	,	,
cord-014712-5u4e00q6	1272	8	mostly	mostly	RB
cord-014712-5u4e00q6	1272	9	within	within	IN
cord-014712-5u4e00q6	1272	10	30	30	CD
cord-014712-5u4e00q6	1272	11	-	-	SYM
cord-014712-5u4e00q6	1272	12	40	40	CD
cord-014712-5u4e00q6	1272	13	months	month	NNS
cord-014712-5u4e00q6	1272	14	of	of	IN
cord-014712-5u4e00q6	1272	15	age	age	NN
cord-014712-5u4e00q6	1272	16	,	,	,
cord-014712-5u4e00q6	1272	17	but	but	CC
cord-014712-5u4e00q6	1272	18	sometimes	sometimes	RB
cord-014712-5u4e00q6	1272	19	recovery	recovery	NN
cord-014712-5u4e00q6	1272	20	may	may	MD
cord-014712-5u4e00q6	1272	21	be	be	VB
cord-014712-5u4e00q6	1272	22	delayed	delay	VBN
cord-014712-5u4e00q6	1272	23	until	until	IN
cord-014712-5u4e00q6	1272	24	5	5	CD
cord-014712-5u4e00q6	1272	25	-	-	SYM
cord-014712-5u4e00q6	1272	26	6	6	CD
cord-014712-5u4e00q6	1272	27	years	year	NNS
cord-014712-5u4e00q6	1272	28	.	.	.
cord-014712-5u4e00q6	1273	1	The	the	DT
cord-014712-5u4e00q6	1273	2	use	use	NN
cord-014712-5u4e00q6	1273	3	of	of	IN
cord-014712-5u4e00q6	1273	4	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1273	5	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1273	6	(	(	-LRB-
cord-014712-5u4e00q6	1273	7	IVIg	ivig	ADD
cord-014712-5u4e00q6	1273	8	)	)	-RRB-
cord-014712-5u4e00q6	1273	9	as	as	IN
cord-014712-5u4e00q6	1273	10	an	an	DT
cord-014712-5u4e00q6	1273	11	alternative	alternative	NN
cord-014712-5u4e00q6	1273	12	to	to	IN
cord-014712-5u4e00q6	1273	13	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	1273	14	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	1273	15	remains	remain	VBZ
cord-014712-5u4e00q6	1273	16	contraversial	contraversial	JJ
cord-014712-5u4e00q6	1273	17	also	also	RB
cord-014712-5u4e00q6	1273	18	in	in	IN
cord-014712-5u4e00q6	1273	19	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	1273	20	patients	patient	NNS
cord-014712-5u4e00q6	1273	21	.	.	.
cord-014712-5u4e00q6	1274	1	Some	some	DT
cord-014712-5u4e00q6	1274	2	authors	author	NNS
cord-014712-5u4e00q6	1274	3	believe	believe	VBP
cord-014712-5u4e00q6	1274	4	that	that	IN
cord-014712-5u4e00q6	1274	5	IVIg	ivig	VBP
cord-014712-5u4e00q6	1274	6	therapy	therapy	NN
cord-014712-5u4e00q6	1274	7	may	may	MD
cord-014712-5u4e00q6	1274	8	cause	cause	VB
cord-014712-5u4e00q6	1274	9	a	a	DT
cord-014712-5u4e00q6	1274	10	delay	delay	NN
cord-014712-5u4e00q6	1274	11	in	in	IN
cord-014712-5u4e00q6	1274	12	the	the	DT
cord-014712-5u4e00q6	1274	13	maturation	maturation	NN
cord-014712-5u4e00q6	1274	14	of	of	IN
cord-014712-5u4e00q6	1274	15	the	the	DT
cord-014712-5u4e00q6	1274	16	humoral	humoral	JJ
cord-014712-5u4e00q6	1274	17	immune	immune	JJ
cord-014712-5u4e00q6	1274	18	system	system	NN
cord-014712-5u4e00q6	1274	19	because	because	IN
cord-014712-5u4e00q6	1274	20	of	of	IN
cord-014712-5u4e00q6	1274	21	the	the	DT
cord-014712-5u4e00q6	1274	22	interference	interference	NN
cord-014712-5u4e00q6	1274	23	from	from	IN
cord-014712-5u4e00q6	1274	24	passively	passively	RB
cord-014712-5u4e00q6	1274	25	transfered	transfer	VBN
cord-014712-5u4e00q6	1274	26	antibodies	antibody	NNS
cord-014712-5u4e00q6	1274	27	.	.	.
cord-014712-5u4e00q6	1275	1	The	the	DT
cord-014712-5u4e00q6	1275	2	aim	aim	NN
cord-014712-5u4e00q6	1275	3	of	of	IN
cord-014712-5u4e00q6	1275	4	this	this	DT
cord-014712-5u4e00q6	1275	5	study	study	NN
cord-014712-5u4e00q6	1275	6	was	be	VBD
cord-014712-5u4e00q6	1275	7	to	to	TO
cord-014712-5u4e00q6	1275	8	investigate	investigate	VB
cord-014712-5u4e00q6	1275	9	the	the	DT
cord-014712-5u4e00q6	1275	10	effect	effect	NN
cord-014712-5u4e00q6	1275	11	of	of	IN
cord-014712-5u4e00q6	1275	12	IVIg	ivig	JJ
cord-014712-5u4e00q6	1275	13	replacement	replacement	NN
cord-014712-5u4e00q6	1275	14	on	on	IN
cord-014712-5u4e00q6	1275	15	recovery	recovery	NN
cord-014712-5u4e00q6	1275	16	from	from	IN
cord-014712-5u4e00q6	1275	17	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1275	18	in	in	IN
cord-014712-5u4e00q6	1275	19	these	these	DT
cord-014712-5u4e00q6	1275	20	patients	patient	NNS
cord-014712-5u4e00q6	1275	21	.	.	.
cord-014712-5u4e00q6	1276	1	43	43	CD
cord-014712-5u4e00q6	1276	2	patients	patient	NNS
cord-014712-5u4e00q6	1276	3	(	(	-LRB-
cord-014712-5u4e00q6	1276	4	65	65	CD
cord-014712-5u4e00q6	1276	5	%	%	NN
cord-014712-5u4e00q6	1276	6	)	)	-RRB-
cord-014712-5u4e00q6	1276	7	received	receive	VBD
cord-014712-5u4e00q6	1276	8	IVIg	ivig	NN
cord-014712-5u4e00q6	1276	9	therapy	therapy	NN
cord-014712-5u4e00q6	1276	10	while	while	IN
cord-014712-5u4e00q6	1276	11	23	23	CD
cord-014712-5u4e00q6	1276	12	patients	patient	NNS
cord-014712-5u4e00q6	1276	13	(	(	-LRB-
cord-014712-5u4e00q6	1276	14	34.8	34.8	CD
cord-014712-5u4e00q6	1276	15	%	%	NN
cord-014712-5u4e00q6	1276	16	)	)	-RRB-
cord-014712-5u4e00q6	1276	17	showed	show	VBD
cord-014712-5u4e00q6	1276	18	spontaneous	spontaneous	JJ
cord-014712-5u4e00q6	1276	19	normalization	normalization	NN
cord-014712-5u4e00q6	1276	20	without	without	IN
cord-014712-5u4e00q6	1276	21	IVIg	IVIg	NNP
cord-014712-5u4e00q6	1276	22	.	.	.
cord-014712-5u4e00q6	1277	1	The	the	DT
cord-014712-5u4e00q6	1277	2	percentages	percentage	NNS
cord-014712-5u4e00q6	1277	3	of	of	IN
cord-014712-5u4e00q6	1277	4	patients	patient	NNS
cord-014712-5u4e00q6	1277	5	who	who	WP
cord-014712-5u4e00q6	1277	6	had	have	VBD
cord-014712-5u4e00q6	1277	7	more	more	JJR
cord-014712-5u4e00q6	1277	8	than	than	IN
cord-014712-5u4e00q6	1277	9	six	six	CD
cord-014712-5u4e00q6	1277	10	times	time	NNS
cord-014712-5u4e00q6	1277	11	the	the	DT
cord-014712-5u4e00q6	1277	12	number	number	NN
cord-014712-5u4e00q6	1277	13	of	of	IN
cord-014712-5u4e00q6	1277	14	febrile	febrile	JJ
cord-014712-5u4e00q6	1277	15	infections	infection	NNS
cord-014712-5u4e00q6	1277	16	in	in	IN
cord-014712-5u4e00q6	1277	17	a	a	DT
cord-014712-5u4e00q6	1277	18	year	year	NN
cord-014712-5u4e00q6	1277	19	decreased	decrease	VBD
cord-014712-5u4e00q6	1277	20	from	from	IN
cord-014712-5u4e00q6	1277	21	91	91	CD
cord-014712-5u4e00q6	1277	22	%	%	NN
cord-014712-5u4e00q6	1277	23	to	to	TO
cord-014712-5u4e00q6	1277	24	21	21	CD
cord-014712-5u4e00q6	1277	25	%	%	NN
cord-014712-5u4e00q6	1277	26	in	in	IN
cord-014712-5u4e00q6	1277	27	the	the	DT
cord-014712-5u4e00q6	1277	28	group	group	NN
cord-014712-5u4e00q6	1277	29	receiving	receive	VBG
cord-014712-5u4e00q6	1277	30	IVIg	ivig	JJ
cord-014712-5u4e00q6	1277	31	treatment	treatment	NN
cord-014712-5u4e00q6	1277	32	.	.	.
cord-014712-5u4e00q6	1278	1	At	at	IN
cord-014712-5u4e00q6	1278	2	admission	admission	NN
cord-014712-5u4e00q6	1278	3	,	,	,
cord-014712-5u4e00q6	1278	4	before	before	IN
cord-014712-5u4e00q6	1278	5	being	be	VBG
cord-014712-5u4e00q6	1278	6	recruited	recruit	VBN
cord-014712-5u4e00q6	1278	7	to	to	IN
cord-014712-5u4e00q6	1278	8	IVIg	ivig	VB
cord-014712-5u4e00q6	1278	9	therapy	therapy	NN
cord-014712-5u4e00q6	1278	10	,	,	,
cord-014712-5u4e00q6	1278	11	serum	serum	NN
cord-014712-5u4e00q6	1278	12	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1278	13	G	G	NNP
cord-014712-5u4e00q6	1278	14	(	(	-LRB-
cord-014712-5u4e00q6	1278	15	IgG	IgG	NNP
cord-014712-5u4e00q6	1278	16	)	)	-RRB-
cord-014712-5u4e00q6	1278	17	levels	level	NNS
cord-014712-5u4e00q6	1278	18	and	and	CC
cord-014712-5u4e00q6	1278	19	anti	anti	JJ
cord-014712-5u4e00q6	1278	20	-	-	JJ
cord-014712-5u4e00q6	1278	21	hemophilus	hemophilus	JJ
cord-014712-5u4e00q6	1278	22	B	b	NN
cord-014712-5u4e00q6	1278	23	(	(	-LRB-
cord-014712-5u4e00q6	1278	24	Hib	Hib	NNP
cord-014712-5u4e00q6	1278	25	)	)	-RRB-
cord-014712-5u4e00q6	1278	26	antibody	antibody	NN
cord-014712-5u4e00q6	1278	27	titers	titer	NNS
cord-014712-5u4e00q6	1278	28	were	be	VBD
cord-014712-5u4e00q6	1278	29	found	find	VBN
cord-014712-5u4e00q6	1278	30	to	to	TO
cord-014712-5u4e00q6	1278	31	be	be	VB
cord-014712-5u4e00q6	1278	32	significantly	significantly	RB
cord-014712-5u4e00q6	1278	33	low	low	JJ
cord-014712-5u4e00q6	1278	34	in	in	IN
cord-014712-5u4e00q6	1278	35	cases	case	NNS
cord-014712-5u4e00q6	1278	36	who	who	WP
cord-014712-5u4e00q6	1278	37	were	be	VBD
cord-014712-5u4e00q6	1278	38	selected	select	VBN
cord-014712-5u4e00q6	1278	39	for	for	IN
cord-014712-5u4e00q6	1278	40	replacement	replacement	NN
cord-014712-5u4e00q6	1278	41	.	.	.
cord-014712-5u4e00q6	1279	1	The	the	DT
cord-014712-5u4e00q6	1279	2	percentages	percentage	NNS
cord-014712-5u4e00q6	1279	3	of	of	IN
cord-014712-5u4e00q6	1279	4	patients	patient	NNS
cord-014712-5u4e00q6	1279	5	who	who	WP
cord-014712-5u4e00q6	1279	6	did	do	VBD
cord-014712-5u4e00q6	1279	7	not	not	RB
cord-014712-5u4e00q6	1279	8	have	have	VB
cord-014712-5u4e00q6	1279	9	protective	protective	JJ
cord-014712-5u4e00q6	1279	10	levels	level	NNS
cord-014712-5u4e00q6	1279	11	of	of	IN
cord-014712-5u4e00q6	1279	12	anti	anti	JJ
cord-014712-5u4e00q6	1279	13	-	-	JJ
cord-014712-5u4e00q6	1279	14	Hib	Hib	NNP
cord-014712-5u4e00q6	1279	15	,	,	,
cord-014712-5u4e00q6	1279	16	anti	anti	JJ
cord-014712-5u4e00q6	1279	17	-	-	JJ
cord-014712-5u4e00q6	1279	18	rubella	rubella	JJ
cord-014712-5u4e00q6	1279	19	or	or	CC
cord-014712-5u4e00q6	1279	20	anti	anti	JJ
cord-014712-5u4e00q6	1279	21	-	-	JJ
cord-014712-5u4e00q6	1279	22	rubeola	rubeola	JJ
cord-014712-5u4e00q6	1279	23	-	-	HYPH
cord-014712-5u4e00q6	1279	24	IgG	IgG	NNP
cord-014712-5u4e00q6	1279	25	were	be	VBD
cord-014712-5u4e00q6	1279	26	also	also	RB
cord-014712-5u4e00q6	1279	27	significantly	significantly	RB
cord-014712-5u4e00q6	1279	28	high	high	JJ
cord-014712-5u4e00q6	1279	29	in	in	IN
cord-014712-5u4e00q6	1279	30	IVIg	ivig	JJ
cord-014712-5u4e00q6	1279	31	cases	case	NNS
cord-014712-5u4e00q6	1279	32	.	.	.
cord-014712-5u4e00q6	1280	1	There	there	EX
cord-014712-5u4e00q6	1280	2	was	be	VBD
cord-014712-5u4e00q6	1280	3	no	no	DT
cord-014712-5u4e00q6	1280	4	statistically	statistically	RB
cord-014712-5u4e00q6	1280	5	significant	significant	JJ
cord-014712-5u4e00q6	1280	6	difference	difference	NN
cord-014712-5u4e00q6	1280	7	in	in	IN
cord-014712-5u4e00q6	1280	8	the	the	DT
cord-014712-5u4e00q6	1280	9	age	age	NN
cord-014712-5u4e00q6	1280	10	at	at	IN
cord-014712-5u4e00q6	1280	11	which	which	WDT
cord-014712-5u4e00q6	1280	12	IgG	IgG	NNP
cord-014712-5u4e00q6	1280	13	levels	level	NNS
cord-014712-5u4e00q6	1280	14	normalized	normalize	VBN
cord-014712-5u4e00q6	1280	15	between	between	IN
cord-014712-5u4e00q6	1280	16	both	both	DT
cord-014712-5u4e00q6	1280	17	groups	group	NNS
cord-014712-5u4e00q6	1280	18	.	.	.
cord-014712-5u4e00q6	1281	1	Patients	patient	NNS
cord-014712-5u4e00q6	1281	2	in	in	IN
cord-014712-5u4e00q6	1281	3	the	the	DT
cord-014712-5u4e00q6	1281	4	IVIg	IVIg	NNP
cord-014712-5u4e00q6	1281	5	group	group	NN
cord-014712-5u4e00q6	1281	6	and	and	CC
cord-014712-5u4e00q6	1281	7	non	non	JJ
cord-014712-5u4e00q6	1281	8	-	-	JJ
cord-014712-5u4e00q6	1281	9	IVIg	ivig	JJ
cord-014712-5u4e00q6	1281	10	group	group	NN
cord-014712-5u4e00q6	1281	11	reached	reach	VBD
cord-014712-5u4e00q6	1281	12	normal	normal	JJ
cord-014712-5u4e00q6	1281	13	IgG	igg	NN
cord-014712-5u4e00q6	1281	14	levels	level	NNS
cord-014712-5u4e00q6	1281	15	at	at	IN
cord-014712-5u4e00q6	1281	16	the	the	DT
cord-014712-5u4e00q6	1281	17	age	age	NN
cord-014712-5u4e00q6	1281	18	of	of	IN
cord-014712-5u4e00q6	1281	19	42.9	42.9	CD
cord-014712-5u4e00q6	1281	20	±	±	CD
cord-014712-5u4e00q6	1281	21	22.0	22.0	CD
cord-014712-5u4e00q6	1281	22	and	and	CC
cord-014712-5u4e00q6	1281	23	40.7	40.7	CD
cord-014712-5u4e00q6	1281	24	±	±	CD
cord-014712-5u4e00q6	1281	25	19.8	19.8	CD
cord-014712-5u4e00q6	1281	26	months	month	NNS
cord-014712-5u4e00q6	1281	27	,	,	,
cord-014712-5u4e00q6	1281	28	respectively	respectively	RB
cord-014712-5u4e00q6	1281	29	.	.	.
cord-014712-5u4e00q6	1282	1	In	in	IN
cord-014712-5u4e00q6	1282	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	1282	3	,	,	,
cord-014712-5u4e00q6	1282	4	IVIg	ivig	JJ
cord-014712-5u4e00q6	1282	5	infusions	infusion	NNS
cord-014712-5u4e00q6	1282	6	do	do	VBP
cord-014712-5u4e00q6	1282	7	not	not	RB
cord-014712-5u4e00q6	1282	8	cause	cause	VB
cord-014712-5u4e00q6	1282	9	a	a	DT
cord-014712-5u4e00q6	1282	10	delay	delay	NN
cord-014712-5u4e00q6	1282	11	in	in	IN
cord-014712-5u4e00q6	1282	12	the	the	DT
cord-014712-5u4e00q6	1282	13	maturation	maturation	NN
cord-014712-5u4e00q6	1282	14	of	of	IN
cord-014712-5u4e00q6	1282	15	the	the	DT
cord-014712-5u4e00q6	1282	16	immune	immune	JJ
cord-014712-5u4e00q6	1282	17	system	system	NN
cord-014712-5u4e00q6	1282	18	in	in	IN
cord-014712-5u4e00q6	1282	19	THI	THI	NNP
cord-014712-5u4e00q6	1282	20	patients	patient	NNS
cord-014712-5u4e00q6	1282	21	.	.	.
cord-014712-5u4e00q6	1283	1	The	the	DT
cord-014712-5u4e00q6	1283	2	very	very	RB
cord-014712-5u4e00q6	1283	3	low	low	JJ
cord-014712-5u4e00q6	1283	4	and	and	CC
cord-014712-5u4e00q6	1283	5	non	non	JJ
cord-014712-5u4e00q6	1283	6	-	-	JJ
cord-014712-5u4e00q6	1283	7	protective	protective	JJ
cord-014712-5u4e00q6	1283	8	specific	specific	JJ
cord-014712-5u4e00q6	1283	9	antibody	antibody	NN
cord-014712-5u4e00q6	1283	10	responses	response	NNS
cord-014712-5u4e00q6	1283	11	against	against	IN
cord-014712-5u4e00q6	1283	12	previously	previously	RB
cord-014712-5u4e00q6	1283	13	applied	apply	VBN
cord-014712-5u4e00q6	1283	14	vaccines	vaccine	NNS
cord-014712-5u4e00q6	1283	15	are	be	VBP
cord-014712-5u4e00q6	1283	16	important	important	JJ
cord-014712-5u4e00q6	1283	17	factors	factor	NNS
cord-014712-5u4e00q6	1283	18	to	to	TO
cord-014712-5u4e00q6	1283	19	consider	consider	VB
cord-014712-5u4e00q6	1283	20	when	when	WRB
cord-014712-5u4e00q6	1283	21	selecting	select	VBG
cord-014712-5u4e00q6	1283	22	patients	patient	NNS
cord-014712-5u4e00q6	1283	23	for	for	IN
cord-014712-5u4e00q6	1283	24	IVIg	ivig	JJ
cord-014712-5u4e00q6	1283	25	therapy	therapy	NN
cord-014712-5u4e00q6	1283	26	.	.	.
cord-014712-5u4e00q6	1284	1	Zoltán	Zoltán	NNP
cord-014712-5u4e00q6	1284	2	Ellenes	Ellenes	NNP
cord-014712-5u4e00q6	1284	3	-	-	HYPH
cord-014712-5u4e00q6	1284	4	Jakabffy	Jakabffy	NNP
cord-014712-5u4e00q6	1284	5	1	1	CD
cord-014712-5u4e00q6	1284	6	;	;	:
cord-014712-5u4e00q6	1284	7	Ibolya	Ibolya	NNP
cord-014712-5u4e00q6	1284	8	Kovács	Kovács	NNP
cord-014712-5u4e00q6	1284	9	1	1	CD
cord-014712-5u4e00q6	1284	10	;	;	:
cord-014712-5u4e00q6	1285	1	Mihaela	Mihaela	NNP
cord-014712-5u4e00q6	1285	2	Bătăneanţ	Bătăneanţ	NNP
cord-014712-5u4e00q6	1285	3	2	2	CD
cord-014712-5u4e00q6	1285	4	;	;	:
cord-014712-5u4e00q6	1285	5	Maria	Maria	NNP
cord-014712-5u4e00q6	1285	6	Cucuruz	Cucuruz	NNP
cord-014712-5u4e00q6	1285	7	2	2	CD
cord-014712-5u4e00q6	1285	8	;	;	:
cord-014712-5u4e00q6	1285	9	Margit	Margit	NNP
cord-014712-5u4e00q6	1285	10	Şerban	Şerban	NNP
cord-014712-5u4e00q6	1285	11	2	2	CD
cord-014712-5u4e00q6	1285	12	;	;	:
cord-014712-5u4e00q6	1285	13	László	László	NNP
cord-014712-5u4e00q6	1285	14	Maródi	Maródi	NNP
cord-014712-5u4e00q6	1285	15	3	3	CD
cord-014712-5u4e00q6	1285	16	1	1	CD
cord-014712-5u4e00q6	1285	17	Department	Department	NNP
cord-014712-5u4e00q6	1285	18	of	of	IN
cord-014712-5u4e00q6	1285	19	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	1285	20	,	,	,
cord-014712-5u4e00q6	1285	21	Clinical	Clinical	NNP
cord-014712-5u4e00q6	1285	22	City	City	NNP
cord-014712-5u4e00q6	1285	23	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1285	24	Oradea	Oradea	NNP
cord-014712-5u4e00q6	1285	25	,	,	,
cord-014712-5u4e00q6	1285	26	Romania	Romania	NNP
cord-014712-5u4e00q6	1285	27	.	.	.
cord-014712-5u4e00q6	1286	1	Objective	objective	NN
cord-014712-5u4e00q6	1286	2	:	:	:
cord-014712-5u4e00q6	1287	1	To	to	TO
cord-014712-5u4e00q6	1287	2	study	study	VB
cord-014712-5u4e00q6	1287	3	the	the	DT
cord-014712-5u4e00q6	1287	4	amplitude	amplitude	NN
cord-014712-5u4e00q6	1287	5	of	of	IN
cord-014712-5u4e00q6	1287	6	the	the	DT
cord-014712-5u4e00q6	1287	7	chronic	chronic	JJ
cord-014712-5u4e00q6	1287	8	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	1287	9	phenomena	phenomenon	NNS
cord-014712-5u4e00q6	1287	10	:	:	:
cord-014712-5u4e00q6	1287	11	atopic	atopic	JJ
cord-014712-5u4e00q6	1287	12	and	and	CC
cord-014712-5u4e00q6	1287	13	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1287	14	diseases	disease	NNS
cord-014712-5u4e00q6	1287	15	,	,	,
cord-014712-5u4e00q6	1287	16	as	as	RB
cord-014712-5u4e00q6	1287	17	well	well	RB
cord-014712-5u4e00q6	1287	18	as	as	IN
cord-014712-5u4e00q6	1287	19	their	-PRON-	PRP$
cord-014712-5u4e00q6	1287	20	associations	association	NNS
cord-014712-5u4e00q6	1287	21	in	in	IN
cord-014712-5u4e00q6	1287	22	pediatric	pediatric	JJ
cord-014712-5u4e00q6	1287	23	sIgAD	sIgAD	NNS
cord-014712-5u4e00q6	1287	24	patients	patient	NNS
cord-014712-5u4e00q6	1287	25	and	and	CC
cord-014712-5u4e00q6	1287	26	to	to	TO
cord-014712-5u4e00q6	1287	27	study	study	VB
cord-014712-5u4e00q6	1287	28	the	the	DT
cord-014712-5u4e00q6	1287	29	sIgAD	sIgAD	NNP
cord-014712-5u4e00q6	1287	30	patients	patient	NNS
cord-014712-5u4e00q6	1287	31	'	'	POS
cord-014712-5u4e00q6	1287	32	family	family	NN
cord-014712-5u4e00q6	1287	33	history	history	NN
cord-014712-5u4e00q6	1287	34	(	(	-LRB-
cord-014712-5u4e00q6	1287	35	1	1	CD
cord-014712-5u4e00q6	1287	36	st	st	NNP
cord-014712-5u4e00q6	1287	37	degree	degree	NN
cord-014712-5u4e00q6	1287	38	relatives	relative	NNS
cord-014712-5u4e00q6	1287	39	)	)	-RRB-
cord-014712-5u4e00q6	1287	40	for	for	IN
cord-014712-5u4e00q6	1287	41	PIDs	PIDs	NNPS
cord-014712-5u4e00q6	1287	42	(	(	-LRB-
cord-014712-5u4e00q6	1287	43	primary	primary	JJ
cord-014712-5u4e00q6	1287	44	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1287	45	)	)	-RRB-
cord-014712-5u4e00q6	1287	46	.	.	.
cord-014712-5u4e00q6	1288	1	Methods	method	NNS
cord-014712-5u4e00q6	1288	2	:	:	:
cord-014712-5u4e00q6	1288	3	Retrospective	retrospective	JJ
cord-014712-5u4e00q6	1288	4	analysis	analysis	NN
cord-014712-5u4e00q6	1288	5	of	of	IN
cord-014712-5u4e00q6	1288	6	the	the	DT
cord-014712-5u4e00q6	1288	7	clinical	clinical	JJ
cord-014712-5u4e00q6	1288	8	and	and	CC
cord-014712-5u4e00q6	1288	9	laboratory	laboratory	NN
cord-014712-5u4e00q6	1288	10	records	record	NNS
cord-014712-5u4e00q6	1288	11	of	of	IN
cord-014712-5u4e00q6	1288	12	pediatric	pediatric	JJ
cord-014712-5u4e00q6	1288	13	sIgAD	sIgAD	NNS
cord-014712-5u4e00q6	1288	14	patients	patient	NNS
cord-014712-5u4e00q6	1288	15	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1288	16	between	between	IN
cord-014712-5u4e00q6	1288	17	1998	1998	CD
cord-014712-5u4e00q6	1288	18	and	and	CC
cord-014712-5u4e00q6	1288	19	2013	2013	CD
cord-014712-5u4e00q6	1288	20	at	at	IN
cord-014712-5u4e00q6	1288	21	the	the	DT
cord-014712-5u4e00q6	1288	22	departments	department	NNS
cord-014712-5u4e00q6	1288	23	for	for	IN
cord-014712-5u4e00q6	1288	24	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	1288	25	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1288	26	of	of	IN
cord-014712-5u4e00q6	1288	27	the	the	DT
cord-014712-5u4e00q6	1288	28	Medical	Medical	NNP
cord-014712-5u4e00q6	1288	29	Universities	Universities	NNPS
cord-014712-5u4e00q6	1288	30	of	of	IN
cord-014712-5u4e00q6	1288	31	Debrecen	Debrecen	NNP
cord-014712-5u4e00q6	1288	32	(	(	-LRB-
cord-014712-5u4e00q6	1288	33	Hungary	Hungary	NNP
cord-014712-5u4e00q6	1288	34	)	)	-RRB-
cord-014712-5u4e00q6	1288	35	,	,	,
cord-014712-5u4e00q6	1288	36	Oradea	Oradea	NNP
cord-014712-5u4e00q6	1288	37	and	and	CC
cord-014712-5u4e00q6	1288	38	Timişoara	Timişoara	NNP
cord-014712-5u4e00q6	1288	39	(	(	-LRB-
cord-014712-5u4e00q6	1288	40	Romania	Romania	NNP
cord-014712-5u4e00q6	1288	41	)	)	-RRB-
cord-014712-5u4e00q6	1288	42	.	.	.
cord-014712-5u4e00q6	1289	1	Results	result	NNS
cord-014712-5u4e00q6	1289	2	:	:	:
cord-014712-5u4e00q6	1290	1	Out	out	IN
cord-014712-5u4e00q6	1290	2	of	of	IN
cord-014712-5u4e00q6	1290	3	148	148	CD
cord-014712-5u4e00q6	1290	4	patients	patient	NNS
cord-014712-5u4e00q6	1290	5	,	,	,
cord-014712-5u4e00q6	1290	6	we	-PRON-	PRP
cord-014712-5u4e00q6	1290	7	found	find	VBD
cord-014712-5u4e00q6	1290	8	out	out	RP
cord-014712-5u4e00q6	1290	9	74	74	CD
cord-014712-5u4e00q6	1290	10	(	(	-LRB-
cord-014712-5u4e00q6	1290	11	50	50	CD
cord-014712-5u4e00q6	1290	12	%	%	NN
cord-014712-5u4e00q6	1290	13	)	)	-RRB-
cord-014712-5u4e00q6	1290	14	with	with	IN
cord-014712-5u4e00q6	1290	15	atopic	atopic	JJ
cord-014712-5u4e00q6	1290	16	diseases	disease	NNS
cord-014712-5u4e00q6	1290	17	,	,	,
cord-014712-5u4e00q6	1290	18	mostly	mostly	RB
cord-014712-5u4e00q6	1290	19	with	with	IN
cord-014712-5u4e00q6	1290	20	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1290	21	localizations	localization	NNS
cord-014712-5u4e00q6	1290	22	(	(	-LRB-
cord-014712-5u4e00q6	1290	23	asthma	asthma	NN
cord-014712-5u4e00q6	1290	24	and	and	CC
cord-014712-5u4e00q6	1290	25	allergic	allergic	JJ
cord-014712-5u4e00q6	1290	26	rhinitis	rhinitis	NN
cord-014712-5u4e00q6	1290	27	)	)	-RRB-
cord-014712-5u4e00q6	1290	28	,	,	,
cord-014712-5u4e00q6	1290	29	16	16	CD
cord-014712-5u4e00q6	1290	30	(	(	-LRB-
cord-014712-5u4e00q6	1290	31	10,81	10,81	CD
cord-014712-5u4e00q6	1290	32	%	%	NN
cord-014712-5u4e00q6	1290	33	)	)	-RRB-
cord-014712-5u4e00q6	1290	34	patients	patient	NNS
cord-014712-5u4e00q6	1290	35	with	with	IN
cord-014712-5u4e00q6	1290	36	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1290	37	diseases	disease	NNS
cord-014712-5u4e00q6	1290	38	(	(	-LRB-
cord-014712-5u4e00q6	1290	39	JIA	JIA	NNP
cord-014712-5u4e00q6	1290	40	,	,	,
cord-014712-5u4e00q6	1290	41	psoriasis	psoriasis	NN
cord-014712-5u4e00q6	1290	42	,	,	,
cord-014712-5u4e00q6	1290	43	celiac	celiac	JJ
cord-014712-5u4e00q6	1290	44	disease	disease	NN
cord-014712-5u4e00q6	1290	45	,	,	,
cord-014712-5u4e00q6	1290	46	thyroiditis	thyroiditis	NN
cord-014712-5u4e00q6	1290	47	etc	etc	FW
cord-014712-5u4e00q6	1290	48	.	.	.
cord-014712-5u4e00q6	1290	49	)	)	-RRB-
cord-014712-5u4e00q6	1291	1	and	and	CC
cord-014712-5u4e00q6	1291	2	other	other	JJ
cord-014712-5u4e00q6	1291	3	15	15	CD
cord-014712-5u4e00q6	1291	4	patients	patient	NNS
cord-014712-5u4e00q6	1291	5	without	without	IN
cord-014712-5u4e00q6	1291	6	clinical	clinical	JJ
cord-014712-5u4e00q6	1291	7	symptoms	symptom	NNS
cord-014712-5u4e00q6	1291	8	of	of	IN
cord-014712-5u4e00q6	1291	9	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	1291	10	but	but	CC
cord-014712-5u4e00q6	1291	11	constantly	constantly	RB
cord-014712-5u4e00q6	1291	12	elevated	elevate	VBN
cord-014712-5u4e00q6	1291	13	autoantibody	autoantibody	NN
cord-014712-5u4e00q6	1291	14	levels	level	NNS
cord-014712-5u4e00q6	1291	15	.	.	.
cord-014712-5u4e00q6	1292	1	There	there	EX
cord-014712-5u4e00q6	1292	2	were	be	VBD
cord-014712-5u4e00q6	1292	3	7	7	CD
cord-014712-5u4e00q6	1292	4	patients	patient	NNS
cord-014712-5u4e00q6	1292	5	with	with	IN
cord-014712-5u4e00q6	1292	6	coexistent	coexistent	JJ
cord-014712-5u4e00q6	1292	7	atopic	atopic	NN
cord-014712-5u4e00q6	1292	8	and	and	CC
cord-014712-5u4e00q6	1292	9	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1292	10	diseases	disease	NNS
cord-014712-5u4e00q6	1292	11	.	.	.
cord-014712-5u4e00q6	1293	1	Regarding	regard	VBG
cord-014712-5u4e00q6	1293	2	the	the	DT
cord-014712-5u4e00q6	1293	3	family	family	NN
cord-014712-5u4e00q6	1293	4	history	history	NN
cord-014712-5u4e00q6	1293	5	,	,	,
cord-014712-5u4e00q6	1293	6	we	-PRON-	PRP
cord-014712-5u4e00q6	1293	7	identified	identify	VBD
cord-014712-5u4e00q6	1293	8	8	8	CD
cord-014712-5u4e00q6	1293	9	families	family	NNS
cord-014712-5u4e00q6	1293	10	with	with	IN
cord-014712-5u4e00q6	1293	11	multiple	multiple	JJ
cord-014712-5u4e00q6	1293	12	cases	case	NNS
cord-014712-5u4e00q6	1293	13	of	of	IN
cord-014712-5u4e00q6	1293	14	PIDs	pid	NNS
cord-014712-5u4e00q6	1293	15	:	:	:
cord-014712-5u4e00q6	1293	16	6	6	CD
cord-014712-5u4e00q6	1293	17	with	with	IN
cord-014712-5u4e00q6	1293	18	multiple	multiple	JJ
cord-014712-5u4e00q6	1293	19	sIgAD	sIgAD	NNS
cord-014712-5u4e00q6	1293	20	,	,	,
cord-014712-5u4e00q6	1293	21	1	1	CD
cord-014712-5u4e00q6	1293	22	with	with	IN
cord-014712-5u4e00q6	1293	23	sIgAD	sIgAD	NNS
cord-014712-5u4e00q6	1293	24	and	and	CC
cord-014712-5u4e00q6	1293	25	CVID	CVID	NNP
cord-014712-5u4e00q6	1293	26	,	,	,
cord-014712-5u4e00q6	1293	27	1	1	CD
cord-014712-5u4e00q6	1293	28	with	with	IN
cord-014712-5u4e00q6	1293	29	sIgAD	sIgAD	NNS
cord-014712-5u4e00q6	1293	30	and	and	CC
cord-014712-5u4e00q6	1293	31	HIgMS	HIgMS	NNP
cord-014712-5u4e00q6	1293	32	(	(	-LRB-
cord-014712-5u4e00q6	1293	33	hyper	hyper	NNP
cord-014712-5u4e00q6	1293	34	IgM	IgM	NNP
cord-014712-5u4e00q6	1293	35	syndrome	syndrome	NN
cord-014712-5u4e00q6	1293	36	)	)	-RRB-
cord-014712-5u4e00q6	1293	37	.	.	.
cord-014712-5u4e00q6	1294	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	1294	2	:	:	:
cord-014712-5u4e00q6	1295	1	The	the	DT
cord-014712-5u4e00q6	1295	2	chronic	chronic	JJ
cord-014712-5u4e00q6	1295	3	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	1295	4	phenomena	phenomenon	NNS
cord-014712-5u4e00q6	1295	5	are	be	VBP
cord-014712-5u4e00q6	1295	6	present	present	JJ
cord-014712-5u4e00q6	1295	7	in	in	IN
cord-014712-5u4e00q6	1295	8	the	the	DT
cord-014712-5u4e00q6	1295	9	majority	majority	NN
cord-014712-5u4e00q6	1295	10	of	of	IN
cord-014712-5u4e00q6	1295	11	the	the	DT
cord-014712-5u4e00q6	1295	12	studied	study	VBN
cord-014712-5u4e00q6	1295	13	sIgAD	sIgAD	NNP
cord-014712-5u4e00q6	1295	14	patients	patient	NNS
cord-014712-5u4e00q6	1295	15	:	:	:
cord-014712-5u4e00q6	1295	16	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	1295	17	atopic	atopic	JJ
cord-014712-5u4e00q6	1295	18	diseases	disease	NNS
cord-014712-5u4e00q6	1295	19	in	in	IN
cord-014712-5u4e00q6	1295	20	50	50	CD
cord-014712-5u4e00q6	1295	21	%	%	NN
cord-014712-5u4e00q6	1295	22	,	,	,
cord-014712-5u4e00q6	1295	23	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	1295	24	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1295	25	diseases	disease	NNS
cord-014712-5u4e00q6	1295	26	in	in	IN
cord-014712-5u4e00q6	1295	27	10,8	10,8	CD
cord-014712-5u4e00q6	1295	28	%	%	NN
cord-014712-5u4e00q6	1295	29	,	,	,
cord-014712-5u4e00q6	1295	30	that	that	DT
cord-014712-5u4e00q6	1295	31	means	mean	VBZ
cord-014712-5u4e00q6	1295	32	a	a	DT
cord-014712-5u4e00q6	1295	33	cumulative	cumulative	JJ
cord-014712-5u4e00q6	1295	34	61	61	CD
cord-014712-5u4e00q6	1295	35	%	%	NN
cord-014712-5u4e00q6	1295	36	.	.	.
cord-014712-5u4e00q6	1296	1	There	there	EX
cord-014712-5u4e00q6	1296	2	are	be	VBP
cord-014712-5u4e00q6	1296	3	comorbid	comorbid	NN
cord-014712-5u4e00q6	1296	4	associations	association	NNS
cord-014712-5u4e00q6	1296	5	within	within	IN
cord-014712-5u4e00q6	1296	6	the	the	DT
cord-014712-5u4e00q6	1296	7	atopic	atopic	JJ
cord-014712-5u4e00q6	1296	8	and	and	CC
cord-014712-5u4e00q6	1296	9	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1296	10	disease	disease	NN
cord-014712-5u4e00q6	1296	11	groups	group	NNS
cord-014712-5u4e00q6	1296	12	and	and	CC
cord-014712-5u4e00q6	1296	13	also	also	RB
cord-014712-5u4e00q6	1296	14	between	between	IN
cord-014712-5u4e00q6	1296	15	the	the	DT
cord-014712-5u4e00q6	1296	16	two	two	CD
cord-014712-5u4e00q6	1296	17	groups	group	NNS
cord-014712-5u4e00q6	1296	18	.	.	.
cord-014712-5u4e00q6	1297	1	SIgAD	SIgAD	NNP
cord-014712-5u4e00q6	1297	2	is	be	VBZ
cord-014712-5u4e00q6	1297	3	the	the	DT
cord-014712-5u4e00q6	1297	4	most	most	RBS
cord-014712-5u4e00q6	1297	5	common	common	JJ
cord-014712-5u4e00q6	1297	6	primary	primary	JJ
cord-014712-5u4e00q6	1297	7	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1297	8	.	.	.
cord-014712-5u4e00q6	1298	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1298	2	's	be	VBZ
cord-014712-5u4e00q6	1298	3	prevalence	prevalence	NN
cord-014712-5u4e00q6	1298	4	is	be	VBZ
cord-014712-5u4e00q6	1298	5	1/400	1/400	CD
cord-014712-5u4e00q6	1298	6	-	-	HYPH
cord-014712-5u4e00q6	1298	7	1/800	1/800	CD
cord-014712-5u4e00q6	1298	8	.	.	.
cord-014712-5u4e00q6	1299	1	Aim	Aim	NNP
cord-014712-5u4e00q6	1299	2	was	be	VBD
cord-014712-5u4e00q6	1299	3	to	to	TO
cord-014712-5u4e00q6	1299	4	assess	assess	VB
cord-014712-5u4e00q6	1299	5	the	the	DT
cord-014712-5u4e00q6	1299	6	prevalence	prevalence	NN
cord-014712-5u4e00q6	1299	7	of	of	IN
cord-014712-5u4e00q6	1299	8	co	co	NN
cord-014712-5u4e00q6	1299	9	-	-	NN
cord-014712-5u4e00q6	1299	10	morbidity	morbidity	NN
cord-014712-5u4e00q6	1299	11	in	in	IN
cord-014712-5u4e00q6	1299	12	patients	patient	NNS
cord-014712-5u4e00q6	1299	13	with	with	IN
cord-014712-5u4e00q6	1299	14	SIgAD	SIgAD	NNS
cord-014712-5u4e00q6	1299	15	in	in	IN
cord-014712-5u4e00q6	1299	16	Latvian	latvian	JJ
cord-014712-5u4e00q6	1299	17	pediatric	pediatric	JJ
cord-014712-5u4e00q6	1299	18	population	population	NN
cord-014712-5u4e00q6	1299	19	and	and	CC
cord-014712-5u4e00q6	1299	20	the	the	DT
cord-014712-5u4e00q6	1299	21	analysis	analysis	NN
cord-014712-5u4e00q6	1299	22	of	of	IN
cord-014712-5u4e00q6	1299	23	some	some	DT
cord-014712-5u4e00q6	1299	24	immunological	immunological	JJ
cord-014712-5u4e00q6	1299	25	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	1299	26	in	in	IN
cord-014712-5u4e00q6	1299	27	these	these	DT
cord-014712-5u4e00q6	1299	28	patients	patient	NNS
cord-014712-5u4e00q6	1299	29	.	.	.
cord-014712-5u4e00q6	1300	1	The	the	DT
cord-014712-5u4e00q6	1300	2	study	study	NN
cord-014712-5u4e00q6	1300	3	included	include	VBD
cord-014712-5u4e00q6	1300	4	120	120	CD
cord-014712-5u4e00q6	1300	5	patients	patient	NNS
cord-014712-5u4e00q6	1300	6	4	4	CD
cord-014712-5u4e00q6	1300	7	-18	-18	CD
cord-014712-5u4e00q6	1300	8	years	year	NNS
cord-014712-5u4e00q6	1300	9	old	old	JJ
cord-014712-5u4e00q6	1300	10	.	.	.
cord-014712-5u4e00q6	1301	1	Medical	medical	JJ
cord-014712-5u4e00q6	1301	2	charts	chart	NNS
cord-014712-5u4e00q6	1301	3	have	have	VBP
cord-014712-5u4e00q6	1301	4	been	be	VBN
cord-014712-5u4e00q6	1301	5	reviewed	review	VBN
cord-014712-5u4e00q6	1301	6	.	.	.
cord-014712-5u4e00q6	1302	1	Into	into	IN
cord-014712-5u4e00q6	1302	2	account	account	NN
cord-014712-5u4e00q6	1302	3	were	be	VBD
cord-014712-5u4e00q6	1302	4	taken	take	VBN
cord-014712-5u4e00q6	1302	5	the	the	DT
cord-014712-5u4e00q6	1302	6	data	datum	NNS
cord-014712-5u4e00q6	1302	7	,	,	,
cord-014712-5u4e00q6	1302	8	which	which	WDT
cord-014712-5u4e00q6	1302	9	were	be	VBD
cord-014712-5u4e00q6	1302	10	made	make	VBN
cord-014712-5u4e00q6	1302	11	at	at	IN
cord-014712-5u4e00q6	1302	12	time	time	NN
cord-014712-5u4e00q6	1302	13	of	of	IN
cord-014712-5u4e00q6	1302	14	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1302	15	.	.	.
cord-014712-5u4e00q6	1303	1	Patients	patient	NNS
cord-014712-5u4e00q6	1303	2	were	be	VBD
cord-014712-5u4e00q6	1303	3	divided	divide	VBN
cord-014712-5u4e00q6	1303	4	into	into	IN
cord-014712-5u4e00q6	1303	5	4	4	CD
cord-014712-5u4e00q6	1303	6	groups	group	NNS
cord-014712-5u4e00q6	1303	7	:	:	:
cord-014712-5u4e00q6	1303	8	1	1	CD
cord-014712-5u4e00q6	1303	9	st	st	NNP
cord-014712-5u4e00q6	1303	10	-patients	-patients	NNP
cord-014712-5u4e00q6	1303	11	with	with	IN
cord-014712-5u4e00q6	1303	12	allergic	allergic	JJ
cord-014712-5u4e00q6	1303	13	disease	disease	NN
cord-014712-5u4e00q6	1303	14	,	,	,
cord-014712-5u4e00q6	1303	15	2	2	CD
cord-014712-5u4e00q6	1303	16	nd	nd	NNP
cord-014712-5u4e00q6	1303	17	-patients	-patient	VBZ
cord-014712-5u4e00q6	1303	18	with	with	IN
cord-014712-5u4e00q6	1303	19	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1303	20	diseases	disease	NNS
cord-014712-5u4e00q6	1303	21	,	,	,
cord-014712-5u4e00q6	1303	22	3	3	CD
cord-014712-5u4e00q6	1303	23	rd	rd	NN
cord-014712-5u4e00q6	1303	24	-patients	-patient	NNS
cord-014712-5u4e00q6	1303	25	with	with	IN
cord-014712-5u4e00q6	1303	26	infectious	infectious	JJ
cord-014712-5u4e00q6	1303	27	diseases	disease	NNS
cord-014712-5u4e00q6	1303	28	,	,	,
cord-014712-5u4e00q6	1303	29	4	4	CD
cord-014712-5u4e00q6	1303	30	th	th	XX
cord-014712-5u4e00q6	1303	31	-asymptomatic	-asymptomatic	JJ
cord-014712-5u4e00q6	1303	32	patients	patient	NNS
cord-014712-5u4e00q6	1303	33	or	or	CC
cord-014712-5u4e00q6	1303	34	patients	patient	NNS
cord-014712-5u4e00q6	1303	35	with	with	IN
cord-014712-5u4e00q6	1303	36	SIgAD	sigad	JJ
cord-014712-5u4e00q6	1303	37	unrelated	unrelated	JJ
cord-014712-5u4e00q6	1303	38	diseases	disease	NNS
cord-014712-5u4e00q6	1303	39	.	.	.
cord-014712-5u4e00q6	1304	1	Patients	patient	NNS
cord-014712-5u4e00q6	1304	2	with	with	IN
cord-014712-5u4e00q6	1304	3	multiple	multiple	JJ
cord-014712-5u4e00q6	1304	4	co	co	NNS
cord-014712-5u4e00q6	1304	5	-	-	NNS
cord-014712-5u4e00q6	1304	6	morbidities	morbidity	NNS
cord-014712-5u4e00q6	1304	7	of	of	IN
cord-014712-5u4e00q6	1304	8	various	various	JJ
cord-014712-5u4e00q6	1304	9	disease	disease	NN
cord-014712-5u4e00q6	1304	10	groups	group	NNS
cord-014712-5u4e00q6	1304	11	were	be	VBD
cord-014712-5u4e00q6	1304	12	not	not	RB
cord-014712-5u4e00q6	1304	13	placed	place	VBN
cord-014712-5u4e00q6	1304	14	in	in	IN
cord-014712-5u4e00q6	1304	15	any	any	DT
cord-014712-5u4e00q6	1304	16	of	of	IN
cord-014712-5u4e00q6	1304	17	these	these	DT
cord-014712-5u4e00q6	1304	18	groups	group	NNS
cord-014712-5u4e00q6	1304	19	.	.	.
cord-014712-5u4e00q6	1305	1	Each	each	DT
cord-014712-5u4e00q6	1305	2	patient	patient	NN
cord-014712-5u4e00q6	1305	3	group	group	NN
cord-014712-5u4e00q6	1305	4	was	be	VBD
cord-014712-5u4e00q6	1305	5	divided	divide	VBN
cord-014712-5u4e00q6	1305	6	by	by	IN
cord-014712-5u4e00q6	1305	7	age	age	NN
cord-014712-5u4e00q6	1305	8	:	:	:
cord-014712-5u4e00q6	1305	9	4	4	CD
cord-014712-5u4e00q6	1305	10	-6	-6	CD
cord-014712-5u4e00q6	1305	11	years	year	NNS
cord-014712-5u4e00q6	1305	12	,	,	,
cord-014712-5u4e00q6	1305	13	7	7	CD
cord-014712-5u4e00q6	1305	14	-13	-13	CD
cord-014712-5u4e00q6	1305	15	years	year	NNS
cord-014712-5u4e00q6	1305	16	14	14	CD
cord-014712-5u4e00q6	1305	17	-18	-18	CD
cord-014712-5u4e00q6	1305	18	years	year	NNS
cord-014712-5u4e00q6	1305	19	.	.	.
cord-014712-5u4e00q6	1306	1	Results.58.4	results.58.4	JJ
cord-014712-5u4e00q6	1306	2	%	%	NN
cord-014712-5u4e00q6	1306	3	were	be	VBD
cord-014712-5u4e00q6	1306	4	boys	boy	NNS
cord-014712-5u4e00q6	1306	5	and	and	CC
cord-014712-5u4e00q6	1306	6	41.6	41.6	CD
cord-014712-5u4e00q6	1306	7	%	%	NN
cord-014712-5u4e00q6	1306	8	girls	girl	NNS
cord-014712-5u4e00q6	1306	9	.	.	.
cord-014712-5u4e00q6	1307	1	SIgAD	SIgAD	NNS
cord-014712-5u4e00q6	1308	1	in	in	IN
cord-014712-5u4e00q6	1308	2	53.9	53.9	CD
cord-014712-5u4e00q6	1308	3	%	%	NN
cord-014712-5u4e00q6	1308	4	of	of	IN
cord-014712-5u4e00q6	1308	5	the	the	DT
cord-014712-5u4e00q6	1308	6	cases	case	NNS
cord-014712-5u4e00q6	1308	7	were	be	VBD
cord-014712-5u4e00q6	1308	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1308	9	before	before	IN
cord-014712-5u4e00q6	1308	10	7	7	CD
cord-014712-5u4e00q6	1308	11	years	year	NNS
cord-014712-5u4e00q6	1308	12	of	of	IN
cord-014712-5u4e00q6	1308	13	age	age	NN
cord-014712-5u4e00q6	1308	14	(	(	-LRB-
cord-014712-5u4e00q6	1308	15	inclusive	inclusive	JJ
cord-014712-5u4e00q6	1308	16	)	)	-RRB-
cord-014712-5u4e00q6	1308	17	.	.	.
cord-014712-5u4e00q6	1309	1	85	85	CD
cord-014712-5u4e00q6	1309	2	%	%	NN
cord-014712-5u4e00q6	1309	3	of	of	IN
cord-014712-5u4e00q6	1309	4	the	the	DT
cord-014712-5u4e00q6	1309	5	patients	patient	NNS
cord-014712-5u4e00q6	1309	6	had	have	VBD
cord-014712-5u4e00q6	1309	7	co	co	NNS
cord-014712-5u4e00q6	1309	8	-	-	NNS
cord-014712-5u4e00q6	1309	9	morbidities	morbidity	NNS
cord-014712-5u4e00q6	1309	10	:	:	:
cord-014712-5u4e00q6	1309	11	allergic	allergic	JJ
cord-014712-5u4e00q6	1309	12	(	(	-LRB-
cord-014712-5u4e00q6	1309	13	30	30	CD
cord-014712-5u4e00q6	1309	14	%	%	NN
cord-014712-5u4e00q6	1309	15	)	)	-RRB-
cord-014712-5u4e00q6	1309	16	,	,	,
cord-014712-5u4e00q6	1309	17	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1309	18	(	(	-LRB-
cord-014712-5u4e00q6	1309	19	37.5	37.5	CD
cord-014712-5u4e00q6	1309	20	%	%	NN
cord-014712-5u4e00q6	1309	21	)	)	-RRB-
cord-014712-5u4e00q6	1309	22	or	or	CC
cord-014712-5u4e00q6	1309	23	infectious	infectious	JJ
cord-014712-5u4e00q6	1309	24	diseases	disease	NNS
cord-014712-5u4e00q6	1309	25	(	(	-LRB-
cord-014712-5u4e00q6	1309	26	17.5	17.5	CD
cord-014712-5u4e00q6	1309	27	%	%	NN
cord-014712-5u4e00q6	1309	28	)	)	-RRB-
cord-014712-5u4e00q6	1309	29	.	.	.
cord-014712-5u4e00q6	1310	1	Patients	patient	NNS
cord-014712-5u4e00q6	1310	2	4	4	CD
cord-014712-5u4e00q6	1310	3	-6	-6	CD
cord-014712-5u4e00q6	1310	4	years	year	NNS
cord-014712-5u4e00q6	1310	5	old	old	JJ
cord-014712-5u4e00q6	1310	6	:	:	:
cord-014712-5u4e00q6	1310	7	children	child	NNS
cord-014712-5u4e00q6	1310	8	with	with	IN
cord-014712-5u4e00q6	1310	9	infectious	infectious	JJ
cord-014712-5u4e00q6	1310	10	and	and	CC
cord-014712-5u4e00q6	1310	11	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1310	12	diseases	disease	NNS
cord-014712-5u4e00q6	1310	13	have	have	VBP
cord-014712-5u4e00q6	1310	14	1.3	1.3	CD
cord-014712-5u4e00q6	1310	15	times	time	NNS
cord-014712-5u4e00q6	1310	16	greater	great	JJR
cord-014712-5u4e00q6	1310	17	IgG	igg	NN
cord-014712-5u4e00q6	1310	18	than	than	IN
cord-014712-5u4e00q6	1310	19	healthy	healthy	JJ
cord-014712-5u4e00q6	1310	20	children	child	NNS
cord-014712-5u4e00q6	1310	21	or	or	CC
cord-014712-5u4e00q6	1310	22	children	child	NNS
cord-014712-5u4e00q6	1310	23	with	with	IN
cord-014712-5u4e00q6	1310	24	allergic	allergic	JJ
cord-014712-5u4e00q6	1310	25	diseases	disease	NNS
cord-014712-5u4e00q6	1310	26	(	(	-LRB-
cord-014712-5u4e00q6	1310	27	p	p	NN
cord-014712-5u4e00q6	1310	28	<	<	XX
cord-014712-5u4e00q6	1310	29	0,05	0,05	NNP
cord-014712-5u4e00q6	1310	30	)	)	-RRB-
cord-014712-5u4e00q6	1310	31	;	;	:
cord-014712-5u4e00q6	1310	32	children	child	NNS
cord-014712-5u4e00q6	1310	33	with	with	IN
cord-014712-5u4e00q6	1310	34	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1310	35	diseases	disease	NNS
cord-014712-5u4e00q6	1310	36	has	have	VBZ
cord-014712-5u4e00q6	1310	37	1.9	1.9	CD
cord-014712-5u4e00q6	1310	38	times	time	NNS
cord-014712-5u4e00q6	1310	39	more	more	JJR
cord-014712-5u4e00q6	1310	40	CD8	cd8	NN
cord-014712-5u4e00q6	1310	41	cells	cell	NNS
cord-014712-5u4e00q6	1310	42	than	than	IN
cord-014712-5u4e00q6	1310	43	children	child	NNS
cord-014712-5u4e00q6	1310	44	with	with	IN
cord-014712-5u4e00q6	1310	45	allergic	allergic	JJ
cord-014712-5u4e00q6	1310	46	diseases	disease	NNS
cord-014712-5u4e00q6	1310	47	(	(	-LRB-
cord-014712-5u4e00q6	1310	48	p	p	NN
cord-014712-5u4e00q6	1310	49	<	<	XX
cord-014712-5u4e00q6	1310	50	0,05	0,05	NNP
cord-014712-5u4e00q6	1310	51	)	)	-RRB-
cord-014712-5u4e00q6	1310	52	.	.	.
cord-014712-5u4e00q6	1311	1	;	;	:
cord-014712-5u4e00q6	1311	2	children	child	NNS
cord-014712-5u4e00q6	1311	3	with	with	IN
cord-014712-5u4e00q6	1311	4	infectious	infectious	JJ
cord-014712-5u4e00q6	1311	5	diseases	disease	NNS
cord-014712-5u4e00q6	1311	6	have	have	VBP
cord-014712-5u4e00q6	1311	7	2.1	2.1	CD
cord-014712-5u4e00q6	1311	8	times	time	NNS
cord-014712-5u4e00q6	1311	9	lower	low	JJR
cord-014712-5u4e00q6	1311	10	absolute	absolute	JJ
cord-014712-5u4e00q6	1311	11	number	number	NN
cord-014712-5u4e00q6	1311	12	of	of	IN
cord-014712-5u4e00q6	1311	13	CD25	cd25	JJ
cord-014712-5u4e00q6	1311	14	cells	cell	NNS
cord-014712-5u4e00q6	1311	15	than	than	IN
cord-014712-5u4e00q6	1311	16	children	child	NNS
cord-014712-5u4e00q6	1311	17	with	with	IN
cord-014712-5u4e00q6	1311	18	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1311	19	diseases	disease	NNS
cord-014712-5u4e00q6	1312	1	(	(	-LRB-
cord-014712-5u4e00q6	1312	2	p	p	NN
cord-014712-5u4e00q6	1312	3	<	<	XX
cord-014712-5u4e00q6	1312	4	0,05	0,05	XX
cord-014712-5u4e00q6	1312	5	)	)	-RRB-
cord-014712-5u4e00q6	1313	1	;	;	:
cord-014712-5u4e00q6	1313	2	Patients	patient	NNS
cord-014712-5u4e00q6	1313	3	7	7	CD
cord-014712-5u4e00q6	1313	4	-13	-13	CD
cord-014712-5u4e00q6	1313	5	years	year	NNS
cord-014712-5u4e00q6	1313	6	old	old	JJ
cord-014712-5u4e00q6	1313	7	:	:	:
cord-014712-5u4e00q6	1313	8	children	child	NNS
cord-014712-5u4e00q6	1313	9	with	with	IN
cord-014712-5u4e00q6	1313	10	infectious	infectious	JJ
cord-014712-5u4e00q6	1313	11	diseases	disease	NNS
cord-014712-5u4e00q6	1313	12	have	have	VBP
cord-014712-5u4e00q6	1313	13	1.5	1.5	CD
cord-014712-5u4e00q6	1313	14	times	time	NNS
cord-014712-5u4e00q6	1313	15	more	more	RBR
cord-014712-5u4e00q6	1313	16	absolute	absolute	JJ
cord-014712-5u4e00q6	1313	17	number	number	NN
cord-014712-5u4e00q6	1313	18	CD25	CD25	NNP
cord-014712-5u4e00q6	1313	19	cells	cell	NNS
cord-014712-5u4e00q6	1313	20	than	than	IN
cord-014712-5u4e00q6	1313	21	children	child	NNS
cord-014712-5u4e00q6	1313	22	with	with	IN
cord-014712-5u4e00q6	1313	23	allergic	allergic	JJ
cord-014712-5u4e00q6	1313	24	diseases	disease	NNS
cord-014712-5u4e00q6	1313	25	(	(	-LRB-
cord-014712-5u4e00q6	1313	26	p	p	NN
cord-014712-5u4e00q6	1313	27	<	<	XX
cord-014712-5u4e00q6	1313	28	0,05	0,05	NNP
cord-014712-5u4e00q6	1313	29	)	)	-RRB-
cord-014712-5u4e00q6	1313	30	.	.	.
cord-014712-5u4e00q6	1314	1	Patients	patient	NNS
cord-014712-5u4e00q6	1314	2	14	14	CD
cord-014712-5u4e00q6	1314	3	-18	-18	SYM
cord-014712-5u4e00q6	1314	4	years	year	NNS
cord-014712-5u4e00q6	1314	5	old	old	JJ
cord-014712-5u4e00q6	1314	6	:	:	:
cord-014712-5u4e00q6	1314	7	children	child	NNS
cord-014712-5u4e00q6	1314	8	with	with	IN
cord-014712-5u4e00q6	1314	9	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1314	10	disease	disease	NN
cord-014712-5u4e00q6	1314	11	have	have	VBP
cord-014712-5u4e00q6	1314	12	1.6	1.6	CD
cord-014712-5u4e00q6	1314	13	times	time	NNS
cord-014712-5u4e00q6	1314	14	higher	high	JJR
cord-014712-5u4e00q6	1314	15	CD4	CD4	NNP
cord-014712-5u4e00q6	1314	16	/	/	SYM
cord-014712-5u4e00q6	1314	17	CD8	CD8	NNP
cord-014712-5u4e00q6	1314	18	index	index	NN
cord-014712-5u4e00q6	1314	19	than	than	IN
cord-014712-5u4e00q6	1314	20	children	child	NNS
cord-014712-5u4e00q6	1314	21	with	with	IN
cord-014712-5u4e00q6	1314	22	infectious	infectious	JJ
cord-014712-5u4e00q6	1314	23	diseases	disease	NNS
cord-014712-5u4e00q6	1314	24	(	(	-LRB-
cord-014712-5u4e00q6	1314	25	p	p	NN
cord-014712-5u4e00q6	1314	26	<	<	XX
cord-014712-5u4e00q6	1314	27	0,05	0,05	XX
cord-014712-5u4e00q6	1314	28	)	)	-RRB-
cord-014712-5u4e00q6	1315	1	Karakina	Karakina	NNP
cord-014712-5u4e00q6	1315	2	M.	M.	NNP
cord-014712-5u4e00q6	1315	3	L.	L.	NNP
cord-014712-5u4e00q6	1315	4	1,2,3	1,2,3	CD
cord-014712-5u4e00q6	1315	5	,	,	,
cord-014712-5u4e00q6	1315	6	Tuzankina	Tuzankina	NNP
cord-014712-5u4e00q6	1315	7	I.	i.	NN
cord-014712-5u4e00q6	1315	8	A.	a.	NN
cord-014712-5u4e00q6	1315	9	1,2	1,2	CD
cord-014712-5u4e00q6	1316	1	,	,	,
cord-014712-5u4e00q6	1316	2	Vlasova	Vlasova	NNP
cord-014712-5u4e00q6	1316	3	E.	E.	NNP
cord-014712-5u4e00q6	1316	4	V.	V.	NNP
cord-014712-5u4e00q6	1317	1	2	2	LS
cord-014712-5u4e00q6	1317	2	1	1	CD
cord-014712-5u4e00q6	1317	3	Introduction	introduction	NN
cord-014712-5u4e00q6	1317	4	:	:	:
cord-014712-5u4e00q6	1318	1	Antiepileptic	antiepileptic	JJ
cord-014712-5u4e00q6	1318	2	drugs	drug	NNS
cord-014712-5u4e00q6	1318	3	are	be	VBP
cord-014712-5u4e00q6	1318	4	known	know	VBN
cord-014712-5u4e00q6	1318	5	to	to	TO
cord-014712-5u4e00q6	1318	6	cause	cause	VB
cord-014712-5u4e00q6	1318	7	immunosupression	immunosupression	NN
cord-014712-5u4e00q6	1318	8	in	in	IN
cord-014712-5u4e00q6	1318	9	some	some	DT
cord-014712-5u4e00q6	1318	10	cases	case	NNS
cord-014712-5u4e00q6	1318	11	.	.	.
cord-014712-5u4e00q6	1319	1	Levetiracetam	Levetiracetam	NNP
cord-014712-5u4e00q6	1319	2	is	be	VBZ
cord-014712-5u4e00q6	1319	3	an	an	DT
cord-014712-5u4e00q6	1319	4	anticonvulsant	anticonvulsant	JJ
cord-014712-5u4e00q6	1319	5	medication	medication	NN
cord-014712-5u4e00q6	1319	6	used	use	VBN
cord-014712-5u4e00q6	1319	7	to	to	TO
cord-014712-5u4e00q6	1319	8	treat	treat	VB
cord-014712-5u4e00q6	1319	9	epilepsy	epilepsy	NN
cord-014712-5u4e00q6	1319	10	in	in	IN
cord-014712-5u4e00q6	1319	11	the	the	DT
cord-014712-5u4e00q6	1319	12	posttraumatic	posttraumatic	JJ
cord-014712-5u4e00q6	1319	13	seizures	seizure	NNS
cord-014712-5u4e00q6	1319	14	.	.	.
cord-014712-5u4e00q6	1320	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1320	2	report	report	VBP
cord-014712-5u4e00q6	1320	3	a	a	DT
cord-014712-5u4e00q6	1320	4	rare	rare	JJ
cord-014712-5u4e00q6	1320	5	case	case	NN
cord-014712-5u4e00q6	1320	6	of	of	IN
cord-014712-5u4e00q6	1320	7	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1320	8	and	and	CC
cord-014712-5u4e00q6	1320	9	B	B	NNP
cord-014712-5u4e00q6	1320	10	cell	cell	NN
cord-014712-5u4e00q6	1320	11	aplasia	aplasia	NNP
cord-014712-5u4e00q6	1320	12	associated	associate	VBN
cord-014712-5u4e00q6	1320	13	with	with	IN
cord-014712-5u4e00q6	1320	14	levetiracetam	levetiracetam	NNP
cord-014712-5u4e00q6	1320	15	treatment	treatment	NN
cord-014712-5u4e00q6	1320	16	.	.	.
cord-014712-5u4e00q6	1321	1	Case	Case	NNP
cord-014712-5u4e00q6	1321	2	Report	Report	NNP
cord-014712-5u4e00q6	1321	3	:	:	:
cord-014712-5u4e00q6	1321	4	A	a	DT
cord-014712-5u4e00q6	1321	5	45-year	45-year	JJ
cord-014712-5u4e00q6	1321	6	-	-	HYPH
cord-014712-5u4e00q6	1321	7	old	old	JJ
cord-014712-5u4e00q6	1321	8	female	female	NN
cord-014712-5u4e00q6	1321	9	was	be	VBD
cord-014712-5u4e00q6	1321	10	operated	operate	VBN
cord-014712-5u4e00q6	1321	11	for	for	IN
cord-014712-5u4e00q6	1321	12	pituitary	pituitary	JJ
cord-014712-5u4e00q6	1321	13	tumor	tumor	NN
cord-014712-5u4e00q6	1321	14	with	with	IN
cord-014712-5u4e00q6	1321	15	transnasal	transnasal	NN
cord-014712-5u4e00q6	1321	16	surgery	surgery	NN
cord-014712-5u4e00q6	1321	17	and	and	CC
cord-014712-5u4e00q6	1321	18	required	require	VBN
cord-014712-5u4e00q6	1321	19	second	second	JJ
cord-014712-5u4e00q6	1321	20	operation	operation	NN
cord-014712-5u4e00q6	1321	21	for	for	IN
cord-014712-5u4e00q6	1321	22	postoperative	postoperative	JJ
cord-014712-5u4e00q6	1321	23	rhinorrhea	rhinorrhea	NN
cord-014712-5u4e00q6	1321	24	.	.	.
cord-014712-5u4e00q6	1322	1	After	after	IN
cord-014712-5u4e00q6	1322	2	operation	operation	NN
cord-014712-5u4e00q6	1322	3	,	,	,
cord-014712-5u4e00q6	1322	4	menengitis	menengitis	NNP
cord-014712-5u4e00q6	1322	5	developed	develop	VBD
cord-014712-5u4e00q6	1322	6	and	and	CC
cord-014712-5u4e00q6	1322	7	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	1322	8	treatment	treatment	NN
cord-014712-5u4e00q6	1322	9	was	be	VBD
cord-014712-5u4e00q6	1322	10	administrated	administrate	VBN
cord-014712-5u4e00q6	1322	11	.	.	.
cord-014712-5u4e00q6	1323	1	However	however	RB
cord-014712-5u4e00q6	1323	2	,	,	,
cord-014712-5u4e00q6	1323	3	there	there	EX
cord-014712-5u4e00q6	1323	4	was	be	VBD
cord-014712-5u4e00q6	1323	5	a	a	DT
cord-014712-5u4e00q6	1323	6	poor	poor	JJ
cord-014712-5u4e00q6	1323	7	response	response	NN
cord-014712-5u4e00q6	1323	8	to	to	IN
cord-014712-5u4e00q6	1323	9	this	this	DT
cord-014712-5u4e00q6	1323	10	treatment	treatment	NN
cord-014712-5u4e00q6	1323	11	after	after	IN
cord-014712-5u4e00q6	1323	12	one	one	CD
cord-014712-5u4e00q6	1323	13	month	month	NN
cord-014712-5u4e00q6	1323	14	and	and	CC
cord-014712-5u4e00q6	1323	15	craniotomy	craniotomy	NN
cord-014712-5u4e00q6	1323	16	was	be	VBD
cord-014712-5u4e00q6	1323	17	performed	perform	VBN
cord-014712-5u4e00q6	1323	18	due	due	IN
cord-014712-5u4e00q6	1323	19	to	to	IN
cord-014712-5u4e00q6	1323	20	the	the	DT
cord-014712-5u4e00q6	1323	21	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1323	22	of	of	IN
cord-014712-5u4e00q6	1323	23	"	"	``
cord-014712-5u4e00q6	1323	24	shimic	shimic	NNP
cord-014712-5u4e00q6	1323	25	menengitis	menengitis	NNP
cord-014712-5u4e00q6	1323	26	"	"	''
cord-014712-5u4e00q6	1323	27	.	.	.
cord-014712-5u4e00q6	1324	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1324	2	seizures	seizure	NNS
cord-014712-5u4e00q6	1324	3	occurred	occur	VBD
cord-014712-5u4e00q6	1324	4	as	as	IN
cord-014712-5u4e00q6	1324	5	a	a	DT
cord-014712-5u4e00q6	1324	6	postoperative	postoperative	JJ
cord-014712-5u4e00q6	1324	7	complication	complication	NN
cord-014712-5u4e00q6	1324	8	and	and	CC
cord-014712-5u4e00q6	1324	9	levetiracetam	levetiracetam	NNS
cord-014712-5u4e00q6	1324	10	was	be	VBD
cord-014712-5u4e00q6	1324	11	initiated	initiate	VBN
cord-014712-5u4e00q6	1324	12	.	.	.
cord-014712-5u4e00q6	1325	1	After	after	IN
cord-014712-5u4e00q6	1325	2	the	the	DT
cord-014712-5u4e00q6	1325	3	9-month	9-month	JJ
cord-014712-5u4e00q6	1325	4	follow	follow	NN
cord-014712-5u4e00q6	1325	5	-	-	HYPH
cord-014712-5u4e00q6	1325	6	up	up	NN
cord-014712-5u4e00q6	1325	7	,	,	,
cord-014712-5u4e00q6	1325	8	the	the	DT
cord-014712-5u4e00q6	1325	9	findings	finding	NNS
cord-014712-5u4e00q6	1325	10	of	of	IN
cord-014712-5u4e00q6	1325	11	menengitis	menengitis	NNP
cord-014712-5u4e00q6	1325	12	could	could	MD
cord-014712-5u4e00q6	1325	13	not	not	RB
cord-014712-5u4e00q6	1325	14	be	be	VB
cord-014712-5u4e00q6	1325	15	controlled	control	VBN
cord-014712-5u4e00q6	1325	16	with	with	IN
cord-014712-5u4e00q6	1325	17	antibiotherapy	antibiotherapy	NNP
cord-014712-5u4e00q6	1325	18	.	.	.
cord-014712-5u4e00q6	1326	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1326	2	was	be	VBD
cord-014712-5u4e00q6	1326	3	referred	refer	VBN
cord-014712-5u4e00q6	1326	4	to	to	IN
cord-014712-5u4e00q6	1326	5	our	-PRON-	PRP$
cord-014712-5u4e00q6	1326	6	immunology	immunology	NN
cord-014712-5u4e00q6	1326	7	department	department	NN
cord-014712-5u4e00q6	1326	8	for	for	IN
cord-014712-5u4e00q6	1326	9	chronic	chronic	JJ
cord-014712-5u4e00q6	1326	10	menengitis	menengitis	NNP
cord-014712-5u4e00q6	1326	11	with	with	IN
cord-014712-5u4e00q6	1326	12	fever	fever	NN
cord-014712-5u4e00q6	1326	13	,	,	,
cord-014712-5u4e00q6	1326	14	headache	headache	NN
cord-014712-5u4e00q6	1326	15	and	and	CC
cord-014712-5u4e00q6	1326	16	high	high	JJ
cord-014712-5u4e00q6	1326	17	cerebrospinal	cerebrospinal	JJ
cord-014712-5u4e00q6	1326	18	white	white	JJ
cord-014712-5u4e00q6	1326	19	blood	blood	NN
cord-014712-5u4e00q6	1326	20	cell	cell	NN
cord-014712-5u4e00q6	1326	21	count	count	NN
cord-014712-5u4e00q6	1326	22	.	.	.
cord-014712-5u4e00q6	1327	1	Results	result	NNS
cord-014712-5u4e00q6	1327	2	:	:	:
cord-014712-5u4e00q6	1328	1	In	in	IN
cord-014712-5u4e00q6	1328	2	her	-PRON-	PRP$
cord-014712-5u4e00q6	1328	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1328	4	evaluation	evaluation	NN
cord-014712-5u4e00q6	1328	5	,	,	,
cord-014712-5u4e00q6	1328	6	it	-PRON-	PRP
cord-014712-5u4e00q6	1328	7	was	be	VBD
cord-014712-5u4e00q6	1328	8	learned	learn	VBN
cord-014712-5u4e00q6	1328	9	that	that	IN
cord-014712-5u4e00q6	1328	10	she	-PRON-	PRP
cord-014712-5u4e00q6	1328	11	had	have	VBD
cord-014712-5u4e00q6	1328	12	previously	previously	RB
cord-014712-5u4e00q6	1328	13	healthy	healthy	JJ
cord-014712-5u4e00q6	1328	14	.	.	.
cord-014712-5u4e00q6	1329	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1329	2	examination	examination	NN
cord-014712-5u4e00q6	1329	3	showed	show	VBD
cord-014712-5u4e00q6	1329	4	that	that	IN
cord-014712-5u4e00q6	1329	5	decreased	decrease	VBD
cord-014712-5u4e00q6	1329	6	levels	level	NNS
cord-014712-5u4e00q6	1329	7	of	of	IN
cord-014712-5u4e00q6	1329	8	IgG	IgG	NNP
cord-014712-5u4e00q6	1329	9	778	778	CD
cord-014712-5u4e00q6	1329	10	mg	mg	NNP
cord-014712-5u4e00q6	1329	11	/	/	SYM
cord-014712-5u4e00q6	1329	12	dl	dl	NNP
cord-014712-5u4e00q6	1329	13	(	(	-LRB-
cord-014712-5u4e00q6	1329	14	normal	normal	JJ
cord-014712-5u4e00q6	1329	15	:	:	:
cord-014712-5u4e00q6	1329	16	913	913	CD
cord-014712-5u4e00q6	1329	17	-	-	HYPH
cord-014712-5u4e00q6	1329	18	1884	1884	CD
cord-014712-5u4e00q6	1329	19	)	)	-RRB-
cord-014712-5u4e00q6	1329	20	and	and	CC
cord-014712-5u4e00q6	1329	21	IgA	IgA	NNP
cord-014712-5u4e00q6	1329	22	97	97	CD
cord-014712-5u4e00q6	1330	1	mg	mg	NNP
cord-014712-5u4e00q6	1330	2	/	/	SYM
cord-014712-5u4e00q6	1330	3	dL	dl	NN
cord-014712-5u4e00q6	1331	1	(	(	-LRB-
cord-014712-5u4e00q6	1331	2	n	n	NN
cord-014712-5u4e00q6	1331	3	:	:	:
cord-014712-5u4e00q6	1331	4	139	139	CD
cord-014712-5u4e00q6	1331	5	-	-	SYM
cord-014712-5u4e00q6	1331	6	378	378	CD
cord-014712-5u4e00q6	1331	7	)	)	-RRB-
cord-014712-5u4e00q6	1331	8	.	.	.
cord-014712-5u4e00q6	1332	1	Peripheral	peripheral	JJ
cord-014712-5u4e00q6	1332	2	blood	blood	NN
cord-014712-5u4e00q6	1332	3	flow	flow	NN
cord-014712-5u4e00q6	1332	4	cytometric	cytometric	NNP
cord-014712-5u4e00q6	1332	5	analysis	analysis	NN
cord-014712-5u4e00q6	1332	6	revealed	reveal	VBD
cord-014712-5u4e00q6	1332	7	the	the	DT
cord-014712-5u4e00q6	1332	8	absence	absence	NN
cord-014712-5u4e00q6	1332	9	of	of	IN
cord-014712-5u4e00q6	1332	10	B	b	NN
cord-014712-5u4e00q6	1332	11	cells	cell	NNS
cord-014712-5u4e00q6	1332	12	(	(	-LRB-
cord-014712-5u4e00q6	1332	13	CD19	CD19	NNP
cord-014712-5u4e00q6	1332	14	+	+	CC
cord-014712-5u4e00q6	1332	15	B	b	NN
cord-014712-5u4e00q6	1332	16	cells	cell	NNS
cord-014712-5u4e00q6	1332	17	;	;	:
cord-014712-5u4e00q6	1332	18	<	<	XX
cord-014712-5u4e00q6	1332	19	1	1	CD
cord-014712-5u4e00q6	1332	20	%	%	NN
cord-014712-5u4e00q6	1332	21	)	)	-RRB-
cord-014712-5u4e00q6	1332	22	.	.	.
cord-014712-5u4e00q6	1333	1	T	T	NNP
cord-014712-5u4e00q6	1333	2	cell	cell	NN
cord-014712-5u4e00q6	1333	3	subsets	subset	NNS
cord-014712-5u4e00q6	1333	4	and	and	CC
cord-014712-5u4e00q6	1333	5	natural	natural	JJ
cord-014712-5u4e00q6	1333	6	killer	killer	NN
cord-014712-5u4e00q6	1333	7	cell	cell	NN
cord-014712-5u4e00q6	1333	8	numbers	number	NNS
cord-014712-5u4e00q6	1333	9	were	be	VBD
cord-014712-5u4e00q6	1333	10	normal	normal	JJ
cord-014712-5u4e00q6	1333	11	.	.	.
cord-014712-5u4e00q6	1334	1	Neutrophil	Neutrophil	NNP
cord-014712-5u4e00q6	1334	2	function	function	NN
cord-014712-5u4e00q6	1334	3	,	,	,
cord-014712-5u4e00q6	1334	4	chemotaxis	chemotaxis	NN
cord-014712-5u4e00q6	1334	5	,	,	,
cord-014712-5u4e00q6	1334	6	phagocytosis	phagocytosis	NN
cord-014712-5u4e00q6	1334	7	and	and	CC
cord-014712-5u4e00q6	1334	8	oxidative	oxidative	JJ
cord-014712-5u4e00q6	1334	9	burst	burst	NN
cord-014712-5u4e00q6	1334	10	activity	activity	NN
cord-014712-5u4e00q6	1334	11	were	be	VBD
cord-014712-5u4e00q6	1334	12	found	find	VBN
cord-014712-5u4e00q6	1334	13	to	to	TO
cord-014712-5u4e00q6	1334	14	be	be	VB
cord-014712-5u4e00q6	1334	15	normal	normal	JJ
cord-014712-5u4e00q6	1334	16	.	.	.
cord-014712-5u4e00q6	1335	1	Isohemaglutinin	Isohemaglutinin	NNP
cord-014712-5u4e00q6	1335	2	titer	titer	NN
cord-014712-5u4e00q6	1335	3	,	,	,
cord-014712-5u4e00q6	1335	4	levels	level	NNS
cord-014712-5u4e00q6	1335	5	of	of	IN
cord-014712-5u4e00q6	1335	6	pneumococal	pneumococal	JJ
cord-014712-5u4e00q6	1335	7	and	and	CC
cord-014712-5u4e00q6	1335	8	tetanus	tetanus	JJ
cord-014712-5u4e00q6	1335	9	specific	specific	JJ
cord-014712-5u4e00q6	1335	10	IgG	igg	NN
cord-014712-5u4e00q6	1335	11	antibodies	antibody	NNS
cord-014712-5u4e00q6	1335	12	were	be	VBD
cord-014712-5u4e00q6	1335	13	also	also	RB
cord-014712-5u4e00q6	1335	14	normal	normal	JJ
cord-014712-5u4e00q6	1335	15	.	.	.
cord-014712-5u4e00q6	1336	1	Antiepileptic	antiepileptic	JJ
cord-014712-5u4e00q6	1336	2	drug	drug	NN
cord-014712-5u4e00q6	1336	3	was	be	VBD
cord-014712-5u4e00q6	1336	4	discontinued	discontinue	VBN
cord-014712-5u4e00q6	1336	5	after	after	IN
cord-014712-5u4e00q6	1336	6	epileptic	epileptic	JJ
cord-014712-5u4e00q6	1336	7	seizure	seizure	NN
cord-014712-5u4e00q6	1336	8	was	be	VBD
cord-014712-5u4e00q6	1336	9	controlled	control	VBN
cord-014712-5u4e00q6	1336	10	.	.	.
cord-014712-5u4e00q6	1337	1	B	b	NN
cord-014712-5u4e00q6	1337	2	cells	cell	NNS
cord-014712-5u4e00q6	1337	3	gradually	gradually	RB
cord-014712-5u4e00q6	1337	4	increased	increase	VBD
cord-014712-5u4e00q6	1337	5	three	three	CD
cord-014712-5u4e00q6	1337	6	weeks	week	NNS
cord-014712-5u4e00q6	1337	7	later	later	RB
cord-014712-5u4e00q6	1337	8	and	and	CC
cord-014712-5u4e00q6	1337	9	returned	return	VBD
cord-014712-5u4e00q6	1337	10	to	to	IN
cord-014712-5u4e00q6	1337	11	normal	normal	JJ
cord-014712-5u4e00q6	1337	12	within	within	IN
cord-014712-5u4e00q6	1337	13	two	two	CD
cord-014712-5u4e00q6	1337	14	months	month	NNS
cord-014712-5u4e00q6	1337	15	(	(	-LRB-
cord-014712-5u4e00q6	1337	16	CD19	CD19	NNP
cord-014712-5u4e00q6	1337	17	+	+	CC
cord-014712-5u4e00q6	1337	18	B	b	NN
cord-014712-5u4e00q6	1337	19	cells	cell	NNS
cord-014712-5u4e00q6	1337	20	:	:	:
cord-014712-5u4e00q6	1337	21	9.8	9.8	CD
cord-014712-5u4e00q6	1337	22	%	%	NN
cord-014712-5u4e00q6	1337	23	)	)	-RRB-
cord-014712-5u4e00q6	1337	24	.	.	.
cord-014712-5u4e00q6	1338	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1338	2	:	:	:
cord-014712-5u4e00q6	1338	3	Patients	patient	NNS
cord-014712-5u4e00q6	1338	4	requiring	require	VBG
cord-014712-5u4e00q6	1338	5	levetiracetam	levetiracetam	NNS
cord-014712-5u4e00q6	1338	6	should	should	MD
cord-014712-5u4e00q6	1338	7	have	have	VB
cord-014712-5u4e00q6	1338	8	serum	serum	NN
cord-014712-5u4e00q6	1338	9	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	1338	10	measured	measure	VBN
cord-014712-5u4e00q6	1338	11	and	and	CC
cord-014712-5u4e00q6	1338	12	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1338	13	subsets	subset	NNS
cord-014712-5u4e00q6	1338	14	analysis	analysis	NN
cord-014712-5u4e00q6	1338	15	performed	perform	VBN
cord-014712-5u4e00q6	1338	16	if	if	IN
cord-014712-5u4e00q6	1338	17	they	-PRON-	PRP
cord-014712-5u4e00q6	1338	18	experience	experience	VBP
cord-014712-5u4e00q6	1338	19	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1338	20	or	or	CC
cord-014712-5u4e00q6	1338	21	persistent	persistent	JJ
cord-014712-5u4e00q6	1338	22	infections	infection	NNS
cord-014712-5u4e00q6	1338	23	.	.	.
cord-014712-5u4e00q6	1339	1	Mustafa	Mustafa	NNP
cord-014712-5u4e00q6	1339	2	Gulec	Gulec	NNP
cord-014712-5u4e00q6	1339	3	1	1	CD
cord-014712-5u4e00q6	1339	4	;	;	:
cord-014712-5u4e00q6	1339	5	Fevzi	Fevzi	NNP
cord-014712-5u4e00q6	1339	6	Demirel	Demirel	NNP
cord-014712-5u4e00q6	1339	7	1	1	CD
cord-014712-5u4e00q6	1339	8	;	;	:
cord-014712-5u4e00q6	1339	9	Ugur	Ugur	NNP
cord-014712-5u4e00q6	1339	10	Musabak	Musabak	NNP
cord-014712-5u4e00q6	1339	11	1	1	CD
cord-014712-5u4e00q6	1339	12	;	;	:
cord-014712-5u4e00q6	1339	13	Ozgur	Ozgur	NNP
cord-014712-5u4e00q6	1339	14	Kartal	Kartal	NNP
cord-014712-5u4e00q6	1339	15	1	1	CD
cord-014712-5u4e00q6	1339	16	;	;	:
cord-014712-5u4e00q6	1339	17	Sait	Sait	NNP
cord-014712-5u4e00q6	1339	18	Yesillik	Yesillik	NNP
cord-014712-5u4e00q6	1339	19	1	1	CD
cord-014712-5u4e00q6	1339	20	;	;	:
cord-014712-5u4e00q6	1339	21	Abdullah	Abdullah	NNP
cord-014712-5u4e00q6	1339	22	Baysan	Baysan	NNP
cord-014712-5u4e00q6	1339	23	1	1	CD
cord-014712-5u4e00q6	1340	1	;	;	:
cord-014712-5u4e00q6	1340	2	Ergun	Ergun	NNP
cord-014712-5u4e00q6	1340	3	Ucar	Ucar	NNP
cord-014712-5u4e00q6	1340	4	2	2	CD
cord-014712-5u4e00q6	1340	5	;	;	:
cord-014712-5u4e00q6	1340	6	Osman	Osman	NNP
cord-014712-5u4e00q6	1340	7	Sener	Sener	NNP
cord-014712-5u4e00q6	1340	8	1	1	CD
cord-014712-5u4e00q6	1340	9	1	1	CD
cord-014712-5u4e00q6	1340	10	Gulhane	Gulhane	NNP
cord-014712-5u4e00q6	1340	11	Medical	Medical	NNP
cord-014712-5u4e00q6	1340	12	School	School	NNP
cord-014712-5u4e00q6	1340	13	,	,	,
cord-014712-5u4e00q6	1340	14	Division	Division	NNP
cord-014712-5u4e00q6	1340	15	of	of	IN
cord-014712-5u4e00q6	1340	16	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1340	17	Allergic	Allergic	NNP
cord-014712-5u4e00q6	1340	18	Diseases	Diseases	NNPS
cord-014712-5u4e00q6	1340	19	,	,	,
cord-014712-5u4e00q6	1340	20	Ankara	Ankara	NNP
cord-014712-5u4e00q6	1340	21	,	,	,
cord-014712-5u4e00q6	1340	22	Turkey	Turkey	NNP
cord-014712-5u4e00q6	1340	23	.	.	.
cord-014712-5u4e00q6	1341	1	2	2	LS
cord-014712-5u4e00q6	1342	1	Gulhane	Gulhane	NNP
cord-014712-5u4e00q6	1342	2	Medical	Medical	NNP
cord-014712-5u4e00q6	1342	3	School	School	NNP
cord-014712-5u4e00q6	1342	4	,	,	,
cord-014712-5u4e00q6	1342	5	Department	Department	NNP
cord-014712-5u4e00q6	1342	6	of	of	IN
cord-014712-5u4e00q6	1342	7	Chest	Chest	NNP
cord-014712-5u4e00q6	1342	8	Diseases	Diseases	NNPS
cord-014712-5u4e00q6	1342	9	,	,	,
cord-014712-5u4e00q6	1342	10	Ankara	Ankara	NNP
cord-014712-5u4e00q6	1342	11	,	,	,
cord-014712-5u4e00q6	1342	12	Turkey	Turkey	NNP
cord-014712-5u4e00q6	1342	13	.	.	.
cord-014712-5u4e00q6	1343	1	Introduction	introduction	NN
cord-014712-5u4e00q6	1343	2	:	:	:
cord-014712-5u4e00q6	1344	1	Common	common	JJ
cord-014712-5u4e00q6	1344	2	Variable	variable	JJ
cord-014712-5u4e00q6	1344	3	Immune	immune	JJ
cord-014712-5u4e00q6	1344	4	Deficiency	deficiency	NN
cord-014712-5u4e00q6	1344	5	(	(	-LRB-
cord-014712-5u4e00q6	1344	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1344	7	)	)	-RRB-
cord-014712-5u4e00q6	1344	8	may	may	MD
cord-014712-5u4e00q6	1344	9	present	present	VB
cord-014712-5u4e00q6	1344	10	with	with	IN
cord-014712-5u4e00q6	1344	11	several	several	JJ
cord-014712-5u4e00q6	1344	12	clinical	clinical	JJ
cord-014712-5u4e00q6	1344	13	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1344	14	involved	involve	VBN
cord-014712-5u4e00q6	1344	15	in	in	IN
cord-014712-5u4e00q6	1344	16	different	different	JJ
cord-014712-5u4e00q6	1344	17	organs	organ	NNS
cord-014712-5u4e00q6	1344	18	and	and	CC
cord-014712-5u4e00q6	1344	19	tissues	tissue	NNS
cord-014712-5u4e00q6	1344	20	in	in	IN
cord-014712-5u4e00q6	1344	21	adults	adult	NNS
cord-014712-5u4e00q6	1344	22	.	.	.
cord-014712-5u4e00q6	1345	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1345	2	present	present	VBP
cord-014712-5u4e00q6	1345	3	a	a	DT
cord-014712-5u4e00q6	1345	4	case	case	NN
cord-014712-5u4e00q6	1345	5	with	with	IN
cord-014712-5u4e00q6	1345	6	a	a	DT
cord-014712-5u4e00q6	1345	7	history	history	NN
cord-014712-5u4e00q6	1345	8	of	of	IN
cord-014712-5u4e00q6	1345	9	chronic	chronic	JJ
cord-014712-5u4e00q6	1345	10	cough	cough	NN
cord-014712-5u4e00q6	1345	11	for	for	IN
cord-014712-5u4e00q6	1345	12	more	more	JJR
cord-014712-5u4e00q6	1345	13	than	than	IN
cord-014712-5u4e00q6	1345	14	twenty	twenty	CD
cord-014712-5u4e00q6	1345	15	years	year	NNS
cord-014712-5u4e00q6	1345	16	and	and	CC
cord-014712-5u4e00q6	1345	17	further	further	RB
cord-014712-5u4e00q6	1345	18	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1345	19	as	as	IN
cord-014712-5u4e00q6	1345	20	CVID	CVID	NNP
cord-014712-5u4e00q6	1345	21	.	.	.
cord-014712-5u4e00q6	1346	1	Case	case	NN
cord-014712-5u4e00q6	1346	2	:	:	:
cord-014712-5u4e00q6	1347	1	A	a	DT
cord-014712-5u4e00q6	1347	2	49-year	49-year	JJ
cord-014712-5u4e00q6	1347	3	-	-	HYPH
cord-014712-5u4e00q6	1347	4	old	old	JJ
cord-014712-5u4e00q6	1347	5	male	male	NN
cord-014712-5u4e00q6	1347	6	who	who	WP
cord-014712-5u4e00q6	1347	7	works	work	VBZ
cord-014712-5u4e00q6	1347	8	in	in	IN
cord-014712-5u4e00q6	1347	9	a	a	DT
cord-014712-5u4e00q6	1347	10	chemistry	chemistry	NN
cord-014712-5u4e00q6	1347	11	lab	lab	NN
cord-014712-5u4e00q6	1347	12	admitted	admit	VBN
cord-014712-5u4e00q6	1347	13	to	to	IN
cord-014712-5u4e00q6	1347	14	our	-PRON-	PRP$
cord-014712-5u4e00q6	1347	15	clinic	clinic	NN
cord-014712-5u4e00q6	1347	16	with	with	IN
cord-014712-5u4e00q6	1347	17	a	a	DT
cord-014712-5u4e00q6	1347	18	history	history	NN
cord-014712-5u4e00q6	1347	19	of	of	IN
cord-014712-5u4e00q6	1347	20	frequent	frequent	JJ
cord-014712-5u4e00q6	1347	21	upper	upper	JJ
cord-014712-5u4e00q6	1347	22	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1347	23	tract	tract	NN
cord-014712-5u4e00q6	1347	24	infections	infection	NNS
cord-014712-5u4e00q6	1347	25	for	for	IN
cord-014712-5u4e00q6	1347	26	more	more	JJR
cord-014712-5u4e00q6	1347	27	than	than	IN
cord-014712-5u4e00q6	1347	28	20	20	CD
cord-014712-5u4e00q6	1347	29	years	year	NNS
cord-014712-5u4e00q6	1347	30	.	.	.
cord-014712-5u4e00q6	1348	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1348	2	also	also	RB
cord-014712-5u4e00q6	1348	3	had	have	VBD
cord-014712-5u4e00q6	1348	4	intermittent	intermittent	JJ
cord-014712-5u4e00q6	1348	5	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	1348	6	symptoms	symptom	NNS
cord-014712-5u4e00q6	1348	7	and	and	CC
cord-014712-5u4e00q6	1348	8	his	-PRON-	PRP$
cord-014712-5u4e00q6	1348	9	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1348	10	symptoms	symptom	NNS
cord-014712-5u4e00q6	1348	11	have	have	VBP
cord-014712-5u4e00q6	1348	12	been	be	VBN
cord-014712-5u4e00q6	1348	13	worsened	worsen	VBN
cord-014712-5u4e00q6	1348	14	since	since	IN
cord-014712-5u4e00q6	1348	15	2009	2009	CD
cord-014712-5u4e00q6	1348	16	.	.	.
cord-014712-5u4e00q6	1349	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1349	2	had	have	VBD
cord-014712-5u4e00q6	1349	3	been	be	VBN
cord-014712-5u4e00q6	1349	4	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	1349	5	due	due	IN
cord-014712-5u4e00q6	1349	6	to	to	IN
cord-014712-5u4e00q6	1349	7	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1349	8	and	and	CC
cord-014712-5u4e00q6	1349	9	empyema	empyema	JJ
cord-014712-5u4e00q6	1349	10	several	several	JJ
cord-014712-5u4e00q6	1349	11	times	time	NNS
cord-014712-5u4e00q6	1349	12	.	.	.
cord-014712-5u4e00q6	1350	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1350	2	had	have	VBD
cord-014712-5u4e00q6	1350	3	undergone	undergo	VBN
cord-014712-5u4e00q6	1350	4	left	leave	VBN
cord-014712-5u4e00q6	1350	5	lower	low	JJR
cord-014712-5u4e00q6	1350	6	lobectomy	lobectomy	NN
cord-014712-5u4e00q6	1350	7	due	due	IN
cord-014712-5u4e00q6	1350	8	to	to	IN
cord-014712-5u4e00q6	1350	9	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	1350	10	in	in	IN
cord-014712-5u4e00q6	1350	11	2012	2012	CD
cord-014712-5u4e00q6	1350	12	.	.	.
cord-014712-5u4e00q6	1351	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1351	2	had	have	VBD
cord-014712-5u4e00q6	1351	3	been	be	VBN
cord-014712-5u4e00q6	1351	4	admitted	admit	VBN
cord-014712-5u4e00q6	1351	5	to	to	IN
cord-014712-5u4e00q6	1351	6	intensive	intensive	JJ
cord-014712-5u4e00q6	1351	7	care	care	NN
cord-014712-5u4e00q6	1351	8	unit	unit	NN
cord-014712-5u4e00q6	1351	9	due	due	JJ
cord-014712-5u4e00q6	1351	10	to	to	IN
cord-014712-5u4e00q6	1351	11	worsening	worsen	VBG
cord-014712-5u4e00q6	1351	12	of	of	IN
cord-014712-5u4e00q6	1351	13	his	-PRON-	PRP$
cord-014712-5u4e00q6	1351	14	medical	medical	JJ
cord-014712-5u4e00q6	1351	15	condition	condition	NN
cord-014712-5u4e00q6	1351	16	.	.	.
cord-014712-5u4e00q6	1352	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1352	2	was	be	VBD
cord-014712-5u4e00q6	1352	3	further	further	RB
cord-014712-5u4e00q6	1352	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1352	5	with	with	IN
cord-014712-5u4e00q6	1352	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1352	7	and	and	CC
cord-014712-5u4e00q6	1352	8	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1352	9	treatment	treatment	NN
cord-014712-5u4e00q6	1352	10	was	be	VBD
cord-014712-5u4e00q6	1352	11	initiated	initiate	VBN
cord-014712-5u4e00q6	1352	12	.	.	.
cord-014712-5u4e00q6	1353	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1353	2	is	be	VBZ
cord-014712-5u4e00q6	1353	3	currently	currently	RB
cord-014712-5u4e00q6	1353	4	under	under	IN
cord-014712-5u4e00q6	1353	5	remission	remission	NN
cord-014712-5u4e00q6	1353	6	with	with	IN
cord-014712-5u4e00q6	1353	7	monthly	monthly	JJ
cord-014712-5u4e00q6	1353	8	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1353	9	treatment	treatment	NN
cord-014712-5u4e00q6	1353	10	and	and	CC
cord-014712-5u4e00q6	1353	11	without	without	IN
cord-014712-5u4e00q6	1353	12	any	any	DT
cord-014712-5u4e00q6	1353	13	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1353	14	or	or	CC
cord-014712-5u4e00q6	1353	15	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	1353	16	symptoms	symptom	NNS
cord-014712-5u4e00q6	1353	17	.	.	.
cord-014712-5u4e00q6	1354	1	Discussion	discussion	NN
cord-014712-5u4e00q6	1354	2	and	and	CC
cord-014712-5u4e00q6	1354	3	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1355	1	:	:	:
cord-014712-5u4e00q6	1355	2	CVID	CVID	NNP
cord-014712-5u4e00q6	1355	3	is	be	VBZ
cord-014712-5u4e00q6	1355	4	a	a	DT
cord-014712-5u4e00q6	1355	5	clinical	clinical	JJ
cord-014712-5u4e00q6	1355	6	disorder	disorder	NN
cord-014712-5u4e00q6	1355	7	in	in	IN
cord-014712-5u4e00q6	1355	8	which	which	WDT
cord-014712-5u4e00q6	1355	9	the	the	DT
cord-014712-5u4e00q6	1355	10	humoral	humoral	JJ
cord-014712-5u4e00q6	1355	11	part	part	NN
cord-014712-5u4e00q6	1355	12	of	of	IN
cord-014712-5u4e00q6	1355	13	the	the	DT
cord-014712-5u4e00q6	1355	14	immune	immune	JJ
cord-014712-5u4e00q6	1355	15	system	system	NN
cord-014712-5u4e00q6	1355	16	is	be	VBZ
cord-014712-5u4e00q6	1355	17	affected	affect	VBN
cord-014712-5u4e00q6	1355	18	.	.	.
cord-014712-5u4e00q6	1356	1	Most	most	RBS
cord-014712-5u4e00q6	1356	2	frequent	frequent	JJ
cord-014712-5u4e00q6	1356	3	presenting	present	VBG
cord-014712-5u4e00q6	1356	4	symptoms	symptom	NNS
cord-014712-5u4e00q6	1356	5	belong	belong	VBP
cord-014712-5u4e00q6	1356	6	to	to	IN
cord-014712-5u4e00q6	1356	7	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1356	8	,	,	,
cord-014712-5u4e00q6	1356	9	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	1356	10	systems	system	NNS
cord-014712-5u4e00q6	1356	11	and	and	CC
cord-014712-5u4e00q6	1356	12	skin	skin	NN
cord-014712-5u4e00q6	1356	13	.	.	.
cord-014712-5u4e00q6	1357	1	However	however	RB
cord-014712-5u4e00q6	1357	2	,	,	,
cord-014712-5u4e00q6	1357	3	due	due	IN
cord-014712-5u4e00q6	1357	4	to	to	IN
cord-014712-5u4e00q6	1357	5	the	the	DT
cord-014712-5u4e00q6	1357	6	organ	organ	NN
cord-014712-5u4e00q6	1357	7	specific	specific	JJ
cord-014712-5u4e00q6	1357	8	physical	physical	JJ
cord-014712-5u4e00q6	1357	9	examination	examination	NN
cord-014712-5u4e00q6	1357	10	and	and	CC
cord-014712-5u4e00q6	1357	11	lack	lack	NN
cord-014712-5u4e00q6	1357	12	of	of	IN
cord-014712-5u4e00q6	1357	13	awareness	awareness	NN
cord-014712-5u4e00q6	1357	14	,	,	,
cord-014712-5u4e00q6	1357	15	the	the	DT
cord-014712-5u4e00q6	1357	16	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1357	17	is	be	VBZ
cord-014712-5u4e00q6	1357	18	frequently	frequently	RB
cord-014712-5u4e00q6	1357	19	overlooked	overlook	VBN
cord-014712-5u4e00q6	1357	20	.	.	.
cord-014712-5u4e00q6	1358	1	In	in	IN
cord-014712-5u4e00q6	1358	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	1358	3	case	case	NN
cord-014712-5u4e00q6	1358	4	,	,	,
cord-014712-5u4e00q6	1358	5	frequent	frequent	JJ
cord-014712-5u4e00q6	1358	6	upper	upper	JJ
cord-014712-5u4e00q6	1358	7	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1358	8	infection	infection	NN
cord-014712-5u4e00q6	1358	9	,	,	,
cord-014712-5u4e00q6	1358	10	loss	loss	NN
cord-014712-5u4e00q6	1358	11	of	of	IN
cord-014712-5u4e00q6	1358	12	weight	weight	NN
cord-014712-5u4e00q6	1358	13	,	,	,
cord-014712-5u4e00q6	1358	14	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	1358	15	,	,	,
cord-014712-5u4e00q6	1358	16	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	1358	17	and	and	CC
cord-014712-5u4e00q6	1358	18	empyema	empyema	NN
cord-014712-5u4e00q6	1358	19	with	with	IN
cord-014712-5u4e00q6	1358	20	unknown	unknown	JJ
cord-014712-5u4e00q6	1358	21	etiology	etiology	NN
cord-014712-5u4e00q6	1358	22	are	be	VBP
cord-014712-5u4e00q6	1358	23	the	the	DT
cord-014712-5u4e00q6	1358	24	most	most	RBS
cord-014712-5u4e00q6	1358	25	informative	informative	JJ
cord-014712-5u4e00q6	1358	26	clinical	clinical	JJ
cord-014712-5u4e00q6	1358	27	signs	sign	NNS
cord-014712-5u4e00q6	1358	28	.	.	.
cord-014712-5u4e00q6	1359	1	Medical	medical	JJ
cord-014712-5u4e00q6	1359	2	history	history	NN
cord-014712-5u4e00q6	1359	3	is	be	VBZ
cord-014712-5u4e00q6	1359	4	the	the	DT
cord-014712-5u4e00q6	1359	5	most	most	RBS
cord-014712-5u4e00q6	1359	6	important	important	JJ
cord-014712-5u4e00q6	1359	7	part	part	NN
cord-014712-5u4e00q6	1359	8	of	of	IN
cord-014712-5u4e00q6	1359	9	patient	patient	JJ
cord-014712-5u4e00q6	1359	10	evaluation	evaluation	NN
cord-014712-5u4e00q6	1359	11	.	.	.
cord-014712-5u4e00q6	1360	1	Immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1360	2	replacement	replacement	NN
cord-014712-5u4e00q6	1360	3	therapy	therapy	NN
cord-014712-5u4e00q6	1360	4	is	be	VBZ
cord-014712-5u4e00q6	1360	5	a	a	DT
cord-014712-5u4e00q6	1360	6	basic	basic	JJ
cord-014712-5u4e00q6	1360	7	treatment	treatment	NN
cord-014712-5u4e00q6	1360	8	in	in	IN
cord-014712-5u4e00q6	1360	9	primary	primary	JJ
cord-014712-5u4e00q6	1360	10	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1360	11	deficiency	deficiency	NN
cord-014712-5u4e00q6	1360	12	disorders	disorder	NNS
cord-014712-5u4e00q6	1360	13	.	.	.
cord-014712-5u4e00q6	1361	1	Immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1361	2	substitution	substitution	NN
cord-014712-5u4e00q6	1361	3	can	can	MD
cord-014712-5u4e00q6	1361	4	be	be	VB
cord-014712-5u4e00q6	1361	5	given	give	VBN
cord-014712-5u4e00q6	1361	6	intravenously	intravenously	RB
cord-014712-5u4e00q6	1361	7	(	(	-LRB-
cord-014712-5u4e00q6	1361	8	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1361	9	)	)	-RRB-
cord-014712-5u4e00q6	1361	10	or	or	CC
cord-014712-5u4e00q6	1361	11	subcutaneously	subcutaneously	RB
cord-014712-5u4e00q6	1361	12	(	(	-LRB-
cord-014712-5u4e00q6	1361	13	SCIG	SCIG	NNP
cord-014712-5u4e00q6	1361	14	)	)	-RRB-
cord-014712-5u4e00q6	1361	15	for	for	IN
cord-014712-5u4e00q6	1361	16	patients	patient	NNS
cord-014712-5u4e00q6	1361	17	with	with	IN
cord-014712-5u4e00q6	1361	18	antibody	antibody	NN
cord-014712-5u4e00q6	1361	19	deficiency	deficiency	NN
cord-014712-5u4e00q6	1361	20	.	.	.
cord-014712-5u4e00q6	1362	1	Both	both	DT
cord-014712-5u4e00q6	1362	2	of	of	IN
cord-014712-5u4e00q6	1362	3	these	these	DT
cord-014712-5u4e00q6	1362	4	treatments	treatment	NNS
cord-014712-5u4e00q6	1362	5	are	be	VBP
cord-014712-5u4e00q6	1362	6	effective	effective	JJ
cord-014712-5u4e00q6	1362	7	in	in	IN
cord-014712-5u4e00q6	1362	8	prevention	prevention	NN
cord-014712-5u4e00q6	1362	9	and	and	CC
cord-014712-5u4e00q6	1362	10	cure	cure	NN
cord-014712-5u4e00q6	1362	11	of	of	IN
cord-014712-5u4e00q6	1362	12	infections	infection	NNS
cord-014712-5u4e00q6	1362	13	,	,	,
cord-014712-5u4e00q6	1362	14	although	although	IN
cord-014712-5u4e00q6	1362	15	differences	difference	NNS
cord-014712-5u4e00q6	1362	16	in	in	IN
cord-014712-5u4e00q6	1362	17	advers	advers	NNP
cord-014712-5u4e00q6	1362	18	events	event	NNS
cord-014712-5u4e00q6	1362	19	profile	profile	VBP
cord-014712-5u4e00q6	1362	20	and	and	CC
cord-014712-5u4e00q6	1362	21	patients	patient	NNS
cord-014712-5u4e00q6	1362	22	'	'	POS
cord-014712-5u4e00q6	1362	23	quality	quality	NN
cord-014712-5u4e00q6	1362	24	of	of	IN
cord-014712-5u4e00q6	1362	25	life	life	NN
cord-014712-5u4e00q6	1362	26	can	can	MD
cord-014712-5u4e00q6	1362	27	be	be	VB
cord-014712-5u4e00q6	1362	28	seen	see	VBN
cord-014712-5u4e00q6	1362	29	.	.	.
cord-014712-5u4e00q6	1363	1	The	the	DT
cord-014712-5u4e00q6	1363	2	authors	author	NNS
cord-014712-5u4e00q6	1363	3	describe	describe	VBP
cord-014712-5u4e00q6	1363	4	here	here	RB
cord-014712-5u4e00q6	1363	5	their	-PRON-	PRP$
cord-014712-5u4e00q6	1363	6	experiences	experience	NNS
cord-014712-5u4e00q6	1363	7	in	in	IN
cord-014712-5u4e00q6	1363	8	switching	switch	VBG
cord-014712-5u4e00q6	1363	9	patients	patient	NNS
cord-014712-5u4e00q6	1363	10	from	from	IN
cord-014712-5u4e00q6	1363	11	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1363	12	treatment	treatment	NN
cord-014712-5u4e00q6	1363	13	to	to	IN
cord-014712-5u4e00q6	1363	14	SCIG	SCIG	NNP
cord-014712-5u4e00q6	1363	15	and	and	CC
cord-014712-5u4e00q6	1363	16	a	a	DT
cord-014712-5u4e00q6	1363	17	few	few	JJ
cord-014712-5u4e00q6	1363	18	years	year	NNS
cord-014712-5u4e00q6	1363	19	observation	observation	NN
cord-014712-5u4e00q6	1363	20	of	of	IN
cord-014712-5u4e00q6	1363	21	SCIG	SCIG	NNP
cord-014712-5u4e00q6	1363	22	therapy	therapy	NN
cord-014712-5u4e00q6	1363	23	of	of	IN
cord-014712-5u4e00q6	1363	24	patients	patient	NNS
cord-014712-5u4e00q6	1363	25	with	with	IN
cord-014712-5u4e00q6	1363	26	antibody	antibody	NN
cord-014712-5u4e00q6	1363	27	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1363	28	.	.	.
cord-014712-5u4e00q6	1364	1	Sirje	Sirje	NNP
cord-014712-5u4e00q6	1364	2	Velbri	Velbri	NNP
cord-014712-5u4e00q6	1364	3	1	1	CD
cord-014712-5u4e00q6	1364	4	,	,	,
cord-014712-5u4e00q6	1364	5	Mirja	Mirja	NNP
cord-014712-5u4e00q6	1364	6	Varik	Varik	NNP
cord-014712-5u4e00q6	1365	1	2	2	CD
cord-014712-5u4e00q6	1365	2	1	1	CD
cord-014712-5u4e00q6	1365	3	Tallinn	Tallinn	NNP
cord-014712-5u4e00q6	1365	4	Children	Children	NNPS
cord-014712-5u4e00q6	1365	5	's	's	POS
cord-014712-5u4e00q6	1365	6	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1365	7	,	,	,
cord-014712-5u4e00q6	1365	8	Tallinn	Tallinn	NNP
cord-014712-5u4e00q6	1365	9	,	,	,
cord-014712-5u4e00q6	1365	10	Estonia	Estonia	NNP
cord-014712-5u4e00q6	1365	11	.	.	.
cord-014712-5u4e00q6	1366	1	2	2	CD
cord-014712-5u4e00q6	1366	2	North	north	JJ
cord-014712-5u4e00q6	1366	3	-	-	HYPH
cord-014712-5u4e00q6	1366	4	Estonian	Estonian	NNP
cord-014712-5u4e00q6	1366	5	Regional	Regional	NNP
cord-014712-5u4e00q6	1366	6	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1366	7	,	,	,
cord-014712-5u4e00q6	1366	8	Tallinn	Tallinn	NNP
cord-014712-5u4e00q6	1366	9	,	,	,
cord-014712-5u4e00q6	1366	10	Estonia	Estonia	NNP
cord-014712-5u4e00q6	1366	11	.	.	.
cord-014712-5u4e00q6	1367	1	J	J	NNP
cord-014712-5u4e00q6	1367	2	Clin	Clin	NNP
cord-014712-5u4e00q6	1367	3	Immunol	Immunol	NNP
cord-014712-5u4e00q6	1367	4	(	(	-LRB-
cord-014712-5u4e00q6	1367	5	2014	2014	CD
cord-014712-5u4e00q6	1367	6	)	)	-RRB-
cord-014712-5u4e00q6	1367	7	34:696	34:696	CD
cord-014712-5u4e00q6	1367	8	-	-	SYM
cord-014712-5u4e00q6	1367	9	747	747	CD
cord-014712-5u4e00q6	1367	10	Antibody	Antibody	NNP
cord-014712-5u4e00q6	1367	11	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1367	12	are	be	VBP
cord-014712-5u4e00q6	1367	13	the	the	DT
cord-014712-5u4e00q6	1367	14	most	most	RBS
cord-014712-5u4e00q6	1367	15	common	common	JJ
cord-014712-5u4e00q6	1367	16	group	group	NN
cord-014712-5u4e00q6	1367	17	of	of	IN
cord-014712-5u4e00q6	1367	18	primary	primary	JJ
cord-014712-5u4e00q6	1367	19	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1367	20	.	.	.
cord-014712-5u4e00q6	1368	1	The	the	DT
cord-014712-5u4e00q6	1368	2	main	main	JJ
cord-014712-5u4e00q6	1368	3	hallmark	hallmark	NN
cord-014712-5u4e00q6	1368	4	of	of	IN
cord-014712-5u4e00q6	1368	5	antibody	antibody	NN
cord-014712-5u4e00q6	1368	6	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1368	7	are	be	VBP
cord-014712-5u4e00q6	1368	8	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1368	9	infections	infection	NNS
cord-014712-5u4e00q6	1368	10	but	but	CC
cord-014712-5u4e00q6	1368	11	the	the	DT
cord-014712-5u4e00q6	1368	12	patients	patient	NNS
cord-014712-5u4e00q6	1368	13	have	have	VBP
cord-014712-5u4e00q6	1368	14	also	also	RB
cord-014712-5u4e00q6	1368	15	higher	high	JJR
cord-014712-5u4e00q6	1368	16	risk	risk	NN
cord-014712-5u4e00q6	1368	17	of	of	IN
cord-014712-5u4e00q6	1368	18	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1368	19	and	and	CC
cord-014712-5u4e00q6	1368	20	allergic	allergic	JJ
cord-014712-5u4e00q6	1368	21	diseases	disease	NNS
cord-014712-5u4e00q6	1368	22	.	.	.
cord-014712-5u4e00q6	1369	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1369	2	analysed	analyse	VBD
cord-014712-5u4e00q6	1369	3	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	1369	4	the	the	DT
cord-014712-5u4e00q6	1369	5	frequency	frequency	NN
cord-014712-5u4e00q6	1369	6	and	and	CC
cord-014712-5u4e00q6	1369	7	character	character	NN
cord-014712-5u4e00q6	1369	8	of	of	IN
cord-014712-5u4e00q6	1369	9	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1369	10	diseases	disease	NNS
cord-014712-5u4e00q6	1369	11	in	in	IN
cord-014712-5u4e00q6	1369	12	159	159	CD
cord-014712-5u4e00q6	1369	13	patients	patient	NNS
cord-014712-5u4e00q6	1369	14	(	(	-LRB-
cord-014712-5u4e00q6	1369	15	98	98	CD
cord-014712-5u4e00q6	1369	16	children	child	NNS
cord-014712-5u4e00q6	1369	17	and	and	CC
cord-014712-5u4e00q6	1369	18	61	61	CD
cord-014712-5u4e00q6	1369	19	adult	adult	NN
cord-014712-5u4e00q6	1369	20	patients	patient	NNS
cord-014712-5u4e00q6	1369	21	)	)	-RRB-
cord-014712-5u4e00q6	1369	22	with	with	IN
cord-014712-5u4e00q6	1369	23	primary	primary	JJ
cord-014712-5u4e00q6	1369	24	antibody	antibody	NN
cord-014712-5u4e00q6	1369	25	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1369	26	.	.	.
cord-014712-5u4e00q6	1370	1	There	there	EX
cord-014712-5u4e00q6	1370	2	were	be	VBD
cord-014712-5u4e00q6	1370	3	ana	ana	JJ
cord-014712-5u4e00q6	1370	4	-	-	HYPH
cord-014712-5u4e00q6	1370	5	lysed	lyse	VBN
cord-014712-5u4e00q6	1370	6	2	2	CD
cord-014712-5u4e00q6	1370	7	patients	patient	NNS
cord-014712-5u4e00q6	1370	8	with	with	IN
cord-014712-5u4e00q6	1370	9	XLA	XLA	NNP
cord-014712-5u4e00q6	1370	10	,	,	,
cord-014712-5u4e00q6	1370	11	24	24	CD
cord-014712-5u4e00q6	1370	12	patients	patient	NNS
cord-014712-5u4e00q6	1370	13	with	with	IN
cord-014712-5u4e00q6	1370	14	CVID	CVID	NNP
cord-014712-5u4e00q6	1370	15	,	,	,
cord-014712-5u4e00q6	1370	16	65	65	CD
cord-014712-5u4e00q6	1370	17	patients	patient	NNS
cord-014712-5u4e00q6	1370	18	with	with	IN
cord-014712-5u4e00q6	1370	19	selective	selective	JJ
cord-014712-5u4e00q6	1370	20	IgA	IgA	NNP
cord-014712-5u4e00q6	1370	21	deficiency	deficiency	NN
cord-014712-5u4e00q6	1370	22	,	,	,
cord-014712-5u4e00q6	1370	23	26	26	CD
cord-014712-5u4e00q6	1370	24	pa	pa	NNP
cord-014712-5u4e00q6	1370	25	-	-	HYPH
cord-014712-5u4e00q6	1370	26	tients	tients	NNP
cord-014712-5u4e00q6	1370	27	with	with	IN
cord-014712-5u4e00q6	1370	28	IgA	IgA	NNP
cord-014712-5u4e00q6	1370	29	/	/	SYM
cord-014712-5u4e00q6	1370	30	IgG	IgG	NNP
cord-014712-5u4e00q6	1370	31	subclass	subclass	NN
cord-014712-5u4e00q6	1370	32	deficiency	deficiency	NN
cord-014712-5u4e00q6	1370	33	and	and	CC
cord-014712-5u4e00q6	1370	34	42	42	CD
cord-014712-5u4e00q6	1370	35	patients	patient	NNS
cord-014712-5u4e00q6	1370	36	with	with	IN
cord-014712-5u4e00q6	1370	37	isolated	isolate	VBN
cord-014712-5u4e00q6	1370	38	IgG	igg	NN
cord-014712-5u4e00q6	1370	39	subclass	subclass	NN
cord-014712-5u4e00q6	1370	40	deficiency	deficiency	NN
cord-014712-5u4e00q6	1370	41	.	.	.
cord-014712-5u4e00q6	1371	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1371	2	diseases	disease	NNS
cord-014712-5u4e00q6	1371	3	were	be	VBD
cord-014712-5u4e00q6	1371	4	found	find	VBN
cord-014712-5u4e00q6	1371	5	in	in	IN
cord-014712-5u4e00q6	1371	6	39	39	CD
cord-014712-5u4e00q6	1371	7	patients	patient	NNS
cord-014712-5u4e00q6	1371	8	(	(	-LRB-
cord-014712-5u4e00q6	1371	9	24,5	24,5	CD
cord-014712-5u4e00q6	1371	10	%	%	NN
cord-014712-5u4e00q6	1371	11	)	)	-RRB-
cord-014712-5u4e00q6	1371	12	besides	besides	IN
cord-014712-5u4e00q6	1371	13	in	in	IN
cord-014712-5u4e00q6	1371	14	17	17	CD
cord-014712-5u4e00q6	1371	15	children	child	NNS
cord-014712-5u4e00q6	1371	16	(	(	-LRB-
cord-014712-5u4e00q6	1371	17	17	17	CD
cord-014712-5u4e00q6	1371	18	%	%	NN
cord-014712-5u4e00q6	1371	19	)	)	-RRB-
cord-014712-5u4e00q6	1371	20	and	and	CC
cord-014712-5u4e00q6	1371	21	in	in	IN
cord-014712-5u4e00q6	1371	22	22	22	CD
cord-014712-5u4e00q6	1371	23	adult	adult	NN
cord-014712-5u4e00q6	1371	24	patients	patient	NNS
cord-014712-5u4e00q6	1371	25	(	(	-LRB-
cord-014712-5u4e00q6	1371	26	36	36	CD
cord-014712-5u4e00q6	1371	27	%	%	NN
cord-014712-5u4e00q6	1371	28	)	)	-RRB-
cord-014712-5u4e00q6	1371	29	.	.	.
cord-014712-5u4e00q6	1372	1	In	in	IN
cord-014712-5u4e00q6	1372	2	two	two	CD
cord-014712-5u4e00q6	1372	3	boys	boy	NNS
cord-014712-5u4e00q6	1372	4	with	with	IN
cord-014712-5u4e00q6	1372	5	XLA	XLA	NNP
cord-014712-5u4e00q6	1372	6	there	there	EX
cord-014712-5u4e00q6	1372	7	was	be	VBD
cord-014712-5u4e00q6	1372	8	not	not	RB
cord-014712-5u4e00q6	1372	9	found	find	VBN
cord-014712-5u4e00q6	1372	10	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1372	11	diseases	disease	NNS
cord-014712-5u4e00q6	1372	12	but	but	CC
cord-014712-5u4e00q6	1372	13	in	in	IN
cord-014712-5u4e00q6	1372	14	patients	patient	NNS
cord-014712-5u4e00q6	1372	15	with	with	IN
cord-014712-5u4e00q6	1372	16	other	other	JJ
cord-014712-5u4e00q6	1372	17	forms	form	NNS
cord-014712-5u4e00q6	1372	18	of	of	IN
cord-014712-5u4e00q6	1372	19	antibody	antibody	NN
cord-014712-5u4e00q6	1372	20	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1372	21	in	in	IN
cord-014712-5u4e00q6	1372	22	12	12	CD
cord-014712-5u4e00q6	1372	23	-	-	SYM
cord-014712-5u4e00q6	1372	24	57	57	CD
cord-014712-5u4e00q6	1372	25	%	%	NN
cord-014712-5u4e00q6	1372	26	of	of	IN
cord-014712-5u4e00q6	1372	27	cases	case	NNS
cord-014712-5u4e00q6	1372	28	.	.	.
cord-014712-5u4e00q6	1373	1	Autoiimmune	Autoiimmune	NNP
cord-014712-5u4e00q6	1373	2	diseases	disease	NNS
cord-014712-5u4e00q6	1373	3	were	be	VBD
cord-014712-5u4e00q6	1373	4	found	find	VBN
cord-014712-5u4e00q6	1373	5	more	more	RBR
cord-014712-5u4e00q6	1373	6	often	often	RB
cord-014712-5u4e00q6	1373	7	in	in	IN
cord-014712-5u4e00q6	1373	8	IgA	IgA	NNP
cord-014712-5u4e00q6	1373	9	/	/	SYM
cord-014712-5u4e00q6	1373	10	IgG	IgG	NNP
cord-014712-5u4e00q6	1373	11	subclass	subclass	NN
cord-014712-5u4e00q6	1373	12	defi	defi	NNP
cord-014712-5u4e00q6	1373	13	-	-	HYPH
cord-014712-5u4e00q6	1373	14	ciency	ciency	NN
cord-014712-5u4e00q6	1373	15	(	(	-LRB-
cord-014712-5u4e00q6	1373	16	57	57	CD
cord-014712-5u4e00q6	1373	17	%	%	NN
cord-014712-5u4e00q6	1373	18	)	)	-RRB-
cord-014712-5u4e00q6	1373	19	than	than	IN
cord-014712-5u4e00q6	1373	20	in	in	IN
cord-014712-5u4e00q6	1373	21	other	other	JJ
cord-014712-5u4e00q6	1373	22	forms	form	NNS
cord-014712-5u4e00q6	1373	23	of	of	IN
cord-014712-5u4e00q6	1373	24	antibody	antibody	NN
cord-014712-5u4e00q6	1373	25	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1373	26	(	(	-LRB-
cord-014712-5u4e00q6	1373	27	0	0	CD
cord-014712-5u4e00q6	1373	28	-	-	SYM
cord-014712-5u4e00q6	1373	29	25	25	CD
cord-014712-5u4e00q6	1373	30	%	%	NN
cord-014712-5u4e00q6	1373	31	)	)	-RRB-
cord-014712-5u4e00q6	1373	32	.	.	.
cord-014712-5u4e00q6	1374	1	The	the	DT
cord-014712-5u4e00q6	1374	2	spectrum	spectrum	NN
cord-014712-5u4e00q6	1374	3	of	of	IN
cord-014712-5u4e00q6	1374	4	auto	auto	NN
cord-014712-5u4e00q6	1374	5	-	-	HYPH
cord-014712-5u4e00q6	1374	6	immune	immune	JJ
cord-014712-5u4e00q6	1374	7	diseases	disease	NNS
cord-014712-5u4e00q6	1374	8	differed	differ	VBD
cord-014712-5u4e00q6	1374	9	in	in	IN
cord-014712-5u4e00q6	1374	10	adults	adult	NNS
cord-014712-5u4e00q6	1374	11	and	and	CC
cord-014712-5u4e00q6	1374	12	child	child	NN
cord-014712-5u4e00q6	1374	13	-	-	HYPH
cord-014712-5u4e00q6	1374	14	ren	ren	NN
cord-014712-5u4e00q6	1374	15	and	and	CC
cord-014712-5u4e00q6	1374	16	in	in	IN
cord-014712-5u4e00q6	1374	17	different	different	JJ
cord-014712-5u4e00q6	1374	18	forms	form	NNS
cord-014712-5u4e00q6	1374	19	of	of	IN
cord-014712-5u4e00q6	1374	20	antibody	antibody	NN
cord-014712-5u4e00q6	1374	21	de	de	NNP
cord-014712-5u4e00q6	1374	22	-	-	HYPH
cord-014712-5u4e00q6	1374	23	ficiencies	ficiencie	NNS
cord-014712-5u4e00q6	1374	24	.	.	.
cord-014712-5u4e00q6	1375	1	Immune	immune	JJ
cord-014712-5u4e00q6	1375	2	thrombocytopenia	thrombocytopenia	NN
cord-014712-5u4e00q6	1375	3	was	be	VBD
cord-014712-5u4e00q6	1375	4	found	find	VBN
cord-014712-5u4e00q6	1375	5	in	in	IN
cord-014712-5u4e00q6	1375	6	adult	adult	NN
cord-014712-5u4e00q6	1375	7	patients	patient	NNS
cord-014712-5u4e00q6	1375	8	with	with	IN
cord-014712-5u4e00q6	1375	9	CVID	CVID	NNP
cord-014712-5u4e00q6	1375	10	or	or	CC
cord-014712-5u4e00q6	1375	11	IgG	IgG	NNP
cord-014712-5u4e00q6	1375	12	subclass	subclass	NNP
cord-014712-5u4e00q6	1375	13	deficien	deficien	NNP
cord-014712-5u4e00q6	1375	14	-	-	HYPH
cord-014712-5u4e00q6	1375	15	cy	cy	NNP
cord-014712-5u4e00q6	1375	16	,	,	,
cord-014712-5u4e00q6	1375	17	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1375	18	connective	connective	JJ
cord-014712-5u4e00q6	1375	19	tissue	tissue	NN
cord-014712-5u4e00q6	1375	20	disorders	disorder	NNS
cord-014712-5u4e00q6	1375	21	in	in	IN
cord-014712-5u4e00q6	1375	22	IgA	IgA	NNP
cord-014712-5u4e00q6	1375	23	and	and	CC
cord-014712-5u4e00q6	1375	24	IgA	IgA	NNP
cord-014712-5u4e00q6	1375	25	/	/	SYM
cord-014712-5u4e00q6	1375	26	IgG	IgG	NNP
cord-014712-5u4e00q6	1375	27	subclass	subclass	NN
cord-014712-5u4e00q6	1375	28	deficiency	deficiency	NN
cord-014712-5u4e00q6	1375	29	.	.	.
cord-014712-5u4e00q6	1376	1	In	in	IN
cord-014712-5u4e00q6	1376	2	children	child	NNS
cord-014712-5u4e00q6	1376	3	there	there	RB
cord-014712-5u4e00q6	1376	4	was	be	VBD
cord-014712-5u4e00q6	1376	5	found	find	VBN
cord-014712-5u4e00q6	1376	6	mainly	mainly	RB
cord-014712-5u4e00q6	1376	7	thyroiditis	thyroiditis	NN
cord-014712-5u4e00q6	1376	8	,	,	,
cord-014712-5u4e00q6	1376	9	diabetes	diabetes	NN
cord-014712-5u4e00q6	1376	10	I	-PRON-	PRP
cord-014712-5u4e00q6	1376	11	type	type	NN
cord-014712-5u4e00q6	1376	12	and	and	CC
cord-014712-5u4e00q6	1376	13	juvenile	juvenile	JJ
cord-014712-5u4e00q6	1376	14	arthritis	arthritis	NN
cord-014712-5u4e00q6	1376	15	.	.	.
cord-014712-5u4e00q6	1377	1	Rostov	Rostov	NNP
cord-014712-5u4e00q6	1377	2	State	State	NNP
cord-014712-5u4e00q6	1377	3	Medical	Medical	NNP
cord-014712-5u4e00q6	1377	4	University	University	NNP
cord-014712-5u4e00q6	1377	5	.	.	.
cord-014712-5u4e00q6	1378	1	Research	Research	NNP
cord-014712-5u4e00q6	1378	2	Institute	Institute	NNP
cord-014712-5u4e00q6	1378	3	of	of	IN
cord-014712-5u4e00q6	1378	4	Clinical	Clinical	NNP
cord-014712-5u4e00q6	1378	5	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1378	6	,	,	,
cord-014712-5u4e00q6	1378	7	Rostov	Rostov	NNP
cord-014712-5u4e00q6	1378	8	-	-	HYPH
cord-014712-5u4e00q6	1378	9	on	on	IN
cord-014712-5u4e00q6	1378	10	-	-	HYPH
cord-014712-5u4e00q6	1378	11	Don	Don	NNP
cord-014712-5u4e00q6	1378	12	,	,	,
cord-014712-5u4e00q6	1378	13	Russia	Russia	NNP
cord-014712-5u4e00q6	1378	14	.	.	.
cord-014712-5u4e00q6	1379	1	Primary	primary	JJ
cord-014712-5u4e00q6	1379	2	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	1379	3	(	(	-LRB-
cord-014712-5u4e00q6	1379	4	PI	PI	NNP
cord-014712-5u4e00q6	1379	5	)	)	-RRB-
cord-014712-5u4e00q6	1379	6	is	be	VBZ
cord-014712-5u4e00q6	1379	7	currently	currently	RB
cord-014712-5u4e00q6	1379	8	one	one	CD
cord-014712-5u4e00q6	1379	9	of	of	IN
cord-014712-5u4e00q6	1379	10	most	most	RBS
cord-014712-5u4e00q6	1379	11	important	important	JJ
cord-014712-5u4e00q6	1379	12	genetically	genetically	RB
cord-014712-5u4e00q6	1379	13	determined	determine	VBN
cord-014712-5u4e00q6	1379	14	immunological	immunological	JJ
cord-014712-5u4e00q6	1379	15	clinical	clinical	JJ
cord-014712-5u4e00q6	1379	16	pathology	pathology	NN
cord-014712-5u4e00q6	1379	17	which	which	WDT
cord-014712-5u4e00q6	1379	18	is	be	VBZ
cord-014712-5u4e00q6	1379	19	hard	hard	JJ
cord-014712-5u4e00q6	1379	20	to	to	TO
cord-014712-5u4e00q6	1379	21	manage	manage	VB
cord-014712-5u4e00q6	1379	22	.	.	.
cord-014712-5u4e00q6	1380	1	Among	among	IN
cord-014712-5u4e00q6	1380	2	different	different	JJ
cord-014712-5u4e00q6	1380	3	types	type	NNS
cord-014712-5u4e00q6	1380	4	of	of	IN
cord-014712-5u4e00q6	1380	5	PIs	pi	NNS
cord-014712-5u4e00q6	1380	6	almost	almost	RB
cord-014712-5u4e00q6	1380	7	60	60	CD
cord-014712-5u4e00q6	1380	8	%	%	NN
cord-014712-5u4e00q6	1380	9	of	of	IN
cord-014712-5u4e00q6	1380	10	cases	case	NNS
cord-014712-5u4e00q6	1380	11	occurs	occur	VBZ
cord-014712-5u4e00q6	1380	12	due	due	IN
cord-014712-5u4e00q6	1380	13	to	to	IN
cord-014712-5u4e00q6	1380	14	a	a	DT
cord-014712-5u4e00q6	1380	15	deficiency	deficiency	NN
cord-014712-5u4e00q6	1380	16	in	in	IN
cord-014712-5u4e00q6	1380	17	antibodies	antibody	NNS
cord-014712-5u4e00q6	1380	18	production	production	NN
cord-014712-5u4e00q6	1380	19	.	.	.
cord-014712-5u4e00q6	1381	1	Injections	injection	NNS
cord-014712-5u4e00q6	1381	2	of	of	IN
cord-014712-5u4e00q6	1381	3	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1381	4	are	be	VBP
cord-014712-5u4e00q6	1381	5	current	current	JJ
cord-014712-5u4e00q6	1381	6	standard	standard	NN
cord-014712-5u4e00q6	1381	7	in	in	IN
cord-014712-5u4e00q6	1381	8	the	the	DT
cord-014712-5u4e00q6	1381	9	management	management	NN
cord-014712-5u4e00q6	1381	10	of	of	IN
cord-014712-5u4e00q6	1381	11	PI	PI	NNP
cord-014712-5u4e00q6	1381	12	.	.	.
cord-014712-5u4e00q6	1382	1	However	however	RB
cord-014712-5u4e00q6	1382	2	this	this	DT
cord-014712-5u4e00q6	1382	3	treatment	treatment	NN
cord-014712-5u4e00q6	1382	4	is	be	VBZ
cord-014712-5u4e00q6	1382	5	expensive	expensive	JJ
cord-014712-5u4e00q6	1382	6	,	,	,
cord-014712-5u4e00q6	1382	7	often	often	RB
cord-014712-5u4e00q6	1382	8	is	be	VBZ
cord-014712-5u4e00q6	1382	9	hard	hard	JJ
cord-014712-5u4e00q6	1382	10	for	for	IN
cord-014712-5u4e00q6	1382	11	patients	patient	NNS
cord-014712-5u4e00q6	1382	12	,	,	,
cord-014712-5u4e00q6	1382	13	and	and	CC
cord-014712-5u4e00q6	1382	14	frequently	frequently	RB
cord-014712-5u4e00q6	1382	15	has	have	VBZ
cord-014712-5u4e00q6	1382	16	limited	limit	VBN
cord-014712-5u4e00q6	1382	17	effectiveness	effectiveness	NN
cord-014712-5u4e00q6	1382	18	.	.	.
cord-014712-5u4e00q6	1383	1	Substitution	substitution	NN
cord-014712-5u4e00q6	1383	2	of	of	IN
cord-014712-5u4e00q6	1383	3	immune	immune	JJ
cord-014712-5u4e00q6	1383	4	proteins	protein	NNS
cord-014712-5u4e00q6	1383	5	frequently	frequently	RB
cord-014712-5u4e00q6	1383	6	is	be	VBZ
cord-014712-5u4e00q6	1383	7	inefficient	inefficient	JJ
cord-014712-5u4e00q6	1383	8	for	for	IN
cord-014712-5u4e00q6	1383	9	treatment	treatment	NN
cord-014712-5u4e00q6	1383	10	of	of	IN
cord-014712-5u4e00q6	1383	11	severe	severe	JJ
cord-014712-5u4e00q6	1383	12	infectious	infectious	JJ
cord-014712-5u4e00q6	1383	13	conditions	condition	NNS
cord-014712-5u4e00q6	1383	14	in	in	IN
cord-014712-5u4e00q6	1383	15	PI	pi	NN
cord-014712-5u4e00q6	1383	16	patients	patient	NNS
cord-014712-5u4e00q6	1383	17	.	.	.
cord-014712-5u4e00q6	1384	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1384	2	investigated	investigate	VBD
cord-014712-5u4e00q6	1384	3	maturation	maturation	NN
cord-014712-5u4e00q6	1384	4	,	,	,
cord-014712-5u4e00q6	1384	5	activation	activation	NN
cord-014712-5u4e00q6	1384	6	and	and	CC
cord-014712-5u4e00q6	1384	7	differentiation	differentiation	NN
cord-014712-5u4e00q6	1384	8	of	of	IN
cord-014712-5u4e00q6	1384	9	immune	immune	JJ
cord-014712-5u4e00q6	1384	10	T	t	NN
cord-014712-5u4e00q6	1384	11	-	-	HYPH
cord-014712-5u4e00q6	1384	12	cells	cell	NNS
cord-014712-5u4e00q6	1384	13	in	in	IN
cord-014712-5u4e00q6	1384	14	the	the	DT
cord-014712-5u4e00q6	1384	15	dynamics	dynamic	NNS
cord-014712-5u4e00q6	1384	16	of	of	IN
cord-014712-5u4e00q6	1384	17	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1384	18	replacement	replacement	NN
cord-014712-5u4e00q6	1384	19	therapy	therapy	NN
cord-014712-5u4e00q6	1384	20	.	.	.
cord-014712-5u4e00q6	1385	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1385	2	observed	observe	VBD
cord-014712-5u4e00q6	1385	3	patients	patient	NNS
cord-014712-5u4e00q6	1385	4	with	with	IN
cord-014712-5u4e00q6	1385	5	with	with	IN
cord-014712-5u4e00q6	1385	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1385	7	(	(	-LRB-
cord-014712-5u4e00q6	1385	8	7	7	CD
cord-014712-5u4e00q6	1385	9	)	)	-RRB-
cord-014712-5u4e00q6	1385	10	and	and	CC
cord-014712-5u4e00q6	1385	11	XLA	XLA	NNP
cord-014712-5u4e00q6	1385	12	(	(	-LRB-
cord-014712-5u4e00q6	1385	13	5	5	CD
cord-014712-5u4e00q6	1385	14	people	people	NNS
cord-014712-5u4e00q6	1385	15	)	)	-RRB-
cord-014712-5u4e00q6	1385	16	over	over	IN
cord-014712-5u4e00q6	1385	17	a	a	DT
cord-014712-5u4e00q6	1385	18	year	year	NN
cord-014712-5u4e00q6	1385	19	of	of	IN
cord-014712-5u4e00q6	1385	20	regular	regular	JJ
cord-014712-5u4e00q6	1385	21	replacement	replacement	NN
cord-014712-5u4e00q6	1385	22	therapy	therapy	NN
cord-014712-5u4e00q6	1385	23	.	.	.
cord-014712-5u4e00q6	1386	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1386	2	have	have	VBP
cord-014712-5u4e00q6	1386	3	found	find	VBN
cord-014712-5u4e00q6	1386	4	that	that	IN
cord-014712-5u4e00q6	1386	5	recovery	recovery	NN
cord-014712-5u4e00q6	1386	6	of	of	IN
cord-014712-5u4e00q6	1386	7	the	the	DT
cord-014712-5u4e00q6	1386	8	humoral	humoral	JJ
cord-014712-5u4e00q6	1386	9	component	component	NN
cord-014712-5u4e00q6	1386	10	does	do	VBZ
cord-014712-5u4e00q6	1386	11	not	not	RB
cord-014712-5u4e00q6	1386	12	affect	affect	VB
cord-014712-5u4e00q6	1386	13	the	the	DT
cord-014712-5u4e00q6	1386	14	maturation	maturation	NN
cord-014712-5u4e00q6	1386	15	and	and	CC
cord-014712-5u4e00q6	1386	16	the	the	DT
cord-014712-5u4e00q6	1386	17	differentiation	differentiation	NN
cord-014712-5u4e00q6	1386	18	of	of	IN
cord-014712-5u4e00q6	1386	19	T	t	NN
cord-014712-5u4e00q6	1386	20	-	-	HYPH
cord-014712-5u4e00q6	1386	21	cells	cell	NNS
cord-014712-5u4e00q6	1386	22	,	,	,
cord-014712-5u4e00q6	1386	23	but	but	CC
cord-014712-5u4e00q6	1386	24	can	can	MD
cord-014712-5u4e00q6	1386	25	reestablish	reestablish	VB
cord-014712-5u4e00q6	1386	26	activation	activation	NN
cord-014712-5u4e00q6	1386	27	and	and	CC
cord-014712-5u4e00q6	1386	28	regulatory	regulatory	JJ
cord-014712-5u4e00q6	1386	29	properties	property	NNS
cord-014712-5u4e00q6	1386	30	.	.	.
cord-014712-5u4e00q6	1387	1	These	these	DT
cord-014712-5u4e00q6	1387	2	changes	change	NNS
cord-014712-5u4e00q6	1387	3	are	be	VBP
cord-014712-5u4e00q6	1387	4	more	more	RBR
cord-014712-5u4e00q6	1387	5	evident	evident	JJ
cord-014712-5u4e00q6	1387	6	among	among	IN
cord-014712-5u4e00q6	1387	7	patients	patient	NNS
cord-014712-5u4e00q6	1387	8	with	with	IN
cord-014712-5u4e00q6	1387	9	CVID	CVID	NNP
cord-014712-5u4e00q6	1387	10	,	,	,
cord-014712-5u4e00q6	1387	11	which	which	WDT
cord-014712-5u4e00q6	1387	12	immuneregulatory	immuneregulatory	JJ
cord-014712-5u4e00q6	1387	13	and	and	CC
cord-014712-5u4e00q6	1387	14	functional	functional	JJ
cord-014712-5u4e00q6	1387	15	potential	potential	JJ
cord-014712-5u4e00q6	1387	16	reestablish	reestablish	NN
cord-014712-5u4e00q6	1387	17	faster	fast	RBR
cord-014712-5u4e00q6	1387	18	.	.	.
cord-014712-5u4e00q6	1388	1	Obviously	obviously	RB
cord-014712-5u4e00q6	1388	2	,	,	,
cord-014712-5u4e00q6	1388	3	the	the	DT
cord-014712-5u4e00q6	1388	4	effects	effect	NNS
cord-014712-5u4e00q6	1388	5	Tlymphocytes	Tlymphocytes	NNPS
cord-014712-5u4e00q6	1388	6	increase	increase	VBP
cord-014712-5u4e00q6	1388	7	the	the	DT
cord-014712-5u4e00q6	1388	8	effectiveness	effectiveness	NN
cord-014712-5u4e00q6	1388	9	of	of	IN
cord-014712-5u4e00q6	1388	10	replacement	replacement	NN
cord-014712-5u4e00q6	1388	11	therapy	therapy	NN
cord-014712-5u4e00q6	1388	12	in	in	IN
cord-014712-5u4e00q6	1388	13	patients	patient	NNS
cord-014712-5u4e00q6	1388	14	with	with	IN
cord-014712-5u4e00q6	1388	15	XLA	XLA	NNP
cord-014712-5u4e00q6	1388	16	,	,	,
cord-014712-5u4e00q6	1388	17	CVID	CVID	NNP
cord-014712-5u4e00q6	1388	18	Common	common	JJ
cord-014712-5u4e00q6	1388	19	variable	variable	JJ
cord-014712-5u4e00q6	1388	20	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1388	21	(	(	-LRB-
cord-014712-5u4e00q6	1388	22	CVID	CVID	NNP
cord-014712-5u4e00q6	1388	23	)	)	-RRB-
cord-014712-5u4e00q6	1388	24	is	be	VBZ
cord-014712-5u4e00q6	1388	25	one	one	CD
cord-014712-5u4e00q6	1388	26	of	of	IN
cord-014712-5u4e00q6	1388	27	the	the	DT
cord-014712-5u4e00q6	1388	28	most	most	RBS
cord-014712-5u4e00q6	1388	29	frequent	frequent	JJ
cord-014712-5u4e00q6	1388	30	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	1388	31	primary	primary	JJ
cord-014712-5u4e00q6	1388	32	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1388	33	.	.	.
cord-014712-5u4e00q6	1389	1	The	the	DT
cord-014712-5u4e00q6	1389	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1389	3	is	be	VBZ
cord-014712-5u4e00q6	1389	4	based	base	VBN
cord-014712-5u4e00q6	1389	5	on	on	IN
cord-014712-5u4e00q6	1389	6	significantly	significantly	RB
cord-014712-5u4e00q6	1389	7	decreased	decrease	VBN
cord-014712-5u4e00q6	1389	8	levels	level	NNS
cord-014712-5u4e00q6	1389	9	of	of	IN
cord-014712-5u4e00q6	1389	10	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	1389	11	,	,	,
cord-014712-5u4e00q6	1389	12	with	with	IN
cord-014712-5u4e00q6	1389	13	poor	poor	JJ
cord-014712-5u4e00q6	1389	14	or	or	CC
cord-014712-5u4e00q6	1389	15	absent	absent	JJ
cord-014712-5u4e00q6	1389	16	response	response	NN
cord-014712-5u4e00q6	1389	17	to	to	IN
cord-014712-5u4e00q6	1389	18	vaccines	vaccine	NNS
cord-014712-5u4e00q6	1389	19	and	and	CC
cord-014712-5u4e00q6	1389	20	by	by	IN
cord-014712-5u4e00q6	1389	21	excluding	exclude	VBG
cord-014712-5u4e00q6	1389	22	other	other	JJ
cord-014712-5u4e00q6	1389	23	defined	define	VBN
cord-014712-5u4e00q6	1389	24	causes	cause	NNS
cord-014712-5u4e00q6	1389	25	of	of	IN
cord-014712-5u4e00q6	1389	26	hypogammaglobulinaemia	hypogammaglobulinaemia	NN
cord-014712-5u4e00q6	1389	27	.	.	.
cord-014712-5u4e00q6	1390	1	As	as	IN
cord-014712-5u4e00q6	1390	2	suboptimal	suboptimal	JJ
cord-014712-5u4e00q6	1390	3	antibody	antibody	NN
cord-014712-5u4e00q6	1390	4	production	production	NN
cord-014712-5u4e00q6	1390	5	is	be	VBZ
cord-014712-5u4e00q6	1390	6	mainly	mainly	RB
cord-014712-5u4e00q6	1390	7	due	due	JJ
cord-014712-5u4e00q6	1390	8	to	to	IN
cord-014712-5u4e00q6	1390	9	B	b	NN
cord-014712-5u4e00q6	1390	10	cell	cell	NN
cord-014712-5u4e00q6	1390	11	defects	defect	NNS
cord-014712-5u4e00q6	1390	12	,	,	,
cord-014712-5u4e00q6	1390	13	therefore	therefore	RB
cord-014712-5u4e00q6	1390	14	,	,	,
cord-014712-5u4e00q6	1390	15	we	-PRON-	PRP
cord-014712-5u4e00q6	1390	16	aimed	aim	VBD
cord-014712-5u4e00q6	1390	17	to	to	TO
cord-014712-5u4e00q6	1390	18	study	study	VB
cord-014712-5u4e00q6	1390	19	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1390	20	subgroups	subgroup	NNS
cord-014712-5u4e00q6	1390	21	of	of	IN
cord-014712-5u4e00q6	1390	22	CVID	CVID	NNP
cord-014712-5u4e00q6	1390	23	patients	patient	NNS
cord-014712-5u4e00q6	1390	24	and	and	CC
cord-014712-5u4e00q6	1390	25	to	to	TO
cord-014712-5u4e00q6	1390	26	compare	compare	VB
cord-014712-5u4e00q6	1390	27	the	the	DT
cord-014712-5u4e00q6	1390	28	patterns	pattern	NNS
cord-014712-5u4e00q6	1390	29	with	with	IN
cord-014712-5u4e00q6	1390	30	the	the	DT
cord-014712-5u4e00q6	1390	31	clinical	clinical	JJ
cord-014712-5u4e00q6	1390	32	presentation	presentation	NN
cord-014712-5u4e00q6	1390	33	in	in	IN
cord-014712-5u4e00q6	1390	34	these	these	DT
cord-014712-5u4e00q6	1390	35	patients	patient	NNS
cord-014712-5u4e00q6	1390	36	.	.	.
cord-014712-5u4e00q6	1391	1	Six	six	CD
cord-014712-5u4e00q6	1391	2	adult	adult	NN
cord-014712-5u4e00q6	1391	3	patients	patient	NNS
cord-014712-5u4e00q6	1391	4	with	with	IN
cord-014712-5u4e00q6	1391	5	CVID	CVID	NNP
cord-014712-5u4e00q6	1391	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1391	7	were	be	VBD
cord-014712-5u4e00q6	1391	8	studied	study	VBN
cord-014712-5u4e00q6	1391	9	.	.	.
cord-014712-5u4e00q6	1392	1	Lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1392	2	subpopulations	subpopulation	NNS
cord-014712-5u4e00q6	1392	3	were	be	VBD
cord-014712-5u4e00q6	1392	4	determined	determine	VBN
cord-014712-5u4e00q6	1392	5	by	by	IN
cord-014712-5u4e00q6	1392	6	flow	flow	NN
cord-014712-5u4e00q6	1392	7	cytometry	cytometry	NN
cord-014712-5u4e00q6	1392	8	.	.	.
cord-014712-5u4e00q6	1393	1	For	for	IN
cord-014712-5u4e00q6	1393	2	B	b	NN
cord-014712-5u4e00q6	1393	3	-	-	HYPH
cord-014712-5u4e00q6	1393	4	cells	cell	NNS
cord-014712-5u4e00q6	1393	5	subgroups	subgroup	NNS
cord-014712-5u4e00q6	1393	6	CD3	CD3	NNP
cord-014712-5u4e00q6	1393	7	,	,	,
cord-014712-5u4e00q6	1393	8	CD27	CD27	NNP
cord-014712-5u4e00q6	1393	9	,	,	,
cord-014712-5u4e00q6	1393	10	IgM	IgM	NNP
cord-014712-5u4e00q6	1393	11	and	and	CC
cord-014712-5u4e00q6	1393	12	IgD	IgD	NNP
cord-014712-5u4e00q6	1393	13	reagents	reagents	NNPS
cord-014712-5u4e00q6	1393	14	w	w	NNP
cord-014712-5u4e00q6	1393	15	e	e	NN
cord-014712-5u4e00q6	1393	16	r	r	NN
cord-014712-5u4e00q6	1393	17	e	e	NN
cord-014712-5u4e00q6	1393	18	u	u	NN
cord-014712-5u4e00q6	1393	19	s	s	NN
cord-014712-5u4e00q6	1393	20	e	e	NN
cord-014712-5u4e00q6	1393	21	d	d	NNP
cord-014712-5u4e00q6	1393	22	.	.	.
cord-014712-5u4e00q6	1394	1	A	a	DT
cord-014712-5u4e00q6	1395	1	l	l	NNP
cord-014712-5u4e00q6	1395	2	l	l	NNP
cord-014712-5u4e00q6	1395	3	l	l	NNP
cord-014712-5u4e00q6	1395	4	y	y	NNP
cord-014712-5u4e00q6	1395	5	m	m	NN
cord-014712-5u4e00q6	1395	6	p	p	NN
cord-014712-5u4e00q6	1395	7	h	h	NN
cord-014712-5u4e00q6	1396	1	o	o	UH
cord-014712-5u4e00q6	1397	1	c	c	NNP
cord-014712-5u4e00q6	1397	2	y	y	NNP
cord-014712-5u4e00q6	1397	3	t	t	NNP
cord-014712-5u4e00q6	1397	4	e	e	NN
cord-014712-5u4e00q6	1397	5	s	s	NNP
cord-014712-5u4e00q6	1398	1	w	w	NNP
cord-014712-5u4e00q6	1398	2	e	e	NN
cord-014712-5u4e00q6	1398	3	r	r	NN
cord-014712-5u4e00q6	1398	4	e	e	NN
cord-014712-5u4e00q6	1398	5	g	g	NN
cord-014712-5u4e00q6	1398	6	a	a	DT
cord-014712-5u4e00q6	1398	7	t	t	NN
cord-014712-5u4e00q6	1398	8	e	e	NN
cord-014712-5u4e00q6	1398	9	d	d	NN
cord-014712-5u4e00q6	1398	10	f	f	NNP
cord-014712-5u4e00q6	1398	11	o	o	NN
cord-014712-5u4e00q6	1398	12	r	r	NN
cord-014712-5u4e00q6	1398	13	f	f	NN
cord-014712-5u4e00q6	1398	14	i	i	NN
cord-014712-5u4e00q6	1399	1	n	n	NNP
cord-014712-5u4e00q6	1399	2	d	d	NNP
cord-014712-5u4e00q6	1399	3	i	i	NNP
cord-014712-5u4e00q6	1399	4	n	n	NNP
cord-014712-5u4e00q6	1400	1	g	g	NNP
cord-014712-5u4e00q6	1400	2	CD19	CD19	NNP
cord-014712-5u4e00q6	1401	1	+	+	CC
cord-014712-5u4e00q6	1402	1	CD27	CD27	NNP
cord-014712-5u4e00q6	1402	2	+	+	CC
cord-014712-5u4e00q6	1403	1	memory	memory	NN
cord-014712-5u4e00q6	1403	2	B	B	NNP
cord-014712-5u4e00q6	1403	3	cells	cell	NNS
cord-014712-5u4e00q6	1403	4	and	and	CC
cord-014712-5u4e00q6	1403	5	from	from	IN
cord-014712-5u4e00q6	1403	6	this	this	DT
cord-014712-5u4e00q6	1403	7	population	population	NN
cord-014712-5u4e00q6	1403	8	switched	switch	VBD
cord-014712-5u4e00q6	1403	9	(	(	-LRB-
cord-014712-5u4e00q6	1403	10	CD19	CD19	NNP
cord-014712-5u4e00q6	1403	11	+	+	CC
cord-014712-5u4e00q6	1403	12	CD27	CD27	NNP
cord-014712-5u4e00q6	1403	13	+	+	CC
cord-014712-5u4e00q6	1403	14	IgD	IgD	NNP
cord-014712-5u4e00q6	1403	15	-IgM	-IgM	:
cord-014712-5u4e00q6	1403	16	-	-	:
cord-014712-5u4e00q6	1403	17	)	)	-RRB-
cord-014712-5u4e00q6	1403	18	and	and	CC
cord-014712-5u4e00q6	1403	19	non	non	JJ
cord-014712-5u4e00q6	1403	20	-	-	JJ
cord-014712-5u4e00q6	1403	21	switched	switched	JJ
cord-014712-5u4e00q6	1403	22	(	(	-LRB-
cord-014712-5u4e00q6	1403	23	CD19	CD19	NNP
cord-014712-5u4e00q6	1403	24	+	+	CC
cord-014712-5u4e00q6	1403	25	CD27	CD27	NNP
cord-014712-5u4e00q6	1403	26	+	+	CC
cord-014712-5u4e00q6	1403	27	IgD	IgD	NNP
cord-014712-5u4e00q6	1403	28	+	+	CC
cord-014712-5u4e00q6	1403	29	IgM	IgM	NNP
cord-014712-5u4e00q6	1403	30	+	+	SYM
cord-014712-5u4e00q6	1403	31	)	)	-RRB-
cord-014712-5u4e00q6	1403	32	memory	memory	NN
cord-014712-5u4e00q6	1403	33	B	b	NN
cord-014712-5u4e00q6	1403	34	cells	cell	NNS
cord-014712-5u4e00q6	1403	35	were	be	VBD
cord-014712-5u4e00q6	1403	36	counted	count	VBN
cord-014712-5u4e00q6	1403	37	.	.	.
cord-014712-5u4e00q6	1404	1	All	all	DT
cord-014712-5u4e00q6	1404	2	patients	patient	NNS
cord-014712-5u4e00q6	1404	3	had	have	VBD
cord-014712-5u4e00q6	1404	4	normal	normal	JJ
cord-014712-5u4e00q6	1404	5	levels	level	NNS
cord-014712-5u4e00q6	1404	6	of	of	IN
cord-014712-5u4e00q6	1404	7	total	total	JJ
cord-014712-5u4e00q6	1404	8	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1404	9	count	count	NN
cord-014712-5u4e00q6	1404	10	and	and	CC
cord-014712-5u4e00q6	1404	11	absolute	absolute	JJ
cord-014712-5u4e00q6	1404	12	counts	count	NNS
cord-014712-5u4e00q6	1404	13	of	of	IN
cord-014712-5u4e00q6	1404	14	CD4	CD4	NNP
cord-014712-5u4e00q6	1404	15	+	+	CC
cord-014712-5u4e00q6	1404	16	,	,	,
cord-014712-5u4e00q6	1404	17	CD8	CD8	NNP
cord-014712-5u4e00q6	1404	18	+	+	CC
cord-014712-5u4e00q6	1404	19	and	and	CC
cord-014712-5u4e00q6	1404	20	CD16	CD16	NNP
cord-014712-5u4e00q6	1405	1	+	+	CC
cord-014712-5u4e00q6	1406	1	/CD56	/CD56	NNP
cord-014712-5u4e00q6	1407	1	+	+	CC
cord-014712-5u4e00q6	1407	2	cells	cell	NNS
cord-014712-5u4e00q6	1407	3	were	be	VBD
cord-014712-5u4e00q6	1407	4	also	also	RB
cord-014712-5u4e00q6	1407	5	normal	normal	JJ
cord-014712-5u4e00q6	1407	6	in	in	IN
cord-014712-5u4e00q6	1407	7	all	all	DT
cord-014712-5u4e00q6	1407	8	patients	patient	NNS
cord-014712-5u4e00q6	1407	9	.	.	.
cord-014712-5u4e00q6	1408	1	Only	only	RB
cord-014712-5u4e00q6	1408	2	one	one	CD
cord-014712-5u4e00q6	1408	3	patient	patient	NN
cord-014712-5u4e00q6	1408	4	showed	show	VBD
cord-014712-5u4e00q6	1408	5	low	low	JJ
cord-014712-5u4e00q6	1408	6	levels	level	NNS
cord-014712-5u4e00q6	1408	7	of	of	IN
cord-014712-5u4e00q6	1408	8	CD19	CD19	NNP
cord-014712-5u4e00q6	1408	9	+	+	CC
cord-014712-5u4e00q6	1408	10	cells	cell	NNS
cord-014712-5u4e00q6	1408	11	levels	level	NNS
cord-014712-5u4e00q6	1408	12	.	.	.
cord-014712-5u4e00q6	1409	1	According	accord	VBG
cord-014712-5u4e00q6	1409	2	to	to	IN
cord-014712-5u4e00q6	1409	3	Paris	Paris	NNP
cord-014712-5u4e00q6	1409	4	classification	classification	NN
cord-014712-5u4e00q6	1409	5	scheme	scheme	NN
cord-014712-5u4e00q6	1409	6	the	the	DT
cord-014712-5u4e00q6	1409	7	patients	patient	NNS
cord-014712-5u4e00q6	1409	8	could	could	MD
cord-014712-5u4e00q6	1409	9	divided	divide	VBN
cord-014712-5u4e00q6	1409	10	into	into	IN
cord-014712-5u4e00q6	1409	11	two	two	CD
cord-014712-5u4e00q6	1409	12	subgroups	subgroup	NNS
cord-014712-5u4e00q6	1409	13	:	:	:
cord-014712-5u4e00q6	1409	14	MB0	MB0	NNP
cord-014712-5u4e00q6	1409	15	and	and	CC
cord-014712-5u4e00q6	1409	16	MB1	MB1	NNP
cord-014712-5u4e00q6	1409	17	.	.	.
cord-014712-5u4e00q6	1410	1	Although	although	IN
cord-014712-5u4e00q6	1410	2	almost	almost	RB
cord-014712-5u4e00q6	1410	3	all	all	PDT
cord-014712-5u4e00q6	1410	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	1410	5	CVID	CVID	NNP
cord-014712-5u4e00q6	1410	6	patients	patient	NNS
cord-014712-5u4e00q6	1410	7	had	have	VBD
cord-014712-5u4e00q6	1410	8	normal	normal	JJ
cord-014712-5u4e00q6	1410	9	number	number	NN
cord-014712-5u4e00q6	1410	10	of	of	IN
cord-014712-5u4e00q6	1410	11	total	total	JJ
cord-014712-5u4e00q6	1410	12	B	b	NN
cord-014712-5u4e00q6	1410	13	cells	cell	NNS
cord-014712-5u4e00q6	1410	14	,	,	,
cord-014712-5u4e00q6	1410	15	most	most	JJS
cord-014712-5u4e00q6	1410	16	of	of	IN
cord-014712-5u4e00q6	1410	17	them	-PRON-	PRP
cord-014712-5u4e00q6	1410	18	showed	show	VBD
cord-014712-5u4e00q6	1410	19	reduced	reduced	JJ
cord-014712-5u4e00q6	1410	20	number	number	NN
cord-014712-5u4e00q6	1410	21	of	of	IN
cord-014712-5u4e00q6	1410	22	memory	memory	NN
cord-014712-5u4e00q6	1410	23	B	b	NN
cord-014712-5u4e00q6	1410	24	cells	cell	NNS
cord-014712-5u4e00q6	1410	25	and/or	and/or	CC
cord-014712-5u4e00q6	1410	26	switched	switch	VBD
cord-014712-5u4e00q6	1410	27	memory	memory	NN
cord-014712-5u4e00q6	1410	28	B	b	NN
cord-014712-5u4e00q6	1410	29	cells	cell	NNS
cord-014712-5u4e00q6	1410	30	.	.	.
cord-014712-5u4e00q6	1411	1	All	all	DT
cord-014712-5u4e00q6	1411	2	of	of	IN
cord-014712-5u4e00q6	1411	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	1411	4	patients	patient	NNS
cord-014712-5u4e00q6	1411	5	had	have	VBD
cord-014712-5u4e00q6	1411	6	very	very	RB
cord-014712-5u4e00q6	1411	7	low	low	JJ
cord-014712-5u4e00q6	1411	8	or	or	CC
cord-014712-5u4e00q6	1411	9	absent	absent	JJ
cord-014712-5u4e00q6	1411	10	level	level	NN
cord-014712-5u4e00q6	1411	11	of	of	IN
cord-014712-5u4e00q6	1411	12	class	class	NN
cord-014712-5u4e00q6	1411	13	-	-	HYPH
cord-014712-5u4e00q6	1411	14	switched	switch	VBN
cord-014712-5u4e00q6	1411	15	memory	memory	NN
cord-014712-5u4e00q6	1411	16	B	b	NN
cord-014712-5u4e00q6	1411	17	cells	cell	NNS
cord-014712-5u4e00q6	1411	18	,	,	,
cord-014712-5u4e00q6	1411	19	therefore	therefore	RB
cord-014712-5u4e00q6	1411	20	can	can	MD
cord-014712-5u4e00q6	1411	21	be	be	VB
cord-014712-5u4e00q6	1411	22	possible	possible	JJ
cord-014712-5u4e00q6	1411	23	associated	associate	VBN
cord-014712-5u4e00q6	1411	24	with	with	IN
cord-014712-5u4e00q6	1411	25	a	a	DT
cord-014712-5u4e00q6	1411	26	higher	high	JJR
cord-014712-5u4e00q6	1411	27	risk	risk	NN
cord-014712-5u4e00q6	1411	28	of	of	IN
cord-014712-5u4e00q6	1411	29	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	1411	30	disease	disease	NN
cord-014712-5u4e00q6	1411	31	and	and	CC
cord-014712-5u4e00q6	1411	32	splenomegaly	splenomegaly	NN
cord-014712-5u4e00q6	1411	33	.	.	.
cord-014712-5u4e00q6	1412	1	Detailed	detailed	JJ
cord-014712-5u4e00q6	1412	2	investigation	investigation	NN
cord-014712-5u4e00q6	1412	3	of	of	IN
cord-014712-5u4e00q6	1412	4	B	b	NN
cord-014712-5u4e00q6	1412	5	-	-	HYPH
cord-014712-5u4e00q6	1412	6	cell	cell	NN
cord-014712-5u4e00q6	1412	7	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	1412	8	can	can	MD
cord-014712-5u4e00q6	1412	9	better	well	RBR
cord-014712-5u4e00q6	1412	10	characterise	characterise	VB
cord-014712-5u4e00q6	1412	11	CVID	CVID	NNP
cord-014712-5u4e00q6	1412	12	patients	patient	NNS
cord-014712-5u4e00q6	1412	13	and	and	CC
cord-014712-5u4e00q6	1412	14	can	can	MD
cord-014712-5u4e00q6	1412	15	provide	provide	VB
cord-014712-5u4e00q6	1412	16	more	more	JJR
cord-014712-5u4e00q6	1412	17	information	information	NN
cord-014712-5u4e00q6	1412	18	about	about	IN
cord-014712-5u4e00q6	1412	19	possible	possible	JJ
cord-014712-5u4e00q6	1412	20	clinical	clinical	JJ
cord-014712-5u4e00q6	1412	21	outcome	outcome	NN
cord-014712-5u4e00q6	1412	22	.	.	.
cord-014712-5u4e00q6	1413	1	Background	background	NN
cord-014712-5u4e00q6	1413	2	:	:	:
cord-014712-5u4e00q6	1414	1	Common	common	JJ
cord-014712-5u4e00q6	1414	2	variable	variable	JJ
cord-014712-5u4e00q6	1414	3	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1414	4	(	(	-LRB-
cord-014712-5u4e00q6	1414	5	CVID	CVID	NNP
cord-014712-5u4e00q6	1414	6	)	)	-RRB-
cord-014712-5u4e00q6	1414	7	is	be	VBZ
cord-014712-5u4e00q6	1414	8	one	one	CD
cord-014712-5u4e00q6	1414	9	of	of	IN
cord-014712-5u4e00q6	1414	10	the	the	DT
cord-014712-5u4e00q6	1414	11	most	most	RBS
cord-014712-5u4e00q6	1414	12	frequent	frequent	JJ
cord-014712-5u4e00q6	1414	13	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	1414	14	primary	primary	JJ
cord-014712-5u4e00q6	1414	15	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1414	16	,	,	,
cord-014712-5u4e00q6	1414	17	often	often	RB
cord-014712-5u4e00q6	1414	18	related	relate	VBN
cord-014712-5u4e00q6	1414	19	to	to	IN
cord-014712-5u4e00q6	1414	20	spectrum	spectrum	NN
cord-014712-5u4e00q6	1414	21	of	of	IN
cord-014712-5u4e00q6	1414	22	infectious	infectious	JJ
cord-014712-5u4e00q6	1414	23	and	and	CC
cord-014712-5u4e00q6	1414	24	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1414	25	diseases	disease	NNS
cord-014712-5u4e00q6	1414	26	.	.	.
cord-014712-5u4e00q6	1415	1	In	in	IN
cord-014712-5u4e00q6	1415	2	CVID	CVID	NNP
cord-014712-5u4e00q6	1415	3	patients	patient	NNS
cord-014712-5u4e00q6	1415	4	wide	wide	JJ
cord-014712-5u4e00q6	1415	5	spectrum	spectrum	NN
cord-014712-5u4e00q6	1415	6	of	of	IN
cord-014712-5u4e00q6	1415	7	gastrointestinal	gastrointestinal	JJ
cord-014712-5u4e00q6	1415	8	disorders	disorder	NNS
cord-014712-5u4e00q6	1415	9	,	,	,
cord-014712-5u4e00q6	1415	10	including	include	VBG
cord-014712-5u4e00q6	1415	11	infections	infection	NNS
cord-014712-5u4e00q6	1415	12	,	,	,
cord-014712-5u4e00q6	1415	13	are	be	VBP
cord-014712-5u4e00q6	1415	14	frequently	frequently	RB
cord-014712-5u4e00q6	1415	15	seen	see	VBN
cord-014712-5u4e00q6	1415	16	.	.	.
cord-014712-5u4e00q6	1416	1	Inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	1416	2	bowel	bowel	NN
cord-014712-5u4e00q6	1416	3	disease	disease	NN
cord-014712-5u4e00q6	1416	4	,	,	,
cord-014712-5u4e00q6	1416	5	Helicobacter	Helicobacter	NNP
cord-014712-5u4e00q6	1416	6	pylori	pylori	NN
cord-014712-5u4e00q6	1416	7	infection	infection	NN
cord-014712-5u4e00q6	1416	8	,	,	,
cord-014712-5u4e00q6	1416	9	Giardia	Giardia	NNP
cord-014712-5u4e00q6	1416	10	lamblia	lamblia	NN
cord-014712-5u4e00q6	1416	11	infection	infection	NN
cord-014712-5u4e00q6	1416	12	,	,	,
cord-014712-5u4e00q6	1416	13	Campylobacter	Campylobacter	NNP
cord-014712-5u4e00q6	1416	14	or	or	CC
cord-014712-5u4e00q6	1416	15	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	1416	16	infection	infection	NN
cord-014712-5u4e00q6	1416	17	have	have	VBP
cord-014712-5u4e00q6	1416	18	been	be	VBN
cord-014712-5u4e00q6	1416	19	reported	report	VBN
cord-014712-5u4e00q6	1416	20	.	.	.
cord-014712-5u4e00q6	1417	1	However	however	RB
cord-014712-5u4e00q6	1417	2	,	,	,
cord-014712-5u4e00q6	1417	3	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1417	4	liver	liver	NN
cord-014712-5u4e00q6	1417	5	function	function	NN
cord-014712-5u4e00q6	1417	6	test	test	NN
cord-014712-5u4e00q6	1417	7	and	and	CC
cord-014712-5u4e00q6	1417	8	liver	liver	NN
cord-014712-5u4e00q6	1417	9	disease	disease	NN
cord-014712-5u4e00q6	1417	10	are	be	VBP
cord-014712-5u4e00q6	1417	11	found	find	VBN
cord-014712-5u4e00q6	1417	12	in	in	IN
cord-014712-5u4e00q6	1417	13	approximately	approximately	RB
cord-014712-5u4e00q6	1417	14	10	10	CD
cord-014712-5u4e00q6	1417	15	%	%	NN
cord-014712-5u4e00q6	1417	16	of	of	IN
cord-014712-5u4e00q6	1417	17	CVID	CVID	NNP
cord-014712-5u4e00q6	1417	18	patients	patient	NNS
cord-014712-5u4e00q6	1417	19	.	.	.
cord-014712-5u4e00q6	1418	1	Case	case	NN
cord-014712-5u4e00q6	1418	2	history	history	NN
cord-014712-5u4e00q6	1418	3	:	:	:
cord-014712-5u4e00q6	1419	1	A	a	DT
cord-014712-5u4e00q6	1419	2	47-year	47-year	JJ
cord-014712-5u4e00q6	1419	3	old	old	JJ
cord-014712-5u4e00q6	1419	4	female	female	JJ
cord-014712-5u4e00q6	1419	5	patient	patient	NN
cord-014712-5u4e00q6	1419	6	was	be	VBD
cord-014712-5u4e00q6	1419	7	admitted	admit	VBN
cord-014712-5u4e00q6	1419	8	to	to	IN
cord-014712-5u4e00q6	1419	9	infectious	infectious	JJ
cord-014712-5u4e00q6	1419	10	disease	disease	NN
cord-014712-5u4e00q6	1419	11	department	department	NN
cord-014712-5u4e00q6	1419	12	due	due	IN
cord-014712-5u4e00q6	1419	13	to	to	IN
cord-014712-5u4e00q6	1419	14	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1419	15	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1419	16	and	and	CC
cord-014712-5u4e00q6	1419	17	purulent	purulent	JJ
cord-014712-5u4e00q6	1419	18	rhinosinusitis	rhinosinusitis	NN
cord-014712-5u4e00q6	1419	19	.	.	.
cord-014712-5u4e00q6	1420	1	Blood	blood	NN
cord-014712-5u4e00q6	1420	2	analysis	analysis	NN
cord-014712-5u4e00q6	1420	3	confirmed	confirm	VBD
cord-014712-5u4e00q6	1420	4	panhypogammaglobulinaemia	panhypogammaglobulinaemia	NN
cord-014712-5u4e00q6	1420	5	with	with	IN
cord-014712-5u4e00q6	1420	6	impaired	impaired	JJ
cord-014712-5u4e00q6	1420	7	responses	response	NNS
cord-014712-5u4e00q6	1420	8	to	to	IN
cord-014712-5u4e00q6	1420	9	vaccinations	vaccination	NNS
cord-014712-5u4e00q6	1420	10	,	,	,
cord-014712-5u4e00q6	1420	11	elevated	elevated	JJ
cord-014712-5u4e00q6	1420	12	liver	liver	NN
cord-014712-5u4e00q6	1420	13	function	function	NN
cord-014712-5u4e00q6	1420	14	tests	test	NNS
cord-014712-5u4e00q6	1420	15	and	and	CC
cord-014712-5u4e00q6	1420	16	anti	anti	JJ
cord-014712-5u4e00q6	1420	17	-	-	JJ
cord-014712-5u4e00q6	1420	18	HCV	hcv	JJ
cord-014712-5u4e00q6	1420	19	positivity	positivity	NN
cord-014712-5u4e00q6	1420	20	,	,	,
cord-014712-5u4e00q6	1420	21	interpreted	interpret	VBD
cord-014712-5u4e00q6	1420	22	as	as	IN
cord-014712-5u4e00q6	1420	23	old	old	JJ
cord-014712-5u4e00q6	1420	24	and	and	CC
cord-014712-5u4e00q6	1420	25	passed	pass	VBD
cord-014712-5u4e00q6	1420	26	infection	infection	NN
cord-014712-5u4e00q6	1420	27	.	.	.
cord-014712-5u4e00q6	1421	1	Due	due	IN
cord-014712-5u4e00q6	1421	2	to	to	IN
cord-014712-5u4e00q6	1421	3	CVID	CVID	NNP
cord-014712-5u4e00q6	1421	4	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1421	5	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1421	6	substitution	substitution	NN
cord-014712-5u4e00q6	1421	7	was	be	VBD
cord-014712-5u4e00q6	1421	8	started	start	VBN
cord-014712-5u4e00q6	1421	9	.	.	.
cord-014712-5u4e00q6	1422	1	However	however	RB
cord-014712-5u4e00q6	1422	2	,	,	,
cord-014712-5u4e00q6	1422	3	liver	liver	NN
cord-014712-5u4e00q6	1422	4	function	function	NN
cord-014712-5u4e00q6	1422	5	tests	test	NNS
cord-014712-5u4e00q6	1422	6	remained	remain	VBD
cord-014712-5u4e00q6	1422	7	elevated	elevated	JJ
cord-014712-5u4e00q6	1422	8	and	and	CC
cord-014712-5u4e00q6	1422	9	with	with	IN
cord-014712-5u4e00q6	1422	10	HCV	HCV	NNP
cord-014712-5u4e00q6	1422	11	-	-	HYPH
cord-014712-5u4e00q6	1422	12	RNA	RNA	NNP
cord-014712-5u4e00q6	1422	13	analysis	analysis	NN
cord-014712-5u4e00q6	1422	14	high	high	JJ
cord-014712-5u4e00q6	1422	15	hepatitis	hepatitis	NN
cord-014712-5u4e00q6	1422	16	C	C	NNP
cord-014712-5u4e00q6	1422	17	viral	viral	JJ
cord-014712-5u4e00q6	1422	18	load	load	NN
cord-014712-5u4e00q6	1422	19	was	be	VBD
cord-014712-5u4e00q6	1422	20	detected	detect	VBN
cord-014712-5u4e00q6	1422	21	.	.	.
cord-014712-5u4e00q6	1423	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	1423	2	hepatitis	hepatitis	NN
cord-014712-5u4e00q6	1423	3	C	c	NN
cord-014712-5u4e00q6	1423	4	virus	virus	NN
cord-014712-5u4e00q6	1423	5	infection	infection	NN
cord-014712-5u4e00q6	1423	6	was	be	VBD
cord-014712-5u4e00q6	1423	7	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1423	8	and	and	CC
cord-014712-5u4e00q6	1423	9	treatment	treatment	NN
cord-014712-5u4e00q6	1423	10	with	with	IN
cord-014712-5u4e00q6	1423	11	peginterferon	peginterferon	NNP
cord-014712-5u4e00q6	1423	12	α-2a	α-2a	NNP
cord-014712-5u4e00q6	1423	13	and	and	CC
cord-014712-5u4e00q6	1423	14	ribavirin	ribavirin	NNP
cord-014712-5u4e00q6	1423	15	was	be	VBD
cord-014712-5u4e00q6	1423	16	started	start	VBN
cord-014712-5u4e00q6	1423	17	.	.	.
cord-014712-5u4e00q6	1424	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1424	2	:	:	:
cord-014712-5u4e00q6	1425	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	1425	2	case	case	NN
cord-014712-5u4e00q6	1425	3	emphasizes	emphasize	VBZ
cord-014712-5u4e00q6	1425	4	the	the	DT
cord-014712-5u4e00q6	1425	5	need	need	NN
cord-014712-5u4e00q6	1425	6	for	for	IN
cord-014712-5u4e00q6	1425	7	HCV	HCV	NNP
cord-014712-5u4e00q6	1425	8	-	-	HYPH
cord-014712-5u4e00q6	1425	9	RNA	RNA	NNP
cord-014712-5u4e00q6	1425	10	and	and	CC
cord-014712-5u4e00q6	1425	11	HBV	HBV	NNP
cord-014712-5u4e00q6	1425	12	-	-	HYPH
cord-014712-5u4e00q6	1425	13	DNA	dna	NN
cord-014712-5u4e00q6	1425	14	analysis	analysis	NN
cord-014712-5u4e00q6	1425	15	in	in	IN
cord-014712-5u4e00q6	1425	16	patients	patient	NNS
cord-014712-5u4e00q6	1425	17	with	with	IN
cord-014712-5u4e00q6	1425	18	hypogammaglobulinaemia	hypogammaglobulinaemia	NNP
cord-014712-5u4e00q6	1425	19	,	,	,
cord-014712-5u4e00q6	1425	20	as	as	IN
cord-014712-5u4e00q6	1425	21	the	the	DT
cord-014712-5u4e00q6	1425	22	serological	serological	JJ
cord-014712-5u4e00q6	1425	23	detection	detection	NN
cord-014712-5u4e00q6	1425	24	is	be	VBZ
cord-014712-5u4e00q6	1425	25	impaired	impair	VBN
cord-014712-5u4e00q6	1425	26	and	and	CC
cord-014712-5u4e00q6	1425	27	prognosis	prognosis	JJ
cord-014712-5u4e00q6	1425	28	for	for	IN
cord-014712-5u4e00q6	1425	29	chronic	chronic	JJ
cord-014712-5u4e00q6	1425	30	hepatitis	hepatitis	NN
cord-014712-5u4e00q6	1425	31	in	in	IN
cord-014712-5u4e00q6	1425	32	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1425	33	patients	patient	NNS
cord-014712-5u4e00q6	1425	34	is	be	VBZ
cord-014712-5u4e00q6	1425	35	poor	poor	JJ
cord-014712-5u4e00q6	1425	36	.	.	.
cord-014712-5u4e00q6	1426	1	Outpaitent	Outpaitent	NNP
cord-014712-5u4e00q6	1426	2	Clinic	Clinic	NNP
cord-014712-5u4e00q6	1426	3	of	of	IN
cord-014712-5u4e00q6	1426	4	Clinical	Clinical	NNP
cord-014712-5u4e00q6	1426	5	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1426	6	and	and	CC
cord-014712-5u4e00q6	1426	7	Allergology	Allergology	NNP
cord-014712-5u4e00q6	1426	8	,	,	,
cord-014712-5u4e00q6	1426	9	East	East	NNP
cord-014712-5u4e00q6	1426	10	Tallinn	Tallinn	NNP
cord-014712-5u4e00q6	1426	11	Central	Central	NNP
cord-014712-5u4e00q6	1426	12	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1426	13	,	,	,
cord-014712-5u4e00q6	1426	14	Tallinn	Tallinn	NNP
cord-014712-5u4e00q6	1426	15	,	,	,
cord-014712-5u4e00q6	1427	1	Estonia	Estonia	NNP
cord-014712-5u4e00q6	1427	2	Background	Background	NNP
cord-014712-5u4e00q6	1427	3	:	:	:
cord-014712-5u4e00q6	1428	1	Primary	primary	JJ
cord-014712-5u4e00q6	1428	2	antibody	antibody	NN
cord-014712-5u4e00q6	1428	3	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1428	4	are	be	VBP
cord-014712-5u4e00q6	1428	5	the	the	DT
cord-014712-5u4e00q6	1428	6	most	most	RBS
cord-014712-5u4e00q6	1428	7	frequent	frequent	JJ
cord-014712-5u4e00q6	1428	8	primary	primary	JJ
cord-014712-5u4e00q6	1428	9	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1428	10	.	.	.
cord-014712-5u4e00q6	1429	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	1429	2	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1429	3	tract	tract	NN
cord-014712-5u4e00q6	1429	4	infections	infection	NNS
cord-014712-5u4e00q6	1429	5	may	may	MD
cord-014712-5u4e00q6	1429	6	result	result	VB
cord-014712-5u4e00q6	1429	7	in	in	IN
cord-014712-5u4e00q6	1429	8	permanent	permanent	JJ
cord-014712-5u4e00q6	1429	9	lung	lung	NN
cord-014712-5u4e00q6	1429	10	damage	damage	NN
cord-014712-5u4e00q6	1429	11	in	in	IN
cord-014712-5u4e00q6	1429	12	20	20	CD
cord-014712-5u4e00q6	1429	13	-	-	SYM
cord-014712-5u4e00q6	1429	14	40	40	CD
cord-014712-5u4e00q6	1429	15	%	%	NN
cord-014712-5u4e00q6	1429	16	of	of	IN
cord-014712-5u4e00q6	1429	17	patients	patient	NNS
cord-014712-5u4e00q6	1429	18	,	,	,
cord-014712-5u4e00q6	1429	19	most	most	RBS
cord-014712-5u4e00q6	1429	20	commonly	commonly	RB
cord-014712-5u4e00q6	1429	21	presenting	present	VBG
cord-014712-5u4e00q6	1429	22	with	with	IN
cord-014712-5u4e00q6	1429	23	the	the	DT
cord-014712-5u4e00q6	1429	24	development	development	NN
cord-014712-5u4e00q6	1429	25	of	of	IN
cord-014712-5u4e00q6	1429	26	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	1429	27	.	.	.
cord-014712-5u4e00q6	1430	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1430	2	aimed	aim	VBD
cord-014712-5u4e00q6	1430	3	to	to	TO
cord-014712-5u4e00q6	1430	4	evaluate	evaluate	VB
cord-014712-5u4e00q6	1430	5	the	the	DT
cord-014712-5u4e00q6	1430	6	lung	lung	NN
cord-014712-5u4e00q6	1430	7	function	function	NN
cord-014712-5u4e00q6	1430	8	and	and	CC
cord-014712-5u4e00q6	1430	9	radiographic	radiographic	JJ
cord-014712-5u4e00q6	1430	10	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	1430	11	changes	change	NNS
cord-014712-5u4e00q6	1430	12	in	in	IN
cord-014712-5u4e00q6	1430	13	our	-PRON-	PRP$
cord-014712-5u4e00q6	1430	14	patients	patient	NNS
cord-014712-5u4e00q6	1430	15	with	with	IN
cord-014712-5u4e00q6	1430	16	primary	primary	JJ
cord-014712-5u4e00q6	1430	17	antibody	antibody	NN
cord-014712-5u4e00q6	1430	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	1430	19	.	.	.
cord-014712-5u4e00q6	1431	1	Material	material	NN
cord-014712-5u4e00q6	1431	2	and	and	CC
cord-014712-5u4e00q6	1431	3	methods	method	NNS
cord-014712-5u4e00q6	1432	1	:	:	:
cord-014712-5u4e00q6	1432	2	We	-PRON-	PRP
cord-014712-5u4e00q6	1432	3	reviewed	review	VBD
cord-014712-5u4e00q6	1432	4	the	the	DT
cord-014712-5u4e00q6	1432	5	records	record	NNS
cord-014712-5u4e00q6	1432	6	of	of	IN
cord-014712-5u4e00q6	1432	7	adult	adult	NN
cord-014712-5u4e00q6	1432	8	patients	patient	NNS
cord-014712-5u4e00q6	1432	9	with	with	IN
cord-014712-5u4e00q6	1432	10	a	a	DT
cord-014712-5u4e00q6	1432	11	confirmed	confirm	VBN
cord-014712-5u4e00q6	1432	12	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1432	13	of	of	IN
cord-014712-5u4e00q6	1432	14	primary	primary	JJ
cord-014712-5u4e00q6	1432	15	antibody	antibody	NN
cord-014712-5u4e00q6	1432	16	deficiency	deficiency	NN
cord-014712-5u4e00q6	1432	17	at	at	IN
cord-014712-5u4e00q6	1432	18	our	-PRON-	PRP$
cord-014712-5u4e00q6	1432	19	clinic	clinic	NN
cord-014712-5u4e00q6	1432	20	.	.	.
cord-014712-5u4e00q6	1433	1	10	10	CD
cord-014712-5u4e00q6	1433	2	patients	patient	NNS
cord-014712-5u4e00q6	1433	3	were	be	VBD
cord-014712-5u4e00q6	1433	4	included	include	VBN
cord-014712-5u4e00q6	1433	5	in	in	IN
cord-014712-5u4e00q6	1433	6	this	this	DT
cord-014712-5u4e00q6	1433	7	analysis	analysis	NN
cord-014712-5u4e00q6	1433	8	in	in	IN
cord-014712-5u4e00q6	1433	9	whom	whom	WP
cord-014712-5u4e00q6	1433	10	CT	CT	NNP
cord-014712-5u4e00q6	1433	11	scan	scan	NNP
cord-014712-5u4e00q6	1433	12	was	be	VBD
cord-014712-5u4e00q6	1433	13	performed	perform	VBN
cord-014712-5u4e00q6	1433	14	during	during	IN
cord-014712-5u4e00q6	1433	15	the	the	DT
cord-014712-5u4e00q6	1433	16	last	last	JJ
cord-014712-5u4e00q6	1433	17	24	24	CD
cord-014712-5u4e00q6	1433	18	months	month	NNS
cord-014712-5u4e00q6	1433	19	,	,	,
cord-014712-5u4e00q6	1433	20	comprising	comprise	VBG
cord-014712-5u4e00q6	1433	21	8	8	CD
cord-014712-5u4e00q6	1433	22	patients	patient	NNS
cord-014712-5u4e00q6	1433	23	with	with	IN
cord-014712-5u4e00q6	1433	24	CVID	CVID	NNP
cord-014712-5u4e00q6	1433	25	and	and	CC
cord-014712-5u4e00q6	1433	26	two	two	CD
cord-014712-5u4e00q6	1433	27	with	with	IN
cord-014712-5u4e00q6	1433	28	IgG	IgG	NNP
cord-014712-5u4e00q6	1433	29	subclass	subclass	NN
cord-014712-5u4e00q6	1433	30	deficiency	deficiency	NN
cord-014712-5u4e00q6	1433	31	(	(	-LRB-
cord-014712-5u4e00q6	1433	32	median	median	JJ
cord-014712-5u4e00q6	1433	33	age	age	NN
cord-014712-5u4e00q6	1433	34	33	33	CD
cord-014712-5u4e00q6	1433	35	years	year	NNS
cord-014712-5u4e00q6	1433	36	;	;	:
cord-014712-5u4e00q6	1433	37	range	range	VBP
cord-014712-5u4e00q6	1433	38	19	19	CD
cord-014712-5u4e00q6	1433	39	-	-	SYM
cord-014712-5u4e00q6	1433	40	68	68	CD
cord-014712-5u4e00q6	1433	41	years	year	NNS
cord-014712-5u4e00q6	1433	42	;	;	:
cord-014712-5u4e00q6	1433	43	60	60	CD
cord-014712-5u4e00q6	1433	44	%	%	NN
cord-014712-5u4e00q6	1433	45	females	female	NNS
cord-014712-5u4e00q6	1433	46	)	)	-RRB-
cord-014712-5u4e00q6	1433	47	.	.	.
cord-014712-5u4e00q6	1434	1	All	all	DT
cord-014712-5u4e00q6	1434	2	patients	patient	NNS
cord-014712-5u4e00q6	1434	3	were	be	VBD
cord-014712-5u4e00q6	1434	4	on	on	IN
cord-014712-5u4e00q6	1434	5	regular	regular	JJ
cord-014712-5u4e00q6	1434	6	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1434	7	replacement	replacement	NN
cord-014712-5u4e00q6	1434	8	and	and	CC
cord-014712-5u4e00q6	1434	9	one	one	CD
cord-014712-5u4e00q6	1434	10	of	of	IN
cord-014712-5u4e00q6	1434	11	the	the	DT
cord-014712-5u4e00q6	1434	12	patients	patient	NNS
cord-014712-5u4e00q6	1434	13	was	be	VBD
cord-014712-5u4e00q6	1434	14	on	on	IN
cord-014712-5u4e00q6	1434	15	prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	1434	16	antibiotic	antibiotic	NN
cord-014712-5u4e00q6	1434	17	at	at	IN
cord-014712-5u4e00q6	1434	18	the	the	DT
cord-014712-5u4e00q6	1434	19	time	time	NN
cord-014712-5u4e00q6	1434	20	of	of	IN
cord-014712-5u4e00q6	1434	21	analysis	analysis	NN
cord-014712-5u4e00q6	1434	22	.	.	.
cord-014712-5u4e00q6	1435	1	Mean	mean	JJ
cord-014712-5u4e00q6	1435	2	trough	trough	NN
cord-014712-5u4e00q6	1435	3	levels	level	NNS
cord-014712-5u4e00q6	1435	4	of	of	IN
cord-014712-5u4e00q6	1435	5	IgG	igg	NN
cord-014712-5u4e00q6	1435	6	were	be	VBD
cord-014712-5u4e00q6	1435	7	calculated	calculate	VBN
cord-014712-5u4e00q6	1435	8	based	base	VBN
cord-014712-5u4e00q6	1435	9	on	on	IN
cord-014712-5u4e00q6	1435	10	the	the	DT
cord-014712-5u4e00q6	1435	11	results	result	NNS
cord-014712-5u4e00q6	1435	12	measured	measure	VBN
cord-014712-5u4e00q6	1435	13	during	during	IN
cord-014712-5u4e00q6	1435	14	the	the	DT
cord-014712-5u4e00q6	1435	15	last	last	JJ
cord-014712-5u4e00q6	1435	16	12	12	CD
cord-014712-5u4e00q6	1435	17	months	month	NNS
cord-014712-5u4e00q6	1435	18	prior	prior	RB
cord-014712-5u4e00q6	1435	19	to	to	IN
cord-014712-5u4e00q6	1435	20	CT	CT	NNP
cord-014712-5u4e00q6	1435	21	scan	scan	NN
cord-014712-5u4e00q6	1435	22	.	.	.
cord-014712-5u4e00q6	1436	1	The	the	DT
cord-014712-5u4e00q6	1436	2	spirometry	spirometry	NN
cord-014712-5u4e00q6	1436	3	was	be	VBD
cord-014712-5u4e00q6	1436	4	performed	perform	VBN
cord-014712-5u4e00q6	1436	5	according	accord	VBG
cord-014712-5u4e00q6	1436	6	to	to	IN
cord-014712-5u4e00q6	1436	7	published	publish	VBN
cord-014712-5u4e00q6	1436	8	protocols	protocol	NNS
cord-014712-5u4e00q6	1436	9	.	.	.
cord-014712-5u4e00q6	1437	1	Results	result	NNS
cord-014712-5u4e00q6	1437	2	:	:	:
cord-014712-5u4e00q6	1438	1	All	all	DT
cord-014712-5u4e00q6	1438	2	patients	patient	NNS
cord-014712-5u4e00q6	1438	3	demonstrated	demonstrate	VBD
cord-014712-5u4e00q6	1438	4	normal	normal	JJ
cord-014712-5u4e00q6	1438	5	spirometry	spirometry	JJ
cord-014712-5u4e00q6	1438	6	data	datum	NNS
cord-014712-5u4e00q6	1438	7	based	base	VBN
cord-014712-5u4e00q6	1438	8	on	on	IN
cord-014712-5u4e00q6	1438	9	FEV1	FEV1	NNP
cord-014712-5u4e00q6	1438	10	and	and	CC
cord-014712-5u4e00q6	1438	11	FVC	FVC	NNP
cord-014712-5u4e00q6	1438	12	.	.	.
cord-014712-5u4e00q6	1439	1	Two	two	CD
cord-014712-5u4e00q6	1439	2	patients	patient	NNS
cord-014712-5u4e00q6	1439	3	had	have	VBD
cord-014712-5u4e00q6	1439	4	slightly	slightly	RB
cord-014712-5u4e00q6	1439	5	lower	low	JJR
cord-014712-5u4e00q6	1439	6	MMEF	MMEF	NNP
cord-014712-5u4e00q6	1439	7	rates	rate	NNS
cord-014712-5u4e00q6	1439	8	,	,	,
cord-014712-5u4e00q6	1439	9	however	however	RB
cord-014712-5u4e00q6	1439	10	,	,	,
cord-014712-5u4e00q6	1439	11	the	the	DT
cord-014712-5u4e00q6	1439	12	changes	change	NNS
cord-014712-5u4e00q6	1439	13	were	be	VBD
cord-014712-5u4e00q6	1439	14	not	not	RB
cord-014712-5u4e00q6	1439	15	associated	associate	VBN
cord-014712-5u4e00q6	1439	16	with	with	IN
cord-014712-5u4e00q6	1439	17	higher	high	JJR
cord-014712-5u4e00q6	1439	18	rate	rate	NN
cord-014712-5u4e00q6	1439	19	of	of	IN
cord-014712-5u4e00q6	1439	20	infection	infection	NN
cord-014712-5u4e00q6	1439	21	nor	nor	CC
cord-014712-5u4e00q6	1439	22	changes	change	NNS
cord-014712-5u4e00q6	1439	23	in	in	IN
cord-014712-5u4e00q6	1439	24	CT	CT	NNP
cord-014712-5u4e00q6	1439	25	scan	scan	NN
cord-014712-5u4e00q6	1439	26	.	.	.
cord-014712-5u4e00q6	1440	1	None	none	NN
cord-014712-5u4e00q6	1440	2	of	of	IN
cord-014712-5u4e00q6	1440	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	1440	4	patients	patient	NNS
cord-014712-5u4e00q6	1440	5	had	have	VBD
cord-014712-5u4e00q6	1440	6	bronchiectasis	bronchiectasi	NNS
cord-014712-5u4e00q6	1440	7	or	or	CC
cord-014712-5u4e00q6	1440	8	atelectasis	atelectasis	NN
cord-014712-5u4e00q6	1440	9	.	.	.
cord-014712-5u4e00q6	1441	1	Among	among	IN
cord-014712-5u4e00q6	1441	2	parenchymal	parenchymal	JJ
cord-014712-5u4e00q6	1441	3	changes	change	NNS
cord-014712-5u4e00q6	1441	4	fibrotic	fibrotic	JJ
cord-014712-5u4e00q6	1441	5	lines	line	NNS
cord-014712-5u4e00q6	1441	6	were	be	VBD
cord-014712-5u4e00q6	1441	7	most	most	RBS
cord-014712-5u4e00q6	1441	8	frequently	frequently	RB
cord-014712-5u4e00q6	1441	9	detected	detect	VBN
cord-014712-5u4e00q6	1441	10	.	.	.
cord-014712-5u4e00q6	1442	1	In	in	IN
cord-014712-5u4e00q6	1442	2	two	two	CD
cord-014712-5u4e00q6	1442	3	patients	patient	NNS
cord-014712-5u4e00q6	1442	4	ground	ground	NN
cord-014712-5u4e00q6	1442	5	glass	glass	NN
cord-014712-5u4e00q6	1442	6	due	due	JJ
cord-014712-5u4e00q6	1442	7	to	to	IN
cord-014712-5u4e00q6	1442	8	fibrosis	fibrosis	NN
cord-014712-5u4e00q6	1442	9	was	be	VBD
cord-014712-5u4e00q6	1442	10	noted	note	VBN
cord-014712-5u4e00q6	1442	11	.	.	.
cord-014712-5u4e00q6	1443	1	Mean	mean	JJ
cord-014712-5u4e00q6	1443	2	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1443	3	trough	trough	NN
cord-014712-5u4e00q6	1443	4	levels	level	NNS
cord-014712-5u4e00q6	1443	5	in	in	IN
cord-014712-5u4e00q6	1443	6	our	-PRON-	PRP$
cord-014712-5u4e00q6	1443	7	patients	patient	NNS
cord-014712-5u4e00q6	1443	8	were	be	VBD
cord-014712-5u4e00q6	1443	9	between	between	IN
cord-014712-5u4e00q6	1443	10	4.9	4.9	CD
cord-014712-5u4e00q6	1443	11	-	-	HYPH
cord-014712-5u4e00q6	1443	12	8.6g	8.6g	CD
cord-014712-5u4e00q6	1443	13	/	/	SYM
cord-014712-5u4e00q6	1443	14	L	l	NN
cord-014712-5u4e00q6	1443	15	,	,	,
cord-014712-5u4e00q6	1443	16	with	with	IN
cord-014712-5u4e00q6	1443	17	the	the	DT
cord-014712-5u4e00q6	1443	18	median	median	NN
cord-014712-5u4e00q6	1443	19	of	of	IN
cord-014712-5u4e00q6	1443	20	mean	mean	JJ
cord-014712-5u4e00q6	1443	21	trough	trough	NN
cord-014712-5u4e00q6	1443	22	levels	level	NNS
cord-014712-5u4e00q6	1443	23	of	of	IN
cord-014712-5u4e00q6	1443	24	all	all	DT
cord-014712-5u4e00q6	1443	25	our	-PRON-	PRP$
cord-014712-5u4e00q6	1443	26	patients	patient	NNS
cord-014712-5u4e00q6	1443	27	6.9g	6.9g	NNP
cord-014712-5u4e00q6	1443	28	/	/	SYM
cord-014712-5u4e00q6	1443	29	L.	L.	NNP
cord-014712-5u4e00q6	1444	1	When	when	WRB
cord-014712-5u4e00q6	1444	2	comparing	compare	VBG
cord-014712-5u4e00q6	1444	3	the	the	DT
cord-014712-5u4e00q6	1444	4	trough	trough	NN
cord-014712-5u4e00q6	1444	5	levels	level	NNS
cord-014712-5u4e00q6	1444	6	to	to	IN
cord-014712-5u4e00q6	1444	7	lung	lung	NN
cord-014712-5u4e00q6	1444	8	function	function	NN
cord-014712-5u4e00q6	1444	9	and	and	CC
cord-014712-5u4e00q6	1444	10	CT	CT	NNP
cord-014712-5u4e00q6	1444	11	scan	scan	JJ
cord-014712-5u4e00q6	1444	12	results	result	NNS
cord-014712-5u4e00q6	1444	13	,	,	,
cord-014712-5u4e00q6	1444	14	no	no	DT
cord-014712-5u4e00q6	1444	15	significant	significant	JJ
cord-014712-5u4e00q6	1444	16	associations	association	NNS
cord-014712-5u4e00q6	1444	17	were	be	VBD
cord-014712-5u4e00q6	1444	18	seen	see	VBN
cord-014712-5u4e00q6	1444	19	.	.	.
cord-014712-5u4e00q6	1445	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1445	2	:	:	:
cord-014712-5u4e00q6	1446	1	No	no	DT
cord-014712-5u4e00q6	1446	2	remarkable	remarkable	JJ
cord-014712-5u4e00q6	1446	3	changes	change	NNS
cord-014712-5u4e00q6	1446	4	in	in	IN
cord-014712-5u4e00q6	1446	5	lung	lung	NN
cord-014712-5u4e00q6	1446	6	function	function	NN
cord-014712-5u4e00q6	1446	7	or	or	CC
cord-014712-5u4e00q6	1446	8	chest	chest	NN
cord-014712-5u4e00q6	1446	9	CT	CT	NNP
cord-014712-5u4e00q6	1446	10	scan	scan	NN
cord-014712-5u4e00q6	1446	11	in	in	IN
cord-014712-5u4e00q6	1446	12	our	-PRON-	PRP$
cord-014712-5u4e00q6	1446	13	patients	patient	NNS
cord-014712-5u4e00q6	1446	14	with	with	IN
cord-014712-5u4e00q6	1446	15	primary	primary	JJ
cord-014712-5u4e00q6	1446	16	antibody	antibody	NN
cord-014712-5u4e00q6	1446	17	deficiency	deficiency	NN
cord-014712-5u4e00q6	1446	18	were	be	VBD
cord-014712-5u4e00q6	1446	19	noted	note	VBN
cord-014712-5u4e00q6	1446	20	.	.	.
cord-014712-5u4e00q6	1447	1	As	as	IN
cord-014712-5u4e00q6	1447	2	regular	regular	JJ
cord-014712-5u4e00q6	1447	3	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1447	4	replacement	replacement	NN
cord-014712-5u4e00q6	1447	5	therapy	therapy	NN
cord-014712-5u4e00q6	1447	6	could	could	MD
cord-014712-5u4e00q6	1447	7	have	have	VB
cord-014712-5u4e00q6	1447	8	prevented	prevent	VBN
cord-014712-5u4e00q6	1447	9	the	the	DT
cord-014712-5u4e00q6	1447	10	development	development	NN
cord-014712-5u4e00q6	1447	11	of	of	IN
cord-014712-5u4e00q6	1447	12	permanent	permanent	JJ
cord-014712-5u4e00q6	1447	13	lung	lung	NN
cord-014712-5u4e00q6	1447	14	damage	damage	NN
cord-014712-5u4e00q6	1447	15	.	.	.
cord-014712-5u4e00q6	1448	1	Rationale	rationale	NN
cord-014712-5u4e00q6	1448	2	:	:	:
cord-014712-5u4e00q6	1449	1	Patients	patient	NNS
cord-014712-5u4e00q6	1449	2	with	with	IN
cord-014712-5u4e00q6	1449	3	primary	primary	JJ
cord-014712-5u4e00q6	1449	4	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1449	5	(	(	-LRB-
cord-014712-5u4e00q6	1449	6	PI	PI	NNP
cord-014712-5u4e00q6	1449	7	)	)	-RRB-
cord-014712-5u4e00q6	1450	1	(	(	-LRB-
cord-014712-5u4e00q6	1450	2	N	n	NN
cord-014712-5u4e00q6	1450	3	=	=	SYM
cord-014712-5u4e00q6	1450	4	83	83	CD
cord-014712-5u4e00q6	1450	5	)	)	-RRB-
cord-014712-5u4e00q6	1450	6	were	be	VBD
cord-014712-5u4e00q6	1450	7	treated	treat	VBN
cord-014712-5u4e00q6	1450	8	subcutaneously	subcutaneously	RB
cord-014712-5u4e00q6	1450	9	(	(	-LRB-
cord-014712-5u4e00q6	1450	10	SC	SC	NNP
cord-014712-5u4e00q6	1450	11	)	)	-RRB-
cord-014712-5u4e00q6	1450	12	with	with	IN
cord-014712-5u4e00q6	1450	13	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1450	14	G	g	NN
cord-014712-5u4e00q6	1450	15	(	(	-LRB-
cord-014712-5u4e00q6	1450	16	IG	IG	NNP
cord-014712-5u4e00q6	1450	17	)	)	-RRB-
cord-014712-5u4e00q6	1450	18	preceded	precede	VBN
cord-014712-5u4e00q6	1450	19	by	by	IN
cord-014712-5u4e00q6	1450	20	recombinant	recombinant	JJ
cord-014712-5u4e00q6	1450	21	human	human	JJ
cord-014712-5u4e00q6	1450	22	hyaluronidase	hyaluronidase	NN
cord-014712-5u4e00q6	1450	23	(	(	-LRB-
cord-014712-5u4e00q6	1450	24	IGHy	IGHy	NNP
cord-014712-5u4e00q6	1450	25	)	)	-RRB-
cord-014712-5u4e00q6	1450	26	at	at	IN
cord-014712-5u4e00q6	1450	27	3	3	CD
cord-014712-5u4e00q6	1450	28	or	or	CC
cord-014712-5u4e00q6	1450	29	4	4	CD
cord-014712-5u4e00q6	1450	30	week	week	NN
cord-014712-5u4e00q6	1450	31	intervals	interval	NNS
cord-014712-5u4e00q6	1450	32	based	base	VBN
cord-014712-5u4e00q6	1450	33	on	on	IN
cord-014712-5u4e00q6	1450	34	their	-PRON-	PRP$
cord-014712-5u4e00q6	1450	35	previous	previous	JJ
cord-014712-5u4e00q6	1450	36	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1450	37	IG	ig	NN
cord-014712-5u4e00q6	1450	38	(	(	-LRB-
cord-014712-5u4e00q6	1450	39	IGIV	IGIV	NNP
cord-014712-5u4e00q6	1450	40	)	)	-RRB-
cord-014712-5u4e00q6	1450	41	dose	dose	NN
cord-014712-5u4e00q6	1450	42	.	.	.
cord-014712-5u4e00q6	1451	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1451	2	report	report	VBP
cord-014712-5u4e00q6	1451	3	data	datum	NNS
cord-014712-5u4e00q6	1451	4	for	for	IN
cord-014712-5u4e00q6	1451	5	a	a	DT
cord-014712-5u4e00q6	1451	6	subset	subset	NN
cord-014712-5u4e00q6	1451	7	of	of	IN
cord-014712-5u4e00q6	1451	8	59	59	CD
cord-014712-5u4e00q6	1451	9	patients	patient	NNS
cord-014712-5u4e00q6	1451	10	aged	age	VBN
cord-014712-5u4e00q6	1451	11	≥18	≥18	IN
cord-014712-5u4e00q6	1451	12	years	year	NNS
cord-014712-5u4e00q6	1451	13	from	from	IN
cord-014712-5u4e00q6	1451	14	the	the	DT
cord-014712-5u4e00q6	1451	15	final	final	JJ
cord-014712-5u4e00q6	1451	16	efficacy	efficacy	NN
cord-014712-5u4e00q6	1451	17	,	,	,
cord-014712-5u4e00q6	1451	18	safety	safety	NN
cord-014712-5u4e00q6	1451	19	and	and	CC
cord-014712-5u4e00q6	1451	20	tolerability	tolerability	NN
cord-014712-5u4e00q6	1451	21	data	datum	NNS
cord-014712-5u4e00q6	1451	22	of	of	IN
cord-014712-5u4e00q6	1451	23	a	a	DT
cord-014712-5u4e00q6	1451	24	pivotal	pivotal	JJ
cord-014712-5u4e00q6	1451	25	phase	phase	NN
cord-014712-5u4e00q6	1451	26	3	3	CD
cord-014712-5u4e00q6	1451	27	trial	trial	NN
cord-014712-5u4e00q6	1451	28	of	of	IN
cord-014712-5u4e00q6	1451	29	IGHy	IGHy	NNS
cord-014712-5u4e00q6	1451	30	.	.	.
cord-014712-5u4e00q6	1452	1	Methods	method	NNS
cord-014712-5u4e00q6	1452	2	:	:	:
cord-014712-5u4e00q6	1452	3	Patients	patient	NNS
cord-014712-5u4e00q6	1452	4	received	receive	VBD
cord-014712-5u4e00q6	1452	5	IGIV	IGIV	NNP
cord-014712-5u4e00q6	1452	6	for	for	IN
cord-014712-5u4e00q6	1452	7	3	3	CD
cord-014712-5u4e00q6	1452	8	months	month	NNS
cord-014712-5u4e00q6	1452	9	at	at	IN
cord-014712-5u4e00q6	1452	10	prestudy	prestudy	NN
cord-014712-5u4e00q6	1452	11	doses	dose	NNS
cord-014712-5u4e00q6	1452	12	and	and	CC
cord-014712-5u4e00q6	1452	13	frequencies	frequency	NNS
cord-014712-5u4e00q6	1452	14	.	.	.
cord-014712-5u4e00q6	1453	1	Subsequently	subsequently	RB
cord-014712-5u4e00q6	1453	2	,	,	,
cord-014712-5u4e00q6	1453	3	IG	IG	NNP
cord-014712-5u4e00q6	1453	4	10	10	CD
cord-014712-5u4e00q6	1453	5	%	%	NN
cord-014712-5u4e00q6	1453	6	was	be	VBD
cord-014712-5u4e00q6	1453	7	administered	administer	VBN
cord-014712-5u4e00q6	1453	8	SC	SC	NNP
cord-014712-5u4e00q6	1453	9	,	,	,
cord-014712-5u4e00q6	1453	10	at	at	IN
cord-014712-5u4e00q6	1453	11	108	108	CD
cord-014712-5u4e00q6	1453	12	%	%	NN
cord-014712-5u4e00q6	1453	13	of	of	IN
cord-014712-5u4e00q6	1453	14	the	the	DT
cord-014712-5u4e00q6	1453	15	weekly	weekly	JJ
cord-014712-5u4e00q6	1453	16	equivalent	equivalent	NN
cord-014712-5u4e00q6	1453	17	of	of	IN
cord-014712-5u4e00q6	1453	18	the	the	DT
cord-014712-5u4e00q6	1453	19	IV	IV	NNP
cord-014712-5u4e00q6	1453	20	dose	dose	NN
cord-014712-5u4e00q6	1453	21	,	,	,
cord-014712-5u4e00q6	1453	22	following	follow	VBG
cord-014712-5u4e00q6	1453	23	rHuPH20	rhuph20	ADD
cord-014712-5u4e00q6	1453	24	infused	infuse	VBN
cord-014712-5u4e00q6	1453	25	through	through	IN
cord-014712-5u4e00q6	1453	26	the	the	DT
cord-014712-5u4e00q6	1453	27	same	same	JJ
cord-014712-5u4e00q6	1453	28	SC	SC	NNP
cord-014712-5u4e00q6	1453	29	needle	needle	NN
cord-014712-5u4e00q6	1453	30	at	at	IN
cord-014712-5u4e00q6	1453	31	a	a	DT
cord-014712-5u4e00q6	1453	32	dose	dose	NN
cord-014712-5u4e00q6	1453	33	of	of	IN
cord-014712-5u4e00q6	1453	34	75	75	CD
cord-014712-5u4e00q6	1453	35	U	u	NN
cord-014712-5u4e00q6	1453	36	/	/	SYM
cord-014712-5u4e00q6	1453	37	g	g	NN
cord-014712-5u4e00q6	1454	1	IgG.	IgG.	NNP
cord-014712-5u4e00q6	1454	2	After	after	IN
cord-014712-5u4e00q6	1454	3	a	a	DT
cord-014712-5u4e00q6	1454	4	ramp	ramp	NN
cord-014712-5u4e00q6	1454	5	up	up	RP
cord-014712-5u4e00q6	1454	6	from	from	IN
cord-014712-5u4e00q6	1454	7	a	a	DT
cord-014712-5u4e00q6	1454	8	1-to	1-to	NN
cord-014712-5u4e00q6	1454	9	a	a	DT
cord-014712-5u4e00q6	1454	10	3-or	3-or	CD
cord-014712-5u4e00q6	1454	11	4-week	4-week	CD
cord-014712-5u4e00q6	1454	12	dose	dose	NN
cord-014712-5u4e00q6	1454	13	interval	interval	NN
cord-014712-5u4e00q6	1454	14	,	,	,
cord-014712-5u4e00q6	1454	15	59	59	CD
cord-014712-5u4e00q6	1454	16	patients	patient	NNS
cord-014712-5u4e00q6	1454	17	received	receive	VBD
cord-014712-5u4e00q6	1454	18	IGHy	IGHy	NNS
cord-014712-5u4e00q6	1454	19	every	every	DT
cord-014712-5u4e00q6	1454	20	3	3	CD
cord-014712-5u4e00q6	1454	21	4	4	CD
cord-014712-5u4e00q6	1454	22	weeks	week	NNS
cord-014712-5u4e00q6	1454	23	for	for	IN
cord-014712-5u4e00q6	1454	24	12	12	CD
cord-014712-5u4e00q6	1454	25	months	month	NNS
cord-014712-5u4e00q6	1454	26	.	.	.
cord-014712-5u4e00q6	1455	1	The	the	DT
cord-014712-5u4e00q6	1455	2	primary	primary	JJ
cord-014712-5u4e00q6	1455	3	efficacy	efficacy	NN
cord-014712-5u4e00q6	1455	4	endpoint	endpoint	NN
cord-014712-5u4e00q6	1455	5	was	be	VBD
cord-014712-5u4e00q6	1455	6	the	the	DT
cord-014712-5u4e00q6	1455	7	mean	mean	JJ
cord-014712-5u4e00q6	1455	8	rate	rate	NN
cord-014712-5u4e00q6	1455	9	of	of	IN
cord-014712-5u4e00q6	1455	10	validated	validate	VBN
cord-014712-5u4e00q6	1455	11	acute	acute	JJ
cord-014712-5u4e00q6	1455	12	serious	serious	JJ
cord-014712-5u4e00q6	1455	13	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1455	14	infections	infection	NNS
cord-014712-5u4e00q6	1455	15	(	(	-LRB-
cord-014712-5u4e00q6	1455	16	SBIs	sbi	NNS
cord-014712-5u4e00q6	1455	17	)	)	-RRB-
cord-014712-5u4e00q6	1455	18	per	per	IN
cord-014712-5u4e00q6	1455	19	patient	patient	NN
cord-014712-5u4e00q6	1455	20	-	-	HYPH
cord-014712-5u4e00q6	1455	21	year	year	NN
cord-014712-5u4e00q6	1455	22	during	during	IN
cord-014712-5u4e00q6	1455	23	the	the	DT
cord-014712-5u4e00q6	1455	24	efficacy	efficacy	NN
cord-014712-5u4e00q6	1455	25	period	period	NN
cord-014712-5u4e00q6	1455	26	.	.	.
cord-014712-5u4e00q6	1456	1	Results	result	NNS
cord-014712-5u4e00q6	1456	2	:	:	:
cord-014712-5u4e00q6	1457	1	Fifty	fifty	CD
cord-014712-5u4e00q6	1457	2	-	-	HYPH
cord-014712-5u4e00q6	1457	3	nine	nine	CD
cord-014712-5u4e00q6	1457	4	patients	patient	NNS
cord-014712-5u4e00q6	1457	5	received	receive	VBD
cord-014712-5u4e00q6	1457	6	985	985	CD
cord-014712-5u4e00q6	1457	7	IGHy	ighy	NN
cord-014712-5u4e00q6	1457	8	infusions	infusion	NNS
cord-014712-5u4e00q6	1457	9	;	;	:
cord-014712-5u4e00q6	1457	10	97.8	97.8	CD
cord-014712-5u4e00q6	1457	11	%	%	NN
cord-014712-5u4e00q6	1457	12	were	be	VBD
cord-014712-5u4e00q6	1457	13	completed	complete	VBN
cord-014712-5u4e00q6	1457	14	without	without	IN
cord-014712-5u4e00q6	1457	15	administration	administration	NN
cord-014712-5u4e00q6	1457	16	changes	change	NNS
cord-014712-5u4e00q6	1457	17	due	due	JJ
cord-014712-5u4e00q6	1457	18	to	to	IN
cord-014712-5u4e00q6	1457	19	tolerability	tolerability	NN
cord-014712-5u4e00q6	1457	20	concerns	concern	NNS
cord-014712-5u4e00q6	1457	21	or	or	CC
cord-014712-5u4e00q6	1457	22	adverse	adverse	JJ
cord-014712-5u4e00q6	1457	23	events	event	NNS
cord-014712-5u4e00q6	1457	24	(	(	-LRB-
cord-014712-5u4e00q6	1457	25	AEs	AEs	NNP
cord-014712-5u4e00q6	1457	26	)	)	-RRB-
cord-014712-5u4e00q6	1457	27	.	.	.
cord-014712-5u4e00q6	1458	1	Median	median	JJ
cord-014712-5u4e00q6	1458	2	infusion	infusion	NN
cord-014712-5u4e00q6	1458	3	sites	site	NNS
cord-014712-5u4e00q6	1458	4	/	/	SYM
cord-014712-5u4e00q6	1458	5	month	month	NN
cord-014712-5u4e00q6	1458	6	was	be	VBD
cord-014712-5u4e00q6	1458	7	1.13	1.13	CD
cord-014712-5u4e00q6	1458	8	.	.	.
cord-014712-5u4e00q6	1459	1	The	the	DT
cord-014712-5u4e00q6	1459	2	temporally	temporally	RB
cord-014712-5u4e00q6	1459	3	associated	associate	VBN
cord-014712-5u4e00q6	1459	4	systemic	systemic	JJ
cord-014712-5u4e00q6	1459	5	AE	ae	NN
cord-014712-5u4e00q6	1459	6	rate	rate	NN
cord-014712-5u4e00q6	1459	7	was	be	VBD
cord-014712-5u4e00q6	1459	8	0.20	0.20	CD
cord-014712-5u4e00q6	1459	9	/	/	SYM
cord-014712-5u4e00q6	1459	10	infusion	infusion	NN
cord-014712-5u4e00q6	1459	11	(	(	-LRB-
cord-014712-5u4e00q6	1459	12	IGHy	IGHy	NNP
cord-014712-5u4e00q6	1459	13	)	)	-RRB-
cord-014712-5u4e00q6	1459	14	vs.	vs.	FW
cord-014712-5u4e00q6	1459	15	0.33	0.33	CD
cord-014712-5u4e00q6	1459	16	/	/	SYM
cord-014712-5u4e00q6	1459	17	infusion	infusion	NN
cord-014712-5u4e00q6	1459	18	(	(	-LRB-
cord-014712-5u4e00q6	1459	19	IGIV	IGIV	NNP
cord-014712-5u4e00q6	1459	20	)	)	-RRB-
cord-014712-5u4e00q6	1459	21	.	.	.
cord-014712-5u4e00q6	1460	1	The	the	DT
cord-014712-5u4e00q6	1460	2	local	local	JJ
cord-014712-5u4e00q6	1460	3	adverse	adverse	JJ
cord-014712-5u4e00q6	1460	4	drug	drug	NN
cord-014712-5u4e00q6	1460	5	reaction	reaction	NN
cord-014712-5u4e00q6	1460	6	rate	rate	NN
cord-014712-5u4e00q6	1460	7	was	be	VBD
cord-014712-5u4e00q6	1460	8	0.286	0.286	CD
cord-014712-5u4e00q6	1460	9	/	/	SYM
cord-014712-5u4e00q6	1460	10	infusion	infusion	NN
cord-014712-5u4e00q6	1460	11	.	.	.
cord-014712-5u4e00q6	1461	1	The	the	DT
cord-014712-5u4e00q6	1461	2	annual	annual	JJ
cord-014712-5u4e00q6	1461	3	SBI	sbi	NN
cord-014712-5u4e00q6	1461	4	rate	rate	NN
cord-014712-5u4e00q6	1461	5	was	be	VBD
cord-014712-5u4e00q6	1461	6	0.00	0.00	CD
cord-014712-5u4e00q6	1461	7	and	and	CC
cord-014712-5u4e00q6	1461	8	3.10	3.10	CD
cord-014712-5u4e00q6	1461	9	/	/	SYM
cord-014712-5u4e00q6	1461	10	patientyear	patientyear	NN
cord-014712-5u4e00q6	1461	11	for	for	IN
cord-014712-5u4e00q6	1461	12	all	all	DT
cord-014712-5u4e00q6	1461	13	infections	infection	NNS
cord-014712-5u4e00q6	1461	14	.	.	.
cord-014712-5u4e00q6	1462	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1462	2	:	:	:
cord-014712-5u4e00q6	1463	1	In	in	IN
cord-014712-5u4e00q6	1463	2	adults	adult	NNS
cord-014712-5u4e00q6	1463	3	with	with	IN
cord-014712-5u4e00q6	1463	4	PI	PI	NNP
cord-014712-5u4e00q6	1463	5	,	,	,
cord-014712-5u4e00q6	1463	6	IGHy	IGHy	NNP
cord-014712-5u4e00q6	1463	7	was	be	VBD
cord-014712-5u4e00q6	1463	8	effective	effective	JJ
cord-014712-5u4e00q6	1463	9	in	in	IN
cord-014712-5u4e00q6	1463	10	preventing	prevent	VBG
cord-014712-5u4e00q6	1463	11	infections	infection	NNS
cord-014712-5u4e00q6	1463	12	.	.	.
cord-014712-5u4e00q6	1464	1	The	the	DT
cord-014712-5u4e00q6	1464	2	majority	majority	NN
cord-014712-5u4e00q6	1464	3	of	of	IN
cord-014712-5u4e00q6	1464	4	patients	patient	NNS
cord-014712-5u4e00q6	1464	5	received	receive	VBD
cord-014712-5u4e00q6	1464	6	full	full	JJ
cord-014712-5u4e00q6	1464	7	3-to	3-to	CD
cord-014712-5u4e00q6	1464	8	4-weekly	4-weekly	CD
cord-014712-5u4e00q6	1464	9	doses	dose	NNS
cord-014712-5u4e00q6	1464	10	of	of	IN
cord-014712-5u4e00q6	1464	11	IG	IG	NNP
cord-014712-5u4e00q6	1464	12	using	use	VBG
cord-014712-5u4e00q6	1464	13	a	a	DT
cord-014712-5u4e00q6	1464	14	single	single	JJ
cord-014712-5u4e00q6	1464	15	SC	SC	NNP
cord-014712-5u4e00q6	1464	16	site	site	NN
cord-014712-5u4e00q6	1464	17	with	with	IN
cord-014712-5u4e00q6	1464	18	good	good	JJ
cord-014712-5u4e00q6	1464	19	local	local	JJ
cord-014712-5u4e00q6	1464	20	and	and	CC
cord-014712-5u4e00q6	1464	21	systemic	systemic	JJ
cord-014712-5u4e00q6	1464	22	tolerability	tolerability	NN
cord-014712-5u4e00q6	1464	23	.	.	.
cord-014712-5u4e00q6	1465	1	Rationale	rationale	NN
cord-014712-5u4e00q6	1465	2	:	:	:
cord-014712-5u4e00q6	1466	1	In	in	IN
cord-014712-5u4e00q6	1466	2	a	a	DT
cord-014712-5u4e00q6	1466	3	pivotal	pivotal	JJ
cord-014712-5u4e00q6	1466	4	phase	phase	NN
cord-014712-5u4e00q6	1466	5	3	3	CD
cord-014712-5u4e00q6	1466	6	trial	trial	NN
cord-014712-5u4e00q6	1466	7	of	of	IN
cord-014712-5u4e00q6	1466	8	facilitated	facilitate	VBN
cord-014712-5u4e00q6	1466	9	-	-	HYPH
cord-014712-5u4e00q6	1466	10	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	1466	11	(	(	-LRB-
cord-014712-5u4e00q6	1466	12	SC	SC	NNP
cord-014712-5u4e00q6	1466	13	)	)	-RRB-
cord-014712-5u4e00q6	1466	14	infusion	infusion	NN
cord-014712-5u4e00q6	1466	15	of	of	IN
cord-014712-5u4e00q6	1466	16	human	human	JJ
cord-014712-5u4e00q6	1466	17	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1466	18	G	G	NNP
cord-014712-5u4e00q6	1466	19	(	(	-LRB-
cord-014712-5u4e00q6	1466	20	IgG	IgG	NNP
cord-014712-5u4e00q6	1466	21	)	)	-RRB-
cord-014712-5u4e00q6	1466	22	,	,	,
cord-014712-5u4e00q6	1466	23	10	10	CD
cord-014712-5u4e00q6	1466	24	%	%	NN
cord-014712-5u4e00q6	1466	25	,	,	,
cord-014712-5u4e00q6	1466	26	and	and	CC
cord-014712-5u4e00q6	1466	27	recombinant	recombinant	JJ
cord-014712-5u4e00q6	1466	28	human	human	JJ
cord-014712-5u4e00q6	1466	29	hyaluronidase	hyaluronidase	NN
cord-014712-5u4e00q6	1466	30	(	(	-LRB-
cord-014712-5u4e00q6	1466	31	rHuPH20	rHuPH20	NNP
cord-014712-5u4e00q6	1466	32	)	)	-RRB-
cord-014712-5u4e00q6	1466	33	(	(	-LRB-
cord-014712-5u4e00q6	1466	34	IGHy	IGHy	NNP
cord-014712-5u4e00q6	1466	35	)	)	-RRB-
cord-014712-5u4e00q6	1466	36	in	in	IN
cord-014712-5u4e00q6	1466	37	patients	patient	NNS
cord-014712-5u4e00q6	1466	38	with	with	IN
cord-014712-5u4e00q6	1466	39	PI	PI	NNP
cord-014712-5u4e00q6	1466	40	,	,	,
cord-014712-5u4e00q6	1466	41	rHuPH20	rHuPH20	NNP
cord-014712-5u4e00q6	1466	42	permitted	permit	VBD
cord-014712-5u4e00q6	1466	43	most	most	JJS
cord-014712-5u4e00q6	1466	44	patients	patient	NNS
cord-014712-5u4e00q6	1466	45	to	to	TO
cord-014712-5u4e00q6	1466	46	have	have	VB
cord-014712-5u4e00q6	1466	47	a	a	DT
cord-014712-5u4e00q6	1466	48	single	single	JJ
cord-014712-5u4e00q6	1466	49	-	-	HYPH
cord-014712-5u4e00q6	1466	50	site	site	NN
cord-014712-5u4e00q6	1466	51	infusion	infusion	NN
cord-014712-5u4e00q6	1466	52	(	(	-LRB-
cord-014712-5u4e00q6	1466	53	every	every	DT
cord-014712-5u4e00q6	1466	54	3	3	CD
cord-014712-5u4e00q6	1466	55	-	-	HYPH
cord-014712-5u4e00q6	1466	56	4-week	4-week	CD
cord-014712-5u4e00q6	1466	57	IgG	igg	NN
cord-014712-5u4e00q6	1466	58	dosing	dose	VBG
cord-014712-5u4e00q6	1466	59	)	)	-RRB-
cord-014712-5u4e00q6	1466	60	with	with	IN
cord-014712-5u4e00q6	1466	61	bioavailability	bioavailability	NN
cord-014712-5u4e00q6	1466	62	and	and	CC
cord-014712-5u4e00q6	1466	63	infusion	infusion	NN
cord-014712-5u4e00q6	1466	64	rates	rate	NNS
cord-014712-5u4e00q6	1466	65	comparable	comparable	JJ
cord-014712-5u4e00q6	1466	66	to	to	IN
cord-014712-5u4e00q6	1466	67	intravenously	intravenously	RB
cord-014712-5u4e00q6	1466	68	administered	administer	VBN
cord-014712-5u4e00q6	1466	69	IgG	igg	NN
cord-014712-5u4e00q6	1466	70	(	(	-LRB-
cord-014712-5u4e00q6	1466	71	IGIV	IGIV	NNP
cord-014712-5u4e00q6	1466	72	)	)	-RRB-
cord-014712-5u4e00q6	1466	73	.	.	.
cord-014712-5u4e00q6	1467	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1467	2	report	report	VBP
cord-014712-5u4e00q6	1467	3	the	the	DT
cord-014712-5u4e00q6	1467	4	final	final	JJ
cord-014712-5u4e00q6	1467	5	analysis	analysis	NN
cord-014712-5u4e00q6	1467	6	of	of	IN
cord-014712-5u4e00q6	1467	7	the	the	DT
cord-014712-5u4e00q6	1467	8	long	long	JJ
cord-014712-5u4e00q6	1467	9	-	-	HYPH
cord-014712-5u4e00q6	1467	10	term	term	NN
cord-014712-5u4e00q6	1467	11	extension	extension	NN
cord-014712-5u4e00q6	1467	12	of	of	IN
cord-014712-5u4e00q6	1467	13	the	the	DT
cord-014712-5u4e00q6	1467	14	initial	initial	JJ
cord-014712-5u4e00q6	1467	15	phase	phase	NN
cord-014712-5u4e00q6	1467	16	3	3	CD
cord-014712-5u4e00q6	1467	17	study	study	NN
cord-014712-5u4e00q6	1467	18	,	,	,
cord-014712-5u4e00q6	1467	19	with	with	IN
cord-014712-5u4e00q6	1467	20	a	a	DT
cord-014712-5u4e00q6	1467	21	duration	duration	NN
cord-014712-5u4e00q6	1467	22	of	of	IN
cord-014712-5u4e00q6	1467	23	up	up	IN
cord-014712-5u4e00q6	1467	24	to	to	TO
cord-014712-5u4e00q6	1467	25	3	3	CD
cord-014712-5u4e00q6	1467	26	years	year	NNS
cord-014712-5u4e00q6	1467	27	of	of	IN
cord-014712-5u4e00q6	1467	28	treatment	treatment	NN
cord-014712-5u4e00q6	1467	29	with	with	IN
cord-014712-5u4e00q6	1467	30	IGHy	ighy	NN
cord-014712-5u4e00q6	1467	31	plus	plus	CC
cord-014712-5u4e00q6	1467	32	additional	additional	JJ
cord-014712-5u4e00q6	1467	33	follow	follow	NN
cord-014712-5u4e00q6	1467	34	-	-	HYPH
cord-014712-5u4e00q6	1467	35	up	up	NN
cord-014712-5u4e00q6	1467	36	.	.	.
cord-014712-5u4e00q6	1468	1	Methods	method	NNS
cord-014712-5u4e00q6	1468	2	:	:	:
cord-014712-5u4e00q6	1468	3	Sixty	sixty	CD
cord-014712-5u4e00q6	1468	4	-	-	HYPH
cord-014712-5u4e00q6	1468	5	six	six	CD
cord-014712-5u4e00q6	1468	6	patients	patient	NNS
cord-014712-5u4e00q6	1468	7	who	who	WP
cord-014712-5u4e00q6	1468	8	completed	complete	VBD
cord-014712-5u4e00q6	1468	9	the	the	DT
cord-014712-5u4e00q6	1468	10	initial	initial	JJ
cord-014712-5u4e00q6	1468	11	phase	phase	NN
cord-014712-5u4e00q6	1468	12	3	3	CD
cord-014712-5u4e00q6	1468	13	study	study	NN
cord-014712-5u4e00q6	1468	14	enrolled	enrol	VBN
cord-014712-5u4e00q6	1468	15	in	in	IN
cord-014712-5u4e00q6	1468	16	the	the	DT
cord-014712-5u4e00q6	1468	17	Extension	Extension	NNP
cord-014712-5u4e00q6	1468	18	study	study	NN
cord-014712-5u4e00q6	1468	19	.	.	.
cord-014712-5u4e00q6	1469	1	Patients	patient	NNS
cord-014712-5u4e00q6	1469	2	continued	continue	VBD
cord-014712-5u4e00q6	1469	3	their	-PRON-	PRP$
cord-014712-5u4e00q6	1469	4	pre	pre	JJ
cord-014712-5u4e00q6	1469	5	-	-	JJ
cord-014712-5u4e00q6	1469	6	study	study	JJ
cord-014712-5u4e00q6	1469	7	IGHy	IGHy	NNS
cord-014712-5u4e00q6	1469	8	dose	dose	NN
cord-014712-5u4e00q6	1469	9	/	/	SYM
cord-014712-5u4e00q6	1469	10	frequency	frequency	NN
cord-014712-5u4e00q6	1469	11	every	every	DT
cord-014712-5u4e00q6	1469	12	3	3	CD
cord-014712-5u4e00q6	1469	13	-	-	SYM
cord-014712-5u4e00q6	1469	14	4	4	CD
cord-014712-5u4e00q6	1469	15	weeks	week	NNS
cord-014712-5u4e00q6	1469	16	.	.	.
cord-014712-5u4e00q6	1470	1	After	after	IN
cord-014712-5u4e00q6	1470	2	3	3	CD
cord-014712-5u4e00q6	1470	3	months	month	NNS
cord-014712-5u4e00q6	1470	4	,	,	,
cord-014712-5u4e00q6	1470	5	some	some	DT
cord-014712-5u4e00q6	1470	6	patients	patient	NNS
cord-014712-5u4e00q6	1470	7	switched	switch	VBD
cord-014712-5u4e00q6	1470	8	to	to	IN
cord-014712-5u4e00q6	1470	9	2-week	2-week	JJ
cord-014712-5u4e00q6	1470	10	dosing	dose	VBG
cord-014712-5u4e00q6	1470	11	to	to	TO
cord-014712-5u4e00q6	1470	12	evaluate	evaluate	VB
cord-014712-5u4e00q6	1470	13	effects	effect	NNS
cord-014712-5u4e00q6	1470	14	of	of	IN
cord-014712-5u4e00q6	1470	15	shorter	short	JJR
cord-014712-5u4e00q6	1470	16	IGHy	ighy	NN
cord-014712-5u4e00q6	1470	17	interval	interval	NN
cord-014712-5u4e00q6	1470	18	on	on	IN
cord-014712-5u4e00q6	1470	19	trough	trough	NN
cord-014712-5u4e00q6	1470	20	IgG	igg	NN
cord-014712-5u4e00q6	1470	21	levels	level	NNS
cord-014712-5u4e00q6	1470	22	.	.	.
cord-014712-5u4e00q6	1471	1	From	from	IN
cord-014712-5u4e00q6	1471	2	the	the	DT
cord-014712-5u4e00q6	1471	3	final	final	JJ
cord-014712-5u4e00q6	1471	4	analysis	analysis	NN
cord-014712-5u4e00q6	1471	5	,	,	,
cord-014712-5u4e00q6	1471	6	tolerability	tolerability	NN
cord-014712-5u4e00q6	1471	7	and	and	CC
cord-014712-5u4e00q6	1471	8	safety	safety	NN
cord-014712-5u4e00q6	1471	9	after	after	IN
cord-014712-5u4e00q6	1471	10	up	up	IN
cord-014712-5u4e00q6	1471	11	to	to	TO
cord-014712-5u4e00q6	1471	12	3	3	CD
cord-014712-5u4e00q6	1471	13	years	year	NNS
cord-014712-5u4e00q6	1471	14	of	of	IN
cord-014712-5u4e00q6	1471	15	treatment	treatment	NN
cord-014712-5u4e00q6	1471	16	were	be	VBD
cord-014712-5u4e00q6	1471	17	evaluated	evaluate	VBN
cord-014712-5u4e00q6	1471	18	.	.	.
cord-014712-5u4e00q6	1472	1	The	the	DT
cord-014712-5u4e00q6	1472	2	IGHy	ighy	JJ
cord-014712-5u4e00q6	1472	3	part	part	NN
cord-014712-5u4e00q6	1472	4	of	of	IN
cord-014712-5u4e00q6	1472	5	the	the	DT
cord-014712-5u4e00q6	1472	6	Extension	Extension	NNP
cord-014712-5u4e00q6	1472	7	study	study	NN
cord-014712-5u4e00q6	1472	8	was	be	VBD
cord-014712-5u4e00q6	1472	9	followed	follow	VBN
cord-014712-5u4e00q6	1472	10	by	by	IN
cord-014712-5u4e00q6	1472	11	a	a	DT
cord-014712-5u4e00q6	1472	12	24	24	CD
cord-014712-5u4e00q6	1472	13	-	-	SYM
cord-014712-5u4e00q6	1472	14	48	48	CD
cord-014712-5u4e00q6	1472	15	week	week	NN
cord-014712-5u4e00q6	1472	16	observation	observation	NN
cord-014712-5u4e00q6	1472	17	period	period	NN
cord-014712-5u4e00q6	1472	18	during	during	IN
cord-014712-5u4e00q6	1472	19	which	which	WDT
cord-014712-5u4e00q6	1472	20	patients	patient	NNS
cord-014712-5u4e00q6	1472	21	received	receive	VBD
cord-014712-5u4e00q6	1472	22	IgG	IgG	NNP
cord-014712-5u4e00q6	1472	23	10	10	CD
cord-014712-5u4e00q6	1472	24	%	%	NN
cord-014712-5u4e00q6	1472	25	administered	administer	VBN
cord-014712-5u4e00q6	1472	26	IV	IV	NNP
cord-014712-5u4e00q6	1472	27	,	,	,
cord-014712-5u4e00q6	1472	28	or	or	CC
cord-014712-5u4e00q6	1472	29	SC	SC	NNP
cord-014712-5u4e00q6	1472	30	weekly	weekly	NN
cord-014712-5u4e00q6	1472	31	without	without	IN
cord-014712-5u4e00q6	1472	32	rHuPH20	rHuPH20	NNP
cord-014712-5u4e00q6	1472	33	.	.	.
cord-014712-5u4e00q6	1473	1	Results	result	NNS
cord-014712-5u4e00q6	1473	2	:	:	:
cord-014712-5u4e00q6	1474	1	In	in	IN
cord-014712-5u4e00q6	1474	2	the	the	DT
cord-014712-5u4e00q6	1474	3	Extension	Extension	NNP
cord-014712-5u4e00q6	1474	4	study	study	NN
cord-014712-5u4e00q6	1474	5	,	,	,
cord-014712-5u4e00q6	1474	6	66	66	CD
cord-014712-5u4e00q6	1474	7	patients	patient	NNS
cord-014712-5u4e00q6	1474	8	were	be	VBD
cord-014712-5u4e00q6	1474	9	treated	treat	VBN
cord-014712-5u4e00q6	1474	10	with	with	IN
cord-014712-5u4e00q6	1474	11	IGHy	IGHy	NNS
cord-014712-5u4e00q6	1474	12	and	and	CC
cord-014712-5u4e00q6	1474	13	14	14	CD
cord-014712-5u4e00q6	1474	14	discontinued	discontinue	VBD
cord-014712-5u4e00q6	1474	15	prior	prior	RB
cord-014712-5u4e00q6	1474	16	to	to	IN
cord-014712-5u4e00q6	1474	17	safety	safety	NN
cord-014712-5u4e00q6	1474	18	follow	follow	NN
cord-014712-5u4e00q6	1474	19	-	-	HYPH
cord-014712-5u4e00q6	1474	20	up	up	NN
cord-014712-5u4e00q6	1474	21	.	.	.
cord-014712-5u4e00q6	1475	1	Following	follow	VBG
cord-014712-5u4e00q6	1475	2	discontinuation	discontinuation	NN
cord-014712-5u4e00q6	1475	3	of	of	IN
cord-014712-5u4e00q6	1475	4	rHuPH20	rHuPH20	NNP
cord-014712-5u4e00q6	1475	5	,	,	,
cord-014712-5u4e00q6	1475	6	48	48	CD
cord-014712-5u4e00q6	1475	7	patients	patient	NNS
cord-014712-5u4e00q6	1475	8	switched	switch	VBD
cord-014712-5u4e00q6	1475	9	to	to	TO
cord-014712-5u4e00q6	1475	10	follow	follow	VB
cord-014712-5u4e00q6	1475	11	-	-	HYPH
cord-014712-5u4e00q6	1475	12	up	up	NN
cord-014712-5u4e00q6	1475	13	.	.	.
cord-014712-5u4e00q6	1476	1	No	no	DT
cord-014712-5u4e00q6	1476	2	patients	patient	NNS
cord-014712-5u4e00q6	1476	3	withdrew	withdraw	VBD
cord-014712-5u4e00q6	1476	4	due	due	IN
cord-014712-5u4e00q6	1476	5	to	to	IN
cord-014712-5u4e00q6	1476	6	IGHy	ighy	NN
cord-014712-5u4e00q6	1476	7	-	-	HYPH
cord-014712-5u4e00q6	1476	8	related	relate	VBN
cord-014712-5u4e00q6	1476	9	reactions	reaction	NNS
cord-014712-5u4e00q6	1476	10	(	(	-LRB-
cord-014712-5u4e00q6	1476	11	ADRs	adr	NNS
cord-014712-5u4e00q6	1476	12	)	)	-RRB-
cord-014712-5u4e00q6	1476	13	.	.	.
cord-014712-5u4e00q6	1477	1	No	no	DT
cord-014712-5u4e00q6	1477	2	serious	serious	JJ
cord-014712-5u4e00q6	1477	3	ADRs	adr	NNS
cord-014712-5u4e00q6	1477	4	related	relate	VBN
cord-014712-5u4e00q6	1477	5	to	to	IN
cord-014712-5u4e00q6	1477	6	IGHy	IGHy	NNS
cord-014712-5u4e00q6	1477	7	were	be	VBD
cord-014712-5u4e00q6	1477	8	reported	report	VBN
cord-014712-5u4e00q6	1477	9	.	.	.
cord-014712-5u4e00q6	1478	1	The	the	DT
cord-014712-5u4e00q6	1478	2	maximum	maximum	JJ
cord-014712-5u4e00q6	1478	3	IGHy	ighy	NN
cord-014712-5u4e00q6	1478	4	exposure	exposure	NN
cord-014712-5u4e00q6	1478	5	for	for	IN
cord-014712-5u4e00q6	1478	6	the	the	DT
cord-014712-5u4e00q6	1478	7	initial	initial	JJ
cord-014712-5u4e00q6	1478	8	and	and	CC
cord-014712-5u4e00q6	1478	9	Extension	Extension	NNP
cord-014712-5u4e00q6	1478	10	studies	study	NNS
cord-014712-5u4e00q6	1478	11	combined	combine	VBN
cord-014712-5u4e00q6	1478	12	was	be	VBD
cord-014712-5u4e00q6	1478	13	3	3	CD
cord-014712-5u4e00q6	1478	14	years	year	NNS
cord-014712-5u4e00q6	1478	15	(	(	-LRB-
cord-014712-5u4e00q6	1478	16	total	total	JJ
cord-014712-5u4e00q6	1478	17	exposure	exposure	NN
cord-014712-5u4e00q6	1478	18	=	=	SYM
cord-014712-5u4e00q6	1478	19	187.69	187.69	CD
cord-014712-5u4e00q6	1478	20	patient	patient	NN
cord-014712-5u4e00q6	1478	21	-	-	HYPH
cord-014712-5u4e00q6	1478	22	years	year	NNS
cord-014712-5u4e00q6	1478	23	;	;	:
cord-014712-5u4e00q6	1478	24	N	n	CD
cord-014712-5u4e00q6	1478	25	=	=	SYM
cord-014712-5u4e00q6	1478	26	2959	2959	CD
cord-014712-5u4e00q6	1478	27	IGHy	IGHy	VBN
cord-014712-5u4e00q6	1478	28	infusions	infusion	NNS
cord-014712-5u4e00q6	1478	29	)	)	-RRB-
cord-014712-5u4e00q6	1478	30	;	;	:
cord-014712-5u4e00q6	1478	31	during	during	IN
cord-014712-5u4e00q6	1478	32	this	this	DT
cord-014712-5u4e00q6	1478	33	time	time	NN
cord-014712-5u4e00q6	1478	34	,	,	,
cord-014712-5u4e00q6	1478	35	there	there	EX
cord-014712-5u4e00q6	1478	36	were	be	VBD
cord-014712-5u4e00q6	1478	37	no	no	DT
cord-014712-5u4e00q6	1478	38	clinically	clinically	RB
cord-014712-5u4e00q6	1478	39	observable	observable	JJ
cord-014712-5u4e00q6	1478	40	long	long	JJ
cord-014712-5u4e00q6	1478	41	-	-	HYPH
cord-014712-5u4e00q6	1478	42	term	term	NN
cord-014712-5u4e00q6	1478	43	changes	change	NNS
cord-014712-5u4e00q6	1478	44	in	in	IN
cord-014712-5u4e00q6	1478	45	the	the	DT
cord-014712-5u4e00q6	1478	46	skin	skin	NN
cord-014712-5u4e00q6	1478	47	or	or	CC
cord-014712-5u4e00q6	1478	48	SC	SC	NNP
cord-014712-5u4e00q6	1478	49	tissue	tissue	NN
cord-014712-5u4e00q6	1478	50	.	.	.
cord-014712-5u4e00q6	1479	1	The	the	DT
cord-014712-5u4e00q6	1479	2	rate	rate	NN
cord-014712-5u4e00q6	1479	3	of	of	IN
cord-014712-5u4e00q6	1479	4	temporally	temporally	RB
cord-014712-5u4e00q6	1479	5	related	relate	VBN
cord-014712-5u4e00q6	1479	6	systemic	systemic	JJ
cord-014712-5u4e00q6	1479	7	adverse	adverse	JJ
cord-014712-5u4e00q6	1479	8	events	event	NNS
cord-014712-5u4e00q6	1479	9	(	(	-LRB-
cord-014712-5u4e00q6	1479	10	AEs	AEs	NNP
cord-014712-5u4e00q6	1479	11	)	)	-RRB-
cord-014712-5u4e00q6	1479	12	,	,	,
cord-014712-5u4e00q6	1479	13	excluding	exclude	VBG
cord-014712-5u4e00q6	1479	14	infections	infection	NNS
cord-014712-5u4e00q6	1479	15	,	,	,
cord-014712-5u4e00q6	1479	16	was	be	VBD
cord-014712-5u4e00q6	1479	17	0.159/	0.159/	CD
cord-014712-5u4e00q6	1479	18	infusion	infusion	NN
cord-014712-5u4e00q6	1479	19	.	.	.
cord-014712-5u4e00q6	1480	1	The	the	DT
cord-014712-5u4e00q6	1480	2	rate	rate	NN
cord-014712-5u4e00q6	1480	3	of	of	IN
cord-014712-5u4e00q6	1480	4	all	all	DT
cord-014712-5u4e00q6	1480	5	local	local	JJ
cord-014712-5u4e00q6	1480	6	AEs	AEs	NNP
cord-014712-5u4e00q6	1480	7	was	be	VBD
cord-014712-5u4e00q6	1480	8	0.103	0.103	CD
cord-014712-5u4e00q6	1480	9	/	/	SYM
cord-014712-5u4e00q6	1480	10	infusion	infusion	NN
cord-014712-5u4e00q6	1480	11	.	.	.
cord-014712-5u4e00q6	1481	1	Of	of	IN
cord-014712-5u4e00q6	1481	2	the	the	DT
cord-014712-5u4e00q6	1481	3	1600	1600	CD
cord-014712-5u4e00q6	1481	4	IGHy	IGHy	NNS
cord-014712-5u4e00q6	1481	5	infusions	infusion	NNS
cord-014712-5u4e00q6	1481	6	administered	administer	VBN
cord-014712-5u4e00q6	1481	7	in	in	IN
cord-014712-5u4e00q6	1481	8	the	the	DT
cord-014712-5u4e00q6	1481	9	Extension	Extension	NNP
cord-014712-5u4e00q6	1481	10	study	study	NN
cord-014712-5u4e00q6	1481	11	,	,	,
cord-014712-5u4e00q6	1481	12	97.9	97.9	CD
cord-014712-5u4e00q6	1481	13	%	%	NN
cord-014712-5u4e00q6	1481	14	had	have	VBD
cord-014712-5u4e00q6	1481	15	no	no	DT
cord-014712-5u4e00q6	1481	16	administration	administration	NN
cord-014712-5u4e00q6	1481	17	changes	change	NNS
cord-014712-5u4e00q6	1481	18	(	(	-LRB-
cord-014712-5u4e00q6	1481	19	rate	rate	NN
cord-014712-5u4e00q6	1481	20	reduction	reduction	NN
cord-014712-5u4e00q6	1481	21	,	,	,
cord-014712-5u4e00q6	1481	22	interruption	interruption	NN
cord-014712-5u4e00q6	1481	23	or	or	CC
cord-014712-5u4e00q6	1481	24	discontinuation	discontinuation	NN
cord-014712-5u4e00q6	1481	25	)	)	-RRB-
cord-014712-5u4e00q6	1481	26	due	due	IN
cord-014712-5u4e00q6	1481	27	to	to	IN
cord-014712-5u4e00q6	1481	28	tolerability	tolerability	NN
cord-014712-5u4e00q6	1481	29	concerns	concern	NNS
cord-014712-5u4e00q6	1481	30	or	or	CC
cord-014712-5u4e00q6	1481	31	adverse	adverse	JJ
cord-014712-5u4e00q6	1481	32	events	event	NNS
cord-014712-5u4e00q6	1481	33	.	.	.
cord-014712-5u4e00q6	1482	1	The	the	DT
cord-014712-5u4e00q6	1482	2	annual	annual	JJ
cord-014712-5u4e00q6	1482	3	rate	rate	NN
cord-014712-5u4e00q6	1482	4	of	of	IN
cord-014712-5u4e00q6	1482	5	all	all	DT
cord-014712-5u4e00q6	1482	6	infections	infection	NNS
cord-014712-5u4e00q6	1482	7	under	under	IN
cord-014712-5u4e00q6	1482	8	IGHy	ighy	NN
cord-014712-5u4e00q6	1482	9	treatment	treatment	NN
cord-014712-5u4e00q6	1482	10	was	be	VBD
cord-014712-5u4e00q6	1482	11	2.86	2.86	CD
cord-014712-5u4e00q6	1482	12	/	/	SYM
cord-014712-5u4e00q6	1482	13	patient	patient	NN
cord-014712-5u4e00q6	1482	14	-	-	HYPH
cord-014712-5u4e00q6	1482	15	year	year	NN
cord-014712-5u4e00q6	1482	16	.	.	.
cord-014712-5u4e00q6	1483	1	Reducing	reduce	VBG
cord-014712-5u4e00q6	1483	2	the	the	DT
cord-014712-5u4e00q6	1483	3	dosing	dosing	NN
cord-014712-5u4e00q6	1483	4	interval	interval	NN
cord-014712-5u4e00q6	1483	5	from	from	IN
cord-014712-5u4e00q6	1483	6	4	4	CD
cord-014712-5u4e00q6	1483	7	to	to	TO
cord-014712-5u4e00q6	1483	8	2	2	CD
cord-014712-5u4e00q6	1483	9	weeks	week	NNS
cord-014712-5u4e00q6	1483	10	(	(	-LRB-
cord-014712-5u4e00q6	1483	11	same	same	JJ
cord-014712-5u4e00q6	1483	12	monthly	monthly	JJ
cord-014712-5u4e00q6	1483	13	dose	dose	NN
cord-014712-5u4e00q6	1483	14	)	)	-RRB-
cord-014712-5u4e00q6	1483	15	resulted	result	VBD
cord-014712-5u4e00q6	1483	16	in	in	IN
cord-014712-5u4e00q6	1483	17	a	a	DT
cord-014712-5u4e00q6	1483	18	13	13	CD
cord-014712-5u4e00q6	1483	19	%	%	NN
cord-014712-5u4e00q6	1483	20	increase	increase	NN
cord-014712-5u4e00q6	1483	21	in	in	IN
cord-014712-5u4e00q6	1483	22	trough	trough	NN
cord-014712-5u4e00q6	1483	23	IgG	igg	NN
cord-014712-5u4e00q6	1483	24	levels	level	NNS
cord-014712-5u4e00q6	1483	25	.	.	.
cord-014712-5u4e00q6	1484	1	Thirteen	thirteen	CD
cord-014712-5u4e00q6	1484	2	patients	patient	NNS
cord-014712-5u4e00q6	1484	3	had	have	VBD
cord-014712-5u4e00q6	1484	4	at	at	RB
cord-014712-5u4e00q6	1484	5	least	least	JJS
cord-014712-5u4e00q6	1484	6	1	1	CD
cord-014712-5u4e00q6	1484	7	non	non	JJ
cord-014712-5u4e00q6	1484	8	-	-	JJ
cord-014712-5u4e00q6	1484	9	neutralizing	neutralizing	JJ
cord-014712-5u4e00q6	1484	10	anti	anti	JJ
cord-014712-5u4e00q6	1484	11	-	-	JJ
cord-014712-5u4e00q6	1484	12	rHuPH20	rhuph20	JJ
cord-014712-5u4e00q6	1484	13	antibody	antibody	NN
cord-014712-5u4e00q6	1484	14	titer	titer	NN
cord-014712-5u4e00q6	1484	15	of	of	IN
cord-014712-5u4e00q6	1484	16	≥1:160	≥1:160	NNP
cord-014712-5u4e00q6	1484	17	with	with	IN
cord-014712-5u4e00q6	1484	18	no	no	DT
cord-014712-5u4e00q6	1484	19	associated	associate	VBN
cord-014712-5u4e00q6	1484	20	AEs	AEs	NNP
cord-014712-5u4e00q6	1484	21	;	;	:
cord-014712-5u4e00q6	1484	22	no	no	DT
cord-014712-5u4e00q6	1484	23	patients	patient	NNS
cord-014712-5u4e00q6	1484	24	had	have	VBD
cord-014712-5u4e00q6	1484	25	neutralizing	neutralize	VBG
cord-014712-5u4e00q6	1484	26	anti	anti	AFX
cord-014712-5u4e00q6	1484	27	-	-	JJ
cord-014712-5u4e00q6	1484	28	rHuPH20	rhuph20	JJ
cord-014712-5u4e00q6	1484	29	antibodies	antibody	NNS
cord-014712-5u4e00q6	1484	30	.	.	.
cord-014712-5u4e00q6	1485	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	1485	2	:	:	:
cord-014712-5u4e00q6	1486	1	In	in	IN
cord-014712-5u4e00q6	1486	2	the	the	DT
cord-014712-5u4e00q6	1486	3	Extension	Extension	NNP
cord-014712-5u4e00q6	1486	4	study	study	NN
cord-014712-5u4e00q6	1486	5	,	,	,
cord-014712-5u4e00q6	1486	6	IGHy	IGHy	NNP
cord-014712-5u4e00q6	1486	7	was	be	VBD
cord-014712-5u4e00q6	1486	8	well	well	RB
cord-014712-5u4e00q6	1486	9	tolerated	tolerate	VBN
cord-014712-5u4e00q6	1486	10	and	and	CC
cord-014712-5u4e00q6	1486	11	effective	effective	JJ
cord-014712-5u4e00q6	1486	12	,	,	,
cord-014712-5u4e00q6	1486	13	with	with	IN
cord-014712-5u4e00q6	1486	14	no	no	DT
cord-014712-5u4e00q6	1486	15	serious	serious	JJ
cord-014712-5u4e00q6	1486	16	ADRs	adr	NNS
cord-014712-5u4e00q6	1486	17	for	for	IN
cord-014712-5u4e00q6	1486	18	treatment	treatment	NN
cord-014712-5u4e00q6	1486	19	periods	period	NNS
cord-014712-5u4e00q6	1486	20	up	up	IN
cord-014712-5u4e00q6	1486	21	to	to	TO
cord-014712-5u4e00q6	1486	22	2	2	CD
cord-014712-5u4e00q6	1486	23	years	year	NNS
cord-014712-5u4e00q6	1486	24	.	.	.
cord-014712-5u4e00q6	1487	1	Over	over	IN
cord-014712-5u4e00q6	1487	2	a	a	DT
cord-014712-5u4e00q6	1487	3	maximum	maximum	JJ
cord-014712-5u4e00q6	1487	4	3-year	3-year	JJ
cord-014712-5u4e00q6	1487	5	IGHy	ighy	NN
cord-014712-5u4e00q6	1487	6	exposure	exposure	NN
cord-014712-5u4e00q6	1487	7	(	(	-LRB-
cord-014712-5u4e00q6	1487	8	for	for	IN
cord-014712-5u4e00q6	1487	9	an	an	DT
cord-014712-5u4e00q6	1487	10	individual	individual	JJ
cord-014712-5u4e00q6	1487	11	patient	patient	NN
cord-014712-5u4e00q6	1487	12	)	)	-RRB-
cord-014712-5u4e00q6	1487	13	in	in	IN
cord-014712-5u4e00q6	1487	14	the	the	DT
cord-014712-5u4e00q6	1487	15	initial	initial	JJ
cord-014712-5u4e00q6	1487	16	phase	phase	NN
cord-014712-5u4e00q6	1487	17	3	3	CD
cord-014712-5u4e00q6	1487	18	and	and	CC
cord-014712-5u4e00q6	1487	19	Extension	Extension	NNP
cord-014712-5u4e00q6	1487	20	studies	study	NNS
cord-014712-5u4e00q6	1487	21	combined	combine	VBN
cord-014712-5u4e00q6	1487	22	,	,	,
cord-014712-5u4e00q6	1487	23	no	no	DT
cord-014712-5u4e00q6	1487	24	long	long	JJ
cord-014712-5u4e00q6	1487	25	-	-	HYPH
cord-014712-5u4e00q6	1487	26	term	term	NN
cord-014712-5u4e00q6	1487	27	changes	change	NNS
cord-014712-5u4e00q6	1487	28	in	in	IN
cord-014712-5u4e00q6	1487	29	skin	skin	NN
cord-014712-5u4e00q6	1487	30	or	or	CC
cord-014712-5u4e00q6	1487	31	SC	SC	NNP
cord-014712-5u4e00q6	1487	32	tissue	tissue	NN
cord-014712-5u4e00q6	1487	33	were	be	VBD
cord-014712-5u4e00q6	1487	34	observed	observe	VBN
cord-014712-5u4e00q6	1487	35	.	.	.
cord-014712-5u4e00q6	1488	1	The	the	DT
cord-014712-5u4e00q6	1488	2	rates	rate	NNS
cord-014712-5u4e00q6	1488	3	of	of	IN
cord-014712-5u4e00q6	1488	4	infections	infection	NNS
cord-014712-5u4e00q6	1488	5	and	and	CC
cord-014712-5u4e00q6	1488	6	adverse	adverse	JJ
cord-014712-5u4e00q6	1488	7	reactions	reaction	NNS
cord-014712-5u4e00q6	1488	8	were	be	VBD
cord-014712-5u4e00q6	1488	9	stable	stable	JJ
cord-014712-5u4e00q6	1488	10	or	or	CC
cord-014712-5u4e00q6	1488	11	decreased	decrease	VBD
cord-014712-5u4e00q6	1488	12	over	over	IN
cord-014712-5u4e00q6	1488	13	the	the	DT
cord-014712-5u4e00q6	1488	14	course	course	NN
cord-014712-5u4e00q6	1488	15	of	of	IN
cord-014712-5u4e00q6	1488	16	the	the	DT
cord-014712-5u4e00q6	1488	17	two	two	CD
cord-014712-5u4e00q6	1488	18	studies	study	NNS
cord-014712-5u4e00q6	1488	19	,	,	,
cord-014712-5u4e00q6	1488	20	suggesting	suggest	VBG
cord-014712-5u4e00q6	1488	21	no	no	DT
cord-014712-5u4e00q6	1488	22	increased	increase	VBN
cord-014712-5u4e00q6	1488	23	risk	risk	NN
cord-014712-5u4e00q6	1488	24	with	with	IN
cord-014712-5u4e00q6	1488	25	continued	continue	VBN
cord-014712-5u4e00q6	1488	26	exposure	exposure	NN
cord-014712-5u4e00q6	1488	27	to	to	IN
cord-014712-5u4e00q6	1488	28	IGHy	IGHy	NNP
cord-014712-5u4e00q6	1488	29	.	.	.
cord-014712-5u4e00q6	1489	1	Rationale	rationale	NN
cord-014712-5u4e00q6	1489	2	:	:	:
cord-014712-5u4e00q6	1490	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1490	2	report	report	VBP
cord-014712-5u4e00q6	1490	3	interim	interim	JJ
cord-014712-5u4e00q6	1490	4	analysis	analysis	NN
cord-014712-5u4e00q6	1490	5	of	of	IN
cord-014712-5u4e00q6	1490	6	safety	safety	NN
cord-014712-5u4e00q6	1490	7	,	,	,
cord-014712-5u4e00q6	1490	8	tolerability	tolerability	NN
cord-014712-5u4e00q6	1490	9	and	and	CC
cord-014712-5u4e00q6	1490	10	pharmacokinetics	pharmacokinetic	NNS
cord-014712-5u4e00q6	1490	11	(	(	-LRB-
cord-014712-5u4e00q6	1490	12	PK	PK	NNP
cord-014712-5u4e00q6	1490	13	)	)	-RRB-
cord-014712-5u4e00q6	1490	14	of	of	IN
cord-014712-5u4e00q6	1490	15	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1490	16	20	20	CD
cord-014712-5u4e00q6	1490	17	%	%	NN
cord-014712-5u4e00q6	1490	18	in	in	IN
cord-014712-5u4e00q6	1490	19	patients	patient	NNS
cord-014712-5u4e00q6	1490	20	with	with	IN
cord-014712-5u4e00q6	1490	21	primary	primary	JJ
cord-014712-5u4e00q6	1490	22	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1490	23	(	(	-LRB-
cord-014712-5u4e00q6	1490	24	PI	PI	NNP
cord-014712-5u4e00q6	1490	25	)	)	-RRB-
cord-014712-5u4e00q6	1490	26	aged	age	VBN
cord-014712-5u4e00q6	1490	27	≥2	≥2	NNP
cord-014712-5u4e00q6	1490	28	years	year	NNS
cord-014712-5u4e00q6	1490	29	in	in	IN
cord-014712-5u4e00q6	1490	30	Europe	Europe	NNP
cord-014712-5u4e00q6	1490	31	.	.	.
cord-014712-5u4e00q6	1491	1	Methods	method	NNS
cord-014712-5u4e00q6	1491	2	:	:	:
cord-014712-5u4e00q6	1491	3	Epoch	epoch	NN
cord-014712-5u4e00q6	1491	4	1	1	CD
cord-014712-5u4e00q6	1491	5	:	:	:
cord-014712-5u4e00q6	1491	6	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1491	7	16	16	CD
cord-014712-5u4e00q6	1491	8	%	%	NN
cord-014712-5u4e00q6	1491	9	or	or	CC
cord-014712-5u4e00q6	1491	10	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1491	11	IG	IG	NNP
cord-014712-5u4e00q6	1491	12	10	10	CD
cord-014712-5u4e00q6	1491	13	%	%	NN
cord-014712-5u4e00q6	1491	14	(	(	-LRB-
cord-014712-5u4e00q6	1491	15	IGIV	IGIV	NNP
cord-014712-5u4e00q6	1491	16	)	)	-RRB-
cord-014712-5u4e00q6	1491	17	administered	administer	VBN
cord-014712-5u4e00q6	1491	18	at	at	IN
cord-014712-5u4e00q6	1491	19	pre	pre	JJ
cord-014712-5u4e00q6	1491	20	-	-	JJ
cord-014712-5u4e00q6	1491	21	study	study	JJ
cord-014712-5u4e00q6	1491	22	doses	dose	NNS
cord-014712-5u4e00q6	1491	23	every	every	DT
cord-014712-5u4e00q6	1491	24	3	3	CD
cord-014712-5u4e00q6	1491	25	months	month	NNS
cord-014712-5u4e00q6	1491	26	.	.	.
cord-014712-5u4e00q6	1492	1	Epoch	epoch	NN
cord-014712-5u4e00q6	1492	2	2	2	CD
cord-014712-5u4e00q6	1492	3	:	:	:
cord-014712-5u4e00q6	1492	4	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1492	5	20	20	CD
cord-014712-5u4e00q6	1492	6	%	%	NN
cord-014712-5u4e00q6	1492	7	administered	administer	VBD
cord-014712-5u4e00q6	1492	8	1	1	CD
cord-014712-5u4e00q6	1492	9	time	time	NN
cord-014712-5u4e00q6	1492	10	per	per	IN
cord-014712-5u4e00q6	1492	11	week	week	NN
cord-014712-5u4e00q6	1492	12	for	for	IN
cord-014712-5u4e00q6	1492	13	12	12	CD
cord-014712-5u4e00q6	1492	14	months	month	NNS
cord-014712-5u4e00q6	1492	15	at	at	IN
cord-014712-5u4e00q6	1492	16	Epoch	epoch	NN
cord-014712-5u4e00q6	1492	17	1	1	CD
cord-014712-5u4e00q6	1492	18	doses	dose	NNS
cord-014712-5u4e00q6	1492	19	.	.	.
cord-014712-5u4e00q6	1493	1	Serum	serum	NN
cord-014712-5u4e00q6	1493	2	IgG	igg	NN
cord-014712-5u4e00q6	1493	3	trough	trough	NN
cord-014712-5u4e00q6	1493	4	levels	level	NNS
cord-014712-5u4e00q6	1493	5	are	be	VBP
cord-014712-5u4e00q6	1493	6	maintained	maintain	VBN
cord-014712-5u4e00q6	1493	7	at	at	IN
cord-014712-5u4e00q6	1493	8	>	>	XX
cord-014712-5u4e00q6	1493	9	5	5	CD
cord-014712-5u4e00q6	1493	10	g	g	NN
cord-014712-5u4e00q6	1493	11	/	/	SYM
cord-014712-5u4e00q6	1493	12	L.	L.	NNP
cord-014712-5u4e00q6	1494	1	The	the	DT
cord-014712-5u4e00q6	1494	2	primary	primary	JJ
cord-014712-5u4e00q6	1494	3	endpoint	endpoint	NN
cord-014712-5u4e00q6	1494	4	is	be	VBZ
cord-014712-5u4e00q6	1494	5	validated	validate	VBN
cord-014712-5u4e00q6	1494	6	acute	acute	JJ
cord-014712-5u4e00q6	1494	7	serious	serious	JJ
cord-014712-5u4e00q6	1494	8	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1494	9	infection	infection	NN
cord-014712-5u4e00q6	1494	10	(	(	-LRB-
cord-014712-5u4e00q6	1494	11	SBI	SBI	NNP
cord-014712-5u4e00q6	1494	12	)	)	-RRB-
cord-014712-5u4e00q6	1494	13	rate	rate	NN
cord-014712-5u4e00q6	1494	14	.	.	.
cord-014712-5u4e00q6	1495	1	Results	result	NNS
cord-014712-5u4e00q6	1495	2	:	:	:
cord-014712-5u4e00q6	1496	1	At	at	IN
cord-014712-5u4e00q6	1496	2	the	the	DT
cord-014712-5u4e00q6	1496	3	interim	interim	JJ
cord-014712-5u4e00q6	1496	4	analysis	analysis	NN
cord-014712-5u4e00q6	1496	5	in	in	IN
cord-014712-5u4e00q6	1496	6	October	October	NNP
cord-014712-5u4e00q6	1496	7	2013	2013	CD
cord-014712-5u4e00q6	1496	8	,	,	,
cord-014712-5u4e00q6	1496	9	49	49	CD
cord-014712-5u4e00q6	1496	10	patients	patient	NNS
cord-014712-5u4e00q6	1496	11	started	start	VBD
cord-014712-5u4e00q6	1496	12	the	the	DT
cord-014712-5u4e00q6	1496	13	study	study	NN
cord-014712-5u4e00q6	1496	14	.	.	.
cord-014712-5u4e00q6	1497	1	During	during	IN
cord-014712-5u4e00q6	1497	2	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1497	3	20	20	CD
cord-014712-5u4e00q6	1497	4	%	%	NN
cord-014712-5u4e00q6	1497	5	treatment	treatment	NN
cord-014712-5u4e00q6	1497	6	(	(	-LRB-
cord-014712-5u4e00q6	1497	7	n	n	NN
cord-014712-5u4e00q6	1497	8	=	=	SYM
cord-014712-5u4e00q6	1497	9	48	48	CD
cord-014712-5u4e00q6	1497	10	)	)	-RRB-
cord-014712-5u4e00q6	1497	11	,	,	,
cord-014712-5u4e00q6	1497	12	1	1	CD
cord-014712-5u4e00q6	1497	13	acute	acute	JJ
cord-014712-5u4e00q6	1497	14	SBI	SBI	NNP
cord-014712-5u4e00q6	1497	15	episode	episode	NN
cord-014712-5u4e00q6	1497	16	(	(	-LRB-
cord-014712-5u4e00q6	1497	17	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1497	18	,	,	,
cord-014712-5u4e00q6	1497	19	moderate	moderate	JJ
cord-014712-5u4e00q6	1497	20	in	in	IN
cord-014712-5u4e00q6	1497	21	severity	severity	NN
cord-014712-5u4e00q6	1497	22	)	)	-RRB-
cord-014712-5u4e00q6	1497	23	was	be	VBD
cord-014712-5u4e00q6	1497	24	reported	report	VBN
cord-014712-5u4e00q6	1497	25	.	.	.
cord-014712-5u4e00q6	1498	1	The	the	DT
cord-014712-5u4e00q6	1498	2	infection	infection	NN
cord-014712-5u4e00q6	1498	3	rate	rate	NN
cord-014712-5u4e00q6	1498	4	per	per	IN
cord-014712-5u4e00q6	1498	5	patientyear	patientyear	NN
cord-014712-5u4e00q6	1498	6	was	be	VBD
cord-014712-5u4e00q6	1498	7	4.3	4.3	CD
cord-014712-5u4e00q6	1498	8	(	(	-LRB-
cord-014712-5u4e00q6	1498	9	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1498	10	20	20	CD
cord-014712-5u4e00q6	1498	11	%	%	NN
cord-014712-5u4e00q6	1498	12	)	)	-RRB-
cord-014712-5u4e00q6	1498	13	.	.	.
cord-014712-5u4e00q6	1499	1	There	there	EX
cord-014712-5u4e00q6	1499	2	were	be	VBD
cord-014712-5u4e00q6	1499	3	no	no	DT
cord-014712-5u4e00q6	1499	4	serious	serious	JJ
cord-014712-5u4e00q6	1499	5	adverse	adverse	JJ
cord-014712-5u4e00q6	1499	6	events	event	NNS
cord-014712-5u4e00q6	1499	7	considered	consider	VBN
cord-014712-5u4e00q6	1499	8	related	related	JJ
cord-014712-5u4e00q6	1499	9	to	to	IN
cord-014712-5u4e00q6	1499	10	any	any	DT
cord-014712-5u4e00q6	1499	11	treatment	treatment	NN
cord-014712-5u4e00q6	1499	12	.	.	.
cord-014712-5u4e00q6	1500	1	The	the	DT
cord-014712-5u4e00q6	1500	2	rate	rate	NN
cord-014712-5u4e00q6	1500	3	of	of	IN
cord-014712-5u4e00q6	1500	4	local	local	JJ
cord-014712-5u4e00q6	1500	5	adverse	adverse	JJ
cord-014712-5u4e00q6	1500	6	drug	drug	NN
cord-014712-5u4e00q6	1500	7	reactions	reaction	NNS
cord-014712-5u4e00q6	1500	8	(	(	-LRB-
cord-014712-5u4e00q6	1500	9	ADRs	adr	NNS
cord-014712-5u4e00q6	1500	10	)	)	-RRB-
cord-014712-5u4e00q6	1500	11	was	be	VBD
cord-014712-5u4e00q6	1500	12	0.055	0.055	CD
cord-014712-5u4e00q6	1500	13	/	/	SYM
cord-014712-5u4e00q6	1500	14	infusion	infusion	NN
cord-014712-5u4e00q6	1500	15	and	and	CC
cord-014712-5u4e00q6	1500	16	all	all	DT
cord-014712-5u4e00q6	1500	17	were	be	VBD
cord-014712-5u4e00q6	1500	18	mild	mild	JJ
cord-014712-5u4e00q6	1500	19	in	in	IN
cord-014712-5u4e00q6	1500	20	severity	severity	NN
cord-014712-5u4e00q6	1500	21	;	;	:
cord-014712-5u4e00q6	1500	22	no	no	DT
cord-014712-5u4e00q6	1500	23	severe	severe	JJ
cord-014712-5u4e00q6	1500	24	systemic	systemic	JJ
cord-014712-5u4e00q6	1500	25	ADRs	adr	NNS
cord-014712-5u4e00q6	1500	26	were	be	VBD
cord-014712-5u4e00q6	1500	27	reported	report	VBN
cord-014712-5u4e00q6	1500	28	with	with	IN
cord-014712-5u4e00q6	1500	29	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1500	30	20	20	CD
cord-014712-5u4e00q6	1500	31	%	%	NN
cord-014712-5u4e00q6	1500	32	.	.	.
cord-014712-5u4e00q6	1501	1	Of	of	IN
cord-014712-5u4e00q6	1501	2	1812	1812	CD
cord-014712-5u4e00q6	1501	3	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1501	4	20	20	CD
cord-014712-5u4e00q6	1501	5	%	%	NN
cord-014712-5u4e00q6	1501	6	infusions	infusion	NNS
cord-014712-5u4e00q6	1501	7	,	,	,
cord-014712-5u4e00q6	1501	8	only	only	RB
cord-014712-5u4e00q6	1501	9	0.4	0.4	CD
cord-014712-5u4e00q6	1501	10	%	%	NN
cord-014712-5u4e00q6	1501	11	required	require	VBN
cord-014712-5u4e00q6	1501	12	slowing	slow	VBG
cord-014712-5u4e00q6	1501	13	or	or	CC
cord-014712-5u4e00q6	1501	14	interrupting	interrupt	VBG
cord-014712-5u4e00q6	1501	15	the	the	DT
cord-014712-5u4e00q6	1501	16	administration	administration	NN
cord-014712-5u4e00q6	1501	17	rate	rate	NN
cord-014712-5u4e00q6	1501	18	.	.	.
cord-014712-5u4e00q6	1502	1	Mean	mean	JJ
cord-014712-5u4e00q6	1502	2	serum	serum	NN
cord-014712-5u4e00q6	1502	3	IgG	igg	NN
cord-014712-5u4e00q6	1502	4	trough	trough	NN
cord-014712-5u4e00q6	1502	5	levels	level	NNS
cord-014712-5u4e00q6	1502	6	were	be	VBD
cord-014712-5u4e00q6	1502	7	9.2	9.2	CD
cord-014712-5u4e00q6	1502	8	g	g	NN
cord-014712-5u4e00q6	1502	9	/	/	SYM
cord-014712-5u4e00q6	1502	10	L	L	NNP
cord-014712-5u4e00q6	1502	11	(	(	-LRB-
cord-014712-5u4e00q6	1502	12	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1502	13	20	20	CD
cord-014712-5u4e00q6	1502	14	%	%	NN
cord-014712-5u4e00q6	1502	15	,	,	,
cord-014712-5u4e00q6	1502	16	n	n	NN
cord-014712-5u4e00q6	1502	17	=	=	SYM
cord-014712-5u4e00q6	1502	18	46	46	CD
cord-014712-5u4e00q6	1502	19	)	)	-RRB-
cord-014712-5u4e00q6	1502	20	,	,	,
cord-014712-5u4e00q6	1502	21	9.1	9.1	CD
cord-014712-5u4e00q6	1502	22	g	g	NN
cord-014712-5u4e00q6	1502	23	/	/	SYM
cord-014712-5u4e00q6	1502	24	L	l	NN
cord-014712-5u4e00q6	1502	25	(	(	-LRB-
cord-014712-5u4e00q6	1502	26	IGIV	IGIV	NNP
cord-014712-5u4e00q6	1502	27	3-week	3-week	CD
cord-014712-5u4e00q6	1502	28	interval	interval	NN
cord-014712-5u4e00q6	1502	29	,	,	,
cord-014712-5u4e00q6	1502	30	n	n	NN
cord-014712-5u4e00q6	1502	31	=	=	SYM
cord-014712-5u4e00q6	1502	32	4	4	CD
cord-014712-5u4e00q6	1502	33	)	)	-RRB-
cord-014712-5u4e00q6	1502	34	and	and	CC
cord-014712-5u4e00q6	1502	35	7.7	7.7	CD
cord-014712-5u4e00q6	1502	36	g	g	NN
cord-014712-5u4e00q6	1502	37	/	/	SYM
cord-014712-5u4e00q6	1502	38	L	L	NNP
cord-014712-5u4e00q6	1502	39	(	(	-LRB-
cord-014712-5u4e00q6	1502	40	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1502	41	4-week	4-week	NNP
cord-014712-5u4e00q6	1502	42	interval	interval	NN
cord-014712-5u4e00q6	1502	43	,	,	,
cord-014712-5u4e00q6	1502	44	n	n	NN
cord-014712-5u4e00q6	1502	45	=	=	SYM
cord-014712-5u4e00q6	1502	46	25	25	CD
cord-014712-5u4e00q6	1502	47	)	)	-RRB-
cord-014712-5u4e00q6	1502	48	.	.	.
cord-014712-5u4e00q6	1503	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1503	2	:	:	:
cord-014712-5u4e00q6	1503	3	IGSC	IGSC	NNP
cord-014712-5u4e00q6	1503	4	20	20	CD
cord-014712-5u4e00q6	1503	5	%	%	NN
cord-014712-5u4e00q6	1503	6	provided	provide	VBD
cord-014712-5u4e00q6	1503	7	an	an	DT
cord-014712-5u4e00q6	1503	8	effective	effective	JJ
cord-014712-5u4e00q6	1503	9	and	and	CC
cord-014712-5u4e00q6	1503	10	well	well	RB
cord-014712-5u4e00q6	1503	11	-	-	HYPH
cord-014712-5u4e00q6	1503	12	tolerated	tolerate	VBN
cord-014712-5u4e00q6	1503	13	therapy	therapy	NN
cord-014712-5u4e00q6	1503	14	,	,	,
cord-014712-5u4e00q6	1503	15	with	with	IN
cord-014712-5u4e00q6	1503	16	no	no	DT
cord-014712-5u4e00q6	1503	17	dose	dose	NN
cord-014712-5u4e00q6	1503	18	adjustments	adjustment	NNS
cord-014712-5u4e00q6	1503	19	needed	need	VBN
cord-014712-5u4e00q6	1503	20	from	from	IN
cord-014712-5u4e00q6	1503	21	pre	pre	JJ
cord-014712-5u4e00q6	1503	22	-	-	JJ
cord-014712-5u4e00q6	1503	23	study	study	JJ
cord-014712-5u4e00q6	1503	24	IG	IG	NNP
cord-014712-5u4e00q6	1503	25	dose	dose	NN
cord-014712-5u4e00q6	1503	26	.	.	.
cord-014712-5u4e00q6	1504	1	This	this	DT
cord-014712-5u4e00q6	1504	2	study	study	NN
cord-014712-5u4e00q6	1504	3	is	be	VBZ
cord-014712-5u4e00q6	1504	4	ongoing	ongoing	JJ
cord-014712-5u4e00q6	1504	5	to	to	TO
cord-014712-5u4e00q6	1504	6	confirm	confirm	VB
cord-014712-5u4e00q6	1504	7	results	result	NNS
cord-014712-5u4e00q6	1504	8	over	over	IN
cord-014712-5u4e00q6	1504	9	12	12	CD
cord-014712-5u4e00q6	1504	10	months	month	NNS
cord-014712-5u4e00q6	1504	11	.	.	.
cord-014712-5u4e00q6	1505	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1505	2	is	be	VBZ
cord-014712-5u4e00q6	1505	3	well	well	RB
cord-014712-5u4e00q6	1505	4	known	known	JJ
cord-014712-5u4e00q6	1505	5	,	,	,
cord-014712-5u4e00q6	1505	6	that	that	IN
cord-014712-5u4e00q6	1505	7	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1505	8	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1505	9	(	(	-LRB-
cord-014712-5u4e00q6	1505	10	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1505	11	)	)	-RRB-
cord-014712-5u4e00q6	1505	12	is	be	VBZ
cord-014712-5u4e00q6	1505	13	the	the	DT
cord-014712-5u4e00q6	1505	14	main	main	JJ
cord-014712-5u4e00q6	1505	15	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	1505	16	modality	modality	NN
cord-014712-5u4e00q6	1505	17	in	in	IN
cord-014712-5u4e00q6	1505	18	B	b	NN
cord-014712-5u4e00q6	1505	19	-	-	HYPH
cord-014712-5u4e00q6	1505	20	cell	cell	NN
cord-014712-5u4e00q6	1505	21	primary	primary	JJ
cord-014712-5u4e00q6	1505	22	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1505	23	(	(	-LRB-
cord-014712-5u4e00q6	1505	24	PID	PID	NNP
cord-014712-5u4e00q6	1505	25	)	)	-RRB-
cord-014712-5u4e00q6	1505	26	,	,	,
cord-014712-5u4e00q6	1505	27	it	-PRON-	PRP
cord-014712-5u4e00q6	1505	28	decreases	decrease	VBZ
cord-014712-5u4e00q6	1505	29	mortality	mortality	NN
cord-014712-5u4e00q6	1505	30	and	and	CC
cord-014712-5u4e00q6	1505	31	morbidity	morbidity	NN
cord-014712-5u4e00q6	1505	32	in	in	IN
cord-014712-5u4e00q6	1505	33	these	these	DT
cord-014712-5u4e00q6	1505	34	patients	patient	NNS
cord-014712-5u4e00q6	1505	35	dramatically	dramatically	RB
cord-014712-5u4e00q6	1505	36	.	.	.
cord-014712-5u4e00q6	1506	1	Yet	yet	CC
cord-014712-5u4e00q6	1506	2	,	,	,
cord-014712-5u4e00q6	1506	3	it	-PRON-	PRP
cord-014712-5u4e00q6	1506	4	is	be	VBZ
cord-014712-5u4e00q6	1506	5	also	also	RB
cord-014712-5u4e00q6	1506	6	well	well	RB
cord-014712-5u4e00q6	1506	7	known	know	VBN
cord-014712-5u4e00q6	1506	8	that	that	IN
cord-014712-5u4e00q6	1506	9	all	all	DT
cord-014712-5u4e00q6	1506	10	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1506	11	products	product	NNS
cord-014712-5u4e00q6	1506	12	are	be	VBP
cord-014712-5u4e00q6	1506	13	very	very	RB
cord-014712-5u4e00q6	1506	14	expensive	expensive	JJ
cord-014712-5u4e00q6	1506	15	,	,	,
cord-014712-5u4e00q6	1506	16	especially	especially	RB
cord-014712-5u4e00q6	1506	17	considering	consider	VBG
cord-014712-5u4e00q6	1506	18	life	life	NN
cord-014712-5u4e00q6	1506	19	-	-	HYPH
cord-014712-5u4e00q6	1506	20	time	time	NN
cord-014712-5u4e00q6	1506	21	use	use	NN
cord-014712-5u4e00q6	1506	22	and	and	CC
cord-014712-5u4e00q6	1506	23	almost	almost	RB
cord-014712-5u4e00q6	1506	24	normal	normal	JJ
cord-014712-5u4e00q6	1506	25	life	life	NN
cord-014712-5u4e00q6	1506	26	expectancy	expectancy	NN
cord-014712-5u4e00q6	1506	27	in	in	IN
cord-014712-5u4e00q6	1506	28	these	these	DT
cord-014712-5u4e00q6	1506	29	patients	patient	NNS
cord-014712-5u4e00q6	1506	30	,	,	,
cord-014712-5u4e00q6	1506	31	if	if	IN
cord-014712-5u4e00q6	1506	32	treated	treat	VBN
cord-014712-5u4e00q6	1506	33	correctly	correctly	RB
cord-014712-5u4e00q6	1506	34	.	.	.
cord-014712-5u4e00q6	1507	1	Irregular	irregular	JJ
cord-014712-5u4e00q6	1507	2	treatment	treatment	NN
cord-014712-5u4e00q6	1507	3	and	and	CC
cord-014712-5u4e00q6	1507	4	problems	problem	NNS
cord-014712-5u4e00q6	1507	5	with	with	IN
cord-014712-5u4e00q6	1507	6	insurance	insurance	NN
cord-014712-5u4e00q6	1507	7	/	/	SYM
cord-014712-5u4e00q6	1507	8	state	state	NN
cord-014712-5u4e00q6	1507	9	coverage	coverage	NN
cord-014712-5u4e00q6	1507	10	of	of	IN
cord-014712-5u4e00q6	1507	11	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1507	12	in	in	IN
cord-014712-5u4e00q6	1507	13	some	some	DT
cord-014712-5u4e00q6	1507	14	countries	country	NNS
cord-014712-5u4e00q6	1507	15	stems	stem	VBZ
cord-014712-5u4e00q6	1507	16	from	from	IN
cord-014712-5u4e00q6	1507	17	this	this	DT
cord-014712-5u4e00q6	1507	18	.	.	.
cord-014712-5u4e00q6	1508	1	GOAL	GOAL	NNP
cord-014712-5u4e00q6	1508	2	:	:	:
cord-014712-5u4e00q6	1509	1	The	the	DT
cord-014712-5u4e00q6	1509	2	goal	goal	NN
cord-014712-5u4e00q6	1509	3	of	of	IN
cord-014712-5u4e00q6	1509	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	1509	5	study	study	NN
cord-014712-5u4e00q6	1509	6	was	be	VBD
cord-014712-5u4e00q6	1509	7	to	to	TO
cord-014712-5u4e00q6	1509	8	compare	compare	VB
cord-014712-5u4e00q6	1509	9	medical	medical	JJ
cord-014712-5u4e00q6	1509	10	and	and	CC
cord-014712-5u4e00q6	1509	11	other	other	JJ
cord-014712-5u4e00q6	1509	12	costs	cost	NNS
cord-014712-5u4e00q6	1509	13	,	,	,
cord-014712-5u4e00q6	1509	14	related	relate	VBN
cord-014712-5u4e00q6	1509	15	to	to	IN
cord-014712-5u4e00q6	1509	16	the	the	DT
cord-014712-5u4e00q6	1509	17	disease	disease	NN
cord-014712-5u4e00q6	1509	18	in	in	IN
cord-014712-5u4e00q6	1509	19	patients	patient	NNS
cord-014712-5u4e00q6	1509	20	with	with	IN
cord-014712-5u4e00q6	1509	21	humoral	humoral	JJ
cord-014712-5u4e00q6	1509	22	PIDs	pid	NNS
cord-014712-5u4e00q6	1509	23	with	with	IN
cord-014712-5u4e00q6	1509	24	or	or	CC
cord-014712-5u4e00q6	1509	25	without	without	IN
cord-014712-5u4e00q6	1509	26	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1509	27	treatment	treatment	NN
cord-014712-5u4e00q6	1509	28	.	.	.
cord-014712-5u4e00q6	1510	1	Patients	patient	NNS
cord-014712-5u4e00q6	1510	2	:	:	:
cord-014712-5u4e00q6	1510	3	21	21	CD
cord-014712-5u4e00q6	1510	4	patient	patient	NN
cord-014712-5u4e00q6	1510	5	with	with	IN
cord-014712-5u4e00q6	1510	6	B	b	NN
cord-014712-5u4e00q6	1510	7	-	-	HYPH
cord-014712-5u4e00q6	1510	8	cell	cell	NN
cord-014712-5u4e00q6	1510	9	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	1510	10	(	(	-LRB-
cord-014712-5u4e00q6	1510	11	73	73	CD
cord-014712-5u4e00q6	1510	12	%	%	NN
cord-014712-5u4e00q6	1510	13	X	x	NN
cord-014712-5u4e00q6	1510	14	-	-	HYPH
cord-014712-5u4e00q6	1510	15	linked	link	VBN
cord-014712-5u4e00q6	1510	16	agammaglobulinemia	agammaglobulinemia	NN
cord-014712-5u4e00q6	1510	17	,	,	,
cord-014712-5u4e00q6	1510	18	all	all	DT
cord-014712-5u4e00q6	1510	19	genetically	genetically	RB
cord-014712-5u4e00q6	1510	20	confirmed	confirm	VBN
cord-014712-5u4e00q6	1510	21	,	,	,
cord-014712-5u4e00q6	1510	22	27	27	CD
cord-014712-5u4e00q6	1510	23	%	%	NN
cord-014712-5u4e00q6	1510	24	common	common	JJ
cord-014712-5u4e00q6	1510	25	variable	variable	JJ
cord-014712-5u4e00q6	1510	26	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1510	27	)	)	-RRB-
cord-014712-5u4e00q6	1510	28	.	.	.
cord-014712-5u4e00q6	1511	1	The	the	DT
cord-014712-5u4e00q6	1511	2	age	age	NN
cord-014712-5u4e00q6	1511	3	of	of	IN
cord-014712-5u4e00q6	1511	4	patients	patient	NNS
cord-014712-5u4e00q6	1511	5	varied	varied	JJ
cord-014712-5u4e00q6	1511	6	from	from	IN
cord-014712-5u4e00q6	1511	7	2	2	CD
cord-014712-5u4e00q6	1511	8	to	to	IN
cord-014712-5u4e00q6	1511	9	16	16	CD
cord-014712-5u4e00q6	1511	10	years	year	NNS
cord-014712-5u4e00q6	1511	11	.	.	.
cord-014712-5u4e00q6	1512	1	Methods	method	NNS
cord-014712-5u4e00q6	1512	2	:	:	:
cord-014712-5u4e00q6	1513	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1513	2	analyzed	analyze	VBD
cord-014712-5u4e00q6	1513	3	medical	medical	JJ
cord-014712-5u4e00q6	1513	4	and	and	CC
cord-014712-5u4e00q6	1513	5	other	other	JJ
cord-014712-5u4e00q6	1513	6	disease	disease	NN
cord-014712-5u4e00q6	1513	7	-	-	HYPH
cord-014712-5u4e00q6	1513	8	related	relate	VBN
cord-014712-5u4e00q6	1513	9	costs	cost	NNS
cord-014712-5u4e00q6	1513	10	during	during	IN
cord-014712-5u4e00q6	1513	11	2	2	CD
cord-014712-5u4e00q6	1513	12	years	year	NNS
cord-014712-5u4e00q6	1513	13	preceding	precede	VBG
cord-014712-5u4e00q6	1513	14	the	the	DT
cord-014712-5u4e00q6	1513	15	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1513	16	(	(	-LRB-
cord-014712-5u4e00q6	1513	17	without	without	IN
cord-014712-5u4e00q6	1513	18	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1513	19	therapy	therapy	NN
cord-014712-5u4e00q6	1513	20	)	)	-RRB-
cord-014712-5u4e00q6	1513	21	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	1513	22	and	and	CC
cord-014712-5u4e00q6	1513	23	during	during	IN
cord-014712-5u4e00q6	1513	24	2	2	CD
cord-014712-5u4e00q6	1513	25	years	year	NNS
cord-014712-5u4e00q6	1513	26	on	on	IN
cord-014712-5u4e00q6	1513	27	regular	regular	JJ
cord-014712-5u4e00q6	1513	28	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1513	29	therapy	therapy	NN
cord-014712-5u4e00q6	1513	30	.	.	.
cord-014712-5u4e00q6	1514	1	The	the	DT
cord-014712-5u4e00q6	1514	2	costs	cost	NNS
cord-014712-5u4e00q6	1514	3	included	include	VBD
cord-014712-5u4e00q6	1514	4	those	those	DT
cord-014712-5u4e00q6	1514	5	incurred	incur	VBN
cord-014712-5u4e00q6	1514	6	by	by	IN
cord-014712-5u4e00q6	1514	7	the	the	DT
cord-014712-5u4e00q6	1514	8	state	state	NN
cord-014712-5u4e00q6	1514	9	(	(	-LRB-
cord-014712-5u4e00q6	1514	10	hospitalization	hospitalization	NN
cord-014712-5u4e00q6	1514	11	,	,	,
cord-014712-5u4e00q6	1514	12	home	home	NN
cord-014712-5u4e00q6	1514	13	visits	visit	NNS
cord-014712-5u4e00q6	1514	14	,	,	,
cord-014712-5u4e00q6	1514	15	emergency	emergency	NN
cord-014712-5u4e00q6	1514	16	calls	call	NNS
cord-014712-5u4e00q6	1514	17	)	)	-RRB-
cord-014712-5u4e00q6	1514	18	and	and	CC
cord-014712-5u4e00q6	1514	19	by	by	IN
cord-014712-5u4e00q6	1514	20	the	the	DT
cord-014712-5u4e00q6	1514	21	parents	parent	NNS
cord-014712-5u4e00q6	1514	22	(	(	-LRB-
cord-014712-5u4e00q6	1514	23	costs	cost	NNS
cord-014712-5u4e00q6	1514	24	of	of	IN
cord-014712-5u4e00q6	1514	25	drugs	drug	NNS
cord-014712-5u4e00q6	1514	26	,	,	,
cord-014712-5u4e00q6	1514	27	private	private	JJ
cord-014712-5u4e00q6	1514	28	consults	consult	NNS
cord-014712-5u4e00q6	1514	29	,	,	,
cord-014712-5u4e00q6	1514	30	etc	etc	FW
cord-014712-5u4e00q6	1514	31	)	)	-RRB-
cord-014712-5u4e00q6	1514	32	.	.	.
cord-014712-5u4e00q6	1515	1	The	the	DT
cord-014712-5u4e00q6	1515	2	state	state	NN
cord-014712-5u4e00q6	1515	3	costs	cost	NNS
cord-014712-5u4e00q6	1515	4	caused	cause	VBN
cord-014712-5u4e00q6	1515	5	by	by	IN
cord-014712-5u4e00q6	1515	6	parents	parent	NNS
cord-014712-5u4e00q6	1515	7	missing	miss	VBG
cord-014712-5u4e00q6	1515	8	work	work	NN
cord-014712-5u4e00q6	1515	9	were	be	VBD
cord-014712-5u4e00q6	1515	10	also	also	RB
cord-014712-5u4e00q6	1515	11	considered	consider	VBN
cord-014712-5u4e00q6	1515	12	.	.	.
cord-014712-5u4e00q6	1516	1	For	for	IN
cord-014712-5u4e00q6	1516	2	standardization	standardization	NN
cord-014712-5u4e00q6	1516	3	purpose	purpose	NN
cord-014712-5u4e00q6	1516	4	for	for	IN
cord-014712-5u4e00q6	1516	5	calculation	calculation	NN
cord-014712-5u4e00q6	1516	6	we	-PRON-	PRP
cord-014712-5u4e00q6	1516	7	used	use	VBD
cord-014712-5u4e00q6	1516	8	the	the	DT
cord-014712-5u4e00q6	1516	9	prices	price	NNS
cord-014712-5u4e00q6	1516	10	for	for	IN
cord-014712-5u4e00q6	1516	11	the	the	DT
cord-014712-5u4e00q6	1516	12	end	end	NN
cord-014712-5u4e00q6	1516	13	of	of	IN
cord-014712-5u4e00q6	1516	14	2013	2013	CD
cord-014712-5u4e00q6	1516	15	.	.	.
cord-014712-5u4e00q6	1517	1	Results	result	NNS
cord-014712-5u4e00q6	1517	2	:	:	:
cord-014712-5u4e00q6	1518	1	The	the	DT
cord-014712-5u4e00q6	1518	2	patients	patient	NNS
cord-014712-5u4e00q6	1518	3	analyzed	analyze	VBD
cord-014712-5u4e00q6	1518	4	fell	fall	VBD
cord-014712-5u4e00q6	1518	5	into	into	IN
cord-014712-5u4e00q6	1518	6	3	3	CD
cord-014712-5u4e00q6	1518	7	different	different	JJ
cord-014712-5u4e00q6	1518	8	categories	category	NNS
cord-014712-5u4e00q6	1518	9	:	:	:
cord-014712-5u4e00q6	1518	10	1	1	CD
cord-014712-5u4e00q6	1518	11	.	.	.
cord-014712-5u4e00q6	1519	1	The	the	DT
cord-014712-5u4e00q6	1519	2	1st	1st	JJ
cord-014712-5u4e00q6	1519	3	group	group	NN
cord-014712-5u4e00q6	1519	4	-(76	-(76	NNP
cord-014712-5u4e00q6	1519	5	%	%	NN
cord-014712-5u4e00q6	1519	6	of	of	IN
cord-014712-5u4e00q6	1519	7	patients	patient	NNS
cord-014712-5u4e00q6	1519	8	studied	study	VBN
cord-014712-5u4e00q6	1519	9	)	)	-RRB-
cord-014712-5u4e00q6	1520	1	-patients	-patient	NNS
cord-014712-5u4e00q6	1521	1	with	with	IN
cord-014712-5u4e00q6	1521	2	several	several	JJ
cord-014712-5u4e00q6	1521	3	severe	severe	JJ
cord-014712-5u4e00q6	1521	4	infections	infection	NNS
cord-014712-5u4e00q6	1521	5	before	before	IN
cord-014712-5u4e00q6	1521	6	therapy	therapy	NN
cord-014712-5u4e00q6	1521	7	,	,	,
cord-014712-5u4e00q6	1521	8	some	some	DT
cord-014712-5u4e00q6	1521	9	chronic	chronic	JJ
cord-014712-5u4e00q6	1521	10	conditions	condition	NNS
cord-014712-5u4e00q6	1521	11	as	as	IN
cord-014712-5u4e00q6	1521	12	a	a	DT
cord-014712-5u4e00q6	1521	13	result	result	NN
cord-014712-5u4e00q6	1521	14	of	of	IN
cord-014712-5u4e00q6	1521	15	those	those	DT
cord-014712-5u4e00q6	1521	16	.	.	.
cord-014712-5u4e00q6	1522	1	Age	age	NN
cord-014712-5u4e00q6	1522	2	of	of	IN
cord-014712-5u4e00q6	1522	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1522	4	varied	varied	JJ
cord-014712-5u4e00q6	1522	5	from	from	IN
cord-014712-5u4e00q6	1522	6	2	2	CD
cord-014712-5u4e00q6	1522	7	years	year	NNS
cord-014712-5u4e00q6	1522	8	to	to	IN
cord-014712-5u4e00q6	1522	9	16	16	CD
cord-014712-5u4e00q6	1522	10	years	year	NNS
cord-014712-5u4e00q6	1522	11	(	(	-LRB-
cord-014712-5u4e00q6	1522	12	with	with	IN
cord-014712-5u4e00q6	1522	13	average	average	JJ
cord-014712-5u4e00q6	1522	14	time	time	NN
cord-014712-5u4e00q6	1522	15	to	to	IN
cord-014712-5u4e00q6	1522	16	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1522	17	5	5	CD
cord-014712-5u4e00q6	1522	18	years	year	NNS
cord-014712-5u4e00q6	1522	19	)	)	-RRB-
cord-014712-5u4e00q6	1522	20	.	.	.
cord-014712-5u4e00q6	1523	1	In	in	IN
cord-014712-5u4e00q6	1523	2	this	this	DT
cord-014712-5u4e00q6	1523	3	group	group	NN
cord-014712-5u4e00q6	1523	4	costs	cost	NNS
cord-014712-5u4e00q6	1523	5	of	of	IN
cord-014712-5u4e00q6	1523	6	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1523	7	treatment	treatment	NN
cord-014712-5u4e00q6	1523	8	were	be	VBD
cord-014712-5u4e00q6	1523	9	2,5	2,5	CD
cord-014712-5u4e00q6	1523	10	times	time	NNS
cord-014712-5u4e00q6	1523	11	higher	high	JJR
cord-014712-5u4e00q6	1523	12	than	than	IN
cord-014712-5u4e00q6	1523	13	before	before	IN
cord-014712-5u4e00q6	1523	14	the	the	DT
cord-014712-5u4e00q6	1523	15	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1523	16	(	(	-LRB-
cord-014712-5u4e00q6	1523	17	Fig	Fig	NNP
cord-014712-5u4e00q6	1523	18	.	.	.
cord-014712-5u4e00q6	1523	19	1	1	CD
cord-014712-5u4e00q6	1523	20	)	)	-RRB-
cord-014712-5u4e00q6	1523	21	.	.	.
cord-014712-5u4e00q6	1524	1	2	2	CD
cord-014712-5u4e00q6	1524	2	nd	nd	NNP
cord-014712-5u4e00q6	1524	3	group(10	group(10	NNP
cord-014712-5u4e00q6	1524	4	%	%	NN
cord-014712-5u4e00q6	1524	5	of	of	IN
cord-014712-5u4e00q6	1524	6	all	all	DT
cord-014712-5u4e00q6	1524	7	)	)	-RRB-
cord-014712-5u4e00q6	1524	8	.	.	.
cord-014712-5u4e00q6	1525	1	Patients	patient	NNS
cord-014712-5u4e00q6	1525	2	with	with	IN
cord-014712-5u4e00q6	1525	3	late	late	JJ
cord-014712-5u4e00q6	1525	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1525	5	(	(	-LRB-
cord-014712-5u4e00q6	1525	6	average	average	JJ
cord-014712-5u4e00q6	1525	7	time	time	NN
cord-014712-5u4e00q6	1525	8	to	to	IN
cord-014712-5u4e00q6	1525	9	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1525	10	7	7	CD
cord-014712-5u4e00q6	1525	11	years	year	NNS
cord-014712-5u4e00q6	1525	12	)	)	-RRB-
cord-014712-5u4e00q6	1525	13	,	,	,
cord-014712-5u4e00q6	1525	14	who	who	WP
cord-014712-5u4e00q6	1525	15	had	have	VBD
cord-014712-5u4e00q6	1525	16	multiple	multiple	JJ
cord-014712-5u4e00q6	1525	17	severe	severe	JJ
cord-014712-5u4e00q6	1525	18	infections	infection	NNS
cord-014712-5u4e00q6	1525	19	before	before	IN
cord-014712-5u4e00q6	1525	20	the	the	DT
cord-014712-5u4e00q6	1525	21	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1525	22	treatment	treatment	NN
cord-014712-5u4e00q6	1525	23	and	and	CC
cord-014712-5u4e00q6	1525	24	acquired	acquire	VBD
cord-014712-5u4e00q6	1525	25	serious	serious	JJ
cord-014712-5u4e00q6	1525	26	chronic	chronic	JJ
cord-014712-5u4e00q6	1525	27	lung	lung	NN
cord-014712-5u4e00q6	1525	28	complications	complication	NNS
cord-014712-5u4e00q6	1525	29	due	due	JJ
cord-014712-5u4e00q6	1525	30	to	to	IN
cord-014712-5u4e00q6	1525	31	it	-PRON-	PRP
cord-014712-5u4e00q6	1525	32	.	.	.
cord-014712-5u4e00q6	1526	1	In	in	IN
cord-014712-5u4e00q6	1526	2	this	this	DT
cord-014712-5u4e00q6	1526	3	group	group	NN
cord-014712-5u4e00q6	1526	4	the	the	DT
cord-014712-5u4e00q6	1526	5	costs	cost	NNS
cord-014712-5u4e00q6	1526	6	before	before	IN
cord-014712-5u4e00q6	1526	7	the	the	DT
cord-014712-5u4e00q6	1526	8	treatment	treatment	NN
cord-014712-5u4e00q6	1526	9	were	be	VBD
cord-014712-5u4e00q6	1526	10	higher	high	JJR
cord-014712-5u4e00q6	1526	11	,	,	,
cord-014712-5u4e00q6	1526	12	than	than	IN
cord-014712-5u4e00q6	1526	13	on	on	IN
cord-014712-5u4e00q6	1526	14	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1526	15	treatment	treatment	NN
cord-014712-5u4e00q6	1526	16	.	.	.
cord-014712-5u4e00q6	1527	1	3	3	LS
cord-014712-5u4e00q6	1527	2	.	.	.
cord-014712-5u4e00q6	1528	1	Very	very	RB
cord-014712-5u4e00q6	1528	2	early	early	JJ
cord-014712-5u4e00q6	1528	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1529	1	-within	-within	.
cord-014712-5u4e00q6	1530	1	the	the	DT
cord-014712-5u4e00q6	1530	2	first	first	JJ
cord-014712-5u4e00q6	1530	3	year	year	NN
cord-014712-5u4e00q6	1530	4	of	of	IN
cord-014712-5u4e00q6	1530	5	life	life	NN
cord-014712-5u4e00q6	1530	6	(	(	-LRB-
cord-014712-5u4e00q6	1530	7	mostly	mostly	RB
cord-014712-5u4e00q6	1530	8	because	because	IN
cord-014712-5u4e00q6	1530	9	of	of	IN
cord-014712-5u4e00q6	1530	10	preceding	precede	VBG
cord-014712-5u4e00q6	1530	11	family	family	NN
cord-014712-5u4e00q6	1530	12	history	history	NN
cord-014712-5u4e00q6	1530	13	)	)	-RRB-
cord-014712-5u4e00q6	1530	14	(	(	-LRB-
cord-014712-5u4e00q6	1530	15	14	14	CD
cord-014712-5u4e00q6	1530	16	%	%	NN
cord-014712-5u4e00q6	1530	17	)	)	-RRB-
cord-014712-5u4e00q6	1530	18	.	.	.
cord-014712-5u4e00q6	1531	1	The	the	DT
cord-014712-5u4e00q6	1531	2	comparative	comparative	JJ
cord-014712-5u4e00q6	1531	3	analysis	analysis	NN
cord-014712-5u4e00q6	1531	4	was	be	VBD
cord-014712-5u4e00q6	1531	5	not	not	RB
cord-014712-5u4e00q6	1531	6	possible	possible	JJ
cord-014712-5u4e00q6	1531	7	,	,	,
cord-014712-5u4e00q6	1531	8	but	but	CC
cord-014712-5u4e00q6	1531	9	it	-PRON-	PRP
cord-014712-5u4e00q6	1531	10	was	be	VBD
cord-014712-5u4e00q6	1531	11	noted	note	VBN
cord-014712-5u4e00q6	1531	12	that	that	IN
cord-014712-5u4e00q6	1531	13	these	these	DT
cord-014712-5u4e00q6	1531	14	patients	patient	NNS
cord-014712-5u4e00q6	1531	15	had	have	VBD
cord-014712-5u4e00q6	1531	16	no	no	DT
cord-014712-5u4e00q6	1531	17	history	history	NN
cord-014712-5u4e00q6	1531	18	of	of	IN
cord-014712-5u4e00q6	1531	19	serious	serious	JJ
cord-014712-5u4e00q6	1531	20	infections	infection	NNS
cord-014712-5u4e00q6	1531	21	before	before	RB
cord-014712-5u4e00q6	1531	22	of	of	IN
cord-014712-5u4e00q6	1531	23	while	while	NN
cord-014712-5u4e00q6	1531	24	on	on	IN
cord-014712-5u4e00q6	1531	25	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1531	26	therapy	therapy	NN
cord-014712-5u4e00q6	1531	27	.	.	.
cord-014712-5u4e00q6	1532	1	The	the	DT
cord-014712-5u4e00q6	1532	2	only	only	JJ
cord-014712-5u4e00q6	1532	3	additional	additional	JJ
cord-014712-5u4e00q6	1532	4	costs	cost	NNS
cord-014712-5u4e00q6	1532	5	,	,	,
cord-014712-5u4e00q6	1532	6	besides	besides	IN
cord-014712-5u4e00q6	1532	7	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1532	8	,	,	,
cord-014712-5u4e00q6	1532	9	were	be	VBD
cord-014712-5u4e00q6	1532	10	related	relate	VBN
cord-014712-5u4e00q6	1532	11	to	to	IN
cord-014712-5u4e00q6	1532	12	bad	bad	JJ
cord-014712-5u4e00q6	1532	13	venous	venous	JJ
cord-014712-5u4e00q6	1532	14	access	access	NN
cord-014712-5u4e00q6	1532	15	,	,	,
cord-014712-5u4e00q6	1532	16	requiring	require	VBG
cord-014712-5u4e00q6	1532	17	occasionally	occasionally	RB
cord-014712-5u4e00q6	1532	18	1	1	CD
cord-014712-5u4e00q6	1532	19	day	day	NN
cord-014712-5u4e00q6	1532	20	in	in	IN
cord-014712-5u4e00q6	1532	21	-	-	HYPH
cord-014712-5u4e00q6	1532	22	patient	patient	NN
cord-014712-5u4e00q6	1532	23	hospitalization	hospitalization	NN
cord-014712-5u4e00q6	1532	24	for	for	IN
cord-014712-5u4e00q6	1532	25	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1532	26	infusion	infusion	NN
cord-014712-5u4e00q6	1532	27	.	.	.
cord-014712-5u4e00q6	1533	1	As	as	IN
cord-014712-5u4e00q6	1533	2	expected	expect	VBN
cord-014712-5u4e00q6	1533	3	,	,	,
cord-014712-5u4e00q6	1533	4	in	in	IN
cord-014712-5u4e00q6	1533	5	all	all	DT
cord-014712-5u4e00q6	1533	6	3	3	CD
cord-014712-5u4e00q6	1533	7	groups	group	NNS
cord-014712-5u4e00q6	1533	8	,	,	,
cord-014712-5u4e00q6	1533	9	the	the	DT
cord-014712-5u4e00q6	1533	10	number	number	NN
cord-014712-5u4e00q6	1533	11	of	of	IN
cord-014712-5u4e00q6	1533	12	infectious	infectious	JJ
cord-014712-5u4e00q6	1533	13	episodes	episode	NNS
cord-014712-5u4e00q6	1533	14	,	,	,
cord-014712-5u4e00q6	1533	15	the	the	DT
cord-014712-5u4e00q6	1533	16	number	number	NN
cord-014712-5u4e00q6	1533	17	of	of	IN
cord-014712-5u4e00q6	1533	18	hospitalizations	hospitalization	NNS
cord-014712-5u4e00q6	1533	19	(	(	-LRB-
cord-014712-5u4e00q6	1533	20	Fig	Fig	NNP
cord-014712-5u4e00q6	1533	21	.	.	NNP
cord-014712-5u4e00q6	1533	22	2	2	CD
cord-014712-5u4e00q6	1533	23	)	)	-RRB-
cord-014712-5u4e00q6	1533	24	and	and	CC
cord-014712-5u4e00q6	1533	25	doctor	doctor	NN
cord-014712-5u4e00q6	1533	26	visits	visit	NNS
cord-014712-5u4e00q6	1533	27	(	(	-LRB-
cord-014712-5u4e00q6	1533	28	Fig	Fig	NNP
cord-014712-5u4e00q6	1533	29	.	.	.
cord-014712-5u4e00q6	1533	30	3	3	CD
cord-014712-5u4e00q6	1533	31	)	)	-RRB-
cord-014712-5u4e00q6	1533	32	after	after	IN
cord-014712-5u4e00q6	1533	33	beginning	beginning	NN
cord-014712-5u4e00q6	1533	34	of	of	IN
cord-014712-5u4e00q6	1533	35	regular	regular	JJ
cord-014712-5u4e00q6	1533	36	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1533	37	treatment	treatment	NN
cord-014712-5u4e00q6	1533	38	dropped	drop	VBD
cord-014712-5u4e00q6	1533	39	dramatically	dramatically	RB
cord-014712-5u4e00q6	1533	40	.	.	.
cord-014712-5u4e00q6	1534	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1534	2	also	also	RB
cord-014712-5u4e00q6	1534	3	followed	follow	VBD
cord-014712-5u4e00q6	1534	4	2	2	CD
cord-014712-5u4e00q6	1534	5	patients	patient	NNS
cord-014712-5u4e00q6	1534	6	with	with	IN
cord-014712-5u4e00q6	1534	7	XLA	XLA	NNP
cord-014712-5u4e00q6	1534	8	,	,	,
cord-014712-5u4e00q6	1534	9	who	who	WP
cord-014712-5u4e00q6	1534	10	did	do	VBD
cord-014712-5u4e00q6	1534	11	not	not	RB
cord-014712-5u4e00q6	1534	12	receive	receive	VB
cord-014712-5u4e00q6	1534	13	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1534	14	therapy	therapy	NN
cord-014712-5u4e00q6	1534	15	because	because	IN
cord-014712-5u4e00q6	1534	16	of	of	IN
cord-014712-5u4e00q6	1534	17	social	social	JJ
cord-014712-5u4e00q6	1534	18	aspects	aspect	NNS
cord-014712-5u4e00q6	1534	19	.	.	.
cord-014712-5u4e00q6	1535	1	Both	both	DT
cord-014712-5u4e00q6	1535	2	patients	patient	NNS
cord-014712-5u4e00q6	1535	3	died	die	VBD
cord-014712-5u4e00q6	1535	4	from	from	IN
cord-014712-5u4e00q6	1535	5	severe	severe	JJ
cord-014712-5u4e00q6	1535	6	infections	infection	NNS
cord-014712-5u4e00q6	1535	7	.	.	.
cord-014712-5u4e00q6	1536	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1536	2	evaluated	evaluate	VBD
cord-014712-5u4e00q6	1536	3	this	this	DT
cord-014712-5u4e00q6	1536	4	fact	fact	NN
cord-014712-5u4e00q6	1536	5	in	in	IN
cord-014712-5u4e00q6	1536	6	economical	economical	JJ
cord-014712-5u4e00q6	1536	7	prospective	prospective	NN
cord-014712-5u4e00q6	1536	8	:	:	:
cord-014712-5u4e00q6	1536	9	in	in	IN
cord-014712-5u4e00q6	1536	10	Russia	Russia	NNP
cord-014712-5u4e00q6	1536	11	one	one	CD
cord-014712-5u4e00q6	1536	12	worker	worker	NN
cord-014712-5u4e00q6	1536	13	,	,	,
cord-014712-5u4e00q6	1536	14	who	who	WP
cord-014712-5u4e00q6	1536	15	works	work	VBZ
cord-014712-5u4e00q6	1536	16	continuously	continuously	RB
cord-014712-5u4e00q6	1536	17	and	and	CC
cord-014712-5u4e00q6	1536	18	retires	retire	VBZ
cord-014712-5u4e00q6	1536	19	at	at	IN
cord-014712-5u4e00q6	1536	20	60	60	CD
cord-014712-5u4e00q6	1536	21	years	year	NNS
cord-014712-5u4e00q6	1536	22	of	of	IN
cord-014712-5u4e00q6	1536	23	age	age	NN
cord-014712-5u4e00q6	1536	24	brings	bring	VBZ
cord-014712-5u4e00q6	1536	25	about	about	RB
cord-014712-5u4e00q6	1536	26	130	130	CD
cord-014712-5u4e00q6	1536	27	mln	mln	CD
cord-014712-5u4e00q6	1536	28	roubles	rouble	NNS
cord-014712-5u4e00q6	1536	29	into	into	IN
cord-014712-5u4e00q6	1536	30	the	the	DT
cord-014712-5u4e00q6	1536	31	state	state	NN
cord-014712-5u4e00q6	1536	32	budget	budget	NN
cord-014712-5u4e00q6	1536	33	(	(	-LRB-
cord-014712-5u4e00q6	1536	34	when	when	WRB
cord-014712-5u4e00q6	1536	35	costs	cost	NNS
cord-014712-5u4e00q6	1536	36	for	for	IN
cord-014712-5u4e00q6	1536	37	schooling	schooling	NN
cord-014712-5u4e00q6	1536	38	and	and	CC
cord-014712-5u4e00q6	1536	39	routine	routine	JJ
cord-014712-5u4e00q6	1536	40	medical	medical	JJ
cord-014712-5u4e00q6	1536	41	care	care	NN
cord-014712-5u4e00q6	1536	42	are	be	VBP
cord-014712-5u4e00q6	1536	43	subtracted	subtract	VBN
cord-014712-5u4e00q6	1536	44	)	)	-RRB-
cord-014712-5u4e00q6	1536	45	.	.	.
cord-014712-5u4e00q6	1537	1	If	if	IN
cord-014712-5u4e00q6	1537	2	one	one	PRP
cord-014712-5u4e00q6	1537	3	supposes	suppose	VBZ
cord-014712-5u4e00q6	1537	4	that	that	IN
cord-014712-5u4e00q6	1537	5	an	an	DT
cord-014712-5u4e00q6	1537	6	XLA	XLA	NNP
cord-014712-5u4e00q6	1537	7	patient	patient	NN
cord-014712-5u4e00q6	1537	8	have	have	VBP
cord-014712-5u4e00q6	1537	9	been	be	VBN
cord-014712-5u4e00q6	1537	10	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1537	11	very	very	RB
cord-014712-5u4e00q6	1537	12	early	early	RB
cord-014712-5u4e00q6	1537	13	in	in	IN
cord-014712-5u4e00q6	1537	14	life	life	NN
cord-014712-5u4e00q6	1537	15	,	,	,
cord-014712-5u4e00q6	1537	16	did	do	VBD
cord-014712-5u4e00q6	1537	17	not	not	RB
cord-014712-5u4e00q6	1537	18	form	form	VB
cord-014712-5u4e00q6	1537	19	complications	complication	NNS
cord-014712-5u4e00q6	1537	20	prior	prior	RB
cord-014712-5u4e00q6	1537	21	to	to	IN
cord-014712-5u4e00q6	1537	22	therapy	therapy	NN
cord-014712-5u4e00q6	1537	23	and	and	CC
cord-014712-5u4e00q6	1537	24	was	be	VBD
cord-014712-5u4e00q6	1537	25	on	on	IN
cord-014712-5u4e00q6	1537	26	regular	regular	JJ
cord-014712-5u4e00q6	1537	27	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1537	28	therapy	therapy	NN
cord-014712-5u4e00q6	1537	29	for	for	IN
cord-014712-5u4e00q6	1537	30	life	life	NN
cord-014712-5u4e00q6	1537	31	,	,	,
cord-014712-5u4e00q6	1537	32	this	this	DT
cord-014712-5u4e00q6	1537	33	sum	sum	NN
cord-014712-5u4e00q6	1537	34	equals	equal	VBZ
cord-014712-5u4e00q6	1537	35	to	to	IN
cord-014712-5u4e00q6	1537	36	160	160	CD
cord-014712-5u4e00q6	1537	37	years	year	NNS
cord-014712-5u4e00q6	1537	38	on	on	IN
cord-014712-5u4e00q6	1537	39	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1537	40	.	.	.
cord-014712-5u4e00q6	1538	1	Conclusions	conclusion	NNS
cord-014712-5u4e00q6	1538	2	:	:	:
cord-014712-5u4e00q6	1539	1	Regular	regular	JJ
cord-014712-5u4e00q6	1539	2	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1539	3	therapy	therapy	NN
cord-014712-5u4e00q6	1539	4	not	not	RB
cord-014712-5u4e00q6	1539	5	only	only	RB
cord-014712-5u4e00q6	1539	6	leads	lead	VBZ
cord-014712-5u4e00q6	1539	7	to	to	IN
cord-014712-5u4e00q6	1539	8	reduction	reduction	NN
cord-014712-5u4e00q6	1539	9	of	of	IN
cord-014712-5u4e00q6	1539	10	infectious	infectious	JJ
cord-014712-5u4e00q6	1539	11	episodes	episode	NNS
cord-014712-5u4e00q6	1539	12	,	,	,
cord-014712-5u4e00q6	1539	13	hospitalizations	hospitalization	NNS
cord-014712-5u4e00q6	1539	14	,	,	,
cord-014712-5u4e00q6	1539	15	and	and	CC
cord-014712-5u4e00q6	1539	16	as	as	IN
cord-014712-5u4e00q6	1539	17	a	a	DT
cord-014712-5u4e00q6	1539	18	result	result	NN
cord-014712-5u4e00q6	1539	19	improved	improve	VBN
cord-014712-5u4e00q6	1539	20	quality	quality	NN
cord-014712-5u4e00q6	1539	21	of	of	IN
cord-014712-5u4e00q6	1539	22	life	life	NN
cord-014712-5u4e00q6	1539	23	.	.	.
cord-014712-5u4e00q6	1540	1	In	in	IN
cord-014712-5u4e00q6	1540	2	some	some	DT
cord-014712-5u4e00q6	1540	3	cases	case	NNS
cord-014712-5u4e00q6	1540	4	it	-PRON-	PRP
cord-014712-5u4e00q6	1540	5	even	even	RB
cord-014712-5u4e00q6	1540	6	brings	bring	VBZ
cord-014712-5u4e00q6	1540	7	down	down	RP
cord-014712-5u4e00q6	1540	8	the	the	DT
cord-014712-5u4e00q6	1540	9	disease	disease	NN
cord-014712-5u4e00q6	1540	10	-	-	HYPH
cord-014712-5u4e00q6	1540	11	related	relate	VBN
cord-014712-5u4e00q6	1540	12	costs	cost	NNS
cord-014712-5u4e00q6	1540	13	,	,	,
cord-014712-5u4e00q6	1540	14	incurred	incur	VBN
cord-014712-5u4e00q6	1540	15	by	by	IN
cord-014712-5u4e00q6	1540	16	the	the	DT
cord-014712-5u4e00q6	1540	17	medical	medical	JJ
cord-014712-5u4e00q6	1540	18	system	system	NN
cord-014712-5u4e00q6	1540	19	and	and	CC
cord-014712-5u4e00q6	1540	20	the	the	DT
cord-014712-5u4e00q6	1540	21	family	family	NN
cord-014712-5u4e00q6	1540	22	,	,	,
cord-014712-5u4e00q6	1540	23	and	and	CC
cord-014712-5u4e00q6	1540	24	is	be	VBZ
cord-014712-5u4e00q6	1540	25	economically	economically	RB
cord-014712-5u4e00q6	1540	26	advantageous	advantageous	JJ
cord-014712-5u4e00q6	1540	27	for	for	IN
cord-014712-5u4e00q6	1540	28	the	the	DT
cord-014712-5u4e00q6	1540	29	state	state	NN
cord-014712-5u4e00q6	1540	30	.	.	.
cord-014712-5u4e00q6	1541	1	Introduction	introduction	NN
cord-014712-5u4e00q6	1541	2	:	:	:
cord-014712-5u4e00q6	1542	1	Replacement	replacement	NN
cord-014712-5u4e00q6	1542	2	of	of	IN
cord-014712-5u4e00q6	1542	3	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	1542	4	is	be	VBZ
cord-014712-5u4e00q6	1542	5	a	a	DT
cord-014712-5u4e00q6	1542	6	standard	standard	JJ
cord-014712-5u4e00q6	1542	7	therapy	therapy	NN
cord-014712-5u4e00q6	1542	8	for	for	IN
cord-014712-5u4e00q6	1542	9	patients	patient	NNS
cord-014712-5u4e00q6	1542	10	with	with	IN
cord-014712-5u4e00q6	1542	11	primary	primary	JJ
cord-014712-5u4e00q6	1542	12	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1542	13	disease	disease	NN
cord-014712-5u4e00q6	1542	14	(	(	-LRB-
cord-014712-5u4e00q6	1542	15	PIDD	PIDD	NNP
cord-014712-5u4e00q6	1542	16	)	)	-RRB-
cord-014712-5u4e00q6	1542	17	characterized	characterize	VBN
cord-014712-5u4e00q6	1542	18	by	by	IN
cord-014712-5u4e00q6	1542	19	primary	primary	JJ
cord-014712-5u4e00q6	1542	20	antibody	antibody	NN
cord-014712-5u4e00q6	1542	21	deficiency	deficiency	NN
cord-014712-5u4e00q6	1542	22	(	(	-LRB-
cord-014712-5u4e00q6	1542	23	PAD	pad	NN
cord-014712-5u4e00q6	1542	24	)	)	-RRB-
cord-014712-5u4e00q6	1542	25	.	.	.
cord-014712-5u4e00q6	1543	1	This	this	DT
cord-014712-5u4e00q6	1543	2	poster	poster	NN
cord-014712-5u4e00q6	1543	3	represents	represent	VBZ
cord-014712-5u4e00q6	1543	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	1543	5	clinical	clinical	JJ
cord-014712-5u4e00q6	1543	6	experiences	experience	NNS
cord-014712-5u4e00q6	1543	7	of	of	IN
cord-014712-5u4e00q6	1543	8	initiation	initiation	NN
cord-014712-5u4e00q6	1543	9	of	of	IN
cord-014712-5u4e00q6	1543	10	home	home	NN
cord-014712-5u4e00q6	1543	11	-	-	HYPH
cord-014712-5u4e00q6	1543	12	based	base	VBN
cord-014712-5u4e00q6	1543	13	treatment	treatment	NN
cord-014712-5u4e00q6	1543	14	with	with	IN
cord-014712-5u4e00q6	1543	15	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	1543	16	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1543	17	(	(	-LRB-
cord-014712-5u4e00q6	1543	18	SCIG	SCIG	NNP
cord-014712-5u4e00q6	1543	19	)	)	-RRB-
cord-014712-5u4e00q6	1543	20	with	with	IN
cord-014712-5u4e00q6	1543	21	the	the	DT
cord-014712-5u4e00q6	1543	22	patients	patient	NNS
cord-014712-5u4e00q6	1543	23	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1543	24	with	with	IN
cord-014712-5u4e00q6	1543	25	primary	primary	JJ
cord-014712-5u4e00q6	1543	26	variable	variable	JJ
cord-014712-5u4e00q6	1543	27	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1543	28	(	(	-LRB-
cord-014712-5u4e00q6	1543	29	CVID	CVID	NNP
cord-014712-5u4e00q6	1543	30	)	)	-RRB-
cord-014712-5u4e00q6	1543	31	.	.	.
cord-014712-5u4e00q6	1544	1	Case	case	NN
cord-014712-5u4e00q6	1544	2	report	report	NN
cord-014712-5u4e00q6	1544	3	:	:	:
cord-014712-5u4e00q6	1544	4	The	the	DT
cord-014712-5u4e00q6	1544	5	patient	patient	NN
cord-014712-5u4e00q6	1544	6	(	(	-LRB-
cord-014712-5u4e00q6	1544	7	age	age	NN
cord-014712-5u4e00q6	1544	8	30	30	CD
cord-014712-5u4e00q6	1544	9	)	)	-RRB-
cord-014712-5u4e00q6	1544	10	has	have	VBZ
cord-014712-5u4e00q6	1544	11	been	be	VBN
cord-014712-5u4e00q6	1544	12	treated	treat	VBN
cord-014712-5u4e00q6	1544	13	at	at	IN
cord-014712-5u4e00q6	1544	14	our	-PRON-	PRP$
cord-014712-5u4e00q6	1544	15	immuno	immuno	JJ
cord-014712-5u4e00q6	1544	16	-	-	HYPH
cord-014712-5u4e00q6	1544	17	allergy	allergy	NN
cord-014712-5u4e00q6	1544	18	outpatient	outpatient	NN
cord-014712-5u4e00q6	1544	19	clinic	clinic	NN
cord-014712-5u4e00q6	1544	20	since	since	IN
cord-014712-5u4e00q6	1544	21	2005	2005	CD
cord-014712-5u4e00q6	1544	22	with	with	IN
cord-014712-5u4e00q6	1544	23	the	the	DT
cord-014712-5u4e00q6	1544	24	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1544	25	of	of	IN
cord-014712-5u4e00q6	1544	26	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1544	27	(	(	-LRB-
cord-014712-5u4e00q6	1544	28	IgG	IgG	NNP
cord-014712-5u4e00q6	1544	29	,	,	,
cord-014712-5u4e00q6	1544	30	IgA	IgA	NNP
cord-014712-5u4e00q6	1544	31	,	,	,
cord-014712-5u4e00q6	1544	32	IgM	IgM	NNP
cord-014712-5u4e00q6	1544	33	)	)	-RRB-
cord-014712-5u4e00q6	1544	34	with	with	IN
cord-014712-5u4e00q6	1544	35	normal	normal	JJ
cord-014712-5u4e00q6	1544	36	B	b	NN
cord-014712-5u4e00q6	1544	37	cell	cell	NN
cord-014712-5u4e00q6	1544	38	count	count	NN
cord-014712-5u4e00q6	1544	39	,	,	,
cord-014712-5u4e00q6	1544	40	withsusp	withsusp	NN
cord-014712-5u4e00q6	1544	41	.	.	.
cord-014712-5u4e00q6	1545	1	CVID	CVID	NNP
cord-014712-5u4e00q6	1545	2	.	.	.
cord-014712-5u4e00q6	1546	1	With	with	IN
cord-014712-5u4e00q6	1546	2	the	the	DT
cord-014712-5u4e00q6	1546	3	repeated	repeated	JJ
cord-014712-5u4e00q6	1546	4	administration	administration	NN
cord-014712-5u4e00q6	1546	5	of	of	IN
cord-014712-5u4e00q6	1546	6	intramuscular	intramuscular	JJ
cord-014712-5u4e00q6	1546	7	and	and	CC
cord-014712-5u4e00q6	1546	8	intravenous	intravenous	JJ
cord-014712-5u4e00q6	1546	9	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	1546	10	(	(	-LRB-
cord-014712-5u4e00q6	1546	11	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1546	12	,	,	,
cord-014712-5u4e00q6	1546	13	IMIG	IMIG	NNP
cord-014712-5u4e00q6	1546	14	)	)	-RRB-
cord-014712-5u4e00q6	1546	15	repeatedly	repeatedly	RB
cord-014712-5u4e00q6	1546	16	occurred	occur	VBD
cord-014712-5u4e00q6	1546	17	serious	serious	JJ
cord-014712-5u4e00q6	1546	18	adverse	adverse	JJ
cord-014712-5u4e00q6	1546	19	reactions	reaction	NNS
cord-014712-5u4e00q6	1546	20	,	,	,
cord-014712-5u4e00q6	1546	21	which	which	WDT
cord-014712-5u4e00q6	1546	22	resulted	result	VBD
cord-014712-5u4e00q6	1546	23	in	in	IN
cord-014712-5u4e00q6	1546	24	discontinuation	discontinuation	NN
cord-014712-5u4e00q6	1546	25	of	of	IN
cord-014712-5u4e00q6	1546	26	the	the	DT
cord-014712-5u4e00q6	1546	27	replacement	replacement	NN
cord-014712-5u4e00q6	1546	28	therapy	therapy	NN
cord-014712-5u4e00q6	1546	29	.	.	.
cord-014712-5u4e00q6	1547	1	In	in	IN
cord-014712-5u4e00q6	1547	2	February	February	NNP
cord-014712-5u4e00q6	1547	3	2012	2012	CD
cord-014712-5u4e00q6	1547	4	the	the	DT
cord-014712-5u4e00q6	1547	5	health	health	NN
cord-014712-5u4e00q6	1547	6	condition	condition	NN
cord-014712-5u4e00q6	1547	7	of	of	IN
cord-014712-5u4e00q6	1547	8	the	the	DT
cord-014712-5u4e00q6	1547	9	patient	patient	NN
cord-014712-5u4e00q6	1547	10	worsened	worsen	VBD
cord-014712-5u4e00q6	1547	11	due	due	IN
cord-014712-5u4e00q6	1547	12	to	to	IN
cord-014712-5u4e00q6	1547	13	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1547	14	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1547	15	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1547	16	infections	infection	NNS
cord-014712-5u4e00q6	1547	17	.	.	.
cord-014712-5u4e00q6	1548	1	There	there	EX
cord-014712-5u4e00q6	1548	2	was	be	VBD
cord-014712-5u4e00q6	1548	3	a	a	DT
cord-014712-5u4e00q6	1548	4	progressive	progressive	JJ
cord-014712-5u4e00q6	1548	5	decrease	decrease	NN
cord-014712-5u4e00q6	1548	6	of	of	IN
cord-014712-5u4e00q6	1548	7	serum	serum	NN
cord-014712-5u4e00q6	1548	8	concentrations	concentration	NNS
cord-014712-5u4e00q6	1548	9	of	of	IN
cord-014712-5u4e00q6	1548	10	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	1548	11	(	(	-LRB-
cord-014712-5u4e00q6	1548	12	IgG	IgG	NNP
cord-014712-5u4e00q6	1548	13	2,1	2,1	CD
cord-014712-5u4e00q6	1548	14	g	g	NNP
cord-014712-5u4e00q6	1548	15	/	/	SYM
cord-014712-5u4e00q6	1548	16	l	l	NNP
cord-014712-5u4e00q6	1548	17	,	,	,
cord-014712-5u4e00q6	1548	18	IgM	IgM	NNP
cord-014712-5u4e00q6	1548	19	0,25	0,25	NNP
cord-014712-5u4e00q6	1548	20	g	g	NNP
cord-014712-5u4e00q6	1548	21	/	/	SYM
cord-014712-5u4e00q6	1548	22	l	l	NNP
cord-014712-5u4e00q6	1548	23	,	,	,
cord-014712-5u4e00q6	1548	24	IgA	IgA	NNP
cord-014712-5u4e00q6	1548	25	0,23	0,23	CD
cord-014712-5u4e00q6	1548	26	g	g	NNP
cord-014712-5u4e00q6	1548	27	/	/	SYM
cord-014712-5u4e00q6	1548	28	l	l	NN
cord-014712-5u4e00q6	1548	29	)	)	-RRB-
cord-014712-5u4e00q6	1548	30	.	.	.
cord-014712-5u4e00q6	1549	1	The	the	DT
cord-014712-5u4e00q6	1549	2	patient	patient	NN
cord-014712-5u4e00q6	1549	3	was	be	VBD
cord-014712-5u4e00q6	1549	4	admitted	admit	VBN
cord-014712-5u4e00q6	1549	5	to	to	IN
cord-014712-5u4e00q6	1549	6	the	the	DT
cord-014712-5u4e00q6	1549	7	intensive	intensive	JJ
cord-014712-5u4e00q6	1549	8	care	care	NN
cord-014712-5u4e00q6	1549	9	unit	unit	NN
cord-014712-5u4e00q6	1549	10	of	of	IN
cord-014712-5u4e00q6	1549	11	the	the	DT
cord-014712-5u4e00q6	1549	12	1	1	CD
cord-014712-5u4e00q6	1549	13	st	st	NNP
cord-014712-5u4e00q6	1549	14	Internal	Internal	NNP
cord-014712-5u4e00q6	1549	15	Department	Department	NNP
cord-014712-5u4e00q6	1549	16	,	,	,
cord-014712-5u4e00q6	1549	17	University	University	NNP
cord-014712-5u4e00q6	1549	18	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1549	19	Bratislava	Bratislava	NNP
cord-014712-5u4e00q6	1549	20	,	,	,
cord-014712-5u4e00q6	1549	21	for	for	IN
cord-014712-5u4e00q6	1549	22	a	a	DT
cord-014712-5u4e00q6	1549	23	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	1549	24	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1549	25	replacement	replacement	NN
cord-014712-5u4e00q6	1549	26	trial	trial	NN
cord-014712-5u4e00q6	1549	27	.	.	.
cord-014712-5u4e00q6	1550	1	Despite	despite	IN
cord-014712-5u4e00q6	1550	2	serious	serious	JJ
cord-014712-5u4e00q6	1550	3	adverse	adverse	JJ
cord-014712-5u4e00q6	1550	4	reactions	reaction	NNS
cord-014712-5u4e00q6	1550	5	with	with	IN
cord-014712-5u4e00q6	1550	6	previous	previous	JJ
cord-014712-5u4e00q6	1550	7	administration	administration	NN
cord-014712-5u4e00q6	1550	8	of	of	IN
cord-014712-5u4e00q6	1550	9	several	several	JJ
cord-014712-5u4e00q6	1550	10	types	type	NNS
cord-014712-5u4e00q6	1550	11	of	of	IN
cord-014712-5u4e00q6	1550	12	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	1550	13	,	,	,
cord-014712-5u4e00q6	1550	14	there	there	EX
cord-014712-5u4e00q6	1550	15	have	have	VBP
cord-014712-5u4e00q6	1550	16	not	not	RB
cord-014712-5u4e00q6	1550	17	occurred	occur	VBN
cord-014712-5u4e00q6	1550	18	any	any	DT
cord-014712-5u4e00q6	1550	19	clinically	clinically	RB
cord-014712-5u4e00q6	1550	20	relevant	relevant	JJ
cord-014712-5u4e00q6	1550	21	side	side	NN
cord-014712-5u4e00q6	1550	22	effects	effect	NNS
cord-014712-5u4e00q6	1550	23	.	.	.
cord-014712-5u4e00q6	1551	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1551	2	:	:	:
cord-014712-5u4e00q6	1552	1	Compared	compare	VBN
cord-014712-5u4e00q6	1552	2	with	with	IN
cord-014712-5u4e00q6	1552	3	IM	IM	NNP
cord-014712-5u4e00q6	1552	4	or	or	CC
cord-014712-5u4e00q6	1552	5	IV	IV	NNP
cord-014712-5u4e00q6	1552	6	formulations	formulation	NNS
cord-014712-5u4e00q6	1552	7	and	and	CC
cord-014712-5u4e00q6	1552	8	administration	administration	NN
cord-014712-5u4e00q6	1552	9	,	,	,
cord-014712-5u4e00q6	1552	10	for	for	IN
cord-014712-5u4e00q6	1552	11	selected	select	VBN
cord-014712-5u4e00q6	1552	12	patients	patient	NNS
cord-014712-5u4e00q6	1552	13	,	,	,
cord-014712-5u4e00q6	1552	14	SCIG	SCIG	NNP
cord-014712-5u4e00q6	1552	15	is	be	VBZ
cord-014712-5u4e00q6	1552	16	better	well	RBR
cord-014712-5u4e00q6	1552	17	tolerated	tolerate	VBN
cord-014712-5u4e00q6	1552	18	,	,	,
cord-014712-5u4e00q6	1552	19	clinically	clinically	RB
cord-014712-5u4e00q6	1552	20	efficacious	efficacious	JJ
cord-014712-5u4e00q6	1552	21	,	,	,
cord-014712-5u4e00q6	1552	22	safe	safe	JJ
cord-014712-5u4e00q6	1552	23	,	,	,
cord-014712-5u4e00q6	1552	24	and	and	CC
cord-014712-5u4e00q6	1552	25	appreciated	appreciate	VBN
cord-014712-5u4e00q6	1552	26	by	by	IN
cord-014712-5u4e00q6	1552	27	the	the	DT
cord-014712-5u4e00q6	1552	28	patients	patient	NNS
cord-014712-5u4e00q6	1552	29	.	.	.
cord-014712-5u4e00q6	1553	1	Background	background	NN
cord-014712-5u4e00q6	1553	2	:	:	:
cord-014712-5u4e00q6	1554	1	Common	common	JJ
cord-014712-5u4e00q6	1554	2	variable	variable	JJ
cord-014712-5u4e00q6	1554	3	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1554	4	(	(	-LRB-
cord-014712-5u4e00q6	1554	5	CVID	CVID	NNP
cord-014712-5u4e00q6	1554	6	)	)	-RRB-
cord-014712-5u4e00q6	1554	7	is	be	VBZ
cord-014712-5u4e00q6	1554	8	primary	primary	JJ
cord-014712-5u4e00q6	1554	9	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1554	10	(	(	-LRB-
cord-014712-5u4e00q6	1554	11	PID	PID	NNP
cord-014712-5u4e00q6	1554	12	)	)	-RRB-
cord-014712-5u4e00q6	1554	13	classically	classically	RB
cord-014712-5u4e00q6	1554	14	viewed	view	VBN
cord-014712-5u4e00q6	1554	15	as	as	IN
cord-014712-5u4e00q6	1554	16	antibody	antibody	NN
cord-014712-5u4e00q6	1554	17	deficit	deficit	NN
cord-014712-5u4e00q6	1554	18	.	.	.
cord-014712-5u4e00q6	1555	1	Although	although	IN
cord-014712-5u4e00q6	1555	2	,	,	,
cord-014712-5u4e00q6	1555	3	CVID	CVID	NNP
cord-014712-5u4e00q6	1555	4	is	be	VBZ
cord-014712-5u4e00q6	1555	5	considerd	considerd	VBN
cord-014712-5u4e00q6	1555	6	to	to	TO
cord-014712-5u4e00q6	1555	7	be	be	VB
cord-014712-5u4e00q6	1555	8	a	a	DT
cord-014712-5u4e00q6	1555	9	humoral	humoral	JJ
cord-014712-5u4e00q6	1555	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1555	11	,	,	,
cord-014712-5u4e00q6	1555	12	approximately	approximately	RB
cord-014712-5u4e00q6	1555	13	40	40	CD
cord-014712-5u4e00q6	1555	14	%	%	NN
cord-014712-5u4e00q6	1555	15	of	of	IN
cord-014712-5u4e00q6	1555	16	CVID	CVID	NNP
cord-014712-5u4e00q6	1555	17	patients	patient	NNS
cord-014712-5u4e00q6	1555	18	have	have	VBP
cord-014712-5u4e00q6	1555	19	low	low	JJ
cord-014712-5u4e00q6	1555	20	T	t	NN
cord-014712-5u4e00q6	1555	21	-	-	HYPH
cord-014712-5u4e00q6	1555	22	cell	cell	NN
cord-014712-5u4e00q6	1555	23	counts	count	NNS
cord-014712-5u4e00q6	1555	24	or	or	CC
cord-014712-5u4e00q6	1555	25	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1555	26	Tcell	Tcell	NNP
cord-014712-5u4e00q6	1555	27	function	function	NN
cord-014712-5u4e00q6	1555	28	.	.	.
cord-014712-5u4e00q6	1556	1	Despite	despite	IN
cord-014712-5u4e00q6	1556	2	adequate	adequate	JJ
cord-014712-5u4e00q6	1556	3	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1556	4	replacement	replacement	NN
cord-014712-5u4e00q6	1556	5	patient	patient	NN
cord-014712-5u4e00q6	1556	6	morbidity	morbidity	NN
cord-014712-5u4e00q6	1556	7	and	and	CC
cord-014712-5u4e00q6	1556	8	mortality	mortality	NN
cord-014712-5u4e00q6	1556	9	is	be	VBZ
cord-014712-5u4e00q6	1556	10	variable	variable	JJ
cord-014712-5u4e00q6	1556	11	and	and	CC
cord-014712-5u4e00q6	1556	12	a	a	DT
cord-014712-5u4e00q6	1556	13	number	number	NN
cord-014712-5u4e00q6	1556	14	of	of	IN
cord-014712-5u4e00q6	1556	15	complications	complication	NNS
cord-014712-5u4e00q6	1556	16	are	be	VBP
cord-014712-5u4e00q6	1556	17	not	not	RB
cord-014712-5u4e00q6	1556	18	those	those	DT
cord-014712-5u4e00q6	1556	19	typically	typically	RB
cord-014712-5u4e00q6	1556	20	seen	see	VBN
cord-014712-5u4e00q6	1556	21	in	in	IN
cord-014712-5u4e00q6	1556	22	pure	pure	JJ
cord-014712-5u4e00q6	1556	23	antibody	antibody	NN
cord-014712-5u4e00q6	1556	24	PID	pid	NN
cord-014712-5u4e00q6	1557	1	e.g.	e.g.	RB
cord-014712-5u4e00q6	1557	2	XLA	XLA	NNP
cord-014712-5u4e00q6	1557	3	.	.	.
cord-014712-5u4e00q6	1558	1	So	so	RB
cord-014712-5u4e00q6	1558	2	,	,	,
cord-014712-5u4e00q6	1558	3	T	t	NN
cord-014712-5u4e00q6	1558	4	-	-	HYPH
cord-014712-5u4e00q6	1558	5	cell	cell	NN
cord-014712-5u4e00q6	1558	6	rather	rather	RB
cord-014712-5u4e00q6	1558	7	than	than	IN
cord-014712-5u4e00q6	1558	8	B	b	NN
cord-014712-5u4e00q6	1558	9	-	-	HYPH
cord-014712-5u4e00q6	1558	10	cell	cell	NN
cord-014712-5u4e00q6	1558	11	phenotype	phenotype	NN
cord-014712-5u4e00q6	1558	12	could	could	MD
cord-014712-5u4e00q6	1558	13	determine	determine	VB
cord-014712-5u4e00q6	1558	14	outcome	outcome	NN
cord-014712-5u4e00q6	1558	15	in	in	IN
cord-014712-5u4e00q6	1558	16	patients	patient	NNS
cord-014712-5u4e00q6	1558	17	with	with	IN
cord-014712-5u4e00q6	1558	18	CVID	CVID	NNP
cord-014712-5u4e00q6	1558	19	.	.	.
cord-014712-5u4e00q6	1559	1	Many	many	JJ
cord-014712-5u4e00q6	1559	2	patients	patient	NNS
cord-014712-5u4e00q6	1559	3	with	with	IN
cord-014712-5u4e00q6	1559	4	CVID	CVID	NNP
cord-014712-5u4e00q6	1559	5	have	have	VBP
cord-014712-5u4e00q6	1559	6	clinical	clinical	JJ
cord-014712-5u4e00q6	1559	7	history	history	NN
cord-014712-5u4e00q6	1559	8	suggestive	suggestive	JJ
cord-014712-5u4e00q6	1559	9	of	of	IN
cord-014712-5u4e00q6	1559	10	allergic	allergic	JJ
cord-014712-5u4e00q6	1559	11	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1559	12	disease	disease	NN
cord-014712-5u4e00q6	1559	13	,	,	,
cord-014712-5u4e00q6	1559	14	but	but	CC
cord-014712-5u4e00q6	1559	15	prevalence	prevalence	NN
cord-014712-5u4e00q6	1559	16	of	of	IN
cord-014712-5u4e00q6	1559	17	asthma	asthma	NN
cord-014712-5u4e00q6	1559	18	and	and	CC
cord-014712-5u4e00q6	1559	19	role	role	NN
cord-014712-5u4e00q6	1559	20	of	of	IN
cord-014712-5u4e00q6	1559	21	atopy	atopy	NN
cord-014712-5u4e00q6	1559	22	have	have	VBP
cord-014712-5u4e00q6	1559	23	not	not	RB
cord-014712-5u4e00q6	1559	24	been	be	VBN
cord-014712-5u4e00q6	1559	25	well	well	RB
cord-014712-5u4e00q6	1559	26	established	establish	VBN
cord-014712-5u4e00q6	1559	27	.	.	.
cord-014712-5u4e00q6	1560	1	Apart	apart	RB
cord-014712-5u4e00q6	1560	2	from	from	IN
cord-014712-5u4e00q6	1560	3	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1560	4	infections	infection	NNS
cord-014712-5u4e00q6	1560	5	and	and	CC
cord-014712-5u4e00q6	1560	6	their	-PRON-	PRP$
cord-014712-5u4e00q6	1560	7	sequelae	sequela	NNS
cord-014712-5u4e00q6	1560	8	,	,	,
cord-014712-5u4e00q6	1560	9	CVID	CVID	NNP
cord-014712-5u4e00q6	1560	10	patients	patient	NNS
cord-014712-5u4e00q6	1560	11	suffer	suffer	VBP
cord-014712-5u4e00q6	1560	12	from	from	IN
cord-014712-5u4e00q6	1560	13	other	other	JJ
cord-014712-5u4e00q6	1560	14	disease	disease	NN
cord-014712-5u4e00q6	1560	15	-	-	HYPH
cord-014712-5u4e00q6	1560	16	related	relate	VBN
cord-014712-5u4e00q6	1560	17	complications	complication	NNS
cord-014712-5u4e00q6	1560	18	in	in	IN
cord-014712-5u4e00q6	1560	19	up	up	IN
cord-014712-5u4e00q6	1560	20	to	to	TO
cord-014712-5u4e00q6	1560	21	45	45	CD
cord-014712-5u4e00q6	1560	22	%	%	NN
cord-014712-5u4e00q6	1560	23	of	of	IN
cord-014712-5u4e00q6	1560	24	the	the	DT
cord-014712-5u4e00q6	1560	25	cases	case	NNS
cord-014712-5u4e00q6	1560	26	.	.	.
cord-014712-5u4e00q6	1561	1	About	about	RB
cord-014712-5u4e00q6	1561	2	25	25	CD
cord-014712-5u4e00q6	1561	3	%	%	NN
cord-014712-5u4e00q6	1561	4	have	have	VBP
cord-014712-5u4e00q6	1561	5	onset	onset	NN
cord-014712-5u4e00q6	1561	6	before	before	IN
cord-014712-5u4e00q6	1561	7	the	the	DT
cord-014712-5u4e00q6	1561	8	age	age	NN
cord-014712-5u4e00q6	1561	9	of	of	IN
cord-014712-5u4e00q6	1561	10	15	15	CD
cord-014712-5u4e00q6	1561	11	years	year	NNS
cord-014712-5u4e00q6	1561	12	.	.	.
cord-014712-5u4e00q6	1562	1	Aims	aim	VBZ
cord-014712-5u4e00q6	1562	2	:	:	:
cord-014712-5u4e00q6	1562	3	1	1	LS
cord-014712-5u4e00q6	1562	4	)	)	-RRB-
cord-014712-5u4e00q6	1562	5	to	to	TO
cord-014712-5u4e00q6	1562	6	present	present	VB
cord-014712-5u4e00q6	1562	7	one	one	CD
cord-014712-5u4e00q6	1562	8	more	more	JJR
cord-014712-5u4e00q6	1562	9	case	case	NN
cord-014712-5u4e00q6	1562	10	of	of	IN
cord-014712-5u4e00q6	1562	11	tadolescent	tadolescent	NN
cord-014712-5u4e00q6	1562	12	with	with	IN
cord-014712-5u4e00q6	1562	13	CVID	CVID	NNP
cord-014712-5u4e00q6	1562	14	and	and	CC
cord-014712-5u4e00q6	1562	15	allergic	allergic	JJ
cord-014712-5u4e00q6	1562	16	asthma	asthma	NN
cord-014712-5u4e00q6	1562	17	,	,	,
cord-014712-5u4e00q6	1562	18	2	2	CD
cord-014712-5u4e00q6	1562	19	)	)	-RRB-
cord-014712-5u4e00q6	1563	1	emphasise	emphasise	VB
cord-014712-5u4e00q6	1563	2	ultimate	ultimate	JJ
cord-014712-5u4e00q6	1563	3	need	need	NN
cord-014712-5u4e00q6	1563	4	of	of	IN
cord-014712-5u4e00q6	1563	5	collaborative	collaborative	JJ
cord-014712-5u4e00q6	1563	6	network	network	NN
cord-014712-5u4e00q6	1563	7	of	of	IN
cord-014712-5u4e00q6	1563	8	primary	primary	JJ
cord-014712-5u4e00q6	1563	9	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1563	10	centers	center	NNS
cord-014712-5u4e00q6	1563	11	.	.	.
cord-014712-5u4e00q6	1564	1	Case	case	NN
cord-014712-5u4e00q6	1564	2	report	report	NN
cord-014712-5u4e00q6	1564	3	:	:	:
cord-014712-5u4e00q6	1564	4	Parents	parent	NNS
cord-014712-5u4e00q6	1564	5	of	of	IN
cord-014712-5u4e00q6	1564	6	12,5	12,5	CD
cord-014712-5u4e00q6	1564	7	y	y	NN
cord-014712-5u4e00q6	1564	8	boy	boy	NN
cord-014712-5u4e00q6	1564	9	were	be	VBD
cord-014712-5u4e00q6	1564	10	sure	sure	JJ
cord-014712-5u4e00q6	1564	11	that	that	IN
cord-014712-5u4e00q6	1564	12	"	"	``
cord-014712-5u4e00q6	1564	13	something	something	NN
cord-014712-5u4e00q6	1564	14	was	be	VBD
cord-014712-5u4e00q6	1564	15	wrong	wrong	JJ
cord-014712-5u4e00q6	1564	16	"	"	''
cord-014712-5u4e00q6	1564	17	with	with	IN
cord-014712-5u4e00q6	1564	18	their	-PRON-	PRP$
cord-014712-5u4e00q6	1564	19	son	son	NN
cord-014712-5u4e00q6	1564	20	and	and	CC
cord-014712-5u4e00q6	1564	21	were	be	VBD
cord-014712-5u4e00q6	1564	22	seaking	seake	VBG
cord-014712-5u4e00q6	1564	23	for	for	IN
cord-014712-5u4e00q6	1564	24	problem	problem	NN
cord-014712-5u4e00q6	1564	25	solution	solution	NN
cord-014712-5u4e00q6	1564	26	for	for	IN
cord-014712-5u4e00q6	1564	27	many	many	JJ
cord-014712-5u4e00q6	1564	28	years	year	NNS
cord-014712-5u4e00q6	1564	29	.	.	.
cord-014712-5u4e00q6	1565	1	Since	since	IN
cord-014712-5u4e00q6	1565	2	age	age	NN
cord-014712-5u4e00q6	1565	3	3	3	CD
cord-014712-5u4e00q6	1565	4	,	,	,
cord-014712-5u4e00q6	1565	5	child	child	NN
cord-014712-5u4e00q6	1565	6	had	have	VBD
cord-014712-5u4e00q6	1565	7	frequent	frequent	JJ
cord-014712-5u4e00q6	1565	8	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1565	9	infections	infection	NNS
cord-014712-5u4e00q6	1565	10	.	.	.
cord-014712-5u4e00q6	1566	1	Adenoidectomy	adenoidectomy	JJ
cord-014712-5u4e00q6	1566	2	and	and	CC
cord-014712-5u4e00q6	1566	3	tonsillectomy	tonsillectomy	NN
cord-014712-5u4e00q6	1566	4	were	be	VBD
cord-014712-5u4e00q6	1566	5	performed	perform	VBN
cord-014712-5u4e00q6	1566	6	at	at	IN
cord-014712-5u4e00q6	1566	7	age	age	NN
cord-014712-5u4e00q6	1566	8	6	6	CD
cord-014712-5u4e00q6	1566	9	.	.	.
cord-014712-5u4e00q6	1567	1	Sinuitis	Sinuitis	NNP
cord-014712-5u4e00q6	1567	2	was	be	VBD
cord-014712-5u4e00q6	1567	3	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1567	4	several	several	JJ
cord-014712-5u4e00q6	1567	5	times	time	NNS
cord-014712-5u4e00q6	1567	6	.	.	.
cord-014712-5u4e00q6	1568	1	Boy	Boy	NNP
cord-014712-5u4e00q6	1568	2	was	be	VBD
cord-014712-5u4e00q6	1568	3	complaining	complain	VBG
cord-014712-5u4e00q6	1568	4	of	of	IN
cord-014712-5u4e00q6	1568	5	fatique	fatique	NN
cord-014712-5u4e00q6	1568	6	for	for	IN
cord-014712-5u4e00q6	1568	7	a	a	DT
cord-014712-5u4e00q6	1568	8	long	long	JJ
cord-014712-5u4e00q6	1568	9	time	time	NN
cord-014712-5u4e00q6	1568	10	.	.	.
cord-014712-5u4e00q6	1569	1	Last	last	JJ
cord-014712-5u4e00q6	1569	2	several	several	JJ
cord-014712-5u4e00q6	1569	3	years	year	NNS
cord-014712-5u4e00q6	1569	4	,	,	,
cord-014712-5u4e00q6	1569	5	his	-PRON-	PRP$
cord-014712-5u4e00q6	1569	6	main	main	JJ
cord-014712-5u4e00q6	1569	7	problems	problem	NNS
cord-014712-5u4e00q6	1569	8	were	be	VBD
cord-014712-5u4e00q6	1569	9	fever	fever	NN
cord-014712-5u4e00q6	1569	10	(	(	-LRB-
cord-014712-5u4e00q6	1569	11	max	max	NNP
cord-014712-5u4e00q6	1569	12	41	41	CD
cord-014712-5u4e00q6	1569	13	C	C	NNP
cord-014712-5u4e00q6	1569	14	)	)	-RRB-
cord-014712-5u4e00q6	1569	15	usually	usually	RB
cord-014712-5u4e00q6	1569	16	lasting	last	VBG
cord-014712-5u4e00q6	1569	17	5	5	CD
cord-014712-5u4e00q6	1569	18	days	day	NNS
cord-014712-5u4e00q6	1569	19	till	till	IN
cord-014712-5u4e00q6	1569	20	2	2	CD
cord-014712-5u4e00q6	1569	21	weeks	week	NNS
cord-014712-5u4e00q6	1569	22	,	,	,
cord-014712-5u4e00q6	1569	23	accompanying	accompany	VBG
cord-014712-5u4e00q6	1569	24	running	run	VBG
cord-014712-5u4e00q6	1569	25	nose	nose	NN
cord-014712-5u4e00q6	1569	26	,	,	,
cord-014712-5u4e00q6	1569	27	coughing	coughing	NN
cord-014712-5u4e00q6	1569	28	,	,	,
cord-014712-5u4e00q6	1569	29	conjunctival	conjunctival	NN
cord-014712-5u4e00q6	1569	30	problems	problem	NNS
cord-014712-5u4e00q6	1569	31	;	;	:
cord-014712-5u4e00q6	1569	32	intermittently	intermittently	RB
cord-014712-5u4e00q6	1569	33	headache	headache	NN
cord-014712-5u4e00q6	1569	34	(	(	-LRB-
cord-014712-5u4e00q6	1569	35	lasting	last	VBG
cord-014712-5u4e00q6	1569	36	for	for	IN
cord-014712-5u4e00q6	1569	37	a	a	DT
cord-014712-5u4e00q6	1569	38	few	few	JJ
cord-014712-5u4e00q6	1569	39	hours	hour	NNS
cord-014712-5u4e00q6	1569	40	till	till	IN
cord-014712-5u4e00q6	1569	41	all	all	DT
cord-014712-5u4e00q6	1569	42	day	day	NN
cord-014712-5u4e00q6	1569	43	)	)	-RRB-
cord-014712-5u4e00q6	1569	44	.	.	.
cord-014712-5u4e00q6	1570	1	Oral	oral	JJ
cord-014712-5u4e00q6	1570	2	aphtae	aphtae	NNP
cord-014712-5u4e00q6	1570	3	were	be	VBD
cord-014712-5u4e00q6	1570	4	present	present	JJ
cord-014712-5u4e00q6	1570	5	almost	almost	RB
cord-014712-5u4e00q6	1570	6	every	every	DT
cord-014712-5u4e00q6	1570	7	two	two	CD
cord-014712-5u4e00q6	1570	8	weeks	week	NNS
cord-014712-5u4e00q6	1570	9	.	.	.
cord-014712-5u4e00q6	1571	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1571	2	was	be	VBD
cord-014712-5u4e00q6	1571	3	incompletely	incompletely	RB
cord-014712-5u4e00q6	1571	4	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	1571	5	(	(	-LRB-
cord-014712-5u4e00q6	1571	6	BCG	BCG	NNP
cord-014712-5u4e00q6	1571	7	,	,	,
cord-014712-5u4e00q6	1571	8	and	and	CC
cord-014712-5u4e00q6	1571	9	once	once	RB
cord-014712-5u4e00q6	1571	10	DiTePer	DiTePer	NNP
cord-014712-5u4e00q6	1571	11	)	)	-RRB-
cord-014712-5u4e00q6	1571	12	.	.	.
cord-014712-5u4e00q6	1572	1	Morbilli	Morbilli	NNP
cord-014712-5u4e00q6	1572	2	and	and	CC
cord-014712-5u4e00q6	1572	3	varicellae	varicellae	NNP
cord-014712-5u4e00q6	1572	4	infections	infection	NNS
cord-014712-5u4e00q6	1572	5	passed	pass	VBN
cord-014712-5u4e00q6	1572	6	without	without	IN
cord-014712-5u4e00q6	1572	7	complications	complication	NNS
cord-014712-5u4e00q6	1572	8	.	.	.
cord-014712-5u4e00q6	1573	1	In	in	IN
cord-014712-5u4e00q6	1573	2	Jan	Jan	NNP
cord-014712-5u4e00q6	1573	3	2012	2012	CD
cord-014712-5u4e00q6	1573	4	he	-PRON-	PRP
cord-014712-5u4e00q6	1573	5	was	be	VBD
cord-014712-5u4e00q6	1573	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1573	7	as	as	IN
cord-014712-5u4e00q6	1573	8	allergic	allergic	JJ
cord-014712-5u4e00q6	1573	9	asthma	asthma	NN
cord-014712-5u4e00q6	1573	10	in	in	IN
cord-014712-5u4e00q6	1573	11	Sarajevo	Sarajevo	NNP
cord-014712-5u4e00q6	1573	12	(	(	-LRB-
cord-014712-5u4e00q6	1573	13	allergy	allergy	NN
cord-014712-5u4e00q6	1573	14	to	to	IN
cord-014712-5u4e00q6	1573	15	pollen	pollen	NN
cord-014712-5u4e00q6	1573	16	,	,	,
cord-014712-5u4e00q6	1573	17	soya	soya	NN
cord-014712-5u4e00q6	1573	18	,	,	,
cord-014712-5u4e00q6	1573	19	nuts	nut	NNS
cord-014712-5u4e00q6	1573	20	and	and	CC
cord-014712-5u4e00q6	1573	21	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	1573	22	(	(	-LRB-
cord-014712-5u4e00q6	1573	23	"	"	``
cord-014712-5u4e00q6	1573	24	Ceclor	Ceclor	NNP
cord-014712-5u4e00q6	1573	25	"	"	''
cord-014712-5u4e00q6	1573	26	and	and	CC
cord-014712-5u4e00q6	1573	27	"	"	``
cord-014712-5u4e00q6	1573	28	Pancef	Pancef	NNP
cord-014712-5u4e00q6	1573	29	"	"	''
cord-014712-5u4e00q6	1573	30	)	)	-RRB-
cord-014712-5u4e00q6	1573	31	.	.	.
cord-014712-5u4e00q6	1574	1	In	in	IN
cord-014712-5u4e00q6	1574	2	February	February	NNP
cord-014712-5u4e00q6	1574	3	2012	2012	CD
cord-014712-5u4e00q6	1574	4	was	be	VBD
cord-014712-5u4e00q6	1574	5	admitted	admit	VBN
cord-014712-5u4e00q6	1574	6	at	at	IN
cord-014712-5u4e00q6	1574	7	Children	Children	NNP
cord-014712-5u4e00q6	1574	8	's	's	POS
cord-014712-5u4e00q6	1574	9	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1574	10	Sarajevo	Sarajevo	NNP
cord-014712-5u4e00q6	1574	11	for	for	IN
cord-014712-5u4e00q6	1574	12	suspected	suspect	VBN
cord-014712-5u4e00q6	1574	13	primary	primary	JJ
cord-014712-5u4e00q6	1574	14	mmunodeficiency	mmunodeficiency	NN
cord-014712-5u4e00q6	1574	15	.	.	.
cord-014712-5u4e00q6	1575	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1575	2	had	have	VBD
cord-014712-5u4e00q6	1575	3	slightly	slightly	RB
cord-014712-5u4e00q6	1575	4	lower	low	JJR
cord-014712-5u4e00q6	1575	5	levels	level	NNS
cord-014712-5u4e00q6	1575	6	of	of	IN
cord-014712-5u4e00q6	1575	7	IgG	IgG	NNP
cord-014712-5u4e00q6	1575	8	and	and	CC
cord-014712-5u4e00q6	1575	9	IgA	IgA	NNP
cord-014712-5u4e00q6	1575	10	(	(	-LRB-
cord-014712-5u4e00q6	1575	11	twice	twice	RB
cord-014712-5u4e00q6	1575	12	measured	measure	VBN
cord-014712-5u4e00q6	1575	13	)	)	-RRB-
cord-014712-5u4e00q6	1575	14	,	,	,
cord-014712-5u4e00q6	1575	15	normal	normal	JJ
cord-014712-5u4e00q6	1575	16	IgE	IgE	NNP
cord-014712-5u4e00q6	1575	17	and	and	CC
cord-014712-5u4e00q6	1575	18	decreased	decrease	VBD
cord-014712-5u4e00q6	1575	19	number	number	NN
cord-014712-5u4e00q6	1575	20	of	of	IN
cord-014712-5u4e00q6	1575	21	T	T	NNP
cord-014712-5u4e00q6	1575	22	helper	helper	NN
cord-014712-5u4e00q6	1575	23	Ly	Ly	NNP
cord-014712-5u4e00q6	1575	24	.	.	.
cord-014712-5u4e00q6	1576	1	Due	due	IN
cord-014712-5u4e00q6	1576	2	to	to	IN
cord-014712-5u4e00q6	1576	3	suspected	suspect	VBN
cord-014712-5u4e00q6	1576	4	PID	pid	NN
cord-014712-5u4e00q6	1576	5	,	,	,
cord-014712-5u4e00q6	1576	6	boy	boy	NN
cord-014712-5u4e00q6	1576	7	was	be	VBD
cord-014712-5u4e00q6	1576	8	checked	check	VBN
cord-014712-5u4e00q6	1576	9	up	up	RP
cord-014712-5u4e00q6	1576	10	in	in	IN
cord-014712-5u4e00q6	1576	11	two	two	CD
cord-014712-5u4e00q6	1576	12	nearest	near	JJS
cord-014712-5u4e00q6	1576	13	regional	regional	JJ
cord-014712-5u4e00q6	1576	14	PID	PID	NNP
cord-014712-5u4e00q6	1576	15	centers	center	NNS
cord-014712-5u4e00q6	1576	16	:	:	:
cord-014712-5u4e00q6	1576	17	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1576	18	was	be	VBD
cord-014712-5u4e00q6	1576	19	confirmed	confirm	VBN
cord-014712-5u4e00q6	1576	20	(	(	-LRB-
cord-014712-5u4e00q6	1576	21	IgG	IgG	NNP
cord-014712-5u4e00q6	1576	22	4,7	4,7	CD
cord-014712-5u4e00q6	1576	23	,	,	,
cord-014712-5u4e00q6	1576	24	IgA	IgA	NNP
cord-014712-5u4e00q6	1576	25	0,24	0,24	NNP
cord-014712-5u4e00q6	1576	26	,	,	,
cord-014712-5u4e00q6	1576	27	IgM	IgM	NNP
cord-014712-5u4e00q6	1576	28	0,46	0,46	NNP
cord-014712-5u4e00q6	1576	29	,	,	,
cord-014712-5u4e00q6	1576	30	as	as	RB
cord-014712-5u4e00q6	1576	31	well	well	RB
cord-014712-5u4e00q6	1576	32	as	as	IN
cord-014712-5u4e00q6	1576	33	deficiency	deficiency	NN
cord-014712-5u4e00q6	1576	34	of	of	IN
cord-014712-5u4e00q6	1576	35	IgG1	IgG1	NNP
cord-014712-5u4e00q6	1576	36	,	,	,
cord-014712-5u4e00q6	1576	37	IgG2	igg2	NN
cord-014712-5u4e00q6	1576	38	and	and	CC
cord-014712-5u4e00q6	1576	39	IgG3	IgG3	NNP
cord-014712-5u4e00q6	1576	40	)	)	-RRB-
cord-014712-5u4e00q6	1576	41	.	.	.
cord-014712-5u4e00q6	1577	1	Flow	flow	NN
cord-014712-5u4e00q6	1577	2	cytometry	cytometry	NN
cord-014712-5u4e00q6	1577	3	showed	show	VBD
cord-014712-5u4e00q6	1577	4	slightly	slightly	RB
cord-014712-5u4e00q6	1577	5	raised	raise	VBN
cord-014712-5u4e00q6	1577	6	concentration	concentration	NN
cord-014712-5u4e00q6	1577	7	of	of	IN
cord-014712-5u4e00q6	1577	8	lymphocites	lymphocite	NNS
cord-014712-5u4e00q6	1577	9	B	B	NNP
cord-014712-5u4e00q6	1577	10	(	(	-LRB-
cord-014712-5u4e00q6	1577	11	CD8	CD8	NNP
cord-014712-5u4e00q6	1577	12	)	)	-RRB-
cord-014712-5u4e00q6	1577	13	,	,	,
cord-014712-5u4e00q6	1577	14	slightly	slightly	RB
cord-014712-5u4e00q6	1577	15	raised	raise	VBN
cord-014712-5u4e00q6	1577	16	number	number	NN
cord-014712-5u4e00q6	1577	17	of	of	IN
cord-014712-5u4e00q6	1577	18	nondifferentiated	nondifferentiate	VBN
cord-014712-5u4e00q6	1577	19	B	B	NNP
cord-014712-5u4e00q6	1577	20	cells	cell	NNS
cord-014712-5u4e00q6	1577	21	.	.	.
cord-014712-5u4e00q6	1578	1	CVID	CVID	NNP
cord-014712-5u4e00q6	1578	2	was	be	VBD
cord-014712-5u4e00q6	1578	3	suspected	suspect	VBN
cord-014712-5u4e00q6	1578	4	but	but	CC
cord-014712-5u4e00q6	1578	5	not	not	RB
cord-014712-5u4e00q6	1578	6	proved	prove	VBN
cord-014712-5u4e00q6	1578	7	.	.	.
cord-014712-5u4e00q6	1579	1	In	in	IN
cord-014712-5u4e00q6	1579	2	July	July	NNP
cord-014712-5u4e00q6	1579	3	2012	2012	CD
cord-014712-5u4e00q6	1579	4	child	child	NN
cord-014712-5u4e00q6	1579	5	visited	visit	VBD
cord-014712-5u4e00q6	1579	6	center	center	NN
cord-014712-5u4e00q6	1579	7	for	for	IN
cord-014712-5u4e00q6	1579	8	primary	primary	JJ
cord-014712-5u4e00q6	1579	9	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	1579	10	in	in	IN
cord-014712-5u4e00q6	1579	11	Munchen	Munchen	NNP
cord-014712-5u4e00q6	1579	12	,	,	,
cord-014712-5u4e00q6	1579	13	Germany	Germany	NNP
cord-014712-5u4e00q6	1579	14	,	,	,
cord-014712-5u4e00q6	1579	15	were	be	VBD
cord-014712-5u4e00q6	1579	16	he	-PRON-	PRP
cord-014712-5u4e00q6	1579	17	was	be	VBD
cord-014712-5u4e00q6	1579	18	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1579	19	ad	ad	NN
cord-014712-5u4e00q6	1579	20	probable	probable	JJ
cord-014712-5u4e00q6	1579	21	CVID	CVID	NNP
cord-014712-5u4e00q6	1579	22	on	on	IN
cord-014712-5u4e00q6	1579	23	the	the	DT
cord-014712-5u4e00q6	1579	24	basis	basis	NN
cord-014712-5u4e00q6	1579	25	of	of	IN
cord-014712-5u4e00q6	1579	26	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1579	27	,	,	,
cord-014712-5u4e00q6	1579	28	lower	low	JJR
cord-014712-5u4e00q6	1579	29	levels	level	NNS
cord-014712-5u4e00q6	1579	30	od	od	LS
cord-014712-5u4e00q6	1579	31	switch	switch	VBP
cord-014712-5u4e00q6	1579	32	memory	memory	NN
cord-014712-5u4e00q6	1579	33	B	b	NN
cord-014712-5u4e00q6	1579	34	cells	cell	NNS
cord-014712-5u4e00q6	1579	35	,	,	,
cord-014712-5u4e00q6	1579	36	normal	normal	JJ
cord-014712-5u4e00q6	1579	37	number	number	NN
cord-014712-5u4e00q6	1579	38	of	of	IN
cord-014712-5u4e00q6	1579	39	T	t	NN
cord-014712-5u4e00q6	1579	40	-	-	HYPH
cord-014712-5u4e00q6	1579	41	cells	cell	NNS
cord-014712-5u4e00q6	1579	42	,	,	,
cord-014712-5u4e00q6	1579	43	positive	positive	JJ
cord-014712-5u4e00q6	1579	44	antibodies	antibody	NNS
cord-014712-5u4e00q6	1579	45	to	to	IN
cord-014712-5u4e00q6	1579	46	vaccinations	vaccination	NNS
cord-014712-5u4e00q6	1579	47	and	and	CC
cord-014712-5u4e00q6	1579	48	overcome	overcome	VB
cord-014712-5u4e00q6	1579	49	infection	infection	NN
cord-014712-5u4e00q6	1579	50	(	(	-LRB-
cord-014712-5u4e00q6	1579	51	morbilli	morbilli	NNP
cord-014712-5u4e00q6	1579	52	,	,	,
cord-014712-5u4e00q6	1579	53	varicellae	varicellae	NNP
cord-014712-5u4e00q6	1579	54	)	)	-RRB-
cord-014712-5u4e00q6	1579	55	.	.	.
cord-014712-5u4e00q6	1580	1	Allergic	allergic	JJ
cord-014712-5u4e00q6	1580	2	asthma	asthma	NN
cord-014712-5u4e00q6	1580	3	was	be	VBD
cord-014712-5u4e00q6	1580	4	additionaly	additionaly	NNS
cord-014712-5u4e00q6	1580	5	confirmed	confirm	VBN
cord-014712-5u4e00q6	1580	6	in	in	IN
cord-014712-5u4e00q6	1580	7	specialised	specialised	JJ
cord-014712-5u4e00q6	1580	8	pediatric	pediatric	NNP
cord-014712-5u4e00q6	1580	9	pulmology	pulmology	NNP
cord-014712-5u4e00q6	1580	10	hospital	hospital	NN
cord-014712-5u4e00q6	1580	11	in	in	IN
cord-014712-5u4e00q6	1580	12	Germany	Germany	NNP
cord-014712-5u4e00q6	1580	13	(	(	-LRB-
cord-014712-5u4e00q6	1580	14	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1580	15	spirometry	spirometry	NN
cord-014712-5u4e00q6	1580	16	,	,	,
cord-014712-5u4e00q6	1580	17	normal	normal	JJ
cord-014712-5u4e00q6	1580	18	IgE	IgE	NNP
cord-014712-5u4e00q6	1580	19	,	,	,
cord-014712-5u4e00q6	1580	20	positive	positive	JJ
cord-014712-5u4e00q6	1580	21	skin	skin	NN
cord-014712-5u4e00q6	1580	22	prick	prick	NN
cord-014712-5u4e00q6	1580	23	test	test	NN
cord-014712-5u4e00q6	1580	24	,	,	,
cord-014712-5u4e00q6	1580	25	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1580	26	fractional	fractional	JJ
cord-014712-5u4e00q6	1580	27	exaled	exaled	JJ
cord-014712-5u4e00q6	1580	28	nitric	nitric	JJ
cord-014712-5u4e00q6	1580	29	oxid	oxid	NN
cord-014712-5u4e00q6	1580	30	test	test	NN
cord-014712-5u4e00q6	1580	31	,	,	,
cord-014712-5u4e00q6	1580	32	incipient	incipient	JJ
cord-014712-5u4e00q6	1580	33	brochiectasies	brochiectasie	NNS
cord-014712-5u4e00q6	1580	34	due	due	IN
cord-014712-5u4e00q6	1580	35	to	to	IN
cord-014712-5u4e00q6	1580	36	asthma	asthma	NN
cord-014712-5u4e00q6	1580	37	confirmed	confirm	VBN
cord-014712-5u4e00q6	1580	38	by	by	IN
cord-014712-5u4e00q6	1580	39	high	high	JJ
cord-014712-5u4e00q6	1580	40	-resolution	-resolution	HYPH
cord-014712-5u4e00q6	1580	41	lung	lung	NN
cord-014712-5u4e00q6	1580	42	CT	CT	NNP
cord-014712-5u4e00q6	1580	43	scan	scan	NN
cord-014712-5u4e00q6	1580	44	)	)	-RRB-
cord-014712-5u4e00q6	1580	45	.	.	.
cord-014712-5u4e00q6	1581	1	Low	low	JJ
cord-014712-5u4e00q6	1581	2	human	human	JJ
cord-014712-5u4e00q6	1581	3	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1581	4	replacement	replacement	NN
cord-014712-5u4e00q6	1581	5	was	be	VBD
cord-014712-5u4e00q6	1581	6	started	start	VBN
cord-014712-5u4e00q6	1581	7	(	(	-LRB-
cord-014712-5u4e00q6	1581	8	200	200	CD
cord-014712-5u4e00q6	1581	9	mg	mg	NNP
cord-014712-5u4e00q6	1581	10	/	/	SYM
cord-014712-5u4e00q6	1581	11	kgBW	kgBW	NNP
cord-014712-5u4e00q6	1581	12	)	)	-RRB-
cord-014712-5u4e00q6	1581	13	as	as	RB
cord-014712-5u4e00q6	1581	14	well	well	RB
cord-014712-5u4e00q6	1581	15	as	as	IN
cord-014712-5u4e00q6	1581	16	antiasthmatic	antiasthmatic	JJ
cord-014712-5u4e00q6	1581	17	therapy	therapy	NN
cord-014712-5u4e00q6	1582	1	(	(	-LRB-
cord-014712-5u4e00q6	1582	2	inhalatory	inhalatory	NNP
cord-014712-5u4e00q6	1582	3	steroids	steroid	NNS
cord-014712-5u4e00q6	1582	4	,	,	,
cord-014712-5u4e00q6	1582	5	antihistaminics	antihistaminic	NNS
cord-014712-5u4e00q6	1582	6	)	)	-RRB-
cord-014712-5u4e00q6	1582	7	.	.	.
cord-014712-5u4e00q6	1583	1	Excellent	excellent	JJ
cord-014712-5u4e00q6	1583	2	therapeutical	therapeutical	JJ
cord-014712-5u4e00q6	1583	3	response	response	NN
cord-014712-5u4e00q6	1583	4	were	be	VBD
cord-014712-5u4e00q6	1583	5	achieved	achieve	VBN
cord-014712-5u4e00q6	1583	6	:	:	:
cord-014712-5u4e00q6	1583	7	after	after	IN
cord-014712-5u4e00q6	1583	8	one	one	CD
cord-014712-5u4e00q6	1583	9	1,5	1,5	CD
cord-014712-5u4e00q6	1583	10	y	y	NN
cord-014712-5u4e00q6	1583	11	follow	follow	VBP
cord-014712-5u4e00q6	1583	12	up	up	RP
cord-014712-5u4e00q6	1583	13	,	,	,
cord-014712-5u4e00q6	1583	14	we	-PRON-	PRP
cord-014712-5u4e00q6	1583	15	can	can	MD
cord-014712-5u4e00q6	1583	16	confirm	confirm	VB
cord-014712-5u4e00q6	1583	17	patient	patient	JJ
cord-014712-5u4e00q6	1583	18	has	have	VBZ
cord-014712-5u4e00q6	1583	19	excellent	excellent	JJ
cord-014712-5u4e00q6	1583	20	general	general	JJ
cord-014712-5u4e00q6	1583	21	condition	condition	NN
cord-014712-5u4e00q6	1583	22	,	,	,
cord-014712-5u4e00q6	1583	23	no	no	DT
cord-014712-5u4e00q6	1583	24	subjective	subjective	JJ
cord-014712-5u4e00q6	1583	25	symptoms	symptom	NNS
cord-014712-5u4e00q6	1583	26	,	,	.
cord-014712-5u4e00q6	1584	1	no	no	DT
cord-014712-5u4e00q6	1584	2	tiredness	tiredness	NN
cord-014712-5u4e00q6	1584	3	,	,	,
cord-014712-5u4e00q6	1584	4	no	no	DT
cord-014712-5u4e00q6	1584	5	severe	severe	JJ
cord-014712-5u4e00q6	1584	6	infections	infection	NNS
cord-014712-5u4e00q6	1584	7	.	.	.
cord-014712-5u4e00q6	1585	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1585	2	:	:	:
cord-014712-5u4e00q6	1585	3	Diagnosing	diagnose	VBG
cord-014712-5u4e00q6	1585	4	CVID	CVID	NNP
cord-014712-5u4e00q6	1585	5	is	be	VBZ
cord-014712-5u4e00q6	1585	6	challenging	challenge	VBG
cord-014712-5u4e00q6	1585	7	task	task	NN
cord-014712-5u4e00q6	1585	8	and	and	CC
cord-014712-5u4e00q6	1585	9	quite	quite	RB
cord-014712-5u4e00q6	1585	10	often	often	RB
cord-014712-5u4e00q6	1585	11	could	could	MD
cord-014712-5u4e00q6	1585	12	be	be	VB
cord-014712-5u4e00q6	1585	13	"	"	``
cord-014712-5u4e00q6	1585	14	per	per	FW
cord-014712-5u4e00q6	1585	15	aspera	aspera	FW
cord-014712-5u4e00q6	1585	16	ad	ad	FW
cord-014712-5u4e00q6	1585	17	astra	astra	NN
cord-014712-5u4e00q6	1585	18	"	"	''
cord-014712-5u4e00q6	1585	19	.	.	.
cord-014712-5u4e00q6	1586	1	There	there	EX
cord-014712-5u4e00q6	1586	2	is	be	VBZ
cord-014712-5u4e00q6	1586	3	ultimate	ultimate	JJ
cord-014712-5u4e00q6	1586	4	need	need	NN
cord-014712-5u4e00q6	1586	5	of	of	IN
cord-014712-5u4e00q6	1586	6	collaborative	collaborative	JJ
cord-014712-5u4e00q6	1586	7	work	work	NN
cord-014712-5u4e00q6	1586	8	of	of	IN
cord-014712-5u4e00q6	1586	9	primary	primary	JJ
cord-014712-5u4e00q6	1586	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1586	11	network	network	NN
cord-014712-5u4e00q6	1586	12	aimed	aim	VBN
cord-014712-5u4e00q6	1586	13	of	of	IN
cord-014712-5u4e00q6	1586	14	diagnosing	diagnose	VBG
cord-014712-5u4e00q6	1586	15	patients	patient	NNS
cord-014712-5u4e00q6	1586	16	on	on	IN
cord-014712-5u4e00q6	1586	17	time	time	NN
cord-014712-5u4e00q6	1586	18	.	.	.
cord-014712-5u4e00q6	1587	1	CVID	CVID	NNP
cord-014712-5u4e00q6	1587	2	patients	patient	NNS
cord-014712-5u4e00q6	1587	3	with	with	IN
cord-014712-5u4e00q6	1587	4	history	history	NN
cord-014712-5u4e00q6	1587	5	suggestive	suggestive	JJ
cord-014712-5u4e00q6	1587	6	of	of	IN
cord-014712-5u4e00q6	1587	7	allergic	allergic	JJ
cord-014712-5u4e00q6	1587	8	asthma	asthma	NN
cord-014712-5u4e00q6	1587	9	,	,	,
cord-014712-5u4e00q6	1587	10	are	be	VBP
cord-014712-5u4e00q6	1587	11	negativne	negativne	NNP
cord-014712-5u4e00q6	1587	12	on	on	IN
cord-014712-5u4e00q6	1587	13	traditional	traditional	JJ
cord-014712-5u4e00q6	1587	14	tests	test	NNS
cord-014712-5u4e00q6	1587	15	,	,	,
cord-014712-5u4e00q6	1587	16	additional	additional	JJ
cord-014712-5u4e00q6	1587	17	test	test	NN
cord-014712-5u4e00q6	1587	18	designed	design	VBN
cord-014712-5u4e00q6	1587	19	to	to	TO
cord-014712-5u4e00q6	1587	20	identify	identify	VB
cord-014712-5u4e00q6	1587	21	allergic	allergic	JJ
cord-014712-5u4e00q6	1587	22	asthma	asthma	NN
cord-014712-5u4e00q6	1587	23	might	may	MD
cord-014712-5u4e00q6	1587	24	be	be	VB
cord-014712-5u4e00q6	1587	25	conducted	conduct	VBN
cord-014712-5u4e00q6	1587	26	.	.	.
cord-014712-5u4e00q6	1588	1	Common	common	JJ
cord-014712-5u4e00q6	1588	2	variable	variable	JJ
cord-014712-5u4e00q6	1588	3	immune	immune	JJ
cord-014712-5u4e00q6	1588	4	deficiency	deficiency	NN
cord-014712-5u4e00q6	1588	5	(	(	-LRB-
cord-014712-5u4e00q6	1588	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1588	7	)	)	-RRB-
cord-014712-5u4e00q6	1588	8	is	be	VBZ
cord-014712-5u4e00q6	1588	9	a	a	DT
cord-014712-5u4e00q6	1588	10	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	1588	11	syndrome	syndrome	NN
cord-014712-5u4e00q6	1588	12	characterized	characterize	VBN
cord-014712-5u4e00q6	1588	13	by	by	IN
cord-014712-5u4e00q6	1588	14	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1588	15	,	,	,
cord-014712-5u4e00q6	1588	16	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1588	17	infections	infection	NNS
cord-014712-5u4e00q6	1588	18	,	,	,
cord-014712-5u4e00q6	1588	19	immune	immune	JJ
cord-014712-5u4e00q6	1588	20	disregularity	disregularity	NN
cord-014712-5u4e00q6	1588	21	(	(	-LRB-
cord-014712-5u4e00q6	1588	22	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	1588	23	,	,	,
cord-014712-5u4e00q6	1588	24	autoinflamation	autoinflamation	NN
cord-014712-5u4e00q6	1588	25	)	)	-RRB-
cord-014712-5u4e00q6	1588	26	and	and	CC
cord-014712-5u4e00q6	1588	27	propensity	propensity	NN
cord-014712-5u4e00q6	1588	28	to	to	IN
cord-014712-5u4e00q6	1588	29	malignancies	malignancy	NNS
cord-014712-5u4e00q6	1588	30	.	.	.
cord-014712-5u4e00q6	1589	1	In	in	IN
cord-014712-5u4e00q6	1589	2	the	the	DT
cord-014712-5u4e00q6	1589	3	US	US	NNP
cord-014712-5u4e00q6	1589	4	report	report	NN
cord-014712-5u4e00q6	1589	5	,	,	,
cord-014712-5u4e00q6	1589	6	8.2	8.2	CD
cord-014712-5u4e00q6	1589	7	%	%	NN
cord-014712-5u4e00q6	1589	8	of	of	IN
cord-014712-5u4e00q6	1589	9	CVID	CVID	NNP
cord-014712-5u4e00q6	1589	10	patients	patient	NNS
cord-014712-5u4e00q6	1589	11	had	have	VBD
cord-014712-5u4e00q6	1589	12	a	a	DT
cord-014712-5u4e00q6	1589	13	lymphoid	lymphoid	JJ
cord-014712-5u4e00q6	1589	14	malignancy	malignancy	NN
cord-014712-5u4e00q6	1589	15	,	,	,
cord-014712-5u4e00q6	1589	16	and	and	CC
cord-014712-5u4e00q6	1589	17	cancers	cancer	NNS
cord-014712-5u4e00q6	1589	18	of	of	IN
cord-014712-5u4e00q6	1589	19	other	other	JJ
cord-014712-5u4e00q6	1589	20	sorts	sort	NNS
cord-014712-5u4e00q6	1589	21	developed	develop	VBN
cord-014712-5u4e00q6	1589	22	in	in	IN
cord-014712-5u4e00q6	1589	23	7	7	CD
cord-014712-5u4e00q6	1589	24	%	%	NN
cord-014712-5u4e00q6	1589	25	of	of	IN
cord-014712-5u4e00q6	1589	26	patients	patient	NNS
cord-014712-5u4e00q6	1589	27	.	.	.
cord-014712-5u4e00q6	1590	1	It	-PRON-	PRP
cord-014712-5u4e00q6	1590	2	is	be	VBZ
cord-014712-5u4e00q6	1590	3	not	not	RB
cord-014712-5u4e00q6	1590	4	clear	clear	JJ
cord-014712-5u4e00q6	1590	5	why	why	WRB
cord-014712-5u4e00q6	1590	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1590	7	patients	patient	NNS
cord-014712-5u4e00q6	1590	8	have	have	VBP
cord-014712-5u4e00q6	1590	9	higher	high	JJR
cord-014712-5u4e00q6	1590	10	risk	risk	NN
cord-014712-5u4e00q6	1590	11	of	of	IN
cord-014712-5u4e00q6	1590	12	malignancy	malignancy	NN
cord-014712-5u4e00q6	1590	13	but	but	CC
cord-014712-5u4e00q6	1590	14	chronic	chronic	JJ
cord-014712-5u4e00q6	1590	15	antigenic	antigenic	JJ
cord-014712-5u4e00q6	1590	16	stimulation	stimulation	NN
cord-014712-5u4e00q6	1590	17	,	,	,
cord-014712-5u4e00q6	1590	18	chronic	chronic	JJ
cord-014712-5u4e00q6	1590	19	inflammation	inflammation	NN
cord-014712-5u4e00q6	1590	20	and	and	CC
cord-014712-5u4e00q6	1590	21	increased	increase	VBN
cord-014712-5u4e00q6	1590	22	chromosomal	chromosomal	JJ
cord-014712-5u4e00q6	1590	23	radiosensitivity	radiosensitivity	NN
cord-014712-5u4e00q6	1590	24	may	may	MD
cord-014712-5u4e00q6	1590	25	be	be	VB
cord-014712-5u4e00q6	1590	26	the	the	DT
cord-014712-5u4e00q6	1590	27	cause	cause	NN
cord-014712-5u4e00q6	1590	28	.	.	.
cord-014712-5u4e00q6	1591	1	CVID	CVID	NNP
cord-014712-5u4e00q6	1591	2	patients	patient	NNS
cord-014712-5u4e00q6	1591	3	with	with	IN
cord-014712-5u4e00q6	1591	4	higher	high	JJR
cord-014712-5u4e00q6	1591	5	IgM	IgM	NNP
cord-014712-5u4e00q6	1591	6	level	level	NN
cord-014712-5u4e00q6	1591	7	,	,	,
cord-014712-5u4e00q6	1591	8	reduced	reduced	JJ
cord-014712-5u4e00q6	1591	9	or	or	CC
cord-014712-5u4e00q6	1591	10	absent	absent	JJ
cord-014712-5u4e00q6	1591	11	B	b	NN
cord-014712-5u4e00q6	1591	12	cell	cell	NN
cord-014712-5u4e00q6	1591	13	numbers	number	NNS
cord-014712-5u4e00q6	1591	14	,	,	,
cord-014712-5u4e00q6	1591	15	CD4	CD4	NNP
cord-014712-5u4e00q6	1591	16	T	T	NNP
cord-014712-5u4e00q6	1591	17	cells	cell	NNS
cord-014712-5u4e00q6	1591	18	lower	low	JJR
cord-014712-5u4e00q6	1591	19	than	than	IN
cord-014712-5u4e00q6	1591	20	200	200	CD
cord-014712-5u4e00q6	1591	21	and	and	CC
cord-014712-5u4e00q6	1591	22	PLI	pli	NN
cord-014712-5u4e00q6	1591	23	phenotype	phenotype	NN
cord-014712-5u4e00q6	1591	24	have	have	VBP
cord-014712-5u4e00q6	1591	25	higher	high	JJR
cord-014712-5u4e00q6	1591	26	prevalence	prevalence	NN
cord-014712-5u4e00q6	1591	27	of	of	IN
cord-014712-5u4e00q6	1591	28	malignancy	malignancy	NN
cord-014712-5u4e00q6	1591	29	.	.	.
cord-014712-5u4e00q6	1592	1	Allergy	allergy	NN
cord-014712-5u4e00q6	1592	2	and	and	CC
cord-014712-5u4e00q6	1592	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1592	4	immunology	immunology	NN
cord-014712-5u4e00q6	1592	5	department	department	NN
cord-014712-5u4e00q6	1592	6	of	of	IN
cord-014712-5u4e00q6	1592	7	Rasool	Rasool	NNP
cord-014712-5u4e00q6	1592	8	E	E	NNP
cord-014712-5u4e00q6	1592	9	Akram	Akram	NNP
cord-014712-5u4e00q6	1592	10	hospital	hospital	NN
cord-014712-5u4e00q6	1592	11	has	have	VBZ
cord-014712-5u4e00q6	1592	12	registered	register	VBN
cord-014712-5u4e00q6	1592	13	47	47	CD
cord-014712-5u4e00q6	1592	14	CVID	CVID	NNP
cord-014712-5u4e00q6	1592	15	patients	patient	NNS
cord-014712-5u4e00q6	1592	16	.	.	.
cord-014712-5u4e00q6	1593	1	Mean	mean	JJ
cord-014712-5u4e00q6	1593	2	age	age	NN
cord-014712-5u4e00q6	1593	3	of	of	IN
cord-014712-5u4e00q6	1593	4	the	the	DT
cord-014712-5u4e00q6	1593	5	onset	onset	NN
cord-014712-5u4e00q6	1593	6	of	of	IN
cord-014712-5u4e00q6	1593	7	CVID	CVID	NNP
cord-014712-5u4e00q6	1593	8	symptoms	symptom	NNS
cord-014712-5u4e00q6	1593	9	was	be	VBD
cord-014712-5u4e00q6	1593	10	11.2	11.2	CD
cord-014712-5u4e00q6	1593	11	years	year	NNS
cord-014712-5u4e00q6	1593	12	.	.	.
cord-014712-5u4e00q6	1594	1	Mean	mean	JJ
cord-014712-5u4e00q6	1594	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1594	3	age	age	NN
cord-014712-5u4e00q6	1594	4	was	be	VBD
cord-014712-5u4e00q6	1594	5	20.2	20.2	CD
cord-014712-5u4e00q6	1594	6	years	year	NNS
cord-014712-5u4e00q6	1594	7	with	with	IN
cord-014712-5u4e00q6	1594	8	mean	mean	JJ
cord-014712-5u4e00q6	1594	9	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	1594	10	delay	delay	NN
cord-014712-5u4e00q6	1594	11	of	of	IN
cord-014712-5u4e00q6	1594	12	9	9	CD
cord-014712-5u4e00q6	1594	13	years	year	NNS
cord-014712-5u4e00q6	1594	14	.	.	.
cord-014712-5u4e00q6	1595	1	Mean	mean	VB
cord-014712-5u4e00q6	1595	2	follow	follow	VB
cord-014712-5u4e00q6	1595	3	up	up	RP
cord-014712-5u4e00q6	1595	4	time	time	NN
cord-014712-5u4e00q6	1595	5	was	be	VBD
cord-014712-5u4e00q6	1595	6	7	7	CD
cord-014712-5u4e00q6	1595	7	years	year	NNS
cord-014712-5u4e00q6	1595	8	(	(	-LRB-
cord-014712-5u4e00q6	1595	9	minimum	minimum	JJ
cord-014712-5u4e00q6	1595	10	0.5-maximum	0.5-maximum	CD
cord-014712-5u4e00q6	1595	11	23	23	CD
cord-014712-5u4e00q6	1595	12	y	y	NNP
cord-014712-5u4e00q6	1595	13	)	)	-RRB-
cord-014712-5u4e00q6	1595	14	.	.	.
cord-014712-5u4e00q6	1596	1	Malignancy	malignancy	NN
cord-014712-5u4e00q6	1596	2	occurred	occur	VBD
cord-014712-5u4e00q6	1596	3	in	in	IN
cord-014712-5u4e00q6	1596	4	the	the	DT
cord-014712-5u4e00q6	1596	5	follow	follow	NN
cord-014712-5u4e00q6	1596	6	up	up	IN
cord-014712-5u4e00q6	1596	7	of	of	IN
cord-014712-5u4e00q6	1596	8	6	6	CD
cord-014712-5u4e00q6	1596	9	patients	patient	NNS
cord-014712-5u4e00q6	1596	10	(	(	-LRB-
cord-014712-5u4e00q6	1596	11	13	13	CD
cord-014712-5u4e00q6	1596	12	%	%	NN
cord-014712-5u4e00q6	1596	13	)	)	-RRB-
cord-014712-5u4e00q6	1596	14	.	.	.
cord-014712-5u4e00q6	1597	1	One	one	CD
cord-014712-5u4e00q6	1597	2	patient	patient	NN
cord-014712-5u4e00q6	1597	3	had	have	VBD
cord-014712-5u4e00q6	1597	4	two	two	CD
cord-014712-5u4e00q6	1597	5	different	different	JJ
cord-014712-5u4e00q6	1597	6	malignancies	malignancy	NNS
cord-014712-5u4e00q6	1597	7	(	(	-LRB-
cord-014712-5u4e00q6	1597	8	breast	breast	NN
cord-014712-5u4e00q6	1597	9	cancer	cancer	NN
cord-014712-5u4e00q6	1597	10	and	and	CC
cord-014712-5u4e00q6	1597	11	GI	GI	NNP
cord-014712-5u4e00q6	1597	12	adenocarcinoma	adenocarcinoma	NN
cord-014712-5u4e00q6	1597	13	)	)	-RRB-
cord-014712-5u4e00q6	1597	14	.	.	.
cord-014712-5u4e00q6	1598	1	Malignancy	malignancy	NN
cord-014712-5u4e00q6	1598	2	risk	risk	NN
cord-014712-5u4e00q6	1598	3	per	per	IN
cord-014712-5u4e00q6	1598	4	case	case	NN
cord-014712-5u4e00q6	1598	5	was	be	VBD
cord-014712-5u4e00q6	1598	6	15	15	CD
cord-014712-5u4e00q6	1598	7	%	%	NN
cord-014712-5u4e00q6	1598	8	.	.	.
cord-014712-5u4e00q6	1599	1	Hodgkin	Hodgkin	NNP
cord-014712-5u4e00q6	1599	2	's	's	POS
cord-014712-5u4e00q6	1599	3	lymphoma	lymphoma	NN
cord-014712-5u4e00q6	1599	4	was	be	VBD
cord-014712-5u4e00q6	1599	5	the	the	DT
cord-014712-5u4e00q6	1599	6	most	most	RBS
cord-014712-5u4e00q6	1599	7	common	common	JJ
cord-014712-5u4e00q6	1599	8	type	type	NN
cord-014712-5u4e00q6	1599	9	(	(	-LRB-
cord-014712-5u4e00q6	1599	10	43	43	CD
cord-014712-5u4e00q6	1599	11	%	%	NN
cord-014712-5u4e00q6	1599	12	of	of	IN
cord-014712-5u4e00q6	1599	13	cancers	cancer	NNS
cord-014712-5u4e00q6	1599	14	Common	common	JJ
cord-014712-5u4e00q6	1599	15	variable	variable	JJ
cord-014712-5u4e00q6	1599	16	immune	immune	JJ
cord-014712-5u4e00q6	1599	17	deficiency	deficiency	NN
cord-014712-5u4e00q6	1599	18	is	be	VBZ
cord-014712-5u4e00q6	1599	19	a	a	DT
cord-014712-5u4e00q6	1599	20	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	1599	21	syndrome	syndrome	NN
cord-014712-5u4e00q6	1599	22	characterized	characterize	VBN
cord-014712-5u4e00q6	1599	23	by	by	IN
cord-014712-5u4e00q6	1599	24	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1599	25	,	,	,
cord-014712-5u4e00q6	1599	26	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1599	27	infections	infection	NNS
cord-014712-5u4e00q6	1599	28	,	,	,
cord-014712-5u4e00q6	1599	29	auto	auto	NN
cord-014712-5u4e00q6	1599	30	immunity	immunity	NN
cord-014712-5u4e00q6	1599	31	and	and	CC
cord-014712-5u4e00q6	1599	32	auto	auto	NN
cord-014712-5u4e00q6	1599	33	-	-	HYPH
cord-014712-5u4e00q6	1599	34	inflammation	inflammation	NN
cord-014712-5u4e00q6	1599	35	.	.	.
cord-014712-5u4e00q6	1600	1	More	More	JJR
cord-014712-5u4e00q6	1600	2	than	than	IN
cord-014712-5u4e00q6	1600	3	25	25	CD
cord-014712-5u4e00q6	1600	4	%	%	NN
cord-014712-5u4e00q6	1600	5	of	of	IN
cord-014712-5u4e00q6	1600	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1600	7	patients	patient	NNS
cord-014712-5u4e00q6	1600	8	have	have	VBP
cord-014712-5u4e00q6	1600	9	auto	auto	NN
cord-014712-5u4e00q6	1600	10	immune	immune	JJ
cord-014712-5u4e00q6	1600	11	complications	complication	NNS
cord-014712-5u4e00q6	1600	12	and	and	CC
cord-014712-5u4e00q6	1600	13	among	among	IN
cord-014712-5u4e00q6	1600	14	them	-PRON-	PRP
cord-014712-5u4e00q6	1600	15	,	,	,
cord-014712-5u4e00q6	1600	16	auto	auto	NN
cord-014712-5u4e00q6	1600	17	immune	immune	NN
cord-014712-5u4e00q6	1600	18	cytopenia	cytopenia	NNP
cord-014712-5u4e00q6	1600	19	is	be	VBZ
cord-014712-5u4e00q6	1600	20	the	the	DT
cord-014712-5u4e00q6	1600	21	most	most	RBS
cord-014712-5u4e00q6	1600	22	common	common	JJ
cord-014712-5u4e00q6	1600	23	.	.	.
cord-014712-5u4e00q6	1601	1	CVID	CVID	NNP
cord-014712-5u4e00q6	1601	2	patients	patient	NNS
cord-014712-5u4e00q6	1601	3	with	with	IN
cord-014712-5u4e00q6	1601	4	higher	high	JJR
cord-014712-5u4e00q6	1601	5	IgM	IgM	NNP
cord-014712-5u4e00q6	1601	6	levelhigher	levelhigher	CC
cord-014712-5u4e00q6	1601	7	21	21	CD
cord-014712-5u4e00q6	1601	8	low	low	JJ
cord-014712-5u4e00q6	1601	9	B	b	NN
cord-014712-5u4e00q6	1601	10	Cellslower	Cellslower	NNP
cord-014712-5u4e00q6	1601	11	T	t	NN
cord-014712-5u4e00q6	1601	12	reg	reg	NN
cord-014712-5u4e00q6	1601	13	levelslower	levelslower	NN
cord-014712-5u4e00q6	1601	14	CD4	CD4	NNP
cord-014712-5u4e00q6	1601	15	/	/	SYM
cord-014712-5u4e00q6	1601	16	CD8	CD8	NNP
cord-014712-5u4e00q6	1601	17	ratio	ratio	NN
cord-014712-5u4e00q6	1601	18	and	and	CC
cord-014712-5u4e00q6	1601	19	lower	low	JJR
cord-014712-5u4e00q6	1601	20	class	class	NN
cord-014712-5u4e00q6	1601	21	switched	switch	VBD
cord-014712-5u4e00q6	1601	22	memory	memory	NN
cord-014712-5u4e00q6	1601	23	B	b	NN
cord-014712-5u4e00q6	1601	24	cells	cell	NNS
cord-014712-5u4e00q6	1601	25	have	have	VBP
cord-014712-5u4e00q6	1601	26	higher	high	JJR
cord-014712-5u4e00q6	1601	27	prevalence	prevalence	NN
cord-014712-5u4e00q6	1601	28	of	of	IN
cord-014712-5u4e00q6	1601	29	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	1601	30	.	.	.
cord-014712-5u4e00q6	1602	1	Allergy	allergy	NN
cord-014712-5u4e00q6	1602	2	and	and	CC
cord-014712-5u4e00q6	1602	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1602	4	immunology	immunology	NN
cord-014712-5u4e00q6	1602	5	department	department	NN
cord-014712-5u4e00q6	1602	6	of	of	IN
cord-014712-5u4e00q6	1602	7	this	this	DT
cord-014712-5u4e00q6	1602	8	hospital	hospital	NN
cord-014712-5u4e00q6	1602	9	has	have	VBZ
cord-014712-5u4e00q6	1602	10	registered	register	VBN
cord-014712-5u4e00q6	1602	11	47	47	CD
cord-014712-5u4e00q6	1602	12	CVID	CVID	NNP
cord-014712-5u4e00q6	1602	13	patients	patient	NNS
cord-014712-5u4e00q6	1602	14	.	.	.
cord-014712-5u4e00q6	1603	1	Mean	mean	JJ
cord-014712-5u4e00q6	1603	2	age	age	NN
cord-014712-5u4e00q6	1603	3	of	of	IN
cord-014712-5u4e00q6	1603	4	onset	onset	NN
cord-014712-5u4e00q6	1603	5	of	of	IN
cord-014712-5u4e00q6	1603	6	CVID	CVID	NNP
cord-014712-5u4e00q6	1603	7	symptoms	symptom	NNS
cord-014712-5u4e00q6	1603	8	was	be	VBD
cord-014712-5u4e00q6	1603	9	11.2	11.2	CD
cord-014712-5u4e00q6	1603	10	years	year	NNS
cord-014712-5u4e00q6	1603	11	.	.	.
cord-014712-5u4e00q6	1604	1	Mean	mean	JJ
cord-014712-5u4e00q6	1604	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1604	3	age	age	NN
cord-014712-5u4e00q6	1604	4	was	be	VBD
cord-014712-5u4e00q6	1604	5	20.2	20.2	CD
cord-014712-5u4e00q6	1604	6	years	year	NNS
cord-014712-5u4e00q6	1604	7	with	with	IN
cord-014712-5u4e00q6	1604	8	mean	mean	JJ
cord-014712-5u4e00q6	1604	9	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	1604	10	delay	delay	NN
cord-014712-5u4e00q6	1604	11	of	of	IN
cord-014712-5u4e00q6	1604	12	9	9	CD
cord-014712-5u4e00q6	1604	13	years	year	NNS
cord-014712-5u4e00q6	1604	14	.	.	.
cord-014712-5u4e00q6	1605	1	Mean	mean	VB
cord-014712-5u4e00q6	1605	2	follow	follow	VB
cord-014712-5u4e00q6	1605	3	up	up	RP
cord-014712-5u4e00q6	1605	4	time	time	NN
cord-014712-5u4e00q6	1605	5	was	be	VBD
cord-014712-5u4e00q6	1605	6	7	7	CD
cord-014712-5u4e00q6	1605	7	years	year	NNS
cord-014712-5u4e00q6	1605	8	(	(	-LRB-
cord-014712-5u4e00q6	1605	9	minimum	minimum	VBP
cord-014712-5u4e00q6	1605	10	0.5	0.5	CD
cord-014712-5u4e00q6	1605	11	maximum	maximum	NN
cord-014712-5u4e00q6	1605	12	23	23	CD
cord-014712-5u4e00q6	1605	13	y	y	NN
cord-014712-5u4e00q6	1605	14	)	)	-RRB-
cord-014712-5u4e00q6	1605	15	.	.	.
cord-014712-5u4e00q6	1606	1	Autoimmunity	Autoimmunity	NNP
cord-014712-5u4e00q6	1606	2	was	be	VBD
cord-014712-5u4e00q6	1606	3	detected	detect	VBN
cord-014712-5u4e00q6	1606	4	in	in	IN
cord-014712-5u4e00q6	1606	5	23	23	CD
cord-014712-5u4e00q6	1606	6	cases	case	NNS
cord-014712-5u4e00q6	1606	7	(	(	-LRB-
cord-014712-5u4e00q6	1606	8	49	49	CD
cord-014712-5u4e00q6	1606	9	%	%	NN
cord-014712-5u4e00q6	1606	10	)	)	-RRB-
cord-014712-5u4e00q6	1606	11	and	and	CC
cord-014712-5u4e00q6	1606	12	12	12	CD
cord-014712-5u4e00q6	1606	13	cases	case	NNS
cord-014712-5u4e00q6	1606	14	(	(	-LRB-
cord-014712-5u4e00q6	1606	15	26	26	CD
cord-014712-5u4e00q6	1606	16	%	%	NN
cord-014712-5u4e00q6	1606	17	)	)	-RRB-
cord-014712-5u4e00q6	1606	18	had	have	VBD
cord-014712-5u4e00q6	1606	19	more	more	JJR
cord-014712-5u4e00q6	1606	20	than	than	IN
cord-014712-5u4e00q6	1606	21	one	one	CD
cord-014712-5u4e00q6	1606	22	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	1606	23	.	.	.
cord-014712-5u4e00q6	1607	1	Autoimmunity	Autoimmunity	NNP
cord-014712-5u4e00q6	1607	2	was	be	VBD
cord-014712-5u4e00q6	1607	3	the	the	DT
cord-014712-5u4e00q6	1607	4	first	first	JJ
cord-014712-5u4e00q6	1607	5	symptom	symptom	NN
cord-014712-5u4e00q6	1607	6	of	of	IN
cord-014712-5u4e00q6	1607	7	CVID	CVID	NNP
cord-014712-5u4e00q6	1607	8	in	in	IN
cord-014712-5u4e00q6	1607	9	15	15	CD
cord-014712-5u4e00q6	1607	10	percent	percent	NN
cord-014712-5u4e00q6	1607	11	of	of	IN
cord-014712-5u4e00q6	1607	12	cases	case	NNS
cord-014712-5u4e00q6	1607	13	.	.	.
cord-014712-5u4e00q6	1608	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1608	2	disorders	disorder	NNS
cord-014712-5u4e00q6	1608	3	should	should	MD
cord-014712-5u4e00q6	1608	4	be	be	VB
cord-014712-5u4e00q6	1608	5	considered	consider	VBN
cord-014712-5u4e00q6	1608	6	in	in	IN
cord-014712-5u4e00q6	1608	7	the	the	DT
cord-014712-5u4e00q6	1608	8	follow	follow	NN
cord-014712-5u4e00q6	1608	9	up	up	IN
cord-014712-5u4e00q6	1608	10	of	of	IN
cord-014712-5u4e00q6	1608	11	CVID	CVID	NNP
cord-014712-5u4e00q6	1608	12	patients	patient	NNS
cord-014712-5u4e00q6	1608	13	.	.	.
cord-014712-5u4e00q6	1609	1	IgG	IgG	NNP
cord-014712-5u4e00q6	1609	2	is	be	VBZ
cord-014712-5u4e00q6	1609	3	major	major	JJ
cord-014712-5u4e00q6	1609	4	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1609	5	and	and	CC
cord-014712-5u4e00q6	1609	6	classified	classify	VBN
cord-014712-5u4e00q6	1609	7	subgroups	subgroup	NNS
cord-014712-5u4e00q6	1609	8	as	as	IN
cord-014712-5u4e00q6	1609	9	IgG1	IgG1	NNP
cord-014712-5u4e00q6	1609	10	,	,	,
cord-014712-5u4e00q6	1609	11	IgG2	igg2	NN
cord-014712-5u4e00q6	1609	12	,	,	,
cord-014712-5u4e00q6	1609	13	IgG3	igg3	NN
cord-014712-5u4e00q6	1609	14	and	and	CC
cord-014712-5u4e00q6	1609	15	IgG4	igg4	NN
cord-014712-5u4e00q6	1609	16	.	.	.
cord-014712-5u4e00q6	1610	1	IgG1	IgG1	NNP
cord-014712-5u4e00q6	1610	2	and	and	CC
cord-014712-5u4e00q6	1610	3	IgG3	IgG3	NNP
cord-014712-5u4e00q6	1610	4	subclasses	subclass	NNS
cord-014712-5u4e00q6	1610	5	are	be	VBP
cord-014712-5u4e00q6	1610	6	rich	rich	JJ
cord-014712-5u4e00q6	1610	7	in	in	IN
cord-014712-5u4e00q6	1610	8	antibodies	antibody	NNS
cord-014712-5u4e00q6	1610	9	aganist	aganist	VBP
cord-014712-5u4e00q6	1610	10	proteins	protein	NNS
cord-014712-5u4e00q6	1610	11	such	such	JJ
cord-014712-5u4e00q6	1610	12	as	as	IN
cord-014712-5u4e00q6	1610	13	the	the	DT
cord-014712-5u4e00q6	1610	14	toxins	toxin	NNS
cord-014712-5u4e00q6	1610	15	produced	produce	VBN
cord-014712-5u4e00q6	1610	16	by	by	IN
cord-014712-5u4e00q6	1610	17	the	the	DT
cord-014712-5u4e00q6	1610	18	diphtheria	diphtheria	NN
cord-014712-5u4e00q6	1610	19	and	and	CC
cord-014712-5u4e00q6	1610	20	tetanus	tetanus	NN
cord-014712-5u4e00q6	1610	21	,	,	,
cord-014712-5u4e00q6	1610	22	as	as	RB
cord-014712-5u4e00q6	1610	23	well	well	RB
cord-014712-5u4e00q6	1610	24	as	as	IN
cord-014712-5u4e00q6	1610	25	antibodies	antibody	NNS
cord-014712-5u4e00q6	1610	26	aganist	aganist	VBP
cord-014712-5u4e00q6	1610	27	viral	viral	JJ
cord-014712-5u4e00q6	1610	28	proteins	protein	NNS
cord-014712-5u4e00q6	1610	29	.	.	.
cord-014712-5u4e00q6	1611	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	1611	2	ear	ear	NN
cord-014712-5u4e00q6	1611	3	infections	infection	NNS
cord-014712-5u4e00q6	1611	4	,	,	,
cord-014712-5u4e00q6	1611	5	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	1611	6	,	,	,
cord-014712-5u4e00q6	1611	7	bronchitis	bronchitis	NN
cord-014712-5u4e00q6	1611	8	and	and	CC
cord-014712-5u4e00q6	1611	9	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1611	10	are	be	VBP
cord-014712-5u4e00q6	1611	11	common	common	JJ
cord-014712-5u4e00q6	1611	12	in	in	IN
cord-014712-5u4e00q6	1611	13	Ig	Ig	NNP
cord-014712-5u4e00q6	1611	14	g	g	NN
cord-014712-5u4e00q6	1611	15	subclass	subclass	NN
cord-014712-5u4e00q6	1611	16	deficiency	deficiency	NN
cord-014712-5u4e00q6	1611	17	.	.	.
cord-014712-5u4e00q6	1612	1	Ig	Ig	NNP
cord-014712-5u4e00q6	1612	2	G1	G1	NNP
cord-014712-5u4e00q6	1612	3	is	be	VBZ
cord-014712-5u4e00q6	1612	4	the	the	DT
cord-014712-5u4e00q6	1612	5	major	major	JJ
cord-014712-5u4e00q6	1612	6	subclass	subclass	NN
cord-014712-5u4e00q6	1612	7	of	of	IN
cord-014712-5u4e00q6	1612	8	Ig	Ig	NNP
cord-014712-5u4e00q6	1612	9	G.	G.	NNP
cord-014712-5u4e00q6	1612	10	IgG1	igg1	NN
cord-014712-5u4e00q6	1612	11	subclass	subclass	NN
cord-014712-5u4e00q6	1612	12	deficiency	deficiency	NN
cord-014712-5u4e00q6	1612	13	is	be	VBZ
cord-014712-5u4e00q6	1612	14	very	very	RB
cord-014712-5u4e00q6	1612	15	rare	rare	JJ
cord-014712-5u4e00q6	1612	16	.	.	.
cord-014712-5u4e00q6	1613	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	1613	2	eosinophilic	eosinophilic	JJ
cord-014712-5u4e00q6	1613	3	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1613	4	is	be	VBZ
cord-014712-5u4e00q6	1613	5	one	one	CD
cord-014712-5u4e00q6	1613	6	of	of	IN
cord-014712-5u4e00q6	1613	7	the	the	DT
cord-014712-5u4e00q6	1613	8	eosinophilic	eosinophilic	JJ
cord-014712-5u4e00q6	1613	9	lung	lung	NN
cord-014712-5u4e00q6	1613	10	disease	disease	NN
cord-014712-5u4e00q6	1613	11	and	and	CC
cord-014712-5u4e00q6	1613	12	is	be	VBZ
cord-014712-5u4e00q6	1613	13	seen	see	VBN
cord-014712-5u4e00q6	1613	14	rarely	rarely	RB
cord-014712-5u4e00q6	1613	15	.	.	.
cord-014712-5u4e00q6	1614	1	In	in	IN
cord-014712-5u4e00q6	1614	2	the	the	DT
cord-014712-5u4e00q6	1614	3	presence	presence	NN
cord-014712-5u4e00q6	1614	4	of	of	IN
cord-014712-5u4e00q6	1614	5	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1614	6	eosinophilia	eosinophilia	JJ
cord-014712-5u4e00q6	1614	7	and	and	CC
cord-014712-5u4e00q6	1614	8	radiological	radiological	JJ
cord-014712-5u4e00q6	1614	9	pulmonary	pulmonary	NN
cord-014712-5u4e00q6	1614	10	infiltrates	infiltrate	VBZ
cord-014712-5u4e00q6	1614	11	diseases	disease	NNS
cord-014712-5u4e00q6	1614	12	suspected	suspect	VBN
cord-014712-5u4e00q6	1614	13	.	.	.
cord-014712-5u4e00q6	1615	1	When	when	WRB
cord-014712-5u4e00q6	1615	2	increase	increase	VB
cord-014712-5u4e00q6	1615	3	in	in	IN
cord-014712-5u4e00q6	1615	4	the	the	DT
cord-014712-5u4e00q6	1615	5	number	number	NN
cord-014712-5u4e00q6	1615	6	of	of	IN
cord-014712-5u4e00q6	1615	7	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1615	8	in	in	IN
cord-014712-5u4e00q6	1615	9	bronchoalveolar	bronchoalveolar	JJ
cord-014712-5u4e00q6	1615	10	lavage	lavage	NN
cord-014712-5u4e00q6	1615	11	fluids	fluid	NNS
cord-014712-5u4e00q6	1615	12	and/or	and/or	CC
cord-014712-5u4e00q6	1615	13	presence	presence	NN
cord-014712-5u4e00q6	1615	14	of	of	IN
cord-014712-5u4e00q6	1615	15	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1615	16	in	in	IN
cord-014712-5u4e00q6	1615	17	lung	lung	NN
cord-014712-5u4e00q6	1615	18	tissue	tissue	NN
cord-014712-5u4e00q6	1615	19	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1615	20	is	be	VBZ
cord-014712-5u4e00q6	1615	21	confirmed	confirm	VBN
cord-014712-5u4e00q6	1615	22	.	.	.
cord-014712-5u4e00q6	1616	1	According	accord	VBG
cord-014712-5u4e00q6	1616	2	to	to	IN
cord-014712-5u4e00q6	1616	3	different	different	JJ
cord-014712-5u4e00q6	1616	4	recording	recording	NN
cord-014712-5u4e00q6	1616	5	systems	system	NNS
cord-014712-5u4e00q6	1616	6	chronic	chronic	JJ
cord-014712-5u4e00q6	1616	7	eosinophilic	eosinophilic	JJ
cord-014712-5u4e00q6	1616	8	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1616	9	is	be	VBZ
cord-014712-5u4e00q6	1616	10	%	%	NN
cord-014712-5u4e00q6	1616	11	0	0	CD
cord-014712-5u4e00q6	1616	12	-	-	SYM
cord-014712-5u4e00q6	1616	13	2	2	CD
cord-014712-5u4e00q6	1616	14	of	of	IN
cord-014712-5u4e00q6	1616	15	the	the	DT
cord-014712-5u4e00q6	1616	16	interstitial	interstitial	JJ
cord-014712-5u4e00q6	1616	17	lung	lung	NNP
cord-014712-5u4e00q6	1616	18	disase	disase	NNP
cord-014712-5u4e00q6	1616	19	.	.	.
cord-014712-5u4e00q6	1617	1	There	there	EX
cord-014712-5u4e00q6	1617	2	is	be	VBZ
cord-014712-5u4e00q6	1617	3	not	not	RB
cord-014712-5u4e00q6	1617	4	any	any	DT
cord-014712-5u4e00q6	1617	5	criteria	criterion	NNS
cord-014712-5u4e00q6	1617	6	for	for	IN
cord-014712-5u4e00q6	1617	7	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1617	8	but	but	CC
cord-014712-5u4e00q6	1617	9	also	also	RB
cord-014712-5u4e00q6	1617	10	diagnoses	diagnosis	NNS
cord-014712-5u4e00q6	1617	11	is	be	VBZ
cord-014712-5u4e00q6	1617	12	confirmed	confirm	VBN
cord-014712-5u4e00q6	1617	13	with	with	IN
cord-014712-5u4e00q6	1617	14	suspected	suspect	VBN
cord-014712-5u4e00q6	1617	15	findings	finding	NNS
cord-014712-5u4e00q6	1617	16	.	.	.
cord-014712-5u4e00q6	1618	1	Symptoms	symptom	NNS
cord-014712-5u4e00q6	1618	2	inludes	inlude	VBZ
cord-014712-5u4e00q6	1618	3	that	that	IN
cord-014712-5u4e00q6	1618	4	:	:	:
cord-014712-5u4e00q6	1618	5	1)In	1)in	CD
cord-014712-5u4e00q6	1618	6	the	the	DT
cord-014712-5u4e00q6	1618	7	presence	presence	NN
cord-014712-5u4e00q6	1618	8	of	of	IN
cord-014712-5u4e00q6	1618	9	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1618	10	symptoms	symptom	NNS
cord-014712-5u4e00q6	1618	11	for	for	IN
cord-014712-5u4e00q6	1618	12	two	two	CD
cord-014712-5u4e00q6	1618	13	weeks	week	NNS
cord-014712-5u4e00q6	1618	14	long	long	JJ
cord-014712-5u4e00q6	1618	15	2)Eosinophilia	2)eosinophilia	CD
cord-014712-5u4e00q6	1618	16	at	at	IN
cord-014712-5u4e00q6	1618	17	alveolar	alveolar	NN
cord-014712-5u4e00q6	1618	18	lavage	lavage	NN
cord-014712-5u4e00q6	1618	19	and\or	and\or	NNP
cord-014712-5u4e00q6	1618	20	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1618	21	blood	blood	NN
cord-014712-5u4e00q6	1619	1	(	(	-LRB-
cord-014712-5u4e00q6	1619	2	BAL	BAL	NNP
cord-014712-5u4e00q6	1619	3	fluid	fluid	JJ
cord-014712-5u4e00q6	1619	4	cytological	cytological	JJ
cord-014712-5u4e00q6	1619	5	examination	examination	NN
cord-014712-5u4e00q6	1619	6	>	>	XX
cord-014712-5u4e00q6	1619	7	%	%	NN
cord-014712-5u4e00q6	1619	8	25	25	CD
cord-014712-5u4e00q6	1619	9	,	,	,
cord-014712-5u4e00q6	1619	10	blood	blood	NN
cord-014712-5u4e00q6	1619	11	>	>	XX
cord-014712-5u4e00q6	1619	12	1500	1500	CD
cord-014712-5u4e00q6	1619	13	/	/	SYM
cord-014712-5u4e00q6	1619	14	mm	mm	NN
cord-014712-5u4e00q6	1619	15	3	3	CD
cord-014712-5u4e00q6	1619	16	)	)	-RRB-
cord-014712-5u4e00q6	1620	1	3)Radiological	3)radiological	CD
cord-014712-5u4e00q6	1620	2	imaging	imaging	NN
cord-014712-5u4e00q6	1620	3	of	of	IN
cord-014712-5u4e00q6	1620	4	the	the	DT
cord-014712-5u4e00q6	1620	5	lung	lung	NN
cord-014712-5u4e00q6	1620	6	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1620	7	infiltration	infiltration	NN
cord-014712-5u4e00q6	1620	8	4)Exclusion	4)exclusion	CD
cord-014712-5u4e00q6	1620	9	of	of	IN
cord-014712-5u4e00q6	1620	10	the	the	DT
cord-014712-5u4e00q6	1620	11	other	other	JJ
cord-014712-5u4e00q6	1620	12	causes	cause	NNS
cord-014712-5u4e00q6	1620	13	of	of	IN
cord-014712-5u4e00q6	1620	14	eosinophlic	eosinophlic	JJ
cord-014712-5u4e00q6	1620	15	lung	lung	NN
cord-014712-5u4e00q6	1620	16	disease	disease	NN
cord-014712-5u4e00q6	1621	1	There	there	EX
cord-014712-5u4e00q6	1621	2	is	be	VBZ
cord-014712-5u4e00q6	1621	3	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	1621	4	over	over	IN
cord-014712-5u4e00q6	1621	5	1000	1000	CD
cord-014712-5u4e00q6	1621	6	/	/	SYM
cord-014712-5u4e00q6	1621	7	mm	mm	NN
cord-014712-5u4e00q6	1621	8	3	3	CD
cord-014712-5u4e00q6	1621	9	nearly	nearly	RB
cord-014712-5u4e00q6	1621	10	all	all	DT
cord-014712-5u4e00q6	1621	11	patients	patient	NNS
cord-014712-5u4e00q6	1621	12	.	.	.
cord-014712-5u4e00q6	1622	1	One	one	CD
cord-014712-5u4e00q6	1622	2	of	of	IN
cord-014712-5u4e00q6	1622	3	third	third	JJ
cord-014712-5u4e00q6	1622	4	or	or	CC
cord-014712-5u4e00q6	1622	5	half	half	NN
cord-014712-5u4e00q6	1622	6	of	of	IN
cord-014712-5u4e00q6	1622	7	patients	patient	NNS
cord-014712-5u4e00q6	1622	8	have	have	VBP
cord-014712-5u4e00q6	1622	9	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1622	10	as	as	IN
cord-014712-5u4e00q6	1622	11	asthma	asthma	NN
cord-014712-5u4e00q6	1622	12	.	.	.
cord-014712-5u4e00q6	1623	1	Disease	Disease	NNP
cord-014712-5u4e00q6	1623	2	begin	begin	VBP
cord-014712-5u4e00q6	1623	3	with	with	IN
cord-014712-5u4e00q6	1623	4	systemic	systemic	JJ
cord-014712-5u4e00q6	1623	5	symptoms	symptom	NNS
cord-014712-5u4e00q6	1623	6	such	such	JJ
cord-014712-5u4e00q6	1623	7	as	as	IN
cord-014712-5u4e00q6	1623	8	night	night	NN
cord-014712-5u4e00q6	1623	9	sweats	sweat	NNS
cord-014712-5u4e00q6	1623	10	,	,	,
cord-014712-5u4e00q6	1623	11	weight	weight	NN
cord-014712-5u4e00q6	1623	12	loss	loss	NN
cord-014712-5u4e00q6	1623	13	,	,	,
cord-014712-5u4e00q6	1623	14	anorexia	anorexia	NN
cord-014712-5u4e00q6	1623	15	and	and	CC
cord-014712-5u4e00q6	1623	16	pulmoner	pulmoner	NN
cord-014712-5u4e00q6	1623	17	symptoms	symptom	NNS
cord-014712-5u4e00q6	1623	18	such	such	JJ
cord-014712-5u4e00q6	1623	19	as	as	IN
cord-014712-5u4e00q6	1623	20	cough	cough	NN
cord-014712-5u4e00q6	1623	21	,	,	,
cord-014712-5u4e00q6	1623	22	shortness	shortness	NN
cord-014712-5u4e00q6	1623	23	of	of	IN
cord-014712-5u4e00q6	1623	24	breath	breath	NN
cord-014712-5u4e00q6	1623	25	,	,	,
cord-014712-5u4e00q6	1623	26	wheezing	wheeze	VBG
cord-014712-5u4e00q6	1623	27	.	.	.
cord-014712-5u4e00q6	1624	1	Patients	patient	NNS
cord-014712-5u4e00q6	1624	2	have	have	VBP
cord-014712-5u4e00q6	1624	3	restrictive	restrictive	JJ
cord-014712-5u4e00q6	1624	4	or	or	CC
cord-014712-5u4e00q6	1624	5	obstructive	obstructive	JJ
cord-014712-5u4e00q6	1624	6	findings	finding	NNS
cord-014712-5u4e00q6	1624	7	in	in	IN
cord-014712-5u4e00q6	1624	8	PFT	PFT	NNP
cord-014712-5u4e00q6	1624	9	.	.	.
cord-014712-5u4e00q6	1625	1	One	one	CD
cord-014712-5u4e00q6	1625	2	of	of	IN
cord-014712-5u4e00q6	1625	3	third	third	JJ
cord-014712-5u4e00q6	1625	4	patients	patient	NNS
cord-014712-5u4e00q6	1625	5	,	,	,
cord-014712-5u4e00q6	1625	6	especially	especially	RB
cord-014712-5u4e00q6	1625	7	with	with	IN
cord-014712-5u4e00q6	1625	8	history	history	NN
cord-014712-5u4e00q6	1625	9	of	of	IN
cord-014712-5u4e00q6	1625	10	asthma	asthma	NN
cord-014712-5u4e00q6	1625	11	,	,	,
cord-014712-5u4e00q6	1625	12	have	have	VBP
cord-014712-5u4e00q6	1625	13	obstruction	obstruction	NN
cord-014712-5u4e00q6	1625	14	in	in	IN
cord-014712-5u4e00q6	1625	15	PFT	PFT	NNP
cord-014712-5u4e00q6	1625	16	.	.	.
cord-014712-5u4e00q6	1626	1	İn	i̇n	VB
cord-014712-5u4e00q6	1626	2	the	the	DT
cord-014712-5u4e00q6	1626	3	pathologic	pathologic	JJ
cord-014712-5u4e00q6	1626	4	biopsy	biopsy	NN
cord-014712-5u4e00q6	1626	5	findings	finding	NNS
cord-014712-5u4e00q6	1626	6	include	include	VBP
cord-014712-5u4e00q6	1626	7	;	;	:
cord-014712-5u4e00q6	1626	8	thickening	thickening	NN
cord-014712-5u4e00q6	1626	9	of	of	IN
cord-014712-5u4e00q6	1626	10	alveolar	alveolar	JJ
cord-014712-5u4e00q6	1626	11	walls	wall	NNS
cord-014712-5u4e00q6	1626	12	and	and	CC
cord-014712-5u4e00q6	1626	13	accumolation	accumolation	NN
cord-014712-5u4e00q6	1626	14	of	of	IN
cord-014712-5u4e00q6	1626	15	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1626	16	and	and	CC
cord-014712-5u4e00q6	1626	17	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1626	18	.	.	.
cord-014712-5u4e00q6	1627	1	Long	long	JJ
cord-014712-5u4e00q6	1627	2	time	time	NN
cord-014712-5u4e00q6	1627	3	used	use	VBD
cord-014712-5u4e00q6	1627	4	corticosteroids	corticosteroid	NNS
cord-014712-5u4e00q6	1627	5	treatment	treatment	NN
cord-014712-5u4e00q6	1627	6	is	be	VBZ
cord-014712-5u4e00q6	1627	7	recomended	recomende	VBN
cord-014712-5u4e00q6	1627	8	.	.	.
cord-014712-5u4e00q6	1628	1	Relaps	Relaps	NNP
cord-014712-5u4e00q6	1628	2	is	be	VBZ
cord-014712-5u4e00q6	1628	3	common	common	JJ
cord-014712-5u4e00q6	1628	4	when	when	WRB
cord-014712-5u4e00q6	1628	5	treatment	treatment	NN
cord-014712-5u4e00q6	1628	6	is	be	VBZ
cord-014712-5u4e00q6	1628	7	discontinued	discontinue	VBN
cord-014712-5u4e00q6	1628	8	.	.	.
cord-014712-5u4e00q6	1629	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1629	2	present	present	VBP
cord-014712-5u4e00q6	1629	3	the	the	DT
cord-014712-5u4e00q6	1629	4	patient	patient	NN
cord-014712-5u4e00q6	1629	5	who	who	WP
cord-014712-5u4e00q6	1629	6	has	have	VBZ
cord-014712-5u4e00q6	1629	7	Ig	Ig	NNP
cord-014712-5u4e00q6	1629	8	G1	G1	NNP
cord-014712-5u4e00q6	1629	9	deficiency	deficiency	NN
cord-014712-5u4e00q6	1629	10	,	,	,
cord-014712-5u4e00q6	1629	11	chronic	chronic	JJ
cord-014712-5u4e00q6	1629	12	eosinophlia	eosinophlia	NNP
cord-014712-5u4e00q6	1629	13	and	and	CC
cord-014712-5u4e00q6	1629	14	%	%	NN
cord-014712-5u4e00q6	1629	15	42	42	CD
cord-014712-5u4e00q6	1629	16	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1629	17	in	in	IN
cord-014712-5u4e00q6	1629	18	bronchoalveolar	bronchoalveolar	NNP
cord-014712-5u4e00q6	1629	19	lavage	lavage	NN
cord-014712-5u4e00q6	1629	20	fluid	fluid	NN
cord-014712-5u4e00q6	1629	21	.	.	.
cord-014712-5u4e00q6	1630	1	The	the	DT
cord-014712-5u4e00q6	1630	2	patient	patient	NN
cord-014712-5u4e00q6	1630	3	improved	improve	VBD
cord-014712-5u4e00q6	1630	4	long	long	JJ
cord-014712-5u4e00q6	1630	5	time	time	NN
cord-014712-5u4e00q6	1630	6	used	use	VBD
cord-014712-5u4e00q6	1630	7	oral	oral	JJ
cord-014712-5u4e00q6	1630	8	steroid	steroid	NN
cord-014712-5u4e00q6	1630	9	then	then	RB
cord-014712-5u4e00q6	1630	10	inhaled	inhale	VBD
cord-014712-5u4e00q6	1630	11	steroids	steroid	NNS
cord-014712-5u4e00q6	1630	12	.	.	.
cord-014712-5u4e00q6	1631	1	This	this	DT
cord-014712-5u4e00q6	1631	2	was	be	VBD
cord-014712-5u4e00q6	1631	3	presented	present	VBN
cord-014712-5u4e00q6	1631	4	in	in	IN
cord-014712-5u4e00q6	1631	5	terms	term	NNS
cord-014712-5u4e00q6	1631	6	of	of	IN
cord-014712-5u4e00q6	1631	7	clinical	clinical	JJ
cord-014712-5u4e00q6	1631	8	association	association	NN
cord-014712-5u4e00q6	1631	9	.	.	.
cord-014712-5u4e00q6	1632	1	Case	case	NN
cord-014712-5u4e00q6	1632	2	:	:	:
cord-014712-5u4e00q6	1633	1	A	a	DT
cord-014712-5u4e00q6	1633	2	12	12	CD
cord-014712-5u4e00q6	1633	3	years	year	NNS
cord-014712-5u4e00q6	1633	4	old	old	JJ
cord-014712-5u4e00q6	1633	5	female	female	JJ
cord-014712-5u4e00q6	1633	6	patient	patient	NN
cord-014712-5u4e00q6	1633	7	who	who	WP
cord-014712-5u4e00q6	1633	8	were	be	VBD
cord-014712-5u4e00q6	1633	9	followed	follow	VBN
cord-014712-5u4e00q6	1633	10	due	due	IN
cord-014712-5u4e00q6	1633	11	to	to	IN
cord-014712-5u4e00q6	1633	12	asthma	asthma	NN
cord-014712-5u4e00q6	1633	13	in	in	IN
cord-014712-5u4e00q6	1633	14	the	the	DT
cord-014712-5u4e00q6	1633	15	other	other	JJ
cord-014712-5u4e00q6	1633	16	center	center	NN
cord-014712-5u4e00q6	1633	17	for	for	IN
cord-014712-5u4e00q6	1633	18	two	two	CD
cord-014712-5u4e00q6	1633	19	years	year	NNS
cord-014712-5u4e00q6	1633	20	,	,	,
cord-014712-5u4e00q6	1633	21	although	although	IN
cord-014712-5u4e00q6	1633	22	use	use	NN
cord-014712-5u4e00q6	1633	23	of	of	IN
cord-014712-5u4e00q6	1633	24	combination	combination	NN
cord-014712-5u4e00q6	1633	25	inhaled	inhale	VBN
cord-014712-5u4e00q6	1633	26	fluticasone	fluticasone	NN
cord-014712-5u4e00q6	1633	27	and	and	CC
cord-014712-5u4e00q6	1633	28	salmeterol	salmeterol	NN
cord-014712-5u4e00q6	1633	29	,	,	,
cord-014712-5u4e00q6	1633	30	patient	patient	NN
cord-014712-5u4e00q6	1633	31	was	be	VBD
cord-014712-5u4e00q6	1633	32	admitted	admit	VBN
cord-014712-5u4e00q6	1633	33	with	with	IN
cord-014712-5u4e00q6	1633	34	cough	cough	NN
cord-014712-5u4e00q6	1633	35	and	and	CC
cord-014712-5u4e00q6	1633	36	sputum	sputum	NN
cord-014712-5u4e00q6	1633	37	production	production	NN
cord-014712-5u4e00q6	1633	38	.	.	.
cord-014712-5u4e00q6	1634	1	In	in	IN
cord-014712-5u4e00q6	1634	2	thorax	thorax	NN
cord-014712-5u4e00q6	1634	3	CT	CT	NNP
cord-014712-5u4e00q6	1634	4	there	there	EX
cord-014712-5u4e00q6	1634	5	were	be	VBD
cord-014712-5u4e00q6	1634	6	,	,	,
cord-014712-5u4e00q6	1634	7	bronchiectasis	bronchiectasis	NN
cord-014712-5u4e00q6	1634	8	at	at	IN
cord-014712-5u4e00q6	1634	9	right	right	JJ
cord-014712-5u4e00q6	1634	10	lower	low	JJR
cord-014712-5u4e00q6	1634	11	lobe	lobe	NN
cord-014712-5u4e00q6	1634	12	,	,	,
cord-014712-5u4e00q6	1634	13	pneumonic	pneumonic	JJ
cord-014712-5u4e00q6	1634	14	consolidation	consolidation	NN
cord-014712-5u4e00q6	1634	15	in	in	IN
cord-014712-5u4e00q6	1634	16	the	the	DT
cord-014712-5u4e00q6	1634	17	right	right	JJ
cord-014712-5u4e00q6	1634	18	lower	low	JJR
cord-014712-5u4e00q6	1634	19	lobe	lobe	NN
cord-014712-5u4e00q6	1634	20	and	and	CC
cord-014712-5u4e00q6	1634	21	ground	ground	NN
cord-014712-5u4e00q6	1634	22	glass	glass	NN
cord-014712-5u4e00q6	1634	23	opacities	opacity	NNS
cord-014712-5u4e00q6	1634	24	.	.	.
cord-014712-5u4e00q6	1635	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1635	2	detected	detect	VBD
cord-014712-5u4e00q6	1635	3	as	as	IN
cord-014712-5u4e00q6	1635	4	IgG	IgG	NNP
cord-014712-5u4e00q6	1635	5	924	924	CD
cord-014712-5u4e00q6	1635	6	mg	mg	NNP
cord-014712-5u4e00q6	1635	7	/	/	SYM
cord-014712-5u4e00q6	1635	8	dl	dl	NNP
cord-014712-5u4e00q6	1635	9	(	(	-LRB-
cord-014712-5u4e00q6	1635	10	835	835	CD
cord-014712-5u4e00q6	1635	11	-	-	HYPH
cord-014712-5u4e00q6	1635	12	2094mg	2094mg	CD
cord-014712-5u4e00q6	1635	13	/	/	SYM
cord-014712-5u4e00q6	1635	14	dl	dl	NNP
cord-014712-5u4e00q6	1635	15	)	)	-RRB-
cord-014712-5u4e00q6	1635	16	,	,	,
cord-014712-5u4e00q6	1635	17	IgA	IgA	NNP
cord-014712-5u4e00q6	1635	18	157	157	CD
cord-014712-5u4e00q6	1635	19	mg	mg	NNP
cord-014712-5u4e00q6	1635	20	/	/	SYM
cord-014712-5u4e00q6	1635	21	dl	dl	NNP
cord-014712-5u4e00q6	1635	22	(	(	-LRB-
cord-014712-5u4e00q6	1635	23	67	67	CD
cord-014712-5u4e00q6	1635	24	-	-	SYM
cord-014712-5u4e00q6	1635	25	433	433	CD
cord-014712-5u4e00q6	1635	26	mg	mg	NNP
cord-014712-5u4e00q6	1635	27	/	/	SYM
cord-014712-5u4e00q6	1635	28	dl	dl	NNP
cord-014712-5u4e00q6	1635	29	)	)	-RRB-
cord-014712-5u4e00q6	1635	30	,	,	.
cord-014712-5u4e00q6	1636	1	IgM180	IgM180	NNP
cord-014712-5u4e00q6	1636	2	mg	mg	NNP
cord-014712-5u4e00q6	1636	3	/	/	SYM
cord-014712-5u4e00q6	1636	4	dl	dl	NNP
cord-014712-5u4e00q6	1636	5	(	(	-LRB-
cord-014712-5u4e00q6	1636	6	47	47	CD
cord-014712-5u4e00q6	1636	7	-	-	SYM
cord-014712-5u4e00q6	1636	8	484	484	CD
cord-014712-5u4e00q6	1636	9	mg	mg	NNP
cord-014712-5u4e00q6	1636	10	/	/	SYM
cord-014712-5u4e00q6	1636	11	dl	dl	NNP
cord-014712-5u4e00q6	1636	12	)	)	-RRB-
cord-014712-5u4e00q6	1636	13	,	,	,
cord-014712-5u4e00q6	1636	14	IgE	IgE	NNP
cord-014712-5u4e00q6	1636	15	108	108	CD
cord-014712-5u4e00q6	1636	16	.	.	.
cord-014712-5u4e00q6	1637	1	6	6	CD
cord-014712-5u4e00q6	1637	2	mg	mg	NNP
cord-014712-5u4e00q6	1637	3	/	/	SYM
cord-014712-5u4e00q6	1637	4	dl	dl	NNP
cord-014712-5u4e00q6	1637	5	,	,	,
cord-014712-5u4e00q6	1637	6	IgG1	IgG1	NNP
cord-014712-5u4e00q6	1637	7	4896	4896	CD
cord-014712-5u4e00q6	1637	8	mg	mg	NNP
cord-014712-5u4e00q6	1637	9	/	/	SYM
cord-014712-5u4e00q6	1637	10	dl	dl	NNP
cord-014712-5u4e00q6	1637	11	(	(	-LRB-
cord-014712-5u4e00q6	1637	12	5990	5990	CD
cord-014712-5u4e00q6	1637	13	-	-	HYPH
cord-014712-5u4e00q6	1637	14	15600	15600	CD
cord-014712-5u4e00q6	1637	15	mg	mg	NNP
cord-014712-5u4e00q6	1637	16	/	/	SYM
cord-014712-5u4e00q6	1637	17	dl	dl	NNP
cord-014712-5u4e00q6	1637	18	)	)	-RRB-
cord-014712-5u4e00q6	1637	19	,	,	.
cord-014712-5u4e00q6	1638	1	IgG2	igg2	NN
cord-014712-5u4e00q6	1638	2	2354	2354	CD
cord-014712-5u4e00q6	1639	1	mg	mg	NNP
cord-014712-5u4e00q6	1639	2	/	/	SYM
cord-014712-5u4e00q6	1639	3	dl	dl	NNP
cord-014712-5u4e00q6	1639	4	(	(	-LRB-
cord-014712-5u4e00q6	1639	5	1110	1110	CD
cord-014712-5u4e00q6	1639	6	-	-	HYPH
cord-014712-5u4e00q6	1639	7	5150mg	5150mg	CD
cord-014712-5u4e00q6	1639	8	/	/	SYM
cord-014712-5u4e00q6	1639	9	dl	dl	NN
cord-014712-5u4e00q6	1639	10	)	)	-RRB-
cord-014712-5u4e00q6	1639	11	,	,	,
cord-014712-5u4e00q6	1639	12	IgG3	igg3	NN
cord-014712-5u4e00q6	1639	13	1024	1024	CD
cord-014712-5u4e00q6	1639	14	mg	mg	NNP
cord-014712-5u4e00q6	1639	15	/	/	SYM
cord-014712-5u4e00q6	1639	16	dl	dl	NNP
cord-014712-5u4e00q6	1639	17	(	(	-LRB-
cord-014712-5u4e00q6	1639	18	290	290	CD
cord-014712-5u4e00q6	1639	19	-	-	HYPH
cord-014712-5u4e00q6	1639	20	2000mg	2000mg	CD
cord-014712-5u4e00q6	1639	21	/	/	SYM
cord-014712-5u4e00q6	1639	22	dl	dl	NN
cord-014712-5u4e00q6	1639	23	)	)	-RRB-
cord-014712-5u4e00q6	1639	24	,	,	.
cord-014712-5u4e00q6	1640	1	IgG4	igg4	CD
cord-014712-5u4e00q6	1640	2	616	616	CD
cord-014712-5u4e00q6	1640	3	mg	mg	NNP
cord-014712-5u4e00q6	1640	4	/	/	SYM
cord-014712-5u4e00q6	1640	5	dl	dl	NNP
cord-014712-5u4e00q6	1640	6	(	(	-LRB-
cord-014712-5u4e00q6	1640	7	40	40	CD
cord-014712-5u4e00q6	1640	8	-	-	SYM
cord-014712-5u4e00q6	1640	9	1600	1600	CD
cord-014712-5u4e00q6	1640	10	mg	mg	NNP
cord-014712-5u4e00q6	1640	11	/	/	SYM
cord-014712-5u4e00q6	1640	12	dl	dl	NNP
cord-014712-5u4e00q6	1640	13	)	)	-RRB-
cord-014712-5u4e00q6	1640	14	.	.	.
cord-014712-5u4e00q6	1641	1	Because	because	IN
cord-014712-5u4e00q6	1641	2	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	1641	3	(	(	-LRB-
cord-014712-5u4e00q6	1641	4	717	717	CD
cord-014712-5u4e00q6	1641	5	cells	cell	NNS
cord-014712-5u4e00q6	1641	6	)	)	-RRB-
cord-014712-5u4e00q6	1641	7	and	and	CC
cord-014712-5u4e00q6	1641	8	symptoms	symptom	NNS
cord-014712-5u4e00q6	1641	9	continued	continue	VBD
cord-014712-5u4e00q6	1641	10	,	,	,
cord-014712-5u4e00q6	1641	11	bronchoscopy	bronchoscopy	NNP
cord-014712-5u4e00q6	1641	12	was	be	VBD
cord-014712-5u4e00q6	1641	13	performed	perform	VBN
cord-014712-5u4e00q6	1641	14	.	.	.
cord-014712-5u4e00q6	1642	1	Left	leave	VBN
cord-014712-5u4e00q6	1642	2	main	main	JJ
cord-014712-5u4e00q6	1642	3	bronchus	bronchus	NN
cord-014712-5u4e00q6	1642	4	was	be	VBD
cord-014712-5u4e00q6	1642	5	normal	normal	JJ
cord-014712-5u4e00q6	1642	6	,	,	,
cord-014712-5u4e00q6	1642	7	right	right	JJ
cord-014712-5u4e00q6	1642	8	bronchus	bronchus	NN
cord-014712-5u4e00q6	1642	9	were	be	VBD
cord-014712-5u4e00q6	1642	10	seen	see	VBN
cord-014712-5u4e00q6	1642	11	dilated	dilated	JJ
cord-014712-5u4e00q6	1642	12	.	.	.
cord-014712-5u4e00q6	1643	1	Purulent	purulent	JJ
cord-014712-5u4e00q6	1643	2	secretion	secretion	NN
cord-014712-5u4e00q6	1643	3	was	be	VBD
cord-014712-5u4e00q6	1643	4	aspirated	aspirate	VBN
cord-014712-5u4e00q6	1643	5	on	on	IN
cord-014712-5u4e00q6	1643	6	rigt	rigt	JJ
cord-014712-5u4e00q6	1643	7	bronchus	bronchus	NN
cord-014712-5u4e00q6	1643	8	with	with	IN
cord-014712-5u4e00q6	1643	9	flexible	flexible	JJ
cord-014712-5u4e00q6	1643	10	bronchoscopy	bronchoscopy	NN
cord-014712-5u4e00q6	1643	11	..	..	.
cord-014712-5u4e00q6	1644	1	In	in	IN
cord-014712-5u4e00q6	1644	2	cytological	cytological	JJ
cord-014712-5u4e00q6	1644	3	examination	examination	NN
cord-014712-5u4e00q6	1644	4	%	%	NN
cord-014712-5u4e00q6	1644	5	42	42	CD
cord-014712-5u4e00q6	1644	6	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1644	7	was	be	VBD
cord-014712-5u4e00q6	1644	8	detected	detect	VBN
cord-014712-5u4e00q6	1644	9	in	in	IN
cord-014712-5u4e00q6	1644	10	BAL	BAL	NNP
cord-014712-5u4e00q6	1644	11	.	.	.
cord-014712-5u4e00q6	1645	1	Bronchoalveolar	Bronchoalveolar	NNP
cord-014712-5u4e00q6	1645	2	lavage	lavage	NN
cord-014712-5u4e00q6	1645	3	cultures	culture	NNS
cord-014712-5u4e00q6	1645	4	was	be	VBD
cord-014712-5u4e00q6	1645	5	negative	negative	JJ
cord-014712-5u4e00q6	1645	6	.	.	.
cord-014712-5u4e00q6	1646	1	The	the	DT
cord-014712-5u4e00q6	1646	2	patient	patient	NN
cord-014712-5u4e00q6	1646	3	was	be	VBD
cord-014712-5u4e00q6	1646	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1646	5	chronic	chronic	JJ
cord-014712-5u4e00q6	1646	6	eosinophilic	eosinophilic	JJ
cord-014712-5u4e00q6	1646	7	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1646	8	and	and	CC
cord-014712-5u4e00q6	1647	1	1	1	CD
cord-014712-5u4e00q6	1647	2	mg/	mg/	NN
cord-014712-5u4e00q6	1647	3	kg	kg	NNP
cord-014712-5u4e00q6	1647	4	oral	oral	JJ
cord-014712-5u4e00q6	1647	5	steroid	steroid	NN
cord-014712-5u4e00q6	1647	6	was	be	VBD
cord-014712-5u4e00q6	1647	7	began	begin	VBN
cord-014712-5u4e00q6	1647	8	.	.	.
cord-014712-5u4e00q6	1648	1	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1648	2	was	be	VBD
cord-014712-5u4e00q6	1648	3	given	give	VBN
cord-014712-5u4e00q6	1648	4	up	up	RP
cord-014712-5u4e00q6	1648	5	to	to	IN
cord-014712-5u4e00q6	1648	6	patient	patient	NN
cord-014712-5u4e00q6	1648	7	;	;	:
cord-014712-5u4e00q6	1648	8	because	because	IN
cord-014712-5u4e00q6	1648	9	of	of	IN
cord-014712-5u4e00q6	1648	10	frequently	frequently	RB
cord-014712-5u4e00q6	1648	11	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1648	12	sinopulmonary	sinopulmonary	JJ
cord-014712-5u4e00q6	1648	13	infection	infection	NN
cord-014712-5u4e00q6	1648	14	and	and	CC
cord-014712-5u4e00q6	1648	15	patient	patient	NN
cord-014712-5u4e00q6	1648	16	had	have	VBD
cord-014712-5u4e00q6	1648	17	IgG1	igg1	XX
cord-014712-5u4e00q6	1648	18	subclass	subclass	NN
cord-014712-5u4e00q6	1648	19	deficiency	deficiency	NN
cord-014712-5u4e00q6	1648	20	.	.	.
cord-014712-5u4e00q6	1649	1	In	in	IN
cord-014712-5u4e00q6	1649	2	the	the	DT
cord-014712-5u4e00q6	1649	3	third	third	JJ
cord-014712-5u4e00q6	1649	4	month	month	NN
cord-014712-5u4e00q6	1649	5	of	of	IN
cord-014712-5u4e00q6	1649	6	oral	oral	JJ
cord-014712-5u4e00q6	1649	7	steroid	steroid	NN
cord-014712-5u4e00q6	1649	8	therapy	therapy	NN
cord-014712-5u4e00q6	1649	9	physical	physical	JJ
cord-014712-5u4e00q6	1649	10	examination	examination	NN
cord-014712-5u4e00q6	1649	11	findings	finding	NNS
cord-014712-5u4e00q6	1649	12	and	and	CC
cord-014712-5u4e00q6	1649	13	PFT	PFT	NNP
cord-014712-5u4e00q6	1649	14	were	be	VBD
cord-014712-5u4e00q6	1649	15	improved	improve	VBN
cord-014712-5u4e00q6	1649	16	and	and	CC
cord-014712-5u4e00q6	1649	17	started	start	VBD
cord-014712-5u4e00q6	1649	18	inhaled	inhale	VBN
cord-014712-5u4e00q6	1649	19	steroid	steroid	NN
cord-014712-5u4e00q6	1649	20	.	.	.
cord-014712-5u4e00q6	1650	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1650	2	:	:	:
cord-014712-5u4e00q6	1651	1	Immunodeficiencies	Immunodeficiencies	NNP
cord-014712-5u4e00q6	1651	2	often	often	RB
cord-014712-5u4e00q6	1651	3	can	can	MD
cord-014712-5u4e00q6	1651	4	be	be	VB
cord-014712-5u4e00q6	1651	5	seen	see	VBN
cord-014712-5u4e00q6	1651	6	alone	alone	JJ
cord-014712-5u4e00q6	1651	7	.	.	.
cord-014712-5u4e00q6	1652	1	Although	although	IN
cord-014712-5u4e00q6	1652	2	,	,	,
cord-014712-5u4e00q6	1652	3	the	the	DT
cord-014712-5u4e00q6	1652	4	pathogenesis	pathogenesis	NN
cord-014712-5u4e00q6	1652	5	of	of	IN
cord-014712-5u4e00q6	1652	6	immundeficiencies	immundeficiencie	NNS
cord-014712-5u4e00q6	1652	7	with	with	IN
cord-014712-5u4e00q6	1652	8	lung	lung	NN
cord-014712-5u4e00q6	1652	9	disease	disease	NN
cord-014712-5u4e00q6	1652	10	is	be	VBZ
cord-014712-5u4e00q6	1652	11	not	not	RB
cord-014712-5u4e00q6	1652	12	well	well	RB
cord-014712-5u4e00q6	1652	13	understood	understand	VBN
cord-014712-5u4e00q6	1652	14	and	and	CC
cord-014712-5u4e00q6	1652	15	associated	associate	VBN
cord-014712-5u4e00q6	1652	16	with	with	IN
cord-014712-5u4e00q6	1652	17	interstitial	interstitial	JJ
cord-014712-5u4e00q6	1652	18	lung	lung	NN
cord-014712-5u4e00q6	1652	19	disease	disease	NN
cord-014712-5u4e00q6	1652	20	.	.	.
cord-014712-5u4e00q6	1653	1	Therefore	therefore	RB
cord-014712-5u4e00q6	1653	2	,	,	,
cord-014712-5u4e00q6	1653	3	investigations	investigation	NNS
cord-014712-5u4e00q6	1653	4	must	must	MD
cord-014712-5u4e00q6	1653	5	be	be	VB
cord-014712-5u4e00q6	1653	6	include	include	VB
cord-014712-5u4e00q6	1653	7	bronchoscopy	bronchoscopy	NN
cord-014712-5u4e00q6	1653	8	and	and	CC
cord-014712-5u4e00q6	1653	9	bronchoalveolar	bronchoalveolar	JJ
cord-014712-5u4e00q6	1653	10	lavage	lavage	NN
cord-014712-5u4e00q6	1653	11	.	.	.
cord-014712-5u4e00q6	1654	1	SCID	SCID	NNP
cord-014712-5u4e00q6	1654	2	is	be	VBZ
cord-014712-5u4e00q6	1654	3	a	a	DT
cord-014712-5u4e00q6	1654	4	congenital	congenital	JJ
cord-014712-5u4e00q6	1654	5	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	1654	6	group	group	NN
cord-014712-5u4e00q6	1654	7	of	of	IN
cord-014712-5u4e00q6	1654	8	diseases	disease	NNS
cord-014712-5u4e00q6	1654	9	characterized	characterize	VBN
cord-014712-5u4e00q6	1654	10	by	by	IN
cord-014712-5u4e00q6	1654	11	severe	severe	JJ
cord-014712-5u4e00q6	1654	12	impairment	impairment	NN
cord-014712-5u4e00q6	1654	13	of	of	IN
cord-014712-5u4e00q6	1654	14	T	t	NN
cord-014712-5u4e00q6	1654	15	,	,	,
cord-014712-5u4e00q6	1654	16	B	B	NNP
cord-014712-5u4e00q6	1654	17	,	,	,
cord-014712-5u4e00q6	1654	18	NK	NK	NNP
cord-014712-5u4e00q6	1654	19	cell	cell	NN
cord-014712-5u4e00q6	1654	20	development	development	NN
cord-014712-5u4e00q6	1654	21	and	and	CC
cord-014712-5u4e00q6	1654	22	function	function	NN
cord-014712-5u4e00q6	1654	23	.	.	.
cord-014712-5u4e00q6	1655	1	The	the	DT
cord-014712-5u4e00q6	1655	2	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	1655	3	stem	stem	NN
cord-014712-5u4e00q6	1655	4	cell	cell	NN
cord-014712-5u4e00q6	1655	5	transplanted	transplant	VBD
cord-014712-5u4e00q6	1655	6	93	93	CD
cord-014712-5u4e00q6	1655	7	patients	patient	NNS
cord-014712-5u4e00q6	1655	8	with	with	IN
cord-014712-5u4e00q6	1655	9	SCID	SCID	NNP
cord-014712-5u4e00q6	1655	10	in	in	IN
cord-014712-5u4e00q6	1655	11	the	the	DT
cord-014712-5u4e00q6	1655	12	time	time	NN
cord-014712-5u4e00q6	1655	13	period	period	NN
cord-014712-5u4e00q6	1655	14	from	from	IN
cord-014712-5u4e00q6	1655	15	1994	1994	CD
cord-014712-5u4e00q6	1655	16	to	to	IN
cord-014712-5u4e00q6	1655	17	2014	2014	CD
cord-014712-5u4e00q6	1655	18	were	be	VBD
cord-014712-5u4e00q6	1655	19	evaluated	evaluate	VBN
cord-014712-5u4e00q6	1655	20	.	.	.
cord-014712-5u4e00q6	1656	1	Male	male	JJ
cord-014712-5u4e00q6	1656	2	/	/	SYM
cord-014712-5u4e00q6	1656	3	female	female	JJ
cord-014712-5u4e00q6	1656	4	ratio	ratio	NN
cord-014712-5u4e00q6	1656	5	is	be	VBZ
cord-014712-5u4e00q6	1656	6	59/34	59/34	CD
cord-014712-5u4e00q6	1656	7	.	.	.
cord-014712-5u4e00q6	1657	1	Median	median	JJ
cord-014712-5u4e00q6	1657	2	follow	follow	NN
cord-014712-5u4e00q6	1657	3	-	-	HYPH
cord-014712-5u4e00q6	1657	4	up	up	NN
cord-014712-5u4e00q6	1657	5	time	time	NN
cord-014712-5u4e00q6	1657	6	is	be	VBZ
cord-014712-5u4e00q6	1657	7	5	5	CD
cord-014712-5u4e00q6	1657	8	years	year	NNS
cord-014712-5u4e00q6	1657	9	(	(	-LRB-
cord-014712-5u4e00q6	1657	10	6	6	CD
cord-014712-5u4e00q6	1657	11	months-20	months-20	CD
cord-014712-5u4e00q6	1657	12	years	year	NNS
cord-014712-5u4e00q6	1657	13	)	)	-RRB-
cord-014712-5u4e00q6	1657	14	.	.	.
cord-014712-5u4e00q6	1658	1	Parental	parental	JJ
cord-014712-5u4e00q6	1658	2	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	1658	3	ratio	ratio	NN
cord-014712-5u4e00q6	1658	4	was	be	VBD
cord-014712-5u4e00q6	1658	5	81,7	81,7	CD
cord-014712-5u4e00q6	1658	6	%	%	NN
cord-014712-5u4e00q6	1658	7	.	.	.
cord-014712-5u4e00q6	1659	1	Mean	mean	JJ
cord-014712-5u4e00q6	1659	2	age	age	NN
cord-014712-5u4e00q6	1659	3	of	of	IN
cord-014712-5u4e00q6	1659	4	onset	onset	NN
cord-014712-5u4e00q6	1659	5	of	of	IN
cord-014712-5u4e00q6	1659	6	the	the	DT
cord-014712-5u4e00q6	1659	7	symptoms	symptom	NNS
cord-014712-5u4e00q6	1659	8	was	be	VBD
cord-014712-5u4e00q6	1659	9	3	3	CD
cord-014712-5u4e00q6	1659	10	±	±	NNP
cord-014712-5u4e00q6	1659	11	2,7	2,7	CD
cord-014712-5u4e00q6	1659	12	months	month	NNS
cord-014712-5u4e00q6	1659	13	.	.	.
cord-014712-5u4e00q6	1660	1	Most	Most	JJS
cord-014712-5u4e00q6	1660	2	common	common	JJ
cord-014712-5u4e00q6	1660	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1660	4	findings	finding	NNS
cord-014712-5u4e00q6	1660	5	on	on	IN
cord-014712-5u4e00q6	1660	6	admission	admission	NN
cord-014712-5u4e00q6	1660	7	were	be	VBD
cord-014712-5u4e00q6	1660	8	;	;	:
cord-014712-5u4e00q6	1660	9	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1660	10	(	(	-LRB-
cord-014712-5u4e00q6	1660	11	75,3	75,3	CD
cord-014712-5u4e00q6	1660	12	%	%	NN
cord-014712-5u4e00q6	1660	13	)	)	-RRB-
cord-014712-5u4e00q6	1660	14	,	,	,
cord-014712-5u4e00q6	1660	15	moniliasis	moniliasis	NNP
cord-014712-5u4e00q6	1660	16	(	(	-LRB-
cord-014712-5u4e00q6	1660	17	62,4	62,4	CD
cord-014712-5u4e00q6	1660	18	%	%	NN
cord-014712-5u4e00q6	1660	19	)	)	-RRB-
cord-014712-5u4e00q6	1660	20	,	,	,
cord-014712-5u4e00q6	1660	21	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	1660	22	(	(	-LRB-
cord-014712-5u4e00q6	1660	23	39,8	39,8	CD
cord-014712-5u4e00q6	1660	24	%	%	NN
cord-014712-5u4e00q6	1660	25	)	)	-RRB-
cord-014712-5u4e00q6	1660	26	,	,	,
cord-014712-5u4e00q6	1660	27	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	1660	28	(	(	-LRB-
cord-014712-5u4e00q6	1660	29	19.4	19.4	CD
cord-014712-5u4e00q6	1660	30	%	%	NN
cord-014712-5u4e00q6	1660	31	)	)	-RRB-
cord-014712-5u4e00q6	1660	32	.	.	.
cord-014712-5u4e00q6	1661	1	Classification	classification	NN
cord-014712-5u4e00q6	1661	2	according	accord	VBG
cord-014712-5u4e00q6	1661	3	to	to	IN
cord-014712-5u4e00q6	1661	4	T	T	NNP
cord-014712-5u4e00q6	1661	5	,	,	,
cord-014712-5u4e00q6	1661	6	B	B	NNP
cord-014712-5u4e00q6	1661	7	,	,	,
cord-014712-5u4e00q6	1661	8	and	and	CC
cord-014712-5u4e00q6	1661	9	NK	NK	NNP
cord-014712-5u4e00q6	1661	10	cell	cell	NN
cord-014712-5u4e00q6	1661	11	counts	count	VBZ
cord-014712-5u4e00q6	1661	12	;	;	,
cord-014712-5u4e00q6	1661	13	(	(	-LRB-
cord-014712-5u4e00q6	1661	14	Figure	figure	NN
cord-014712-5u4e00q6	1661	15	1	1	CD
cord-014712-5u4e00q6	1661	16	)	)	-RRB-
cord-014712-5u4e00q6	1661	17	.	.	.
cord-014712-5u4e00q6	1662	1	Molecular	molecular	JJ
cord-014712-5u4e00q6	1662	2	genetic	genetic	JJ
cord-014712-5u4e00q6	1662	3	defects	defect	NNS
cord-014712-5u4e00q6	1662	4	were	be	VBD
cord-014712-5u4e00q6	1662	5	determined	determine	VBN
cord-014712-5u4e00q6	1662	6	in	in	IN
cord-014712-5u4e00q6	1662	7	60	60	CD
cord-014712-5u4e00q6	1662	8	patients	patient	NNS
cord-014712-5u4e00q6	1662	9	(	(	-LRB-
cord-014712-5u4e00q6	1662	10	Figure	figure	NN
cord-014712-5u4e00q6	1662	11	2	2	CD
cord-014712-5u4e00q6	1662	12	)	)	-RRB-
cord-014712-5u4e00q6	1662	13	are	be	VBP
cord-014712-5u4e00q6	1662	14	given	give	VBN
cord-014712-5u4e00q6	1662	15	.	.	.
cord-014712-5u4e00q6	1663	1	There	there	EX
cord-014712-5u4e00q6	1663	2	is	be	VBZ
cord-014712-5u4e00q6	1663	3	no	no	DT
cord-014712-5u4e00q6	1663	4	difference	difference	NN
cord-014712-5u4e00q6	1663	5	between	between	IN
cord-014712-5u4e00q6	1663	6	age	age	NN
cord-014712-5u4e00q6	1663	7	groups	group	NNS
cord-014712-5u4e00q6	1663	8	according	accord	VBG
cord-014712-5u4e00q6	1663	9	to	to	IN
cord-014712-5u4e00q6	1663	10	occurrence	occurrence	NN
cord-014712-5u4e00q6	1663	11	of	of	IN
cord-014712-5u4e00q6	1663	12	acute	acute	JJ
cord-014712-5u4e00q6	1663	13	and	and	CC
cord-014712-5u4e00q6	1663	14	chronic	chronic	JJ
cord-014712-5u4e00q6	1663	15	gvhd	gvhd	NNP
cord-014712-5u4e00q6	1663	16	.	.	.
cord-014712-5u4e00q6	1664	1	Death	death	NN
cord-014712-5u4e00q6	1664	2	ratio	ratio	NN
cord-014712-5u4e00q6	1664	3	increases	increase	VBZ
cord-014712-5u4e00q6	1664	4	with	with	IN
cord-014712-5u4e00q6	1664	5	the	the	DT
cord-014712-5u4e00q6	1664	6	increasing	increase	VBG
cord-014712-5u4e00q6	1664	7	age	age	NN
cord-014712-5u4e00q6	1664	8	.	.	.
cord-014712-5u4e00q6	1665	1	Acute	acute	JJ
cord-014712-5u4e00q6	1665	2	and	and	CC
cord-014712-5u4e00q6	1665	3	chronic	chronic	JJ
cord-014712-5u4e00q6	1665	4	gvhd	gvhd	NN
cord-014712-5u4e00q6	1665	5	and	and	CC
cord-014712-5u4e00q6	1665	6	number	number	NN
cord-014712-5u4e00q6	1665	7	of	of	IN
cord-014712-5u4e00q6	1665	8	deaths	death	NNS
cord-014712-5u4e00q6	1665	9	were	be	VBD
cord-014712-5u4e00q6	1665	10	significantly	significantly	RB
cord-014712-5u4e00q6	1665	11	higher	high	JJR
cord-014712-5u4e00q6	1665	12	in	in	IN
cord-014712-5u4e00q6	1665	13	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1665	14	stem	stem	NN
cord-014712-5u4e00q6	1665	15	cell	cell	NN
cord-014712-5u4e00q6	1665	16	transplanted	transplant	VBN
cord-014712-5u4e00q6	1665	17	patients	patient	NNS
cord-014712-5u4e00q6	1665	18	.	.	.
cord-014712-5u4e00q6	1666	1	There	there	EX
cord-014712-5u4e00q6	1666	2	is	be	VBZ
cord-014712-5u4e00q6	1666	3	no	no	DT
cord-014712-5u4e00q6	1666	4	statistically	statistically	RB
cord-014712-5u4e00q6	1666	5	significant	significant	JJ
cord-014712-5u4e00q6	1666	6	difference	difference	NN
cord-014712-5u4e00q6	1666	7	in	in	IN
cord-014712-5u4e00q6	1666	8	occurrence	occurrence	NN
cord-014712-5u4e00q6	1666	9	of	of	IN
cord-014712-5u4e00q6	1666	10	acute	acute	JJ
cord-014712-5u4e00q6	1666	11	/	/	SYM
cord-014712-5u4e00q6	1666	12	chronic	chronic	JJ
cord-014712-5u4e00q6	1666	13	GVHD	GVHD	NNP
cord-014712-5u4e00q6	1666	14	between	between	IN
cord-014712-5u4e00q6	1666	15	B	b	NN
cord-014712-5u4e00q6	1666	16	-	-	:
cord-014712-5u4e00q6	1666	17	and	and	CC
cord-014712-5u4e00q6	1666	18	B	b	NN
cord-014712-5u4e00q6	1666	19	+	+	CC
cord-014712-5u4e00q6	1666	20	SCID	SCID	NNP
cord-014712-5u4e00q6	1666	21	,	,	,
cord-014712-5u4e00q6	1666	22	who	who	WP
cord-014712-5u4e00q6	1666	23	had	have	VBD
cord-014712-5u4e00q6	1666	24	been	be	VBN
cord-014712-5u4e00q6	1666	25	HLA	HLA	NNP
cord-014712-5u4e00q6	1666	26	idantically	idantically	RB
cord-014712-5u4e00q6	1666	27	transplanted	transplant	VBN
cord-014712-5u4e00q6	1666	28	from	from	IN
cord-014712-5u4e00q6	1666	29	family	family	NN
cord-014712-5u4e00q6	1666	30	donor	donor	NN
cord-014712-5u4e00q6	1666	31	.	.	.
cord-014712-5u4e00q6	1667	1	Both	both	DT
cord-014712-5u4e00q6	1667	2	groups	group	NNS
cord-014712-5u4e00q6	1667	3	have	have	VBP
cord-014712-5u4e00q6	1667	4	similar	similar	JJ
cord-014712-5u4e00q6	1667	5	ratios	ratio	NNS
cord-014712-5u4e00q6	1667	6	of	of	IN
cord-014712-5u4e00q6	1667	7	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1667	8	treatment	treatment	NN
cord-014712-5u4e00q6	1667	9	need	need	NN
cord-014712-5u4e00q6	1667	10	after	after	IN
cord-014712-5u4e00q6	1667	11	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1667	12	.	.	.
cord-014712-5u4e00q6	1668	1	There	there	EX
cord-014712-5u4e00q6	1668	2	is	be	VBZ
cord-014712-5u4e00q6	1668	3	no	no	DT
cord-014712-5u4e00q6	1668	4	statistically	statistically	RB
cord-014712-5u4e00q6	1668	5	significant	significant	JJ
cord-014712-5u4e00q6	1668	6	difference	difference	NN
cord-014712-5u4e00q6	1668	7	in	in	IN
cord-014712-5u4e00q6	1668	8	occurrence	occurrence	NN
cord-014712-5u4e00q6	1668	9	of	of	IN
cord-014712-5u4e00q6	1668	10	acute/	acute/	NN
cord-014712-5u4e00q6	1668	11	chronic	chronic	JJ
cord-014712-5u4e00q6	1668	12	GVHD	GVHD	NNP
cord-014712-5u4e00q6	1668	13	between	between	IN
cord-014712-5u4e00q6	1668	14	NK	NK	NNP
cord-014712-5u4e00q6	1668	15	-	-	:
cord-014712-5u4e00q6	1668	16	and	and	CC
cord-014712-5u4e00q6	1668	17	NK	NK	NNP
cord-014712-5u4e00q6	1668	18	+	+	CC
cord-014712-5u4e00q6	1668	19	SCID	SCID	NNP
cord-014712-5u4e00q6	1668	20	,	,	,
cord-014712-5u4e00q6	1668	21	who	who	WP
cord-014712-5u4e00q6	1668	22	had	have	VBD
cord-014712-5u4e00q6	1668	23	been	be	VBN
cord-014712-5u4e00q6	1668	24	HLA	HLA	NNP
cord-014712-5u4e00q6	1668	25	idantically	idantically	RB
cord-014712-5u4e00q6	1668	26	transplanted	transplant	VBN
cord-014712-5u4e00q6	1668	27	from	from	IN
cord-014712-5u4e00q6	1668	28	family	family	NN
cord-014712-5u4e00q6	1668	29	donor	donor	NN
cord-014712-5u4e00q6	1668	30	.	.	.
cord-014712-5u4e00q6	1669	1	Both	both	DT
cord-014712-5u4e00q6	1669	2	groups	group	NNS
cord-014712-5u4e00q6	1669	3	have	have	VBP
cord-014712-5u4e00q6	1669	4	similar	similar	JJ
cord-014712-5u4e00q6	1669	5	ratios	ratio	NNS
cord-014712-5u4e00q6	1669	6	of	of	IN
cord-014712-5u4e00q6	1669	7	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1669	8	treatment	treatment	NN
cord-014712-5u4e00q6	1669	9	need	need	NN
cord-014712-5u4e00q6	1669	10	after	after	IN
cord-014712-5u4e00q6	1669	11	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1669	12	.	.	.
cord-014712-5u4e00q6	1670	1	Death	death	NN
cord-014712-5u4e00q6	1670	2	ratio	ratio	NN
cord-014712-5u4e00q6	1670	3	was	be	VBD
cord-014712-5u4e00q6	1670	4	similar	similar	JJ
cord-014712-5u4e00q6	1670	5	in	in	IN
cord-014712-5u4e00q6	1670	6	groups	group	NNS
cord-014712-5u4e00q6	1670	7	.	.	.
cord-014712-5u4e00q6	1671	1	BCG	BCG	NNP
cord-014712-5u4e00q6	1671	2	dissemination	dissemination	NN
cord-014712-5u4e00q6	1671	3	in	in	IN
cord-014712-5u4e00q6	1671	4	BCG	BCG	NNP
cord-014712-5u4e00q6	1671	5	vaccinated	vaccinate	VBD
cord-014712-5u4e00q6	1671	6	patients	patient	NNS
cord-014712-5u4e00q6	1671	7	is	be	VBZ
cord-014712-5u4e00q6	1671	8	significantly	significantly	RB
cord-014712-5u4e00q6	1671	9	higher	high	JJR
cord-014712-5u4e00q6	1671	10	in	in	IN
cord-014712-5u4e00q6	1671	11	the	the	DT
cord-014712-5u4e00q6	1671	12	NK	NK	NNP
cord-014712-5u4e00q6	1671	13	+	+	CC
cord-014712-5u4e00q6	1671	14	group	group	NN
cord-014712-5u4e00q6	1671	15	.	.	.
cord-014712-5u4e00q6	1672	1	The	the	DT
cord-014712-5u4e00q6	1672	2	rate	rate	NN
cord-014712-5u4e00q6	1672	3	of	of	IN
cord-014712-5u4e00q6	1672	4	complications	complication	NNS
cord-014712-5u4e00q6	1672	5	due	due	JJ
cord-014712-5u4e00q6	1672	6	to	to	IN
cord-014712-5u4e00q6	1672	7	severe	severe	JJ
cord-014712-5u4e00q6	1672	8	infections	infection	NNS
cord-014712-5u4e00q6	1672	9	is	be	VBZ
cord-014712-5u4e00q6	1672	10	high	high	JJ
cord-014712-5u4e00q6	1672	11	and	and	CC
cord-014712-5u4e00q6	1672	12	increases	increase	VBZ
cord-014712-5u4e00q6	1672	13	with	with	IN
cord-014712-5u4e00q6	1672	14	age	age	NN
cord-014712-5u4e00q6	1672	15	in	in	IN
cord-014712-5u4e00q6	1672	16	patients	patient	NNS
cord-014712-5u4e00q6	1672	17	with	with	IN
cord-014712-5u4e00q6	1672	18	SCID	SCID	NNP
cord-014712-5u4e00q6	1672	19	.	.	.
cord-014712-5u4e00q6	1673	1	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1673	2	is	be	VBZ
cord-014712-5u4e00q6	1673	3	curative	curative	JJ
cord-014712-5u4e00q6	1673	4	,	,	,
cord-014712-5u4e00q6	1673	5	should	should	MD
cord-014712-5u4e00q6	1673	6	be	be	VB
cord-014712-5u4e00q6	1673	7	considered	consider	VBN
cord-014712-5u4e00q6	1673	8	as	as	RB
cord-014712-5u4e00q6	1673	9	early	early	RB
cord-014712-5u4e00q6	1673	10	as	as	IN
cord-014712-5u4e00q6	1673	11	possible	possible	JJ
cord-014712-5u4e00q6	1673	12	.	.	.
cord-014712-5u4e00q6	1674	1	TREC	trec	JJ
cord-014712-5u4e00q6	1674	2	analysis	analysis	NN
cord-014712-5u4e00q6	1674	3	for	for	IN
cord-014712-5u4e00q6	1674	4	neonatal	neonatal	JJ
cord-014712-5u4e00q6	1674	5	screening	screening	NN
cord-014712-5u4e00q6	1674	6	will	will	MD
cord-014712-5u4e00q6	1674	7	give	give	VB
cord-014712-5u4e00q6	1674	8	chance	chance	NN
cord-014712-5u4e00q6	1674	9	for	for	IN
cord-014712-5u4e00q6	1674	10	early	early	JJ
cord-014712-5u4e00q6	1674	11	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1674	12	and	and	CC
cord-014712-5u4e00q6	1674	13	treatment	treatment	NN
cord-014712-5u4e00q6	1674	14	of	of	IN
cord-014712-5u4e00q6	1674	15	the	the	DT
cord-014712-5u4e00q6	1674	16	patients	patient	NNS
cord-014712-5u4e00q6	1674	17	.	.	.
cord-014712-5u4e00q6	1675	1	The	the	DT
cord-014712-5u4e00q6	1675	2	hyper	hyper	NNP
cord-014712-5u4e00q6	1675	3	-	-	JJ
cord-014712-5u4e00q6	1675	4	IgE	ige	JJ
cord-014712-5u4e00q6	1675	5	syndromes	syndrome	NNS
cord-014712-5u4e00q6	1675	6	are	be	VBP
cord-014712-5u4e00q6	1675	7	rare	rare	JJ
cord-014712-5u4e00q6	1675	8	PIDs	pid	NNS
cord-014712-5u4e00q6	1675	9	and	and	CC
cord-014712-5u4e00q6	1675	10	are	be	VBP
cord-014712-5u4e00q6	1675	11	characterized	characterize	VBN
cord-014712-5u4e00q6	1675	12	by	by	IN
cord-014712-5u4e00q6	1675	13	atopic	atopic	JJ
cord-014712-5u4e00q6	1675	14	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	1675	15	,	,	,
cord-014712-5u4e00q6	1675	16	skin	skin	NN
cord-014712-5u4e00q6	1675	17	abscesses	abscess	NNS
cord-014712-5u4e00q6	1675	18	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1675	19	pneumonias	pneumonia	NNS
cord-014712-5u4e00q6	1675	20	,	,	,
cord-014712-5u4e00q6	1675	21	elevated	elevated	JJ
cord-014712-5u4e00q6	1675	22	serum	serum	NN
cord-014712-5u4e00q6	1675	23	IgE	ige	NN
cord-014712-5u4e00q6	1675	24	levels	level	NNS
cord-014712-5u4e00q6	1675	25	and	and	CC
cord-014712-5u4e00q6	1675	26	sometimes	sometimes	RB
cord-014712-5u4e00q6	1675	27	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	1675	28	candidiasis	candidiasi	NNS
cord-014712-5u4e00q6	1675	29	.	.	.
cord-014712-5u4e00q6	1676	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1676	2	have	have	VBP
cord-014712-5u4e00q6	1676	3	been	be	VBN
cord-014712-5u4e00q6	1676	4	evaluating	evaluate	VBG
cord-014712-5u4e00q6	1676	5	and	and	CC
cord-014712-5u4e00q6	1676	6	following	follow	VBG
cord-014712-5u4e00q6	1676	7	up	up	RP
cord-014712-5u4e00q6	1676	8	a	a	DT
cord-014712-5u4e00q6	1676	9	group	group	NN
cord-014712-5u4e00q6	1676	10	of	of	IN
cord-014712-5u4e00q6	1676	11	patients	patient	NNS
cord-014712-5u4e00q6	1676	12	with	with	IN
cord-014712-5u4e00q6	1676	13	features	feature	NNS
cord-014712-5u4e00q6	1676	14	suggestive	suggestive	JJ
cord-014712-5u4e00q6	1676	15	for	for	IN
cord-014712-5u4e00q6	1676	16	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1676	17	recessive	recessive	JJ
cord-014712-5u4e00q6	1676	18	Hyper	Hyper	NNP
cord-014712-5u4e00q6	1676	19	IgE	IgE	NNP
cord-014712-5u4e00q6	1676	20	Syndrome	Syndrome	NNP
cord-014712-5u4e00q6	1676	21	(	(	-LRB-
cord-014712-5u4e00q6	1676	22	AR	AR	NNP
cord-014712-5u4e00q6	1676	23	-	-	HYPH
cord-014712-5u4e00q6	1676	24	HIES	HIES	NNP
cord-014712-5u4e00q6	1676	25	)	)	-RRB-
cord-014712-5u4e00q6	1676	26	.	.	.
cord-014712-5u4e00q6	1677	1	Homozygous	Homozygous	NNP
cord-014712-5u4e00q6	1677	2	Dock8	Dock8	NNP
cord-014712-5u4e00q6	1677	3	mutations	mutation	NNS
cord-014712-5u4e00q6	1677	4	were	be	VBD
cord-014712-5u4e00q6	1677	5	identified	identify	VBN
cord-014712-5u4e00q6	1677	6	in	in	IN
cord-014712-5u4e00q6	1677	7	several	several	JJ
cord-014712-5u4e00q6	1677	8	of	of	IN
cord-014712-5u4e00q6	1677	9	these	these	DT
cord-014712-5u4e00q6	1677	10	patients	patient	NNS
cord-014712-5u4e00q6	1677	11	.	.	.
cord-014712-5u4e00q6	1678	1	However	however	RB
cord-014712-5u4e00q6	1678	2	,	,	,
cord-014712-5u4e00q6	1678	3	two	two	CD
cord-014712-5u4e00q6	1678	4	siblings	sibling	NNS
cord-014712-5u4e00q6	1678	5	from	from	IN
cord-014712-5u4e00q6	1678	6	a	a	DT
cord-014712-5u4e00q6	1678	7	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	1678	8	family	family	NN
cord-014712-5u4e00q6	1678	9	in	in	IN
cord-014712-5u4e00q6	1678	10	this	this	DT
cord-014712-5u4e00q6	1678	11	group	group	NN
cord-014712-5u4e00q6	1678	12	of	of	IN
cord-014712-5u4e00q6	1678	13	patients	patient	NNS
cord-014712-5u4e00q6	1678	14	showed	show	VBD
cord-014712-5u4e00q6	1678	15	homozygous	homozygous	JJ
cord-014712-5u4e00q6	1678	16	block	block	NN
cord-014712-5u4e00q6	1678	17	in	in	IN
cord-014712-5u4e00q6	1678	18	chromosome	chromosome	NN
cord-014712-5u4e00q6	1678	19	20p1.2	20p1.2	CD
cord-014712-5u4e00q6	1678	20	in	in	IN
cord-014712-5u4e00q6	1678	21	homozygosity	homozygosity	NN
cord-014712-5u4e00q6	1678	22	mapping	mapping	NN
cord-014712-5u4e00q6	1678	23	which	which	WDT
cord-014712-5u4e00q6	1678	24	includes	include	VBZ
cord-014712-5u4e00q6	1678	25	STK4	STK4	NNP
cord-014712-5u4e00q6	1678	26	gene	gene	NN
cord-014712-5u4e00q6	1678	27	.	.	.
cord-014712-5u4e00q6	1679	1	Sanger	Sanger	NNP
cord-014712-5u4e00q6	1679	2	sequencing	sequencing	NN
cord-014712-5u4e00q6	1679	3	was	be	VBD
cord-014712-5u4e00q6	1679	4	performed	perform	VBN
cord-014712-5u4e00q6	1679	5	for	for	IN
cord-014712-5u4e00q6	1679	6	STK4	STK4	NNP
cord-014712-5u4e00q6	1679	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	1679	8	and	and	CC
cord-014712-5u4e00q6	1679	9	showed	show	VBD
cord-014712-5u4e00q6	1679	10	a	a	DT
cord-014712-5u4e00q6	1679	11	novel	novel	NN
cord-014712-5u4e00q6	1679	12	c.57	c.57	NN
cord-014712-5u4e00q6	1679	13	-	-	HYPH
cord-014712-5u4e00q6	1679	14	60delGATA	60delgata	CD
cord-014712-5u4e00q6	1679	15	mutation	mutation	NN
cord-014712-5u4e00q6	1679	16	in	in	IN
cord-014712-5u4e00q6	1679	17	STK4	STK4	NNP
cord-014712-5u4e00q6	1679	18	gene	gene	NN
cord-014712-5u4e00q6	1679	19	causing	cause	VBG
cord-014712-5u4e00q6	1679	20	a	a	DT
cord-014712-5u4e00q6	1679	21	premature	premature	JJ
cord-014712-5u4e00q6	1679	22	stop	stop	NN
cord-014712-5u4e00q6	1679	23	codon	codon	NN
cord-014712-5u4e00q6	1679	24	.	.	.
cord-014712-5u4e00q6	1680	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	1680	2	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1680	3	of	of	IN
cord-014712-5u4e00q6	1680	4	STK4	STK4	NNP
cord-014712-5u4e00q6	1680	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	1680	6	,	,	,
cord-014712-5u4e00q6	1680	7	also	also	RB
cord-014712-5u4e00q6	1680	8	known	know	VBN
cord-014712-5u4e00q6	1680	9	as	as	IN
cord-014712-5u4e00q6	1680	10	a	a	DT
cord-014712-5u4e00q6	1680	11	Macrophage	macrophage	NN
cord-014712-5u4e00q6	1680	12	Stimulating	stimulate	VBG
cord-014712-5u4e00q6	1680	13	1	1	CD
cord-014712-5u4e00q6	1681	1	(	(	-LRB-
cord-014712-5u4e00q6	1681	2	MST1	MST1	NNP
cord-014712-5u4e00q6	1681	3	)	)	-RRB-
cord-014712-5u4e00q6	1681	4	deficiency	deficiency	NN
cord-014712-5u4e00q6	1681	5	,	,	,
cord-014712-5u4e00q6	1681	6	STK4	STK4	NNP
cord-014712-5u4e00q6	1681	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	1681	8	comprise	comprise	VBP
cord-014712-5u4e00q6	1681	9	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1681	10	and	and	CC
cord-014712-5u4e00q6	1681	11	severe	severe	JJ
cord-014712-5u4e00q6	1681	12	viral	viral	JJ
cord-014712-5u4e00q6	1681	13	skin	skin	NN
cord-014712-5u4e00q6	1681	14	infections	infection	NNS
cord-014712-5u4e00q6	1681	15	including	include	VBG
cord-014712-5u4e00q6	1681	16	molluscum	molluscum	NN
cord-014712-5u4e00q6	1681	17	contagiosum	contagiosum	NN
cord-014712-5u4e00q6	1681	18	and	and	CC
cord-014712-5u4e00q6	1681	19	warts	wart	NNS
cord-014712-5u4e00q6	1681	20	,	,	,
cord-014712-5u4e00q6	1681	21	fungal	fungal	JJ
cord-014712-5u4e00q6	1681	22	and	and	CC
cord-014712-5u4e00q6	1681	23	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1681	24	infections	infection	NNS
cord-014712-5u4e00q6	1681	25	and	and	CC
cord-014712-5u4e00q6	1681	26	autoimmunity	autoimmunity	NN
cord-014712-5u4e00q6	1681	27	which	which	WDT
cord-014712-5u4e00q6	1681	28	are	be	VBP
cord-014712-5u4e00q6	1681	29	also	also	RB
cord-014712-5u4e00q6	1681	30	the	the	DT
cord-014712-5u4e00q6	1681	31	features	feature	NNS
cord-014712-5u4e00q6	1681	32	of	of	IN
cord-014712-5u4e00q6	1681	33	AR	AR	NNP
cord-014712-5u4e00q6	1681	34	-	-	HYPH
cord-014712-5u4e00q6	1681	35	HIES	HIES	NNP
cord-014712-5u4e00q6	1681	36	.	.	.
cord-014712-5u4e00q6	1682	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	1682	2	patients	patient	NNS
cord-014712-5u4e00q6	1682	3	's	's	POS
cord-014712-5u4e00q6	1682	4	main	main	JJ
cord-014712-5u4e00q6	1682	5	features	feature	NNS
cord-014712-5u4e00q6	1682	6	include	include	VBP
cord-014712-5u4e00q6	1682	7	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	1682	8	cytopenias	cytopenia	NNS
cord-014712-5u4e00q6	1682	9	(	(	-LRB-
cord-014712-5u4e00q6	1682	10	AIHA	AIHA	NNP
cord-014712-5u4e00q6	1682	11	and	and	CC
cord-014712-5u4e00q6	1682	12	ITP	ITP	NNP
cord-014712-5u4e00q6	1682	13	)	)	-RRB-
cord-014712-5u4e00q6	1682	14	,	,	,
cord-014712-5u4e00q6	1682	15	cutaneous	cutaneous	JJ
cord-014712-5u4e00q6	1682	16	viral	viral	JJ
cord-014712-5u4e00q6	1682	17	(	(	-LRB-
cord-014712-5u4e00q6	1682	18	molluscum	molluscum	NN
cord-014712-5u4e00q6	1682	19	contagiosum	contagiosum	NN
cord-014712-5u4e00q6	1682	20	and	and	CC
cord-014712-5u4e00q6	1682	21	mild	mild	JJ
cord-014712-5u4e00q6	1682	22	perioral	perioral	JJ
cord-014712-5u4e00q6	1682	23	herpetic	herpetic	JJ
cord-014712-5u4e00q6	1682	24	lesion	lesion	NN
cord-014712-5u4e00q6	1682	25	)	)	-RRB-
cord-014712-5u4e00q6	1682	26	,	,	,
cord-014712-5u4e00q6	1682	27	mild	mild	JJ
cord-014712-5u4e00q6	1682	28	atopic	atopic	JJ
cord-014712-5u4e00q6	1682	29	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	1682	30	,	,	,
cord-014712-5u4e00q6	1682	31	seborrheic	seborrheic	NN
cord-014712-5u4e00q6	1682	32	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	1682	33	,	,	,
cord-014712-5u4e00q6	1682	34	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	1682	35	(	(	-LRB-
cord-014712-5u4e00q6	1682	36	particularly	particularly	RB
cord-014712-5u4e00q6	1682	37	CD4	CD4	NNP
cord-014712-5u4e00q6	1682	38	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	1682	39	)	)	-RRB-
cord-014712-5u4e00q6	1682	40	,	,	,
cord-014712-5u4e00q6	1682	41	and	and	CC
cord-014712-5u4e00q6	1682	42	intermittent	intermittent	JJ
cord-014712-5u4e00q6	1682	43	mild	mild	JJ
cord-014712-5u4e00q6	1682	44	neutropenia	neutropenia	NN
cord-014712-5u4e00q6	1682	45	.	.	.
cord-014712-5u4e00q6	1683	1	Serum	serum	NN
cord-014712-5u4e00q6	1683	2	IgE	IgE	NNP
cord-014712-5u4e00q6	1683	3	level	level	NN
cord-014712-5u4e00q6	1683	4	was	be	VBD
cord-014712-5u4e00q6	1683	5	mildly	mildly	RB
cord-014712-5u4e00q6	1683	6	high	high	JJ
cord-014712-5u4e00q6	1683	7	in	in	IN
cord-014712-5u4e00q6	1683	8	these	these	DT
cord-014712-5u4e00q6	1683	9	patients	patient	NNS
cord-014712-5u4e00q6	1683	10	.	.	.
cord-014712-5u4e00q6	1684	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	1684	2	results	result	NNS
cord-014712-5u4e00q6	1684	3	indicates	indicate	VBZ
cord-014712-5u4e00q6	1684	4	that	that	IN
cord-014712-5u4e00q6	1684	5	patients	patient	NNS
cord-014712-5u4e00q6	1684	6	that	that	WDT
cord-014712-5u4e00q6	1684	7	show	show	VBP
cord-014712-5u4e00q6	1684	8	clinical	clinical	JJ
cord-014712-5u4e00q6	1684	9	phenotype	phenotype	NN
cord-014712-5u4e00q6	1684	10	of	of	IN
cord-014712-5u4e00q6	1684	11	AR	AR	NNP
cord-014712-5u4e00q6	1684	12	-	-	HYPH
cord-014712-5u4e00q6	1684	13	HIES	HIES	NNP
cord-014712-5u4e00q6	1684	14	needs	need	VBZ
cord-014712-5u4e00q6	1684	15	to	to	TO
cord-014712-5u4e00q6	1684	16	be	be	VB
cord-014712-5u4e00q6	1684	17	also	also	RB
cord-014712-5u4e00q6	1684	18	evaluated	evaluate	VBN
cord-014712-5u4e00q6	1684	19	for	for	IN
cord-014712-5u4e00q6	1684	20	STK4	STK4	NNP
cord-014712-5u4e00q6	1684	21	deficiency	deficiency	NN
cord-014712-5u4e00q6	1684	22	.	.	.
cord-014712-5u4e00q6	1685	1	Determination	determination	NN
cord-014712-5u4e00q6	1685	2	of	of	IN
cord-014712-5u4e00q6	1685	3	the	the	DT
cord-014712-5u4e00q6	1685	4	underlying	underlying	JJ
cord-014712-5u4e00q6	1685	5	defect	defect	NN
cord-014712-5u4e00q6	1685	6	and	and	CC
cord-014712-5u4e00q6	1685	7	reporting	report	VBG
cord-014712-5u4e00q6	1685	8	the	the	DT
cord-014712-5u4e00q6	1685	9	patients	patient	NNS
cord-014712-5u4e00q6	1685	10	are	be	VBP
cord-014712-5u4e00q6	1685	11	required	require	VBN
cord-014712-5u4e00q6	1685	12	for	for	IN
cord-014712-5u4e00q6	1685	13	the	the	DT
cord-014712-5u4e00q6	1685	14	description	description	NN
cord-014712-5u4e00q6	1685	15	of	of	IN
cord-014712-5u4e00q6	1685	16	the	the	DT
cord-014712-5u4e00q6	1685	17	phenotypic	phenotypic	JJ
cord-014712-5u4e00q6	1685	18	spectrum	spectrum	NN
cord-014712-5u4e00q6	1685	19	of	of	IN
cord-014712-5u4e00q6	1685	20	PIDs	pid	NNS
cord-014712-5u4e00q6	1685	21	and	and	CC
cord-014712-5u4e00q6	1685	22	the	the	DT
cord-014712-5u4e00q6	1685	23	frequency	frequency	NN
cord-014712-5u4e00q6	1685	24	of	of	IN
cord-014712-5u4e00q6	1685	25	these	these	DT
cord-014712-5u4e00q6	1685	26	diseases	disease	NNS
cord-014712-5u4e00q6	1685	27	as	as	RB
cord-014712-5u4e00q6	1685	28	well	well	RB
cord-014712-5u4e00q6	1685	29	as	as	IN
cord-014712-5u4e00q6	1685	30	for	for	IN
cord-014712-5u4e00q6	1685	31	genetic	genetic	JJ
cord-014712-5u4e00q6	1685	32	counselling	counselling	NN
cord-014712-5u4e00q6	1685	33	.	.	.
cord-014712-5u4e00q6	1686	1	Mendelian	mendelian	JJ
cord-014712-5u4e00q6	1686	2	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	1686	3	to	to	IN
cord-014712-5u4e00q6	1686	4	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	1686	5	disease	disease	NN
cord-014712-5u4e00q6	1686	6	(	(	-LRB-
cord-014712-5u4e00q6	1686	7	MSMD	MSMD	NNP
cord-014712-5u4e00q6	1686	8	)	)	-RRB-
cord-014712-5u4e00q6	1686	9	is	be	VBZ
cord-014712-5u4e00q6	1686	10	a	a	DT
cord-014712-5u4e00q6	1686	11	rare	rare	JJ
cord-014712-5u4e00q6	1686	12	entity	entity	NN
cord-014712-5u4e00q6	1686	13	.	.	.
cord-014712-5u4e00q6	1687	1	Patients	patient	NNS
cord-014712-5u4e00q6	1687	2	with	with	IN
cord-014712-5u4e00q6	1687	3	MSMD	MSMD	NNP
cord-014712-5u4e00q6	1687	4	have	have	VBP
cord-014712-5u4e00q6	1687	5	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	1687	6	to	to	IN
cord-014712-5u4e00q6	1687	7	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	1687	8	and	and	CC
cord-014712-5u4e00q6	1687	9	some	some	DT
cord-014712-5u4e00q6	1687	10	other	other	JJ
cord-014712-5u4e00q6	1687	11	intracellular	intracellular	JJ
cord-014712-5u4e00q6	1687	12	microorganisms	microorganism	NNS
cord-014712-5u4e00q6	1687	13	in	in	IN
cord-014712-5u4e00q6	1687	14	addition	addition	NN
cord-014712-5u4e00q6	1687	15	to	to	IN
cord-014712-5u4e00q6	1687	16	weakly	weakly	RB
cord-014712-5u4e00q6	1687	17	pathogenic	pathogenic	JJ
cord-014712-5u4e00q6	1687	18	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	1687	19	species	specie	NNS
cord-014712-5u4e00q6	1687	20	.	.	.
cord-014712-5u4e00q6	1688	1	IL-12Rβ1	il-12rβ1	NN
cord-014712-5u4e00q6	1688	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	1688	3	,	,	,
cord-014712-5u4e00q6	1688	4	most	most	RBS
cord-014712-5u4e00q6	1688	5	common	common	JJ
cord-014712-5u4e00q6	1688	6	form	form	NN
cord-014712-5u4e00q6	1688	7	of	of	IN
cord-014712-5u4e00q6	1688	8	MSMD	MSMD	NNP
cord-014712-5u4e00q6	1688	9	,	,	,
cord-014712-5u4e00q6	1688	10	is	be	VBZ
cord-014712-5u4e00q6	1688	11	caused	cause	VBN
cord-014712-5u4e00q6	1688	12	by	by	IN
cord-014712-5u4e00q6	1688	13	mutations	mutation	NNS
cord-014712-5u4e00q6	1688	14	in	in	IN
cord-014712-5u4e00q6	1688	15	the	the	DT
cord-014712-5u4e00q6	1688	16	IL12RB	IL12RB	NNP
cord-014712-5u4e00q6	1688	17	gene	gene	NN
cord-014712-5u4e00q6	1688	18	.	.	.
cord-014712-5u4e00q6	1689	1	37	37	CD
cord-014712-5u4e00q6	1689	2	patients	patient	NNS
cord-014712-5u4e00q6	1689	3	who	who	WP
cord-014712-5u4e00q6	1689	4	have	have	VBP
cord-014712-5u4e00q6	1689	5	symptoms	symptom	NNS
cord-014712-5u4e00q6	1689	6	suggestive	suggestive	JJ
cord-014712-5u4e00q6	1689	7	for	for	IN
cord-014712-5u4e00q6	1689	8	MSMD	MSMD	NNP
cord-014712-5u4e00q6	1689	9	or	or	CC
cord-014712-5u4e00q6	1689	10	history	history	NN
cord-014712-5u4e00q6	1689	11	of	of	IN
cord-014712-5u4e00q6	1689	12	sibling	sibling	NN
cord-014712-5u4e00q6	1689	13	death	death	NN
cord-014712-5u4e00q6	1689	14	due	due	IN
cord-014712-5u4e00q6	1689	15	to	to	IN
cord-014712-5u4e00q6	1689	16	BCGosis	BCGosis	NNP
cord-014712-5u4e00q6	1689	17	were	be	VBD
cord-014712-5u4e00q6	1689	18	evaluated	evaluate	VBN
cord-014712-5u4e00q6	1689	19	.	.	.
cord-014712-5u4e00q6	1690	1	The	the	DT
cord-014712-5u4e00q6	1690	2	expression	expression	NN
cord-014712-5u4e00q6	1690	3	of	of	IN
cord-014712-5u4e00q6	1690	4	the	the	DT
cord-014712-5u4e00q6	1690	5	IL-12RB1	il-12rb1	CD
cord-014712-5u4e00q6	1690	6	was	be	VBD
cord-014712-5u4e00q6	1690	7	detected	detect	VBN
cord-014712-5u4e00q6	1690	8	in	in	IN
cord-014712-5u4e00q6	1690	9	patients	patient	NNS
cord-014712-5u4e00q6	1690	10	and	and	CC
cord-014712-5u4e00q6	1690	11	family	family	NN
cord-014712-5u4e00q6	1690	12	members	member	NNS
cord-014712-5u4e00q6	1690	13	by	by	IN
cord-014712-5u4e00q6	1690	14	monoclonal	monoclonal	JJ
cord-014712-5u4e00q6	1690	15	antibodies	antibody	NNS
cord-014712-5u4e00q6	1690	16	on	on	IN
cord-014712-5u4e00q6	1690	17	the	the	DT
cord-014712-5u4e00q6	1690	18	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1690	19	surface	surface	NN
cord-014712-5u4e00q6	1690	20	by	by	IN
cord-014712-5u4e00q6	1690	21	flow	flow	NN
cord-014712-5u4e00q6	1690	22	cytometry	cytometry	NN
cord-014712-5u4e00q6	1690	23	after	after	IN
cord-014712-5u4e00q6	1690	24	the	the	DT
cord-014712-5u4e00q6	1690	25	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1690	26	were	be	VBD
cord-014712-5u4e00q6	1690	27	stimulated	stimulate	VBN
cord-014712-5u4e00q6	1690	28	in	in	IN
cord-014712-5u4e00q6	1690	29	vitro	vitro	FW
cord-014712-5u4e00q6	1690	30	with	with	IN
cord-014712-5u4e00q6	1690	31	PHA	PHA	NNP
cord-014712-5u4e00q6	1690	32	.	.	.
cord-014712-5u4e00q6	1691	1	Mutation	mutation	NN
cord-014712-5u4e00q6	1691	2	analyses	analysis	NNS
cord-014712-5u4e00q6	1691	3	was	be	VBD
cord-014712-5u4e00q6	1691	4	done	do	VBN
cord-014712-5u4e00q6	1691	5	by	by	IN
cord-014712-5u4e00q6	1691	6	Sanger	Sanger	NNP
cord-014712-5u4e00q6	1691	7	sequencing	sequencing	NN
cord-014712-5u4e00q6	1691	8	.	.	.
cord-014712-5u4e00q6	1692	1	All	all	DT
cord-014712-5u4e00q6	1692	2	index	index	NN
cord-014712-5u4e00q6	1692	3	cases	case	NNS
cord-014712-5u4e00q6	1692	4	were	be	VBD
cord-014712-5u4e00q6	1692	5	presented	present	VBN
cord-014712-5u4e00q6	1692	6	either	either	CC
cord-014712-5u4e00q6	1692	7	with	with	IN
cord-014712-5u4e00q6	1692	8	BCG	BCG	NNP
cord-014712-5u4e00q6	1692	9	or	or	CC
cord-014712-5u4e00q6	1692	10	salmonella	salmonella	NN
cord-014712-5u4e00q6	1692	11	infection	infection	NN
cord-014712-5u4e00q6	1692	12	.	.	.
cord-014712-5u4e00q6	1693	1	Two	two	CD
cord-014712-5u4e00q6	1693	2	patients	patient	NNS
cord-014712-5u4e00q6	1693	3	,	,	,
cord-014712-5u4e00q6	1693	4	though	though	IN
cord-014712-5u4e00q6	1693	5	they	-PRON-	PRP
cord-014712-5u4e00q6	1693	6	were	be	VBD
cord-014712-5u4e00q6	1693	7	BCG	BCG	NNP
cord-014712-5u4e00q6	1693	8	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	1693	9	had	have	VBD
cord-014712-5u4e00q6	1693	10	no	no	DT
cord-014712-5u4e00q6	1693	11	clinical	clinical	JJ
cord-014712-5u4e00q6	1693	12	symptom	symptom	NN
cord-014712-5u4e00q6	1693	13	,	,	,
cord-014712-5u4e00q6	1693	14	six	six	CD
cord-014712-5u4e00q6	1693	15	presented	present	VBN
cord-014712-5u4e00q6	1693	16	with	with	IN
cord-014712-5u4e00q6	1693	17	the	the	DT
cord-014712-5u4e00q6	1693	18	symptoms	symptom	NNS
cord-014712-5u4e00q6	1693	19	of	of	IN
cord-014712-5u4e00q6	1693	20	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	1693	21	infections	infection	NNS
cord-014712-5u4e00q6	1693	22	,	,	,
cord-014712-5u4e00q6	1693	23	two	two	CD
cord-014712-5u4e00q6	1693	24	developed	develop	VBN
cord-014712-5u4e00q6	1693	25	leukocytoclastic	leukocytoclastic	NNP
cord-014712-5u4e00q6	1693	26	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	1693	27	,	,	,
cord-014712-5u4e00q6	1693	28	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	1693	29	was	be	VBD
cord-014712-5u4e00q6	1693	30	the	the	DT
cord-014712-5u4e00q6	1693	31	accompanying	accompanying	JJ
cord-014712-5u4e00q6	1693	32	feature	feature	NN
cord-014712-5u4e00q6	1693	33	in	in	IN
cord-014712-5u4e00q6	1693	34	seven	seven	CD
cord-014712-5u4e00q6	1693	35	.	.	.
cord-014712-5u4e00q6	1694	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	1694	2	Leishmaniasis	Leishmaniasis	NNP
cord-014712-5u4e00q6	1694	3	that	that	WDT
cord-014712-5u4e00q6	1694	4	necessitated	necessitate	VBD
cord-014712-5u4e00q6	1694	5	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	1694	6	interferon	interferon	NN
cord-014712-5u4e00q6	1694	7	-	-	HYPH
cord-014712-5u4e00q6	1694	8	γ	γ	NN
cord-014712-5u4e00q6	1694	9	and	and	CC
cord-014712-5u4e00q6	1694	10	prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	1694	11	Amphotericine	Amphotericine	NNP
cord-014712-5u4e00q6	1694	12	B	B	NNP
cord-014712-5u4e00q6	1694	13	therapy	therapy	NN
cord-014712-5u4e00q6	1694	14	was	be	VBD
cord-014712-5u4e00q6	1694	15	present	present	JJ
cord-014712-5u4e00q6	1694	16	in	in	IN
cord-014712-5u4e00q6	1694	17	a	a	DT
cord-014712-5u4e00q6	1694	18	patient	patient	NN
cord-014712-5u4e00q6	1694	19	.	.	.
cord-014712-5u4e00q6	1695	1	In	in	IN
cord-014712-5u4e00q6	1695	2	all	all	DT
cord-014712-5u4e00q6	1695	3	patients	patient	NNS
cord-014712-5u4e00q6	1695	4	the	the	DT
cord-014712-5u4e00q6	1695	5	percentage	percentage	NN
cord-014712-5u4e00q6	1695	6	of	of	IN
cord-014712-5u4e00q6	1695	7	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1695	8	with	with	IN
cord-014712-5u4e00q6	1695	9	IL12Rβ1	il12rβ1	NN
cord-014712-5u4e00q6	1695	10	expression	expression	NN
cord-014712-5u4e00q6	1695	11	was	be	VBD
cord-014712-5u4e00q6	1695	12	found	find	VBN
cord-014712-5u4e00q6	1695	13	to	to	TO
cord-014712-5u4e00q6	1695	14	be	be	VB
cord-014712-5u4e00q6	1695	15	less	less	JJR
cord-014712-5u4e00q6	1695	16	than	than	IN
cord-014712-5u4e00q6	1695	17	%	%	NN
cord-014712-5u4e00q6	1695	18	1	1	CD
cord-014712-5u4e00q6	1695	19	.	.	.
cord-014712-5u4e00q6	1696	1	Prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	1696	2	antimycrobial	antimycrobial	JJ
cord-014712-5u4e00q6	1696	3	treatment	treatment	NN
cord-014712-5u4e00q6	1696	4	and	and	CC
cord-014712-5u4e00q6	1696	5	in	in	IN
cord-014712-5u4e00q6	1696	6	severe	severe	JJ
cord-014712-5u4e00q6	1696	7	and	and	CC
cord-014712-5u4e00q6	1696	8	resistant	resistant	JJ
cord-014712-5u4e00q6	1696	9	infectious	infectious	JJ
cord-014712-5u4e00q6	1696	10	episodes	episode	NNS
cord-014712-5u4e00q6	1696	11	IF	if	NN
cord-014712-5u4e00q6	1696	12	-	-	HYPH
cord-014712-5u4e00q6	1696	13	γ	γ	NN
cord-014712-5u4e00q6	1696	14	therapy	therapy	NN
cord-014712-5u4e00q6	1696	15	,	,	,
cord-014712-5u4e00q6	1696	16	should	should	MD
cord-014712-5u4e00q6	1696	17	be	be	VB
cord-014712-5u4e00q6	1696	18	given	give	VBN
cord-014712-5u4e00q6	1696	19	.	.	.
cord-014712-5u4e00q6	1697	1	Many	many	JJ
cord-014712-5u4e00q6	1697	2	patients	patient	NNS
cord-014712-5u4e00q6	1697	3	have	have	VBP
cord-014712-5u4e00q6	1697	4	associated	associate	VBN
cord-014712-5u4e00q6	1697	5	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	1697	6	candidiasis	candidiasi	NNS
cord-014712-5u4e00q6	1697	7	.	.	.
cord-014712-5u4e00q6	1698	1	The	the	DT
cord-014712-5u4e00q6	1698	2	prognosis	prognosis	NN
cord-014712-5u4e00q6	1698	3	is	be	VBZ
cord-014712-5u4e00q6	1698	4	good	good	JJ
cord-014712-5u4e00q6	1698	5	unless	unless	IN
cord-014712-5u4e00q6	1698	6	the	the	DT
cord-014712-5u4e00q6	1698	7	patient	patient	NN
cord-014712-5u4e00q6	1698	8	admits	admit	VBZ
cord-014712-5u4e00q6	1698	9	at	at	IN
cord-014712-5u4e00q6	1698	10	the	the	DT
cord-014712-5u4e00q6	1698	11	later	later	JJ
cord-014712-5u4e00q6	1698	12	stages	stage	NNS
cord-014712-5u4e00q6	1698	13	of	of	IN
cord-014712-5u4e00q6	1698	14	BCG	BCG	NNP
cord-014712-5u4e00q6	1698	15	infection	infection	NN
cord-014712-5u4e00q6	1698	16	.	.	.
cord-014712-5u4e00q6	1699	1	The	the	DT
cord-014712-5u4e00q6	1699	2	results	result	NNS
cord-014712-5u4e00q6	1699	3	of	of	IN
cord-014712-5u4e00q6	1699	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	1699	5	patients	patient	NNS
cord-014712-5u4e00q6	1699	6	showed	show	VBD
cord-014712-5u4e00q6	1699	7	that	that	IN
cord-014712-5u4e00q6	1699	8	the	the	DT
cord-014712-5u4e00q6	1699	9	analysis	analysis	NN
cord-014712-5u4e00q6	1699	10	of	of	IN
cord-014712-5u4e00q6	1699	11	the	the	DT
cord-014712-5u4e00q6	1699	12	surface	surface	NN
cord-014712-5u4e00q6	1699	13	expression	expression	NN
cord-014712-5u4e00q6	1699	14	of	of	IN
cord-014712-5u4e00q6	1699	15	IL12Rβ1	il12rβ1	NN
cord-014712-5u4e00q6	1699	16	on	on	IN
cord-014712-5u4e00q6	1699	17	activated	activate	VBN
cord-014712-5u4e00q6	1699	18	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1699	19	is	be	VBZ
cord-014712-5u4e00q6	1699	20	an	an	DT
cord-014712-5u4e00q6	1699	21	effective	effective	JJ
cord-014712-5u4e00q6	1699	22	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	1699	23	method	method	NN
cord-014712-5u4e00q6	1699	24	which	which	WDT
cord-014712-5u4e00q6	1699	25	can	can	MD
cord-014712-5u4e00q6	1699	26	also	also	RB
cord-014712-5u4e00q6	1699	27	be	be	VB
cord-014712-5u4e00q6	1699	28	used	use	VBN
cord-014712-5u4e00q6	1699	29	in	in	IN
cord-014712-5u4e00q6	1699	30	screening	screening	NN
cord-014712-5u4e00q6	1699	31	of	of	IN
cord-014712-5u4e00q6	1699	32	the	the	DT
cord-014712-5u4e00q6	1699	33	patients	patient	NNS
cord-014712-5u4e00q6	1699	34	with	with	IN
cord-014712-5u4e00q6	1699	35	probable	probable	JJ
cord-014712-5u4e00q6	1699	36	MSMD	MSMD	NNP
cord-014712-5u4e00q6	1699	37	.	.	.
cord-014712-5u4e00q6	1700	1	Ataxia	ataxia	NN
cord-014712-5u4e00q6	1700	2	-	-	HYPH
cord-014712-5u4e00q6	1700	3	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1700	4	(	(	-LRB-
cord-014712-5u4e00q6	1700	5	A	A	NNP
cord-014712-5u4e00q6	1700	6	-	-	HYPH
cord-014712-5u4e00q6	1700	7	T	T	NNP
cord-014712-5u4e00q6	1700	8	)	)	-RRB-
cord-014712-5u4e00q6	1700	9	results	result	VBZ
cord-014712-5u4e00q6	1700	10	from	from	IN
cord-014712-5u4e00q6	1700	11	the	the	DT
cord-014712-5u4e00q6	1700	12	loss	loss	NN
cord-014712-5u4e00q6	1700	13	of	of	IN
cord-014712-5u4e00q6	1700	14	ataxia	ataxia	NN
cord-014712-5u4e00q6	1700	15	-	-	HYPH
cord-014712-5u4e00q6	1700	16	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1700	17	mutated	mutate	VBN
cord-014712-5u4e00q6	1700	18	gene	gene	NN
cord-014712-5u4e00q6	1700	19	(	(	-LRB-
cord-014712-5u4e00q6	1700	20	ATM	ATM	NNP
cord-014712-5u4e00q6	1700	21	)	)	-RRB-
cord-014712-5u4e00q6	1700	22	function	function	NN
cord-014712-5u4e00q6	1700	23	and	and	CC
cord-014712-5u4e00q6	1700	24	is	be	VBZ
cord-014712-5u4e00q6	1700	25	a	a	DT
cord-014712-5u4e00q6	1700	26	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	1700	27	,	,	,
cord-014712-5u4e00q6	1700	28	multisystemic	multisystemic	JJ
cord-014712-5u4e00q6	1700	29	disease	disease	NN
cord-014712-5u4e00q6	1700	30	and	and	CC
cord-014712-5u4e00q6	1700	31	characterized	characterize	VBN
cord-014712-5u4e00q6	1700	32	by	by	IN
cord-014712-5u4e00q6	1700	33	accelerated	accelerated	JJ
cord-014712-5u4e00q6	1700	34	telomere	telomere	NN
cord-014712-5u4e00q6	1700	35	loss	loss	NN
cord-014712-5u4e00q6	1700	36	,	,	,
cord-014712-5u4e00q6	1700	37	genomic	genomic	JJ
cord-014712-5u4e00q6	1700	38	instability	instability	NN
cord-014712-5u4e00q6	1700	39	,	,	,
cord-014712-5u4e00q6	1700	40	progressive	progressive	JJ
cord-014712-5u4e00q6	1700	41	neurological	neurological	JJ
cord-014712-5u4e00q6	1700	42	degeneration	degeneration	NN
cord-014712-5u4e00q6	1700	43	,	,	,
cord-014712-5u4e00q6	1700	44	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1700	45	,	,	,
cord-014712-5u4e00q6	1700	46	premature	premature	JJ
cord-014712-5u4e00q6	1700	47	ageing	ageing	NN
cord-014712-5u4e00q6	1700	48	and	and	CC
cord-014712-5u4e00q6	1700	49	increased	increase	VBN
cord-014712-5u4e00q6	1700	50	neoplasia	neoplasia	NN
cord-014712-5u4e00q6	1700	51	incidence	incidence	NN
cord-014712-5u4e00q6	1700	52	.	.	.
cord-014712-5u4e00q6	1701	1	Even	even	RB
cord-014712-5u4e00q6	1701	2	in	in	IN
cord-014712-5u4e00q6	1701	3	classic	classic	JJ
cord-014712-5u4e00q6	1701	4	A	A	NNP
cord-014712-5u4e00q6	1701	5	-	-	HYPH
cord-014712-5u4e00q6	1701	6	T	t	NN
cord-014712-5u4e00q6	1701	7	with	with	IN
cord-014712-5u4e00q6	1701	8	ataxia	ataxia	NN
cord-014712-5u4e00q6	1701	9	and	and	CC
cord-014712-5u4e00q6	1701	10	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1701	11	,	,	,
cord-014712-5u4e00q6	1701	12	the	the	DT
cord-014712-5u4e00q6	1701	13	onset	onset	NN
cord-014712-5u4e00q6	1701	14	of	of	IN
cord-014712-5u4e00q6	1701	15	clinical	clinical	JJ
cord-014712-5u4e00q6	1701	16	symptoms	symptom	NNS
cord-014712-5u4e00q6	1701	17	and	and	CC
cord-014712-5u4e00q6	1701	18	the	the	DT
cord-014712-5u4e00q6	1701	19	rate	rate	NN
cord-014712-5u4e00q6	1701	20	of	of	IN
cord-014712-5u4e00q6	1701	21	progression	progression	NN
cord-014712-5u4e00q6	1701	22	are	be	VBP
cord-014712-5u4e00q6	1701	23	variable	variable	JJ
cord-014712-5u4e00q6	1701	24	.	.	.
cord-014712-5u4e00q6	1702	1	Here	here	RB
cord-014712-5u4e00q6	1702	2	,	,	,
cord-014712-5u4e00q6	1702	3	we	-PRON-	PRP
cord-014712-5u4e00q6	1702	4	report	report	VBP
cord-014712-5u4e00q6	1702	5	two	two	CD
cord-014712-5u4e00q6	1702	6	siblings	sibling	NNS
cord-014712-5u4e00q6	1702	7	was	be	VBD
cord-014712-5u4e00q6	1702	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1702	9	as	as	IN
cord-014712-5u4e00q6	1702	10	A	A	NNP
cord-014712-5u4e00q6	1702	11	-	-	HYPH
cord-014712-5u4e00q6	1702	12	T	t	NN
cord-014712-5u4e00q6	1702	13	with	with	IN
cord-014712-5u4e00q6	1702	14	severe	severe	JJ
cord-014712-5u4e00q6	1702	15	and	and	CC
cord-014712-5u4e00q6	1702	16	early	early	JJ
cord-014712-5u4e00q6	1702	17	hypogamaglobulinemia	hypogamaglobulinemia	NN
cord-014712-5u4e00q6	1702	18	,	,	,
cord-014712-5u4e00q6	1702	19	decreased	decrease	VBD
cord-014712-5u4e00q6	1702	20	CD19	CD19	NNP
cord-014712-5u4e00q6	1702	21	,	,	,
cord-014712-5u4e00q6	1702	22	increased	increase	VBD
cord-014712-5u4e00q6	1702	23	CD45RO	CD45RO	NNP
cord-014712-5u4e00q6	1702	24	,	,	,
cord-014712-5u4e00q6	1702	25	no	no	DT
cord-014712-5u4e00q6	1702	26	ataxia	ataxia	NN
cord-014712-5u4e00q6	1702	27	and	and	CC
cord-014712-5u4e00q6	1702	28	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1702	29	,	,	,
cord-014712-5u4e00q6	1702	30	purulent	purulent	JJ
cord-014712-5u4e00q6	1702	31	otitis	otitis	NN
cord-014712-5u4e00q6	1702	32	and	and	CC
cord-014712-5u4e00q6	1702	33	hemophagocytosis	hemophagocytosis	NN
cord-014712-5u4e00q6	1702	34	that	that	WDT
cord-014712-5u4e00q6	1702	35	harbor	harbor	VBP
cord-014712-5u4e00q6	1702	36	a	a	DT
cord-014712-5u4e00q6	1702	37	rare	rare	JJ
cord-014712-5u4e00q6	1702	38	frameshift	frameshift	NN
cord-014712-5u4e00q6	1702	39	mutation	mutation	NN
cord-014712-5u4e00q6	1702	40	of	of	IN
cord-014712-5u4e00q6	1702	41	ATM	atm	NN
cord-014712-5u4e00q6	1702	42	gene	gene	NN
cord-014712-5u4e00q6	1702	43	.	.	.
cord-014712-5u4e00q6	1703	1	Özdemir	Özdemir	NNP
cord-014712-5u4e00q6	1703	2	Öner	Öner	NNP
cord-014712-5u4e00q6	1703	3	1	1	CD
cord-014712-5u4e00q6	1703	4	;	;	:
cord-014712-5u4e00q6	1703	5	Bozdoğan	Bozdoğan	NNP
cord-014712-5u4e00q6	1703	6	Sıla	Sıla	NNP
cord-014712-5u4e00q6	1703	7	2	2	CD
cord-014712-5u4e00q6	1703	8	1	1	CD
cord-014712-5u4e00q6	1703	9	Department	Department	NNP
cord-014712-5u4e00q6	1703	10	of	of	IN
cord-014712-5u4e00q6	1703	11	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	1703	12	,	,	,
cord-014712-5u4e00q6	1703	13	Division	Division	NNP
cord-014712-5u4e00q6	1703	14	of	of	IN
cord-014712-5u4e00q6	1703	15	Allergy	Allergy	NNP
cord-014712-5u4e00q6	1703	16	/	/	SYM
cord-014712-5u4e00q6	1703	17	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1703	18	,	,	,
cord-014712-5u4e00q6	1703	19	Sakarya	Sakarya	NNP
cord-014712-5u4e00q6	1703	20	University	University	NNP
cord-014712-5u4e00q6	1703	21	,	,	,
cord-014712-5u4e00q6	1703	22	Medical	Medical	NNP
cord-014712-5u4e00q6	1703	23	Faculty	Faculty	NNP
cord-014712-5u4e00q6	1703	24	,	,	,
cord-014712-5u4e00q6	1703	25	Adapazarı	Adapazarı	NNP
cord-014712-5u4e00q6	1703	26	,	,	,
cord-014712-5u4e00q6	1703	27	Türkiye	Türkiye	NNP
cord-014712-5u4e00q6	1703	28	.	.	.
cord-014712-5u4e00q6	1704	1	2	2	LS
cord-014712-5u4e00q6	1704	2	Department	Department	NNP
cord-014712-5u4e00q6	1704	3	of	of	IN
cord-014712-5u4e00q6	1704	4	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	1704	5	,	,	,
cord-014712-5u4e00q6	1704	6	Sakarya	Sakarya	NNP
cord-014712-5u4e00q6	1704	7	University	University	NNP
cord-014712-5u4e00q6	1704	8	,	,	,
cord-014712-5u4e00q6	1704	9	Medical	Medical	NNP
cord-014712-5u4e00q6	1704	10	Faculty	Faculty	NNP
cord-014712-5u4e00q6	1704	11	,	,	,
cord-014712-5u4e00q6	1704	12	Adapazarı	Adapazarı	NNP
cord-014712-5u4e00q6	1704	13	,	,	,
cord-014712-5u4e00q6	1704	14	Türkiye	Türkiye	NNP
cord-014712-5u4e00q6	1704	15	.	.	.
cord-014712-5u4e00q6	1705	1	Background	background	NN
cord-014712-5u4e00q6	1705	2	:	:	:
cord-014712-5u4e00q6	1706	1	The	the	DT
cord-014712-5u4e00q6	1706	2	acquisition	acquisition	NN
cord-014712-5u4e00q6	1706	3	of	of	IN
cord-014712-5u4e00q6	1706	4	new	new	JJ
cord-014712-5u4e00q6	1706	5	food	food	NN
cord-014712-5u4e00q6	1706	6	allergy	allergy	NN
cord-014712-5u4e00q6	1706	7	after	after	IN
cord-014712-5u4e00q6	1706	8	transplantation	transplantation	NN
cord-014712-5u4e00q6	1706	9	or	or	CC
cord-014712-5u4e00q6	1706	10	transplant	transplant	NN
cord-014712-5u4e00q6	1706	11	-	-	HYPH
cord-014712-5u4e00q6	1706	12	acquired	acquire	VBN
cord-014712-5u4e00q6	1706	13	food	food	NN
cord-014712-5u4e00q6	1706	14	allergy	allergy	NN
cord-014712-5u4e00q6	1706	15	(	(	-LRB-
cord-014712-5u4e00q6	1706	16	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1706	17	)	)	-RRB-
cord-014712-5u4e00q6	1706	18	is	be	VBZ
cord-014712-5u4e00q6	1706	19	usually	usually	RB
cord-014712-5u4e00q6	1706	20	reported	report	VBN
cord-014712-5u4e00q6	1706	21	in	in	IN
cord-014712-5u4e00q6	1706	22	adults	adult	NNS
cord-014712-5u4e00q6	1706	23	and	and	CC
cord-014712-5u4e00q6	1706	24	rarely	rarely	RB
cord-014712-5u4e00q6	1706	25	in	in	IN
cord-014712-5u4e00q6	1706	26	children	child	NNS
cord-014712-5u4e00q6	1706	27	.	.	.
cord-014712-5u4e00q6	1707	1	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1707	2	is	be	VBZ
cord-014712-5u4e00q6	1707	3	described	describe	VBN
cord-014712-5u4e00q6	1707	4	mainly	mainly	RB
cord-014712-5u4e00q6	1707	5	after	after	IN
cord-014712-5u4e00q6	1707	6	liver	liver	NN
cord-014712-5u4e00q6	1707	7	,	,	,
cord-014712-5u4e00q6	1707	8	but	but	CC
cord-014712-5u4e00q6	1707	9	also	also	RB
cord-014712-5u4e00q6	1707	10	after	after	IN
cord-014712-5u4e00q6	1707	11	small	small	JJ
cord-014712-5u4e00q6	1707	12	bowel	bowel	NN
cord-014712-5u4e00q6	1707	13	/	/	SYM
cord-014712-5u4e00q6	1707	14	intestinal	intestinal	JJ
cord-014712-5u4e00q6	1707	15	,	,	,
cord-014712-5u4e00q6	1707	16	lung	lung	NN
cord-014712-5u4e00q6	1707	17	and	and	CC
cord-014712-5u4e00q6	1707	18	heart	heart	NN
cord-014712-5u4e00q6	1707	19	transplantations	transplantation	NNS
cord-014712-5u4e00q6	1707	20	.	.	.
cord-014712-5u4e00q6	1708	1	In	in	IN
cord-014712-5u4e00q6	1708	2	different	different	JJ
cord-014712-5u4e00q6	1708	3	studies	study	NNS
cord-014712-5u4e00q6	1708	4	,	,	,
cord-014712-5u4e00q6	1708	5	the	the	DT
cord-014712-5u4e00q6	1708	6	male	male	JJ
cord-014712-5u4e00q6	1708	7	/	/	SYM
cord-014712-5u4e00q6	1708	8	female	female	JJ
cord-014712-5u4e00q6	1708	9	ratio	ratio	NN
cord-014712-5u4e00q6	1708	10	is	be	VBZ
cord-014712-5u4e00q6	1708	11	equal	equal	JJ
cord-014712-5u4e00q6	1708	12	.	.	.
cord-014712-5u4e00q6	1709	1	Literature	literature	NN
cord-014712-5u4e00q6	1709	2	data	datum	NNS
cord-014712-5u4e00q6	1709	3	suggest	suggest	VBP
cord-014712-5u4e00q6	1709	4	that	that	IN
cord-014712-5u4e00q6	1709	5	children	child	NNS
cord-014712-5u4e00q6	1709	6	with	with	IN
cord-014712-5u4e00q6	1709	7	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1709	8	typically	typically	RB
cord-014712-5u4e00q6	1709	9	present	present	VBP
cord-014712-5u4e00q6	1709	10	within	within	IN
cord-014712-5u4e00q6	1709	11	the	the	DT
cord-014712-5u4e00q6	1709	12	first	first	JJ
cord-014712-5u4e00q6	1709	13	year	year	NN
cord-014712-5u4e00q6	1709	14	after	after	IN
cord-014712-5u4e00q6	1709	15	surgery	surgery	NN
cord-014712-5u4e00q6	1710	1	and	and	CC
cord-014712-5u4e00q6	1710	2	they	-PRON-	PRP
cord-014712-5u4e00q6	1710	3	are	be	VBP
cord-014712-5u4e00q6	1710	4	typically	typically	RB
cord-014712-5u4e00q6	1710	5	allergic	allergic	JJ
cord-014712-5u4e00q6	1710	6	to	to	IN
cord-014712-5u4e00q6	1710	7	multiple	multiple	JJ
cord-014712-5u4e00q6	1710	8	foods	food	NNS
cord-014712-5u4e00q6	1710	9	.	.	.
cord-014712-5u4e00q6	1711	1	Aim	aim	VB
cord-014712-5u4e00q6	1711	2	:	:	:
cord-014712-5u4e00q6	1712	1	TAFA	TAFA	NNP
cord-014712-5u4e00q6	1712	2	is	be	VBZ
cord-014712-5u4e00q6	1712	3	generally	generally	RB
cord-014712-5u4e00q6	1712	4	characterized	characterize	VBN
cord-014712-5u4e00q6	1712	5	with	with	IN
cord-014712-5u4e00q6	1712	6	allergy	allergy	NN
cord-014712-5u4e00q6	1712	7	to	to	IN
cord-014712-5u4e00q6	1712	8	multiple	multiple	JJ
cord-014712-5u4e00q6	1712	9	foods	food	NNS
cord-014712-5u4e00q6	1712	10	and	and	CC
cord-014712-5u4e00q6	1712	11	increased	increase	VBN
cord-014712-5u4e00q6	1712	12	level	level	NN
cord-014712-5u4e00q6	1712	13	of	of	IN
cord-014712-5u4e00q6	1712	14	total	total	NN
cord-014712-5u4e00q6	1712	15	and/or	and/or	CC
cord-014712-5u4e00q6	1712	16	spesific	spesific	JJ
cord-014712-5u4e00q6	1712	17	IgE.	ige.	NN
cord-014712-5u4e00q6	1713	1	Here	here	RB
cord-014712-5u4e00q6	1713	2	,	,	,
cord-014712-5u4e00q6	1713	3	a	a	DT
cord-014712-5u4e00q6	1713	4	patient	patient	NN
cord-014712-5u4e00q6	1714	1	although	although	IN
cord-014712-5u4e00q6	1714	2	who	who	WP
cord-014712-5u4e00q6	1714	3	had	have	VBD
cord-014712-5u4e00q6	1714	4	normal	normal	JJ
cord-014712-5u4e00q6	1714	5	total	total	NN
cord-014712-5u4e00q6	1714	6	.	.	.
cord-014712-5u4e00q6	1715	1	IgE	IgE	NNP
cord-014712-5u4e00q6	1715	2	and	and	CC
cord-014712-5u4e00q6	1715	3	specific	specific	NNP
cord-014712-5u4e00q6	1715	4	IgE	IgE	NNP
cord-014712-5u4e00q6	1715	5	test	test	NN
cord-014712-5u4e00q6	1715	6	results	result	NNS
cord-014712-5u4e00q6	1715	7	,	,	,
cord-014712-5u4e00q6	1715	8	he	-PRON-	PRP
cord-014712-5u4e00q6	1715	9	developed	develop	VBD
cord-014712-5u4e00q6	1715	10	reaction	reaction	NN
cord-014712-5u4e00q6	1715	11	to	to	IN
cord-014712-5u4e00q6	1715	12	skin	skin	NN
cord-014712-5u4e00q6	1715	13	prick	prick	NN
cord-014712-5u4e00q6	1715	14	test	test	NN
cord-014712-5u4e00q6	1715	15	for	for	IN
cord-014712-5u4e00q6	1715	16	cow	cow	NN
cord-014712-5u4e00q6	1715	17	's	's	POS
cord-014712-5u4e00q6	1715	18	milk	milk	NN
cord-014712-5u4e00q6	1715	19	is	be	VBZ
cord-014712-5u4e00q6	1715	20	presented	present	VBN
cord-014712-5u4e00q6	1715	21	and	and	CC
cord-014712-5u4e00q6	1715	22	his	-PRON-	PRP$
cord-014712-5u4e00q6	1715	23	clinical	clinical	JJ
cord-014712-5u4e00q6	1715	24	presentation	presentation	NN
cord-014712-5u4e00q6	1715	25	will	will	MD
cord-014712-5u4e00q6	1715	26	be	be	VB
cord-014712-5u4e00q6	1715	27	discussed	discuss	VBN
cord-014712-5u4e00q6	1715	28	.	.	.
cord-014712-5u4e00q6	1716	1	Case	case	NN
cord-014712-5u4e00q6	1716	2	presentation	presentation	NN
cord-014712-5u4e00q6	1716	3	:	:	:
cord-014712-5u4e00q6	1717	1	15	15	CD
cord-014712-5u4e00q6	1717	2	month	month	NN
cord-014712-5u4e00q6	1717	3	-	-	HYPH
cord-014712-5u4e00q6	1717	4	old	old	JJ
cord-014712-5u4e00q6	1717	5	-	-	HYPH
cord-014712-5u4e00q6	1717	6	boy	boy	NN
cord-014712-5u4e00q6	1717	7	came	come	VBD
cord-014712-5u4e00q6	1717	8	to	to	IN
cord-014712-5u4e00q6	1717	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	1717	10	allergy	allergy	NN
cord-014712-5u4e00q6	1717	11	clinic	clinic	NN
cord-014712-5u4e00q6	1717	12	with	with	IN
cord-014712-5u4e00q6	1717	13	complaints	complaint	NNS
cord-014712-5u4e00q6	1717	14	of	of	IN
cord-014712-5u4e00q6	1717	15	vomiting	vomit	VBG
cord-014712-5u4e00q6	1717	16	after	after	IN
cord-014712-5u4e00q6	1717	17	drinking	drink	VBG
cord-014712-5u4e00q6	1717	18	cow	cow	NN
cord-014712-5u4e00q6	1717	19	's	's	POS
cord-014712-5u4e00q6	1717	20	milk	milk	NN
cord-014712-5u4e00q6	1717	21	and	and	CC
cord-014712-5u4e00q6	1717	22	skin	skin	NN
cord-014712-5u4e00q6	1717	23	rush	rush	NN
cord-014712-5u4e00q6	1717	24	on	on	IN
cord-014712-5u4e00q6	1717	25	the	the	DT
cord-014712-5u4e00q6	1717	26	area	area	NN
cord-014712-5u4e00q6	1717	27	where	where	WRB
cord-014712-5u4e00q6	1717	28	contact	contact	NN
cord-014712-5u4e00q6	1717	29	ed	ed	NN
cord-014712-5u4e00q6	1717	30	with	with	IN
cord-014712-5u4e00q6	1717	31	chocolate	chocolate	NN
cord-014712-5u4e00q6	1717	32	.	.	.
cord-014712-5u4e00q6	1718	1	In	in	IN
cord-014712-5u4e00q6	1718	2	his	-PRON-	PRP$
cord-014712-5u4e00q6	1718	3	past	past	JJ
cord-014712-5u4e00q6	1718	4	medical	medical	JJ
cord-014712-5u4e00q6	1718	5	histroy	histroy	NN
cord-014712-5u4e00q6	1718	6	,	,	,
cord-014712-5u4e00q6	1718	7	left	leave	VBD
cord-014712-5u4e00q6	1718	8	lateral	lateral	JJ
cord-014712-5u4e00q6	1718	9	segment	segment	NN
cord-014712-5u4e00q6	1718	10	of	of	IN
cord-014712-5u4e00q6	1718	11	liver	liver	NN
cord-014712-5u4e00q6	1718	12	(	(	-LRB-
cord-014712-5u4e00q6	1718	13	donor	donor	NN
cord-014712-5u4e00q6	1718	14	was	be	VBD
cord-014712-5u4e00q6	1718	15	his	-PRON-	PRP$
cord-014712-5u4e00q6	1718	16	mother	mother	NN
cord-014712-5u4e00q6	1718	17	)	)	-RRB-
cord-014712-5u4e00q6	1718	18	was	be	VBD
cord-014712-5u4e00q6	1718	19	transplanted	transplant	VBN
cord-014712-5u4e00q6	1718	20	to	to	IN
cord-014712-5u4e00q6	1718	21	him	-PRON-	PRP
cord-014712-5u4e00q6	1718	22	when	when	WRB
cord-014712-5u4e00q6	1718	23	he	-PRON-	PRP
cord-014712-5u4e00q6	1718	24	was	be	VBD
cord-014712-5u4e00q6	1718	25	at	at	IN
cord-014712-5u4e00q6	1718	26	5	5	CD
cord-014712-5u4e00q6	1718	27	months	month	NNS
cord-014712-5u4e00q6	1718	28	.	.	.
cord-014712-5u4e00q6	1719	1	The	the	DT
cord-014712-5u4e00q6	1719	2	liver	liver	NN
cord-014712-5u4e00q6	1719	3	donor	donor	NN
cord-014712-5u4e00q6	1719	4	was	be	VBD
cord-014712-5u4e00q6	1719	5	not	not	RB
cord-014712-5u4e00q6	1719	6	recorded	record	VBN
cord-014712-5u4e00q6	1719	7	as	as	IN
cord-014712-5u4e00q6	1719	8	having	have	VBG
cord-014712-5u4e00q6	1719	9	a	a	DT
cord-014712-5u4e00q6	1719	10	history	history	NN
cord-014712-5u4e00q6	1719	11	of	of	IN
cord-014712-5u4e00q6	1719	12	allergic	allergic	JJ
cord-014712-5u4e00q6	1719	13	disease	disease	NN
cord-014712-5u4e00q6	1719	14	.	.	.
cord-014712-5u4e00q6	1720	1	Methylprednisolone	Methylprednisolone	NNP
cord-014712-5u4e00q6	1720	2	and	and	CC
cord-014712-5u4e00q6	1720	3	tacrolimus	tacrolimus	NN
cord-014712-5u4e00q6	1720	4	immunosuppression	immunosuppression	NN
cord-014712-5u4e00q6	1720	5	were	be	VBD
cord-014712-5u4e00q6	1720	6	used	use	VBN
cord-014712-5u4e00q6	1720	7	after	after	IN
cord-014712-5u4e00q6	1720	8	the	the	DT
cord-014712-5u4e00q6	1720	9	transplantation	transplantation	NN
cord-014712-5u4e00q6	1720	10	,	,	,
cord-014712-5u4e00q6	1720	11	and	and	CC
cord-014712-5u4e00q6	1720	12	tacrolimus	tacrolimus	NN
cord-014712-5u4e00q6	1720	13	therapy	therapy	NN
cord-014712-5u4e00q6	1720	14	was	be	VBD
cord-014712-5u4e00q6	1720	15	continued	continue	VBN
cord-014712-5u4e00q6	1720	16	for	for	IN
cord-014712-5u4e00q6	1720	17	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	1720	18	of	of	IN
cord-014712-5u4e00q6	1720	19	chronic	chronic	JJ
cord-014712-5u4e00q6	1720	20	rejection	rejection	NN
cord-014712-5u4e00q6	1720	21	.	.	.
cord-014712-5u4e00q6	1721	1	When	when	WRB
cord-014712-5u4e00q6	1721	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1721	3	was	be	VBD
cord-014712-5u4e00q6	1721	4	at	at	IN
cord-014712-5u4e00q6	1721	5	7	7	CD
cord-014712-5u4e00q6	1721	6	months	month	NNS
cord-014712-5u4e00q6	1721	7	,	,	,
cord-014712-5u4e00q6	1721	8	family	family	NN
cord-014712-5u4e00q6	1721	9	fed	feed	VBD
cord-014712-5u4e00q6	1721	10	the	the	DT
cord-014712-5u4e00q6	1721	11	patient	patient	NN
cord-014712-5u4e00q6	1721	12	with	with	IN
cord-014712-5u4e00q6	1721	13	cow	cow	NN
cord-014712-5u4e00q6	1721	14	's	's	POS
cord-014712-5u4e00q6	1721	15	milk	milk	NN
cord-014712-5u4e00q6	1721	16	but	but	CC
cord-014712-5u4e00q6	1721	17	3	3	CD
cord-014712-5u4e00q6	1721	18	hours	hour	NNS
cord-014712-5u4e00q6	1721	19	later	later	RBR
cord-014712-5u4e00q6	1721	20	he	-PRON-	PRP
cord-014712-5u4e00q6	1721	21	began	begin	VBD
cord-014712-5u4e00q6	1721	22	to	to	TO
cord-014712-5u4e00q6	1721	23	vomit	vomit	VB
cord-014712-5u4e00q6	1721	24	.	.	.
cord-014712-5u4e00q6	1722	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1722	2	vomited	vomit	VBD
cord-014712-5u4e00q6	1722	3	five	five	CD
cord-014712-5u4e00q6	1722	4	times	time	NNS
cord-014712-5u4e00q6	1722	5	in	in	IN
cord-014712-5u4e00q6	1722	6	two	two	CD
cord-014712-5u4e00q6	1722	7	hours	hour	NNS
cord-014712-5u4e00q6	1722	8	.	.	.
cord-014712-5u4e00q6	1723	1	Then	then	RB
cord-014712-5u4e00q6	1723	2	,	,	,
cord-014712-5u4e00q6	1723	3	he	-PRON-	PRP
cord-014712-5u4e00q6	1723	4	developed	develop	VBD
cord-014712-5u4e00q6	1723	5	constipation	constipation	NN
cord-014712-5u4e00q6	1723	6	.	.	.
cord-014712-5u4e00q6	1724	1	Rectal	rectal	JJ
cord-014712-5u4e00q6	1724	2	irrigation	irrigation	NN
cord-014712-5u4e00q6	1724	3	was	be	VBD
cord-014712-5u4e00q6	1724	4	used	use	VBN
cord-014712-5u4e00q6	1724	5	.	.	.
cord-014712-5u4e00q6	1725	1	Then	then	RB
cord-014712-5u4e00q6	1725	2	oral	oral	JJ
cord-014712-5u4e00q6	1725	3	intake	intake	NN
cord-014712-5u4e00q6	1725	4	stopped	stop	VBD
cord-014712-5u4e00q6	1725	5	for	for	IN
cord-014712-5u4e00q6	1725	6	two	two	CD
cord-014712-5u4e00q6	1725	7	days	day	NNS
cord-014712-5u4e00q6	1725	8	.	.	.
cord-014712-5u4e00q6	1726	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1726	2	was	be	VBD
cord-014712-5u4e00q6	1726	3	thought	think	VBN
cord-014712-5u4e00q6	1726	4	to	to	TO
cord-014712-5u4e00q6	1726	5	be	be	VB
cord-014712-5u4e00q6	1726	6	having	have	VBG
cord-014712-5u4e00q6	1726	7	food	food	NN
cord-014712-5u4e00q6	1726	8	protein	protein	NN
cord-014712-5u4e00q6	1726	9	induced	induce	VBN
cord-014712-5u4e00q6	1726	10	enterocolitis	enterocolitis	NN
cord-014712-5u4e00q6	1726	11	.	.	.
cord-014712-5u4e00q6	1727	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1727	2	vomiting	vomiting	NN
cord-014712-5u4e00q6	1727	3	complaints	complaint	NNS
cord-014712-5u4e00q6	1727	4	repeated	repeat	VBN
cord-014712-5u4e00q6	1727	5	after	after	IN
cord-014712-5u4e00q6	1727	6	intake	intake	NN
cord-014712-5u4e00q6	1727	7	of	of	IN
cord-014712-5u4e00q6	1727	8	formula	formula	NN
cord-014712-5u4e00q6	1727	9	and	and	CC
cord-014712-5u4e00q6	1727	10	baby	baby	NN
cord-014712-5u4e00q6	1727	11	food	food	NN
cord-014712-5u4e00q6	1727	12	which	which	WDT
cord-014712-5u4e00q6	1727	13	include	include	VBP
cord-014712-5u4e00q6	1727	14	grain	grain	NN
cord-014712-5u4e00q6	1727	15	.	.	.
cord-014712-5u4e00q6	1728	1	So	so	RB
cord-014712-5u4e00q6	1728	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1728	3	fed	feed	VBD
cord-014712-5u4e00q6	1728	4	with	with	IN
cord-014712-5u4e00q6	1728	5	special	special	JJ
cord-014712-5u4e00q6	1728	6	formula	formula	NN
cord-014712-5u4e00q6	1728	7	including	include	VBG
cord-014712-5u4e00q6	1728	8	short	short	JJ
cord-014712-5u4e00q6	1728	9	-	-	HYPH
cord-014712-5u4e00q6	1728	10	chain	chain	NN
cord-014712-5u4e00q6	1728	11	peptides	peptide	NNS
cord-014712-5u4e00q6	1728	12	and	and	CC
cord-014712-5u4e00q6	1728	13	free	free	JJ
cord-014712-5u4e00q6	1728	14	aminoacids	aminoacid	NNS
cord-014712-5u4e00q6	1728	15	and	and	CC
cord-014712-5u4e00q6	1728	16	his	-PRON-	PRP$
cord-014712-5u4e00q6	1728	17	symptoms	symptom	NNS
cord-014712-5u4e00q6	1728	18	improved	improve	VBD
cord-014712-5u4e00q6	1728	19	.	.	.
cord-014712-5u4e00q6	1729	1	Past	past	JJ
cord-014712-5u4e00q6	1729	2	medical	medical	JJ
cord-014712-5u4e00q6	1729	3	history	history	NN
cord-014712-5u4e00q6	1729	4	:	:	:
cord-014712-5u4e00q6	1729	5	Extrahepatic	extrahepatic	JJ
cord-014712-5u4e00q6	1729	6	biliary	biliary	JJ
cord-014712-5u4e00q6	1729	7	atresia	atresia	NN
cord-014712-5u4e00q6	1729	8	was	be	VBD
cord-014712-5u4e00q6	1729	9	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1729	10	at	at	IN
cord-014712-5u4e00q6	1729	11	3	3	CD
cord-014712-5u4e00q6	1729	12	weeks	week	NNS
cord-014712-5u4e00q6	1729	13	age	age	NN
cord-014712-5u4e00q6	1729	14	with	with	IN
cord-014712-5u4e00q6	1729	15	conjugated	conjugate	VBN
cord-014712-5u4e00q6	1729	16	hyperbilirubinemia	hyperbilirubinemia	NNP
cord-014712-5u4e00q6	1729	17	(	(	-LRB-
cord-014712-5u4e00q6	1729	18	according	accord	VBG
cord-014712-5u4e00q6	1729	19	to	to	IN
cord-014712-5u4e00q6	1729	20	scintigraphy	scintigraphy	NN
cord-014712-5u4e00q6	1729	21	and	and	CC
cord-014712-5u4e00q6	1729	22	biopsy	biopsy	NN
cord-014712-5u4e00q6	1729	23	results	result	NNS
cord-014712-5u4e00q6	1729	24	)	)	-RRB-
cord-014712-5u4e00q6	1729	25	.	.	.
cord-014712-5u4e00q6	1730	1	Family	family	NN
cord-014712-5u4e00q6	1730	2	history	history	NN
cord-014712-5u4e00q6	1730	3	:	:	:
cord-014712-5u4e00q6	1731	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1731	2	father	father	NN
cord-014712-5u4e00q6	1731	3	has	have	VBZ
cord-014712-5u4e00q6	1731	4	penicillin	penicillin	NN
cord-014712-5u4e00q6	1731	5	allergy	allergy	NN
cord-014712-5u4e00q6	1731	6	and	and	CC
cord-014712-5u4e00q6	1731	7	his	-PRON-	PRP$
cord-014712-5u4e00q6	1731	8	aunt	aunt	NN
cord-014712-5u4e00q6	1731	9	has	have	VBZ
cord-014712-5u4e00q6	1731	10	asthma	asthma	NN
cord-014712-5u4e00q6	1731	11	.	.	.
cord-014712-5u4e00q6	1732	1	At	at	IN
cord-014712-5u4e00q6	1732	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	1732	3	outpatient	outpatient	NN
cord-014712-5u4e00q6	1732	4	clinic	clinic	NN
cord-014712-5u4e00q6	1732	5	:	:	:
cord-014712-5u4e00q6	1732	6	Height	height	NN
cord-014712-5u4e00q6	1732	7	and	and	CC
cord-014712-5u4e00q6	1732	8	weight	weight	NN
cord-014712-5u4e00q6	1732	9	were	be	VBD
cord-014712-5u4e00q6	1732	10	within	within	IN
cord-014712-5u4e00q6	1732	11	normal	normal	JJ
cord-014712-5u4e00q6	1732	12	percentiles	percentile	NNS
cord-014712-5u4e00q6	1732	13	.	.	.
cord-014712-5u4e00q6	1733	1	Physical	physical	JJ
cord-014712-5u4e00q6	1733	2	examination	examination	NN
cord-014712-5u4e00q6	1733	3	reevaled	reevale	VBD
cord-014712-5u4e00q6	1733	4	normal	normal	JJ
cord-014712-5u4e00q6	1733	5	examination	examination	NN
cord-014712-5u4e00q6	1733	6	findings	finding	NNS
cord-014712-5u4e00q6	1733	7	.	.	.
cord-014712-5u4e00q6	1734	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1734	2	findings	finding	NNS
cord-014712-5u4e00q6	1734	3	:	:	:
cord-014712-5u4e00q6	1735	1	WBC	WBC	NNP
cord-014712-5u4e00q6	1735	2	was	be	VBD
cord-014712-5u4e00q6	1735	3	4.420	4.420	CD
cord-014712-5u4e00q6	1735	4	/	/	SYM
cord-014712-5u4e00q6	1735	5	mm	mm	NNP
cord-014712-5u4e00q6	1735	6	3	3	CD
cord-014712-5u4e00q6	1735	7	,	,	,
cord-014712-5u4e00q6	1735	8	with	with	IN
cord-014712-5u4e00q6	1735	9	21	21	CD
cord-014712-5u4e00q6	1735	10	%	%	NN
cord-014712-5u4e00q6	1735	11	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	1735	12	,	,	,
cord-014712-5u4e00q6	1735	13	6	6	CD
cord-014712-5u4e00q6	1735	14	%	%	NN
cord-014712-5u4e00q6	1735	15	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	1735	16	and	and	CC
cord-014712-5u4e00q6	1735	17	69	69	CD
cord-014712-5u4e00q6	1735	18	%	%	NN
cord-014712-5u4e00q6	1735	19	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1735	20	.	.	.
cord-014712-5u4e00q6	1736	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	1736	2	hemoglobin	hemoglobin	NN
cord-014712-5u4e00q6	1736	3	was	be	VBD
cord-014712-5u4e00q6	1736	4	8.2	8.2	CD
cord-014712-5u4e00q6	1736	5	g/	g/	JJ
cord-014712-5u4e00q6	1736	6	dL	dl	NN
cord-014712-5u4e00q6	1736	7	,	,	,
cord-014712-5u4e00q6	1736	8	platelet	platelet	NN
cord-014712-5u4e00q6	1736	9	count	count	NN
cord-014712-5u4e00q6	1736	10	was	be	VBD
cord-014712-5u4e00q6	1736	11	280.000	280.000	CD
cord-014712-5u4e00q6	1736	12	/	/	SYM
cord-014712-5u4e00q6	1736	13	mm	mm	NN
cord-014712-5u4e00q6	1736	14	3	3	CD
cord-014712-5u4e00q6	1736	15	.	.	.
cord-014712-5u4e00q6	1737	1	Background	background	NN
cord-014712-5u4e00q6	1737	2	:	:	:
cord-014712-5u4e00q6	1738	1	Except	except	IN
cord-014712-5u4e00q6	1738	2	for	for	IN
cord-014712-5u4e00q6	1738	3	antibody	antibody	NN
cord-014712-5u4e00q6	1738	4	deficiency	deficiency	NN
cord-014712-5u4e00q6	1738	5	and	and	CC
cord-014712-5u4e00q6	1738	6	complement	complement	VB
cord-014712-5u4e00q6	1738	7	defects	defect	NNS
cord-014712-5u4e00q6	1738	8	,	,	,
cord-014712-5u4e00q6	1738	9	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	1738	10	stem	stem	NN
cord-014712-5u4e00q6	1738	11	cell	cell	NN
cord-014712-5u4e00q6	1738	12	transplantation	transplantation	NN
cord-014712-5u4e00q6	1738	13	(	(	-LRB-
cord-014712-5u4e00q6	1738	14	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1738	15	)	)	-RRB-
cord-014712-5u4e00q6	1738	16	is	be	VBZ
cord-014712-5u4e00q6	1738	17	the	the	DT
cord-014712-5u4e00q6	1738	18	single	single	JJ
cord-014712-5u4e00q6	1738	19	best	good	JJS
cord-014712-5u4e00q6	1738	20	curative	curative	JJ
cord-014712-5u4e00q6	1738	21	treatment	treatment	NN
cord-014712-5u4e00q6	1738	22	defined	define	VBN
cord-014712-5u4e00q6	1738	23	for	for	IN
cord-014712-5u4e00q6	1738	24	Primary	primary	JJ
cord-014712-5u4e00q6	1738	25	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1738	26	(	(	-LRB-
cord-014712-5u4e00q6	1738	27	PID	PID	NNP
cord-014712-5u4e00q6	1738	28	)	)	-RRB-
cord-014712-5u4e00q6	1738	29	so	so	RB
cord-014712-5u4e00q6	1738	30	far	far	RB
cord-014712-5u4e00q6	1738	31	.	.	.
cord-014712-5u4e00q6	1739	1	In	in	IN
cord-014712-5u4e00q6	1739	2	the	the	DT
cord-014712-5u4e00q6	1739	3	current	current	JJ
cord-014712-5u4e00q6	1739	4	study	study	NN
cord-014712-5u4e00q6	1739	5	,	,	,
cord-014712-5u4e00q6	1739	6	we	-PRON-	PRP
cord-014712-5u4e00q6	1739	7	aimed	aim	VBD
cord-014712-5u4e00q6	1739	8	to	to	TO
cord-014712-5u4e00q6	1739	9	assess	assess	VB
cord-014712-5u4e00q6	1739	10	the	the	DT
cord-014712-5u4e00q6	1739	11	role	role	NN
cord-014712-5u4e00q6	1739	12	of	of	IN
cord-014712-5u4e00q6	1739	13	PID	PID	NNP
cord-014712-5u4e00q6	1739	14	type	type	NN
cord-014712-5u4e00q6	1739	15	,	,	,
cord-014712-5u4e00q6	1739	16	donor	donor	NN
cord-014712-5u4e00q6	1739	17	type	type	NN
cord-014712-5u4e00q6	1739	18	and	and	CC
cord-014712-5u4e00q6	1739	19	clinical	clinical	JJ
cord-014712-5u4e00q6	1739	20	status	status	NN
cord-014712-5u4e00q6	1739	21	on	on	IN
cord-014712-5u4e00q6	1739	22	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1739	23	success	success	NN
cord-014712-5u4e00q6	1739	24	rates	rate	NNS
cord-014712-5u4e00q6	1739	25	.	.	.
cord-014712-5u4e00q6	1740	1	Materials	material	NNS
cord-014712-5u4e00q6	1740	2	and	and	CC
cord-014712-5u4e00q6	1740	3	Methods	method	NNS
cord-014712-5u4e00q6	1740	4	:	:	:
cord-014712-5u4e00q6	1740	5	We	-PRON-	PRP
cord-014712-5u4e00q6	1740	6	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	1740	7	reviewed	review	VBD
cord-014712-5u4e00q6	1740	8	the	the	DT
cord-014712-5u4e00q6	1740	9	records	record	NNS
cord-014712-5u4e00q6	1740	10	of	of	IN
cord-014712-5u4e00q6	1740	11	a	a	DT
cord-014712-5u4e00q6	1740	12	total	total	NN
cord-014712-5u4e00q6	1740	13	of	of	IN
cord-014712-5u4e00q6	1740	14	91	91	CD
cord-014712-5u4e00q6	1740	15	HSCTs	HSCTs	NNP
cord-014712-5u4e00q6	1740	16	procedures	procedure	NNS
cord-014712-5u4e00q6	1740	17	performed	perform	VBN
cord-014712-5u4e00q6	1740	18	in	in	IN
cord-014712-5u4e00q6	1740	19	68	68	CD
cord-014712-5u4e00q6	1740	20	patients	patient	NNS
cord-014712-5u4e00q6	1740	21	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1740	22	with	with	IN
cord-014712-5u4e00q6	1740	23	PID	PID	NNP
cord-014712-5u4e00q6	1740	24	between	between	IN
cord-014712-5u4e00q6	1740	25	1997	1997	CD
cord-014712-5u4e00q6	1740	26	and	and	CC
cord-014712-5u4e00q6	1740	27	2013	2013	CD
cord-014712-5u4e00q6	1740	28	,	,	,
cord-014712-5u4e00q6	1740	29	in	in	IN
cord-014712-5u4e00q6	1740	30	Ankara	Ankara	NNP
cord-014712-5u4e00q6	1740	31	University	University	NNP
cord-014712-5u4e00q6	1740	32	Pediatric	Pediatric	NNP
cord-014712-5u4e00q6	1740	33	Allergy	Allergy	NNP
cord-014712-5u4e00q6	1740	34	and	and	CC
cord-014712-5u4e00q6	1740	35	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1740	36	Department	Department	NNP
cord-014712-5u4e00q6	1740	37	.	.	.
cord-014712-5u4e00q6	1741	1	Results	result	NNS
cord-014712-5u4e00q6	1741	2	:	:	:
cord-014712-5u4e00q6	1742	1	Of	of	IN
cord-014712-5u4e00q6	1742	2	the	the	DT
cord-014712-5u4e00q6	1742	3	68	68	CD
cord-014712-5u4e00q6	1742	4	patients	patient	NNS
cord-014712-5u4e00q6	1742	5	,	,	,
cord-014712-5u4e00q6	1742	6	40	40	CD
cord-014712-5u4e00q6	1742	7	had	have	VBD
cord-014712-5u4e00q6	1742	8	severe	severe	JJ
cord-014712-5u4e00q6	1742	9	combined	combine	VBN
cord-014712-5u4e00q6	1742	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1742	11	(	(	-LRB-
cord-014712-5u4e00q6	1742	12	SCID	SCID	NNP
cord-014712-5u4e00q6	1742	13	)	)	-RRB-
cord-014712-5u4e00q6	1742	14	and	and	CC
cord-014712-5u4e00q6	1742	15	28	28	CD
cord-014712-5u4e00q6	1742	16	had	have	VBD
cord-014712-5u4e00q6	1742	17	non	non	JJ
cord-014712-5u4e00q6	1742	18	-	-	JJ
cord-014712-5u4e00q6	1742	19	SCID	scid	JJ
cord-014712-5u4e00q6	1742	20	.	.	.
cord-014712-5u4e00q6	1743	1	The	the	DT
cord-014712-5u4e00q6	1743	2	survival	survival	NN
cord-014712-5u4e00q6	1743	3	rates	rate	NNS
cord-014712-5u4e00q6	1743	4	following	follow	VBG
cord-014712-5u4e00q6	1743	5	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1743	6	,	,	,
cord-014712-5u4e00q6	1743	7	in	in	IN
cord-014712-5u4e00q6	1743	8	both	both	DT
cord-014712-5u4e00q6	1743	9	SCID	SCID	NNP
cord-014712-5u4e00q6	1743	10	and	and	CC
cord-014712-5u4e00q6	1743	11	non	non	JJ
cord-014712-5u4e00q6	1743	12	-	-	JJ
cord-014712-5u4e00q6	1743	13	SCID	scid	JJ
cord-014712-5u4e00q6	1743	14	patients	patient	NNS
cord-014712-5u4e00q6	1743	15	were	be	VBD
cord-014712-5u4e00q6	1743	16	75	75	CD
cord-014712-5u4e00q6	1743	17	%	%	NN
cord-014712-5u4e00q6	1743	18	.	.	.
cord-014712-5u4e00q6	1744	1	When	when	WRB
cord-014712-5u4e00q6	1744	2	classified	classify	VBN
cord-014712-5u4e00q6	1744	3	according	accord	VBG
cord-014712-5u4e00q6	1744	4	to	to	IN
cord-014712-5u4e00q6	1744	5	the	the	DT
cord-014712-5u4e00q6	1744	6	source	source	NN
cord-014712-5u4e00q6	1744	7	of	of	IN
cord-014712-5u4e00q6	1744	8	donor	donor	NN
cord-014712-5u4e00q6	1744	9	,	,	,
cord-014712-5u4e00q6	1744	10	patients	patient	NNS
cord-014712-5u4e00q6	1744	11	who	who	WP
cord-014712-5u4e00q6	1744	12	had	have	VBD
cord-014712-5u4e00q6	1744	13	a	a	DT
cord-014712-5u4e00q6	1744	14	HLA	HLA	NNP
cord-014712-5u4e00q6	1744	15	-	-	HYPH
cord-014712-5u4e00q6	1744	16	matched	match	VBN
cord-014712-5u4e00q6	1744	17	sibling	sibling	NN
cord-014712-5u4e00q6	1744	18	donor	donor	NN
cord-014712-5u4e00q6	1744	19	(	(	-LRB-
cord-014712-5u4e00q6	1744	20	MSD	MSD	NNP
cord-014712-5u4e00q6	1744	21	)	)	-RRB-
cord-014712-5u4e00q6	1744	22	in	in	IN
cord-014712-5u4e00q6	1744	23	the	the	DT
cord-014712-5u4e00q6	1744	24	SCID	SCID	NNP
cord-014712-5u4e00q6	1744	25	group	group	NN
cord-014712-5u4e00q6	1744	26	had	have	VBD
cord-014712-5u4e00q6	1744	27	90.9	90.9	CD
cord-014712-5u4e00q6	1744	28	%	%	NN
cord-014712-5u4e00q6	1744	29	survival	survival	NN
cord-014712-5u4e00q6	1744	30	rate	rate	NN
cord-014712-5u4e00q6	1744	31	post	post	NN
cord-014712-5u4e00q6	1744	32	transplantation	transplantation	NN
cord-014712-5u4e00q6	1744	33	,	,	,
cord-014712-5u4e00q6	1744	34	those	those	DT
cord-014712-5u4e00q6	1744	35	who	who	WP
cord-014712-5u4e00q6	1744	36	had	have	VBD
cord-014712-5u4e00q6	1744	37	a	a	DT
cord-014712-5u4e00q6	1744	38	matched	match	VBN
cord-014712-5u4e00q6	1744	39	related	related	JJ
cord-014712-5u4e00q6	1744	40	donor	donor	NN
cord-014712-5u4e00q6	1744	41	(	(	-LRB-
cord-014712-5u4e00q6	1744	42	MRD	MRD	NNP
cord-014712-5u4e00q6	1744	43	)	)	-RRB-
cord-014712-5u4e00q6	1744	44	had	have	VBD
cord-014712-5u4e00q6	1744	45	85.7	85.7	CD
cord-014712-5u4e00q6	1744	46	%	%	NN
cord-014712-5u4e00q6	1744	47	and	and	CC
cord-014712-5u4e00q6	1744	48	those	those	DT
cord-014712-5u4e00q6	1744	49	who	who	WP
cord-014712-5u4e00q6	1744	50	received	receive	VBD
cord-014712-5u4e00q6	1744	51	a	a	DT
cord-014712-5u4e00q6	1744	52	haploidentical	haploidentical	JJ
cord-014712-5u4e00q6	1744	53	donor	donor	NN
cord-014712-5u4e00q6	1744	54	had	have	VBD
cord-014712-5u4e00q6	1744	55	63.6	63.6	CD
cord-014712-5u4e00q6	1744	56	%	%	NN
cord-014712-5u4e00q6	1744	57	survival	survival	NN
cord-014712-5u4e00q6	1744	58	rates	rate	NNS
cord-014712-5u4e00q6	1744	59	.	.	.
cord-014712-5u4e00q6	1745	1	In	in	IN
cord-014712-5u4e00q6	1745	2	the	the	DT
cord-014712-5u4e00q6	1745	3	non	non	JJ
cord-014712-5u4e00q6	1745	4	-	-	JJ
cord-014712-5u4e00q6	1745	5	SCID	scid	JJ
cord-014712-5u4e00q6	1745	6	group	group	NN
cord-014712-5u4e00q6	1745	7	there	there	EX
cord-014712-5u4e00q6	1745	8	were	be	VBD
cord-014712-5u4e00q6	1745	9	3	3	CD
cord-014712-5u4e00q6	1745	10	patients	patient	NNS
cord-014712-5u4e00q6	1745	11	with	with	IN
cord-014712-5u4e00q6	1745	12	haploidentical	haploidentical	JJ
cord-014712-5u4e00q6	1745	13	transplants	transplant	NNS
cord-014712-5u4e00q6	1745	14	(	(	-LRB-
cord-014712-5u4e00q6	1745	15	2	2	CD
cord-014712-5u4e00q6	1745	16	Omenn	Omenn	NNP
cord-014712-5u4e00q6	1745	17	syndrome	syndrome	NN
cord-014712-5u4e00q6	1745	18	and	and	CC
cord-014712-5u4e00q6	1745	19	1	1	CD
cord-014712-5u4e00q6	1745	20	MHC	MHC	NNP
cord-014712-5u4e00q6	1745	21	Class	Class	NNP
cord-014712-5u4e00q6	1745	22	II	II	NNP
cord-014712-5u4e00q6	1745	23	deficiency	deficiency	NN
cord-014712-5u4e00q6	1745	24	)	)	-RRB-
cord-014712-5u4e00q6	1745	25	and	and	CC
cord-014712-5u4e00q6	1745	26	all	all	DT
cord-014712-5u4e00q6	1745	27	patients	patient	NNS
cord-014712-5u4e00q6	1745	28	died	die	VBD
cord-014712-5u4e00q6	1745	29	.	.	.
cord-014712-5u4e00q6	1746	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1746	2	assessed	assess	VBD
cord-014712-5u4e00q6	1746	3	several	several	JJ
cord-014712-5u4e00q6	1746	4	potential	potential	JJ
cord-014712-5u4e00q6	1746	5	risk	risk	NN
cord-014712-5u4e00q6	1746	6	factors	factor	NNS
cord-014712-5u4e00q6	1746	7	associated	associate	VBN
cord-014712-5u4e00q6	1746	8	with	with	IN
cord-014712-5u4e00q6	1746	9	survival	survival	NN
cord-014712-5u4e00q6	1746	10	in	in	IN
cord-014712-5u4e00q6	1746	11	SCID	SCID	NNP
cord-014712-5u4e00q6	1746	12	patients	patient	NNS
cord-014712-5u4e00q6	1746	13	.	.	.
cord-014712-5u4e00q6	1747	1	Patients	patient	NNS
cord-014712-5u4e00q6	1747	2	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1747	3	over	over	IN
cord-014712-5u4e00q6	1747	4	6	6	CD
cord-014712-5u4e00q6	1747	5	months	month	NNS
cord-014712-5u4e00q6	1747	6	of	of	IN
cord-014712-5u4e00q6	1747	7	age	age	NN
cord-014712-5u4e00q6	1747	8	with	with	IN
cord-014712-5u4e00q6	1747	9	a	a	DT
cord-014712-5u4e00q6	1747	10	pre	pre	JJ
cord-014712-5u4e00q6	1747	11	-	-	JJ
cord-014712-5u4e00q6	1747	12	existing	existing	JJ
cord-014712-5u4e00q6	1747	13	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	1747	14	infection	infection	NN
cord-014712-5u4e00q6	1747	15	,	,	,
cord-014712-5u4e00q6	1747	16	requiring	require	VBG
cord-014712-5u4e00q6	1747	17	intensive	intensive	JJ
cord-014712-5u4e00q6	1747	18	care	care	NN
cord-014712-5u4e00q6	1747	19	and/or	and/or	CC
cord-014712-5u4e00q6	1747	20	mechanical	mechanical	JJ
cord-014712-5u4e00q6	1747	21	ventilation	ventilation	NN
cord-014712-5u4e00q6	1747	22	had	have	VBD
cord-014712-5u4e00q6	1747	23	significantly	significantly	RB
cord-014712-5u4e00q6	1747	24	lower	low	JJR
cord-014712-5u4e00q6	1747	25	survival	survival	NN
cord-014712-5u4e00q6	1747	26	rates	rate	NNS
cord-014712-5u4e00q6	1747	27	.	.	.
cord-014712-5u4e00q6	1748	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1748	2	:	:	:
cord-014712-5u4e00q6	1748	3	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1748	4	is	be	VBZ
cord-014712-5u4e00q6	1748	5	the	the	DT
cord-014712-5u4e00q6	1748	6	best	good	JJS
cord-014712-5u4e00q6	1748	7	curative	curative	JJ
cord-014712-5u4e00q6	1748	8	treatment	treatment	NN
cord-014712-5u4e00q6	1748	9	for	for	IN
cord-014712-5u4e00q6	1748	10	PID	PID	NNP
cord-014712-5u4e00q6	1748	11	.	.	.
cord-014712-5u4e00q6	1749	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	1749	2	results	result	NNS
cord-014712-5u4e00q6	1749	3	demonstrated	demonstrate	VBD
cord-014712-5u4e00q6	1749	4	that	that	IN
cord-014712-5u4e00q6	1749	5	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1749	6	performed	perform	VBD
cord-014712-5u4e00q6	1749	7	from	from	IN
cord-014712-5u4e00q6	1749	8	matched	match	VBN
cord-014712-5u4e00q6	1749	9	family	family	NN
cord-014712-5u4e00q6	1749	10	donors	donor	NNS
cord-014712-5u4e00q6	1749	11	or	or	CC
cord-014712-5u4e00q6	1749	12	even	even	RB
cord-014712-5u4e00q6	1749	13	haploidentical	haploidentical	JJ
cord-014712-5u4e00q6	1749	14	parents	parent	NNS
cord-014712-5u4e00q6	1749	15	is	be	VBZ
cord-014712-5u4e00q6	1749	16	a	a	DT
cord-014712-5u4e00q6	1749	17	lifesaving	lifesaving	JJ
cord-014712-5u4e00q6	1749	18	treatment	treatment	NN
cord-014712-5u4e00q6	1749	19	in	in	IN
cord-014712-5u4e00q6	1749	20	various	various	JJ
cord-014712-5u4e00q6	1749	21	types	type	NNS
cord-014712-5u4e00q6	1749	22	of	of	IN
cord-014712-5u4e00q6	1749	23	PID	PID	NNP
cord-014712-5u4e00q6	1749	24	's	's	POS
cord-014712-5u4e00q6	1749	25	,	,	,
cord-014712-5u4e00q6	1749	26	especially	especially	RB
cord-014712-5u4e00q6	1749	27	in	in	IN
cord-014712-5u4e00q6	1749	28	SCID	SCID	NNP
cord-014712-5u4e00q6	1749	29	.	.	.
cord-014712-5u4e00q6	1750	1	Introduction	introduction	NN
cord-014712-5u4e00q6	1750	2	:	:	:
cord-014712-5u4e00q6	1751	1	In	in	IN
cord-014712-5u4e00q6	1751	2	case	case	NN
cord-014712-5u4e00q6	1751	3	of	of	IN
cord-014712-5u4e00q6	1751	4	donor	donor	NN
cord-014712-5u4e00q6	1751	5	availability	availability	NN
cord-014712-5u4e00q6	1751	6	allogeneic	allogeneic	IN
cord-014712-5u4e00q6	1751	7	hematopoietic	hematopoietic	JJ
cord-014712-5u4e00q6	1751	8	stem	stem	NN
cord-014712-5u4e00q6	1751	9	cell	cell	NN
cord-014712-5u4e00q6	1751	10	transplantation	transplantation	NN
cord-014712-5u4e00q6	1751	11	(	(	-LRB-
cord-014712-5u4e00q6	1751	12	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1751	13	)	)	-RRB-
cord-014712-5u4e00q6	1751	14	can	can	MD
cord-014712-5u4e00q6	1751	15	be	be	VB
cord-014712-5u4e00q6	1751	16	regarded	regard	VBN
cord-014712-5u4e00q6	1751	17	as	as	IN
cord-014712-5u4e00q6	1751	18	a	a	DT
cord-014712-5u4e00q6	1751	19	definitive	definitive	JJ
cord-014712-5u4e00q6	1751	20	therapy	therapy	NN
cord-014712-5u4e00q6	1751	21	for	for	IN
cord-014712-5u4e00q6	1751	22	a	a	DT
cord-014712-5u4e00q6	1751	23	variety	variety	NN
cord-014712-5u4e00q6	1751	24	of	of	IN
cord-014712-5u4e00q6	1751	25	primary	primary	JJ
cord-014712-5u4e00q6	1751	26	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1751	27	syndromes	syndrome	NNS
cord-014712-5u4e00q6	1751	28	(	(	-LRB-
cord-014712-5u4e00q6	1751	29	PIDs	PIDs	NNP
cord-014712-5u4e00q6	1751	30	)	)	-RRB-
cord-014712-5u4e00q6	1751	31	,	,	,
cord-014712-5u4e00q6	1751	32	including	include	VBG
cord-014712-5u4e00q6	1751	33	severe	severe	JJ
cord-014712-5u4e00q6	1751	34	combined	combine	VBN
cord-014712-5u4e00q6	1751	35	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1751	36	(	(	-LRB-
cord-014712-5u4e00q6	1751	37	SCID	SCID	NNP
cord-014712-5u4e00q6	1751	38	)	)	-RRB-
cord-014712-5u4e00q6	1751	39	and	and	CC
cord-014712-5u4e00q6	1751	40	non	non	JJ
cord-014712-5u4e00q6	1751	41	-	-	JJ
cord-014712-5u4e00q6	1751	42	SCID	scid	JJ
cord-014712-5u4e00q6	1751	43	PIDs	pid	NNS
cord-014712-5u4e00q6	1751	44	.	.	.
cord-014712-5u4e00q6	1752	1	Study	Study	NNP
cord-014712-5u4e00q6	1752	2	Period	Period	NNP
cord-014712-5u4e00q6	1752	3	:	:	:
cord-014712-5u4e00q6	1752	4	We	-PRON-	PRP
cord-014712-5u4e00q6	1752	5	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	1752	6	reviewed	review	VBD
cord-014712-5u4e00q6	1752	7	the	the	DT
cord-014712-5u4e00q6	1752	8	hospital	hospital	NN
cord-014712-5u4e00q6	1752	9	records	record	NNS
cord-014712-5u4e00q6	1752	10	of	of	IN
cord-014712-5u4e00q6	1752	11	32	32	CD
cord-014712-5u4e00q6	1752	12	consecutive	consecutive	JJ
cord-014712-5u4e00q6	1752	13	children	child	NNS
cord-014712-5u4e00q6	1752	14	with	with	IN
cord-014712-5u4e00q6	1752	15	PID	PID	NNP
cord-014712-5u4e00q6	1752	16	,	,	,
cord-014712-5u4e00q6	1752	17	who	who	WP
cord-014712-5u4e00q6	1752	18	had	have	VBD
cord-014712-5u4e00q6	1752	19	41	41	CD
cord-014712-5u4e00q6	1752	20	allogeneic	allogeneic	NN
cord-014712-5u4e00q6	1752	21	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1752	22	in	in	IN
cord-014712-5u4e00q6	1752	23	the	the	DT
cord-014712-5u4e00q6	1752	24	last	last	JJ
cord-014712-5u4e00q6	1752	25	22	22	CD
cord-014712-5u4e00q6	1752	26	years	year	NNS
cord-014712-5u4e00q6	1752	27	,	,	,
cord-014712-5u4e00q6	1752	28	between	between	IN
cord-014712-5u4e00q6	1752	29	January	January	NNP
cord-014712-5u4e00q6	1752	30	1991	1991	CD
cord-014712-5u4e00q6	1752	31	and	and	CC
cord-014712-5u4e00q6	1752	32	January	January	NNP
cord-014712-5u4e00q6	1752	33	2014	2014	CD
cord-014712-5u4e00q6	1752	34	.	.	.
cord-014712-5u4e00q6	1753	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	1753	2	median	median	JJ
cord-014712-5u4e00q6	1753	3	follow	follow	NN
cord-014712-5u4e00q6	1753	4	-	-	HYPH
cord-014712-5u4e00q6	1753	5	up	up	NN
cord-014712-5u4e00q6	1753	6	time	time	NN
cord-014712-5u4e00q6	1753	7	is	be	VBZ
cord-014712-5u4e00q6	1753	8	2,1	2,1	CD
cord-014712-5u4e00q6	1753	9	years	year	NNS
cord-014712-5u4e00q6	1753	10	(	(	-LRB-
cord-014712-5u4e00q6	1753	11	2	2	CD
cord-014712-5u4e00q6	1753	12	months	month	NNS
cord-014712-5u4e00q6	1753	13	-22,1	-22,1	CD
cord-014712-5u4e00q6	1753	14	years	year	NNS
cord-014712-5u4e00q6	1753	15	)	)	-RRB-
cord-014712-5u4e00q6	1754	1	Patients	patient	NNS
cord-014712-5u4e00q6	1754	2	and	and	CC
cord-014712-5u4e00q6	1754	3	Methods	method	NNS
cord-014712-5u4e00q6	1754	4	:	:	:
cord-014712-5u4e00q6	1754	5	The	the	DT
cord-014712-5u4e00q6	1754	6	median	median	JJ
cord-014712-5u4e00q6	1754	7	age	age	NN
cord-014712-5u4e00q6	1754	8	of	of	IN
cord-014712-5u4e00q6	1754	9	children	child	NNS
cord-014712-5u4e00q6	1754	10	at	at	IN
cord-014712-5u4e00q6	1754	11	HSCT	HSCT	NNP
cord-014712-5u4e00q6	1754	12	was	be	VBD
cord-014712-5u4e00q6	1754	13	10,5	10,5	CD
cord-014712-5u4e00q6	1754	14	months	month	NNS
cord-014712-5u4e00q6	1754	15	(	(	-LRB-
cord-014712-5u4e00q6	1754	16	3,5	3,5	CD
cord-014712-5u4e00q6	1754	17	months-18	months-18	CD
cord-014712-5u4e00q6	1754	18	years	year	NNS
cord-014712-5u4e00q6	1754	19	)	)	-RRB-
cord-014712-5u4e00q6	1754	20	.	.	.
cord-014712-5u4e00q6	1755	1	23	23	CD
cord-014712-5u4e00q6	1756	1	boys/9	boys/9	NNP
cord-014712-5u4e00q6	1756	2	girls	girl	NNS
cord-014712-5u4e00q6	1756	3	Diagnoses	Diagnoses	NNPS
cord-014712-5u4e00q6	1756	4	were	be	VBD
cord-014712-5u4e00q6	1756	5	based	base	VBN
cord-014712-5u4e00q6	1756	6	on	on	IN
cord-014712-5u4e00q6	1756	7	anamnestic	anamnestic	JJ
cord-014712-5u4e00q6	1756	8	data	datum	NNS
cord-014712-5u4e00q6	1756	9	,	,	,
cord-014712-5u4e00q6	1756	10	clinical	clinical	JJ
cord-014712-5u4e00q6	1756	11	findings	finding	NNS
cord-014712-5u4e00q6	1756	12	,	,	,
cord-014712-5u4e00q6	1756	13	and	and	CC
cord-014712-5u4e00q6	1756	14	immunological	immunological	JJ
cord-014712-5u4e00q6	1756	15	and	and	CC
cord-014712-5u4e00q6	1756	16	genetic	genetic	JJ
cord-014712-5u4e00q6	1756	17	analysis	analysis	NN
cord-014712-5u4e00q6	1756	18	.	.	.
cord-014712-5u4e00q6	1757	1	Conditioning	conditioning	NN
cord-014712-5u4e00q6	1757	2	regimens	regimen	NNS
cord-014712-5u4e00q6	1757	3	included	include	VBD
cord-014712-5u4e00q6	1757	4	busulphan	busulphan	NNP
cord-014712-5u4e00q6	1757	5	+	+	CC
cord-014712-5u4e00q6	1757	6	cyclophosphamide	cyclophosphamide	RB
cord-014712-5u4e00q6	1757	7	,	,	,
cord-014712-5u4e00q6	1757	8	busulphan	busulphan	NNP
cord-014712-5u4e00q6	1757	9	+	+	CC
cord-014712-5u4e00q6	1757	10	cyclophosphamide	cyclophosphamide	RB
cord-014712-5u4e00q6	1758	1	+	+	CC
cord-014712-5u4e00q6	1758	2	ATG	ATG	NNP
cord-014712-5u4e00q6	1758	3	,	,	,
cord-014712-5u4e00q6	1758	4	fludarabine	fludarabine	NN
cord-014712-5u4e00q6	1758	5	+	+	CC
cord-014712-5u4e00q6	1758	6	melphalan	melphalan	NN
cord-014712-5u4e00q6	1758	7	or	or	CC
cord-014712-5u4e00q6	1758	8	fludarabine	fludarabine	NN
cord-014712-5u4e00q6	1758	9	+	+	CC
cord-014712-5u4e00q6	1758	10	anti	anti	JJ
cord-014712-5u4e00q6	1758	11	-	-	JJ
cord-014712-5u4e00q6	1758	12	CD52	CD52	NNP
cord-014712-5u4e00q6	1759	1	In	in	IN
cord-014712-5u4e00q6	1759	2	B-	B-	NNP
cord-014712-5u4e00q6	1759	3	,	,	,
cord-014712-5u4e00q6	1759	4	T-	T-	NNP
cord-014712-5u4e00q6	1759	5	,	,	,
cord-014712-5u4e00q6	1759	6	NK	NK	NNP
cord-014712-5u4e00q6	1759	7	-	-	HYPH
cord-014712-5u4e00q6	1759	8	SCID	SCID	NNP
cord-014712-5u4e00q6	1759	9	cases	case	NNS
cord-014712-5u4e00q6	1759	10	conditioning	conditioning	NN
cord-014712-5u4e00q6	1759	11	was	be	VBD
cord-014712-5u4e00q6	1759	12	not	not	RB
cord-014712-5u4e00q6	1759	13	used	use	VBN
cord-014712-5u4e00q6	1759	14	.	.	.
cord-014712-5u4e00q6	1760	1	Indications	indication	NNS
cord-014712-5u4e00q6	1760	2	for	for	IN
cord-014712-5u4e00q6	1760	3	transplantation	transplantation	NN
cord-014712-5u4e00q6	1760	4	:	:	:
cord-014712-5u4e00q6	1760	5	Patients	patient	NNS
cord-014712-5u4e00q6	1760	6	'	'	POS
cord-014712-5u4e00q6	1760	7	diagnoses	diagnosis	NNS
cord-014712-5u4e00q6	1760	8	were	be	VBD
cord-014712-5u4e00q6	1760	9	severe	severe	JJ
cord-014712-5u4e00q6	1760	10	combined	combine	VBN
cord-014712-5u4e00q6	1760	11	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1761	1	(	(	-LRB-
cord-014712-5u4e00q6	1761	2	N	n	NN
cord-014712-5u4e00q6	1761	3	=	=	SYM
cord-014712-5u4e00q6	1761	4	16	16	CD
cord-014712-5u4e00q6	1761	5	)	)	-RRB-
cord-014712-5u4e00q6	1761	6	,	,	,
cord-014712-5u4e00q6	1761	7	Wiskott	Wiskott	NNP
cord-014712-5u4e00q6	1761	8	-	-	HYPH
cord-014712-5u4e00q6	1761	9	Aldrich	Aldrich	NNP
cord-014712-5u4e00q6	1761	10	syndrome	syndrome	NN
cord-014712-5u4e00q6	1761	11	(	(	-LRB-
cord-014712-5u4e00q6	1761	12	WAS	be	VBD
cord-014712-5u4e00q6	1761	13	,	,	,
cord-014712-5u4e00q6	1761	14	N	n	NN
cord-014712-5u4e00q6	1761	15	=	=	SYM
cord-014712-5u4e00q6	1761	16	6	6	CD
cord-014712-5u4e00q6	1761	17	)	)	-RRB-
cord-014712-5u4e00q6	1761	18	,	,	,
cord-014712-5u4e00q6	1761	19	chronic	chronic	JJ
cord-014712-5u4e00q6	1761	20	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	1761	21	disease	disease	NN
cord-014712-5u4e00q6	1761	22	(	(	-LRB-
cord-014712-5u4e00q6	1761	23	CGD	CGD	NNP
cord-014712-5u4e00q6	1761	24	,	,	,
cord-014712-5u4e00q6	1761	25	N	N	NNP
cord-014712-5u4e00q6	1761	26	=	=	SYM
cord-014712-5u4e00q6	1761	27	3	3	CD
cord-014712-5u4e00q6	1761	28	)	)	-RRB-
cord-014712-5u4e00q6	1761	29	,	,	,
cord-014712-5u4e00q6	1761	30	Xlinked	Xlinked	NNP
cord-014712-5u4e00q6	1761	31	lymphoproliferative	lymphoproliferative	JJ
cord-014712-5u4e00q6	1761	32	disease	disease	NN
cord-014712-5u4e00q6	1761	33	(	(	-LRB-
cord-014712-5u4e00q6	1761	34	XLP	XLP	NNP
cord-014712-5u4e00q6	1761	35	,	,	,
cord-014712-5u4e00q6	1761	36	N	n	NN
cord-014712-5u4e00q6	1761	37	=	=	SYM
cord-014712-5u4e00q6	1761	38	3	3	CD
cord-014712-5u4e00q6	1761	39	)	)	-RRB-
cord-014712-5u4e00q6	1761	40	,	,	,
cord-014712-5u4e00q6	1761	41	Whim	Whim	NNP
cord-014712-5u4e00q6	1761	42	-	-	HYPH
cord-014712-5u4e00q6	1761	43	syndrome	syndrome	NN
cord-014712-5u4e00q6	1762	1	(	(	-LRB-
cord-014712-5u4e00q6	1762	2	N	n	NN
cord-014712-5u4e00q6	1762	3	=	=	SYM
cord-014712-5u4e00q6	1762	4	1	1	CD
cord-014712-5u4e00q6	1762	5	)	)	-RRB-
cord-014712-5u4e00q6	1762	6	,	,	,
cord-014712-5u4e00q6	1762	7	hyper	hyper	NNP
cord-014712-5u4e00q6	1762	8	IgM	IgM	NNP
cord-014712-5u4e00q6	1762	9	syndrome	syndrome	NN
cord-014712-5u4e00q6	1762	10	(	(	-LRB-
cord-014712-5u4e00q6	1762	11	CD40	CD40	NNP
cord-014712-5u4e00q6	1762	12	ligand	ligand	NN
cord-014712-5u4e00q6	1762	13	deficiency	deficiency	NN
cord-014712-5u4e00q6	1762	14	,	,	,
cord-014712-5u4e00q6	1762	15	N	n	NN
cord-014712-5u4e00q6	1762	16	=	=	SYM
cord-014712-5u4e00q6	1762	17	1	1	CD
cord-014712-5u4e00q6	1762	18	)	)	-RRB-
cord-014712-5u4e00q6	1762	19	,	,	,
cord-014712-5u4e00q6	1762	20	leukocyte	leukocyte	NN
cord-014712-5u4e00q6	1762	21	adhesion	adhesion	NN
cord-014712-5u4e00q6	1762	22	deficiency	deficiency	NN
cord-014712-5u4e00q6	1762	23	(	(	-LRB-
cord-014712-5u4e00q6	1762	24	LAD	lad	NN
cord-014712-5u4e00q6	1762	25	,	,	,
cord-014712-5u4e00q6	1762	26	N	n	NN
cord-014712-5u4e00q6	1762	27	=	=	SYM
cord-014712-5u4e00q6	1762	28	1	1	CD
cord-014712-5u4e00q6	1762	29	)	)	-RRB-
cord-014712-5u4e00q6	1762	30	,	,	,
cord-014712-5u4e00q6	1762	31	DOCK8	DOCK8	NNP
cord-014712-5u4e00q6	1762	32	mutation	mutation	NN
cord-014712-5u4e00q6	1762	33	(	(	-LRB-
cord-014712-5u4e00q6	1762	34	N	n	NN
cord-014712-5u4e00q6	1762	35	=	=	SYM
cord-014712-5u4e00q6	1762	36	1	1	CD
cord-014712-5u4e00q6	1762	37	)	)	-RRB-
cord-014712-5u4e00q6	1762	38	Transplantations	Transplantations	NNP
cord-014712-5u4e00q6	1762	39	:	:	:
cord-014712-5u4e00q6	1763	1	41	41	CD
cord-014712-5u4e00q6	1763	2	HSCTs	hsct	NNS
cord-014712-5u4e00q6	1763	3	for	for	IN
cord-014712-5u4e00q6	1763	4	32	32	CD
cord-014712-5u4e00q6	1763	5	children	child	NNS
cord-014712-5u4e00q6	1763	6	were	be	VBD
cord-014712-5u4e00q6	1763	7	performed	perform	VBN
cord-014712-5u4e00q6	1763	8	.	.	.
cord-014712-5u4e00q6	1764	1	6	6	CD
cord-014712-5u4e00q6	1764	2	patients	patient	NNS
cord-014712-5u4e00q6	1764	3	were	be	VBD
cord-014712-5u4e00q6	1764	4	retransplanted	retransplanted	JJ
cord-014712-5u4e00q6	1764	5	(	(	-LRB-
cord-014712-5u4e00q6	1764	6	4	4	CD
cord-014712-5u4e00q6	1764	7	pt	pt	NN
cord-014712-5u4e00q6	1764	8	once	once	RB
cord-014712-5u4e00q6	1764	9	,	,	,
cord-014712-5u4e00q6	1764	10	1	1	CD
cord-014712-5u4e00q6	1764	11	pt	pt	NN
cord-014712-5u4e00q6	1764	12	twice	twice	RB
cord-014712-5u4e00q6	1764	13	,	,	,
cord-014712-5u4e00q6	1764	14	1	1	CD
cord-014712-5u4e00q6	1764	15	pt	pt	NN
cord-014712-5u4e00q6	1764	16	3	3	CD
cord-014712-5u4e00q6	1764	17	times	time	NNS
cord-014712-5u4e00q6	1764	18	)	)	-RRB-
cord-014712-5u4e00q6	1764	19	,	,	,
cord-014712-5u4e00q6	1764	20	because	because	IN
cord-014712-5u4e00q6	1764	21	of	of	IN
cord-014712-5u4e00q6	1764	22	rejections	rejection	NNS
cord-014712-5u4e00q6	1764	23	.	.	.
cord-014712-5u4e00q6	1765	1	At	at	IN
cord-014712-5u4e00q6	1765	2	the	the	DT
cord-014712-5u4e00q6	1765	3	first	first	JJ
cord-014712-5u4e00q6	1765	4	HSCTs	hsct	NNS
cord-014712-5u4e00q6	1765	5	in	in	IN
cord-014712-5u4e00q6	1765	6	5/32	5/32	CD
cord-014712-5u4e00q6	1765	7	cases	case	NNS
cord-014712-5u4e00q6	1765	8	sibling	sibling	NN
cord-014712-5u4e00q6	1765	9	bone	bone	NN
cord-014712-5u4e00q6	1765	10	marrow	marrow	NN
cord-014712-5u4e00q6	1765	11	,	,	,
cord-014712-5u4e00q6	1765	12	1/32	1/32	CD
cord-014712-5u4e00q6	1765	13	sibling	sibling	NN
cord-014712-5u4e00q6	1765	14	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1765	15	blood	blood	NN
cord-014712-5u4e00q6	1765	16	,	,	,
cord-014712-5u4e00q6	1765	17	1/32	1/32	CD
cord-014712-5u4e00q6	1765	18	sibling	sibling	NN
cord-014712-5u4e00q6	1765	19	cord	cord	NN
cord-014712-5u4e00q6	1765	20	blood	blood	NN
cord-014712-5u4e00q6	1765	21	,	,	,
cord-014712-5u4e00q6	1765	22	4/32	4/32	CD
cord-014712-5u4e00q6	1765	23	unrelated	unrelated	JJ
cord-014712-5u4e00q6	1765	24	cord	cord	NN
cord-014712-5u4e00q6	1765	25	blood	blood	NN
cord-014712-5u4e00q6	1765	26	,	,	,
cord-014712-5u4e00q6	1765	27	9/32	9/32	CD
cord-014712-5u4e00q6	1765	28	unrelated	unrelated	JJ
cord-014712-5u4e00q6	1765	29	bone	bone	NN
cord-014712-5u4e00q6	1765	30	marrow	marrow	NN
cord-014712-5u4e00q6	1765	31	,	,	,
cord-014712-5u4e00q6	1765	32	2/32	2/32	CD
cord-014712-5u4e00q6	1765	33	unrelated	unrelated	JJ
cord-014712-5u4e00q6	1765	34	peripheral	peripheral	JJ
cord-014712-5u4e00q6	1765	35	blood	blood	NN
cord-014712-5u4e00q6	1765	36	,	,	,
cord-014712-5u4e00q6	1765	37	7/32	7/32	CD
cord-014712-5u4e00q6	1765	38	haploidentical	haploidentical	JJ
cord-014712-5u4e00q6	1765	39	donors	donor	NNS
cord-014712-5u4e00q6	1765	40	were	be	VBD
cord-014712-5u4e00q6	1765	41	used	use	VBN
cord-014712-5u4e00q6	1765	42	Median	Median	NNP
cord-014712-5u4e00q6	1765	43	CD34	CD34	NNP
cord-014712-5u4e00q6	1765	44	count	count	NN
cord-014712-5u4e00q6	1765	45	was	be	VBD
cord-014712-5u4e00q6	1765	46	2,52x10	2,52x10	CD
cord-014712-5u4e00q6	1765	47	6	6	CD
cord-014712-5u4e00q6	1766	1	/kg	/kg	NFP
cord-014712-5u4e00q6	1766	2	(	(	-LRB-
cord-014712-5u4e00q6	1766	3	0,13x10	0,13x10	CD
cord-014712-5u4e00q6	1766	4	6	6	CD
cord-014712-5u4e00q6	1766	5	-26,95x10	-26,95x10	CD
cord-014712-5u4e00q6	1766	6	6	6	CD
cord-014712-5u4e00q6	1767	1	/kg	/kg	NFP
cord-014712-5u4e00q6	1767	2	)	)	-RRB-
cord-014712-5u4e00q6	1768	1	Patients	patient	NNS
cord-014712-5u4e00q6	1768	2	engrafted	engraft	VBN
cord-014712-5u4e00q6	1768	3	on	on	IN
cord-014712-5u4e00q6	1768	4	median	median	NN
cord-014712-5u4e00q6	1768	5	27	27	CD
cord-014712-5u4e00q6	1768	6	±	±	CD
cord-014712-5u4e00q6	1768	7	8	8	CD
cord-014712-5u4e00q6	1768	8	day	day	NN
cord-014712-5u4e00q6	1768	9	(	(	-LRB-
cord-014712-5u4e00q6	1768	10	ANC	ANC	NNP
cord-014712-5u4e00q6	1768	11	>	>	XX
cord-014712-5u4e00q6	1769	1	0,5	0,5	NFP
cord-014712-5u4e00q6	1770	1	G	G	NNP
cord-014712-5u4e00q6	1770	2	/	/	SYM
cord-014712-5u4e00q6	1770	3	l	l	NN
cord-014712-5u4e00q6	1770	4	)	)	-RRB-
cord-014712-5u4e00q6	1770	5	Acute	acute	JJ
cord-014712-5u4e00q6	1770	6	GVHD	GVHD	NNP
cord-014712-5u4e00q6	1770	7	occured	occur	VBD
cord-014712-5u4e00q6	1770	8	in	in	IN
cord-014712-5u4e00q6	1770	9	17/32	17/32	CD
cord-014712-5u4e00q6	1770	10	cases	case	NNS
cord-014712-5u4e00q6	1770	11	(	(	-LRB-
cord-014712-5u4e00q6	1771	1	Pathomorphological	Pathomorphological	NNP
cord-014712-5u4e00q6	1771	2	findes	finde	NNS
cord-014712-5u4e00q6	1771	3	:	:	:
cord-014712-5u4e00q6	1771	4	distortion	distortion	NN
cord-014712-5u4e00q6	1771	5	of	of	IN
cord-014712-5u4e00q6	1771	6	the	the	DT
cord-014712-5u4e00q6	1771	7	structure	structure	NN
cord-014712-5u4e00q6	1771	8	of	of	IN
cord-014712-5u4e00q6	1771	9	lymph	lymph	NN
cord-014712-5u4e00q6	1771	10	nodes	node	NNS
cord-014712-5u4e00q6	1771	11	due	due	JJ
cord-014712-5u4e00q6	1771	12	to	to	IN
cord-014712-5u4e00q6	1771	13	enlargement	enlargement	NN
cord-014712-5u4e00q6	1771	14	of	of	IN
cord-014712-5u4e00q6	1771	15	paracortical	paracortical	JJ
cord-014712-5u4e00q6	1771	16	zones	zone	NNS
cord-014712-5u4e00q6	1771	17	and	and	CC
cord-014712-5u4e00q6	1771	18	follicules	follicule	NNS
cord-014712-5u4e00q6	1771	19	was	be	VBD
cord-014712-5u4e00q6	1771	20	found	find	VBN
cord-014712-5u4e00q6	1771	21	in	in	IN
cord-014712-5u4e00q6	1771	22	all	all	DT
cord-014712-5u4e00q6	1771	23	patients	patient	NNS
cord-014712-5u4e00q6	1771	24	.	.	.
cord-014712-5u4e00q6	1772	1	Presumed	presume	VBN
cord-014712-5u4e00q6	1772	2	atypical	atypical	JJ
cord-014712-5u4e00q6	1772	3	cells	cell	NNS
cord-014712-5u4e00q6	1772	4	(	(	-LRB-
cord-014712-5u4e00q6	1772	5	makrolymphoblastes	makrolymphoblaste	NNS
cord-014712-5u4e00q6	1772	6	and	and	CC
cord-014712-5u4e00q6	1772	7	Berezovsky	Berezovsky	NNP
cord-014712-5u4e00q6	1772	8	-	-	HYPH
cord-014712-5u4e00q6	1772	9	Sternberg	Sternberg	NNP
cord-014712-5u4e00q6	1772	10	-	-	HYPH
cord-014712-5u4e00q6	1772	11	Reed	Reed	NNP
cord-014712-5u4e00q6	1772	12	cells	cell	NNS
cord-014712-5u4e00q6	1772	13	)	)	-RRB-
cord-014712-5u4e00q6	1772	14	,	,	,
cord-014712-5u4e00q6	1772	15	were	be	VBD
cord-014712-5u4e00q6	1772	16	detected	detect	VBN
cord-014712-5u4e00q6	1772	17	in	in	IN
cord-014712-5u4e00q6	1772	18	2	2	CD
cord-014712-5u4e00q6	1772	19	patients	patient	NNS
cord-014712-5u4e00q6	1772	20	overwise	overwise	VBP
cord-014712-5u4e00q6	1772	21	during	during	IN
cord-014712-5u4e00q6	1772	22	follow	follow	NN
cord-014712-5u4e00q6	1772	23	-	-	HYPH
cord-014712-5u4e00q6	1772	24	up	up	NN
cord-014712-5u4e00q6	1772	25	for	for	IN
cord-014712-5u4e00q6	1772	26	2	2	CD
cord-014712-5u4e00q6	1772	27	-	-	SYM
cord-014712-5u4e00q6	1772	28	5	5	CD
cord-014712-5u4e00q6	1772	29	years	year	NNS
cord-014712-5u4e00q6	1772	30	in	in	IN
cord-014712-5u4e00q6	1772	31	these	these	DT
cord-014712-5u4e00q6	1772	32	patients	patient	NNS
cord-014712-5u4e00q6	1772	33	revealed	reveal	VBD
cord-014712-5u4e00q6	1772	34	no	no	DT
cord-014712-5u4e00q6	1772	35	specific	specific	JJ
cord-014712-5u4e00q6	1772	36	infectious	infectious	JJ
cord-014712-5u4e00q6	1772	37	and	and	CC
cord-014712-5u4e00q6	1772	38	malignansy	malignansy	NN
cord-014712-5u4e00q6	1772	39	.	.	.
cord-014712-5u4e00q6	1773	1	Accumulation	accumulation	NN
cord-014712-5u4e00q6	1773	2	of	of	IN
cord-014712-5u4e00q6	1773	3	proliferating	proliferate	VBG
cord-014712-5u4e00q6	1773	4	DN	DN	NNP
cord-014712-5u4e00q6	1773	5	cells	cell	NNS
cord-014712-5u4e00q6	1773	6	(	(	-LRB-
cord-014712-5u4e00q6	1773	7	a	a	DT
cord-014712-5u4e00q6	1773	8	lot	lot	NN
cord-014712-5u4e00q6	1773	9	of	of	IN
cord-014712-5u4e00q6	1773	10	mitoses	mitose	NNS
cord-014712-5u4e00q6	1773	11	)	)	-RRB-
cord-014712-5u4e00q6	1773	12	was	be	VBD
cord-014712-5u4e00q6	1773	13	characteristic	characteristic	JJ
cord-014712-5u4e00q6	1773	14	fiture	fiture	NN
cord-014712-5u4e00q6	1773	15	in	in	IN
cord-014712-5u4e00q6	1773	16	lymph	lymph	NN
cord-014712-5u4e00q6	1773	17	nodes	node	NNS
cord-014712-5u4e00q6	1773	18	and	and	CC
cord-014712-5u4e00q6	1773	19	spleen	spleen	NNS
cord-014712-5u4e00q6	1773	20	of	of	IN
cord-014712-5u4e00q6	1773	21	ALPS	ALPS	NNP
cord-014712-5u4e00q6	1773	22	patients	patient	NNS
cord-014712-5u4e00q6	1773	23	.	.	.
cord-014712-5u4e00q6	1774	1	Setting	set	VBG
cord-014712-5u4e00q6	1774	2	of	of	IN
cord-014712-5u4e00q6	1774	3	plasma	plasma	NN
cord-014712-5u4e00q6	1774	4	cells	cell	NNS
cord-014712-5u4e00q6	1774	5	in	in	IN
cord-014712-5u4e00q6	1774	6	follicular	follicular	JJ
cord-014712-5u4e00q6	1774	7	zones	zone	NNS
cord-014712-5u4e00q6	1774	8	in	in	IN
cord-014712-5u4e00q6	1774	9	the	the	DT
cord-014712-5u4e00q6	1774	10	lymph	lymph	NN
cord-014712-5u4e00q6	1774	11	nodes	node	NNS
cord-014712-5u4e00q6	1774	12	was	be	VBD
cord-014712-5u4e00q6	1774	13	reveald	reveald	NN
cord-014712-5u4e00q6	1774	14	in	in	IN
cord-014712-5u4e00q6	1774	15	5	5	CD
cord-014712-5u4e00q6	1774	16	cases	case	NNS
cord-014712-5u4e00q6	1774	17	,	,	,
cord-014712-5u4e00q6	1774	18	and	and	CC
cord-014712-5u4e00q6	1774	19	eosinophilesin	eosinophilesin	NNP
cord-014712-5u4e00q6	1774	20	2	2	CD
cord-014712-5u4e00q6	1774	21	,	,	,
cord-014712-5u4e00q6	1774	22	pronounced	pronounce	VBN
cord-014712-5u4e00q6	1774	23	immunoblast	immunoblast	JJ
cord-014712-5u4e00q6	1774	24	proliferation	proliferation	NN
cord-014712-5u4e00q6	1774	25	in	in	IN
cord-014712-5u4e00q6	1774	26	2	2	CD
cord-014712-5u4e00q6	1774	27	,	,	,
cord-014712-5u4e00q6	1774	28	sinus	sinus	NNP
cord-014712-5u4e00q6	1774	29	histiocytosisin	histiocytosisin	NNP
cord-014712-5u4e00q6	1774	30	3	3	CD
cord-014712-5u4e00q6	1774	31	.	.	.
cord-014712-5u4e00q6	1775	1	Multiple	multiple	JJ
cord-014712-5u4e00q6	1775	2	hyperplastic	hyperplastic	JJ
cord-014712-5u4e00q6	1775	3	follicles	follicle	NNS
cord-014712-5u4e00q6	1775	4	,	,	,
cord-014712-5u4e00q6	1775	5	extended	extended	JJ
cord-014712-5u4e00q6	1775	6	sinuses	sinus	NNS
cord-014712-5u4e00q6	1775	7	with	with	IN
cord-014712-5u4e00q6	1775	8	many	many	JJ
cord-014712-5u4e00q6	1775	9	phagocytizing	phagocytizing	NN
cord-014712-5u4e00q6	1775	10	macrophages	macrophage	NNS
cord-014712-5u4e00q6	1775	11	,	,	,
cord-014712-5u4e00q6	1775	12	lymphocytic	lymphocytic	JJ
cord-014712-5u4e00q6	1775	13	infiltration	infiltration	NN
cord-014712-5u4e00q6	1775	14	was	be	VBD
cord-014712-5u4e00q6	1775	15	revealed	reveal	VBN
cord-014712-5u4e00q6	1775	16	by	by	IN
cord-014712-5u4e00q6	1775	17	histological	histological	JJ
cord-014712-5u4e00q6	1775	18	examination	examination	NN
cord-014712-5u4e00q6	1775	19	of	of	IN
cord-014712-5u4e00q6	1775	20	the	the	DT
cord-014712-5u4e00q6	1775	21	spleen	spleen	NNS
cord-014712-5u4e00q6	1775	22	in	in	IN
cord-014712-5u4e00q6	1775	23	all	all	DT
cord-014712-5u4e00q6	1775	24	cases	case	NNS
cord-014712-5u4e00q6	1775	25	.	.	.
cord-014712-5u4e00q6	1776	1	Immunohistochemistry	Immunohistochemistry	NNP
cord-014712-5u4e00q6	1776	2	findes	findes	NNP
cord-014712-5u4e00q6	1776	3	:	:	:
cord-014712-5u4e00q6	1776	4	T	T	NNP
cord-014712-5u4e00q6	1776	5	-	-	HYPH
cord-014712-5u4e00q6	1776	6	and	and	CC
cord-014712-5u4e00q6	1776	7	B	b	NN
cord-014712-5u4e00q6	1776	8	-	-	HYPH
cord-014712-5u4e00q6	1776	9	cells	cell	NNS
cord-014712-5u4e00q6	1776	10	proliferation	proliferation	NN
cord-014712-5u4e00q6	1776	11	(	(	-LRB-
cord-014712-5u4e00q6	1776	12	Ki-67	ki-67	CD
cord-014712-5u4e00q6	1776	13	expression	expression	NN
cord-014712-5u4e00q6	1776	14	)	)	-RRB-
cord-014712-5u4e00q6	1776	15	,	,	,
cord-014712-5u4e00q6	1776	16	atypical	atypical	JJ
cord-014712-5u4e00q6	1776	17	location	location	NN
cord-014712-5u4e00q6	1776	18	of	of	IN
cord-014712-5u4e00q6	1776	19	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1776	20	populations	population	NNS
cord-014712-5u4e00q6	1776	21	,	,	,
cord-014712-5u4e00q6	1776	22	settings	setting	NNS
cord-014712-5u4e00q6	1776	23	of	of	IN
cord-014712-5u4e00q6	1776	24	plasma	plasma	NN
cord-014712-5u4e00q6	1776	25	cells	cell	NNS
cord-014712-5u4e00q6	1776	26	in	in	IN
cord-014712-5u4e00q6	1776	27	all	all	DT
cord-014712-5u4e00q6	1776	28	lymph	lymph	NN
cord-014712-5u4e00q6	1776	29	node	node	NN
cord-014712-5u4e00q6	1776	30	zones	zone	NNS
cord-014712-5u4e00q6	1776	31	.	.	.
cord-014712-5u4e00q6	1777	1	In	in	IN
cord-014712-5u4e00q6	1777	2	paracortical	paracortical	JJ
cord-014712-5u4e00q6	1777	3	zones	zone	NNS
cord-014712-5u4e00q6	1777	4	was	be	VBD
cord-014712-5u4e00q6	1777	5	found	find	VBN
cord-014712-5u4e00q6	1777	6	CD5	CD5	NNP
cord-014712-5u4e00q6	1777	7	+	+	SYM
cord-014712-5u4e00q6	1777	8	,	,	,
cord-014712-5u4e00q6	1777	9	CD7	CD7	NNP
cord-014712-5u4e00q6	1777	10	+	+	CC
cord-014712-5u4e00q6	1777	11	,	,	,
cord-014712-5u4e00q6	1777	12	CD3	CD3	NNP
cord-014712-5u4e00q6	1778	1	+	+	CC
cord-014712-5u4e00q6	1778	2	CD4-	CD4-	NNP
cord-014712-5u4e00q6	1778	3	,	,	,
cord-014712-5u4e00q6	1778	4	CD3	CD3	NNP
cord-014712-5u4e00q6	1778	5	+	+	CC
cord-014712-5u4e00q6	1778	6	CD8-cells	cd8-cell	NNS
cord-014712-5u4e00q6	1778	7	in	in	IN
cord-014712-5u4e00q6	1778	8	5	5	CD
cord-014712-5u4e00q6	1778	9	patients	patient	NNS
cord-014712-5u4e00q6	1778	10	,	,	,
cord-014712-5u4e00q6	1778	11	CD38	CD38	NNP
cord-014712-5u4e00q6	1778	12	+	+	CC
cord-014712-5u4e00q6	1778	13	,	,	,
cord-014712-5u4e00q6	1778	14	CD68	CD68	NNP
cord-014712-5u4e00q6	1778	15	+	+	CC
cord-014712-5u4e00q6	1778	16	cells	cell	NNS
cord-014712-5u4e00q6	1778	17	in	in	IN
cord-014712-5u4e00q6	1778	18	1	1	CD
cord-014712-5u4e00q6	1778	19	patient	patient	NN
cord-014712-5u4e00q6	1778	20	;	;	:
cord-014712-5u4e00q6	1778	21	and	and	CC
cord-014712-5u4e00q6	1778	22	in	in	IN
cord-014712-5u4e00q6	1778	23	restricted	restricted	JJ
cord-014712-5u4e00q6	1778	24	follicular	follicular	JJ
cord-014712-5u4e00q6	1778	25	zones	zone	NNS
cord-014712-5u4e00q6	1778	26	-CD19	-CD19	.
cord-014712-5u4e00q6	1779	1	+	+	UH
cord-014712-5u4e00q6	1779	2	,	,	.
cord-014712-5u4e00q6	1780	1	CD22	CD22	NNP
cord-014712-5u4e00q6	1780	2	+	+	CC
cord-014712-5u4e00q6	1780	3	,	,	,
cord-014712-5u4e00q6	1780	4	HLA	HLA	NNP
cord-014712-5u4e00q6	1780	5	-	-	HYPH
cord-014712-5u4e00q6	1780	6	DR	DR	NNP
cord-014712-5u4e00q6	1781	1	+	+	CC
cord-014712-5u4e00q6	1781	2	cells	cell	NNS
cord-014712-5u4e00q6	1781	3	in	in	IN
cord-014712-5u4e00q6	1781	4	4	4	CD
cord-014712-5u4e00q6	1781	5	patients	patient	NNS
cord-014712-5u4e00q6	1781	6	,	,	,
cord-014712-5u4e00q6	1781	7	CD3	CD3	NNP
cord-014712-5u4e00q6	1781	8	+	+	CC
cord-014712-5u4e00q6	1781	9	,	,	,
cord-014712-5u4e00q6	1781	10	CD15	CD15	NNP
cord-014712-5u4e00q6	1781	11	+	+	CC
cord-014712-5u4e00q6	1781	12	and	and	CC
cord-014712-5u4e00q6	1781	13	CD68	CD68	NNP
cord-014712-5u4e00q6	1781	14	+	+	CC
cord-014712-5u4e00q6	1781	15	in	in	IN
cord-014712-5u4e00q6	1781	16	2	2	CD
cord-014712-5u4e00q6	1781	17	patients	patient	NNS
cord-014712-5u4e00q6	1781	18	.	.	.
cord-014712-5u4e00q6	1782	1	The	the	DT
cord-014712-5u4e00q6	1782	2	presentation	presentation	NN
cord-014712-5u4e00q6	1782	3	of	of	IN
cord-014712-5u4e00q6	1782	4	a	a	DT
cord-014712-5u4e00q6	1782	5	case	case	NN
cord-014712-5u4e00q6	1782	6	of	of	IN
cord-014712-5u4e00q6	1782	7	Kimura	Kimura	NNP
cord-014712-5u4e00q6	1782	8	disease	disease	NN
cord-014712-5u4e00q6	1782	9	in	in	IN
cord-014712-5u4e00q6	1782	10	a	a	DT
cord-014712-5u4e00q6	1782	11	patient	patient	NN
cord-014712-5u4e00q6	1782	12	with	with	IN
cord-014712-5u4e00q6	1782	13	WAS	be	VBD
cord-014712-5u4e00q6	1782	14	.	.	.
cord-014712-5u4e00q6	1783	1	The	the	DT
cord-014712-5u4e00q6	1783	2	WAS	be	VBD
cord-014712-5u4e00q6	1783	3	was	be	VBD
cord-014712-5u4e00q6	1783	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1783	5	In	in	IN
cord-014712-5u4e00q6	1783	6	1	1	CD
cord-014712-5u4e00q6	1783	7	year	year	NN
cord-014712-5u4e00q6	1783	8	2months	2months	CD
cord-014712-5u4e00q6	1783	9	,	,	,
cord-014712-5u4e00q6	1783	10	based	base	VBN
cord-014712-5u4e00q6	1783	11	on	on	IN
cord-014712-5u4e00q6	1783	12	infectious	infectious	JJ
cord-014712-5u4e00q6	1783	13	syndrome	syndrome	NN
cord-014712-5u4e00q6	1783	14	,	,	,
cord-014712-5u4e00q6	1783	15	atopic	atopic	JJ
cord-014712-5u4e00q6	1783	16	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	1783	17	,	,	.
cord-014712-5u4e00q6	1784	1	hematological	hematological	JJ
cord-014712-5u4e00q6	1784	2	syndrome	syndrome	NN
cord-014712-5u4e00q6	1784	3	-skin	-skin	:
cord-014712-5u4e00q6	1784	4	hemorrhages	hemorrhage	NNS
cord-014712-5u4e00q6	1784	5	and	and	CC
cord-014712-5u4e00q6	1785	1	thrombocytopenia	thrombocytopenia	NNP
cord-014712-5u4e00q6	1785	2	-25	-25	CD
cord-014712-5u4e00q6	1785	3	*	*	NFP
cord-014712-5u4e00q6	1785	4	10	10	CD
cord-014712-5u4e00q6	1785	5	9	9	CD
cord-014712-5u4e00q6	1785	6	/L.	/L.	.
cord-014712-5u4e00q6	1786	1	After	after	IN
cord-014712-5u4e00q6	1786	2	he	-PRON-	PRP
cord-014712-5u4e00q6	1786	3	performed	perform	VBD
cord-014712-5u4e00q6	1786	4	often	often	RB
cord-014712-5u4e00q6	1786	5	SARS	SARS	NNP
cord-014712-5u4e00q6	1786	6	.	.	.
cord-014712-5u4e00q6	1787	1	Regularly	regularly	RB
cord-014712-5u4e00q6	1787	2	received	receive	VBD
cord-014712-5u4e00q6	1787	3	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1787	4	at	at	IN
cord-014712-5u4e00q6	1787	5	400mg	400mg	NNP
cord-014712-5u4e00q6	1787	6	/	/	SYM
cord-014712-5u4e00q6	1787	7	kg	kg	NN
cord-014712-5u4e00q6	1787	8	,	,	,
cord-014712-5u4e00q6	1787	9	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	1787	10	therapy	therapy	NN
cord-014712-5u4e00q6	1787	11	with	with	IN
cord-014712-5u4e00q6	1787	12	a	a	DT
cord-014712-5u4e00q6	1787	13	positive	positive	JJ
cord-014712-5u4e00q6	1787	14	effect	effect	NN
cord-014712-5u4e00q6	1787	15	-infectious	-infectious	JJ
cord-014712-5u4e00q6	1787	16	syndrome	syndrome	NN
cord-014712-5u4e00q6	1787	17	stopped	stop	VBD
cord-014712-5u4e00q6	1787	18	,	,	,
cord-014712-5u4e00q6	1787	19	controlled	control	VBN
cord-014712-5u4e00q6	1787	20	hemorrhagic	hemorrhagic	JJ
cord-014712-5u4e00q6	1787	21	syndrome	syndrome	NN
cord-014712-5u4e00q6	1787	22	.	.	.
cord-014712-5u4e00q6	1788	1	Since	since	IN
cord-014712-5u4e00q6	1788	2	2010	2010	CD
cord-014712-5u4e00q6	1788	3	there	there	EX
cord-014712-5u4e00q6	1788	4	was	be	VBD
cord-014712-5u4e00q6	1788	5	a	a	DT
cord-014712-5u4e00q6	1788	6	herpes	herpes	NN
cord-014712-5u4e00q6	1788	7	virus	virus	NN
cord-014712-5u4e00q6	1788	8	infection	infection	NN
cord-014712-5u4e00q6	1788	9	with	with	IN
cord-014712-5u4e00q6	1788	10	frequent	frequent	JJ
cord-014712-5u4e00q6	1788	11	exacerbations	exacerbation	NNS
cord-014712-5u4e00q6	1788	12	on	on	IN
cord-014712-5u4e00q6	1788	13	the	the	DT
cord-014712-5u4e00q6	1788	14	face	face	NN
cord-014712-5u4e00q6	1788	15	.	.	.
cord-014712-5u4e00q6	1789	1	Patient	Patient	NNP
cord-014712-5u4e00q6	1789	2	received	receive	VBD
cord-014712-5u4e00q6	1789	3	acyclovir	acyclovir	NNP
cord-014712-5u4e00q6	1789	4	,	,	,
cord-014712-5u4e00q6	1789	5	valacyclovir	valacyclovir	NNP
cord-014712-5u4e00q6	1789	6	,	,	,
cord-014712-5u4e00q6	1789	7	Famvir	Famvir	NNP
cord-014712-5u4e00q6	1789	8	with	with	IN
cord-014712-5u4e00q6	1789	9	a	a	DT
cord-014712-5u4e00q6	1789	10	temporary	temporary	JJ
cord-014712-5u4e00q6	1789	11	effect	effect	NN
cord-014712-5u4e00q6	1789	12	.	.	.
cord-014712-5u4e00q6	1790	1	In	in	IN
cord-014712-5u4e00q6	1790	2	08.2011	08.2011	CD
cord-014712-5u4e00q6	1790	3	on	on	IN
cord-014712-5u4e00q6	1790	4	the	the	DT
cord-014712-5u4e00q6	1790	5	left	left	JJ
cord-014712-5u4e00q6	1790	6	side	side	NN
cord-014712-5u4e00q6	1790	7	of	of	IN
cord-014712-5u4e00q6	1790	8	the	the	DT
cord-014712-5u4e00q6	1790	9	face	face	NN
cord-014712-5u4e00q6	1790	10	-periorbital	-periorbital	JJ
cord-014712-5u4e00q6	1790	11	region	region	NN
cord-014712-5u4e00q6	1790	12	,	,	,
cord-014712-5u4e00q6	1790	13	eyelids	eyelid	NNS
cord-014712-5u4e00q6	1790	14	,	,	,
cord-014712-5u4e00q6	1790	15	malar	malar	NNP
cord-014712-5u4e00q6	1790	16	region	region	NN
cord-014712-5u4e00q6	1790	17	appeared	appear	VBD
cord-014712-5u4e00q6	1790	18	the	the	DT
cord-014712-5u4e00q6	1790	19	site	site	NN
cord-014712-5u4e00q6	1790	20	of	of	IN
cord-014712-5u4e00q6	1790	21	soft	soft	JJ
cord-014712-5u4e00q6	1790	22	tissue	tissue	NN
cord-014712-5u4e00q6	1790	23	hyperproliferation	hyperproliferation	NNP
cord-014712-5u4e00q6	1790	24	10	10	CD
cord-014712-5u4e00q6	1790	25	-12	-12	NN
cord-014712-5u4e00q6	1790	26	cm	cm	NNS
cord-014712-5u4e00q6	1790	27	in	in	IN
cord-014712-5u4e00q6	1790	28	diameter	diameter	NN
cord-014712-5u4e00q6	1790	29	with	with	IN
cord-014712-5u4e00q6	1790	30	a	a	DT
cord-014712-5u4e00q6	1790	31	thickness	thickness	NN
cord-014712-5u4e00q6	1790	32	of	of	IN
cord-014712-5u4e00q6	1790	33	3	3	CD
cord-014712-5u4e00q6	1790	34	-	-	SYM
cord-014712-5u4e00q6	1790	35	4	4	CD
cord-014712-5u4e00q6	1790	36	cm	cm	NNS
cord-014712-5u4e00q6	1790	37	,	,	,
cord-014712-5u4e00q6	1790	38	with	with	IN
cord-014712-5u4e00q6	1790	39	moderate	moderate	JJ
cord-014712-5u4e00q6	1790	40	moist	moist	JJ
cord-014712-5u4e00q6	1790	41	,	,	,
cord-014712-5u4e00q6	1790	42	painful	painful	JJ
cord-014712-5u4e00q6	1790	43	on	on	IN
cord-014712-5u4e00q6	1790	44	palpation	palpation	NN
cord-014712-5u4e00q6	1790	45	,	,	,
cord-014712-5u4e00q6	1790	46	the	the	DT
cord-014712-5u4e00q6	1790	47	left	left	JJ
cord-014712-5u4e00q6	1790	48	eye	eye	NN
cord-014712-5u4e00q6	1790	49	was	be	VBD
cord-014712-5u4e00q6	1790	50	closed	close	VBN
cord-014712-5u4e00q6	1790	51	,	,	,
cord-014712-5u4e00q6	1790	52	the	the	DT
cord-014712-5u4e00q6	1790	53	lid	lid	NN
cord-014712-5u4e00q6	1790	54	margin	margin	NN
cord-014712-5u4e00q6	1790	55	ciliated	ciliated	JJ
cord-014712-5u4e00q6	1790	56	dramatically	dramatically	RB
cord-014712-5u4e00q6	1790	57	thickened	thicken	VBN
cord-014712-5u4e00q6	1790	58	,	,	,
cord-014712-5u4e00q6	1790	59	deformed	deformed	JJ
cord-014712-5u4e00q6	1790	60	.	.	.
cord-014712-5u4e00q6	1791	1	In	in	IN
cord-014712-5u4e00q6	1791	2	October	October	NNP
cord-014712-5u4e00q6	1791	3	-	-	HYPH
cord-014712-5u4e00q6	1791	4	November	November	NNP
cord-014712-5u4e00q6	1791	5	2011	2011	CD
cord-014712-5u4e00q6	1791	6	was	be	VBD
cord-014712-5u4e00q6	1791	7	admitted	admit	VBN
cord-014712-5u4e00q6	1791	8	in	in	IN
cord-014712-5u4e00q6	1791	9	Diagnostic	Diagnostic	NNP
cord-014712-5u4e00q6	1791	10	department	department	NN
cord-014712-5u4e00q6	1791	11	,	,	,
cord-014712-5u4e00q6	1791	12	massive	massive	JJ
cord-014712-5u4e00q6	1791	13	antibiotic	antibiotic	NN
cord-014712-5u4e00q6	1791	14	,	,	,
cord-014712-5u4e00q6	1791	15	antimycotic	antimycotic	JJ
cord-014712-5u4e00q6	1791	16	,	,	,
cord-014712-5u4e00q6	1791	17	antiviral	antiviral	JJ
cord-014712-5u4e00q6	1791	18	therapy	therapy	NN
cord-014712-5u4e00q6	1791	19	,	,	,
cord-014712-5u4e00q6	1791	20	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1791	21	therapy	therapy	NN
cord-014712-5u4e00q6	1791	22	.	.	.
cord-014712-5u4e00q6	1792	1	The	the	DT
cord-014712-5u4e00q6	1792	2	histological	histological	JJ
cord-014712-5u4e00q6	1792	3	study	study	NN
cord-014712-5u4e00q6	1792	4	showed	show	VBD
cord-014712-5u4e00q6	1792	5	the	the	DT
cord-014712-5u4e00q6	1792	6	angiolimphoid	angiolimphoid	NNP
cord-014712-5u4e00q6	1792	7	hyperplasia	hyperplasia	NN
cord-014712-5u4e00q6	1792	8	with	with	IN
cord-014712-5u4e00q6	1792	9	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	1792	10	without	without	IN
cord-014712-5u4e00q6	1792	11	Immunomorphological	Immunomorphological	NNP
cord-014712-5u4e00q6	1792	12	signs	sign	NNS
cord-014712-5u4e00q6	1792	13	of	of	IN
cord-014712-5u4e00q6	1792	14	malignant	malignant	JJ
cord-014712-5u4e00q6	1792	15	tumor	tumor	NN
cord-014712-5u4e00q6	1792	16	growth	growth	NN
cord-014712-5u4e00q6	1792	17	.	.	.
cord-014712-5u4e00q6	1793	1	Based	base	VBN
cord-014712-5u4e00q6	1793	2	on	on	IN
cord-014712-5u4e00q6	1793	3	histological	histological	JJ
cord-014712-5u4e00q6	1793	4	,	,	,
cord-014712-5u4e00q6	1793	5	immunohistochemical	immunohistochemical	JJ
cord-014712-5u4e00q6	1793	6	studies	study	NNS
cord-014712-5u4e00q6	1793	7	of	of	IN
cord-014712-5u4e00q6	1793	8	the	the	DT
cord-014712-5u4e00q6	1793	9	skin	skin	NN
cord-014712-5u4e00q6	1793	10	,	,	,
cord-014712-5u4e00q6	1793	11	these	these	DT
cord-014712-5u4e00q6	1793	12	clinical	clinical	JJ
cord-014712-5u4e00q6	1793	13	and	and	CC
cord-014712-5u4e00q6	1793	14	laboratory	laboratory	NN
cord-014712-5u4e00q6	1793	15	findings	finding	NNS
cord-014712-5u4e00q6	1793	16	,	,	,
cord-014712-5u4e00q6	1793	17	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1793	18	:	:	:
cord-014712-5u4e00q6	1793	19	mass	mass	JJ
cord-014712-5u4e00q6	1793	20	lesion	lesion	NN
cord-014712-5u4e00q6	1793	21	of	of	IN
cord-014712-5u4e00q6	1793	22	the	the	DT
cord-014712-5u4e00q6	1793	23	left	left	JJ
cord-014712-5u4e00q6	1793	24	face	face	NN
cord-014712-5u4e00q6	1793	25	-Kimura	-Kimura	VBZ
cord-014712-5u4e00q6	1793	26	disease	disease	NN
cord-014712-5u4e00q6	1793	27	.	.	.
cord-014712-5u4e00q6	1794	1	Patient	patient	NN
cord-014712-5u4e00q6	1794	2	helded	helde	VBD
cord-014712-5u4e00q6	1794	3	6	6	CD
cord-014712-5u4e00q6	1794	4	courses	course	NNS
cord-014712-5u4e00q6	1794	5	of	of	IN
cord-014712-5u4e00q6	1794	6	chemotherapy	chemotherapy	NN
cord-014712-5u4e00q6	1794	7	with	with	IN
cord-014712-5u4e00q6	1794	8	positive	positive	JJ
cord-014712-5u4e00q6	1794	9	dynamics	dynamic	NNS
cord-014712-5u4e00q6	1794	10	:	:	:
cord-014712-5u4e00q6	1794	11	mass	mass	NN
cord-014712-5u4e00q6	1794	12	lesion	lesion	NN
cord-014712-5u4e00q6	1794	13	decreased	decrease	VBD
cord-014712-5u4e00q6	1794	14	,	,	,
cord-014712-5u4e00q6	1794	15	erosive	erosive	JJ
cord-014712-5u4e00q6	1794	16	surfaces	surface	NNS
cord-014712-5u4e00q6	1794	17	disappeared	disappear	VBD
cord-014712-5u4e00q6	1794	18	and	and	CC
cord-014712-5u4e00q6	1794	19	now	now	RB
cord-014712-5u4e00q6	1794	20	receives	receive	VBZ
cord-014712-5u4e00q6	1794	21	Romiplostimum	Romiplostimum	NNP
cord-014712-5u4e00q6	1794	22	,	,	,
cord-014712-5u4e00q6	1794	23	Acyclovir	Acyclovir	NNP
cord-014712-5u4e00q6	1794	24	,	,	,
cord-014712-5u4e00q6	1794	25	Biseptolum	Biseptolum	NNP
cord-014712-5u4e00q6	1794	26	,	,	,
cord-014712-5u4e00q6	1794	27	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1794	28	0.5	0.5	CD
cord-014712-5u4e00q6	1794	29	g	g	NN
cord-014712-5u4e00q6	1794	30	/	/	SYM
cord-014712-5u4e00q6	1794	31	kg	kg	NN
cord-014712-5u4e00q6	1794	32	1	1	CD
cord-014712-5u4e00q6	1794	33	time	time	NN
cord-014712-5u4e00q6	1794	34	per	per	IN
cord-014712-5u4e00q6	1794	35	month	month	NN
cord-014712-5u4e00q6	1794	36	.	.	.
cord-014712-5u4e00q6	1795	1	Under	under	IN
cord-014712-5u4e00q6	1795	2	the	the	DT
cord-014712-5u4e00q6	1795	3	observation	observation	NN
cord-014712-5u4e00q6	1795	4	there	there	EX
cord-014712-5u4e00q6	1795	5	is	be	VBZ
cord-014712-5u4e00q6	1795	6	a	a	DT
cord-014712-5u4e00q6	1795	7	family	family	NN
cord-014712-5u4e00q6	1795	8	K.	K.	NNP
cord-014712-5u4e00q6	1795	9	,	,	,
cord-014712-5u4e00q6	1795	10	which	which	WDT
cord-014712-5u4e00q6	1795	11	is	be	VBZ
cord-014712-5u4e00q6	1795	12	unique	unique	JJ
cord-014712-5u4e00q6	1795	13	in	in	IN
cord-014712-5u4e00q6	1795	14	the	the	DT
cord-014712-5u4e00q6	1795	15	deletion	deletion	NN
cord-014712-5u4e00q6	1795	16	variants	variant	NNS
cord-014712-5u4e00q6	1795	17	of	of	IN
cord-014712-5u4e00q6	1795	18	the	the	DT
cord-014712-5u4e00q6	1795	19	same	same	JJ
cord-014712-5u4e00q6	1795	20	region	region	NN
cord-014712-5u4e00q6	1795	21	22q.11.2	22q.11.2	CD
cord-014712-5u4e00q6	1795	22	and	and	CC
cord-014712-5u4e00q6	1795	23	the	the	DT
cord-014712-5u4e00q6	1795	24	presence	presence	NN
cord-014712-5u4e00q6	1795	25	of	of	IN
cord-014712-5u4e00q6	1795	26	an	an	DT
cord-014712-5u4e00q6	1795	27	adult	adult	NN
cord-014712-5u4e00q6	1795	28	patient	patient	NN
cord-014712-5u4e00q6	1795	29	with	with	IN
cord-014712-5u4e00q6	1795	30	the	the	DT
cord-014712-5u4e00q6	1795	31	Di	Di	NNP
cord-014712-5u4e00q6	1795	32	George	George	NNP
cord-014712-5u4e00q6	1795	33	syndrome	syndrome	NN
cord-014712-5u4e00q6	1795	34	.	.	.
cord-014712-5u4e00q6	1796	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	1796	2	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1796	3	of	of	IN
cord-014712-5u4e00q6	1796	4	the	the	DT
cord-014712-5u4e00q6	1796	5	syndrome	syndrome	NN
cord-014712-5u4e00q6	1796	6	in	in	IN
cord-014712-5u4e00q6	1796	7	family	family	NN
cord-014712-5u4e00q6	1796	8	members	member	NNS
cord-014712-5u4e00q6	1796	9	is	be	VBZ
cord-014712-5u4e00q6	1796	10	differ	differ	JJ
cord-014712-5u4e00q6	1796	11	.	.	.
cord-014712-5u4e00q6	1797	1	Methods	method	NNS
cord-014712-5u4e00q6	1797	2	:	:	:
cord-014712-5u4e00q6	1797	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1797	4	,	,	,
cord-014712-5u4e00q6	1797	5	laboratory	laboratory	NN
cord-014712-5u4e00q6	1797	6	,	,	,
cord-014712-5u4e00q6	1797	7	instrumental	instrumental	JJ
cord-014712-5u4e00q6	1797	8	and	and	CC
cord-014712-5u4e00q6	1797	9	genetic	genetic	JJ
cord-014712-5u4e00q6	1797	10	(	(	-LRB-
cord-014712-5u4e00q6	1797	11	DNA	DNA	NNP
cord-014712-5u4e00q6	1797	12	was	be	VBD
cord-014712-5u4e00q6	1797	13	isolated	isolate	VBN
cord-014712-5u4e00q6	1797	14	using	use	VBG
cord-014712-5u4e00q6	1797	15	a	a	DT
cord-014712-5u4e00q6	1797	16	kit	kit	NN
cord-014712-5u4e00q6	1797	17	«	«	NN
cord-014712-5u4e00q6	1797	18	QIAamp	QIAamp	NNP
cord-014712-5u4e00q6	1797	19	DNA	DNA	NNP
cord-014712-5u4e00q6	1797	20	Mini	Mini	NNP
cord-014712-5u4e00q6	1797	21	Kit	kit	NN
cord-014712-5u4e00q6	1797	22	»	»	''
cord-014712-5u4e00q6	1797	23	and	and	CC
cord-014712-5u4e00q6	1797	24	DNA	DNA	NNP
cord-014712-5u4e00q6	1797	25	from	from	IN
cord-014712-5u4e00q6	1797	26	dried	dry	VBN
cord-014712-5u4e00q6	1797	27	blood	blood	NN
cord-014712-5u4e00q6	1797	28	spots	spot	NNS
cord-014712-5u4e00q6	1797	29	was	be	VBD
cord-014712-5u4e00q6	1797	30	isolated	isolate	VBN
cord-014712-5u4e00q6	1797	31	using	use	VBG
cord-014712-5u4e00q6	1797	32	a	a	DT
cord-014712-5u4e00q6	1797	33	commercial	commercial	JJ
cord-014712-5u4e00q6	1797	34	kit	kit	NN
cord-014712-5u4e00q6	1797	35	"	"	``
cord-014712-5u4e00q6	1797	36	DNA	dna	NN
cord-014712-5u4e00q6	1797	37	-	-	HYPH
cord-014712-5u4e00q6	1797	38	sorb	sorb	NN
cord-014712-5u4e00q6	1797	39	-	-	HYPH
cord-014712-5u4e00q6	1797	40	B	B	NNP
cord-014712-5u4e00q6	1797	41	»	»	NN
cord-014712-5u4e00q6	1797	42	.	.	.
cord-014712-5u4e00q6	1798	1	MLPAanalysis	MLPAanalysis	NNP
cord-014712-5u4e00q6	1798	2	set	set	VBD
cord-014712-5u4e00q6	1798	3	SALSA	SALSA	NNP
cord-014712-5u4e00q6	1798	4	MLPA	MLPA	NNP
cord-014712-5u4e00q6	1798	5	probemix	probemix	XX
cord-014712-5u4e00q6	1799	1	P250-B2	P250-B2	NNP
cord-014712-5u4e00q6	1799	2	DiGeorge	DiGeorge	NNP
cord-014712-5u4e00q6	1799	3	,	,	,
cord-014712-5u4e00q6	1799	4	Genetic	Genetic	NNP
cord-014712-5u4e00q6	1799	5	Analyzer	Analyzer	NNP
cord-014712-5u4e00q6	1799	6	Applied	Applied	NNP
cord-014712-5u4e00q6	1799	7	Biosystems	Biosystems	NNP
cord-014712-5u4e00q6	1799	8	3500	3500	CD
cord-014712-5u4e00q6	1799	9	)	)	-RRB-
cord-014712-5u4e00q6	1799	10	.	.	.
cord-014712-5u4e00q6	1800	1	Mother	mother	NN
cord-014712-5u4e00q6	1800	2	(	(	-LRB-
cord-014712-5u4e00q6	1800	3	34	34	CD
cord-014712-5u4e00q6	1800	4	years	year	NNS
cord-014712-5u4e00q6	1800	5	)	)	-RRB-
cord-014712-5u4e00q6	1800	6	,	,	,
cord-014712-5u4e00q6	1800	7	had	have	VBD
cord-014712-5u4e00q6	1800	8	few	few	JJ
cord-014712-5u4e00q6	1800	9	incidents	incident	NNS
cord-014712-5u4e00q6	1800	10	of	of	IN
cord-014712-5u4e00q6	1800	11	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1800	12	before	before	IN
cord-014712-5u4e00q6	1800	13	10	10	CD
cord-014712-5u4e00q6	1800	14	years	year	NNS
cord-014712-5u4e00q6	1800	15	.	.	.
cord-014712-5u4e00q6	1801	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1801	2	was	be	VBD
cord-014712-5u4e00q6	1801	3	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1801	4	Ullrich	Ullrich	NNP
cord-014712-5u4e00q6	1801	5	-	-	HYPH
cord-014712-5u4e00q6	1801	6	Turner	Turner	NNP
cord-014712-5u4e00q6	1801	7	syndrome	syndrome	NN
cord-014712-5u4e00q6	1801	8	at	at	IN
cord-014712-5u4e00q6	1801	9	age	age	NN
cord-014712-5u4e00q6	1801	10	10	10	CD
cord-014712-5u4e00q6	1801	11	years	year	NNS
cord-014712-5u4e00q6	1801	12	.	.	.
cord-014712-5u4e00q6	1802	1	All	all	DT
cord-014712-5u4e00q6	1802	2	childbirths	childbirth	NNS
cord-014712-5u4e00q6	1802	3	by	by	IN
cord-014712-5u4e00q6	1802	4	Caesarean	caesarean	JJ
cord-014712-5u4e00q6	1802	5	section	section	NN
cord-014712-5u4e00q6	1802	6	.	.	.
cord-014712-5u4e00q6	1803	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1803	2	has	have	VBZ
cord-014712-5u4e00q6	1803	3	not	not	RB
cord-014712-5u4e00q6	1803	4	any	any	DT
cord-014712-5u4e00q6	1803	5	laboratory	laboratory	NN
cord-014712-5u4e00q6	1803	6	and	and	CC
cord-014712-5u4e00q6	1803	7	instrumental	instrumental	JJ
cord-014712-5u4e00q6	1803	8	findings	finding	NNS
cord-014712-5u4e00q6	1803	9	of	of	IN
cord-014712-5u4e00q6	1803	10	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1803	11	,	,	,
cord-014712-5u4e00q6	1803	12	endocrinopathy	endocrinopathy	NNP
cord-014712-5u4e00q6	1803	13	,	,	,
cord-014712-5u4e00q6	1803	14	cardiac	cardiac	NN
cord-014712-5u4e00q6	1803	15	and	and	CC
cord-014712-5u4e00q6	1803	16	thyroid	thyroid	JJ
cord-014712-5u4e00q6	1803	17	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	1803	18	.	.	.
cord-014712-5u4e00q6	1804	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1804	2	has	have	VBZ
cord-014712-5u4e00q6	1804	3	deletion	deletion	NN
cord-014712-5u4e00q6	1804	4	in	in	IN
cord-014712-5u4e00q6	1804	5	the	the	DT
cord-014712-5u4e00q6	1804	6	starting	starting	NN
cord-014712-5u4e00q6	1804	7	area	area	NN
cord-014712-5u4e00q6	1804	8	of	of	IN
cord-014712-5u4e00q6	1804	9	the	the	DT
cord-014712-5u4e00q6	1804	10	Di	Di	NNP
cord-014712-5u4e00q6	1804	11	George	George	NNP
cord-014712-5u4e00q6	1804	12	region	region	NN
cord-014712-5u4e00q6	1804	13	(	(	-LRB-
cord-014712-5u4e00q6	1804	14	LCR22-A	LCR22-A	NNP
cord-014712-5u4e00q6	1804	15	)	)	-RRB-
cord-014712-5u4e00q6	1804	16	,	,	,
cord-014712-5u4e00q6	1804	17	including	include	VBG
cord-014712-5u4e00q6	1804	18	genes	gene	NNS
cord-014712-5u4e00q6	1804	19	CLTCL1	CLTCL1	NNP
cord-014712-5u4e00q6	1804	20	,	,	,
cord-014712-5u4e00q6	1804	21	HIRA	HIRA	NNP
cord-014712-5u4e00q6	1804	22	,	,	,
cord-014712-5u4e00q6	1804	23	CDC45	CDC45	NNP
cord-014712-5u4e00q6	1804	24	,	,	,
cord-014712-5u4e00q6	1804	25	CLDN5	CLDN5	NNP
cord-014712-5u4e00q6	1804	26	,	,	,
cord-014712-5u4e00q6	1804	27	GP1BB	GP1BB	NNP
cord-014712-5u4e00q6	1804	28	,	,	,
cord-014712-5u4e00q6	1804	29	TBX1	TBX1	NNP
cord-014712-5u4e00q6	1804	30	,	,	,
cord-014712-5u4e00q6	1804	31	TXNRD2	txnrd2	NN
cord-014712-5u4e00q6	1804	32	,	,	,
cord-014712-5u4e00q6	1804	33	DGCR8	DGCR8	NNP
cord-014712-5u4e00q6	1804	34	.	.	.
cord-014712-5u4e00q6	1805	1	Father	Father	NNP
cord-014712-5u4e00q6	1805	2	(	(	-LRB-
cord-014712-5u4e00q6	1805	3	36	36	CD
cord-014712-5u4e00q6	1805	4	years	year	NNS
cord-014712-5u4e00q6	1805	5	)	)	-RRB-
cord-014712-5u4e00q6	1805	6	,	,	,
cord-014712-5u4e00q6	1805	7	healthy	healthy	JJ
cord-014712-5u4e00q6	1805	8	,	,	,
cord-014712-5u4e00q6	1805	9	current	current	JJ
cord-014712-5u4e00q6	1805	10	smoker	smoker	NN
cord-014712-5u4e00q6	1805	11	.	.	.
cord-014712-5u4e00q6	1806	1	The	the	DT
cord-014712-5u4e00q6	1806	2	DNA	dna	NN
cord-014712-5u4e00q6	1806	3	microstructural	microstructural	JJ
cord-014712-5u4e00q6	1806	4	violations	violation	NNS
cord-014712-5u4e00q6	1806	5	in	in	IN
cord-014712-5u4e00q6	1806	6	Di	Di	NNP
cord-014712-5u4e00q6	1806	7	George	George	NNP
cord-014712-5u4e00q6	1806	8	region	region	NN
cord-014712-5u4e00q6	1806	9	have	have	VBP
cord-014712-5u4e00q6	1806	10	n't	not	RB
cord-014712-5u4e00q6	1806	11	been	be	VBN
cord-014712-5u4e00q6	1806	12	identified	identify	VBN
cord-014712-5u4e00q6	1806	13	.	.	.
cord-014712-5u4e00q6	1807	1	Son	Son	NNP
cord-014712-5u4e00q6	1807	2	was	be	VBD
cord-014712-5u4e00q6	1807	3	from	from	IN
cord-014712-5u4e00q6	1807	4	I	-PRON-	PRP
cord-014712-5u4e00q6	1807	5	pregnancy	pregnancy	NN
cord-014712-5u4e00q6	1807	6	,	,	,
cord-014712-5u4e00q6	1807	7	heart	heart	NN
cord-014712-5u4e00q6	1807	8	defect	defect	NN
cord-014712-5u4e00q6	1807	9	was	be	VBD
cord-014712-5u4e00q6	1807	10	set	set	VBN
cord-014712-5u4e00q6	1807	11	prenatally	prenatally	RB
cord-014712-5u4e00q6	1807	12	,	,	,
cord-014712-5u4e00q6	1807	13	marked	mark	VBN
cord-014712-5u4e00q6	1807	14	growth	growth	NN
cord-014712-5u4e00q6	1807	15	retardation	retardation	NN
cord-014712-5u4e00q6	1807	16	.	.	.
cord-014712-5u4e00q6	1808	1	Childbirth	childbirth	NN
cord-014712-5u4e00q6	1808	2	at	at	IN
cord-014712-5u4e00q6	1808	3	38	38	CD
cord-014712-5u4e00q6	1808	4	weeks	week	NNS
cord-014712-5u4e00q6	1808	5	.	.	.
cord-014712-5u4e00q6	1809	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1809	2	had	have	VBD
cord-014712-5u4e00q6	1809	3	unstable	unstable	JJ
cord-014712-5u4e00q6	1809	4	reduced	reduce	VBN
cord-014712-5u4e00q6	1809	5	cell	cell	NN
cord-014712-5u4e00q6	1809	6	parameters	parameter	NNS
cord-014712-5u4e00q6	1809	7	and	and	CC
cord-014712-5u4e00q6	1809	8	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-014712-5u4e00q6	1809	9	,	,	,
cord-014712-5u4e00q6	1809	10	the	the	DT
cord-014712-5u4e00q6	1809	11	size	size	NN
cord-014712-5u4e00q6	1809	12	reduction	reduction	NN
cord-014712-5u4e00q6	1809	13	of	of	IN
cord-014712-5u4e00q6	1809	14	the	the	DT
cord-014712-5u4e00q6	1809	15	thymus	thymus	NN
cord-014712-5u4e00q6	1809	16	and	and	CC
cord-014712-5u4e00q6	1809	17	congenital	congenital	JJ
cord-014712-5u4e00q6	1809	18	heart	heart	NN
cord-014712-5u4e00q6	1809	19	disease	disease	NN
cord-014712-5u4e00q6	1809	20	:	:	:
cord-014712-5u4e00q6	1809	21	truncus	truncus	NNP
cord-014712-5u4e00q6	1809	22	arteriosus	arteriosus	NNP
cord-014712-5u4e00q6	1809	23	,	,	,
cord-014712-5u4e00q6	1809	24	DC	DC	NNP
cord-014712-5u4e00q6	1809	25	2b	2b	CD
cord-014712-5u4e00q6	1809	26	stage	stage	NN
cord-014712-5u4e00q6	1809	27	by	by	IN
cord-014712-5u4e00q6	1809	28	Lang	Lang	NNP
cord-014712-5u4e00q6	1809	29	.	.	.
cord-014712-5u4e00q6	1810	1	After	after	IN
cord-014712-5u4e00q6	1810	2	42	42	CD
cord-014712-5u4e00q6	1810	3	days	day	NNS
cord-014712-5u4e00q6	1810	4	of	of	IN
cord-014712-5u4e00q6	1810	5	life	life	NN
cord-014712-5u4e00q6	1810	6	operated	operate	VBN
cord-014712-5u4e00q6	1810	7	for	for	IN
cord-014712-5u4e00q6	1810	8	congenital	congenital	JJ
cord-014712-5u4e00q6	1810	9	heart	heart	NN
cord-014712-5u4e00q6	1810	10	disease	disease	NN
cord-014712-5u4e00q6	1810	11	.	.	.
cord-014712-5u4e00q6	1811	1	During	during	IN
cord-014712-5u4e00q6	1811	2	the	the	DT
cord-014712-5u4e00q6	1811	3	surgical	surgical	JJ
cord-014712-5u4e00q6	1811	4	intervention	intervention	NN
cord-014712-5u4e00q6	1811	5	the	the	DT
cord-014712-5u4e00q6	1811	6	thymus	thymus	NN
cord-014712-5u4e00q6	1811	7	was	be	VBD
cord-014712-5u4e00q6	1811	8	n't	not	RB
cord-014712-5u4e00q6	1811	9	found	find	VBN
cord-014712-5u4e00q6	1811	10	in	in	IN
cord-014712-5u4e00q6	1811	11	a	a	DT
cord-014712-5u4e00q6	1811	12	typical	typical	JJ
cord-014712-5u4e00q6	1811	13	place	place	NN
cord-014712-5u4e00q6	1811	14	.	.	.
cord-014712-5u4e00q6	1812	1	The	the	DT
cord-014712-5u4e00q6	1812	2	postoperative	postoperative	JJ
cord-014712-5u4e00q6	1812	3	period	period	NN
cord-014712-5u4e00q6	1812	4	was	be	VBD
cord-014712-5u4e00q6	1812	5	complicated	complicate	VBN
cord-014712-5u4e00q6	1812	6	by	by	IN
cord-014712-5u4e00q6	1812	7	sepsis	sepsis	NN
cord-014712-5u4e00q6	1812	8	,	,	,
cord-014712-5u4e00q6	1812	9	heart	heart	NN
cord-014712-5u4e00q6	1812	10	and	and	CC
cord-014712-5u4e00q6	1812	11	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1812	12	failure	failure	NN
cord-014712-5u4e00q6	1812	13	.	.	.
cord-014712-5u4e00q6	1813	1	Received	receive	VBN
cord-014712-5u4e00q6	1813	2	IVIG	IVIG	NNP
cord-014712-5u4e00q6	1813	3	,	,	,
cord-014712-5u4e00q6	1813	4	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	1813	5	and	and	CC
cord-014712-5u4e00q6	1813	6	antifungal	antifungal	JJ
cord-014712-5u4e00q6	1813	7	therapy	therapy	NN
cord-014712-5u4e00q6	1813	8	.	.	.
cord-014712-5u4e00q6	1814	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1814	2	suffered	suffer	VBD
cord-014712-5u4e00q6	1814	3	from	from	IN
cord-014712-5u4e00q6	1814	4	SARS	SARS	NNP
cord-014712-5u4e00q6	1814	5	,	,	,
cord-014712-5u4e00q6	1814	6	severe	severe	JJ
cord-014712-5u4e00q6	1814	7	course	course	NN
cord-014712-5u4e00q6	1814	8	,	,	,
cord-014712-5u4e00q6	1814	9	the	the	DT
cord-014712-5u4e00q6	1814	10	degree	degree	NN
cord-014712-5u4e00q6	1814	11	of	of	IN
cord-014712-5u4e00q6	1814	12	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1814	13	failure	failure	NN
cord-014712-5u4e00q6	1814	14	2	2	CD
cord-014712-5u4e00q6	1814	15	(	(	-LRB-
cord-014712-5u4e00q6	1814	16	8	8	CD
cord-014712-5u4e00q6	1814	17	months	month	NNS
cord-014712-5u4e00q6	1814	18	)	)	-RRB-
cord-014712-5u4e00q6	1814	19	-death	-death	CD
cord-014712-5u4e00q6	1814	20	.	.	.
cord-014712-5u4e00q6	1815	1	In	in	IN
cord-014712-5u4e00q6	1815	2	MLPA	MLPA	NNP
cord-014712-5u4e00q6	1815	3	-	-	HYPH
cord-014712-5u4e00q6	1815	4	DNA	DNA	NNP
cord-014712-5u4e00q6	1815	5	defined	define	VBN
cord-014712-5u4e00q6	1815	6	microdeletion	microdeletion	NN
cord-014712-5u4e00q6	1815	7	disorders	disorder	NNS
cord-014712-5u4e00q6	1815	8	starting	start	VBG
cord-014712-5u4e00q6	1815	9	region	region	NN
cord-014712-5u4e00q6	1815	10	Di	Di	NNP
cord-014712-5u4e00q6	1815	11	George	George	NNP
cord-014712-5u4e00q6	1815	12	(	(	-LRB-
cord-014712-5u4e00q6	1815	13	LCR22-A	LCR22-A	NNP
cord-014712-5u4e00q6	1815	14	)	)	-RRB-
cord-014712-5u4e00q6	1816	1	-from	-from	JJ
cord-014712-5u4e00q6	1817	1	the	the	DT
cord-014712-5u4e00q6	1817	2	4-year	4-year	JJ
cord-014712-5u4e00q6	1817	3	-	-	HYPH
cord-014712-5u4e00q6	1817	4	old	old	JJ
cord-014712-5u4e00q6	1817	5	dry	dry	JJ
cord-014712-5u4e00q6	1817	6	blood	blood	NN
cord-014712-5u4e00q6	1817	7	sample	sample	NN
cord-014712-5u4e00q6	1817	8	(	(	-LRB-
cord-014712-5u4e00q6	1817	9	postmortem	postmortem	JJ
cord-014712-5u4e00q6	1817	10	study	study	NN
cord-014712-5u4e00q6	1817	11	 	 	_SP
cord-014712-5u4e00q6	1817	12	A	a	DT
cord-014712-5u4e00q6	1817	13	3	3	CD
cord-014712-5u4e00q6	1817	14	year	year	NN
cord-014712-5u4e00q6	1817	15	old	old	JJ
cord-014712-5u4e00q6	1817	16	boy	boy	NN
cord-014712-5u4e00q6	1817	17	with	with	IN
cord-014712-5u4e00q6	1817	18	bleeding	bleeding	NN
cord-014712-5u4e00q6	1817	19	,	,	,
cord-014712-5u4e00q6	1817	20	eczema	eczema	NN
cord-014712-5u4e00q6	1817	21	and	and	CC
cord-014712-5u4e00q6	1817	22	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1817	23	pyogenic	pyogenic	JJ
cord-014712-5u4e00q6	1817	24	infection	infection	NN
cord-014712-5u4e00q6	1817	25	was	be	VBD
cord-014712-5u4e00q6	1817	26	admitted	admit	VBN
cord-014712-5u4e00q6	1817	27	to	to	IN
cord-014712-5u4e00q6	1817	28	our	-PRON-	PRP$
cord-014712-5u4e00q6	1817	29	department	department	NN
cord-014712-5u4e00q6	1817	30	.	.	.
cord-014712-5u4e00q6	1818	1	The	the	DT
cord-014712-5u4e00q6	1818	2	child	child	NN
cord-014712-5u4e00q6	1818	3	who	who	WP
cord-014712-5u4e00q6	1818	4	received	receive	VBD
cord-014712-5u4e00q6	1818	5	treatment	treatment	NN
cord-014712-5u4e00q6	1818	6	in	in	IN
cord-014712-5u4e00q6	1818	7	hematology	hematology	NN
cord-014712-5u4e00q6	1818	8	accidentally	accidentally	RB
cord-014712-5u4e00q6	1818	9	a	a	DT
cord-014712-5u4e00q6	1818	10	few	few	JJ
cord-014712-5u4e00q6	1818	11	times	time	NNS
cord-014712-5u4e00q6	1818	12	,	,	,
cord-014712-5u4e00q6	1818	13	but	but	CC
cord-014712-5u4e00q6	1818	14	has	have	VBZ
cord-014712-5u4e00q6	1818	15	not	not	RB
cord-014712-5u4e00q6	1818	16	had	have	VBN
cord-014712-5u4e00q6	1818	17	the	the	DT
cord-014712-5u4e00q6	1818	18	effect	effect	NN
cord-014712-5u4e00q6	1818	19	of	of	IN
cord-014712-5u4e00q6	1818	20	treatment	treatment	NN
cord-014712-5u4e00q6	1818	21	.	.	.
cord-014712-5u4e00q6	1819	1	Laboratory	laboratory	NN
cord-014712-5u4e00q6	1819	2	parameters	parameter	NNS
cord-014712-5u4e00q6	1819	3	-CD3-cells-59	-cd3-cells-59	IN
cord-014712-5u4e00q6	1819	4	%	%	NN
cord-014712-5u4e00q6	1819	5	(	(	-LRB-
cord-014712-5u4e00q6	1819	6	5550	5550	CD
cord-014712-5u4e00q6	1819	7	)	)	-RRB-
cord-014712-5u4e00q6	1819	8	,	,	,
cord-014712-5u4e00q6	1819	9	CD4-cells	cd4-cell	NNS
cord-014712-5u4e00q6	1819	10	-22	-22	IN
cord-014712-5u4e00q6	1819	11	%	%	NN
cord-014712-5u4e00q6	1819	12	(	(	-LRB-
cord-014712-5u4e00q6	1819	13	1221	1221	CD
cord-014712-5u4e00q6	1819	14	)	)	-RRB-
cord-014712-5u4e00q6	1819	15	,	,	,
cord-014712-5u4e00q6	1819	16	CD8-cells	CD8-cells	NNP
cord-014712-5u4e00q6	1819	17	-37	-37	NNP
cord-014712-5u4e00q6	1819	18	%	%	NN
cord-014712-5u4e00q6	1819	19	(	(	-LRB-
cord-014712-5u4e00q6	1819	20	2053	2053	CD
cord-014712-5u4e00q6	1819	21	)	)	-RRB-
cord-014712-5u4e00q6	1819	22	,	,	,
cord-014712-5u4e00q6	1819	23	CD19-cells	CD19-cells	NNP
cord-014712-5u4e00q6	1819	24	-29	-29	CD
cord-014712-5u4e00q6	1819	25	%	%	NN
cord-014712-5u4e00q6	1819	26	(	(	-LRB-
cord-014712-5u4e00q6	1819	27	2728	2728	CD
cord-014712-5u4e00q6	1819	28	)	)	-RRB-
cord-014712-5u4e00q6	1819	29	,	,	,
cord-014712-5u4e00q6	1819	30	CD16	CD16	NNP
cord-014712-5u4e00q6	1819	31	/	/	SYM
cord-014712-5u4e00q6	1819	32	56-cells	56-cells	CD
cord-014712-5u4e00q6	1819	33	-15	-15	CD
cord-014712-5u4e00q6	1819	34	%	%	NN
cord-014712-5u4e00q6	1819	35	(	(	-LRB-
cord-014712-5u4e00q6	1819	36	1411	1411	CD
cord-014712-5u4e00q6	1819	37	)	)	-RRB-
cord-014712-5u4e00q6	1819	38	,	,	,
cord-014712-5u4e00q6	1819	39	CD4	CD4	NNP
cord-014712-5u4e00q6	1819	40	/	/	SYM
cord-014712-5u4e00q6	1819	41	CD8	CD8	NNP
cord-014712-5u4e00q6	1819	42	-	-	HYPH
cord-014712-5u4e00q6	1819	43	0.59	0.59	CD
cord-014712-5u4e00q6	1819	44	,	,	,
cord-014712-5u4e00q6	1819	45	HLA	HLA	NNP
cord-014712-5u4e00q6	1819	46	-	-	HYPH
cord-014712-5u4e00q6	1819	47	DR-22	DR-22	NNP
cord-014712-5u4e00q6	1819	48	,	,	,
cord-014712-5u4e00q6	1819	49	NBT-73	NBT-73	NNPS
cord-014712-5u4e00q6	1819	50	.	.	.
cord-014712-5u4e00q6	1820	1	IgG-14.6	IgG-14.6	NNP
cord-014712-5u4e00q6	1821	1	q	q	NNP
cord-014712-5u4e00q6	1821	2	/l	/l	NNP
cord-014712-5u4e00q6	1821	3	,	,	,
cord-014712-5u4e00q6	1821	4	IgA-3.3	IgA-3.3	NNP
cord-014712-5u4e00q6	1822	1	q	q	NNP
cord-014712-5u4e00q6	1822	2	/	/	SYM
cord-014712-5u4e00q6	1822	3	l	l	NNP
cord-014712-5u4e00q6	1822	4	,	,	,
cord-014712-5u4e00q6	1822	5	IgM	IgM	NNP
cord-014712-5u4e00q6	1822	6	-4.3	-4.3	NNP
cord-014712-5u4e00q6	1822	7	q	q	NNP
cord-014712-5u4e00q6	1822	8	/	/	SYM
cord-014712-5u4e00q6	1822	9	l	l	NN
cord-014712-5u4e00q6	1822	10	,	,	,
cord-014712-5u4e00q6	1822	11	IgE-328	ige-328	RB
cord-014712-5u4e00q6	1822	12	U	u	NN
cord-014712-5u4e00q6	1822	13	/	/	SYM
cord-014712-5u4e00q6	1822	14	ml	ml	NN
cord-014712-5u4e00q6	1822	15	.	.	.
cord-014712-5u4e00q6	1822	16	HB-40	HB-40	NNP
cord-014712-5u4e00q6	1822	17	g	g	NNP
cord-014712-5u4e00q6	1822	18	/	/	SYM
cord-014712-5u4e00q6	1822	19	l	l	NN
cord-014712-5u4e00q6	1822	20	,	,	,
cord-014712-5u4e00q6	1822	21	erythrocytes-1.75x	erythrocytes-1.75x	NN
cord-014712-5u4e00q6	1822	22	10	10	CD
cord-014712-5u4e00q6	1822	23	12	12	CD
cord-014712-5u4e00q6	1822	24	/	/	SYM
cord-014712-5u4e00q6	1822	25	l	l	NN
cord-014712-5u4e00q6	1822	26	,	,	,
cord-014712-5u4e00q6	1822	27	leukosytes	leukosytes	NNP
cord-014712-5u4e00q6	1822	28	-15.6x10	-15.6x10	NNP
cord-014712-5u4e00q6	1822	29	9	9	CD
cord-014712-5u4e00q6	1822	30	/	/	SYM
cord-014712-5u4e00q6	1822	31	l	l	NN
cord-014712-5u4e00q6	1822	32	,	,	,
cord-014712-5u4e00q6	1822	33	neutrophils-31	neutrophils-31	CD
cord-014712-5u4e00q6	1822	34	%	%	NN
cord-014712-5u4e00q6	1822	35	,	,	,
cord-014712-5u4e00q6	1822	36	lymphocytes	lymphocyte	VBZ
cord-014712-5u4e00q6	1822	37	-56	-56	IN
cord-014712-5u4e00q6	1822	38	%	%	NN
cord-014712-5u4e00q6	1822	39	(	(	-LRB-
cord-014712-5u4e00q6	1822	40	9408	9408	CD
cord-014712-5u4e00q6	1822	41	)	)	-RRB-
cord-014712-5u4e00q6	1822	42	,	,	,
cord-014712-5u4e00q6	1822	43	eosinophils-2	eosinophils-2	NNP
cord-014712-5u4e00q6	1822	44	%	%	NN
cord-014712-5u4e00q6	1822	45	,	,	,
cord-014712-5u4e00q6	1822	46	monocytes-2	monocytes-2	NNP
cord-014712-5u4e00q6	1822	47	%	%	NN
cord-014712-5u4e00q6	1822	48	,	,	,
cord-014712-5u4e00q6	1822	49	metamielosytes:-9	metamielosytes:-9	NNP
cord-014712-5u4e00q6	1822	50	%	%	NN
cord-014712-5u4e00q6	1822	51	,	,	,
cord-014712-5u4e00q6	1822	52	plateletsrare	plateletsrare	NNP
cord-014712-5u4e00q6	1822	53	was	be	VBD
cord-014712-5u4e00q6	1822	54	observed	observe	VBN
cord-014712-5u4e00q6	1822	55	.	.	.
cord-014712-5u4e00q6	1823	1	Normal	normal	JJ
cord-014712-5u4e00q6	1823	2	bone	bone	NN
cord-014712-5u4e00q6	1823	3	marrow	marrow	NN
cord-014712-5u4e00q6	1823	4	cells	cell	NNS
cord-014712-5u4e00q6	1823	5	,	,	,
cord-014712-5u4e00q6	1823	6	the	the	DT
cord-014712-5u4e00q6	1823	7	separation	separation	NN
cord-014712-5u4e00q6	1823	8	of	of	IN
cord-014712-5u4e00q6	1823	9	platelets	platelet	NNS
cord-014712-5u4e00q6	1823	10	from	from	IN
cord-014712-5u4e00q6	1823	11	meqakariosyt	meqakariosyt	NNP
cord-014712-5u4e00q6	1823	12	has	have	VBZ
cord-014712-5u4e00q6	1823	13	become	become	VBN
cord-014712-5u4e00q6	1823	14	weak	weak	JJ
cord-014712-5u4e00q6	1823	15	.	.	.
cord-014712-5u4e00q6	1824	1	The	the	DT
cord-014712-5u4e00q6	1824	2	advantage	advantage	NN
cord-014712-5u4e00q6	1824	3	of	of	IN
cord-014712-5u4e00q6	1824	4	erythroid	erythroid	NN
cord-014712-5u4e00q6	1824	5	unordered	unordered	JJ
cord-014712-5u4e00q6	1824	6	have	have	VBP
cord-014712-5u4e00q6	1824	7	been	be	VBN
cord-014712-5u4e00q6	1824	8	observed	observe	VBN
cord-014712-5u4e00q6	1824	9	.	.	.
cord-014712-5u4e00q6	1825	1	Bone	bone	NN
cord-014712-5u4e00q6	1825	2	marrow	marrow	NN
cord-014712-5u4e00q6	1825	3	puncture	puncture	VBP
cord-014712-5u4e00q6	1825	4	the	the	DT
cord-014712-5u4e00q6	1825	5	mielokariosytes	mielokariosytes	NNPS
cord-014712-5u4e00q6	1825	6	-87.0	-87.0	ADD
cord-014712-5u4e00q6	1826	1	x10	x10	NNP
cord-014712-5u4e00q6	1826	2	9	9	CD
cord-014712-5u4e00q6	1826	3	/	/	SYM
cord-014712-5u4e00q6	1826	4	l	l	NNP
cord-014712-5u4e00q6	1826	5	,	,	,
cord-014712-5u4e00q6	1826	6	meqakariosytes	meqakariosytes	NNP
cord-014712-5u4e00q6	1826	7	-0.01x10	-0.01x10	NNP
cord-014712-5u4e00q6	1826	8	9	9	CD
cord-014712-5u4e00q6	1826	9	/	/	SYM
cord-014712-5u4e00q6	1826	10	l	l	NNP
cord-014712-5u4e00q6	1826	11	,	,	,
cord-014712-5u4e00q6	1826	12	blasts-1.2	blasts-1.2	NNP
cord-014712-5u4e00q6	1826	13	%	%	NN
cord-014712-5u4e00q6	1826	14	,	,	,
cord-014712-5u4e00q6	1826	15	myelosytes	myelosyte	VBZ
cord-014712-5u4e00q6	1826	16	-7.4	-7.4	NNP
cord-014712-5u4e00q6	1826	17	%	%	NN
cord-014712-5u4e00q6	1826	18	,	,	,
cord-014712-5u4e00q6	1826	19	metamyelosytes	metamyelosytes	NNP
cord-014712-5u4e00q6	1826	20	-9.2	-9.2	NNP
cord-014712-5u4e00q6	1826	21	%	%	NN
cord-014712-5u4e00q6	1826	22	,	,	,
cord-014712-5u4e00q6	1826	23	seqments	seqment	NNS
cord-014712-5u4e00q6	1826	24	-14.2	-14.2	XX
cord-014712-5u4e00q6	1827	1	%	%	NN
cord-014712-5u4e00q6	1827	2	neutrophils-%	neutrophils-%	NNP
cord-014712-5u4e00q6	1827	3	51.6	51.6	CD
cord-014712-5u4e00q6	1827	4	,	,	,
cord-014712-5u4e00q6	1827	5	eosinophils-1.4	eosinophils-1.4	VB
cord-014712-5u4e00q6	1827	6	%	%	NN
cord-014712-5u4e00q6	1827	7	,	,	,
cord-014712-5u4e00q6	1827	8	lymphocytes-5.8	lymphocytes-5.8	CD
cord-014712-5u4e00q6	1827	9	%	%	NN
cord-014712-5u4e00q6	1827	10	,	,	,
cord-014712-5u4e00q6	1827	11	monocytes-0.4	monocytes-0.4	NNS
cord-014712-5u4e00q6	1827	12	%	%	NN
cord-014712-5u4e00q6	1827	13	erythroblasts-2.0	erythroblasts-2.0	CD
cord-014712-5u4e00q6	1827	14	%	%	NN
cord-014712-5u4e00q6	1827	15	,	,	,
cord-014712-5u4e00q6	1827	16	pronormoblasts-2.8	pronormoblasts-2.8	VBG
cord-014712-5u4e00q6	1827	17	%	%	NN
cord-014712-5u4e00q6	1827	18	,	,	,
cord-014712-5u4e00q6	1827	19	normoblasts-40.0	normoblasts-40.0	NNP
cord-014712-5u4e00q6	1827	20	%	%	NN
cord-014712-5u4e00q6	1827	21	meqakariosytes	meqakariosyte	NNS
cord-014712-5u4e00q6	1827	22	-0.4	-0.4	CD
cord-014712-5u4e00q6	1827	23	%	%	NN
cord-014712-5u4e00q6	1827	24	,	,	,
cord-014712-5u4e00q6	1828	1	plasmatic	plasmatic	NNP
cord-014712-5u4e00q6	1828	2	cells-0.2%.His	cells-0.2%.His	NNP
cord-014712-5u4e00q6	1828	3	younger	young	JJR
cord-014712-5u4e00q6	1828	4	brother	brother	NN
cord-014712-5u4e00q6	1828	5	with	with	IN
cord-014712-5u4e00q6	1828	6	eczema	eczema	NN
cord-014712-5u4e00q6	1828	7	,	,	,
cord-014712-5u4e00q6	1829	1	pyogenic	pyogenic	JJ
cord-014712-5u4e00q6	1829	2	infections	infection	NNS
cord-014712-5u4e00q6	1829	3	(	(	-LRB-
cord-014712-5u4e00q6	1829	4	furunculosis	furunculosis	NNP
cord-014712-5u4e00q6	1829	5	)	)	-RRB-
cord-014712-5u4e00q6	1829	6	was	be	VBD
cord-014712-5u4e00q6	1829	7	admitted	admit	VBN
cord-014712-5u4e00q6	1829	8	to	to	IN
cord-014712-5u4e00q6	1829	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	1829	10	department	department	NN
cord-014712-5u4e00q6	1829	11	.	.	.
cord-014712-5u4e00q6	1830	1	CD3	CD3	NNP
cord-014712-5u4e00q6	1830	2	-	-	HYPH
cord-014712-5u4e00q6	1830	3	38	38	CD
cord-014712-5u4e00q6	1830	4	%	%	NN
cord-014712-5u4e00q6	1830	5	(	(	-LRB-
cord-014712-5u4e00q6	1830	6	1761	1761	CD
cord-014712-5u4e00q6	1830	7	)	)	-RRB-
cord-014712-5u4e00q6	1831	1	Ataxia	Ataxia	NNP
cord-014712-5u4e00q6	1831	2	telangiectasia	telangiectasia	NNP
cord-014712-5u4e00q6	1831	3	(	(	-LRB-
cord-014712-5u4e00q6	1831	4	A	A	NNP
cord-014712-5u4e00q6	1831	5	-	-	HYPH
cord-014712-5u4e00q6	1831	6	T	T	NNP
cord-014712-5u4e00q6	1831	7	)	)	-RRB-
cord-014712-5u4e00q6	1831	8	,	,	,
cord-014712-5u4e00q6	1831	9	is	be	VBZ
cord-014712-5u4e00q6	1831	10	a	a	DT
cord-014712-5u4e00q6	1831	11	genetic	genetic	JJ
cord-014712-5u4e00q6	1831	12	disorder	disorder	NN
cord-014712-5u4e00q6	1831	13	caused	cause	VBN
cord-014712-5u4e00q6	1831	14	by	by	IN
cord-014712-5u4e00q6	1831	15	the	the	DT
cord-014712-5u4e00q6	1831	16	homozygous	homozygous	JJ
cord-014712-5u4e00q6	1831	17	mutation	mutation	NN
cord-014712-5u4e00q6	1831	18	of	of	IN
cord-014712-5u4e00q6	1831	19	the	the	DT
cord-014712-5u4e00q6	1831	20	ATM	ATM	NNP
cord-014712-5u4e00q6	1831	21	gene	gene	NN
cord-014712-5u4e00q6	1831	22	and	and	CC
cord-014712-5u4e00q6	1831	23	,	,	,
cord-014712-5u4e00q6	1831	24	frequently	frequently	RB
cord-014712-5u4e00q6	1831	25	associates	associate	VBZ
cord-014712-5u4e00q6	1831	26	with	with	IN
cord-014712-5u4e00q6	1831	27	variable	variable	JJ
cord-014712-5u4e00q6	1831	28	degrees	degree	NNS
cord-014712-5u4e00q6	1831	29	of	of	IN
cord-014712-5u4e00q6	1831	30	cellular	cellular	JJ
cord-014712-5u4e00q6	1831	31	and	and	CC
cord-014712-5u4e00q6	1831	32	humoral	humoral	JJ
cord-014712-5u4e00q6	1831	33	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1831	34	.	.	.
cord-014712-5u4e00q6	1832	1	However	however	RB
cord-014712-5u4e00q6	1832	2	,	,	,
cord-014712-5u4e00q6	1832	3	the	the	DT
cord-014712-5u4e00q6	1832	4	immune	immune	JJ
cord-014712-5u4e00q6	1832	5	defects	defect	NNS
cord-014712-5u4e00q6	1832	6	in	in	IN
cord-014712-5u4e00q6	1832	7	patients	patient	NNS
cord-014712-5u4e00q6	1832	8	with	with	IN
cord-014712-5u4e00q6	1832	9	A	A	NNP
cord-014712-5u4e00q6	1832	10	-	-	HYPH
cord-014712-5u4e00q6	1832	11	T	T	NNP
cord-014712-5u4e00q6	1832	12	are	be	VBP
cord-014712-5u4e00q6	1832	13	not	not	RB
cord-014712-5u4e00q6	1832	14	well	well	RB
cord-014712-5u4e00q6	1832	15	characterized	characterize	VBN
cord-014712-5u4e00q6	1832	16	.	.	.
cord-014712-5u4e00q6	1833	1	To	to	IN
cord-014712-5u4e00q6	1833	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	1833	3	knowledge	knowledge	NN
cord-014712-5u4e00q6	1833	4	,	,	,
cord-014712-5u4e00q6	1833	5	there	there	EX
cord-014712-5u4e00q6	1833	6	is	be	VBZ
cord-014712-5u4e00q6	1833	7	no	no	DT
cord-014712-5u4e00q6	1833	8	work	work	NN
cord-014712-5u4e00q6	1833	9	on	on	IN
cord-014712-5u4e00q6	1833	10	major	major	JJ
cord-014712-5u4e00q6	1833	11	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1833	12	subpopulations	subpopulation	NNS
cord-014712-5u4e00q6	1833	13	and	and	CC
cord-014712-5u4e00q6	1833	14	recent	recent	JJ
cord-014712-5u4e00q6	1833	15	thymic	thymic	JJ
cord-014712-5u4e00q6	1833	16	emigrants	emigrant	NNS
cord-014712-5u4e00q6	1833	17	of	of	IN
cord-014712-5u4e00q6	1833	18	A	A	NNP
cord-014712-5u4e00q6	1833	19	-	-	HYPH
cord-014712-5u4e00q6	1833	20	T	t	NN
cord-014712-5u4e00q6	1833	21	patients	patient	NNS
cord-014712-5u4e00q6	1833	22	comparing	compare	VBG
cord-014712-5u4e00q6	1833	23	to	to	IN
cord-014712-5u4e00q6	1833	24	age	age	NN
cord-014712-5u4e00q6	1833	25	-	-	HYPH
cord-014712-5u4e00q6	1833	26	matched	match	VBN
cord-014712-5u4e00q6	1833	27	healthy	healthy	JJ
cord-014712-5u4e00q6	1833	28	controls	control	NNS
cord-014712-5u4e00q6	1833	29	.	.	.
cord-014712-5u4e00q6	1834	1	According	accord	VBG
cord-014712-5u4e00q6	1834	2	to	to	IN
cord-014712-5u4e00q6	1834	3	ESID	ESID	NNP
cord-014712-5u4e00q6	1834	4	criteria	criterion	NNS
cord-014712-5u4e00q6	1834	5	,	,	,
cord-014712-5u4e00q6	1834	6	17	17	CD
cord-014712-5u4e00q6	1834	7	patients	patient	NNS
cord-014712-5u4e00q6	1834	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1834	9	as	as	IN
cord-014712-5u4e00q6	1834	10	A	A	NNP
cord-014712-5u4e00q6	1834	11	-	-	HYPH
cord-014712-5u4e00q6	1834	12	T	t	NN
cord-014712-5u4e00q6	1834	13	and	and	CC
cord-014712-5u4e00q6	1834	14	12	12	CD
cord-014712-5u4e00q6	1834	15	agematched	agematche	VBD
cord-014712-5u4e00q6	1834	16	healthy	healthy	JJ
cord-014712-5u4e00q6	1834	17	children	child	NNS
cord-014712-5u4e00q6	1834	18	were	be	VBD
cord-014712-5u4e00q6	1834	19	assigned	assign	VBN
cord-014712-5u4e00q6	1834	20	to	to	IN
cord-014712-5u4e00q6	1834	21	the	the	DT
cord-014712-5u4e00q6	1834	22	study	study	NN
cord-014712-5u4e00q6	1834	23	.	.	.
cord-014712-5u4e00q6	1835	1	Both	both	DT
cord-014712-5u4e00q6	1835	2	patients	patient	NNS
cord-014712-5u4e00q6	1835	3	and	and	CC
cord-014712-5u4e00q6	1835	4	healthy	healthy	JJ
cord-014712-5u4e00q6	1835	5	controls	control	NNS
cord-014712-5u4e00q6	1835	6	were	be	VBD
cord-014712-5u4e00q6	1835	7	grouped	group	VBN
cord-014712-5u4e00q6	1835	8	as	as	IN
cord-014712-5u4e00q6	1835	9	0	0	CD
cord-014712-5u4e00q6	1835	10	-	-	SYM
cord-014712-5u4e00q6	1835	11	5	5	CD
cord-014712-5u4e00q6	1835	12	,	,	,
cord-014712-5u4e00q6	1835	13	6	6	CD
cord-014712-5u4e00q6	1835	14	-	-	SYM
cord-014712-5u4e00q6	1835	15	10	10	CD
cord-014712-5u4e00q6	1835	16	,	,	,
cord-014712-5u4e00q6	1835	17	7	7	CD
cord-014712-5u4e00q6	1835	18	-	-	SYM
cord-014712-5u4e00q6	1835	19	15	15	CD
cord-014712-5u4e00q6	1835	20	years	year	NNS
cord-014712-5u4e00q6	1835	21	and	and	CC
cord-014712-5u4e00q6	1835	22	older	old	JJR
cord-014712-5u4e00q6	1835	23	than	than	IN
cord-014712-5u4e00q6	1835	24	16	16	CD
cord-014712-5u4e00q6	1835	25	years	year	NNS
cord-014712-5u4e00q6	1835	26	.	.	.
cord-014712-5u4e00q6	1836	1	Using	use	VBG
cord-014712-5u4e00q6	1836	2	flow	flow	NN
cord-014712-5u4e00q6	1836	3	cytometer	cytometer	NN
cord-014712-5u4e00q6	1836	4	,	,	,
cord-014712-5u4e00q6	1836	5	major	major	JJ
cord-014712-5u4e00q6	1836	6	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1836	7	subpopulations	subpopulation	NNS
cord-014712-5u4e00q6	1836	8	and	and	CC
cord-014712-5u4e00q6	1836	9	CD4	CD4	NNP
cord-014712-5u4e00q6	1836	10	+	+	CC
cord-014712-5u4e00q6	1836	11	CD45RA	CD45RA	NNP
cord-014712-5u4e00q6	1836	12	+	+	CC
cord-014712-5u4e00q6	1836	13	CD31	CD31	NNP
cord-014712-5u4e00q6	1836	14	+	+	CC
cord-014712-5u4e00q6	1836	15	recent	recent	JJ
cord-014712-5u4e00q6	1836	16	thymic	thymic	JJ
cord-014712-5u4e00q6	1836	17	emigrants	emigrant	NNS
cord-014712-5u4e00q6	1836	18	(	(	-LRB-
cord-014712-5u4e00q6	1836	19	RTE	RTE	NNP
cord-014712-5u4e00q6	1836	20	)	)	-RRB-
cord-014712-5u4e00q6	1836	21	were	be	VBD
cord-014712-5u4e00q6	1836	22	determined	determine	VBN
cord-014712-5u4e00q6	1836	23	as	as	IN
cord-014712-5u4e00q6	1836	24	per	per	IN
cord-014712-5u4e00q6	1836	25	cent	cent	NN
cord-014712-5u4e00q6	1836	26	and	and	CC
cord-014712-5u4e00q6	1836	27	absolute	absolute	JJ
cord-014712-5u4e00q6	1836	28	cell	cell	NN
cord-014712-5u4e00q6	1836	29	numbers	number	NNS
cord-014712-5u4e00q6	1836	30	and	and	CC
cord-014712-5u4e00q6	1836	31	compared	compare	VBN
cord-014712-5u4e00q6	1836	32	.	.	.
cord-014712-5u4e00q6	1837	1	No	no	DT
cord-014712-5u4e00q6	1837	2	significant	significant	JJ
cord-014712-5u4e00q6	1837	3	differences	difference	NNS
cord-014712-5u4e00q6	1837	4	regarding	regard	VBG
cord-014712-5u4e00q6	1837	5	all	all	DT
cord-014712-5u4e00q6	1837	6	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1837	7	subpopulations	subpopulation	NNS
cord-014712-5u4e00q6	1837	8	were	be	VBD
cord-014712-5u4e00q6	1837	9	observed	observe	VBN
cord-014712-5u4e00q6	1837	10	between	between	IN
cord-014712-5u4e00q6	1837	11	age	age	NN
cord-014712-5u4e00q6	1837	12	groups	group	NNS
cord-014712-5u4e00q6	1837	13	of	of	IN
cord-014712-5u4e00q6	1838	1	A	a	LS
cord-014712-5u4e00q6	1838	2	-	-	HYPH
cord-014712-5u4e00q6	1838	3	T.	t.	NN
cord-014712-5u4e00q6	1838	4	Comparing	comparing	NN
cord-014712-5u4e00q6	1838	5	to	to	IN
cord-014712-5u4e00q6	1838	6	the	the	DT
cord-014712-5u4e00q6	1838	7	healthy	healthy	JJ
cord-014712-5u4e00q6	1838	8	controls	control	NNS
cord-014712-5u4e00q6	1838	9	,	,	,
cord-014712-5u4e00q6	1838	10	there	there	EX
cord-014712-5u4e00q6	1838	11	were	be	VBD
cord-014712-5u4e00q6	1838	12	a	a	DT
cord-014712-5u4e00q6	1838	13	decrease	decrease	NN
cord-014712-5u4e00q6	1838	14	(	(	-LRB-
cord-014712-5u4e00q6	1838	15	in	in	IN
cord-014712-5u4e00q6	1838	16	T	t	NN
cord-014712-5u4e00q6	1838	17	cells	cell	NNS
cord-014712-5u4e00q6	1838	18	,	,	,
cord-014712-5u4e00q6	1838	19	effector	effector	JJ
cord-014712-5u4e00q6	1838	20	memory	memory	NN
cord-014712-5u4e00q6	1838	21	T4	T4	NNP
cord-014712-5u4e00q6	1838	22	cells	cell	NNS
cord-014712-5u4e00q6	1838	23	,	,	,
cord-014712-5u4e00q6	1838	24	B	b	NN
cord-014712-5u4e00q6	1838	25	cells	cell	NNS
cord-014712-5u4e00q6	1838	26	,	,	,
cord-014712-5u4e00q6	1838	27	naïve	naïve	JJ
cord-014712-5u4e00q6	1838	28	B	B	NNP
cord-014712-5u4e00q6	1838	29	cells	cell	NNS
cord-014712-5u4e00q6	1838	30	,	,	,
cord-014712-5u4e00q6	1838	31	switched	switch	VBD
cord-014712-5u4e00q6	1838	32	B	b	NN
cord-014712-5u4e00q6	1838	33	cells	cell	NNS
cord-014712-5u4e00q6	1838	34	and	and	CC
cord-014712-5u4e00q6	1838	35	RTE	RTE	NNP
cord-014712-5u4e00q6	1838	36	)	)	-RRB-
cord-014712-5u4e00q6	1838	37	and	and	CC
cord-014712-5u4e00q6	1838	38	there	there	EX
cord-014712-5u4e00q6	1838	39	were	be	VBD
cord-014712-5u4e00q6	1838	40	an	an	DT
cord-014712-5u4e00q6	1838	41	increase	increase	NN
cord-014712-5u4e00q6	1838	42	(	(	-LRB-
cord-014712-5u4e00q6	1838	43	in	in	IN
cord-014712-5u4e00q6	1838	44	active	active	JJ
cord-014712-5u4e00q6	1838	45	T8	T8	NNP
cord-014712-5u4e00q6	1838	46	cells	cell	NNS
cord-014712-5u4e00q6	1838	47	,	,	,
cord-014712-5u4e00q6	1838	48	naïve	naïve	JJ
cord-014712-5u4e00q6	1838	49	T4	T4	NNP
cord-014712-5u4e00q6	1838	50	cells	cell	NNS
cord-014712-5u4e00q6	1838	51	and	and	CC
cord-014712-5u4e00q6	1838	52	nonswitched	nonswitche	VBN
cord-014712-5u4e00q6	1838	53	B	b	NN
cord-014712-5u4e00q6	1838	54	cells	cell	NNS
cord-014712-5u4e00q6	1838	55	)	)	-RRB-
cord-014712-5u4e00q6	1838	56	in	in	IN
cord-014712-5u4e00q6	1838	57	the	the	DT
cord-014712-5u4e00q6	1838	58	absolute	absolute	JJ
cord-014712-5u4e00q6	1838	59	number	number	NN
cord-014712-5u4e00q6	1838	60	and	and	CC
cord-014712-5u4e00q6	1838	61	percent	percent	NN
cord-014712-5u4e00q6	1838	62	of	of	IN
cord-014712-5u4e00q6	1838	63	some	some	DT
cord-014712-5u4e00q6	1838	64	cell	cell	NN
cord-014712-5u4e00q6	1838	65	populations	population	NNS
cord-014712-5u4e00q6	1838	66	in	in	IN
cord-014712-5u4e00q6	1838	67	the	the	DT
cord-014712-5u4e00q6	1838	68	A	A	NNP
cord-014712-5u4e00q6	1838	69	-	-	HYPH
cord-014712-5u4e00q6	1838	70	T	t	NN
cord-014712-5u4e00q6	1838	71	group	group	NN
cord-014712-5u4e00q6	1838	72	.	.	.
cord-014712-5u4e00q6	1839	1	Findings	finding	NNS
cord-014712-5u4e00q6	1839	2	of	of	IN
cord-014712-5u4e00q6	1839	3	this	this	DT
cord-014712-5u4e00q6	1839	4	study	study	NN
cord-014712-5u4e00q6	1839	5	showed	show	VBD
cord-014712-5u4e00q6	1839	6	effector	effector	JJ
cord-014712-5u4e00q6	1839	7	functions	function	NNS
cord-014712-5u4e00q6	1839	8	in	in	IN
cord-014712-5u4e00q6	1839	9	some	some	DT
cord-014712-5u4e00q6	1839	10	cell	cell	NN
cord-014712-5u4e00q6	1839	11	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	1839	12	populations	population	NNS
cord-014712-5u4e00q6	1839	13	were	be	VBD
cord-014712-5u4e00q6	1839	14	decreased	decrease	VBN
cord-014712-5u4e00q6	1839	15	and	and	CC
cord-014712-5u4e00q6	1839	16	could	could	MD
cord-014712-5u4e00q6	1839	17	be	be	VB
cord-014712-5u4e00q6	1839	18	thought	think	VBN
cord-014712-5u4e00q6	1839	19	that	that	IN
cord-014712-5u4e00q6	1839	20	bone	bone	NN
cord-014712-5u4e00q6	1839	21	marrow	marrow	NN
cord-014712-5u4e00q6	1839	22	of	of	IN
cord-014712-5u4e00q6	1839	23	patients	patient	NNS
cord-014712-5u4e00q6	1839	24	should	should	MD
cord-014712-5u4e00q6	1839	25	be	be	VB
cord-014712-5u4e00q6	1839	26	tried	try	VBN
cord-014712-5u4e00q6	1839	27	to	to	TO
cord-014712-5u4e00q6	1839	28	increase	increase	VB
cord-014712-5u4e00q6	1839	29	the	the	DT
cord-014712-5u4e00q6	1839	30	cells	cell	NNS
cord-014712-5u4e00q6	1839	31	numbers	number	NNS
cord-014712-5u4e00q6	1839	32	.	.	.
cord-014712-5u4e00q6	1840	1	However	however	RB
cord-014712-5u4e00q6	1840	2	,	,	,
cord-014712-5u4e00q6	1840	3	the	the	DT
cord-014712-5u4e00q6	1840	4	study	study	NN
cord-014712-5u4e00q6	1840	5	has	have	VBZ
cord-014712-5u4e00q6	1840	6	an	an	DT
cord-014712-5u4e00q6	1840	7	important	important	JJ
cord-014712-5u4e00q6	1840	8	limitation	limitation	NN
cord-014712-5u4e00q6	1840	9	about	about	IN
cord-014712-5u4e00q6	1840	10	patient	patient	JJ
cord-014712-5u4e00q6	1840	11	and	and	CC
cord-014712-5u4e00q6	1840	12	healthy	healthy	JJ
cord-014712-5u4e00q6	1840	13	population	population	NN
cord-014712-5u4e00q6	1840	14	.	.	.
cord-014712-5u4e00q6	1841	1	Ataxia	ataxia	NN
cord-014712-5u4e00q6	1841	2	-	-	HYPH
cord-014712-5u4e00q6	1841	3	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1841	4	(	(	-LRB-
cord-014712-5u4e00q6	1841	5	A	A	NNP
cord-014712-5u4e00q6	1841	6	-	-	HYPH
cord-014712-5u4e00q6	1841	7	T	T	NNP
cord-014712-5u4e00q6	1841	8	)	)	-RRB-
cord-014712-5u4e00q6	1841	9	results	result	VBZ
cord-014712-5u4e00q6	1841	10	from	from	IN
cord-014712-5u4e00q6	1841	11	the	the	DT
cord-014712-5u4e00q6	1841	12	loss	loss	NN
cord-014712-5u4e00q6	1841	13	of	of	IN
cord-014712-5u4e00q6	1841	14	ataxia	ataxia	NN
cord-014712-5u4e00q6	1841	15	-	-	HYPH
cord-014712-5u4e00q6	1841	16	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1841	17	mutated	mutate	VBN
cord-014712-5u4e00q6	1841	18	gene	gene	NN
cord-014712-5u4e00q6	1841	19	(	(	-LRB-
cord-014712-5u4e00q6	1841	20	ATM	ATM	NNP
cord-014712-5u4e00q6	1841	21	)	)	-RRB-
cord-014712-5u4e00q6	1841	22	function	function	NN
cord-014712-5u4e00q6	1841	23	and	and	CC
cord-014712-5u4e00q6	1841	24	is	be	VBZ
cord-014712-5u4e00q6	1841	25	a	a	DT
cord-014712-5u4e00q6	1841	26	heterogeneous	heterogeneous	JJ
cord-014712-5u4e00q6	1841	27	,	,	,
cord-014712-5u4e00q6	1841	28	multisystemic	multisystemic	JJ
cord-014712-5u4e00q6	1841	29	disease	disease	NN
cord-014712-5u4e00q6	1841	30	and	and	CC
cord-014712-5u4e00q6	1841	31	characterized	characterize	VBN
cord-014712-5u4e00q6	1841	32	by	by	IN
cord-014712-5u4e00q6	1841	33	accelerated	accelerated	JJ
cord-014712-5u4e00q6	1841	34	telomere	telomere	NN
cord-014712-5u4e00q6	1841	35	loss	loss	NN
cord-014712-5u4e00q6	1841	36	,	,	,
cord-014712-5u4e00q6	1841	37	genomic	genomic	JJ
cord-014712-5u4e00q6	1841	38	instability	instability	NN
cord-014712-5u4e00q6	1841	39	,	,	,
cord-014712-5u4e00q6	1841	40	progressive	progressive	JJ
cord-014712-5u4e00q6	1841	41	neurological	neurological	JJ
cord-014712-5u4e00q6	1841	42	degeneration	degeneration	NN
cord-014712-5u4e00q6	1841	43	,	,	,
cord-014712-5u4e00q6	1841	44	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1841	45	,	,	,
cord-014712-5u4e00q6	1841	46	premature	premature	JJ
cord-014712-5u4e00q6	1841	47	ageing	ageing	NN
cord-014712-5u4e00q6	1841	48	and	and	CC
cord-014712-5u4e00q6	1841	49	increased	increase	VBN
cord-014712-5u4e00q6	1841	50	neoplasia	neoplasia	NN
cord-014712-5u4e00q6	1841	51	incidence	incidence	NN
cord-014712-5u4e00q6	1841	52	.	.	.
cord-014712-5u4e00q6	1842	1	Even	even	RB
cord-014712-5u4e00q6	1842	2	in	in	IN
cord-014712-5u4e00q6	1842	3	classic	classic	JJ
cord-014712-5u4e00q6	1842	4	A	A	NNP
cord-014712-5u4e00q6	1842	5	-	-	HYPH
cord-014712-5u4e00q6	1842	6	T	t	NN
cord-014712-5u4e00q6	1842	7	with	with	IN
cord-014712-5u4e00q6	1842	8	ataxia	ataxia	NN
cord-014712-5u4e00q6	1842	9	and	and	CC
cord-014712-5u4e00q6	1842	10	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1842	11	,	,	,
cord-014712-5u4e00q6	1842	12	the	the	DT
cord-014712-5u4e00q6	1842	13	onset	onset	NN
cord-014712-5u4e00q6	1842	14	of	of	IN
cord-014712-5u4e00q6	1842	15	clinical	clinical	JJ
cord-014712-5u4e00q6	1842	16	symptoms	symptom	NNS
cord-014712-5u4e00q6	1842	17	and	and	CC
cord-014712-5u4e00q6	1842	18	the	the	DT
cord-014712-5u4e00q6	1842	19	rate	rate	NN
cord-014712-5u4e00q6	1842	20	of	of	IN
cord-014712-5u4e00q6	1842	21	progression	progression	NN
cord-014712-5u4e00q6	1842	22	are	be	VBP
cord-014712-5u4e00q6	1842	23	variable	variable	JJ
cord-014712-5u4e00q6	1842	24	.	.	.
cord-014712-5u4e00q6	1843	1	Here	here	RB
cord-014712-5u4e00q6	1843	2	,	,	,
cord-014712-5u4e00q6	1843	3	we	-PRON-	PRP
cord-014712-5u4e00q6	1843	4	report	report	VBP
cord-014712-5u4e00q6	1843	5	two	two	CD
cord-014712-5u4e00q6	1843	6	siblings	sibling	NNS
cord-014712-5u4e00q6	1843	7	was	be	VBD
cord-014712-5u4e00q6	1843	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1843	9	as	as	IN
cord-014712-5u4e00q6	1843	10	A	A	NNP
cord-014712-5u4e00q6	1843	11	-	-	HYPH
cord-014712-5u4e00q6	1843	12	T	t	NN
cord-014712-5u4e00q6	1843	13	with	with	IN
cord-014712-5u4e00q6	1843	14	severe	severe	JJ
cord-014712-5u4e00q6	1843	15	and	and	CC
cord-014712-5u4e00q6	1843	16	early	early	JJ
cord-014712-5u4e00q6	1843	17	hypogamaglobulinemia	hypogamaglobulinemia	NN
cord-014712-5u4e00q6	1843	18	,	,	,
cord-014712-5u4e00q6	1843	19	decreased	decrease	VBD
cord-014712-5u4e00q6	1843	20	CD19	CD19	NNP
cord-014712-5u4e00q6	1843	21	,	,	,
cord-014712-5u4e00q6	1843	22	increased	increase	VBD
cord-014712-5u4e00q6	1843	23	CD45RO	CD45RO	NNP
cord-014712-5u4e00q6	1843	24	,	,	,
cord-014712-5u4e00q6	1843	25	no	no	DT
cord-014712-5u4e00q6	1843	26	ataxia	ataxia	NN
cord-014712-5u4e00q6	1843	27	and	and	CC
cord-014712-5u4e00q6	1843	28	telangiectasia	telangiectasia	NN
cord-014712-5u4e00q6	1843	29	,	,	,
cord-014712-5u4e00q6	1843	30	purulent	purulent	JJ
cord-014712-5u4e00q6	1843	31	otitis	otitis	NN
cord-014712-5u4e00q6	1843	32	and	and	CC
cord-014712-5u4e00q6	1843	33	hemophagocytosis	hemophagocytosis	NN
cord-014712-5u4e00q6	1843	34	that	that	WDT
cord-014712-5u4e00q6	1843	35	harbor	harbor	VBP
cord-014712-5u4e00q6	1843	36	a	a	DT
cord-014712-5u4e00q6	1843	37	rare	rare	JJ
cord-014712-5u4e00q6	1843	38	frameshift	frameshift	NN
cord-014712-5u4e00q6	1843	39	mutation	mutation	NN
cord-014712-5u4e00q6	1843	40	of	of	IN
cord-014712-5u4e00q6	1843	41	ATM	atm	NN
cord-014712-5u4e00q6	1843	42	gene	gene	NN
cord-014712-5u4e00q6	1843	43	.	.	.
cord-014712-5u4e00q6	1844	1	Nijmegen	Nijmegen	NNP
cord-014712-5u4e00q6	1844	2	breakage	breakage	NN
cord-014712-5u4e00q6	1844	3	syndrome(NBS	syndrome(NBS	NNP
cord-014712-5u4e00q6	1844	4	)	)	-RRB-
cord-014712-5u4e00q6	1844	5	is	be	VBZ
cord-014712-5u4e00q6	1844	6	a	a	DT
cord-014712-5u4e00q6	1844	7	rare	rare	JJ
cord-014712-5u4e00q6	1844	8	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1844	9	recessive	recessive	JJ
cord-014712-5u4e00q6	1844	10	disease	disease	NN
cord-014712-5u4e00q6	1844	11	usually	usually	RB
cord-014712-5u4e00q6	1844	12	presenting	present	VBG
cord-014712-5u4e00q6	1844	13	at	at	IN
cord-014712-5u4e00q6	1844	14	birth	birth	NN
cord-014712-5u4e00q6	1844	15	with	with	IN
cord-014712-5u4e00q6	1844	16	microcephaly	microcephaly	NNS
cord-014712-5u4e00q6	1844	17	.	.	.
cord-014712-5u4e00q6	1845	1	Here	here	RB
cord-014712-5u4e00q6	1845	2	we	-PRON-	PRP
cord-014712-5u4e00q6	1845	3	present	present	VBP
cord-014712-5u4e00q6	1845	4	a	a	DT
cord-014712-5u4e00q6	1845	5	case	case	NN
cord-014712-5u4e00q6	1845	6	of	of	IN
cord-014712-5u4e00q6	1845	7	NBS	NBS	NNP
cord-014712-5u4e00q6	1845	8	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1845	9	at	at	IN
cord-014712-5u4e00q6	1845	10	the	the	DT
cord-014712-5u4e00q6	1845	11	age	age	NN
cord-014712-5u4e00q6	1845	12	of	of	IN
cord-014712-5u4e00q6	1845	13	twenty	twenty	CD
cord-014712-5u4e00q6	1845	14	seven	seven	CD
cord-014712-5u4e00q6	1845	15	who	who	WP
cord-014712-5u4e00q6	1845	16	admitted	admit	VBD
cord-014712-5u4e00q6	1845	17	to	to	IN
cord-014712-5u4e00q6	1845	18	our	-PRON-	PRP$
cord-014712-5u4e00q6	1845	19	outpatient	outpatient	NN
cord-014712-5u4e00q6	1845	20	clinic	clinic	NN
cord-014712-5u4e00q6	1845	21	with	with	IN
cord-014712-5u4e00q6	1845	22	malaise	malaise	NN
cord-014712-5u4e00q6	1845	23	,	,	,
cord-014712-5u4e00q6	1845	24	loss	loss	NN
cord-014712-5u4e00q6	1845	25	of	of	IN
cord-014712-5u4e00q6	1845	26	appetite	appetite	NN
cord-014712-5u4e00q6	1845	27	,	,	,
cord-014712-5u4e00q6	1845	28	weight	weight	NN
cord-014712-5u4e00q6	1845	29	loss	loss	NN
cord-014712-5u4e00q6	1845	30	and	and	CC
cord-014712-5u4e00q6	1845	31	dyspnea	dyspnea	NN
cord-014712-5u4e00q6	1845	32	on	on	IN
cord-014712-5u4e00q6	1845	33	effort	effort	NN
cord-014712-5u4e00q6	1845	34	.	.	.
cord-014712-5u4e00q6	1846	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1846	2	was	be	VBD
cord-014712-5u4e00q6	1846	3	hospitalized	hospitalize	VBN
cord-014712-5u4e00q6	1846	4	in	in	IN
cord-014712-5u4e00q6	1846	5	another	another	DT
cord-014712-5u4e00q6	1846	6	centre	centre	NN
cord-014712-5u4e00q6	1846	7	2	2	CD
cord-014712-5u4e00q6	1846	8	years	year	NNS
cord-014712-5u4e00q6	1846	9	before	before	IN
cord-014712-5u4e00q6	1846	10	because	because	IN
cord-014712-5u4e00q6	1846	11	of	of	IN
cord-014712-5u4e00q6	1846	12	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1846	13	,	,	,
cord-014712-5u4e00q6	1846	14	pancytopenia	pancytopenia	NNP
cord-014712-5u4e00q6	1846	15	,	,	,
cord-014712-5u4e00q6	1846	16	generalized	generalize	VBN
cord-014712-5u4e00q6	1846	17	lymphadenopathy	lymphadenopathy	NNP
cord-014712-5u4e00q6	1846	18	,	,	,
cord-014712-5u4e00q6	1846	19	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-014712-5u4e00q6	1846	20	and	and	CC
cord-014712-5u4e00q6	1846	21	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1846	22	(	(	-LRB-
cord-014712-5u4e00q6	1846	23	very	very	RB
cord-014712-5u4e00q6	1846	24	low	low	JJ
cord-014712-5u4e00q6	1846	25	IgG	IgG	NNP
cord-014712-5u4e00q6	1846	26	and	and	CC
cord-014712-5u4e00q6	1846	27	IgA	IgA	NNP
cord-014712-5u4e00q6	1846	28	)	)	-RRB-
cord-014712-5u4e00q6	1846	29	where	where	WRB
cord-014712-5u4e00q6	1846	30	she	-PRON-	PRP
cord-014712-5u4e00q6	1846	31	could	could	MD
cord-014712-5u4e00q6	1846	32	n't	not	RB
cord-014712-5u4e00q6	1846	33	have	have	VB
cord-014712-5u4e00q6	1846	34	any	any	DT
cord-014712-5u4e00q6	1846	35	definite	definite	JJ
cord-014712-5u4e00q6	1846	36	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1846	37	.	.	.
cord-014712-5u4e00q6	1847	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1847	2	past	past	JJ
cord-014712-5u4e00q6	1847	3	medical	medical	JJ
cord-014712-5u4e00q6	1847	4	history	history	NN
cord-014712-5u4e00q6	1847	5	was	be	VBD
cord-014712-5u4e00q6	1847	6	remarkable	remarkable	JJ
cord-014712-5u4e00q6	1847	7	for	for	IN
cord-014712-5u4e00q6	1847	8	primary	primary	JJ
cord-014712-5u4e00q6	1847	9	amenorrhea	amenorrhea	NN
cord-014712-5u4e00q6	1847	10	and	and	CC
cord-014712-5u4e00q6	1847	11	basal	basal	NN
cord-014712-5u4e00q6	1847	12	cell	cell	NN
cord-014712-5u4e00q6	1847	13	carcinoma	carcinoma	NN
cord-014712-5u4e00q6	1847	14	excision	excision	NN
cord-014712-5u4e00q6	1847	15	from	from	IN
cord-014712-5u4e00q6	1847	16	preaericular	preaericular	JJ
cord-014712-5u4e00q6	1847	17	region	region	NN
cord-014712-5u4e00q6	1847	18	when	when	WRB
cord-014712-5u4e00q6	1847	19	she	-PRON-	PRP
cord-014712-5u4e00q6	1847	20	was	be	VBD
cord-014712-5u4e00q6	1847	21	23	23	CD
cord-014712-5u4e00q6	1847	22	.	.	.
cord-014712-5u4e00q6	1848	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1848	2	had	have	VBD
cord-014712-5u4e00q6	1848	3	no	no	DT
cord-014712-5u4e00q6	1848	4	severe	severe	JJ
cord-014712-5u4e00q6	1848	5	infection	infection	NN
cord-014712-5u4e00q6	1848	6	history	history	NN
cord-014712-5u4e00q6	1848	7	before	before	IN
cord-014712-5u4e00q6	1848	8	25	25	CD
cord-014712-5u4e00q6	1848	9	except	except	IN
cord-014712-5u4e00q6	1848	10	frequent	frequent	JJ
cord-014712-5u4e00q6	1848	11	upper	upper	JJ
cord-014712-5u4e00q6	1848	12	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1848	13	tract	tract	NN
cord-014712-5u4e00q6	1848	14	infections	infection	NNS
cord-014712-5u4e00q6	1848	15	.	.	.
cord-014712-5u4e00q6	1849	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	1849	2	parents	parent	NNS
cord-014712-5u4e00q6	1849	3	were	be	VBD
cord-014712-5u4e00q6	1849	4	consanginous	consanginous	JJ
cord-014712-5u4e00q6	1849	5	and	and	CC
cord-014712-5u4e00q6	1849	6	she	-PRON-	PRP
cord-014712-5u4e00q6	1849	7	had	have	VBD
cord-014712-5u4e00q6	1849	8	a	a	DT
cord-014712-5u4e00q6	1849	9	brother	brother	NN
cord-014712-5u4e00q6	1849	10	died	die	VBD
cord-014712-5u4e00q6	1849	11	at	at	IN
cord-014712-5u4e00q6	1849	12	6	6	CD
cord-014712-5u4e00q6	1849	13	months	month	NNS
cord-014712-5u4e00q6	1849	14	of	of	IN
cord-014712-5u4e00q6	1849	15	age	age	NN
cord-014712-5u4e00q6	1849	16	.	.	.
cord-014712-5u4e00q6	1850	1	Microcephaly	Microcephaly	NNP
cord-014712-5u4e00q6	1850	2	together	together	RB
cord-014712-5u4e00q6	1850	3	with	with	IN
cord-014712-5u4e00q6	1850	4	short	short	JJ
cord-014712-5u4e00q6	1850	5	stature	stature	NN
cord-014712-5u4e00q6	1850	6	,	,	,
cord-014712-5u4e00q6	1850	7	multiple	multiple	JJ
cord-014712-5u4e00q6	1850	8	palpable	palpable	JJ
cord-014712-5u4e00q6	1850	9	lymphadenopathies	lymphadenopathy	NNS
cord-014712-5u4e00q6	1850	10	,	,	,
cord-014712-5u4e00q6	1850	11	splenomegaly	splenomegaly	NN
cord-014712-5u4e00q6	1850	12	and	and	CC
cord-014712-5u4e00q6	1850	13	absent	absent	JJ
cord-014712-5u4e00q6	1850	14	secondary	secondary	JJ
cord-014712-5u4e00q6	1850	15	sexual	sexual	JJ
cord-014712-5u4e00q6	1850	16	characteristics	characteristic	NNS
cord-014712-5u4e00q6	1850	17	were	be	VBD
cord-014712-5u4e00q6	1850	18	prominent	prominent	JJ
cord-014712-5u4e00q6	1850	19	features	feature	NNS
cord-014712-5u4e00q6	1850	20	in	in	IN
cord-014712-5u4e00q6	1850	21	physical	physical	JJ
cord-014712-5u4e00q6	1850	22	examination	examination	NN
cord-014712-5u4e00q6	1850	23	.	.	.
cord-014712-5u4e00q6	1851	1	Direct	direct	JJ
cord-014712-5u4e00q6	1851	2	fluorescence	fluorescence	NN
cord-014712-5u4e00q6	1851	3	sequencing	sequencing	NN
cord-014712-5u4e00q6	1851	4	of	of	IN
cord-014712-5u4e00q6	1851	5	the	the	DT
cord-014712-5u4e00q6	1851	6	NBN	NBN	NNP
cord-014712-5u4e00q6	1851	7	gene	gene	NN
cord-014712-5u4e00q6	1851	8	showed	show	VBD
cord-014712-5u4e00q6	1851	9	a	a	DT
cord-014712-5u4e00q6	1851	10	homozygous	homozygous	JJ
cord-014712-5u4e00q6	1851	11	mutation	mutation	NN
cord-014712-5u4e00q6	1851	12	in	in	IN
cord-014712-5u4e00q6	1851	13	exon	exon	NN
cord-014712-5u4e00q6	1851	14	6	6	CD
cord-014712-5u4e00q6	1851	15	(	(	-LRB-
cord-014712-5u4e00q6	1851	16	c.657_661delACAAA	c.657_661delACAAA	NNP
cord-014712-5u4e00q6	1851	17	)	)	-RRB-
cord-014712-5u4e00q6	1851	18	which	which	WDT
cord-014712-5u4e00q6	1851	19	confirmed	confirm	VBD
cord-014712-5u4e00q6	1851	20	the	the	DT
cord-014712-5u4e00q6	1851	21	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1851	22	of	of	IN
cord-014712-5u4e00q6	1851	23	NBS	NBS	NNP
cord-014712-5u4e00q6	1851	24	in	in	IN
cord-014712-5u4e00q6	1851	25	our	-PRON-	PRP$
cord-014712-5u4e00q6	1851	26	patient	patient	NN
cord-014712-5u4e00q6	1851	27	.	.	.
cord-014712-5u4e00q6	1852	1	NBS	NBS	NNP
cord-014712-5u4e00q6	1852	2	is	be	VBZ
cord-014712-5u4e00q6	1852	3	mostly	mostly	RB
cord-014712-5u4e00q6	1852	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1852	5	in	in	IN
cord-014712-5u4e00q6	1852	6	childhood	childhood	NN
cord-014712-5u4e00q6	1852	7	.	.	.
cord-014712-5u4e00q6	1853	1	The	the	DT
cord-014712-5u4e00q6	1853	2	delay	delay	NN
cord-014712-5u4e00q6	1853	3	in	in	IN
cord-014712-5u4e00q6	1853	4	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1853	5	was	be	VBD
cord-014712-5u4e00q6	1853	6	partly	partly	RB
cord-014712-5u4e00q6	1853	7	due	due	JJ
cord-014712-5u4e00q6	1853	8	to	to	IN
cord-014712-5u4e00q6	1853	9	the	the	DT
cord-014712-5u4e00q6	1853	10	lack	lack	NN
cord-014712-5u4e00q6	1853	11	of	of	IN
cord-014712-5u4e00q6	1853	12	severe	severe	JJ
cord-014712-5u4e00q6	1853	13	infections	infection	NNS
cord-014712-5u4e00q6	1853	14	in	in	IN
cord-014712-5u4e00q6	1853	15	her	-PRON-	PRP$
cord-014712-5u4e00q6	1853	16	past	past	JJ
cord-014712-5u4e00q6	1853	17	medical	medical	JJ
cord-014712-5u4e00q6	1853	18	history	history	NN
cord-014712-5u4e00q6	1853	19	until	until	IN
cord-014712-5u4e00q6	1853	20	she	-PRON-	PRP
cord-014712-5u4e00q6	1853	21	was	be	VBD
cord-014712-5u4e00q6	1853	22	25	25	CD
cord-014712-5u4e00q6	1853	23	.	.	.
cord-014712-5u4e00q6	1854	1	Another	another	DT
cord-014712-5u4e00q6	1854	2	factor	factor	NN
cord-014712-5u4e00q6	1854	3	that	that	WDT
cord-014712-5u4e00q6	1854	4	lead	lead	VBP
cord-014712-5u4e00q6	1854	5	to	to	IN
cord-014712-5u4e00q6	1854	6	the	the	DT
cord-014712-5u4e00q6	1854	7	delay	delay	NN
cord-014712-5u4e00q6	1854	8	is	be	VBZ
cord-014712-5u4e00q6	1854	9	that	that	IN
cord-014712-5u4e00q6	1854	10	it	-PRON-	PRP
cord-014712-5u4e00q6	1854	11	is	be	VBZ
cord-014712-5u4e00q6	1854	12	an	an	DT
cord-014712-5u4e00q6	1854	13	unknown	unknown	JJ
cord-014712-5u4e00q6	1854	14	disease	disease	NN
cord-014712-5u4e00q6	1854	15	among	among	IN
cord-014712-5u4e00q6	1854	16	physicians	physician	NNS
cord-014712-5u4e00q6	1854	17	in	in	IN
cord-014712-5u4e00q6	1854	18	Turkey	Turkey	NNP
cord-014712-5u4e00q6	1854	19	.	.	.
cord-014712-5u4e00q6	1855	1	The	the	DT
cord-014712-5u4e00q6	1855	2	longest	long	RBS
cord-014712-5u4e00q6	1855	3	known	know	VBN
cord-014712-5u4e00q6	1855	4	survival	survival	NN
cord-014712-5u4e00q6	1855	5	is	be	VBZ
cord-014712-5u4e00q6	1855	6	53	53	CD
cord-014712-5u4e00q6	1855	7	years	year	NNS
cord-014712-5u4e00q6	1855	8	in	in	IN
cord-014712-5u4e00q6	1855	9	a	a	DT
cord-014712-5u4e00q6	1855	10	patient	patient	NN
cord-014712-5u4e00q6	1855	11	who	who	WP
cord-014712-5u4e00q6	1855	12	had	have	VBD
cord-014712-5u4e00q6	1855	13	no	no	DT
cord-014712-5u4e00q6	1855	14	clinical	clinical	JJ
cord-014712-5u4e00q6	1855	15	features	feature	NNS
cord-014712-5u4e00q6	1855	16	of	of	IN
cord-014712-5u4e00q6	1855	17	NBS	NBS	NNP
cord-014712-5u4e00q6	1855	18	other	other	JJ
cord-014712-5u4e00q6	1855	19	than	than	IN
cord-014712-5u4e00q6	1855	20	primary	primary	JJ
cord-014712-5u4e00q6	1855	21	amenorrhea	amenorrhea	NN
cord-014712-5u4e00q6	1855	22	.	.	.
cord-014712-5u4e00q6	1856	1	As	as	IN
cord-014712-5u4e00q6	1856	2	a	a	DT
cord-014712-5u4e00q6	1856	3	result	result	NN
cord-014712-5u4e00q6	1856	4	,	,	,
cord-014712-5u4e00q6	1856	5	our	-PRON-	PRP$
cord-014712-5u4e00q6	1856	6	patient	patient	NN
cord-014712-5u4e00q6	1856	7	is	be	VBZ
cord-014712-5u4e00q6	1856	8	one	one	CD
cord-014712-5u4e00q6	1856	9	of	of	IN
cord-014712-5u4e00q6	1856	10	the	the	DT
cord-014712-5u4e00q6	1856	11	oldest	old	JJS
cord-014712-5u4e00q6	1856	12	patients	patient	NNS
cord-014712-5u4e00q6	1856	13	reported	report	VBN
cord-014712-5u4e00q6	1856	14	in	in	IN
cord-014712-5u4e00q6	1856	15	the	the	DT
cord-014712-5u4e00q6	1856	16	literature	literature	NN
cord-014712-5u4e00q6	1856	17	presenting	present	VBG
cord-014712-5u4e00q6	1856	18	nearly	nearly	RB
cord-014712-5u4e00q6	1856	19	all	all	DT
cord-014712-5u4e00q6	1856	20	of	of	IN
cord-014712-5u4e00q6	1856	21	the	the	DT
cord-014712-5u4e00q6	1856	22	classical	classical	JJ
cord-014712-5u4e00q6	1856	23	features	feature	NNS
cord-014712-5u4e00q6	1856	24	of	of	IN
cord-014712-5u4e00q6	1856	25	the	the	DT
cord-014712-5u4e00q6	1856	26	disease	disease	NN
cord-014712-5u4e00q6	1856	27	and	and	CC
cord-014712-5u4e00q6	1856	28	carrying	carry	VBG
cord-014712-5u4e00q6	1856	29	the	the	DT
cord-014712-5u4e00q6	1856	30	most	most	RBS
cord-014712-5u4e00q6	1856	31	common	common	JJ
cord-014712-5u4e00q6	1856	32	pathologic	pathologic	JJ
cord-014712-5u4e00q6	1856	33	mutation	mutation	NN
cord-014712-5u4e00q6	1856	34	.	.	.
cord-014712-5u4e00q6	1857	1	Wiscott	Wiscott	NNP
cord-014712-5u4e00q6	1857	2	-	-	HYPH
cord-014712-5u4e00q6	1857	3	Aldrich	Aldrich	NNP
cord-014712-5u4e00q6	1857	4	syndrome	syndrome	NN
cord-014712-5u4e00q6	1857	5	(	(	-LRB-
cord-014712-5u4e00q6	1857	6	WAS	be	VBD
cord-014712-5u4e00q6	1857	7	)	)	-RRB-
cord-014712-5u4e00q6	1857	8	is	be	VBZ
cord-014712-5u4e00q6	1857	9	a	a	DT
cord-014712-5u4e00q6	1857	10	rare	rare	JJ
cord-014712-5u4e00q6	1857	11	X	x	NN
cord-014712-5u4e00q6	1857	12	-	-	HYPH
cord-014712-5u4e00q6	1857	13	linked	link	VBN
cord-014712-5u4e00q6	1857	14	recessive	recessive	JJ
cord-014712-5u4e00q6	1857	15	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1857	16	disorder	disorder	NN
cord-014712-5u4e00q6	1857	17	characterized	characterize	VBN
cord-014712-5u4e00q6	1857	18	by	by	IN
cord-014712-5u4e00q6	1857	19	thrombocytopenia	thrombocytopenia	NN
cord-014712-5u4e00q6	1857	20	,	,	,
cord-014712-5u4e00q6	1857	21	small	small	JJ
cord-014712-5u4e00q6	1857	22	platelets	platelet	NNS
cord-014712-5u4e00q6	1857	23	,	,	,
cord-014712-5u4e00q6	1857	24	eczama	eczama	NNP
cord-014712-5u4e00q6	1857	25	,	,	,
cord-014712-5u4e00q6	1857	26	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1857	27	infections	infection	NNS
cord-014712-5u4e00q6	1857	28	and	and	CC
cord-014712-5u4e00q6	1857	29	an	an	DT
cord-014712-5u4e00q6	1857	30	increased	increase	VBN
cord-014712-5u4e00q6	1857	31	risk	risk	NN
cord-014712-5u4e00q6	1857	32	of	of	IN
cord-014712-5u4e00q6	1857	33	autoimunity	autoimunity	NN
cord-014712-5u4e00q6	1857	34	and	and	CC
cord-014712-5u4e00q6	1857	35	malignancy	malignancy	NN
cord-014712-5u4e00q6	1857	36	.	.	.
cord-014712-5u4e00q6	1858	1	The	the	DT
cord-014712-5u4e00q6	1858	2	gene	gene	NN
cord-014712-5u4e00q6	1858	3	responsible	responsible	JJ
cord-014712-5u4e00q6	1858	4	for	for	IN
cord-014712-5u4e00q6	1858	5	WAS	be	VBD
cord-014712-5u4e00q6	1858	6	is	be	VBZ
cord-014712-5u4e00q6	1858	7	located	locate	VBN
cord-014712-5u4e00q6	1858	8	in	in	IN
cord-014712-5u4e00q6	1858	9	chromosome	chromosome	NN
cord-014712-5u4e00q6	1858	10	Xp11.22-p11	xp11.22-p11	CD
cord-014712-5u4e00q6	1858	11	-	-	HYPH
cord-014712-5u4e00q6	1858	12	23	23	CD
cord-014712-5u4e00q6	1858	13	,	,	,
cord-014712-5u4e00q6	1858	14	which	which	WDT
cord-014712-5u4e00q6	1858	15	consists	consist	VBZ
cord-014712-5u4e00q6	1858	16	of	of	IN
cord-014712-5u4e00q6	1858	17	12	12	CD
cord-014712-5u4e00q6	1858	18	exons	exon	NNS
cord-014712-5u4e00q6	1858	19	,	,	,
cord-014712-5u4e00q6	1858	20	and	and	CC
cord-014712-5u4e00q6	1858	21	encodes	encode	VBZ
cord-014712-5u4e00q6	1858	22	a	a	DT
cord-014712-5u4e00q6	1858	23	502-amino	502-amino	CD
cord-014712-5u4e00q6	1858	24	acid	acid	NN
cord-014712-5u4e00q6	1858	25	protein	protein	NN
cord-014712-5u4e00q6	1858	26	.	.	.
cord-014712-5u4e00q6	1859	1	In	in	IN
cord-014712-5u4e00q6	1859	2	this	this	DT
cord-014712-5u4e00q6	1859	3	study	study	NN
cord-014712-5u4e00q6	1859	4	,	,	,
cord-014712-5u4e00q6	1859	5	we	-PRON-	PRP
cord-014712-5u4e00q6	1859	6	aimed	aim	VBD
cord-014712-5u4e00q6	1859	7	to	to	IN
cord-014712-5u4e00q6	1859	8	screen	screen	NN
cord-014712-5u4e00q6	1859	9	WAS	be	VBD
cord-014712-5u4e00q6	1859	10	gene	gene	NN
cord-014712-5u4e00q6	1859	11	mutations	mutation	NNS
cord-014712-5u4e00q6	1859	12	and	and	CC
cord-014712-5u4e00q6	1859	13	analyze	analyze	VB
cord-014712-5u4e00q6	1859	14	the	the	DT
cord-014712-5u4e00q6	1859	15	effects	effect	NNS
cord-014712-5u4e00q6	1859	16	of	of	IN
cord-014712-5u4e00q6	1859	17	determined	determined	JJ
cord-014712-5u4e00q6	1859	18	mutations	mutation	NNS
cord-014712-5u4e00q6	1859	19	in	in	IN
cord-014712-5u4e00q6	1859	20	2	2	CD
cord-014712-5u4e00q6	1859	21	boys	boy	NNS
cord-014712-5u4e00q6	1859	22	with	with	IN
cord-014712-5u4e00q6	1859	23	non	non	JJ
cord-014712-5u4e00q6	1859	24	-	-	JJ
cord-014712-5u4e00q6	1859	25	classical	classical	JJ
cord-014712-5u4e00q6	1859	26	WAS	be	VBD
cord-014712-5u4e00q6	1859	27	phenotype	phenotype	NN
cord-014712-5u4e00q6	1859	28	.	.	.
cord-014712-5u4e00q6	1860	1	IVS10	IVS10	NNP
cord-014712-5u4e00q6	1861	1	+	+	SYM
cord-014712-5u4e00q6	1861	2	1	1	CD
cord-014712-5u4e00q6	1861	3	G	g	NN
cord-014712-5u4e00q6	1861	4	>	>	XX
cord-014712-5u4e00q6	1862	1	A	a	DT
cord-014712-5u4e00q6	1862	2	gene	gene	NN
cord-014712-5u4e00q6	1862	3	alteration	alteration	NN
cord-014712-5u4e00q6	1862	4	in	in	IN
cord-014712-5u4e00q6	1862	5	intron	intron	NN
cord-014712-5u4e00q6	1862	6	10	10	CD
cord-014712-5u4e00q6	1862	7	of	of	IN
cord-014712-5u4e00q6	1862	8	WAS	be	VBD
cord-014712-5u4e00q6	1862	9	gene	gene	NN
cord-014712-5u4e00q6	1862	10	was	be	VBD
cord-014712-5u4e00q6	1862	11	identified	identify	VBN
cord-014712-5u4e00q6	1862	12	in	in	IN
cord-014712-5u4e00q6	1862	13	Case	case	NN
cord-014712-5u4e00q6	1862	14	1	1	CD
cord-014712-5u4e00q6	1862	15	,	,	,
cord-014712-5u4e00q6	1862	16	previously	previously	RB
cord-014712-5u4e00q6	1862	17	.	.	.
cord-014712-5u4e00q6	1863	1	So	so	RB
cord-014712-5u4e00q6	1863	2	,	,	,
cord-014712-5u4e00q6	1863	3	RNA	RNA	NNP
cord-014712-5u4e00q6	1863	4	isolation	isolation	NN
cord-014712-5u4e00q6	1863	5	and	and	CC
cord-014712-5u4e00q6	1863	6	then	then	RB
cord-014712-5u4e00q6	1863	7	cDNA	cDNA	NNP
cord-014712-5u4e00q6	1863	8	synthesized	synthesize	VBN
cord-014712-5u4e00q6	1863	9	was	be	VBD
cord-014712-5u4e00q6	1863	10	carried	carry	VBN
cord-014712-5u4e00q6	1863	11	out	out	RP
cord-014712-5u4e00q6	1863	12	.	.	.
cord-014712-5u4e00q6	1864	1	In	in	IN
cord-014712-5u4e00q6	1864	2	Case	case	NN
cord-014712-5u4e00q6	1864	3	2	2	CD
cord-014712-5u4e00q6	1864	4	,	,	,
cord-014712-5u4e00q6	1864	5	after	after	IN
cord-014712-5u4e00q6	1864	6	amplification	amplification	NN
cord-014712-5u4e00q6	1864	7	of	of	IN
cord-014712-5u4e00q6	1864	8	12	12	CD
cord-014712-5u4e00q6	1864	9	exons	exon	NNS
cord-014712-5u4e00q6	1864	10	of	of	IN
cord-014712-5u4e00q6	1864	11	WAS	be	VBD
cord-014712-5u4e00q6	1864	12	gene	gene	NN
cord-014712-5u4e00q6	1864	13	by	by	IN
cord-014712-5u4e00q6	1864	14	PCR	PCR	NNP
cord-014712-5u4e00q6	1864	15	,	,	,
cord-014712-5u4e00q6	1864	16	the	the	DT
cord-014712-5u4e00q6	1864	17	amplicons	amplicon	NNS
cord-014712-5u4e00q6	1864	18	were	be	VBD
cord-014712-5u4e00q6	1864	19	sequenced	sequence	VBN
cord-014712-5u4e00q6	1864	20	.	.	.
cord-014712-5u4e00q6	1865	1	In	in	IN
cord-014712-5u4e00q6	1865	2	this	this	DT
cord-014712-5u4e00q6	1865	3	patient	patient	NN
cord-014712-5u4e00q6	1865	4	,	,	,
cord-014712-5u4e00q6	1865	5	G	g	NN
cord-014712-5u4e00q6	1865	6	>	>	XX
cord-014712-5u4e00q6	1865	7	C	c	NN
cord-014712-5u4e00q6	1865	8	alteration	alteration	NN
cord-014712-5u4e00q6	1865	9	was	be	VBD
cord-014712-5u4e00q6	1865	10	detected	detect	VBN
cord-014712-5u4e00q6	1865	11	in	in	IN
cord-014712-5u4e00q6	1865	12	the	the	DT
cord-014712-5u4e00q6	1865	13	first	first	JJ
cord-014712-5u4e00q6	1865	14	base	base	NN
cord-014712-5u4e00q6	1865	15	of	of	IN
cord-014712-5u4e00q6	1865	16	intron	intron	NN
cord-014712-5u4e00q6	1865	17	9	9	CD
cord-014712-5u4e00q6	1865	18	.	.	.
cord-014712-5u4e00q6	1866	1	Afterwards	afterwards	RB
cord-014712-5u4e00q6	1866	2	,	,	,
cord-014712-5u4e00q6	1866	3	cDNA	cdna	NN
cord-014712-5u4e00q6	1866	4	synthesized	synthesize	VBN
cord-014712-5u4e00q6	1866	5	for	for	IN
cord-014712-5u4e00q6	1866	6	detecting	detect	VBG
cord-014712-5u4e00q6	1866	7	the	the	DT
cord-014712-5u4e00q6	1866	8	splicing	splicing	NN
cord-014712-5u4e00q6	1866	9	effect	effect	NN
cord-014712-5u4e00q6	1866	10	.	.	.
cord-014712-5u4e00q6	1867	1	Based	base	VBN
cord-014712-5u4e00q6	1867	2	on	on	IN
cord-014712-5u4e00q6	1867	3	the	the	DT
cord-014712-5u4e00q6	1867	4	gel	gel	NN
cord-014712-5u4e00q6	1867	5	image	image	NN
cord-014712-5u4e00q6	1867	6	results	result	NNS
cord-014712-5u4e00q6	1867	7	,	,	,
cord-014712-5u4e00q6	1867	8	cDNA	cdna	NN
cord-014712-5u4e00q6	1867	9	found	find	VBD
cord-014712-5u4e00q6	1867	10	to	to	TO
cord-014712-5u4e00q6	1867	11	be	be	VB
cord-014712-5u4e00q6	1867	12	400	400	CD
cord-014712-5u4e00q6	1867	13	base	base	NN
cord-014712-5u4e00q6	1867	14	pairs	pair	NNS
cord-014712-5u4e00q6	1867	15	smaller	small	JJR
cord-014712-5u4e00q6	1867	16	than	than	IN
cord-014712-5u4e00q6	1867	17	the	the	DT
cord-014712-5u4e00q6	1867	18	normal	normal	JJ
cord-014712-5u4e00q6	1867	19	in	in	IN
cord-014712-5u4e00q6	1867	20	Case	case	NN
cord-014712-5u4e00q6	1867	21	1	1	CD
cord-014712-5u4e00q6	1867	22	.	.	.
cord-014712-5u4e00q6	1868	1	In	in	IN
cord-014712-5u4e00q6	1868	2	Case	case	NN
cord-014712-5u4e00q6	1868	3	2	2	CD
cord-014712-5u4e00q6	1868	4	,	,	,
cord-014712-5u4e00q6	1868	5	G	g	NN
cord-014712-5u4e00q6	1868	6	>	>	XX
cord-014712-5u4e00q6	1868	7	C	c	NN
cord-014712-5u4e00q6	1868	8	alteration	alteration	NN
cord-014712-5u4e00q6	1868	9	was	be	VBD
cord-014712-5u4e00q6	1868	10	detected	detect	VBN
cord-014712-5u4e00q6	1868	11	in	in	IN
cord-014712-5u4e00q6	1868	12	the	the	DT
cord-014712-5u4e00q6	1868	13	first	first	JJ
cord-014712-5u4e00q6	1868	14	base	base	NN
cord-014712-5u4e00q6	1868	15	of	of	IN
cord-014712-5u4e00q6	1868	16	intron	intron	NN
cord-014712-5u4e00q6	1868	17	9	9	CD
cord-014712-5u4e00q6	1869	1	and	and	CC
cord-014712-5u4e00q6	1869	2	then	then	RB
cord-014712-5u4e00q6	1869	3	we	-PRON-	PRP
cord-014712-5u4e00q6	1869	4	determined	determine	VBD
cord-014712-5u4e00q6	1869	5	multiple	multiple	JJ
cord-014712-5u4e00q6	1869	6	splicing	splicing	NN
cord-014712-5u4e00q6	1869	7	products	product	NNS
cord-014712-5u4e00q6	1869	8	.	.	.
cord-014712-5u4e00q6	1870	1	Two	two	CD
cord-014712-5u4e00q6	1870	2	different	different	JJ
cord-014712-5u4e00q6	1870	3	splicing	splicing	NN
cord-014712-5u4e00q6	1870	4	mutations	mutation	NNS
cord-014712-5u4e00q6	1870	5	(	(	-LRB-
cord-014712-5u4e00q6	1870	6	IVS10	ivs10	VB
cord-014712-5u4e00q6	1870	7	+	+	SYM
cord-014712-5u4e00q6	1870	8	1	1	CD
cord-014712-5u4e00q6	1870	9	G	g	NN
cord-014712-5u4e00q6	1870	10	>	>	XX
cord-014712-5u4e00q6	1870	11	A	a	NN
cord-014712-5u4e00q6	1870	12	and	and	CC
cord-014712-5u4e00q6	1870	13	IVS9	IVS9	NNP
cord-014712-5u4e00q6	1870	14	+	+	SYM
cord-014712-5u4e00q6	1870	15	1	1	CD
cord-014712-5u4e00q6	1870	16	G	g	NN
cord-014712-5u4e00q6	1870	17	>	>	XX
cord-014712-5u4e00q6	1870	18	C	c	NN
cord-014712-5u4e00q6	1870	19	)	)	-RRB-
cord-014712-5u4e00q6	1870	20	were	be	VBD
cord-014712-5u4e00q6	1870	21	detected	detect	VBN
cord-014712-5u4e00q6	1870	22	in	in	IN
cord-014712-5u4e00q6	1870	23	two	two	CD
cord-014712-5u4e00q6	1870	24	cases	case	NNS
cord-014712-5u4e00q6	1870	25	with	with	IN
cord-014712-5u4e00q6	1870	26	non	non	JJ
cord-014712-5u4e00q6	1870	27	-	-	JJ
cord-014712-5u4e00q6	1870	28	classical	classical	JJ
cord-014712-5u4e00q6	1870	29	phenotype	phenotype	NN
cord-014712-5u4e00q6	1870	30	.	.	.
cord-014712-5u4e00q6	1871	1	IVS9	IVS9	NNP
cord-014712-5u4e00q6	1871	2	+	+	SYM
cord-014712-5u4e00q6	1871	3	1	1	CD
cord-014712-5u4e00q6	1871	4	G	g	NN
cord-014712-5u4e00q6	1871	5	>	>	XX
cord-014712-5u4e00q6	1872	1	A	a	DT
cord-014712-5u4e00q6	1872	2	splicing	splicing	NN
cord-014712-5u4e00q6	1872	3	mutation	mutation	NN
cord-014712-5u4e00q6	1872	4	was	be	VBD
cord-014712-5u4e00q6	1872	5	stated	state	VBN
cord-014712-5u4e00q6	1872	6	in	in	IN
cord-014712-5u4e00q6	1872	7	the	the	DT
cord-014712-5u4e00q6	1872	8	literature	literature	NN
cord-014712-5u4e00q6	1872	9	,	,	,
cord-014712-5u4e00q6	1872	10	previously	previously	RB
cord-014712-5u4e00q6	1872	11	,	,	,
cord-014712-5u4e00q6	1872	12	but	but	CC
cord-014712-5u4e00q6	1872	13	IVS9	IVS9	NNP
cord-014712-5u4e00q6	1872	14	+	+	SYM
cord-014712-5u4e00q6	1872	15	1	1	CD
cord-014712-5u4e00q6	1872	16	G	g	NN
cord-014712-5u4e00q6	1872	17	>	>	XX
cord-014712-5u4e00q6	1872	18	C	c	NN
cord-014712-5u4e00q6	1872	19	mutation	mutation	NN
cord-014712-5u4e00q6	1872	20	was	be	VBD
cord-014712-5u4e00q6	1872	21	first	first	JJ
cord-014712-5u4e00q6	1872	22	time	time	NN
cord-014712-5u4e00q6	1872	23	identified	identify	VBN
cord-014712-5u4e00q6	1872	24	in	in	IN
cord-014712-5u4e00q6	1872	25	this	this	DT
cord-014712-5u4e00q6	1872	26	study	study	NN
cord-014712-5u4e00q6	1872	27	.	.	.
cord-014712-5u4e00q6	1873	1	WHIM	whim	NN
cord-014712-5u4e00q6	1873	2	is	be	VBZ
cord-014712-5u4e00q6	1873	3	rare	rare	JJ
cord-014712-5u4e00q6	1873	4	(	(	-LRB-
cord-014712-5u4e00q6	1873	5	<	<	NNP
cord-014712-5u4e00q6	1873	6	1	1	CD
cord-014712-5u4e00q6	1873	7	/	/	SYM
cord-014712-5u4e00q6	1873	8	1	1	CD
cord-014712-5u4e00q6	1873	9	000	000	CD
cord-014712-5u4e00q6	1873	10	000	000	CD
cord-014712-5u4e00q6	1873	11	)	)	-RRB-
cord-014712-5u4e00q6	1873	12	,	,	,
cord-014712-5u4e00q6	1873	13	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	1873	14	,	,	,
cord-014712-5u4e00q6	1873	15	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1873	16	dominantly	dominantly	RB
cord-014712-5u4e00q6	1873	17	inherited	inherit	VBN
cord-014712-5u4e00q6	1873	18	PID	PID	NNP
cord-014712-5u4e00q6	1873	19	,	,	,
cord-014712-5u4e00q6	1873	20	caused	cause	VBN
cord-014712-5u4e00q6	1873	21	by	by	IN
cord-014712-5u4e00q6	1873	22	mutations	mutation	NNS
cord-014712-5u4e00q6	1873	23	in	in	IN
cord-014712-5u4e00q6	1873	24	the	the	DT
cord-014712-5u4e00q6	1873	25	gene	gene	NN
cord-014712-5u4e00q6	1873	26	encoding	encoding	NN
cord-014712-5u4e00q6	1873	27	for	for	IN
cord-014712-5u4e00q6	1873	28	the	the	DT
cord-014712-5u4e00q6	1873	29	chemokine	chemokine	NN
cord-014712-5u4e00q6	1873	30	receptor	receptor	NN
cord-014712-5u4e00q6	1873	31	CXCR4	CXCR4	NNP
cord-014712-5u4e00q6	1873	32	,	,	,
cord-014712-5u4e00q6	1873	33	mapped	map	VBN
cord-014712-5u4e00q6	1873	34	on	on	IN
cord-014712-5u4e00q6	1873	35	2q21	2q21	CD
cord-014712-5u4e00q6	1873	36	locus	locus	NN
cord-014712-5u4e00q6	1873	37	.	.	.
cord-014712-5u4e00q6	1874	1	The	the	DT
cord-014712-5u4e00q6	1874	2	altered	altered	JJ
cord-014712-5u4e00q6	1874	3	CXCR4/	cxcr4/	NN
cord-014712-5u4e00q6	1875	1	CXCL12	cxcl12	NN
cord-014712-5u4e00q6	1875	2	interaction	interaction	NN
cord-014712-5u4e00q6	1875	3	impairs	impair	VBZ
cord-014712-5u4e00q6	1875	4	cellular	cellular	JJ
cord-014712-5u4e00q6	1875	5	homeostasis	homeostasis	NN
cord-014712-5u4e00q6	1875	6	and	and	CC
cord-014712-5u4e00q6	1875	7	trafficking	trafficking	NN
cord-014712-5u4e00q6	1875	8	,	,	,
cord-014712-5u4e00q6	1875	9	resulting	result	VBG
cord-014712-5u4e00q6	1875	10	in	in	IN
cord-014712-5u4e00q6	1875	11	immunological	immunological	JJ
cord-014712-5u4e00q6	1875	12	dysfunctions	dysfunction	NNS
cord-014712-5u4e00q6	1875	13	with	with	IN
cord-014712-5u4e00q6	1875	14	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1875	15	retention	retention	NN
cord-014712-5u4e00q6	1875	16	of	of	IN
cord-014712-5u4e00q6	1875	17	mature	mature	JJ
cord-014712-5u4e00q6	1875	18	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	1875	19	in	in	IN
cord-014712-5u4e00q6	1875	20	the	the	DT
cord-014712-5u4e00q6	1875	21	bone	bone	NN
cord-014712-5u4e00q6	1875	22	marrow	marrow	NN
cord-014712-5u4e00q6	1875	23	(	(	-LRB-
cord-014712-5u4e00q6	1875	24	myelokathexis	myelokathexis	NNP
cord-014712-5u4e00q6	1875	25	)	)	-RRB-
cord-014712-5u4e00q6	1875	26	and	and	CC
cord-014712-5u4e00q6	1875	27	consecutive	consecutive	JJ
cord-014712-5u4e00q6	1875	28	severe	severe	JJ
cord-014712-5u4e00q6	1875	29	neutropenia	neutropenia	NN
cord-014712-5u4e00q6	1875	30	,	,	,
cord-014712-5u4e00q6	1875	31	variable	variable	JJ
cord-014712-5u4e00q6	1875	32	degree	degree	NN
cord-014712-5u4e00q6	1875	33	of	of	IN
cord-014712-5u4e00q6	1875	34	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	1875	35	and	and	CC
cord-014712-5u4e00q6	1875	36	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-014712-5u4e00q6	1875	37	.	.	.
cord-014712-5u4e00q6	1876	1	WHIM	whim	NN
cord-014712-5u4e00q6	1876	2	patients	patient	NNS
cord-014712-5u4e00q6	1876	3	suffer	suffer	VBP
cord-014712-5u4e00q6	1876	4	from	from	IN
cord-014712-5u4e00q6	1876	5	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1876	6	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1876	7	infections	infection	NNS
cord-014712-5u4e00q6	1876	8	since	since	IN
cord-014712-5u4e00q6	1876	9	early	early	JJ
cord-014712-5u4e00q6	1876	10	childhood	childhood	NN
cord-014712-5u4e00q6	1876	11	and	and	CC
cord-014712-5u4e00q6	1876	12	later	later	RB
cord-014712-5u4e00q6	1876	13	on	on	IN
cord-014712-5u4e00q6	1876	14	manifest	manif	JJS
cord-014712-5u4e00q6	1876	15	a	a	DT
cord-014712-5u4e00q6	1876	16	specific	specific	JJ
cord-014712-5u4e00q6	1876	17	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	1876	18	to	to	IN
cord-014712-5u4e00q6	1876	19	HPV	hpv	NN
cord-014712-5u4e00q6	1876	20	infections	infection	NNS
cord-014712-5u4e00q6	1876	21	with	with	IN
cord-014712-5u4e00q6	1876	22	developing	develop	VBG
cord-014712-5u4e00q6	1876	23	widespread	widespread	JJ
cord-014712-5u4e00q6	1876	24	warts	wart	NNS
cord-014712-5u4e00q6	1876	25	.	.	.
cord-014712-5u4e00q6	1877	1	Because	because	IN
cord-014712-5u4e00q6	1877	2	of	of	IN
cord-014712-5u4e00q6	1877	3	rarity	rarity	NN
cord-014712-5u4e00q6	1877	4	of	of	IN
cord-014712-5u4e00q6	1877	5	the	the	DT
cord-014712-5u4e00q6	1877	6	disease	disease	NN
cord-014712-5u4e00q6	1877	7	,	,	,
cord-014712-5u4e00q6	1877	8	heterogeneity	heterogeneity	NN
cord-014712-5u4e00q6	1877	9	in	in	IN
cord-014712-5u4e00q6	1877	10	clinical	clinical	JJ
cord-014712-5u4e00q6	1877	11	presentation	presentation	NN
cord-014712-5u4e00q6	1877	12	and	and	CC
cord-014712-5u4e00q6	1877	13	usually	usually	RB
cord-014712-5u4e00q6	1877	14	incomplete	incomplete	JJ
cord-014712-5u4e00q6	1877	15	phenotype	phenotype	NN
cord-014712-5u4e00q6	1877	16	,	,	,
cord-014712-5u4e00q6	1877	17	the	the	DT
cord-014712-5u4e00q6	1877	18	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1877	19	is	be	VBZ
cord-014712-5u4e00q6	1877	20	often	often	RB
cord-014712-5u4e00q6	1877	21	delayed	delay	VBN
cord-014712-5u4e00q6	1877	22	and	and	CC
cord-014712-5u4e00q6	1877	23	WHIM	whim	NN
cord-014712-5u4e00q6	1877	24	syndrome	syndrome	NN
cord-014712-5u4e00q6	1877	25	is	be	VBZ
cord-014712-5u4e00q6	1877	26	not	not	RB
cord-014712-5u4e00q6	1877	27	suspected	suspect	VBN
cord-014712-5u4e00q6	1877	28	.	.	.
cord-014712-5u4e00q6	1878	1	A	a	DT
cord-014712-5u4e00q6	1878	2	13	13	CD
cord-014712-5u4e00q6	1878	3	year	year	NN
cord-014712-5u4e00q6	1878	4	old	old	JJ
cord-014712-5u4e00q6	1878	5	boy	boy	NN
cord-014712-5u4e00q6	1878	6	who	who	WP
cord-014712-5u4e00q6	1878	7	is	be	VBZ
cord-014712-5u4e00q6	1878	8	suffering	suffer	VBG
cord-014712-5u4e00q6	1878	9	from	from	IN
cord-014712-5u4e00q6	1878	10	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1878	11	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1878	12	infections	infection	NNS
cord-014712-5u4e00q6	1878	13	,	,	,
cord-014712-5u4e00q6	1878	14	often	often	RB
cord-014712-5u4e00q6	1878	15	complicated	complicate	VBN
cord-014712-5u4e00q6	1878	16	with	with	IN
cord-014712-5u4e00q6	1878	17	bronchopneumonia	bronchopneumonia	NN
cord-014712-5u4e00q6	1878	18	,	,	,
cord-014712-5u4e00q6	1878	19	with	with	IN
cord-014712-5u4e00q6	1878	20	severe	severe	JJ
cord-014712-5u4e00q6	1878	21	neutropenia	neutropenia	NN
cord-014712-5u4e00q6	1878	22	,	,	,
cord-014712-5u4e00q6	1878	23	but	but	CC
cord-014712-5u4e00q6	1878	24	also	also	RB
cord-014712-5u4e00q6	1878	25	,	,	,
cord-014712-5u4e00q6	1878	26	with	with	IN
cord-014712-5u4e00q6	1878	27	lower	low	JJR
cord-014712-5u4e00q6	1878	28	level	level	NN
cord-014712-5u4e00q6	1878	29	of	of	IN
cord-014712-5u4e00q6	1878	30	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	1878	31	and	and	CC
cord-014712-5u4e00q6	1878	32	still	still	RB
cord-014712-5u4e00q6	1878	33	,	,	,
cord-014712-5u4e00q6	1878	34	normal	normal	JJ
cord-014712-5u4e00q6	1878	35	serum	serum	NN
cord-014712-5u4e00q6	1878	36	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	1878	37	level	level	NN
cord-014712-5u4e00q6	1878	38	is	be	VBZ
cord-014712-5u4e00q6	1878	39	presented	present	VBN
cord-014712-5u4e00q6	1878	40	.	.	.
cord-014712-5u4e00q6	1879	1	He	-PRON-	PRP
cord-014712-5u4e00q6	1879	2	has	have	VBZ
cord-014712-5u4e00q6	1879	3	no	no	DT
cord-014712-5u4e00q6	1879	4	developed	develop	VBN
cord-014712-5u4e00q6	1879	5	warts	wart	NNS
cord-014712-5u4e00q6	1879	6	;	;	:
cord-014712-5u4e00q6	1879	7	neither	neither	CC
cord-014712-5u4e00q6	1879	8	his	-PRON-	PRP$
cord-014712-5u4e00q6	1879	9	parents	parent	NNS
cord-014712-5u4e00q6	1879	10	nor	nor	CC
cord-014712-5u4e00q6	1879	11	relatives	relative	NNS
cord-014712-5u4e00q6	1879	12	have	have	VBP
cord-014712-5u4e00q6	1879	13	warts	wart	NNS
cord-014712-5u4e00q6	1879	14	.	.	.
cord-014712-5u4e00q6	1880	1	At	at	IN
cord-014712-5u4e00q6	1880	2	the	the	DT
cord-014712-5u4e00q6	1880	3	age	age	NN
cord-014712-5u4e00q6	1880	4	of	of	IN
cord-014712-5u4e00q6	1880	5	10	10	CD
cord-014712-5u4e00q6	1880	6	years	year	NNS
cord-014712-5u4e00q6	1880	7	was	be	VBD
cord-014712-5u4e00q6	1880	8	unveiled	unveil	VBN
cord-014712-5u4e00q6	1880	9	the	the	DT
cord-014712-5u4e00q6	1880	10	diseasecausing	diseasecausing	NN
cord-014712-5u4e00q6	1880	11	mutation	mutation	NN
cord-014712-5u4e00q6	1880	12	in	in	IN
cord-014712-5u4e00q6	1880	13	the	the	DT
cord-014712-5u4e00q6	1880	14	CXCR4	cxcr4	NN
cord-014712-5u4e00q6	1880	15	gene	gene	NN
cord-014712-5u4e00q6	1880	16	(	(	-LRB-
cord-014712-5u4e00q6	1880	17	c.1000C	c.1000c	CD
cord-014712-5u4e00q6	1881	1	>	>	XX
cord-014712-5u4e00q6	1882	1	T	T	NNP
cord-014712-5u4e00q6	1882	2	;	;	:
cord-014712-5u4e00q6	1882	3	p.	p.	NN
cord-014712-5u4e00q6	1883	1	R334X	r334x	NN
cord-014712-5u4e00q6	1883	2	;	;	:
cord-014712-5u4e00q6	1883	3	heterozygote	heterozygote	NN
cord-014712-5u4e00q6	1883	4	)	)	-RRB-
cord-014712-5u4e00q6	1883	5	.	.	.
cord-014712-5u4e00q6	1884	1	Severe	severe	JJ
cord-014712-5u4e00q6	1884	2	congenital	congenital	JJ
cord-014712-5u4e00q6	1884	3	neutropenia	neutropenia	NN
cord-014712-5u4e00q6	1884	4	accompanied	accompany	VBN
cord-014712-5u4e00q6	1884	5	with	with	IN
cord-014712-5u4e00q6	1884	6	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	1884	7	and	and	CC
cord-014712-5u4e00q6	1884	8	findings	finding	NNS
cord-014712-5u4e00q6	1884	9	of	of	IN
cord-014712-5u4e00q6	1884	10	mature	mature	JJ
cord-014712-5u4e00q6	1884	11	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	1884	12	in	in	IN
cord-014712-5u4e00q6	1884	13	bone	bone	NN
cord-014712-5u4e00q6	1884	14	marrow	marrow	NN
cord-014712-5u4e00q6	1884	15	,	,	,
cord-014712-5u4e00q6	1884	16	might	may	MD
cord-014712-5u4e00q6	1884	17	be	be	VB
cord-014712-5u4e00q6	1884	18	an	an	DT
cord-014712-5u4e00q6	1884	19	easy	easy	JJ
cord-014712-5u4e00q6	1884	20	approach	approach	NN
cord-014712-5u4e00q6	1884	21	for	for	IN
cord-014712-5u4e00q6	1884	22	getting	get	VBG
cord-014712-5u4e00q6	1884	23	closer	close	RBR
cord-014712-5u4e00q6	1884	24	to	to	IN
cord-014712-5u4e00q6	1884	25	the	the	DT
cord-014712-5u4e00q6	1884	26	clinical	clinical	JJ
cord-014712-5u4e00q6	1884	27	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1884	28	of	of	IN
cord-014712-5u4e00q6	1884	29	WHIM	WHIM	NNP
cord-014712-5u4e00q6	1884	30	syndrome	syndrome	NN
cord-014712-5u4e00q6	1884	31	.	.	.
cord-014712-5u4e00q6	1885	1	Early	early	JJ
cord-014712-5u4e00q6	1885	2	identification	identification	NN
cord-014712-5u4e00q6	1885	3	is	be	VBZ
cord-014712-5u4e00q6	1885	4	important	important	JJ
cord-014712-5u4e00q6	1885	5	for	for	IN
cord-014712-5u4e00q6	1885	6	clinical	clinical	JJ
cord-014712-5u4e00q6	1885	7	and	and	CC
cord-014712-5u4e00q6	1885	8	therapeutic	therapeutic	JJ
cord-014712-5u4e00q6	1885	9	management	management	NN
cord-014712-5u4e00q6	1885	10	,	,	,
cord-014712-5u4e00q6	1885	11	allowing	allow	VBG
cord-014712-5u4e00q6	1885	12	a	a	DT
cord-014712-5u4e00q6	1885	13	more	more	RBR
cord-014712-5u4e00q6	1885	14	comprehensive	comprehensive	JJ
cord-014712-5u4e00q6	1885	15	follow	follow	NN
cord-014712-5u4e00q6	1885	16	-	-	HYPH
cord-014712-5u4e00q6	1885	17	up	up	NN
cord-014712-5u4e00q6	1885	18	and	and	CC
cord-014712-5u4e00q6	1885	19	administration	administration	NN
cord-014712-5u4e00q6	1885	20	of	of	IN
cord-014712-5u4e00q6	1885	21	appropriate	appropriate	JJ
cord-014712-5u4e00q6	1885	22	therapy	therapy	NN
cord-014712-5u4e00q6	1885	23	.	.	.
cord-014712-5u4e00q6	1886	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1886	2	report	report	VBP
cord-014712-5u4e00q6	1886	3	two	two	CD
cord-014712-5u4e00q6	1886	4	cases	case	NNS
cord-014712-5u4e00q6	1886	5	of	of	IN
cord-014712-5u4e00q6	1886	6	congenital	congenital	JJ
cord-014712-5u4e00q6	1886	7	heart	heart	NN
cord-014712-5u4e00q6	1886	8	disease	disease	NN
cord-014712-5u4e00q6	1886	9	(	(	-LRB-
cord-014712-5u4e00q6	1886	10	Tetralogia	Tetralogia	NNP
cord-014712-5u4e00q6	1886	11	Fallot	Fallot	NNP
cord-014712-5u4e00q6	1886	12	and	and	CC
cord-014712-5u4e00q6	1886	13	Interruption	interruption	NN
cord-014712-5u4e00q6	1886	14	aortic	aortic	JJ
cord-014712-5u4e00q6	1886	15	arch	arch	NN
cord-014712-5u4e00q6	1886	16	)	)	-RRB-
cord-014712-5u4e00q6	1886	17	with	with	IN
cord-014712-5u4e00q6	1886	18	confirmed	confirm	VBN
cord-014712-5u4e00q6	1886	19	microdeletion	microdeletion	NN
cord-014712-5u4e00q6	1886	20	chromosome	chromosome	NN
cord-014712-5u4e00q6	1886	21	22q11.2	22q11.2	NN
cord-014712-5u4e00q6	1886	22	by	by	IN
cord-014712-5u4e00q6	1886	23	karyotype	karyotype	NN
cord-014712-5u4e00q6	1886	24	and	and	CC
cord-014712-5u4e00q6	1886	25	Fluorescence	fluorescence	NN
cord-014712-5u4e00q6	1886	26	In	in	IN
cord-014712-5u4e00q6	1886	27	Situ	Situ	NNP
cord-014712-5u4e00q6	1886	28	Hybridization	hybridization	NN
cord-014712-5u4e00q6	1886	29	analysis	analysis	NN
cord-014712-5u4e00q6	1886	30	(	(	-LRB-
cord-014712-5u4e00q6	1886	31	FISH	fish	NN
cord-014712-5u4e00q6	1886	32	)	)	-RRB-
cord-014712-5u4e00q6	1886	33	.	.	.
cord-014712-5u4e00q6	1887	1	Children	child	NNS
cord-014712-5u4e00q6	1887	2	underwent	undergo	VBD
cord-014712-5u4e00q6	1887	3	surgical	surgical	JJ
cord-014712-5u4e00q6	1887	4	correction	correction	NN
cord-014712-5u4e00q6	1887	5	of	of	IN
cord-014712-5u4e00q6	1887	6	congenital	congenital	JJ
cord-014712-5u4e00q6	1887	7	heart	heart	NN
cord-014712-5u4e00q6	1887	8	defects	defect	NNS
cord-014712-5u4e00q6	1887	9	with	with	IN
cord-014712-5u4e00q6	1887	10	good	good	JJ
cord-014712-5u4e00q6	1887	11	postoperative	postoperative	JJ
cord-014712-5u4e00q6	1887	12	outcome	outcome	NN
cord-014712-5u4e00q6	1887	13	,	,	,
cord-014712-5u4e00q6	1887	14	although	although	IN
cord-014712-5u4e00q6	1887	15	were	be	VBD
cord-014712-5u4e00q6	1887	16	complex	complex	JJ
cord-014712-5u4e00q6	1887	17	.	.	.
cord-014712-5u4e00q6	1888	1	The	the	DT
cord-014712-5u4e00q6	1888	2	phenotype	phenotype	NN
cord-014712-5u4e00q6	1888	3	of	of	IN
cord-014712-5u4e00q6	1888	4	these	these	DT
cord-014712-5u4e00q6	1888	5	patients	patient	NNS
cord-014712-5u4e00q6	1888	6	can	can	MD
cord-014712-5u4e00q6	1888	7	be	be	VB
cord-014712-5u4e00q6	1888	8	extremely	extremely	RB
cord-014712-5u4e00q6	1888	9	variable	variable	JJ
cord-014712-5u4e00q6	1888	10	,	,	,
cord-014712-5u4e00q6	1888	11	frequently	frequently	RB
cord-014712-5u4e00q6	1888	12	leading	lead	VBG
cord-014712-5u4e00q6	1888	13	to	to	IN
cord-014712-5u4e00q6	1888	14	clinical	clinical	JJ
cord-014712-5u4e00q6	1888	15	confusion	confusion	NN
cord-014712-5u4e00q6	1888	16	,	,	,
cord-014712-5u4e00q6	1888	17	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	1888	18	delay	delay	NN
cord-014712-5u4e00q6	1888	19	,	,	,
cord-014712-5u4e00q6	1888	20	excess	excess	JJ
cord-014712-5u4e00q6	1888	21	morbidity	morbidity	NN
cord-014712-5u4e00q6	1888	22	,	,	,
cord-014712-5u4e00q6	1888	23	early	early	JJ
cord-014712-5u4e00q6	1888	24	mortality	mortality	NN
cord-014712-5u4e00q6	1888	25	.	.	.
cord-014712-5u4e00q6	1889	1	Identification	identification	NN
cord-014712-5u4e00q6	1889	2	of	of	IN
cord-014712-5u4e00q6	1889	3	these	these	DT
cord-014712-5u4e00q6	1889	4	patients	patient	NNS
cord-014712-5u4e00q6	1889	5	is	be	VBZ
cord-014712-5u4e00q6	1889	6	essential	essential	JJ
cord-014712-5u4e00q6	1889	7	for	for	IN
cord-014712-5u4e00q6	1889	8	their	-PRON-	PRP$
cord-014712-5u4e00q6	1889	9	adequate	adequate	JJ
cord-014712-5u4e00q6	1889	10	management	management	NN
cord-014712-5u4e00q6	1889	11	and	and	CC
cord-014712-5u4e00q6	1889	12	genetic	genetic	JJ
cord-014712-5u4e00q6	1889	13	counseling	counseling	NN
cord-014712-5u4e00q6	1889	14	.	.	.
cord-014712-5u4e00q6	1890	1	A	a	DT
cord-014712-5u4e00q6	1890	2	multidisciplinary	multidisciplinary	JJ
cord-014712-5u4e00q6	1890	3	approach	approach	NN
cord-014712-5u4e00q6	1890	4	is	be	VBZ
cord-014712-5u4e00q6	1890	5	fundamental	fundamental	JJ
cord-014712-5u4e00q6	1890	6	to	to	TO
cord-014712-5u4e00q6	1890	7	ensure	ensure	VB
cord-014712-5u4e00q6	1890	8	that	that	IN
cord-014712-5u4e00q6	1890	9	the	the	DT
cord-014712-5u4e00q6	1890	10	patient	patient	NN
cord-014712-5u4e00q6	1890	11	will	will	MD
cord-014712-5u4e00q6	1890	12	be	be	VB
cord-014712-5u4e00q6	1890	13	able	able	JJ
cord-014712-5u4e00q6	1890	14	to	to	TO
cord-014712-5u4e00q6	1890	15	attain	attain	VB
cord-014712-5u4e00q6	1890	16	his	-PRON-	PRP$
cord-014712-5u4e00q6	1890	17	or	or	CC
cord-014712-5u4e00q6	1890	18	her	-PRON-	PRP$
cord-014712-5u4e00q6	1890	19	maximal	maximal	JJ
cord-014712-5u4e00q6	1890	20	potential	potential	NN
cord-014712-5u4e00q6	1890	21	.	.	.
cord-014712-5u4e00q6	1891	1	The	the	DT
cord-014712-5u4e00q6	1891	2	underlying	underlying	JJ
cord-014712-5u4e00q6	1891	3	cause	cause	NN
cord-014712-5u4e00q6	1891	4	of	of	IN
cord-014712-5u4e00q6	1891	5	the	the	DT
cord-014712-5u4e00q6	1891	6	juvenile	juvenile	JJ
cord-014712-5u4e00q6	1891	7	periodentitis	periodentitis	NN
cord-014712-5u4e00q6	1891	8	is	be	VBZ
cord-014712-5u4e00q6	1891	9	not	not	RB
cord-014712-5u4e00q6	1891	10	well	well	RB
cord-014712-5u4e00q6	1891	11	understood	understand	VBN
cord-014712-5u4e00q6	1891	12	but	but	CC
cord-014712-5u4e00q6	1891	13	is	be	VBZ
cord-014712-5u4e00q6	1891	14	now	now	RB
cord-014712-5u4e00q6	1891	15	thought	think	VBN
cord-014712-5u4e00q6	1891	16	to	to	TO
cord-014712-5u4e00q6	1891	17	be	be	VB
cord-014712-5u4e00q6	1891	18	related	relate	VBN
cord-014712-5u4e00q6	1891	19	to	to	IN
cord-014712-5u4e00q6	1891	20	an	an	DT
cord-014712-5u4e00q6	1891	21	abnormal	abnormal	JJ
cord-014712-5u4e00q6	1891	22	immune	immune	JJ
cord-014712-5u4e00q6	1891	23	system	system	NN
cord-014712-5u4e00q6	1891	24	and	and	CC
cord-014712-5u4e00q6	1891	25	to	to	IN
cord-014712-5u4e00q6	1891	26	invading	invade	VBG
cord-014712-5u4e00q6	1891	27	bacteria	bacteria	NNS
cord-014712-5u4e00q6	1891	28	in	in	IN
cord-014712-5u4e00q6	1891	29	the	the	DT
cord-014712-5u4e00q6	1891	30	cementum	cementum	NN
cord-014712-5u4e00q6	1891	31	of	of	IN
cord-014712-5u4e00q6	1891	32	the	the	DT
cord-014712-5u4e00q6	1891	33	teeth	tooth	NNS
cord-014712-5u4e00q6	1891	34	.	.	.
cord-014712-5u4e00q6	1892	1	Instead	instead	RB
cord-014712-5u4e00q6	1892	2	painful	painful	JJ
cord-014712-5u4e00q6	1892	3	fissures	fissure	NNS
cord-014712-5u4e00q6	1892	4	and	and	CC
cord-014712-5u4e00q6	1892	5	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1892	6	pyogenic	pyogenic	JJ
cord-014712-5u4e00q6	1892	7	infections	infection	NNS
cord-014712-5u4e00q6	1892	8	of	of	IN
cord-014712-5u4e00q6	1892	9	the	the	DT
cord-014712-5u4e00q6	1892	10	skin	skin	NN
cord-014712-5u4e00q6	1892	11	seem	seem	VBP
cord-014712-5u4e00q6	1892	12	to	to	TO
cord-014712-5u4e00q6	1892	13	be	be	VB
cord-014712-5u4e00q6	1892	14	the	the	DT
cord-014712-5u4e00q6	1892	15	most	most	RBS
cord-014712-5u4e00q6	1892	16	common	common	JJ
cord-014712-5u4e00q6	1892	17	medical	medical	JJ
cord-014712-5u4e00q6	1892	18	complications	complication	NNS
cord-014712-5u4e00q6	1892	19	.	.	.
cord-014712-5u4e00q6	1893	1	However	however	RB
cord-014712-5u4e00q6	1893	2	,	,	,
cord-014712-5u4e00q6	1893	3	a	a	DT
cord-014712-5u4e00q6	1893	4	number	number	NN
cord-014712-5u4e00q6	1893	5	of	of	IN
cord-014712-5u4e00q6	1893	6	PLS	PLS	NNP
cord-014712-5u4e00q6	1893	7	patients	patient	NNS
cord-014712-5u4e00q6	1893	8	with	with	IN
cord-014712-5u4e00q6	1893	9	abscesses	abscess	NNS
cord-014712-5u4e00q6	1893	10	or	or	CC
cord-014712-5u4e00q6	1893	11	pseudotumors	pseudotumor	NNS
cord-014712-5u4e00q6	1893	12	of	of	IN
cord-014712-5u4e00q6	1893	13	the	the	DT
cord-014712-5u4e00q6	1893	14	liver	liver	NN
cord-014712-5u4e00q6	1893	15	have	have	VBP
cord-014712-5u4e00q6	1893	16	been	be	VBN
cord-014712-5u4e00q6	1893	17	described	describe	VBN
cord-014712-5u4e00q6	1893	18	.	.	.
cord-014712-5u4e00q6	1894	1	There	there	EX
cord-014712-5u4e00q6	1894	2	have	have	VBP
cord-014712-5u4e00q6	1894	3	been	be	VBN
cord-014712-5u4e00q6	1894	4	reports	report	NNS
cord-014712-5u4e00q6	1894	5	of	of	IN
cord-014712-5u4e00q6	1894	6	PLS	PLS	NNP
cord-014712-5u4e00q6	1894	7	patients	patient	NNS
cord-014712-5u4e00q6	1894	8	with	with	IN
cord-014712-5u4e00q6	1894	9	other	other	JJ
cord-014712-5u4e00q6	1894	10	stigmata	stigmata	NN
cord-014712-5u4e00q6	1894	11	such	such	JJ
cord-014712-5u4e00q6	1894	12	as	as	IN
cord-014712-5u4e00q6	1894	13	growth	growth	NN
cord-014712-5u4e00q6	1894	14	retardation	retardation	NN
cord-014712-5u4e00q6	1894	15	,	,	,
cord-014712-5u4e00q6	1894	16	non	non	JJ
cord-014712-5u4e00q6	1894	17	-	-	JJ
cord-014712-5u4e00q6	1894	18	symptomatic	symptomatic	JJ
cord-014712-5u4e00q6	1894	19	intracranial	intracranial	JJ
cord-014712-5u4e00q6	1894	20	calcifications	calcification	NNS
cord-014712-5u4e00q6	1894	21	and	and	CC
cord-014712-5u4e00q6	1894	22	mental	mental	JJ
cord-014712-5u4e00q6	1894	23	retardation	retardation	NN
cord-014712-5u4e00q6	1895	1	Furthermore	furthermore	RB
cord-014712-5u4e00q6	1895	2	,	,	,
cord-014712-5u4e00q6	1895	3	coinheritance	coinheritance	NN
cord-014712-5u4e00q6	1895	4	of	of	IN
cord-014712-5u4e00q6	1895	5	PLS	PLS	NNP
cord-014712-5u4e00q6	1895	6	and	and	CC
cord-014712-5u4e00q6	1895	7	albinism	albinism	NN
cord-014712-5u4e00q6	1895	8	type	type	NN
cord-014712-5u4e00q6	1895	9	1	1	CD
cord-014712-5u4e00q6	1895	10	has	have	VBZ
cord-014712-5u4e00q6	1895	11	been	be	VBN
cord-014712-5u4e00q6	1895	12	reported	report	VBN
cord-014712-5u4e00q6	1895	13	.	.	.
cord-014712-5u4e00q6	1896	1	Case	case	NN
cord-014712-5u4e00q6	1896	2	Presentation	presentation	NN
cord-014712-5u4e00q6	1896	3	:	:	:
cord-014712-5u4e00q6	1897	1	A	a	DT
cord-014712-5u4e00q6	1897	2	13	13	CD
cord-014712-5u4e00q6	1897	3	yr	yr	NN
cord-014712-5u4e00q6	1897	4	old	old	JJ
cord-014712-5u4e00q6	1897	5	girl	girl	NN
cord-014712-5u4e00q6	1897	6	admitted	admit	VBD
cord-014712-5u4e00q6	1897	7	to	to	IN
cord-014712-5u4e00q6	1897	8	our	-PRON-	PRP$
cord-014712-5u4e00q6	1897	9	hospital	hospital	NN
cord-014712-5u4e00q6	1897	10	with	with	IN
cord-014712-5u4e00q6	1897	11	chief	chief	JJ
cord-014712-5u4e00q6	1897	12	compliant	compliant	NN
cord-014712-5u4e00q6	1897	13	of	of	IN
cord-014712-5u4e00q6	1897	14	skin	skin	NN
cord-014712-5u4e00q6	1897	15	lesions	lesion	NNS
cord-014712-5u4e00q6	1897	16	since	since	IN
cord-014712-5u4e00q6	1897	17	early	early	JJ
cord-014712-5u4e00q6	1897	18	months	month	NNS
cord-014712-5u4e00q6	1897	19	of	of	IN
cord-014712-5u4e00q6	1897	20	birth	birth	NN
cord-014712-5u4e00q6	1897	21	.	.	.
cord-014712-5u4e00q6	1898	1	In	in	IN
cord-014712-5u4e00q6	1898	2	the	the	DT
cord-014712-5u4e00q6	1898	3	past	past	JJ
cord-014712-5u4e00q6	1898	4	medical	medical	JJ
cord-014712-5u4e00q6	1898	5	history	history	NN
cord-014712-5u4e00q6	1898	6	;	;	:
cord-014712-5u4e00q6	1898	7	she	-PRON-	PRP
cord-014712-5u4e00q6	1898	8	had	have	VBD
cord-014712-5u4e00q6	1898	9	skin	skin	NN
cord-014712-5u4e00q6	1898	10	abscess	abscess	NN
cord-014712-5u4e00q6	1898	11	and	and	CC
cord-014712-5u4e00q6	1898	12	failure	failure	NN
cord-014712-5u4e00q6	1898	13	to	to	TO
cord-014712-5u4e00q6	1898	14	thrive	thrive	VB
cord-014712-5u4e00q6	1898	15	.	.	.
cord-014712-5u4e00q6	1899	1	On	on	IN
cord-014712-5u4e00q6	1899	2	admission	admission	NN
cord-014712-5u4e00q6	1899	3	she	-PRON-	PRP
cord-014712-5u4e00q6	1899	4	had	have	VBD
cord-014712-5u4e00q6	1899	5	erythematous	erythematous	JJ
cord-014712-5u4e00q6	1899	6	,	,	,
cord-014712-5u4e00q6	1899	7	shiny	shiny	JJ
cord-014712-5u4e00q6	1899	8	skin	skin	NN
cord-014712-5u4e00q6	1899	9	with	with	IN
cord-014712-5u4e00q6	1899	10	generalized	generalized	JJ
cord-014712-5u4e00q6	1899	11	dry	dry	JJ
cord-014712-5u4e00q6	1899	12	scaly	scaly	JJ
cord-014712-5u4e00q6	1899	13	predominantly	predominantly	RB
cord-014712-5u4e00q6	1899	14	palmoplantar	palmoplantar	NNP
cord-014712-5u4e00q6	1899	15	hyperkeratosis	hyperkeratosis	NNP
cord-014712-5u4e00q6	1899	16	and	and	CC
cord-014712-5u4e00q6	1899	17	loss	loss	NN
cord-014712-5u4e00q6	1899	18	of	of	IN
cord-014712-5u4e00q6	1899	19	teeth	tooth	NNS
cord-014712-5u4e00q6	1899	20	except	except	IN
cord-014712-5u4e00q6	1899	21	four	four	CD
cord-014712-5u4e00q6	1899	22	or	or	CC
cord-014712-5u4e00q6	1899	23	five	five	CD
cord-014712-5u4e00q6	1899	24	molar	molar	JJ
cord-014712-5u4e00q6	1899	25	teeth	tooth	NNS
cord-014712-5u4e00q6	1899	26	.	.	.
cord-014712-5u4e00q6	1900	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1900	2	informed	inform	VBD
cord-014712-5u4e00q6	1900	3	that	that	IN
cord-014712-5u4e00q6	1900	4	she	-PRON-	PRP
cord-014712-5u4e00q6	1900	5	had	have	VBD
cord-014712-5u4e00q6	1900	6	malformed	malformed	JJ
cord-014712-5u4e00q6	1900	7	teeth	tooth	NNS
cord-014712-5u4e00q6	1900	8	since	since	IN
cord-014712-5u4e00q6	1900	9	childhood	childhood	NN
cord-014712-5u4e00q6	1900	10	which	which	WDT
cord-014712-5u4e00q6	1900	11	fell	fall	VBD
cord-014712-5u4e00q6	1900	12	off	off	RB
cord-014712-5u4e00q6	1900	13	one	one	CD
cord-014712-5u4e00q6	1900	14	by	by	IN
cord-014712-5u4e00q6	1900	15	one	one	CD
cord-014712-5u4e00q6	1900	16	.	.	.
cord-014712-5u4e00q6	1901	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1901	2	had	have	VBD
cord-014712-5u4e00q6	1901	3	also	also	RB
cord-014712-5u4e00q6	1901	4	poor	poor	JJ
cord-014712-5u4e00q6	1901	5	oral	oral	JJ
cord-014712-5u4e00q6	1901	6	hygiene	hygiene	NN
cord-014712-5u4e00q6	1901	7	non	non	JJ
cord-014712-5u4e00q6	1901	8	-	-	JJ
cord-014712-5u4e00q6	1901	9	pitting	pitting	JJ
cord-014712-5u4e00q6	1901	10	edema	edema	NN
cord-014712-5u4e00q6	1901	11	on	on	IN
cord-014712-5u4e00q6	1901	12	lower	low	JJR
cord-014712-5u4e00q6	1901	13	extremities	extremity	NNS
cord-014712-5u4e00q6	1901	14	.	.	.
cord-014712-5u4e00q6	1902	1	No	no	DT
cord-014712-5u4e00q6	1902	2	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-014712-5u4e00q6	1902	3	detected	detect	VBD
cord-014712-5u4e00q6	1902	4	.	.	.
cord-014712-5u4e00q6	1903	1	Family	family	NN
cord-014712-5u4e00q6	1903	2	history	history	NN
cord-014712-5u4e00q6	1903	3	was	be	VBD
cord-014712-5u4e00q6	1903	4	negative	negative	JJ
cord-014712-5u4e00q6	1903	5	.	.	.
cord-014712-5u4e00q6	1904	1	She	-PRON-	PRP
cord-014712-5u4e00q6	1904	2	investigated	investigate	VBD
cord-014712-5u4e00q6	1904	3	for	for	IN
cord-014712-5u4e00q6	1904	4	probable	probable	JJ
cord-014712-5u4e00q6	1904	5	immune	immune	JJ
cord-014712-5u4e00q6	1904	6	-	-	HYPH
cord-014712-5u4e00q6	1904	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	1904	8	with	with	IN
cord-014712-5u4e00q6	1904	9	regard	regard	NN
cord-014712-5u4e00q6	1904	10	to	to	IN
cord-014712-5u4e00q6	1904	11	skin	skin	NN
cord-014712-5u4e00q6	1904	12	lesions	lesion	NNS
cord-014712-5u4e00q6	1904	13	,	,	,
cord-014712-5u4e00q6	1904	14	history	history	NN
cord-014712-5u4e00q6	1904	15	of	of	IN
cord-014712-5u4e00q6	1904	16	skin	skin	NN
cord-014712-5u4e00q6	1904	17	abscess	abscess	NN
cord-014712-5u4e00q6	1904	18	and	and	CC
cord-014712-5u4e00q6	1904	19	FTT	FTT	NNP
cord-014712-5u4e00q6	1904	20	the	the	DT
cord-014712-5u4e00q6	1904	21	lab	lab	NN
cord-014712-5u4e00q6	1904	22	finding	finding	NN
cord-014712-5u4e00q6	1904	23	are	be	VBP
cord-014712-5u4e00q6	1904	24	as	as	IN
cord-014712-5u4e00q6	1904	25	following	follow	VBG
cord-014712-5u4e00q6	1904	26	:	:	:
cord-014712-5u4e00q6	1904	27	CBC	CBC	NNP
cord-014712-5u4e00q6	1904	28	diff	diff	NNP
cord-014712-5u4e00q6	1904	29	=	=	.
cord-014712-5u4e00q6	1905	1	Normal	normal	JJ
cord-014712-5u4e00q6	1905	2	,	,	,
cord-014712-5u4e00q6	1905	3	CRP	CRP	NNP
cord-014712-5u4e00q6	1905	4	=	=	NFP
cord-014712-5u4e00q6	1906	1	Neg	Neg	NNP
cord-014712-5u4e00q6	1906	2	,	,	,
cord-014712-5u4e00q6	1906	3	ESR	ESR	NNP
cord-014712-5u4e00q6	1906	4	=	=	SYM
cord-014712-5u4e00q6	1906	5	6	6	CD
cord-014712-5u4e00q6	1907	1	,	,	,
cord-014712-5u4e00q6	1907	2	AST	AST	NNP
cord-014712-5u4e00q6	1907	3	=	=	SYM
cord-014712-5u4e00q6	1907	4	31	31	CD
cord-014712-5u4e00q6	1907	5	,	,	,
cord-014712-5u4e00q6	1907	6	AlT	alt	NN
cord-014712-5u4e00q6	1907	7	=	=	SYM
cord-014712-5u4e00q6	1907	8	15	15	CD
cord-014712-5u4e00q6	1907	9	,	,	,
cord-014712-5u4e00q6	1907	10	Alph	Alph	NNP
cord-014712-5u4e00q6	1907	11	=	=	SYM
cord-014712-5u4e00q6	1907	12	1656	1656	CD
cord-014712-5u4e00q6	1907	13	,	,	,
cord-014712-5u4e00q6	1907	14	Alb	Alb	NNP
cord-014712-5u4e00q6	1907	15	=	=	SYM
cord-014712-5u4e00q6	1907	16	3.8	3.8	CD
cord-014712-5u4e00q6	1907	17	,	,	,
cord-014712-5u4e00q6	1907	18	Total	total	JJ
cord-014712-5u4e00q6	1907	19	Pr	pr	NN
cord-014712-5u4e00q6	1907	20	=	=	NN
cord-014712-5u4e00q6	1907	21	6.2	6.2	CD
cord-014712-5u4e00q6	1908	1	,	,	,
cord-014712-5u4e00q6	1908	2	Urea	urea	NN
cord-014712-5u4e00q6	1908	3	=	=	SYM
cord-014712-5u4e00q6	1908	4	16	16	CD
cord-014712-5u4e00q6	1908	5	,	,	,
cord-014712-5u4e00q6	1908	6	Cr	cr	NN
cord-014712-5u4e00q6	1908	7	=	=	SYM
cord-014712-5u4e00q6	1908	8	0.4	0.4	CD
cord-014712-5u4e00q6	1908	9	IgG	igg	NN
cord-014712-5u4e00q6	1908	10	=	=	SYM
cord-014712-5u4e00q6	1908	11	1620	1620	CD
cord-014712-5u4e00q6	1908	12	,	,	,
cord-014712-5u4e00q6	1908	13	IgM	IgM	NNP
cord-014712-5u4e00q6	1908	14	=	=	SYM
cord-014712-5u4e00q6	1908	15	230	230	CD
cord-014712-5u4e00q6	1908	16	,	,	,
cord-014712-5u4e00q6	1908	17	IgA	IgA	NNP
cord-014712-5u4e00q6	1908	18	=	=	SYM
cord-014712-5u4e00q6	1908	19	43	43	CD
cord-014712-5u4e00q6	1908	20	,	,	,
cord-014712-5u4e00q6	1908	21	IgE	IgE	NNP
cord-014712-5u4e00q6	1908	22	=	=	SYM
cord-014712-5u4e00q6	1908	23	10.8	10.8	CD
cord-014712-5u4e00q6	1908	24	,	,	,
cord-014712-5u4e00q6	1908	25	CD19	CD19	NNP
cord-014712-5u4e00q6	1908	26	=	=	SYM
cord-014712-5u4e00q6	1908	27	17	17	CD
cord-014712-5u4e00q6	1908	28	%	%	NN
cord-014712-5u4e00q6	1908	29	,	,	,
cord-014712-5u4e00q6	1908	30	CD	CD	NNP
cord-014712-5u4e00q6	1908	31	8	8	CD
cord-014712-5u4e00q6	1908	32	=	=	SYM
cord-014712-5u4e00q6	1908	33	20	20	CD
cord-014712-5u4e00q6	1908	34	%	%	NN
cord-014712-5u4e00q6	1908	35	,	,	,
cord-014712-5u4e00q6	1908	36	CD3	CD3	NNP
cord-014712-5u4e00q6	1908	37	=	=	SYM
cord-014712-5u4e00q6	1908	38	55	55	CD
cord-014712-5u4e00q6	1908	39	%	%	NN
cord-014712-5u4e00q6	1908	40	,	,	,
cord-014712-5u4e00q6	1908	41	CD4	CD4	NNP
cord-014712-5u4e00q6	1908	42	=	=	SYM
cord-014712-5u4e00q6	1908	43	34	34	CD
cord-014712-5u4e00q6	1908	44	%	%	NN
cord-014712-5u4e00q6	1908	45	,	,	,
cord-014712-5u4e00q6	1908	46	CD8	CD8	NNP
cord-014712-5u4e00q6	1908	47	=	=	SYM
cord-014712-5u4e00q6	1908	48	20	20	CD
cord-014712-5u4e00q6	1908	49	%	%	NN
cord-014712-5u4e00q6	1908	50	,	,	,
cord-014712-5u4e00q6	1908	51	CD	CD	NNP
cord-014712-5u4e00q6	1908	52	56	56	CD
cord-014712-5u4e00q6	1908	53	=	=	SYM
cord-014712-5u4e00q6	1908	54	15	15	CD
cord-014712-5u4e00q6	1908	55	%	%	NN
cord-014712-5u4e00q6	1908	56	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1908	57	:	:	:
cord-014712-5u4e00q6	1909	1	According	accord	VBG
cord-014712-5u4e00q6	1909	2	to	to	IN
cord-014712-5u4e00q6	1909	3	nearly	nearly	RB
cord-014712-5u4e00q6	1909	4	normal	normal	JJ
cord-014712-5u4e00q6	1909	5	lab	lab	NN
cord-014712-5u4e00q6	1909	6	values	value	NNS
cord-014712-5u4e00q6	1909	7	and	and	CC
cord-014712-5u4e00q6	1909	8	presenting	present	VBG
cord-014712-5u4e00q6	1909	9	signs	sign	NNS
cord-014712-5u4e00q6	1909	10	such	such	JJ
cord-014712-5u4e00q6	1909	11	as	as	IN
cord-014712-5u4e00q6	1909	12	:	:	:
cord-014712-5u4e00q6	1909	13	Generalized	generalized	JJ
cord-014712-5u4e00q6	1909	14	pyogenic	pyogenic	JJ
cord-014712-5u4e00q6	1909	15	periodentitis	periodentitis	NN
cord-014712-5u4e00q6	1909	16	,	,	,
cord-014712-5u4e00q6	1909	17	palmoplantar	palmoplantar	NNP
cord-014712-5u4e00q6	1909	18	hyper	hyper	NNP
cord-014712-5u4e00q6	1909	19	keratosis	keratosis	NNP
cord-014712-5u4e00q6	1909	20	and	and	CC
cord-014712-5u4e00q6	1909	21	negative	negative	JJ
cord-014712-5u4e00q6	1909	22	family	family	NN
cord-014712-5u4e00q6	1909	23	history	history	NN
cord-014712-5u4e00q6	1909	24	were	be	VBD
cord-014712-5u4e00q6	1909	25	attributed	attribute	VBN
cord-014712-5u4e00q6	1909	26	to	to	IN
cord-014712-5u4e00q6	1909	27	a	a	DT
cord-014712-5u4e00q6	1909	28	very	very	RB
cord-014712-5u4e00q6	1909	29	rare	rare	JJ
cord-014712-5u4e00q6	1909	30	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1909	31	recessive	recessive	JJ
cord-014712-5u4e00q6	1909	32	disorder	disorder	NN
cord-014712-5u4e00q6	1909	33	with	with	IN
cord-014712-5u4e00q6	1909	34	ectodermal	ectodermal	JJ
cord-014712-5u4e00q6	1909	35	dysplasia	dysplasia	NN
cord-014712-5u4e00q6	1909	36	known	know	VBN
cord-014712-5u4e00q6	1909	37	as	as	IN
cord-014712-5u4e00q6	1909	38	papillon	papillon	NN
cord-014712-5u4e00q6	1909	39	-	-	HYPH
cord-014712-5u4e00q6	1909	40	lefevresyndrome	lefevresyndrome	NNP
cord-014712-5u4e00q6	1909	41	manifesting	manifest	VBG
cord-014712-5u4e00q6	1909	42	with	with	IN
cord-014712-5u4e00q6	1909	43	palmoplantar	palmoplantar	NNP
cord-014712-5u4e00q6	1909	44	hyperkeratosis	hyperkeratosis	NNP
cord-014712-5u4e00q6	1909	45	and	and	CC
cord-014712-5u4e00q6	1909	46	severe	severe	JJ
cord-014712-5u4e00q6	1909	47	early	early	JJ
cord-014712-5u4e00q6	1909	48	onset	onset	NN
cord-014712-5u4e00q6	1909	49	of	of	IN
cord-014712-5u4e00q6	1909	50	destructive	destructive	JJ
cord-014712-5u4e00q6	1909	51	periodontal	periodontal	NN
cord-014712-5u4e00q6	1909	52	leading	lead	VBG
cord-014712-5u4e00q6	1909	53	to	to	IN
cord-014712-5u4e00q6	1909	54	pre	pre	VB
cord-014712-5u4e00q6	1909	55	-	-	JJ
cord-014712-5u4e00q6	1909	56	mature	mature	JJ
cord-014712-5u4e00q6	1909	57	loss	loss	NN
cord-014712-5u4e00q6	1909	58	of	of	IN
cord-014712-5u4e00q6	1909	59	both	both	CC
cord-014712-5u4e00q6	1909	60	primary	primary	JJ
cord-014712-5u4e00q6	1909	61	and	and	CC
cord-014712-5u4e00q6	1909	62	permanent	permanent	JJ
cord-014712-5u4e00q6	1909	63	dentitions	dentition	NNS
cord-014712-5u4e00q6	1909	64	.	.	.
cord-014712-5u4e00q6	1910	1	Nijmegen	Nijmegen	NNP
cord-014712-5u4e00q6	1910	2	breakage	breakage	NN
cord-014712-5u4e00q6	1910	3	syndrome	syndrome	NN
cord-014712-5u4e00q6	1910	4	(	(	-LRB-
cord-014712-5u4e00q6	1910	5	NBS	NBS	NNP
cord-014712-5u4e00q6	1910	6	)	)	-RRB-
cord-014712-5u4e00q6	1910	7	is	be	VBZ
cord-014712-5u4e00q6	1910	8	a	a	DT
cord-014712-5u4e00q6	1910	9	rare	rare	JJ
cord-014712-5u4e00q6	1910	10	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1910	11	recessive	recessive	JJ
cord-014712-5u4e00q6	1910	12	syndrome	syndrome	NN
cord-014712-5u4e00q6	1910	13	of	of	IN
cord-014712-5u4e00q6	1910	14	chromosomal	chromosomal	JJ
cord-014712-5u4e00q6	1910	15	instability	instability	NN
cord-014712-5u4e00q6	1910	16	mainly	mainly	RB
cord-014712-5u4e00q6	1910	17	characterized	characterize	VBN
cord-014712-5u4e00q6	1910	18	by	by	IN
cord-014712-5u4e00q6	1910	19	microcephaly	microcephaly	NNS
cord-014712-5u4e00q6	1910	20	at	at	IN
cord-014712-5u4e00q6	1910	21	birth	birth	NN
cord-014712-5u4e00q6	1910	22	,	,	,
cord-014712-5u4e00q6	1910	23	combined	combine	VBN
cord-014712-5u4e00q6	1910	24	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1910	25	and	and	CC
cord-014712-5u4e00q6	1910	26	predisposition	predisposition	NN
cord-014712-5u4e00q6	1910	27	to	to	IN
cord-014712-5u4e00q6	1910	28	malignancies	malignancy	NNS
cord-014712-5u4e00q6	1910	29	.	.	.
cord-014712-5u4e00q6	1911	1	The	the	DT
cord-014712-5u4e00q6	1911	2	disease	disease	NN
cord-014712-5u4e00q6	1911	3	is	be	VBZ
cord-014712-5u4e00q6	1911	4	caused	cause	VBN
cord-014712-5u4e00q6	1911	5	by	by	IN
cord-014712-5u4e00q6	1911	6	mutations	mutation	NNS
cord-014712-5u4e00q6	1911	7	in	in	IN
cord-014712-5u4e00q6	1911	8	the	the	DT
cord-014712-5u4e00q6	1911	9	NBS1	NBS1	NNP
cord-014712-5u4e00q6	1911	10	gene	gene	NN
cord-014712-5u4e00q6	1911	11	,	,	,
cord-014712-5u4e00q6	1911	12	which	which	WDT
cord-014712-5u4e00q6	1911	13	encodes	encode	VBZ
cord-014712-5u4e00q6	1911	14	nibrin	nibrin	NNP
cord-014712-5u4e00q6	1911	15	,	,	,
cord-014712-5u4e00q6	1911	16	a	a	DT
cord-014712-5u4e00q6	1911	17	component	component	NN
cord-014712-5u4e00q6	1911	18	of	of	IN
cord-014712-5u4e00q6	1911	19	the	the	DT
cord-014712-5u4e00q6	1911	20	hMre11-Rad50-p95	hmre11-rad50-p95	JJ
cord-014712-5u4e00q6	1911	21	complex	complex	NN
cord-014712-5u4e00q6	1911	22	involved	involve	VBN
cord-014712-5u4e00q6	1911	23	in	in	IN
cord-014712-5u4e00q6	1911	24	cellular	cellular	JJ
cord-014712-5u4e00q6	1911	25	response	response	NN
cord-014712-5u4e00q6	1911	26	to	to	IN
cord-014712-5u4e00q6	1911	27	DNA	dna	NN
cord-014712-5u4e00q6	1911	28	doublestrand	doublestrand	NN
cord-014712-5u4e00q6	1911	29	breaks	break	NNS
cord-014712-5u4e00q6	1911	30	.	.	.
cord-014712-5u4e00q6	1912	1	The	the	DT
cord-014712-5u4e00q6	1912	2	aim	aim	NN
cord-014712-5u4e00q6	1912	3	of	of	IN
cord-014712-5u4e00q6	1912	4	the	the	DT
cord-014712-5u4e00q6	1912	5	present	present	JJ
cord-014712-5u4e00q6	1912	6	case	case	NN
cord-014712-5u4e00q6	1912	7	report	report	NN
cord-014712-5u4e00q6	1912	8	was	be	VBD
cord-014712-5u4e00q6	1912	9	to	to	TO
cord-014712-5u4e00q6	1912	10	discuss	discuss	VB
cord-014712-5u4e00q6	1912	11	two	two	CD
cord-014712-5u4e00q6	1912	12	siblings	sibling	NNS
cord-014712-5u4e00q6	1912	13	with	with	IN
cord-014712-5u4e00q6	1912	14	immunologically	immunologically	RB
cord-014712-5u4e00q6	1912	15	and	and	CC
cord-014712-5u4e00q6	1912	16	clinically	clinically	RB
cord-014712-5u4e00q6	1912	17	different	different	JJ
cord-014712-5u4e00q6	1912	18	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	1912	19	of	of	IN
cord-014712-5u4e00q6	1912	20	disease	disease	NN
cord-014712-5u4e00q6	1912	21	presentation	presentation	NN
cord-014712-5u4e00q6	1912	22	and	and	CC
cord-014712-5u4e00q6	1912	23	to	to	TO
cord-014712-5u4e00q6	1912	24	make	make	VB
cord-014712-5u4e00q6	1912	25	an	an	DT
cord-014712-5u4e00q6	1912	26	attempt	attempt	NN
cord-014712-5u4e00q6	1912	27	to	to	TO
cord-014712-5u4e00q6	1912	28	explain	explain	VB
cord-014712-5u4e00q6	1912	29	possible	possible	JJ
cord-014712-5u4e00q6	1912	30	genotype	genotype	NN
cord-014712-5u4e00q6	1912	31	-	-	HYPH
cord-014712-5u4e00q6	1912	32	phenotype	phenotype	NN
cord-014712-5u4e00q6	1912	33	relation	relation	NN
cord-014712-5u4e00q6	1912	34	.	.	.
cord-014712-5u4e00q6	1913	1	The	the	DT
cord-014712-5u4e00q6	1913	2	two	two	CD
cord-014712-5u4e00q6	1913	3	patients	patient	NNS
cord-014712-5u4e00q6	1913	4	and	and	CC
cord-014712-5u4e00q6	1913	5	their	-PRON-	PRP$
cord-014712-5u4e00q6	1913	6	non	non	JJ
cord-014712-5u4e00q6	1913	7	-	-	JJ
cord-014712-5u4e00q6	1913	8	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	1913	9	parents	parent	NNS
cord-014712-5u4e00q6	1913	10	were	be	VBD
cord-014712-5u4e00q6	1913	11	clinically	clinically	RB
cord-014712-5u4e00q6	1913	12	,	,	,
cord-014712-5u4e00q6	1913	13	laboratory	laboratory	NN
cord-014712-5u4e00q6	1913	14	and	and	CC
cord-014712-5u4e00q6	1913	15	genetically	genetically	RB
cord-014712-5u4e00q6	1913	16	investigated	investigate	VBN
cord-014712-5u4e00q6	1913	17	.	.	.
cord-014712-5u4e00q6	1914	1	For	for	IN
cord-014712-5u4e00q6	1914	2	mother	mother	NN
cord-014712-5u4e00q6	1914	3	and	and	CC
cord-014712-5u4e00q6	1914	4	father	father	NN
cord-014712-5u4e00q6	1914	5	we	-PRON-	PRP
cord-014712-5u4e00q6	1914	6	observed	observe	VBD
cord-014712-5u4e00q6	1914	7	no	no	DT
cord-014712-5u4e00q6	1914	8	clinical	clinical	JJ
cord-014712-5u4e00q6	1914	9	presentation	presentation	NN
cord-014712-5u4e00q6	1914	10	and	and	CC
cord-014712-5u4e00q6	1914	11	no	no	DT
cord-014712-5u4e00q6	1914	12	immunological	immunological	JJ
cord-014712-5u4e00q6	1914	13	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	1914	14	.	.	.
cord-014712-5u4e00q6	1915	1	Sibling	sibling	NN
cord-014712-5u4e00q6	1915	2	no.1	no.1	NN
cord-014712-5u4e00q6	1915	3	(	(	-LRB-
cord-014712-5u4e00q6	1915	4	6	6	CD
cord-014712-5u4e00q6	1915	5	years	year	NNS
cord-014712-5u4e00q6	1915	6	old	old	JJ
cord-014712-5u4e00q6	1915	7	boy	boy	NN
cord-014712-5u4e00q6	1915	8	)	)	-RRB-
cord-014712-5u4e00q6	1915	9	had	have	VBD
cord-014712-5u4e00q6	1915	10	no	no	DT
cord-014712-5u4e00q6	1915	11	history	history	NN
cord-014712-5u4e00q6	1915	12	of	of	IN
cord-014712-5u4e00q6	1915	13	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1915	14	infections	infection	NNS
cord-014712-5u4e00q6	1915	15	and	and	CC
cord-014712-5u4e00q6	1915	16	no	no	DT
cord-014712-5u4e00q6	1915	17	deviation	deviation	NN
cord-014712-5u4e00q6	1915	18	in	in	IN
cord-014712-5u4e00q6	1915	19	immunological	immunological	JJ
cord-014712-5u4e00q6	1915	20	tests	test	NNS
cord-014712-5u4e00q6	1915	21	.	.	.
cord-014712-5u4e00q6	1916	1	Sibling	sibling	NN
cord-014712-5u4e00q6	1916	2	no.2	no.2	NN
cord-014712-5u4e00q6	1916	3	.	.	.
cord-014712-5u4e00q6	1917	1	(	(	-LRB-
cord-014712-5u4e00q6	1917	2	6	6	CD
cord-014712-5u4e00q6	1917	3	month	month	NN
cord-014712-5u4e00q6	1917	4	old	old	JJ
cord-014712-5u4e00q6	1917	5	girl	girl	NN
cord-014712-5u4e00q6	1917	6	)	)	-RRB-
cord-014712-5u4e00q6	1917	7	had	have	VBD
cord-014712-5u4e00q6	1917	8	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1917	9	infections	infection	NNS
cord-014712-5u4e00q6	1917	10	since	since	IN
cord-014712-5u4e00q6	1917	11	birth	birth	NN
cord-014712-5u4e00q6	1917	12	and	and	CC
cord-014712-5u4e00q6	1917	13	IgA	IgA	NNP
cord-014712-5u4e00q6	1917	14	,	,	,
cord-014712-5u4e00q6	1917	15	IgG2	igg2	NN
cord-014712-5u4e00q6	1917	16	and	and	CC
cord-014712-5u4e00q6	1917	17	IgG4	igg4	JJ
cord-014712-5u4e00q6	1917	18	deficiency	deficiency	NN
cord-014712-5u4e00q6	1917	19	as	as	RB
cord-014712-5u4e00q6	1917	20	well	well	RB
cord-014712-5u4e00q6	1917	21	as	as	IN
cord-014712-5u4e00q6	1917	22	T	T	NNP
cord-014712-5u4e00q6	1917	23	-	-	HYPH
cord-014712-5u4e00q6	1917	24	and	and	CC
cord-014712-5u4e00q6	1917	25	B	b	NN
cord-014712-5u4e00q6	1917	26	-	-	HYPH
cord-014712-5u4e00q6	1917	27	cells	cell	NNS
cord-014712-5u4e00q6	1917	28	deficiency	deficiency	NN
cord-014712-5u4e00q6	1917	29	.	.	.
cord-014712-5u4e00q6	1918	1	Cytogenetic	cytogenetic	JJ
cord-014712-5u4e00q6	1918	2	analysis	analysis	NN
cord-014712-5u4e00q6	1918	3	revealed	reveal	VBD
cord-014712-5u4e00q6	1918	4	variable	variable	JJ
cord-014712-5u4e00q6	1918	5	percent	percent	NN
cord-014712-5u4e00q6	1918	6	of	of	IN
cord-014712-5u4e00q6	1918	7	spontaneous	spontaneous	JJ
cord-014712-5u4e00q6	1918	8	chromosomal	chromosomal	JJ
cord-014712-5u4e00q6	1918	9	instability	instability	NN
cord-014712-5u4e00q6	1918	10	which	which	WDT
cord-014712-5u4e00q6	1918	11	was	be	VBD
cord-014712-5u4e00q6	1918	12	more	more	RBR
cord-014712-5u4e00q6	1918	13	severe	severe	JJ
cord-014712-5u4e00q6	1918	14	(	(	-LRB-
cord-014712-5u4e00q6	1918	15	in	in	IN
cord-014712-5u4e00q6	1918	16	50	50	CD
cord-014712-5u4e00q6	1918	17	%	%	NN
cord-014712-5u4e00q6	1918	18	of	of	IN
cord-014712-5u4e00q6	1918	19	chromosomes	chromosome	NNS
cord-014712-5u4e00q6	1918	20	analyzed	analyze	VBN
cord-014712-5u4e00q6	1918	21	)	)	-RRB-
cord-014712-5u4e00q6	1918	22	in	in	IN
cord-014712-5u4e00q6	1918	23	sibling	sibling	NN
cord-014712-5u4e00q6	1918	24	no.2	no.2	NN
cord-014712-5u4e00q6	1918	25	.	.	.
cord-014712-5u4e00q6	1919	1	Additionally	additionally	RB
cord-014712-5u4e00q6	1919	2	we	-PRON-	PRP
cord-014712-5u4e00q6	1919	3	sequenced	sequence	VBD
cord-014712-5u4e00q6	1919	4	bi	bi	NN
cord-014712-5u4e00q6	1919	5	-	-	HYPH
cord-014712-5u4e00q6	1919	6	directionally	directionally	RB
cord-014712-5u4e00q6	1919	7	(	(	-LRB-
cord-014712-5u4e00q6	1919	8	26	26	CD
cord-014712-5u4e00q6	1919	9	amplicons	amplicon	NNS
cord-014712-5u4e00q6	1919	10	)	)	-RRB-
cord-014712-5u4e00q6	1920	1	the	the	DT
cord-014712-5u4e00q6	1920	2	DNA	dna	NN
cord-014712-5u4e00q6	1920	3	samples	sample	NNS
cord-014712-5u4e00q6	1920	4	from	from	IN
cord-014712-5u4e00q6	1920	5	all	all	DT
cord-014712-5u4e00q6	1920	6	family	family	NN
cord-014712-5u4e00q6	1920	7	members	member	NNS
cord-014712-5u4e00q6	1920	8	to	to	TO
cord-014712-5u4e00q6	1920	9	survey	survey	VB
cord-014712-5u4e00q6	1920	10	the	the	DT
cord-014712-5u4e00q6	1920	11	germline	germline	JJ
cord-014712-5u4e00q6	1920	12	genetic	genetic	JJ
cord-014712-5u4e00q6	1920	13	variation	variation	NN
cord-014712-5u4e00q6	1920	14	in	in	IN
cord-014712-5u4e00q6	1920	15	the	the	DT
cord-014712-5u4e00q6	1920	16	NBS1gene	NBS1gene	NNP
cord-014712-5u4e00q6	1920	17	.	.	.
cord-014712-5u4e00q6	1921	1	The	the	DT
cord-014712-5u4e00q6	1921	2	657del5	657del5	CD
cord-014712-5u4e00q6	1921	3	(	(	-LRB-
cord-014712-5u4e00q6	1921	4	exon	exon	NN
cord-014712-5u4e00q6	1921	5	6	6	CD
cord-014712-5u4e00q6	1921	6	)	)	-RRB-
cord-014712-5u4e00q6	1921	7	was	be	VBD
cord-014712-5u4e00q6	1921	8	detected	detect	VBN
cord-014712-5u4e00q6	1921	9	in	in	IN
cord-014712-5u4e00q6	1921	10	both	both	DT
cord-014712-5u4e00q6	1921	11	siblings	sibling	NNS
cord-014712-5u4e00q6	1921	12	in	in	IN
cord-014712-5u4e00q6	1921	13	homozygous	homozygous	JJ
cord-014712-5u4e00q6	1921	14	and	and	CC
cord-014712-5u4e00q6	1921	15	in	in	IN
cord-014712-5u4e00q6	1921	16	both	both	DT
cord-014712-5u4e00q6	1921	17	parents	parent	NNS
cord-014712-5u4e00q6	1921	18	in	in	IN
cord-014712-5u4e00q6	1921	19	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	1921	20	feature	feature	NN
cord-014712-5u4e00q6	1921	21	.	.	.
cord-014712-5u4e00q6	1922	1	In	in	IN
cord-014712-5u4e00q6	1922	2	order	order	NN
cord-014712-5u4e00q6	1922	3	to	to	TO
cord-014712-5u4e00q6	1922	4	explain	explain	VB
cord-014712-5u4e00q6	1922	5	different	different	JJ
cord-014712-5u4e00q6	1922	6	clinical	clinical	JJ
cord-014712-5u4e00q6	1922	7	and	and	CC
cord-014712-5u4e00q6	1922	8	immunological	immunological	JJ
cord-014712-5u4e00q6	1922	9	presentation	presentation	NN
cord-014712-5u4e00q6	1922	10	of	of	IN
cord-014712-5u4e00q6	1922	11	two	two	CD
cord-014712-5u4e00q6	1922	12	siblings	sibling	NNS
cord-014712-5u4e00q6	1922	13	the	the	DT
cord-014712-5u4e00q6	1922	14	rest	rest	NN
cord-014712-5u4e00q6	1922	15	of	of	IN
cord-014712-5u4e00q6	1922	16	the	the	DT
cord-014712-5u4e00q6	1922	17	NBS	NBS	NNP
cord-014712-5u4e00q6	1922	18	exones	exones	NNPS
cord-014712-5u4e00q6	1922	19	were	be	VBD
cord-014712-5u4e00q6	1922	20	analyzed	analyze	VBN
cord-014712-5u4e00q6	1922	21	for	for	IN
cord-014712-5u4e00q6	1922	22	genetic	genetic	JJ
cord-014712-5u4e00q6	1922	23	heterogeneity	heterogeneity	NN
cord-014712-5u4e00q6	1922	24	.	.	.
cord-014712-5u4e00q6	1923	1	No	no	DT
cord-014712-5u4e00q6	1923	2	additional	additional	JJ
cord-014712-5u4e00q6	1923	3	changes	change	NNS
cord-014712-5u4e00q6	1923	4	were	be	VBD
cord-014712-5u4e00q6	1923	5	observed	observe	VBN
cord-014712-5u4e00q6	1923	6	.	.	.
cord-014712-5u4e00q6	1924	1	In	in	IN
cord-014712-5u4e00q6	1924	2	conclusion	conclusion	NN
cord-014712-5u4e00q6	1924	3	patients	patient	NNS
cord-014712-5u4e00q6	1924	4	with	with	IN
cord-014712-5u4e00q6	1924	5	the	the	DT
cord-014712-5u4e00q6	1924	6	same	same	JJ
cord-014712-5u4e00q6	1924	7	NBS1	NBS1	NNP
cord-014712-5u4e00q6	1924	8	genotype	genotype	NN
cord-014712-5u4e00q6	1924	9	may	may	MD
cord-014712-5u4e00q6	1924	10	show	show	VB
cord-014712-5u4e00q6	1924	11	different	different	JJ
cord-014712-5u4e00q6	1924	12	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	1924	13	.	.	.
cord-014712-5u4e00q6	1925	1	Other	other	JJ
cord-014712-5u4e00q6	1925	2	gene	gene	NN
cord-014712-5u4e00q6	1925	3	/	/	SYM
cord-014712-5u4e00q6	1925	4	epigenetic	epigenetic	JJ
cord-014712-5u4e00q6	1925	5	factors	factor	NNS
cord-014712-5u4e00q6	1925	6	seem	seem	VBP
cord-014712-5u4e00q6	1925	7	to	to	TO
cord-014712-5u4e00q6	1925	8	play	play	VB
cord-014712-5u4e00q6	1925	9	a	a	DT
cord-014712-5u4e00q6	1925	10	role	role	NN
cord-014712-5u4e00q6	1925	11	in	in	IN
cord-014712-5u4e00q6	1925	12	phenotype	phenotype	NN
cord-014712-5u4e00q6	1925	13	modulation	modulation	NN
cord-014712-5u4e00q6	1925	14	.	.	.
cord-014712-5u4e00q6	1926	1	Omenn	Omenn	NNP
cord-014712-5u4e00q6	1926	2	syndrome	syndrome	NN
cord-014712-5u4e00q6	1927	1	[	[	-LRB-
cord-014712-5u4e00q6	1927	2	Mendelian	Mendelian	NNP
cord-014712-5u4e00q6	1927	3	Inheritance	Inheritance	NNP
cord-014712-5u4e00q6	1927	4	(	(	-LRB-
cord-014712-5u4e00q6	1927	5	OMIM	OMIM	NNP
cord-014712-5u4e00q6	1927	6	603554	603554	CD
cord-014712-5u4e00q6	1927	7	)	)	-RRB-
cord-014712-5u4e00q6	1927	8	]	]	-RRB-
cord-014712-5u4e00q6	1927	9	is	be	VBZ
cord-014712-5u4e00q6	1927	10	an	an	DT
cord-014712-5u4e00q6	1927	11	autosomal	autosomal	JJ
cord-014712-5u4e00q6	1927	12	recessive	recessive	JJ
cord-014712-5u4e00q6	1927	13	form	form	NN
cord-014712-5u4e00q6	1927	14	characterized	characterize	VBN
cord-014712-5u4e00q6	1927	15	by	by	IN
cord-014712-5u4e00q6	1927	16	the	the	DT
cord-014712-5u4e00q6	1927	17	presence	presence	NN
cord-014712-5u4e00q6	1927	18	of	of	IN
cord-014712-5u4e00q6	1927	19	fatal	fatal	JJ
cord-014712-5u4e00q6	1927	20	generalized	generalized	JJ
cord-014712-5u4e00q6	1927	21	severe	severe	JJ
cord-014712-5u4e00q6	1927	22	erythroderma	erythroderma	NNS
cord-014712-5u4e00q6	1927	23	,	,	,
cord-014712-5u4e00q6	1927	24	lymphoadenopathy	lymphoadenopathy	NNP
cord-014712-5u4e00q6	1927	25	,	,	,
cord-014712-5u4e00q6	1927	26	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	1927	27	and	and	CC
cord-014712-5u4e00q6	1927	28	profound	profound	JJ
cord-014712-5u4e00q6	1927	29	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1927	30	.	.	.
cord-014712-5u4e00q6	1928	1	Objective	objective	NN
cord-014712-5u4e00q6	1928	2	:	:	:
cord-014712-5u4e00q6	1929	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1929	2	studied	study	VBD
cord-014712-5u4e00q6	1929	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1929	4	and	and	CC
cord-014712-5u4e00q6	1929	5	immunological	immunological	JJ
cord-014712-5u4e00q6	1929	6	presentation	presentation	NN
cord-014712-5u4e00q6	1929	7	of	of	IN
cord-014712-5u4e00q6	1929	8	the	the	DT
cord-014712-5u4e00q6	1929	9	disease	disease	NN
cord-014712-5u4e00q6	1929	10	manifestation	manifestation	NN
cord-014712-5u4e00q6	1929	11	and	and	CC
cord-014712-5u4e00q6	1929	12	frequency	frequency	NN
cord-014712-5u4e00q6	1929	13	c.368	c.368	NNP
cord-014712-5u4e00q6	1929	14	-	-	HYPH
cord-014712-5u4e00q6	1929	15	369delAA	369delaa	CD
cord-014712-5u4e00q6	1930	1	(	(	-LRB-
cord-014712-5u4e00q6	1930	2	p	p	NN
cord-014712-5u4e00q6	1930	3	.	.	.
cord-014712-5u4e00q6	1930	4	K86Vfs118	K86Vfs118	NNP
cord-014712-5u4e00q6	1930	5	)	)	-RRB-
cord-014712-5u4e00q6	1930	6	in	in	IN
cord-014712-5u4e00q6	1930	7	RAG1	RAG1	NNP
cord-014712-5u4e00q6	1930	8	gene	gene	NN
cord-014712-5u4e00q6	1930	9	among	among	IN
cord-014712-5u4e00q6	1930	10	Eastern	Eastern	NNP
cord-014712-5u4e00q6	1930	11	Slavs	Slavs	NNPS
cord-014712-5u4e00q6	1930	12	population	population	NN
cord-014712-5u4e00q6	1930	13	.	.	.
cord-014712-5u4e00q6	1931	1	Results	result	NNS
cord-014712-5u4e00q6	1931	2	:	:	:
cord-014712-5u4e00q6	1932	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1932	2	collected	collect	VBD
cord-014712-5u4e00q6	1932	3	clinical	clinical	JJ
cord-014712-5u4e00q6	1932	4	and	and	CC
cord-014712-5u4e00q6	1932	5	immunological	immunological	JJ
cord-014712-5u4e00q6	1932	6	data	datum	NNS
cord-014712-5u4e00q6	1932	7	of	of	IN
cord-014712-5u4e00q6	1932	8	9	9	CD
cord-014712-5u4e00q6	1932	9	patients	patient	NNS
cord-014712-5u4e00q6	1932	10	(	(	-LRB-
cord-014712-5u4e00q6	1932	11	1	1	CD
cord-014712-5u4e00q6	1932	12	from	from	IN
cord-014712-5u4e00q6	1932	13	Belarus	Belarus	NNP
cord-014712-5u4e00q6	1932	14	,	,	,
cord-014712-5u4e00q6	1932	15	5	5	CD
cord-014712-5u4e00q6	1932	16	-Ukraine	-ukraine	DT
cord-014712-5u4e00q6	1932	17	,	,	,
cord-014712-5u4e00q6	1932	18	3	3	CD
cord-014712-5u4e00q6	1932	19	-Russia	-Russia	JJS
cord-014712-5u4e00q6	1932	20	)	)	-RRB-
cord-014712-5u4e00q6	1932	21	6	6	CD
cord-014712-5u4e00q6	1932	22	females	female	NNS
cord-014712-5u4e00q6	1932	23	,	,	,
cord-014712-5u4e00q6	1932	24	3	3	CD
cord-014712-5u4e00q6	1932	25	males	male	NNS
cord-014712-5u4e00q6	1932	26	.	.	.
cord-014712-5u4e00q6	1933	1	Age	age	NN
cord-014712-5u4e00q6	1933	2	of	of	IN
cord-014712-5u4e00q6	1933	3	Omenn	Omenn	NNP
cord-014712-5u4e00q6	1933	4	syndrome	syndrome	NN
cord-014712-5u4e00q6	1933	5	manifestation	manifestation	NN
cord-014712-5u4e00q6	1933	6	varied	vary	VBN
cord-014712-5u4e00q6	1933	7	from	from	IN
cord-014712-5u4e00q6	1933	8	1	1	CD
cord-014712-5u4e00q6	1933	9	st	st	NNP
cord-014712-5u4e00q6	1933	10	day	day	NNP
cord-014712-5u4e00q6	1933	11	of	of	IN
cord-014712-5u4e00q6	1933	12	life	life	NN
cord-014712-5u4e00q6	1933	13	to	to	IN
cord-014712-5u4e00q6	1933	14	1	1	CD
cord-014712-5u4e00q6	1933	15	yr	yr	NN
cord-014712-5u4e00q6	1933	16	1	1	CD
cord-014712-5u4e00q6	1933	17	month	month	NN
cord-014712-5u4e00q6	1933	18	.	.	.
cord-014712-5u4e00q6	1934	1	Age	age	NN
cord-014712-5u4e00q6	1934	2	of	of	IN
cord-014712-5u4e00q6	1934	3	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1934	4	-20	-20	CD
cord-014712-5u4e00q6	1934	5	days	day	NNS
cord-014712-5u4e00q6	1934	6	to	to	IN
cord-014712-5u4e00q6	1934	7	1	1	CD
cord-014712-5u4e00q6	1934	8	year	year	NN
cord-014712-5u4e00q6	1934	9	10	10	CD
cord-014712-5u4e00q6	1934	10	months	month	NNS
cord-014712-5u4e00q6	1934	11	.	.	.
cord-014712-5u4e00q6	1935	1	8	8	CD
cord-014712-5u4e00q6	1935	2	in	in	IN
cord-014712-5u4e00q6	1935	3	9	9	CD
cord-014712-5u4e00q6	1935	4	patients	patient	NNS
cord-014712-5u4e00q6	1935	5	had	have	VBD
cord-014712-5u4e00q6	1935	6	classical	classical	JJ
cord-014712-5u4e00q6	1935	7	immunological	immunological	JJ
cord-014712-5u4e00q6	1935	8	phenotype	phenotype	NN
cord-014712-5u4e00q6	1936	1	T(+/-)B-	T(+/-)B-	NNS
cord-014712-5u4e00q6	1937	1	NK+	NK+	NNP
cord-014712-5u4e00q6	1938	1	,	,	,
cord-014712-5u4e00q6	1938	2	1	1	CD
cord-014712-5u4e00q6	1938	3	pt	pt	NN
cord-014712-5u4e00q6	1938	4	had	have	VBD
cord-014712-5u4e00q6	1938	5	TlowB	TlowB	NNP
cord-014712-5u4e00q6	1938	6	+	+	CC
cord-014712-5u4e00q6	1938	7	NK	nk	NN
cord-014712-5u4e00q6	1939	1	+	+	CC
cord-014712-5u4e00q6	1939	2	with	with	IN
cord-014712-5u4e00q6	1939	3	CD3	CD3	NNP
cord-014712-5u4e00q6	1940	1	+	+	CC
cord-014712-5u4e00q6	1941	1	TCRgd	tcrgd	DT
cord-014712-5u4e00q6	1941	2	+	+	CC
cord-014712-5u4e00q6	1941	3	expansion	expansion	NN
cord-014712-5u4e00q6	1941	4	.	.	.
cord-014712-5u4e00q6	1942	1	6	6	CD
cord-014712-5u4e00q6	1942	2	in	in	IN
cord-014712-5u4e00q6	1942	3	9	9	CD
cord-014712-5u4e00q6	1942	4	pts	pt	NNS
cord-014712-5u4e00q6	1942	5	had	have	VBD
cord-014712-5u4e00q6	1942	6	mutation	mutation	NN
cord-014712-5u4e00q6	1942	7	in	in	IN
cord-014712-5u4e00q6	1942	8	RAG1	RAG1	NNP
cord-014712-5u4e00q6	1942	9	gene	gene	NN
cord-014712-5u4e00q6	1942	10	,	,	,
cord-014712-5u4e00q6	1942	11	4	4	CD
cord-014712-5u4e00q6	1942	12	in	in	IN
cord-014712-5u4e00q6	1942	13	6	6	CD
cord-014712-5u4e00q6	1942	14	had	have	VBD
cord-014712-5u4e00q6	1942	15	c.368	c.368	NNP
cord-014712-5u4e00q6	1942	16	-	-	HYPH
cord-014712-5u4e00q6	1942	17	369delAA	369delaa	CD
cord-014712-5u4e00q6	1943	1	(	(	-LRB-
cord-014712-5u4e00q6	1943	2	p	p	NN
cord-014712-5u4e00q6	1943	3	.	.	.
cord-014712-5u4e00q6	1943	4	K86Vfs118	K86Vfs118	NNP
cord-014712-5u4e00q6	1943	5	)	)	-RRB-
cord-014712-5u4e00q6	1943	6	in	in	IN
cord-014712-5u4e00q6	1943	7	one	one	CD
cord-014712-5u4e00q6	1943	8	or	or	CC
cord-014712-5u4e00q6	1943	9	two	two	CD
cord-014712-5u4e00q6	1943	10	alleles	allele	NNS
cord-014712-5u4e00q6	1943	11	.	.	.
cord-014712-5u4e00q6	1944	1	At	at	IN
cord-014712-5u4e00q6	1944	2	present	present	JJ
cord-014712-5u4e00q6	1944	3	moment	moment	NN
cord-014712-5u4e00q6	1944	4	4	4	CD
cord-014712-5u4e00q6	1944	5	in	in	IN
cord-014712-5u4e00q6	1944	6	9	9	CD
cord-014712-5u4e00q6	1944	7	pts	pt	NNS
cord-014712-5u4e00q6	1944	8	are	be	VBP
cord-014712-5u4e00q6	1944	9	alive	alive	JJ
cord-014712-5u4e00q6	1944	10	,	,	,
cord-014712-5u4e00q6	1944	11	3	3	CD
cord-014712-5u4e00q6	1944	12	were	be	VBD
cord-014712-5u4e00q6	1944	13	transplanted	transplant	VBN
cord-014712-5u4e00q6	1944	14	,	,	,
cord-014712-5u4e00q6	1944	15	1	1	CD
cord-014712-5u4e00q6	1944	16	pt	pt	NN
cord-014712-5u4e00q6	1944	17	is	be	VBZ
cord-014712-5u4e00q6	1944	18	prepared	prepared	JJ
cord-014712-5u4e00q6	1944	19	to	to	IN
cord-014712-5u4e00q6	1944	20	BMT	BMT	NNP
cord-014712-5u4e00q6	1944	21	.	.	.
cord-014712-5u4e00q6	1945	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	1945	2	:	:	:
cord-014712-5u4e00q6	1946	1	This	this	DT
cord-014712-5u4e00q6	1946	2	study	study	NN
cord-014712-5u4e00q6	1946	3	demonstrates	demonstrate	VBZ
cord-014712-5u4e00q6	1946	4	that	that	IN
cord-014712-5u4e00q6	1946	5	the	the	DT
cord-014712-5u4e00q6	1946	6	most	most	RBS
cord-014712-5u4e00q6	1946	7	popular	popular	JJ
cord-014712-5u4e00q6	1946	8	genetic	genetic	JJ
cord-014712-5u4e00q6	1946	9	abnormalities	abnormality	NNS
cord-014712-5u4e00q6	1946	10	in	in	IN
cord-014712-5u4e00q6	1946	11	Eastern	eastern	JJ
cord-014712-5u4e00q6	1946	12	Slavs	Slavs	NNPS
cord-014712-5u4e00q6	1946	13	children	child	NNS
cord-014712-5u4e00q6	1946	14	with	with	IN
cord-014712-5u4e00q6	1946	15	Omenn	Omenn	NNP
cord-014712-5u4e00q6	1946	16	syndrome	syndrome	NN
cord-014712-5u4e00q6	1946	17	is	be	VBZ
cord-014712-5u4e00q6	1946	18	c.368	c.368	NNP
cord-014712-5u4e00q6	1946	19	-	-	:
cord-014712-5u4e00q6	1946	20	369delAA	369delaa	CD
cord-014712-5u4e00q6	1947	1	(	(	-LRB-
cord-014712-5u4e00q6	1947	2	p	p	NN
cord-014712-5u4e00q6	1947	3	.	.	.
cord-014712-5u4e00q6	1947	4	K86Vfs118	K86Vfs118	NNP
cord-014712-5u4e00q6	1947	5	)	)	-RRB-
cord-014712-5u4e00q6	1947	6	in	in	IN
cord-014712-5u4e00q6	1947	7	RAG1	RAG1	NNP
cord-014712-5u4e00q6	1947	8	gene	gene	NN
cord-014712-5u4e00q6	1947	9	.	.	.
cord-014712-5u4e00q6	1948	1	This	this	DT
cord-014712-5u4e00q6	1948	2	information	information	NN
cord-014712-5u4e00q6	1948	3	may	may	MD
cord-014712-5u4e00q6	1948	4	be	be	VB
cord-014712-5u4e00q6	1948	5	useful	useful	JJ
cord-014712-5u4e00q6	1948	6	for	for	IN
cord-014712-5u4e00q6	1948	7	rapid	rapid	JJ
cord-014712-5u4e00q6	1948	8	diagnostic	diagnostic	NN
cord-014712-5u4e00q6	1948	9	of	of	IN
cord-014712-5u4e00q6	1948	10	Omenn	Omenn	NNP
cord-014712-5u4e00q6	1948	11	syndrome	syndrome	NN
cord-014712-5u4e00q6	1948	12	in	in	IN
cord-014712-5u4e00q6	1948	13	laboratories	laboratory	NNS
cord-014712-5u4e00q6	1948	14	used	use	VBD
cord-014712-5u4e00q6	1948	15	SSCP	SSCP	NNP
cord-014712-5u4e00q6	1948	16	(	(	-LRB-
cord-014712-5u4e00q6	1948	17	single	single	JJ
cord-014712-5u4e00q6	1948	18	strand	strand	NN
cord-014712-5u4e00q6	1948	19	conformation	conformation	NN
cord-014712-5u4e00q6	1948	20	polymorphism	polymorphism	NN
cord-014712-5u4e00q6	1948	21	)	)	-RRB-
cord-014712-5u4e00q6	1948	22	before	before	IN
cord-014712-5u4e00q6	1948	23	sequencing	sequencing	NN
cord-014712-5u4e00q6	1948	24	.	.	.
cord-014712-5u4e00q6	1949	1	Under	under	IN
cord-014712-5u4e00q6	1949	2	examination	examination	NN
cord-014712-5u4e00q6	1949	3	the	the	DT
cord-014712-5u4e00q6	1949	4	patient	patient	NN
cord-014712-5u4e00q6	1949	5	particularly	particularly	RB
cord-014712-5u4e00q6	1949	6	bright	bright	JJ
cord-014712-5u4e00q6	1949	7	phenotype	phenotype	NN
cord-014712-5u4e00q6	1949	8	attracted	attract	VBD
cord-014712-5u4e00q6	1949	9	attention	attention	NN
cord-014712-5u4e00q6	1949	10	:	:	:
cord-014712-5u4e00q6	1949	11	microcephaly	microcephaly	NNS
cord-014712-5u4e00q6	1949	12	,	,	,
cord-014712-5u4e00q6	1949	13	"	"	``
cord-014712-5u4e00q6	1949	14	birdlike	birdlike	JJ
cord-014712-5u4e00q6	1949	15	"	"	''
cord-014712-5u4e00q6	1949	16	facial	facial	JJ
cord-014712-5u4e00q6	1949	17	features	feature	NNS
cord-014712-5u4e00q6	1949	18	(	(	-LRB-
cord-014712-5u4e00q6	1949	19	sloping	slope	VBG
cord-014712-5u4e00q6	1949	20	forehead	forehead	NN
cord-014712-5u4e00q6	1949	21	,	,	,
cord-014712-5u4e00q6	1949	22	nape	nape	NN
cord-014712-5u4e00q6	1949	23	,	,	,
cord-014712-5u4e00q6	1949	24	hypoplasia	hypoplasia	NN
cord-014712-5u4e00q6	1949	25	of	of	IN
cord-014712-5u4e00q6	1949	26	brow	brow	NN
cord-014712-5u4e00q6	1949	27	ridges	ridge	NNS
cord-014712-5u4e00q6	1949	28	,	,	,
cord-014712-5u4e00q6	1949	29	broad	broad	JJ
cord-014712-5u4e00q6	1949	30	nasal	nasal	NN
cord-014712-5u4e00q6	1949	31	bridge	bridge	NN
cord-014712-5u4e00q6	1949	32	and	and	CC
cord-014712-5u4e00q6	1949	33	protruding	protruding	JJ
cord-014712-5u4e00q6	1949	34	midface	midface	NN
cord-014712-5u4e00q6	1949	35	,	,	,
cord-014712-5u4e00q6	1949	36	hypoplasia	hypoplasia	NN
cord-014712-5u4e00q6	1949	37	of	of	IN
cord-014712-5u4e00q6	1949	38	the	the	DT
cord-014712-5u4e00q6	1949	39	mandible	mandible	NN
cord-014712-5u4e00q6	1949	40	)	)	-RRB-
cord-014712-5u4e00q6	1949	41	.	.	.
cord-014712-5u4e00q6	1950	1	In	in	IN
cord-014712-5u4e00q6	1950	2	addition	addition	NN
cord-014712-5u4e00q6	1950	3	,	,	,
cord-014712-5u4e00q6	1950	4	besides	besides	IN
cord-014712-5u4e00q6	1950	5	specific	specific	JJ
cord-014712-5u4e00q6	1950	6	anomaly	anomaly	NN
cord-014712-5u4e00q6	1950	7	of	of	IN
cord-014712-5u4e00q6	1950	8	the	the	DT
cord-014712-5u4e00q6	1950	9	facial	facial	JJ
cord-014712-5u4e00q6	1950	10	bones	bone	NNS
cord-014712-5u4e00q6	1950	11	we	-PRON-	PRP
cord-014712-5u4e00q6	1950	12	noted	note	VBD
cord-014712-5u4e00q6	1950	13	:	:	:
cord-014712-5u4e00q6	1950	14	big	big	JJ
cord-014712-5u4e00q6	1950	15	ears	ear	NNS
cord-014712-5u4e00q6	1950	16	,	,	,
cord-014712-5u4e00q6	1950	17	sparse	sparse	JJ
cord-014712-5u4e00q6	1950	18	hair	hair	NN
cord-014712-5u4e00q6	1950	19	and	and	CC
cord-014712-5u4e00q6	1950	20	clinodactyly	clinodactyly	NN
cord-014712-5u4e00q6	1950	21	of	of	IN
cord-014712-5u4e00q6	1950	22	the	the	DT
cord-014712-5u4e00q6	1950	23	fifth	fifth	JJ
cord-014712-5u4e00q6	1950	24	fingers	finger	NNS
cord-014712-5u4e00q6	1950	25	.	.	.
cord-014712-5u4e00q6	1951	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	1951	2	and	and	CC
cord-014712-5u4e00q6	1951	3	immunological	immunological	JJ
cord-014712-5u4e00q6	1951	4	characteristics	characteristic	NNS
cord-014712-5u4e00q6	1951	5	:	:	:
cord-014712-5u4e00q6	1951	6	The	the	DT
cord-014712-5u4e00q6	1951	7	feature	feature	NN
cord-014712-5u4e00q6	1951	8	of	of	IN
cord-014712-5u4e00q6	1951	9	the	the	DT
cord-014712-5u4e00q6	1951	10	case	case	NN
cord-014712-5u4e00q6	1951	11	is	be	VBZ
cord-014712-5u4e00q6	1951	12	pancytopenia	pancytopenia	NNP
cord-014712-5u4e00q6	1951	13	syndrome	syndrome	NN
cord-014712-5u4e00q6	1951	14	we	-PRON-	PRP
cord-014712-5u4e00q6	1951	15	have	have	VBP
cord-014712-5u4e00q6	1951	16	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	1951	17	at	at	IN
cord-014712-5u4e00q6	1951	18	the	the	DT
cord-014712-5u4e00q6	1951	19	early	early	JJ
cord-014712-5u4e00q6	1951	20	stages	stage	NNS
cord-014712-5u4e00q6	1951	21	of	of	IN
cord-014712-5u4e00q6	1951	22	observation	observation	NN
cord-014712-5u4e00q6	1951	23	and	and	CC
cord-014712-5u4e00q6	1951	24	which	which	WDT
cord-014712-5u4e00q6	1951	25	is	be	VBZ
cord-014712-5u4e00q6	1951	26	continued	continue	VBN
cord-014712-5u4e00q6	1951	27	throughout	throughout	IN
cord-014712-5u4e00q6	1951	28	the	the	DT
cord-014712-5u4e00q6	1951	29	period	period	NN
cord-014712-5u4e00q6	1951	30	of	of	IN
cord-014712-5u4e00q6	1951	31	observation	observation	NN
cord-014712-5u4e00q6	1951	32	.	.	.
cord-014712-5u4e00q6	1952	1	Erc	Erc	NNP
cord-014712-5u4e00q6	1952	2	-2.9	-2.9	NNP
cord-014712-5u4e00q6	1952	3	-	-	HYPH
cord-014712-5u4e00q6	1952	4	3.6	3.6	CD
cord-014712-5u4e00q6	1952	5	x	x	SYM
cord-014712-5u4e00q6	1952	6	10	10	CD
cord-014712-5u4e00q6	1952	7	12	12	CD
cord-014712-5u4e00q6	1953	1	/l	/l	NNP
cord-014712-5u4e00q6	1954	1	Hb	Hb	NNP
cord-014712-5u4e00q6	1954	2	-71	-71	NNP
cord-014712-5u4e00q6	1955	1	-105	-105	NNP
cord-014712-5u4e00q6	1955	2	g	g	NNP
cord-014712-5u4e00q6	1955	3	/	/	SYM
cord-014712-5u4e00q6	1955	4	l	l	NNP
cord-014712-5u4e00q6	1955	5	Leuk	Leuk	NNP
cord-014712-5u4e00q6	1955	6	-0.5	-0.5	NNP
cord-014712-5u4e00q6	1955	7	-	-	HYPH
cord-014712-5u4e00q6	1955	8	3.0	3.0	NNP
cord-014712-5u4e00q6	1955	9	x	x	SYM
cord-014712-5u4e00q6	1955	10	10	10	CD
cord-014712-5u4e00q6	1955	11	9	9	CD
cord-014712-5u4e00q6	1955	12	/l	/l	NN
cord-014712-5u4e00q6	1956	1	Neu	Neu	NNP
cord-014712-5u4e00q6	1957	1	-10	-10	NNP
cord-014712-5u4e00q6	1957	2	-	-	SYM
cord-014712-5u4e00q6	1957	3	26	26	CD
cord-014712-5u4e00q6	1957	4	%	%	NN
cord-014712-5u4e00q6	1957	5	(	(	-LRB-
cord-014712-5u4e00q6	1957	6	300	300	CD
cord-014712-5u4e00q6	1957	7	-	-	SYM
cord-014712-5u4e00q6	1957	8	780	780	CD
cord-014712-5u4e00q6	1957	9	cells	cell	NNS
cord-014712-5u4e00q6	1957	10	/	/	SYM
cord-014712-5u4e00q6	1957	11	mcl	mcl	NN
cord-014712-5u4e00q6	1957	12	)	)	-RRB-
cord-014712-5u4e00q6	1958	1	PLT	PLT	NNP
cord-014712-5u4e00q6	1958	2	-40	-40	NNP
cord-014712-5u4e00q6	1958	3	-	-	HYPH
cord-014712-5u4e00q6	1958	4	60	60	CD
cord-014712-5u4e00q6	1958	5	x	x	SYM
cord-014712-5u4e00q6	1958	6	10	10	CD
cord-014712-5u4e00q6	1958	7	9	9	CD
cord-014712-5u4e00q6	1959	1	/l	/l	NNP
cord-014712-5u4e00q6	1959	2	Data	Data	NNP
cord-014712-5u4e00q6	1959	3	of	of	IN
cord-014712-5u4e00q6	1959	4	immunological	immunological	JJ
cord-014712-5u4e00q6	1959	5	examination	examination	NN
cord-014712-5u4e00q6	1959	6	:	:	:
cord-014712-5u4e00q6	1959	7	IgA	IgA	NNP
cord-014712-5u4e00q6	1959	8	-0,06	-0,06	.
cord-014712-5u4e00q6	1960	1	g	g	NNP
cord-014712-5u4e00q6	1960	2	/	/	SYM
cord-014712-5u4e00q6	1960	3	l	l	NNP
cord-014712-5u4e00q6	1960	4	IgM	IgM	NNP
cord-014712-5u4e00q6	1960	5	-0,6	-0,6	NNP
cord-014712-5u4e00q6	1961	1	g	g	NNP
cord-014712-5u4e00q6	1961	2	/	/	SYM
cord-014712-5u4e00q6	1961	3	l	l	NNP
cord-014712-5u4e00q6	1961	4	IgG	IgG	NNP
cord-014712-5u4e00q6	1961	5	-0,75	-0,75	:
cord-014712-5u4e00q6	1961	6	g	g	NNP
cord-014712-5u4e00q6	1961	7	/	/	SYM
cord-014712-5u4e00q6	1961	8	l	l	NN
cord-014712-5u4e00q6	1961	9	(	(	-LRB-
cord-014712-5u4e00q6	1961	10	Other	other	JJ
cord-014712-5u4e00q6	1961	11	results	result	NNS
cord-014712-5u4e00q6	1961	12	of	of	IN
cord-014712-5u4e00q6	1961	13	immunological	immunological	JJ
cord-014712-5u4e00q6	1961	14	examination	examination	NN
cord-014712-5u4e00q6	1961	15	are	be	VBP
cord-014712-5u4e00q6	1961	16	without	without	IN
cord-014712-5u4e00q6	1961	17	features	feature	NNS
cord-014712-5u4e00q6	1961	18	)	)	-RRB-
cord-014712-5u4e00q6	1962	1	The	the	DT
cord-014712-5u4e00q6	1962	2	deep	deep	JJ
cord-014712-5u4e00q6	1962	3	insufficiency	insufficiency	NN
cord-014712-5u4e00q6	1962	4	of	of	IN
cord-014712-5u4e00q6	1962	5	antibody	antibody	NN
cord-014712-5u4e00q6	1962	6	production	production	NN
cord-014712-5u4e00q6	1962	7	in	in	IN
cord-014712-5u4e00q6	1962	8	our	-PRON-	PRP$
cord-014712-5u4e00q6	1962	9	patient	patient	NN
cord-014712-5u4e00q6	1962	10	was	be	VBD
cord-014712-5u4e00q6	1962	11	the	the	DT
cord-014712-5u4e00q6	1962	12	cause	cause	NN
cord-014712-5u4e00q6	1962	13	of	of	IN
cord-014712-5u4e00q6	1962	14	serious	serious	JJ
cord-014712-5u4e00q6	1962	15	,	,	,
cord-014712-5u4e00q6	1962	16	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1962	17	,	,	,
cord-014712-5u4e00q6	1962	18	and	and	CC
cord-014712-5u4e00q6	1962	19	subsequently	subsequently	RB
cord-014712-5u4e00q6	1962	20	chronic	chronic	JJ
cord-014712-5u4e00q6	1962	21	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1962	22	sinopulmonary	sinopulmonary	JJ
cord-014712-5u4e00q6	1962	23	infections	infection	NNS
cord-014712-5u4e00q6	1962	24	after	after	IN
cord-014712-5u4e00q6	1962	25	3	3	CD
cord-014712-5u4e00q6	1962	26	years	year	NNS
cord-014712-5u4e00q6	1962	27	old	old	JJ
cord-014712-5u4e00q6	1962	28	.	.	.
cord-014712-5u4e00q6	1963	1	The	the	DT
cord-014712-5u4e00q6	1963	2	results	result	NNS
cord-014712-5u4e00q6	1963	3	of	of	IN
cord-014712-5u4e00q6	1963	4	clinical	clinical	JJ
cord-014712-5u4e00q6	1963	5	laboratory	laboratory	NN
cord-014712-5u4e00q6	1963	6	and	and	CC
cord-014712-5u4e00q6	1963	7	immunological	immunological	JJ
cord-014712-5u4e00q6	1963	8	examination	examination	NN
cord-014712-5u4e00q6	1963	9	without	without	IN
cord-014712-5u4e00q6	1963	10	significant	significant	JJ
cord-014712-5u4e00q6	1963	11	features	feature	NNS
cord-014712-5u4e00q6	1963	12	:	:	:
cord-014712-5u4e00q6	1963	13	Erc	Erc	NNP
cord-014712-5u4e00q6	1963	14	-4,0	-4,0	JJS
cord-014712-5u4e00q6	1963	15	-	-	HYPH
cord-014712-5u4e00q6	1963	16	5,4	5,4	CD
cord-014712-5u4e00q6	1964	1	x	x	LS
cord-014712-5u4e00q6	1964	2	10	10	CD
cord-014712-5u4e00q6	1964	3	12	12	CD
cord-014712-5u4e00q6	1965	1	/l	/l	NNP
cord-014712-5u4e00q6	1966	1	Hb	Hb	NNP
cord-014712-5u4e00q6	1966	2	-121	-121	NN
cord-014712-5u4e00q6	1966	3	-	-	HYPH
cord-014712-5u4e00q6	1966	4	133	133	CD
cord-014712-5u4e00q6	1966	5	g	g	NN
cord-014712-5u4e00q6	1966	6	/	/	SYM
cord-014712-5u4e00q6	1966	7	l	l	NNP
cord-014712-5u4e00q6	1966	8	Leuk	Leuk	NNP
cord-014712-5u4e00q6	1966	9	-11,5	-11,5	NNP
cord-014712-5u4e00q6	1966	10	-	-	HYPH
cord-014712-5u4e00q6	1966	11	6,2	6,2	CD
cord-014712-5u4e00q6	1967	1	x	x	SYM
cord-014712-5u4e00q6	1967	2	10	10	CD
cord-014712-5u4e00q6	1967	3	9	9	CD
cord-014712-5u4e00q6	1968	1	/l	/l	NNP
cord-014712-5u4e00q6	1968	2	Neu	Neu	NNP
cord-014712-5u4e00q6	1969	1	-40	-40	NNP
cord-014712-5u4e00q6	1969	2	-	-	HYPH
cord-014712-5u4e00q6	1969	3	70	70	CD
cord-014712-5u4e00q6	1969	4	%	%	NN
cord-014712-5u4e00q6	1969	5	(	(	-LRB-
cord-014712-5u4e00q6	1969	6	2640	2640	CD
cord-014712-5u4e00q6	1969	7	-	-	SYM
cord-014712-5u4e00q6	1969	8	11680	11680	CD
cord-014712-5u4e00q6	1969	9	cells/	cells/	CD
cord-014712-5u4e00q6	1969	10	mcl	mcl	NN
cord-014712-5u4e00q6	1969	11	)	)	-RRB-
cord-014712-5u4e00q6	1970	1	PLT	PLT	NNP
cord-014712-5u4e00q6	1970	2	-512	-512	NNP
cord-014712-5u4e00q6	1971	1	x	x	LS
cord-014712-5u4e00q6	1972	1	10	10	CD
cord-014712-5u4e00q6	1972	2	9	9	CD
cord-014712-5u4e00q6	1972	3	/l	/l	NNP
cord-014712-5u4e00q6	1972	4	IgA	IgA	NNP
cord-014712-5u4e00q6	1972	5	-0,85	-0,85	:
cord-014712-5u4e00q6	1972	6	g	g	NNP
cord-014712-5u4e00q6	1972	7	/	/	SYM
cord-014712-5u4e00q6	1972	8	l	l	NN
cord-014712-5u4e00q6	1972	9	-1.45	-1.45	CD
cord-014712-5u4e00q6	1972	10	g	g	NNP
cord-014712-5u4e00q6	1972	11	/	/	SYM
cord-014712-5u4e00q6	1972	12	l	l	NNP
cord-014712-5u4e00q6	1972	13	IgM	IgM	NNP
cord-014712-5u4e00q6	1972	14	-1,33	-1,33	HYPH
cord-014712-5u4e00q6	1972	15	g	g	NNP
cord-014712-5u4e00q6	1972	16	/	/	SYM
cord-014712-5u4e00q6	1972	17	l	l	NN
cord-014712-5u4e00q6	1972	18	-0.66	-0.66	NNP
cord-014712-5u4e00q6	1972	19	g	g	NNP
cord-014712-5u4e00q6	1972	20	/	/	SYM
cord-014712-5u4e00q6	1972	21	l	l	NNP
cord-014712-5u4e00q6	1972	22	IgG	IgG	NNP
cord-014712-5u4e00q6	1972	23	-11,3	-11,3	.
cord-014712-5u4e00q6	1972	24	g	g	NNP
cord-014712-5u4e00q6	1972	25	/	/	SYM
cord-014712-5u4e00q6	1972	26	l	l	NN
cord-014712-5u4e00q6	1972	27	-11.8	-11.8	NNP
cord-014712-5u4e00q6	1972	28	g	g	NNP
cord-014712-5u4e00q6	1972	29	/	/	SYM
cord-014712-5u4e00q6	1972	30	l	l	NN
cord-014712-5u4e00q6	1972	31	(	(	-LRB-
cord-014712-5u4e00q6	1972	32	Other	other	JJ
cord-014712-5u4e00q6	1972	33	results	result	NNS
cord-014712-5u4e00q6	1972	34	of	of	IN
cord-014712-5u4e00q6	1972	35	immunological	immunological	JJ
cord-014712-5u4e00q6	1972	36	examination	examination	NN
cord-014712-5u4e00q6	1972	37	are	be	VBP
cord-014712-5u4e00q6	1972	38	without	without	IN
cord-014712-5u4e00q6	1972	39	features	feature	NNS
cord-014712-5u4e00q6	1972	40	)	)	-RRB-
cord-014712-5u4e00q6	1973	1	The	the	DT
cord-014712-5u4e00q6	1973	2	X	x	NN
cord-014712-5u4e00q6	1973	3	-	-	HYPH
cord-014712-5u4e00q6	1973	4	linked	link	VBN
cord-014712-5u4e00q6	1973	5	chronic	chronic	JJ
cord-014712-5u4e00q6	1973	6	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	1973	7	disease	disease	NN
cord-014712-5u4e00q6	1973	8	(	(	-LRB-
cord-014712-5u4e00q6	1973	9	CGD	CGD	NNP
cord-014712-5u4e00q6	1973	10	)	)	-RRB-
cord-014712-5u4e00q6	1973	11	is	be	VBZ
cord-014712-5u4e00q6	1973	12	a	a	DT
cord-014712-5u4e00q6	1973	13	primary	primary	JJ
cord-014712-5u4e00q6	1973	14	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	1973	15	cell	cell	NN
cord-014712-5u4e00q6	1973	16	deficiency	deficiency	NN
cord-014712-5u4e00q6	1973	17	characterized	characterize	VBN
cord-014712-5u4e00q6	1973	18	by	by	IN
cord-014712-5u4e00q6	1973	19	severe	severe	JJ
cord-014712-5u4e00q6	1973	20	bacterial	bacterial	JJ
cord-014712-5u4e00q6	1973	21	and	and	CC
cord-014712-5u4e00q6	1973	22	fungal	fungal	JJ
cord-014712-5u4e00q6	1973	23	infections	infection	NNS
cord-014712-5u4e00q6	1973	24	of	of	IN
cord-014712-5u4e00q6	1973	25	various	various	JJ
cord-014712-5u4e00q6	1973	26	organs	organ	NNS
cord-014712-5u4e00q6	1973	27	.	.	.
cord-014712-5u4e00q6	1974	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1974	2	report	report	VBP
cord-014712-5u4e00q6	1974	3	of	of	IN
cord-014712-5u4e00q6	1974	4	a	a	DT
cord-014712-5u4e00q6	1974	5	19	19	CD
cord-014712-5u4e00q6	1974	6	years	year	NNS
cord-014712-5u4e00q6	1974	7	of	of	IN
cord-014712-5u4e00q6	1974	8	a	a	DT
cord-014712-5u4e00q6	1974	9	male	male	JJ
cord-014712-5u4e00q6	1974	10	patient	patient	NN
cord-014712-5u4e00q6	1974	11	with	with	IN
cord-014712-5u4e00q6	1974	12	Xlinked	Xlinked	NNP
cord-014712-5u4e00q6	1974	13	CGD	CGD	NNP
cord-014712-5u4e00q6	1974	14	who	who	WP
cord-014712-5u4e00q6	1974	15	presented	present	VBD
cord-014712-5u4e00q6	1974	16	with	with	IN
cord-014712-5u4e00q6	1974	17	recurrent	recurrent	JJ
cord-014712-5u4e00q6	1974	18	hepatic	hepatic	JJ
cord-014712-5u4e00q6	1974	19	abscesses	abscess	NNS
cord-014712-5u4e00q6	1974	20	as	as	IN
cord-014712-5u4e00q6	1974	21	the	the	DT
cord-014712-5u4e00q6	1974	22	sole	sole	JJ
cord-014712-5u4e00q6	1974	23	manifestation	manifestation	NN
cord-014712-5u4e00q6	1974	24	of	of	IN
cord-014712-5u4e00q6	1974	25	the	the	DT
cord-014712-5u4e00q6	1974	26	disease	disease	NN
cord-014712-5u4e00q6	1974	27	.	.	.
cord-014712-5u4e00q6	1975	1	Phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	1975	2	and	and	CC
cord-014712-5u4e00q6	1975	3	bactericidal	bactericidal	JJ
cord-014712-5u4e00q6	1975	4	activities	activity	NNS
cord-014712-5u4e00q6	1975	5	of	of	IN
cord-014712-5u4e00q6	1975	6	granulocytes	granulocyte	NNS
cord-014712-5u4e00q6	1975	7	were	be	VBD
cord-014712-5u4e00q6	1975	8	studied	study	VBN
cord-014712-5u4e00q6	1975	9	by	by	IN
cord-014712-5u4e00q6	1975	10	using	use	VBG
cord-014712-5u4e00q6	1975	11	microbiological	microbiological	JJ
cord-014712-5u4e00q6	1975	12	assays	assay	NNS
cord-014712-5u4e00q6	1975	13	.	.	.
cord-014712-5u4e00q6	1976	1	Generation	generation	NN
cord-014712-5u4e00q6	1976	2	of	of	IN
cord-014712-5u4e00q6	1976	3	superoxide	superoxide	NN
cord-014712-5u4e00q6	1976	4	anion	anion	NN
cord-014712-5u4e00q6	1976	5	by	by	IN
cord-014712-5u4e00q6	1976	6	blood	blood	NN
cord-014712-5u4e00q6	1976	7	granulocytes	granulocyte	NNS
cord-014712-5u4e00q6	1976	8	was	be	VBD
cord-014712-5u4e00q6	1976	9	measured	measure	VBN
cord-014712-5u4e00q6	1976	10	by	by	IN
cord-014712-5u4e00q6	1976	11	the	the	DT
cord-014712-5u4e00q6	1976	12	ferricytochrome	ferricytochrome	NNP
cord-014712-5u4e00q6	1976	13	c	c	NNP
cord-014712-5u4e00q6	1976	14	reduction	reduction	NN
cord-014712-5u4e00q6	1976	15	test	test	NN
cord-014712-5u4e00q6	1976	16	.	.	.
cord-014712-5u4e00q6	1977	1	CGD	CGD	NNP
cord-014712-5u4e00q6	1977	2	is	be	VBZ
cord-014712-5u4e00q6	1977	3	an	an	DT
cord-014712-5u4e00q6	1977	4	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1977	5	caused	cause	VBN
cord-014712-5u4e00q6	1977	6	by	by	IN
cord-014712-5u4e00q6	1977	7	mutations	mutation	NNS
cord-014712-5u4e00q6	1977	8	in	in	IN
cord-014712-5u4e00q6	1977	9	genes	gene	NNS
cord-014712-5u4e00q6	1977	10	encoding	encoding	NN
cord-014712-5u4e00q6	1977	11	subunits	subunit	NNS
cord-014712-5u4e00q6	1977	12	of	of	IN
cord-014712-5u4e00q6	1977	13	the	the	DT
cord-014712-5u4e00q6	1977	14	NADPH	NADPH	NNP
cord-014712-5u4e00q6	1977	15	oxidase	oxidase	NN
cord-014712-5u4e00q6	1977	16	complex	complex	NN
cord-014712-5u4e00q6	1977	17	.	.	.
cord-014712-5u4e00q6	1978	1	Normally	normally	RB
cord-014712-5u4e00q6	1978	2	,	,	,
cord-014712-5u4e00q6	1978	3	assembly	assembly	NN
cord-014712-5u4e00q6	1978	4	of	of	IN
cord-014712-5u4e00q6	1978	5	the	the	DT
cord-014712-5u4e00q6	1978	6	NADPH	NADPH	NNP
cord-014712-5u4e00q6	1978	7	oxidase	oxidase	NN
cord-014712-5u4e00q6	1978	8	complex	complex	NN
cord-014712-5u4e00q6	1978	9	in	in	IN
cord-014712-5u4e00q6	1978	10	phagosomes	phagosome	NNS
cord-014712-5u4e00q6	1978	11	of	of	IN
cord-014712-5u4e00q6	1978	12	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	1978	13	cells	cell	NNS
cord-014712-5u4e00q6	1978	14	leads	lead	VBZ
cord-014712-5u4e00q6	1978	15	to	to	IN
cord-014712-5u4e00q6	1978	16	a	a	DT
cord-014712-5u4e00q6	1978	17	"	"	``
cord-014712-5u4e00q6	1978	18	respiratory	respiratory	JJ
cord-014712-5u4e00q6	1978	19	burst	burst	NN
cord-014712-5u4e00q6	1978	20	"	"	''
cord-014712-5u4e00q6	1978	21	essential	essential	JJ
cord-014712-5u4e00q6	1978	22	for	for	IN
cord-014712-5u4e00q6	1978	23	the	the	DT
cord-014712-5u4e00q6	1978	24	clearance	clearance	NN
cord-014712-5u4e00q6	1978	25	of	of	IN
cord-014712-5u4e00q6	1978	26	microorganisms	microorganism	NNS
cord-014712-5u4e00q6	1978	27	.	.	.
cord-014712-5u4e00q6	1979	1	CGD	CGD	NNP
cord-014712-5u4e00q6	1979	2	patients	patient	NNS
cord-014712-5u4e00q6	1979	3	lack	lack	VBP
cord-014712-5u4e00q6	1979	4	this	this	DT
cord-014712-5u4e00q6	1979	5	mechanism	mechanism	NN
cord-014712-5u4e00q6	1979	6	,	,	,
cord-014712-5u4e00q6	1979	7	which	which	WDT
cord-014712-5u4e00q6	1979	8	results	result	VBZ
cord-014712-5u4e00q6	1979	9	in	in	IN
cord-014712-5u4e00q6	1979	10	life	life	NN
cord-014712-5u4e00q6	1979	11	-	-	HYPH
cord-014712-5u4e00q6	1979	12	threatening	threaten	VBG
cord-014712-5u4e00q6	1979	13	infections	infection	NNS
cord-014712-5u4e00q6	1979	14	and	and	CC
cord-014712-5u4e00q6	1979	15	granuloma	granuloma	NN
cord-014712-5u4e00q6	1979	16	formations	formation	NNS
cord-014712-5u4e00q6	1979	17	.	.	.
cord-014712-5u4e00q6	1980	1	The	the	DT
cord-014712-5u4e00q6	1980	2	leading	leading	JJ
cord-014712-5u4e00q6	1980	3	cause	cause	NN
cord-014712-5u4e00q6	1980	4	of	of	IN
cord-014712-5u4e00q6	1980	5	death	death	NN
cord-014712-5u4e00q6	1980	6	are	be	VBP
cord-014712-5u4e00q6	1980	7	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	1980	8	and	and	CC
cord-014712-5u4e00q6	1980	9	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	1980	10	abscess	abscess	NN
cord-014712-5u4e00q6	1980	11	,	,	,
cord-014712-5u4e00q6	1980	12	septicemia	septicemia	NN
cord-014712-5u4e00q6	1980	13	and	and	CC
cord-014712-5u4e00q6	1980	14	brain	brain	NN
cord-014712-5u4e00q6	1980	15	abscess	abscess	NN
cord-014712-5u4e00q6	1980	16	.	.	.
cord-014712-5u4e00q6	1981	1	In	in	IN
cord-014712-5u4e00q6	1981	2	neurogical	neurogical	JJ
cord-014712-5u4e00q6	1981	3	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1981	4	various	various	JJ
cord-014712-5u4e00q6	1981	5	pathogens	pathogen	NNS
cord-014712-5u4e00q6	1981	6	have	have	VBP
cord-014712-5u4e00q6	1981	7	been	be	VBN
cord-014712-5u4e00q6	1981	8	involved	involve	VBN
cord-014712-5u4e00q6	1981	9	including	include	VBG
cord-014712-5u4e00q6	1981	10	Aspergillus	aspergillus	NN
cord-014712-5u4e00q6	1981	11	spp	spp	NNS
cord-014712-5u4e00q6	1981	12	.	.	.
cord-014712-5u4e00q6	1982	1	,	,	,
cord-014712-5u4e00q6	1982	2	S.	S.	NNP
cord-014712-5u4e00q6	1982	3	prolificans	prolificans	NNP
cord-014712-5u4e00q6	1982	4	,	,	,
cord-014712-5u4e00q6	1982	5	A.	A.	NNP
cord-014712-5u4e00q6	1982	6	infectoria	infectoria	NNP
cord-014712-5u4e00q6	1982	7	,	,	,
cord-014712-5u4e00q6	1982	8	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	1982	9	and	and	CC
cord-014712-5u4e00q6	1982	10	Staphylococcus	Staphylococcus	NNP
cord-014712-5u4e00q6	1982	11	spp	spp	NNS
cord-014712-5u4e00q6	1982	12	.	.	.
cord-014712-5u4e00q6	1983	1	There	there	EX
cord-014712-5u4e00q6	1983	2	are	be	VBP
cord-014712-5u4e00q6	1983	3	only	only	RB
cord-014712-5u4e00q6	1983	4	some	some	DT
cord-014712-5u4e00q6	1983	5	several	several	JJ
cord-014712-5u4e00q6	1983	6	reports	report	NNS
cord-014712-5u4e00q6	1983	7	on	on	IN
cord-014712-5u4e00q6	1983	8	fungal	fungal	JJ
cord-014712-5u4e00q6	1983	9	brain	brain	NN
cord-014712-5u4e00q6	1983	10	and	and	CC
cord-014712-5u4e00q6	1983	11	spinal	spinal	JJ
cord-014712-5u4e00q6	1983	12	cord	cord	NN
cord-014712-5u4e00q6	1983	13	infection	infection	NN
cord-014712-5u4e00q6	1983	14	,	,	,
cord-014712-5u4e00q6	1983	15	Aspergillus	aspergillus	NN
cord-014712-5u4e00q6	1983	16	abscess	abscess	NN
cord-014712-5u4e00q6	1983	17	resembling	resemble	VBG
cord-014712-5u4e00q6	1983	18	brain	brain	NN
cord-014712-5u4e00q6	1983	19	tumor	tumor	NN
cord-014712-5u4e00q6	1983	20	,	,	,
cord-014712-5u4e00q6	1983	21	meningitis	meningitis	NN
cord-014712-5u4e00q6	1983	22	due	due	IN
cord-014712-5u4e00q6	1983	23	to	to	IN
cord-014712-5u4e00q6	1983	24	Streptococcus	Streptococcus	NNP
cord-014712-5u4e00q6	1983	25	and	and	CC
cord-014712-5u4e00q6	1983	26	Candida	Candida	NNP
cord-014712-5u4e00q6	1983	27	spp	spp	NNS
cord-014712-5u4e00q6	1983	28	.	.	.
cord-014712-5u4e00q6	1984	1	In	in	IN
cord-014712-5u4e00q6	1984	2	the	the	DT
cord-014712-5u4e00q6	1984	3	past	past	JJ
cord-014712-5u4e00q6	1984	4	20	20	CD
cord-014712-5u4e00q6	1984	5	years	year	NNS
cord-014712-5u4e00q6	1984	6	we	-PRON-	PRP
cord-014712-5u4e00q6	1984	7	treated	treat	VBD
cord-014712-5u4e00q6	1984	8	7	7	CD
cord-014712-5u4e00q6	1984	9	children	child	NNS
cord-014712-5u4e00q6	1984	10	with	with	IN
cord-014712-5u4e00q6	1984	11	CGD	CGD	NNP
cord-014712-5u4e00q6	1984	12	.	.	.
cord-014712-5u4e00q6	1985	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1985	2	present	present	VBP
cord-014712-5u4e00q6	1985	3	the	the	DT
cord-014712-5u4e00q6	1985	4	infectological	infectological	JJ
cord-014712-5u4e00q6	1985	5	challenge	challenge	NN
cord-014712-5u4e00q6	1985	6	of	of	IN
cord-014712-5u4e00q6	1985	7	an	an	DT
cord-014712-5u4e00q6	1985	8	X	x	NN
cord-014712-5u4e00q6	1985	9	-	-	HYPH
cord-014712-5u4e00q6	1985	10	linked	link	VBN
cord-014712-5u4e00q6	1985	11	CGD	CGD	NNP
cord-014712-5u4e00q6	1985	12	patient	patient	NN
cord-014712-5u4e00q6	1985	13	with	with	IN
cord-014712-5u4e00q6	1985	14	brain	brain	NN
cord-014712-5u4e00q6	1985	15	abscess	abscess	NN
cord-014712-5u4e00q6	1985	16	.	.	.
cord-014712-5u4e00q6	1986	1	In	in	IN
cord-014712-5u4e00q6	1986	2	spite	spite	NN
cord-014712-5u4e00q6	1986	3	of	of	IN
cord-014712-5u4e00q6	1986	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	1986	5	effort	effort	NN
cord-014712-5u4e00q6	1986	6	we	-PRON-	PRP
cord-014712-5u4e00q6	1986	7	were	be	VBD
cord-014712-5u4e00q6	1986	8	unable	unable	JJ
cord-014712-5u4e00q6	1986	9	to	to	TO
cord-014712-5u4e00q6	1986	10	identify	identify	VB
cord-014712-5u4e00q6	1986	11	its	-PRON-	PRP$
cord-014712-5u4e00q6	1986	12	causative	causative	JJ
cord-014712-5u4e00q6	1986	13	pathogen	pathogen	NN
cord-014712-5u4e00q6	1986	14	.	.	.
cord-014712-5u4e00q6	1987	1	Empiric	empiric	NN
cord-014712-5u4e00q6	1987	2	therapy	therapy	NN
cord-014712-5u4e00q6	1987	3	sometimes	sometimes	RB
cord-014712-5u4e00q6	1987	4	resembles	resemble	VBZ
cord-014712-5u4e00q6	1987	5	polypragmasia	polypragmasia	NNP
cord-014712-5u4e00q6	1987	6	in	in	IN
cord-014712-5u4e00q6	1987	7	CGD	CGD	NNP
cord-014712-5u4e00q6	1987	8	.	.	.
cord-014712-5u4e00q6	1988	1	To	to	TO
cord-014712-5u4e00q6	1988	2	decrease	decrease	VB
cord-014712-5u4e00q6	1988	3	mortality	mortality	NN
cord-014712-5u4e00q6	1988	4	and	and	CC
cord-014712-5u4e00q6	1988	5	morbidity	morbidity	NN
cord-014712-5u4e00q6	1988	6	from	from	IN
cord-014712-5u4e00q6	1988	7	fungal	fungal	JJ
cord-014712-5u4e00q6	1988	8	infections	infection	NNS
cord-014712-5u4e00q6	1988	9	in	in	IN
cord-014712-5u4e00q6	1988	10	CGD	CGD	NNP
cord-014712-5u4e00q6	1988	11	the	the	DT
cord-014712-5u4e00q6	1988	12	prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	1988	13	use	use	NN
cord-014712-5u4e00q6	1988	14	of	of	IN
cord-014712-5u4e00q6	1988	15	itraconazole	itraconazole	NNP
cord-014712-5u4e00q6	1988	16	or	or	CC
cord-014712-5u4e00q6	1988	17	voriconazole	voriconazole	NNP
cord-014712-5u4e00q6	1988	18	is	be	VBZ
cord-014712-5u4e00q6	1988	19	widely	widely	RB
cord-014712-5u4e00q6	1988	20	recommended	recommend	VBN
cord-014712-5u4e00q6	1988	21	.	.	.
cord-014712-5u4e00q6	1989	1	A	a	DT
cord-014712-5u4e00q6	1989	2	relatively	relatively	RB
cord-014712-5u4e00q6	1989	3	new	new	JJ
cord-014712-5u4e00q6	1989	4	azole	azole	NNP
cord-014712-5u4e00q6	1989	5	,	,	,
cord-014712-5u4e00q6	1989	6	posaconazole	posaconazole	NNP
cord-014712-5u4e00q6	1989	7	is	be	VBZ
cord-014712-5u4e00q6	1989	8	active	active	JJ
cord-014712-5u4e00q6	1989	9	in	in	IN
cord-014712-5u4e00q6	1989	10	pulmonary	pulmonary	JJ
cord-014712-5u4e00q6	1989	11	and	and	CC
cord-014712-5u4e00q6	1989	12	cerebral	cerebral	JJ
cord-014712-5u4e00q6	1989	13	fungal	fungal	JJ
cord-014712-5u4e00q6	1989	14	manifestations	manifestation	NNS
cord-014712-5u4e00q6	1989	15	,	,	,
cord-014712-5u4e00q6	1989	16	indeed	indeed	RB
cord-014712-5u4e00q6	1989	17	may	may	MD
cord-014712-5u4e00q6	1989	18	be	be	VB
cord-014712-5u4e00q6	1989	19	effective	effective	JJ
cord-014712-5u4e00q6	1989	20	against	against	IN
cord-014712-5u4e00q6	1989	21	fungi	fungus	NNS
cord-014712-5u4e00q6	1989	22	with	with	IN
cord-014712-5u4e00q6	1989	23	inherent	inherent	JJ
cord-014712-5u4e00q6	1989	24	resistance	resistance	NN
cord-014712-5u4e00q6	1989	25	to	to	IN
cord-014712-5u4e00q6	1989	26	AmpB	AmpB	NNP
cord-014712-5u4e00q6	1989	27	or	or	CC
cord-014712-5u4e00q6	1989	28	voriconazole	voriconazole	NN
cord-014712-5u4e00q6	1989	29	.	.	.
cord-014712-5u4e00q6	1990	1	There	there	EX
cord-014712-5u4e00q6	1990	2	was	be	VBD
cord-014712-5u4e00q6	1990	3	no	no	DT
cord-014712-5u4e00q6	1990	4	etiological	etiological	JJ
cord-014712-5u4e00q6	1990	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1990	6	in	in	IN
cord-014712-5u4e00q6	1990	7	our	-PRON-	PRP$
cord-014712-5u4e00q6	1990	8	case	case	NN
cord-014712-5u4e00q6	1991	1	that	that	WDT
cord-014712-5u4e00q6	1991	2	did	do	VBD
cord-014712-5u4e00q6	1991	3	not	not	RB
cord-014712-5u4e00q6	1991	4	respond	respond	VB
cord-014712-5u4e00q6	1991	5	to	to	IN
cord-014712-5u4e00q6	1991	6	conventional	conventional	JJ
cord-014712-5u4e00q6	1991	7	antifungal	antifungal	JJ
cord-014712-5u4e00q6	1991	8	and	and	CC
cord-014712-5u4e00q6	1991	9	antibacterial	antibacterial	JJ
cord-014712-5u4e00q6	1991	10	treatment	treatment	NN
cord-014712-5u4e00q6	1991	11	.	.	.
cord-014712-5u4e00q6	1992	1	Based	base	VBN
cord-014712-5u4e00q6	1992	2	upon	upon	IN
cord-014712-5u4e00q6	1992	3	the	the	DT
cord-014712-5u4e00q6	1992	4	findings	finding	NNS
cord-014712-5u4e00q6	1992	5	and	and	CC
cord-014712-5u4e00q6	1992	6	literature	literature	NN
cord-014712-5u4e00q6	1992	7	data	datum	NNS
cord-014712-5u4e00q6	1992	8	we	-PRON-	PRP
cord-014712-5u4e00q6	1992	9	presume	presume	VBP
cord-014712-5u4e00q6	1992	10	the	the	DT
cord-014712-5u4e00q6	1992	11	causative	causative	JJ
cord-014712-5u4e00q6	1992	12	agent	agent	NN
cord-014712-5u4e00q6	1992	13	might	may	MD
cord-014712-5u4e00q6	1992	14	be	be	VB
cord-014712-5u4e00q6	1992	15	some	some	DT
cord-014712-5u4e00q6	1992	16	kind	kind	NN
cord-014712-5u4e00q6	1992	17	of	of	IN
cord-014712-5u4e00q6	1992	18	moulds	mould	NNS
cord-014712-5u4e00q6	1992	19	.	.	.
cord-014712-5u4e00q6	1993	1	We	-PRON-	PRP
cord-014712-5u4e00q6	1993	2	suppose	suppose	VBP
cord-014712-5u4e00q6	1993	3	the	the	DT
cord-014712-5u4e00q6	1993	4	use	use	NN
cord-014712-5u4e00q6	1993	5	of	of	IN
cord-014712-5u4e00q6	1993	6	echinocandin	echinocandin	NNP
cord-014712-5u4e00q6	1993	7	and	and	CC
cord-014712-5u4e00q6	1993	8	posaconazole	posaconazole	NNP
cord-014712-5u4e00q6	1993	9	as	as	IN
cord-014712-5u4e00q6	1993	10	salvage	salvage	NN
cord-014712-5u4e00q6	1993	11	(	(	-LRB-
cord-014712-5u4e00q6	1993	12	"	"	``
cord-014712-5u4e00q6	1993	13	prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	1993	14	"	"	''
cord-014712-5u4e00q6	1993	15	)	)	-RRB-
cord-014712-5u4e00q6	1993	16	therapy	therapy	NN
cord-014712-5u4e00q6	1993	17	has	have	VBZ
cord-014712-5u4e00q6	1993	18	resulted	result	VBN
cord-014712-5u4e00q6	1993	19	significant	significant	JJ
cord-014712-5u4e00q6	1993	20	regression	regression	NN
cord-014712-5u4e00q6	1993	21	of	of	IN
cord-014712-5u4e00q6	1993	22	the	the	DT
cord-014712-5u4e00q6	1993	23	brain	brain	NN
cord-014712-5u4e00q6	1993	24	abscess	abscess	NN
cord-014712-5u4e00q6	1993	25	.	.	.
cord-014712-5u4e00q6	1994	1	The	the	DT
cord-014712-5u4e00q6	1994	2	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1994	3	of	of	IN
cord-014712-5u4e00q6	1994	4	chronic	chronic	JJ
cord-014712-5u4e00q6	1994	5	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	1994	6	disease	disease	NN
cord-014712-5u4e00q6	1994	7	(	(	-LRB-
cord-014712-5u4e00q6	1994	8	CGD	CGD	NNP
cord-014712-5u4e00q6	1994	9	)	)	-RRB-
cord-014712-5u4e00q6	1994	10	was	be	VBD
cord-014712-5u4e00q6	1994	11	verified	verify	VBN
cord-014712-5u4e00q6	1994	12	in	in	IN
cord-014712-5u4e00q6	1994	13	7	7	CD
cord-014712-5u4e00q6	1994	14	children	child	NNS
cord-014712-5u4e00q6	1994	15	during	during	IN
cord-014712-5u4e00q6	1994	16	the	the	DT
cord-014712-5u4e00q6	1994	17	past	past	JJ
cord-014712-5u4e00q6	1994	18	few	few	JJ
cord-014712-5u4e00q6	1994	19	years	year	NNS
cord-014712-5u4e00q6	1994	20	in	in	IN
cord-014712-5u4e00q6	1994	21	the	the	DT
cord-014712-5u4e00q6	1994	22	Department	Department	NNP
cord-014712-5u4e00q6	1994	23	of	of	IN
cord-014712-5u4e00q6	1994	24	Clinical	Clinical	NNP
cord-014712-5u4e00q6	1994	25	Immunology	Immunology	NNP
cord-014712-5u4e00q6	1994	26	of	of	IN
cord-014712-5u4e00q6	1994	27	Regional	Regional	NNP
cord-014712-5u4e00q6	1994	28	Children	Children	NNPS
cord-014712-5u4e00q6	1994	29	's	's	POS
cord-014712-5u4e00q6	1994	30	Hospital	Hospital	NNP
cord-014712-5u4e00q6	1994	31	of	of	IN
cord-014712-5u4e00q6	1994	32	Chelyabinsk	Chelyabinsk	NNP
cord-014712-5u4e00q6	1994	33	(	(	-LRB-
cord-014712-5u4e00q6	1994	34	Russia	Russia	NNP
cord-014712-5u4e00q6	1994	35	)	)	-RRB-
cord-014712-5u4e00q6	1994	36	.	.	.
cord-014712-5u4e00q6	1995	1	In	in	IN
cord-014712-5u4e00q6	1995	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	1995	3	opinionin	opinionin	NNS
cord-014712-5u4e00q6	1995	4	3	3	CD
cord-014712-5u4e00q6	1995	5	casesthe	casesthe	NNP
cord-014712-5u4e00q6	1995	6	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1995	7	was	be	VBD
cord-014712-5u4e00q6	1995	8	establishedearly	establishedearly	RB
cord-014712-5u4e00q6	1995	9	enough	enough	JJ
cord-014712-5u4e00q6	1995	10	.	.	.
cord-014712-5u4e00q6	1996	1	Michael	Michael	NNP
cord-014712-5u4e00q6	1996	2	W.	W.	NNP
cord-014712-5u4e00q6	1996	3	Transferred	transfer	VBN
cord-014712-5u4e00q6	1996	4	to	to	IN
cord-014712-5u4e00q6	1996	5	the	the	DT
cord-014712-5u4e00q6	1996	6	neonatal	neonatal	JJ
cord-014712-5u4e00q6	1996	7	pathology	pathology	NN
cord-014712-5u4e00q6	1996	8	unit	unit	NN
cord-014712-5u4e00q6	1996	9	of	of	IN
cord-014712-5u4e00q6	1996	10	our	-PRON-	PRP$
cord-014712-5u4e00q6	1996	11	clinic	clinic	NN
cord-014712-5u4e00q6	1996	12	at	at	IN
cord-014712-5u4e00q6	1996	13	the	the	DT
cord-014712-5u4e00q6	1996	14	age	age	NN
cord-014712-5u4e00q6	1996	15	of	of	IN
cord-014712-5u4e00q6	1996	16	5	5	CD
cord-014712-5u4e00q6	1996	17	days	day	NNS
cord-014712-5u4e00q6	1996	18	with	with	IN
cord-014712-5u4e00q6	1996	19	vesiculopustules	vesiculopustules	NNP
cord-014712-5u4e00q6	1996	20	.	.	.
cord-014712-5u4e00q6	1997	1	Take	take	VB
cord-014712-5u4e00q6	1997	2	into	into	IN
cord-014712-5u4e00q6	1997	3	consideration	consideration	NN
cord-014712-5u4e00q6	1997	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	1997	5	own	own	JJ
cord-014712-5u4e00q6	1997	6	experience	experience	NN
cord-014712-5u4e00q6	1997	7	of	of	IN
cord-014712-5u4e00q6	1997	8	observing	observe	VBG
cord-014712-5u4e00q6	1997	9	children	child	NNS
cord-014712-5u4e00q6	1997	10	with	with	IN
cord-014712-5u4e00q6	1997	11	this	this	DT
cord-014712-5u4e00q6	1997	12	form	form	NN
cord-014712-5u4e00q6	1997	13	of	of	IN
cord-014712-5u4e00q6	1997	14	primary	primary	JJ
cord-014712-5u4e00q6	1997	15	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	1997	16	in	in	IN
cord-014712-5u4e00q6	1997	17	previous	previous	JJ
cord-014712-5u4e00q6	1997	18	years	year	NNS
cord-014712-5u4e00q6	1997	19	,	,	,
cord-014712-5u4e00q6	1997	20	the	the	DT
cord-014712-5u4e00q6	1997	21	child	child	NN
cord-014712-5u4e00q6	1997	22	was	be	VBD
cord-014712-5u4e00q6	1997	23	conducted	conduct	VBN
cord-014712-5u4e00q6	1997	24	immunological	immunological	JJ
cord-014712-5u4e00q6	1997	25	examination	examination	NN
cord-014712-5u4e00q6	1997	26	,	,	,
cord-014712-5u4e00q6	1997	27	in	in	IN
cord-014712-5u4e00q6	1997	28	particular	particular	JJ
cord-014712-5u4e00q6	1997	29	,	,	,
cord-014712-5u4e00q6	1997	30	the	the	DT
cord-014712-5u4e00q6	1997	31	test	test	NN
cord-014712-5u4e00q6	1997	32	of	of	IN
cord-014712-5u4e00q6	1997	33	restoration	restoration	NN
cord-014712-5u4e00q6	1997	34	Nitroblue	Nitroblue	NNP
cord-014712-5u4e00q6	1997	35	tetrazolium	tetrazolium	NN
cord-014712-5u4e00q6	1997	36	by	by	IN
cord-014712-5u4e00q6	1997	37	superoxide	superoxide	NN
cord-014712-5u4e00q6	1997	38	anionformed	anionforme	VBN
cord-014712-5u4e00q6	1997	39	when	when	WRB
cord-014712-5u4e00q6	1997	40	oxygen	oxygen	NN
cord-014712-5u4e00q6	1997	41	explodes	explode	VBZ
cord-014712-5u4e00q6	1997	42	in	in	IN
cord-014712-5u4e00q6	1997	43	leukocyte	leukocyte	NN
cord-014712-5u4e00q6	1997	44	(	(	-LRB-
cord-014712-5u4e00q6	1997	45	nitro	nitro	NNP
cord-014712-5u4e00q6	1997	46	blau	blau	NNP
cord-014712-5u4e00q6	1997	47	tetrasolium	tetrasolium	NNP
cord-014712-5u4e00q6	1997	48	-NBT	-NBT	-LRB-
cord-014712-5u4e00q6	1997	49	-	-	HYPH
cord-014712-5u4e00q6	1997	50	test	test	NN
cord-014712-5u4e00q6	1997	51	)	)	-RRB-
cord-014712-5u4e00q6	1997	52	.	.	.
cord-014712-5u4e00q6	1998	1	This	this	DT
cord-014712-5u4e00q6	1998	2	decision	decision	NN
cord-014712-5u4e00q6	1998	3	is	be	VBZ
cord-014712-5u4e00q6	1998	4	caused	cause	VBN
cord-014712-5u4e00q6	1998	5	by	by	IN
cord-014712-5u4e00q6	1998	6	the	the	DT
cord-014712-5u4e00q6	1998	7	fact	fact	NN
cord-014712-5u4e00q6	1998	8	that	that	IN
cord-014712-5u4e00q6	1998	9	previously	previously	RB
cord-014712-5u4e00q6	1998	10	observed	observe	VBD
cord-014712-5u4e00q6	1998	11	children	child	NNS
cord-014712-5u4e00q6	1998	12	with	with	IN
cord-014712-5u4e00q6	1998	13	chronic	chronic	JJ
cord-014712-5u4e00q6	1998	14	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	1998	15	disease	disease	NN
cord-014712-5u4e00q6	1998	16	,	,	,
cord-014712-5u4e00q6	1998	17	had	have	VBD
cord-014712-5u4e00q6	1998	18	vesiculopustules	vesiculopustule	NNS
cord-014712-5u4e00q6	1998	19	in	in	IN
cord-014712-5u4e00q6	1998	20	90	90	CD
cord-014712-5u4e00q6	1998	21	%	%	NN
cord-014712-5u4e00q6	1998	22	at	at	IN
cord-014712-5u4e00q6	1998	23	birth	birth	NN
cord-014712-5u4e00q6	1998	24	.	.	.
cord-014712-5u4e00q6	1999	1	The	the	DT
cord-014712-5u4e00q6	1999	2	survey	survey	NN
cord-014712-5u4e00q6	1999	3	has	have	VBZ
cord-014712-5u4e00q6	1999	4	revealed	reveal	VBN
cord-014712-5u4e00q6	1999	5	a	a	DT
cord-014712-5u4e00q6	1999	6	complete	complete	JJ
cord-014712-5u4e00q6	1999	7	lack	lack	NN
cord-014712-5u4e00q6	1999	8	of	of	IN
cord-014712-5u4e00q6	1999	9	production	production	NN
cord-014712-5u4e00q6	1999	10	of	of	IN
cord-014712-5u4e00q6	1999	11	reactive	reactive	JJ
cord-014712-5u4e00q6	1999	12	oxygen	oxygen	NN
cord-014712-5u4e00q6	1999	13	species	specie	NNS
cord-014712-5u4e00q6	1999	14	by	by	IN
cord-014712-5u4e00q6	1999	15	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	1999	16	in	in	IN
cord-014712-5u4e00q6	1999	17	the	the	DT
cord-014712-5u4e00q6	1999	18	evaluation	evaluation	NN
cord-014712-5u4e00q6	1999	19	of	of	IN
cord-014712-5u4e00q6	1999	20	NBT	NBT	NNP
cord-014712-5u4e00q6	1999	21	-	-	HYPH
cord-014712-5u4e00q6	1999	22	test	test	NN
cord-014712-5u4e00q6	1999	23	,	,	,
cord-014712-5u4e00q6	1999	24	which	which	WDT
cord-014712-5u4e00q6	1999	25	allowed	allow	VBD
cord-014712-5u4e00q6	1999	26	us	-PRON-	PRP
cord-014712-5u4e00q6	1999	27	to	to	TO
cord-014712-5u4e00q6	1999	28	suggest	suggest	VB
cord-014712-5u4e00q6	1999	29	the	the	DT
cord-014712-5u4e00q6	1999	30	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	1999	31	of	of	IN
cord-014712-5u4e00q6	1999	32	CGD	CGD	NNP
cord-014712-5u4e00q6	1999	33	.	.	.
cord-014712-5u4e00q6	2000	1	The	the	DT
cord-014712-5u4e00q6	2000	2	baby	baby	NN
cord-014712-5u4e00q6	2000	3	was	be	VBD
cord-014712-5u4e00q6	2000	4	banned	ban	VBN
cord-014712-5u4e00q6	2000	5	vaccination	vaccination	NN
cord-014712-5u4e00q6	2000	6	against	against	IN
cord-014712-5u4e00q6	2000	7	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2000	8	,	,	,
cord-014712-5u4e00q6	2000	9	and	and	CC
cord-014712-5u4e00q6	2000	10	after	after	IN
cord-014712-5u4e00q6	2000	11	reliever	reliever	NN
cord-014712-5u4e00q6	2000	12	vesiculopustules	vesiculopustule	VBZ
cord-014712-5u4e00q6	2000	13	the	the	DT
cord-014712-5u4e00q6	2000	14	boy	boy	NN
cord-014712-5u4e00q6	2000	15	was	be	VBD
cord-014712-5u4e00q6	2000	16	discharged	discharge	VBN
cord-014712-5u4e00q6	2000	17	home	home	RB
cord-014712-5u4e00q6	2000	18	.	.	.
cord-014712-5u4e00q6	2001	1	However	however	RB
cord-014712-5u4e00q6	2001	2	,	,	,
cord-014712-5u4e00q6	2001	3	at	at	IN
cord-014712-5u4e00q6	2001	4	the	the	DT
cord-014712-5u4e00q6	2001	5	age	age	NN
cord-014712-5u4e00q6	2001	6	of	of	IN
cord-014712-5u4e00q6	2001	7	1	1	CD
cord-014712-5u4e00q6	2001	8	month	month	NN
cord-014712-5u4e00q6	2001	9	the	the	DT
cord-014712-5u4e00q6	2001	10	baby	baby	NN
cord-014712-5u4e00q6	2001	11	suffered	suffer	VBD
cord-014712-5u4e00q6	2001	12	from	from	IN
cord-014712-5u4e00q6	2001	13	glandular	glandular	JJ
cord-014712-5u4e00q6	2001	14	abscess	abscess	NN
cord-014712-5u4e00q6	2001	15	and	and	CC
cord-014712-5u4e00q6	2001	16	right	right	RB
cord-014712-5u4e00q6	2001	17	-	-	HYPH
cord-014712-5u4e00q6	2001	18	segmental	segmental	JJ
cord-014712-5u4e00q6	2001	19	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2001	20	.	.	.
cord-014712-5u4e00q6	2002	1	In	in	IN
cord-014712-5u4e00q6	2002	2	CBC	CBC	NNP
cord-014712-5u4e00q6	2002	3	there	there	EX
cord-014712-5u4e00q6	2002	4	is	be	VBZ
cord-014712-5u4e00q6	2002	5	expressed	express	VBN
cord-014712-5u4e00q6	2002	6	anemia	anemia	NN
cord-014712-5u4e00q6	2002	7	(	(	-LRB-
cord-014712-5u4e00q6	2002	8	Hb	Hb	NNP
cord-014712-5u4e00q6	2002	9	60	60	CD
cord-014712-5u4e00q6	2002	10	g	g	NN
cord-014712-5u4e00q6	2002	11	/	/	SYM
cord-014712-5u4e00q6	2002	12	l	l	NN
cord-014712-5u4e00q6	2002	13	,	,	,
cord-014712-5u4e00q6	2002	14	erythrocytes	erythrocyte	VBZ
cord-014712-5u4e00q6	2003	1	-1.98	-1.98	.
cord-014712-5u4e00q6	2004	1	x	x	LS
cord-014712-5u4e00q6	2004	2	10	10	CD
cord-014712-5u4e00q6	2004	3	12	12	CD
cord-014712-5u4e00q6	2004	4	/l	/l	NN
cord-014712-5u4e00q6	2004	5	)	)	-RRB-
cord-014712-5u4e00q6	2004	6	,	,	,
cord-014712-5u4e00q6	2004	7	leukocytosis	leukocytosis	NNP
cord-014712-5u4e00q6	2004	8	(	(	-LRB-
cord-014712-5u4e00q6	2004	9	22x	22x	CD
cord-014712-5u4e00q6	2004	10	10	10	CD
cord-014712-5u4e00q6	2004	11	9	9	CD
cord-014712-5u4e00q6	2004	12	/l	/l	NN
cord-014712-5u4e00q6	2004	13	)	)	-RRB-
cord-014712-5u4e00q6	2004	14	,	,	,
cord-014712-5u4e00q6	2004	15	accelerated	accelerate	VBN
cord-014712-5u4e00q6	2004	16	ESR	ESR	NNP
cord-014712-5u4e00q6	2004	17	(	(	-LRB-
cord-014712-5u4e00q6	2004	18	36	36	CD
cord-014712-5u4e00q6	2004	19	-	-	SYM
cord-014712-5u4e00q6	2004	20	55	55	CD
cord-014712-5u4e00q6	2004	21	mm	mm	NNP
cord-014712-5u4e00q6	2004	22	/	/	SYM
cord-014712-5u4e00q6	2004	23	h	h	NN
cord-014712-5u4e00q6	2004	24	)	)	-RRB-
cord-014712-5u4e00q6	2004	25	.	.	.
cord-014712-5u4e00q6	2005	1	At	at	IN
cord-014712-5u4e00q6	2005	2	the	the	DT
cord-014712-5u4e00q6	2005	3	age	age	NN
cord-014712-5u4e00q6	2005	4	of	of	IN
cord-014712-5u4e00q6	2005	5	3	3	CD
cord-014712-5u4e00q6	2005	6	months	month	NNS
cord-014712-5u4e00q6	2005	7	in	in	IN
cord-014712-5u4e00q6	2005	8	the	the	DT
cord-014712-5u4e00q6	2005	9	University	University	NNP
cord-014712-5u4e00q6	2005	10	of	of	IN
cord-014712-5u4e00q6	2005	11	Debrecen	Debrecen	NNP
cord-014712-5u4e00q6	2005	12	,	,	,
cord-014712-5u4e00q6	2005	13	Medical	Medical	NNP
cord-014712-5u4e00q6	2005	14	and	and	CC
cord-014712-5u4e00q6	2005	15	Health	Health	NNP
cord-014712-5u4e00q6	2005	16	Science	Science	NNP
cord-014712-5u4e00q6	2005	17	Center	Center	NNP
cord-014712-5u4e00q6	2005	18	Debrecen	Debrecen	NNP
cord-014712-5u4e00q6	2005	19	,	,	,
cord-014712-5u4e00q6	2005	20	Hungary	Hungary	NNP
cord-014712-5u4e00q6	2005	21	,	,	,
cord-014712-5u4e00q6	2005	22	molecular	molecular	JJ
cord-014712-5u4e00q6	2005	23	genetic	genetic	JJ
cord-014712-5u4e00q6	2005	24	studywas	studywas	NN
cord-014712-5u4e00q6	2005	25	conducted	conduct	VBN
cord-014712-5u4e00q6	2005	26	by	by	IN
cord-014712-5u4e00q6	2005	27	prof	prof	NNP
cord-014712-5u4e00q6	2005	28	.	.	.
cord-014712-5u4e00q6	2006	1	Dr.	Dr.	NNP
cord-014712-5u4e00q6	2006	2	Laszlo	Laszlo	NNP
cord-014712-5u4e00q6	2006	3	Marodi	Marodi	NNP
cord-014712-5u4e00q6	2006	4	.	.	.
cord-014712-5u4e00q6	2007	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2007	2	was	be	VBD
cord-014712-5u4e00q6	2007	3	revealed	reveal	VBN
cord-014712-5u4e00q6	2007	4	a	a	DT
cord-014712-5u4e00q6	2007	5	mutation	mutation	NN
cord-014712-5u4e00q6	2007	6	in	in	IN
cord-014712-5u4e00q6	2007	7	c.	c.	NN
cord-014712-5u4e00q6	2007	8	374	374	CD
cord-014712-5u4e00q6	2007	9	G	g	NN
cord-014712-5u4e00q6	2007	10	>	>	XX
cord-014712-5u4e00q6	2008	1	A	a	DT
cord-014712-5u4e00q6	2008	2	in	in	IN
cord-014712-5u4e00q6	2008	3	exon	exon	NN
cord-014712-5u4e00q6	2008	4	of	of	IN
cord-014712-5u4e00q6	2008	5	6	6	CD
cord-014712-5u4e00q6	2008	6	gene	gene	NN
cord-014712-5u4e00q6	2008	7	CYBB	CYBB	NNP
cord-014712-5u4e00q6	2008	8	(	(	-LRB-
cord-014712-5u4e00q6	2008	9	encoding	encode	VBG
cord-014712-5u4e00q6	2008	10	subunit	subunit	NN
cord-014712-5u4e00q6	2008	11	gp91-phox	gp91-phox	NNP
cord-014712-5u4e00q6	2008	12	)	)	-RRB-
cord-014712-5u4e00q6	2008	13	,	,	,
cord-014712-5u4e00q6	2008	14	after	after	IN
cord-014712-5u4e00q6	2008	15	that	that	DT
cord-014712-5u4e00q6	2008	16	the	the	DT
cord-014712-5u4e00q6	2008	17	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	2008	18	of	of	IN
cord-014712-5u4e00q6	2008	19	CGD	CGD	NNP
cord-014712-5u4e00q6	2008	20	was	be	VBD
cord-014712-5u4e00q6	2008	21	finally	finally	RB
cord-014712-5u4e00q6	2008	22	verified	verify	VBN
cord-014712-5u4e00q6	2008	23	.	.	.
cord-014712-5u4e00q6	2009	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2009	2	was	be	VBD
cord-014712-5u4e00q6	2009	3	assigned	assign	VBN
cord-014712-5u4e00q6	2009	4	a	a	DT
cord-014712-5u4e00q6	2009	5	basic	basic	JJ
cord-014712-5u4e00q6	2009	6	preventive	preventive	JJ
cord-014712-5u4e00q6	2009	7	antimicrobial	antimicrobial	JJ
cord-014712-5u4e00q6	2009	8	therapy	therapy	NN
cord-014712-5u4e00q6	2009	9	by	by	IN
cord-014712-5u4e00q6	2009	10	trimethoprimsulfamethoxazole	trimethoprimsulfamethoxazole	NNP
cord-014712-5u4e00q6	2009	11	,	,	,
cord-014712-5u4e00q6	2009	12	and	and	CC
cord-014712-5u4e00q6	2009	13	itraconazoleto	itraconazoleto	NN
cord-014712-5u4e00q6	2009	14	prevent	prevent	VBP
cord-014712-5u4e00q6	2009	15	fungal	fungal	JJ
cord-014712-5u4e00q6	2009	16	infections	infection	NNS
cord-014712-5u4e00q6	2009	17	.	.	.
cord-014712-5u4e00q6	2010	1	Despite	despite	IN
cord-014712-5u4e00q6	2010	2	this	this	DT
cord-014712-5u4e00q6	2010	3	since	since	IN
cord-014712-5u4e00q6	2010	4	6	6	CD
cord-014712-5u4e00q6	2010	5	months	month	NNS
cord-014712-5u4e00q6	2010	6	the	the	DT
cord-014712-5u4e00q6	2010	7	child	child	NN
cord-014712-5u4e00q6	2010	8	has	have	VBZ
cord-014712-5u4e00q6	2010	9	repeatedly	repeatedly	RB
cord-014712-5u4e00q6	2010	10	and	and	CC
cord-014712-5u4e00q6	2010	11	consistently	consistently	RB
cord-014712-5u4e00q6	2010	12	suffered	suffer	VBN
cord-014712-5u4e00q6	2010	13	from	from	IN
cord-014712-5u4e00q6	2010	14	bilateral	bilateral	JJ
cord-014712-5u4e00q6	2010	15	groin	groin	NN
cord-014712-5u4e00q6	2010	16	lymphadenitis	lymphadenitis	RB
cord-014712-5u4e00q6	2010	17	during	during	IN
cord-014712-5u4e00q6	2010	18	the	the	DT
cord-014712-5u4e00q6	2010	19	year	year	NN
cord-014712-5u4e00q6	2010	20	,	,	,
cord-014712-5u4e00q6	2010	21	acute	acute	JJ
cord-014712-5u4e00q6	2010	22	hematogenous	hematogenous	JJ
cord-014712-5u4e00q6	2010	23	osteomyelitis	osteomyelitis	NN
cord-014712-5u4e00q6	2010	24	of	of	IN
cord-014712-5u4e00q6	2010	25	the	the	DT
cord-014712-5u4e00q6	2010	26	left	left	JJ
cord-014712-5u4e00q6	2010	27	ulna	ulna	NN
cord-014712-5u4e00q6	2010	28	,	,	,
cord-014712-5u4e00q6	2010	29	2	2	CD
cord-014712-5u4e00q6	2010	30	pneumonias	pneumonia	NNS
cord-014712-5u4e00q6	2010	31	,	,	,
cord-014712-5u4e00q6	2010	32	purulent	purulent	JJ
cord-014712-5u4e00q6	2010	33	mesadenitis	mesadenitis	NN
cord-014712-5u4e00q6	2010	34	,	,	,
cord-014712-5u4e00q6	2010	35	endoperitonitis	endoperitonitis	NNP
cord-014712-5u4e00q6	2010	36	.	.	.
cord-014712-5u4e00q6	2011	1	The	the	DT
cord-014712-5u4e00q6	2011	2	fact	fact	NN
cord-014712-5u4e00q6	2011	3	that	that	IN
cord-014712-5u4e00q6	2011	4	the	the	DT
cord-014712-5u4e00q6	2011	5	child	child	NN
cord-014712-5u4e00q6	2011	6	aged	age	VBN
cord-014712-5u4e00q6	2011	7	8	8	CD
cord-014712-5u4e00q6	2011	8	months	month	NNS
cord-014712-5u4e00q6	2011	9	was	be	VBD
cord-014712-5u4e00q6	2011	10	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2011	11	sepsisis	sepsisis	NN
cord-014712-5u4e00q6	2011	12	evidence	evidence	NN
cord-014712-5u4e00q6	2011	13	of	of	IN
cord-014712-5u4e00q6	2011	14	the	the	DT
cord-014712-5u4e00q6	2011	15	severity	severity	NN
cord-014712-5u4e00q6	2011	16	of	of	IN
cord-014712-5u4e00q6	2011	17	infectious	infectious	JJ
cord-014712-5u4e00q6	2011	18	complications	complication	NNS
cord-014712-5u4e00q6	2011	19	.	.	.
cord-014712-5u4e00q6	2012	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	2012	2	and	and	CC
cord-014712-5u4e00q6	2012	3	biochemical	biochemical	JJ
cord-014712-5u4e00q6	2012	4	blood	blood	NN
cord-014712-5u4e00q6	2012	5	tests	test	NNS
cord-014712-5u4e00q6	2012	6	were	be	VBD
cord-014712-5u4e00q6	2012	7	distinguished	distinguish	VBN
cord-014712-5u4e00q6	2012	8	by	by	IN
cord-014712-5u4e00q6	2012	9	consistently	consistently	RB
cord-014712-5u4e00q6	2012	10	high	high	JJ
cord-014712-5u4e00q6	2012	11	levels	level	NNS
cord-014712-5u4e00q6	2012	12	of	of	IN
cord-014712-5u4e00q6	2012	13	ESR	ESR	NNP
cord-014712-5u4e00q6	2012	14	and	and	CC
cord-014712-5u4e00q6	2012	15	the	the	DT
cord-014712-5u4e00q6	2012	16	presence	presence	NN
cord-014712-5u4e00q6	2012	17	of	of	IN
cord-014712-5u4e00q6	2012	18	leukocytosis	leukocytosis	NNP
cord-014712-5u4e00q6	2012	19	,	,	,
cord-014712-5u4e00q6	2012	20	and	and	CC
cord-014712-5u4e00q6	2012	21	also	also	RB
cord-014712-5u4e00q6	2012	22	severe	severe	JJ
cord-014712-5u4e00q6	2012	23	anemia	anemia	NN
cord-014712-5u4e00q6	2012	24	.	.	.
cord-014712-5u4e00q6	2013	1	Now	now	RB
cord-014712-5u4e00q6	2013	2	the	the	DT
cord-014712-5u4e00q6	2013	3	child	child	NN
cord-014712-5u4e00q6	2013	4	is	be	VBZ
cord-014712-5u4e00q6	2013	5	2	2	CD
cord-014712-5u4e00q6	2013	6	years	year	NNS
cord-014712-5u4e00q6	2013	7	11	11	CD
cord-014712-5u4e00q6	2013	8	months	month	NNS
cord-014712-5u4e00q6	2013	9	,	,	,
cord-014712-5u4e00q6	2013	10	he	-PRON-	PRP
cord-014712-5u4e00q6	2013	11	is	be	VBZ
cord-014712-5u4e00q6	2013	12	undergoing	undergo	VBG
cord-014712-5u4e00q6	2013	13	treatment	treatment	NN
cord-014712-5u4e00q6	2013	14	at	at	IN
cord-014712-5u4e00q6	2013	15	the	the	DT
cord-014712-5u4e00q6	2013	16	Department	Department	NNP
cord-014712-5u4e00q6	2013	17	of	of	IN
cord-014712-5u4e00q6	2013	18	Clinical	Clinical	NNP
cord-014712-5u4e00q6	2013	19	Immunology	Immunology	NNP
cord-014712-5u4e00q6	2013	20	,	,	,
cord-014712-5u4e00q6	2013	21	Russian	Russian	NNP
cord-014712-5u4e00q6	2013	22	Children	Children	NNPS
cord-014712-5u4e00q6	2013	23	's	's	POS
cord-014712-5u4e00q6	2013	24	Clinical	Clinical	NNP
cord-014712-5u4e00q6	2013	25	Hospital	Hospital	NNP
cord-014712-5u4e00q6	2013	26	(	(	-LRB-
cord-014712-5u4e00q6	2013	27	Moscow	Moscow	NNP
cord-014712-5u4e00q6	2013	28	)	)	-RRB-
cord-014712-5u4e00q6	2013	29	after	after	IN
cord-014712-5u4e00q6	2013	30	bone	bone	NN
cord-014712-5u4e00q6	2013	31	marrow	marrow	NN
cord-014712-5u4e00q6	2013	32	transplantation	transplantation	NN
cord-014712-5u4e00q6	2013	33	.	.	.
cord-014712-5u4e00q6	2014	1	Case	case	NN
cord-014712-5u4e00q6	2014	2	history	history	NN
cord-014712-5u4e00q6	2014	3	№	№	NNP
cord-014712-5u4e00q6	2014	4	2	2	CD
cord-014712-5u4e00q6	2014	5	,	,	,
cord-014712-5u4e00q6	2014	6	3	3	CD
cord-014712-5u4e00q6	2014	7	Christina	Christina	NNP
cord-014712-5u4e00q6	2014	8	N.	N.	NNP
cord-014712-5u4e00q6	2015	1	From	from	IN
cord-014712-5u4e00q6	2015	2	the	the	DT
cord-014712-5u4e00q6	2015	3	early	early	JJ
cord-014712-5u4e00q6	2015	4	history	history	NN
cord-014712-5u4e00q6	2015	5	we	-PRON-	PRP
cord-014712-5u4e00q6	2015	6	know	know	VBP
cord-014712-5u4e00q6	2015	7	that	that	IN
cord-014712-5u4e00q6	2015	8	the	the	DT
cord-014712-5u4e00q6	2015	9	girl	girl	NN
cord-014712-5u4e00q6	2015	10	's	's	POS
cord-014712-5u4e00q6	2015	11	newborn	newborn	JJ
cord-014712-5u4e00q6	2015	12	period	period	NN
cord-014712-5u4e00q6	2015	13	was	be	VBD
cord-014712-5u4e00q6	2015	14	uneventful	uneventful	JJ
cord-014712-5u4e00q6	2015	15	.	.	.
cord-014712-5u4e00q6	2016	1	She	-PRON-	PRP
cord-014712-5u4e00q6	2016	2	was	be	VBD
cord-014712-5u4e00q6	2016	3	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	2016	4	against	against	IN
cord-014712-5u4e00q6	2016	5	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2016	6	in	in	IN
cord-014712-5u4e00q6	2016	7	the	the	DT
cord-014712-5u4e00q6	2016	8	nursing	nursing	NN
cord-014712-5u4e00q6	2016	9	home	home	NN
cord-014712-5u4e00q6	2016	10	(	(	-LRB-
cord-014712-5u4e00q6	2016	11	no	no	DT
cord-014712-5u4e00q6	2016	12	reaction	reaction	NN
cord-014712-5u4e00q6	2016	13	)	)	-RRB-
cord-014712-5u4e00q6	2016	14	.	.	.
cord-014712-5u4e00q6	2017	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2017	2	was	be	VBD
cord-014712-5u4e00q6	2017	3	noted	note	VBN
cord-014712-5u4e00q6	2017	4	the	the	DT
cord-014712-5u4e00q6	2017	5	formation	formation	NN
cord-014712-5u4e00q6	2017	6	of	of	IN
cord-014712-5u4e00q6	2017	7	abscesses	abscess	NNS
cord-014712-5u4e00q6	2017	8	after	after	IN
cord-014712-5u4e00q6	2017	9	vaccination	vaccination	NN
cord-014712-5u4e00q6	2017	10	against	against	IN
cord-014712-5u4e00q6	2017	11	whooping	whooping	JJ
cord-014712-5u4e00q6	2017	12	cough	cough	NN
cord-014712-5u4e00q6	2017	13	,	,	,
cord-014712-5u4e00q6	2017	14	diphtheria	diphtheria	NN
cord-014712-5u4e00q6	2017	15	and	and	CC
cord-014712-5u4e00q6	2017	16	tetanus	tetanus	NN
cord-014712-5u4e00q6	2017	17	in	in	IN
cord-014712-5u4e00q6	2017	18	3	3	CD
cord-014712-5u4e00q6	2017	19	and	and	CC
cord-014712-5u4e00q6	2017	20	4.5	4.5	CD
cord-014712-5u4e00q6	2017	21	months	month	NNS
cord-014712-5u4e00q6	2017	22	.	.	.
cord-014712-5u4e00q6	2018	1	In	in	IN
cord-014712-5u4e00q6	2018	2	2	2	CD
cord-014712-5u4e00q6	2018	3	years	year	NNS
cord-014712-5u4e00q6	2018	4	8	8	CD
cord-014712-5u4e00q6	2018	5	months	month	NNS
cord-014712-5u4e00q6	2018	6	she	-PRON-	PRP
cord-014712-5u4e00q6	2018	7	suffered	suffer	VBD
cord-014712-5u4e00q6	2018	8	from	from	IN
cord-014712-5u4e00q6	2018	9	mezootit	mezootit	NNP
cord-014712-5u4e00q6	2018	10	.	.	.
cord-014712-5u4e00q6	2019	1	For	for	IN
cord-014712-5u4e00q6	2019	2	the	the	DT
cord-014712-5u4e00q6	2019	3	first	first	JJ
cord-014712-5u4e00q6	2019	4	time	time	NN
cord-014712-5u4e00q6	2019	5	the	the	DT
cord-014712-5u4e00q6	2019	6	girl	girl	NN
cord-014712-5u4e00q6	2019	7	came	come	VBD
cord-014712-5u4e00q6	2019	8	under	under	IN
cord-014712-5u4e00q6	2019	9	our	-PRON-	PRP$
cord-014712-5u4e00q6	2019	10	observation	observation	NN
cord-014712-5u4e00q6	2019	11	in	in	IN
cord-014712-5u4e00q6	2019	12	the	the	DT
cord-014712-5u4e00q6	2019	13	children	child	NNS
cord-014712-5u4e00q6	2019	14	's	's	POS
cord-014712-5u4e00q6	2019	15	hospital	hospital	NN
cord-014712-5u4e00q6	2019	16	in	in	IN
cord-014712-5u4e00q6	2019	17	Chelyabinsk	Chelyabinsk	NNP
cord-014712-5u4e00q6	2019	18	(	(	-LRB-
cord-014712-5u4e00q6	2019	19	Russia	Russia	NNP
cord-014712-5u4e00q6	2019	20	)	)	-RRB-
cord-014712-5u4e00q6	2019	21	at	at	IN
cord-014712-5u4e00q6	2019	22	the	the	DT
cord-014712-5u4e00q6	2019	23	age	age	NN
cord-014712-5u4e00q6	2019	24	of	of	IN
cord-014712-5u4e00q6	2019	25	3	3	CD
cord-014712-5u4e00q6	2019	26	years	year	NNS
cord-014712-5u4e00q6	2019	27	with	with	IN
cord-014712-5u4e00q6	2019	28	right	right	JJ
cord-014712-5u4e00q6	2019	29	segmental	segmental	JJ
cord-014712-5u4e00q6	2019	30	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2019	31	,	,	,
cord-014712-5u4e00q6	2019	32	complicated	complicate	VBN
cord-014712-5u4e00q6	2019	33	by	by	IN
cord-014712-5u4e00q6	2019	34	the	the	DT
cord-014712-5u4e00q6	2019	35	destruction	destruction	NN
cord-014712-5u4e00q6	2019	36	.	.	.
cord-014712-5u4e00q6	2020	1	After	after	IN
cord-014712-5u4e00q6	2020	2	further	further	JJ
cord-014712-5u4e00q6	2020	3	examination	examination	NN
cord-014712-5u4e00q6	2020	4	it	-PRON-	PRP
cord-014712-5u4e00q6	2020	5	was	be	VBD
cord-014712-5u4e00q6	2020	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2020	7	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2020	8	of	of	IN
cord-014712-5u4e00q6	2020	9	intrathoracic	intrathoracic	JJ
cord-014712-5u4e00q6	2020	10	lymph	lymph	NN
cord-014712-5u4e00q6	2020	11	nodes	node	NNS
cord-014712-5u4e00q6	2020	12	to	to	IN
cord-014712-5u4e00q6	2020	13	the	the	DT
cord-014712-5u4e00q6	2020	14	right	right	NN
cord-014712-5u4e00q6	2020	15	with	with	IN
cord-014712-5u4e00q6	2020	16	upper	upper	JJ
cord-014712-5u4e00q6	2020	17	lobe	lobe	NNP
cord-014712-5u4e00q6	2020	18	bronchopulmonary	bronchopulmonary	NNP
cord-014712-5u4e00q6	2020	19	defeat	defeat	NN
cord-014712-5u4e00q6	2020	20	.	.	.
cord-014712-5u4e00q6	2021	1	To	to	TO
cord-014712-5u4e00q6	2021	2	take	take	VB
cord-014712-5u4e00q6	2021	3	into	into	IN
cord-014712-5u4e00q6	2021	4	consideration	consideration	NN
cord-014712-5u4e00q6	2021	5	given	give	VBN
cord-014712-5u4e00q6	2021	6	above	above	RB
cord-014712-5u4e00q6	2021	7	,	,	,
cord-014712-5u4e00q6	2021	8	it	-PRON-	PRP
cord-014712-5u4e00q6	2021	9	was	be	VBD
cord-014712-5u4e00q6	2021	10	conducted	conduct	VBN
cord-014712-5u4e00q6	2021	11	immunological	immunological	JJ
cord-014712-5u4e00q6	2021	12	test	test	NN
cord-014712-5u4e00q6	2021	13	that	that	WDT
cord-014712-5u4e00q6	2021	14	revealed	reveal	VBD
cord-014712-5u4e00q6	2021	15	a	a	DT
cord-014712-5u4e00q6	2021	16	complete	complete	JJ
cord-014712-5u4e00q6	2021	17	lack	lack	NN
cord-014712-5u4e00q6	2021	18	of	of	IN
cord-014712-5u4e00q6	2021	19	production	production	NN
cord-014712-5u4e00q6	2021	20	of	of	IN
cord-014712-5u4e00q6	2021	21	reactive	reactive	JJ
cord-014712-5u4e00q6	2021	22	oxygen	oxygen	NN
cord-014712-5u4e00q6	2021	23	species	specie	NNS
cord-014712-5u4e00q6	2021	24	by	by	IN
cord-014712-5u4e00q6	2021	25	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	2021	26	in	in	IN
cord-014712-5u4e00q6	2021	27	the	the	DT
cord-014712-5u4e00q6	2021	28	evaluation	evaluation	NN
cord-014712-5u4e00q6	2021	29	of	of	IN
cord-014712-5u4e00q6	2021	30	NBT	NBT	NNP
cord-014712-5u4e00q6	2021	31	-	-	HYPH
cord-014712-5u4e00q6	2021	32	test	test	NN
cord-014712-5u4e00q6	2021	33	.	.	.
cord-014712-5u4e00q6	2022	1	On	on	IN
cord-014712-5u4e00q6	2022	2	the	the	DT
cord-014712-5u4e00q6	2022	3	basis	basis	NN
cord-014712-5u4e00q6	2022	4	of	of	IN
cord-014712-5u4e00q6	2022	5	the	the	DT
cord-014712-5u4e00q6	2022	6	history	history	NN
cord-014712-5u4e00q6	2022	7	,	,	,
cord-014712-5u4e00q6	2022	8	clinical	clinical	JJ
cord-014712-5u4e00q6	2022	9	manifestations	manifestation	NNS
cord-014712-5u4e00q6	2022	10	and	and	CC
cord-014712-5u4e00q6	2022	11	results	result	NNS
cord-014712-5u4e00q6	2022	12	of	of	IN
cord-014712-5u4e00q6	2022	13	immunological	immunological	JJ
cord-014712-5u4e00q6	2022	14	examination	examination	NN
cord-014712-5u4e00q6	2022	15	chronic	chronic	JJ
cord-014712-5u4e00q6	2022	16	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2022	17	disease	disease	NN
cord-014712-5u4e00q6	2022	18	was	be	VBD
cord-014712-5u4e00q6	2022	19	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2022	20	.	.	.
cord-014712-5u4e00q6	2023	1	After	after	IN
cord-014712-5u4e00q6	2023	2	fourmonth	fourmonth	JJ
cord-014712-5u4e00q6	2023	3	period	period	NN
cord-014712-5u4e00q6	2023	4	treatment	treatment	NN
cord-014712-5u4e00q6	2023	5	a	a	DT
cord-014712-5u4e00q6	2023	6	recovery	recovery	NN
cord-014712-5u4e00q6	2023	7	came	come	VBD
cord-014712-5u4e00q6	2023	8	from	from	IN
cord-014712-5u4e00q6	2023	9	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2023	10	and	and	CC
cord-014712-5u4e00q6	2023	11	child	child	NN
cord-014712-5u4e00q6	2023	12	was	be	VBD
cord-014712-5u4e00q6	2023	13	transferred	transfer	VBN
cord-014712-5u4e00q6	2023	14	to	to	IN
cord-014712-5u4e00q6	2023	15	outpatient	outpatient	NN
cord-014712-5u4e00q6	2023	16	monitoring	monitoring	NN
cord-014712-5u4e00q6	2023	17	.	.	.
cord-014712-5u4e00q6	2024	1	In	in	IN
cord-014712-5u4e00q6	2024	2	2	2	CD
cord-014712-5u4e00q6	2024	3	years	year	NNS
cord-014712-5u4e00q6	2024	4	in	in	IN
cord-014712-5u4e00q6	2024	5	this	this	DT
cord-014712-5u4e00q6	2024	6	family	family	NN
cord-014712-5u4e00q6	2024	7	a	a	DT
cord-014712-5u4e00q6	2024	8	second	second	JJ
cord-014712-5u4e00q6	2024	9	daughter	daughter	NN
cord-014712-5u4e00q6	2024	10	was	be	VBD
cord-014712-5u4e00q6	2024	11	born	bear	VBN
cord-014712-5u4e00q6	2024	12	-Arina	-Arina	.
cord-014712-5u4e00q6	2024	13	N.	N.	NNP
cord-014712-5u4e00q6	2024	14	Taking	take	VBG
cord-014712-5u4e00q6	2024	15	into	into	IN
cord-014712-5u4e00q6	2024	16	account	account	NN
cord-014712-5u4e00q6	2024	17	revealed	reveal	VBN
cord-014712-5u4e00q6	2024	18	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	2024	19	of	of	IN
cord-014712-5u4e00q6	2024	20	her	-PRON-	PRP$
cord-014712-5u4e00q6	2024	21	sister	sister	NN
cord-014712-5u4e00q6	2024	22	,	,	,
cord-014712-5u4e00q6	2024	23	the	the	DT
cord-014712-5u4e00q6	2024	24	child	child	NN
cord-014712-5u4e00q6	2024	25	was	be	VBD
cord-014712-5u4e00q6	2024	26	not	not	RB
cord-014712-5u4e00q6	2024	27	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	2024	28	against	against	IN
cord-014712-5u4e00q6	2024	29	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2024	30	on	on	IN
cord-014712-5u4e00q6	2024	31	our	-PRON-	PRP$
cord-014712-5u4e00q6	2024	32	recommendations	recommendation	NNS
cord-014712-5u4e00q6	2024	33	.	.	.
cord-014712-5u4e00q6	2025	1	A	a	DT
cord-014712-5u4e00q6	2025	2	six	six	CD
cord-014712-5u4e00q6	2025	3	-	-	HYPH
cord-014712-5u4e00q6	2025	4	month	month	NN
cord-014712-5u4e00q6	2025	5	-	-	HYPH
cord-014712-5u4e00q6	2025	6	old	old	JJ
cord-014712-5u4e00q6	2025	7	child	child	NN
cord-014712-5u4e00q6	2025	8	was	be	VBD
cord-014712-5u4e00q6	2025	9	conducted	conduct	VBN
cord-014712-5u4e00q6	2025	10	immunological	immunological	JJ
cord-014712-5u4e00q6	2025	11	examination	examination	NN
cord-014712-5u4e00q6	2025	12	,	,	,
cord-014712-5u4e00q6	2025	13	which	which	WDT
cord-014712-5u4e00q6	2025	14	,	,	,
cord-014712-5u4e00q6	2025	15	like	like	IN
cord-014712-5u4e00q6	2025	16	her	-PRON-	PRP$
cord-014712-5u4e00q6	2025	17	older	old	JJR
cord-014712-5u4e00q6	2025	18	sister	sister	NN
cord-014712-5u4e00q6	2025	19	,	,	,
cord-014712-5u4e00q6	2025	20	also	also	RB
cord-014712-5u4e00q6	2025	21	shows	show	VBZ
cord-014712-5u4e00q6	2025	22	a	a	DT
cord-014712-5u4e00q6	2025	23	complete	complete	JJ
cord-014712-5u4e00q6	2025	24	lack	lack	NN
cord-014712-5u4e00q6	2025	25	of	of	IN
cord-014712-5u4e00q6	2025	26	production	production	NN
cord-014712-5u4e00q6	2025	27	of	of	IN
cord-014712-5u4e00q6	2025	28	reactive	reactive	JJ
cord-014712-5u4e00q6	2025	29	oxygen	oxygen	NN
cord-014712-5u4e00q6	2025	30	species	specie	NNS
cord-014712-5u4e00q6	2025	31	by	by	IN
cord-014712-5u4e00q6	2025	32	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	2025	33	in	in	IN
cord-014712-5u4e00q6	2025	34	the	the	DT
cord-014712-5u4e00q6	2025	35	evaluation	evaluation	NN
cord-014712-5u4e00q6	2025	36	of	of	IN
cord-014712-5u4e00q6	2025	37	NBT	NBT	NNP
cord-014712-5u4e00q6	2025	38	-	-	HYPH
cord-014712-5u4e00q6	2025	39	test	test	NN
cord-014712-5u4e00q6	2025	40	.	.	.
cord-014712-5u4e00q6	2026	1	During	during	IN
cord-014712-5u4e00q6	2026	2	the	the	DT
cord-014712-5u4e00q6	2026	3	molecular	molecular	JJ
cord-014712-5u4e00q6	2026	4	genetic	genetic	JJ
cord-014712-5u4e00q6	2026	5	studies	study	NNS
cord-014712-5u4e00q6	2026	6	of	of	IN
cord-014712-5u4e00q6	2026	7	both	both	DT
cord-014712-5u4e00q6	2026	8	sisters	sister	NNS
cord-014712-5u4e00q6	2026	9	it	-PRON-	PRP
cord-014712-5u4e00q6	2026	10	was	be	VBD
cord-014712-5u4e00q6	2026	11	identified	identify	VBN
cord-014712-5u4e00q6	2026	12	identical	identical	JJ
cord-014712-5u4e00q6	2026	13	mutation	mutation	NN
cord-014712-5u4e00q6	2026	14	c.	c.	NNP
cord-014712-5u4e00q6	2026	15	73	73	CD
cord-014712-5u4e00q6	2026	16	-	-	SYM
cord-014712-5u4e00q6	2026	17	74	74	CD
cord-014712-5u4e00q6	2026	18	del	del	NNP
cord-014712-5u4e00q6	2026	19	GT	GT	NNP
cord-014712-5u4e00q6	2026	20	gene	gene	NN
cord-014712-5u4e00q6	2026	21	NCF1	NCF1	NNP
cord-014712-5u4e00q6	2026	22	(	(	-LRB-
cord-014712-5u4e00q6	2026	23	encoding	encode	VBG
cord-014712-5u4e00q6	2026	24	subunit	subunit	NN
cord-014712-5u4e00q6	2026	25	p47phox	p47phox	NNP
cord-014712-5u4e00q6	2026	26	)	)	-RRB-
cord-014712-5u4e00q6	2026	27	.	.	.
cord-014712-5u4e00q6	2027	1	Now	now	RB
cord-014712-5u4e00q6	2027	2	the	the	DT
cord-014712-5u4e00q6	2027	3	older	old	JJR
cord-014712-5u4e00q6	2027	4	girl	girl	NN
cord-014712-5u4e00q6	2027	5	is	be	VBZ
cord-014712-5u4e00q6	2027	6	8	8	CD
cord-014712-5u4e00q6	2027	7	and	and	CC
cord-014712-5u4e00q6	2027	8	her	-PRON-	PRP$
cord-014712-5u4e00q6	2027	9	sister	sister	NN
cord-014712-5u4e00q6	2027	10	is	be	VBZ
cord-014712-5u4e00q6	2027	11	3	3	CD
cord-014712-5u4e00q6	2027	12	years	year	NNS
cord-014712-5u4e00q6	2027	13	old	old	JJ
cord-014712-5u4e00q6	2027	14	.	.	.
cord-014712-5u4e00q6	2028	1	Observing	observe	VBG
cord-014712-5u4e00q6	2028	2	them	-PRON-	PRP
cord-014712-5u4e00q6	2028	3	in	in	IN
cord-014712-5u4e00q6	2028	4	the	the	DT
cord-014712-5u4e00q6	2028	5	dynamics	dynamic	NNS
cord-014712-5u4e00q6	2028	6	neither	neither	DT
cord-014712-5u4e00q6	2028	7	of	of	IN
cord-014712-5u4e00q6	2028	8	them	-PRON-	PRP
cord-014712-5u4e00q6	2028	9	do	do	VBP
cord-014712-5u4e00q6	2028	10	not	not	RB
cord-014712-5u4e00q6	2028	11	show	show	VB
cord-014712-5u4e00q6	2028	12	any	any	DT
cord-014712-5u4e00q6	2028	13	life	life	NN
cord-014712-5u4e00q6	2028	14	-	-	HYPH
cord-014712-5u4e00q6	2028	15	threatening	threaten	VBG
cord-014712-5u4e00q6	2028	16	infections	infection	NNS
cord-014712-5u4e00q6	2028	17	.	.	.
cord-014712-5u4e00q6	2029	1	Thus	thus	RB
cord-014712-5u4e00q6	2029	2	,	,	,
cord-014712-5u4e00q6	2029	3	the	the	DT
cord-014712-5u4e00q6	2029	4	recovery	recovery	NN
cord-014712-5u4e00q6	2029	5	test	test	NN
cord-014712-5u4e00q6	2029	6	of	of	IN
cord-014712-5u4e00q6	2029	7	nitrobluetetrazolium	nitrobluetetrazolium	NN
cord-014712-5u4e00q6	2029	8	by	by	IN
cord-014712-5u4e00q6	2029	9	superoxide	superoxide	NN
cord-014712-5u4e00q6	2029	10	anion	anion	NN
cord-014712-5u4e00q6	2029	11	formed	form	VBN
cord-014712-5u4e00q6	2029	12	when	when	WRB
cord-014712-5u4e00q6	2029	13	oxygen	oxygen	NN
cord-014712-5u4e00q6	2029	14	explodes	explode	VBZ
cord-014712-5u4e00q6	2029	15	in	in	IN
cord-014712-5u4e00q6	2029	16	leukocyte	leukocyte	NN
cord-014712-5u4e00q6	2029	17	(	(	-LRB-
cord-014712-5u4e00q6	2029	18	nitro	nitro	NNP
cord-014712-5u4e00q6	2029	19	blau	blau	NNP
cord-014712-5u4e00q6	2029	20	tetrasolium	tetrasolium	NNP
cord-014712-5u4e00q6	2029	21	-NBT	-NBT	-LRB-
cord-014712-5u4e00q6	2029	22	-	-	HYPH
cord-014712-5u4e00q6	2029	23	test	test	NN
cord-014712-5u4e00q6	2029	24	)	)	-RRB-
cord-014712-5u4e00q6	2029	25	is	be	VBZ
cord-014712-5u4e00q6	2029	26	a	a	DT
cord-014712-5u4e00q6	2029	27	fairly	fairly	RB
cord-014712-5u4e00q6	2029	28	reliable	reliable	JJ
cord-014712-5u4e00q6	2029	29	method	method	NN
cord-014712-5u4e00q6	2029	30	of	of	IN
cord-014712-5u4e00q6	2029	31	early	early	JJ
cord-014712-5u4e00q6	2029	32	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	2029	33	of	of	IN
cord-014712-5u4e00q6	2029	34	chronic	chronic	JJ
cord-014712-5u4e00q6	2029	35	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2029	36	disease	disease	NN
cord-014712-5u4e00q6	2029	37	.	.	.
cord-014712-5u4e00q6	2030	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	2030	2	granolomatous	granolomatous	JJ
cord-014712-5u4e00q6	2030	3	disease	disease	NN
cord-014712-5u4e00q6	2030	4	(	(	-LRB-
cord-014712-5u4e00q6	2030	5	CGD	CGD	NNP
cord-014712-5u4e00q6	2030	6	)	)	-RRB-
cord-014712-5u4e00q6	2030	7	is	be	VBZ
cord-014712-5u4e00q6	2030	8	due	due	JJ
cord-014712-5u4e00q6	2030	9	to	to	IN
cord-014712-5u4e00q6	2030	10	defective	defective	JJ
cord-014712-5u4e00q6	2030	11	phagocyte	phagocyte	NN
cord-014712-5u4e00q6	2030	12	superoxide	superoxide	NN
cord-014712-5u4e00q6	2030	13	production	production	NN
cord-014712-5u4e00q6	2030	14	leading	lead	VBG
cord-014712-5u4e00q6	2030	15	to	to	IN
cord-014712-5u4e00q6	2030	16	impaired	impaired	JJ
cord-014712-5u4e00q6	2030	17	microbial	microbial	JJ
cord-014712-5u4e00q6	2030	18	killing	killing	NN
cord-014712-5u4e00q6	2030	19	.	.	.
cord-014712-5u4e00q6	2031	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2031	2	is	be	VBZ
cord-014712-5u4e00q6	2031	3	comprised	comprise	VBN
cord-014712-5u4e00q6	2031	4	of	of	IN
cord-014712-5u4e00q6	2031	5	a	a	DT
cord-014712-5u4e00q6	2031	6	group	group	NN
cord-014712-5u4e00q6	2031	7	of	of	IN
cord-014712-5u4e00q6	2031	8	five	five	CD
cord-014712-5u4e00q6	2031	9	genotypes	genotype	NNS
cord-014712-5u4e00q6	2031	10	with	with	IN
cord-014712-5u4e00q6	2031	11	a	a	DT
cord-014712-5u4e00q6	2031	12	common	common	JJ
cord-014712-5u4e00q6	2031	13	phenotype	phenotype	NN
cord-014712-5u4e00q6	2031	14	,	,	,
cord-014712-5u4e00q6	2031	15	chracterized	chracterize	VBN
cord-014712-5u4e00q6	2031	16	by	by	IN
cord-014712-5u4e00q6	2031	17	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2031	18	severe	severe	JJ
cord-014712-5u4e00q6	2031	19	bacterial	bacterial	JJ
cord-014712-5u4e00q6	2031	20	and	and	CC
cord-014712-5u4e00q6	2031	21	fungal	fungal	JJ
cord-014712-5u4e00q6	2031	22	infections	infection	NNS
cord-014712-5u4e00q6	2031	23	and	and	CC
cord-014712-5u4e00q6	2031	24	tissue	tissue	NN
cord-014712-5u4e00q6	2031	25	granuloma	granuloma	NN
cord-014712-5u4e00q6	2031	26	formation	formation	NN
cord-014712-5u4e00q6	2031	27	.	.	.
cord-014712-5u4e00q6	2032	1	Patients	patient	NNS
cord-014712-5u4e00q6	2032	2	with	with	IN
cord-014712-5u4e00q6	2032	3	CGD	CGD	NNP
cord-014712-5u4e00q6	2032	4	often	often	RB
cord-014712-5u4e00q6	2032	5	present	present	JJ
cord-014712-5u4e00q6	2032	6	with	with	IN
cord-014712-5u4e00q6	2032	7	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2032	8	,	,	,
cord-014712-5u4e00q6	2032	9	liver	liver	NN
cord-014712-5u4e00q6	2032	10	abscess	abscess	NN
cord-014712-5u4e00q6	2032	11	,	,	,
cord-014712-5u4e00q6	2032	12	skin	skin	NN
cord-014712-5u4e00q6	2032	13	infections	infection	NNS
cord-014712-5u4e00q6	2032	14	,	,	,
cord-014712-5u4e00q6	2032	15	lymphadenitis	lymphadenitis	NN
cord-014712-5u4e00q6	2032	16	,	,	,
cord-014712-5u4e00q6	2032	17	osteomyelitis	osteomyelitis	NN
cord-014712-5u4e00q6	2032	18	.	.	.
cord-014712-5u4e00q6	2033	1	A	a	DT
cord-014712-5u4e00q6	2033	2	five	five	CD
cord-014712-5u4e00q6	2033	3	month	month	NN
cord-014712-5u4e00q6	2033	4	old	old	JJ
cord-014712-5u4e00q6	2033	5	boy	boy	NN
cord-014712-5u4e00q6	2033	6	was	be	VBD
cord-014712-5u4e00q6	2033	7	referred	refer	VBN
cord-014712-5u4e00q6	2033	8	to	to	IN
cord-014712-5u4e00q6	2033	9	pediatric	pediatric	JJ
cord-014712-5u4e00q6	2033	10	infection	infection	NN
cord-014712-5u4e00q6	2033	11	unit	unit	NN
cord-014712-5u4e00q6	2033	12	by	by	IN
cord-014712-5u4e00q6	2033	13	lymphadenitis	lymphadenitis	NNP
cord-014712-5u4e00q6	2033	14	.	.	.
cord-014712-5u4e00q6	2034	1	On	on	IN
cord-014712-5u4e00q6	2034	2	the	the	DT
cord-014712-5u4e00q6	2034	3	medical	medical	JJ
cord-014712-5u4e00q6	2034	4	history	history	NN
cord-014712-5u4e00q6	2034	5	,	,	,
cord-014712-5u4e00q6	2034	6	he	-PRON-	PRP
cord-014712-5u4e00q6	2034	7	had	have	VBD
cord-014712-5u4e00q6	2034	8	taken	take	VBN
cord-014712-5u4e00q6	2034	9	antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	2034	10	therapy	therapy	NN
cord-014712-5u4e00q6	2034	11	for	for	IN
cord-014712-5u4e00q6	2034	12	lymphadenopathy	lymphadenopathy	NN
cord-014712-5u4e00q6	2034	13	when	when	WRB
cord-014712-5u4e00q6	2034	14	he	-PRON-	PRP
cord-014712-5u4e00q6	2034	15	was	be	VBD
cord-014712-5u4e00q6	2034	16	2	2	CD
cord-014712-5u4e00q6	2034	17	months	month	NNS
cord-014712-5u4e00q6	2034	18	old	old	JJ
cord-014712-5u4e00q6	2034	19	.	.	.
cord-014712-5u4e00q6	2035	1	The	the	DT
cord-014712-5u4e00q6	2035	2	abnormal	abnormal	JJ
cord-014712-5u4e00q6	2035	3	eye	eye	NN
cord-014712-5u4e00q6	2035	4	movement	movement	NN
cord-014712-5u4e00q6	2035	5	was	be	VBD
cord-014712-5u4e00q6	2035	6	noticed	notice	VBN
cord-014712-5u4e00q6	2035	7	by	by	IN
cord-014712-5u4e00q6	2035	8	the	the	DT
cord-014712-5u4e00q6	2035	9	family	family	NN
cord-014712-5u4e00q6	2035	10	and	and	CC
cord-014712-5u4e00q6	2035	11	on	on	IN
cord-014712-5u4e00q6	2035	12	the	the	DT
cord-014712-5u4e00q6	2035	13	eye	eye	NN
cord-014712-5u4e00q6	2035	14	examination	examination	NN
cord-014712-5u4e00q6	2035	15	peripheric	peripheric	JJ
cord-014712-5u4e00q6	2035	16	chorioretinal	chorioretinal	NNP
cord-014712-5u4e00q6	2035	17	hypopigmented	hypopigmente	VBN
cord-014712-5u4e00q6	2035	18	lesions	lesion	NNS
cord-014712-5u4e00q6	2035	19	were	be	VBD
cord-014712-5u4e00q6	2035	20	determined	determine	VBN
cord-014712-5u4e00q6	2035	21	when	when	WRB
cord-014712-5u4e00q6	2035	22	he	-PRON-	PRP
cord-014712-5u4e00q6	2035	23	was	be	VBD
cord-014712-5u4e00q6	2035	24	4	4	CD
cord-014712-5u4e00q6	2035	25	months	month	NNS
cord-014712-5u4e00q6	2035	26	old	old	JJ
cord-014712-5u4e00q6	2035	27	.	.	.
cord-014712-5u4e00q6	2036	1	İn	i̇n	VB
cord-014712-5u4e00q6	2036	2	his	-PRON-	PRP$
cord-014712-5u4e00q6	2036	3	labratory	labratory	NN
cord-014712-5u4e00q6	2036	4	examination	examination	NN
cord-014712-5u4e00q6	2036	5	,	,	,
cord-014712-5u4e00q6	2036	6	viral	viral	JJ
cord-014712-5u4e00q6	2036	7	serology	serology	NN
cord-014712-5u4e00q6	2036	8	were	be	VBD
cord-014712-5u4e00q6	2036	9	negative	negative	JJ
cord-014712-5u4e00q6	2036	10	.	.	.
cord-014712-5u4e00q6	2037	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	2037	2	parents	parent	NNS
cord-014712-5u4e00q6	2037	3	were	be	VBD
cord-014712-5u4e00q6	2037	4	not	not	RB
cord-014712-5u4e00q6	2037	5	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	2037	6	.	.	.
cord-014712-5u4e00q6	2038	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	2038	2	mother	mother	NN
cord-014712-5u4e00q6	2038	3	's	's	POS
cord-014712-5u4e00q6	2038	4	brother	brother	NN
cord-014712-5u4e00q6	2038	5	had	have	VBD
cord-014712-5u4e00q6	2038	6	died	die	VBN
cord-014712-5u4e00q6	2038	7	at	at	IN
cord-014712-5u4e00q6	2038	8	3	3	CD
cord-014712-5u4e00q6	2038	9	years	year	NNS
cord-014712-5u4e00q6	2038	10	old	old	JJ
cord-014712-5u4e00q6	2038	11	.	.	.
cord-014712-5u4e00q6	2039	1	He	-PRON-	PRP
cord-014712-5u4e00q6	2039	2	had	have	VBD
cord-014712-5u4e00q6	2039	3	history	history	NN
cord-014712-5u4e00q6	2039	4	of	of	IN
cord-014712-5u4e00q6	2039	5	skin	skin	NN
cord-014712-5u4e00q6	2039	6	infections	infection	NNS
cord-014712-5u4e00q6	2039	7	and	and	CC
cord-014712-5u4e00q6	2039	8	osteomyelitis	osteomyelitis	NN
cord-014712-5u4e00q6	2039	9	.	.	.
cord-014712-5u4e00q6	2040	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	2040	2	grandmother	grandmother	NN
cord-014712-5u4e00q6	2040	3	had	have	VBD
cord-014712-5u4e00q6	2040	4	been	be	VBN
cord-014712-5u4e00q6	2040	5	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2040	6	as	as	IN
cord-014712-5u4e00q6	2040	7	having	have	VBG
cord-014712-5u4e00q6	2040	8	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2040	9	lymphadenitis	lymphadenitis	NNP
cord-014712-5u4e00q6	2040	10	one	one	CD
cord-014712-5u4e00q6	2040	11	year	year	NN
cord-014712-5u4e00q6	2040	12	ago	ago	RB
cord-014712-5u4e00q6	2040	13	.	.	.
cord-014712-5u4e00q6	2041	1	On	on	IN
cord-014712-5u4e00q6	2041	2	his	-PRON-	PRP$
cord-014712-5u4e00q6	2041	3	physical	physical	JJ
cord-014712-5u4e00q6	2041	4	examination	examination	NN
cord-014712-5u4e00q6	2041	5	,	,	,
cord-014712-5u4e00q6	2041	6	his	-PRON-	PRP$
cord-014712-5u4e00q6	2041	7	growth	growth	NN
cord-014712-5u4e00q6	2041	8	was	be	VBD
cord-014712-5u4e00q6	2041	9	normal	normal	JJ
cord-014712-5u4e00q6	2041	10	,	,	,
cord-014712-5u4e00q6	2041	11	patological	patological	JJ
cord-014712-5u4e00q6	2041	12	findings	finding	NNS
cord-014712-5u4e00q6	2041	13	were	be	VBD
cord-014712-5u4e00q6	2041	14	horizontal	horizontal	JJ
cord-014712-5u4e00q6	2041	15	nistagmus	nistagmus	NNP
cord-014712-5u4e00q6	2041	16	,	,	,
cord-014712-5u4e00q6	2041	17	2/6	2/6	CD
cord-014712-5u4e00q6	2041	18	degree	degree	NN
cord-014712-5u4e00q6	2041	19	systolic	systolic	JJ
cord-014712-5u4e00q6	2041	20	murmur	murmur	NN
cord-014712-5u4e00q6	2041	21	,	,	,
cord-014712-5u4e00q6	2041	22	fistulized	fistulize	VBN
cord-014712-5u4e00q6	2041	23	lymph	lymph	NN
cord-014712-5u4e00q6	2041	24	tissue	tissue	NN
cord-014712-5u4e00q6	2041	25	on	on	IN
cord-014712-5u4e00q6	2041	26	the	the	DT
cord-014712-5u4e00q6	2041	27	left	left	JJ
cord-014712-5u4e00q6	2041	28	submandibuler	submandibuler	NN
cord-014712-5u4e00q6	2041	29	region	region	NN
cord-014712-5u4e00q6	2041	30	.	.	.
cord-014712-5u4e00q6	2042	1	On	on	IN
cord-014712-5u4e00q6	2042	2	the	the	DT
cord-014712-5u4e00q6	2042	3	laboratory	laboratory	NN
cord-014712-5u4e00q6	2042	4	findings	finding	NNS
cord-014712-5u4e00q6	2042	5	;	;	:
cord-014712-5u4e00q6	2042	6	he	-PRON-	PRP
cord-014712-5u4e00q6	2042	7	had	have	VBD
cord-014712-5u4e00q6	2042	8	anemia	anemia	NN
cord-014712-5u4e00q6	2042	9	and	and	CC
cord-014712-5u4e00q6	2042	10	neutropenia	neutropenia	NN
cord-014712-5u4e00q6	2042	11	.	.	.
cord-014712-5u4e00q6	2043	1	Immunglobulin	Immunglobulin	NNP
cord-014712-5u4e00q6	2043	2	levels	level	NNS
cord-014712-5u4e00q6	2043	3	and	and	CC
cord-014712-5u4e00q6	2043	4	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	2043	5	subtypes	subtype	NNS
cord-014712-5u4e00q6	2043	6	were	be	VBD
cord-014712-5u4e00q6	2043	7	normal	normal	JJ
cord-014712-5u4e00q6	2043	8	.	.	.
cord-014712-5u4e00q6	2044	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	2044	2	respiratory	respiratory	JJ
cord-014712-5u4e00q6	2044	3	burst	burst	NN
cord-014712-5u4e00q6	2044	4	activity	activity	NN
cord-014712-5u4e00q6	2044	5	was	be	VBD
cord-014712-5u4e00q6	2044	6	very	very	RB
cord-014712-5u4e00q6	2044	7	low	low	JJ
cord-014712-5u4e00q6	2044	8	.	.	.
cord-014712-5u4e00q6	2045	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	2045	2	granulamatous	granulamatous	JJ
cord-014712-5u4e00q6	2045	3	disease	disease	NN
cord-014712-5u4e00q6	2045	4	was	be	VBD
cord-014712-5u4e00q6	2045	5	thougth	thougth	VBN
cord-014712-5u4e00q6	2045	6	in	in	IN
cord-014712-5u4e00q6	2045	7	the	the	DT
cord-014712-5u4e00q6	2045	8	patient	patient	NN
cord-014712-5u4e00q6	2045	9	by	by	IN
cord-014712-5u4e00q6	2045	10	the	the	DT
cord-014712-5u4e00q6	2045	11	clinical	clinical	JJ
cord-014712-5u4e00q6	2045	12	and	and	CC
cord-014712-5u4e00q6	2045	13	laboratory	laboratory	NN
cord-014712-5u4e00q6	2045	14	findings	finding	NNS
cord-014712-5u4e00q6	2045	15	.	.	.
cord-014712-5u4e00q6	2046	1	İt	i̇t	PRP
cord-014712-5u4e00q6	2046	2	was	be	VBD
cord-014712-5u4e00q6	2046	3	detected	detect	VBN
cord-014712-5u4e00q6	2046	4	gp91phox	gp91phox	JJ
cord-014712-5u4e00q6	2046	5	mutation	mutation	NN
cord-014712-5u4e00q6	2046	6	in	in	IN
cord-014712-5u4e00q6	2046	7	the	the	DT
cord-014712-5u4e00q6	2046	8	genetical	genetical	JJ
cord-014712-5u4e00q6	2046	9	analysis	analysis	NN
cord-014712-5u4e00q6	2046	10	.	.	.
cord-014712-5u4e00q6	2047	1	He	-PRON-	PRP
cord-014712-5u4e00q6	2047	2	was	be	VBD
cord-014712-5u4e00q6	2047	3	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2047	4	as	as	IN
cord-014712-5u4e00q6	2047	5	having	have	VBG
cord-014712-5u4e00q6	2047	6	X	x	NN
cord-014712-5u4e00q6	2047	7	-	-	HYPH
cord-014712-5u4e00q6	2047	8	linked	link	VBN
cord-014712-5u4e00q6	2047	9	CGD	CGD	NNP
cord-014712-5u4e00q6	2047	10	.	.	.
cord-014712-5u4e00q6	2048	1	Antibiotic	antibiotic	JJ
cord-014712-5u4e00q6	2048	2	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	2048	3	(	(	-LRB-
cord-014712-5u4e00q6	2048	4	tmpsmx	tmpsmx	NNP
cord-014712-5u4e00q6	2048	5	,	,	,
cord-014712-5u4e00q6	2048	6	flucanazol	flucanazol	NNP
cord-014712-5u4e00q6	2048	7	)	)	-RRB-
cord-014712-5u4e00q6	2048	8	and	and	CC
cord-014712-5u4e00q6	2048	9	interferon	interferon	NN
cord-014712-5u4e00q6	2048	10	gamma	gamma	NNP
cord-014712-5u4e00q6	2048	11	were	be	VBD
cord-014712-5u4e00q6	2048	12	started	start	VBN
cord-014712-5u4e00q6	2048	13	.	.	.
cord-014712-5u4e00q6	2049	1	He	-PRON-	PRP
cord-014712-5u4e00q6	2049	2	is	be	VBZ
cord-014712-5u4e00q6	2049	3	14	14	CD
cord-014712-5u4e00q6	2049	4	months	month	NNS
cord-014712-5u4e00q6	2049	5	old	old	JJ
cord-014712-5u4e00q6	2049	6	now	now	RB
cord-014712-5u4e00q6	2050	1	and	and	CC
cord-014712-5u4e00q6	2050	2	he	-PRON-	PRP
cord-014712-5u4e00q6	2050	3	is	be	VBZ
cord-014712-5u4e00q6	2050	4	on	on	IN
cord-014712-5u4e00q6	2050	5	the	the	DT
cord-014712-5u4e00q6	2050	6	list	list	NN
cord-014712-5u4e00q6	2050	7	of	of	IN
cord-014712-5u4e00q6	2050	8	match	match	VB
cord-014712-5u4e00q6	2050	9	unrelated	unrelated	JJ
cord-014712-5u4e00q6	2050	10	donor	donor	NN
cord-014712-5u4e00q6	2050	11	screening	screening	NN
cord-014712-5u4e00q6	2050	12	.	.	.
cord-014712-5u4e00q6	2051	1	Patiens	Patiens	NNP
cord-014712-5u4e00q6	2051	2	who	who	WP
cord-014712-5u4e00q6	2051	3	has	have	VBZ
cord-014712-5u4e00q6	2051	4	history	history	NN
cord-014712-5u4e00q6	2051	5	of	of	IN
cord-014712-5u4e00q6	2051	6	lympadenitis	lympadenitis	NNP
cord-014712-5u4e00q6	2051	7	,	,	,
cord-014712-5u4e00q6	2051	8	skin	skin	NN
cord-014712-5u4e00q6	2051	9	infections	infection	NNS
cord-014712-5u4e00q6	2051	10	and	and	CC
cord-014712-5u4e00q6	2051	11	chorioretinal	chorioretinal	JJ
cord-014712-5u4e00q6	2051	12	findings	finding	NNS
cord-014712-5u4e00q6	2051	13	should	should	MD
cord-014712-5u4e00q6	2051	14	be	be	VB
cord-014712-5u4e00q6	2051	15	evaulated	evaulate	VBN
cord-014712-5u4e00q6	2051	16	for	for	IN
cord-014712-5u4e00q6	2051	17	the	the	DT
cord-014712-5u4e00q6	2051	18	X	X	NNP
cord-014712-5u4e00q6	2051	19	-	-	NN
cord-014712-5u4e00q6	2051	20	CGD	CGD	NNP
cord-014712-5u4e00q6	2051	21	.	.	.
cord-014712-5u4e00q6	2052	1	Leucocyte	Leucocyte	NNP
cord-014712-5u4e00q6	2052	2	adhesion	adhesion	NN
cord-014712-5u4e00q6	2052	3	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	2052	4	(	(	-LRB-
cord-014712-5u4e00q6	2052	5	LADs	lad	NNS
cord-014712-5u4e00q6	2052	6	)	)	-RRB-
cord-014712-5u4e00q6	2052	7	are	be	VBP
cord-014712-5u4e00q6	2052	8	rare	rare	JJ
cord-014712-5u4e00q6	2052	9	autosomal	autosomal	JJ
cord-014712-5u4e00q6	2052	10	recessive	recessive	JJ
cord-014712-5u4e00q6	2052	11	inherited	inherit	VBN
cord-014712-5u4e00q6	2052	12	disorders	disorder	NNS
cord-014712-5u4e00q6	2052	13	.	.	.
cord-014712-5u4e00q6	2053	1	Three	three	CD
cord-014712-5u4e00q6	2053	2	different	different	JJ
cord-014712-5u4e00q6	2053	3	forms	form	NNS
cord-014712-5u4e00q6	2053	4	of	of	IN
cord-014712-5u4e00q6	2053	5	LADs	lad	NNS
cord-014712-5u4e00q6	2053	6	have	have	VBP
cord-014712-5u4e00q6	2053	7	been	be	VBN
cord-014712-5u4e00q6	2053	8	described	describe	VBN
cord-014712-5u4e00q6	2053	9	so	so	RB
cord-014712-5u4e00q6	2053	10	far	far	RB
cord-014712-5u4e00q6	2053	11	.	.	.
cord-014712-5u4e00q6	2054	1	In	in	IN
cord-014712-5u4e00q6	2054	2	LAD	lad	NN
cord-014712-5u4e00q6	2054	3	-	-	HYPH
cord-014712-5u4e00q6	2054	4	I	I	NNP
cord-014712-5u4e00q6	2054	5	,	,	,
cord-014712-5u4e00q6	2054	6	the	the	DT
cord-014712-5u4e00q6	2054	7	most	most	RBS
cord-014712-5u4e00q6	2054	8	common	common	JJ
cord-014712-5u4e00q6	2054	9	leucocyte	leucocyte	JJ
cord-014712-5u4e00q6	2054	10	adhesion	adhesion	NN
cord-014712-5u4e00q6	2054	11	deficiency	deficiency	NN
cord-014712-5u4e00q6	2054	12	,	,	,
cord-014712-5u4e00q6	2054	13	the	the	DT
cord-014712-5u4e00q6	2054	14	function	function	NN
cord-014712-5u4e00q6	2054	15	of	of	IN
cord-014712-5u4e00q6	2054	16	β2	β2	NN
cord-014712-5u4e00q6	2054	17	integrin	integrin	VBD
cord-014712-5u4e00q6	2054	18	CD18	CD18	NNP
cord-014712-5u4e00q6	2054	19	is	be	VBZ
cord-014712-5u4e00q6	2054	20	lost	lose	VBN
cord-014712-5u4e00q6	2054	21	.	.	.
cord-014712-5u4e00q6	2054	22	.	.	.
cord-014712-5u4e00q6	2055	1	While	while	IN
cord-014712-5u4e00q6	2055	2	one	one	CD
cord-014712-5u4e00q6	2055	3	of	of	IN
cord-014712-5u4e00q6	2055	4	the	the	DT
cord-014712-5u4e00q6	2055	5	first	first	JJ
cord-014712-5u4e00q6	2055	6	signs	sign	NNS
cord-014712-5u4e00q6	2055	7	of	of	IN
cord-014712-5u4e00q6	2055	8	the	the	DT
cord-014712-5u4e00q6	2055	9	disease	disease	NN
cord-014712-5u4e00q6	2055	10	consist	consist	VBP
cord-014712-5u4e00q6	2055	11	in	in	IN
cord-014712-5u4e00q6	2055	12	delayed	delay	VBN
cord-014712-5u4e00q6	2055	13	separation	separation	NN
cord-014712-5u4e00q6	2055	14	of	of	IN
cord-014712-5u4e00q6	2055	15	the	the	DT
cord-014712-5u4e00q6	2055	16	umblical	umblical	JJ
cord-014712-5u4e00q6	2055	17	cord	cord	NN
cord-014712-5u4e00q6	2055	18	,	,	,
cord-014712-5u4e00q6	2055	19	severe	severe	JJ
cord-014712-5u4e00q6	2055	20	infections	infection	NNS
cord-014712-5u4e00q6	2055	21	already	already	RB
cord-014712-5u4e00q6	2055	22	start	start	VBP
cord-014712-5u4e00q6	2055	23	early	early	RB
cord-014712-5u4e00q6	2055	24	during	during	IN
cord-014712-5u4e00q6	2055	25	infancy	infancy	NN
cord-014712-5u4e00q6	2055	26	.	.	.
cord-014712-5u4e00q6	2056	1	Another	another	DT
cord-014712-5u4e00q6	2056	2	feature	feature	NN
cord-014712-5u4e00q6	2056	3	of	of	IN
cord-014712-5u4e00q6	2056	4	LAD	lad	NN
cord-014712-5u4e00q6	2056	5	-	-	:
cord-014712-5u4e00q6	2056	6	I	-PRON-	PRP
cord-014712-5u4e00q6	2056	7	includes	include	VBZ
cord-014712-5u4e00q6	2056	8	impaired	impaired	JJ
cord-014712-5u4e00q6	2056	9	wound	wound	NN
cord-014712-5u4e00q6	2056	10	healing	healing	NN
cord-014712-5u4e00q6	2056	11	.	.	.
cord-014712-5u4e00q6	2057	1	Therefore	therefore	RB
cord-014712-5u4e00q6	2057	2	,	,	,
cord-014712-5u4e00q6	2057	3	mortality	mortality	NN
cord-014712-5u4e00q6	2057	4	during	during	IN
cord-014712-5u4e00q6	2057	5	infancy	infancy	NN
cord-014712-5u4e00q6	2057	6	is	be	VBZ
cord-014712-5u4e00q6	2057	7	high	high	JJ
cord-014712-5u4e00q6	2057	8	.	.	.
cord-014712-5u4e00q6	2058	1	A	a	DT
cord-014712-5u4e00q6	2058	2	fifty	fifty	CD
cord-014712-5u4e00q6	2058	3	day	day	NN
cord-014712-5u4e00q6	2058	4	old	old	JJ
cord-014712-5u4e00q6	2058	5	boy	boy	NN
cord-014712-5u4e00q6	2058	6	was	be	VBD
cord-014712-5u4e00q6	2058	7	referred	refer	VBN
cord-014712-5u4e00q6	2058	8	to	to	IN
cord-014712-5u4e00q6	2058	9	the	the	DT
cord-014712-5u4e00q6	2058	10	hospital	hospital	NN
cord-014712-5u4e00q6	2058	11	due	due	IN
cord-014712-5u4e00q6	2058	12	to	to	IN
cord-014712-5u4e00q6	2058	13	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	2058	14	and	and	CC
cord-014712-5u4e00q6	2058	15	leukocytosis	leukocytosis	NN
cord-014712-5u4e00q6	2058	16	.	.	.
cord-014712-5u4e00q6	2059	1	The	the	DT
cord-014712-5u4e00q6	2059	2	patient	patient	NN
cord-014712-5u4e00q6	2059	3	was	be	VBD
cord-014712-5u4e00q6	2059	4	delivered	deliver	VBN
cord-014712-5u4e00q6	2059	5	following	follow	VBG
cord-014712-5u4e00q6	2059	6	an	an	DT
cord-014712-5u4e00q6	2059	7	uncomplicated	uncomplicated	JJ
cord-014712-5u4e00q6	2059	8	full	full	JJ
cord-014712-5u4e00q6	2059	9	term	term	NN
cord-014712-5u4e00q6	2059	10	pregnancy	pregnancy	NN
cord-014712-5u4e00q6	2059	11	.	.	.
cord-014712-5u4e00q6	2060	1	The	the	DT
cord-014712-5u4e00q6	2060	2	parents	parent	NNS
cord-014712-5u4e00q6	2060	3	were	be	VBD
cord-014712-5u4e00q6	2060	4	first	first	JJ
cord-014712-5u4e00q6	2060	5	degree	degree	NN
cord-014712-5u4e00q6	2060	6	cousins	cousin	NNS
cord-014712-5u4e00q6	2060	7	.	.	.
cord-014712-5u4e00q6	2061	1	Father	Father	NNP
cord-014712-5u4e00q6	2061	2	's	's	POS
cord-014712-5u4e00q6	2061	3	brother	brother	NN
cord-014712-5u4e00q6	2061	4	and	and	CC
cord-014712-5u4e00q6	2061	5	mother	mother	NN
cord-014712-5u4e00q6	2061	6	's	's	POS
cord-014712-5u4e00q6	2061	7	uncle	uncle	NN
cord-014712-5u4e00q6	2061	8	had	have	VBD
cord-014712-5u4e00q6	2061	9	died	die	VBN
cord-014712-5u4e00q6	2061	10	during	during	IN
cord-014712-5u4e00q6	2061	11	infancy	infancy	JJ
cord-014712-5u4e00q6	2061	12	period	period	NN
cord-014712-5u4e00q6	2061	13	.	.	.
cord-014712-5u4e00q6	2062	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	2062	2	umblical	umblical	JJ
cord-014712-5u4e00q6	2062	3	cord	cord	NN
cord-014712-5u4e00q6	2062	4	had	have	VBD
cord-014712-5u4e00q6	2062	5	separated	separate	VBN
cord-014712-5u4e00q6	2062	6	on	on	IN
cord-014712-5u4e00q6	2062	7	the	the	DT
cord-014712-5u4e00q6	2062	8	19th	19th	JJ
cord-014712-5u4e00q6	2062	9	day	day	NN
cord-014712-5u4e00q6	2062	10	.	.	.
cord-014712-5u4e00q6	2063	1	Patient	Patient	NNP
cord-014712-5u4e00q6	2063	2	had	have	VBD
cord-014712-5u4e00q6	2063	3	applied	apply	VBN
cord-014712-5u4e00q6	2063	4	because	because	IN
cord-014712-5u4e00q6	2063	5	of	of	IN
cord-014712-5u4e00q6	2063	6	diarrhea	diarrhea	NN
cord-014712-5u4e00q6	2063	7	by	by	IN
cord-014712-5u4e00q6	2063	8	starting	start	VBG
cord-014712-5u4e00q6	2063	9	in	in	IN
cord-014712-5u4e00q6	2063	10	the	the	DT
cord-014712-5u4e00q6	2063	11	first	first	JJ
cord-014712-5u4e00q6	2063	12	days	day	NNS
cord-014712-5u4e00q6	2063	13	of	of	IN
cord-014712-5u4e00q6	2063	14	life	life	NN
cord-014712-5u4e00q6	2063	15	and	and	CC
cord-014712-5u4e00q6	2063	16	leukocytosis	leukocytosis	NN
cord-014712-5u4e00q6	2063	17	was	be	VBD
cord-014712-5u4e00q6	2063	18	detected	detect	VBN
cord-014712-5u4e00q6	2063	19	(	(	-LRB-
cord-014712-5u4e00q6	2063	20	61.000/	61.000/	CD
cord-014712-5u4e00q6	2063	21	mm	mm	NNP
cord-014712-5u4e00q6	2063	22	3	3	CD
cord-014712-5u4e00q6	2063	23	)	)	-RRB-
cord-014712-5u4e00q6	2063	24	.	.	.
cord-014712-5u4e00q6	2064	1	On	on	IN
cord-014712-5u4e00q6	2064	2	the	the	DT
cord-014712-5u4e00q6	2064	3	physical	physical	JJ
cord-014712-5u4e00q6	2064	4	examination	examination	NN
cord-014712-5u4e00q6	2064	5	,	,	,
cord-014712-5u4e00q6	2064	6	his	-PRON-	PRP$
cord-014712-5u4e00q6	2064	7	body	body	NN
cord-014712-5u4e00q6	2064	8	weight	weight	NN
cord-014712-5u4e00q6	2064	9	was	be	VBD
cord-014712-5u4e00q6	2064	10	5200	5200	CD
cord-014712-5u4e00q6	2064	11	gr	gr	NN
cord-014712-5u4e00q6	2064	12	(	(	-LRB-
cord-014712-5u4e00q6	2064	13	10th	10th	NN
cord-014712-5u4e00q6	2064	14	to	to	IN
cord-014712-5u4e00q6	2064	15	25th	25th	JJ
cord-014712-5u4e00q6	2064	16	percentile	percentile	NN
cord-014712-5u4e00q6	2064	17	)	)	-RRB-
cord-014712-5u4e00q6	2064	18	and	and	CC
cord-014712-5u4e00q6	2064	19	his	-PRON-	PRP$
cord-014712-5u4e00q6	2064	20	height	height	NN
cord-014712-5u4e00q6	2064	21	was	be	VBD
cord-014712-5u4e00q6	2064	22	56	56	CD
cord-014712-5u4e00q6	2064	23	cm	cm	NNS
cord-014712-5u4e00q6	2064	24	(	(	-LRB-
cord-014712-5u4e00q6	2064	25	10th	10th	JJ
cord-014712-5u4e00q6	2064	26	percentile	percentile	NN
cord-014712-5u4e00q6	2064	27	)	)	-RRB-
cord-014712-5u4e00q6	2064	28	.	.	.
cord-014712-5u4e00q6	2065	1	There	there	EX
cord-014712-5u4e00q6	2065	2	was	be	VBD
cord-014712-5u4e00q6	2065	3	a	a	DT
cord-014712-5u4e00q6	2065	4	granuloma	granuloma	NN
cord-014712-5u4e00q6	2065	5	on	on	IN
cord-014712-5u4e00q6	2065	6	the	the	DT
cord-014712-5u4e00q6	2065	7	umbliculus	umbliculus	NNP
cord-014712-5u4e00q6	2065	8	.	.	.
cord-014712-5u4e00q6	2066	1	Other	other	JJ
cord-014712-5u4e00q6	2066	2	systems	system	NNS
cord-014712-5u4e00q6	2066	3	were	be	VBD
cord-014712-5u4e00q6	2066	4	normal	normal	JJ
cord-014712-5u4e00q6	2066	5	.	.	.
cord-014712-5u4e00q6	2067	1	In	in	IN
cord-014712-5u4e00q6	2067	2	the	the	DT
cord-014712-5u4e00q6	2067	3	laboratory	laboratory	NN
cord-014712-5u4e00q6	2067	4	examination	examination	NN
cord-014712-5u4e00q6	2067	5	,	,	,
cord-014712-5u4e00q6	2067	6	leukocyte	leukocyte	NN
cord-014712-5u4e00q6	2067	7	count	count	NN
cord-014712-5u4e00q6	2067	8	was	be	VBD
cord-014712-5u4e00q6	2067	9	high	high	JJ
cord-014712-5u4e00q6	2067	10	,	,	,
cord-014712-5u4e00q6	2067	11	Immunoglobulins	Immunoglobulins	NNP
cord-014712-5u4e00q6	2067	12	,	,	,
cord-014712-5u4e00q6	2067	13	respiratory	respiratory	JJ
cord-014712-5u4e00q6	2067	14	burst	burst	NN
cord-014712-5u4e00q6	2067	15	activity	activity	NN
cord-014712-5u4e00q6	2067	16	,	,	,
cord-014712-5u4e00q6	2067	17	gaita	gaita	NNP
cord-014712-5u4e00q6	2067	18	analysing	analysing	NN
cord-014712-5u4e00q6	2067	19	and	and	CC
cord-014712-5u4e00q6	2067	20	culture	culture	NN
cord-014712-5u4e00q6	2067	21	were	be	VBD
cord-014712-5u4e00q6	2067	22	normal	normal	JJ
cord-014712-5u4e00q6	2067	23	.	.	.
cord-014712-5u4e00q6	2068	1	In	in	IN
cord-014712-5u4e00q6	2068	2	the	the	DT
cord-014712-5u4e00q6	2068	3	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	2068	4	subtype	subtype	NN
cord-014712-5u4e00q6	2068	5	analysing	analyse	VBG
cord-014712-5u4e00q6	2068	6	,	,	,
cord-014712-5u4e00q6	2068	7	CD19	CD19	NNP
cord-014712-5u4e00q6	2068	8	+	+	CC
cord-014712-5u4e00q6	2068	9	B	b	NN
cord-014712-5u4e00q6	2068	10	cells	cell	NNS
cord-014712-5u4e00q6	2068	11	ratio	ratio	NN
cord-014712-5u4e00q6	2068	12	was	be	VBD
cord-014712-5u4e00q6	2068	13	mildly	mildly	RB
cord-014712-5u4e00q6	2068	14	low	low	JJ
cord-014712-5u4e00q6	2068	15	.	.	.
cord-014712-5u4e00q6	2069	1	CD18	CD18	NNP
cord-014712-5u4e00q6	2069	2	,	,	,
cord-014712-5u4e00q6	2069	3	CD11a	CD11a	NNS
cord-014712-5u4e00q6	2069	4	,	,	,
cord-014712-5u4e00q6	2069	5	CD11b	CD11b	NNPS
cord-014712-5u4e00q6	2069	6	,	,	,
cord-014712-5u4e00q6	2069	7	CD11c	CD11c	NNP
cord-014712-5u4e00q6	2069	8	levels	level	NNS
cord-014712-5u4e00q6	2069	9	were	be	VBD
cord-014712-5u4e00q6	2069	10	found	find	VBN
cord-014712-5u4e00q6	2069	11	to	to	TO
cord-014712-5u4e00q6	2069	12	be	be	VB
cord-014712-5u4e00q6	2069	13	very	very	RB
cord-014712-5u4e00q6	2069	14	low	low	JJ
cord-014712-5u4e00q6	2069	15	.	.	.
cord-014712-5u4e00q6	2070	1	In	in	IN
cord-014712-5u4e00q6	2070	2	the	the	DT
cord-014712-5u4e00q6	2070	3	genetic	genetic	JJ
cord-014712-5u4e00q6	2070	4	analysing	analysing	NN
cord-014712-5u4e00q6	2070	5	,	,	,
cord-014712-5u4e00q6	2070	6	it	-PRON-	PRP
cord-014712-5u4e00q6	2070	7	was	be	VBD
cord-014712-5u4e00q6	2070	8	detected	detect	VBN
cord-014712-5u4e00q6	2070	9	two	two	CD
cord-014712-5u4e00q6	2070	10	deleterious	deleterious	JJ
cord-014712-5u4e00q6	2070	11	mutations	mutation	NNS
cord-014712-5u4e00q6	2070	12	in	in	IN
cord-014712-5u4e00q6	2070	13	the	the	DT
cord-014712-5u4e00q6	2070	14	ITGB2	itgb2	NN
cord-014712-5u4e00q6	2070	15	gene	gene	NN
cord-014712-5u4e00q6	2070	16	.	.	.
cord-014712-5u4e00q6	2071	1	Patient	Patient	NNP
cord-014712-5u4e00q6	2071	2	had	have	VBD
cord-014712-5u4e00q6	2071	3	been	be	VBN
cord-014712-5u4e00q6	2071	4	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2071	5	as	as	IN
cord-014712-5u4e00q6	2071	6	LAD-1	LAD-1	NNP
cord-014712-5u4e00q6	2071	7	.	.	.
cord-014712-5u4e00q6	2072	1	He	-PRON-	PRP
cord-014712-5u4e00q6	2072	2	treated	treat	VBD
cord-014712-5u4e00q6	2072	3	by	by	IN
cord-014712-5u4e00q6	2072	4	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	2072	5	and	and	CC
cord-014712-5u4e00q6	2072	6	then	then	RB
cord-014712-5u4e00q6	2072	7	started	start	VBD
cord-014712-5u4e00q6	2072	8	prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	2072	9	antibiotherapy	antibiotherapy	NNP
cord-014712-5u4e00q6	2072	10	.	.	.
cord-014712-5u4e00q6	2073	1	Family	family	NN
cord-014712-5u4e00q6	2073	2	screened	screen	VBD
cord-014712-5u4e00q6	2073	3	for	for	IN
cord-014712-5u4e00q6	2073	4	tissue	tissue	NN
cord-014712-5u4e00q6	2073	5	match	match	NN
cord-014712-5u4e00q6	2073	6	.	.	.
cord-014712-5u4e00q6	2074	1	His	-PRON-	PRP$
cord-014712-5u4e00q6	2074	2	older	old	JJR
cord-014712-5u4e00q6	2074	3	sister	sister	NN
cord-014712-5u4e00q6	2074	4	was	be	VBD
cord-014712-5u4e00q6	2074	5	found	find	VBN
cord-014712-5u4e00q6	2074	6	full	full	RB
cord-014712-5u4e00q6	2074	7	matched	match	VBN
cord-014712-5u4e00q6	2074	8	.	.	.
cord-014712-5u4e00q6	2075	1	He	-PRON-	PRP
cord-014712-5u4e00q6	2075	2	was	be	VBD
cord-014712-5u4e00q6	2075	3	referred	refer	VBN
cord-014712-5u4e00q6	2075	4	to	to	IN
cord-014712-5u4e00q6	2075	5	transplantation	transplantation	NN
cord-014712-5u4e00q6	2075	6	unit	unit	NN
cord-014712-5u4e00q6	2075	7	.	.	.
cord-014712-5u4e00q6	2076	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2076	2	was	be	VBD
cord-014712-5u4e00q6	2076	3	applied	apply	VBN
cord-014712-5u4e00q6	2076	4	bone	bone	NN
cord-014712-5u4e00q6	2076	5	marrow	marrow	NN
cord-014712-5u4e00q6	2076	6	transplantation	transplantation	NN
cord-014712-5u4e00q6	2076	7	when	when	WRB
cord-014712-5u4e00q6	2076	8	he	-PRON-	PRP
cord-014712-5u4e00q6	2076	9	was	be	VBD
cord-014712-5u4e00q6	2076	10	3	3	CD
cord-014712-5u4e00q6	2076	11	months	month	NNS
cord-014712-5u4e00q6	2076	12	old	old	JJ
cord-014712-5u4e00q6	2076	13	.	.	.
cord-014712-5u4e00q6	2077	1	Presence	presence	NN
cord-014712-5u4e00q6	2077	2	of	of	IN
cord-014712-5u4e00q6	2077	3	delayed	delay	VBN
cord-014712-5u4e00q6	2077	4	umblical	umblical	JJ
cord-014712-5u4e00q6	2077	5	cord	cord	NN
cord-014712-5u4e00q6	2077	6	separation	separation	NN
cord-014712-5u4e00q6	2077	7	and	and	CC
cord-014712-5u4e00q6	2077	8	leucocytosis	leucocytosis	NNP
cord-014712-5u4e00q6	2077	9	should	should	MD
cord-014712-5u4e00q6	2077	10	be	be	VB
cord-014712-5u4e00q6	2077	11	considered	consider	VBN
cord-014712-5u4e00q6	2077	12	in	in	IN
cord-014712-5u4e00q6	2077	13	the	the	DT
cord-014712-5u4e00q6	2077	14	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	2077	15	of	of	IN
cord-014712-5u4e00q6	2077	16	LAD	lad	NN
cord-014712-5u4e00q6	2077	17	but	but	CC
cord-014712-5u4e00q6	2077	18	these	these	DT
cord-014712-5u4e00q6	2077	19	patients	patient	NNS
cord-014712-5u4e00q6	2077	20	might	may	MD
cord-014712-5u4e00q6	2077	21	have	have	VB
cord-014712-5u4e00q6	2077	22	different	different	JJ
cord-014712-5u4e00q6	2077	23	symptoms	symptom	NNS
cord-014712-5u4e00q6	2077	24	such	such	JJ
cord-014712-5u4e00q6	2077	25	as	as	IN
cord-014712-5u4e00q6	2077	26	diarrea	diarrea	NNP
cord-014712-5u4e00q6	2077	27	.	.	.
cord-014712-5u4e00q6	2078	1	Mendelian	mendelian	JJ
cord-014712-5u4e00q6	2078	2	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2078	3	to	to	IN
cord-014712-5u4e00q6	2078	4	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	2078	5	disease	disease	NN
cord-014712-5u4e00q6	2078	6	(	(	-LRB-
cord-014712-5u4e00q6	2078	7	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2078	8	)	)	-RRB-
cord-014712-5u4e00q6	2078	9	is	be	VBZ
cord-014712-5u4e00q6	2078	10	a	a	DT
cord-014712-5u4e00q6	2078	11	rare	rare	JJ
cord-014712-5u4e00q6	2078	12	entity	entity	NN
cord-014712-5u4e00q6	2078	13	.	.	.
cord-014712-5u4e00q6	2079	1	Patients	patient	NNS
cord-014712-5u4e00q6	2079	2	with	with	IN
cord-014712-5u4e00q6	2079	3	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2079	4	have	have	VBP
cord-014712-5u4e00q6	2079	5	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2079	6	to	to	IN
cord-014712-5u4e00q6	2079	7	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2079	8	and	and	CC
cord-014712-5u4e00q6	2079	9	some	some	DT
cord-014712-5u4e00q6	2079	10	other	other	JJ
cord-014712-5u4e00q6	2079	11	intracellular	intracellular	JJ
cord-014712-5u4e00q6	2079	12	microorganisms	microorganism	NNS
cord-014712-5u4e00q6	2079	13	in	in	IN
cord-014712-5u4e00q6	2079	14	addition	addition	NN
cord-014712-5u4e00q6	2079	15	to	to	IN
cord-014712-5u4e00q6	2079	16	weakly	weakly	RB
cord-014712-5u4e00q6	2079	17	pathogenic	pathogenic	JJ
cord-014712-5u4e00q6	2079	18	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2079	19	species	specie	NNS
cord-014712-5u4e00q6	2079	20	.	.	.
cord-014712-5u4e00q6	2080	1	IL-12Rβ1	il-12rβ1	NN
cord-014712-5u4e00q6	2080	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	2080	3	,	,	,
cord-014712-5u4e00q6	2080	4	most	most	RBS
cord-014712-5u4e00q6	2080	5	common	common	JJ
cord-014712-5u4e00q6	2080	6	form	form	NN
cord-014712-5u4e00q6	2080	7	of	of	IN
cord-014712-5u4e00q6	2080	8	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2080	9	,	,	,
cord-014712-5u4e00q6	2080	10	is	be	VBZ
cord-014712-5u4e00q6	2080	11	caused	cause	VBN
cord-014712-5u4e00q6	2080	12	by	by	IN
cord-014712-5u4e00q6	2080	13	mutations	mutation	NNS
cord-014712-5u4e00q6	2080	14	in	in	IN
cord-014712-5u4e00q6	2080	15	the	the	DT
cord-014712-5u4e00q6	2080	16	IL12RB	IL12RB	NNP
cord-014712-5u4e00q6	2080	17	gene	gene	NN
cord-014712-5u4e00q6	2080	18	.	.	.
cord-014712-5u4e00q6	2081	1	37	37	CD
cord-014712-5u4e00q6	2081	2	patients	patient	NNS
cord-014712-5u4e00q6	2081	3	who	who	WP
cord-014712-5u4e00q6	2081	4	have	have	VBP
cord-014712-5u4e00q6	2081	5	symptoms	symptom	NNS
cord-014712-5u4e00q6	2081	6	suggestive	suggestive	JJ
cord-014712-5u4e00q6	2081	7	for	for	IN
cord-014712-5u4e00q6	2081	8	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2081	9	or	or	CC
cord-014712-5u4e00q6	2081	10	history	history	NN
cord-014712-5u4e00q6	2081	11	of	of	IN
cord-014712-5u4e00q6	2081	12	sibling	sibling	NN
cord-014712-5u4e00q6	2081	13	death	death	NN
cord-014712-5u4e00q6	2081	14	due	due	IN
cord-014712-5u4e00q6	2081	15	to	to	IN
cord-014712-5u4e00q6	2081	16	BCGosis	BCGosis	NNP
cord-014712-5u4e00q6	2081	17	were	be	VBD
cord-014712-5u4e00q6	2081	18	evaluated	evaluate	VBN
cord-014712-5u4e00q6	2081	19	.	.	.
cord-014712-5u4e00q6	2082	1	The	the	DT
cord-014712-5u4e00q6	2082	2	expression	expression	NN
cord-014712-5u4e00q6	2082	3	of	of	IN
cord-014712-5u4e00q6	2082	4	the	the	DT
cord-014712-5u4e00q6	2082	5	IL-12RB1	il-12rb1	CD
cord-014712-5u4e00q6	2082	6	was	be	VBD
cord-014712-5u4e00q6	2082	7	detected	detect	VBN
cord-014712-5u4e00q6	2082	8	in	in	IN
cord-014712-5u4e00q6	2082	9	patients	patient	NNS
cord-014712-5u4e00q6	2082	10	and	and	CC
cord-014712-5u4e00q6	2082	11	family	family	NN
cord-014712-5u4e00q6	2082	12	members	member	NNS
cord-014712-5u4e00q6	2082	13	by	by	IN
cord-014712-5u4e00q6	2082	14	monoclonal	monoclonal	JJ
cord-014712-5u4e00q6	2082	15	antibodies	antibody	NNS
cord-014712-5u4e00q6	2082	16	on	on	IN
cord-014712-5u4e00q6	2082	17	the	the	DT
cord-014712-5u4e00q6	2082	18	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	2082	19	surface	surface	NN
cord-014712-5u4e00q6	2082	20	by	by	IN
cord-014712-5u4e00q6	2082	21	flow	flow	NN
cord-014712-5u4e00q6	2082	22	cytometry	cytometry	NN
cord-014712-5u4e00q6	2082	23	after	after	IN
cord-014712-5u4e00q6	2082	24	the	the	DT
cord-014712-5u4e00q6	2082	25	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	2082	26	were	be	VBD
cord-014712-5u4e00q6	2082	27	stimulated	stimulate	VBN
cord-014712-5u4e00q6	2082	28	in	in	IN
cord-014712-5u4e00q6	2082	29	vitro	vitro	FW
cord-014712-5u4e00q6	2082	30	with	with	IN
cord-014712-5u4e00q6	2082	31	PHA	PHA	NNP
cord-014712-5u4e00q6	2082	32	.	.	.
cord-014712-5u4e00q6	2083	1	Mutation	mutation	NN
cord-014712-5u4e00q6	2083	2	analyses	analysis	NNS
cord-014712-5u4e00q6	2083	3	was	be	VBD
cord-014712-5u4e00q6	2083	4	done	do	VBN
cord-014712-5u4e00q6	2083	5	by	by	IN
cord-014712-5u4e00q6	2083	6	Sanger	Sanger	NNP
cord-014712-5u4e00q6	2083	7	sequencing	sequencing	NN
cord-014712-5u4e00q6	2083	8	.	.	.
cord-014712-5u4e00q6	2084	1	All	all	DT
cord-014712-5u4e00q6	2084	2	index	index	NN
cord-014712-5u4e00q6	2084	3	cases	case	NNS
cord-014712-5u4e00q6	2084	4	were	be	VBD
cord-014712-5u4e00q6	2084	5	presented	present	VBN
cord-014712-5u4e00q6	2084	6	either	either	CC
cord-014712-5u4e00q6	2084	7	with	with	IN
cord-014712-5u4e00q6	2084	8	BCG	BCG	NNP
cord-014712-5u4e00q6	2084	9	or	or	CC
cord-014712-5u4e00q6	2084	10	salmonella	salmonella	NN
cord-014712-5u4e00q6	2084	11	infection	infection	NN
cord-014712-5u4e00q6	2084	12	.	.	.
cord-014712-5u4e00q6	2085	1	Two	two	CD
cord-014712-5u4e00q6	2085	2	patients	patient	NNS
cord-014712-5u4e00q6	2085	3	,	,	,
cord-014712-5u4e00q6	2085	4	though	though	IN
cord-014712-5u4e00q6	2085	5	they	-PRON-	PRP
cord-014712-5u4e00q6	2085	6	were	be	VBD
cord-014712-5u4e00q6	2085	7	BCG	BCG	NNP
cord-014712-5u4e00q6	2085	8	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	2085	9	had	have	VBD
cord-014712-5u4e00q6	2085	10	no	no	DT
cord-014712-5u4e00q6	2085	11	clinical	clinical	JJ
cord-014712-5u4e00q6	2085	12	symptom	symptom	NN
cord-014712-5u4e00q6	2085	13	,	,	,
cord-014712-5u4e00q6	2085	14	six	six	CD
cord-014712-5u4e00q6	2085	15	presented	present	VBN
cord-014712-5u4e00q6	2085	16	with	with	IN
cord-014712-5u4e00q6	2085	17	the	the	DT
cord-014712-5u4e00q6	2085	18	symptoms	symptom	NNS
cord-014712-5u4e00q6	2085	19	of	of	IN
cord-014712-5u4e00q6	2085	20	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2085	21	infections	infection	NNS
cord-014712-5u4e00q6	2085	22	,	,	,
cord-014712-5u4e00q6	2085	23	two	two	CD
cord-014712-5u4e00q6	2085	24	developed	develop	VBN
cord-014712-5u4e00q6	2085	25	leukocytoclastic	leukocytoclastic	NNP
cord-014712-5u4e00q6	2085	26	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2085	27	,	,	,
cord-014712-5u4e00q6	2085	28	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	2085	29	was	be	VBD
cord-014712-5u4e00q6	2085	30	the	the	DT
cord-014712-5u4e00q6	2085	31	accompanying	accompanying	JJ
cord-014712-5u4e00q6	2085	32	feature	feature	NN
cord-014712-5u4e00q6	2085	33	in	in	IN
cord-014712-5u4e00q6	2085	34	seven	seven	CD
cord-014712-5u4e00q6	2085	35	.	.	.
cord-014712-5u4e00q6	2086	1	Recurrent	recurrent	JJ
cord-014712-5u4e00q6	2086	2	Leishmaniasis	Leishmaniasis	NNP
cord-014712-5u4e00q6	2086	3	that	that	WDT
cord-014712-5u4e00q6	2086	4	necessitated	necessitate	VBD
cord-014712-5u4e00q6	2086	5	subcutaneous	subcutaneous	JJ
cord-014712-5u4e00q6	2086	6	interferon	interferon	NN
cord-014712-5u4e00q6	2086	7	-	-	HYPH
cord-014712-5u4e00q6	2086	8	γ	γ	NN
cord-014712-5u4e00q6	2086	9	and	and	CC
cord-014712-5u4e00q6	2086	10	prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	2086	11	Amphotericine	Amphotericine	NNP
cord-014712-5u4e00q6	2086	12	B	B	NNP
cord-014712-5u4e00q6	2086	13	therapy	therapy	NN
cord-014712-5u4e00q6	2086	14	was	be	VBD
cord-014712-5u4e00q6	2086	15	present	present	JJ
cord-014712-5u4e00q6	2086	16	in	in	IN
cord-014712-5u4e00q6	2086	17	a	a	DT
cord-014712-5u4e00q6	2086	18	patient	patient	NN
cord-014712-5u4e00q6	2086	19	.	.	.
cord-014712-5u4e00q6	2087	1	In	in	IN
cord-014712-5u4e00q6	2087	2	all	all	DT
cord-014712-5u4e00q6	2087	3	patients	patient	NNS
cord-014712-5u4e00q6	2087	4	the	the	DT
cord-014712-5u4e00q6	2087	5	percentage	percentage	NN
cord-014712-5u4e00q6	2087	6	of	of	IN
cord-014712-5u4e00q6	2087	7	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	2087	8	with	with	IN
cord-014712-5u4e00q6	2087	9	IL12Rβ1	il12rβ1	NN
cord-014712-5u4e00q6	2087	10	expression	expression	NN
cord-014712-5u4e00q6	2087	11	was	be	VBD
cord-014712-5u4e00q6	2087	12	found	find	VBN
cord-014712-5u4e00q6	2087	13	to	to	TO
cord-014712-5u4e00q6	2087	14	be	be	VB
cord-014712-5u4e00q6	2087	15	less	less	JJR
cord-014712-5u4e00q6	2087	16	than	than	IN
cord-014712-5u4e00q6	2087	17	%	%	NN
cord-014712-5u4e00q6	2087	18	1	1	CD
cord-014712-5u4e00q6	2087	19	.	.	.
cord-014712-5u4e00q6	2088	1	Prophylactic	prophylactic	JJ
cord-014712-5u4e00q6	2088	2	antimycrobial	antimycrobial	JJ
cord-014712-5u4e00q6	2088	3	treatment	treatment	NN
cord-014712-5u4e00q6	2088	4	and	and	CC
cord-014712-5u4e00q6	2088	5	in	in	IN
cord-014712-5u4e00q6	2088	6	severe	severe	JJ
cord-014712-5u4e00q6	2088	7	and	and	CC
cord-014712-5u4e00q6	2088	8	resistant	resistant	JJ
cord-014712-5u4e00q6	2088	9	infectious	infectious	JJ
cord-014712-5u4e00q6	2088	10	episodes	episode	NNS
cord-014712-5u4e00q6	2088	11	IF	if	NN
cord-014712-5u4e00q6	2088	12	-	-	HYPH
cord-014712-5u4e00q6	2088	13	γ	γ	NN
cord-014712-5u4e00q6	2088	14	therapy	therapy	NN
cord-014712-5u4e00q6	2088	15	,	,	,
cord-014712-5u4e00q6	2088	16	should	should	MD
cord-014712-5u4e00q6	2088	17	be	be	VB
cord-014712-5u4e00q6	2088	18	given	give	VBN
cord-014712-5u4e00q6	2088	19	.	.	.
cord-014712-5u4e00q6	2089	1	Many	many	JJ
cord-014712-5u4e00q6	2089	2	patients	patient	NNS
cord-014712-5u4e00q6	2089	3	have	have	VBP
cord-014712-5u4e00q6	2089	4	associated	associate	VBN
cord-014712-5u4e00q6	2089	5	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	2089	6	candidiasis	candidiasi	NNS
cord-014712-5u4e00q6	2089	7	.	.	.
cord-014712-5u4e00q6	2090	1	The	the	DT
cord-014712-5u4e00q6	2090	2	prognosis	prognosis	NN
cord-014712-5u4e00q6	2090	3	is	be	VBZ
cord-014712-5u4e00q6	2090	4	good	good	JJ
cord-014712-5u4e00q6	2090	5	unless	unless	IN
cord-014712-5u4e00q6	2090	6	the	the	DT
cord-014712-5u4e00q6	2090	7	patient	patient	NN
cord-014712-5u4e00q6	2090	8	admits	admit	VBZ
cord-014712-5u4e00q6	2090	9	at	at	IN
cord-014712-5u4e00q6	2090	10	the	the	DT
cord-014712-5u4e00q6	2090	11	later	later	JJ
cord-014712-5u4e00q6	2090	12	stages	stage	NNS
cord-014712-5u4e00q6	2090	13	of	of	IN
cord-014712-5u4e00q6	2090	14	BCG	BCG	NNP
cord-014712-5u4e00q6	2090	15	infection	infection	NN
cord-014712-5u4e00q6	2090	16	.	.	.
cord-014712-5u4e00q6	2091	1	The	the	DT
cord-014712-5u4e00q6	2091	2	results	result	NNS
cord-014712-5u4e00q6	2091	3	of	of	IN
cord-014712-5u4e00q6	2091	4	our	-PRON-	PRP$
cord-014712-5u4e00q6	2091	5	patients	patient	NNS
cord-014712-5u4e00q6	2091	6	showed	show	VBD
cord-014712-5u4e00q6	2091	7	that	that	IN
cord-014712-5u4e00q6	2091	8	the	the	DT
cord-014712-5u4e00q6	2091	9	analysis	analysis	NN
cord-014712-5u4e00q6	2091	10	of	of	IN
cord-014712-5u4e00q6	2091	11	the	the	DT
cord-014712-5u4e00q6	2091	12	surface	surface	NN
cord-014712-5u4e00q6	2091	13	expression	expression	NN
cord-014712-5u4e00q6	2091	14	of	of	IN
cord-014712-5u4e00q6	2091	15	IL12Rβ1	il12rβ1	NN
cord-014712-5u4e00q6	2091	16	on	on	IN
cord-014712-5u4e00q6	2091	17	activated	activate	VBN
cord-014712-5u4e00q6	2091	18	lymphocytes	lymphocyte	NNS
cord-014712-5u4e00q6	2091	19	is	be	VBZ
cord-014712-5u4e00q6	2091	20	an	an	DT
cord-014712-5u4e00q6	2091	21	effective	effective	JJ
cord-014712-5u4e00q6	2091	22	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	2091	23	method	method	NN
cord-014712-5u4e00q6	2091	24	which	which	WDT
cord-014712-5u4e00q6	2091	25	can	can	MD
cord-014712-5u4e00q6	2091	26	also	also	RB
cord-014712-5u4e00q6	2091	27	be	be	VB
cord-014712-5u4e00q6	2091	28	used	use	VBN
cord-014712-5u4e00q6	2091	29	in	in	IN
cord-014712-5u4e00q6	2091	30	screening	screening	NN
cord-014712-5u4e00q6	2091	31	of	of	IN
cord-014712-5u4e00q6	2091	32	the	the	DT
cord-014712-5u4e00q6	2091	33	patients	patient	NNS
cord-014712-5u4e00q6	2091	34	with	with	IN
cord-014712-5u4e00q6	2091	35	probable	probable	JJ
cord-014712-5u4e00q6	2091	36	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2091	37	.	.	.
cord-014712-5u4e00q6	2092	1	Introduction	introduction	NN
cord-014712-5u4e00q6	2092	2	:	:	:
cord-014712-5u4e00q6	2093	1	Mendelian	mendelian	JJ
cord-014712-5u4e00q6	2093	2	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2093	3	to	to	IN
cord-014712-5u4e00q6	2093	4	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	2093	5	disease	disease	NNP
cord-014712-5u4e00q6	2094	1	(	(	-LRB-
cord-014712-5u4e00q6	2094	2	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2094	3	,	,	,
cord-014712-5u4e00q6	2094	4	Online	Online	NNP
cord-014712-5u4e00q6	2094	5	Mendelian	Mendelian	NNP
cord-014712-5u4e00q6	2094	6	Inheritance	Inheritance	NNP
cord-014712-5u4e00q6	2094	7	inMan	inMan	NNP
cord-014712-5u4e00q6	2094	8	209950	209950	CD
cord-014712-5u4e00q6	2094	9	)	)	-RRB-
cord-014712-5u4e00q6	2094	10	is	be	VBZ
cord-014712-5u4e00q6	2094	11	a	a	DT
cord-014712-5u4e00q6	2094	12	rare	rare	JJ
cord-014712-5u4e00q6	2094	13	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	2094	14	characterized	characterize	VBN
cord-014712-5u4e00q6	2094	15	by	by	IN
cord-014712-5u4e00q6	2094	16	predisposition	predisposition	NN
cord-014712-5u4e00q6	2094	17	to	to	IN
cord-014712-5u4e00q6	2094	18	infections	infection	NNS
cord-014712-5u4e00q6	2094	19	caused	cause	VBN
cord-014712-5u4e00q6	2094	20	by	by	IN
cord-014712-5u4e00q6	2094	21	weakly	weakly	RB
cord-014712-5u4e00q6	2094	22	virulent	virulent	JJ
cord-014712-5u4e00q6	2094	23	mycobacteria	mycobacterium	NNS
cord-014712-5u4e00q6	2094	24	,	,	,
cord-014712-5u4e00q6	2094	25	such	such	JJ
cord-014712-5u4e00q6	2094	26	as	as	IN
cord-014712-5u4e00q6	2094	27	Mycobacterium	Mycobacterium	NNP
cord-014712-5u4e00q6	2094	28	bovis	bovis	NN
cord-014712-5u4e00q6	2094	29	bacille	bacille	NNP
cord-014712-5u4e00q6	2094	30	Calmette	Calmette	NNP
cord-014712-5u4e00q6	2094	31	-	-	HYPH
cord-014712-5u4e00q6	2094	32	Gue´rin	Gue´rin	NNP
cord-014712-5u4e00q6	2094	33	(	(	-LRB-
cord-014712-5u4e00q6	2094	34	BCG	BCG	NNP
cord-014712-5u4e00q6	2094	35	)	)	-RRB-
cord-014712-5u4e00q6	2094	36	,	,	,
cord-014712-5u4e00q6	2094	37	environmental	environmental	JJ
cord-014712-5u4e00q6	2094	38	nontuberculous	nontuberculous	JJ
cord-014712-5u4e00q6	2094	39	mycobacteria	mycobacterium	NNS
cord-014712-5u4e00q6	2094	40	(	(	-LRB-
cord-014712-5u4e00q6	2094	41	NTM	NTM	NNP
cord-014712-5u4e00q6	2094	42	)	)	-RRB-
cord-014712-5u4e00q6	2094	43	,	,	,
cord-014712-5u4e00q6	2094	44	and	and	CC
cord-014712-5u4e00q6	2094	45	Salmonella	salmonella	NN
cord-014712-5u4e00q6	2094	46	strains	strain	NNS
cord-014712-5u4e00q6	2094	47	in	in	IN
cord-014712-5u4e00q6	2094	48	otherwise	otherwise	RB
cord-014712-5u4e00q6	2094	49	healthy	healthy	JJ
cord-014712-5u4e00q6	2094	50	individuals	individual	NNS
cord-014712-5u4e00q6	2094	51	.	.	.
cord-014712-5u4e00q6	2095	1	IL-12Rb1	IL-12Rb1	NNP
cord-014712-5u4e00q6	2095	2	deficiency	deficiency	NN
cord-014712-5u4e00q6	2095	3	is	be	VBZ
cord-014712-5u4e00q6	2095	4	the	the	DT
cord-014712-5u4e00q6	2095	5	most	most	RBS
cord-014712-5u4e00q6	2095	6	common	common	JJ
cord-014712-5u4e00q6	2095	7	form	form	NN
cord-014712-5u4e00q6	2095	8	of	of	IN
cord-014712-5u4e00q6	2095	9	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2095	10	and	and	CC
cord-014712-5u4e00q6	2095	11	is	be	VBZ
cord-014712-5u4e00q6	2095	12	characterized	characterize	VBN
cord-014712-5u4e00q6	2095	13	by	by	IN
cord-014712-5u4e00q6	2095	14	childhoodonset	childhoodonset	NNP
cord-014712-5u4e00q6	2095	15	mycobacteriosis	mycobacteriosis	NNP
cord-014712-5u4e00q6	2095	16	with	with	IN
cord-014712-5u4e00q6	2095	17	frequent	frequent	JJ
cord-014712-5u4e00q6	2095	18	recurrence	recurrence	NN
cord-014712-5u4e00q6	2095	19	.	.	.
cord-014712-5u4e00q6	2096	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2096	2	has	have	VBZ
cord-014712-5u4e00q6	2096	3	been	be	VBN
cord-014712-5u4e00q6	2096	4	found	find	VBN
cord-014712-5u4e00q6	2096	5	that	that	IN
cord-014712-5u4e00q6	2096	6	patients	patient	NNS
cord-014712-5u4e00q6	2096	7	with	with	IN
cord-014712-5u4e00q6	2096	8	IL-12Rb1	IL-12Rb1	NNP
cord-014712-5u4e00q6	2096	9	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	2096	10	are	be	VBP
cord-014712-5u4e00q6	2096	11	also	also	RB
cord-014712-5u4e00q6	2096	12	prone	prone	JJ
cord-014712-5u4e00q6	2096	13	to	to	IN
cord-014712-5u4e00q6	2096	14	developing	develop	VBG
cord-014712-5u4e00q6	2096	15	infections	infection	NNS
cord-014712-5u4e00q6	2096	16	with	with	IN
cord-014712-5u4e00q6	2096	17	nontyphoidal	nontyphoidal	JJ
cord-014712-5u4e00q6	2096	18	salmonella	salmonella	NN
cord-014712-5u4e00q6	2096	19	species	specie	NNS
cord-014712-5u4e00q6	2096	20	with	with	IN
cord-014712-5u4e00q6	2096	21	bacteremia	bacteremia	NN
cord-014712-5u4e00q6	2096	22	and	and	CC
cord-014712-5u4e00q6	2096	23	lymphadenopathy	lymphadenopathy	JJ
cord-014712-5u4e00q6	2096	24	.	.	.
cord-014712-5u4e00q6	2097	1	Here	here	RB
cord-014712-5u4e00q6	2097	2	we	-PRON-	PRP
cord-014712-5u4e00q6	2097	3	present	present	VBP
cord-014712-5u4e00q6	2097	4	a	a	DT
cord-014712-5u4e00q6	2097	5	girl	girl	NN
cord-014712-5u4e00q6	2097	6	with	with	IN
cord-014712-5u4e00q6	2097	7	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2097	8	cutaneous	cutaneous	JJ
cord-014712-5u4e00q6	2097	9	leukocytoclastic	leukocytoclastic	JJ
cord-014712-5u4e00q6	2097	10	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2097	11	(	(	-LRB-
cord-014712-5u4e00q6	2097	12	CLV	CLV	NNP
cord-014712-5u4e00q6	2097	13	)	)	-RRB-
cord-014712-5u4e00q6	2097	14	with	with	IN
cord-014712-5u4e00q6	2097	15	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2097	16	enteritidis	enteritidis	NN
cord-014712-5u4e00q6	2097	17	due	due	JJ
cord-014712-5u4e00q6	2097	18	to	to	IN
cord-014712-5u4e00q6	2097	19	IL-12Rb1	il-12rb1	JJ
cord-014712-5u4e00q6	2097	20	deficiency	deficiency	NN
cord-014712-5u4e00q6	2097	21	.	.	.
cord-014712-5u4e00q6	2098	1	Case	case	NN
cord-014712-5u4e00q6	2098	2	report	report	NN
cord-014712-5u4e00q6	2098	3	:	:	:
cord-014712-5u4e00q6	2098	4	A	a	DT
cord-014712-5u4e00q6	2098	5	four	four	CD
cord-014712-5u4e00q6	2098	6	year	year	NN
cord-014712-5u4e00q6	2098	7	old	old	JJ
cord-014712-5u4e00q6	2098	8	girl	girl	NN
cord-014712-5u4e00q6	2098	9	that	that	WDT
cord-014712-5u4e00q6	2098	10	had	have	VBD
cord-014712-5u4e00q6	2098	11	been	be	VBN
cord-014712-5u4e00q6	2098	12	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2098	13	serologically	serologically	RB
cord-014712-5u4e00q6	2098	14	with	with	IN
cord-014712-5u4e00q6	2098	15	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2098	16	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2098	17	infections	infection	NNS
cord-014712-5u4e00q6	2098	18	,	,	,
cord-014712-5u4e00q6	2098	19	associated	associate	VBN
cord-014712-5u4e00q6	2098	20	with	with	IN
cord-014712-5u4e00q6	2098	21	lymphadenopathy	lymphadenopathy	NN
cord-014712-5u4e00q6	2098	22	and	and	CC
cord-014712-5u4e00q6	2098	23	skin	skin	NN
cord-014712-5u4e00q6	2098	24	eruption	eruption	NN
cord-014712-5u4e00q6	2098	25	was	be	VBD
cord-014712-5u4e00q6	2098	26	admitted	admit	VBN
cord-014712-5u4e00q6	2098	27	as	as	IN
cord-014712-5u4e00q6	2098	28	having	have	VBG
cord-014712-5u4e00q6	2098	29	Henoch	Henoch	NNP
cord-014712-5u4e00q6	2098	30	-	-	HYPH
cord-014712-5u4e00q6	2098	31	Schönlein	Schönlein	NNP
cord-014712-5u4e00q6	2098	32	purpura	purpura	NN
cord-014712-5u4e00q6	2098	33	.	.	.
cord-014712-5u4e00q6	2099	1	She	-PRON-	PRP
cord-014712-5u4e00q6	2099	2	had	have	VBD
cord-014712-5u4e00q6	2099	3	been	be	VBN
cord-014712-5u4e00q6	2099	4	vaccinated	vaccinate	VBN
cord-014712-5u4e00q6	2099	5	with	with	IN
cord-014712-5u4e00q6	2099	6	BCG	BCG	NNP
cord-014712-5u4e00q6	2099	7	and	and	CC
cord-014712-5u4e00q6	2099	8	developed	develop	VBD
cord-014712-5u4e00q6	2099	9	left	leave	VBN
cord-014712-5u4e00q6	2099	10	axillary	axillary	JJ
cord-014712-5u4e00q6	2099	11	lymphadenitis	lymphadenitis	NN
cord-014712-5u4e00q6	2099	12	which	which	WDT
cord-014712-5u4e00q6	2099	13	spontaneously	spontaneously	RB
cord-014712-5u4e00q6	2099	14	drained	drain	VBD
cord-014712-5u4e00q6	2099	15	and	and	CC
cord-014712-5u4e00q6	2099	16	had	have	VBD
cord-014712-5u4e00q6	2099	17	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2099	18	oral	oral	JJ
cord-014712-5u4e00q6	2099	19	monilia	monilia	JJ
cord-014712-5u4e00q6	2099	20	plaque	plaque	NN
cord-014712-5u4e00q6	2099	21	.	.	.
cord-014712-5u4e00q6	2100	1	Edema	edema	NN
cord-014712-5u4e00q6	2100	2	and	and	CC
cord-014712-5u4e00q6	2100	3	purpuric	purpuric	NNP
cord-014712-5u4e00q6	2100	4	eruptions	eruption	NNS
cord-014712-5u4e00q6	2100	5	were	be	VBD
cord-014712-5u4e00q6	2100	6	present	present	JJ
cord-014712-5u4e00q6	2100	7	on	on	IN
cord-014712-5u4e00q6	2100	8	the	the	DT
cord-014712-5u4e00q6	2100	9	upper	upper	JJ
cord-014712-5u4e00q6	2100	10	and	and	CC
cord-014712-5u4e00q6	2100	11	lower	low	JJR
cord-014712-5u4e00q6	2100	12	extremities	extremity	NNS
cord-014712-5u4e00q6	2100	13	and	and	CC
cord-014712-5u4e00q6	2100	14	the	the	DT
cord-014712-5u4e00q6	2100	15	abdomen	abdomen	NN
cord-014712-5u4e00q6	2100	16	.	.	.
cord-014712-5u4e00q6	2101	1	Multiple	multiple	JJ
cord-014712-5u4e00q6	2101	2	mobile	mobile	JJ
cord-014712-5u4e00q6	2101	3	,	,	,
cord-014712-5u4e00q6	2101	4	painful	painful	JJ
cord-014712-5u4e00q6	2101	5	,	,	,
cord-014712-5u4e00q6	2101	6	enlarged	enlarged	JJ
cord-014712-5u4e00q6	2101	7	submandibular	submandibular	JJ
cord-014712-5u4e00q6	2101	8	lymph	lymph	NN
cord-014712-5u4e00q6	2101	9	nodes	node	NNS
cord-014712-5u4e00q6	2101	10	of	of	IN
cord-014712-5u4e00q6	2101	11	about	about	RB
cord-014712-5u4e00q6	2101	12	2x2	2x2	CD
cord-014712-5u4e00q6	2101	13	cm	cm	NNS
cord-014712-5u4e00q6	2101	14	in	in	IN
cord-014712-5u4e00q6	2101	15	diameter	diameter	NN
cord-014712-5u4e00q6	2101	16	were	be	VBD
cord-014712-5u4e00q6	2101	17	palpable	palpable	JJ
cord-014712-5u4e00q6	2101	18	.	.	.
cord-014712-5u4e00q6	2102	1	Skin	skin	NN
cord-014712-5u4e00q6	2102	2	biopsy	biopsy	NN
cord-014712-5u4e00q6	2102	3	showed	show	VBD
cord-014712-5u4e00q6	2102	4	a	a	DT
cord-014712-5u4e00q6	2102	5	dense	dense	JJ
cord-014712-5u4e00q6	2102	6	inflammatory	inflammatory	JJ
cord-014712-5u4e00q6	2102	7	site	site	NN
cord-014712-5u4e00q6	2102	8	with	with	IN
cord-014712-5u4e00q6	2102	9	eosinophils	eosinophil	NNS
cord-014712-5u4e00q6	2102	10	,	,	,
cord-014712-5u4e00q6	2102	11	neutrophils	neutrophil	NNS
cord-014712-5u4e00q6	2102	12	and	and	CC
cord-014712-5u4e00q6	2102	13	fibrin	fibrin	NN
cord-014712-5u4e00q6	2102	14	in	in	IN
cord-014712-5u4e00q6	2102	15	the	the	DT
cord-014712-5u4e00q6	2102	16	upper	upper	JJ
cord-014712-5u4e00q6	2102	17	dermis	dermis	NN
cord-014712-5u4e00q6	2102	18	and	and	CC
cord-014712-5u4e00q6	2102	19	dermal	dermal	JJ
cord-014712-5u4e00q6	2102	20	vessel	vessel	NN
cord-014712-5u4e00q6	2102	21	wall	wall	NN
cord-014712-5u4e00q6	2102	22	,	,	,
cord-014712-5u4e00q6	2102	23	compatible	compatible	JJ
cord-014712-5u4e00q6	2102	24	with	with	IN
cord-014712-5u4e00q6	2102	25	leukocytoclastic	leukocytoclastic	JJ
cord-014712-5u4e00q6	2102	26	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2102	27	.	.	.
cord-014712-5u4e00q6	2103	1	Serological	serological	JJ
cord-014712-5u4e00q6	2103	2	studies	study	NNS
cord-014712-5u4e00q6	2103	3	to	to	TO
cord-014712-5u4e00q6	2103	4	assess	assess	VB
cord-014712-5u4e00q6	2103	5	diagnostic	diagnostic	JJ
cord-014712-5u4e00q6	2103	6	markers	marker	NNS
cord-014712-5u4e00q6	2103	7	for	for	IN
cord-014712-5u4e00q6	2103	8	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2103	9	and	and	CC
cord-014712-5u4e00q6	2103	10	infectious	infectious	JJ
cord-014712-5u4e00q6	2103	11	agents	agent	NNS
cord-014712-5u4e00q6	2103	12	were	be	VBD
cord-014712-5u4e00q6	2103	13	all	all	DT
cord-014712-5u4e00q6	2103	14	negative	negative	JJ
cord-014712-5u4e00q6	2103	15	.	.	.
cord-014712-5u4e00q6	2104	1	Immune	immune	JJ
cord-014712-5u4e00q6	2104	2	work	work	NN
cord-014712-5u4e00q6	2104	3	-	-	HYPH
cord-014712-5u4e00q6	2104	4	up	up	NN
cord-014712-5u4e00q6	2104	5	were	be	VBD
cord-014712-5u4e00q6	2104	6	unremarkable	unremarkable	JJ
cord-014712-5u4e00q6	2104	7	other	other	JJ
cord-014712-5u4e00q6	2104	8	than	than	IN
cord-014712-5u4e00q6	2104	9	hypergammaglobulinemia	hypergammaglobulinemia	NNP
cord-014712-5u4e00q6	2104	10	.	.	.
cord-014712-5u4e00q6	2105	1	Salmonella	salmonella	NN
cord-014712-5u4e00q6	2105	2	enteritidis	enteritidis	NN
cord-014712-5u4e00q6	2105	3	was	be	VBD
cord-014712-5u4e00q6	2105	4	identified	identify	VBN
cord-014712-5u4e00q6	2105	5	in	in	IN
cord-014712-5u4e00q6	2105	6	blood	blood	NN
cord-014712-5u4e00q6	2105	7	culture	culture	NN
cord-014712-5u4e00q6	2105	8	.	.	.
cord-014712-5u4e00q6	2106	1	She	-PRON-	PRP
cord-014712-5u4e00q6	2106	2	responded	respond	VBD
cord-014712-5u4e00q6	2106	3	dramatically	dramatically	RB
cord-014712-5u4e00q6	2106	4	to	to	IN
cord-014712-5u4e00q6	2106	5	ceftriaxone	ceftriaxone	NN
cord-014712-5u4e00q6	2106	6	treatment	treatment	NN
cord-014712-5u4e00q6	2106	7	within	within	IN
cord-014712-5u4e00q6	2106	8	a	a	DT
cord-014712-5u4e00q6	2106	9	few	few	JJ
cord-014712-5u4e00q6	2106	10	days	day	NNS
cord-014712-5u4e00q6	2106	11	and	and	CC
cord-014712-5u4e00q6	2106	12	lesions	lesion	NNS
cord-014712-5u4e00q6	2106	13	cleared	clear	VBD
cord-014712-5u4e00q6	2106	14	completely	completely	RB
cord-014712-5u4e00q6	2106	15	.	.	.
cord-014712-5u4e00q6	2107	1	Extended	extended	JJ
cord-014712-5u4e00q6	2107	2	immunological	immunological	JJ
cord-014712-5u4e00q6	2107	3	and	and	CC
cord-014712-5u4e00q6	2107	4	molecular	molecular	JJ
cord-014712-5u4e00q6	2107	5	genetic	genetic	JJ
cord-014712-5u4e00q6	2107	6	examination	examination	NN
cord-014712-5u4e00q6	2107	7	of	of	IN
cord-014712-5u4e00q6	2107	8	the	the	DT
cord-014712-5u4e00q6	2107	9	patient	patient	NN
cord-014712-5u4e00q6	2107	10	was	be	VBD
cord-014712-5u4e00q6	2107	11	carried	carry	VBN
cord-014712-5u4e00q6	2107	12	out	out	RP
cord-014712-5u4e00q6	2107	13	for	for	IN
cord-014712-5u4e00q6	2107	14	IL-12	IL-12	NNP
cord-014712-5u4e00q6	2107	15	/	/	SYM
cord-014712-5u4e00q6	2107	16	IFN	IFN	NNP
cord-014712-5u4e00q6	2107	17	-	-	HYPH
cord-014712-5u4e00q6	2107	18	γ	γ	NNP
cord-014712-5u4e00q6	2107	19	pathway	pathway	NN
cord-014712-5u4e00q6	2107	20	defects	defect	NNS
cord-014712-5u4e00q6	2107	21	.	.	.
cord-014712-5u4e00q6	2108	1	On	on	IN
cord-014712-5u4e00q6	2108	2	the	the	DT
cord-014712-5u4e00q6	2108	3	FACS	FACS	NNP
cord-014712-5u4e00q6	2108	4	analysis	analysis	NN
cord-014712-5u4e00q6	2108	5	of	of	IN
cord-014712-5u4e00q6	2108	6	T	T	NNP
cord-014712-5u4e00q6	2108	7	cells	cell	NNS
cord-014712-5u4e00q6	2108	8	for	for	IN
cord-014712-5u4e00q6	2108	9	cell	cell	NN
cord-014712-5u4e00q6	2108	10	surface	surface	NN
cord-014712-5u4e00q6	2108	11	expression	expression	NN
cord-014712-5u4e00q6	2108	12	of	of	IN
cord-014712-5u4e00q6	2108	13	the	the	DT
cord-014712-5u4e00q6	2108	14	cytokine	cytokine	NN
cord-014712-5u4e00q6	2108	15	receptor	receptor	NN
cord-014712-5u4e00q6	2108	16	chains	chain	NNS
cord-014712-5u4e00q6	2108	17	,	,	,
cord-014712-5u4e00q6	2108	18	she	-PRON-	PRP
cord-014712-5u4e00q6	2108	19	did	do	VBD
cord-014712-5u4e00q6	2108	20	not	not	RB
cord-014712-5u4e00q6	2108	21	express	express	VB
cord-014712-5u4e00q6	2108	22	any	any	DT
cord-014712-5u4e00q6	2108	23	IL-12Rβ1	il-12rβ1	NN
cord-014712-5u4e00q6	2108	24	.	.	.
cord-014712-5u4e00q6	2109	1	Discussion	discussion	NN
cord-014712-5u4e00q6	2109	2	:	:	:
cord-014712-5u4e00q6	2110	1	In	in	IN
cord-014712-5u4e00q6	2110	2	thepresent	thepresent	NN
cord-014712-5u4e00q6	2110	3	report	report	NN
cord-014712-5u4e00q6	2110	4	,	,	,
cord-014712-5u4e00q6	2110	5	we	-PRON-	PRP
cord-014712-5u4e00q6	2110	6	describe	describe	VBP
cord-014712-5u4e00q6	2110	7	a	a	DT
cord-014712-5u4e00q6	2110	8	child	child	NN
cord-014712-5u4e00q6	2110	9	with	with	IN
cord-014712-5u4e00q6	2110	10	CLV	CLV	NNP
cord-014712-5u4e00q6	2110	11	with	with	IN
cord-014712-5u4e00q6	2110	12	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2110	13	enteritidis	enteritidis	NN
cord-014712-5u4e00q6	2110	14	due	due	IN
cord-014712-5u4e00q6	2110	15	to	to	IN
cord-014712-5u4e00q6	2110	16	IL-12Rb1	IL-12Rb1	NNP
cord-014712-5u4e00q6	2110	17	defi	defi	NN
cord-014712-5u4e00q6	2110	18	-	-	HYPH
cord-014712-5u4e00q6	2110	19	ciency	ciency	NN
cord-014712-5u4e00q6	2110	20	.	.	.
cord-014712-5u4e00q6	2111	1	In	in	IN
cord-014712-5u4e00q6	2111	2	a	a	DT
cord-014712-5u4e00q6	2111	3	large	large	JJ
cord-014712-5u4e00q6	2111	4	cohort	cohort	NN
cord-014712-5u4e00q6	2111	5	of	of	IN
cord-014712-5u4e00q6	2111	6	patients	patient	NNS
cord-014712-5u4e00q6	2111	7	with	with	IN
cord-014712-5u4e00q6	2111	8	IL-12Rb1	IL-12Rb1	NNP
cord-014712-5u4e00q6	2111	9	deficiency	deficiency	NN
cord-014712-5u4e00q6	2111	10	,	,	,
cord-014712-5u4e00q6	2111	11	NTM	NTM	NNP
cord-014712-5u4e00q6	2111	12	,	,	,
cord-014712-5u4e00q6	2111	13	M.	M.	NNP
cord-014712-5u4e00q6	2111	14	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2111	15	,	,	,
cord-014712-5u4e00q6	2111	16	disseminated	disseminate	VBD
cord-014712-5u4e00q6	2111	17	BCG	BCG	NNP
cord-014712-5u4e00q6	2111	18	infection	infection	NN
cord-014712-5u4e00q6	2111	19	after	after	IN
cord-014712-5u4e00q6	2111	20	inoculation	inoculation	NN
cord-014712-5u4e00q6	2111	21	with	with	IN
cord-014712-5u4e00q6	2111	22	the	the	DT
cord-014712-5u4e00q6	2111	23	vaccine	vaccine	NN
cord-014712-5u4e00q6	2111	24	,	,	,
cord-014712-5u4e00q6	2111	25	and	and	CC
cord-014712-5u4e00q6	2111	26	salmonella	salmonella	NN
cord-014712-5u4e00q6	2111	27	infection	infection	NN
cord-014712-5u4e00q6	2111	28	have	have	VBP
cord-014712-5u4e00q6	2111	29	been	be	VBN
cord-014712-5u4e00q6	2111	30	described	describe	VBN
cord-014712-5u4e00q6	2111	31	.	.	.
cord-014712-5u4e00q6	2112	1	Sporadic	sporadic	JJ
cord-014712-5u4e00q6	2112	2	cases	case	NNS
cord-014712-5u4e00q6	2112	3	with	with	IN
cord-014712-5u4e00q6	2112	4	other	other	JJ
cord-014712-5u4e00q6	2112	5	infectious	infectious	JJ
cord-014712-5u4e00q6	2112	6	agents	agent	NNS
cord-014712-5u4e00q6	2112	7	have	have	VBP
cord-014712-5u4e00q6	2112	8	also	also	RB
cord-014712-5u4e00q6	2112	9	been	be	VBN
cord-014712-5u4e00q6	2112	10	reported	report	VBN
cord-014712-5u4e00q6	2112	11	.	.	.
cord-014712-5u4e00q6	2113	1	Salmonella	salmonella	NN
cord-014712-5u4e00q6	2113	2	infections	infection	NNS
cord-014712-5u4e00q6	2113	3	reported	report	VBN
cord-014712-5u4e00q6	2113	4	in	in	IN
cord-014712-5u4e00q6	2113	5	these	these	DT
cord-014712-5u4e00q6	2113	6	patients	patient	NNS
cord-014712-5u4e00q6	2113	7	were	be	VBD
cord-014712-5u4e00q6	2113	8	due	due	JJ
cord-014712-5u4e00q6	2113	9	to	to	IN
cord-014712-5u4e00q6	2113	10	extraintestinal	extraintestinal	JJ
cord-014712-5u4e00q6	2113	11	,	,	,
cord-014712-5u4e00q6	2113	12	or	or	CC
cord-014712-5u4e00q6	2113	13	septicemic	septicemic	NNP
cord-014712-5u4e00q6	2113	14	,	,	,
cord-014712-5u4e00q6	2113	15	recurring	recur	VBG
cord-014712-5u4e00q6	2113	16	infections	infection	NNS
cord-014712-5u4e00q6	2113	17	caused	cause	VBN
cord-014712-5u4e00q6	2113	18	by	by	IN
cord-014712-5u4e00q6	2113	19	nontyphoidal	nontyphoidal	NNP
cord-014712-5u4e00q6	2113	20	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2113	21	species	specie	NNS
cord-014712-5u4e00q6	2113	22	.	.	.
cord-014712-5u4e00q6	2114	1	Only	only	RB
cord-014712-5u4e00q6	2114	2	two	two	CD
cord-014712-5u4e00q6	2114	3	IL-12Rb1-deficient	IL-12Rb1-deficient	NNP
cord-014712-5u4e00q6	2114	4	patients	patient	NNS
cord-014712-5u4e00q6	2114	5	have	have	VBP
cord-014712-5u4e00q6	2114	6	been	be	VBN
cord-014712-5u4e00q6	2114	7	identified	identify	VBN
cord-014712-5u4e00q6	2114	8	with	with	IN
cord-014712-5u4e00q6	2114	9	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2114	10	due	due	IN
cord-014712-5u4e00q6	2114	11	to	to	IN
cord-014712-5u4e00q6	2114	12	salmonella	salmonella	NN
cord-014712-5u4e00q6	2114	13	strains	strain	NNS
cord-014712-5u4e00q6	2114	14	;	;	:
cord-014712-5u4e00q6	2114	15	both	both	DT
cord-014712-5u4e00q6	2114	16	came	come	VBD
cord-014712-5u4e00q6	2114	17	from	from	IN
cord-014712-5u4e00q6	2114	18	Turkey	Turkey	NNP
cord-014712-5u4e00q6	2114	19	,	,	,
cord-014712-5u4e00q6	2114	20	where	where	WRB
cord-014712-5u4e00q6	2114	21	consanguineous	consanguineous	JJ
cord-014712-5u4e00q6	2114	22	marriages	marriage	NNS
cord-014712-5u4e00q6	2114	23	are	be	VBP
cord-014712-5u4e00q6	2114	24	common	common	JJ
cord-014712-5u4e00q6	2114	25	.	.	.
cord-014712-5u4e00q6	2115	1	Kutukculer	Kutukculer	NNP
cord-014712-5u4e00q6	2115	2	and	and	CC
cord-014712-5u4e00q6	2115	3	colleagues	colleague	NNS
cord-014712-5u4e00q6	2115	4	reported	report	VBD
cord-014712-5u4e00q6	2115	5	the	the	DT
cord-014712-5u4e00q6	2115	6	first	first	JJ
cord-014712-5u4e00q6	2115	7	case	case	NN
cord-014712-5u4e00q6	2115	8	of	of	IN
cord-014712-5u4e00q6	2115	9	S.	S.	NNP
cord-014712-5u4e00q6	2115	10	enteritidis	enteritidis	NN
cord-014712-5u4e00q6	2115	11	-	-	HYPH
cord-014712-5u4e00q6	2115	12	associated	associate	VBN
cord-014712-5u4e00q6	2115	13	CLV	CLV	NNP
cord-014712-5u4e00q6	2115	14	.	.	.
cord-014712-5u4e00q6	2116	1	Sanal	Sanal	NNP
cord-014712-5u4e00q6	2116	2	and	and	CC
cord-014712-5u4e00q6	2116	3	colleagues	colleague	NNS
cord-014712-5u4e00q6	2116	4	reported	report	VBD
cord-014712-5u4e00q6	2116	5	a	a	DT
cord-014712-5u4e00q6	2116	6	CLV	CLV	NNP
cord-014712-5u4e00q6	2116	7	case	case	NN
cord-014712-5u4e00q6	2116	8	associated	associate	VBN
cord-014712-5u4e00q6	2116	9	with	with	IN
cord-014712-5u4e00q6	2116	10	group	group	NN
cord-014712-5u4e00q6	2116	11	D	D	NNP
cord-014712-5u4e00q6	2116	12	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2116	13	infection	infection	NN
cord-014712-5u4e00q6	2116	14	.	.	.
cord-014712-5u4e00q6	2117	1	Leukocytoclastic	leukocytoclastic	JJ
cord-014712-5u4e00q6	2117	2	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2117	3	is	be	VBZ
cord-014712-5u4e00q6	2117	4	an	an	DT
cord-014712-5u4e00q6	2117	5	immune	immune	JJ
cord-014712-5u4e00q6	2117	6	complex	complex	NN
cord-014712-5u4e00q6	2117	7	mediated	mediate	VBN
cord-014712-5u4e00q6	2117	8	disease	disease	NN
cord-014712-5u4e00q6	2117	9	predominantly	predominantly	RB
cord-014712-5u4e00q6	2117	10	involving	involve	VBG
cord-014712-5u4e00q6	2117	11	small	small	JJ
cord-014712-5u4e00q6	2117	12	vessels	vessel	NNS
cord-014712-5u4e00q6	2117	13	of	of	IN
cord-014712-5u4e00q6	2117	14	the	the	DT
cord-014712-5u4e00q6	2117	15	skin	skin	NN
cord-014712-5u4e00q6	2117	16	and	and	CC
cord-014712-5u4e00q6	2117	17	can	can	MD
cord-014712-5u4e00q6	2117	18	be	be	VB
cord-014712-5u4e00q6	2117	19	associated	associate	VBN
cord-014712-5u4e00q6	2117	20	with	with	IN
cord-014712-5u4e00q6	2117	21	drugs	drug	NNS
cord-014712-5u4e00q6	2117	22	or	or	CC
cord-014712-5u4e00q6	2117	23	can	can	MD
cord-014712-5u4e00q6	2117	24	be	be	VB
cord-014712-5u4e00q6	2117	25	found	find	VBN
cord-014712-5u4e00q6	2117	26	as	as	IN
cord-014712-5u4e00q6	2117	27	a	a	DT
cord-014712-5u4e00q6	2117	28	component	component	NN
cord-014712-5u4e00q6	2117	29	of	of	IN
cord-014712-5u4e00q6	2117	30	other	other	JJ
cord-014712-5u4e00q6	2117	31	disease	disease	NN
cord-014712-5u4e00q6	2117	32	,	,	,
cord-014712-5u4e00q6	2117	33	such	such	JJ
cord-014712-5u4e00q6	2117	34	as	as	IN
cord-014712-5u4e00q6	2117	35	infections	infection	NNS
cord-014712-5u4e00q6	2117	36	,	,	,
cord-014712-5u4e00q6	2117	37	connective	connective	JJ
cord-014712-5u4e00q6	2117	38	tissue	tissue	NN
cord-014712-5u4e00q6	2117	39	disorders	disorder	NNS
cord-014712-5u4e00q6	2117	40	,	,	,
cord-014712-5u4e00q6	2117	41	and	and	CC
cord-014712-5u4e00q6	2117	42	malignancies	malignancy	NNS
cord-014712-5u4e00q6	2117	43	.	.	.
cord-014712-5u4e00q6	2118	1	Infectious	infectious	JJ
cord-014712-5u4e00q6	2118	2	agents	agent	NNS
cord-014712-5u4e00q6	2118	3	can	can	MD
cord-014712-5u4e00q6	2118	4	cause	cause	VB
cord-014712-5u4e00q6	2118	5	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2118	6	directly	directly	RB
cord-014712-5u4e00q6	2118	7	or	or	CC
cord-014712-5u4e00q6	2118	8	clinically	clinically	RB
cord-014712-5u4e00q6	2118	9	mimic	mimic	VB
cord-014712-5u4e00q6	2118	10	primary	primary	JJ
cord-014712-5u4e00q6	2118	11	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2118	12	.Multiple	.Multiple	.
cord-014712-5u4e00q6	2118	13	infectious	infectious	JJ
cord-014712-5u4e00q6	2118	14	agents	agent	NNS
cord-014712-5u4e00q6	2118	15	have	have	VBP
cord-014712-5u4e00q6	2118	16	been	be	VBN
cord-014712-5u4e00q6	2118	17	suspected	suspect	VBN
cord-014712-5u4e00q6	2118	18	as	as	IN
cord-014712-5u4e00q6	2118	19	triggering	trigger	VBG
cord-014712-5u4e00q6	2118	20	or	or	CC
cord-014712-5u4e00q6	2118	21	contributory	contributory	JJ
cord-014712-5u4e00q6	2118	22	factors	factor	NNS
cord-014712-5u4e00q6	2118	23	in	in	IN
cord-014712-5u4e00q6	2118	24	the	the	DT
cord-014712-5u4e00q6	2118	25	vasculitic	vasculitic	JJ
cord-014712-5u4e00q6	2118	26	process	process	NN
cord-014712-5u4e00q6	2118	27	.	.	.
cord-014712-5u4e00q6	2119	1	Several	several	JJ
cord-014712-5u4e00q6	2119	2	factors	factor	NNS
cord-014712-5u4e00q6	2119	3	contribute	contribute	VBP
cord-014712-5u4e00q6	2119	4	to	to	IN
cord-014712-5u4e00q6	2119	5	the	the	DT
cord-014712-5u4e00q6	2119	6	primary	primary	JJ
cord-014712-5u4e00q6	2119	7	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2119	8	related	relate	VBN
cord-014712-5u4e00q6	2119	9	to	to	IN
cord-014712-5u4e00q6	2119	10	infections	infection	NNS
cord-014712-5u4e00q6	2119	11	:	:	:
cord-014712-5u4e00q6	2119	12	a	a	DT
cord-014712-5u4e00q6	2119	13	type	type	NN
cord-014712-5u4e00q6	2119	14	3	3	CD
cord-014712-5u4e00q6	2119	15	or	or	CC
cord-014712-5u4e00q6	2119	16	immune	immune	JJ
cord-014712-5u4e00q6	2119	17	-	-	HYPH
cord-014712-5u4e00q6	2119	18	complex	complex	JJ
cord-014712-5u4e00q6	2119	19	reaction	reaction	NN
cord-014712-5u4e00q6	2119	20	,	,	,
cord-014712-5u4e00q6	2119	21	cell	cell	NN
cord-014712-5u4e00q6	2119	22	-	-	HYPH
cord-014712-5u4e00q6	2119	23	mediated	mediate	VBN
cord-014712-5u4e00q6	2119	24	hypersensitivity	hypersensitivity	NN
cord-014712-5u4e00q6	2119	25	,	,	,
cord-014712-5u4e00q6	2119	26	abnormal	abnormal	JJ
cord-014712-5u4e00q6	2119	27	immune	immune	JJ
cord-014712-5u4e00q6	2119	28	regulation	regulation	NN
cord-014712-5u4e00q6	2119	29	,	,	,
cord-014712-5u4e00q6	2119	30	and	and	CC
cord-014712-5u4e00q6	2119	31	direct	direct	JJ
cord-014712-5u4e00q6	2119	32	endothelial	endothelial	JJ
cord-014712-5u4e00q6	2119	33	cell	cell	NN
cord-014712-5u4e00q6	2119	34	invasion	invasion	NN
cord-014712-5u4e00q6	2119	35	by	by	IN
cord-014712-5u4e00q6	2119	36	infectious	infectious	JJ
cord-014712-5u4e00q6	2119	37	agents	agent	NNS
cord-014712-5u4e00q6	2119	38	.	.	.
cord-014712-5u4e00q6	2120	1	In	in	IN
cord-014712-5u4e00q6	2120	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	2120	3	case	case	NN
cord-014712-5u4e00q6	2120	4	,	,	,
cord-014712-5u4e00q6	2120	5	extensive	extensive	JJ
cord-014712-5u4e00q6	2120	6	evaluation	evaluation	NN
cord-014712-5u4e00q6	2120	7	was	be	VBD
cord-014712-5u4e00q6	2120	8	performed	perform	VBN
cord-014712-5u4e00q6	2120	9	to	to	TO
cord-014712-5u4e00q6	2120	10	determine	determine	VB
cord-014712-5u4e00q6	2120	11	the	the	DT
cord-014712-5u4e00q6	2120	12	underlying	underlying	JJ
cord-014712-5u4e00q6	2120	13	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2120	14	process	process	NN
cord-014712-5u4e00q6	2120	15	.	.	.
cord-014712-5u4e00q6	2121	1	Clinical	clinical	JJ
cord-014712-5u4e00q6	2121	2	and	and	CC
cord-014712-5u4e00q6	2121	3	laboratory	laboratory	NN
cord-014712-5u4e00q6	2121	4	examinations	examination	NNS
cord-014712-5u4e00q6	2121	5	revealed	reveal	VBD
cord-014712-5u4e00q6	2121	6	no	no	DT
cord-014712-5u4e00q6	2121	7	association	association	NN
cord-014712-5u4e00q6	2121	8	between	between	IN
cord-014712-5u4e00q6	2121	9	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2121	10	and	and	CC
cord-014712-5u4e00q6	2121	11	other	other	JJ
cord-014712-5u4e00q6	2121	12	infections	infection	NNS
cord-014712-5u4e00q6	2121	13	or	or	CC
cord-014712-5u4e00q6	2121	14	an	an	DT
cord-014712-5u4e00q6	2121	15	underlying	underlying	JJ
cord-014712-5u4e00q6	2121	16	connective	connective	JJ
cord-014712-5u4e00q6	2121	17	tissue	tissue	NN
cord-014712-5u4e00q6	2121	18	disease	disease	NN
cord-014712-5u4e00q6	2121	19	or	or	CC
cord-014712-5u4e00q6	2121	20	medication	medication	NN
cord-014712-5u4e00q6	2121	21	.	.	.
cord-014712-5u4e00q6	2122	1	She	-PRON-	PRP
cord-014712-5u4e00q6	2122	2	responded	respond	VBD
cord-014712-5u4e00q6	2122	3	well	well	RB
cord-014712-5u4e00q6	2122	4	to	to	IN
cord-014712-5u4e00q6	2122	5	ceftriaxone	ceftriaxone	NN
cord-014712-5u4e00q6	2122	6	treatment	treatment	NN
cord-014712-5u4e00q6	2122	7	,	,	,
cord-014712-5u4e00q6	2122	8	and	and	CC
cord-014712-5u4e00q6	2122	9	clinical	clinical	JJ
cord-014712-5u4e00q6	2122	10	manifestations	manifestation	NNS
cord-014712-5u4e00q6	2122	11	gradually	gradually	RB
cord-014712-5u4e00q6	2122	12	resolved	resolve	VBN
cord-014712-5u4e00q6	2122	13	within	within	IN
cord-014712-5u4e00q6	2122	14	a	a	DT
cord-014712-5u4e00q6	2122	15	few	few	JJ
cord-014712-5u4e00q6	2122	16	days	day	NNS
cord-014712-5u4e00q6	2122	17	,	,	,
cord-014712-5u4e00q6	2122	18	providing	provide	VBG
cord-014712-5u4e00q6	2122	19	strong	strong	JJ
cord-014712-5u4e00q6	2122	20	evidence	evidence	NN
cord-014712-5u4e00q6	2122	21	that	that	IN
cord-014712-5u4e00q6	2122	22	improvement	improvement	NN
cord-014712-5u4e00q6	2122	23	of	of	IN
cord-014712-5u4e00q6	2122	24	the	the	DT
cord-014712-5u4e00q6	2122	25	vasculitic	vasculitic	JJ
cord-014712-5u4e00q6	2122	26	lesions	lesion	NNS
cord-014712-5u4e00q6	2122	27	was	be	VBD
cord-014712-5u4e00q6	2122	28	due	due	JJ
cord-014712-5u4e00q6	2122	29	to	to	IN
cord-014712-5u4e00q6	2122	30	elimination	elimination	NN
cord-014712-5u4e00q6	2122	31	of	of	IN
cord-014712-5u4e00q6	2122	32	the	the	DT
cord-014712-5u4e00q6	2122	33	salmonella	salmonella	NN
cord-014712-5u4e00q6	2122	34	with	with	IN
cord-014712-5u4e00q6	2122	35	antibiotics	antibiotic	NNS
cord-014712-5u4e00q6	2122	36	Conclusion	conclusion	NN
cord-014712-5u4e00q6	2122	37	:	:	:
cord-014712-5u4e00q6	2122	38	Our	-PRON-	PRP$
cord-014712-5u4e00q6	2122	39	patient	patient	NN
cord-014712-5u4e00q6	2122	40	has	have	VBZ
cord-014712-5u4e00q6	2122	41	one	one	CD
cord-014712-5u4e00q6	2122	42	of	of	IN
cord-014712-5u4e00q6	2122	43	the	the	DT
cord-014712-5u4e00q6	2122	44	exceptional	exceptional	JJ
cord-014712-5u4e00q6	2122	45	forms	form	NNS
cord-014712-5u4e00q6	2122	46	of	of	IN
cord-014712-5u4e00q6	2122	47	IL-12Rb1	IL-12Rb1	NNS
cord-014712-5u4e00q6	2122	48	deficiency	deficiency	NN
cord-014712-5u4e00q6	2122	49	,	,	,
cord-014712-5u4e00q6	2122	50	with	with	IN
cord-014712-5u4e00q6	2122	51	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2122	52	CLV	CLV	NNP
cord-014712-5u4e00q6	2122	53	due	due	IN
cord-014712-5u4e00q6	2122	54	to	to	IN
cord-014712-5u4e00q6	2122	55	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2122	56	enteritidis	enteritidis	NN
cord-014712-5u4e00q6	2122	57	.	.	.
cord-014712-5u4e00q6	2123	1	Although	although	IN
cord-014712-5u4e00q6	2123	2	common	common	JJ
cord-014712-5u4e00q6	2123	3	presentations	presentation	NNS
cord-014712-5u4e00q6	2123	4	for	for	IN
cord-014712-5u4e00q6	2123	5	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2123	6	infection	infection	NN
cord-014712-5u4e00q6	2123	7	in	in	IN
cord-014712-5u4e00q6	2123	8	individuals	individual	NNS
cord-014712-5u4e00q6	2123	9	with	with	IN
cord-014712-5u4e00q6	2123	10	IL-12Rb1	IL-12Rb1	NNP
cord-014712-5u4e00q6	2123	11	deficiency	deficiency	NN
cord-014712-5u4e00q6	2123	12	are	be	VBP
cord-014712-5u4e00q6	2123	13	lymphadenopathy	lymphadenopathy	JJ
cord-014712-5u4e00q6	2123	14	and	and	CC
cord-014712-5u4e00q6	2123	15	bacteremia	bacteremia	NN
cord-014712-5u4e00q6	2123	16	,	,	,
cord-014712-5u4e00q6	2123	17	it	-PRON-	PRP
cord-014712-5u4e00q6	2123	18	can	can	MD
cord-014712-5u4e00q6	2123	19	be	be	VB
cord-014712-5u4e00q6	2123	20	present	present	JJ
cord-014712-5u4e00q6	2123	21	clinically	clinically	RB
cord-014712-5u4e00q6	2123	22	as	as	IN
cord-014712-5u4e00q6	2123	23	CLV	CLV	NNP
cord-014712-5u4e00q6	2123	24	.	.	.
cord-014712-5u4e00q6	2124	1	Some	some	DT
cord-014712-5u4e00q6	2124	2	infections	infection	NNS
cord-014712-5u4e00q6	2124	3	such	such	JJ
cord-014712-5u4e00q6	2124	4	as	as	IN
cord-014712-5u4e00q6	2124	5	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2124	6	may	may	MD
cord-014712-5u4e00q6	2124	7	be	be	VB
cord-014712-5u4e00q6	2124	8	responsible	responsible	JJ
cord-014712-5u4e00q6	2124	9	for	for	IN
cord-014712-5u4e00q6	2124	10	different	different	JJ
cord-014712-5u4e00q6	2124	11	types	type	NNS
cord-014712-5u4e00q6	2124	12	of	of	IN
cord-014712-5u4e00q6	2124	13	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2124	14	even	even	RB
cord-014712-5u4e00q6	2124	15	though	though	IN
cord-014712-5u4e00q6	2124	16	they	-PRON-	PRP
cord-014712-5u4e00q6	2124	17	are	be	VBP
cord-014712-5u4e00q6	2124	18	not	not	RB
cord-014712-5u4e00q6	2124	19	common	common	JJ
cord-014712-5u4e00q6	2124	20	.	.	.
cord-014712-5u4e00q6	2125	1	In	in	IN
cord-014712-5u4e00q6	2125	2	this	this	DT
cord-014712-5u4e00q6	2125	3	respect	respect	NN
cord-014712-5u4e00q6	2125	4	,	,	,
cord-014712-5u4e00q6	2125	5	clinicians	clinician	NNS
cord-014712-5u4e00q6	2125	6	should	should	MD
cord-014712-5u4e00q6	2125	7	be	be	VB
cord-014712-5u4e00q6	2125	8	aware	aware	JJ
cord-014712-5u4e00q6	2125	9	of	of	IN
cord-014712-5u4e00q6	2125	10	possible	possible	JJ
cord-014712-5u4e00q6	2125	11	infectious	infectious	JJ
cord-014712-5u4e00q6	2125	12	causes	cause	NNS
cord-014712-5u4e00q6	2125	13	of	of	IN
cord-014712-5u4e00q6	2125	14	vasculitis	vasculitis	NN
cord-014712-5u4e00q6	2125	15	,	,	,
cord-014712-5u4e00q6	2125	16	and	and	CC
cord-014712-5u4e00q6	2125	17	children	child	NNS
cord-014712-5u4e00q6	2125	18	presenting	present	VBG
cord-014712-5u4e00q6	2125	19	with	with	IN
cord-014712-5u4e00q6	2125	20	unusual	unusual	JJ
cord-014712-5u4e00q6	2125	21	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2125	22	infections	infection	NNS
cord-014712-5u4e00q6	2125	23	caused	cause	VBN
cord-014712-5u4e00q6	2125	24	by	by	IN
cord-014712-5u4e00q6	2125	25	non	non	JJ
cord-014712-5u4e00q6	2125	26	typhoidal	typhoidal	NNP
cord-014712-5u4e00q6	2125	27	Salmonella	Salmonella	NNP
cord-014712-5u4e00q6	2125	28	,	,	,
cord-014712-5u4e00q6	2125	29	BCG	BCG	NNP
cord-014712-5u4e00q6	2125	30	,	,	,
cord-014712-5u4e00q6	2125	31	or	or	CC
cord-014712-5u4e00q6	2125	32	NTM	NTM	NNP
cord-014712-5u4e00q6	2125	33	should	should	MD
cord-014712-5u4e00q6	2125	34	be	be	VB
cord-014712-5u4e00q6	2125	35	investigated	investigate	VBN
cord-014712-5u4e00q6	2125	36	for	for	IN
cord-014712-5u4e00q6	2125	37	IFN	IFN	NNP
cord-014712-5u4e00q6	2125	38	-	-	HYPH
cord-014712-5u4e00q6	2125	39	γ	γ	NN
cord-014712-5u4e00q6	2125	40	⁄	⁄	NN
cord-014712-5u4e00q6	2125	41	IL-12	IL-12	NNP
cord-014712-5u4e00q6	2125	42	pathway	pathway	NN
cord-014712-5u4e00q6	2125	43	defects	defect	NNS
cord-014712-5u4e00q6	2125	44	.	.	.
cord-014712-5u4e00q6	2126	1	Gülez	Gülez	NNP
cord-014712-5u4e00q6	2126	2	N.	N.	NNP
cord-014712-5u4e00q6	2126	3	;	;	:
cord-014712-5u4e00q6	2126	4	Genel	Genel	NNP
cord-014712-5u4e00q6	2126	5	F.	F.	NNP
cord-014712-5u4e00q6	2127	1	Dr.	Dr.	NNP
cord-014712-5u4e00q6	2127	2	Behcet	Behcet	NNP
cord-014712-5u4e00q6	2127	3	Uz	Uz	NNP
cord-014712-5u4e00q6	2127	4	Children	Children	NNP
cord-014712-5u4e00q6	2127	5	Hospital	Hospital	NNP
cord-014712-5u4e00q6	2127	6	Allergy	Allergy	NNP
cord-014712-5u4e00q6	2127	7	-	-	HYPH
cord-014712-5u4e00q6	2127	8	Immunology	Immunology	NNP
cord-014712-5u4e00q6	2127	9	Department	Department	NNP
cord-014712-5u4e00q6	2127	10	,	,	,
cord-014712-5u4e00q6	2127	11	Izmir	Izmir	NNP
cord-014712-5u4e00q6	2127	12	,	,	,
cord-014712-5u4e00q6	2127	13	Turkiye	Turkiye	NNP
cord-014712-5u4e00q6	2128	1	The	the	DT
cord-014712-5u4e00q6	2128	2	complement	complement	NN
cord-014712-5u4e00q6	2128	3	system	system	NN
cord-014712-5u4e00q6	2128	4	is	be	VBZ
cord-014712-5u4e00q6	2128	5	an	an	DT
cord-014712-5u4e00q6	2128	6	important	important	JJ
cord-014712-5u4e00q6	2128	7	part	part	NN
cord-014712-5u4e00q6	2128	8	of	of	IN
cord-014712-5u4e00q6	2128	9	the	the	DT
cord-014712-5u4e00q6	2128	10	innate	innate	JJ
cord-014712-5u4e00q6	2128	11	immune	immune	JJ
cord-014712-5u4e00q6	2128	12	defense	defense	NN
cord-014712-5u4e00q6	2128	13	and	and	CC
cord-014712-5u4e00q6	2128	14	also	also	RB
cord-014712-5u4e00q6	2128	15	plays	play	VBZ
cord-014712-5u4e00q6	2128	16	a	a	DT
cord-014712-5u4e00q6	2128	17	major	major	JJ
cord-014712-5u4e00q6	2128	18	role	role	NN
cord-014712-5u4e00q6	2128	19	in	in	IN
cord-014712-5u4e00q6	2128	20	shaping	shape	VBG
cord-014712-5u4e00q6	2128	21	the	the	DT
cord-014712-5u4e00q6	2128	22	adaptive	adaptive	JJ
cord-014712-5u4e00q6	2128	23	immune	immune	JJ
cord-014712-5u4e00q6	2128	24	response	response	NN
cord-014712-5u4e00q6	2128	25	.	.	.
cord-014712-5u4e00q6	2129	1	These	these	DT
cord-014712-5u4e00q6	2129	2	functions	function	NNS
cord-014712-5u4e00q6	2129	3	are	be	VBP
cord-014712-5u4e00q6	2129	4	required	require	VBN
cord-014712-5u4e00q6	2129	5	for	for	IN
cord-014712-5u4e00q6	2129	6	a	a	DT
cord-014712-5u4e00q6	2129	7	good	good	JJ
cord-014712-5u4e00q6	2129	8	defense	defense	NN
cord-014712-5u4e00q6	2129	9	against	against	IN
cord-014712-5u4e00q6	2129	10	infections	infection	NNS
cord-014712-5u4e00q6	2129	11	,	,	,
cord-014712-5u4e00q6	2129	12	especially	especially	RB
cord-014712-5u4e00q6	2129	13	bacteria	bacteria	NNS
cord-014712-5u4e00q6	2129	14	.	.	.
cord-014712-5u4e00q6	2130	1	The	the	DT
cord-014712-5u4e00q6	2130	2	C8	c8	NN
cord-014712-5u4e00q6	2130	3	deficiency	deficiency	NN
cord-014712-5u4e00q6	2130	4	is	be	VBZ
cord-014712-5u4e00q6	2130	5	a	a	DT
cord-014712-5u4e00q6	2130	6	rare	rare	JJ
cord-014712-5u4e00q6	2130	7	disease	disease	NN
cord-014712-5u4e00q6	2130	8	that	that	WDT
cord-014712-5u4e00q6	2130	9	is	be	VBZ
cord-014712-5u4e00q6	2130	10	associated	associate	VBN
cord-014712-5u4e00q6	2130	11	with	with	IN
cord-014712-5u4e00q6	2130	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2130	13	neisserial	neisserial	JJ
cord-014712-5u4e00q6	2130	14	infections	infection	NNS
cord-014712-5u4e00q6	2130	15	,	,	,
cord-014712-5u4e00q6	2130	16	especially	especially	RB
cord-014712-5u4e00q6	2130	17	meningits	meningit	NNS
cord-014712-5u4e00q6	2130	18	caused	cause	VBN
cord-014712-5u4e00q6	2130	19	by	by	IN
cord-014712-5u4e00q6	2130	20	N.	N.	NNP
cord-014712-5u4e00q6	2130	21	meningitidis	meningitidis	NNP
cord-014712-5u4e00q6	2130	22	.	.	.
cord-014712-5u4e00q6	2131	1	The	the	DT
cord-014712-5u4e00q6	2131	2	patient	patient	NN
cord-014712-5u4e00q6	2131	3	,	,	,
cord-014712-5u4e00q6	2131	4	a	a	DT
cord-014712-5u4e00q6	2131	5	seven	seven	CD
cord-014712-5u4e00q6	2131	6	years	year	NNS
cord-014712-5u4e00q6	2131	7	old	old	JJ
cord-014712-5u4e00q6	2131	8	girl	girl	NN
cord-014712-5u4e00q6	2131	9	was	be	VBD
cord-014712-5u4e00q6	2131	10	admitted	admit	VBN
cord-014712-5u4e00q6	2131	11	to	to	IN
cord-014712-5u4e00q6	2131	12	hospital	hospital	NN
cord-014712-5u4e00q6	2131	13	with	with	IN
cord-014712-5u4e00q6	2131	14	high	high	JJ
cord-014712-5u4e00q6	2131	15	fever	fever	NN
cord-014712-5u4e00q6	2131	16	and	and	CC
cord-014712-5u4e00q6	2131	17	diffuse	diffuse	JJ
cord-014712-5u4e00q6	2131	18	,	,	,
cord-014712-5u4e00q6	2131	19	purple	purple	JJ
cord-014712-5u4e00q6	2131	20	-	-	HYPH
cord-014712-5u4e00q6	2131	21	coloured	coloured	JJ
cord-014712-5u4e00q6	2131	22	skin	skin	NN
cord-014712-5u4e00q6	2131	23	lesions	lesion	NNS
cord-014712-5u4e00q6	2131	24	.	.	.
cord-014712-5u4e00q6	2132	1	Her	-PRON-	PRP$
cord-014712-5u4e00q6	2132	2	symptoms	symptom	NNS
cord-014712-5u4e00q6	2132	3	gave	give	VBD
cord-014712-5u4e00q6	2132	4	the	the	DT
cord-014712-5u4e00q6	2132	5	diagnosise	diagnosise	NN
cord-014712-5u4e00q6	2132	6	meningococcal	meningococcal	JJ
cord-014712-5u4e00q6	2132	7	meningitis	meningitis	NN
cord-014712-5u4e00q6	2132	8	.	.	.
cord-014712-5u4e00q6	2133	1	She	-PRON-	PRP
cord-014712-5u4e00q6	2133	2	had	have	VBD
cord-014712-5u4e00q6	2133	3	also	also	RB
cord-014712-5u4e00q6	2133	4	earlier	early	RBR
cord-014712-5u4e00q6	2133	5	been	be	VBN
cord-014712-5u4e00q6	2133	6	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2133	7	with	with	IN
cord-014712-5u4e00q6	2133	8	the	the	DT
cord-014712-5u4e00q6	2133	9	same	same	JJ
cord-014712-5u4e00q6	2133	10	disease	disease	NN
cord-014712-5u4e00q6	2133	11	when	when	WRB
cord-014712-5u4e00q6	2133	12	she	-PRON-	PRP
cord-014712-5u4e00q6	2133	13	was	be	VBD
cord-014712-5u4e00q6	2133	14	5	5	CD
cord-014712-5u4e00q6	2133	15	years	year	NNS
cord-014712-5u4e00q6	2133	16	old	old	JJ
cord-014712-5u4e00q6	2133	17	.	.	.
cord-014712-5u4e00q6	2134	1	A	a	DT
cord-014712-5u4e00q6	2134	2	sister	sister	NN
cord-014712-5u4e00q6	2134	3	to	to	IN
cord-014712-5u4e00q6	2134	4	the	the	DT
cord-014712-5u4e00q6	2134	5	patient	patient	NN
cord-014712-5u4e00q6	2134	6	had	have	VBD
cord-014712-5u4e00q6	2134	7	died	die	VBN
cord-014712-5u4e00q6	2134	8	from	from	IN
cord-014712-5u4e00q6	2134	9	meningitis	meningitis	NN
cord-014712-5u4e00q6	2134	10	at	at	IN
cord-014712-5u4e00q6	2134	11	3	3	CD
cord-014712-5u4e00q6	2134	12	years	year	NNS
cord-014712-5u4e00q6	2134	13	of	of	IN
cord-014712-5u4e00q6	2134	14	age	age	NN
cord-014712-5u4e00q6	2134	15	.	.	.
cord-014712-5u4e00q6	2135	1	She	-PRON-	PRP
cord-014712-5u4e00q6	2135	2	has	have	VBZ
cord-014712-5u4e00q6	2135	3	also	also	RB
cord-014712-5u4e00q6	2135	4	one	one	CD
cord-014712-5u4e00q6	2135	5	older	old	JJR
cord-014712-5u4e00q6	2135	6	and	and	CC
cord-014712-5u4e00q6	2135	7	one	one	CD
cord-014712-5u4e00q6	2135	8	younger	young	JJR
cord-014712-5u4e00q6	2135	9	sister	sister	NN
cord-014712-5u4e00q6	2135	10	.	.	.
cord-014712-5u4e00q6	2136	1	There	there	EX
cord-014712-5u4e00q6	2136	2	is	be	VBZ
cord-014712-5u4e00q6	2136	3	no	no	DT
cord-014712-5u4e00q6	2136	4	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	2136	5	between	between	IN
cord-014712-5u4e00q6	2136	6	her	-PRON-	PRP$
cord-014712-5u4e00q6	2136	7	parents	parent	NNS
cord-014712-5u4e00q6	2136	8	.	.	.
cord-014712-5u4e00q6	2137	1	The	the	DT
cord-014712-5u4e00q6	2137	2	laboratory	laboratory	NN
cord-014712-5u4e00q6	2137	3	analyses	analysis	NNS
cord-014712-5u4e00q6	2137	4	of	of	IN
cord-014712-5u4e00q6	2137	5	the	the	DT
cord-014712-5u4e00q6	2137	6	classical	classical	JJ
cord-014712-5u4e00q6	2137	7	pathway	pathway	NN
cord-014712-5u4e00q6	2137	8	measured	measure	VBN
cord-014712-5u4e00q6	2137	9	as	as	IN
cord-014712-5u4e00q6	2137	10	complement	complement	JJ
cord-014712-5u4e00q6	2137	11	hemolytic	hemolytic	JJ
cord-014712-5u4e00q6	2137	12	activity	activity	NN
cord-014712-5u4e00q6	2137	13	(	(	-LRB-
cord-014712-5u4e00q6	2137	14	CH50	CH50	NNP
cord-014712-5u4e00q6	2137	15	)	)	-RRB-
cord-014712-5u4e00q6	2137	16	and	and	CC
cord-014712-5u4e00q6	2138	1	C8	c8	NN
cord-014712-5u4e00q6	2138	2	concentration	concentration	NN
cord-014712-5u4e00q6	2138	3	revealed	reveal	VBD
cord-014712-5u4e00q6	2138	4	no	no	DT
cord-014712-5u4e00q6	2138	5	activity	activity	NN
cord-014712-5u4e00q6	2138	6	and	and	CC
cord-014712-5u4e00q6	2138	7	absence	absence	NN
cord-014712-5u4e00q6	2138	8	of	of	IN
cord-014712-5u4e00q6	2138	9	C8	c8	NN
cord-014712-5u4e00q6	2138	10	,	,	,
cord-014712-5u4e00q6	2138	11	respectively	respectively	RB
cord-014712-5u4e00q6	2138	12	.	.	.
cord-014712-5u4e00q6	2139	1	Analysis	analysis	NN
cord-014712-5u4e00q6	2139	2	of	of	IN
cord-014712-5u4e00q6	2139	3	serum	serum	NN
cord-014712-5u4e00q6	2139	4	from	from	IN
cord-014712-5u4e00q6	2139	5	her	-PRON-	PRP$
cord-014712-5u4e00q6	2139	6	younger	young	JJR
cord-014712-5u4e00q6	2139	7	sister	sister	NN
cord-014712-5u4e00q6	2139	8	showed	show	VBD
cord-014712-5u4e00q6	2139	9	the	the	DT
cord-014712-5u4e00q6	2139	10	same	same	JJ
cord-014712-5u4e00q6	2139	11	results	result	NNS
cord-014712-5u4e00q6	2139	12	,	,	,
cord-014712-5u4e00q6	2139	13	while	while	IN
cord-014712-5u4e00q6	2139	14	her	-PRON-	PRP$
cord-014712-5u4e00q6	2139	15	older	old	JJR
cord-014712-5u4e00q6	2139	16	sister	sister	NN
cord-014712-5u4e00q6	2139	17	's	's	POS
cord-014712-5u4e00q6	2139	18	CH50	CH50	NNP
cord-014712-5u4e00q6	2139	19	and	and	CC
cord-014712-5u4e00q6	2139	20	C8	c8	NN
cord-014712-5u4e00q6	2139	21	levels	level	NNS
cord-014712-5u4e00q6	2139	22	were	be	VBD
cord-014712-5u4e00q6	2139	23	found	find	VBN
cord-014712-5u4e00q6	2139	24	normal	normal	JJ
cord-014712-5u4e00q6	2139	25	.	.	.
cord-014712-5u4e00q6	2140	1	Thus	thus	RB
cord-014712-5u4e00q6	2140	2	,	,	,
cord-014712-5u4e00q6	2140	3	our	-PRON-	PRP$
cord-014712-5u4e00q6	2140	4	patient	patient	NN
cord-014712-5u4e00q6	2140	5	and	and	CC
cord-014712-5u4e00q6	2140	6	her	-PRON-	PRP$
cord-014712-5u4e00q6	2140	7	younger	young	JJR
cord-014712-5u4e00q6	2140	8	sister	sister	NN
cord-014712-5u4e00q6	2140	9	were	be	VBD
cord-014712-5u4e00q6	2140	10	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2140	11	with	with	IN
cord-014712-5u4e00q6	2140	12	hereditary	hereditary	JJ
cord-014712-5u4e00q6	2140	13	C8	C8	NNP
cord-014712-5u4e00q6	2140	14	deficiency	deficiency	NN
cord-014712-5u4e00q6	2140	15	.	.	.
cord-014712-5u4e00q6	2141	1	The	the	DT
cord-014712-5u4e00q6	2141	2	genetic	genetic	JJ
cord-014712-5u4e00q6	2141	3	analyses	analysis	NNS
cord-014712-5u4e00q6	2141	4	have	have	VBP
cord-014712-5u4e00q6	2141	5	not	not	RB
cord-014712-5u4e00q6	2141	6	been	be	VBN
cord-014712-5u4e00q6	2141	7	completed	complete	VBN
cord-014712-5u4e00q6	2141	8	yet	yet	RB
cord-014712-5u4e00q6	2141	9	.	.	.
cord-014712-5u4e00q6	2142	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2142	2	here	here	RB
cord-014712-5u4e00q6	2142	3	report	report	VBP
cord-014712-5u4e00q6	2142	4	the	the	DT
cord-014712-5u4e00q6	2142	5	third	third	JJ
cord-014712-5u4e00q6	2142	6	and	and	CC
cord-014712-5u4e00q6	2142	7	fourth	fourth	JJ
cord-014712-5u4e00q6	2142	8	cases	case	NNS
cord-014712-5u4e00q6	2142	9	of	of	IN
cord-014712-5u4e00q6	2142	10	C8	c8	NN
cord-014712-5u4e00q6	2142	11	deficiency	deficiency	NN
cord-014712-5u4e00q6	2142	12	in	in	IN
cord-014712-5u4e00q6	2142	13	Turkish	turkish	JJ
cord-014712-5u4e00q6	2142	14	patients	patient	NNS
cord-014712-5u4e00q6	2142	15	.	.	.
cord-014712-5u4e00q6	2143	1	Interferon	interferon	NN
cord-014712-5u4e00q6	2143	2	-	-	HYPH
cord-014712-5u4e00q6	2143	3	g	g	NN
cord-014712-5u4e00q6	2143	4	receptor-1	receptor-1	NNP
cord-014712-5u4e00q6	2143	5	(	(	-LRB-
cord-014712-5u4e00q6	2143	6	IFNgR1	IFNgR1	NNP
cord-014712-5u4e00q6	2143	7	)	)	-RRB-
cord-014712-5u4e00q6	2143	8	deficiency	deficiency	NN
cord-014712-5u4e00q6	2143	9	is	be	VBZ
cord-014712-5u4e00q6	2143	10	caused	cause	VBN
cord-014712-5u4e00q6	2143	11	by	by	IN
cord-014712-5u4e00q6	2143	12	mutations	mutation	NNS
cord-014712-5u4e00q6	2143	13	in	in	IN
cord-014712-5u4e00q6	2143	14	IFN	IFN	NNP
cord-014712-5u4e00q6	2143	15	-	-	HYPH
cord-014712-5u4e00q6	2143	16	γ	γ	NNP
cord-014712-5u4e00q6	2143	17	receptor-1	receptor-1	NNP
cord-014712-5u4e00q6	2143	18	gene	gene	NN
cord-014712-5u4e00q6	2143	19	and	and	CC
cord-014712-5u4e00q6	2143	20	is	be	VBZ
cord-014712-5u4e00q6	2143	21	characterized	characterize	VBN
cord-014712-5u4e00q6	2143	22	mainly	mainly	RB
cord-014712-5u4e00q6	2143	23	by	by	IN
cord-014712-5u4e00q6	2143	24	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2143	25	to	to	IN
cord-014712-5u4e00q6	2143	26	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	2143	27	disease	disease	NN
cord-014712-5u4e00q6	2143	28	.	.	.
cord-014712-5u4e00q6	2144	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2144	2	report	report	VBP
cord-014712-5u4e00q6	2144	3	a	a	DT
cord-014712-5u4e00q6	2144	4	boy	boy	NN
cord-014712-5u4e00q6	2144	5	with	with	IN
cord-014712-5u4e00q6	2144	6	complete	complete	JJ
cord-014712-5u4e00q6	2144	7	recessive	recessive	JJ
cord-014712-5u4e00q6	2144	8	IFNgR1	IFNgR1	NNP
cord-014712-5u4e00q6	2144	9	deficiency	deficiency	NN
cord-014712-5u4e00q6	2144	10	,	,	,
cord-014712-5u4e00q6	2144	11	afflicted	afflict	VBN
cord-014712-5u4e00q6	2144	12	by	by	IN
cord-014712-5u4e00q6	2144	13	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2144	14	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2144	15	diseases	disease	NNS
cord-014712-5u4e00q6	2144	16	with	with	IN
cord-014712-5u4e00q6	2144	17	M.	M.	NNP
cord-014712-5u4e00q6	2144	18	Bovis	Bovis	NNP
cord-014712-5u4e00q6	2144	19	,	,	,
cord-014712-5u4e00q6	2144	20	M	M	NNP
cord-014712-5u4e00q6	2144	21	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2144	22	,	,	,
cord-014712-5u4e00q6	2144	23	M.	M.	NNP
cord-014712-5u4e00q6	2144	24	avium	avium	NN
cord-014712-5u4e00q6	2144	25	intracellulare	intracellulare	NNP
cord-014712-5u4e00q6	2144	26	and	and	CC
cord-014712-5u4e00q6	2144	27	M.fortuitum	M.fortuitum	NNS
cord-014712-5u4e00q6	2144	28	.	.	.
cord-014712-5u4e00q6	2145	1	Genetic	genetic	JJ
cord-014712-5u4e00q6	2145	2	analysis	analysis	NN
cord-014712-5u4e00q6	2145	3	showed	show	VBD
cord-014712-5u4e00q6	2145	4	a	a	DT
cord-014712-5u4e00q6	2145	5	homozygous	homozygous	JJ
cord-014712-5u4e00q6	2145	6	mutation	mutation	NN
cord-014712-5u4e00q6	2145	7	(	(	-LRB-
cord-014712-5u4e00q6	2145	8	106insT	106inst	CD
cord-014712-5u4e00q6	2145	9	)	)	-RRB-
cord-014712-5u4e00q6	2145	10	in	in	IN
cord-014712-5u4e00q6	2145	11	IFNgR1	IFNgR1	NNP
cord-014712-5u4e00q6	2145	12	gene	gene	NN
cord-014712-5u4e00q6	2145	13	leading	lead	VBG
cord-014712-5u4e00q6	2145	14	to	to	TO
cord-014712-5u4e00q6	2145	15	complete	complete	VB
cord-014712-5u4e00q6	2145	16	IFNgR1	IFNgR1	NNP
cord-014712-5u4e00q6	2145	17	deficiency	deficiency	NN
cord-014712-5u4e00q6	2145	18	.	.	.
cord-014712-5u4e00q6	2146	1	In	in	IN
cord-014712-5u4e00q6	2146	2	addition	addition	NN
cord-014712-5u4e00q6	2146	3	,	,	,
cord-014712-5u4e00q6	2146	4	he	-PRON-	PRP
cord-014712-5u4e00q6	2146	5	had	have	VBD
cord-014712-5u4e00q6	2146	6	atypical	atypical	JJ
cord-014712-5u4e00q6	2146	7	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2146	8	skin	skin	NN
cord-014712-5u4e00q6	2146	9	lesions	lesion	NNS
cord-014712-5u4e00q6	2146	10	caused	cause	VBN
cord-014712-5u4e00q6	2146	11	by	by	IN
cord-014712-5u4e00q6	2146	12	M.avium	M.avium	NNP
cord-014712-5u4e00q6	2146	13	intracellulare	intracellulare	NNP
cord-014712-5u4e00q6	2147	1	and	and	CC
cord-014712-5u4e00q6	2147	2	he	-PRON-	PRP
cord-014712-5u4e00q6	2147	3	developed	develop	VBD
cord-014712-5u4e00q6	2147	4	scrotal	scrotal	JJ
cord-014712-5u4e00q6	2147	5	and	and	CC
cord-014712-5u4e00q6	2147	6	lower	low	JJR
cord-014712-5u4e00q6	2147	7	limb	limb	NN
cord-014712-5u4e00q6	2147	8	lymphedema	lymphedema	NN
cord-014712-5u4e00q6	2147	9	secondary	secondary	JJ
cord-014712-5u4e00q6	2147	10	to	to	IN
cord-014712-5u4e00q6	2147	11	compression	compression	NN
cord-014712-5u4e00q6	2147	12	of	of	IN
cord-014712-5u4e00q6	2147	13	large	large	JJ
cord-014712-5u4e00q6	2147	14	and	and	CC
cord-014712-5u4e00q6	2147	15	fixed	fix	VBN
cord-014712-5u4e00q6	2147	16	inguinal	inguinal	JJ
cord-014712-5u4e00q6	2147	17	lymphadenopathies	lymphadenopathy	NNS
cord-014712-5u4e00q6	2147	18	.	.	.
cord-014712-5u4e00q6	2148	1	To	to	IN
cord-014712-5u4e00q6	2148	2	our	-PRON-	PRP$
cord-014712-5u4e00q6	2148	3	knowledge	knowledge	NN
cord-014712-5u4e00q6	2148	4	,	,	,
cord-014712-5u4e00q6	2148	5	the	the	DT
cord-014712-5u4e00q6	2148	6	patient	patient	NN
cord-014712-5u4e00q6	2148	7	is	be	VBZ
cord-014712-5u4e00q6	2148	8	the	the	DT
cord-014712-5u4e00q6	2148	9	first	first	JJ
cord-014712-5u4e00q6	2148	10	case	case	NN
cord-014712-5u4e00q6	2148	11	with	with	IN
cord-014712-5u4e00q6	2148	12	interleukin-12	interleukin-12	XX
cord-014712-5u4e00q6	2148	13	/	/	SYM
cord-014712-5u4e00q6	2148	14	interferon	interferon	NN
cord-014712-5u4e00q6	2148	15	−	−	NNP
cord-014712-5u4e00q6	2148	16	γ	γ	NN
cord-014712-5u4e00q6	2148	17	pathway	pathway	NN
cord-014712-5u4e00q6	2148	18	defect	defect	NN
cord-014712-5u4e00q6	2148	19	and	and	CC
cord-014712-5u4e00q6	2148	20	severe	severe	JJ
cord-014712-5u4e00q6	2148	21	lymphedema	lymphedema	NN
cord-014712-5u4e00q6	2148	22	.	.	.
cord-014712-5u4e00q6	2149	1	Defects	defect	NNS
cord-014712-5u4e00q6	2149	2	in	in	IN
cord-014712-5u4e00q6	2149	3	the	the	DT
cord-014712-5u4e00q6	2149	4	IL-12/	IL-12/	NNP
cord-014712-5u4e00q6	2149	5	IFN	IFN	NNP
cord-014712-5u4e00q6	2149	6	−	−	NNP
cord-014712-5u4e00q6	2149	7	γ	γ	NN
cord-014712-5u4e00q6	2149	8	pathway	pathway	NN
cord-014712-5u4e00q6	2149	9	must	must	MD
cord-014712-5u4e00q6	2149	10	be	be	VB
cord-014712-5u4e00q6	2149	11	considered	consider	VBN
cord-014712-5u4e00q6	2149	12	in	in	IN
cord-014712-5u4e00q6	2149	13	patients	patient	NNS
cord-014712-5u4e00q6	2149	14	with	with	IN
cord-014712-5u4e00q6	2149	15	disseminated	disseminate	VBN
cord-014712-5u4e00q6	2149	16	or	or	CC
cord-014712-5u4e00q6	2149	17	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2149	18	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2149	19	infections	infection	NNS
cord-014712-5u4e00q6	2149	20	and	and	CC
cord-014712-5u4e00q6	2149	21	in	in	IN
cord-014712-5u4e00q6	2149	22	patients	patient	NNS
cord-014712-5u4e00q6	2149	23	with	with	IN
cord-014712-5u4e00q6	2149	24	severe	severe	JJ
cord-014712-5u4e00q6	2149	25	viral	viral	JJ
cord-014712-5u4e00q6	2149	26	infections	infection	NNS
cord-014712-5u4e00q6	2149	27	,	,	,
cord-014712-5u4e00q6	2149	28	especially	especially	RB
cord-014712-5u4e00q6	2149	29	in	in	IN
cord-014712-5u4e00q6	2149	30	countries	country	NNS
cord-014712-5u4e00q6	2149	31	where	where	WRB
cord-014712-5u4e00q6	2149	32	BCG	BCG	NNP
cord-014712-5u4e00q6	2149	33	vaccination	vaccination	NN
cord-014712-5u4e00q6	2149	34	is	be	VBZ
cord-014712-5u4e00q6	2149	35	part	part	NN
cord-014712-5u4e00q6	2149	36	of	of	IN
cord-014712-5u4e00q6	2149	37	the	the	DT
cord-014712-5u4e00q6	2149	38	national	national	NNP
cord-014712-5u4e00q6	2149	39	health	health	NN
cord-014712-5u4e00q6	2149	40	programme	programme	NN
cord-014712-5u4e00q6	2149	41	.	.	.
cord-014712-5u4e00q6	2150	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2150	2	must	must	MD
cord-014712-5u4e00q6	2150	3	be	be	VB
cord-014712-5u4e00q6	2150	4	kept	keep	VBN
cord-014712-5u4e00q6	2150	5	in	in	IN
cord-014712-5u4e00q6	2150	6	mind	mind	NN
cord-014712-5u4e00q6	2150	7	that	that	IN
cord-014712-5u4e00q6	2150	8	these	these	DT
cord-014712-5u4e00q6	2150	9	patients	patient	NNS
cord-014712-5u4e00q6	2150	10	may	may	MD
cord-014712-5u4e00q6	2150	11	develop	develop	VB
cord-014712-5u4e00q6	2150	12	granuloma	granuloma	NN
cord-014712-5u4e00q6	2150	13	-	-	HYPH
cord-014712-5u4e00q6	2150	14	like	like	JJ
cord-014712-5u4e00q6	2150	15	skin	skin	NN
cord-014712-5u4e00q6	2150	16	lesions	lesion	NNS
cord-014712-5u4e00q6	2150	17	and	and	CC
cord-014712-5u4e00q6	2150	18	severe	severe	JJ
cord-014712-5u4e00q6	2150	19	lymphedema	lymphedema	NN
cord-014712-5u4e00q6	2150	20	.	.	.
cord-014712-5u4e00q6	2151	1	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2151	2	must	must	MD
cord-014712-5u4e00q6	2151	3	be	be	VB
cord-014712-5u4e00q6	2151	4	applied	apply	VBN
cord-014712-5u4e00q6	2151	5	at	at	IN
cord-014712-5u4e00q6	2151	6	the	the	DT
cord-014712-5u4e00q6	2151	7	earliest	early	JJS
cord-014712-5u4e00q6	2151	8	time	time	NN
cord-014712-5u4e00q6	2151	9	before	before	IN
cord-014712-5u4e00q6	2151	10	developing	develop	VBG
cord-014712-5u4e00q6	2151	11	organ	organ	NN
cord-014712-5u4e00q6	2151	12	damages	damage	NNS
cord-014712-5u4e00q6	2151	13	.	.	.
cord-014712-5u4e00q6	2152	1	T	T	NNP
cord-014712-5u4e00q6	2152	2	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	2152	3	/	/	SYM
cord-014712-5u4e00q6	2152	4	NK	NK	NNP
cord-014712-5u4e00q6	2152	5	cells	cell	NNS
cord-014712-5u4e00q6	2152	6	.	.	.
cord-014712-5u4e00q6	2153	1	Restricted	restricted	JJ
cord-014712-5u4e00q6	2153	2	defective	defective	JJ
cord-014712-5u4e00q6	2153	3	molecules	molecule	NNS
cord-014712-5u4e00q6	2153	4	in	in	IN
cord-014712-5u4e00q6	2153	5	the	the	DT
cord-014712-5u4e00q6	2153	6	circuit	circuit	NN
cord-014712-5u4e00q6	2153	7	and	and	CC
cord-014712-5u4e00q6	2153	8	recently	recently	RB
cord-014712-5u4e00q6	2153	9	discovered	discover	VBD
cord-014712-5u4e00q6	2153	10	CYBB	CYBB	NNP
cord-014712-5u4e00q6	2153	11	responsible	responsible	JJ
cord-014712-5u4e00q6	2153	12	for	for	IN
cord-014712-5u4e00q6	2153	13	autophagocytic	autophagocytic	JJ
cord-014712-5u4e00q6	2153	14	vacuole	vacuole	NN
cord-014712-5u4e00q6	2153	15	and	and	CC
cord-014712-5u4e00q6	2153	16	proteolysis	proteolysis	NN
cord-014712-5u4e00q6	2153	17	have	have	VBP
cord-014712-5u4e00q6	2153	18	been	be	VBN
cord-014712-5u4e00q6	2153	19	identified	identify	VBN
cord-014712-5u4e00q6	2153	20	in	in	IN
cord-014712-5u4e00q6	2153	21	around	around	RB
cord-014712-5u4e00q6	2153	22	60	60	CD
cord-014712-5u4e00q6	2153	23	%	%	NN
cord-014712-5u4e00q6	2153	24	of	of	IN
cord-014712-5u4e00q6	2153	25	patients	patient	NNS
cord-014712-5u4e00q6	2153	26	with	with	IN
cord-014712-5u4e00q6	2153	27	the	the	DT
cord-014712-5u4e00q6	2153	28	Mendelian	mendelian	JJ
cord-014712-5u4e00q6	2153	29	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2153	30	to	to	IN
cord-014712-5u4e00q6	2153	31	the	the	DT
cord-014712-5u4e00q6	2153	32	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2153	33	disease	disease	NN
cord-014712-5u4e00q6	2153	34	(	(	-LRB-
cord-014712-5u4e00q6	2153	35	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2153	36	)	)	-RRB-
cord-014712-5u4e00q6	2153	37	phenotype	phenotype	NN
cord-014712-5u4e00q6	2153	38	.	.	.
cord-014712-5u4e00q6	2154	1	Primary	primary	JJ
cord-014712-5u4e00q6	2154	2	defects	defect	NNS
cord-014712-5u4e00q6	2154	3	in	in	IN
cord-014712-5u4e00q6	2154	4	oxidase	oxidase	NN
cord-014712-5u4e00q6	2154	5	activity	activity	NN
cord-014712-5u4e00q6	2154	6	in	in	IN
cord-014712-5u4e00q6	2154	7	chronic	chronic	JJ
cord-014712-5u4e00q6	2154	8	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2154	9	disease	disease	NN
cord-014712-5u4e00q6	2154	10	(	(	-LRB-
cord-014712-5u4e00q6	2154	11	CGD	CGD	NNP
cord-014712-5u4e00q6	2154	12	)	)	-RRB-
cord-014712-5u4e00q6	2154	13	lead	lead	NN
cord-014712-5u4e00q6	2154	14	to	to	IN
cord-014712-5u4e00q6	2154	15	severe	severe	JJ
cord-014712-5u4e00q6	2154	16	,	,	,
cord-014712-5u4e00q6	2154	17	life	life	NN
cord-014712-5u4e00q6	2154	18	-	-	HYPH
cord-014712-5u4e00q6	2154	19	threatening	threaten	VBG
cord-014712-5u4e00q6	2154	20	infections	infection	NNS
cord-014712-5u4e00q6	2154	21	.	.	.
cord-014712-5u4e00q6	2155	1	The	the	DT
cord-014712-5u4e00q6	2155	2	role	role	NN
cord-014712-5u4e00q6	2155	3	of	of	IN
cord-014712-5u4e00q6	2155	4	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	2155	5	respiratory	respiratory	JJ
cord-014712-5u4e00q6	2155	6	burst	burst	NN
cord-014712-5u4e00q6	2155	7	in	in	IN
cord-014712-5u4e00q6	2155	8	host	host	NN
cord-014712-5u4e00q6	2155	9	defense	defense	NN
cord-014712-5u4e00q6	2155	10	against	against	IN
cord-014712-5u4e00q6	2155	11	mycobacterium	mycobacterium	NNP
cord-014712-5u4e00q6	2155	12	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2155	13	was	be	VBD
cord-014712-5u4e00q6	2155	14	controversial	controversial	JJ
cord-014712-5u4e00q6	2155	15	.	.	.
cord-014712-5u4e00q6	2156	1	Previous	previous	JJ
cord-014712-5u4e00q6	2156	2	studied	study	VBN
cord-014712-5u4e00q6	2156	3	showed	show	VBD
cord-014712-5u4e00q6	2156	4	that	that	IN
cord-014712-5u4e00q6	2156	5	the	the	DT
cord-014712-5u4e00q6	2156	6	critical	critical	JJ
cord-014712-5u4e00q6	2156	7	role	role	NN
cord-014712-5u4e00q6	2156	8	at	at	IN
cord-014712-5u4e00q6	2156	9	reactive	reactive	JJ
cord-014712-5u4e00q6	2156	10	oxidants	oxidant	NNS
cord-014712-5u4e00q6	2156	11	is	be	VBZ
cord-014712-5u4e00q6	2156	12	to	to	TO
cord-014712-5u4e00q6	2156	13	serve	serve	VB
cord-014712-5u4e00q6	2156	14	as	as	IN
cord-014712-5u4e00q6	2156	15	intracellular	intracellular	JJ
cord-014712-5u4e00q6	2156	16	signals	signal	NNS
cord-014712-5u4e00q6	2156	17	for	for	IN
cord-014712-5u4e00q6	2156	18	activation	activation	NN
cord-014712-5u4e00q6	2156	19	of	of	IN
cord-014712-5u4e00q6	2156	20	microbicidal	microbicidal	JJ
cord-014712-5u4e00q6	2156	21	enzymes	enzyme	NNS
cord-014712-5u4e00q6	2156	22	,	,	,
cord-014712-5u4e00q6	2156	23	rather	rather	RB
cord-014712-5u4e00q6	2156	24	than	than	IN
cord-014712-5u4e00q6	2156	25	excretions	excretion	NNS
cord-014712-5u4e00q6	2156	26	a	a	DT
cord-014712-5u4e00q6	2156	27	microbicidal	microbicidal	JJ
cord-014712-5u4e00q6	2156	28	effect	effect	NN
cord-014712-5u4e00q6	2156	29	perse	perse	NN
cord-014712-5u4e00q6	2156	30	.	.	.
cord-014712-5u4e00q6	2157	1	The	the	DT
cord-014712-5u4e00q6	2157	2	role	role	NN
cord-014712-5u4e00q6	2157	3	of	of	IN
cord-014712-5u4e00q6	2157	4	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	2157	5	respiratory	respiratory	JJ
cord-014712-5u4e00q6	2157	6	burst	burst	NN
cord-014712-5u4e00q6	2157	7	in	in	IN
cord-014712-5u4e00q6	2157	8	host	host	NN
cord-014712-5u4e00q6	2157	9	defense	defense	NN
cord-014712-5u4e00q6	2157	10	against	against	IN
cord-014712-5u4e00q6	2157	11	M.	M.	NNP
cord-014712-5u4e00q6	2157	12	TB	TB	NNP
cord-014712-5u4e00q6	2157	13	is	be	VBZ
cord-014712-5u4e00q6	2157	14	further	far	RBR
cord-014712-5u4e00q6	2157	15	supported	support	VBN
cord-014712-5u4e00q6	2157	16	by	by	IN
cord-014712-5u4e00q6	2157	17	recent	recent	JJ
cord-014712-5u4e00q6	2157	18	studies	study	NNS
cord-014712-5u4e00q6	2157	19	discovered	discover	VBD
cord-014712-5u4e00q6	2157	20	immunological	immunological	JJ
cord-014712-5u4e00q6	2157	21	defects	defect	NNS
cord-014712-5u4e00q6	2157	22	secondarily	secondarily	RB
cord-014712-5u4e00q6	2157	23	affecting	affect	VBG
cord-014712-5u4e00q6	2157	24	phagocyte	phagocyte	NNS
cord-014712-5u4e00q6	2157	25	respiratory	respiratory	JJ
cord-014712-5u4e00q6	2157	26	burst	burst	NN
cord-014712-5u4e00q6	2157	27	function	function	NN
cord-014712-5u4e00q6	2157	28	and	and	CC
cord-014712-5u4e00q6	2157	29	resulting	result	VBG
cord-014712-5u4e00q6	2157	30	in	in	IN
cord-014712-5u4e00q6	2157	31	primary	primary	JJ
cord-014712-5u4e00q6	2157	32	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	2157	33	with	with	IN
cord-014712-5u4e00q6	2157	34	varied	varied	JJ
cord-014712-5u4e00q6	2157	35	phenotypes	phenotype	NNS
cord-014712-5u4e00q6	2157	36	,	,	,
cord-014712-5u4e00q6	2157	37	including	include	VBG
cord-014712-5u4e00q6	2157	38	susceptibilities	susceptibility	NNS
cord-014712-5u4e00q6	2157	39	to	to	IN
cord-014712-5u4e00q6	2157	40	pyogenic	pyogenic	JJ
cord-014712-5u4e00q6	2157	41	or	or	CC
cord-014712-5u4e00q6	2157	42	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2157	43	infections	infection	NNS
cord-014712-5u4e00q6	2157	44	.	.	.
cord-014712-5u4e00q6	2158	1	The	the	DT
cord-014712-5u4e00q6	2158	2	patients	patient	NNS
cord-014712-5u4e00q6	2158	3	with	with	IN
cord-014712-5u4e00q6	2158	4	severe	severe	JJ
cord-014712-5u4e00q6	2158	5	PID	PID	NNP
cord-014712-5u4e00q6	2158	6	's	's	POS
cord-014712-5u4e00q6	2158	7	like	like	IN
cord-014712-5u4e00q6	2158	8	SCID	SCID	NNP
cord-014712-5u4e00q6	2158	9	have	have	VBP
cord-014712-5u4e00q6	2158	10	broader	broad	JJR
cord-014712-5u4e00q6	2158	11	diverse	diverse	JJ
cord-014712-5u4e00q6	2158	12	infections	infection	NNS
cord-014712-5u4e00q6	2158	13	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2158	14	and	and	CC
cord-014712-5u4e00q6	2158	15	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2158	16	infections	infection	NNS
cord-014712-5u4e00q6	2158	17	as	as	RB
cord-014712-5u4e00q6	2158	18	well	well	RB
cord-014712-5u4e00q6	2158	19	,	,	,
cord-014712-5u4e00q6	2158	20	however	however	RB
cord-014712-5u4e00q6	2158	21	,	,	,
cord-014712-5u4e00q6	2158	22	Common	common	JJ
cord-014712-5u4e00q6	2158	23	variable	variable	JJ
cord-014712-5u4e00q6	2158	24	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	2158	25	(	(	-LRB-
cord-014712-5u4e00q6	2158	26	CVID	CVID	NNP
cord-014712-5u4e00q6	2158	27	)	)	-RRB-
cord-014712-5u4e00q6	2158	28	mostly	mostly	RB
cord-014712-5u4e00q6	2158	29	characterized	characterize	VBN
cord-014712-5u4e00q6	2158	30	by	by	IN
cord-014712-5u4e00q6	2158	31	a	a	DT
cord-014712-5u4e00q6	2158	32	deficiency	deficiency	NN
cord-014712-5u4e00q6	2158	33	of	of	IN
cord-014712-5u4e00q6	2158	34	immunoglobulins	immunoglobulin	NNS
cord-014712-5u4e00q6	2158	35	and	and	CC
cord-014712-5u4e00q6	2158	36	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2158	37	sinopulmonary	sinopulmonary	JJ
cord-014712-5u4e00q6	2158	38	infections	infection	NNS
cord-014712-5u4e00q6	2158	39	.	.	.
cord-014712-5u4e00q6	2159	1	Method	method	NN
cord-014712-5u4e00q6	2159	2	:	:	:
cord-014712-5u4e00q6	2160	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2160	2	overview	overview	VBP
cord-014712-5u4e00q6	2160	3	the	the	DT
cord-014712-5u4e00q6	2160	4	clinical	clinical	JJ
cord-014712-5u4e00q6	2160	5	rate	rate	NN
cord-014712-5u4e00q6	2160	6	of	of	IN
cord-014712-5u4e00q6	2160	7	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2160	8	disease	disease	NN
cord-014712-5u4e00q6	2160	9	in	in	IN
cord-014712-5u4e00q6	2160	10	our	-PRON-	PRP$
cord-014712-5u4e00q6	2160	11	PID	pid	NN
cord-014712-5u4e00q6	2160	12	cases	case	NNS
cord-014712-5u4e00q6	2160	13	and	and	CC
cord-014712-5u4e00q6	2160	14	evaluate	evaluate	VB
cord-014712-5u4e00q6	2160	15	the	the	DT
cord-014712-5u4e00q6	2160	16	complex	complex	JJ
cord-014712-5u4e00q6	2160	17	cases	case	NNS
cord-014712-5u4e00q6	2160	18	.	.	.
cord-014712-5u4e00q6	2161	1	Results	result	NNS
cord-014712-5u4e00q6	2161	2	:	:	:
cord-014712-5u4e00q6	2162	1	Two	two	CD
cord-014712-5u4e00q6	2162	2	hundred	hundred	CD
cord-014712-5u4e00q6	2162	3	PID	pid	NN
cord-014712-5u4e00q6	2162	4	cases	case	NNS
cord-014712-5u4e00q6	2162	5	were	be	VBD
cord-014712-5u4e00q6	2162	6	evaluate	evaluate	VBN
cord-014712-5u4e00q6	2162	7	between	between	IN
cord-014712-5u4e00q6	2162	8	1996	1996	CD
cord-014712-5u4e00q6	2162	9	-	-	SYM
cord-014712-5u4e00q6	2162	10	2013	2013	CD
cord-014712-5u4e00q6	2162	11	in	in	IN
cord-014712-5u4e00q6	2162	12	our	-PRON-	PRP$
cord-014712-5u4e00q6	2162	13	clinic	clinic	NN
cord-014712-5u4e00q6	2162	14	,	,	,
cord-014712-5u4e00q6	2162	15	Among	among	IN
cord-014712-5u4e00q6	2162	16	5	5	CD
cord-014712-5u4e00q6	2162	17	%	%	NN
cord-014712-5u4e00q6	2162	18	of	of	IN
cord-014712-5u4e00q6	2162	19	them	-PRON-	PRP
cord-014712-5u4e00q6	2162	20	which	which	WDT
cord-014712-5u4e00q6	2162	21	diagnosed	diagnose	VBD
cord-014712-5u4e00q6	2162	22	as	as	IN
cord-014712-5u4e00q6	2162	23	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2162	24	nearly	nearly	RB
cord-014712-5u4e00q6	2162	25	all	all	DT
cord-014712-5u4e00q6	2162	26	presented	present	VBN
cord-014712-5u4e00q6	2162	27	with	with	IN
cord-014712-5u4e00q6	2162	28	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	2162	29	infection.8	infection.8	NNP
cord-014712-5u4e00q6	2162	30	%	%	NN
cord-014712-5u4e00q6	2162	31	diagnosed	diagnose	VBN
cord-014712-5u4e00q6	2162	32	as	as	IN
cord-014712-5u4e00q6	2162	33	CGD	CGD	NNP
cord-014712-5u4e00q6	2162	34	and	and	CC
cord-014712-5u4e00q6	2163	1	interestingly	interestingly	RB
cord-014712-5u4e00q6	2163	2	60	60	CD
cord-014712-5u4e00q6	2163	3	%	%	NN
cord-014712-5u4e00q6	2163	4	of	of	IN
cord-014712-5u4e00q6	2163	5	them	-PRON-	PRP
cord-014712-5u4e00q6	2163	6	have	have	VBP
cord-014712-5u4e00q6	2163	7	been	be	VBN
cord-014712-5u4e00q6	2163	8	experienced	experience	VBN
cord-014712-5u4e00q6	2163	9	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2163	10	disease	disease	NN
cord-014712-5u4e00q6	2163	11	sometimes	sometimes	RB
cord-014712-5u4e00q6	2163	12	in	in	IN
cord-014712-5u4e00q6	2163	13	their	-PRON-	PRP$
cord-014712-5u4e00q6	2163	14	life	life	NN
cord-014712-5u4e00q6	2163	15	,	,	,
cord-014712-5u4e00q6	2163	16	as	as	IN
cord-014712-5u4e00q6	2163	17	disseminated	disseminate	VBN
cord-014712-5u4e00q6	2163	18	BCG	BCG	NNP
cord-014712-5u4e00q6	2163	19	or	or	CC
cord-014712-5u4e00q6	2163	20	late	late	JJ
cord-014712-5u4e00q6	2163	21	onset	onset	NN
cord-014712-5u4e00q6	2163	22	complications	complication	NNS
cord-014712-5u4e00q6	2163	23	of	of	IN
cord-014712-5u4e00q6	2163	24	BCG	BCG	NNP
cord-014712-5u4e00q6	2163	25	including	include	VBG
cord-014712-5u4e00q6	2163	26	osteomyelitis	osteomyelitis	NN
cord-014712-5u4e00q6	2163	27	or	or	CC
cord-014712-5u4e00q6	2163	28	MTB	MTB	NNP
cord-014712-5u4e00q6	2163	29	once	once	RB
cord-014712-5u4e00q6	2163	30	or	or	CC
cord-014712-5u4e00q6	2163	31	more	more	JJR
cord-014712-5u4e00q6	2163	32	than	than	IN
cord-014712-5u4e00q6	2163	33	one	one	CD
cord-014712-5u4e00q6	2163	34	episode	episode	NN
cord-014712-5u4e00q6	2163	35	through	through	IN
cord-014712-5u4e00q6	2163	36	their	-PRON-	PRP$
cord-014712-5u4e00q6	2163	37	life	life	NN
cord-014712-5u4e00q6	2163	38	.	.	.
cord-014712-5u4e00q6	2164	1	Also	also	RB
cord-014712-5u4e00q6	2164	2	we	-PRON-	PRP
cord-014712-5u4e00q6	2164	3	have	have	VBP
cord-014712-5u4e00q6	2164	4	presented	present	VBN
cord-014712-5u4e00q6	2164	5	a	a	DT
cord-014712-5u4e00q6	2164	6	CVID	CVID	NNP
cord-014712-5u4e00q6	2164	7	patient	patient	NN
cord-014712-5u4e00q6	2164	8	with	with	IN
cord-014712-5u4e00q6	2164	9	disseminated	disseminate	VBN
cord-014712-5u4e00q6	2164	10	TB	TB	NNP
cord-014712-5u4e00q6	2164	11	and	and	CC
cord-014712-5u4e00q6	2164	12	granulomatouse	granulomatouse	NNP
cord-014712-5u4e00q6	2164	13	hepatitis	hepatitis	NNP
cord-014712-5u4e00q6	2164	14	,	,	,
cord-014712-5u4e00q6	2164	15	TB	TB	NNP
cord-014712-5u4e00q6	2164	16	arthritis	arthritis	NN
cord-014712-5u4e00q6	2164	17	,	,	,
cord-014712-5u4e00q6	2164	18	peritonitis	peritonitis	NN
cord-014712-5u4e00q6	2164	19	and	and	CC
cord-014712-5u4e00q6	2164	20	a	a	DT
cord-014712-5u4e00q6	2164	21	patient	patient	NN
cord-014712-5u4e00q6	2164	22	with	with	IN
cord-014712-5u4e00q6	2164	23	LAD	LAD	NNP
cord-014712-5u4e00q6	2164	24	and	and	CC
cord-014712-5u4e00q6	2164	25	nontubercolouse	nontubercolouse	NNP
cord-014712-5u4e00q6	2164	26	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	2164	27	infectiouse	infectiouse	NNP
cord-014712-5u4e00q6	2164	28	abcesses	abcesse	NNS
cord-014712-5u4e00q6	2164	29	of	of	IN
cord-014712-5u4e00q6	2164	30	her	-PRON-	PRP$
cord-014712-5u4e00q6	2164	31	skin	skin	NN
cord-014712-5u4e00q6	2164	32	.	.	.
cord-014712-5u4e00q6	2165	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	2165	2	:	:	:
cord-014712-5u4e00q6	2165	3	PID	pid	NN
cord-014712-5u4e00q6	2165	4	cases	case	NNS
cord-014712-5u4e00q6	2165	5	Like	like	IN
cord-014712-5u4e00q6	2165	6	CGD	CGD	NNP
cord-014712-5u4e00q6	2165	7	,	,	,
cord-014712-5u4e00q6	2165	8	MSMD	MSMD	NNP
cord-014712-5u4e00q6	2165	9	or	or	CC
cord-014712-5u4e00q6	2165	10	CVID	CVID	NNP
cord-014712-5u4e00q6	2165	11	which	which	WDT
cord-014712-5u4e00q6	2165	12	are	be	VBP
cord-014712-5u4e00q6	2165	13	living	live	VBG
cord-014712-5u4e00q6	2165	14	in	in	IN
cord-014712-5u4e00q6	2165	15	area	area	NN
cord-014712-5u4e00q6	2165	16	's	's	POS
cord-014712-5u4e00q6	2165	17	with	with	IN
cord-014712-5u4e00q6	2165	18	high	high	JJ
cord-014712-5u4e00q6	2165	19	prevalence	prevalence	NN
cord-014712-5u4e00q6	2165	20	of	of	IN
cord-014712-5u4e00q6	2165	21	mycobacterial	mycobacterial	JJ
cord-014712-5u4e00q6	2165	22	infection	infection	NN
cord-014712-5u4e00q6	2165	23	could	could	MD
cord-014712-5u4e00q6	2165	24	have	have	VB
cord-014712-5u4e00q6	2165	25	quiet	quiet	JJ
cord-014712-5u4e00q6	2165	26	different	different	JJ
cord-014712-5u4e00q6	2165	27	presentations	presentation	NNS
cord-014712-5u4e00q6	2165	28	and	and	CC
cord-014712-5u4e00q6	2165	29	the	the	DT
cord-014712-5u4e00q6	2165	30	study	study	NN
cord-014712-5u4e00q6	2165	31	of	of	IN
cord-014712-5u4e00q6	2165	32	these	these	DT
cord-014712-5u4e00q6	2165	33	complex	complex	JJ
cord-014712-5u4e00q6	2165	34	cases	case	NNS
cord-014712-5u4e00q6	2165	35	has	have	VBZ
cord-014712-5u4e00q6	2165	36	provided	provide	VBN
cord-014712-5u4e00q6	2165	37	essential	essential	JJ
cord-014712-5u4e00q6	2165	38	insights	insight	NNS
cord-014712-5u4e00q6	2165	39	into	into	IN
cord-014712-5u4e00q6	2165	40	the	the	DT
cord-014712-5u4e00q6	2165	41	functioning	functioning	NN
cord-014712-5u4e00q6	2165	42	of	of	IN
cord-014712-5u4e00q6	2165	43	the	the	DT
cord-014712-5u4e00q6	2165	44	immune	immune	JJ
cord-014712-5u4e00q6	2165	45	system	system	NN
cord-014712-5u4e00q6	2165	46	.	.	.
cord-014712-5u4e00q6	2166	1	Despite	despite	IN
cord-014712-5u4e00q6	2166	2	the	the	DT
cord-014712-5u4e00q6	2166	3	conventional	conventional	JJ
cord-014712-5u4e00q6	2166	4	view	view	NN
cord-014712-5u4e00q6	2166	5	we	-PRON-	PRP
cord-014712-5u4e00q6	2166	6	have	have	VBP
cord-014712-5u4e00q6	2166	7	confirmed	confirm	VBN
cord-014712-5u4e00q6	2166	8	that	that	IN
cord-014712-5u4e00q6	2166	9	the	the	DT
cord-014712-5u4e00q6	2166	10	generation	generation	NN
cord-014712-5u4e00q6	2166	11	of	of	IN
cord-014712-5u4e00q6	2166	12	ROIS	ROIS	NNP
cord-014712-5u4e00q6	2166	13	by	by	IN
cord-014712-5u4e00q6	2166	14	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	2166	15	respiratory	respiratory	JJ
cord-014712-5u4e00q6	2166	16	burst	burst	NN
cord-014712-5u4e00q6	2166	17	may	may	MD
cord-014712-5u4e00q6	2166	18	play	play	VB
cord-014712-5u4e00q6	2166	19	a	a	DT
cord-014712-5u4e00q6	2166	20	role	role	NN
cord-014712-5u4e00q6	2166	21	in	in	IN
cord-014712-5u4e00q6	2166	22	the	the	DT
cord-014712-5u4e00q6	2166	23	defense	defense	NN
cord-014712-5u4e00q6	2166	24	of	of	IN
cord-014712-5u4e00q6	2166	25	the	the	DT
cord-014712-5u4e00q6	2166	26	host	host	NN
cord-014712-5u4e00q6	2166	27	against	against	IN
cord-014712-5u4e00q6	2166	28	M.	M.	NNP
cord-014712-5u4e00q6	2166	29	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2166	30	by	by	IN
cord-014712-5u4e00q6	2166	31	clinical	clinical	JJ
cord-014712-5u4e00q6	2166	32	evidence	evidence	NN
cord-014712-5u4e00q6	2166	33	.	.	.
cord-014712-5u4e00q6	2167	1	Goran	Goran	NNP
cord-014712-5u4e00q6	2167	2	Ristic	Ristic	NNP
cord-014712-5u4e00q6	2167	3	,	,	,
cord-014712-5u4e00q6	2167	4	Srdjan	Srdjan	NNP
cord-014712-5u4e00q6	2167	5	Pasic	Pasic	NNP
cord-014712-5u4e00q6	2167	6	,	,	,
cord-014712-5u4e00q6	2167	7	Bojana	Bojana	NNP
cord-014712-5u4e00q6	2167	8	Slavkovic	Slavkovic	NNP
cord-014712-5u4e00q6	2167	9	Division	Division	NNP
cord-014712-5u4e00q6	2167	10	of	of	IN
cord-014712-5u4e00q6	2167	11	Clinical	Clinical	NNP
cord-014712-5u4e00q6	2167	12	Immunology	Immunology	NNP
cord-014712-5u4e00q6	2167	13	,	,	,
cord-014712-5u4e00q6	2167	14	Mother	Mother	NNP
cord-014712-5u4e00q6	2167	15	and	and	CC
cord-014712-5u4e00q6	2167	16	Child	Child	NNP
cord-014712-5u4e00q6	2167	17	Health	Health	NNP
cord-014712-5u4e00q6	2167	18	Care	Care	NNP
cord-014712-5u4e00q6	2167	19	Institute	Institute	NNP
cord-014712-5u4e00q6	2167	20	of	of	IN
cord-014712-5u4e00q6	2167	21	Serbia	Serbia	NNP
cord-014712-5u4e00q6	2167	22	,	,	,
cord-014712-5u4e00q6	2167	23	Belgrade	Belgrade	NNP
cord-014712-5u4e00q6	2167	24	Chronic	Chronic	NNP
cord-014712-5u4e00q6	2167	25	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2167	26	disease	disease	NN
cord-014712-5u4e00q6	2167	27	(	(	-LRB-
cord-014712-5u4e00q6	2167	28	CGD	CGD	NNP
cord-014712-5u4e00q6	2167	29	)	)	-RRB-
cord-014712-5u4e00q6	2167	30	is	be	VBZ
cord-014712-5u4e00q6	2167	31	a	a	DT
cord-014712-5u4e00q6	2167	32	rare	rare	JJ
cord-014712-5u4e00q6	2167	33	disease	disease	NN
cord-014712-5u4e00q6	2167	34	caused	cause	VBN
cord-014712-5u4e00q6	2167	35	by	by	IN
cord-014712-5u4e00q6	2167	36	mutation	mutation	NN
cord-014712-5u4e00q6	2167	37	in	in	IN
cord-014712-5u4e00q6	2167	38	any	any	DT
cord-014712-5u4e00q6	2167	39	of	of	IN
cord-014712-5u4e00q6	2167	40	the	the	DT
cord-014712-5u4e00q6	2167	41	five	five	CD
cord-014712-5u4e00q6	2167	42	components	component	NNS
cord-014712-5u4e00q6	2167	43	of	of	IN
cord-014712-5u4e00q6	2167	44	the	the	DT
cord-014712-5u4e00q6	2167	45	nicotinamide	nicotinamide	NN
cord-014712-5u4e00q6	2167	46	adenine	adenine	NN
cord-014712-5u4e00q6	2167	47	dinucleotide	dinucleotide	NN
cord-014712-5u4e00q6	2167	48	phosphate	phosphate	NN
cord-014712-5u4e00q6	2167	49	(	(	-LRB-
cord-014712-5u4e00q6	2167	50	NADPH	NADPH	NNP
cord-014712-5u4e00q6	2167	51	)	)	-RRB-
cord-014712-5u4e00q6	2167	52	oxidase	oxidase	NN
cord-014712-5u4e00q6	2167	53	in	in	IN
cord-014712-5u4e00q6	2167	54	phagocytes	phagocyte	NNS
cord-014712-5u4e00q6	2167	55	,	,	,
cord-014712-5u4e00q6	2167	56	resulting	result	VBG
cord-014712-5u4e00q6	2167	57	in	in	IN
cord-014712-5u4e00q6	2167	58	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2167	59	,	,	,
cord-014712-5u4e00q6	2167	60	life	life	NN
cord-014712-5u4e00q6	2167	61	-	-	HYPH
cord-014712-5u4e00q6	2167	62	threatening	threaten	VBG
cord-014712-5u4e00q6	2167	63	bacterial	bacterial	JJ
cord-014712-5u4e00q6	2167	64	and	and	CC
cord-014712-5u4e00q6	2167	65	fungal	fungal	JJ
cord-014712-5u4e00q6	2167	66	infections	infection	NNS
cord-014712-5u4e00q6	2167	67	of	of	IN
cord-014712-5u4e00q6	2167	68	the	the	DT
cord-014712-5u4e00q6	2167	69	affected	affect	VBN
cord-014712-5u4e00q6	2167	70	individuals	individual	NNS
cord-014712-5u4e00q6	2167	71	.	.	.
cord-014712-5u4e00q6	2168	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	2168	2	proband	proband	NN
cord-014712-5u4e00q6	2168	3	male	male	JJ
cord-014712-5u4e00q6	2168	4	patient	patient	NN
cord-014712-5u4e00q6	2168	5	presented	present	VBN
cord-014712-5u4e00q6	2168	6	at	at	IN
cord-014712-5u4e00q6	2168	7	age	age	NN
cord-014712-5u4e00q6	2168	8	of	of	IN
cord-014712-5u4e00q6	2168	9	2	2	CD
cord-014712-5u4e00q6	2168	10	years	year	NNS
cord-014712-5u4e00q6	2168	11	with	with	IN
cord-014712-5u4e00q6	2168	12	bilateral	bilateral	JJ
cord-014712-5u4e00q6	2168	13	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2168	14	and	and	CC
cord-014712-5u4e00q6	2168	15	positive	positive	JJ
cord-014712-5u4e00q6	2168	16	serology	serology	NN
cord-014712-5u4e00q6	2168	17	for	for	IN
cord-014712-5u4e00q6	2168	18	Aspergillus	aspergillus	NN
cord-014712-5u4e00q6	2168	19	sp	sp	NN
cord-014712-5u4e00q6	2168	20	.	.	.
cord-014712-5u4e00q6	2169	1	The	the	DT
cord-014712-5u4e00q6	2169	2	phorbol	phorbol	NNP
cord-014712-5u4e00q6	2169	3	myristate	myristate	NNP
cord-014712-5u4e00q6	2169	4	acetate	acetate	NNP
cord-014712-5u4e00q6	2169	5	(	(	-LRB-
cord-014712-5u4e00q6	2169	6	PMA	PMA	NNP
cord-014712-5u4e00q6	2169	7	)	)	-RRB-
cord-014712-5u4e00q6	2169	8	stimulated	stimulate	VBD
cord-014712-5u4e00q6	2169	9	nitroblue	nitroblue	NNP
cord-014712-5u4e00q6	2169	10	tetrazolium	tetrazolium	NNP
cord-014712-5u4e00q6	2170	1	(	(	-LRB-
cord-014712-5u4e00q6	2170	2	NBT	NBT	NNP
cord-014712-5u4e00q6	2170	3	)	)	-RRB-
cord-014712-5u4e00q6	2170	4	test	test	NN
cord-014712-5u4e00q6	2170	5	showed	show	VBD
cord-014712-5u4e00q6	2170	6	no	no	DT
cord-014712-5u4e00q6	2170	7	reduction	reduction	NN
cord-014712-5u4e00q6	2170	8	(	(	-LRB-
cord-014712-5u4e00q6	2170	9	0	0	CD
cord-014712-5u4e00q6	2170	10	%	%	NN
cord-014712-5u4e00q6	2170	11	)	)	-RRB-
cord-014712-5u4e00q6	2170	12	in	in	IN
cord-014712-5u4e00q6	2170	13	our	-PRON-	PRP$
cord-014712-5u4e00q6	2170	14	patient	patient	JJ
cord-014712-5u4e00q6	2170	15	and	and	CC
cord-014712-5u4e00q6	2170	16	partial	partial	JJ
cord-014712-5u4e00q6	2170	17	reduction	reduction	NN
cord-014712-5u4e00q6	2170	18	(	(	-LRB-
cord-014712-5u4e00q6	2170	19	58	58	CD
cord-014712-5u4e00q6	2170	20	%	%	NN
cord-014712-5u4e00q6	2170	21	)	)	-RRB-
cord-014712-5u4e00q6	2170	22	in	in	IN
cord-014712-5u4e00q6	2170	23	his	-PRON-	PRP$
cord-014712-5u4e00q6	2170	24	mother	mother	NN
cord-014712-5u4e00q6	2170	25	.	.	.
cord-014712-5u4e00q6	2171	1	Analysis	analysis	NN
cord-014712-5u4e00q6	2171	2	of	of	IN
cord-014712-5u4e00q6	2171	3	the	the	DT
cord-014712-5u4e00q6	2171	4	CYBB	CYBB	NNP
cord-014712-5u4e00q6	2171	5	gene	gene	NN
cord-014712-5u4e00q6	2171	6	showed	show	VBD
cord-014712-5u4e00q6	2171	7	a	a	DT
cord-014712-5u4e00q6	2171	8	deletion	deletion	NN
cord-014712-5u4e00q6	2171	9	of	of	IN
cord-014712-5u4e00q6	2171	10	nucleotide	nucleotide	JJ
cord-014712-5u4e00q6	2171	11	G	g	NN
cord-014712-5u4e00q6	2171	12	(	(	-LRB-
cord-014712-5u4e00q6	2171	13	c.1237delG	c.1237delG	NNP
cord-014712-5u4e00q6	2171	14	)	)	-RRB-
cord-014712-5u4e00q6	2171	15	exon	exon	NN
cord-014712-5u4e00q6	2171	16	10	10	CD
cord-014712-5u4e00q6	2171	17	causing	cause	VBG
cord-014712-5u4e00q6	2171	18	frame	frame	NN
cord-014712-5u4e00q6	2171	19	shift	shift	NN
cord-014712-5u4e00q6	2171	20	mutation	mutation	NN
cord-014712-5u4e00q6	2171	21	and	and	CC
cord-014712-5u4e00q6	2171	22	early	early	JJ
cord-014712-5u4e00q6	2171	23	termination	termination	NN
cord-014712-5u4e00q6	2171	24	of	of	IN
cord-014712-5u4e00q6	2171	25	translation	translation	NN
cord-014712-5u4e00q6	2171	26	(	(	-LRB-
cord-014712-5u4e00q6	2171	27	p	p	NN
cord-014712-5u4e00q6	2171	28	.	.	.
cord-014712-5u4e00q6	2171	29	Val413Serfs	Val413Serfs	NNP
cord-014712-5u4e00q6	2171	30	)	)	-RRB-
cord-014712-5u4e00q6	2171	31	.	.	.
cord-014712-5u4e00q6	2172	1	This	this	DT
cord-014712-5u4e00q6	2172	2	mutation	mutation	NN
cord-014712-5u4e00q6	2172	3	was	be	VBD
cord-014712-5u4e00q6	2172	4	not	not	RB
cord-014712-5u4e00q6	2172	5	previously	previously	RB
cord-014712-5u4e00q6	2172	6	described	describe	VBN
cord-014712-5u4e00q6	2172	7	.	.	.
cord-014712-5u4e00q6	2173	1	At	at	IN
cord-014712-5u4e00q6	2173	2	the	the	DT
cord-014712-5u4e00q6	2173	3	moment	moment	NN
cord-014712-5u4e00q6	2173	4	of	of	IN
cord-014712-5u4e00q6	2173	5	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	2173	6	,	,	,
cord-014712-5u4e00q6	2173	7	his	-PRON-	PRP$
cord-014712-5u4e00q6	2173	8	mother	mother	NN
cord-014712-5u4e00q6	2173	9	was	be	VBD
cord-014712-5u4e00q6	2173	10	already	already	RB
cord-014712-5u4e00q6	2173	11	pregnant	pregnant	JJ
cord-014712-5u4e00q6	2173	12	,	,	,
cord-014712-5u4e00q6	2173	13	19	19	CD
cord-014712-5u4e00q6	2173	14	th	th	CD
cord-014712-5u4e00q6	2173	15	week	week	NN
cord-014712-5u4e00q6	2173	16	of	of	IN
cord-014712-5u4e00q6	2173	17	gestation	gestation	NN
cord-014712-5u4e00q6	2173	18	.	.	.
cord-014712-5u4e00q6	2174	1	Fetal	fetal	JJ
cord-014712-5u4e00q6	2174	2	ultrasound	ultrasound	NN
cord-014712-5u4e00q6	2174	3	showed	show	VBD
cord-014712-5u4e00q6	2174	4	that	that	IN
cord-014712-5u4e00q6	2174	5	she	-PRON-	PRP
cord-014712-5u4e00q6	2174	6	was	be	VBD
cord-014712-5u4e00q6	2174	7	carrying	carry	VBG
cord-014712-5u4e00q6	2174	8	a	a	DT
cord-014712-5u4e00q6	2174	9	male	male	JJ
cord-014712-5u4e00q6	2174	10	fetus	fetus	NN
cord-014712-5u4e00q6	2174	11	.	.	.
cord-014712-5u4e00q6	2175	1	The	the	DT
cord-014712-5u4e00q6	2175	2	fetal	fetal	JJ
cord-014712-5u4e00q6	2175	3	blood	blood	NN
cord-014712-5u4e00q6	2175	4	sample	sample	NN
cord-014712-5u4e00q6	2175	5	,	,	,
cord-014712-5u4e00q6	2175	6	obtained	obtain	VBN
cord-014712-5u4e00q6	2175	7	by	by	IN
cord-014712-5u4e00q6	2175	8	the	the	DT
cord-014712-5u4e00q6	2175	9	percutaneous	percutaneous	JJ
cord-014712-5u4e00q6	2175	10	umbilical	umbilical	JJ
cord-014712-5u4e00q6	2175	11	cord	cord	NN
cord-014712-5u4e00q6	2175	12	blood	blood	NN
cord-014712-5u4e00q6	2175	13	sampling	sampling	NN
cord-014712-5u4e00q6	2175	14	,	,	,
cord-014712-5u4e00q6	2175	15	showed	show	VBD
cord-014712-5u4e00q6	2175	16	male	male	JJ
cord-014712-5u4e00q6	2175	17	karyotype	karyotype	NN
cord-014712-5u4e00q6	2175	18	and	and	CC
cord-014712-5u4e00q6	2175	19	the	the	DT
cord-014712-5u4e00q6	2175	20	PMA	PMA	NNP
cord-014712-5u4e00q6	2175	21	stimulated	stimulate	VBD
cord-014712-5u4e00q6	2175	22	NBT	NBT	NNP
cord-014712-5u4e00q6	2175	23	test	test	NN
cord-014712-5u4e00q6	2175	24	showed	show	VBD
cord-014712-5u4e00q6	2175	25	100	100	CD
cord-014712-5u4e00q6	2175	26	%	%	NN
cord-014712-5u4e00q6	2175	27	reduction	reduction	NN
cord-014712-5u4e00q6	2175	28	.	.	.
cord-014712-5u4e00q6	2176	1	There	there	EX
cord-014712-5u4e00q6	2176	2	were	be	VBD
cord-014712-5u4e00q6	2176	3	no	no	DT
cord-014712-5u4e00q6	2176	4	complication	complication	NN
cord-014712-5u4e00q6	2176	5	during	during	IN
cord-014712-5u4e00q6	2176	6	pregnancy	pregnancy	NN
cord-014712-5u4e00q6	2176	7	or	or	CC
cord-014712-5u4e00q6	2176	8	delivery	delivery	NN
cord-014712-5u4e00q6	2176	9	and	and	CC
cord-014712-5u4e00q6	2176	10	a	a	DT
cord-014712-5u4e00q6	2176	11	healthy	healthy	JJ
cord-014712-5u4e00q6	2176	12	boy	boy	NN
cord-014712-5u4e00q6	2176	13	was	be	VBD
cord-014712-5u4e00q6	2176	14	born	bear	VBN
cord-014712-5u4e00q6	2176	15	.	.	.
cord-014712-5u4e00q6	2177	1	The	the	DT
cord-014712-5u4e00q6	2177	2	proband	proband	JJ
cord-014712-5u4e00q6	2177	3	patient	patient	NN
cord-014712-5u4e00q6	2177	4	underwent	undergo	VBD
cord-014712-5u4e00q6	2177	5	allogenic	allogenic	JJ
cord-014712-5u4e00q6	2177	6	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2177	7	,	,	,
cord-014712-5u4e00q6	2177	8	his	-PRON-	PRP$
cord-014712-5u4e00q6	2177	9	sister	sister	NN
cord-014712-5u4e00q6	2177	10	was	be	VBD
cord-014712-5u4e00q6	2177	11	the	the	DT
cord-014712-5u4e00q6	2177	12	identical	identical	JJ
cord-014712-5u4e00q6	2177	13	sibling	sibling	NN
cord-014712-5u4e00q6	2177	14	donor	donor	NN
cord-014712-5u4e00q6	2177	15	.	.	.
cord-014712-5u4e00q6	2178	1	In	in	IN
cord-014712-5u4e00q6	2178	2	the	the	DT
cord-014712-5u4e00q6	2178	3	cases	case	NNS
cord-014712-5u4e00q6	2178	4	where	where	WRB
cord-014712-5u4e00q6	2178	5	the	the	DT
cord-014712-5u4e00q6	2178	6	family	family	NN
cord-014712-5u4e00q6	2178	7	-	-	HYPH
cord-014712-5u4e00q6	2178	8	specific	specific	JJ
cord-014712-5u4e00q6	2178	9	mutations	mutation	NNS
cord-014712-5u4e00q6	2178	10	are	be	VBP
cord-014712-5u4e00q6	2178	11	unknown	unknown	JJ
cord-014712-5u4e00q6	2178	12	,	,	,
cord-014712-5u4e00q6	2178	13	partial	partial	JJ
cord-014712-5u4e00q6	2178	14	or	or	CC
cord-014712-5u4e00q6	2178	15	complete	complete	JJ
cord-014712-5u4e00q6	2178	16	gene	gene	NN
cord-014712-5u4e00q6	2178	17	deletions	deletion	NNS
cord-014712-5u4e00q6	2178	18	can	can	MD
cord-014712-5u4e00q6	2178	19	be	be	VB
cord-014712-5u4e00q6	2178	20	recognized	recognize	VBN
cord-014712-5u4e00q6	2178	21	by	by	IN
cord-014712-5u4e00q6	2178	22	multiplex	multiplex	JJ
cord-014712-5u4e00q6	2178	23	ligase	ligase	NN
cord-014712-5u4e00q6	2178	24	-	-	HYPH
cord-014712-5u4e00q6	2178	25	dependent	dependent	JJ
cord-014712-5u4e00q6	2178	26	probe	probe	NN
cord-014712-5u4e00q6	2178	27	amplification	amplification	NN
cord-014712-5u4e00q6	2178	28	(	(	-LRB-
cord-014712-5u4e00q6	2178	29	MLPA	MLPA	NNP
cord-014712-5u4e00q6	2178	30	)	)	-RRB-
cord-014712-5u4e00q6	2178	31	or	or	CC
cord-014712-5u4e00q6	2178	32	array	array	VB
cord-014712-5u4e00q6	2178	33	comparative	comparative	JJ
cord-014712-5u4e00q6	2178	34	genomic	genomic	JJ
cord-014712-5u4e00q6	2178	35	hybridization	hybridization	NN
cord-014712-5u4e00q6	2179	1	(	(	-LRB-
cord-014712-5u4e00q6	2179	2	Features	feature	NNS
cord-014712-5u4e00q6	2179	3	of	of	IN
cord-014712-5u4e00q6	2179	4	the	the	DT
cord-014712-5u4e00q6	2179	5	patients	patient	NNS
cord-014712-5u4e00q6	2179	6	with	with	IN
cord-014712-5u4e00q6	2179	7	AR	AR	NNP
cord-014712-5u4e00q6	2179	8	-	-	HYPH
cord-014712-5u4e00q6	2179	9	HIES	HIES	NNP
cord-014712-5u4e00q6	2180	1	Dock-8	Dock-8	NNP
cord-014712-5u4e00q6	2180	2	Deficient	Deficient	NNP
cord-014712-5u4e00q6	2180	3	and	and	CC
cord-014712-5u4e00q6	2180	4	non	non	JJ
cord-014712-5u4e00q6	2180	5	-	-	JJ
cord-014712-5u4e00q6	2180	6	Dock-8	dock-8	JJ
cord-014712-5u4e00q6	2180	7	deficient	deficient	JJ
cord-014712-5u4e00q6	2180	8	group	group	NN
cord-014712-5u4e00q6	2180	9	are	be	VBP
cord-014712-5u4e00q6	2180	10	given	give	VBN
cord-014712-5u4e00q6	2180	11	in	in	IN
cord-014712-5u4e00q6	2180	12	the	the	DT
cord-014712-5u4e00q6	2180	13	Table	Table	NNP
cord-014712-5u4e00q6	2180	14	1	1	CD
cord-014712-5u4e00q6	2180	15	.	.	.
cord-014712-5u4e00q6	2181	1	All	all	DT
cord-014712-5u4e00q6	2181	2	patients	patient	NNS
cord-014712-5u4e00q6	2181	3	with	with	IN
cord-014712-5u4e00q6	2181	4	Dock-8	dock-8	JJ
cord-014712-5u4e00q6	2181	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	2181	6	presented	present	VBN
cord-014712-5u4e00q6	2181	7	with	with	IN
cord-014712-5u4e00q6	2181	8	cutaneous	cutaneous	JJ
cord-014712-5u4e00q6	2181	9	viral	viral	JJ
cord-014712-5u4e00q6	2181	10	infections	infection	NNS
cord-014712-5u4e00q6	2181	11	or	or	CC
cord-014712-5u4e00q6	2181	12	early	early	JJ
cord-014712-5u4e00q6	2181	13	onset	onset	NN
cord-014712-5u4e00q6	2181	14	and	and	CC
cord-014712-5u4e00q6	2181	15	severe	severe	JJ
cord-014712-5u4e00q6	2181	16	atopic	atopic	JJ
cord-014712-5u4e00q6	2181	17	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	2181	18	.	.	.
cord-014712-5u4e00q6	2182	1	Many	many	JJ
cord-014712-5u4e00q6	2182	2	have	have	VBP
cord-014712-5u4e00q6	2182	3	also	also	RB
cord-014712-5u4e00q6	2182	4	food	food	NN
cord-014712-5u4e00q6	2182	5	allergy	allergy	NN
cord-014712-5u4e00q6	2182	6	and/or	and/or	CC
cord-014712-5u4e00q6	2182	7	asthma	asthma	NN
cord-014712-5u4e00q6	2182	8	.	.	.
cord-014712-5u4e00q6	2183	1	Neurological	neurological	JJ
cord-014712-5u4e00q6	2183	2	complications	complication	NNS
cord-014712-5u4e00q6	2183	3	and	and	CC
cord-014712-5u4e00q6	2183	4	malignancy	malignancy	NN
cord-014712-5u4e00q6	2183	5	were	be	VBD
cord-014712-5u4e00q6	2183	6	seen	see	VBN
cord-014712-5u4e00q6	2183	7	in	in	IN
cord-014712-5u4e00q6	2183	8	20	20	CD
cord-014712-5u4e00q6	2183	9	%	%	NN
cord-014712-5u4e00q6	2183	10	and	and	CC
cord-014712-5u4e00q6	2183	11	27	27	CD
cord-014712-5u4e00q6	2183	12	%	%	NN
cord-014712-5u4e00q6	2183	13	respectively	respectively	RB
cord-014712-5u4e00q6	2183	14	.	.	.
cord-014712-5u4e00q6	2184	1	Sixty	sixty	CD
cord-014712-5u4e00q6	2184	2	seven	seven	CD
cord-014712-5u4e00q6	2184	3	percent	percent	NN
cord-014712-5u4e00q6	2184	4	of	of	IN
cord-014712-5u4e00q6	2184	5	patients	patient	NNS
cord-014712-5u4e00q6	2184	6	had	have	VBD
cord-014712-5u4e00q6	2184	7	low	low	JJ
cord-014712-5u4e00q6	2184	8	T	t	NN
cord-014712-5u4e00q6	2184	9	;	;	:
cord-014712-5u4e00q6	2184	10	83	83	CD
cord-014712-5u4e00q6	2184	11	%	%	NN
cord-014712-5u4e00q6	2184	12	,	,	,
cord-014712-5u4e00q6	2184	13	low	low	JJ
cord-014712-5u4e00q6	2184	14	CD4	CD4	NNP
cord-014712-5u4e00q6	2184	15	levels	level	NNS
cord-014712-5u4e00q6	2184	16	;	;	:
cord-014712-5u4e00q6	2184	17	100	100	CD
cord-014712-5u4e00q6	2184	18	%	%	NN
cord-014712-5u4e00q6	2184	19	,	,	,
cord-014712-5u4e00q6	2184	20	high	high	JJ
cord-014712-5u4e00q6	2184	21	IgE.	ige.	NN
cord-014712-5u4e00q6	2185	1	The	the	DT
cord-014712-5u4e00q6	2185	2	latter	latter	JJ
cord-014712-5u4e00q6	2185	3	features	feature	NNS
cord-014712-5u4e00q6	2185	4	were	be	VBD
cord-014712-5u4e00q6	2185	5	shared	share	VBN
cord-014712-5u4e00q6	2185	6	between	between	IN
cord-014712-5u4e00q6	2185	7	patients	patient	NNS
cord-014712-5u4e00q6	2185	8	with	with	IN
cord-014712-5u4e00q6	2185	9	or	or	CC
cord-014712-5u4e00q6	2185	10	without	without	IN
cord-014712-5u4e00q6	2185	11	Dock-8	dock-8	JJ
cord-014712-5u4e00q6	2185	12	deficiency	deficiency	NN
cord-014712-5u4e00q6	2185	13	,	,	,
cord-014712-5u4e00q6	2185	14	except	except	IN
cord-014712-5u4e00q6	2185	15	atopic	atopic	JJ
cord-014712-5u4e00q6	2185	16	dermatitis	dermatitis	NN
cord-014712-5u4e00q6	2185	17	which	which	WDT
cord-014712-5u4e00q6	2185	18	was	be	VBD
cord-014712-5u4e00q6	2185	19	mild	mild	JJ
cord-014712-5u4e00q6	2185	20	when	when	WRB
cord-014712-5u4e00q6	2185	21	present	present	JJ
cord-014712-5u4e00q6	2185	22	in	in	IN
cord-014712-5u4e00q6	2185	23	patients	patient	NNS
cord-014712-5u4e00q6	2185	24	without	without	IN
cord-014712-5u4e00q6	2185	25	Dock-8	dock-8	JJ
cord-014712-5u4e00q6	2185	26	deficiency	deficiency	NN
cord-014712-5u4e00q6	2185	27	and	and	CC
cord-014712-5u4e00q6	2185	28	IgE	ige	NN
cord-014712-5u4e00q6	2185	29	levels	level	NNS
cord-014712-5u4e00q6	2185	30	were	be	VBD
cord-014712-5u4e00q6	2185	31	only	only	RB
cord-014712-5u4e00q6	2185	32	mildly	mildly	RB
cord-014712-5u4e00q6	2185	33	high	high	JJ
cord-014712-5u4e00q6	2185	34	or	or	CC
cord-014712-5u4e00q6	2185	35	normal	normal	JJ
cord-014712-5u4e00q6	2185	36	.	.	.
cord-014712-5u4e00q6	2186	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2186	2	identified	identify	VBD
cord-014712-5u4e00q6	2186	3	STK4	STK4	NNP
cord-014712-5u4e00q6	2186	4	and	and	CC
cord-014712-5u4e00q6	2186	5	coronin	coronin	NNP
cord-014712-5u4e00q6	2186	6	1A	1a	CD
cord-014712-5u4e00q6	2186	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	2186	8	in	in	IN
cord-014712-5u4e00q6	2186	9	two	two	CD
cord-014712-5u4e00q6	2186	10	siblings	sibling	NNS
cord-014712-5u4e00q6	2186	11	each	each	DT
cord-014712-5u4e00q6	2186	12	among	among	IN
cord-014712-5u4e00q6	2186	13	the	the	DT
cord-014712-5u4e00q6	2186	14	11	11	CD
cord-014712-5u4e00q6	2186	15	patients	patient	NNS
cord-014712-5u4e00q6	2186	16	who	who	WP
cord-014712-5u4e00q6	2186	17	showed	show	VBD
cord-014712-5u4e00q6	2186	18	overlapping	overlap	VBG
cord-014712-5u4e00q6	2186	19	features	feature	NNS
cord-014712-5u4e00q6	2186	20	with	with	IN
cord-014712-5u4e00q6	2186	21	AR	AR	NNP
cord-014712-5u4e00q6	2186	22	-	-	HYPH
cord-014712-5u4e00q6	2186	23	HIES	HIES	NNP
cord-014712-5u4e00q6	2186	24	and	and	CC
cord-014712-5u4e00q6	2186	25	do	do	VBP
cord-014712-5u4e00q6	2186	26	not	not	RB
cord-014712-5u4e00q6	2186	27	have	have	VB
cord-014712-5u4e00q6	2186	28	Dock-8	dock-8	JJ
cord-014712-5u4e00q6	2186	29	deficiency	deficiency	NN
cord-014712-5u4e00q6	2186	30	.	.	.
cord-014712-5u4e00q6	2187	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	2187	2	results	result	NNS
cord-014712-5u4e00q6	2187	3	showed	show	VBD
cord-014712-5u4e00q6	2187	4	that	that	IN
cord-014712-5u4e00q6	2187	5	patients	patient	NNS
cord-014712-5u4e00q6	2187	6	with	with	IN
cord-014712-5u4e00q6	2187	7	Dock8	dock8	JJ
cord-014712-5u4e00q6	2187	8	deficiency	deficiency	NN
cord-014712-5u4e00q6	2187	9	have	have	VBP
cord-014712-5u4e00q6	2187	10	early	early	JJ
cord-014712-5u4e00q6	2187	11	onset	onset	NN
cord-014712-5u4e00q6	2187	12	and	and	CC
cord-014712-5u4e00q6	2187	13	more	more	RBR
cord-014712-5u4e00q6	2187	14	remarkable	remarkable	JJ
cord-014712-5u4e00q6	2187	15	eczema	eczema	NN
cord-014712-5u4e00q6	2187	16	,	,	,
cord-014712-5u4e00q6	2187	17	food	food	NN
cord-014712-5u4e00q6	2187	18	allergy	allergy	NN
cord-014712-5u4e00q6	2187	19	,	,	,
cord-014712-5u4e00q6	2187	20	asthma	asthma	NN
cord-014712-5u4e00q6	2187	21	,	,	,
cord-014712-5u4e00q6	2187	22	more	more	RBR
cord-014712-5u4e00q6	2187	23	marked	marked	JJ
cord-014712-5u4e00q6	2187	24	eosinophilia	eosinophilia	NN
cord-014712-5u4e00q6	2187	25	,	,	,
cord-014712-5u4e00q6	2187	26	higher	high	JJR
cord-014712-5u4e00q6	2187	27	IgE	IgE	NNP
cord-014712-5u4e00q6	2187	28	,	,	,
cord-014712-5u4e00q6	2187	29	low	low	JJ
cord-014712-5u4e00q6	2187	30	IgM	IgM	NNP
cord-014712-5u4e00q6	2187	31	levels	level	NNS
cord-014712-5u4e00q6	2187	32	and	and	CC
cord-014712-5u4e00q6	2187	33	development	development	NN
cord-014712-5u4e00q6	2187	34	of	of	IN
cord-014712-5u4e00q6	2187	35	malignancy	malignancy	NN
cord-014712-5u4e00q6	2187	36	.	.	.
cord-014712-5u4e00q6	2188	1	These	these	DT
cord-014712-5u4e00q6	2188	2	features	feature	NNS
cord-014712-5u4e00q6	2188	3	may	may	MD
cord-014712-5u4e00q6	2188	4	be	be	VB
cord-014712-5u4e00q6	2188	5	helpful	helpful	JJ
cord-014712-5u4e00q6	2188	6	in	in	IN
cord-014712-5u4e00q6	2188	7	differentiation	differentiation	NN
cord-014712-5u4e00q6	2189	1	Dock8	dock8	JJ
cord-014712-5u4e00q6	2189	2	patients	patient	NNS
cord-014712-5u4e00q6	2189	3	from	from	IN
cord-014712-5u4e00q6	2189	4	patients	patient	NNS
cord-014712-5u4e00q6	2189	5	without	without	IN
cord-014712-5u4e00q6	2189	6	Dock-8	dock-8	JJ
cord-014712-5u4e00q6	2189	7	deficiency	deficiency	NN
cord-014712-5u4e00q6	2189	8	.	.	.
cord-014712-5u4e00q6	2190	1	It	-PRON-	PRP
cord-014712-5u4e00q6	2190	2	seems	seem	VBZ
cord-014712-5u4e00q6	2190	3	routine	routine	JJ
cord-014712-5u4e00q6	2190	4	lymphocyte	lymphocyte	NN
cord-014712-5u4e00q6	2190	5	subset	subset	VBN
cord-014712-5u4e00q6	2190	6	study	study	NN
cord-014712-5u4e00q6	2190	7	results	result	NNS
cord-014712-5u4e00q6	2190	8	are	be	VBP
cord-014712-5u4e00q6	2190	9	not	not	RB
cord-014712-5u4e00q6	2190	10	helpful	helpful	JJ
cord-014712-5u4e00q6	2190	11	for	for	IN
cord-014712-5u4e00q6	2190	12	this	this	DT
cord-014712-5u4e00q6	2190	13	differentiation	differentiation	NN
cord-014712-5u4e00q6	2190	14	.	.	.
cord-014712-5u4e00q6	2191	1	Alişan	Alişan	NNP
cord-014712-5u4e00q6	2191	2	Yıldıran	Yıldıran	NNP
cord-014712-5u4e00q6	2191	3	1	1	CD
cord-014712-5u4e00q6	2191	4	,	,	,
cord-014712-5u4e00q6	2191	5	Stephan	Stephan	NNP
cord-014712-5u4e00q6	2191	6	Borte	Borte	NNP
cord-014712-5u4e00q6	2191	7	2	2	CD
cord-014712-5u4e00q6	2191	8	Murat	Murat	NNP
cord-014712-5u4e00q6	2191	9	Elli	Elli	NNP
cord-014712-5u4e00q6	2191	10	1	1	CD
cord-014712-5u4e00q6	2191	11	,	,	,
cord-014712-5u4e00q6	2191	12	Tunç	Tunç	NNP
cord-014712-5u4e00q6	2191	13	Fışgın	Fışgın	NNP
cord-014712-5u4e00q6	2192	1	1	1	CD
cord-014712-5u4e00q6	2192	2	1	1	CD
cord-014712-5u4e00q6	2192	3	Ondokuz	Ondokuz	NNP
cord-014712-5u4e00q6	2192	4	Mayıs	Mayıs	NNP
cord-014712-5u4e00q6	2192	5	University	University	NNP
cord-014712-5u4e00q6	2192	6	,	,	,
cord-014712-5u4e00q6	2192	7	School	School	NNP
cord-014712-5u4e00q6	2192	8	of	of	IN
cord-014712-5u4e00q6	2192	9	Medicine	Medicine	NNP
cord-014712-5u4e00q6	2192	10	,	,	,
cord-014712-5u4e00q6	2192	11	Samsun	Samsun	NNP
cord-014712-5u4e00q6	2192	12	-	-	HYPH
cord-014712-5u4e00q6	2192	13	Turkiye	Turkiye	NNP
cord-014712-5u4e00q6	2192	14	2	2	CD
cord-014712-5u4e00q6	2192	15	ImmunoDeficiency	ImmunoDeficiency	NNP
cord-014712-5u4e00q6	2192	16	Center	Center	NNP
cord-014712-5u4e00q6	2192	17	Leipzig	Leipzig	NNP
cord-014712-5u4e00q6	2192	18	(	(	-LRB-
cord-014712-5u4e00q6	2192	19	IDCL	IDCL	NNP
cord-014712-5u4e00q6	2192	20	)	)	-RRB-
cord-014712-5u4e00q6	2192	21	at	at	IN
cord-014712-5u4e00q6	2192	22	Klinikum	Klinikum	NNP
cord-014712-5u4e00q6	2192	23	St.	St.	NNP
cord-014712-5u4e00q6	2192	24	Georg	Georg	NNP
cord-014712-5u4e00q6	2192	25	gGmbH	gGmbH	NNP
cord-014712-5u4e00q6	2192	26	,	,	,
cord-014712-5u4e00q6	2192	27	Leipzig	Leipzig	NNP
cord-014712-5u4e00q6	2192	28	-	-	HYPH
cord-014712-5u4e00q6	2192	29	Germany	Germany	NNP
cord-014712-5u4e00q6	2192	30	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2192	31	might	may	MD
cord-014712-5u4e00q6	2192	32	be	be	VB
cord-014712-5u4e00q6	2192	33	curative	curative	JJ
cord-014712-5u4e00q6	2192	34	for	for	IN
cord-014712-5u4e00q6	2192	35	some	some	DT
cord-014712-5u4e00q6	2192	36	PIDs	pid	NNS
cord-014712-5u4e00q6	2192	37	.	.	.
cord-014712-5u4e00q6	2193	1	Our	-PRON-	PRP$
cord-014712-5u4e00q6	2193	2	immunology	immunology	NN
cord-014712-5u4e00q6	2193	3	and	and	CC
cord-014712-5u4e00q6	2193	4	transplantation	transplantation	NN
cord-014712-5u4e00q6	2193	5	center	center	NN
cord-014712-5u4e00q6	2193	6	was	be	VBD
cord-014712-5u4e00q6	2193	7	newly	newly	RB
cord-014712-5u4e00q6	2193	8	established	establish	VBN
cord-014712-5u4e00q6	2193	9	.	.	.
cord-014712-5u4e00q6	2194	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2194	2	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	2194	3	reviewed	review	VBD
cord-014712-5u4e00q6	2194	4	all	all	DT
cord-014712-5u4e00q6	2194	5	children	child	NNS
cord-014712-5u4e00q6	2194	6	with	with	IN
cord-014712-5u4e00q6	2194	7	PID	PID	NNP
cord-014712-5u4e00q6	2194	8	who	who	WP
cord-014712-5u4e00q6	2194	9	diagnosed	diagnose	VBD
cord-014712-5u4e00q6	2194	10	and	and	CC
cord-014712-5u4e00q6	2194	11	received	receive	VBD
cord-014712-5u4e00q6	2194	12	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2194	13	at	at	IN
cord-014712-5u4e00q6	2194	14	Ondokuz	Ondokuz	NNP
cord-014712-5u4e00q6	2194	15	Mayıs	Mayıs	NNP
cord-014712-5u4e00q6	2194	16	University	University	NNP
cord-014712-5u4e00q6	2194	17	or	or	CC
cord-014712-5u4e00q6	2194	18	somewhere	somewhere	RB
cord-014712-5u4e00q6	2194	19	between	between	IN
cord-014712-5u4e00q6	2194	20	June	June	NNP
cord-014712-5u4e00q6	2194	21	2010	2010	CD
cord-014712-5u4e00q6	2194	22	and	and	CC
cord-014712-5u4e00q6	2194	23	December	December	NNP
cord-014712-5u4e00q6	2194	24	2013	2013	CD
cord-014712-5u4e00q6	2194	25	.	.	.
cord-014712-5u4e00q6	2195	1	Twenty	twenty	CD
cord-014712-5u4e00q6	2195	2	-	-	HYPH
cord-014712-5u4e00q6	2195	3	two	two	CD
cord-014712-5u4e00q6	2195	4	patients	patient	NNS
cord-014712-5u4e00q6	2195	5	were	be	VBD
cord-014712-5u4e00q6	2195	6	identified	identify	VBN
cord-014712-5u4e00q6	2195	7	.	.	.
cord-014712-5u4e00q6	2196	1	Four	four	CD
cord-014712-5u4e00q6	2196	2	of	of	IN
cord-014712-5u4e00q6	2196	3	them	-PRON-	PRP
cord-014712-5u4e00q6	2196	4	were	be	VBD
cord-014712-5u4e00q6	2196	5	referred	refer	VBN
cord-014712-5u4e00q6	2196	6	to	to	IN
cord-014712-5u4e00q6	2196	7	us	-PRON-	PRP
cord-014712-5u4e00q6	2196	8	for	for	IN
cord-014712-5u4e00q6	2196	9	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2196	10	from	from	IN
cord-014712-5u4e00q6	2196	11	other	other	JJ
cord-014712-5u4e00q6	2196	12	centers	center	NNS
cord-014712-5u4e00q6	2196	13	.	.	.
cord-014712-5u4e00q6	2197	1	The	the	DT
cord-014712-5u4e00q6	2197	2	median	median	JJ
cord-014712-5u4e00q6	2197	3	age	age	NN
cord-014712-5u4e00q6	2197	4	was	be	VBD
cord-014712-5u4e00q6	2197	5	6	6	CD
cord-014712-5u4e00q6	2197	6	months	month	NNS
cord-014712-5u4e00q6	2197	7	(	(	-LRB-
cord-014712-5u4e00q6	2197	8	1	1	CD
cord-014712-5u4e00q6	2197	9	month-10	month-10	CD
cord-014712-5u4e00q6	2197	10	yr	yr	NN
cord-014712-5u4e00q6	2197	11	)	)	-RRB-
cord-014712-5u4e00q6	2197	12	at	at	IN
cord-014712-5u4e00q6	2197	13	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2197	14	.	.	.
cord-014712-5u4e00q6	2198	1	Patients	patient	NNS
cord-014712-5u4e00q6	2198	2	'	'	POS
cord-014712-5u4e00q6	2198	3	diagnoses	diagnosis	NNS
cord-014712-5u4e00q6	2198	4	were	be	VBD
cord-014712-5u4e00q6	2198	5	SCID	SCID	NNP
cord-014712-5u4e00q6	2198	6	(	(	-LRB-
cord-014712-5u4e00q6	2198	7	n	n	NN
cord-014712-5u4e00q6	2198	8	=	=	SYM
cord-014712-5u4e00q6	2198	9	11	11	CD
cord-014712-5u4e00q6	2198	10	)	)	-RRB-
cord-014712-5u4e00q6	2198	11	,	,	,
cord-014712-5u4e00q6	2198	12	CHS	CHS	NNP
cord-014712-5u4e00q6	2198	13	(	(	-LRB-
cord-014712-5u4e00q6	2198	14	n	n	NN
cord-014712-5u4e00q6	2198	15	=	=	SYM
cord-014712-5u4e00q6	2198	16	2	2	CD
cord-014712-5u4e00q6	2198	17	)	)	-RRB-
cord-014712-5u4e00q6	2198	18	,	,	,
cord-014712-5u4e00q6	2198	19	Leukocyte	Leukocyte	NNP
cord-014712-5u4e00q6	2198	20	adhesion	adhesion	NN
cord-014712-5u4e00q6	2198	21	deficiency	deficiency	NN
cord-014712-5u4e00q6	2198	22	(	(	-LRB-
cord-014712-5u4e00q6	2198	23	n=2	n=2	NNS
cord-014712-5u4e00q6	2198	24	)	)	-RRB-
cord-014712-5u4e00q6	2198	25	,	,	,
cord-014712-5u4e00q6	2198	26	MHC	MHC	NNP
cord-014712-5u4e00q6	2198	27	Class	Class	NNP
cord-014712-5u4e00q6	2198	28	II	II	NNP
cord-014712-5u4e00q6	2198	29	deficiency	deficiency	NN
cord-014712-5u4e00q6	2198	30	(	(	-LRB-
cord-014712-5u4e00q6	2198	31	n=2	n=2	NNS
cord-014712-5u4e00q6	2198	32	)	)	-RRB-
cord-014712-5u4e00q6	2198	33	,	,	,
cord-014712-5u4e00q6	2198	34	Chronic	Chronic	NNP
cord-014712-5u4e00q6	2198	35	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2198	36	syndrome	syndrome	NN
cord-014712-5u4e00q6	2198	37	(	(	-LRB-
cord-014712-5u4e00q6	2198	38	n	n	NN
cord-014712-5u4e00q6	2198	39	=	=	SYM
cord-014712-5u4e00q6	2198	40	2	2	CD
cord-014712-5u4e00q6	2198	41	)	)	-RRB-
cord-014712-5u4e00q6	2198	42	,	,	,
cord-014712-5u4e00q6	2198	43	HLH	HLH	NNP
cord-014712-5u4e00q6	2198	44	(	(	-LRB-
cord-014712-5u4e00q6	2198	45	n	n	NN
cord-014712-5u4e00q6	2198	46	=	=	SYM
cord-014712-5u4e00q6	2198	47	1	1	CD
cord-014712-5u4e00q6	2198	48	)	)	-RRB-
cord-014712-5u4e00q6	2198	49	,	,	,
cord-014712-5u4e00q6	2198	50	WAS	be	VBD
cord-014712-5u4e00q6	2198	51	(	(	-LRB-
cord-014712-5u4e00q6	2198	52	n	n	NN
cord-014712-5u4e00q6	2198	53	=	=	SYM
cord-014712-5u4e00q6	2198	54	1	1	CD
cord-014712-5u4e00q6	2198	55	)	)	-RRB-
cord-014712-5u4e00q6	2198	56	and	and	CC
cord-014712-5u4e00q6	2198	57	Omenn	Omenn	NNP
cord-014712-5u4e00q6	2198	58	's	's	POS
cord-014712-5u4e00q6	2198	59	syndrome	syndrome	NN
cord-014712-5u4e00q6	2198	60	(	(	-LRB-
cord-014712-5u4e00q6	2198	61	n	n	NN
cord-014712-5u4e00q6	2198	62	=	=	SYM
cord-014712-5u4e00q6	2198	63	1	1	CD
cord-014712-5u4e00q6	2198	64	)	)	-RRB-
cord-014712-5u4e00q6	2198	65	.	.	.
cord-014712-5u4e00q6	2199	1	Seven	seven	CD
cord-014712-5u4e00q6	2199	2	patients	patient	NNS
cord-014712-5u4e00q6	2199	3	received	receive	VBD
cord-014712-5u4e00q6	2199	4	HLA	HLA	NNP
cord-014712-5u4e00q6	2199	5	-	-	HYPH
cord-014712-5u4e00q6	2199	6	matched	match	VBN
cord-014712-5u4e00q6	2199	7	related	relate	VBN
cord-014712-5u4e00q6	2199	8	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2199	9	;	;	:
cord-014712-5u4e00q6	2199	10	twelve	twelve	CD
cord-014712-5u4e00q6	2199	11	haploidentical	haploidentical	JJ
cord-014712-5u4e00q6	2199	12	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2199	13	and	and	CC
cord-014712-5u4e00q6	2199	14	two	two	CD
cord-014712-5u4e00q6	2199	15	matched	match	VBD
cord-014712-5u4e00q6	2199	16	unrelated	unrelated	JJ
cord-014712-5u4e00q6	2199	17	HSCT	HSCT	NNP
cord-014712-5u4e00q6	2199	18	.	.	.
cord-014712-5u4e00q6	2200	1	One	one	CD
cord-014712-5u4e00q6	2200	2	SCID	SCID	NNP
cord-014712-5u4e00q6	2200	3	patient	patient	NN
cord-014712-5u4e00q6	2200	4	died	die	VBD
cord-014712-5u4e00q6	2200	5	just	just	RB
cord-014712-5u4e00q6	2200	6	after	after	IN
cord-014712-5u4e00q6	2200	7	her	-PRON-	PRP$
cord-014712-5u4e00q6	2200	8	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	2200	9	.	.	.
cord-014712-5u4e00q6	2201	1	Two	two	CD
cord-014712-5u4e00q6	2201	2	patients	patient	NNS
cord-014712-5u4e00q6	2201	3	developed	develop	VBD
cord-014712-5u4e00q6	2201	4	BCGosis	BCGosis	NNP
cord-014712-5u4e00q6	2201	5	secondary	secondary	JJ
cord-014712-5u4e00q6	2201	6	to	to	IN
cord-014712-5u4e00q6	2201	7	reactivation	reactivation	NN
cord-014712-5u4e00q6	2201	8	of	of	IN
cord-014712-5u4e00q6	2201	9	pretransplant	pretransplant	JJ
cord-014712-5u4e00q6	2201	10	vaccination	vaccination	NN
cord-014712-5u4e00q6	2201	11	.	.	.
cord-014712-5u4e00q6	2202	1	One	one	CD
cord-014712-5u4e00q6	2202	2	of	of	IN
cord-014712-5u4e00q6	2202	3	them	-PRON-	PRP
cord-014712-5u4e00q6	2202	4	died	die	VBD
cord-014712-5u4e00q6	2202	5	due	due	IN
cord-014712-5u4e00q6	2202	6	to	to	IN
cord-014712-5u4e00q6	2202	7	hemophagocytic	hemophagocytic	JJ
cord-014712-5u4e00q6	2202	8	bone	bone	NN
cord-014712-5u4e00q6	2202	9	marrow	marrow	NN
cord-014712-5u4e00q6	2202	10	aplasia	aplasia	NNP
cord-014712-5u4e00q6	2202	11	,	,	,
cord-014712-5u4e00q6	2202	12	and	and	CC
cord-014712-5u4e00q6	2202	13	the	the	DT
cord-014712-5u4e00q6	2202	14	other	other	JJ
cord-014712-5u4e00q6	2202	15	has	have	VBZ
cord-014712-5u4e00q6	2202	16	recovered	recover	VBN
cord-014712-5u4e00q6	2202	17	.	.	.
cord-014712-5u4e00q6	2203	1	Five	five	CD
cord-014712-5u4e00q6	2203	2	patients	patient	NNS
cord-014712-5u4e00q6	2203	3	had	have	VBD
cord-014712-5u4e00q6	2203	4	graft	graft	NN
cord-014712-5u4e00q6	2203	5	failure	failure	NN
cord-014712-5u4e00q6	2203	6	;	;	:
cord-014712-5u4e00q6	2203	7	two	two	CD
cord-014712-5u4e00q6	2203	8	of	of	IN
cord-014712-5u4e00q6	2203	9	them	-PRON-	PRP
cord-014712-5u4e00q6	2203	10	received	receive	VBD
cord-014712-5u4e00q6	2203	11	no	no	DT
cord-014712-5u4e00q6	2203	12	conditioning	conditioning	NN
cord-014712-5u4e00q6	2203	13	regimens	regimen	NNS
cord-014712-5u4e00q6	2203	14	because	because	IN
cord-014712-5u4e00q6	2203	15	of	of	IN
cord-014712-5u4e00q6	2203	16	general	general	JJ
cord-014712-5u4e00q6	2203	17	health	health	NN
cord-014712-5u4e00q6	2203	18	status	status	NN
cord-014712-5u4e00q6	2203	19	and	and	CC
cord-014712-5u4e00q6	2203	20	the	the	DT
cord-014712-5u4e00q6	2203	21	other	other	JJ
cord-014712-5u4e00q6	2203	22	because	because	IN
cord-014712-5u4e00q6	2203	23	of	of	IN
cord-014712-5u4e00q6	2203	24	CMV	CMV	NNP
cord-014712-5u4e00q6	2203	25	infection	infection	NN
cord-014712-5u4e00q6	2203	26	.	.	.
cord-014712-5u4e00q6	2204	1	At	at	IN
cord-014712-5u4e00q6	2204	2	a	a	DT
cord-014712-5u4e00q6	2204	3	median	median	NN
cord-014712-5u4e00q6	2204	4	follow	follow	NN
cord-014712-5u4e00q6	2204	5	up	up	IN
cord-014712-5u4e00q6	2204	6	of	of	IN
cord-014712-5u4e00q6	2204	7	6	6	CD
cord-014712-5u4e00q6	2204	8	months	month	NNS
cord-014712-5u4e00q6	2204	9	(	(	-LRB-
cord-014712-5u4e00q6	2204	10	range	range	VBP
cord-014712-5u4e00q6	2204	11	0	0	CD
cord-014712-5u4e00q6	2204	12	-	-	HYPH
cord-014712-5u4e00q6	2204	13	64	64	CD
cord-014712-5u4e00q6	2204	14	)	)	-RRB-
cord-014712-5u4e00q6	2204	15	,	,	,
cord-014712-5u4e00q6	2204	16	15	15	CD
cord-014712-5u4e00q6	2204	17	patients	patient	NNS
cord-014712-5u4e00q6	2204	18	are	be	VBP
cord-014712-5u4e00q6	2204	19	alive	alive	JJ
cord-014712-5u4e00q6	2204	20	,	,	,
cord-014712-5u4e00q6	2204	21	with	with	IN
cord-014712-5u4e00q6	2204	22	overall	overall	JJ
cord-014712-5u4e00q6	2204	23	survival	survival	NN
cord-014712-5u4e00q6	2204	24	of	of	IN
cord-014712-5u4e00q6	2204	25	68	68	CD
cord-014712-5u4e00q6	2204	26	%	%	NN
cord-014712-5u4e00q6	2204	27	.	.	.
cord-014712-5u4e00q6	2205	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2205	2	conclude	conclude	VBP
cord-014712-5u4e00q6	2205	3	that	that	DT
cord-014712-5u4e00q6	2205	4	;	;	:
cord-014712-5u4e00q6	2205	5	our	-PRON-	PRP$
cord-014712-5u4e00q6	2205	6	clinic	clinic	NN
cord-014712-5u4e00q6	2205	7	undertakes	undertake	VBZ
cord-014712-5u4e00q6	2205	8	an	an	DT
cord-014712-5u4e00q6	2205	9	important	important	JJ
cord-014712-5u4e00q6	2205	10	duty	duty	NN
cord-014712-5u4e00q6	2205	11	in	in	IN
cord-014712-5u4e00q6	2205	12	our	-PRON-	PRP$
cord-014712-5u4e00q6	2205	13	region	region	NN
cord-014712-5u4e00q6	2205	14	for	for	IN
cord-014712-5u4e00q6	2205	15	PID	PID	NNP
cord-014712-5u4e00q6	2205	16	patients	patient	NNS
cord-014712-5u4e00q6	2205	17	.	.	.
cord-014712-5u4e00q6	2206	1	Also	also	RB
cord-014712-5u4e00q6	2206	2	,	,	,
cord-014712-5u4e00q6	2206	3	different	different	JJ
cord-014712-5u4e00q6	2206	4	PID	PID	NNP
cord-014712-5u4e00q6	2206	5	's	's	POS
cord-014712-5u4e00q6	2206	6	could	could	MD
cord-014712-5u4e00q6	2206	7	be	be	VB
cord-014712-5u4e00q6	2206	8	seen	see	VBN
cord-014712-5u4e00q6	2206	9	in	in	IN
cord-014712-5u4e00q6	2206	10	our	-PRON-	PRP$
cord-014712-5u4e00q6	2206	11	region	region	NN
cord-014712-5u4e00q6	2206	12	.	.	.
cord-014712-5u4e00q6	2207	1	Nerological	nerological	JJ
cord-014712-5u4e00q6	2207	2	complication	complication	NN
cord-014712-5u4e00q6	2208	1	20	20	CD
cord-014712-5u4e00q6	2208	2	1	1	CD
cord-014712-5u4e00q6	2208	3	patient	patient	NN
cord-014712-5u4e00q6	2208	4	(	(	-LRB-
cord-014712-5u4e00q6	2208	5	epilepsy	epilepsy	NN
cord-014712-5u4e00q6	2208	6	,	,	,
cord-014712-5u4e00q6	2208	7	brain	brain	NN
cord-014712-5u4e00q6	2208	8	infarct	infarct	NN
cord-014712-5u4e00q6	2208	9	)	)	-RRB-
cord-014712-5u4e00q6	2209	1	Outcome	outcome	NN
cord-014712-5u4e00q6	2209	2	3	3	CD
cord-014712-5u4e00q6	2209	3	died	die	VBD
cord-014712-5u4e00q6	2209	4	(	(	-LRB-
cord-014712-5u4e00q6	2209	5	one	one	CD
cord-014712-5u4e00q6	2209	6	with	with	IN
cord-014712-5u4e00q6	2209	7	post	post	NNP
cord-014712-5u4e00q6	2209	8	-BMT	-bmt	JJ
cord-014712-5u4e00q6	2209	9	comp	comp	NN
cord-014712-5u4e00q6	2209	10	.	.	NNP
cord-014712-5u4e00q6	2209	11	,	,	,
cord-014712-5u4e00q6	2209	12	2	2	CD
cord-014712-5u4e00q6	2209	13	with	with	IN
cord-014712-5u4e00q6	2209	14	malignancy	malignancy	NN
cord-014712-5u4e00q6	2210	1	All	all	DT
cord-014712-5u4e00q6	2210	2	alive	alive	JJ
cord-014712-5u4e00q6	2210	3	Department	Department	NNP
cord-014712-5u4e00q6	2210	4	of	of	IN
cord-014712-5u4e00q6	2210	5	Pediatrics	Pediatrics	NNP
cord-014712-5u4e00q6	2210	6	and	and	CC
cord-014712-5u4e00q6	2210	7	Adolescent	Adolescent	NNP
cord-014712-5u4e00q6	2210	8	medicine	medicine	NN
cord-014712-5u4e00q6	2210	9	1	1	CD
cord-014712-5u4e00q6	2210	10	Department	Department	NNP
cord-014712-5u4e00q6	2210	11	of	of	IN
cord-014712-5u4e00q6	2210	12	Allergology	Allergology	NNP
cord-014712-5u4e00q6	2210	13	,	,	,
cord-014712-5u4e00q6	2210	14	Rheumatology	Rheumatology	NNP
cord-014712-5u4e00q6	2210	15	and	and	CC
cord-014712-5u4e00q6	2210	16	Clinical	Clinical	NNP
cord-014712-5u4e00q6	2210	17	Immunology	Immunology	NNP
cord-014712-5u4e00q6	2210	18	,	,	,
cord-014712-5u4e00q6	2210	19	University	University	NNP
cord-014712-5u4e00q6	2210	20	Children	Children	NNPS
cord-014712-5u4e00q6	2210	21	's	's	POS
cord-014712-5u4e00q6	2210	22	Hospital	Hospital	NNP
cord-014712-5u4e00q6	2210	23	,	,	,
cord-014712-5u4e00q6	2210	24	University	University	NNP
cord-014712-5u4e00q6	2210	25	Medical	Medical	NNP
cord-014712-5u4e00q6	2210	26	Centre	Centre	NNP
cord-014712-5u4e00q6	2210	27	,	,	,
cord-014712-5u4e00q6	2210	28	Ljubljana	Ljubljana	NNP
cord-014712-5u4e00q6	2210	29	,	,	,
cord-014712-5u4e00q6	2210	30	Slovenia	Slovenia	NNP
cord-014712-5u4e00q6	2210	31	.	.	.
cord-014712-5u4e00q6	2210	32	developed	develop	VBD
cord-014712-5u4e00q6	2210	33	.	.	.
cord-014712-5u4e00q6	2211	1	There	there	EX
cord-014712-5u4e00q6	2211	2	is	be	VBZ
cord-014712-5u4e00q6	2211	3	no	no	DT
cord-014712-5u4e00q6	2211	4	severe	severe	JJ
cord-014712-5u4e00q6	2211	5	life	life	NN
cord-014712-5u4e00q6	2211	6	-	-	HYPH
cord-014712-5u4e00q6	2211	7	threatening	threaten	VBG
cord-014712-5u4e00q6	2211	8	complications	complication	NNS
cord-014712-5u4e00q6	2211	9	development	development	NN
cord-014712-5u4e00q6	2211	10	.	.	.
cord-014712-5u4e00q6	2212	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2212	2	describe	describe	VBP
cord-014712-5u4e00q6	2212	3	here	here	RB
cord-014712-5u4e00q6	2212	4	a	a	DT
cord-014712-5u4e00q6	2212	5	patient	patient	NN
cord-014712-5u4e00q6	2212	6	with	with	IN
cord-014712-5u4e00q6	2212	7	invasive	invasive	JJ
cord-014712-5u4e00q6	2212	8	Cryptococcus	Cryptococcus	NNP
cord-014712-5u4e00q6	2212	9	laurentii	laurentii	NN
cord-014712-5u4e00q6	2212	10	infection	infection	NN
cord-014712-5u4e00q6	2212	11	and	and	CC
cord-014712-5u4e00q6	2212	12	the	the	DT
cord-014712-5u4e00q6	2212	13	X	x	NN
cord-014712-5u4e00q6	2212	14	-	-	HYPH
cord-014712-5u4e00q6	2212	15	linked	link	VBN
cord-014712-5u4e00q6	2212	16	form	form	NN
cord-014712-5u4e00q6	2212	17	of	of	IN
cord-014712-5u4e00q6	2212	18	hyper	hyper	JJ
cord-014712-5u4e00q6	2212	19	-	-	JJ
cord-014712-5u4e00q6	2212	20	IgM	igm	JJ
cord-014712-5u4e00q6	2212	21	syndrome	syndrome	NN
cord-014712-5u4e00q6	2212	22	(	(	-LRB-
cord-014712-5u4e00q6	2212	23	X	X	NNP
cord-014712-5u4e00q6	2212	24	-	-	NNP
cord-014712-5u4e00q6	2212	25	HIGM	HIGM	NNP
cord-014712-5u4e00q6	2212	26	)	)	-RRB-
cord-014712-5u4e00q6	2212	27	.	.	.
cord-014712-5u4e00q6	2213	1	C.laurentii	C.laurentii	NNP
cord-014712-5u4e00q6	2213	2	is	be	VBZ
cord-014712-5u4e00q6	2213	3	an	an	DT
cord-014712-5u4e00q6	2213	4	extremely	extremely	RB
cord-014712-5u4e00q6	2213	5	rare	rare	JJ
cord-014712-5u4e00q6	2213	6	human	human	JJ
cord-014712-5u4e00q6	2213	7	pathogen	pathogen	NN
cord-014712-5u4e00q6	2213	8	.	.	.
cord-014712-5u4e00q6	2214	1	This	this	DT
cord-014712-5u4e00q6	2214	2	fungus	fungus	NN
cord-014712-5u4e00q6	2214	3	was	be	VBD
cord-014712-5u4e00q6	2214	4	previously	previously	RB
cord-014712-5u4e00q6	2214	5	considered	consider	VBN
cord-014712-5u4e00q6	2214	6	saprophytic	saprophytic	JJ
cord-014712-5u4e00q6	2214	7	and	and	CC
cord-014712-5u4e00q6	2214	8	non	non	JJ
cord-014712-5u4e00q6	2214	9	-	-	JJ
cord-014712-5u4e00q6	2214	10	pathogenic	pathogenic	JJ
cord-014712-5u4e00q6	2214	11	to	to	IN
cord-014712-5u4e00q6	2214	12	humans	human	NNS
cord-014712-5u4e00q6	2214	13	,	,	,
cord-014712-5u4e00q6	2214	14	but	but	CC
cord-014712-5u4e00q6	2214	15	it	-PRON-	PRP
cord-014712-5u4e00q6	2214	16	has	have	VBZ
cord-014712-5u4e00q6	2214	17	been	be	VBN
cord-014712-5u4e00q6	2214	18	isolated	isolate	VBN
cord-014712-5u4e00q6	2214	19	as	as	IN
cord-014712-5u4e00q6	2214	20	the	the	DT
cord-014712-5u4e00q6	2214	21	etiologic	etiologic	JJ
cord-014712-5u4e00q6	2214	22	agent	agent	NN
cord-014712-5u4e00q6	2214	23	of	of	IN
cord-014712-5u4e00q6	2214	24	skin	skin	NN
cord-014712-5u4e00q6	2214	25	infection	infection	NN
cord-014712-5u4e00q6	2214	26	,	,	,
cord-014712-5u4e00q6	2214	27	keratitis	keratitis	NN
cord-014712-5u4e00q6	2214	28	,	,	,
cord-014712-5u4e00q6	2214	29	endophthalmitis	endophthalmitis	NNP
cord-014712-5u4e00q6	2214	30	,	,	,
cord-014712-5u4e00q6	2214	31	lung	lung	NN
cord-014712-5u4e00q6	2214	32	abscess	abscess	NN
cord-014712-5u4e00q6	2214	33	,	,	,
cord-014712-5u4e00q6	2214	34	peritonitis	peritonitis	NN
cord-014712-5u4e00q6	2214	35	,	,	,
cord-014712-5u4e00q6	2214	36	meningitis	meningitis	NN
cord-014712-5u4e00q6	2214	37	,	,	,
cord-014712-5u4e00q6	2214	38	and	and	CC
cord-014712-5u4e00q6	2214	39	fungemia	fungemia	NN
cord-014712-5u4e00q6	2214	40	.	.	.
cord-014712-5u4e00q6	2215	1	Most	most	RBS
cord-014712-5u4e00q6	2215	2	affected	affect	VBN
cord-014712-5u4e00q6	2215	3	individuals	individual	NNS
cord-014712-5u4e00q6	2215	4	had	have	VBD
cord-014712-5u4e00q6	2215	5	a	a	DT
cord-014712-5u4e00q6	2215	6	compromised	compromised	JJ
cord-014712-5u4e00q6	2215	7	immune	immune	JJ
cord-014712-5u4e00q6	2215	8	system	system	NN
cord-014712-5u4e00q6	2215	9	because	because	IN
cord-014712-5u4e00q6	2215	10	of	of	IN
cord-014712-5u4e00q6	2215	11	leukemia	leukemia	NN
cord-014712-5u4e00q6	2215	12	,	,	,
cord-014712-5u4e00q6	2215	13	cancer	cancer	NN
cord-014712-5u4e00q6	2215	14	,	,	,
cord-014712-5u4e00q6	2215	15	diabetes	diabetes	NN
cord-014712-5u4e00q6	2215	16	mellitus	mellitus	NN
cord-014712-5u4e00q6	2215	17	,	,	,
cord-014712-5u4e00q6	2215	18	AIDS	AIDS	NNP
cord-014712-5u4e00q6	2215	19	,	,	,
cord-014712-5u4e00q6	2215	20	or	or	CC
cord-014712-5u4e00q6	2215	21	prematurity	prematurity	NN
cord-014712-5u4e00q6	2215	22	.	.	.
cord-014712-5u4e00q6	2216	1	Repeated	repeat	VBN
cord-014712-5u4e00q6	2216	2	isolation	isolation	NN
cord-014712-5u4e00q6	2216	3	of	of	IN
cord-014712-5u4e00q6	2216	4	C.laurentii	C.laurentii	NNP
cord-014712-5u4e00q6	2216	5	from	from	IN
cord-014712-5u4e00q6	2216	6	the	the	DT
cord-014712-5u4e00q6	2216	7	oropharynx	oropharynx	NN
cord-014712-5u4e00q6	2216	8	of	of	IN
cord-014712-5u4e00q6	2216	9	an	an	DT
cord-014712-5u4e00q6	2216	10	immunocompromised	immunocompromised	JJ
cord-014712-5u4e00q6	2216	11	patient	patient	NN
cord-014712-5u4e00q6	2216	12	has	have	VBZ
cord-014712-5u4e00q6	2216	13	also	also	RB
cord-014712-5u4e00q6	2216	14	been	be	VBN
cord-014712-5u4e00q6	2216	15	documented	document	VBN
cord-014712-5u4e00q6	2216	16	.	.	.
cord-014712-5u4e00q6	2217	1	Invasive	invasive	JJ
cord-014712-5u4e00q6	2217	2	C.laurentii	C.laurentii	NNP
cord-014712-5u4e00q6	2217	3	infection	infection	NN
cord-014712-5u4e00q6	2217	4	has	have	VBZ
cord-014712-5u4e00q6	2217	5	not	not	RB
cord-014712-5u4e00q6	2217	6	been	be	VBN
cord-014712-5u4e00q6	2217	7	reported	report	VBN
cord-014712-5u4e00q6	2217	8	in	in	IN
cord-014712-5u4e00q6	2217	9	patients	patient	NNS
cord-014712-5u4e00q6	2217	10	with	with	IN
cord-014712-5u4e00q6	2217	11	any	any	DT
cord-014712-5u4e00q6	2217	12	form	form	NN
cord-014712-5u4e00q6	2217	13	of	of	IN
cord-014712-5u4e00q6	2217	14	primary	primary	JJ
cord-014712-5u4e00q6	2217	15	immunodeficiency	immunodeficiency	NN
cord-014712-5u4e00q6	2217	16	disorder	disorder	NN
cord-014712-5u4e00q6	2217	17	emphasizing	emphasize	VBG
cord-014712-5u4e00q6	2217	18	the	the	DT
cord-014712-5u4e00q6	2217	19	true	true	JJ
cord-014712-5u4e00q6	2217	20	rarity	rarity	NN
cord-014712-5u4e00q6	2217	21	of	of	IN
cord-014712-5u4e00q6	2217	22	disease	disease	NN
cord-014712-5u4e00q6	2217	23	due	due	IN
cord-014712-5u4e00q6	2217	24	to	to	IN
cord-014712-5u4e00q6	2217	25	this	this	DT
cord-014712-5u4e00q6	2217	26	fungus	fungus	NN
cord-014712-5u4e00q6	2217	27	.	.	.
cord-014712-5u4e00q6	2218	1	Two	two	CD
cord-014712-5u4e00q6	2218	2	groups	group	NNS
cord-014712-5u4e00q6	2218	3	have	have	VBP
cord-014712-5u4e00q6	2218	4	recently	recently	RB
cord-014712-5u4e00q6	2218	5	reported	report	VBN
cord-014712-5u4e00q6	2218	6	that	that	IN
cord-014712-5u4e00q6	2218	7	dectin-1	dectin-1	NNP
cord-014712-5u4e00q6	2218	8	deficiency	deficiency	NN
cord-014712-5u4e00q6	2218	9	due	due	IN
cord-014712-5u4e00q6	2218	10	to	to	IN
cord-014712-5u4e00q6	2218	11	the	the	DT
cord-014712-5u4e00q6	2218	12	mutation	mutation	NN
cord-014712-5u4e00q6	2218	13	of	of	IN
cord-014712-5u4e00q6	2218	14	CLEC7A	clec7a	NN
cord-014712-5u4e00q6	2218	15	or	or	CC
cord-014712-5u4e00q6	2218	16	premature	premature	JJ
cord-014712-5u4e00q6	2218	17	termination	termination	NN
cord-014712-5u4e00q6	2218	18	of	of	IN
cord-014712-5u4e00q6	2218	19	the	the	DT
cord-014712-5u4e00q6	2218	20	dectin-1	dectin-1	NNP
cord-014712-5u4e00q6	2218	21	signal	signal	NN
cord-014712-5u4e00q6	2218	22	transduction	transduction	NN
cord-014712-5u4e00q6	2218	23	molecule	molecule	NN
cord-014712-5u4e00q6	2218	24	CARD9	CARD9	NNP
cord-014712-5u4e00q6	2218	25	may	may	MD
cord-014712-5u4e00q6	2218	26	predispose	predispose	VB
cord-014712-5u4e00q6	2218	27	patients	patient	NNS
cord-014712-5u4e00q6	2218	28	to	to	IN
cord-014712-5u4e00q6	2218	29	chronic	chronic	JJ
cord-014712-5u4e00q6	2218	30	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	2218	31	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	2218	32	(	(	-LRB-
cord-014712-5u4e00q6	2218	33	CMC	CMC	NNP
cord-014712-5u4e00q6	2218	34	)	)	-RRB-
cord-014712-5u4e00q6	2218	35	.	.	.
cord-014712-5u4e00q6	2219	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2219	2	studied	study	VBD
cord-014712-5u4e00q6	2219	3	the	the	DT
cord-014712-5u4e00q6	2219	4	frequency	frequency	NN
cord-014712-5u4e00q6	2219	5	of	of	IN
cord-014712-5u4e00q6	2219	6	CLEC7A	CLEC7A	NNP
cord-014712-5u4e00q6	2219	7	mutation	mutation	NN
cord-014712-5u4e00q6	2219	8	in	in	IN
cord-014712-5u4e00q6	2219	9	76	76	CD
cord-014712-5u4e00q6	2219	10	healthy	healthy	JJ
cord-014712-5u4e00q6	2219	11	individuals	individual	NNS
cord-014712-5u4e00q6	2219	12	,	,	,
cord-014712-5u4e00q6	2219	13	10	10	CD
cord-014712-5u4e00q6	2219	14	patients	patient	NNS
cord-014712-5u4e00q6	2219	15	with	with	IN
cord-014712-5u4e00q6	2219	16	the	the	DT
cord-014712-5u4e00q6	2219	17	hyper	hyper	NNP
cord-014712-5u4e00q6	2219	18	-	-	HYPH
cord-014712-5u4e00q6	2219	19	IgE	ige	JJ
cord-014712-5u4e00q6	2219	20	syndrome	syndrome	NN
cord-014712-5u4e00q6	2219	21	(	(	-LRB-
cord-014712-5u4e00q6	2219	22	HIES	HIES	NNP
cord-014712-5u4e00q6	2219	23	)	)	-RRB-
cord-014712-5u4e00q6	2219	24	,	,	,
cord-014712-5u4e00q6	2219	25	and	and	CC
cord-014712-5u4e00q6	2219	26	8	8	CD
cord-014712-5u4e00q6	2219	27	patients	patient	NNS
cord-014712-5u4e00q6	2219	28	with	with	IN
cord-014712-5u4e00q6	2219	29	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	2219	30	polyendocrine	polyendocrine	NNP
cord-014712-5u4e00q6	2219	31	syndrome	syndrome	NN
cord-014712-5u4e00q6	2219	32	type	type	NN
cord-014712-5u4e00q6	2219	33	1	1	CD
cord-014712-5u4e00q6	2219	34	(	(	-LRB-
cord-014712-5u4e00q6	2219	35	APS-1	APS-1	NNP
cord-014712-5u4e00q6	2219	36	)	)	-RRB-
cord-014712-5u4e00q6	2219	37	,	,	,
cord-014712-5u4e00q6	2219	38	all	all	DT
cord-014712-5u4e00q6	2219	39	aged	age	VBN
cord-014712-5u4e00q6	2219	40	between	between	IN
cord-014712-5u4e00q6	2219	41	2	2	CD
cord-014712-5u4e00q6	2219	42	to	to	TO
cord-014712-5u4e00q6	2219	43	60	60	CD
cord-014712-5u4e00q6	2219	44	years	year	NNS
cord-014712-5u4e00q6	2219	45	.	.	.
cord-014712-5u4e00q6	2220	1	Genomic	genomic	JJ
cord-014712-5u4e00q6	2220	2	DNA	dna	NN
cord-014712-5u4e00q6	2220	3	was	be	VBD
cord-014712-5u4e00q6	2220	4	isolated	isolate	VBN
cord-014712-5u4e00q6	2220	5	from	from	IN
cord-014712-5u4e00q6	2220	6	peripheral	peripheral	JJ
cord-014712-5u4e00q6	2220	7	blood	blood	NN
cord-014712-5u4e00q6	2220	8	.	.	.
cord-014712-5u4e00q6	2221	1	Monocytes	monocyte	NNS
cord-014712-5u4e00q6	2221	2	and	and	CC
cord-014712-5u4e00q6	2221	3	monocyte	monocyte	NN
cord-014712-5u4e00q6	2221	4	-	-	HYPH
cord-014712-5u4e00q6	2221	5	derived	derive	VBN
cord-014712-5u4e00q6	2221	6	dendritic	dendritic	JJ
cord-014712-5u4e00q6	2221	7	cells	cell	NNS
cord-014712-5u4e00q6	2221	8	(	(	-LRB-
cord-014712-5u4e00q6	2221	9	MDDCs	mddc	NNS
cord-014712-5u4e00q6	2221	10	)	)	-RRB-
cord-014712-5u4e00q6	2221	11	were	be	VBD
cord-014712-5u4e00q6	2221	12	used	use	VBN
cord-014712-5u4e00q6	2221	13	to	to	TO
cord-014712-5u4e00q6	2221	14	study	study	VB
cord-014712-5u4e00q6	2221	15	the	the	DT
cord-014712-5u4e00q6	2221	16	phenotypic	phenotypic	JJ
cord-014712-5u4e00q6	2221	17	expression	expression	NN
cord-014712-5u4e00q6	2221	18	of	of	IN
cord-014712-5u4e00q6	2221	19	dectin-1	dectin-1	NNP
cord-014712-5u4e00q6	2221	20	.	.	.
cord-014712-5u4e00q6	2222	1	CLEC7A	CLEC7A	NNP
cord-014712-5u4e00q6	2222	2	gene	gene	NN
cord-014712-5u4e00q6	2222	3	was	be	VBD
cord-014712-5u4e00q6	2222	4	sequenced	sequence	VBN
cord-014712-5u4e00q6	2222	5	with	with	IN
cord-014712-5u4e00q6	2222	6	the	the	DT
cord-014712-5u4e00q6	2222	7	Big	big	JJ
cord-014712-5u4e00q6	2222	8	Dye	Dye	NNP
cord-014712-5u4e00q6	2222	9	Terminator	Terminator	NNP
cord-014712-5u4e00q6	2222	10	cycle	cycle	NN
cord-014712-5u4e00q6	2222	11	sequencing	sequencing	NN
cord-014712-5u4e00q6	2222	12	kit	kit	NN
cord-014712-5u4e00q6	2222	13	.	.	.
cord-014712-5u4e00q6	2223	1	Mononuclear	Mononuclear	NNP
cord-014712-5u4e00q6	2223	2	cells	cell	NNS
cord-014712-5u4e00q6	2223	3	(	(	-LRB-
cord-014712-5u4e00q6	2223	4	MCs	mc	NNS
cord-014712-5u4e00q6	2223	5	)	)	-RRB-
cord-014712-5u4e00q6	2223	6	were	be	VBD
cord-014712-5u4e00q6	2223	7	isolated	isolate	VBN
cord-014712-5u4e00q6	2223	8	from	from	IN
cord-014712-5u4e00q6	2223	9	heparin	heparin	NN
cord-014712-5u4e00q6	2223	10	-	-	HYPH
cord-014712-5u4e00q6	2223	11	treated	treat	VBN
cord-014712-5u4e00q6	2223	12	venous	venous	JJ
cord-014712-5u4e00q6	2223	13	blood	blood	NN
cord-014712-5u4e00q6	2223	14	.	.	.
cord-014712-5u4e00q6	2224	1	MDCCs	mdcc	NNS
cord-014712-5u4e00q6	2224	2	were	be	VBD
cord-014712-5u4e00q6	2224	3	obtained	obtain	VBN
cord-014712-5u4e00q6	2224	4	by	by	IN
cord-014712-5u4e00q6	2224	5	culturing	culture	VBG
cord-014712-5u4e00q6	2224	6	monocytes	monocyte	NNS
cord-014712-5u4e00q6	2224	7	isolated	isolate	VBN
cord-014712-5u4e00q6	2224	8	by	by	IN
cord-014712-5u4e00q6	2224	9	immunomagnetic	immunomagnetic	JJ
cord-014712-5u4e00q6	2224	10	cell	cell	NN
cord-014712-5u4e00q6	2224	11	separation	separation	NN
cord-014712-5u4e00q6	2224	12	assay	assay	NN
cord-014712-5u4e00q6	2224	13	.	.	.
cord-014712-5u4e00q6	2225	1	Receptor	receptor	NN
cord-014712-5u4e00q6	2225	2	expression	expression	NN
cord-014712-5u4e00q6	2225	3	was	be	VBD
cord-014712-5u4e00q6	2225	4	assessed	assess	VBN
cord-014712-5u4e00q6	2225	5	by	by	IN
cord-014712-5u4e00q6	2225	6	flow	flow	NN
cord-014712-5u4e00q6	2225	7	cytometry	cytometry	NN
cord-014712-5u4e00q6	2225	8	.	.	.
cord-014712-5u4e00q6	2226	1	Secretion	secretion	NN
cord-014712-5u4e00q6	2226	2	of	of	IN
cord-014712-5u4e00q6	2226	3	IL-17A	IL-17A	NNP
cord-014712-5u4e00q6	2226	4	by	by	IN
cord-014712-5u4e00q6	2226	5	MCs	MCs	NNPS
cord-014712-5u4e00q6	2226	6	stimulated	stimulate	VBD
cord-014712-5u4e00q6	2226	7	with	with	IN
cord-014712-5u4e00q6	2226	8	killed	kill	VBN
cord-014712-5u4e00q6	2226	9	C.	C.	NNP
cord-014712-5u4e00q6	2226	10	albicans	albican	NNS
cord-014712-5u4e00q6	2226	11	blastoconidia	blastoconidia	NNP
cord-014712-5u4e00q6	2226	12	was	be	VBD
cord-014712-5u4e00q6	2226	13	assessed	assess	VBN
cord-014712-5u4e00q6	2226	14	by	by	IN
cord-014712-5u4e00q6	2226	15	ELISA	ELISA	NNP
cord-014712-5u4e00q6	2226	16	.	.	.
cord-014712-5u4e00q6	2227	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2227	2	report	report	VBP
cord-014712-5u4e00q6	2227	3	here	here	RB
cord-014712-5u4e00q6	2227	4	on	on	IN
cord-014712-5u4e00q6	2227	5	healthy	healthy	JJ
cord-014712-5u4e00q6	2227	6	individuals	individual	NNS
cord-014712-5u4e00q6	2227	7	with	with	IN
cord-014712-5u4e00q6	2227	8	homozygous	homozygous	JJ
cord-014712-5u4e00q6	2227	9	(	(	-LRB-
cord-014712-5u4e00q6	2227	10	one	one	CD
cord-014712-5u4e00q6	2227	11	38year	38year	JJ
cord-014712-5u4e00q6	2227	12	-	-	HYPH
cord-014712-5u4e00q6	2227	13	old	old	JJ
cord-014712-5u4e00q6	2227	14	man	man	NN
cord-014712-5u4e00q6	2227	15	)	)	-RRB-
cord-014712-5u4e00q6	2227	16	or	or	CC
cord-014712-5u4e00q6	2227	17	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	2227	18	(	(	-LRB-
cord-014712-5u4e00q6	2227	19	32	32	CD
cord-014712-5u4e00q6	2227	20	men	man	NNS
cord-014712-5u4e00q6	2227	21	and	and	CC
cord-014712-5u4e00q6	2227	22	44	44	CD
cord-014712-5u4e00q6	2227	23	women	woman	NNS
cord-014712-5u4e00q6	2227	24	)	)	-RRB-
cord-014712-5u4e00q6	2228	1	Tyr238X	Tyr238X	NNP
cord-014712-5u4e00q6	2228	2	mutation	mutation	NN
cord-014712-5u4e00q6	2228	3	in	in	IN
cord-014712-5u4e00q6	2228	4	the	the	DT
cord-014712-5u4e00q6	2228	5	dectin-1	dectin-1	NNP
cord-014712-5u4e00q6	2228	6	gene	gene	NN
cord-014712-5u4e00q6	2228	7	but	but	CC
cord-014712-5u4e00q6	2228	8	no	no	DT
cord-014712-5u4e00q6	2228	9	signs	sign	NNS
cord-014712-5u4e00q6	2228	10	of	of	IN
cord-014712-5u4e00q6	2228	11	CMC	CMC	NNP
cord-014712-5u4e00q6	2228	12	.	.	.
cord-014712-5u4e00q6	2229	1	Dectin-1	Dectin-1	NNP
cord-014712-5u4e00q6	2229	2	levels	level	NNS
cord-014712-5u4e00q6	2229	3	on	on	IN
cord-014712-5u4e00q6	2229	4	monocytes	monocyte	NNS
cord-014712-5u4e00q6	2229	5	and	and	CC
cord-014712-5u4e00q6	2229	6	MDDCs	mddc	NNS
cord-014712-5u4e00q6	2229	7	were	be	VBD
cord-014712-5u4e00q6	2229	8	negligible	negligible	JJ
cord-014712-5u4e00q6	2229	9	in	in	IN
cord-014712-5u4e00q6	2229	10	the	the	DT
cord-014712-5u4e00q6	2229	11	homozygous	homozygous	JJ
cord-014712-5u4e00q6	2229	12	man	man	NN
cord-014712-5u4e00q6	2229	13	and	and	CC
cord-014712-5u4e00q6	2229	14	the	the	DT
cord-014712-5u4e00q6	2229	15	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	2229	16	individuals	individual	NNS
cord-014712-5u4e00q6	2229	17	displayed	display	VBD
cord-014712-5u4e00q6	2229	18	intermediate	intermediate	JJ
cord-014712-5u4e00q6	2229	19	levels	level	NNS
cord-014712-5u4e00q6	2229	20	of	of	IN
cord-014712-5u4e00q6	2229	21	dectin-1	dectin-1	NNP
cord-014712-5u4e00q6	2229	22	,	,	,
cord-014712-5u4e00q6	2229	23	between	between	IN
cord-014712-5u4e00q6	2229	24	those	those	DT
cord-014712-5u4e00q6	2229	25	of	of	IN
cord-014712-5u4e00q6	2229	26	the	the	DT
cord-014712-5u4e00q6	2229	27	homozygous	homozygous	JJ
cord-014712-5u4e00q6	2229	28	man	man	NN
cord-014712-5u4e00q6	2229	29	and	and	CC
cord-014712-5u4e00q6	2229	30	the	the	DT
cord-014712-5u4e00q6	2229	31	wild	wild	JJ
cord-014712-5u4e00q6	2229	32	-	-	HYPH
cord-014712-5u4e00q6	2229	33	type	type	NN
cord-014712-5u4e00q6	2229	34	controls	control	NNS
cord-014712-5u4e00q6	2229	35	.	.	.
cord-014712-5u4e00q6	2230	1	Markedly	markedly	RB
cord-014712-5u4e00q6	2230	2	lower	low	JJR
cord-014712-5u4e00q6	2230	3	levels	level	NNS
cord-014712-5u4e00q6	2230	4	of	of	IN
cord-014712-5u4e00q6	2230	5	IL-17A	il-17a	JJ
cord-014712-5u4e00q6	2230	6	production	production	NN
cord-014712-5u4e00q6	2230	7	were	be	VBD
cord-014712-5u4e00q6	2230	8	observed	observe	VBN
cord-014712-5u4e00q6	2230	9	in	in	IN
cord-014712-5u4e00q6	2230	10	the	the	DT
cord-014712-5u4e00q6	2230	11	cells	cell	NNS
cord-014712-5u4e00q6	2230	12	of	of	IN
cord-014712-5u4e00q6	2230	13	the	the	DT
cord-014712-5u4e00q6	2230	14	man	man	NN
cord-014712-5u4e00q6	2230	15	with	with	IN
cord-014712-5u4e00q6	2230	16	the	the	DT
cord-014712-5u4e00q6	2230	17	homozygous	homozygous	JJ
cord-014712-5u4e00q6	2230	18	mutation	mutation	NN
cord-014712-5u4e00q6	2230	19	than	than	IN
cord-014712-5u4e00q6	2230	20	in	in	IN
cord-014712-5u4e00q6	2230	21	the	the	DT
cord-014712-5u4e00q6	2230	22	control	control	NN
cord-014712-5u4e00q6	2230	23	cells	cell	NNS
cord-014712-5u4e00q6	2230	24	.	.	.
cord-014712-5u4e00q6	2231	1	Levels	level	NNS
cord-014712-5u4e00q6	2231	2	of	of	IN
cord-014712-5u4e00q6	2231	3	production	production	NN
cord-014712-5u4e00q6	2231	4	of	of	IN
cord-014712-5u4e00q6	2231	5	this	this	DT
cord-014712-5u4e00q6	2231	6	cytokine	cytokine	NN
cord-014712-5u4e00q6	2231	7	were	be	VBD
cord-014712-5u4e00q6	2231	8	intermediate	intermediate	JJ
cord-014712-5u4e00q6	2231	9	in	in	IN
cord-014712-5u4e00q6	2231	10	heterozygotes	heterozygote	NNS
cord-014712-5u4e00q6	2231	11	.	.	.
cord-014712-5u4e00q6	2232	1	The	the	DT
cord-014712-5u4e00q6	2232	2	frequency	frequency	NN
cord-014712-5u4e00q6	2232	3	of	of	IN
cord-014712-5u4e00q6	2232	4	Tyr238X	tyr238x	CD
cord-014712-5u4e00q6	2232	5	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	2232	6	individuals	individual	NNS
cord-014712-5u4e00q6	2232	7	was	be	VBD
cord-014712-5u4e00q6	2232	8	21	21	CD
cord-014712-5u4e00q6	2232	9	%	%	NN
cord-014712-5u4e00q6	2232	10	among	among	IN
cord-014712-5u4e00q6	2232	11	healthy	healthy	JJ
cord-014712-5u4e00q6	2232	12	donors	donor	NNS
cord-014712-5u4e00q6	2232	13	and	and	CC
cord-014712-5u4e00q6	2232	14	10	10	CD
cord-014712-5u4e00q6	2232	15	%	%	NN
cord-014712-5u4e00q6	2232	16	in	in	IN
cord-014712-5u4e00q6	2232	17	patients	patient	NNS
cord-014712-5u4e00q6	2232	18	with	with	IN
cord-014712-5u4e00q6	2232	19	HIES	HIES	NNP
cord-014712-5u4e00q6	2232	20	and	and	CC
cord-014712-5u4e00q6	2232	21	20	20	CD
cord-014712-5u4e00q6	2232	22	%	%	NN
cord-014712-5u4e00q6	2232	23	in	in	IN
cord-014712-5u4e00q6	2232	24	patients	patient	NNS
cord-014712-5u4e00q6	2232	25	with	with	IN
cord-014712-5u4e00q6	2232	26	APS1	APS1	NNP
cord-014712-5u4e00q6	2232	27	.	.	.
cord-014712-5u4e00q6	2233	1	Importantly	importantly	RB
cord-014712-5u4e00q6	2233	2	,	,	,
cord-014712-5u4e00q6	2233	3	the	the	DT
cord-014712-5u4e00q6	2233	4	10	10	CD
cord-014712-5u4e00q6	2233	5	year	year	NN
cord-014712-5u4e00q6	2233	6	-	-	HYPH
cord-014712-5u4e00q6	2233	7	old	old	JJ
cord-014712-5u4e00q6	2233	8	HIES	hies	JJ
cord-014712-5u4e00q6	2233	9	girl	girl	NN
cord-014712-5u4e00q6	2233	10	with	with	IN
cord-014712-5u4e00q6	2233	11	heterozygous	heterozygous	JJ
cord-014712-5u4e00q6	2233	12	Tyr238X	Tyr238X	NNP
cord-014712-5u4e00q6	2233	13	mutations	mutation	NNS
cord-014712-5u4e00q6	2233	14	has	have	VBZ
cord-014712-5u4e00q6	2233	15	never	never	RB
cord-014712-5u4e00q6	2233	16	had	have	VBN
cord-014712-5u4e00q6	2233	17	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	2233	18	candidiasis	candidiasi	NNS
cord-014712-5u4e00q6	2233	19	.	.	.
cord-014712-5u4e00q6	2234	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2234	2	suggest	suggest	VBP
cord-014712-5u4e00q6	2234	3	that	that	IN
cord-014712-5u4e00q6	2234	4	dectin-1	dectin-1	NNP
cord-014712-5u4e00q6	2234	5	receptor	receptor	NN
cord-014712-5u4e00q6	2234	6	-	-	HYPH
cord-014712-5u4e00q6	2234	7	mediated	mediate	VBN
cord-014712-5u4e00q6	2234	8	immunity	immunity	NN
cord-014712-5u4e00q6	2234	9	is	be	VBZ
cord-014712-5u4e00q6	2234	10	redundant	redundant	JJ
cord-014712-5u4e00q6	2234	11	for	for	IN
cord-014712-5u4e00q6	2234	12	host	host	NN
cord-014712-5u4e00q6	2234	13	defense	defense	NN
cord-014712-5u4e00q6	2234	14	against	against	IN
cord-014712-5u4e00q6	2234	15	CMC	CMC	NNP
cord-014712-5u4e00q6	2234	16	,	,	,
cord-014712-5u4e00q6	2234	17	possibly	possibly	RB
cord-014712-5u4e00q6	2234	18	due	due	IN
cord-014712-5u4e00q6	2234	19	to	to	IN
cord-014712-5u4e00q6	2234	20	the	the	DT
cord-014712-5u4e00q6	2234	21	involvement	involvement	NN
cord-014712-5u4e00q6	2234	22	of	of	IN
cord-014712-5u4e00q6	2234	23	multiple	multiple	JJ
cord-014712-5u4e00q6	2234	24	lectin	lectin	NN
cord-014712-5u4e00q6	2234	25	receptors	receptor	NNS
cord-014712-5u4e00q6	2234	26	in	in	IN
cord-014712-5u4e00q6	2234	27	the	the	DT
cord-014712-5u4e00q6	2234	28	recognition	recognition	NN
cord-014712-5u4e00q6	2234	29	and	and	CC
cord-014712-5u4e00q6	2234	30	uptake	uptake	NN
cord-014712-5u4e00q6	2234	31	of	of	IN
cord-014712-5u4e00q6	2234	32	Candida	Candida	NNP
cord-014712-5u4e00q6	2234	33	.	.	.
cord-014712-5u4e00q6	2235	1	Chronic	chronic	JJ
cord-014712-5u4e00q6	2235	2	mucocutaneous	mucocutaneous	JJ
cord-014712-5u4e00q6	2235	3	candidiasis	candidiasis	NN
cord-014712-5u4e00q6	2235	4	(	(	-LRB-
cord-014712-5u4e00q6	2235	5	CMC	CMC	NNP
cord-014712-5u4e00q6	2235	6	)	)	-RRB-
cord-014712-5u4e00q6	2235	7	is	be	VBZ
cord-014712-5u4e00q6	2235	8	a	a	DT
cord-014712-5u4e00q6	2235	9	heterogenous	heterogenous	JJ
cord-014712-5u4e00q6	2235	10	group	group	NN
cord-014712-5u4e00q6	2235	11	with	with	IN
cord-014712-5u4e00q6	2235	12	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2235	13	chronic	chronic	JJ
cord-014712-5u4e00q6	2235	14	Candida	Candida	NNP
cord-014712-5u4e00q6	2235	15	infections	infection	NNS
cord-014712-5u4e00q6	2235	16	spesifically	spesifically	RB
cord-014712-5u4e00q6	2235	17	involving	involve	VBG
cord-014712-5u4e00q6	2235	18	nails	nail	NNS
cord-014712-5u4e00q6	2235	19	,	,	,
cord-014712-5u4e00q6	2235	20	skin	skin	NN
cord-014712-5u4e00q6	2235	21	and	and	CC
cord-014712-5u4e00q6	2235	22	oropharynx	oropharynx	NN
cord-014712-5u4e00q6	2235	23	.	.	.
cord-014712-5u4e00q6	2236	1	Several	several	JJ
cord-014712-5u4e00q6	2236	2	immunodeficiencies	immunodeficiency	NNS
cord-014712-5u4e00q6	2236	3	as	as	IN
cord-014712-5u4e00q6	2236	4	DOCK-8	dock-8	JJ
cord-014712-5u4e00q6	2236	5	deficiency	deficiency	NN
cord-014712-5u4e00q6	2236	6	,	,	,
cord-014712-5u4e00q6	2236	7	severe	severe	JJ
cord-014712-5u4e00q6	2236	8	combined	combine	VBN
cord-014712-5u4e00q6	2236	9	immune	immune	JJ
cord-014712-5u4e00q6	2236	10	deficiency	deficiency	NN
cord-014712-5u4e00q6	2236	11	,	,	,
cord-014712-5u4e00q6	2236	12	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	2236	13	polyglandular	polyglandular	NNP
cord-014712-5u4e00q6	2236	14	syndrome	syndrome	NN
cord-014712-5u4e00q6	2236	15	type	type	NN
cord-014712-5u4e00q6	2236	16	1	1	CD
cord-014712-5u4e00q6	2236	17	(	(	-LRB-
cord-014712-5u4e00q6	2236	18	APECED	APECED	NNP
cord-014712-5u4e00q6	2236	19	)	)	-RRB-
cord-014712-5u4e00q6	2236	20	,	,	,
cord-014712-5u4e00q6	2236	21	IL-12Rβ1	il-12rβ1	NN
cord-014712-5u4e00q6	2236	22	and	and	CC
cord-014712-5u4e00q6	2236	23	IL-12p40	IL-12p40	NNP
cord-014712-5u4e00q6	2236	24	deficiencies	deficiency	NNS
cord-014712-5u4e00q6	2236	25	,	,	,
cord-014712-5u4e00q6	2236	26	CARD	card	NN
cord-014712-5u4e00q6	2236	27	9	9	CD
cord-014712-5u4e00q6	2236	28	,	,	,
cord-014712-5u4e00q6	2236	29	STAT-3	STAT-3	NNP
cord-014712-5u4e00q6	2236	30	and	and	CC
cord-014712-5u4e00q6	2236	31	STAT-1	STAT-1	NNS
cord-014712-5u4e00q6	2236	32	can	can	MD
cord-014712-5u4e00q6	2236	33	cause	cause	VB
cord-014712-5u4e00q6	2236	34	CMC	CMC	NNP
cord-014712-5u4e00q6	2236	35	.	.	.
cord-014712-5u4e00q6	2237	1	We	-PRON-	PRP
cord-014712-5u4e00q6	2237	2	report	report	VBP
cord-014712-5u4e00q6	2237	3	here	here	RB
cord-014712-5u4e00q6	2237	4	a	a	DT
cord-014712-5u4e00q6	2237	5	3	3	CD
cord-014712-5u4e00q6	2237	6	years	year	NNS
cord-014712-5u4e00q6	2237	7	old	old	JJ
cord-014712-5u4e00q6	2237	8	boy	boy	NN
cord-014712-5u4e00q6	2237	9	,	,	,
cord-014712-5u4e00q6	2237	10	born	bear	VBN
cord-014712-5u4e00q6	2237	11	to	to	IN
cord-014712-5u4e00q6	2237	12	consaginous	consaginous	JJ
cord-014712-5u4e00q6	2237	13	parents	parent	NNS
cord-014712-5u4e00q6	2237	14	with	with	IN
cord-014712-5u4e00q6	2237	15	onicomycosis	onicomycosis	NNP
cord-014712-5u4e00q6	2237	16	,	,	,
cord-014712-5u4e00q6	2237	17	moniliasis	moniliasis	NNP
cord-014712-5u4e00q6	2237	18	,	,	,
cord-014712-5u4e00q6	2237	19	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2237	20	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2237	21	,	,	,
cord-014712-5u4e00q6	2237	22	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2237	23	herpetic	herpetic	JJ
cord-014712-5u4e00q6	2237	24	lesions	lesion	NNS
cord-014712-5u4e00q6	2237	25	,	,	,
cord-014712-5u4e00q6	2237	26	autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	2237	27	thyroiditis	thyroiditis	NN
cord-014712-5u4e00q6	2237	28	and	and	CC
cord-014712-5u4e00q6	2237	29	trombocytopenia	trombocytopenia	NNP
cord-014712-5u4e00q6	2237	30	.	.	.
cord-014712-5u4e00q6	2238	1	Last	last	JJ
cord-014712-5u4e00q6	2238	2	admission	admission	NN
cord-014712-5u4e00q6	2238	3	was	be	VBD
cord-014712-5u4e00q6	2238	4	due	due	JJ
cord-014712-5u4e00q6	2238	5	to	to	IN
cord-014712-5u4e00q6	2238	6	generalized	generalized	JJ
cord-014712-5u4e00q6	2238	7	tonic	tonic	JJ
cord-014712-5u4e00q6	2238	8	-	-	HYPH
cord-014712-5u4e00q6	2238	9	clonic	clonic	JJ
cord-014712-5u4e00q6	2238	10	convulsion	convulsion	NN
cord-014712-5u4e00q6	2238	11	and	and	CC
cord-014712-5u4e00q6	2238	12	mycotic	mycotic	JJ
cord-014712-5u4e00q6	2238	13	aneurism	aneurism	NN
cord-014712-5u4e00q6	2238	14	on	on	IN
cord-014712-5u4e00q6	2238	15	middle	middle	JJ
cord-014712-5u4e00q6	2238	16	cerebral	cerebral	JJ
cord-014712-5u4e00q6	2238	17	artery	artery	NN
cord-014712-5u4e00q6	2238	18	was	be	VBD
cord-014712-5u4e00q6	2238	19	detected	detect	VBN
cord-014712-5u4e00q6	2238	20	.	.	.
cord-014712-5u4e00q6	2239	1	Flow	flow	NN
cord-014712-5u4e00q6	2239	2	cytometry	cytometry	NN
cord-014712-5u4e00q6	2239	3	revealed	reveal	VBD
cord-014712-5u4e00q6	2239	4	CD4	CD4	NNP
cord-014712-5u4e00q6	2239	5	lymphopenia	lymphopenia	NNP
cord-014712-5u4e00q6	2239	6	,	,	,
cord-014712-5u4e00q6	2239	7	immunoglobulin	immunoglobulin	NN
cord-014712-5u4e00q6	2239	8	values	value	NNS
cord-014712-5u4e00q6	2239	9	were	be	VBD
cord-014712-5u4e00q6	2239	10	in	in	IN
cord-014712-5u4e00q6	2239	11	normal	normal	JJ
cord-014712-5u4e00q6	2239	12	range	range	NN
cord-014712-5u4e00q6	2239	13	.	.	.
cord-014712-5u4e00q6	2240	1	Polymorphism	polymorphism	NN
cord-014712-5u4e00q6	2240	2	on	on	IN
cord-014712-5u4e00q6	2240	3	exon	exon	NN
cord-014712-5u4e00q6	2240	4	6	6	CD
cord-014712-5u4e00q6	2240	5	for	for	IN
cord-014712-5u4e00q6	2240	6	AIRE	AIRE	NNP
cord-014712-5u4e00q6	2240	7	gene	gene	NN
cord-014712-5u4e00q6	2240	8	(	(	-LRB-
cord-014712-5u4e00q6	2240	9	T	T	NNP
cord-014712-5u4e00q6	2240	10	/	/	SYM
cord-014712-5u4e00q6	2240	11	C	C	NNP
cord-014712-5u4e00q6	2240	12	heterozygot	heterozygot	NN
cord-014712-5u4e00q6	2240	13	G227	G227	NNP
cord-014712-5u4e00q6	2240	14	G	G	NNP
cord-014712-5u4e00q6	2240	15	)	)	-RRB-
cord-014712-5u4e00q6	2240	16	and	and	CC
cord-014712-5u4e00q6	2240	17	heterozygot	heterozygot	NNP
cord-014712-5u4e00q6	2240	18	STAT1	STAT1	NNP
cord-014712-5u4e00q6	2240	19	mutation	mutation	NN
cord-014712-5u4e00q6	2240	20	(	(	-LRB-
cord-014712-5u4e00q6	2240	21	c.501	c.501	NNP
cord-014712-5u4e00q6	2240	22	>	>	XX
cord-014712-5u4e00q6	2241	1	A	a	LS
cord-014712-5u4e00q6	2241	2	;	;	:
cord-014712-5u4e00q6	2241	3	Q167H	q167h	ADD
cord-014712-5u4e00q6	2241	4	)	)	-RRB-
cord-014712-5u4e00q6	2241	5	were	be	VBD
cord-014712-5u4e00q6	2241	6	detected	detect	VBN
cord-014712-5u4e00q6	2241	7	.	.	.
cord-014712-5u4e00q6	2242	1	Various	various	JJ
cord-014712-5u4e00q6	2242	2	STAT1	stat1	NN
cord-014712-5u4e00q6	2242	3	GOF	GOF	NNP
cord-014712-5u4e00q6	2242	4	mutations	mutation	NNS
cord-014712-5u4e00q6	2242	5	(	(	-LRB-
cord-014712-5u4e00q6	2242	6	affecting	affect	VBG
cord-014712-5u4e00q6	2242	7	the	the	DT
cord-014712-5u4e00q6	2242	8	Coiled	coil	VBN
cord-014712-5u4e00q6	2242	9	-	-	HYPH
cord-014712-5u4e00q6	2242	10	coin	coin	NN
cord-014712-5u4e00q6	2242	11	domain	domain	NN
cord-014712-5u4e00q6	2242	12	or	or	CC
cord-014712-5u4e00q6	2242	13	the	the	DT
cord-014712-5u4e00q6	2242	14	DNA	dna	NN
cord-014712-5u4e00q6	2242	15	-	-	HYPH
cord-014712-5u4e00q6	2242	16	binding	bind	VBG
cord-014712-5u4e00q6	2242	17	domain	domain	NN
cord-014712-5u4e00q6	2242	18	)	)	-RRB-
cord-014712-5u4e00q6	2242	19	have	have	VBP
cord-014712-5u4e00q6	2242	20	been	be	VBN
cord-014712-5u4e00q6	2242	21	systematically	systematically	RB
cord-014712-5u4e00q6	2242	22	associated	associate	VBN
cord-014712-5u4e00q6	2242	23	with	with	IN
cord-014712-5u4e00q6	2242	24	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2242	25	to	to	IN
cord-014712-5u4e00q6	2242	26	CMC	CMC	NNP
cord-014712-5u4e00q6	2242	27	.	.	.
cord-014712-5u4e00q6	2243	1	Autoimmune	autoimmune	JJ
cord-014712-5u4e00q6	2243	2	manifestations	manifestation	NNS
cord-014712-5u4e00q6	2243	3	associated	associate	VBN
cord-014712-5u4e00q6	2243	4	with	with	IN
cord-014712-5u4e00q6	2243	5	STAT-1	STAT-1	NNS
cord-014712-5u4e00q6	2243	6	mutations	mutation	NNS
cord-014712-5u4e00q6	2243	7	have	have	VBP
cord-014712-5u4e00q6	2243	8	been	be	VBN
cord-014712-5u4e00q6	2243	9	attributed	attribute	VBN
cord-014712-5u4e00q6	2243	10	to	to	IN
cord-014712-5u4e00q6	2243	11	increased	increase	VBN
cord-014712-5u4e00q6	2243	12	type	type	NN
cord-014712-5u4e00q6	2243	13	1	1	CD
cord-014712-5u4e00q6	2243	14	interferon	interferon	NN
cord-014712-5u4e00q6	2243	15	.	.	.
cord-014712-5u4e00q6	2244	1	The	the	DT
cord-014712-5u4e00q6	2244	2	aneurism	aneurism	NN
cord-014712-5u4e00q6	2244	3	formation	formation	NN
cord-014712-5u4e00q6	2244	4	is	be	VBZ
cord-014712-5u4e00q6	2244	5	not	not	RB
cord-014712-5u4e00q6	2244	6	elucidated	elucidate	VBN
cord-014712-5u4e00q6	2244	7	whether	whether	IN
cord-014712-5u4e00q6	2244	8	it	-PRON-	PRP
cord-014712-5u4e00q6	2244	9	's	be	VBZ
cord-014712-5u4e00q6	2244	10	due	due	JJ
cord-014712-5u4e00q6	2244	11	to	to	IN
cord-014712-5u4e00q6	2244	12	Candida	candida	NN
cord-014712-5u4e00q6	2244	13	infection	infection	NN
cord-014712-5u4e00q6	2244	14	or	or	CC
cord-014712-5u4e00q6	2244	15	vascular	vascular	JJ
cord-014712-5u4e00q6	2244	16	damage	damage	NN
cord-014712-5u4e00q6	2244	17	directly	directly	RB
cord-014712-5u4e00q6	2244	18	affected	affect	VBN
cord-014712-5u4e00q6	2244	19	by	by	IN
cord-014712-5u4e00q6	2244	20	STAT-1	stat-1	NN
cord-014712-5u4e00q6	2244	21	mutation	mutation	NN
cord-014712-5u4e00q6	2244	22	.	.	.
cord-014712-5u4e00q6	2245	1	Purpose	purpose	NN
cord-014712-5u4e00q6	2245	2	:	:	:
cord-014712-5u4e00q6	2245	3	Chronic	chronic	JJ
cord-014712-5u4e00q6	2245	4	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2245	5	disease	disease	NN
cord-014712-5u4e00q6	2245	6	(	(	-LRB-
cord-014712-5u4e00q6	2245	7	CGD	CGD	NNP
cord-014712-5u4e00q6	2245	8	)	)	-RRB-
cord-014712-5u4e00q6	2245	9	is	be	VBZ
cord-014712-5u4e00q6	2245	10	a	a	DT
cord-014712-5u4e00q6	2245	11	rare	rare	JJ
cord-014712-5u4e00q6	2245	12	genetic	genetic	JJ
cord-014712-5u4e00q6	2245	13	disease	disease	NN
cord-014712-5u4e00q6	2245	14	of	of	IN
cord-014712-5u4e00q6	2245	15	phagocytic	phagocytic	JJ
cord-014712-5u4e00q6	2245	16	system	system	NN
cord-014712-5u4e00q6	2245	17	.	.	.
cord-014712-5u4e00q6	2246	1	Affected	affected	JJ
cord-014712-5u4e00q6	2246	2	patients	patient	NNS
cord-014712-5u4e00q6	2246	3	commonly	commonly	RB
cord-014712-5u4e00q6	2246	4	present	present	JJ
cord-014712-5u4e00q6	2246	5	with	with	IN
cord-014712-5u4e00q6	2246	6	bacterial	bacterial	JJ
cord-014712-5u4e00q6	2246	7	infections	infection	NNS
cord-014712-5u4e00q6	2246	8	associated	associate	VBN
cord-014712-5u4e00q6	2246	9	with	with	IN
cord-014712-5u4e00q6	2246	10	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2246	11	,	,	,
cord-014712-5u4e00q6	2246	12	abscesses	abscess	NNS
cord-014712-5u4e00q6	2246	13	and	and	CC
cord-014712-5u4e00q6	2246	14	lymphadenitis	lymphadenitis	NNP
cord-014712-5u4e00q6	2246	15	.	.	.
cord-014712-5u4e00q6	2247	1	In	in	IN
cord-014712-5u4e00q6	2247	2	this	this	DT
cord-014712-5u4e00q6	2247	3	study	study	NN
cord-014712-5u4e00q6	2247	4	,	,	,
cord-014712-5u4e00q6	2247	5	we	-PRON-	PRP
cord-014712-5u4e00q6	2247	6	investigated	investigate	VBD
cord-014712-5u4e00q6	2247	7	the	the	DT
cord-014712-5u4e00q6	2247	8	clinical	clinical	JJ
cord-014712-5u4e00q6	2247	9	and	and	CC
cord-014712-5u4e00q6	2247	10	laboratory	laboratory	NN
cord-014712-5u4e00q6	2247	11	findings	finding	NNS
cord-014712-5u4e00q6	2247	12	of	of	IN
cord-014712-5u4e00q6	2247	13	our	-PRON-	PRP$
cord-014712-5u4e00q6	2247	14	CGD	CGD	NNP
cord-014712-5u4e00q6	2247	15	patients	patient	NNS
cord-014712-5u4e00q6	2247	16	.	.	.
cord-014712-5u4e00q6	2248	1	Materials	material	NNS
cord-014712-5u4e00q6	2248	2	and	and	CC
cord-014712-5u4e00q6	2248	3	Methods	method	NNS
cord-014712-5u4e00q6	2248	4	:	:	:
cord-014712-5u4e00q6	2248	5	The	the	DT
cord-014712-5u4e00q6	2248	6	demographic	demographic	JJ
cord-014712-5u4e00q6	2248	7	data	data	NN
cord-014712-5u4e00q6	2248	8	(	(	-LRB-
cord-014712-5u4e00q6	2248	9	age	age	NN
cord-014712-5u4e00q6	2248	10	at	at	IN
cord-014712-5u4e00q6	2248	11	diagnosis	diagnosis	NN
cord-014712-5u4e00q6	2248	12	,	,	,
cord-014712-5u4e00q6	2248	13	initial	initial	JJ
cord-014712-5u4e00q6	2248	14	presenting	present	VBG
cord-014712-5u4e00q6	2248	15	symptoms	symptom	NNS
cord-014712-5u4e00q6	2248	16	,	,	,
cord-014712-5u4e00q6	2248	17	family	family	NN
cord-014712-5u4e00q6	2248	18	history	history	NN
cord-014712-5u4e00q6	2248	19	,	,	,
cord-014712-5u4e00q6	2248	20	follow	follow	NN
cord-014712-5u4e00q6	2248	21	-	-	HYPH
cord-014712-5u4e00q6	2248	22	up	up	NN
cord-014712-5u4e00q6	2248	23	period	period	NN
cord-014712-5u4e00q6	2248	24	)	)	-RRB-
cord-014712-5u4e00q6	2248	25	,	,	,
cord-014712-5u4e00q6	2248	26	mutation	mutation	NN
cord-014712-5u4e00q6	2248	27	analysis	analysis	NN
cord-014712-5u4e00q6	2248	28	,	,	,
cord-014712-5u4e00q6	2248	29	therapy	therapy	NN
cord-014712-5u4e00q6	2248	30	options	option	NNS
cord-014712-5u4e00q6	2248	31	,	,	,
cord-014712-5u4e00q6	2248	32	complications	complication	NNS
cord-014712-5u4e00q6	2248	33	,	,	,
cord-014712-5u4e00q6	2248	34	radiological	radiological	JJ
cord-014712-5u4e00q6	2248	35	findings	finding	NNS
cord-014712-5u4e00q6	2248	36	and	and	CC
cord-014712-5u4e00q6	2248	37	prognosis	prognosis	NN
cord-014712-5u4e00q6	2248	38	were	be	VBD
cord-014712-5u4e00q6	2248	39	evaluated	evaluate	VBN
cord-014712-5u4e00q6	2248	40	retrospectively	retrospectively	RB
cord-014712-5u4e00q6	2248	41	.	.	.
cord-014712-5u4e00q6	2249	1	Results	result	NNS
cord-014712-5u4e00q6	2249	2	:	:	:
cord-014712-5u4e00q6	2250	1	Among	among	IN
cord-014712-5u4e00q6	2250	2	9	9	CD
cord-014712-5u4e00q6	2250	3	CGD	CGD	NNP
cord-014712-5u4e00q6	2250	4	patients	patient	NNS
cord-014712-5u4e00q6	2250	5	,	,	,
cord-014712-5u4e00q6	2250	6	autosomal	autosomal	JJ
cord-014712-5u4e00q6	2250	7	recessive	recessive	JJ
cord-014712-5u4e00q6	2250	8	form	form	NN
cord-014712-5u4e00q6	2250	9	was	be	VBD
cord-014712-5u4e00q6	2250	10	detected	detect	VBN
cord-014712-5u4e00q6	2250	11	in	in	IN
cord-014712-5u4e00q6	2250	12	4	4	CD
cord-014712-5u4e00q6	2250	13	of	of	IN
cord-014712-5u4e00q6	2250	14	them	-PRON-	PRP
cord-014712-5u4e00q6	2250	15	.	.	.
cord-014712-5u4e00q6	2251	1	The	the	DT
cord-014712-5u4e00q6	2251	2	age	age	NN
cord-014712-5u4e00q6	2251	3	at	at	IN
cord-014712-5u4e00q6	2251	4	onset	onset	NN
cord-014712-5u4e00q6	2251	5	was	be	VBD
cord-014712-5u4e00q6	2251	6	statistically	statistically	RB
cord-014712-5u4e00q6	2251	7	lower	low	JJR
cord-014712-5u4e00q6	2251	8	in	in	IN
cord-014712-5u4e00q6	2251	9	X	X	NNP
cord-014712-5u4e00q6	2251	10	'	'	''
cord-014712-5u4e00q6	2251	11	linked	link	VBN
cord-014712-5u4e00q6	2251	12	CGD	CGD	NNP
cord-014712-5u4e00q6	2251	13	patients	patient	NNS
cord-014712-5u4e00q6	2251	14	than	than	IN
cord-014712-5u4e00q6	2251	15	AR	AR	NNP
cord-014712-5u4e00q6	2251	16	form	form	NN
cord-014712-5u4e00q6	2251	17	(	(	-LRB-
cord-014712-5u4e00q6	2251	18	11.2	11.2	CD
cord-014712-5u4e00q6	2251	19	±	±	NNP
cord-014712-5u4e00q6	2251	20	7.6	7.6	CD
cord-014712-5u4e00q6	2251	21	mo	mo	NN
cord-014712-5u4e00q6	2251	22	vs	vs	IN
cord-014712-5u4e00q6	2251	23	43.5	43.5	CD
cord-014712-5u4e00q6	2251	24	±	±	CD
cord-014712-5u4e00q6	2251	25	21.5	21.5	CD
cord-014712-5u4e00q6	2251	26	mo	mo	NN
cord-014712-5u4e00q6	2251	27	;	;	:
cord-014712-5u4e00q6	2251	28	p	p	NN
cord-014712-5u4e00q6	2251	29	=	=	SYM
cord-014712-5u4e00q6	2251	30	0.001).Respiratory	0.001).respiratory	CD
cord-014712-5u4e00q6	2251	31	tract	tract	NN
cord-014712-5u4e00q6	2251	32	infections	infection	NNS
cord-014712-5u4e00q6	2251	33	(	(	-LRB-
cord-014712-5u4e00q6	2251	34	sinusitis	sinusitis	NN
cord-014712-5u4e00q6	2251	35	,	,	,
cord-014712-5u4e00q6	2251	36	otitis	otitis	NN
cord-014712-5u4e00q6	2251	37	,	,	,
cord-014712-5u4e00q6	2251	38	pneumonia	pneumonia	NN
cord-014712-5u4e00q6	2251	39	)	)	-RRB-
cord-014712-5u4e00q6	2251	40	and	and	CC
cord-014712-5u4e00q6	2251	41	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2251	42	abscesses	abscess	NNS
cord-014712-5u4e00q6	2251	43	were	be	VBD
cord-014712-5u4e00q6	2251	44	more	more	RBR
cord-014712-5u4e00q6	2251	45	commonly	commonly	RB
cord-014712-5u4e00q6	2251	46	seen	see	VBN
cord-014712-5u4e00q6	2251	47	at	at	IN
cord-014712-5u4e00q6	2251	48	onset	onset	NN
cord-014712-5u4e00q6	2251	49	.	.	.
cord-014712-5u4e00q6	2252	1	Microbiological	microbiological	JJ
cord-014712-5u4e00q6	2252	2	culture	culture	NN
cord-014712-5u4e00q6	2252	3	revealed	reveal	VBD
cord-014712-5u4e00q6	2252	4	A.	A.	NNP
cord-014712-5u4e00q6	2252	5	fumigates	fumigate	NNS
cord-014712-5u4e00q6	2252	6	from	from	IN
cord-014712-5u4e00q6	2252	7	lung	lung	NN
cord-014712-5u4e00q6	2252	8	biopsy	biopsy	NN
cord-014712-5u4e00q6	2252	9	in	in	IN
cord-014712-5u4e00q6	2252	10	one	one	CD
cord-014712-5u4e00q6	2252	11	patient	patient	NN
cord-014712-5u4e00q6	2252	12	and	and	CC
cord-014712-5u4e00q6	2252	13	S.marcescens	s.marcescen	NNS
cord-014712-5u4e00q6	2252	14	from	from	IN
cord-014712-5u4e00q6	2252	15	blood	blood	NN
cord-014712-5u4e00q6	2252	16	specimen	specimen	NN
cord-014712-5u4e00q6	2252	17	in	in	IN
cord-014712-5u4e00q6	2252	18	other	other	JJ
cord-014712-5u4e00q6	2252	19	ones	one	NNS
cord-014712-5u4e00q6	2252	20	.	.	.
cord-014712-5u4e00q6	2253	1	BCGitis	BCGitis	NNP
cord-014712-5u4e00q6	2253	2	was	be	VBD
cord-014712-5u4e00q6	2253	3	observed	observe	VBN
cord-014712-5u4e00q6	2253	4	in	in	IN
cord-014712-5u4e00q6	2253	5	one	one	CD
cord-014712-5u4e00q6	2253	6	patient	patient	NN
cord-014712-5u4e00q6	2253	7	and	and	CC
cord-014712-5u4e00q6	2253	8	five	five	CD
cord-014712-5u4e00q6	2253	9	patients	patient	NNS
cord-014712-5u4e00q6	2253	10	received	receive	VBD
cord-014712-5u4e00q6	2253	11	anti	anti	JJ
cord-014712-5u4e00q6	2253	12	-	-	JJ
cord-014712-5u4e00q6	2253	13	TB	tb	JJ
cord-014712-5u4e00q6	2253	14	therapy	therapy	NN
cord-014712-5u4e00q6	2253	15	.	.	.
cord-014712-5u4e00q6	2254	1	Non	non	JJ
cord-014712-5u4e00q6	2254	2	-	-	JJ
cord-014712-5u4e00q6	2254	3	infectious	infectious	JJ
cord-014712-5u4e00q6	2254	4	complications	complication	NNS
cord-014712-5u4e00q6	2254	5	were	be	VBD
cord-014712-5u4e00q6	2254	6	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2254	7	uveitis	uveitis	NN
cord-014712-5u4e00q6	2254	8	,	,	,
cord-014712-5u4e00q6	2254	9	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2254	10	pericardial	pericardial	JJ
cord-014712-5u4e00q6	2254	11	effusion	effusion	NN
cord-014712-5u4e00q6	2254	12	,	,	,
cord-014712-5u4e00q6	2254	13	skin	skin	NN
cord-014712-5u4e00q6	2254	14	granuloma	granuloma	NN
cord-014712-5u4e00q6	2254	15	,	,	,
cord-014712-5u4e00q6	2254	16	noduler	noduler	NNP
cord-014712-5u4e00q6	2254	17	formation	formation	NN
cord-014712-5u4e00q6	2254	18	in	in	IN
cord-014712-5u4e00q6	2254	19	lung	lung	NN
cord-014712-5u4e00q6	2254	20	and	and	CC
cord-014712-5u4e00q6	2254	21	brain	brain	NN
cord-014712-5u4e00q6	2254	22	area	area	NN
cord-014712-5u4e00q6	2254	23	.	.	.
cord-014712-5u4e00q6	2255	1	Conclusion	conclusion	NN
cord-014712-5u4e00q6	2255	2	:	:	:
cord-014712-5u4e00q6	2255	3	Due	due	IN
cord-014712-5u4e00q6	2255	4	to	to	IN
cord-014712-5u4e00q6	2255	5	high	high	JJ
cord-014712-5u4e00q6	2255	6	rate	rate	NN
cord-014712-5u4e00q6	2255	7	of	of	IN
cord-014712-5u4e00q6	2255	8	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	2255	9	,	,	,
cord-014712-5u4e00q6	2255	10	autosomal	autosomal	JJ
cord-014712-5u4e00q6	2255	11	recessive	recessive	JJ
cord-014712-5u4e00q6	2255	12	inheritance	inheritance	NN
cord-014712-5u4e00q6	2255	13	was	be	VBD
cord-014712-5u4e00q6	2255	14	observed	observe	VBN
cord-014712-5u4e00q6	2255	15	highly	highly	RB
cord-014712-5u4e00q6	2255	16	in	in	IN
cord-014712-5u4e00q6	2255	17	our	-PRON-	PRP$
cord-014712-5u4e00q6	2255	18	patient	patient	JJ
cord-014712-5u4e00q6	2255	19	cohort	cohort	NN
cord-014712-5u4e00q6	2255	20	.	.	.
cord-014712-5u4e00q6	2256	1	Since	since	IN
cord-014712-5u4e00q6	2256	2	,	,	,
cord-014712-5u4e00q6	2256	3	patients	patient	NNS
cord-014712-5u4e00q6	2256	4	with	with	IN
cord-014712-5u4e00q6	2256	5	CGD	CGD	NNP
cord-014712-5u4e00q6	2256	6	are	be	VBP
cord-014712-5u4e00q6	2256	7	susceptible	susceptible	JJ
cord-014712-5u4e00q6	2256	8	to	to	IN
cord-014712-5u4e00q6	2256	9	Tuberculosis	Tuberculosis	NNP
cord-014712-5u4e00q6	2256	10	and	and	CC
cord-014712-5u4e00q6	2256	11	BCG	BCG	NNP
cord-014712-5u4e00q6	2256	12	complications	complication	NNS
cord-014712-5u4e00q6	2256	13	;	;	:
cord-014712-5u4e00q6	2256	14	initiation	initiation	NN
cord-014712-5u4e00q6	2256	15	of	of	IN
cord-014712-5u4e00q6	2256	16	tuberculosis	tuberculosis	NN
cord-014712-5u4e00q6	2256	17	prophylaxis	prophylaxis	NN
cord-014712-5u4e00q6	2256	18	is	be	VBZ
cord-014712-5u4e00q6	2256	19	advisable	advisable	JJ
cord-014712-5u4e00q6	2256	20	in	in	IN
cord-014712-5u4e00q6	2256	21	countries	country	NNS
cord-014712-5u4e00q6	2256	22	where	where	WRB
cord-014712-5u4e00q6	2256	23	BCG	BCG	NNP
cord-014712-5u4e00q6	2256	24	is	be	VBZ
cord-014712-5u4e00q6	2256	25	still	still	RB
cord-014712-5u4e00q6	2256	26	administrated	administrate	VBN
cord-014712-5u4e00q6	2256	27	at	at	IN
cord-014712-5u4e00q6	2256	28	birth	birth	NN
cord-014712-5u4e00q6	2256	29	.	.	.
cord-014712-5u4e00q6	2257	1	Key	key	JJ
cord-014712-5u4e00q6	2257	2	words	word	NNS
cord-014712-5u4e00q6	2257	3	:	:	:
cord-014712-5u4e00q6	2257	4	Chronic	chronic	JJ
cord-014712-5u4e00q6	2257	5	granulomatous	granulomatous	JJ
cord-014712-5u4e00q6	2257	6	disease	disease	NN
cord-014712-5u4e00q6	2257	7	,	,	,
cord-014712-5u4e00q6	2257	8	consanguinity	consanguinity	NN
cord-014712-5u4e00q6	2257	9	,	,	,
cord-014712-5u4e00q6	2257	10	BCG	BCG	NNP
cord-014712-5u4e00q6	2257	11	.	.	.
cord-014712-5u4e00q6	2258	1	Acquired	Acquired	NNP
cord-014712-5u4e00q6	2258	2	Immunodeficiency	Immunodeficiency	NNP
cord-014712-5u4e00q6	2258	3	Research	Research	NNP
cord-014712-5u4e00q6	2258	4	Center	Center	NNP
cord-014712-5u4e00q6	2258	5	,	,	,
cord-014712-5u4e00q6	2258	6	Isfahan	Isfahan	NNP
cord-014712-5u4e00q6	2258	7	University	University	NNP
cord-014712-5u4e00q6	2258	8	of	of	IN
cord-014712-5u4e00q6	2258	9	Medical	Medical	NNP
cord-014712-5u4e00q6	2258	10	Sciences	Sciences	NNPS
cord-014712-5u4e00q6	2258	11	,	,	,
cord-014712-5u4e00q6	2258	12	Isfahan	Isfahan	NNP
cord-014712-5u4e00q6	2258	13	,	,	,
cord-014712-5u4e00q6	2258	14	IranBackground	IranBackground	NNP
cord-014712-5u4e00q6	2258	15	:	:	:
cord-014712-5u4e00q6	2259	1	Defects	defect	NNS
cord-014712-5u4e00q6	2259	2	of	of	IN
cord-014712-5u4e00q6	2259	3	the	the	DT
cord-014712-5u4e00q6	2259	4	immune	immune	JJ
cord-014712-5u4e00q6	2259	5	system	system	NN
cord-014712-5u4e00q6	2259	6	in	in	IN
cord-014712-5u4e00q6	2259	7	Primary	primary	JJ
cord-014712-5u4e00q6	2259	8	immunodeficient	immunodeficient	JJ
cord-014712-5u4e00q6	2259	9	diseases	disease	NNS
cord-014712-5u4e00q6	2259	10	(	(	-LRB-
cord-014712-5u4e00q6	2259	11	PIDs	pid	NNS
cord-014712-5u4e00q6	2259	12	)	)	-RRB-
cord-014712-5u4e00q6	2259	13	predispose	predispose	VB
cord-014712-5u4e00q6	2259	14	individuals	individual	NNS
cord-014712-5u4e00q6	2259	15	to	to	IN
cord-014712-5u4e00q6	2259	16	recurrent	recurrent	JJ
cord-014712-5u4e00q6	2259	17	infections	infection	NNS
cord-014712-5u4e00q6	2259	18	.	.	.
cord-014712-5u4e00q6	2260	1	Complex	complex	JJ
cord-014712-5u4e00q6	2260	2	genetic	genetic	JJ
cord-014712-5u4e00q6	2260	3	components	component	NNS
cord-014712-5u4e00q6	2260	4	for	for	IN
cord-014712-5u4e00q6	2260	5	susceptibility	susceptibility	NN
cord-014712-5u4e00q6	2260	6	to	to	IN
cord-014712-5u4e00q6	2260	7	mycobacterial	mycobacterial	NNP
cord-014712-5u4e00q6	2260	8	disease	disease	NNP
cord-014712-5u4e00q6	2260	9	have	have	VBP
cord-014712-5u4e00q6	2260	10	been	be	VBN
cord-014712-5u4e00q6	2260	11	suggested	suggest	VBN
cord-014712-5u4e00q6	2260	12	.	.	.
cord-014712-5u4e00q6	2261	1	Natural	natural	JJ
cord-014712-5u4e00q6	2261	2	human	human	JJ
cord-014712-5u4e00q6	2261	3	immunity	immunity	NN
cord-014712-5u4e00q6	2261	4	to	to	IN
cord-014712-5u4e00q6	2261	5	the	the	DT
cord-014712-5u4e00q6	2261	6	mycobacteria	mycobacterium	NNS
cord-014712-5u4e00q6	2261	7	group	group	NN
cord-014712-5u4e00q6	2261	8	,	,	,
cord-014712-5u4e00q6	2261	9	including	include	VBG
cord-014712-5u4e00q6	2261	10	Mycobacterium	Mycobacterium	NNP
cord-014712-5u4e00q6	2261	11	tuberculosis(MTB	tuberculosis(MTB	NNP
cord-014712-5u4e00q6	2261	12	)	)	-RRB-
cord-014712-5u4e00q6	2261	13	,	,	,
cord-014712-5u4e00q6	2261	14	Bacille	Bacille	NNP
cord-014712-5u4e00q6	2261	15	Calmette	Calmette	NNP
cord-014712-5u4e00q6	2261	16	-	-	HYPH
cord-014712-5u4e00q6	2261	17	Guérin	Guérin	NNP
cord-014712-5u4e00q6	2261	18	(	(	-LRB-
cord-014712-5u4e00q6	2261	19	BCG	BCG	NNP
cord-014712-5u4e00q6	2261	20	)	)	-RRB-
cord-014712-5u4e00q6	2261	21	or	or	CC
cord-014712-5u4e00q6	2261	22	nontuberculous	nontuberculous	JJ
cord-014712-5u4e00q6	2261	23	mycobacteria	mycobacterium	NNS
cord-014712-5u4e00q6	2261	24	(	(	-LRB-
cord-014712-5u4e00q6	2261	25	NTM	NTM	NNP
cord-014712-5u4e00q6	2261	26	)	)	-RRB-
cord-014712-5u4e00q6	2261	27	relies	rely	VBZ
cord-014712-5u4e00q6	2261	28	on	on	IN
cord-014712-5u4e00q6	2261	29	the	the	DT
cord-014712-5u4e00q6	2261	30	functional	functional	JJ
cord-014712-5u4e00q6	2261	31	IL-12/23-IFN	il-12/23-ifn	NN
cord-014712-5u4e00q6	2261	32	-	-	HYPH
cord-014712-5u4e00q6	2261	33	γ	γ	NN
cord-014712-5u4e00q6	2261	34	integrity	integrity	NN
cord-014712-5u4e00q6	2261	35	of	of	IN
cord-014712-5u4e00q6	2261	36	macrophages	macrophage	NNS
cord-014712-5u4e00q6	2261	37	(	(	-LRB-
cord-014712-5u4e00q6	2261	38	monocyte	monocyte	NNP
cord-014712-5u4e00q6	2261	39	/	/	SYM
cord-014712-5u4e00q6	2261	40	dendritic	dendritic	JJ
cord-014712-5u4e00q6	2261	41	cell	cell	NN
cord-014712-5u4e00q6	2261	42	)	)	-RRB-
cord-014712-5u4e00q6	2261	43	connecting	connect	VBG
cord-014712-5u4e00q6	2261	44	to	to	IN